

Reckitt Benckiser

1 STUDY REPORT TITLE PAGE

EudraCT Number:	2011-004725-27		
Study Number:	GA1109	Project Name:	Project Panoramix
Study Phase:	II	Study Country:	United Kingdom (UK)
Indication:	Not Applicable.		
Test Product:	Gaviscon Double Action Aniseed Liquid (PL 00063/0543)		
Reference Product:	Placebo Aniseed Liquid		
Date of First Subject Visit:	21 Feb 2012		
Date of Last Subject Visit:	24 May 2012		
Principal Investigator:	Dr Simon L Singer, BSc MB, ChB, MRCS, ICON Development Solutions, Skelton House, Lloyd Street North, Manchester, M15 6SH, UK		
Study Title:	A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid activity of Gaviscon Double Action Liquid in the fasted state		
Short Study Title:	Pilot Gaviscon Double Action pH monitoring study		
Report Date:	14 Feb 2013		
Report Version:	Final		
Study Conduct Statement:	This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and the ethical principles contained within the Declaration of Helsinki, as referenced in European Union (EU) Directive 2001/20/EC.		
Confidentiality Statement:	The information contained in this document is privileged and confidential. Do not copy, circulate or otherwise distribute without written authority from the Reckitt Benckiser Clinical Project Manager function.		

2 REPORT APPROVAL

Reviewed and Agreed by:

Reckitt Benckiser Healthcare (UK) Ltd

Clinical Project Manager Function:

Statistician:


Mrs Joanne Wilkinson, BSc
(Hons)

06/MAR/2013
Date


Mr Gary Smith, MSc

05/MAR/13
Date

ICON Development Solutions/ICON Clinical Research

Statistician:

Report Author:

Ms Sally Anderton, MSc
ICON Development Solutions

Date


Mr Leon Conradie, BA Hons
ICON Clinical Research

Date


Reviewed and Approved by:

R&D Manager - Clinical (Healthcare):

Global Medical Director:


Dr Sue Aspley PhD

05 MAR 13
Date


Dr Phil Berry MB, ChB, MPH

5 March 2013
Date


2 REPORT APPROVAL

Reviewed and Agreed by:Reckitt Benckiser Healthcare (UK) Ltd**Clinical Project Manager Function:****Statistician:**

Mrs Joanne Wilkinson, BSc
(Hons)

Date

Mr Gary Smith, MSc

DateICON Development Solutions/ICON Clinical Research**Statistician:****Report Author:**Ms Sally Anderton, MSc
ICON Development Solutions26 Feb 2013

Date

Mr Leon Conradie, BA Hons
ICON Clinical Research26 Feb 2013

Date

Reviewed and Approved by:**R&D Manager - Clinical (Healthcare):****Global Medical Director:**

Dr Sue Aspley PhD

Date

Dr Phil Berry MB, ChB, MPH

Date

3 SYNOPSIS

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		
Title of Trial: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid activity of Gaviscon Double Action Liquid in the fasted state		
Investigator: Dr Simon L Singer, BSc MB, ChB, MRCS		
Trial Site: This study was conducted at the Phase 1 unit of ICON Development Solutions, Manchester Royal Infirmary Campus, Oxford Road, Manchester, M13 9WL, United Kingdom (UK).		
Publication (reference): None		
Studied Period: The duration of the study was approximately 3 month Date first subject enrolled: 21 Feb 2012 Date last subject completed: 24 May 2012		Phase of Development: II
Objectives: The objectives of this study were to pilot the use of a novel pH catheter for the measurement of simultaneous oesophageal and intragastric pH to compare the onset and duration of antacid action of Gaviscon Double Action Aniseed Liquid versus a matched placebo liquid. This study was designed to develop appropriate endpoints for future studies.		
<p>Methodology: Subjects attended the clinic on a total of 4 separate occasions: a screening visit, 2 dosing visits (each including an overnight stay) and a post-study visit.</p> <p>After written informed consent had been given by the subject, the following screening assessments took place to confirm subject eligibility: demographic data, vital signs, medical history, medication and therapy history, physical examination, pregnancy test and laboratory investigations.</p> <p>Eligible subjects were assigned a randomisation number when they attended the clinical pharmacology unit (CPU) on Day 1 of each treatment period. Day 1 of Treatment Period 1 took place within 21 days of the screening visit.</p> <p>On Day 1 of Treatment Period 1, subjects reported to the CPU in the afternoon/evening, where eligibility was confirmed. Subjects were requested to fast from approximately 22:00 until they were provided with a drink and meal the next day (approximately 4 hours post-dose).</p> <p>On the morning of Day 2, fasted subjects had the pH catheter inserted under endoscopic guidance. It was positioned in relation to the lower oesophageal sphincter and a fluoroscopic study was performed to confirm the position of the catheter for comparison later in the day. In this study, the fluoroscopic technique was used in place of a traditional x-ray to reduce the level of ionizing radiation exposure to subjects. A minimum of 90 minutes after catheter insertion, baseline pH monitoring commenced for 30 minutes to enable the pH readings to stabilise.</p> <p>Subjects were then dosed with either Gaviscon Double Action Aniseed Liquid or placebo and pH was monitored for 4 hours. Following the 4-hour pH monitoring period, the subject was escorted back to</p>		

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		
<p>the hospital for a repeat fluoroscopic study. The pH catheter was removed upon return to the CPU. The subject was provided with a meal and vital signs assessed by the Investigator before being discharged.</p> <p>Throughout the study, at various time-points, subjects were asked whether they had experienced any symptoms or complaints. Any spontaneously reported or observed adverse events (AEs) were recorded. Any concomitant medication taken by the subject during the study was recorded.</p> <p>The clinical and sample collection procedures for Treatment Period 2 were identical to those described for Treatment Period 1, except that each subject received the alternative study treatment according to the randomisation schedule. There was a washout period of at least 5 days between treatment visits.</p>		
Number of Subjects: Planned: Twelve subjects were considered to be sufficient to meet the objectives of the study. Analysed: Twelve subjects were enrolled, and all subjects completed the study.		
Diagnosis and Main Criteria for Inclusion: Healthy male and female subjects, aged ≥ 18 to ≤ 50 years, with the absence of relevant abnormalities and who gave written informed consent, were included in the study. Main criteria for exclusion included: <ul style="list-style-type: none"> • A history of gastro-oesophageal reflux or active gastrointestinal disease (gastroduodenal ulcer, gastrointestinal haemorrhage, mechanical obstruction or perforation) within the last year. • Clinically significant allergic, pulmonary, neurological, renal, hepatic, cardiovascular, psychiatric, metabolic, endocrine or haematological disease. • A history of basal skull fracture or trans-sphenoidal surgery. • Hospitalisation within the previous 3 months for major surgery or medical illness. • A clinically significant illness within the previous 4 weeks. • Use of any prescription medication or non-prescription medication within the last 7 days, prior to the screening visit, which the Principal Investigator considered might interfere with the study. • Use of antacids, H₂ antagonists, motility stimulants or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to enrolment in the study and during the study. • Use of proton pump inhibitors 4 weeks prior to enrolment into the study and during the study. • A drug hypersensitivity, which in the opinion of the Principal Investigator might interfere with the study. • Evidence of columnar lined oesophagus or any other significant abnormality to the 		

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		
gastro-intestinal tract (as determined during the endoscopy procedure to place the catheter). <ul style="list-style-type: none"> Unable to tolerate insertion of the catheter or endoscope. Pregnant or lactating women. 		
Test Product: Gaviscon Double Action Aniseed Liquid (300 ml bottles; batch number: 109071) was manufactured to Good Manufacturing Practice (GMP) standards by Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK.		
Duration of Treatment: Approximately 3 months (from screening to post-study follow-up visit)		
Reference Therapy: The placebo Liquid (150 ml bottles; batch number: PMBN11071) was manufactured to GMP standards by Pharmaterials Ltd, Unit B, 5 Bolton Road, Reading, RG2 0NH for Reckitt Benckiser Healthcare (UK) Ltd.		
Criteria for Evaluation: Efficacy: The primary endpoint was the assessment of electrode 6 at 1-minute intervals post-dose. The primary analyses were the comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at electrode 6 at each 1-minute interval up to 4 hours post-dose during the fasted state. The secondary endpoints were: <ul style="list-style-type: none"> Comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at all other electrodes at each 1-minute interval up to 4 hours post-dose during the fasted state. If the 4-second intervals at which the pH was captured did not match with the end of a 1-minute interval since dosing, linear interpolation was used between values either side of the smoothed pH curve. Time to reach pH 3 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo. Time to reach pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo. Duration of time at which \geq pH 3 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo. Duration of time at which \geq pH 4 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo. Change in pH on the smoothed curve at electrode 1 over time for Gaviscon Double Action Aniseed Liquid versus placebo. 		

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		
<ul style="list-style-type: none"> Change in pH on the smoothed curve at electrode 2 over time for Gaviscon Double Action Aniseed Liquid versus placebo. 		
<p>Safety: Safety was assessed in terms of the proportion of subjects with AEs. Tolerability was evaluated using data obtained from vital signs and laboratory tests.</p>		
<p>Statistical Methods: The pH values from the smoothed pH curve at electrode 6 at each identified interval post-dose during the fasted state was analysed using an analysis of variance (ANOVA) model that included fixed effects for treatment sequence, treatment and period. The mean pH from the smoothed curve over the 10 minutes pre-dose was included as a covariate. Subject was included as a random effect nested within treatment sequence. Area under the curve for each electrode at varying time-points was analysed with an ANOVA model with fixed effect terms for treatment sequence, treatment and period, and subject(treatment sequence) as a random effect. Time to reach pH 3 and pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo was analysed using the Kaplan-Meier method.</p> <p>As an alternative endpoint to those planned in the statistical analysis plan, the percentage of time that the pH level was \geq pH 3 and pH 4 were considered separately for each subject over the first hour post-dose. This analysis was conducted post-hoc after the analyses described above had been completed. For these additional endpoints, no smoothing procedure was applied.</p> <p>The percentage of time (averaged across electrodes 6 to 10) that the (unsmoothed) pH level was \geq pH 3 and pH 4 was calculated during each 10 and 30-minute interval from dosing to 1 hour post-dose for each electrode. Comparisons were made between treatments using an analysis of covariance (ANCOVA) model with the same endpoint from the same interval pre-dose included as a covariate, treatment, period and sequence as fixed effects, and subject nested within sequence as a random effect.</p> <p>The change in the percentage of time that the pH level was \geq pH 3 or pH 4 during a particular interval from the same interval at baseline was derived for each treatment. To compare treatments, the period differences in the changes obtained (Period 2 change – Period 1 change) were compared between sequence groups using a Wilcoxon Rank Sum test.</p> <p>All AEs recorded during the study were coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities. Treatment emergent AEs (TEAEs) are summarised and tabulated by treatment, indicating severity and causal relationship to study treatment. Any serious adverse events (SAEs), AEs with outcome of death and AEs resulting in discontinuation of treatment are listed separately.</p> <p>The overall incidence of TEAEs (number and percentage of subjects) as well as the number of events are summarised by study treatment and overall for the following: categories of degree of severity, SAEs, causally related TEAEs and SAEs, TEAEs leading to discontinuation of treatment, life-threatening SAEs and SAEs resulting in death.</p>		

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		

SUMMARY & CONCLUSIONS

EFFICACY RESULTS:

Primary Efficacy Analysis

The primary endpoint was the comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at electrode 6 at each 1-minute interval up to 4 hours post-dose during the fasted state. A statistically significantly higher mean smoothed pH value at electrode 6 was noted after administration of Gaviscon Double Action Aniseed Liquid as compared to placebo between the 3-minute and 20-minute time points. Differences in pH between the 2 treatments peaked at the 7-minute time-point, at 3.9. This finding is consistent with the expected effect of Gaviscon Double Action Aniseed Liquid, neutralising acidic fluids.

Time-point (Minute)	N	LS Mean Treatment A (Placebo)	LS Mean Treatment B (Gaviscon Double Action)	LS Mean Difference	90% CI	P-value
3	12	3.310	5.612	2.3027	(0.0318, 4.5737)	0.096
4	12	2.790	5.775	2.9858	(1.1563, 4.8153)	0.014
5	12	2.996	5.646	2.6495	(0.8574, 4.4416)	0.023
6	12	2.682	6.055	3.3734	(1.9447, 4.8021)	0.002
7	12	2.760	6.615	3.8555	(2.4212, 5.2898)	<0.001
8	12	2.708	6.213	3.5054	(1.8966, 5.1141)	0.003
9	12	2.718	5.711	2.9930	(1.4101, 4.5760)	0.006
10	12	2.634	5.913	3.2792	(1.9389, 4.6194)	0.001
11	12	2.805	5.464	2.6594	(1.5469, 3.7720)	0.001
12	12	2.782	5.299	2.5172	(0.8079, 4.2266)	0.024
13	12	2.600	5.405	2.8054	(1.5202, 4.0906)	0.003
14	12	2.573	5.005	2.4316	(0.9896, 3.8736)	0.012
15	12	2.586	4.808	2.2219	(0.6088, 3.8350)	0.032
16	12	2.645	5.132	2.4871	(0.8686, 4.1056)	0.019
17	12	2.623	4.716	2.0925	(0.4966, 3.6883)	0.039
18	12	2.577	4.555	1.9776	(0.4073, 3.5480)	0.046
19	12	2.598	4.535	1.9370	(0.3366, 3.5374)	0.053
20	12	2.559	4.128	1.5688	(0.0004, 3.1373)	0.100

Beyond 20 minutes, statistically significant differences between treatment groups were shown at several time-points, at which pH was higher after administration of placebo. These differences were not as consistent as the increase seen between the 3-minute and 20 minute time-points. The

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		

difference in pH between the 2 treatments, beyond 20 minutes was generally also smaller (< 1) than the differences seen between the 3-minute and 20 minute time-points and given the number of tests, it is possible that these values were observed by chance.

Secondary Efficacy Analysis

Comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at all other electrodes at each 1-minute interval up to 4 hours post-dose during the fasted state

For electrodes 1 to 4, statistically significant differences in pH were seen between the 1 minute and 9-minute time-points and at consistent time points within the first 15 minutes, following administration of Gaviscon Double Action Aniseed Liquid as compared to placebo. For electrodes 5 to 11, statistically significant differences in pH were seen between the 2 minute (range: 2 to 4 minutes) and 15-minute time-points and at consistent time-points within the first 30 minutes. The effect was greatest in electrode 8, in which a consistent, statistically significant difference in pH was observed between 2 minutes and 26 minutes.

At later time-points, statistically significant differences were seen across all electrodes, with the pH being lower following administration of Gaviscon Double Action Aniseed Liquid compared to placebo, though these results were less consistent and represented smaller differences in pH and were likely to be due to chance.

It is likely that in many subjects, electrode 11 lay within the duodenum, as suggested by higher pH values recorded throughout the 4-hour period. Consequently, few time-points with statistically significant differences in pH between the two treatments were observed.

Time to reach pH 3 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo

The median time (minutes) to reach pH 3 was comparable or shorter for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except at electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median time (minutes) to reach pH 3 between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 10 (2.2 minutes vs 12.6 minutes), electrode 9 (2.4 minutes vs 9.0 minutes) and electrode 6 (1.7 minutes vs 6.1 minutes). The median time (minutes) to reach pH 3 at electrode 11 was shorter for placebo compared with Gaviscon Double Action Aniseed Liquid (0.1 minutes vs 2.1 minutes).

A statistically significant difference in the median time (minutes) to reach pH 3 was observed at electrode 9 (p=0.0439) and at electrode 6 (p=0.0858) in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Time to reach pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo

The median time (minutes) to reach pH 4 was notably shorter for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median time (minutes) to reach pH 4 between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 8 (1.8 minutes vs 96.9 minutes), electrode 9 (2.9 minutes vs 45.2 minutes), electrode 10 (2.4 minutes vs 36.4 minutes), electrode 6

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid	Volume:	
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate	Page:	

(2.0 minutes vs 32.3 minutes) and electrode 7 (1.6 minutes vs 30.0 minutes). The median time (minutes) to reach pH 4 at electrode 11 was shorter for placebo compared with Gaviscon Double Action Aniseed Liquid (0.1 minutes vs 2.2 minutes).

A statistically significant difference in the median time (minutes) to reach pH 4 was observed at electrode 8 (p=0.0058), electrode 7 (p=0.0094), electrode 6 (p=0.0109), electrode 9 (p=0.0143), electrode 10 (p=0.0446) and at electrode 5 (p=0.0617) in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Duration of time at which \geq pH 3 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo

The median duration of time (minutes) at which \geq pH 3 was maintained was considerably longer for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median duration of time (minutes) at which \geq pH 3 was maintained between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 3 (82.8 minutes vs 47.7 minutes), electrode 9 (37.9 minutes vs 14.4 minutes), electrode 4 (39.3 minutes vs 20.7 minutes), and electrode 5 (28.2 minutes vs 13.0 minutes). The median duration of time (minutes) at which \geq pH 3 was maintained at electrode 11 was longer for placebo compared with Gaviscon Double Action Aniseed Liquid (101.4 minutes vs 67.7 minutes).

No statistically significant difference in the duration at which \geq pH 3 was maintained on the smoothed curve was observed at any electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Duration of time at which \geq pH 4 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo

The median duration of time (minutes) at which \geq pH 4 was maintained was considerably longer for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median duration of time (minutes) at which \geq pH 4 was maintained between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 3 (68.8 minutes vs 36.5 minutes), electrode 9 (34.1 minutes vs 9.9 minutes), electrode 7 (24.5 minutes vs 3.3 minutes), and electrode 8 (26.5 minutes vs 9.8 minutes). The median duration of time (minutes) at which \geq pH 4 was maintained at electrode 11 was slightly longer for placebo compared with Gaviscon Double Action Aniseed Liquid (60.2 minutes vs 57.7 minutes).

A statistically significant difference in duration at which \geq pH 4 was maintained at electrode 5 (p=0.027), electrode 4 (p=0.035) and electrode 3 (p=0.080) was observed for Gaviscon Double Action Aniseed Liquid when compared with placebo.

Change in pH on the smoothed curve at electrode 1 over time for Gaviscon Double Action Aniseed Liquid versus placebo

Statistically significant differences in the change over time in pH values at electrode 1 were observed for the first 10 minutes and then intermittently up to 30 minutes post-dose. Between 30 minutes and 240 minutes post-dose, a statistically significant difference in the change over time in pH values at electrode 1 were noted at 39, 60, 82, 136, 155, 160, 161, 167, 183, 185, 203, 204 and 221 minutes

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid	Volume:	
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate	Page:	

post-dose, with no obvious trend and the number of significant values is as expected by chance.

Change in pH on the smoothed curve at electrode 2 over time for Gaviscon Double Action Aniseed Liquid versus placebo

Statistically significant differences in the change over time in pH values at electrode 2 were observed for the first 9 minutes and then intermittently up to 17 minutes post-dose. Between 30 minutes and 240 minutes post-dose, statistically significant differences in the change over time in pH values at electrode 2 were noted at 30, 31, 53, 60, 81, 86, 153 and 156 minutes post-dose, with no obvious trend and the number of significant values is as expected by chance.

Percentage of time that the pH level was \geq pH 3 and pH 4

There was statistically significant evidence of a greater percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing for Gaviscon Double Action Aniseed Liquid compared to placebo ($p < 0.1$).

Change from baseline in the percentage of time that the pH level was \geq pH 3 and pH 4

There was statistically significant evidence of a greater change from baseline in the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing for Gaviscon Double Action Aniseed Liquid compared to placebo ($p < 0.1$).

SAFETY RESULTS:

No deaths, SAEs or other significant AEs occurred during the study and no subjects were withdrawn due to a TEAE.

Overall, 4 TEAEs were reported in 3 (25.0%) subjects following administration of Gaviscon Double Action Aniseed Liquid; no subjects reported TEAEs following administration of placebo. All of the TEAEs were mild in severity and none were considered related to the study treatment.

CONCLUSION:

Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the percentage of time that the pH level was \geq pH 3 and pH 4 (average across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during **the first hour** of dosing compared to placebo.

The 11 electrode pH catheter was clearly effective at monitoring pH change in the stomach following administration of Gaviscon Double Action Aniseed Liquid. As the data from electrodes 6 to 10 were consistent throughout the recording period the results were combined for analysis. This data set provides a good understanding of pH change throughout the stomach.

Electrodes 1 to 2 were positioned in the oesophagus and although data in this location are not relevant when assessing gastric pH, the results from these electrodes provided useful information on the location of the catheter.

Name of Sponsor/ Company: Reckitt Benckiser Healthcare UK Ltd	Individual Trial Table Referring to Part of the Dossier Volume: Page:	(For National Authority use only)
Name of Finished Product: Gaviscon Double Action Aniseed Liquid		
Name of Active Ingredients: Sodium alginate, sodium bicarbonate and calcium carbonate		
Date of the report: 14 Feb 2013		

4 TABLE OF CONTENTS

1	STUDY REPORT TITLE PAGE	1
2	REPORT APPROVAL	2
3	SYNOPSIS	3
4	TABLE OF CONTENTS.....	12
4.1	List of Tables and Figures Contained in the Body of the Report	21
4.2	List of Abbreviations	23
5	ETHICS	24
5.1	Independent Ethics Committee (IEC)	24
5.2	Ethical Conduct of the Study	24
5.3	Subject Information and Consent.....	24
6	INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE.....	25
7	INTRODUCTION.....	25
8	STUDY OBJECTIVES	26
9	INVESTIGATIONAL PLAN	26
9.1	Overall Study Design and Plan – Description	26
9.2	Discussion of Study Design, Including the Choice of Control Groups	28
9.3	Selection of Study Population.....	31
9.3.1	Inclusion Criteria.....	31
9.3.2	Exclusion Criteria.....	31
9.3.3	Removal of Subjects from Therapy or Assessment.....	32
9.4	Treatments	33
9.4.1	Treatments Administered.....	33
9.4.2	Identity of Investigational Medicinal Product(s)	33

9.4.3	Method of Assigning Subjects to Treatment Groups	34
9.4.4	Selection of Doses in the Study	34
9.4.5	Selection and Timing of Dose for Each Subject	34
9.4.6	Blinding.....	35
9.4.7	Prior and Concomitant Therapy	35
9.4.8	Treatment Compliance	36
9.5	Study Variables and Methods of Assessment.....	36
9.5.1	Measurements Assessed and Schedule	36
9.5.2	Baseline Assessments.....	37
9.5.2.1	Overview of Baseline Assessments.....	37
9.5.2.2	Methods of Baseline Assessment	38
9.5.3	Efficacy Variables	39
9.5.3.1	Overview of Efficacy Variables	39
9.5.3.2	Methods of Efficacy Assessment.....	39
9.5.3.2.1	Catheter Insertion	39
9.5.4	Safety Variables	40
9.5.4.1	Overview of Safety Variables	40
9.5.4.2	Methods of Safety Assessment.....	41
9.5.5	Adverse Events	41
9.5.6	Clinical Laboratory Investigations	42
9.5.7	Vital signs	44
9.5.8	Physical Examinations.....	44
9.5.9	Appropriateness of Measurements	44
9.5.10	Primary Efficacy Variable(s).....	44
9.5.11	Drug Concentration Measurements	45
9.6	Data Quality Assurance.....	45
9.7	Statistical Methods Planned in the Protocol and Determination of Sample Size	46
9.7.1	Statistical and Analytical Plans	46

9.7.1.1	General	47
9.7.1.2	Study Populations	47
9.7.1.3	Baseline, Screening and Compliance with Study Procedures	47
9.7.1.4	Analysis of Efficacy Data.....	48
9.7.1.4.1	Smoothed pH Curve	48
9.7.1.4.2	Area Under the Smoothed pH Curve	49
9.7.1.5	Statistical Analysis of Efficacy Endpoints	49
9.7.1.5.1	Primary Efficacy Analysis.....	49
9.7.1.5.2	Secondary Efficacy Analysis	49
9.7.1.5.3	Additional Efficacy Analysis	50
9.7.1.6	Analysis of Safety Data	51
9.7.1.6.1	Adverse Events	51
9.7.1.6.2	Clinical Laboratory Assessments	53
9.7.1.6.3	Vital Signs.....	53
9.7.1.6.4	Physical Examination.....	54
9.7.1.6.5	Concomitant Medication	54
9.7.2	Determination of Sample Size	54
9.8	Changes in the Conduct of the Study or Planned Analysis	54
9.8.1	Changes in the Conduct of the Study	54
9.8.2	Changes in the Planned Statistical Analysis of the Study	55
10	STUDY SUBJECTS.....	55
10.1	Disposition of Subjects	56
10.2	Protocol Deviations.....	57
11	EFFICACY EVALUATION	58
11.1	Data Sets Analysed.....	59
11.2	Demographic and Other Baseline Assessments.....	59
11.2.1	Demographics	59
11.2.2	Medical History	60

11.2.3	Pre-study Medication	60
11.2.4	Concomitant Medication	60
11.3	Measurements of Treatment Compliance	60
11.4	Efficacy Results and Tabulations of Individual Subject Data.....	61
11.4.1	Analysis of Efficacy.....	61
11.4.1.1	Primary Efficacy Analysis - pH Value at Electrode 6 at 1 minute Intervals Post-dose	61
11.4.1.2	Secondary Efficacy Analyses	67
11.4.1.2.1	Comparison of the pH Values for Gaviscon Double Action Aniseed Liquid versus Placebo from the Smoothed pH Curve at All Other Electrodes at each 1 minute Interval up to 4 hours Post-dose During the Fasted State	67
11.4.1.2.2	Time to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo	68
11.4.1.2.3	Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo	71
11.4.1.2.4	Duration of Time at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo	73
11.4.1.2.5	Duration of Time at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo	76
11.4.1.2.6	Change in pH on the Smoothed Curve at Electrode 1 over Time for Gaviscon Double Action Aniseed Liquid versus Placebo	79
11.4.1.2.7	Change in pH on the Smoothed Curve at Electrode 2 over Time for Gaviscon Double Action Aniseed Liquid versus Placebo	79
11.4.1.2.8	The percentage of time that the pH level was \geq pH 3 and pH 4 over 10- and 30-minute intervals during the first hour post-dose (Electrode 6 to 10 combined).....	80
11.4.2	Statistical/Analytical Issues.....	84
11.4.2.1	Adjustments for Covariates	84
11.4.2.2	Handling of Withdrawals or Missing Data	84

11.4.2.3	Interim Analyses and Data Monitoring.....	85
11.4.2.4	Multi-site Studies.....	85
11.4.2.5	Multiple Comparison/Multiplicity	85
11.4.2.6	Use of an “Efficacy Subset” of Subjects	85
11.4.2.7	Active-Control Studies Intended to Show Equivalence	85
11.4.2.8	Examination of Subgroups	85
11.4.3	Tabulation of Individual Response Data.....	85
11.4.4	Drug Dose, Drug Concentration and Relationships to Response	85
11.4.4.1	Drug Dose and Relationships to Response	85
11.4.4.2	Drug Concentration, Pharmacokinetics, and Relationships to Response.....	85
11.4.5	Drug-Drug and Drug-Disease Interactions	86
11.4.6	By-subject Displays	86
11.4.7	Efficacy Conclusions.....	86
12	SAFETY EVALUATION	87
12.1	Extent of Exposure	88
12.2	Adverse Events	88
12.2.1	Brief Summary of Adverse Events	88
12.2.2	Display of Adverse Events	89
12.2.3	Analysis of Adverse Events	89
12.2.3.1	Analysis of Treatment-emergent Adverse Events.....	89
12.2.3.2	Analysis of Treatment-emergent Adverse Events by Intensity	90
12.2.3.3	Analysis of Treatment-emergent Adverse Events by Relationship.....	90
12.3	Deaths, Other Serious Adverse Events and Other Significant Adverse Events	91
12.4	Clinical Laboratory Evaluation	91
12.4.1	Listing of Individual Laboratory Measurements by Subject and Each Clinically Significant Abnormal Laboratory Value	91
12.4.2	Evaluation of Each Laboratory Parameter	91

12.4.2.1	Individual Subject Changes	91
12.4.2.2	Individual Clinically Significant Abnormalities	92
12.5	Vital Signs, Physical Findings and Other Observations Related to Safety	92
12.5.1	Vital Signs	92
12.5.2	Physical Examination.....	93
12.5.3	Pregnancy	93
12.6	Safety Conclusions.....	93
13	DISCUSSION AND OVERALL CONCLUSIONS.....	93
13.1	Discussion	93
13.2	Conclusion	94
14	TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT	95
14.1	Demographic Data.....	95
14.1.1	Summary of Subject Disposition (All Subjects)	96
14.1.2	Summary of Analysis Populations (All Subjects).....	97
14.1.3	Summary of Demographic Data and Baseline Characteristics (Safety Population)	98
14.1.4	Summary of Pre-study Medication (Safety Population)	100
14.1.5	Summary of Concomitant Medication (Safety Population)	101
14.2	Efficacy Data	102
14.2.1.1	Summary of pH Smoothed Values by Treatment and Electrode (PP Population).....	103
14.2.1.2	Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode (PP Population)	279
14.2.1.3	Summary of pH Original Values by Treatment and Electrode (PP Population).....	455
14.2.1.4	Summary of pH Smoothed Parameters by Treatment and Electrode (PP Population).....	631
14.2.1.5	Mean Smoothed pH Values over Time by Electrode and Treatment (PP Population).....	636

14.2.1.6	Median Smoothed pH Values over Time by Electrode and Treatment (PP Population).....	647
14.2.1.7	Mean Change from Baseline in Smoothed pH Values over Time by Electrode and Treatment (PP Population)	658
14.2.1.8	Median Change from Baseline in Smoothed pH Values over Time by Electrode and Treatment (PP Population)	669
14.2.1.9	Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time-point (PP Population).....	680
14.2.1.10	Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time-point (PP Population).....	766
14.2.1.11	Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time-point (PP Population).....	774
14.2.1.12	Statistical Assessment of pH Smoothed Parameters Between Treatments (PP Population)	782
14.2.1.13	Statistical Assessment of Time to Reach pH 3 and pH 4 on the Smoothed Curve in the Stomach (PP Population)	783
14.2.1.14	Kaplan-Meier Plot of Time to Reach pH 3 by Electrode (3 to 11) and Treatment (PP Population).....	784
14.2.1.15	Kaplan-Meier Plot of Time to Reach pH 4 by Electrode (3 to 11) and Treatment (PP Population).....	793
14.2.1.16	Mean pH values over each 4 second interval	802
14.2.1.17	Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 10-minute Intervals	830
14.2.1.18	Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 30-minute Intervals	832
14.2.1.19	Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 10-minute Intervals	833
14.2.1.20	Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 30-minute Intervals	835
14.2.1.21	Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 10-minute Intervals.....	836
14.2.1.22	Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 30-minute Intervals.....	838
14.2.1.23	Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 10-minute Intervals.....	839

14.2.1.24	Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 30-minute Intervals.....	841
14.2.1.25	Mean % Time the pH \geq 3 over 10-minute Intervals (electrodes 6 to 10 Averaged)	842
14.2.1.26	Mean Change from Baseline in % time pH \geq 3 over 10-minute Intervals (Electrodes 6 to 10 Averaged)	843
14.2.1.27	Mean % Time the pH \geq 3 over 30-minute Intervals (Electrodes 6 to 10 Averaged)	844
14.2.1.28	Mean Change from Baseline in % Time pH \geq 3 over 30-minute Intervals (Electrodes 6 to 10 Averaged)	845
14.2.1.29	Mean % Time the pH \geq 4 over 10-minute Intervals (Electrodes 6 to 10 Averaged)	846
14.2.1.30	Mean Change from Baseline in % Time pH \geq 4 over 10-minute Intervals (Electrodes 6 to 10 Averaged)	847
14.2.1.31	Mean % Time the pH \geq 4 over 30-minute Intervals (Electrodes 6 to 10 Averaged)	848
14.2.1.32	Mean Change from Baseline in % Time pH \geq 4 over 30-minute Intervals (Electrodes 6 to 10 Averaged)	849
14.3	Safety Data	850
14.3.1	Displays of Adverse Events	851
14.3.1.1	Overall Summary of Treatment-emergent Adverse Events (Safety Population).....	851
14.3.1.2	Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Treatment (Safety Population)	852
14.3.1.3	Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term, Severity Grade and Treatment (Safety Population).....	853
14.3.1.4	Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term, Relationship to Study Drug and Treatment (Safety Population).....	854
14.3.2	Listings of Deaths, Other Serious and Significant Adverse Events.....	855
14.3.2.1	Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events (Safety Population).....	855
14.3.3	Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events	856
14.3.4	Abnormal Laboratory Value Listing	857

14.3.5	Additional Safety Data Summaries	857
14.3.5.1	Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time-point (Safety Population)	858
14.3.5.2	Shift Table of Haematology and Biochemistry Clinical Laboratory Parameters (Safety Population)	865
14.3.5.3	Summary of Vital Signs by Time-point (Safety Population).....	867
15	REFERENCE LIST	871
16	APPENDICES	871
16.1	Study Information	872
16.1.1	Protocol and Protocol Amendments.....	873
16.1.2	Sample Case Report Form (Unique Pages Only)	874
16.1.3	List of IECs or IRBs	875
16.1.4	List and Description of Investigators and Other Important Participants in the Study	876
16.1.5	Signature of Principal Investigator	878
16.1.6	Listing of Subjects Receiving Study Drug(s)/Investigational Product from Specific Batches, where more than One Batch was Used	880
16.1.7	Randomisation Scheme and Codes (Subject Identification and Treatment Assigned)	881
16.1.8	Audit Certificates	882
16.1.9	Documentation of Statistical Methods.....	883
16.1.10	Documentation of Inter-Laboratory Standardisation Methods and Quality Assurance Procedures if Used.....	884
16.1.11	Publications Based on the Study	885
16.1.12	Important Publications Referenced in the Report.....	886
16.2	Subject Data Listings.....	887
16.2.1	Withdrawn Subjects.....	888
16.2.2	Protocol Deviations.....	889
16.2.3	Subjects Excluded from the Efficacy Analysis.....	890
16.2.4	Demographic data	891

16.2.5	Compliance and/or Drug Concentration Data.....	892
16.2.6	Individual pH Data	893
16.2.7	Adverse Event Listings (each subject)	894
16.2.8	Listing of Individual Laboratory Measurements by Subject.....	895
16.2.9	Additional Measurements	896
16.2.10	General Comments.....	897
16.3	Case Report Forms	898

4.1 List of Tables and Figures Contained in the Body of the Report

Table 9-1 Schedule of Assessments	37
Table 9-2 Rating Systems used to Determine Adverse Event Intensity and Relationship to IMP	42
Table 10-1 Location of Tables, Figures, and Listings for Subject Disposition and Protocol Deviation Data	56
Table 11-1 Location of Tables, Figures, and Listings for Efficacy Data	58
Table 11-2 Study Populations	59
Table 11-3 Summary of pH Smoothed Values by Treatment for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)	62
Table 11-4 Statistical Assessment of pH Smoothed Values between Treatments for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)	65
Table 11-5 Time (Minutes) to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	69
Table 11-6 Statistical Assessment of Time to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	70
Table 11-7 Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	71

Table 11-8 Statistical Assessment of Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	73
Table 11-9 Duration of Time at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	74
Table 11-10 Statistical Assessment of Duration at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	76
Table 11-11 Duration of Time at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	77
Table 11-12 Statistical Assessment of Duration at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)	79
Table 12-1 Location of Tables, Figures, and Listings for Safety Data.....	87
Table 12-2 Extent of Exposure (Safety Population)	88
Table 12-3 Summary of Treatment-emergent Adverse Events (Safety Population)	89
Table 12-4 Treatment-emergent Adverse Events Reported by System Organ Class, Preferred Term and Treatment (Safety Population)	90
Figure 9-1 Probe Specification	30
Figure 10-1 Disposition of Subjects.....	57
Figure 11-1 Mean Smoothed pH Values over Time at Electrode 6 (PP Population)	66
Figure 11-2 Mean % time the pH \geq 3 and pH \geq 4 over 10- and 30-minute intervals (electrodes 6 to 10 averaged)	81
Figure 11-3 Mean pH values over each 4-second interval.....	83

4.2 List of Abbreviations

Abbreviation	Abbreviation in Full
AE	Adverse event
ANC	Acid neutralizing capacity
ANOVA	Analysis of variance
AUC	Area under the curve
BMI	Body mass index
CI	Confidence interval
CPU	Clinical pharmacology unit
CRF	Case Report Form
CV%	Coefficient of variation
EU	European Union
GAM	Generalised additive model
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
GMP	Good Manufacturing Practice
HIV	Human Immunodeficiency Virus
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IMP	Investigational Medicinal Product
IMSU	Investigational Material Supply Unit
LOS	Lower oesophageal sphincter
MedDRA	Medical Dictionary for Regulatory Activities
MHRA	Medicines and Healthcare products Regulatory Agency
PI	Principal Investigator
PP	Per protocol
PT	Preferred term
QA	Quality assurance
SAE	Serious adverse event
SAP	Statistical analysis plan
SCJ	Squamo-columnar junction
SD	Standard deviation
SDV	Source Data Verification
SOC	System organ class
SOP	Standard Operating Procedure
TEAE	Treatment-emergent adverse event
UK	United Kingdom (of Great Britain and Northern Ireland)

5 ETHICS

5.1 Independent Ethics Committee (IEC)

The name and full address of the IEC consulted is provided in Appendix 16.1.3.

The study protocol and all relevant amendments, together with subject information and consent documents were reviewed and approved on 24 Jan 2012 by National Research Ethics Service Committee North West - Greater Manchester Central.

The protocol was submitted for consideration by the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and written approval from the MHRA was obtained on 13 Jan 2012, before clinical activities of the study commenced.

NHS R&D approval was granted from the Central Manchester University Hospitals NHS Foundation Trust on 01 Mar 2012, before clinical activities commenced.

5.2 Ethical Conduct of the Study

This study was conducted in accordance with the Declaration of Helsinki (South Africa, 1996), as referenced in European Union (EU) Directive 2001/20/EC. It complied with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and applicable regulatory requirements.

5.3 Subject Information and Consent

Copies of a representative subject information sheet and a blank informed consent form are provided in Appendix 16.1.3.

Subjects who were considered by the Investigator to be suitable for entry into the study were given the opportunity to read the subject information sheet and informed consent form, and to ask questions. If they understood and agreed with the information and instructions provided, they were asked to sign the informed consent form. The Investigator also signed the form.

The subject was given a copy of the information sheet and the signed informed consent form. No protocol-related procedures were performed prior to the subject signing the informed consent form.

6 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

Appendix 16.1.4 contains a table listing the names and affiliations of the individuals whose participation materially affected the conduct of the study, together with their roles. The Curriculum Vitae of the Principal Investigator (PI) is also included in the appendix.

Dr Simon L Singer was the PI for this study.

The clinical pathology and bioanalytical laboratories of ICON Development Solutions were used for this study. Statistical analysis and reporting were undertaken by ICON Development Solutions.

ICON Development Solutions was responsible for all sponsor-related tasks.

7 INTRODUCTION

Reckitt Benckiser was interested to understand the antacid effect of Gaviscon Double Action Aniseed. The aim of this study was to assess the effect of the minimum dose of Gaviscon Double Action Aniseed Liquid on stomach pH. Data which demonstrates a change in gastric pH will be used to support hyperacidity/antacid claims for Gaviscon Double Action Aniseed Liquid in future and existing licence applications.

In this pilot study, a comparison was made between the antacid action of Gaviscon Double Action Aniseed Liquid versus a matched placebo. The study used a novel 11 electrode pH catheter to measure pH simultaneously in various positions through the oesophagus and stomach in fasted conditions. This pilot study also intended to assess the suitability of this novel probe for this purpose. Healthy volunteers were used in the study. The catheter was inserted nasogastrically with the aid of endoscopy. Intragastric and oesophageal pH were monitored in the fasted state prior to and following dosing.

The results of this study will also be used to provide a basis for sample size calculation for future studies. Each subject received Gaviscon Double Action Aniseed Liquid and its matching placebo in a randomised crossover design. The potential risks to subjects taking part in the present study were considered to be low. The adverse reactions that occur very rarely (< 1/10,000) as a result of taking Gaviscon[®] products are allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions as a result of a subject being sensitive to any of the active substances (sodium alginate, sodium bicarbonate/sodium hydrogen carbonate, and calcium carbonate) or any of the excipients (e.g. hydroxybenzoates [parabens]). Other adverse reactions include:

- 1) Sodium bicarbonate/sodium hydrogen carbonate – increased plasma sodium levels especially for those with renal and cardiovascular conditions on a highly restricted salt diet.
- 2) Calcium carbonate – high doses of calcium may cause alkalosis, hypercalcaemia, acid rebound, milk alkali syndrome or constipation.

The upper gastrointestinal endoscopy and electrode insertion/positioning could be associated with risks including bleeding, perforation of the oesophagus, stomach or duodenum and reactions to any drugs administered as part of the procedure, such as local anaesthetics. The use of endoscopy for placement of the pH catheter ensured its accurate placement was verified visually.

Subjects had fluoroscopic assessments performed over the course of the study, in order to confirm that the pH catheter had maintained a consistent position during procedures. Fluoroscopic assessments with as many radiation dose reducing features as feasible were performed. Full details of information relating to the level of radiation and associated risk to the subject are provided in the subject information and consent forms.

Healthy volunteers were not expected to derive any benefit from participation in the study, however through their participation in this study they helped Reckitt Benckiser to better understand the onset and duration of action of the product.

The study was conducted in accordance with the Declaration of Helsinki (South Africa, 1996), as referenced in EU Directive 2001/20/EC. It complied with ICH GCP and applicable regulatory requirements.

8 STUDY OBJECTIVES

The objectives of this study were to pilot the use of a novel pH catheter for the measurement of simultaneous oesophageal and intragastric pH to compare the onset and duration of antacid action of Gaviscon Double Action Aniseed Liquid versus a matched placebo liquid. This study was designed to develop appropriate endpoints for future studies.

9 INVESTIGATIONAL PLAN

9.1 Overall Study Design and Plan – Description

The study protocol and amendment are included as Appendix 16.1.1. The Case Report Form (CRF) is included as Appendix 16.1.2.

This was a single-centre, randomised, double-blind, 2-way crossover, placebo-controlled study, to investigate the use of the novel pH catheter and to compare the acid neutralisation capacity (ANC) and antacid action of Gaviscon Double Action Aniseed Liquid (10 ml) versus placebo. There was a minimum 5-day and a maximum 7-day washout period prior to the cross over treatment arm. Follow-up was performed 3 to 7 days after the second dosing day.

As this was a pilot study, no formal sample size calculation had been performed due to the experimental nature of the study. Twelve subjects were considered to be sufficient to meet the objectives of the study; therefore sufficient subjects were recruited and randomised to aim to have 12 subjects complete the study. Up to 2 subjects were assessed per day.

Subjects attended the clinic on a total of 4 separate occasions: a screening visit, 2 dosing visits (each included an overnight stay) and a post-study visit. There was a minimum 5-day and a maximum 7-day washout period prior to the cross over treatment arm.

The duration of each subject's participation in the study was approximately 4 weeks (from the screening visit to post-study follow-up visit). The screening visit was followed by 2 separate treatment visits.

On Day 1 of each treatment period, subjects reported to the clinical pharmacology unit (CPU) in the afternoon/evening, where eligibility was confirmed. The subjects were then required to stay in the CPU overnight and fast from approximately 22:00 on the evening of admission until they were provided with a drink and meal the next day (approximately 4 hours post-dose).

On the morning of Day 2 of each treatment period, fasted subjects had the pH catheter inserted under endoscopic guidance. It was positioned in relation to the lower oesophageal sphincter (LOS) and a fluoroscopic study was performed to confirm the position of the catheter for comparison later in the day. In this study, the fluoroscopic technique was used in place of a traditional x-ray to reduce the level of ionizing radiation exposure to subjects.

A minimum of 90 minutes after catheter insertion, baseline pH monitoring commenced for 30 minutes to enable the pH readings to stabilise. Subjects were then dosed with either Gaviscon Double Action Aniseed Liquid or placebo (as defined in the randomisation schedule) and pH was monitored for 4 hours.

Following the 4-hour pH monitoring period, the subject was escorted back to the hospital for a repeat fluoroscopic study. The pH catheter was removed upon return to the ICON CPU. The subject was provided with a meal and vital signs assessed by the Investigator before being discharged.

The schedule of assessments is provided in Section 9.5.1 (Table 9-1).

9.2 Discussion of Study Design, Including the Choice of Control Groups

Recent market research with consumers suffering symptoms of dyspepsia or reflux disease has shown that 68% of patients reported suffering from heartburn and indigestion¹. This research also highlighted that these patients would like one product which would effectively deal with all these symptoms¹.

Gaviscon Double Action Aniseed Liquid (Reckitt Benckiser Healthcare [UK] Ltd) is an oral liquid suspension containing both alginate and antacid components for the treatment of heartburn and indigestion². The product is available in both mint and aniseed flavours. For the purpose of this study, the aniseed variant was investigated. This product has an ANC in-vitro of approximately 10 mEq H⁺, and as such meets the requirements of the United States Antacid Monograph³. Data were required for the product to demonstrate antacid activity in-vivo.

Previous studies assessing ANC have used fasted patients^{4,5,6}. Published data have shown that the volume of acid in the fasted stomach is 26 ± 13 ml with a pH of 2.3 (1.3-7.1)⁷. Data assessing the ANC of Gaviscon Double Action Aniseed Liquid at pH 1 and pH 4 at 25 ml and 100 ml suggested Gaviscon Double Action Aniseed Liquid would demonstrate an antacid effect in a fasted human stomach⁸.


Additionally, recent research had demonstrated that patients with dyspepsia have 'short segment' reflux immediately above the squamo-columnar junction (SCJ), compared to the conventional oesophageal pH measuring point of 5 cm above the SCJ⁹.

This study used a novel catheter containing 11 pH electrodes (Figure 9-1). This catheter has a diameter of 2.1 mm and measured pH from 4 cm proximal to 22.5 cm distal to the LOS. Full details of the catheter are provided in the schematic in Appendix 1 of the study protocol (Appendix 16.1.1). This allowed this study to characterise the antacid activity of Gaviscon Double Action Aniseed Liquid compared to placebo in the fasted state.

The catheter was inserted nasally and taped to the face. After passing through the stomach it had approximately 25 cm fed into the duodenum to further aid anchoring. Anchoring was assisted by way of 2 x 2.5 g tungsten weights attached to the end of the catheter but it was not tethered to the mucosal lining of the gastrointestinal tract. The catheter which was used in this study had been specifically designed and made for this study. Each catheter was used for 2 periods only (i.e. by each person for both treatments). The catheter was cleaned between uses as per the study manual. Full details of the cleaning procedure were documented in the equipment instruction manual.

The study was conducted in normal healthy subjects.

Figure 9-1 Probe Specification



Abbreviations: LOS = lower oesophageal Sphincter

Total length of catheter: 175 cm, tubing diameter 2.1 mm, sensor diameter 2.5 mm, tungsten weights 2 x 2.5 g
Marker between electrodes 2 and 3 to aid placement. This marker was positioned at the upper border of the LOS.
Once in position, the catheter coming from the nose was taped to the nose.

9.3 Selection of Study Population

Subjects were recruited from the ICON Development Solutions' volunteer database.

9.3.1 Inclusion Criteria

To be eligible for inclusion into this study, each subject had to fulfil the following criteria:

- 1) Those who were willing to volunteer and gave written informed consent.
- 2) Age: ≥ 18 years, ≤ 50 years.
- 3) Sex: male or female subjects.
- 4) Status: healthy subjects.
- 5) Those whose cigarette consumption was < 6 per day and who were willing to abstain from smoking while at the CPU.

9.3.2 Exclusion Criteria

A subject was excluded from the study if they met any of the following criteria:

- 1) Those who had a history of gastro-oesophageal reflux or active gastrointestinal disease (gastroduodenal ulcer, gastrointestinal haemorrhage, mechanical obstruction or perforation) within the last year.
- 2) Those who showed clinically significant allergic, pulmonary, neurological, renal, hepatic, cardiovascular, psychiatric, metabolic, endocrine, or haematological disease.
- 3) Those who had a history of basal skull fracture or who have undergone trans-sphenoidal surgery.
- 4) Those who had been hospitalised within the previous 3 months for major surgery or medical illness.
- 5) Those who had a clinically significant illness within the previous 4 weeks.
- 6) Those who had taken any prescription medication or non-prescription medication within the last 7 days, prior to the screening visit, which the PI considered might interfere with the study.
- 7) Those who had taken antacids, H_2 antagonists, motility stimulants or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to enrolment in the study and during the study.
- 8) Those who had taken proton pump inhibitors 4 weeks prior to enrolment into the study and during the study.
- 9) Those who had a drug hypersensitivity, which in the opinion of the PI might have interfered with the study.
- 10) Those who had a current or recent (1 year) history of alcohol abuse or abuse of any legal or illegal drugs, substances, solvents.

- 11) Those who consumed abnormal quantities of coffee, tea or cola (e.g. more than 3 cups) according to the Investigator's judgement or consumed excessive amounts of alcohol regularly.
- 12) Those who had taken part in any clinical study within the previous 4 months, or had taken part in a total of 4 or more studies in the last 12 months.
- 13) Those who were unable to communicate well with the Investigator (i.e. language problem, poor mental development or impaired cerebral function) in the opinion of the Investigator.
- 14) Those who had evidence of columnar lined oesophagus or any other significant abnormality to the gastro-intestinal tract (as determined during the endoscopy procedure to place the catheter).
- 15) Those unable to tolerate insertion of the catheter or endoscope.
- 16) Woman of childbearing potential, who were pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch, an intrauterine device, abstinence [should the subject become sexually active, she agreed to use a double barrier method] or condoms/diaphragm and spermicide). A woman of childbearing potential was defined as any female who was less than 2 years post-menopausal or had not undergone a hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy).
- 17) Those previously randomised into this study.
- 18) Those unable in the opinion of the Investigator to comply fully with the study requirements.

9.3.3 Removal of Subjects from Therapy or Assessment

The Investigator could withdraw a subject from the study at any time. Reasons for removing a subject from the study included, but were not limited to:

- Adverse events (AEs) that in the judgement of the Investigator could cause severe or permanent harm (significant clinical deterioration was considered an AE).
- Violation of the study protocol.
- In the Investigator's judgement, it was in the subject's best interest.
- Subject declined further study participation.

The primary reason for withdrawal was to be documented as one of the following: AEs; lack of efficacy; lost to follow-up; no further need for study treatment (unless this was a study endpoint); protocol violation; death or other. The Investigator made reasonable attempts to contact subjects who were lost to follow-up; a minimum of 2 documented telephone calls or a letter was considered reasonable.

If a subject was withdrawn prematurely from the study, the following assessments were to be carried out:

- Vital signs (as for screening).
- Physical examination.
- Laboratory Investigations (as for screening with the exception that viral serology and urine drug screen were not necessary at follow-up).
- Review of concomitant medication and AEs.

9.4 Treatments

9.4.1 Treatments Administered

The following blinded medication was supplied:

Gaviscon Double Action Aniseed Liquid in 300 ml bottles (PL 00063/0543) (Treatment B).
Placebo Liquid in 150 ml bottles (Treatment A).

Supplies were provided to the ICON pharmacy as bulk. Samples were labelled and dispensed to study nurses to ensure that the blind was maintained. Study staff and the investigator were unaware of the identity of the products being dosed.

9.4.2 Identity of Investigational Medicinal Product(s)

Gaviscon Double Action Aniseed Liquid (300 ml; batch number: 109071) was manufactured to Good Manufacturing Practice (GMP) standards by Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK.

The placebo Liquid (150 ml; batch number: PMBN11071) was manufactured to GMP standards by Pharmaterials Ltd, Unit B, 5 Bolton Road, Reading, RG2 0NH for Reckitt Benckiser Healthcare (UK) Ltd.

All drug supplies were packed and labelled to GMP standards by the Investigational Material Supply Unit (IMSU), Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull HU8 7DS, UK. Both the Gaviscon Double Action Aniseed Liquid and the placebo were supplied as double blind. Investigational medicinal product (IMP) was shipped directly from the Reckitt Benckiser Healthcare (UK) Ltd IMSU to ICON.

9.4.3 Method of Assigning Subjects to Treatment Groups

A detailed description of the randomisation method, including how it was executed, is provided in Appendix 16.1.7.

A randomisation schedule was produced by the Reckitt Benckiser statistician and provided to IMSU. On entry, subjects were allocated a unique subject number in numerical sequence. Issue of the study treatment in this sequence ensured randomisation.

There were no subject withdrawals during the study.

Subjects were randomised to one of the following 2 sequences:

Treatment Sequence	Treatment	
	Period 1	Period 2
AB	A	B
BA	B	A

9.4.4 Selection of Doses in the Study

Subjects received one single oral dose of 10 ml suspension (Gaviscon Double Action Aniseed Liquid or placebo as defined in the randomisation schedule) on Day 2 of Treatment Period 1 and the alternative treatment on Day 2 of Treatment Period 2. Dosing took place under the supervision of ICON staff.

9.4.5 Selection and Timing of Dose for Each Subject

On the morning of Day 2, fasted subjects had the pH catheter inserted under endoscopic guidance. A minimum of 90 minutes after catheter insertion, baseline pH monitoring commenced for 30 minutes to enable the pH readings to stabilise. Subjects were then dosed with either Gaviscon Double Action Aniseed Liquid or placebo (as defined in the randomisation schedule) and pH was monitored for 4 hours. Subjects were required to fast from 22:00 on Day 1 until approximately 4 hours post-dose (Day 2).

9.4.6 Blinding

This study employed a double-blind study design.

The IMP was labelled in accordance with EudraLex - Volume 4 GMP guidelines, Annex 13 - Manufacture of IMP, parts 26 to 33 (labelling) and in accordance with EU directive 2003/94/EC as amended and including any other applicable national/state legislation.

The IMSU held the master code for the randomisation schedule and supplied the Investigator (via the ICON Pharmacy department) with the randomisation code for each subject as sealed envelopes. The code was only to be broken for an individual subject in an emergency such as a serious adverse event (SAE) that required knowledge of what study treatment was taken in order that the SAE could be treated appropriately.

The study monitor checked the randomisation codes on a regular basis at monitoring visits, to ensure the above procedures were being followed at the study site. All codes, whether sealed or opened, were returned to Reckitt Benckiser at the end of the study.

9.4.7 Prior and Concomitant Therapy

Concomitant therapies were defined as prescribed medications, physical therapy, and over-the-counter preparations, including herbal preparations licensed for medicinal use, other than study treatment and supplementary medication that the subject received during the course of the study.

The Investigator recorded any medications given for the treatment of AEs on the concomitant medication page in the subject's CRF. Any medication taken by the subject during the course of the study was also recorded on this form. Any changes in concomitant therapy during the study were documented, including cessation of therapy, initiation of therapy and dose changes.

The use of the following treatments was not permitted:

Subjects were asked to withhold any medication that affected gastric acid secretion prior to and during monitoring (see also Section 9.3.2).

- Antacids, H₂ antagonists, motility stimulants or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to enrolment in the study and during the study,
- Proton pump inhibitors 4 weeks prior to enrolment into the study and during the study.

If concomitant medication was taken the Investigator decided if the healthy volunteer should remain in the study or be withdrawn.

Subjects who used these therapies during the study were to be withdrawn from the study.

In addition, no drinking or eating, including caffeine-containing food and drinks were allowed other than what was provided by ICON during the clinical phase. No alcohol was allowed 48 hours prior to each visit and the treatment visits. In addition, smoking was not permitted during each visit, though nicotine replacement patches may have been used, provided their use was consistent over the treatment periods.

9.4.8 Treatment Compliance

Study treatment was taken by the subject under supervision of the PI or appropriately trained ICON staff who conducted a mouth inspection to ensure compliance with dosing. Any subjects who did not take the study treatment as required were to be withdrawn from the study.

9.5 Study Variables and Methods of Assessment

9.5.1 Measurements Assessed and Schedule

The schedule of assessments is presented in Table 9-1.

Table 9-1 Schedule of Assessments

Study Period	Screening (up to 21 days prior to admission to the clinical unit)	Admission to the CPU Treatment Period 1: Day 1	Treatment Period 1: Day 2	5-7 day Washout	Admission to the CPU: Treatment Period 2: Day 1	Treatment period 2: Day 2	Follow-up (3-7 days after completion of Treatment Period 2)
Informed consent	X						
Demography	X						
Medical history	X						
Concomitant medication	X	X	X	X	X	X	X
Vital signs	X	X			X		X
Physical examination	X						X
Alcohol and drug of abuse test	X	X			X		
Pregnancy test (women only)	X	X			X		
Laboratory Analysis	X						X
Eligibility decision/confirmation	X						
Insertion of pH catheter			X			X	
pH recordings			X			X	
Dosing			X			X	
Meal			X			X	
Removal of pH catheter			X			X	
Adverse events record		X	X	X	X	X	X

The efficacy and safety variables, and their methods of assessment, are described in Sections 9.5.3 and 9.5.4, respectively.

9.5.2 Baseline Assessments

9.5.2.1 Overview of Baseline Assessments

The following demographic assessments were performed:

- sex

- race (categorised as: Caucasian, Asian, Afro-Caribbean and Other)
- date of birth
- height (cm)
- weight (kg)
- body mass index (BMI) (kg/m^2)
- smoking/alcohol/drugs of abuse history/use

The following baseline assessments were performed:

- Vital Signs
 - blood pressure (after sitting for 5 minutes with both feet flat on the floor; mmHg)
 - heart rate (recorded using the blood pressure monitor)
 - oral temperature ($^{\circ}\text{C}$).
- Medical history and current status
 - primary diagnosis
 - duration of disease
 - medical history and current status
- Medication and therapy history
 - current medication usage
 - therapy taken in the previous 7 days were recorded
- Physical examination
 - a standard physical examination was conducted
- Pregnancy testing
 - women of childbearing potential underwent urine pregnancy testing

Safety related baseline assessments are described in Section 9.5.4.

9.5.2.2 Methods of Baseline Assessment

Standard methods at the study site(s) were used for evaluating subject baseline assessments.

9.5.3 Efficacy Variables

9.5.3.1 Overview of Efficacy Variables

Oesophageal and intragastric pH monitoring were performed using a high definition 11 electrode, CE marked pH catheter (custom made by Sandhill Scientific, Inc) and recorded using the Insight device from Sandhill.

After the subject returned to the ICON CPU, baseline readings were performed continuously over a period of 30 minutes. Fasted subjects were dosed with 10 ml of either Gaviscon Double Action Aniseed Liquid or placebo as defined in the randomisation schedule. Changes in oesophageal and intragastric pH were continuously measured over a 4-hour period using the pH catheter. Data were stored on a compact flash card and were downloaded onto the CPU computer.

Subjects were then escorted to Manchester Royal Infirmary Radiology Department, to have a repeat fluoroscopic study performed, to confirm that the catheter had not significantly moved during the study. The catheter was removed by simple traction by ICON staff after returning to the ICON CPU.

The Investigator compared the reports of the fluoroscopic studies performed before and after pH monitoring and noted any significant changes in the subjects CRF.

The efficacy endpoints assessed during the study are provided in Section 9.5.10.

9.5.3.2 Methods of Efficacy Assessment

9.5.3.2.1 Catheter Insertion

On Day 2 (of Treatment Period 1), following confirmation of negative test results for the alcohol, drugs of abuse and pregnancy tests, subjects were asked whether they had experienced any symptoms or complaints and were instructed to inform the Investigator during the treatment visit if they suffered any AEs.

Subjects were escorted the short walking distance to the endoscopy suite at Manchester Royal Infirmary by ICON nursing staff where the pH catheter was inserted nasogastrically and positioned by a consultant gastroenterologist under endoscopy guidance.

Xylocaine throat spray was used for the endoscopy procedure.

The LOS was located visually using endoscopy and the catheter positioned so that a marker (present on the catheter between electrodes 2 and 3) sat on top of the upper border of the LOS.

The top of the catheter was anchored by taping the catheter to the nose. To aid anchoring of the bottom end of the catheter, 25 cm of catheter extended beyond the pylorus into the duodenum. The weighted tip of the catheter further assisted with anchoring.

The distance from the end of the catheter to the nose was recorded for each subject by observing the cm marking on the catheter. This information was recorded by ICON clinical staff in the source data documentation to ensure that the second positioning of the catheter coincided with the first.

Following the procedure, the endoscope was removed and subjects were transferred to the Manchester Royal Infirmary Radiology Department (a wheelchair was available for transport but was not required during this study).

The subject then had a fluoroscopic study of the upper abdomen performed to demonstrate the position of the pH catheter. This involved the same procedure as a traditional dynamic x-ray but with the addition of a fluorescent screen between the subject and the instrument. Upon completion of the fluoroscopic study, subjects were returned to the ICON CPU (using a wheelchair) accompanied by ICON nursing staff for dosing and pH monitoring. Prior to any further study procedures subjects were randomised.

Prior to commencement of pH monitoring, at least 90 minutes would have elapsed since the endoscopic and catheter insertion procedure, within this period fluoroscopic assessments were scheduled. During collection of pH data, subjects were required to remain seated on the clinical ward attached to the recording device.

9.5.4 Safety Variables

9.5.4.1 Overview of Safety Variables

Safety was assessed on the basis of the following variables:

- AEs
- Clinical laboratory investigations
- Vital signs
- Physical examinations

9.5.4.2 Methods of Safety Assessment

Methods of safety assessment are discussed for AEs (Section 9.5.5), clinical laboratory investigations (Section 9.5.6), vital signs (Section 9.5.7) and physical examinations (Section 9.5.8).

9.5.5 Adverse Events

AE was defined as any untoward medical occurrence in a patient or clinical study subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Comment: an AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not considered related to the IMP.

All AEs that occurred after the subject had received study treatment were recorded in the subject's CRF. AEs were reported spontaneously by the subject or in response to questioning or observation by the Investigator or were a significant laboratory abnormality.

The PI or designee asked the subject: "Are you experiencing any symptoms or complaints?" at the baseline visit and "Have you had any symptoms or complaints since the last visit?" during the study.

AEs were recorded according to the criteria given in Table 9-2. Relationship to study treatment was determined by the Investigator.

Assessments of the relationship of AEs to study treatment were made by a physician.

Table 9-2 Rating Systems used to Determine Adverse Event Intensity and Relationship to IMP

Variable	Category	Definition
Intensity		Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied, but medical experience and judgement were also to be used in the assessment of intensity.
	Mild	The AE did not limit usual activities; the subject may have experienced slight discomfort.
	Moderate	The AE resulted in some limitation of usual activities; the subject may have experienced significant discomfort.
	Severe	The AE resulted in an inability to carry out usual activities; the subject may have experienced intolerable discomfort or pain.
Relationship to IMP	Unassessable/ Unclassified	Insufficient information to be able to make an assessment.
	Conditional/ Unclassified	Insufficient information to make an assessment at present (causality was conditional on additional information).
	Unrelated	No possibility that the AE was caused by the IMP.
	Unlikely	Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the IMP.
	Possible	Reasonable suspicion that the AE was caused by the IMP.
	Probable	Most likely that the AE was caused by the IMP.
	Certain	The AE was definitely caused by the IMP.

The procedures for reporting AEs and SAEs are described in Sections 13.1.3 to 13.1.5 of the protocol and procedures for subjects who experienced onset of AEs after completion of the study are detailed in Section 13.1.6 of the protocol (Appendix 16.1.1).

All SAEs, and those which caused premature withdrawal of the subject from the study, that had not resolved by the end of the study, were to be followed up by the Investigator until resolution or until the Investigator believed there was no further change. This could have involved the subject making additional visits to the CPU. All other AEs (including clinically significant laboratory abnormalities) were followed up wherever possible to resolution or until the Investigator believed there was no further change, whichever was the earlier.

9.5.6 Clinical Laboratory Investigations

Standard methods at the CPU were used for the clinical laboratory investigations.

Samples for haematology, biochemistry and urinalysis assessments were collected at screening and follow-up. Alcohol, drugs of abuse tests and pregnancy tests were performed at screening and on Day 1 of each treatment period.

The following haematology, biochemistry and urinalysis parameters were assessed:

Haematology

- Haemoglobin (g/L)
- Red blood cell count ($10^{12}/L$)
- White blood cells ($10^9/L$)
- Platelets ($10^9/L$)
- Differential white cell count ($10^9/L$), neutrophils, lymphocytes, monocytes, basophils and eosinophils

Biochemistry

- Blood urea nitrogen (mmol/L)
- Creatinine ($\mu\text{mol}/L$)
- Alanine transaminase (ALT) (IU/L or U/L)
- Aspartate transaminase (AST) (IU/L or U/L)

Urinalysis

- Blood (positive or negative)
- Protein (positive or negative)
- Urine pregnancy test for females of childbearing potential
- Drugs of abuse (positive or negative for: opiates, amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines, methadone)

Blood samples were collected and labelled in tubes provided by the ICON Clinical Pathology laboratory. Urine samples were collected and labelled in cups, provided by the CPU, at the screening as well as treatment visits. ICON's standard labelling was used.

The laboratory conducting the analysis in this study worked to good laboratory practice (GLP) and provided documented evidence of suitable accreditation for the laboratory to conduct testing. The Investigator reviewed the results and commented, on the laboratory results sheet, upon all abnormal values, identifying those that were clinically significantly abnormal. The Investigator signed and dated the laboratory results sheet, to indicate that the review had taken place.

9.5.7 Vital signs

Standard methods at the CPU were used for evaluating vital signs. Vital signs (systolic blood pressure, diastolic blood pressure, heart rate and oral temperature) were measured at screening, on admission to the CPU and follow-up.

9.5.8 Physical Examinations

Standard physical examination (general appearance, ears, nose and throat, neck and thyroid, eyes, heart, lungs, abdomen, extremities, dermatological and neurological) was performed at screening and follow-up.

9.5.9 Appropriateness of Measurements

Although assessment of pH is a standard method for the measurement of antacid effects, this study used a novel CE marked catheter containing 11 pH electrodes. The catheter had a diameter of 2.1 mm and measured pH from 4 cm proximal to 22.5 cm distal to the LOS. Full details of the catheter are provided in Appendix 1 of the study protocol (Appendix 16.1.1).

9.5.10 Primary Efficacy Variable(s)

Efficacy was assessed on the basis of the following variables:

Primary efficacy variable:

- The assessment of the pH value at electrode 6 at 1 minute intervals post-dose.

Secondary efficacy variables:

- Comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at each electrode at each 1 minute interval up to 4 hours post-dose during the fasted state.
- Time to reach pH 3 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

- Time to reach pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Duration of time at which \geq pH 3 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Duration of time at which \geq pH 4 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Change in pH on the smoothed curve at electrode 1 over time for Gaviscon Double Action Aniseed Liquid versus placebo.
- Change in pH on the smoothed curve at electrode 2 over time for Gaviscon Double Action Aniseed Liquid versus placebo.

9.5.11 Drug Concentration Measurements

Drug concentrations were not measured in this study.

9.6 Data Quality Assurance

The Investigator was responsible for the quality of the data recorded in the CRF. The data recorded were to be a complete and accurate account of the subject's record collected during the study. The Investigator and study monitor identified any data that were recorded directly on the CRF such that the CRF was considered the source document (i.e. no prior written or electronic record of the data). The study monitor documented this on the Initiation Visit Report.

The Investigator reviewed all entries for completeness and correctness. When changes or corrections were made on any CRF, the Investigator or authorised persons drew a single line through the error then initialled and dated the correction, as well as stating the reason for the error, except when due to a transcription error. The original entry was not to be obscured.

The Investigator completed and signed the CRFs in a timely fashion after completion of each subject and made them available to the study monitor for full inspection. In addition, any data queries prepared after the original CRF had been completed were answered promptly. Before acceptance, the study monitor reviewed the CRFs for completeness and adherence to the protocol.

On-site monitoring also included source document verification (SDV). SDV is the procedure whereby the data contained in the CRFs are compared with the primary source data (e.g. patient notes, original recordings from automated instruments, X-ray films, ECG tracings, and laboratory results) contained in the subject records held at the investigational site, and thereby verified as accurate.

Data management was performed by ICON Development Solutions in accordance with internal standard operating procedures (SOPs). The ICON Development Solutions data management system in SAS[®] (version 9.1.3) was used to database study data necessary for the preparation of the final clinical study report¹⁰. A study-specific database specification document was produced and the study database set-up, validated and approved ready for data entry by the director of data management. A validation plan was also produced that detailed what electronic checks were performed. Data were entered using double data entry, followed by electronic compare and validation. SAS programs were used to manipulate the data into the correct format for summarising and listing in Rich Text File (rtf) tables and listings.

ICON Development Solutions' activities were audited on both a study-specific and system basis. A risk assessment was conducted for this study to focus quality assurance (QA) activity appropriately. A study-specific QA audit program was developed for this study and involved the observation of study procedures and data collection, and the confirmation of accuracy of the final report to raw data. For all audits, comparison to national or international regulatory standards, SOPs and the study protocol was involved.

Audits were documented in a report, discussed with managers and actions closely followed up. Work not conducted at ICON Development Solutions that was subcontracted by ICON was not audited by the QA department, unless explicitly arranged in the contract.

The clinical study report was subject to a GCP compliance audit, conducted by ICON QA. The ICON Development Solutions QA audit certificate is provided in Appendix 16.1.8.

9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size

9.7.1 Statistical and Analytical Plans

Details of the statistical analyses are described in the final statistical analysis plan (SAP), which was finalised before the database was locked. A copy of the final SAP is available in Appendix 16.1.9. Changes in the planned analyses between the study protocol and the SAP are described in Section 9.8.2.

9.7.1.1 General

All statistical analyses were performed using SAS® (Version 9.1.3). Unless otherwise specified, descriptive data summaries of continuous outcomes included number of subjects with observations (n), mean, standard deviation (SD), median, minimum, maximum and coefficient of variation (CV%). CV% was not presented for change from baseline data. Categorical outcomes are summarised by number and percent of subjects.

All hypothesis tests were performed using the 10% significance level unless otherwise specified. As this was an exploratory study, no adjustments for multiple comparisons were made.

All clinical data collected in CRFs are listed including data not presented in tables. As appropriate, missing values were marked and explained in individual data tables.

Missing data were not imputed and all analyses were based on observed cases. No subgroup analysis was planned.

9.7.1.2 Study Populations

All Subjects Population: all subjects recruited to the study were included in the all subjects population for presentation of information on subject disposition, withdrawals and protocol deviations.

Safety Population: all subjects who were recruited to the study and received at least one dose of study treatment or were subjected to any invasive study procedure. This population was used for safety analyses and demographics.

Per protocol (PP) Population: all subjects who were recruited to the study and completed and had evaluable efficacy data for both treatment periods, had adequate treatment compliance and no major protocol deviations. Exclusions from this population were decided during a blind data review prior to database lock. This population was used for analysis of efficacy endpoints.

9.7.1.3 Baseline, Screening and Compliance with Study Procedures

The following demographic data are listed and summarised descriptively by treatment sequence and overall for the safety population, and tabulated:

- sex
- race (categorised as: Caucasian, Asian, Afro-Caribbean and Other)

- date of birth
- height (cm)
- weight (kg)
- body mass index (BMI) (kg/m^2)

Past and current medical history was coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 14.1 and listed and summarised descriptively for the safety population¹¹.

Summaries of analysis populations, subject disposition and the number of subjects on study at each visit are provided. These data summaries contain the following information: number of subjects randomised, number and percent of subjects who received each treatment, number and percent of subjects who completed the treatment, number and percent of subjects who completed the study, number and percent of subjects who discontinued early and reason for early discontinuation, number and percent of subjects in the safety and the PP analysis populations, number and percent of subjects at each visit.

Excluded subjects are documented, together with the reason for exclusion.

All major protocol deviations that had an effect on the analysis populations are listed by subject, if applicable.

9.7.1.4 Analysis of Efficacy Data

9.7.1.4.1 Smoothed pH Curve

Prior to pH analysis, raw pH data (recorded at 4 second intervals) at each electrode were smoothed in order to remove any random fluctuations in pH due to noise. For each subject and study day, the original pH profiles and smoothed pH profiles were plotted against time. The generalised additive model (GAM) was used to smooth the pH profiles. The GAM model for each pH profile was estimated through a generalised cross-validation technique, which selected the smoothing splines automatically. SAS PROC GAM procedure was used to estimate the GAM model and the smoothed function was a direct output of this procedure.

Change from baseline to each minute on the smoothed pH curve was calculated by subtracting the mean pH from the smoothed curve over the 10 minutes pre-dose from each post-dose smoothed pH value.

9.7.1.4.2 Area Under the Smoothed pH Curve

Due to the absence of several data points, the area under the curve was not calculated.

9.7.1.5 Statistical Analysis of Efficacy Endpoints

Subject pH levels at each electrode (original, smoothed and change from baseline values) and pH parameters are listed and summarised descriptively. All pH summaries were presented for the PP population.

9.7.1.5.1 Primary Efficacy Analysis

The primary endpoints (pH value from the smoothed pH curve at electrode 6 at each identified interval post-dose during the fasted state) were analysed using an analysis of variance (ANOVA) model that included fixed effects for treatment sequence, treatment and period. The mean pH from the smoothed curve over the 10 minutes pre-dose was included as a covariate. Subject was included as a random effect nested within treatment sequence. All statistical analyses were performed using the 10% significance level. The difference between least squares means (Gaviscon - Placebo) along with respective 90% confidence intervals (CI) were used to compare treatments.

The following ANOVA model was used:

pH = Subject (Treatment Sequence) + Treatment Sequence + Treatment + Period + Pre-dose pH + Error,

where Subject (Treatment Sequence) was a random effect, Treatment Sequence, Treatment, Period and Pre-dose pH were fixed effects and Error was a random residual error.

Separate models were constructed for each time-point. Log transformations of the outcomes were performed if the normality assumption of the standardised residuals was unreasonable using histograms and normal probability plots.

9.7.1.5.2 Secondary Efficacy Analysis

The change in the pH on the smoothed curve from baseline at electrodes 1 and 2 was calculated at each identified interval post-dose as the change from the mean pH of the smoothed curve over the 10 minutes pre-dose. Treatment differences and associated 90% CIs (Placebo - Gaviscon) were obtained from an ANOVA model with the same model terms as used for the primary efficacy analysis.

The duration of time at which $\text{pH} \geq 3$ and $\text{pH} \geq 4$ were maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) was analysed with an ANOVA model with fixed effect terms for treatment sequence, treatment and period, and subject(treatment sequence) as random effects. The difference between least squares means (Gaviscon - Placebo) along with respective 90% CIs were used to compare treatments.

AUCs for each electrode at varying time-points were analysed with an ANOVA model with fixed effect terms for treatment sequence, treatment and period, and subject(treatment sequence) as random effects. The difference between least squares means (Gaviscon - Placebo) along with respective 90% CIs were used to compare treatments.

Time to reach pH 3 and pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo was analysed using the Kaplan-Meier method. Median time to reach pH 3 and pH 4 along with corresponding 90% CIs are summarised by treatment. Time to reach pH 3 and pH 4 was compared between treatments using the log-rank test. For the log-rank test, proportional hazards were assumed. This assumption was examined by inspection of a plot of the logarithm of the estimated cumulative hazard function. Kaplan-Meier curves of time to reach pH 3 and pH 4 for each electrode by treatment are presented.

9.7.1.5.3 Additional Efficacy Analysis

As an alternative endpoint to those planned in the SAP, the percentage of time that the pH level was $\geq \text{pH } 3$ and $\text{pH } 4$ was considered separately for each subject over the first hour post-dose. This analysis was conducted post-hoc after the analyses in Section 9.7.1.5.1 and Section 9.7.1.5.2 had been completed. For these additional endpoints, no smoothing procedure was applied.

To visually illustrate these endpoints, bar charts showing the pH threshold ($\text{pH } 3$, $3 \leq \text{pH} < 4$, $\geq \text{pH } 4$) for all electrodes within a subject were plotted for each treatment during the first hour post-dose. The mean and median profiles were also plotted in this fashion using the nominal 4 second time-points post-dose. Only pH values that were taken within the 4 seconds prior to the nominal time were included in the mean/median calculation at that time.

The percentage of time that the pH level was $\geq \text{pH } 3$ and $\text{pH } 4$ was calculated during each 10- and 30-minute interval from dosing to 1 hour post-dose for each electrode. To capture the possible differences in electrode positions between subjects, the mean value of the percentage of time that the pH level was $\geq \text{pH } 3$ and $\text{pH } 4$ from electrodes 6 to 10 was used at each interval for comparison between treatments.

To reduce the impact of the high volume of missing pH readings and potential for any skewed findings, a minimum set of data was required to be obtained. This was defined as an electrode having at least 75 pH readings of 4 seconds in duration from the 150 available over a 10-minute period and 225 pH readings of 4 seconds in duration from the 450 available over a 30-minute period.

The percentage of time that the pH level was \geq pH 3 or pH 4 during a 10-or 30-minute interval was compared between Gaviscon Double Action Aniseed Liquid and placebo using an ANOVA model with the same endpoint from the same interval pre-dose included as a covariate, treatment, period and sequence as fixed effects, and subject nested within sequence as a random effect.

There were occasions when the ANOVA models described above required negative variance estimates of the between subject variance in order to obtain unbiased estimates of the treatment effect. It is likely that this was due to the small sample size. To ensure unbiased estimates, the option NOBOUND was set in PROC MIXED in SAS to allow negative estimates. However, the presence of negative variance components often suggests an inadequate model and therefore additional non-parametric analyses were conducted. The change in the percentage of time that the pH level was \geq pH 3 or pH 4 during a particular interval from the same interval at baseline was derived for each treatment. To compare treatments, the period differences in the changes obtained (Period 2 change – Period 1 change) were compared between sequence groups using a Wilcoxon Rank Sum test. This method accounts for the period effect in the treatment comparison.

The mean percentage of time that the pH level was \geq pH 3 and pH 4 during each 10- and 30-minute interval and the mean change in the percentage of time that the pH level was above or equal to pH 3 and pH 4 during each 10- and 30-minute interval from baseline were represented visually with bar charts.

9.7.1.6 Analysis of Safety Data

Unless otherwise specified, repeated measurements and unscheduled assessments are included in the data listings but are not included in data summaries.

9.7.1.6.1 Adverse Events

All AEs recorded on the AE CRF during the study were coded to system organ class (SOC) and preferred terms (PT) using MedDRA, Version 14.1.

All AEs were classified as treatment-emergent (TEAE), if the AE was not present prior to administration of study treatment in the first treatment period and started at or after the time of the first administration of study treatment, or if the AE presented prior to first administration of study treatment, continued, and increased in intensity after administration of study treatment.

The number and percentage of subjects reporting AEs, SAEs, treatment-related AEs, and AEs leading to withdrawal are summarised.

AEs were allocated to treatment as follows:

Treatment A: Placebo

For subjects randomised to sequence AB, events with onset on or after administration of Treatment A in Period 1 but prior to administration of Treatment B in Period 2. For subjects randomised to sequence BA, events with onset on or after administration of Treatment A in Period 2 through the follow-up visit.

Treatment B: Gaviscon Double Action Aniseed

For subjects randomised to sequence BA, events with onset on or after administration of Treatment B in Period 1 but prior to administration of Treatment A in Period 2. For subjects randomised to sequence AB, events with onset on or after administration of Treatment B in Period 2 through the follow-up visit.

TEAEs are listed by treatment. These listings detail the MedDRA PT and SOC, CRF description, onset and resolution dates and times, duration of AE, time of onset relative to last dose of study treatment, severity, outcome, serious or not serious including serious criteria, relationship to study treatment and any action taken.

TEAEs are summarised and tabulated by treatment, giving severity and causal relationship to study treatment. Any SAEs, AEs with outcome of deaths and AEs that resulted in discontinuation of treatment are listed separately.

The overall incidence of TEAEs (number and percentage of subjects) as well as the number of events are summarised by study treatment and overall, categories of degree of severity, SAEs, causally related TEAEs and SAEs, TEAEs leading to discontinuation of treatment, life-threatening SAEs and SAEs resulting in death.

TEAEs are summarised and tabulated at both the subject [number (%) of subjects] and event [number of events] level:

- By treatment, SOC and PT
- By treatment, SOC, PT and maximum reported severity
- By treatment, SOC, PT and causal relationship to study drug

For the incidence at the subject level by SOC and PT, if a subject experienced more than one event within the same SOC and PT during a treatment period, only one occurrence was included in the incidence for that treatment.

For the incidence at the subject level by SOC, PT and severity, if a subject experienced more than one event within the same SOC and PT, only the most severe occurrence was included in the incidence.

9.7.1.6.2 Clinical Laboratory Assessments

Clinical laboratory values (biochemistry, haematology and urinalysis) are listed for each subject. Each pre-study screening and post-study assessment laboratory result along with the change in result from pre-study screening are summarised. Each pre-study screening baseline laboratory value was classified as low, normal, or high based on the reference range. Scores of “1” were assigned to low values, “2” to normal values, and “3” to high values. Using these scores, shifts from baseline were also assigned a score. For example, a laboratory value that shifted from low to high was assigned a score of 2, while a laboratory value that remained at a low value was assigned a score of 0.

All low and high values are listed separately together with associated repeats, giving an assessment of clinical significance. Any clinical laboratory comments are also included in the data listings. Drugs of abuse and urine pregnancy test results are listed.

9.7.1.6.3 Vital Signs

At each post-dose measurement of vital signs, summary statistics for the absolute vital sign values and absolute change in values are presented as follows:

- By post-dose visit by treatment sequence and overall (change from baseline)
- By treatment (change from pre-dose to post-dose assessment) by post-dose visit and overall

Vital signs and oral temperature data are listed by subject at each time-point. Out of range vital signs values are flagged in the data listings. Absolute and change from baseline vital signs values are summarised by treatment at each time-point.

Changes in vital signs (systolic and diastolic blood pressure) both across the study (from baseline to follow-up) and between treatments were compared using the Wilcoxon Signed-Rank Test.

9.7.1.6.4 Physical Examination

Abnormalities in physical examination findings are listed by subject and visit.

9.7.1.6.5 Concomitant Medication

Pre-study and concomitant medications were classified according to the World Health Organisation Drug Dictionary (Version Mar2012) Anatomical Therapeutic Chemical codes levels 2 to 4 and summarised overall.

9.7.2 Determination of Sample Size

As this was a pilot study, no formal sample size calculation was performed due to the experimental nature of the study. Twelve subjects were considered to be sufficient to meet the objectives of the study. Therefore approximately 15 subjects were to be recruited and randomised to aim to have 12 complete. Up to 2 subjects were assessed per day. This was a pilot study intended to provide estimates of effect size and variance for use in later studies.

9.8 Changes in the Conduct of the Study or Planned Analysis

9.8.1 Changes in the Conduct of the Study

One protocol amendment was issued during the course of the study. No amendments were implemented prior to documented ethics approval being received. The study protocol and amendment are included as Appendix 16.1.1.

Protocol Amendment No. 1 (dated 31 Jan 2012)

The protocol amendment was implemented to clarify minor typographical errors in the final study protocol (dated 09 Dec 2011).

The following changes were made:

- Section 12.1 (Identity of Investigational Medicinal Product): It was clarified that Gaviscon Double Action Aniseed Liquid was used for this study. The reference to Gaviscon Double Action "Peppermint" Liquid in this section was included in error; all other references in the protocol are to "Aniseed". All product information supplied to the ethics committee and MHRA were for the Aniseed variant; the product used in this study was the Aniseed variant.
- Section 13.3 (Vital Signs, Physical Findings and other Observations Related to Safety): The following text was added to this section: Vital signs will be recorded at Screening, Treatment Period 1 Day 1, Treatment Period 2 Day 1 and Follow-up. Physical examinations will be conducted at Screening and the follow-up visit. Subjects will be asked about AEs at all visits. The information was provided throughout the protocol, but was omitted in error from Section 13.3 of the protocol (Appendix 16.1.1).

9.8.2 Changes in the Planned Statistical Analysis of the Study

No changes were made in the planned statistical analyses. However additional analyses were performed (see Section 9.7.1.5.3). The additional analyses were performed due to the amount of missing or negative pH readings that were obtained and the unreliability of the duration of pH above pH 3 and pH 4 endpoints. Also as these endpoints focused on the full 4 hours, after looking at the pH profiles, it was decided to focus the new endpoints on the first 1 hour from dosing only.

There are discrepancies in the protocol, with the CIs differing between protocol sections. This discrepancy was noted upon review of the SAP, but a protocol amendment was not deemed to be required. Statistical analysis to 90% confidence was agreed upon and documented in the SAP.

10 STUDY SUBJECTS

The locations of all tables, figures, and listings pertinent to Section 10 are provided in Table 10-1.

Table 10-1 Location of Tables, Figures, and Listings for Subject Disposition and Protocol Deviation Data

Data	Location	
	Tables and Figures	Listings
Disposition of Subjects	Table 14.1.1	Appendix 16.2.1.1
Protocol Deviations	-	Appendix 16.2.2.1
Inclusion Criteria	-	Appendix 16.2.4.2
Exclusion Criteria	-	Appendix 16.2.4.2
Consent Information	-	Appendix 16.2.5.1
Screening Outcome	-	Appendix 16.2.5.2
Randomisation Number Allocation	-	Appendix 16.2.5.6


10.1 Disposition of Subjects

A listing of the consent information and screening outcome of all subjects is presented in Appendix 16.2.5, Listing 16.2.5.1 and Listing 16.2.5.2, respectively. A listing of all subjects discontinued from the study after enrolment is presented in Appendix 16.2.1, Listing 16.2.1.1.

Twelve subjects were randomised onto the study. All 12 (100.0%) subjects completed the study per protocol.

Disposition of subjects is presented in Figure 10-1.

Figure 10-1 Disposition of Subjects



Source: Section 14, Table 14.1.1, Appendix 16.2.5, Listing 16.2.5.2

Abbreviations: DOA = drugs of abuse; GPQ = general practitioner's questionnaire

Treatment A: Placebo

Treatment B: Gaviskon Double Action Aniseed Liquid (10 ml)

10.2 Protocol Deviations

A listing of individual subjects who deviated from the protocol is presented in Appendix 16.2.2, Listing 16.2.2.1. No protocol deviations were noted in this study.

11 EFFICACY EVALUATION

The locations of all tables, figures, and listings pertinent to Section 11 are provided in Table 11-1.

Table 11-1 Location of Tables, Figures, and Listings for Efficacy Data

Topic	Location	
	Tables and Figures	Listings
Data Sets Analysed	Table 14.1.2	Appendix 16.2.3.1
Demographic and Baseline Characteristics	Table 14.1.3	Appendix 16.2.4.1
Medical History	-	Appendix 16.2.4.3
Drugs of Abuse, Pregnancy and Alcohol Breath Test	-	Appendix 16.2.4.4
Pre-study Medication	Table 14.1.4	Appendix 16.2.4.5
Concomitant Medication	Table 14.1.5	Appendix 16.2.4.6
Substance Use	-	Appendix 16.2.4.7
Study Treatment Dosing Record	-	Appendix 16.2.5.3
Catheter Insertion Record	-	Appendix 16.2.5.4
Catheter Removal Record	-	Appendix 16.2.5.5
Meal Time and Fasting	-	Appendix 16.2.5.7
Fluoroscopic Study Pre-dose	-	Appendix 16.2.6.1
Fluoroscopic Study Post-dose	-	Appendix 16.2.6.2
Individual and Summary of pH Smoothed Values	Table 14.2.1.1	Appendix 16.2.6.4
Individual and Summary of Change from Baseline in pH Smoothed Values	Table 14.2.1.2	Appendix 16.2.6.4
Individual and Summary of pH Original Values	Table 14.2.1.3	Appendix 16.2.6.3
Individual Profile Pots of Original and Smoothed pH Values over Time	-	Figure 16.2.6.5
Individual Profile Pots of Change from Baseline in Smoothed pH Values over Time	-	Figure 16.2.6.6
Individual and Summary of pH Smoothed Parameters	Table 14.2.1.4	Appendix 16.2.6.7
Mean Smoothed pH Values over Time	Figure 14.2.1.5	-
Median Smoothed pH Values over Time	Figure 14.2.1.6	-
Mean Change from Baseline in Smoothed pH Values over Time	Figure 14.2.1.7	-
Median Change from Baseline in Smoothed pH Values over Time	Figure 14.2.1.8	-
Statistical Assessment of pH Smoothed Values	Table 14.2.1.9	-
Statistical Assessment of pH Smoothed Values at Electrode 1	Table 14.2.1.10	-

Table 11-1 Location of Tables, Figures, and Listings for Efficacy Data (Continued)

Topic	Location	
	Tables and Figures	Listings
Statistical Assessment of pH Smoothed Values at Electrode 2	Table 14.2.1.11	Appendix 16.2.6.4
Statistical Assessment of pH Smoothed Parameters	Table 14.2.1.12	Appendix 16.2.6.4
Statistical Assessment of Time to reach pH 3 and pH 4 on the Smoothed Curve in the Stomach	Table 14.2.1.13	Appendix 16.2.6.4
Kaplan-Meier Plot of Time to reach pH 3 by Electrode	Figure 14.2.1.14	-
Kaplan-Meier Plot of Time to reach pH 4 by Electrode	Figure 14.2.1.15	-

11.1 Data Sets Analysed

Appendix 16.2.3, Listing 16.2.3.1 contains a tabular listing of all subjects excluded from the analyses. No subjects were excluded from any of the analysis populations (Section 14, Table 14.1.2).

The strategy for the inclusion/exclusion criteria for each of the data sets analysed was included in the SAP for the study and finalised following discussions of evaluability held after the database had been locked and prior to the blind being broken.

The number of subjects in each of the study populations is shown in Table 11-2.

Table 11-2 Study Populations

	AB	BA	Overall
Number of subjects in All Subjects Population	6 (100.0%)	6 (100.0%)	12 (100.0%)
Number of subjects in safety population	6 (100.0%)	6 (100.0%)	12 (100.0%)
Number of subjects in PP population	6 (100.0%)	6 (100.0%)	12 (100.0%)

Source: Section 14, Table 14.1.2

Abbreviations: PP = per protocol

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

11.2 Demographic and Other Baseline Assessments

11.2.1 Demographics

Subject demographics and other baseline characteristics are listed by subject in Appendix 16.2.4, Listing 16.2.4.1 and summarised in Section 14, Table 14.1.3.

Nine (75.0%) subjects were male and 3 (25.0%) subjects were female, with a mean age of 25.2 years (SD=4.47 years). The range in age for subjects was 20 to 33 years. All but one subject was Caucasian; the race of the remaining subject was Afro-Caribbean (Section 14, Table 14.1.3).

11.2.2 Medical History

Medical history was reported in 4 (33.3%) subjects (Appendix 16.2.4, Listing 16.2.4.3).

11.2.3 Pre-study Medication

Pre-study medication is listed by subject in Appendix 16.2.4, Listing 16.2.4.5 and summarised in Section 14, Table 14.1.4.

Two (16.7%) subjects had used pre-study medication in the 4 weeks prior to the start of the study. Both subjects were female, who took hormonal contraceptives.

No subjects had a positive drugs of abuse or alcohol breath test at screening (Appendix 16.2.4, Listing 16.2.4.4).

11.2.4 Concomitant Medication

Concomitant medication is listed by subject in Appendix 16.2.4, Listing 16.2.4.6 and summarised in Section 14, Table 14.1.5.

One (8.3%) subject had used concomitant medication during the study. Subject 005 used 1000 mg of paracetamol for headache during the washout period.

11.3 Measurements of Treatment Compliance

Compliance was not an issue in this study as study treatment was taken by subjects under supervision of the PI or appropriately trained staff who conducted a mouth inspection to ensure compliance with dosing. The study treatment dosing record is presented in Appendix 16.2.5, Listing 16.2.5.3 and discussed in Section 12.1.

11.4 Efficacy Results and Tabulations of Individual Subject Data

11.4.1 Analysis of Efficacy

Efficacy analysis data are presented in Appendix 16.2, Listing 16.2.5.4 (catheter insertion record), Listing 16.2.5.5 (catheter removal record), Listing 16.2.6.1 (fluoroscopic study pre-dose) and Listing 16.2.6.2 (fluoroscopic study post-dose). Individual pH original values are listed by treatment, electrode and time in Appendix 16.2.6, Listing 16.2.6.3 and summarised for the PP population in Section 14, Table 14.2.1.3. Individual and change from baseline pH smoothed values are listed by treatment, electrode and time in Appendix 16.2.6, Listing 16.2.6.4 and summarised for the PP population in Section 14, Table 14.2.1.1 (individual and summary values) and Table 14.2.1.2 (individual and change from baseline). Individual pH smoothed parameters are listed by treatment, electrode and time in Appendix 16.2.6, Listing 16.2.6.7 and summarised for the PP population in Section 14, Table 14.2.1.4.

Individual profile plots by electrode and treatment are presented in Appendix 16.2.6, Figure 16.2.6.5 (original and smoothed pH values over time) and Figure 16.2.6.6 (change from baseline in smoothed pH values over time). Summary plots over time by electrode and treatment are presented for the PP population in Section 14, Figure 14.2.1.5 (mean smoothed pH values), Figure 14.2.1.6 (median smoothed pH values), Figure 14.2.1.7 (mean change from baseline in smoothed pH values) and Figure 14.2.1.8 (median change from baseline in smoothed pH values).

Statistical assessments of pH smoothed values by time are presented for the PP population in Section 14, Table 14.2.1.9 (between treatments by electrode), Table 14.2.1.10 (change in pH at electrode 1), Table 14.2.1.11 (change in pH at electrode 2) and Table 14.2.1.12 (pH smoothed parameters). Statistical assessment of time to reach pH 3 and pH 4 on the smooth curve in the stomach is summarised for the PP population in Section 14, Table 14.2.1.13 and presented by electrode (3 to 11) and treatment as Kaplan-Meier plots in Figure 14.2.1.14 (time to reach pH 3) and Figure 14.2.1.15 (time to reach pH 4).

11.4.1.1 Primary Efficacy Analysis - pH Value at Electrode 6 at 1 minute Intervals Post-dose

The primary efficacy endpoint was the comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at electrode 6 at each 1-minute interval up to 4 hours post-dose during the fasted state.

The pH smoothed values by treatment, electrode and time are summarised for the PP population in Section 14, Table 14.2.1.1 and presented graphically in Section 14, Figure 14.2.1.5 (mean smoothed pH values). The pH smoothed values by treatment and time (1-minute to 20-minute time-points) is presented for electrode 6 in Table 11-3.

Table 11-3 Summary of pH Smoothed Values by Treatment for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)

Time-point (Minute)	Summary Statistic	Placebo (10 ml) (N=12)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12)
1	n	12	12
	Mean (SD)	2.970 (1.7553)	3.732 (3.1086)
	Median	2.350	1.901
	Min - Max	1.28 - 6.82	1.15 - 8.94
2	n	12	12
	Mean (SD)	3.217 (2.0542)	4.864 (3.2179)
	Median	2.364	4.707
	Min - Max	1.30 - 7.07	1.15 - 10.01
3	n	12	12
	Mean (SD)	3.310 (2.1675)	5.612 (2.9303)
	Median	2.586	6.678
	Min - Max	1.09 - 7.67	1.16 - 10.16
4	n	12	12
	Mean (SD)	2.790 (1.5798)	5.775 (3.1087)
	Median	2.443	7.396
	Min - Max	1.01 - 6.98	1.05 - 10.18
5	n	12	12
	Mean (SD)	2.996 (1.7375)	5.646 (3.1425)
	Median	2.440	7.095
	Min - Max	1.24 - 7.00	1.43 - 9.92
6	n	12	12
	Mean (SD)	2.682 (1.5822)	6.055 (2.8548)
	Median	2.249	7.376
	Min - Max	1.10 - 6.94	2.17 - 9.97
7	n	12	12
	Mean (SD)	2.760 (1.6381)	6.615 (2.1408)
	Median	2.282	7.194
	Min - Max	1.13 - 6.98	2.20 - 9.82

continued

Table 11-3 Summary of pH Smoothed Values by Treatment for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)

Time-point (Minute)	Summary Statistic	Placebo (10 ml) (N=12)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12)
8	n	12	12
	Mean (SD)	2.708 (1.6698)	6.213 (2.3552)
	Median	2.133	7.029
	Min - Max	1.20 - 7.02	2.13 - 9.88
9	n	12	12
	Mean (SD)	2.718 (1.5219)	5.711 (2.6383)
	Median	2.147	6.351
	Min - Max	1.23 - 6.81	1.98 - 9.74
10	n	12	12
	Mean (SD)	2.634 (1.5053)	5.913 (2.5824)
	Median	2.120	6.853
	Min - Max	1.32 - 6.85	1.64 - 9.78
11	n	12	12
	Mean (SD)	2.805 (1.4969)	5.464 (2.7964)
	Median	2.178	6.611
	Min - Max	1.38 - 6.86	1.64 - 9.71
12	n	12	12
	Mean (SD)	2.782 (1.5454)	5.299 (2.8720)
	Median	2.191	6.577
	Min - Max	1.24 - 6.89	1.52 - 9.30
13	n	12	12
	Mean (SD)	2.600 (1.5145)	5.405 (2.8015)
	Median	2.119	6.598
	Min - Max	1.32 - 6.81	1.57 - 9.17
14	n	12	12
	Mean (SD)	2.573 (1.5425)	5.005 (2.9329)
	Median	2.109	5.124
	Min - Max	1.05 - 6.85	1.40 - 9.24
15	n	12	12
	Mean (SD)	2.586 (1.5739)	4.808 (3.0689)
	Median	2.128	5.250
	Min - Max	0.98 - 6.97	1.19 - 9.03

continued

Table 11-3 Summary of pH Smoothed Values by Treatment for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)

Time-point (Minute)	Summary Statistic	Placebo (10 ml) (N=12)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12)
16	n	12	12
	Mean (SD)	2.645 (1.5684)	5.132 (2.9189)
	Median	2.140	6.327
	Min - Max	1.42 - 7.08	1.20 - 8.86
17	n	12	12
	Mean (SD)	2.623 (1.5734)	4.716 (2.9231)
	Median	2.147	5.055
	Min - Max	1.37 - 6.90	1.13 - 8.58
18	n	12	12
	Mean (SD)	2.577 (1.5991)	4.555 (2.9268)
	Median	2.135	4.950
	Min - Max	1.19 - 7.07	1.05 - 8.70
19	n	12	12
	Mean (SD)	2.598 (1.5639)	4.535 (2.8855)
	Median	2.102	5.435
	Min - Max	1.13 - 6.96	1.02 - 8.64
20	n	12	12
	Mean (SD)	2.559 (1.5562)	4.128 (2.8437)
	Median	2.137	3.446
	Min - Max	1.18 - 6.91	0.82 - 8.53

Source: Section 14, Table 14.2.1.1

Abbreviations: Max = maximum; Min = minimum; N = number of subjects exposed; n = number of evaluable subjects; SD = standard deviation

Test = Treatment A: Placebo

Reference = Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

The mean smoothed pH values over time at electrode 6 are presented in Figure 11-1.

The statistical assessment of pH smoothed values by time-point are summarised for the PP population in Table 14.2.1.9 and presented in Table 11-4.

The results show a statistically significantly higher mean smoothed pH value at electrode 6 after administration of Gaviscon Double Action Aniseed Liquid as compared to placebo between the 3-minute and 20-minute time-points. Differences in pH between the 2 treatments peaked at the 7-minute time-point, at 3.9. This finding is consistent with the expected effect of Gaviscon Double Action Aniseed Liquid, neutralising acidic fluids.

Beyond 20 minutes, statistically significant differences between treatment groups were shown at several time-points, at which pH was higher after administration of placebo. These differences were not as consistent as the increase seen between the 3-minute and 20-minute time-points. The difference in pH between the 2 treatments, beyond 20 minutes was generally also smaller (< 1) than the differences seen between the 3-minute and 20-minute time-points and given the number of data points recorded, it is possible that these values were observed by chance.

Table 11-4 Statistical Assessment of pH Smoothed Values between Treatments for Electrode 6 between the 1-minute and 20-minute Time-points (PP Population)

Time-point (Minute)	N	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	90% CI	P-value
1	12	2.970	3.732	0.7614	(-1.1532, 2.6760)	0.488
2	12	3.217	4.864	1.6469	(-0.3808, 3.6746)	0.172
3	12	3.310	5.612	2.3027	(0.0318, 4.5737)	0.096
4	12	2.790	5.775	2.9858	(1.1563, 4.8153)	0.014
5	12	2.996	5.646	2.6495	(0.8574, 4.4416)	0.023
6	12	2.682	6.055	3.3734	(1.9447, 4.8021)	0.002
7	12	2.760	6.615	3.8555	(2.4212, 5.2898)	<0.001
8	12	2.708	6.213	3.5054	(1.8966, 5.1141)	0.003
9	12	2.718	5.711	2.9930	(1.4101, 4.5760)	0.006
10	12	2.634	5.913	3.2792	(1.9389, 4.6194)	0.001
11	12	2.805	5.464	2.6594	(1.5469, 3.7720)	0.001
12	12	2.782	5.299	2.5172	(0.8079, 4.2266)	0.024
13	12	2.600	5.405	2.8054	(1.5202, 4.0906)	0.003
14	12	2.573	5.005	2.4316	(0.9896, 3.8736)	0.012
15	12	2.586	4.808	2.2219	(0.6088, 3.8350)	0.032
16	12	2.645	5.132	2.4871	(0.8686, 4.1056)	0.019
17	12	2.623	4.716	2.0925	(0.4966, 3.6883)	0.039
18	12	2.577	4.555	1.9776	(0.4073, 3.5480)	0.046
19	12	2.598	4.535	1.9370	(0.3366, 3.5374)	0.053
20	12	2.559	4.128	1.5688	(0.0004, 3.1373)	0.100


Source: Section 14, Table 14.2.1.9

Abbreviations: CI = confidence interval; N = number of subjects

Test = Treatment A: Placebo

Reference = Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

Figure 11-1 Mean Smoothed pH Values over Time at Electrode 6 (PP Population)



11.4.1.2 Secondary Efficacy Analyses

Secondary efficacy endpoints were:

- Comparison of the pH values for Gaviscon Double Action Aniseed Liquid versus placebo from the smoothed pH curve at all other electrodes at each 1 minute interval up to 4 hours post-dose during the fasted state.
- Time to reach pH 3 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Time to reach pH 4 on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Duration of time at which \geq pH 3 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Duration of time at which \geq pH 4 was maintained on the smoothed curve at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.
- Change in pH on the smoothed curve at electrode 1 over time for Gaviscon Double Action Aniseed Liquid versus placebo.
- Change in pH on the smoothed curve at electrode 2 over time for Gaviscon Double Action Aniseed Liquid versus placebo.

11.4.1.2.1 Comparison of the pH Values for Gaviscon Double Action Aniseed Liquid versus Placebo from the Smoothed pH Curve at All Other Electrodes at each 1 minute Interval up to 4 hours Post-dose During the Fasted State

The pH smoothed values by treatment, electrode and time are summarised for the PP population in Section 14, Table 14.2.1.1 and presented graphically in Section 14, Figure 14.2.1.5 (mean smoothed pH values).

For electrodes 1 to 4, statistically significant differences in pH were seen between the 1-minute and 9-minute time-points and at consistent time-points within the first 15 minutes, following administration of Gaviscon Double Action Aniseed Liquid as compared to placebo. For electrodes 5 to 11, statistically significant differences in pH were seen between the 2-minute (range: 2 to 4 minutes) and 15-minute time-points and at consistent time-points within the first 30 minutes. The effect was greatest in electrode 8, in which a consistent, statistically significant difference in pH was observed between 2 minutes and 26 minutes (Section 14, Table 14.2.1.9).

At later time-points, statistically significant differences were seen across all electrodes, with the pH being lower following administration of Gaviscon Double Action Aniseed Liquid compared to placebo, though these results were less consistent and represented smaller differences in pH and were likely to be due to chance (Section 14, Table 14.2.1.9).

It is likely that in many subjects, electrode 11 lay within the duodenum, as suggested by higher pH values recorded throughout the 4-hour period. Consequently, few time-points with statistically significant differences in pH between the two treatments were observed.

11.4.1.2.2 Time to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo

A summary of pH smoothed parameters by treatment and electrode for the PP population is provided in Section 14, Table 14.2.1.4 and presented in Table 11-5.

The median time (minutes) to reach pH 3 was comparable or shorter for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except at electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median time (minutes) to reach pH 3 between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 10 (2.2 minutes [range: 0 to 121 minutes] vs 12.6 minutes [range: 0 to 234 minutes]), electrode 9 (2.4 minutes [range: 0 to 10 minutes] vs 9.0 minutes [range: 0 to 178 minutes]) and electrode 6 (1.7 minutes [range: 0 to 8 minutes] vs 6.1 minutes [range: 0 to 259 minutes]). The median time (minutes) to reach pH 3 at electrode 11 was shorter for placebo compared with Gaviscon Double Action Aniseed Liquid (0.1 minutes [range: 0 to 172 minutes] vs 2.1 minutes [range: 0 to 116 minutes]).

Table 11-5 Time (Minutes) to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
3	n	12	12
	Mean (SD)	24.9 (76.39)	0.3 (0.66)
	Median	0.1	0.0
	Min - Max	0 - 266	0 - 2
4	n	12	12
	Mean (SD)	5.3 (15.46)	1.2 (1.86)
	Median	0.5	0.4
	Min - Max	0 - 54	0 - 5
5	n	12	12
	Mean (SD)	18.8 (46.78)	2.2 (2.92)
	Median	1.2	0.7
	Min - Max	0 - 159	0 - 8
6	n	12	12
	Mean (SD)	61.1 (86.90)	2.4 (2.56)
	Median	6.1	1.7
	Min - Max	0 - 259	0 - 8
7	n	12	12
	Mean (SD)	62.3 (94.49)	2.4 (2.34)
	Median	1.1	1.5
	Min - Max	0 - 259	0 - 8
8	n	12	12
	Mean (SD)	47.7 (61.94)	2.4 (1.83)
	Median	1.8	1.8
	Min - Max	0 - 150	0 - 7
9	n	12	12
	Mean (SD)	39.3 (54.69)	3.3 (2.98)
	Median	9.0	2.4
	Min - Max	0 - 178	0 - 10
10	n	12	12
	Mean (SD)	53.9 (78.64)	12.7 (34.28)
	Median	12.6	2.2
	Min - Max	0 - 234	0 - 121

continued

Table 11-5 Time (Minutes) to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (PP Population) (Continued)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
11	n	12	12
	Mean (SD)	30.9 (57.42)	11.9 (33.00)
	Median	0.1	2.1
	Min - Max	0 - 172	0 - 116

Source: Section 14, Table 14.2.1.4

Abbreviations: Max = maximum; Min = minimum; N = number of subjects exposed; n = number of evaluable subjects; SD = standard deviation

Statistical assessment of time to reach pH 3 on the smooth curve in the stomach is summarised for the PP population in Section 14, Table 14.2.1.13 and presented by electrode (3 to 11) and treatment as Kaplan-Meier plots in Figure 14.2.1.14. Statistical assessment of time to reach pH 3 on the smooth curve in the stomach is presented for the PP population in Table 11-6.

Median time (minutes) to reach pH 3 was comparable for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach (i.e. electrodes 3 to 11 inclusive). A statistically significant difference in the median time (minutes) to reach pH 3 was observed at electrode 9 ($p=0.0439$) and at electrode 6 ($p=0.0858$) in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Table 11-6 Statistical Assessment of Time to Reach pH 3 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Test Median Time (90% CI)	Reference Median Time (90% CI)	Log-rank P-value
3	0.1 (0.0, 0.5)	0.0 (0.0, 0.3)	0.3505
4	0.5 (0.0, 2.2)	0.4 (0.0, 2.4)	0.6252
5	1.2 (0.0, 3.7)	0.7 (0.0, 4.6)	0.5610
6	6.1 (0.0, 135.9)	1.7 (0.1, 2.9)	0.0858
7	1.1 (0.0, 155.8)	1.5 (0.7, 3.6)	0.3512
8	1.8 (0.0, 108.4)	1.8 (1.0, 3.5)	0.1914
9	9.0 (0.0, 72.9)	2.4 (1.0, 4.1)	0.0439
10	12.6 (0.0, 87.3)	2.2 (1.4, 4.3)	0.2789
11	0.1 (0.0, 82.0)	2.1 (0.0, 4.4)	0.7491

Source: Section 14, Table 14.2.1.13

Abbreviations: CI = confidence interval

Test = Treatment A: Placebo

Reference = Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

11.4.1.2.3 Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo

A summary of pH smoothed parameters by treatment and electrode for the PP population is provided in Section 14, Table 14.2.1.4 and presented in Table 11-7.

The median time (minutes) to reach pH 4 was notably shorter for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median time (minutes) to reach pH 3 between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 8 (1.8 minutes [range: 0 to 7 minutes] vs 96.9 minutes [range: 0 to 282 minutes]), electrode 9 (2.9 minutes [range: 0 to 10 minutes] vs 45.2 minutes [range: 0 to 261 minutes]), electrode 10 (2.4 minutes [range: 0 to 124 minutes] vs 36.4 minutes [range: 0 to 261 minutes]), electrode 6 (2.0 minutes [range: 0 to 9 minutes] vs 32.3 minutes [range: 0 to 299 minutes]) and electrode 7 (1.6 minutes [range: 0 to 8 minutes] vs 30.0 minutes [range: 0 to 282 minutes]). The median time (minutes) to reach pH 4 at electrode 11 was shorter for placebo compared with Gaviscon Double Action Aniseed Liquid (0.1 minutes [range: 0 to 173 minutes] vs 2.2 minutes [range: 0 to 116 minutes]).

Table 11-7 Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
3	n	12	12
	Mean (SD)	27.4 (77.18)	0.4 (0.74)
	Median	0.3	0.0
	Min - Max	0 - 267	0 - 3
4	n	12	12
	Mean (SD)	5.8 (15.35)	1.3 (2.16)
	Median	0.8	0.4
	Min - Max	0 - 54	0 - 6
5	n	12	12
	Mean (SD)	65.0 (102.57)	2.8 (3.08)
	Median	3.8	1.3
	Min - Max	0 - 269	0 - 9

continued

Table 11-7 Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (PP Population) (Continued)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
6	n	12	12
	Mean (SD)	81.3 (105.84)	2.9 (2.92)
	Median	32.3	2.0
	Min - Max	0 - 299	0 - 9
7	n	12	12
	Mean (SD)	90.9 (107.96)	2.5 (2.45)
	Median	30.0	1.6
	Min - Max	0 - 282	0 - 8
8	n	12	12
	Mean (SD)	96.1 (91.68)	2.5 (1.82)
	Median	96.9	1.8
	Min - Max	0 - 282	0 - 7
9	n	11	12
	Mean (SD)	73.5 (91.38)	3.7 (3.14)
	Median	45.2	2.9
	Min - Max	0 - 261	0 - 10
10	n	12	12
	Mean (SD)	83.8 (99.77)	13.1 (35.01)
	Median	36.4	2.4
	Min - Max	0 - 261	0 - 124
11	n	11	12
	Mean (SD)	35.0 (57.68)	12.0 (32.99)
	Median	0.1	2.2
	Min - Max	0 - 173	0 - 116

Source: Section 14, Table 14.2.1.4

Abbreviations: Max = maximum; Min = minimum; N = number of subjects exposed; n = number of evaluable subjects; SD = standard deviation

Statistical assessment of time to reach pH 4 on the smooth curve in the stomach is summarised for the PP population in Section 14, Table 14.2.1.13 and presented by electrode (3 to 11) and treatment as Kaplan-Meier plots in Figure 14.2.1.15. Statistical assessment of time to reach pH 4 on the smooth curve in the stomach is presented for the PP population in Table 11-8.

A statistically significant difference in the median time (minutes) to reach pH 4 was observed at electrode 8 ($p=0.0058$), electrode 7 ($p=0.0094$), electrode 6 ($p=0.0109$), electrode 9 ($p=0.0143$), electrode 10 ($p=0.0446$) and at electrode 5 ($p=0.0617$) in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Table 11-8 Statistical Assessment of Time to Reach pH 4 on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Test Median Time (90% CI)	Reference Median Time (90% CI)	Log-rank P-value
3	0.3 (0.0, 1.6)	0.0 (0.0, 0.4)	0.1061
4	0.8 (0.3, 3.7)	0.4 (0.0, 2.4)	0.3570
5	3.8 (0.1, 157.2)	1.3 (0.3, 5.6)	0.0617
6	32.3 (0.1, 137.4)	2.0 (0.1, 5.8)	0.0109
7	30.0 (0.1, 176.9)	1.6 (0.7, 3.6)	0.0094
8	96.9 (0.1, 155.3)	1.8 (1.0, 3.5)	0.0058
9	45.2 (0.1, 102.6)	2.9 (1.0, 4.5)	0.0143
10	36.4 (0.1, 220.9)	2.4 (1.4, 4.4)	0.0446
11	0.1 (0.0, 82.1)	2.2 (0.2, 4.5)	0.6789

Source: Section 14, Table 14.2.1.13

Abbreviations: CI = confidence interval

Test = Treatment A: Placebo

Reference = Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

11.4.1.2.4 Duration of Time at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo

A summary of pH smoothed parameters by treatment and electrode for the PP population is provided in Section 14, Table 14.2.1.4 and presented in Table 11-9.

The median duration of time (minutes) at which \geq pH 3 was maintained was considerably longer for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median duration of time (minutes) at which \geq pH 3 was maintained between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 3 (82.8 minutes [range: 10 to 233 minutes] vs 47.7 minutes [range: 10 to 229 minutes]), electrode 9 (37.9 minutes [range: 6 to 233 minutes] vs 14.4 minutes [range: 0 to 211 minutes]), electrode 4 (39.3 minutes [range: 7 to 233 minutes] vs 20.7 minutes [range: 0 to 228 minutes]), and electrode 5 (28.2 minutes [range: 5 to 233 minutes] vs 13.0 minutes [range: 0 to 206 minutes]). The median duration of time (minutes) at which \geq pH 3 was maintained at electrode 11 was longer for placebo compared with Gaviscon Double Action Aniseed Liquid (101.4 minutes [range: 1 to 228 minutes] vs 67.7 minutes [range: 6 to 233 minutes]).

Table 11-9 Duration of Time at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
3	n	11	12
	Mean (SD)	75.8 (73.19)	101.8 (76.80)
	Median	47.7	82.8
	Min - Max	10 - 229	10 - 233
4	n	12	12
	Mean (SD)	52.1 (70.26)	58.8 (65.36)
	Median	20.7	39.3
	Min - Max	0 - 228	7 - 233
5	n	12	12
	Mean (SD)	42.0 (66.05)	44.0 (61.81)
	Median	13.0	28.2
	Min - Max	0 - 206	5 - 233
6	n	11	12
	Mean (SD)	45.1 (61.94)	41.4 (61.98)
	Median	15.7	25.9
	Min - Max	0 - 180	6 - 232
7	n	11	12
	Mean (SD)	56.3 (73.41)	45.7 (60.63)
	Median	16.1	28.2
	Min - Max	1 - 189	3 - 229

continued

Table 11-9 Duration of Time at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population) (Continued)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
8	n	12	12
	Mean (SD)	55.8 (71.42)	51.8 (62.60)
	Median	23.0	27.5
	Min - Max	0 - 198	6 - 233
9	n	12	12
	Mean (SD)	58.3 (73.40)	54.2 (62.00)
	Median	14.4	37.9
	Min - Max	0 - 211	6 - 233
10	n	12	12
	Mean (SD)	64.5 (78.97)	57.2 (60.93)
	Median	26.7	36.1
	Min - Max	0 - 228	5 - 233
11	n	12	12
	Mean (SD)	102.8 (84.35)	84.9 (66.74)
	Median	101.4	67.7
	Min - Max	1 - 228	6 - 233

Source: Section 14, Table 14.2.1.4

Abbreviations: Max = maximum; Min = minimum; N = number of subjects exposed; n = number of evaluable subjects; SD = standard deviation

Statistical assessments of duration at which \geq pH 3 was maintained on the smoothed curve by electrode are presented for the PP population in Section 14, Table 14.2.1.12 and presented in Table 11-10.

No statistically significant difference in the duration at which \geq pH 3 was maintained on the smoothed curve was observed at any electrode in the stomach (i.e. electrodes 3 to 11 inclusive) for Gaviscon Double Action Aniseed Liquid versus placebo.

Table 11-10 Statistical Assessment of Duration at which \geq pH 3 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	N	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
3	11	72.46	101.776	29.3161	(-18.1291, 76.7613)	0.287
4	12	52.069	58.789	6.7194	(-20.6001, 34.0390)	0.665
5	12	42.036	44.035	1.9986	(-23.0796, 27.0768)	0.888
6	11	42.385	41.422	-0.9628	(-30.6549, 28.7293)	0.954
7	11	51.814	45.714	-6.1000	(-46.5645, 34.3645)	0.789
8	12	55.81	51.758	-4.0514	(-43.9128, 35.8101)	0.858
9	12	58.315	54.244	-4.0708	(-46.4339, 38.2922)	0.865
10	12	64.513	57.175	-7.3375	(-48.7448, 34.0698)	0.755
11	12	102.776	84.881	-17.8958	(-51.1021, 15.3104)	0.352

Source: Section 14, Table 14.2.1.12

Abbreviations: CI = confidence interval; LS Mean = least squares mean; N = number of evaluable subjects

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

11.4.1.2.5 Duration of Time at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (i.e. Electrodes 3 to 11 Inclusive) for Gaviscon Double Action Aniseed Liquid versus Placebo

A summary of pH smoothed parameters by treatment and electrode for the PP population is provided in Section 14, Table 14.2.1.4 and presented in Table 11-11.

The median duration of time (minutes) at which \geq pH 4 was maintained was considerably longer for Gaviscon Double Action Aniseed Liquid versus placebo at each electrode in the stomach, except electrode 11 (i.e. electrodes 3 to 10 inclusive). The greatest differences in median duration of time (minutes) at which \geq pH 4 was maintained between Gaviscon Double Action Aniseed Liquid versus placebo were observed at electrode 3 (68.8 minutes [range: 8 to 233 minutes] vs 36.5 minutes [range: 5 to 229 minutes]), electrode 9 (34.1 minutes [range: 5 to 233 minutes] vs 9.9 minutes [range: 1 to 201 minutes]), electrode 7 (24.5 minutes [range: 2 to 227 minutes] vs 3.3 minutes [range: 0 to 173 minutes]), and electrode 8 (26.5 minutes [range: 5 to 233 minutes] vs 9.8 minutes [range: 1 to 185 minutes]). The median duration of time (minutes) at which \geq pH 4 was maintained at electrode 11 was slightly longer for placebo compared with Gaviscon Double Action Aniseed Liquid (60.2 minutes [range: 0 to 220 minutes] vs 57.7 minutes [range: 5 to 233 minutes]).

Table 11-11 Duration of Time at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
3	n	11	12
	Mean (SD)	55.4 (67.55)	90.6 (74.92)
	Median	36.5	68.8
	Min - Max	5 - 229	8 - 233
4	n	12	12
	Mean (SD)	32.6 (62.63)	50.7 (65.80)
	Median	12.5	27.3
	Min - Max	0 - 227	6 - 233
5	n	10	12
	Mean (SD)	25.4 (60.93)	38.2 (62.83)
	Median	5.3	20.5
	Min - Max	0 - 198	4 - 233
6	n	9	12
	Mean (SD)	31.3 (57.98)	35.7 (62.54)
	Median	4.7	17.5
	Min - Max	0 - 172	4 - 230
7	n	10	12
	Mean (SD)	39.8 (70.30)	39.6 (60.66)
	Median	3.3	24.5
	Min - Max	0 - 173	2 - 227
8	n	11	12
	Mean (SD)	43.5 (65.67)	46.4 (61.92)
	Median	9.8	26.5
	Min - Max	1 - 185	5 - 233
9	n	10	12
	Mean (SD)	51.4 (71.21)	48.4 (61.61)
	Median	9.9	34.1
	Min - Max	1 - 201	5 - 233
10	n	11	12
	Mean (SD)	53.4 (76.33)	51.5 (61.57)
	Median	17.3	30.8
	Min - Max	0 - 220	5 - 233

continued

Table 11-11 Duration of Time at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population) (Continued)

Electrode	Summary Statistic	Placebo (10 ml) (N=12) (min)	Gaviscon Double Action Aniseed Liquid (10 ml) (N=12) (min)
11	n	11	12
	Mean (SD)	90.6 (85.72)	78.3 (66.40)
	Median	60.2	57.7
	Min - Max	0 - 220	5 - 233

Source: Section 14, Table 14.2.1.4

Abbreviations: Max = maximum; Min = minimum; N = number of subjects exposed; n = number of evaluable subjects; SD = standard deviation

Statistical assessments of duration at which \geq pH 4 was maintained on the smoothed curve by electrode are presented for the PP population in Section 14, Table 14.2.1.12 and presented in Table 11-12.

The LS mean duration at which \geq pH 4 was maintained was 52.098, 32.639, and 22.635 for placebo and 90.579, 50.746 and 38.193 for Gaviscon Double Action Aniseed Liquid, resulting in a LS mean treatment difference of 38.4817 (90% CI: 2.7586, 74.2047), 18.1069 (90% CI: 4.6729, 31.5410) and 15.5583 (90% CI: 4.8919, 26.2248) at electrodes 3, 4 and 5, respectively. A statistically significant difference in duration at which \geq pH 4 was maintained at electrode 5 ($p=0.027$), electrode 4 ($p=0.035$) and electrode 3 ($p=0.080$) was observed for Gaviscon Double Action Aniseed Liquid when compared with placebo.

Table 11-12 Statistical Assessment of Duration at which \geq pH 4 was Maintained on the Smoothed Curve at Each Electrode in the Stomach (PP Population)

Electrode	N	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
3	11	52.098	90.579	38.4817	(2.7586, 74.2047)	0.080
4	12	32.639	50.746	18.1069	(4.6729, 31.5410)	0.035
5	10	22.635	38.193	15.5583	(4.8919, 26.2248)	0.027
6	9	26.93	35.708	8.7783	(-10.3740, 27.9307)	0.414
7	10	36.906	39.561	2.6550	(-29.7385, 35.0485)	0.883
8	11	45.666	46.368	0.7022	(-32.8599, 34.2644)	0.970
9	10	45.912	48.406	2.4938	(-43.2627, 48.2502)	0.922
10	11	49.808	51.542	1.7339	(-38.3821, 41.8498)	0.939
11	11	82.154	78.331	-3.8233	(-39.1607, 31.5140)	0.847

Source: Section 14, Table 14.2.1.12

Abbreviations: CI = confidence interval; LS Mean = least squares mean; N = number of evaluable subjects

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

11.4.1.2.6 Change in pH on the Smoothed Curve at Electrode 1 over Time for Gaviscon Double Action Aniseed Liquid versus Placebo

Statistical assessment of change in pH smoothed values at electrode 1 is summarised by time-point for the PP population in Section 14, Table 14.2.1.10.

Statistically significant differences in the change over time in pH values at electrode 1 were observed for the first 10 minutes post-dose and then intermittently up to 30 minutes post-dose. Between 30 minutes and 240 minutes post-dose, a statistically significant difference in the change over time in pH values at electrode 1 were noted at 39, 60, 82, 136, 155, 160, 161, 167, 183, 185, 203, 204 and 221 minutes post-dose, with no obvious trend and the number of significant values is as expected by chance.

11.4.1.2.7 Change in pH on the Smoothed Curve at Electrode 2 over Time for Gaviscon Double Action Aniseed Liquid versus Placebo

Statistical assessment of change in pH smoothed values at electrode 2 is summarised by time-point for the PP population in Section 14, Table 14.2.1.11.

Statistically significant differences in the change over time in pH values at electrode 2 were observed for the first 9 minutes and then intermittently up to 17 minutes post-dose. Between 30 minutes and 240 minutes post-dose, statistically significant differences in the change over time in pH values at electrode 2 were noted at 30, 31, 53, 60, 81, 86, 153 and 156 minutes post-dose, with no obvious trend and the number of significant values is as expected by chance.

The short lived separation from placebo, at electrodes 1 and 2, is as expected due to the short transit time of the product in the oesophagus.



11.4.1.2.8 The percentage of time that the pH level was \geq pH 3 and pH 4 over 10- and 30-minute intervals during the first hour post-dose (Electrode 6 to 10 combined)



Statistical assessment of the percentage of time that the pH level was \geq pH 3 and pH 4 over 10- and 30-minute intervals during the first hour post-dose (electrode 6 to 10 combined) is summarised for the PP population in Section 14, Tables 14.2.1.17 to 14.2.1.20.

There was statistically significant evidence of a greater percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing for Gaviscon Double Action Aniseed Liquid compared to placebo ($p < 0.1$).

Figure 11-2 below shows the obvious disparity in the baseline pH values between Gaviscon Double Action Aniseed Liquid and placebo, with placebo observed to have greater time with $\text{pH} \geq \text{pH 3}$ and pH 4 across electrodes 6 to 10. Even the 50- to 60-minute intervals showed superiority for Gaviscon Double Action Aniseed Liquid compared to placebo after adjustment for baseline levels in the ANOVA model (pH 3: $p = 0.0861$, pH 4: $p = 0.0361$).

Figure 11-2 Mean % time the pH ≥ 3 and pH ≥ 4 over 10- and 30-minute intervals (electrodes 6 to 10 averaged)







Statistical assessment of the change from baseline in the percentage of time that the pH level was \geq pH 3 and pH 4 over 10- and 30-minute intervals during the first hour post-dose (electrodes 6 to 10 combined) is summarised for the PP population in Section 14, Table 14.2.1.21 to 14.2.1.24.

There was statistically significant evidence of a greater change in the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing for Gaviscon Double Action Aniseed Liquid compared to placebo ($p < 0.1$).

Figure 11-3 shows the mean pH value across subjects at each 4-second time-point during the first hour post-dose for both treatments and illustrates both the disparity in pH levels at baseline between the treatments and the effect of Gaviscon Double Action Aniseed Liquid at increasing the pH compared to placebo across electrodes.

Figure 11-3 Mean pH values over each 4-second interval





11.4.2 Statistical/Analytical Issues

Detailed documentation of statistical methods, as the final SAP, is presented in Appendix 16.1.9.

11.4.2.1 Adjustments for Covariates

No adjustments were made for covariates, therefore this section is not applicable.

11.4.2.2 Handling of Withdrawals or Missing Data

No subjects withdrew from the study.

Due to the amount of missing or negative pH readings that were obtained and the unreliability of the duration of pH above pH 3 and pH 4 endpoints, additional analyses were performed. The new endpoints focused on the first 1 hour from dosing only.

Due to the absence of several data points, the area under the curve was not calculated.

11.4.2.3 Interim Analyses and Data Monitoring

No interim analyses were performed and there was no data monitoring, therefore this section is not applicable.

11.4.2.4 Multi-site Studies

This was a single-site study, therefore this section is not applicable.

11.4.2.5 Multiple Comparison/Multiplicity

No multiple comparisons were made, therefore this section is not applicable.

11.4.2.6 Use of an “Efficacy Subset” of Subjects

No efficacy subsets of subjects were analysed, therefore this section is not applicable.

11.4.2.7 Active-Control Studies Intended to Show Equivalence

This study was not designed to test equivalence, therefore this section is not applicable.

11.4.2.8 Examination of Subgroups

No sub-groups were examined in this study, therefore this section is not applicable.

11.4.3 Tabulation of Individual Response Data

In addition to tables providing group data for efficacy variables, relevant individual subject data are presented in by-subject tabular listings in Appendix 16.2.6.

No individual response data are included in the body of the report.

11.4.4 Drug Dose, Drug Concentration and Relationships to Response

11.4.4.1 Drug Dose and Relationships to Response

This was not a dose response study and fixed doses of study treatment were used, therefore this section is not applicable.

11.4.4.2 Drug Concentration, Pharmacokinetics, and Relationships to Response

Drug concentrations were not measured, therefore this section is not applicable.

11.4.5 Drug-Drug and Drug-Disease Interactions

No drug-drug or drug-disease interactions were seen, therefore this section is not applicable.

11.4.6 By-subject Displays

Group mean data represent the principal analysis in this study and so this section is not applicable.

11.4.7 Efficacy Conclusions

The efficacy conclusions are summarised below:

- Gaviscon Double Action Aniseed Liquid was shown to increase the pH measured at electrode 6, as compared to placebo, for the period between the 3-minute and 20-minute time-points following its administration.
- Gaviscon Double Action Aniseed Liquid was shown to increase the pH measured at all other electrodes except electrode 11, as compared to placebo, though this effect was restricted to the first 30 minutes following its administration.
- Gaviscon Double Action Aniseed Liquid was shown to statistically significantly reduce the median time (minutes) to reach pH 3 at electrodes 6 and 9 in the stomach (i.e. electrodes 3 to 11 inclusive) as compared to placebo.
- Gaviscon Double Action Aniseed Liquid was shown to statistically significantly reduce the median time (minutes) to reach pH 4 at electrodes 5, 6, 7, 8, 9 and 10 in the stomach (i.e. electrodes 3 to 11 inclusive) as compared to placebo.
- Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the duration at which \geq pH 4 was maintained at electrodes 3, 4 and 5 in the stomach as compared to placebo.
- A statistically significant effect on oesophageal pH (electrodes 1 and 2) was observed in the first 10 minutes following administration of Gaviscon Double Action Aniseed Liquid as compared to placebo.

Statistical assessment of the percentage of time that the pH level was \geq pH 3 and pH 4 over 10- and 30-minute intervals during the first hour post-dose (electrodes 6 to 10 combined) was conducted for the PP population, the results are described below:

- Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing compared to placebo.
- Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the change from baseline in the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing compared to placebo.

12 SAFETY EVALUATION

All subjects who received at least one dose of IMP were included in the safety analysis.

The locations of all tables, figures, and listings pertinent to Section 12 are provided in Table 12-1.

Table 12-1 Location of Tables, Figures, and Listings for Safety Data

Topic	Location	
	Tables and Figures	Listings
Duration of IMP Exposure	-	Appendix 16.2.5.3
Summary of AEs	Table 14.3.1.1	Appendix 16.2.7.1
Summary of TEAEs by SOC and PT	Table 14.3.1.2	Appendix 16.2.7.1
Summary of TEAEs by SOC, PT and Severity	Table 14.3.1.3	Appendix 16.2.7.1
Summary of TEAEs by SOC, PT and Relationship to Study treatment	Table 14.3.1.4	Appendix 16.2.7.1
Listing of Deaths, Other SAEs and Other Significant AEs	Table 14.3.2.1	Appendix 16.2.7.1
Normal Ranges for Laboratory Data	-	Appendix 16.2.8.1
Summary of Haematology and Biochemistry Clinical Laboratory Parameters	Table 14.3.5.1	Appendix 16.2.8.2
Shift Table of Haematology and Biochemistry Clinical Laboratory Parameters	Table 14.3.5.2	Appendix 16.2.8.2
Abnormal Laboratory Results	-	Appendix 16.2.8.3
Summary of Vital Signs	Table 14.3.5.3	Appendix 16.2.9.1
Abnormal Physical Examination Findings	-	Appendix 16.2.9.2
Investigator Comments	-	Appendix 16.2.10.1

12.1 Extent of Exposure

Study treatment dosing record is listed by subject in Appendix 16.2.5, Listing 16.2.5.3.

The number of subjects who received study treatment is presented in Table 12-2.

Table 12-2 Extent of Exposure (Safety Population)

	AB	BA	Overall
Number (%) of subjects who received study treatment	6 (100.0%)	6 (100.0%)	12 (100.0%)

Source: Section 14, Table 14.1.1

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

12.2 Adverse Events

All AEs for each subject, including the same event on several occasions are listed in Appendix 16.2.7, Listing 16.2.7.1, giving both PT according to MedDRA, version 14.1 and the original term used by the Investigator.

An overview of the locations of tables, figures, and listings reporting AE data is provided in Table 12-1.

The tables in the sections that follow describe AEs occurring after the initiation of treatment with IMP.

12.2.1 Brief Summary of Adverse Events

Overall, there were no deaths or SAEs during the study and no subjects were withdrawn due to a TEAE. There were 4 TEAEs in 3 (25.0%) subjects (3 subjects following administration of Gaviscon Double Action Aniseed Liquid; no subjects reported TEAEs following administration of placebo).

A summary of TEAEs is presented in Table 12-3.

Table 12-3 Summary of Treatment-emergent Adverse Events (Safety Population)

AE Category	Treatment A (N=12) n (%) [E]	Treatment B (N=12) n (%) [E]	Overall
Any TEAEs	0 (0%) [0]	3 (25.0%) [4]	3 (25.0%) [4]
Severity in TEAEs			
Mild	0 (0%) [0]	3 (25.0%) [4]	3 (25.0%) [4]
Moderate	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Severe	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Causality in TEAEs			
None	0 (0%) [0]	3 (25.0%) [4]	3 (25.0%) [4]
Unlikely	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Possible	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Probable	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Definite	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Any SAEs	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]
Any TEAEs leading to discontinuation	0 (0%) [0]	0 (0%) [0]	0 (0%) [0]

Source: Section 14, Table 14.3.1.1, Table 14.3.1.3, Table 14.3.1.4

Abbreviations: E = number of events; n = number of subjects with an event; SAE = serious adverse event; TEAE = treatment-emergent adverse event

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

12.2.2 Display of Adverse Events

All AEs for each subject, including the same event on several occasions are listed in Appendix 16.2.7, Listing 16.2.7.1, giving both PTs according to MedDRA, version 14.1 and the original term used by the Investigator.

An overview of the locations of tables, figures, and listings reporting AE data is provided in Table 12-1.

The sections that follow describe AEs occurring after the initiation of treatment with IMP. Full tables are included in Section 14.2.1.17.

12.2.3 Analysis of Adverse Events

12.2.3.1 Analysis of Treatment-emergent Adverse Events

Treatment-emergent AEs by SOC, PT and treatment are summarised in Section 14, Table 14.3.1.2 and presented in Table 12-4.

The 4 TEAEs reported during the study were abdominal discomfort (1 instance), increased AST (1 instance) and headache (2 instances). There were no TEAEs reported following administration of placebo.

Table 12-4 Treatment-emergent Adverse Events Reported by System Organ Class, Preferred Term and Treatment (Safety Population)

System organ Class Preferred Term	Treatment A (N=12) n (%) [E]	Treatment B (N=12) n (%) [E]	Overall
Any TEAEs	0 (0%) [0]	3 (25.0%) [4]	3 (25.0%) [4]
Gastrointestinal disorders	0 (0%) [0]	1 (8.3%) [1]	1 (8.3%) [1]
Abdominal discomfort	0 (0%) [0]	1 (8.3%) [1]	1 (8.3%) [1]
Investigations	0 (0%) [0]	1 (8.3%) [1]	1 (8.3%) [1]
AST increased	0 (0%) [0]	1 (8.3%) [1]	1 (8.3%) [1]
Nervous system disorders	0 (0%) [0]	1 (8.3%) [2]	1 (8.3%) [2]
Headache	0 (0%) [0]	1 (8.3%) [2]	1 (8.3%) [2]

Source: Section 14, Table 14.3.1.2

Abbreviations: AST = aspartate aminotransferase; E = number of events; n = number of subjects with an event; TEAE = treatment-emergent adverse event

Treatment A: Placebo

Treatment B: Gaviscon Double Action Aniseed Liquid (10 ml)

12.2.3.2 Analysis of Treatment-emergent Adverse Events by Intensity

Treatment-emergent AEs by SOC, PT, severity grade and treatment are summarised in Section 14, Table 14.3.1.3.

No severe or moderate TEAEs were reported. All of the TEAEs were mild in intensity (4 TEAEs) and were experienced by 3 subjects following treatment with Gaviscon Double Action Aniseed Liquid (10 ml). No subject reported more than one TEAE, except for Subject 005 who reported two TEAEs of headache. All other TEAEs were reported by individual subjects.

12.2.3.3 Analysis of Treatment-emergent Adverse Events by Relationship

Treatment-emergent AEs by SOC, PT, relationship to study treatment and treatment are summarised in Section 14, Table 14.3.1.4.

No related TEAEs were reported. All of the TEAEs were not related to study treatment (4 TEAEs) and were experienced by 3 subjects following treatment with Gaviscon Double Action Aniseed Liquid (10 ml).

12.3 Deaths, Other Serious Adverse Events and Other Significant Adverse Events

There were no deaths, other SAEs, or other significant AEs in this study (Section 14, Table 14.3.2.1).

12.4 Clinical Laboratory Evaluation

12.4.1 Listing of Individual Laboratory Measurements by Subject and Each Clinically Significant Abnormal Laboratory Value

Normal ranges for laboratory data are presented in Appendix 16.2.8, Listing 16.2.8.1; individual clinical laboratory data by category are presented in Appendix 16.2.8, Listing 16.2.8.2; abnormal laboratory results by category are presented in Appendix 16.2.8., Listing 16.2.8.3. Summary statistics for the safety population by time-point are presented in Section 14, Table 14.3.5.1; a shift table of laboratory parameters is presented in Section 14, Table 14.3.5.2.

12.4.2 Evaluation of Each Laboratory Parameter

The active moiety of the IMP used in this study has been licensed for use in man for many years. Their safety profile is very well established. For the purposes of this study, a clinically significant laboratory abnormal value is based on the clinical judgement of the Investigator.

12.4.2.1 Individual Subject Changes

A shift table of laboratory parameters is presented in Section 14, Table 14.3.5.2.

The majority of subjects had normal haematology and biochemistry values at screening and at follow-up. For some parameters, only a small number of subjects deviated (high or low) from normal at the follow-up.

Shifts in haematology parameters from normal to low were seen for haemoglobin (3 [25.0%] subjects) and red blood cells (2 [16.7%] subjects). Shifts from low to normal were seen for basophil count (3 [25.0%] subjects), eosinophil count (1 [8.3%] subject) and lymphocyte count (2 [16.7%] subjects). Shifts from high to normal were seen for platelet count (1 [8.3%] subject). Eosinophil count and lymphocyte count was low at screening and low at follow-up for 1 (8.3%) subject each.

Shifts in biochemistry parameters from normal to high were seen for ALT (1 [8.3%] subject) and AST (1 [8.3%] subject). Creatinine was high at screening and high at follow-up for 1 (8.3%) subject.

12.4.2.2 Individual Clinically Significant Abnormalities

Individual clinical laboratory data by category are presented in Appendix 16.2.8, Listing 16.2.8.2; abnormal laboratory results by category are presented in Appendix 16.2.8., Listing 16.2.8.3. Summary statistics for the safety population by time-point are presented in Section 14, Table 14.3.5.1.

One subject (Subject 011) had abnormal ALT (55 U/L; normal range: 2 to 41 U/L) and AST (178 U/L; normal range: 2 to 40 U/L) values at follow-up (14 May 2012) that, based on the clinical judgement of the Investigator, were considered clinically significant. The increased AST was reported as a TEAE (see Table 12-4), but none of the abnormalities led to the withdrawal of the subject (see Section 12.2.3.1). Results of the repeat analysis performed on 18 May 2012 (ALT [56 U/L], AST [89 U/L] and creatine kinase [1166 U/L; normal range: 40 - 320 U/L]) were, based on the clinical judgement of the Investigator, still considered clinically significant. Values upon repeat analysis performed on 24 May 2012 returned to within normal ranges: ALT (30 U/L), AST (31 U/L) and creatine kinase (213 U/L). The TEAE of AST increased was also considered to have been resolved on 24 May 2012 (see Appendix 16.2.7, Listing 16.2.7.1).

12.5 Vital Signs, Physical Findings and Other Observations Related to Safety

12.5.1 Vital Signs

Individual vital sign measurements are presented in Appendix 16.2.9, Listing 16.2.9.1. Summary statistics for the safety population by time-point are presented in Section 14, Table 14.3.5.3. There were no clinically significant changes in vital signs during the study.

12.5.2 Physical Examination

Individual physical examination abnormalities are presented in Appendix 16.2.9, Listing 16.2.9.2. There were no clinically significant abnormalities in physical examination at screening or follow-up.

12.5.3 Pregnancy

No female subjects had a positive pregnancy test at screening or admission to the CPU (Appendix 16.2.4, Listing 16.2.4.4).

12.6 Safety Conclusions

- Administration of Gaviscon Double Action Aniseed Liquid (10 ml) was well tolerated.
- Of the 12 subjects randomised in the study, all 12 subjects completed the study as per protocol.
- No deaths, SAEs or withdrawals due to TEAEs were reported.
- Overall, 4 TEAEs were reported during the study, reported by 3 subjects following treatment with Gaviscon Double Action Aniseed Liquid (10 ml).
- All of the TEAEs were mild in severity and none were considered related to the study treatment.
- One subject had abnormal ALT and AST values at follow-up that were considered to be clinically significant, but returned to within normal ranges upon repeat examinations. There were no clinically significant vital signs or physical examinations during the study.

13 DISCUSSION AND OVERALL CONCLUSIONS

13.1 Discussion

The study demonstrated that Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing compared to placebo.

In addition Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the change from baseline in the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during the first hour of dosing compared to placebo.

When looking at the individual data points (i.e., each minute), at several electrodes, statistically significant differences were observed at later time-points, with a lower pH following administration of Gaviscon Double Action Aniseed Liquid than placebo. However, given the number of data points recorded it is possible that these values were observed by chance.

Trends demonstrating that Gaviscon Double Action Aniseed Liquid significantly altered gastric pH when compared to placebo were clearly visible in the plots of smoothed pH against time for each electrode.

The novel 11 channel pH catheter used in the study was considered to be effective in demonstrating changes in gastric pH following administration of Gaviscon Double Action Aniseed Liquid.

Gaviscon Double Action Aniseed Liquid (10 ml) and procedures were well tolerated by all subjects.

13.2 Conclusion

Gaviscon Double Action Aniseed Liquid was shown to statistically significantly increase the percentage of time that the pH level was \geq pH 3 and pH 4 (averaged across electrodes 6 to 10) during **every** 10-minute and 30-minute interval post-dose during **the first hour** of dosing compared to placebo.

The 11 electrode pH catheter was clearly effective at monitoring pH change in the stomach following administration of Gaviscon Double Action Aniseed Liquid. As the data from electrodes 6 to 10 were consistent throughout the recording period the results were combined for analysis. This data set provides a good understanding of pH change throughout the stomach.

Electrodes 1 to 2 were positioned in the oesophagus and although data in this location are not relevant when assessing gastric pH, the results from these electrodes provided useful information on the location of the catheter.

14 TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT

14.1 Demographic Data

14.1.1 Summary of Subject Disposition (All Subjects)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.1.1 Summary of Subject Disposition
All Subjects (N=12)

Disposition	AB	BA	Overall
Subjects randomised	6	6	12
Subjects who received both treatments and completed study	6 (100.0%)	6 (100.0%)	12 (100.0%)
Subjects who received 1 treatment	0	0	0
Subjects who received Gaviscon Double Action Aniseed Liquid (10mL)	6 (100.0%)	6 (100.0%)	12 (100.0%)
Subjects who did not receive Gaviscon Double Action Aniseed Liquid	0	0	0
Subjects who completed treatment	6 (100.0%)	6 (100.0%)	12 (100.0%)
Subjects who discontinued treatment	0	0	0
Subjects who received Placebo	6 (100.0%)	6 (100.0%)	12 (100.0%)
Subjects who did not receive Placebo	0	0	0
Subjects who completed treatment	6 (100.0%)	6 (100.0%)	12 (100.0%)
Subjects who discontinued treatment	0	0	0

Data Source: Appendices 16.2.1.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_01.sas

29JAN2013 4:42

14.1.2 Summary of Analysis Populations (All Subjects)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.1.2 Summary of Analysis Populations
All Subjects (N=12)

Criterion	AB	BA	Overall
Subjects Randomised	6	6	12
All Subjects Population			
Number of Subjects Included	6 (100.0%)	6 (100.0%)	12 (100.0%)
Number of Subjects Excluded	0 (0.0%)	0 (0.0%)	0 (0.0%)
Safety Population			
Number of Subjects Included	6 (100.0%)	6 (100.0%)	12 (100.0%)
Number of Subjects Excluded	0 (0.0%)	0 (0.0%)	0 (0.0%)
Per-protocol (PP) Population			
Number of Subjects Included	6 (100.0%)	6 (100.0%)	12 (100.0%)
Number of Subjects Excluded	0 (0.0%)	0 (0.0%)	0 (0.0%)

Data Source: Appendix 16.2.3.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_02.sas

29JAN2013 4:43

14.1.3 Summary of Demographic Data and Baseline Characteristics (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 2

Table 14.1.3 Summary of Demographic Data and Baseline Characteristics
Safety Population (N=12)

Parameter	Statistic	AB	BA	Overall
Age (Years)	n	6	6	12
	Mean	28.0	22.3	25.2
	SD	4.47	2.16	4.47
	CV (%)	16.0	9.7	17.8
	Median	29.5	21.5	24.0
	Minimum	22	20	20
	Maximum	33	25	33
Sex				
Male	n (%)	5 (83.3%)	4 (66.7%)	9 (75.0%)
Female	n (%)	1 (16.7%)	2 (33.3%)	3 (25.0%)
Race				
Caucasian	n (%)	5 (83.3%)	6 (100.0%)	11 (91.7%)
Afro-Caribbean	n (%)	1 (16.7%)	0	1 (8.3%)
Weight (kg)	n	6	6	12
	Mean	79.15	73.93	76.54
	SD	9.483	8.290	8.919
	CV (%)	12.0	11.2	11.7
	Median	76.35	77.45	76.85
	Minimum	69.5	63.3	63.3
	Maximum	92.3	83.2	92.3

Data Source: Appendix 16.2.4.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_03.sas

29JAN2013 4:43

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 2

Table 14.1.3 Summary of Demographic Data and Baseline Characteristics
Safety Population (N=12)

Parameter	Statistic	AB	BA	Overall
Height (m)	n	6	6	12
	Mean	1.750	1.772	1.761
	SD	0.0219	0.0679	0.0494
	CV (%)	1.3	3.8	2.8
	Median	1.755	1.785	1.760
	Minimum	1.72	1.66	1.66
	Maximum	1.78	1.85	1.85
BMI (kg/m ²)	n	6	6	12
	Mean	25.82	23.50	24.66
	SD	2.574	1.384	2.312
	CV (%)	10.0	5.9	9.4
	Median	24.80	23.55	24.35
	Minimum	23.5	21.3	21.3
	Maximum	29.8	25.1	29.8
Number of Smokers	n (%)	2 (33.3%)	1 (16.7%)	3 (25.0%)

Data Source: Appendix 16.2.4.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_03.sas

29JAN2013 4:43

14.1.4 Summary of Pre-study Medication (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.1.4 Summary of Pre-study Medication
Safety Population (N=12)

ATC CODE LEVEL 2/ ATC CODE LEVEL 4	AB	BA	Overall
All subjects with at least one pre-study drug treatment	1 (16.7%)	1 (16.7%)	2 (16.7%)
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	1 (16.7%)	1 (16.7%)	2 (16.7%)
PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS	1 (16.7%)	1 (16.7%)	2 (16.7%)

Data Source: Appendix 16.2.4.5

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_04.sas

29JAN2013 4:44

14.1.5 Summary of Concomitant Medication (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.1.5 Summary of Concomitant Medication
Safety Population (N=12)

ATC CODE LEVEL 2/ ATC CODE LEVEL 4	AB	BA	Overall
All subjects with at least one concomitant drug treatment	0	1 (16.7%)	1 (8.3%)
ANALGESICS	0	1 (16.7%)	1 (8.3%)
ANILIDES	0	1 (16.7%)	1 (8.3%)

Data Source: Appendix 16.2.4.6

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_01_05.sas

29JAN2013 4:44

14.2 Efficacy Data

14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	1 min	12	6.478	1.6583	1.29	6.857	7.51	25.6
		2 min	12	6.723	1.7572	1.53	6.991	8.87	26.1
		3 min	12	6.507	1.7323	1.31	6.936	8.24	26.6
		4 min	12	6.393	1.6766	1.45	6.766	8.04	26.2
		5 min	12	6.684	1.6950	1.65	6.980	8.24	25.4
		6 min	12	6.503	1.6915	1.45	6.882	7.72	26.0
		7 min	12	6.677	1.8383	1.34	7.047	8.65	27.5
		8 min	12	6.644	1.7613	1.39	7.060	8.17	26.5
		9 min	12	6.389	1.6669	1.41	6.838	7.87	26.1
		10 min	12	6.512	1.7399	1.48	6.808	8.77	26.7
		11 min	12	6.707	1.8530	1.39	6.943	9.02	27.6
		12 min	12	6.625	1.7493	1.56	6.933	8.95	26.4
		13 min	12	6.625	1.7987	1.44	6.902	8.88	27.2
		14 min	12	6.599	1.7617	1.38	6.781	8.67	26.7
		15 min	12	6.482	1.6636	1.51	6.823	7.74	25.7
		16 min	12	6.271	2.2258	1.58	6.913	9.18	35.5
		17 min	12	6.431	1.9507	1.49	6.927	8.91	30.3
		18 min	12	6.696	1.8021	1.41	7.060	8.12	26.9
		19 min	12	6.760	1.9329	1.45	7.080	9.31	28.6
		20 min	12	6.434	1.8151	1.45	6.945	9.09	28.2
		21 min	12	6.158	1.6363	1.39	6.758	7.48	26.6
		22 min	12	6.553	1.8453	1.37	6.858	9.18	28.2
		23 min	12	6.426	1.7811	1.41	6.756	9.07	27.7
		24 min	12	6.654	1.8356	1.50	6.884	9.11	27.6
		25 min	12	6.417	2.0405	1.36	6.725	8.95	31.8
		26 min	12	6.647	1.7961	1.57	6.832	9.11	27.0
		27 min	12	6.351	1.5774	1.61	6.764	7.64	24.8
		28 min	12	6.940	0.8372	5.36	6.893	8.65	12.1
		29 min	12	6.499	1.7188	1.43	6.832	8.26	26.4
		30 min	12	6.606	1.7432	1.71	6.749	8.97	26.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	31 min	12	6.662	1.6852	1.84	6.880	8.78	25.3
		32 min	11	6.514	1.6265	1.77	6.873	7.65	25.0
		33 min	10	6.587	1.8836	1.81	6.773	8.80	28.6
		34 min	10	6.402	1.9483	2.38	6.959	8.25	30.4
		35 min	10	6.260	2.0863	1.53	6.715	8.06	33.3
		36 min	10	6.335	1.7912	1.80	6.660	8.31	28.3
		37 min	10	6.430	2.0128	1.38	6.665	8.76	31.3
		38 min	10	6.086	2.3873	1.35	6.789	8.55	39.2
		39 min	10	6.075	2.1849	1.33	6.746	8.19	36.0
		40 min	10	6.438	2.2960	1.36	6.812	9.18	35.7
		41 min	10	6.497	2.1679	1.42	6.996	8.67	33.4
		42 min	11	6.640	2.0665	1.12	7.066	8.45	31.1
		43 min	12	6.623	2.0226	1.22	6.839	8.46	30.5
		44 min	12	6.115	2.1212	1.20	6.702	8.05	34.7
		45 min	12	6.585	1.8811	1.20	7.037	7.87	28.6
		46 min	12	6.445	2.0550	1.19	6.843	8.16	31.9
		47 min	12	6.567	1.9840	1.15	6.833	8.86	30.2
		48 min	12	6.396	1.7853	1.22	6.758	8.10	27.9
		49 min	12	6.497	1.9629	1.08	6.524	8.90	30.2
		50 min	12	6.177	2.3622	1.13	6.836	8.06	38.2
		51 min	11	6.126	2.1643	1.25	6.764	8.43	35.3
		52 min	11	6.244	1.7423	1.30	6.701	7.54	27.9
		53 min	11	6.239	1.7855	1.18	6.729	7.63	28.6
		54 min	11	6.411	1.8003	1.26	6.820	7.76	28.1
		55 min	11	6.454	1.8103	1.28	6.810	8.08	28.0
		56 min	11	6.470	1.8514	1.23	6.838	7.99	28.6
		57 min	11	6.563	1.8934	1.20	7.050	8.04	28.9
		58 min	11	6.415	1.8267	1.21	6.852	7.81	28.5
		59 min	11	6.552	1.8675	1.22	7.084	8.02	28.5
		60 min	11	6.291	1.7859	1.07	6.855	7.47	28.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	61 min	11	6.341	1.8257	1.19	6.895	7.89	28.8
		62 min	11	6.536	1.8827	1.14	6.892	8.28	28.8
		63 min	10	5.942	1.9836	1.31	6.765	7.44	33.4
		64 min	10	5.892	2.1551	1.28	6.894	7.37	36.6
		65 min	9	6.224	2.0668	1.29	7.145	7.98	33.2
		66 min	9	5.998	2.2228	1.35	6.970	7.82	37.1
		67 min	9	6.000	2.4395	1.19	7.030	8.02	40.7
		68 min	9	6.355	2.3527	1.28	6.857	8.82	37.0
		69 min	9	6.374	2.2206	1.27	6.800	8.44	34.8
		70 min	9	6.298	2.2178	1.41	7.050	8.29	35.2
		71 min	9	6.167	1.9766	1.53	6.770	7.90	32.1
		72 min	9	6.340	1.9580	1.53	7.159	7.89	30.9
		73 min	9	6.235	2.1383	1.44	6.790	8.08	34.3
		74 min	9	6.230	2.1603	1.05	6.794	8.40	34.7
		75 min	9	6.168	2.0245	1.25	6.690	8.30	32.8
		76 min	9	5.898	2.0908	1.31	6.584	7.78	35.5
		77 min	9	6.322	1.9645	1.25	6.971	7.68	31.1
		78 min	9	6.540	2.1171	1.24	7.278	8.25	32.4
		79 min	9	6.485	2.0738	1.22	7.294	7.71	32.0
		80 min	9	6.342	1.9858	1.31	6.900	7.80	31.3
		81 min	9	5.563	2.1944	1.35	6.452	7.83	39.4
		82 min	9	6.591	2.0883	1.41	6.944	8.65	31.7
		83 min	9	6.291	1.9213	1.41	6.740	7.85	30.5
		84 min	9	6.320	1.7302	2.03	6.935	7.94	27.4
		85 min	9	5.841	2.0934	1.22	6.700	7.67	35.8
		86 min	9	6.313	1.9734	1.39	6.777	8.24	31.3
		87 min	9	6.415	1.8976	1.73	6.890	8.05	29.6
		88 min	9	6.517	2.0376	1.36	7.079	8.17	31.3
		89 min	9	6.380	2.0158	1.36	6.907	8.03	31.6
		90 min	9	6.456	2.0243	1.37	6.939	8.29	31.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	91 min	9	6.260	2.0824	1.51	6.960	8.06	33.3
		92 min	9	6.415	2.1293	1.21	6.956	8.28	33.2
		93 min	10	6.020	2.4017	1.28	6.843	8.31	39.9
		94 min	10	6.479	2.0122	1.36	7.088	8.46	31.1
		95 min	11	6.938	1.1779	4.52	7.084	8.63	17.0
		96 min	11	6.572	1.8639	1.42	6.860	8.09	28.4
		97 min	11	6.622	1.9498	1.35	6.851	9.06	29.4
		98 min	11	6.425	2.0422	1.37	6.957	9.00	31.8
		99 min	11	6.560	1.8966	1.29	7.029	8.43	28.9
		100 min	11	6.576	1.9136	1.28	7.185	8.11	29.1
		101 min	11	6.701	1.9790	1.45	7.201	9.27	29.5
		102 min	11	6.626	1.8155	1.73	6.811	8.90	27.4
		103 min	11	6.714	1.8945	1.53	6.929	8.73	28.2
		104 min	11	6.639	1.9245	1.33	6.959	9.02	29.0
		105 min	11	6.508	2.2637	1.35	7.008	8.68	34.8
		106 min	11	6.472	1.9765	1.20	6.837	9.11	30.5
		107 min	11	6.482	1.9197	1.30	6.806	8.49	29.6
		108 min	11	6.545	1.9205	1.28	6.997	8.97	29.3
		109 min	11	6.627	1.9167	1.34	6.995	8.62	28.9
		110 min	11	6.630	1.9356	1.23	7.113	8.55	29.2
		111 min	11	6.431	1.7848	1.25	6.951	7.87	27.8
		112 min	11	6.475	1.9400	1.21	6.873	8.54	30.0
		113 min	11	6.171	1.9918	1.17	6.870	7.93	32.3
		114 min	11	6.403	1.8831	1.31	6.877	7.97	29.4
		115 min	11	6.557	1.9263	1.20	6.882	8.45	29.4
		116 min	11	6.549	1.8953	1.25	6.884	8.02	28.9
		117 min	10	6.507	1.9047	1.44	6.856	7.91	29.3
		118 min	10	6.396	1.8853	1.24	6.784	8.10	29.5
		119 min	10	6.320	1.8837	1.25	6.632	7.86	29.8
		120 min	10	6.136	1.8186	1.19	6.510	7.82	29.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	121 min	10	6.478	1.9993	1.28	6.773	8.60	30.9
		122 min	10	6.458	1.9593	1.19	6.975	8.12	30.3
		123 min	11	6.223	1.8569	1.27	6.839	7.72	29.8
		124 min	11	6.412	1.7990	1.26	6.809	8.13	28.1
		125 min	11	6.578	1.8984	1.20	6.793	8.54	28.9
		126 min	11	6.107	2.1762	1.16	6.754	9.08	35.6
		127 min	11	6.671	1.9285	1.25	6.942	8.97	28.9
		128 min	11	6.514	1.9293	1.15	6.874	8.55	29.6
		129 min	11	6.551	1.9097	1.16	7.068	8.32	29.2
		130 min	11	6.552	1.9745	1.26	6.790	9.08	30.1
		131 min	11	6.522	1.9306	1.24	6.853	8.68	29.6
		132 min	11	6.520	2.0122	1.28	7.033	9.01	30.9
		133 min	10	6.298	1.7592	1.58	6.621	7.92	27.9
		134 min	11	6.359	1.7365	1.36	6.774	7.93	27.3
		135 min	11	6.591	1.9970	1.25	6.840	9.45	30.3
		136 min	11	6.725	1.9885	1.32	7.008	9.40	29.6
		137 min	11	6.575	1.9083	1.33	6.791	8.95	29.0
		138 min	11	6.643	1.9301	1.31	6.985	8.74	29.1
		139 min	11	6.673	1.9220	1.21	7.220	8.12	28.8
		140 min	11	6.660	1.8631	1.38	7.117	8.10	28.0
		141 min	11	6.670	1.8489	1.34	7.052	7.93	27.7
		142 min	11	6.206	2.1784	1.24	6.933	7.90	35.1
		143 min	11	6.499	1.7517	1.33	6.900	7.55	27.0
		144 min	11	6.594	1.8317	1.36	6.833	8.42	27.8
		145 min	10	6.525	1.9286	1.24	6.905	8.14	29.6
		146 min	10	6.530	1.9475	1.34	6.869	8.34	29.8
		147 min	10	6.138	1.9410	1.31	6.821	7.90	31.6
		148 min	10	6.351	1.9134	1.49	6.694	8.08	30.1
		149 min	10	6.501	1.9076	1.47	6.831	8.51	29.3
		150 min	10	6.516	1.8580	1.53	6.847	8.42	28.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	151 min	10	6.570	1.9580	1.47	6.848	8.66	29.8
		152 min	10	6.500	1.8829	1.50	6.787	8.63	29.0
		153 min	10	6.536	1.9978	1.46	6.729	9.14	30.6
		154 min	10	6.532	1.9003	1.49	6.806	8.33	29.1
		155 min	10	6.486	1.8755	1.55	6.757	8.36	28.9
		156 min	10	6.456	1.8905	1.57	6.788	8.61	29.3
		157 min	10	6.602	1.9129	1.51	7.114	7.89	29.0
		158 min	10	6.663	1.9468	1.53	7.079	8.36	29.2
		159 min	10	6.616	1.8443	1.55	7.090	7.83	27.9
		160 min	10	6.607	1.8524	1.57	7.003	7.91	28.0
		161 min	10	6.754	1.9674	1.54	7.139	8.90	29.1
		162 min	10	6.412	1.8505	1.55	6.572	8.26	28.9
		163 min	11	6.558	1.7849	1.49	7.056	8.23	27.2
		164 min	11	6.649	1.8268	1.44	7.030	7.84	27.5
		165 min	11	6.677	1.8107	1.40	7.201	8.04	27.1
		166 min	11	6.783	1.8599	1.45	7.317	8.11	27.4
		167 min	11	6.807	1.8912	1.47	7.341	8.33	27.8
		168 min	11	6.610	1.7924	1.53	7.148	8.05	27.1
		169 min	10	6.662	1.9269	1.47	7.320	8.02	28.9
		170 min	10	6.518	1.8102	1.55	7.174	7.67	27.8
		171 min	10	6.651	1.8690	1.50	6.991	7.88	28.1
		172 min	10	6.507	1.8247	1.52	6.852	8.10	28.0
		173 min	10	6.761	1.9691	1.41	7.482	8.13	29.1
		174 min	10	6.937	2.1641	1.59	7.301	9.58	31.2
		175 min	10	6.827	2.0738	1.44	7.307	8.89	30.4
		176 min	10	6.494	1.9836	1.49	7.032	8.37	30.5
		177 min	10	6.633	2.0508	1.43	6.839	9.14	30.9
		178 min	10	6.654	2.0673	1.47	6.699	9.41	31.1
		179 min	10	6.684	1.9968	1.40	7.091	8.39	29.9
		180 min	10	6.638	2.0713	1.52	6.854	9.69	31.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	181 min	10	6.720	2.0091	1.46	6.996	9.04	29.9
		182 min	10	6.645	2.0289	1.45	6.859	9.12	30.5
		183 min	10	6.719	2.0699	1.46	6.987	9.32	30.8
		184 min	10	6.641	2.0074	1.43	6.826	9.18	30.2
		185 min	9	6.572	2.1526	1.36	7.146	9.14	32.8
		186 min	8	6.874	2.3207	1.50	7.722	9.03	33.8
		187 min	9	6.756	2.1057	1.45	7.442	8.27	31.2
		188 min	9	6.462	2.0066	1.32	6.888	7.75	31.1
		189 min	9	6.713	2.0679	1.50	7.171	8.80	30.8
		190 min	9	6.454	1.9751	1.46	6.821	8.42	30.6
		191 min	9	6.755	2.1093	1.42	7.297	8.81	31.2
		192 min	9	6.479	1.9113	1.52	6.907	7.62	29.5
		193 min	9	6.142	2.1236	1.51	7.109	8.09	34.6
		194 min	9	6.262	2.1044	1.51	6.982	8.11	33.6
		195 min	9	6.521	1.9485	1.54	6.850	8.09	29.9
		196 min	9	6.518	1.9394	1.50	7.058	8.07	29.8
		197 min	9	6.486	1.9328	1.60	6.897	8.21	29.8
		198 min	10	6.416	1.7622	1.55	6.908	7.48	27.5
		199 min	10	6.355	1.8008	1.46	6.890	7.87	28.3
		200 min	10	6.439	1.8248	1.62	6.869	8.07	28.3
		201 min	10	6.183	1.7476	1.54	6.586	7.59	28.3
		202 min	10	6.384	1.8459	1.54	6.769	8.09	28.9
		203 min	11	6.919	1.8865	1.61	7.469	8.61	27.3
		204 min	11	6.789	1.8809	1.57	7.578	8.36	27.7
		205 min	11	6.647	1.9516	1.47	6.744	8.99	29.4
		206 min	11	6.144	2.1972	1.51	6.873	8.45	35.8
		207 min	10	6.651	1.8798	1.59	7.024	8.14	28.3
		208 min	10	6.121	2.4495	1.55	6.616	9.13	40.0
		209 min	10	6.267	2.2027	1.43	6.745	9.10	35.1
		210 min	10	6.406	1.8328	1.67	6.716	8.03	28.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	211 min	10	6.770	1.4123	3.70	6.741	8.91	20.9
		212 min	10	6.547	1.8734	1.64	6.913	8.16	28.6
		213 min	10	6.555	1.9010	1.58	6.776	8.17	29.0
		214 min	10	6.464	1.7926	1.60	6.865	7.86	27.7
		215 min	10	5.920	2.4043	1.43	6.833	7.86	40.6
		216 min	10	6.273	1.8278	1.63	7.104	7.54	29.1
		217 min	10	6.335	1.6957	1.72	6.878	7.85	26.8
		218 min	10	6.421	1.7761	1.69	6.949	7.88	27.7
		219 min	10	6.536	1.8769	1.61	7.222	7.98	28.7
		220 min	10	6.654	1.9680	1.75	7.028	9.10	29.6
		221 min	10	6.268	2.4172	1.89	7.062	8.57	38.6
		222 min	10	6.246	2.5199	1.74	6.731	9.35	40.3
		223 min	10	6.344	2.3963	1.57	6.631	9.68	37.8
		224 min	10	6.448	1.9904	1.53	6.577	9.33	30.9
		225 min	10	6.550	1.8694	1.54	6.811	8.32	28.5
		226 min	10	6.367	1.9693	1.66	6.686	9.22	30.9
		227 min	10	6.651	1.9805	1.66	6.917	8.93	29.8
		228 min	10	6.673	1.8814	1.66	7.061	8.43	28.2
		229 min	11	6.805	1.8655	1.70	7.120	8.92	27.4
		230 min	11	6.660	1.7908	1.61	6.946	8.03	26.9
		231 min	11	6.749	1.8647	1.70	7.296	9.10	27.6
		232 min	11	6.601	1.8344	1.67	7.224	8.55	27.8
		233 min	11	6.675	1.8051	1.75	6.794	8.70	27.0
		234 min	11	6.351	2.2452	1.82	6.782	9.12	35.4
		235 min	10	6.197	1.4942	3.77	6.665	7.85	24.1
		236 min	11	6.604	1.8190	1.75	6.723	8.58	27.5
		237 min	11	6.544	1.8396	1.83	6.633	8.98	28.1
		238 min	11	6.562	1.8527	1.55	6.700	8.16	28.2
		239 min	11	6.417	1.7942	1.48	6.618	8.07	28.0
		240 min	6	6.041	2.3398	1.45	6.654	7.90	38.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 9 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	1 min	12	6.518	1.5261	1.70	6.915	7.30	23.4
		2 min	12	6.589	1.5951	1.81	6.843	8.49	24.2
		3 min	12	6.488	1.5204	1.81	6.812	7.58	23.4
		4 min	12	6.535	1.6931	1.71	6.967	7.94	25.9
		5 min	12	6.648	1.6352	1.66	7.129	7.72	24.6
		6 min	12	6.529	1.5610	1.67	6.889	7.51	23.9
		7 min	12	6.450	1.6089	1.60	6.757	8.29	24.9
		8 min	12	6.719	1.7010	1.53	7.144	7.97	25.3
		9 min	12	6.443	1.5453	1.57	6.876	7.14	24.0
		10 min	12	6.561	1.5637	1.86	6.925	7.73	23.8
		11 min	12	6.561	1.6470	1.56	6.908	7.74	25.1
		12 min	12	6.481	1.6293	1.58	6.829	7.82	25.1
		13 min	12	6.597	1.6983	1.59	6.948	8.07	25.7
		14 min	12	6.477	1.6606	1.52	6.823	7.66	25.6
		15 min	12	6.396	1.7556	1.54	6.851	7.83	27.4
		16 min	12	6.246	2.1310	1.56	6.867	8.28	34.1
		17 min	12	6.330	1.7299	1.56	6.928	7.72	27.3
		18 min	12	6.666	1.7715	1.55	7.121	7.94	26.6
		19 min	12	6.666	1.8483	1.53	7.222	8.21	27.7
		20 min	12	6.417	1.6997	1.57	6.880	7.90	26.5
		21 min	12	5.745	1.9803	1.55	6.829	7.64	34.5
		22 min	12	6.523	1.7323	1.48	6.890	8.07	26.6
		23 min	12	6.394	1.5947	1.59	6.779	7.68	24.9
		24 min	12	6.435	1.6391	1.49	6.726	7.61	25.5
		25 min	12	6.318	1.9599	1.48	6.889	8.20	31.0
		26 min	12	6.502	1.7305	1.50	6.849	7.99	26.6
		27 min	12	5.987	2.2125	1.08	6.813	7.49	37.0
		28 min	12	6.298	1.5699	1.77	6.858	7.38	24.9
		29 min	12	6.397	1.6340	1.73	6.690	8.06	25.5
		30 min	12	6.307	1.6225	1.54	6.773	8.14	25.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 10 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	31 min	12	6.351	1.5824	1.58	6.794	7.53	24.9
		32 min	11	6.259	1.9319	1.43	6.893	7.99	30.9
		33 min	10	6.366	1.8073	1.55	6.766	7.99	28.4
		34 min	10	5.921	2.1145	1.48	6.744	7.96	35.7
		35 min	10	5.938	1.9000	1.48	6.324	7.78	32.0
		36 min	10	6.020	1.9587	1.43	6.723	7.73	32.5
		37 min	10	6.007	2.0672	1.17	6.756	7.86	34.4
		38 min	10	6.041	2.2952	1.50	6.879	8.04	38.0
		39 min	10	5.802	2.0934	1.34	6.781	7.81	36.1
		40 min	10	6.260	1.8149	2.06	6.829	7.94	29.0
		41 min	10	5.807	2.0933	1.48	6.626	8.02	36.0
		42 min	11	6.211	1.8532	1.41	6.899	7.87	29.8
		43 min	12	5.868	2.1143	1.41	6.758	7.88	36.0
		44 min	12	5.812	2.2414	1.38	6.727	7.75	38.6
		45 min	12	6.371	1.6946	1.61	6.776	7.73	26.6
		46 min	12	6.293	1.8717	1.37	6.832	7.81	29.7
		47 min	12	6.265	1.8325	1.17	6.823	7.80	29.2
		48 min	12	6.074	1.6460	1.30	6.821	7.23	27.1
		49 min	12	6.257	1.6760	1.37	6.555	7.94	26.8
		50 min	12	5.893	2.1945	1.28	6.561	8.04	37.2
		51 min	11	5.527	1.9552	1.16	6.118	7.75	35.4
		52 min	11	6.056	1.6459	1.44	6.533	7.18	27.2
		53 min	11	5.806	1.8628	1.36	6.702	7.28	32.1
		54 min	11	6.250	1.6925	1.35	6.800	7.36	27.1
		55 min	11	5.979	2.1996	1.22	6.730	8.15	36.8
		56 min	11	5.998	2.1939	1.29	6.830	7.90	36.6
		57 min	11	6.323	1.7783	1.31	6.919	7.77	28.1
		58 min	11	6.274	1.7333	1.22	6.835	7.58	27.6
		59 min	11	6.433	1.7881	1.26	6.843	7.90	27.8
		60 min	11	5.979	2.0037	1.23	6.820	7.28	33.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 11 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	61 min	11	6.133	1.7260	1.20	6.570	7.21	28.1
		62 min	11	6.103	1.8841	1.14	6.676	7.54	30.9
		63 min	10	5.934	2.2244	1.22	6.878	7.70	37.5
		64 min	10	6.034	1.9346	1.23	6.785	7.26	32.1
		65 min	9	6.092	1.9877	1.34	6.880	7.82	32.6
		66 min	9	5.594	2.0061	1.28	6.481	7.23	35.9
		67 min	9	5.354	2.6940	1.23	6.329	7.86	50.3
		68 min	9	6.142	1.9753	1.41	6.670	7.79	32.2
		69 min	9	6.371	2.0102	1.38	6.923	7.67	31.6
		70 min	9	6.188	1.9570	1.42	6.752	7.82	31.6
		71 min	9	6.315	1.8987	1.49	6.900	7.60	30.1
		72 min	9	6.433	1.9126	1.53	6.872	7.75	29.7
		73 min	9	6.003	2.1216	1.51	6.557	8.10	35.3
		74 min	9	6.198	2.0101	1.13	6.770	7.97	32.4
		75 min	9	5.970	1.8719	1.31	6.810	7.29	31.4
		76 min	9	5.676	2.1053	1.44	6.457	7.76	37.1
		77 min	9	5.758	2.1815	1.45	6.673	7.84	37.9
		78 min	9	6.079	1.8821	1.44	6.412	7.96	31.0
		79 min	9	5.966	1.7961	1.36	6.597	7.21	30.1
		80 min	9	6.026	1.7971	1.48	6.772	7.21	29.8
		81 min	9	4.981	2.6071	1.11	6.071	7.79	52.3
		82 min	9	5.903	1.9724	1.47	6.730	7.73	33.4
		83 min	9	5.793	1.8338	1.34	6.154	7.60	31.7
		84 min	9	6.111	1.7706	1.56	6.622	7.64	29.0
		85 min	9	5.075	2.2143	1.61	6.400	6.95	43.6
		86 min	9	6.148	1.6899	1.70	6.639	7.31	27.5
		87 min	9	6.266	1.6852	1.90	6.624	7.68	26.9
		88 min	9	6.071	1.8461	1.59	6.739	7.24	30.4
		89 min	9	5.778	2.0142	1.54	6.614	7.62	34.9
		90 min	9	6.186	1.7637	1.55	6.750	7.11	28.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 12 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	91 min	9	5.670	1.9491	1.67	6.400	7.34	34.4
		92 min	9	5.765	1.9837	1.44	6.692	7.66	34.4
		93 min	10	5.882	2.1434	1.48	6.737	7.88	36.4
		94 min	10	5.905	1.7939	1.55	6.439	7.88	30.4
		95 min	11	6.197	1.7623	1.43	6.743	7.91	28.4
		96 min	11	6.217	1.6458	1.60	6.766	7.49	26.5
		97 min	11	6.415	1.7498	1.55	6.909	7.78	27.3
		98 min	11	6.243	1.7709	1.59	6.790	7.61	28.4
		99 min	11	6.273	1.6392	1.58	6.570	7.76	26.1
		100 min	11	6.303	1.8411	1.47	6.788	7.98	29.2
		101 min	11	6.583	1.6900	1.64	6.930	7.80	25.7
		102 min	11	6.348	1.6636	2.40	6.815	7.73	26.2
		103 min	11	6.503	1.7233	1.74	7.008	7.73	26.5
		104 min	11	6.571	1.7109	1.61	6.914	7.90	26.0
		105 min	11	6.283	2.0489	1.56	7.021	7.81	32.6
		106 min	11	6.414	1.8327	1.43	6.854	8.07	28.6
		107 min	11	6.409	1.7327	1.54	7.026	7.72	27.0
		108 min	11	6.470	1.7790	1.39	6.919	7.93	27.5
		109 min	11	6.420	1.7623	1.41	6.891	7.99	27.5
		110 min	11	6.527	1.7769	1.38	6.670	7.88	27.2
		111 min	11	5.849	2.1112	1.52	6.594	7.83	36.1
		112 min	11	6.098	1.6863	1.48	6.450	7.63	27.7
		113 min	11	6.115	1.8483	1.33	6.660	7.87	30.2
		114 min	11	6.061	1.7937	1.46	6.620	7.51	29.6
		115 min	11	6.142	1.7240	1.52	6.750	7.54	28.1
		116 min	11	6.298	1.7584	1.31	6.775	7.75	27.9
		117 min	10	6.243	1.7772	1.60	6.634	7.94	28.5
		118 min	10	6.156	1.8050	1.53	6.771	7.93	29.3
		119 min	10	6.248	1.8502	1.53	6.631	7.93	29.6
		120 min	10	6.245	1.8175	1.41	6.747	7.94	29.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 13 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	121 min	10	6.500	1.7813	1.66	6.803	7.84	27.4
		122 min	10	6.265	1.8152	1.37	6.878	7.71	29.0
		123 min	11	6.137	1.8276	1.56	6.821	7.60	29.8
		124 min	11	5.938	2.0824	1.37	6.905	7.85	35.1
		125 min	11	6.211	1.8643	1.15	6.860	7.86	30.0
		126 min	11	5.830	2.1948	1.36	6.630	7.32	37.6
		127 min	11	6.114	2.0133	1.22	6.835	7.90	32.9
		128 min	11	6.085	1.8965	1.20	6.720	7.97	31.2
		129 min	11	6.234	1.9245	1.14	6.737	7.88	30.9
		130 min	11	6.338	1.9968	1.23	6.794	7.90	31.5
		131 min	11	6.504	1.7686	1.43	7.109	7.98	27.2
		132 min	11	6.301	1.8727	1.64	6.836	8.05	29.7
		133 min	10	6.039	1.8288	1.99	6.520	7.79	30.3
		134 min	11	6.442	1.7573	1.36	6.824	7.83	27.3
		135 min	11	6.575	1.8085	1.42	6.815	8.18	27.5
		136 min	11	6.496	1.8623	1.13	6.996	8.23	28.7
		137 min	11	6.562	1.7333	1.57	6.810	7.80	26.4
		138 min	11	6.249	1.6307	1.49	6.623	7.51	26.1
		139 min	11	6.423	1.6990	1.52	6.943	7.78	26.4
		140 min	11	6.493	1.6859	1.61	6.932	7.77	26.0
		141 min	11	6.707	1.6953	1.70	7.192	7.67	25.3
		142 min	11	6.310	1.7952	1.45	7.018	7.58	28.5
		143 min	11	6.327	1.8006	1.37	6.805	7.79	28.5
		144 min	11	6.323	1.6567	1.51	6.737	7.57	26.2
		145 min	10	6.328	1.7936	1.41	6.786	7.91	28.3
		146 min	10	6.288	1.7388	1.59	6.738	7.83	27.7
		147 min	10	6.049	1.8799	1.56	6.797	7.26	31.1
		148 min	10	6.392	1.7484	1.64	6.878	7.73	27.4
		149 min	10	6.199	1.9985	1.65	6.984	7.80	32.2
		150 min	10	6.444	1.7035	1.70	6.822	7.60	26.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 14 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	151 min	10	6.236	1.9350	1.70	6.939	7.90	31.0
		152 min	10	6.493	1.7241	1.69	6.931	7.80	26.6
		153 min	10	6.425	1.6883	1.69	6.832	7.47	26.3
		154 min	10	6.417	1.7310	1.67	6.820	7.76	27.0
		155 min	10	6.557	1.7385	1.71	6.967	7.82	26.5
		156 min	10	6.605	1.8072	1.71	6.959	7.90	27.4
		157 min	10	6.444	1.7336	1.70	6.829	7.84	26.9
		158 min	10	6.542	1.7293	1.75	6.983	7.65	26.4
		159 min	10	6.594	1.7411	1.74	6.944	7.64	26.4
		160 min	10	6.308	1.7097	1.74	6.779	7.76	27.1
		161 min	10	6.521	1.7481	1.73	6.862	8.08	26.8
		162 min	10	5.855	1.8307	1.72	6.584	7.76	31.3
		163 min	11	6.547	1.6511	1.68	7.022	7.57	25.2
		164 min	11	6.358	1.6516	1.57	6.888	7.64	26.0
		165 min	11	6.365	1.7281	1.64	6.980	7.65	27.2
		166 min	11	6.692	1.7410	1.62	7.164	7.91	26.0
		167 min	11	6.701	1.7491	1.65	7.212	7.88	26.1
		168 min	11	6.586	1.7344	1.66	7.243	7.87	26.3
		169 min	10	6.385	1.8626	1.66	7.040	7.77	29.2
		170 min	10	6.398	1.6980	1.66	6.879	7.51	26.5
		171 min	10	6.030	2.3199	1.63	6.923	7.73	38.5
		172 min	10	6.383	1.6823	1.69	6.848	7.33	26.4
		173 min	10	6.573	1.7750	1.71	6.913	7.70	27.0
		174 min	10	6.413	1.8107	1.63	6.935	7.74	28.2
		175 min	10	6.265	1.8302	1.60	6.730	7.81	29.2
		176 min	10	6.111	1.8044	1.63	6.717	7.66	29.5
		177 min	10	6.327	1.6989	1.63	6.707	7.60	26.9
		178 min	10	6.348	1.6955	1.68	6.832	7.57	26.7
		179 min	10	6.462	1.7604	1.64	6.752	7.66	27.2
		180 min	10	6.276	2.0636	1.66	7.032	7.72	32.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 15 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	181 min	10	6.578	1.7947	1.67	6.929	7.84	27.3
		182 min	10	6.561	1.8174	1.67	6.927	8.20	27.7
		183 min	10	6.345	1.8072	1.63	6.806	7.61	28.5
		184 min	10	6.313	1.6965	1.57	6.740	7.62	26.9
		185 min	9	6.105	1.8039	1.51	6.733	7.29	29.5
		186 min	8	6.095	1.9941	1.57	6.789	7.64	32.7
		187 min	9	6.158	1.9176	1.57	6.739	7.57	31.1
		188 min	9	6.408	1.8313	1.57	7.002	7.41	28.6
		189 min	9	6.498	1.8893	1.60	6.968	8.05	29.1
		190 min	9	6.497	1.8936	1.61	6.907	8.08	29.1
		191 min	9	6.423	1.8498	1.58	6.858	7.74	28.8
		192 min	9	6.222	1.9419	1.63	6.932	7.66	31.2
		193 min	9	5.875	1.9699	1.63	6.926	7.29	33.5
		194 min	9	6.186	1.8919	1.68	6.926	7.46	30.6
		195 min	9	6.303	1.9760	1.68	7.084	7.59	31.3
		196 min	9	6.316	1.8306	1.70	6.914	7.52	29.0
		197 min	9	5.999	2.0653	1.67	6.899	7.84	34.4
		198 min	10	6.075	2.1550	1.70	6.918	7.69	35.5
		199 min	10	5.804	2.0057	1.67	6.709	7.56	34.6
		200 min	10	5.969	2.1156	1.64	6.894	7.95	35.4
		201 min	10	6.061	1.7850	1.65	6.799	7.48	29.4
		202 min	10	5.978	1.7159	1.68	6.503	8.05	28.7
		203 min	11	6.573	1.7125	1.70	6.965	7.86	26.1
		204 min	11	6.592	1.7538	1.68	6.888	8.13	26.6
		205 min	11	6.509	1.6784	1.70	6.880	7.57	25.8
		206 min	11	5.976	1.8451	1.69	6.565	7.50	30.9
		207 min	10	6.279	1.7195	1.68	6.764	7.50	27.4
		208 min	10	5.908	2.2766	1.70	6.694	7.91	38.5
		209 min	10	6.119	1.8086	1.58	6.593	7.68	29.6
		210 min	10	6.023	1.7277	1.73	6.607	7.36	28.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 16 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	211 min	10	6.229	1.7871	1.72	6.830	7.61	28.7
		212 min	10	6.382	1.7106	1.72	6.735	7.76	26.8
		213 min	10	6.415	1.7102	1.75	6.751	7.66	26.7
		214 min	10	5.836	2.3270	1.38	6.780	7.66	39.9
		215 min	10	5.757	2.0691	1.72	6.546	7.71	35.9
		216 min	10	5.891	1.8025	1.73	6.576	7.27	30.6
		217 min	10	6.032	1.6181	1.76	6.343	7.73	26.8
		218 min	10	6.215	1.6738	1.77	6.625	7.69	26.9
		219 min	10	6.348	1.6722	1.78	6.661	7.89	26.3
		220 min	10	6.519	1.7275	1.78	6.980	7.82	26.5
		221 min	10	6.102	2.3475	1.75	6.908	7.95	38.5
		222 min	10	6.305	1.8015	1.78	6.800	7.86	28.6
		223 min	10	6.327	1.7886	1.77	6.792	7.73	28.3
		224 min	10	6.199	1.8367	1.78	6.753	7.77	29.6
		225 min	10	6.142	1.6783	1.79	6.692	7.56	27.3
		226 min	10	6.361	1.6778	1.79	6.892	7.53	26.4
		227 min	10	6.408	1.7347	1.73	6.737	7.87	27.1
		228 min	10	6.257	1.6809	1.80	6.757	8.03	26.9
		229 min	11	6.519	1.6117	1.80	6.903	7.61	24.7
		230 min	11	6.264	1.6914	1.76	6.755	7.75	27.0
		231 min	11	6.496	1.6158	1.79	6.878	7.70	24.9
		232 min	11	6.460	1.6209	1.81	6.723	8.18	25.1
		233 min	11	6.430	1.5995	1.80	6.753	7.64	24.9
		234 min	11	6.106	2.0545	1.80	6.712	8.12	33.6
		235 min	10	5.826	2.1424	2.14	6.550	7.97	36.8
		236 min	11	6.445	1.5894	2.30	6.865	7.91	24.7
		237 min	11	6.412	1.6430	1.95	7.049	7.74	25.6
		238 min	11	6.452	1.6379	1.94	6.736	8.04	25.4
		239 min	11	6.551	1.6170	1.90	7.113	7.71	24.7
		240 min	6	6.190	2.1664	1.80	7.016	7.43	35.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 17 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	1 min	12	4.999	2.6503	1.36	4.530	8.82	53.0
		2 min	12	5.282	2.8085	1.40	6.532	8.56	53.2
		3 min	12	4.851	2.7962	1.09	5.058	8.69	57.6
		4 min	12	4.418	2.4494	1.10	4.352	8.00	55.4
		5 min	12	3.775	2.3489	1.02	3.178	7.49	62.2
		6 min	12	4.384	2.3739	1.04	4.508	7.62	54.1
		7 min	12	4.160	2.5729	1.07	4.224	7.76	61.8
		8 min	12	4.127	2.6418	1.00	3.406	8.24	64.0
		9 min	12	3.658	2.2092	1.16	2.730	7.24	60.4
		10 min	12	4.044	2.2740	1.08	4.517	7.33	56.2
		11 min	12	3.471	2.2363	1.14	2.686	8.04	64.4
		12 min	12	4.061	2.3811	1.13	3.655	7.64	58.6
		13 min	12	3.722	2.3177	1.35	2.662	7.66	62.3
		14 min	12	4.176	2.2105	1.29	4.254	7.31	52.9
		15 min	12	4.193	2.2729	1.34	4.411	7.18	54.2
		16 min	12	3.764	2.2548	1.35	3.284	7.27	59.9
		17 min	12	3.945	2.2111	1.38	3.392	7.18	56.1
		18 min	12	3.745	2.3433	1.46	2.975	7.27	62.6
		19 min	12	3.721	2.4565	1.40	2.658	7.51	66.0
		20 min	12	3.639	2.0723	1.44	2.952	7.42	56.9
		21 min	12	3.776	2.3629	1.46	2.660	7.12	62.6
		22 min	12	3.199	2.0187	1.44	2.407	7.24	63.1
		23 min	12	3.327	2.2383	1.32	2.386	7.64	67.3
		24 min	12	3.595	2.4630	1.26	2.413	7.58	68.5
		25 min	12	3.422	2.4317	1.28	2.158	7.33	71.1
		26 min	12	3.350	2.2553	1.29	2.225	7.24	67.3
		27 min	12	3.495	2.4900	1.29	2.169	8.06	71.2
		28 min	12	3.519	2.5255	1.25	2.325	7.61	71.8
		29 min	12	3.815	2.6528	1.27	2.152	7.33	69.5
		30 min	12	3.504	2.5109	1.23	1.999	7.86	71.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 18 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	31 min	12	3.606	2.5244	1.21	2.243	7.25	70.0
		32 min	11	3.246	2.2763	1.18	2.212	7.75	70.1
		33 min	10	2.984	2.1788	1.19	1.930	7.31	73.0
		34 min	10	3.134	2.1192	1.21	2.091	7.21	67.6
		35 min	10	2.754	1.9953	1.09	1.976	7.39	72.5
		36 min	10	2.944	2.2930	1.19	1.750	7.04	77.9
		37 min	10	2.900	2.1906	1.18	1.806	7.35	75.5
		38 min	10	3.294	2.2537	1.10	2.344	7.57	68.4
		39 min	10	2.937	2.0608	1.12	1.931	7.37	70.2
		40 min	10	2.771	2.0620	1.12	1.722	7.08	74.4
		41 min	10	2.970	2.3919	1.13	1.815	7.81	80.5
		42 min	11	3.463	2.5894	1.21	2.177	7.94	74.8
		43 min	12	3.260	2.1860	1.16	2.138	7.38	67.1
		44 min	12	3.359	2.4613	1.12	1.983	7.49	73.3
		45 min	12	3.314	2.2904	1.22	2.066	7.41	69.1
		46 min	12	2.810	1.9471	1.28	1.960	7.34	69.3
		47 min	12	2.663	1.7892	1.19	2.164	7.36	67.2
		48 min	12	2.644	1.7127	1.14	2.113	7.24	64.8
		49 min	12	2.905	1.9773	1.25	2.064	7.25	68.1
		50 min	12	2.875	1.8482	1.12	2.175	7.47	64.3
		51 min	11	2.536	1.9105	0.98	1.923	7.56	75.3
		52 min	11	2.697	1.8455	1.15	1.912	7.35	68.4
		53 min	11	2.511	1.7897	1.09	2.021	7.24	71.3
		54 min	11	2.719	1.9001	1.09	1.863	7.34	69.9
		55 min	11	2.604	1.7549	0.94	2.169	7.11	67.4
		56 min	11	2.772	1.8898	1.13	2.139	7.38	68.2
		57 min	11	2.749	1.8762	0.98	1.885	7.44	68.3
		58 min	11	3.247	2.3787	1.11	2.381	7.54	73.3
		59 min	11	3.196	2.5149	1.02	1.922	7.18	78.7
		60 min	11	3.275	2.4661	0.95	1.905	7.68	75.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 19 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	61 min	11	3.254	2.5778	0.90	2.178	7.87	79.2
		62 min	11	3.086	2.4778	0.83	2.374	7.82	80.3
		63 min	10	2.899	2.5067	1.02	1.740	7.66	86.5
		64 min	10	2.862	2.3697	0.95	1.930	7.53	82.8
		65 min	9	2.916	2.7121	1.01	1.539	7.71	93.0
		66 min	9	2.870	2.7678	1.12	1.469	8.04	96.4
		67 min	9	2.758	2.6652	1.07	1.433	7.50	96.6
		68 min	9	2.755	2.6296	0.92	1.741	7.40	95.4
		69 min	9	2.775	2.5187	1.07	1.828	7.36	90.8
		70 min	9	2.809	2.5692	0.98	1.743	7.37	91.5
		71 min	9	2.914	2.5887	1.10	1.860	7.56	88.8
		72 min	9	2.825	2.4004	0.81	1.869	7.34	85.0
		73 min	9	2.808	2.6417	1.11	1.698	7.75	94.1
		74 min	9	2.932	2.7968	0.87	1.891	7.93	95.4
		75 min	9	3.229	2.5521	1.11	2.110	7.49	79.0
		76 min	9	2.978	2.6288	0.94	1.808	7.66	88.3
		77 min	9	3.273	2.7720	1.18	1.736	7.87	84.7
		78 min	9	3.164	2.7010	1.15	1.779	7.64	85.4
		79 min	9	2.966	2.4604	1.16	1.615	7.33	83.0
		80 min	9	3.168	2.5241	1.07	2.116	7.49	79.7
		81 min	9	2.704	2.1461	1.17	1.725	7.53	79.4
		82 min	9	2.716	2.1275	1.27	1.628	7.44	78.3
		83 min	9	2.902	2.3095	1.22	1.699	7.23	79.6
		84 min	9	3.151	2.3820	1.25	1.651	7.37	75.6
		85 min	9	2.968	2.2431	1.15	2.146	7.45	75.6
		86 min	9	2.710	1.9569	1.17	1.693	7.24	72.2
		87 min	9	2.619	2.0104	1.20	1.795	7.34	76.8
		88 min	9	2.550	1.9303	1.25	1.786	7.41	75.7
		89 min	9	2.802	1.9287	1.22	2.233	7.37	68.8
		90 min	9	2.640	1.9049	1.25	2.035	7.33	72.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 20 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	91 min	9	2.451	1.8283	1.26	1.929	7.01	74.6
		92 min	9	2.518	1.8891	1.26	1.752	7.33	75.0
		93 min	10	2.688	1.8459	1.34	1.902	7.24	68.7
		94 min	10	2.661	1.9477	1.27	1.765	7.16	73.2
		95 min	11	2.500	1.8015	1.15	1.711	7.30	72.1
		96 min	11	2.677	1.8537	1.15	1.987	7.37	69.2
		97 min	11	2.714	2.0074	1.21	1.791	7.43	74.0
		98 min	11	2.656	1.9992	1.36	1.738	7.29	75.3
		99 min	11	2.595	1.8371	1.35	1.834	7.32	70.8
		100 min	11	2.470	1.7350	1.38	1.527	6.97	70.2
		101 min	11	2.412	1.8242	1.05	1.646	7.34	75.6
		102 min	11	2.660	1.8869	1.29	1.871	7.23	70.9
		103 min	11	3.053	2.4303	1.18	1.672	7.10	79.6
		104 min	11	2.796	1.9937	1.02	2.385	7.12	71.3
		105 min	11	2.678	1.9335	0.97	1.761	7.50	72.2
		106 min	11	3.063	2.3854	1.32	1.644	7.33	77.9
		107 min	11	2.883	2.1933	1.04	1.645	7.17	76.1
		108 min	11	2.768	1.9424	1.34	1.900	7.51	70.2
		109 min	11	2.581	1.9493	1.11	1.791	7.41	75.5
		110 min	11	2.595	1.9027	1.02	1.853	7.65	73.3
		111 min	11	2.434	1.8176	1.00	1.680	7.18	74.7
		112 min	11	2.536	1.8232	0.96	1.782	7.11	71.9
		113 min	11	2.675	1.8212	1.14	1.931	7.18	68.1
		114 min	11	2.975	2.1562	1.14	1.696	7.08	72.5
		115 min	11	2.896	2.1056	1.29	1.623	7.02	72.7
		116 min	11	2.555	1.7631	1.24	2.104	7.35	69.0
		117 min	10	2.652	1.7945	1.20	1.830	7.01	67.7
		118 min	10	2.551	1.9130	1.10	1.664	7.31	75.0
		119 min	10	2.463	1.8478	1.09	1.741	7.21	75.0
		120 min	10	2.490	1.8755	1.07	1.651	7.23	75.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 21 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	121 min	10	2.545	1.8764	1.12	1.606	7.20	73.7
		122 min	10	2.712	2.0721	1.09	1.530	7.17	76.4
		123 min	11	2.994	2.1904	1.15	1.673	7.37	73.2
		124 min	11	3.128	2.1217	1.21	1.831	7.27	67.8
		125 min	11	2.877	2.1310	1.18	1.800	7.24	74.1
		126 min	11	2.862	1.8773	1.15	2.349	7.12	65.6
		127 min	11	2.885	1.9615	1.02	1.957	7.43	68.0
		128 min	11	3.017	2.2450	1.08	1.822	7.37	74.4
		129 min	11	3.189	2.4408	1.11	1.678	7.07	76.5
		130 min	11	3.129	2.2965	1.07	2.130	7.35	73.4
		131 min	11	2.918	2.3456	1.11	1.573	7.34	80.4
		132 min	11	3.046	2.3261	1.08	1.512	7.42	76.4
		133 min	10	2.623	2.0444	1.18	1.598	7.56	77.9
		134 min	11	2.754	1.9501	1.12	1.650	7.19	70.8
		135 min	11	2.694	1.8652	1.03	1.737	7.25	69.2
		136 min	11	2.750	1.8873	1.03	1.857	7.00	68.6
		137 min	11	3.034	2.3727	1.16	1.803	7.56	78.2
		138 min	11	2.983	2.1709	1.18	1.792	7.70	72.8
		139 min	11	3.047	2.3163	1.29	1.684	7.67	76.0
		140 min	11	3.387	2.2718	1.21	2.136	7.17	67.1
		141 min	11	2.918	2.0144	1.22	2.125	6.92	69.0
		142 min	11	3.001	2.0104	1.18	2.156	7.19	67.0
		143 min	11	3.209	2.2058	1.13	2.280	7.40	68.7
		144 min	11	3.182	2.4840	1.06	1.616	7.28	78.1
		145 min	10	2.752	1.9007	1.07	1.860	7.16	69.1
		146 min	10	3.310	2.0765	1.14	2.568	6.98	62.7
		147 min	10	2.627	1.7365	1.09	1.922	6.89	66.1
		148 min	10	2.615	1.8508	1.19	1.851	7.30	70.8
		149 min	10	2.672	1.8055	1.32	2.311	7.34	67.6
		150 min	10	2.638	1.7083	1.35	2.131	6.99	64.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 22 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	151 min	10	2.660	1.9721	1.35	2.012	7.87	74.1
		152 min	10	2.795	1.8402	1.32	2.000	7.17	65.9
		153 min	10	2.670	1.8010	1.29	2.146	7.25	67.4
		154 min	10	2.733	1.8124	1.39	2.329	7.41	66.3
		155 min	10	2.923	1.8153	1.31	2.639	7.28	62.1
		156 min	10	2.807	1.7664	1.36	2.153	7.20	62.9
		157 min	10	3.293	2.1865	1.30	2.649	8.18	66.4
		158 min	10	3.090	1.9401	1.39	2.768	7.79	62.8
		159 min	10	3.117	1.8807	1.37	2.333	7.17	60.3
		160 min	10	2.997	1.8377	1.32	2.354	7.08	61.3
		161 min	10	3.036	1.9868	1.43	2.471	7.58	65.4
		162 min	10	3.134	2.0134	1.41	2.520	7.62	64.2
		163 min	11	3.445	2.3365	1.36	2.288	7.81	67.8
		164 min	11	3.471	2.4280	1.19	2.345	7.99	69.9
		165 min	11	3.283	2.1838	1.29	2.295	7.65	66.5
		166 min	11	3.276	2.0195	1.26	2.812	7.35	61.6
		167 min	11	2.937	1.8604	1.31	2.267	7.62	63.3
		168 min	11	3.117	2.0646	1.27	2.274	7.40	66.2
		169 min	10	3.442	2.4974	1.33	2.263	7.22	72.6
		170 min	10	2.809	1.9322	1.28	2.220	7.41	68.8
		171 min	10	3.197	2.3245	1.29	2.511	7.83	72.7
		172 min	10	2.993	2.2442	1.41	2.235	7.15	75.0
		173 min	10	3.022	2.1622	1.31	2.446	7.87	71.5
		174 min	10	3.068	2.1310	1.43	2.314	7.26	69.5
		175 min	10	3.055	2.2368	1.37	2.230	7.44	73.2
		176 min	10	3.170	2.1941	1.46	2.193	7.69	69.2
		177 min	10	3.349	2.0739	1.49	2.877	7.48	61.9
		178 min	10	3.435	2.2046	1.52	2.340	7.50	64.2
		179 min	10	3.263	2.1356	1.43	2.335	7.27	65.4
		180 min	10	3.031	1.8375	1.38	2.397	7.32	60.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 23 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	181 min	10	2.743	1.9239	1.36	2.152	7.83	70.1
		182 min	10	3.225	2.2920	1.38	2.261	7.57	71.1
		183 min	10	3.339	2.2566	1.37	2.308	7.34	67.6
		184 min	10	3.209	2.1802	1.41	2.560	7.51	67.9
		185 min	9	3.271	2.3766	1.32	2.337	7.66	72.7
		186 min	8	2.661	1.6118	1.33	2.140	6.28	60.6
		187 min	9	2.808	1.8835	1.42	1.921	7.37	67.1
		188 min	9	2.962	1.9514	1.36	2.078	7.16	65.9
		189 min	9	2.936	1.8936	1.35	2.338	7.29	64.5
		190 min	9	3.126	1.9587	1.30	2.388	7.18	62.7
		191 min	9	3.572	2.0940	1.32	3.489	7.20	58.6
		192 min	9	3.453	2.2807	1.29	2.634	7.23	66.0
		193 min	9	3.827	2.5760	1.27	2.503	7.24	67.3
		194 min	9	3.751	2.5317	1.29	2.489	7.21	67.5
		195 min	9	3.958	2.8282	1.21	2.301	7.78	71.5
		196 min	9	3.518	2.4082	1.18	3.076	7.90	68.5
		197 min	9	3.491	2.2498	1.21	2.692	7.81	64.4
		198 min	10	4.090	2.4689	1.19	3.176	7.44	60.4
		199 min	10	3.254	2.0250	1.21	2.749	7.22	62.2
		200 min	10	2.932	2.0668	1.24	1.866	7.34	70.5
		201 min	10	3.355	2.4095	1.17	2.197	7.67	71.8
		202 min	10	3.357	2.4862	1.42	2.008	7.17	74.1
		203 min	11	3.546	2.4927	1.42	1.847	7.35	70.3
		204 min	11	3.226	2.2492	1.36	1.954	7.60	69.7
		205 min	11	3.524	2.4609	1.33	2.088	7.38	69.8
		206 min	11	3.024	2.0731	1.36	1.992	6.92	68.5
		207 min	10	2.907	2.3748	1.30	1.920	7.82	81.7
		208 min	10	2.781	2.1096	1.26	1.780	7.34	75.9
		209 min	10	2.426	1.5926	1.20	1.881	6.61	65.6
		210 min	10	3.328	2.4392	1.22	2.053	7.44	73.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 24 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	211 min	10	3.137	2.4256	1.24	1.836	7.13	77.3
		212 min	10	2.830	1.9975	1.20	1.982	7.24	70.6
		213 min	10	2.901	2.3948	1.17	1.966	7.91	82.6
		214 min	10	2.653	2.2191	1.28	1.720	7.36	83.6
		215 min	10	2.399	1.8457	1.27	1.842	7.48	76.9
		216 min	10	2.871	1.8606	1.26	2.009	7.17	64.8
		217 min	10	2.489	1.7632	1.22	1.847	7.18	70.8
		218 min	10	2.347	1.6653	1.22	1.910	6.95	71.0
		219 min	10	2.509	1.6700	1.34	1.897	7.03	66.6
		220 min	10	2.588	1.7019	1.31	1.937	7.02	65.8
		221 min	10	2.773	1.7427	1.36	2.159	6.88	62.8
		222 min	10	2.515	1.6559	1.26	2.252	7.06	65.8
		223 min	10	2.486	1.7545	1.30	2.053	7.24	70.6
		224 min	10	2.623	1.9304	1.06	1.908	6.91	73.6
		225 min	10	2.978	2.1398	1.08	2.113	7.11	71.8
		226 min	10	3.065	1.7377	1.29	2.570	6.93	56.7
		227 min	10	2.562	1.6877	1.08	2.173	6.99	65.9
		228 min	10	2.873	2.0073	1.15	2.012	7.06	69.9
		229 min	11	2.897	1.8656	1.05	2.141	7.00	64.4
		230 min	11	3.398	2.0791	1.18	2.558	7.06	61.2
		231 min	11	2.871	1.8232	1.14	2.193	7.07	63.5
		232 min	11	3.408	2.0891	1.05	2.794	6.83	61.3
		233 min	11	3.076	2.1327	1.14	2.059	6.89	69.3
		234 min	11	2.754	1.9337	1.18	1.915	6.87	70.2
		235 min	10	2.468	1.7661	1.07	1.819	7.05	71.6
		236 min	11	2.986	1.9170	1.44	2.426	7.92	64.2
		237 min	11	2.905	2.2081	1.09	2.028	7.89	76.0
		238 min	11	2.461	1.9883	0.99	1.726	7.94	80.8
		239 min	11	2.945	2.0623	1.15	2.028	7.76	70.0
		240 min	6	3.905	2.5421	1.54	3.153	8.21	65.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 25 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	1 min	12	4.179	2.0913	1.27	4.007	7.39	50.0
		2 min	12	4.179	1.9181	1.33	3.902	7.50	45.9
		3 min	12	4.304	2.2525	1.36	3.725	7.52	52.3
		4 min	12	4.503	2.4138	1.35	4.138	8.38	53.6
		5 min	12	4.066	2.2893	1.30	3.296	7.58	56.3
		6 min	12	3.586	2.4281	1.42	2.334	8.01	67.7
		7 min	12	3.874	2.5299	1.40	2.342	7.85	65.3
		8 min	12	3.731	2.0952	1.41	3.134	7.53	56.2
		9 min	12	3.905	2.2796	1.37	3.075	7.69	58.4
		10 min	12	4.603	2.2489	1.43	4.401	8.28	48.9
		11 min	12	3.300	1.6954	1.39	2.796	7.37	51.4
		12 min	12	2.848	1.7134	1.36	2.292	7.40	60.2
		13 min	12	3.155	1.9163	1.40	2.275	7.54	60.7
		14 min	12	3.385	2.0013	1.34	2.301	7.27	59.1
		15 min	12	3.059	1.8196	1.38	2.307	7.56	59.5
		16 min	12	3.603	2.1259	1.35	2.715	7.50	59.0
		17 min	12	3.106	2.2306	1.35	2.169	7.68	71.8
		18 min	12	3.275	2.0782	1.39	2.379	7.67	63.5
		19 min	12	2.739	1.7275	1.35	2.202	7.68	63.1
		20 min	12	2.666	1.6867	1.19	2.131	7.30	63.3
		21 min	12	3.329	1.9863	1.30	2.565	7.45	59.7
		22 min	12	2.853	1.7045	1.46	2.111	7.50	59.8
		23 min	12	2.750	1.7167	1.29	2.137	7.53	62.4
		24 min	12	2.664	1.7429	1.30	1.950	7.43	65.4
		25 min	12	2.552	1.7470	1.35	1.970	7.61	68.4
		26 min	12	2.669	1.7687	1.30	2.046	7.42	66.3
		27 min	12	2.755	1.7868	1.27	2.028	7.37	64.8
		28 min	12	2.644	1.6496	1.31	2.016	7.11	62.4
		29 min	12	2.566	1.7598	1.31	2.013	7.52	68.6
		30 min	12	2.491	1.7425	1.33	1.900	7.48	69.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 26 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	31 min	12	2.885	1.9742	1.31	2.159	7.34	68.4
		32 min	11	3.086	2.1145	1.28	2.095	7.30	68.5
		33 min	10	2.643	1.8651	1.21	1.917	7.22	70.6
		34 min	10	2.569	1.8920	1.31	1.947	7.47	73.7
		35 min	10	3.023	2.3926	1.30	1.970	7.54	79.2
		36 min	10	2.730	2.0113	1.31	1.914	7.50	73.7
		37 min	10	2.930	2.2652	1.24	1.980	7.63	77.3
		38 min	10	2.584	1.9005	1.20	1.960	7.50	73.5
		39 min	10	2.531	1.8963	1.26	1.946	7.57	74.9
		40 min	10	2.382	1.8374	1.26	1.802	7.38	77.1
		41 min	10	2.380	1.8896	1.25	1.745	7.52	79.4
		42 min	11	2.427	1.8404	1.22	1.946	7.62	75.8
		43 min	12	2.448	1.8013	1.14	1.955	7.59	73.6
		44 min	12	2.420	1.8171	1.22	1.922	7.59	75.1
		45 min	12	2.557	1.9447	1.21	1.861	7.60	76.0
		46 min	12	2.686	1.7584	1.21	2.034	7.58	65.5
		47 min	12	2.427	1.7874	1.19	1.821	7.53	73.6
		48 min	12	2.458	1.7950	1.21	1.960	7.58	73.0
		49 min	12	2.367	1.7910	1.18	1.760	7.49	75.7
		50 min	12	2.758	1.9750	1.13	1.978	7.51	71.6
		51 min	11	2.493	1.8588	1.13	1.902	7.51	74.6
		52 min	11	2.528	1.8458	1.16	1.935	7.42	73.0
		53 min	11	2.470	1.8509	1.15	1.911	7.46	74.9
		54 min	11	2.486	1.8887	1.19	1.917	7.60	76.0
		55 min	11	2.474	1.8357	1.14	1.870	7.47	74.2
		56 min	11	2.437	1.9100	1.06	1.870	7.57	78.4
		57 min	11	2.542	1.9404	0.95	1.827	7.59	76.3
		58 min	11	2.597	2.0379	1.08	1.717	7.52	78.5
		59 min	11	2.572	1.8974	1.08	1.909	7.56	73.8
		60 min	11	2.733	1.9889	1.17	1.829	7.68	72.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 27 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	61 min	11	2.548	1.9187	1.22	1.793	7.66	75.3
		62 min	11	2.516	1.9292	1.07	1.888	7.69	76.7
		63 min	10	2.611	1.9919	1.13	1.859	7.50	76.3
		64 min	10	2.591	1.9651	0.96	1.908	7.52	75.8
		65 min	9	2.434	2.0466	0.91	1.822	7.42	84.1
		66 min	9	2.443	2.0330	1.08	1.831	7.50	83.2
		67 min	9	2.529	2.0677	1.06	1.804	7.66	81.8
		68 min	9	2.495	2.0509	1.12	1.814	7.43	82.2
		69 min	9	2.423	2.0182	1.00	1.847	7.39	83.3
		70 min	9	2.479	2.0872	0.82	1.808	7.45	84.2
		71 min	9	2.506	2.1355	0.85	1.779	7.56	85.2
		72 min	9	2.435	2.0074	1.04	1.777	7.46	82.5
		73 min	9	2.510	2.0072	1.19	1.736	7.54	80.0
		74 min	9	2.581	2.0339	1.08	1.799	7.37	78.8
		75 min	9	2.567	1.9700	1.15	2.093	7.44	76.8
		76 min	9	2.600	2.0911	1.05	1.947	7.34	80.4
		77 min	9	2.590	2.0098	1.21	1.894	7.37	77.6
		78 min	9	2.627	2.0560	1.20	1.901	7.43	78.3
		79 min	9	2.575	2.0517	1.14	1.934	7.52	79.7
		80 min	9	3.186	2.3223	1.14	2.111	7.53	72.9
		81 min	9	2.648	2.0647	1.14	1.890	7.51	78.0
		82 min	9	2.586	2.0223	1.17	2.058	7.46	78.2
		83 min	9	2.689	2.0808	1.22	2.027	7.47	77.4
		84 min	9	2.778	2.0214	1.29	2.190	7.46	72.8
		85 min	9	2.653	2.0683	1.19	1.939	7.42	78.0
		86 min	9	2.602	1.9296	1.27	1.933	7.37	74.2
		87 min	9	2.624	1.9928	1.29	1.984	7.61	76.0
		88 min	9	2.577	1.9370	1.32	1.987	7.55	75.2
		89 min	9	2.579	1.9225	1.22	1.998	7.50	74.5
		90 min	9	2.530	1.8673	1.35	1.920	7.27	73.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 28 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	91 min	9	2.544	1.8202	1.29	1.962	7.17	71.5
		92 min	9	2.540	1.9069	1.31	1.948	7.44	75.1
		93 min	10	2.704	1.8957	1.28	2.015	7.44	70.1
		94 min	10	2.670	1.8237	1.41	2.039	7.29	68.3
		95 min	11	2.540	1.7652	1.26	1.801	7.32	69.5
		96 min	11	2.566	1.7681	1.20	1.813	7.39	68.9
		97 min	11	2.737	1.8461	1.26	1.996	7.53	67.5
		98 min	11	2.732	1.9807	1.19	2.063	7.50	72.5
		99 min	11	2.576	1.7690	1.22	1.938	7.24	68.7
		100 min	11	2.567	1.7847	1.23	1.969	7.32	69.5
		101 min	11	2.717	1.8991	1.17	1.853	7.30	69.9
		102 min	11	2.505	1.7815	1.11	1.873	7.30	71.1
		103 min	11	2.540	1.7578	1.18	2.048	7.19	69.2
		104 min	11	2.485	1.8545	1.00	1.811	7.43	74.6
		105 min	11	2.487	1.8323	1.07	1.942	7.40	73.7
		106 min	11	2.554	1.8365	1.16	1.840	7.38	71.9
		107 min	11	2.594	1.7975	1.26	1.970	7.35	69.3
		108 min	11	2.662	1.9319	1.32	1.932	7.47	72.6
		109 min	11	2.470	1.7953	1.24	1.791	7.27	72.7
		110 min	11	2.429	1.7707	1.12	1.853	7.18	72.9
		111 min	11	2.417	1.7873	1.03	1.845	7.16	74.0
		112 min	11	2.392	1.8157	1.07	1.563	7.15	75.9
		113 min	11	2.413	1.8144	1.16	1.593	7.16	75.2
		114 min	11	2.531	1.8339	1.15	1.657	7.22	72.5
		115 min	11	2.417	1.8035	1.23	1.575	7.21	74.6
		116 min	11	2.477	1.7775	1.22	1.858	7.30	71.8
		117 min	10	2.611	1.8435	1.15	1.727	7.11	70.6
		118 min	10	2.607	1.9198	1.23	1.798	7.28	73.6
		119 min	10	2.524	1.8802	1.15	1.861	7.35	74.5
		120 min	10	2.488	1.8472	1.16	1.777	7.23	74.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 29 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	121 min	10	2.582	1.9079	1.14	1.809	7.37	73.9
		122 min	10	2.746	2.0385	1.10	1.718	7.22	74.2
		123 min	11	2.629	1.8450	1.09	1.746	7.26	70.2
		124 min	11	2.717	1.9595	1.23	1.819	7.26	72.1
		125 min	11	2.480	1.7891	1.17	1.596	7.31	72.1
		126 min	11	2.706	1.8086	1.13	2.092	7.09	66.8
		127 min	11	2.589	1.8420	1.14	1.880	7.34	71.1
		128 min	11	2.468	1.8371	1.08	1.772	7.18	74.4
		129 min	11	2.665	1.7881	1.04	2.129	7.14	67.1
		130 min	11	2.438	1.7162	0.99	1.697	6.94	70.4
		131 min	11	2.385	1.7305	1.04	1.580	6.90	72.6
		132 min	11	2.663	1.7975	0.96	1.917	6.75	67.5
		133 min	10	2.304	1.5608	1.15	1.903	6.43	67.7
		134 min	11	2.391	1.5523	1.18	1.626	6.17	64.9
		135 min	11	2.496	1.6581	1.10	2.088	6.81	66.4
		136 min	11	2.230	1.1343	1.30	1.669	4.81	50.9
		137 min	11	2.378	1.5052	1.23	1.837	6.36	63.3
		138 min	11	2.752	1.7148	1.22	1.957	6.35	62.3
		139 min	11	2.716	1.6457	1.21	1.949	6.03	60.6
		140 min	11	2.424	1.5289	1.18	1.815	6.43	63.1
		141 min	11	2.863	1.6089	1.15	2.135	6.62	56.2
		142 min	11	2.427	1.5488	1.05	1.948	6.51	63.8
		143 min	11	2.528	1.4100	0.86	2.050	5.98	55.8
		144 min	11	2.539	1.7783	0.86	1.786	6.68	70.0
		145 min	10	2.444	1.6019	0.96	1.836	6.40	65.6
		146 min	10	2.659	1.7710	1.16	1.939	6.66	66.6
		147 min	10	2.582	1.7756	1.21	1.985	7.17	68.8
		148 min	10	2.585	1.7504	1.36	1.918	7.12	67.7
		149 min	10	2.791	1.7324	1.37	2.198	7.34	62.1
		150 min	10	2.719	1.7700	1.35	2.196	7.26	65.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 30 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	151 min	10	2.769	1.7347	1.39	2.300	7.29	62.6
		152 min	10	2.673	1.7397	1.40	2.088	7.15	65.1
		153 min	10	2.679	1.7566	1.33	2.149	7.24	65.6
		154 min	10	2.648	1.7114	1.38	2.103	7.12	64.6
		155 min	10	2.835	1.7745	1.32	2.383	7.10	62.6
		156 min	10	2.786	1.6987	1.38	2.490	7.16	61.0
		157 min	10	2.794	1.7526	1.35	2.281	7.14	62.7
		158 min	10	2.838	1.7505	1.27	2.391	7.06	61.7
		159 min	10	2.907	1.7620	1.21	2.622	7.08	60.6
		160 min	10	2.775	1.7640	1.14	2.534	7.20	63.6
		161 min	10	2.936	1.8169	1.22	2.684	7.25	61.9
		162 min	10	3.055	1.9198	1.16	2.760	7.28	62.8
		163 min	11	3.129	1.9034	1.23	2.699	7.32	60.8
		164 min	11	3.188	2.0743	1.11	2.485	7.22	65.1
		165 min	11	2.729	1.7135	1.10	2.293	7.27	62.8
		166 min	11	2.771	1.6814	1.10	2.603	7.13	60.7
		167 min	11	2.615	1.6860	1.17	2.139	7.15	64.5
		168 min	11	3.090	2.0047	1.20	2.273	7.22	64.9
		169 min	10	2.961	1.9736	1.21	2.195	7.03	66.6
		170 min	10	2.873	1.8895	1.20	2.333	7.25	65.8
		171 min	10	3.125	2.0429	1.34	2.429	7.32	65.4
		172 min	10	3.159	2.1048	1.41	2.477	7.37	66.6
		173 min	10	3.214	2.2326	1.44	2.324	7.32	69.5
		174 min	10	3.191	2.1312	1.52	2.301	7.32	66.8
		175 min	10	3.042	1.9179	1.39	2.322	7.05	63.0
		176 min	10	3.057	1.8710	1.39	2.295	7.29	61.2
		177 min	10	2.960	1.7176	1.45	2.568	7.16	58.0
		178 min	10	2.829	1.6805	1.51	2.393	7.16	59.4
		179 min	10	2.660	1.7310	1.46	2.165	7.24	65.1
		180 min	10	2.756	1.6872	1.42	2.488	7.23	61.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 31 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	181 min	10	2.674	1.7056	1.13	2.321	7.15	63.8
		182 min	10	2.928	1.9048	1.15	2.354	7.27	65.1
		183 min	10	2.968	1.9944	1.24	2.376	7.38	67.2
		184 min	10	2.995	2.0701	1.17	2.399	7.37	69.1
		185 min	9	2.683	1.8300	1.34	2.350	7.27	68.2
		186 min	8	1.996	0.6400	1.03	2.156	2.90	32.1
		187 min	9	2.097	0.6462	1.18	2.264	3.07	30.8
		188 min	9	2.267	1.0019	1.12	2.316	4.46	44.2
		189 min	9	2.073	0.5757	1.23	2.310	2.79	27.8
		190 min	9	2.459	1.4565	1.10	2.294	5.99	59.2
		191 min	9	2.282	0.7811	1.28	2.511	3.49	34.2
		192 min	9	2.708	1.5938	1.31	2.403	6.39	58.8
		193 min	9	2.520	1.5569	1.37	2.258	6.34	61.8
		194 min	9	2.615	1.6813	1.27	2.277	6.56	64.3
		195 min	9	2.747	1.7866	1.20	2.360	5.80	65.0
		196 min	9	2.472	1.7854	1.31	1.914	7.06	72.2
		197 min	9	2.700	1.6708	1.33	2.121	6.34	61.9
		198 min	10	2.952	1.8942	1.27	2.252	7.28	64.2
		199 min	10	2.728	1.7240	1.28	2.330	7.15	63.2
		200 min	10	2.524	1.7804	1.33	1.946	7.34	70.5
		201 min	10	2.621	1.7597	1.20	2.239	7.22	67.1
		202 min	10	2.999	2.0932	1.19	2.025	6.78	69.8
		203 min	11	3.180	2.1974	1.12	2.105	6.68	69.1
		204 min	11	2.512	1.4329	1.26	1.984	6.21	57.0
		205 min	11	3.059	2.0606	1.28	2.108	6.55	67.4
		206 min	11	2.471	1.5674	1.31	1.965	6.79	63.4
		207 min	10	2.623	1.7946	1.20	1.977	6.76	68.4
		208 min	10	2.505	1.6994	1.26	1.857	6.72	67.9
		209 min	10	2.431	1.6137	1.30	1.926	6.73	66.4
		210 min	10	2.662	1.9760	1.21	1.863	6.75	74.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 32 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	211 min	10	2.644	2.0342	1.24	1.831	6.49	76.9
		212 min	10	2.585	1.5395	1.28	1.985	5.39	59.6
		213 min	10	2.277	1.0929	1.38	2.002	5.05	48.0
		214 min	10	2.862	2.0632	1.34	2.033	6.74	72.1
		215 min	10	2.412	1.6597	1.29	1.923	6.87	68.8
		216 min	10	2.318	1.5648	1.18	1.960	6.53	67.5
		217 min	10	2.391	1.6488	1.25	1.866	6.92	69.0
		218 min	10	2.309	1.6319	1.29	1.829	6.79	70.7
		219 min	10	2.315	1.6788	1.29	1.769	6.91	72.5
		220 min	10	2.474	1.7012	1.21	1.853	7.04	68.8
		221 min	10	2.399	1.6698	1.42	1.860	7.02	69.6
		222 min	10	2.350	1.6709	1.36	1.831	6.95	71.1
		223 min	10	2.401	1.6783	1.34	1.867	7.00	69.9
		224 min	10	2.486	1.5846	1.28	2.090	6.77	63.7
		225 min	10	2.568	1.7004	1.34	2.049	6.93	66.2
		226 min	10	2.760	1.6949	1.32	2.114	6.77	61.4
		227 min	10	2.377	1.6583	1.15	2.062	6.90	69.8
		228 min	10	2.547	1.8406	1.04	1.890	6.94	72.3
		229 min	11	2.939	1.9830	1.19	2.032	6.90	67.5
		230 min	11	2.379	1.6004	1.06	1.966	6.96	67.3
		231 min	11	2.464	1.6529	1.09	2.185	6.95	67.1
		232 min	11	2.501	1.5500	1.14	2.283	6.81	62.0
		233 min	11	2.608	1.6362	1.10	2.374	6.92	62.7
		234 min	11	2.200	1.6816	1.11	1.706	6.93	76.4
		235 min	10	2.214	1.7262	1.08	1.586	6.91	78.0
		236 min	11	2.402	1.7806	0.97	1.586	7.07	74.1
		237 min	11	2.683	1.8358	0.83	2.200	7.05	68.4
		238 min	11	2.746	1.8810	0.95	2.110	7.07	68.5
		239 min	11	2.462	1.8075	0.90	1.939	7.18	73.4
		240 min	6	3.457	2.1821	1.58	2.737	7.14	63.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 33 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	1 min	12	4.014	2.7258	1.27	2.924	8.52	67.9
		2 min	12	3.597	2.6134	1.30	2.263	8.44	72.7
		3 min	12	3.594	2.4894	1.34	2.271	8.16	69.3
		4 min	12	3.710	2.3869	1.36	2.674	8.02	64.3
		5 min	12	3.272	2.1859	1.27	2.470	8.01	66.8
		6 min	12	3.220	2.1179	1.35	2.652	7.84	65.8
		7 min	12	3.213	2.1037	1.36	2.532	7.79	65.5
		8 min	12	3.089	2.0775	1.44	2.209	7.57	67.3
		9 min	12	3.364	2.2409	1.42	2.121	7.04	66.6
		10 min	12	3.171	1.9906	1.40	2.117	7.00	62.8
		11 min	12	2.972	1.8987	1.30	2.125	6.97	63.9
		12 min	12	3.117	1.9739	1.23	2.258	7.00	63.3
		13 min	12	2.700	1.5795	1.30	2.223	7.11	58.5
		14 min	12	2.665	1.6528	1.26	2.090	7.27	62.0
		15 min	12	2.718	1.5770	1.26	2.209	7.05	58.0
		16 min	12	3.229	1.8822	1.35	2.588	6.85	58.3
		17 min	12	2.745	1.5608	1.11	2.418	6.92	56.9
		18 min	12	2.742	1.4980	1.45	2.484	6.90	54.6
		19 min	12	2.669	1.5524	1.43	2.228	6.96	58.2
		20 min	12	2.580	1.6168	1.14	2.221	7.01	62.7
		21 min	12	2.887	1.6410	1.39	2.333	6.85	56.8
		22 min	12	2.617	1.5286	1.48	2.104	6.80	58.4
		23 min	12	2.590	1.5784	1.33	2.067	7.05	60.9
		24 min	12	2.549	1.5531	1.37	2.023	6.91	60.9
		25 min	12	2.511	1.5498	1.27	2.002	6.85	61.7
		26 min	12	2.520	1.6121	1.33	2.012	7.06	64.0
		27 min	12	2.490	1.5485	1.29	1.949	6.81	62.2
		28 min	12	2.463	1.5308	1.21	1.931	6.80	62.2
		29 min	12	2.541	1.6884	1.29	2.052	7.36	66.4
		30 min	12	2.486	1.7536	1.23	1.816	7.47	70.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 34 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	31 min	12	2.490	1.5587	1.27	2.010	6.82	62.6
		32 min	11	2.780	1.7563	1.20	2.092	7.07	63.2
		33 min	10	2.851	2.0628	1.23	2.012	7.21	72.4
		34 min	10	2.953	2.2800	1.20	1.987	7.40	77.2
		35 min	10	2.798	1.9886	1.27	2.053	7.42	71.1
		36 min	10	2.895	2.1631	1.22	2.033	7.15	74.7
		37 min	10	2.964	2.3761	1.22	2.058	7.48	80.2
		38 min	10	3.004	2.2996	1.24	2.061	7.47	76.6
		39 min	10	2.449	1.8446	1.29	1.960	7.45	75.3
		40 min	10	2.504	1.7780	1.30	2.017	7.28	71.0
		41 min	10	2.438	1.8004	1.24	1.959	7.26	73.8
		42 min	11	2.400	1.7524	1.28	1.960	7.38	73.0
		43 min	12	2.467	1.7161	1.27	1.933	7.28	69.6
		44 min	12	2.493	1.7366	1.28	1.981	7.39	69.7
		45 min	12	2.459	1.8036	1.21	1.832	7.47	73.3
		46 min	12	2.535	1.7658	1.17	2.033	7.48	69.7
		47 min	12	2.481	1.7627	1.18	1.986	7.48	71.0
		48 min	12	2.490	1.7834	1.24	1.820	7.56	71.6
		49 min	12	2.484	1.7676	1.21	1.853	7.57	71.2
		50 min	12	2.463	1.8412	1.01	1.873	7.62	74.7
		51 min	11	2.468	1.8942	1.12	1.965	7.59	76.7
		52 min	11	2.524	1.8815	1.19	1.972	7.58	74.5
		53 min	11	2.535	1.8833	1.20	1.988	7.61	74.3
		54 min	11	3.027	2.3102	1.20	1.984	7.56	76.3
		55 min	11	2.481	1.8621	1.06	1.934	7.49	75.0
		56 min	11	2.500	1.8835	1.08	1.905	7.53	75.3
		57 min	11	2.472	1.9116	0.85	1.909	7.60	77.3
		58 min	11	2.495	1.8980	1.08	1.898	7.58	76.1
		59 min	11	2.461	1.9668	1.06	1.916	7.70	79.9
		60 min	11	2.452	1.9441	1.05	1.661	7.69	79.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 35 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	61 min	11	2.522	1.8999	1.21	1.832	7.69	75.3
		62 min	11	2.502	1.9208	1.11	1.844	7.66	76.8
		63 min	10	3.087	2.2361	1.22	2.069	7.63	72.4
		64 min	10	2.565	2.0068	1.10	1.876	7.64	78.3
		65 min	9	2.474	2.0410	1.19	1.872	7.62	82.5
		66 min	9	2.475	2.0470	1.08	1.922	7.64	82.7
		67 min	9	2.433	2.0756	1.08	1.877	7.65	85.3
		68 min	9	2.455	2.0261	1.12	1.883	7.53	82.5
		69 min	9	2.447	2.0550	1.15	1.867	7.59	84.0
		70 min	9	2.462	2.0720	1.04	1.883	7.58	84.2
		71 min	9	2.463	2.0789	0.96	1.777	7.60	84.4
		72 min	9	2.491	2.0325	1.06	1.785	7.53	81.6
		73 min	9	2.489	2.0404	0.96	1.853	7.55	82.0
		74 min	9	2.713	1.9745	0.96	1.988	7.52	72.8
		75 min	9	2.563	1.9919	1.09	1.829	7.52	77.7
		76 min	9	2.508	2.0283	1.14	1.841	7.53	80.9
		77 min	9	2.501	2.0324	1.13	1.879	7.49	81.3
		78 min	9	2.512	2.0380	1.00	1.962	7.46	81.1
		79 min	9	2.548	2.0582	1.11	1.971	7.55	80.8
		80 min	9	2.538	2.0815	1.06	1.978	7.51	82.0
		81 min	9	2.587	2.0523	1.15	1.997	7.55	79.3
		82 min	9	2.514	2.0404	1.12	1.936	7.55	81.2
		83 min	9	2.534	2.0055	1.15	1.961	7.54	79.2
		84 min	9	2.560	2.0024	1.11	2.037	7.54	78.2
		85 min	9	2.530	1.9968	1.15	2.017	7.53	78.9
		86 min	9	2.553	1.9841	1.16	1.841	7.50	77.7
		87 min	9	2.559	1.9558	1.26	2.125	7.50	76.4
		88 min	9	2.542	1.9508	1.30	2.046	7.52	76.7
		89 min	9	2.851	1.9433	1.42	2.074	7.51	68.2
		90 min	9	2.585	1.8908	1.48	2.071	7.48	73.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 36 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	91 min	9	2.483	1.8238	1.26	2.019	7.20	73.5
		92 min	9	2.583	1.8469	1.29	2.085	7.33	71.5
		93 min	10	2.680	1.8831	1.24	2.053	7.53	70.3
		94 min	10	2.674	1.8722	1.30	2.040	7.52	70.0
		95 min	11	2.584	1.7906	1.33	1.933	7.53	69.3
		96 min	11	2.570	1.7606	1.30	1.898	7.42	68.5
		97 min	11	2.669	1.7783	1.34	1.857	7.53	66.6
		98 min	11	2.605	1.7792	1.36	1.840	7.52	68.3
		99 min	11	2.547	1.7788	1.29	1.827	7.41	69.8
		100 min	11	2.532	1.7853	1.30	1.756	7.38	70.5
		101 min	11	2.674	1.7307	1.37	2.204	7.38	64.7
		102 min	11	2.599	1.7225	1.30	1.876	7.29	66.3
		103 min	11	2.671	1.6262	1.34	2.053	7.01	60.9
		104 min	11	2.506	1.6426	1.40	1.767	6.86	65.5
		105 min	11	2.543	1.6541	1.37	1.781	6.98	65.0
		106 min	11	2.500	1.7076	1.24	1.745	7.07	68.3
		107 min	11	2.525	1.7241	1.29	1.738	7.16	68.3
		108 min	11	2.456	1.6828	1.23	1.810	6.87	68.5
		109 min	11	2.437	1.7585	1.03	1.805	7.08	72.2
		110 min	11	2.468	1.7748	1.19	1.798	7.23	71.9
		111 min	11	2.456	1.7640	1.05	1.828	7.21	71.8
		112 min	11	2.371	1.8094	1.10	1.662	7.19	76.3
		113 min	11	2.376	1.7951	1.02	1.832	7.14	75.6
		114 min	11	2.375	1.7330	1.13	1.803	6.99	73.0
		115 min	11	2.427	1.8520	1.12	1.711	7.43	76.3
		116 min	11	2.432	1.7923	1.14	1.822	7.28	73.7
		117 min	10	2.615	2.0122	1.15	1.809	7.03	77.0
		118 min	10	2.467	1.8043	1.19	1.780	7.06	73.1
		119 min	10	2.503	1.8691	1.20	1.767	7.29	74.7
		120 min	10	2.494	1.7669	1.21	1.778	6.99	70.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 37 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	121 min	10	2.463	1.8371	1.20	1.798	7.15	74.6
		122 min	10	2.471	1.9612	1.04	1.783	7.49	79.4
		123 min	11	2.312	1.8296	0.91	1.562	7.18	79.1
		124 min	11	2.363	1.6933	1.07	1.762	6.91	71.7
		125 min	11	2.372	1.8005	0.94	1.598	7.23	75.9
		126 min	11	2.355	1.7490	1.16	1.601	7.03	74.3
		127 min	11	2.406	1.7303	1.17	1.753	7.08	71.9
		128 min	11	2.295	1.4918	1.09	1.588	6.10	65.0
		129 min	11	2.677	1.8913	1.06	1.950	6.54	70.7
		130 min	11	2.297	1.5017	1.00	1.671	6.10	65.4
		131 min	11	1.932	0.8026	1.14	1.628	3.79	41.6
		132 min	11	1.947	0.8869	0.94	1.670	3.77	45.6
		133 min	10	1.790	0.6508	1.09	1.623	3.14	36.4
		134 min	11	1.922	0.8137	1.12	1.658	3.72	42.3
		135 min	11	2.304	1.1791	1.21	2.043	4.85	51.2
		136 min	11	2.099	0.7150	1.38	1.978	3.70	34.1
		137 min	11	2.394	1.5246	1.27	1.968	6.36	63.7
		138 min	11	2.191	0.9776	1.23	2.094	4.00	44.6
		139 min	11	2.280	1.1291	1.23	2.043	4.81	49.5
		140 min	11	1.961	0.7629	1.18	1.668	3.78	38.9
		141 min	11	2.214	1.1145	1.07	1.721	4.58	50.3
		142 min	11	2.358	1.5262	1.07	1.647	6.37	64.7
		143 min	11	2.282	1.0208	0.88	2.084	4.28	44.7
		144 min	11	2.487	1.6916	1.30	1.826	7.09	68.0
		145 min	10	2.266	0.7557	1.39	2.056	3.78	33.4
		146 min	10	3.026	2.1114	1.43	1.989	6.91	69.8
		147 min	10	3.164	2.2891	1.42	2.118	7.53	72.3
		148 min	10	3.006	2.0967	1.39	2.015	7.71	69.7
		149 min	10	3.113	2.2113	1.40	2.146	7.67	71.0
		150 min	10	3.075	1.9953	1.40	2.156	6.96	64.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 38 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	151 min	10	3.088	1.9876	1.39	2.182	6.89	64.4
		152 min	10	2.689	1.6105	1.40	2.088	6.82	59.9
		153 min	10	2.638	1.7196	1.34	2.048	7.05	65.2
		154 min	10	2.598	1.6117	1.40	2.143	6.83	62.0
		155 min	10	2.653	1.6132	1.36	2.196	6.84	60.8
		156 min	10	2.658	1.5728	1.37	2.187	6.66	59.2
		157 min	10	2.840	1.5745	1.42	2.232	6.65	55.4
		158 min	10	2.710	1.6197	1.41	2.168	6.86	59.8
		159 min	10	2.683	1.6046	1.35	2.226	6.76	59.8
		160 min	10	2.705	1.6025	1.38	2.422	6.81	59.2
		161 min	10	2.745	1.6049	1.37	2.374	6.77	58.5
		162 min	10	2.767	1.5823	1.37	2.506	6.62	57.2
		163 min	11	2.676	1.4921	1.42	2.297	6.63	55.8
		164 min	11	2.611	1.5006	1.39	2.271	6.61	57.5
		165 min	11	2.674	1.5915	1.23	2.462	7.02	59.5
		166 min	11	2.594	1.5547	1.12	2.254	6.81	59.9
		167 min	11	2.595	1.5417	1.34	2.191	6.79	59.4
		168 min	11	2.554	1.5798	1.01	2.175	6.78	61.9
		169 min	10	2.504	1.6021	1.34	2.107	6.77	64.0
		170 min	10	2.507	1.6843	1.32	2.048	7.01	67.2
		171 min	10	2.636	1.7258	1.34	2.177	7.08	65.5
		172 min	10	2.931	1.7261	1.35	2.282	7.02	58.9
		173 min	10	3.015	1.9671	1.30	2.258	6.94	65.3
		174 min	10	3.019	1.9651	1.19	2.275	7.09	65.1
		175 min	10	2.979	1.8994	1.11	2.250	6.78	63.8
		176 min	10	2.880	1.7386	1.40	2.313	7.18	60.4
		177 min	10	2.673	1.6857	1.46	2.294	7.24	63.1
		178 min	10	2.729	1.6547	1.40	2.539	7.14	60.6
		179 min	10	2.617	1.5809	1.28	2.366	6.83	60.4
		180 min	10	2.673	1.5792	1.47	2.421	6.91	59.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 39 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	181 min	10	2.691	1.7014	1.37	2.272	7.15	63.2
		182 min	10	2.690	1.6952	1.06	2.288	6.92	63.0
		183 min	10	2.712	1.6668	1.13	2.291	6.71	61.5
		184 min	10	2.643	1.6213	1.33	2.211	6.77	61.3
		185 min	9	2.747	1.7467	1.22	2.213	6.62	63.6
		186 min	8	2.075	0.7072	1.11	2.242	2.95	34.1
		187 min	9	2.140	0.6761	1.27	2.226	3.27	31.6
		188 min	9	2.061	0.6382	1.26	2.152	2.98	31.0
		189 min	9	2.069	0.5309	1.39	2.196	2.77	25.7
		190 min	9	2.156	0.6583	1.26	2.218	3.34	30.5
		191 min	9	2.131	0.6354	1.30	2.179	3.30	29.8
		192 min	9	2.211	0.6435	1.41	2.133	3.25	29.1
		193 min	9	2.109	0.5054	1.38	2.116	2.96	24.0
		194 min	9	2.144	0.6005	1.39	2.130	3.32	28.0
		195 min	9	2.201	0.6508	1.24	2.182	3.17	29.6
		196 min	9	2.129	0.4642	1.35	2.052	3.01	21.8
		197 min	9	2.112	0.5502	1.36	2.079	3.08	26.1
		198 min	10	2.422	1.1707	1.35	2.087	5.42	48.3
		199 min	10	2.601	1.6978	1.30	2.043	7.20	65.3
		200 min	10	2.087	0.4373	1.36	2.054	2.89	21.0
		201 min	10	2.488	1.6937	1.30	2.005	7.15	68.1
		202 min	10	2.067	0.4387	1.29	2.013	3.01	21.2
		203 min	11	1.930	0.5235	1.36	1.752	3.21	27.1
		204 min	11	1.940	0.5095	1.23	1.863	2.98	26.3
		205 min	11	2.196	0.9249	1.29	1.883	4.62	42.1
		206 min	11	2.330	1.3245	1.28	1.875	6.09	56.8
		207 min	10	2.391	1.4556	1.28	1.980	6.31	60.9
		208 min	10	2.371	1.4249	1.30	1.902	6.19	60.1
		209 min	10	2.317	1.3894	1.29	1.944	5.98	60.0
		210 min	10	2.395	1.6626	1.26	1.953	6.88	69.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 40 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	211 min	10	2.386	1.6912	1.35	1.872	6.98	70.9
		212 min	10	1.979	0.5365	1.31	1.891	2.86	27.1
		213 min	10	1.969	0.4037	1.33	1.959	2.83	20.5
		214 min	10	2.212	0.9064	1.34	1.933	4.47	41.0
		215 min	10	2.550	1.4033	1.31	1.944	5.42	55.0
		216 min	10	2.639	1.6593	1.28	1.899	6.30	62.9
		217 min	10	1.984	0.6357	1.26	1.829	3.33	32.0
		218 min	10	1.834	0.4306	1.28	1.772	2.81	23.5
		219 min	10	1.762	0.4501	1.28	1.618	2.74	25.5
		220 min	10	1.769	0.4341	1.30	1.758	2.67	24.5
		221 min	10	1.797	0.4315	1.31	1.705	2.70	24.0
		222 min	10	1.765	0.4111	1.19	1.710	2.58	23.3
		223 min	10	1.952	0.5350	1.35	1.963	2.96	27.4
		224 min	10	2.149	1.2161	1.33	1.893	5.43	56.6
		225 min	10	1.959	0.5169	1.30	1.977	2.84	26.4
		226 min	10	2.138	0.5844	1.42	2.081	3.06	27.3
		227 min	10	2.055	0.5832	1.31	1.940	3.09	28.4
		228 min	10	2.047	0.6685	1.28	2.125	3.43	32.7
		229 min	11	2.059	0.6977	1.31	1.968	3.65	33.9
		230 min	11	2.013	0.7667	1.34	2.022	3.98	38.1
		231 min	11	2.078	0.8545	1.26	1.933	4.17	41.1
		232 min	11	2.053	0.9831	1.13	1.998	4.63	47.9
		233 min	11	2.143	1.1550	0.99	2.154	5.18	53.9
		234 min	11	2.092	1.2063	1.18	1.764	5.48	57.7
		235 min	10	2.196	1.5919	1.26	1.601	6.58	72.5
		236 min	11	2.288	1.4680	1.24	1.594	6.12	64.2
		237 min	11	2.312	1.5198	1.19	1.718	6.34	65.7
		238 min	11	2.343	1.5906	1.26	1.600	6.67	67.9
		239 min	11	2.299	1.6126	0.81	1.491	6.43	70.1
		240 min	6	3.053	1.8567	1.50	2.530	6.44	60.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 41 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	1 min	12	2.970	1.7553	1.28	2.350	6.82	59.1
		2 min	12	3.217	2.0542	1.30	2.364	7.07	63.9
		3 min	12	3.310	2.1675	1.09	2.586	7.67	65.5
		4 min	12	2.790	1.5798	1.01	2.443	6.98	56.6
		5 min	12	2.996	1.7375	1.24	2.440	7.00	58.0
		6 min	12	2.682	1.5822	1.10	2.249	6.94	59.0
		7 min	12	2.760	1.6381	1.13	2.282	6.98	59.4
		8 min	12	2.708	1.6698	1.20	2.133	7.02	61.7
		9 min	12	2.718	1.5219	1.23	2.147	6.81	56.0
		10 min	12	2.634	1.5053	1.32	2.120	6.85	57.2
		11 min	12	2.805	1.4969	1.38	2.178	6.86	53.4
		12 min	12	2.782	1.5454	1.24	2.191	6.89	55.6
		13 min	12	2.600	1.5145	1.32	2.119	6.81	58.3
		14 min	12	2.573	1.5425	1.05	2.109	6.85	59.9
		15 min	12	2.586	1.5739	0.98	2.128	6.97	60.9
		16 min	12	2.645	1.5684	1.42	2.140	7.08	59.3
		17 min	12	2.623	1.5734	1.37	2.147	6.90	60.0
		18 min	12	2.577	1.5991	1.19	2.135	7.07	62.0
		19 min	12	2.598	1.5639	1.13	2.102	6.96	60.2
		20 min	12	2.559	1.5562	1.18	2.137	6.91	60.8
		21 min	12	2.604	1.5695	1.27	2.107	7.07	60.3
		22 min	12	2.560	1.5818	1.33	2.029	7.08	61.8
		23 min	12	2.689	1.5712	1.21	2.176	7.06	58.4
		24 min	12	2.521	1.6171	1.21	2.029	7.15	64.1
		25 min	12	2.479	1.5608	1.11	2.013	6.89	63.0
		26 min	12	2.485	1.6149	1.27	1.961	7.10	65.0
		27 min	12	2.467	1.6394	1.07	1.953	7.11	66.5
		28 min	12	2.464	1.5664	1.06	1.964	6.89	63.6
		29 min	12	2.455	1.5547	1.06	1.951	6.85	63.3
		30 min	12	2.477	1.7106	1.15	1.935	7.39	69.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 42 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	31 min	12	2.471	1.6964	0.99	1.943	7.36	68.7
		32 min	11	2.541	1.6912	1.03	1.981	7.09	66.6
		33 min	10	2.387	1.6693	1.00	2.006	6.91	69.9
		34 min	10	2.417	1.7028	1.07	2.002	7.04	70.5
		35 min	10	2.435	1.7417	1.13	1.985	7.15	71.5
		36 min	10	2.388	1.6991	1.34	1.885	7.06	71.2
		37 min	10	2.408	1.7552	1.26	1.937	7.24	72.9
		38 min	10	2.484	1.7970	1.13	2.067	7.37	72.3
		39 min	10	2.368	1.6960	1.33	1.851	6.99	71.6
		40 min	10	2.402	1.7513	1.34	1.927	7.19	72.9
		41 min	10	2.316	1.7245	0.98	1.890	6.95	74.5
		42 min	11	2.284	1.6482	1.17	1.785	6.98	72.2
		43 min	12	2.382	1.5488	1.22	1.910	6.74	65.0
		44 min	12	2.408	1.6888	1.20	1.885	7.21	70.1
		45 min	12	2.424	1.6892	1.32	1.918	7.24	69.7
		46 min	12	2.416	1.6484	1.30	1.871	7.09	68.2
		47 min	12	2.507	1.6799	1.23	2.009	7.28	67.0
		48 min	12	2.515	1.6643	1.32	2.009	7.31	66.2
		49 min	12	2.623	1.7151	1.19	2.029	7.36	65.4
		50 min	12	2.420	1.7513	1.01	1.953	7.37	72.4
		51 min	11	2.564	1.8088	1.14	1.992	7.53	70.5
		52 min	11	2.583	1.9355	1.28	1.989	7.92	74.9
		53 min	11	3.039	2.1816	1.06	2.031	7.61	71.8
		54 min	11	3.050	2.3095	1.02	2.059	7.47	75.7
		55 min	11	2.499	1.7759	1.25	2.016	7.33	71.1
		56 min	11	2.913	2.0223	1.12	2.161	7.62	69.4
		57 min	11	2.663	1.7920	1.10	2.041	7.43	67.3
		58 min	11	2.956	2.0382	1.23	2.028	7.34	69.0
		59 min	11	2.723	1.9329	0.75	2.000	7.58	71.0
		60 min	11	3.063	2.2878	1.26	1.948	7.44	74.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 43 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	61 min	11	3.080	2.3734	0.95	1.958	7.58	77.0
		62 min	11	2.765	1.8682	1.00	1.991	7.44	67.6
		63 min	10	3.160	2.2401	1.21	2.147	7.38	70.9
		64 min	10	2.972	2.0616	1.15	2.136	7.45	69.4
		65 min	9	2.449	2.0275	0.51	1.899	7.43	82.8
		66 min	9	3.059	2.5707	0.54	1.996	7.40	84.0
		67 min	9	3.100	2.5445	0.79	1.985	7.42	82.1
		68 min	9	2.974	2.2661	0.89	1.981	7.36	76.2
		69 min	9	2.403	2.0147	0.65	1.907	7.38	83.9
		70 min	9	2.500	2.0056	1.14	1.939	7.49	80.2
		71 min	9	2.496	2.0301	1.15	1.839	7.50	81.3
		72 min	9	3.019	2.2350	1.19	2.054	7.34	74.0
		73 min	9	3.185	2.3887	1.22	2.050	7.40	75.0
		74 min	9	3.092	2.3411	1.27	2.058	7.39	75.7
		75 min	9	3.057	2.3574	1.04	2.055	7.38	77.1
		76 min	9	3.122	2.3368	1.16	2.098	7.42	74.9
		77 min	9	3.145	2.3391	1.14	2.015	7.40	74.4
		78 min	9	2.728	1.9734	0.73	2.012	7.37	72.3
		79 min	9	2.539	1.9643	1.25	1.964	7.44	77.4
		80 min	9	2.499	1.9657	1.16	1.889	7.46	78.6
		81 min	9	2.933	2.0656	1.32	2.035	7.46	70.4
		82 min	9	3.010	2.2265	1.16	2.002	7.44	74.0
		83 min	9	2.529	1.9496	1.26	1.980	7.46	77.1
		84 min	9	2.606	1.8937	1.24	2.090	7.42	72.7
		85 min	9	2.580	1.8983	1.17	1.999	7.39	73.6
		86 min	9	2.481	1.9562	1.12	1.972	7.46	78.8
		87 min	9	3.060	2.2770	1.14	2.073	7.46	74.4
		88 min	9	2.973	2.1094	1.16	2.068	7.34	70.9
		89 min	9	3.049	2.2668	1.24	2.040	7.38	74.3
		90 min	9	3.089	2.3576	1.28	2.019	7.38	76.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 44 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	91 min	9	3.133	2.4022	1.15	2.039	7.37	76.7
		92 min	9	2.548	1.8411	0.99	2.142	7.27	72.3
		93 min	10	2.580	1.8389	1.25	2.041	7.39	71.3
		94 min	10	2.908	1.8230	1.34	2.217	7.31	62.7
		95 min	11	3.075	2.1813	1.37	2.124	7.31	70.9
		96 min	11	3.093	2.2027	1.46	2.127	7.39	71.2
		97 min	11	2.789	1.7365	1.46	2.088	7.31	62.3
		98 min	11	2.543	1.7130	1.44	1.831	7.31	67.4
		99 min	11	2.526	1.7619	1.27	1.828	7.40	69.7
		100 min	11	2.519	1.7145	1.20	1.892	7.25	68.1
		101 min	11	2.495	1.7332	1.28	1.730	7.22	69.5
		102 min	11	2.509	1.7467	1.24	1.734	7.27	69.6
		103 min	11	2.512	1.6820	1.35	1.752	7.08	67.0
		104 min	11	2.527	1.6716	1.49	1.820	7.06	66.1
		105 min	11	2.505	1.7051	1.35	1.825	7.13	68.1
		106 min	11	2.456	1.7203	1.07	1.830	7.08	70.0
		107 min	11	2.505	1.6785	1.36	1.838	7.06	67.0
		108 min	11	2.385	1.7258	0.90	1.720	6.93	72.4
		109 min	11	2.344	1.7116	0.91	1.770	6.83	73.0
		110 min	11	2.569	1.7198	1.01	2.101	7.12	67.0
		111 min	11	2.412	1.6610	1.16	1.840	6.80	68.9
		112 min	11	2.417	1.7148	1.19	1.850	7.02	71.0
		113 min	11	2.339	1.7359	0.97	1.840	6.94	74.2
		114 min	11	2.360	1.7217	0.97	1.900	6.93	72.9
		115 min	11	2.341	1.6767	0.90	1.874	6.70	71.6
		116 min	11	2.486	1.6891	1.20	1.900	6.86	68.0
		117 min	10	2.396	1.7630	0.90	1.839	6.77	73.6
		118 min	10	2.419	1.7474	0.98	1.770	6.78	72.2
		119 min	10	2.459	1.7427	1.02	1.795	6.80	70.9
		120 min	10	2.514	1.7538	1.04	1.819	6.93	69.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 45 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	121 min	10	2.352	1.6918	1.00	1.761	6.46	71.9
		122 min	10	2.814	1.8880	0.98	2.015	6.88	67.1
		123 min	11	2.519	1.7419	0.95	1.870	7.10	69.2
		124 min	11	2.759	2.0024	0.93	1.940	6.93	72.6
		125 min	11	2.890	2.2133	0.90	1.910	7.51	76.6
		126 min	11	2.692	1.7371	1.20	1.940	6.35	64.5
		127 min	11	2.472	1.7670	1.27	1.890	7.33	71.5
		128 min	11	2.384	1.5532	1.21	1.930	6.51	65.2
		129 min	11	1.903	0.7729	1.09	1.710	3.75	40.6
		130 min	11	2.221	1.3141	1.14	1.705	5.46	59.2
		131 min	11	2.000	0.7872	1.19	1.660	3.77	39.4
		132 min	11	2.163	1.1351	1.26	1.563	4.75	52.5
		133 min	10	2.038	1.1706	1.09	1.620	5.08	57.4
		134 min	11	2.329	1.4738	1.42	1.573	6.22	63.3
		135 min	11	2.297	1.4666	1.21	1.777	6.11	63.8
		136 min	11	2.060	0.6882	1.37	1.943	3.73	33.4
		137 min	11	2.435	1.7109	1.40	1.741	7.14	70.3
		138 min	11	2.704	1.9007	1.17	1.900	7.52	70.3
		139 min	11	2.483	1.2682	1.32	2.043	5.50	51.1
		140 min	11	1.942	0.7646	1.02	1.704	3.78	39.4
		141 min	11	1.855	0.8269	0.87	1.670	3.77	44.6
		142 min	11	2.271	1.1143	1.34	1.980	4.91	49.1
		143 min	11	2.219	0.8752	1.33	1.948	3.78	39.4
		144 min	11	2.577	1.8087	1.34	2.024	7.58	70.2
		145 min	10	2.651	1.8922	1.42	2.099	7.64	71.4
		146 min	10	2.930	1.9181	1.45	2.062	7.02	65.5
		147 min	10	2.902	2.0066	1.44	2.075	7.59	69.2
		148 min	10	2.821	1.7454	1.39	2.076	6.14	61.9
		149 min	10	3.021	1.7400	1.45	2.187	6.80	57.6
		150 min	10	2.756	1.6567	1.37	2.170	7.06	60.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 46 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	151 min	10	2.487	1.2164	1.34	2.091	5.44	48.9
		152 min	10	2.692	1.6134	1.43	2.193	6.92	59.9
		153 min	10	2.678	1.4409	1.45	2.164	6.37	53.8
		154 min	10	2.656	1.4880	1.43	2.126	6.40	56.0
		155 min	10	2.706	1.6637	0.65	2.163	6.40	61.5
		156 min	10	2.612	1.4690	0.41	2.191	5.10	56.2
		157 min	10	2.686	1.5206	0.57	2.170	5.41	56.6
		158 min	10	2.882	1.9151	0.55	2.183	6.78	66.4
		159 min	10	2.742	1.5125	0.64	2.425	5.48	55.2
		160 min	10	2.975	1.9713	0.68	2.433	6.95	66.3
		161 min	10	2.693	1.6175	0.50	2.550	6.45	60.1
		162 min	10	2.628	1.6596	0.35	2.528	6.56	63.1
		163 min	11	2.568	1.4686	1.27	2.110	6.48	57.2
		164 min	11	3.103	1.9342	1.44	2.284	7.05	62.3
		165 min	11	2.842	1.3885	1.42	2.244	6.23	48.8
		166 min	11	2.713	1.4245	1.40	2.180	6.52	52.5
		167 min	11	2.928	1.7731	1.44	2.160	6.53	60.6
		168 min	11	2.746	1.5667	1.33	2.192	6.56	57.1
		169 min	10	2.479	1.4671	1.42	2.190	6.52	59.2
		170 min	10	2.398	1.3291	1.22	2.204	5.99	55.4
		171 min	10	2.885	1.8809	1.37	2.197	6.63	65.2
		172 min	10	2.953	1.9639	1.39	2.240	7.00	66.5
		173 min	10	2.964	2.0625	1.28	2.172	7.26	69.6
		174 min	10	2.935	1.9031	1.22	2.245	6.77	64.8
		175 min	10	2.892	1.9268	1.12	2.206	6.96	66.6
		176 min	10	2.957	1.8395	1.54	2.235	6.93	62.2
		177 min	10	2.893	1.6652	1.57	2.257	6.08	57.6
		178 min	10	2.887	1.6390	1.51	2.324	6.54	56.8
		179 min	10	3.099	1.7800	1.56	2.233	6.65	57.4
		180 min	10	3.175	1.7842	1.55	2.326	5.97	56.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 47 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	181 min	10	3.091	1.8151	1.50	2.272	6.31	58.7
		182 min	10	2.843	1.5256	1.44	2.347	6.54	53.7
		183 min	10	2.758	1.5632	1.51	2.248	6.84	56.7
		184 min	10	2.613	1.4881	1.52	2.219	6.67	57.0
		185 min	9	2.744	1.4599	1.46	2.261	6.07	53.2
		186 min	8	2.854	1.6054	1.49	2.223	6.26	56.3
		187 min	9	2.745	1.4489	1.50	2.190	5.91	52.8
		188 min	9	2.535	1.4347	1.42	2.160	6.16	56.6
		189 min	9	2.578	1.2232	1.38	2.161	4.83	47.4
		190 min	9	2.308	0.7139	1.38	2.190	3.58	30.9
		191 min	9	2.278	0.8128	1.16	2.181	3.99	35.7
		192 min	9	2.094	0.4491	1.46	2.066	2.81	21.5
		193 min	9	1.958	0.5007	1.29	2.036	2.82	25.6
		194 min	9	2.071	0.5625	1.38	2.004	3.08	27.2
		195 min	9	2.005	0.5184	1.17	1.970	2.82	25.9
		196 min	9	2.016	0.5414	1.33	2.015	3.00	26.9
		197 min	9	2.123	0.5612	1.34	2.060	2.97	26.4
		198 min	10	2.308	0.7082	1.42	2.157	3.44	30.7
		199 min	10	2.105	0.5412	1.28	2.042	2.94	25.7
		200 min	10	1.924	0.4510	1.35	1.919	2.81	23.4
		201 min	10	1.879	0.4400	1.30	1.814	2.80	23.4
		202 min	10	1.947	0.5132	1.32	1.971	2.87	26.4
		203 min	11	1.901	0.4783	1.23	1.812	2.91	25.2
		204 min	11	1.797	0.4840	1.19	1.812	2.84	26.9
		205 min	11	1.796	0.5129	1.15	1.810	2.91	28.6
		206 min	11	1.883	0.6346	1.09	1.776	3.04	33.7
		207 min	10	1.787	0.5336	1.22	1.668	2.87	29.9
		208 min	10	1.749	0.5543	0.83	1.690	2.77	31.7
		209 min	10	1.923	0.4559	1.32	1.940	2.80	23.7
		210 min	10	2.253	1.1133	1.27	2.000	5.16	49.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 48 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	211 min	10	2.553	1.5971	1.34	1.931	5.84	62.6
		212 min	10	2.417	1.6574	1.35	1.945	7.00	68.6
		213 min	10	2.400	1.6942	1.36	1.911	7.06	70.6
		214 min	10	2.416	1.6550	1.28	1.911	6.97	68.5
		215 min	10	2.664	1.8131	1.32	1.822	6.95	68.1
		216 min	10	2.653	1.8045	1.29	1.814	6.77	68.0
		217 min	10	2.242	1.3398	1.28	1.781	5.88	59.8
		218 min	10	2.341	1.6632	1.33	1.803	6.94	71.0
		219 min	10	2.141	1.1400	1.35	1.774	5.17	53.2
		220 min	10	2.230	1.5311	1.34	1.661	6.43	68.7
		221 min	10	2.073	0.7726	1.37	1.808	4.03	37.3
		222 min	10	2.249	1.1461	1.38	1.828	5.25	50.9
		223 min	10	2.178	0.7944	1.37	1.866	3.71	36.5
		224 min	10	2.132	0.8179	1.36	1.814	3.63	38.4
		225 min	10	2.390	1.2263	1.39	1.897	4.83	51.3
		226 min	10	2.630	1.7008	1.43	1.874	6.24	64.7
		227 min	10	2.552	1.5644	1.33	1.874	5.59	61.3
		228 min	10	2.563	1.6244	1.16	2.011	5.81	63.4
		229 min	11	2.728	2.0634	1.43	2.020	7.54	75.6
		230 min	11	2.159	1.3786	1.32	1.878	6.15	63.9
		231 min	11	2.187	1.4127	1.35	1.814	6.27	64.6
		232 min	11	2.229	1.1747	1.18	2.000	5.37	52.7
		233 min	11	2.161	1.2050	1.32	1.950	5.61	55.7
		234 min	11	2.277	1.2859	1.34	2.098	5.84	56.5
		235 min	10	2.100	1.3060	1.32	1.621	5.67	62.2
		236 min	11	2.329	1.4010	1.40	1.780	6.03	60.2
		237 min	11	2.655	1.8428	1.22	1.818	6.09	69.4
		238 min	11	2.403	1.4952	1.29	1.756	6.31	62.2
		239 min	11	2.435	1.5576	1.08	1.828	6.37	64.0
		240 min	6	3.067	1.8656	1.58	2.329	6.54	60.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 49 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	1 min	12	2.979	1.7786	1.43	2.345	6.79	59.7
		2 min	12	2.888	1.7359	1.08	2.423	6.92	60.1
		3 min	12	2.757	1.5500	0.93	2.422	6.93	56.2
		4 min	12	2.988	1.6738	0.93	2.606	6.86	56.0
		5 min	12	3.102	1.7830	1.08	2.582	6.86	57.5
		6 min	12	2.844	1.6857	1.07	2.391	6.80	59.3
		7 min	12	2.970	1.8284	1.02	2.261	6.70	61.6
		8 min	12	3.023	1.8751	1.08	2.387	6.70	62.0
		9 min	12	3.045	1.8760	1.21	2.386	6.73	61.6
		10 min	12	2.750	1.4743	1.23	2.490	6.72	53.6
		11 min	12	2.895	1.5686	1.32	2.337	6.79	54.2
		12 min	12	2.919	1.7537	1.25	2.219	7.00	60.1
		13 min	12	2.669	1.3484	1.28	2.211	6.17	50.5
		14 min	12	2.548	1.4667	1.23	2.048	6.50	57.6
		15 min	12	2.648	1.4682	1.02	2.207	6.66	55.5
		16 min	12	3.003	1.9239	1.03	2.165	6.83	64.1
		17 min	12	3.015	1.9368	1.26	2.100	7.00	64.2
		18 min	12	2.846	1.7326	0.77	2.156	7.21	60.9
		19 min	12	3.037	1.9721	1.16	2.133	7.01	64.9
		20 min	12	2.750	1.6299	1.07	2.101	7.32	59.3
		21 min	12	2.932	1.8113	1.12	2.095	7.30	61.8
		22 min	12	2.614	1.6597	1.06	2.030	7.30	63.5
		23 min	12	2.691	1.6455	1.06	2.065	7.35	61.1
		24 min	12	2.538	1.6930	0.75	2.009	7.27	66.7
		25 min	12	2.583	1.5585	1.10	2.021	6.97	60.3
		26 min	12	2.470	1.7681	0.98	1.952	7.42	71.6
		27 min	12	2.490	1.7017	0.78	2.000	7.25	68.3
		28 min	12	2.458	1.6140	0.82	1.955	6.90	65.7
		29 min	12	2.464	1.6483	0.83	1.893	7.07	66.9
		30 min	12	2.441	1.6779	0.85	1.873	7.14	68.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 50 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	31 min	12	2.416	1.3809	0.89	1.962	6.11	57.2
		32 min	11	2.534	1.6820	1.04	1.912	7.01	66.4
		33 min	10	2.338	1.6058	0.88	1.957	6.65	68.7
		34 min	10	2.356	1.5560	1.17	1.863	6.57	66.0
		35 min	10	2.446	1.6533	0.84	1.882	6.76	67.6
		36 min	10	2.283	1.6656	0.57	1.827	6.70	73.0
		37 min	10	2.299	1.7708	0.72	1.811	7.04	77.0
		38 min	10	2.636	1.8801	0.54	1.996	6.96	71.3
		39 min	10	2.907	2.2091	1.04	1.975	7.47	76.0
		40 min	10	2.522	1.6909	0.79	1.983	6.71	67.0
		41 min	10	2.728	2.0292	0.82	1.979	7.42	74.4
		42 min	11	2.739	2.1708	0.71	1.960	7.37	79.3
		43 min	12	2.300	1.5549	0.64	1.921	6.41	67.6
		44 min	12	2.894	2.0744	0.98	2.037	7.18	71.7
		45 min	12	2.852	2.0932	0.66	2.067	7.49	73.4
		46 min	12	2.857	2.1190	0.71	2.016	7.32	74.2
		47 min	12	2.827	2.0864	0.66	2.044	7.43	73.8
		48 min	12	2.801	1.9980	0.84	2.043	7.12	71.3
		49 min	12	2.777	1.9676	0.92	1.995	7.48	70.9
		50 min	12	2.535	1.7917	1.07	2.022	7.65	70.7
		51 min	11	2.995	2.3132	0.58	2.019	7.62	77.2
		52 min	11	2.922	2.0158	0.86	2.060	7.23	69.0
		53 min	11	2.903	1.9825	0.87	2.030	7.15	68.3
		54 min	11	2.984	2.2683	0.55	1.993	7.34	76.0
		55 min	11	2.718	1.8081	1.00	2.030	7.28	66.5
		56 min	11	2.869	2.0921	0.71	2.010	7.11	72.9
		57 min	11	2.649	1.7773	0.82	2.000	7.12	67.1
		58 min	11	2.863	1.9639	0.82	2.232	7.05	68.6
		59 min	11	2.397	1.8879	0.66	1.883	7.36	78.8
		60 min	11	2.690	1.8340	0.95	1.950	7.40	68.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 51 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	61 min	11	3.029	2.3071	0.95	1.970	7.40	76.2
		62 min	11	2.861	2.0540	0.64	1.950	7.46	71.8
		63 min	10	3.134	2.3788	0.65	2.130	7.36	75.9
		64 min	10	2.662	1.8868	0.74	2.140	7.35	70.9
		65 min	9	2.473	1.9790	0.97	1.970	7.43	80.0
		66 min	9	3.047	2.3942	1.02	1.993	7.33	78.6
		67 min	9	3.091	2.5437	0.73	1.963	7.48	82.3
		68 min	9	2.971	2.2878	0.75	1.960	7.29	77.0
		69 min	9	2.383	2.0111	0.57	1.890	7.38	84.4
		70 min	9	3.067	2.5010	0.65	1.980	7.43	81.5
		71 min	9	3.209	2.6526	1.13	1.970	8.01	82.7
		72 min	9	3.190	2.6265	1.26	2.018	8.01	82.3
		73 min	9	3.117	2.5188	1.14	2.026	7.45	80.8
		74 min	9	3.159	2.2576	1.32	2.158	7.44	71.5
		75 min	9	3.116	2.4052	0.91	2.038	7.35	77.2
		76 min	9	2.946	2.0986	1.14	2.055	7.43	71.2
		77 min	9	2.890	2.1402	0.78	1.924	7.38	74.1
		78 min	9	3.156	2.3603	1.34	2.002	7.33	74.8
		79 min	9	3.078	2.2354	1.28	2.035	7.28	72.6
		80 min	9	3.190	2.3532	1.42	2.011	7.38	73.8
		81 min	9	3.117	2.3803	1.37	1.992	7.43	76.4
		82 min	9	3.115	2.4114	1.20	1.989	7.47	77.4
		83 min	9	3.160	2.4930	1.24	1.966	7.51	78.9
		84 min	9	3.170	2.4176	1.33	1.982	7.46	76.3
		85 min	9	3.053	2.1973	1.25	1.998	7.32	72.0
		86 min	9	3.070	2.3529	1.16	2.058	7.45	76.6
		87 min	9	2.804	1.9608	1.31	2.017	7.42	69.9
		88 min	9	3.001	2.2203	1.38	1.941	7.46	74.0
		89 min	9	3.160	2.4385	1.53	1.909	7.42	77.2
		90 min	9	3.169	2.4144	1.54	2.016	7.47	76.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 52 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	91 min	9	3.185	2.3770	1.60	1.935	7.45	74.6
		92 min	9	3.179	2.3464	1.61	1.999	7.30	73.8
		93 min	10	3.244	2.1589	1.59	2.089	7.30	66.6
		94 min	10	3.193	1.8932	1.67	2.341	7.03	59.3
		95 min	11	3.097	1.9613	1.67	2.154	7.16	63.3
		96 min	11	3.159	2.1658	1.64	2.073	7.38	68.6
		97 min	11	3.015	1.9457	1.56	2.107	7.35	64.5
		98 min	11	3.100	2.0649	1.71	2.083	7.37	66.6
		99 min	11	3.003	1.9734	1.69	2.018	7.46	65.7
		100 min	11	2.570	1.7294	1.34	1.843	7.31	67.3
		101 min	11	2.884	1.7714	1.65	1.973	7.27	61.4
		102 min	11	2.675	1.6582	1.68	1.956	7.21	62.0
		103 min	11	2.650	1.6779	1.65	2.024	7.27	63.3
		104 min	11	2.555	1.6893	1.44	1.790	7.15	66.1
		105 min	11	2.929	1.8799	1.53	2.043	7.09	64.2
		106 min	11	2.549	1.4715	1.31	2.116	6.34	57.7
		107 min	11	2.536	1.5056	1.26	2.098	6.45	59.4
		108 min	11	2.467	1.5469	1.21	1.730	6.47	62.7
		109 min	11	2.656	1.4878	1.55	2.086	6.50	56.0
		110 min	11	2.939	1.8966	1.56	2.084	7.09	64.5
		111 min	11	2.584	1.1464	1.46	2.198	4.85	44.4
		112 min	11	2.403	1.2650	1.15	2.084	5.42	52.6
		113 min	11	2.447	1.6224	1.06	1.915	6.70	66.3
		114 min	11	2.754	1.7056	1.06	2.077	6.61	61.9
		115 min	11	2.931	2.0652	1.08	2.077	6.91	70.5
		116 min	11	2.576	1.5852	1.22	2.060	6.68	61.5
		117 min	10	3.111	2.1763	0.93	2.078	7.12	70.0
		118 min	10	3.031	1.8518	1.48	2.088	6.69	61.1
		119 min	10	2.882	1.6958	1.37	2.100	6.46	58.8
		120 min	10	2.904	1.6129	1.62	2.062	6.63	55.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 53 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	121 min	10	2.648	1.5867	1.59	2.023	6.69	59.9
		122 min	10	2.648	1.5174	1.47	1.972	6.33	57.3
		123 min	11	2.709	1.7013	1.44	1.888	6.88	62.8
		124 min	11	2.700	1.6092	1.38	1.915	6.09	59.6
		125 min	11	2.916	1.8710	1.47	1.868	6.78	64.2
		126 min	11	2.316	1.2486	1.38	1.891	5.34	53.9
		127 min	11	2.412	1.7060	1.30	1.604	7.01	70.7
		128 min	11	2.379	1.6485	1.11	1.589	6.72	69.3
		129 min	11	2.303	1.5148	1.01	1.550	6.14	65.8
		130 min	11	2.231	1.2084	0.97	1.639	4.94	54.2
		131 min	11	2.007	0.8851	1.03	1.600	3.79	44.1
		132 min	11	2.168	1.1610	0.92	1.720	4.67	53.6
		133 min	10	1.812	0.7326	0.80	1.518	3.04	40.4
		134 min	11	2.488	1.6772	1.17	1.951	6.97	67.4
		135 min	11	2.494	1.8184	1.20	1.573	7.41	72.9
		136 min	11	2.623	1.8332	1.24	1.965	7.43	69.9
		137 min	11	2.494	1.8426	1.12	1.931	7.53	73.9
		138 min	11	2.922	2.2503	1.05	1.976	7.46	77.0
		139 min	11	2.929	2.2924	0.98	1.929	7.65	78.3
		140 min	11	2.541	1.9154	0.73	2.064	7.75	75.4
		141 min	11	2.858	2.1357	0.96	2.001	7.36	74.7
		142 min	11	2.884	2.2749	0.96	2.102	7.73	78.9
		143 min	11	2.979	2.3338	0.96	2.076	7.92	78.3
		144 min	11	2.970	2.2378	1.27	2.059	8.06	75.4
		145 min	10	3.199	2.5149	1.31	2.080	8.07	78.6
		146 min	10	3.173	2.5260	0.99	2.084	8.12	79.6
		147 min	10	3.241	2.4738	1.41	2.110	8.22	76.3
		148 min	10	3.225	2.5399	1.06	2.116	8.37	78.8
		149 min	10	3.516	2.4168	1.40	2.329	8.30	68.7
		150 min	10	3.415	2.3928	1.39	2.288	8.30	70.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 54 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	151 min	10	3.593	2.6742	0.98	2.273	8.23	74.4
		152 min	10	3.223	2.4355	1.24	2.227	8.27	75.6
		153 min	10	3.336	2.3270	1.42	2.287	8.05	69.8
		154 min	10	3.320	2.3305	1.43	2.298	8.13	70.2
		155 min	10	3.392	2.3201	1.40	2.299	8.25	68.4
		156 min	10	3.470	2.2331	1.43	2.253	8.05	64.4
		157 min	10	4.050	2.4650	1.38	3.067	8.05	60.9
		158 min	10	3.764	2.4769	1.39	2.493	8.32	65.8
		159 min	10	3.737	2.4258	1.43	2.546	8.17	64.9
		160 min	10	4.075	2.3987	1.43	3.158	7.72	58.9
		161 min	10	3.626	2.3768	1.27	2.471	7.74	65.5
		162 min	10	3.701	2.3847	1.39	2.631	7.77	64.4
		163 min	11	3.510	2.2917	1.38	2.676	7.42	65.3
		164 min	11	3.510	2.2688	1.41	2.606	7.26	64.6
		165 min	11	3.364	1.9343	1.37	2.450	6.75	57.5
		166 min	11	3.531	2.1517	1.41	2.790	7.17	60.9
		167 min	11	3.506	2.3045	1.44	2.310	7.79	65.7
		168 min	11	3.331	2.0466	1.35	2.220	6.87	61.4
		169 min	10	2.522	1.5510	1.35	2.146	6.72	61.5
		170 min	10	2.576	1.5719	1.39	2.126	6.72	61.0
		171 min	10	2.930	2.0583	1.30	2.147	6.76	70.2
		172 min	10	2.969	2.0765	1.37	2.122	6.98	69.9
		173 min	10	2.977	2.0884	1.18	2.123	7.05	70.1
		174 min	10	2.888	1.9634	0.99	2.100	6.83	68.0
		175 min	10	2.860	1.9462	0.98	2.132	6.74	68.1
		176 min	10	3.026	1.9293	1.49	2.146	6.80	63.8
		177 min	10	3.386	2.2309	1.50	2.151	6.94	65.9
		178 min	10	2.824	1.6470	1.39	2.152	6.66	58.3
		179 min	10	2.940	1.7107	1.44	2.105	6.79	58.2
		180 min	10	3.110	1.8628	1.52	2.159	6.93	59.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 55 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	181 min	10	3.085	1.8742	1.43	2.120	6.71	60.8
		182 min	10	3.328	2.1361	1.42	2.192	6.56	64.2
		183 min	10	3.352	2.2457	1.48	2.136	6.62	67.0
		184 min	10	3.333	2.2193	1.34	2.131	6.76	66.6
		185 min	9	3.530	2.3271	1.40	2.144	6.76	65.9
		186 min	8	2.972	1.8559	1.45	2.126	6.53	62.4
		187 min	9	2.838	1.7998	1.31	2.092	6.62	63.4
		188 min	9	2.712	1.6830	1.19	2.079	6.42	62.1
		189 min	9	2.798	1.7510	1.50	2.081	6.74	62.6
		190 min	9	2.858	1.9191	1.32	2.183	7.04	67.1
		191 min	9	2.836	1.8049	1.29	2.117	6.61	63.6
		192 min	9	2.857	1.8974	1.36	2.108	7.07	66.4
		193 min	9	2.641	1.7676	1.43	2.060	7.15	66.9
		194 min	9	2.607	1.7108	1.42	2.030	6.96	65.6
		195 min	9	2.642	1.7916	1.24	2.090	7.18	67.8
		196 min	9	2.708	1.7056	1.40	2.070	7.01	63.0
		197 min	9	2.609	1.6632	1.31	2.070	6.78	63.8
		198 min	10	2.493	1.5213	1.35	1.995	6.60	61.0
		199 min	10	2.467	1.5431	1.29	1.975	6.61	62.6
		200 min	10	2.411	1.5580	1.34	1.955	6.59	64.6
		201 min	10	2.344	1.7083	1.14	1.934	6.97	72.9
		202 min	10	2.376	1.7467	1.20	1.921	7.11	73.5
		203 min	11	2.287	1.6052	1.14	1.848	6.87	70.2
		204 min	11	2.283	1.7422	0.83	1.838	7.27	76.3
		205 min	11	2.291	1.6949	0.45	1.966	7.03	74.0
		206 min	11	2.393	1.6725	0.81	1.977	6.97	69.9
		207 min	10	2.309	1.7584	0.63	1.872	7.01	76.2
		208 min	10	2.292	1.7257	0.63	1.897	6.93	75.3
		209 min	10	2.140	1.2269	0.82	1.897	5.24	57.3
		210 min	10	1.976	0.6920	1.21	1.836	3.31	35.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 56 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	211 min	10	2.306	1.5464	1.27	1.836	6.50	67.1
		212 min	10	2.445	1.7242	1.26	1.988	7.16	70.5
		213 min	10	2.388	1.7685	1.28	1.845	7.25	74.1
		214 min	10	2.422	1.7949	1.28	1.895	7.38	74.1
		215 min	10	2.281	1.7265	0.96	1.707	7.00	75.7
		216 min	10	2.336	1.7825	1.21	1.715	7.22	76.3
		217 min	10	2.187	1.3818	1.10	1.755	5.87	63.2
		218 min	10	2.301	1.7210	0.91	1.797	6.97	74.8
		219 min	10	2.329	1.7488	1.23	1.780	7.12	75.1
		220 min	10	2.311	1.7715	1.24	1.739	7.19	76.6
		221 min	10	2.285	1.6986	1.28	1.739	6.95	74.3
		222 min	10	2.322	1.6963	1.35	1.735	7.04	73.0
		223 min	10	2.439	1.7210	1.35	1.841	7.17	70.5
		224 min	10	2.517	1.7289	1.43	1.816	7.11	68.7
		225 min	10	2.634	1.7437	1.44	1.872	7.03	66.2
		226 min	10	2.531	1.3528	1.44	1.978	5.17	53.5
		227 min	10	2.366	1.2425	1.34	1.993	5.58	52.5
		228 min	10	2.531	1.3505	1.49	2.022	5.73	53.4
		229 min	11	2.690	1.9835	1.21	1.873	7.18	73.7
		230 min	11	2.171	1.3949	1.29	1.851	6.16	64.2
		231 min	11	2.290	1.4025	1.31	1.894	6.28	61.2
		232 min	11	2.279	1.2797	1.29	2.004	5.68	56.1
		233 min	11	2.176	1.3472	1.20	1.877	6.01	61.9
		234 min	11	2.386	1.5182	1.31	1.846	6.17	63.6
		235 min	10	2.253	1.4657	1.28	1.802	6.19	65.1
		236 min	11	2.378	1.4951	1.37	1.758	6.36	62.9
		237 min	11	2.509	1.5752	1.33	1.879	6.47	62.8
		238 min	11	2.510	1.6218	1.30	1.893	6.56	64.6
		239 min	11	2.364	1.5451	1.28	1.913	6.48	65.4
		240 min	6	3.184	1.8423	1.42	2.608	6.62	57.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 57 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	1 min	12	3.385	2.2714	1.50	2.433	7.66	67.1
		2 min	12	2.991	1.9542	1.25	2.182	7.29	65.3
		3 min	12	2.828	1.9826	0.82	1.922	7.07	70.1
		4 min	12	3.013	1.8245	0.99	2.366	6.57	60.6
		5 min	12	2.890	1.9023	0.75	2.188	6.88	65.8
		6 min	12	2.851	1.8477	0.91	2.171	6.59	64.8
		7 min	12	2.968	1.9054	1.24	2.185	7.30	64.2
		8 min	12	2.984	1.9707	0.92	2.313	7.45	66.0
		9 min	12	2.962	1.9417	1.33	2.174	7.15	65.6
		10 min	12	2.532	1.2077	1.27	2.225	5.68	47.7
		11 min	12	2.443	0.9026	1.34	2.193	3.86	37.0
		12 min	12	2.675	1.4877	1.33	2.093	6.81	55.6
		13 min	12	2.767	1.1866	1.45	2.380	5.48	42.9
		14 min	12	3.347	2.1028	1.31	2.449	7.01	62.8
		15 min	12	3.399	2.1850	1.28	2.428	7.25	64.3
		16 min	12	3.256	2.0210	1.24	2.383	7.14	62.1
		17 min	12	2.869	1.5749	1.17	2.329	6.23	54.9
		18 min	12	2.888	1.7444	1.02	2.145	6.42	60.4
		19 min	12	2.795	1.5333	1.29	2.026	6.09	54.9
		20 min	12	2.565	1.4226	1.01	2.111	6.55	55.5
		21 min	12	3.251	2.1182	1.13	2.342	7.27	65.1
		22 min	12	2.919	1.8255	1.08	2.161	6.73	62.5
		23 min	12	2.369	1.4126	0.99	1.999	6.18	59.6
		24 min	12	2.351	1.4065	1.00	1.920	6.16	59.8
		25 min	12	2.502	1.3322	1.08	2.026	6.14	53.3
		26 min	12	2.369	1.3126	0.93	1.926	5.90	55.4
		27 min	12	2.307	1.3212	1.04	1.926	5.78	57.3
		28 min	12	2.395	1.4037	0.92	1.910	6.31	58.6
		29 min	12	2.575	1.3148	1.10	2.015	5.75	51.1
		30 min	12	2.368	1.5260	1.14	1.882	6.64	64.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 58 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	31 min	12	2.429	1.4632	0.99	1.940	6.60	60.2
		32 min	11	2.434	1.5428	1.02	1.853	6.60	63.4
		33 min	10	2.456	1.1700	1.14	2.092	4.98	47.6
		34 min	10	2.291	1.2505	1.14	1.955	5.64	54.6
		35 min	10	2.066	0.9719	0.89	1.848	4.46	47.0
		36 min	10	2.260	1.4277	0.88	1.877	6.06	63.2
		37 min	10	2.588	1.6094	0.99	1.916	6.34	62.2
		38 min	10	2.290	1.4281	1.16	1.941	6.18	62.4
		39 min	10	2.895	1.9754	0.98	2.147	6.88	68.2
		40 min	10	2.422	1.4124	0.99	1.928	5.50	58.3
		41 min	10	2.618	1.7843	0.86	1.958	6.49	68.1
		42 min	11	2.113	0.8417	1.07	2.030	4.02	39.8
		43 min	12	1.798	0.8218	0.72	1.641	3.74	45.7
		44 min	12	2.237	1.0735	0.99	2.038	4.84	48.0
		45 min	12	2.505	1.6521	0.68	2.090	7.03	66.0
		46 min	12	2.238	1.0419	1.03	2.013	4.69	46.5
		47 min	12	2.630	1.5806	0.94	2.060	5.79	60.1
		48 min	12	2.524	1.5237	1.03	2.053	6.52	60.4
		49 min	12	2.650	1.6643	1.22	2.036	6.31	62.8
		50 min	12	2.370	1.4837	0.83	2.026	6.45	62.6
		51 min	11	2.845	2.0494	0.65	2.007	7.00	72.0
		52 min	11	2.789	1.7101	1.24	2.031	6.38	61.3
		53 min	11	2.883	2.0308	0.93	2.030	6.92	70.4
		54 min	11	3.024	2.1814	1.29	2.042	7.63	72.1
		55 min	11	2.718	1.7607	0.89	2.030	6.70	64.8
		56 min	11	2.779	1.8828	1.09	1.962	6.94	67.7
		57 min	11	2.775	1.8154	1.13	2.015	6.91	65.4
		58 min	11	2.879	2.0308	1.15	2.025	6.99	70.5
		59 min	11	2.408	1.7516	1.08	1.871	7.14	72.7
		60 min	11	2.879	1.9886	1.30	1.959	7.15	69.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 59 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	61 min	11	2.967	2.2181	1.08	1.980	7.18	74.8
		62 min	11	2.791	1.9324	0.90	2.000	7.27	69.2
		63 min	10	3.009	2.2460	1.01	2.093	7.25	74.6
		64 min	10	2.802	1.9047	0.96	2.080	7.25	68.0
		65 min	9	2.334	1.9173	1.00	1.850	7.21	82.2
		66 min	9	2.939	2.3828	0.98	1.990	7.28	81.1
		67 min	9	3.007	2.5189	0.94	1.976	7.38	83.8
		68 min	9	2.940	2.3448	0.95	1.991	7.18	79.7
		69 min	9	2.415	1.8933	1.05	1.890	7.27	78.4
		70 min	9	3.166	2.5344	1.23	2.219	7.75	80.1
		71 min	9	3.300	2.4554	1.18	2.321	7.68	74.4
		72 min	9	3.080	2.5303	0.95	2.076	7.59	82.2
		73 min	9	3.394	2.4690	1.05	2.161	7.45	72.7
		74 min	9	3.089	2.2122	1.06	2.228	7.36	71.6
		75 min	9	3.462	2.4133	1.20	2.155	7.35	69.7
		76 min	9	3.535	2.3181	1.04	2.454	7.35	65.6
		77 min	9	3.776	2.6198	1.17	2.344	7.34	69.4
		78 min	9	3.446	2.3586	1.24	2.096	7.39	68.4
		79 min	9	3.215	2.2625	1.44	2.137	7.37	70.4
		80 min	9	3.749	2.7080	1.34	2.021	7.62	72.2
		81 min	9	3.436	2.2925	1.49	2.071	7.24	66.7
		82 min	9	3.566	2.4920	1.26	2.004	7.17	69.9
		83 min	9	3.636	2.5079	1.39	2.070	7.35	69.0
		84 min	9	3.611	2.6082	1.16	2.019	7.26	72.2
		85 min	9	3.702	2.5336	1.50	2.041	7.37	68.4
		86 min	9	3.572	2.4946	1.35	2.035	7.38	69.8
		87 min	9	2.781	1.8840	1.51	1.976	7.38	67.7
		88 min	9	2.687	1.8137	1.50	1.965	7.34	67.5
		89 min	9	3.656	2.6981	1.23	1.986	7.60	73.8
		90 min	9	3.719	2.7027	1.59	1.925	8.08	72.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 60 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	91 min	9	3.729	2.6762	1.54	2.100	8.11	71.8
		92 min	9	3.975	2.6345	1.75	2.637	8.14	66.3
		93 min	10	3.699	2.4894	1.36	2.341	7.53	67.3
		94 min	10	3.575	2.3883	1.35	2.316	7.75	66.8
		95 min	11	3.804	2.3257	1.67	2.568	7.67	61.1
		96 min	11	3.536	2.5292	1.12	2.022	7.92	71.5
		97 min	11	3.379	2.2973	1.17	2.133	7.90	68.0
		98 min	11	3.557	2.5149	1.36	2.179	7.78	70.7
		99 min	11	3.508	2.5453	1.13	1.979	7.81	72.6
		100 min	11	3.551	2.5721	1.35	2.067	7.90	72.4
		101 min	11	3.381	2.4244	0.98	1.973	7.98	71.7
		102 min	11	3.470	2.5409	0.90	2.025	7.90	73.2
		103 min	11	3.238	2.2576	1.62	2.096	8.00	69.7
		104 min	11	3.462	2.2701	1.53	2.709	8.05	65.6
		105 min	11	3.850	2.3746	1.62	2.686	8.09	61.7
		106 min	11	3.293	2.2835	1.14	2.613	7.96	69.3
		107 min	11	3.613	2.4226	1.65	2.729	7.93	67.0
		108 min	11	3.528	2.3134	1.14	2.667	7.98	65.6
		109 min	11	3.207	2.0055	1.56	2.617	7.91	62.5
		110 min	11	3.483	2.2807	1.56	2.597	8.00	65.5
		111 min	11	2.914	1.9571	1.00	2.270	7.80	67.2
		112 min	11	2.984	1.8924	1.37	2.338	8.04	63.4
		113 min	11	2.932	2.0255	1.26	2.088	7.97	69.1
		114 min	11	3.501	2.2637	1.41	2.707	8.07	64.7
		115 min	11	3.342	2.1387	1.11	2.647	7.96	64.0
		116 min	11	3.147	1.9839	1.40	2.585	8.06	63.1
		117 min	10	2.967	2.1539	0.84	2.274	7.97	72.6
		118 min	10	3.282	1.9516	1.29	3.195	7.82	59.5
		119 min	10	3.220	2.0378	1.46	2.366	7.40	63.3
		120 min	10	3.480	1.8634	1.49	3.022	6.83	53.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 61 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	121 min	10	2.672	1.3450	1.13	2.380	5.62	50.3
		122 min	10	2.713	0.9554	1.56	2.561	4.06	35.2
		123 min	11	3.713	2.2536	1.52	2.630	7.03	60.7
		124 min	11	2.779	1.4447	1.49	2.145	5.54	52.0
		125 min	11	2.574	1.5773	1.44	1.804	6.72	61.3
		126 min	11	2.655	1.5776	1.30	2.149	6.34	59.4
		127 min	11	2.330	1.6966	0.81	1.674	6.86	72.8
		128 min	11	2.209	1.5396	0.44	1.701	6.09	69.7
		129 min	11	2.122	1.0886	0.92	1.724	4.47	51.3
		130 min	11	2.247	1.4159	0.78	1.701	5.81	63.0
		131 min	11	2.202	1.3898	0.83	1.752	5.62	63.1
		132 min	11	2.281	1.5363	0.84	1.760	6.24	67.3
		133 min	10	2.462	1.6912	0.86	1.713	5.93	68.7
		134 min	11	2.533	1.6071	1.43	1.942	6.96	63.5
		135 min	11	2.373	1.8357	0.97	1.590	7.39	77.3
		136 min	11	3.157	2.2811	1.40	2.272	7.63	72.3
		137 min	11	3.066	2.4701	1.45	1.861	8.24	80.6
		138 min	11	3.024	2.4556	1.09	1.885	8.17	81.2
		139 min	11	2.979	2.2881	1.14	1.861	7.99	76.8
		140 min	11	2.542	1.9948	1.15	1.952	8.14	78.5
		141 min	11	2.919	2.1851	1.22	1.936	7.96	74.9
		142 min	11	2.870	2.1250	1.39	1.898	7.75	74.0
		143 min	11	2.945	2.1682	1.28	2.001	7.70	73.6
		144 min	11	2.965	2.2389	1.37	1.966	7.75	75.5
		145 min	10	3.377	2.3606	1.47	2.418	7.78	69.9
		146 min	10	3.163	2.4135	1.32	2.106	7.65	76.3
		147 min	10	3.186	2.4440	1.42	2.146	7.76	76.7
		148 min	10	3.844	2.5991	1.47	2.458	7.77	67.6
		149 min	10	3.638	2.6466	1.16	2.289	7.78	72.7
		150 min	10	3.638	2.5901	1.35	2.223	7.70	71.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 62 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	151 min	10	3.576	2.5673	1.10	2.216	7.62	71.8
		152 min	10	3.586	2.5092	1.42	2.212	7.59	70.0
		153 min	10	3.642	2.4771	1.48	2.164	7.59	68.0
		154 min	10	3.638	2.4488	1.48	2.179	7.55	67.3
		155 min	10	3.461	2.2088	1.48	2.300	7.66	63.8
		156 min	10	3.955	2.4228	1.49	3.132	7.71	61.3
		157 min	10	4.220	2.6545	1.48	2.950	7.84	62.9
		158 min	10	3.916	2.5558	1.46	2.963	7.73	65.3
		159 min	10	3.923	2.5005	1.53	2.926	7.71	63.7
		160 min	10	3.996	2.4818	1.49	2.974	7.36	62.1
		161 min	10	3.728	2.3275	1.42	2.976	7.49	62.4
		162 min	10	3.569	2.2865	1.39	2.573	7.17	64.1
		163 min	11	3.569	2.2263	1.43	2.377	6.94	62.4
		164 min	11	3.593	2.2205	1.39	2.385	7.10	61.8
		165 min	11	3.468	2.1870	1.47	2.349	7.24	63.1
		166 min	11	3.450	2.1976	1.51	2.373	7.46	63.7
		167 min	11	3.386	2.2489	1.47	2.353	7.29	66.4
		168 min	11	3.137	1.8758	1.47	2.280	6.37	59.8
		169 min	10	2.851	1.9417	1.38	2.051	6.59	68.1
		170 min	10	2.829	2.0623	1.50	1.974	6.97	72.9
		171 min	10	2.846	1.9571	1.35	2.025	6.66	68.8
		172 min	10	2.912	2.1543	1.37	1.989	7.23	74.0
		173 min	10	2.861	2.1468	1.24	1.983	7.13	75.0
		174 min	10	3.026	2.0962	1.35	2.140	7.08	69.3
		175 min	10	2.971	2.0891	1.17	2.102	7.06	70.3
		176 min	10	3.129	2.0743	1.47	2.055	7.05	66.3
		177 min	10	2.982	2.0426	1.54	2.093	7.00	68.5
		178 min	10	3.051	2.0712	1.45	2.111	7.00	67.9
		179 min	10	3.063	2.0493	1.29	2.164	6.90	66.9
		180 min	10	3.043	2.0631	1.47	2.073	7.10	67.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 63 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	181 min	10	3.074	2.0020	1.65	2.046	6.79	65.1
		182 min	10	3.087	1.9670	1.59	2.095	6.79	63.7
		183 min	10	3.138	2.0341	1.54	2.075	6.98	64.8
		184 min	10	3.062	1.9181	1.45	2.122	6.76	62.6
		185 min	9	2.894	1.7970	1.41	2.284	6.91	62.1
		186 min	8	2.724	1.7215	1.53	2.116	6.79	63.2
		187 min	9	2.675	1.6668	1.45	2.001	6.71	62.3
		188 min	9	2.644	1.6070	1.46	2.020	6.54	60.8
		189 min	9	2.738	1.7489	1.43	2.010	6.73	63.9
		190 min	9	2.801	1.8463	1.40	2.043	6.70	65.9
		191 min	9	2.809	1.9695	1.15	2.033	6.65	70.1
		192 min	9	2.861	1.9829	1.14	2.029	6.67	69.3
		193 min	9	2.494	1.6461	1.10	1.970	6.72	66.0
		194 min	9	2.576	1.6277	1.34	1.950	6.63	63.2
		195 min	9	3.028	1.7524	1.33	2.010	6.43	57.9
		196 min	9	2.637	1.7374	0.89	1.966	6.51	65.9
		197 min	9	2.705	1.7428	1.25	1.970	6.47	64.4
		198 min	10	2.669	1.7574	1.11	1.903	6.40	65.8
		199 min	10	2.499	1.6637	0.96	1.894	6.37	66.6
		200 min	10	2.405	1.5689	1.09	1.836	6.40	65.2
		201 min	10	2.304	1.5500	0.89	1.923	6.41	67.3
		202 min	10	2.270	1.6357	0.84	1.941	6.63	72.1
		203 min	11	2.420	1.5787	0.92	1.830	6.34	65.2
		204 min	11	2.707	2.1219	0.98	1.834	7.32	78.4
		205 min	11	2.193	1.4875	0.64	1.906	6.37	67.8
		206 min	11	2.249	1.5991	0.73	1.909	6.82	71.1
		207 min	10	2.228	1.5282	0.89	1.831	6.34	68.6
		208 min	10	2.240	1.6124	0.75	1.826	6.60	72.0
		209 min	10	2.120	1.2531	0.70	1.835	5.37	59.1
		210 min	10	2.130	1.0776	1.13	1.796	4.87	50.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 64 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	211 min	10	2.255	1.7647	0.84	1.793	7.04	78.3
		212 min	10	2.338	1.8302	1.05	1.803	7.38	78.3
		213 min	10	2.299	1.7717	1.01	1.753	7.16	77.1
		214 min	10	2.272	1.7952	0.97	1.735	7.19	79.0
		215 min	10	2.311	1.6570	1.20	1.783	6.91	71.7
		216 min	10	2.241	1.7268	0.96	1.743	6.94	77.1
		217 min	10	2.225	1.7137	0.94	1.698	6.92	77.0
		218 min	10	2.267	1.7322	0.94	1.761	7.02	76.4
		219 min	10	2.247	1.6151	1.16	1.728	6.70	71.9
		220 min	10	2.404	1.7189	0.95	1.820	7.01	71.5
		221 min	10	2.475	1.7311	1.23	1.932	7.12	69.9
		222 min	10	2.712	1.9476	1.25	1.897	6.90	71.8
		223 min	10	2.552	1.7580	1.23	1.891	7.00	68.9
		224 min	10	2.673	1.8479	1.14	1.969	6.94	69.1
		225 min	10	2.865	1.8933	1.21	2.145	6.99	66.1
		226 min	10	3.241	2.2261	1.02	2.117	6.63	68.7
		227 min	10	2.737	1.8156	1.15	2.030	6.24	66.3
		228 min	10	2.849	1.9095	1.45	2.069	6.49	67.0
		229 min	11	3.042	2.1709	1.24	2.050	6.49	71.4
		230 min	11	2.702	1.6374	1.25	2.028	6.54	60.6
		231 min	11	2.599	1.8727	1.03	1.962	6.60	72.1
		232 min	11	2.568	1.8590	1.14	1.851	6.31	72.4
		233 min	11	2.434	1.5601	1.16	2.010	6.44	64.1
		234 min	11	2.639	1.8022	1.31	1.919	6.47	68.3
		235 min	10	2.519	1.6857	1.24	1.790	6.17	66.9
		236 min	11	2.782	1.6340	1.37	2.060	6.53	58.7
		237 min	11	2.616	1.7417	1.36	1.880	6.55	66.6
		238 min	11	2.531	1.6524	1.11	1.930	6.50	65.3
		239 min	11	2.583	1.6569	1.35	1.894	6.54	64.2
		240 min	6	3.555	1.9841	1.61	3.014	6.49	55.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 65 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	1 min	12	3.318	2.2964	1.37	2.276	7.79	69.2
		2 min	12	3.351	2.2964	1.22	2.361	7.53	68.5
		3 min	12	3.244	2.2951	1.01	2.306	7.22	70.8
		4 min	12	2.944	1.9715	0.77	2.363	7.32	67.0
		5 min	12	3.267	2.2581	0.93	2.358	7.08	69.1
		6 min	12	3.225	2.0987	0.99	2.477	6.71	65.1
		7 min	12	3.254	2.1135	1.15	2.293	6.89	65.0
		8 min	12	3.266	2.2325	0.88	2.293	7.18	68.4
		9 min	12	3.339	2.2468	1.36	2.331	7.47	67.3
		10 min	12	3.141	2.0696	1.32	2.334	7.51	65.9
		11 min	12	3.001	1.7114	1.39	2.512	6.63	57.0
		12 min	12	3.234	2.0528	1.37	2.382	6.81	63.5
		13 min	12	3.178	1.8802	1.49	2.367	6.95	59.2
		14 min	12	3.276	2.0713	1.42	2.470	7.24	63.2
		15 min	12	3.399	2.2652	1.27	2.353	7.42	66.6
		16 min	12	3.084	1.8145	1.32	2.367	7.06	58.8
		17 min	12	3.117	1.8302	1.27	2.378	6.37	58.7
		18 min	12	2.993	1.9570	1.14	2.117	6.80	65.4
		19 min	12	2.905	1.9653	1.28	2.003	7.01	67.7
		20 min	12	2.684	1.4822	1.12	2.024	6.11	55.2
		21 min	12	2.969	1.8511	1.28	2.317	6.72	62.3
		22 min	12	2.684	1.4326	1.32	2.073	5.58	53.4
		23 min	12	2.419	1.5185	1.25	1.868	6.70	62.8
		24 min	12	2.330	1.5729	1.17	1.835	6.72	67.5
		25 min	12	3.198	2.0361	1.11	2.418	7.09	63.7
		26 min	12	2.812	1.8313	1.14	2.075	6.72	65.1
		27 min	12	2.405	1.1978	1.25	2.090	5.55	49.8
		28 min	12	2.658	1.5376	1.11	1.986	6.28	57.9
		29 min	12	2.457	1.5254	1.09	2.030	6.76	62.1
		30 min	12	2.456	1.5977	0.91	1.934	6.74	65.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 66 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	31 min	12	2.486	1.4808	1.03	2.000	6.68	59.6
		32 min	11	2.434	1.6240	1.11	1.958	6.83	66.7
		33 min	10	2.239	1.2050	1.07	1.893	5.45	53.8
		34 min	10	2.100	1.3323	1.00	1.773	5.58	63.4
		35 min	10	2.182	1.4562	1.01	1.777	6.09	66.7
		36 min	10	2.348	1.4397	0.96	1.968	6.09	61.3
		37 min	10	2.892	2.0527	1.14	2.136	6.83	71.0
		38 min	10	2.534	1.6093	1.24	1.992	6.44	63.5
		39 min	10	2.796	1.9198	1.25	1.942	6.69	68.7
		40 min	10	2.614	1.8519	1.02	1.895	6.34	70.8
		41 min	10	2.358	1.5318	1.02	1.904	6.31	65.0
		42 min	11	2.043	0.7265	1.18	1.920	3.55	35.6
		43 min	12	1.960	0.6951	1.17	1.877	3.69	35.5
		44 min	12	2.353	1.5127	1.06	1.934	6.61	64.3
		45 min	12	2.511	1.5840	1.15	2.105	6.99	63.1
		46 min	12	2.081	0.8177	0.86	1.984	3.70	39.3
		47 min	12	2.412	1.4492	0.97	2.005	6.42	60.1
		48 min	12	2.389	1.3304	0.93	1.975	5.67	55.7
		49 min	12	2.526	1.5812	0.88	1.928	5.57	62.6
		50 min	12	2.597	1.7547	0.80	1.970	6.11	67.6
		51 min	11	2.821	2.0141	0.68	2.038	6.78	71.4
		52 min	11	2.868	1.9723	0.92	2.042	6.74	68.8
		53 min	11	3.030	1.8715	0.90	2.253	6.55	61.8
		54 min	11	2.916	2.2156	0.60	2.019	7.36	76.0
		55 min	11	2.625	1.7441	0.76	1.983	6.69	66.4
		56 min	11	2.773	1.8325	1.06	1.996	6.82	66.1
		57 min	11	2.898	2.0083	1.19	2.068	6.90	69.3
		58 min	11	2.842	1.9887	1.09	2.165	6.94	70.0
		59 min	11	2.382	1.7621	1.00	1.949	7.10	74.0
		60 min	11	2.783	1.9826	1.05	1.951	7.18	71.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 67 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	61 min	11	2.897	2.2221	0.85	2.054	7.19	76.7
		62 min	11	2.811	1.9547	0.81	2.055	7.26	69.5
		63 min	10	3.021	2.3245	0.94	2.106	7.19	76.9
		64 min	10	2.744	1.9054	0.81	2.192	7.17	69.4
		65 min	9	2.485	1.9531	1.00	1.924	7.34	78.6
		66 min	9	2.923	2.4543	0.87	2.129	7.33	84.0
		67 min	9	2.964	2.5223	0.66	2.166	7.34	85.1
		68 min	9	2.945	2.3314	1.18	1.955	7.22	79.2
		69 min	9	2.550	1.9607	0.67	2.028	7.28	76.9
		70 min	9	3.097	2.5897	0.86	1.957	7.69	83.6
		71 min	9	3.724	2.7626	1.03	2.479	7.57	74.2
		72 min	9	3.739	2.7462	1.28	2.231	7.54	73.4
		73 min	9	3.907	2.4935	1.06	2.879	7.48	63.8
		74 min	9	3.638	2.6810	0.93	2.372	7.38	73.7
		75 min	9	3.544	2.5379	1.19	2.231	7.45	71.6
		76 min	9	4.103	2.7398	0.60	2.777	7.43	66.8
		77 min	9	4.216	2.6993	1.08	2.774	7.38	64.0
		78 min	9	3.638	2.5145	1.41	2.082	7.40	69.1
		79 min	9	3.880	2.8149	1.46	2.512	8.22	72.6
		80 min	9	3.711	2.7609	1.34	2.006	7.73	74.4
		81 min	9	2.937	2.2054	1.13	1.930	7.36	75.1
		82 min	9	3.584	2.4070	1.51	2.038	7.29	67.2
		83 min	9	3.683	2.5742	1.65	2.037	7.39	69.9
		84 min	9	3.519	2.5473	1.15	2.025	7.38	72.4
		85 min	9	3.735	2.6204	1.65	1.999	7.54	70.2
		86 min	9	3.675	2.5923	1.54	2.027	7.33	70.5
		87 min	9	3.426	1.8738	1.77	2.634	7.23	54.7
		88 min	9	3.913	2.4803	1.62	2.657	7.75	63.4
		89 min	9	4.338	2.8660	1.53	2.524	7.97	66.1
		90 min	9	4.266	2.7885	1.52	2.704	8.06	65.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 68 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	91 min	9	4.243	2.7001	1.78	2.682	7.53	63.6
		92 min	9	4.024	2.5466	1.80	2.590	7.58	63.3
		93 min	10	3.788	2.3848	1.65	2.806	7.46	63.0
		94 min	10	3.777	2.5040	1.69	2.356	7.61	66.3
		95 min	11	4.030	2.5015	1.75	2.625	7.37	62.1
		96 min	11	3.659	2.3473	1.77	2.618	7.31	64.2
		97 min	11	3.526	2.0349	1.75	2.623	6.83	57.7
		98 min	11	3.748	2.1761	1.77	2.533	6.87	58.1
		99 min	11	3.439	2.2790	1.21	2.401	6.93	66.3
		100 min	11	3.706	2.1968	1.74	2.697	6.86	59.3
		101 min	11	3.360	2.3040	0.96	2.057	6.85	68.6
		102 min	11	3.237	2.1147	1.22	1.839	6.88	65.3
		103 min	11	3.344	2.0993	1.69	1.910	6.73	62.8
		104 min	11	3.417	1.8568	1.55	2.681	6.90	54.3
		105 min	11	3.645	2.2131	1.61	2.712	7.10	60.7
		106 min	11	3.395	1.9851	1.70	2.597	6.89	58.5
		107 min	11	3.581	2.2349	1.66	2.655	6.95	62.4
		108 min	11	2.762	1.6294	1.64	2.170	6.99	59.0
		109 min	11	3.240	2.0550	1.64	2.270	7.30	63.4
		110 min	11	3.456	2.2195	1.63	2.170	6.93	64.2
		111 min	11	2.511	1.6455	1.22	2.108	6.93	65.5
		112 min	11	3.032	1.9351	1.51	2.137	6.97	63.8
		113 min	11	3.125	1.9949	1.48	2.401	6.94	63.8
		114 min	11	3.130	2.0543	1.52	2.324	7.11	65.6
		115 min	11	3.236	1.8214	1.53	2.632	7.33	56.3
		116 min	11	2.831	1.5919	1.47	2.330	7.12	56.2
		117 min	10	2.555	1.8619	0.62	1.813	7.29	72.9
		118 min	10	3.140	2.1953	1.42	2.112	7.82	69.9
		119 min	10	3.290	2.0443	1.56	2.352	7.65	62.1
		120 min	10	3.606	2.3397	1.65	2.737	8.22	64.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 69 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	121 min	10	3.322	2.3210	1.55	2.329	8.11	69.9
		122 min	10	3.255	1.9596	1.56	2.738	8.04	60.2
		123 min	11	3.740	2.4024	1.43	2.638	7.35	64.2
		124 min	11	3.514	2.5014	1.41	2.348	7.63	71.2
		125 min	11	2.922	2.1178	1.33	1.890	7.51	72.5
		126 min	11	3.401	2.4548	1.43	2.160	8.30	72.2
		127 min	11	2.696	1.7699	0.98	2.110	6.98	65.6
		128 min	11	2.435	1.5914	0.83	2.060	6.62	65.4
		129 min	11	2.374	1.5957	0.61	1.804	6.39	67.2
		130 min	11	2.748	1.8697	1.17	1.961	7.19	68.0
		131 min	11	2.221	1.4858	0.92	1.677	6.02	66.9
		132 min	11	2.894	2.1442	1.17	1.802	7.77	74.1
		133 min	10	2.692	2.1515	1.17	1.692	7.36	79.9
		134 min	11	2.438	1.1084	1.37	2.000	5.01	45.5
		135 min	11	2.409	1.7606	1.14	1.793	7.23	73.1
		136 min	11	3.207	2.3590	1.42	2.010	7.76	73.6
		137 min	11	3.050	2.3707	1.32	1.897	7.99	77.7
		138 min	11	2.975	2.3369	1.29	1.878	7.79	78.5
		139 min	11	2.988	2.3788	1.21	1.801	7.77	79.6
		140 min	11	2.561	1.9150	1.06	2.070	7.86	74.8
		141 min	11	2.832	2.1646	0.99	1.910	7.82	76.4
		142 min	11	2.797	2.0471	1.35	2.003	7.85	73.2
		143 min	11	2.879	2.0794	1.45	1.998	7.82	72.2
		144 min	11	2.970	2.3495	1.33	1.927	7.79	79.1
		145 min	10	3.482	2.4361	1.46	2.263	7.81	70.0
		146 min	10	3.184	2.4114	1.43	1.971	7.73	75.7
		147 min	10	3.168	2.4691	1.29	1.981	7.74	77.9
		148 min	10	3.470	2.3800	1.45	2.383	7.86	68.6
		149 min	10	3.441	2.4529	1.11	2.249	7.82	71.3
		150 min	10	3.505	2.3436	0.96	2.679	7.72	66.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 70 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	151 min	10	3.184	2.3869	1.07	2.182	7.79	75.0
		152 min	10	3.410	2.3071	1.36	2.145	7.67	67.7
		153 min	10	3.516	2.4282	1.32	2.164	7.71	69.1
		154 min	10	3.770	2.3336	1.48	2.675	7.62	61.9
		155 min	10	3.801	2.2816	1.47	2.930	7.66	60.0
		156 min	10	3.624	2.1047	1.51	3.232	7.64	58.1
		157 min	10	3.438	2.1619	1.49	2.343	7.47	62.9
		158 min	10	3.328	2.1524	1.50	2.318	7.76	64.7
		159 min	10	3.309	2.1326	1.49	2.613	7.62	64.4
		160 min	10	3.309	2.1808	1.48	2.232	7.66	65.9
		161 min	10	3.258	2.1687	1.37	2.153	7.63	66.6
		162 min	10	3.302	2.1579	1.36	2.138	7.38	65.4
		163 min	11	3.089	2.0721	1.38	1.893	7.40	67.1
		164 min	11	3.177	2.1675	1.52	1.914	7.28	68.2
		165 min	11	3.290	2.2145	1.49	2.113	7.46	67.3
		166 min	11	3.306	2.0388	1.48	2.405	7.45	61.7
		167 min	11	3.407	2.3027	1.53	2.385	7.39	67.6
		168 min	11	3.311	2.1428	1.43	2.294	6.87	64.7
		169 min	10	3.322	2.3006	1.48	2.123	7.11	69.2
		170 min	10	3.256	2.2388	1.48	2.004	6.98	68.7
		171 min	10	3.226	2.1971	1.43	2.053	6.72	68.1
		172 min	10	3.293	2.1838	1.63	2.026	6.88	66.3
		173 min	10	2.849	2.0462	1.46	2.002	7.10	71.8
		174 min	10	2.895	2.0287	1.40	2.062	7.12	70.1
		175 min	10	2.829	1.9990	1.25	2.067	6.99	70.7
		176 min	10	2.922	2.0529	1.33	2.092	6.95	70.3
		177 min	10	2.925	2.0336	1.42	2.085	6.87	69.5
		178 min	10	2.984	2.0700	1.52	2.101	6.97	69.4
		179 min	10	3.086	1.9831	1.58	2.217	6.94	64.3
		180 min	10	3.058	2.0616	1.53	2.114	7.20	67.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 71 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	181 min	10	2.989	2.0865	1.17	2.046	6.92	69.8
		182 min	10	2.977	1.9739	1.27	2.085	6.64	66.3
		183 min	10	3.071	2.0364	1.59	2.110	7.09	66.3
		184 min	10	3.077	1.9435	1.11	2.210	6.77	63.2
		185 min	9	3.133	1.9904	1.09	2.471	6.59	63.5
		186 min	8	2.680	1.8747	1.11	2.191	7.14	70.0
		187 min	9	2.571	1.6998	1.14	2.061	6.90	66.1
		188 min	9	2.594	1.8407	1.11	2.033	7.30	71.0
		189 min	9	2.634	1.8264	1.34	2.051	7.30	69.3
		190 min	9	2.559	1.6956	1.08	1.987	6.78	66.3
		191 min	9	2.537	1.7013	1.29	2.058	6.87	67.1
		192 min	9	2.509	1.6568	1.02	2.029	6.67	66.0
		193 min	9	2.487	1.6211	1.17	1.987	6.64	65.2
		194 min	9	3.263	2.3670	1.59	2.070	7.56	72.5
		195 min	9	3.099	2.0426	1.45	2.012	6.68	65.9
		196 min	9	2.998	1.8403	1.72	2.034	6.60	61.4
		197 min	9	2.846	1.6650	1.52	2.044	6.75	58.5
		198 min	10	2.971	2.0798	1.62	1.857	6.82	70.0
		199 min	10	2.404	1.6151	1.15	1.922	6.71	67.2
		200 min	10	2.392	1.7496	0.98	1.859	7.17	73.1
		201 min	10	2.264	1.5773	0.89	1.870	6.53	69.7
		202 min	10	2.464	1.6992	0.80	1.933	6.54	69.0
		203 min	11	2.483	1.5636	1.23	2.017	6.78	63.0
		204 min	11	2.444	1.7062	1.02	1.836	6.86	69.8
		205 min	11	2.161	1.4792	0.82	1.848	6.35	68.4
		206 min	11	2.151	1.5056	0.80	1.804	6.43	70.0
		207 min	10	2.202	1.6225	0.87	1.833	6.58	73.7
		208 min	10	2.172	1.6050	0.86	1.803	6.52	73.9
		209 min	10	2.156	1.5708	0.77	1.826	6.35	72.9
		210 min	10	2.169	1.3339	0.89	1.851	5.69	61.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 72 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	211 min	10	2.305	1.6744	0.86	1.834	6.89	72.6
		212 min	10	2.314	1.7902	0.99	1.822	7.25	77.4
		213 min	10	2.356	1.7634	1.17	1.816	7.26	74.8
		214 min	10	2.324	1.7018	1.45	1.772	7.06	73.2
		215 min	10	2.335	1.7172	0.88	1.906	7.07	73.5
		216 min	10	2.229	1.7799	0.91	1.735	7.10	79.8
		217 min	10	2.190	1.6932	0.90	1.702	6.79	77.3
		218 min	10	2.184	1.6772	0.85	1.767	6.73	76.8
		219 min	10	2.159	1.6742	0.87	1.728	6.70	77.6
		220 min	10	2.219	1.7098	0.94	1.730	6.88	77.1
		221 min	10	2.564	1.7479	0.95	1.882	7.09	68.2
		222 min	10	2.822	1.9625	1.08	1.895	7.07	69.5
		223 min	10	2.775	2.0017	0.99	1.862	7.15	72.1
		224 min	10	3.002	2.1070	0.89	1.846	7.20	70.2
		225 min	10	2.934	1.9881	1.09	2.033	6.90	67.8
		226 min	10	3.306	2.1545	0.96	2.083	6.93	65.2
		227 min	10	3.150	2.0819	0.92	1.985	6.54	66.1
		228 min	10	3.004	1.9938	1.19	2.004	6.75	66.4
		229 min	11	3.003	2.1285	1.07	1.900	6.50	70.9
		230 min	11	2.807	1.6975	1.30	2.150	6.56	60.5
		231 min	11	2.692	1.8487	1.00	1.860	6.62	68.7
		232 min	11	2.852	1.9714	1.37	1.880	6.83	69.1
		233 min	11	3.064	2.3185	1.20	1.790	6.71	75.7
		234 min	11	3.062	2.3695	0.93	2.030	6.88	77.4
		235 min	10	2.772	2.0193	1.30	1.831	6.85	72.9
		236 min	11	3.032	1.8106	1.33	2.356	6.55	59.7
		237 min	11	2.748	2.0355	0.93	1.940	6.65	74.1
		238 min	11	3.293	2.2435	1.35	2.295	6.93	68.1
		239 min	11	2.562	1.7130	1.26	1.858	6.54	66.9
		240 min	6	3.704	2.1735	1.54	3.048	6.46	58.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 73 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	1 min	12	3.585	2.3743	1.32	2.328	7.82	66.2
		2 min	12	3.546	2.3892	1.15	2.388	7.91	67.4
		3 min	12	3.341	2.3366	1.05	2.380	7.62	69.9
		4 min	12	3.277	2.3111	0.91	2.371	7.68	70.5
		5 min	12	3.338	2.3721	0.87	2.371	7.56	71.1
		6 min	12	3.478	2.2045	1.17	2.404	7.28	63.4
		7 min	12	3.375	2.2931	1.05	2.362	7.63	68.0
		8 min	12	3.298	2.2347	1.09	2.379	7.70	67.8
		9 min	12	3.144	2.0879	1.36	2.359	7.62	66.4
		10 min	12	3.318	2.1331	1.31	2.334	7.13	64.3
		11 min	12	3.266	1.9991	1.40	2.323	6.76	61.2
		12 min	12	3.228	2.0385	1.43	2.346	6.81	63.1
		13 min	12	3.105	1.9049	1.43	2.346	6.85	61.3
		14 min	12	3.387	2.2819	1.32	2.299	7.22	67.4
		15 min	12	3.238	2.0269	1.35	2.313	7.42	62.6
		16 min	12	3.333	2.0747	1.34	2.351	7.14	62.2
		17 min	12	3.096	1.9834	1.28	2.364	7.05	64.1
		18 min	12	2.872	1.7766	1.19	2.027	6.66	61.9
		19 min	12	3.074	1.8294	1.14	2.349	6.70	59.5
		20 min	12	2.884	1.7935	1.13	2.173	6.99	62.2
		21 min	12	3.293	1.9935	1.26	2.637	6.44	60.5
		22 min	12	3.114	1.8511	1.23	2.443	6.61	59.5
		23 min	12	2.887	1.5819	1.20	2.568	6.74	54.8
		24 min	12	2.909	1.7587	1.07	2.382	6.40	60.5
		25 min	12	3.411	1.9831	1.12	2.751	6.95	58.1
		26 min	12	2.916	1.8107	1.21	2.262	6.54	62.1
		27 min	12	2.870	1.8654	1.21	2.216	6.65	65.0
		28 min	12	3.193	1.6862	1.14	2.587	6.11	52.8
		29 min	12	2.944	1.7168	1.06	2.373	6.78	58.3
		30 min	12	2.830	1.9769	1.07	2.259	6.90	69.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 74 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	31 min	12	2.846	1.7697	1.15	2.271	6.82	62.2
		32 min	11	2.431	1.6186	0.96	1.953	6.80	66.6
		33 min	10	2.513	1.5403	1.08	2.214	6.64	61.3
		34 min	10	2.371	1.6261	1.17	1.820	6.82	68.6
		35 min	10	3.143	2.1047	1.12	2.231	6.81	67.0
		36 min	10	2.736	1.6605	1.15	2.237	6.92	60.7
		37 min	10	3.211	2.2084	1.07	2.524	7.62	68.8
		38 min	10	3.087	1.8439	1.24	2.439	6.74	59.7
		39 min	10	3.178	1.9328	1.08	2.476	6.31	60.8
		40 min	10	3.066	1.9484	1.09	2.323	6.83	63.6
		41 min	10	2.397	1.3431	0.95	1.976	5.57	56.0
		42 min	11	2.035	0.7051	1.04	2.018	3.05	34.6
		43 min	12	2.411	0.9149	1.28	2.118	4.41	37.9
		44 min	12	2.402	1.5568	1.08	1.920	6.81	64.8
		45 min	12	2.473	1.7464	0.86	1.944	7.32	70.6
		46 min	12	2.091	0.9483	1.00	1.829	4.01	45.4
		47 min	12	2.474	1.5365	1.00	2.156	6.74	62.1
		48 min	12	2.531	1.4176	1.08	1.982	5.60	56.0
		49 min	12	2.520	1.5116	0.90	2.015	5.35	60.0
		50 min	12	2.727	1.7792	0.97	2.093	6.21	65.2
		51 min	11	2.968	1.8343	1.12	2.186	6.47	61.8
		52 min	11	3.308	1.9831	0.97	2.479	6.54	60.0
		53 min	11	3.278	1.9695	1.02	2.462	6.60	60.1
		54 min	11	2.975	2.2584	0.64	2.050	7.21	75.9
		55 min	11	2.866	1.9818	0.99	2.095	6.73	69.2
		56 min	11	2.911	2.1915	0.73	2.011	7.15	75.3
		57 min	11	2.950	2.1629	1.06	2.332	7.12	73.3
		58 min	11	2.871	2.1138	0.86	2.210	7.02	73.6
		59 min	11	2.477	1.7244	1.01	2.057	7.13	69.6
		60 min	11	2.860	2.0817	1.06	1.977	7.15	72.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 75 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	61 min	11	2.887	2.1943	0.85	2.124	7.16	76.0
		62 min	11	2.920	2.1073	0.86	2.144	7.31	72.2
		63 min	10	3.037	2.3780	0.89	2.117	7.41	78.3
		64 min	10	2.491	1.8714	0.79	1.947	7.22	75.1
		65 min	9	2.490	1.9224	0.80	2.034	7.27	77.2
		66 min	9	3.002	2.5554	0.54	2.190	7.34	85.1
		67 min	9	3.047	2.5357	0.85	2.138	7.44	83.2
		68 min	9	3.001	2.2811	1.01	1.998	7.15	76.0
		69 min	9	2.723	2.0896	0.87	2.047	7.25	76.7
		70 min	9	3.208	2.4308	1.32	2.259	7.55	75.8
		71 min	9	4.297	2.8325	1.13	2.781	7.50	65.9
		72 min	9	4.412	3.0083	1.22	2.842	8.06	68.2
		73 min	9	4.350	2.8113	1.11	2.800	7.58	64.6
		74 min	9	3.786	2.7785	0.82	2.740	7.57	73.4
		75 min	9	4.243	2.7114	1.21	2.868	7.42	63.9
		76 min	9	4.193	2.7474	0.85	2.755	7.43	65.5
		77 min	9	4.309	2.7475	1.05	2.808	7.34	63.8
		78 min	9	3.490	2.2671	1.44	2.155	7.18	65.0
		79 min	9	3.848	2.7274	1.47	2.155	8.02	70.9
		80 min	9	3.816	2.6688	1.37	2.356	7.69	69.9
		81 min	9	2.994	2.2572	1.16	2.013	7.40	75.4
		82 min	9	3.024	2.2705	1.31	1.992	7.31	75.1
		83 min	9	3.570	2.3906	1.62	2.031	7.30	67.0
		84 min	9	3.543	2.5068	1.21	2.026	7.29	70.8
		85 min	9	3.715	2.6305	1.35	2.021	7.36	70.8
		86 min	9	3.662	2.6205	1.51	2.019	7.34	71.6
		87 min	9	3.115	2.2115	1.48	2.073	7.18	71.0
		88 min	9	3.496	2.4915	1.29	2.081	7.55	71.3
		89 min	9	3.943	2.4082	1.47	2.645	7.20	61.1
		90 min	9	4.092	2.5700	1.52	2.782	7.22	62.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 76 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	91 min	9	4.222	2.6341	1.65	2.729	7.16	62.4
		92 min	9	4.256	2.6506	1.62	2.695	7.20	62.3
		93 min	10	4.006	2.1309	1.81	3.471	7.21	53.2
		94 min	10	3.867	2.4155	1.67	2.756	7.28	62.5
		95 min	11	4.084	2.5806	1.67	2.626	7.54	63.2
		96 min	11	4.041	2.5233	1.70	2.635	7.57	62.4
		97 min	11	3.795	2.2512	1.67	2.731	7.49	59.3
		98 min	11	3.723	2.1954	1.73	2.614	7.21	59.0
		99 min	11	3.925	2.2995	1.71	2.743	7.43	58.6
		100 min	11	3.737	2.1445	1.70	2.771	7.51	57.4
		101 min	11	3.368	2.2011	1.29	2.379	7.48	65.4
		102 min	11	3.915	2.3113	1.70	2.738	7.50	59.0
		103 min	11	3.606	2.1311	1.66	2.726	7.52	59.1
		104 min	11	3.854	2.3658	1.64	2.794	7.50	61.4
		105 min	11	3.978	2.5230	1.70	2.784	7.71	63.4
		106 min	11	3.685	2.1424	1.68	2.736	6.98	58.1
		107 min	11	3.774	2.2844	1.62	2.729	7.29	60.5
		108 min	11	3.577	2.0466	1.65	2.711	7.40	57.2
		109 min	11	3.530	2.1975	1.58	2.643	7.78	62.3
		110 min	11	3.482	2.2727	1.58	2.097	7.28	65.3
		111 min	11	2.950	1.7161	1.60	2.089	7.30	58.2
		112 min	11	3.122	1.8830	1.43	2.186	7.31	60.3
		113 min	11	3.368	2.1626	1.42	2.508	7.53	64.2
		114 min	11	3.640	2.2556	1.45	2.749	7.60	62.0
		115 min	11	3.448	2.0352	1.45	2.660	7.22	59.0
		116 min	11	3.560	2.1840	1.41	2.650	7.50	61.3
		117 min	10	3.415	2.3900	0.79	2.351	7.66	70.0
		118 min	10	3.666	2.0111	1.71	3.177	7.37	54.9
		119 min	10	3.773	2.2544	1.60	3.148	7.38	59.8
		120 min	10	3.914	2.3123	1.55	3.161	7.24	59.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 77 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	121 min	10	3.534	2.1868	1.56	3.008	7.38	61.9
		122 min	10	4.053	2.4660	1.61	3.236	7.65	60.8
		123 min	11	3.805	2.4581	1.49	2.698	7.34	64.6
		124 min	11	3.831	2.5638	1.44	2.660	7.49	66.9
		125 min	11	3.311	2.3561	1.30	1.934	7.57	71.2
		126 min	11	3.717	2.3119	1.40	2.692	7.55	62.2
		127 min	11	2.965	1.8547	1.53	1.995	7.22	62.5
		128 min	11	2.636	1.4971	1.38	2.017	6.41	56.8
		129 min	11	2.193	1.0121	1.27	1.811	4.32	46.2
		130 min	11	2.570	1.6733	1.25	1.880	7.14	65.1
		131 min	11	2.263	1.4914	1.18	1.610	6.18	65.9
		132 min	11	2.958	2.1332	0.84	1.901	7.66	72.1
		133 min	10	3.085	2.3220	1.52	1.930	7.55	75.3
		134 min	11	2.690	1.6953	1.19	1.866	6.14	63.0
		135 min	11	2.639	1.7457	1.29	1.976	7.13	66.1
		136 min	11	3.053	2.3979	1.45	1.870	7.94	78.5
		137 min	11	2.976	2.3567	1.31	1.892	7.94	79.2
		138 min	11	2.982	2.3384	1.20	1.817	7.93	78.4
		139 min	11	3.062	2.2824	1.49	1.973	7.89	74.6
		140 min	11	2.696	1.9473	1.09	1.974	7.92	72.2
		141 min	11	2.715	2.0153	1.01	1.956	8.01	74.2
		142 min	11	3.098	2.0582	1.24	2.232	7.94	66.4
		143 min	11	3.428	2.3901	1.38	2.087	7.94	69.7
		144 min	11	2.986	2.3712	1.37	1.991	7.86	79.4
		145 min	10	3.367	2.3409	1.59	2.219	7.85	69.5
		146 min	10	3.361	2.2901	1.50	2.555	7.86	68.1
		147 min	10	3.687	2.6260	1.51	2.261	7.85	71.2
		148 min	10	4.033	2.5453	1.43	3.163	7.90	63.1
		149 min	10	3.653	2.6251	1.37	2.240	7.87	71.9
		150 min	10	3.760	2.5850	1.17	2.641	7.82	68.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 78 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	151 min	10	3.856	2.5487	1.50	2.922	7.90	66.1
		152 min	10	3.696	2.5396	0.85	2.656	7.82	68.7
		153 min	10	3.560	2.6116	0.93	2.100	7.74	73.4
		154 min	10	3.706	2.4143	1.64	2.318	7.69	65.1
		155 min	10	3.641	2.4311	1.54	2.145	7.69	66.8
		156 min	10	3.561	2.4686	1.49	2.101	7.65	69.3
		157 min	10	3.612	2.2742	1.48	2.588	7.70	63.0
		158 min	10	3.261	2.1623	1.54	2.220	7.72	66.3
		159 min	10	3.301	2.1428	1.55	2.208	7.63	64.9
		160 min	10	3.394	2.3088	1.49	2.122	7.80	68.0
		161 min	10	3.293	2.2441	1.47	2.148	7.63	68.1
		162 min	10	3.371	2.2703	1.40	2.150	7.44	67.4
		163 min	11	3.208	2.1746	1.43	1.902	7.41	67.8
		164 min	11	3.200	2.1524	1.47	1.899	7.45	67.3
		165 min	11	3.251	2.0784	1.50	2.414	7.45	63.9
		166 min	11	3.529	2.2767	1.44	2.421	7.62	64.5
		167 min	11	3.465	2.2843	1.51	2.452	7.28	65.9
		168 min	11	3.657	2.3039	1.27	2.430	6.78	63.0
		169 min	10	3.276	2.1854	1.44	2.190	6.75	66.7
		170 min	10	3.229	2.0565	1.38	2.255	6.69	63.7
		171 min	10	3.252	2.0581	1.47	2.288	6.62	63.3
		172 min	10	3.352	2.2258	1.65	2.178	6.99	66.4
		173 min	10	2.836	1.9572	1.40	2.129	6.84	69.0
		174 min	10	2.958	2.0486	1.35	2.188	7.14	69.3
		175 min	10	2.967	1.9995	1.34	2.122	7.04	67.4
		176 min	10	2.980	1.9767	1.42	2.189	7.02	66.3
		177 min	10	3.080	1.8791	1.53	2.362	6.68	61.0
		178 min	10	3.081	2.0008	1.51	2.174	6.97	64.9
		179 min	10	3.246	1.9134	1.62	2.334	6.67	58.9
		180 min	10	3.016	1.9837	1.60	2.128	6.82	65.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 79 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	181 min	10	2.973	2.0214	1.33	2.097	6.76	68.0
		182 min	10	2.978	1.9815	1.56	2.134	6.85	66.5
		183 min	10	3.064	1.9349	1.65	2.253	6.72	63.1
		184 min	10	3.151	2.0149	1.29	2.192	6.62	63.9
		185 min	9	3.279	1.9301	1.59	2.521	6.62	58.9
		186 min	8	2.603	1.7690	1.15	2.162	6.85	68.0
		187 min	9	2.555	1.6497	1.33	2.073	6.85	64.6
		188 min	9	2.549	1.6214	1.37	2.065	6.75	63.6
		189 min	9	3.031	1.9305	1.52	2.212	6.63	63.7
		190 min	9	2.464	1.5913	1.15	2.010	6.50	64.6
		191 min	9	2.489	1.5772	1.43	1.943	6.58	63.4
		192 min	9	2.485	1.6075	1.24	2.088	6.63	64.7
		193 min	9	2.517	1.5363	1.24	2.109	6.47	61.0
		194 min	9	3.132	2.2274	1.63	2.198	7.64	71.1
		195 min	9	2.912	1.7932	1.47	2.195	6.22	61.6
		196 min	9	3.006	1.8721	1.65	2.126	6.60	62.3
		197 min	9	2.948	1.8450	1.52	2.133	6.37	62.6
		198 min	10	2.934	2.0548	1.62	2.030	6.90	70.0
		199 min	10	2.382	1.5077	1.22	2.065	6.50	63.3
		200 min	10	2.493	1.5296	0.96	2.077	6.45	61.4
		201 min	10	2.405	1.5233	0.94	2.012	6.43	63.3
		202 min	10	2.314	1.5394	0.96	1.973	6.50	66.5
		203 min	11	2.415	1.3865	1.34	1.997	6.17	57.4
		204 min	11	2.319	1.3798	1.49	1.838	6.39	59.5
		205 min	11	2.246	1.4386	1.07	1.862	6.23	64.0
		206 min	11	2.222	1.4685	0.78	1.948	6.32	66.1
		207 min	10	2.189	1.4586	0.93	1.848	6.08	66.6
		208 min	10	2.170	1.6418	0.48	1.858	6.52	75.7
		209 min	10	2.120	1.4174	0.76	1.815	5.87	66.9
		210 min	10	2.205	1.4150	0.97	1.883	5.98	64.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 80 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	211 min	10	2.254	1.6086	0.92	1.834	6.63	71.4
		212 min	10	2.469	1.6936	1.13	1.908	7.11	68.6
		213 min	10	2.288	1.5988	1.23	1.809	6.69	69.9
		214 min	10	2.357	1.5847	1.20	1.908	6.74	67.2
		215 min	10	2.227	1.6480	1.03	1.777	6.73	74.0
		216 min	10	2.254	1.7619	0.87	1.798	7.07	78.2
		217 min	10	2.238	1.7309	0.91	1.724	6.96	77.4
		218 min	10	2.210	1.7070	0.94	1.751	6.87	77.2
		219 min	10	2.268	1.6295	0.95	1.744	6.73	71.8
		220 min	10	2.349	1.6401	0.94	1.762	6.79	69.8
		221 min	10	3.018	1.8782	1.09	2.061	6.86	62.2
		222 min	10	2.938	1.9609	1.27	1.969	7.03	66.8
		223 min	10	3.068	2.0111	1.70	2.029	7.12	65.5
		224 min	10	2.993	2.0628	1.05	1.860	7.02	68.9
		225 min	10	3.223	2.0907	1.57	2.073	6.91	64.9
		226 min	10	3.081	2.1167	1.25	1.992	6.94	68.7
		227 min	10	3.335	2.2479	1.03	2.014	6.96	67.4
		228 min	10	3.093	1.8445	1.55	1.959	6.63	59.6
		229 min	11	3.136	2.1921	1.25	1.837	7.08	69.9
		230 min	11	3.106	1.6526	1.50	2.244	6.61	53.2
		231 min	11	3.010	1.8465	1.27	2.272	6.49	61.3
		232 min	11	3.139	2.0542	1.31	2.206	6.98	65.4
		233 min	11	3.301	2.1404	1.29	2.129	6.98	64.9
		234 min	11	2.971	2.2411	0.92	1.908	7.00	75.4
		235 min	10	3.153	2.4026	1.30	1.813	7.06	76.2
		236 min	11	3.566	2.1937	1.37	2.598	7.34	61.5
		237 min	11	3.161	2.1987	1.19	1.863	6.96	69.6
		238 min	11	3.661	2.4893	1.22	2.537	7.11	68.0
		239 min	11	3.205	1.9849	1.28	2.517	6.45	61.9
		240 min	6	3.482	1.8024	1.29	3.137	5.98	51.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 81 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	1 min	12	3.954	2.4972	1.16	3.491	7.77	63.1
		2 min	12	4.065	2.5691	0.97	3.391	7.94	63.2
		3 min	12	4.005	2.5886	1.16	3.281	7.84	64.6
		4 min	12	3.742	2.4266	1.21	3.184	7.83	64.8
		5 min	12	3.425	2.2156	1.22	2.708	7.62	64.7
		6 min	12	3.546	2.2638	1.24	2.663	7.22	63.8
		7 min	12	3.607	2.3781	1.03	2.780	7.65	65.9
		8 min	12	3.883	2.5296	0.95	3.341	7.66	65.2
		9 min	12	3.784	2.2922	1.42	3.159	7.33	60.6
		10 min	12	4.047	2.5792	1.37	3.159	7.46	63.7
		11 min	12	3.789	2.3378	1.42	3.147	7.40	61.7
		12 min	12	3.700	2.3682	1.49	2.547	7.61	64.0
		13 min	12	3.706	2.2382	1.42	3.163	7.26	60.4
		14 min	12	3.842	2.3473	1.45	3.141	7.23	61.1
		15 min	12	4.081	2.5045	1.44	3.179	7.36	61.4
		16 min	12	3.667	2.3800	1.51	2.302	7.34	64.9
		17 min	12	3.646	2.3476	1.44	2.365	7.03	64.4
		18 min	12	3.594	2.1852	1.11	2.802	7.30	60.8
		19 min	12	3.742	2.3189	1.43	2.679	7.47	62.0
		20 min	12	3.879	2.3242	1.36	3.180	7.01	59.9
		21 min	12	4.201	2.4167	1.39	3.893	7.37	57.5
		22 min	12	4.291	2.3911	1.47	4.274	7.27	55.7
		23 min	12	4.279	2.4354	1.34	4.715	6.88	56.9
		24 min	12	4.257	2.3624	1.35	4.715	6.99	55.5
		25 min	12	4.118	2.3412	1.20	3.334	7.19	56.9
		26 min	12	3.481	1.9452	1.28	2.892	6.67	55.9
		27 min	12	3.549	2.0049	1.37	2.988	6.75	56.5
		28 min	12	3.971	2.4634	1.20	3.289	7.25	62.0
		29 min	12	3.425	2.1469	1.24	2.671	6.92	62.7
		30 min	12	4.199	2.2362	1.36	4.297	6.90	53.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 82 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	31 min	12	4.120	2.5060	1.11	3.220	7.67	60.8
		32 min	11	3.821	2.2380	1.26	3.599	7.09	58.6
		33 min	10	3.647	2.1858	0.96	3.392	6.97	59.9
		34 min	10	3.526	2.3252	1.01	2.460	7.13	65.9
		35 min	10	3.856	2.7252	1.38	2.263	7.34	70.7
		36 min	10	3.580	2.0695	1.13	3.538	7.02	57.8
		37 min	10	3.991	2.3980	1.18	4.239	6.96	60.1
		38 min	10	4.213	2.6423	1.15	4.634	6.97	62.7
		39 min	10	4.184	2.5465	1.26	4.332	7.00	60.9
		40 min	10	4.190	2.5883	1.01	4.630	7.10	61.8
		41 min	10	3.676	2.4034	1.04	3.135	7.08	65.4
		42 min	11	3.563	2.0102	1.37	2.880	6.42	56.4
		43 min	12	3.586	2.0247	1.33	3.315	6.80	56.5
		44 min	12	2.885	1.7593	1.11	2.550	6.21	61.0
		45 min	12	3.448	2.1619	1.02	2.824	7.25	62.7
		46 min	12	3.324	2.2816	0.90	2.475	6.85	68.6
		47 min	12	3.260	2.1370	0.91	2.688	6.79	65.5
		48 min	12	3.371	2.2283	0.97	2.671	7.25	66.1
		49 min	12	3.083	2.0852	0.83	2.618	6.67	67.6
		50 min	12	3.569	2.3969	0.81	3.136	7.16	67.2
		51 min	11	4.161	2.2363	1.35	3.719	7.52	53.7
		52 min	11	3.918	2.2846	1.17	3.635	7.04	58.3
		53 min	11	3.866	2.4029	0.78	3.357	7.77	62.2
		54 min	11	3.418	2.2586	0.92	3.598	7.64	66.1
		55 min	11	3.247	2.1241	0.98	2.535	6.80	65.4
		56 min	11	2.985	2.1977	1.28	2.088	7.58	73.6
		57 min	11	3.707	2.2501	1.17	3.177	7.41	60.7
		58 min	11	3.881	2.3815	1.21	3.660	7.63	61.4
		59 min	11	3.316	2.5259	0.88	2.133	7.58	76.2
		60 min	11	3.801	2.5060	1.04	3.254	7.35	65.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 83 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	61 min	11	3.716	2.4373	0.73	3.190	7.26	65.6
		62 min	11	3.593	2.4673	0.89	2.926	7.27	68.7
		63 min	10	3.785	2.6378	0.82	3.286	7.65	69.7
		64 min	10	3.802	2.5478	0.78	3.365	6.99	67.0
		65 min	9	3.332	2.3244	1.00	2.729	6.89	69.8
		66 min	9	3.902	2.8169	0.71	2.784	7.53	72.2
		67 min	9	3.921	2.8593	1.01	2.867	7.77	72.9
		68 min	9	3.860	2.5486	1.17	2.802	7.80	66.0
		69 min	9	3.289	2.1771	1.08	2.909	7.04	66.2
		70 min	9	4.114	2.8276	0.82	2.801	7.42	68.7
		71 min	9	4.811	2.6927	0.95	6.683	7.57	56.0
		72 min	9	5.456	2.5815	1.57	6.493	8.06	47.3
		73 min	9	4.216	2.9884	0.92	2.950	7.76	70.9
		74 min	9	4.125	2.7420	0.98	2.884	7.15	66.5
		75 min	9	4.361	2.6492	1.32	3.402	7.25	60.8
		76 min	9	4.676	2.7466	1.21	6.382	7.43	58.7
		77 min	9	4.929	2.6226	1.26	6.934	7.34	53.2
		78 min	9	3.836	2.4923	1.38	3.085	7.30	65.0
		79 min	9	4.568	2.6156	1.26	5.114	7.41	57.3
		80 min	9	4.711	2.8525	0.93	5.717	7.80	60.6
		81 min	9	4.064	2.3006	0.91	3.602	7.16	56.6
		82 min	9	4.565	2.4616	1.56	4.447	7.77	53.9
		83 min	9	4.481	2.4614	1.56	4.323	7.56	54.9
		84 min	9	4.472	2.5728	1.49	4.829	7.91	57.5
		85 min	9	4.582	2.5423	1.71	4.498	7.92	55.5
		86 min	9	4.211	2.8425	0.99	2.889	7.79	67.5
		87 min	9	4.818	2.7152	1.57	6.473	7.60	56.4
		88 min	9	5.077	2.3891	1.49	6.001	7.35	47.1
		89 min	9	4.665	2.7273	1.44	6.449	7.39	58.5
		90 min	9	5.076	2.5008	1.49	6.544	7.62	49.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 84 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	91 min	9	5.174	2.3587	1.54	6.516	7.66	45.6
		92 min	9	4.855	2.7285	1.63	6.687	7.63	56.2
		93 min	10	4.790	2.5025	1.32	5.081	7.74	52.2
		94 min	10	5.181	2.3893	1.52	6.223	7.65	46.1
		95 min	11	5.113	2.3352	1.72	6.435	7.63	45.7
		96 min	11	4.793	2.3695	1.66	5.513	7.81	49.4
		97 min	11	4.643	2.5483	1.68	4.023	7.88	54.9
		98 min	11	4.642	2.5617	1.74	3.999	7.89	55.2
		99 min	11	4.344	2.5161	1.60	4.030	7.93	57.9
		100 min	11	4.468	2.5499	1.61	4.003	7.96	57.1
		101 min	11	4.182	2.4290	1.39	4.031	7.98	58.1
		102 min	11	4.376	2.5472	1.62	4.005	7.87	58.2
		103 min	11	4.700	2.4733	1.49	4.970	8.09	52.6
		104 min	11	4.539	2.6745	1.53	4.066	8.01	58.9
		105 min	11	4.615	2.6022	1.57	3.968	7.84	56.4
		106 min	11	4.611	2.4703	1.53	3.974	7.78	53.6
		107 min	11	4.312	2.5886	1.56	3.982	8.06	60.0
		108 min	11	4.967	2.5235	1.54	6.347	7.98	50.8
		109 min	11	4.289	2.5494	1.57	3.556	8.40	59.4
		110 min	11	4.771	2.3756	1.66	5.639	7.93	49.8
		111 min	11	4.306	2.3593	1.72	3.858	7.56	54.8
		112 min	11	4.692	2.5404	1.55	4.855	8.32	54.1
		113 min	11	4.631	2.4842	1.50	4.283	7.82	53.6
		114 min	11	4.233	2.4529	1.45	3.879	7.61	57.9
		115 min	11	4.298	2.3447	1.51	3.700	7.36	54.6
		116 min	11	4.481	2.7879	1.45	3.695	7.61	62.2
		117 min	10	4.579	2.2345	1.60	4.138	7.51	48.8
		118 min	10	4.417	2.4491	1.80	3.531	7.49	55.4
		119 min	10	4.411	2.3476	1.36	3.489	7.51	53.2
		120 min	10	5.150	2.4748	1.64	5.803	7.63	48.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 85 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	121 min	10	4.938	2.4737	1.56	5.127	7.54	50.1
		122 min	10	4.738	2.7455	1.49	5.114	7.74	58.0
		123 min	11	5.167	2.4596	1.50	6.755	7.40	47.6
		124 min	11	4.296	2.5029	1.46	3.664	7.29	58.3
		125 min	11	4.228	2.4744	1.46	3.620	7.34	58.5
		126 min	11	4.729	2.2963	1.56	5.272	7.38	48.6
		127 min	11	4.291	2.5661	1.48	3.563	7.71	59.8
		128 min	11	3.680	2.2289	1.56	3.060	7.70	60.6
		129 min	11	4.559	2.2408	1.54	4.176	7.16	49.1
		130 min	11	3.790	2.1333	1.45	2.916	6.81	56.3
		131 min	11	2.782	1.7836	1.46	1.878	7.13	64.1
		132 min	11	4.426	2.3496	1.51	3.927	7.91	53.1
		133 min	10	4.334	2.2913	1.59	3.899	7.79	52.9
		134 min	11	4.096	2.3334	1.30	3.612	7.13	57.0
		135 min	11	4.102	2.3548	1.54	3.079	7.20	57.4
		136 min	11	3.687	2.5220	1.33	2.789	7.99	68.4
		137 min	11	4.250	2.6206	1.47	3.565	7.89	61.7
		138 min	11	3.662	2.4756	1.34	2.757	7.65	67.6
		139 min	11	3.947	2.4527	1.19	3.148	7.73	62.1
		140 min	11	3.778	2.2227	1.36	2.791	7.95	58.8
		141 min	11	3.681	2.4569	0.98	2.746	7.87	66.7
		142 min	11	3.930	2.7203	1.22	2.677	7.92	69.2
		143 min	11	3.947	2.5521	1.26	2.989	8.02	64.7
		144 min	11	3.949	2.2956	1.62	2.946	7.28	58.1
		145 min	10	4.739	2.1496	1.87	4.253	7.39	45.4
		146 min	10	4.080	2.3109	1.29	3.695	7.27	56.6
		147 min	10	4.306	2.3018	1.14	3.515	7.31	53.5
		148 min	10	4.580	2.3484	0.91	4.388	7.63	51.3
		149 min	10	4.398	2.5813	1.05	4.393	7.88	58.7
		150 min	10	4.599	2.8671	0.93	5.056	7.80	62.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 86 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	151 min	10	4.542	2.7528	1.00	5.187	7.86	60.6
		152 min	10	4.612	2.7170	1.19	5.173	7.78	58.9
		153 min	10	4.052	2.5805	0.88	2.951	7.80	63.7
		154 min	10	3.865	2.3932	1.05	3.006	7.75	61.9
		155 min	10	4.394	2.4422	1.01	4.737	7.68	55.6
		156 min	10	3.854	2.3993	1.08	3.321	7.63	62.3
		157 min	10	3.870	2.3479	1.09	3.243	7.61	60.7
		158 min	10	3.893	2.3840	1.13	3.237	7.57	61.2
		159 min	10	4.133	2.3948	0.99	4.077	7.66	57.9
		160 min	10	3.976	2.3417	1.09	3.535	7.70	58.9
		161 min	10	4.324	2.4188	1.10	4.355	7.91	55.9
		162 min	10	4.367	2.4952	0.80	4.625	7.87	57.1
		163 min	11	4.097	2.4427	1.10	3.707	7.79	59.6
		164 min	11	3.787	2.5318	1.03	2.433	7.69	66.9
		165 min	11	3.810	2.4979	1.11	2.453	7.89	65.6
		166 min	11	3.818	2.3011	1.14	3.599	7.73	60.3
		167 min	11	3.366	2.4509	1.03	1.943	7.78	72.8
		168 min	11	3.355	2.3886	1.01	2.160	7.66	71.2
		169 min	10	3.812	2.6478	1.34	2.240	7.35	69.5
		170 min	10	3.797	2.6906	0.72	2.380	7.35	70.9
		171 min	10	4.395	2.6506	1.26	4.522	7.43	60.3
		172 min	10	4.255	2.5922	0.55	4.505	7.36	60.9
		173 min	10	4.349	2.2281	1.17	4.273	7.44	51.2
		174 min	10	4.484	2.2226	1.15	4.773	7.49	49.6
		175 min	10	4.745	2.4418	1.07	5.765	7.78	51.5
		176 min	10	4.286	2.5290	0.93	3.991	7.49	59.0
		177 min	10	3.929	2.7174	1.16	2.611	7.63	69.2
		178 min	10	4.368	2.5654	1.21	4.255	7.54	58.7
		179 min	10	3.925	2.6036	1.32	2.477	7.45	66.3
		180 min	10	3.799	2.4139	1.10	2.462	6.91	63.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 87 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	181 min	10	4.157	2.3949	1.28	3.528	7.19	57.6
		182 min	10	3.981	2.5389	1.22	2.461	7.24	63.8
		183 min	10	4.530	2.5780	1.08	4.617	7.55	56.9
		184 min	10	4.365	2.5610	1.28	4.437	7.18	58.7
		185 min	9	4.208	2.3560	1.40	3.426	6.88	56.0
		186 min	8	3.529	2.3076	1.00	2.372	6.70	65.4
		187 min	9	2.882	1.5529	1.30	2.538	6.61	53.9
		188 min	9	2.983	1.8615	1.02	2.182	6.60	62.4
		189 min	9	3.314	2.1615	0.82	2.190	6.53	65.2
		190 min	9	3.563	1.9765	1.80	2.495	6.49	55.5
		191 min	9	3.366	2.2731	1.18	2.049	6.67	67.5
		192 min	9	3.521	2.5977	1.04	2.025	7.51	73.8
		193 min	9	3.530	2.3356	1.60	2.081	6.67	66.2
		194 min	9	3.735	2.4597	1.28	2.548	7.14	65.9
		195 min	9	3.344	2.2687	1.23	2.069	6.55	67.9
		196 min	9	4.082	2.1284	1.58	4.221	7.08	52.1
		197 min	9	3.609	2.1776	1.54	2.563	7.13	60.3
		198 min	10	4.091	2.5132	1.24	3.478	7.49	61.4
		199 min	10	3.611	2.1634	1.28	2.390	6.66	59.9
		200 min	10	2.858	1.8969	1.13	2.182	6.53	66.4
		201 min	10	3.475	2.3191	0.82	2.492	6.66	66.7
		202 min	10	3.021	1.7787	1.12	2.598	6.46	58.9
		203 min	11	3.183	2.0133	0.89	2.201	6.32	63.3
		204 min	11	3.986	2.3579	1.21	2.998	7.08	59.2
		205 min	11	3.355	2.0781	1.49	2.751	6.72	61.9
		206 min	11	2.654	2.0783	1.00	1.877	6.97	78.3
		207 min	10	2.665	2.2698	0.86	1.794	7.53	85.2
		208 min	10	2.832	2.0201	1.26	1.738	6.46	71.3
		209 min	10	2.516	1.8236	0.79	1.810	6.14	72.5
		210 min	10	3.430	2.2038	1.03	2.271	6.68	64.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 88 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	211 min	10	3.302	2.4244	0.85	2.241	7.32	73.4
		212 min	10	3.638	2.3478	1.16	2.706	7.14	64.5
		213 min	10	3.905	2.0952	1.40	3.398	7.33	53.6
		214 min	10	3.315	2.4245	1.32	1.911	7.10	73.1
		215 min	10	3.219	2.2544	1.34	2.179	7.15	70.0
		216 min	10	3.317	2.3868	0.87	2.136	7.33	71.9
		217 min	10	3.589	2.4531	1.22	2.596	7.43	68.4
		218 min	10	3.306	2.5916	0.89	2.193	7.21	78.4
		219 min	10	3.140	2.5324	0.99	1.668	7.33	80.6
		220 min	10	3.454	2.3612	1.25	2.500	6.88	68.4
		221 min	10	3.296	2.4035	1.35	2.150	6.86	72.9
		222 min	10	3.648	2.4132	0.99	2.535	7.22	66.2
		223 min	10	3.642	2.5604	1.32	2.561	7.47	70.3
		224 min	10	3.258	2.4589	0.76	2.483	7.14	75.5
		225 min	10	4.180	2.4311	1.38	5.044	7.39	58.2
		226 min	10	3.675	2.6624	0.89	2.702	7.32	72.5
		227 min	10	3.641	2.4885	1.29	2.403	7.25	68.3
		228 min	10	3.673	2.6602	1.22	2.299	7.14	72.4
		229 min	11	3.279	2.4016	1.10	1.732	7.18	73.2
		230 min	11	3.739	2.5206	1.01	2.776	7.27	67.4
		231 min	11	3.445	2.3294	1.12	2.590	7.25	67.6
		232 min	11	4.060	2.3794	1.12	4.942	7.08	58.6
		233 min	11	3.680	2.3772	1.12	2.592	7.12	64.6
		234 min	11	3.221	2.3588	1.17	1.900	7.20	73.2
		235 min	10	3.214	2.4028	1.06	2.103	7.25	74.8
		236 min	11	3.686	2.3560	1.27	2.815	7.00	63.9
		237 min	11	4.031	2.3948	1.13	3.716	7.03	59.4
		238 min	11	3.695	2.4970	1.02	2.728	7.18	67.6
		239 min	11	3.718	2.4929	1.06	2.663	7.18	67.1
		240 min	6	4.496	2.2941	1.35	4.706	7.10	51.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 89 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	1 min	12	8.093	0.5338	7.16	8.084	9.12	6.6
		2 min	12	7.994	0.4696	7.18	7.905	8.97	5.9
		3 min	12	7.974	0.4796	7.10	7.977	8.69	6.0
		4 min	12	7.991	0.5436	7.12	7.911	8.80	6.8
		5 min	12	7.807	0.6797	6.47	7.716	8.72	8.7
		6 min	12	7.874	0.6285	6.67	7.918	8.80	8.0
		7 min	12	7.779	0.7813	6.86	7.426	9.16	10.0
		8 min	12	7.755	0.6500	6.70	7.785	8.63	8.4
		9 min	12	7.713	0.6719	6.60	7.768	8.74	8.7
		10 min	12	7.572	0.6514	6.62	7.412	8.61	8.6
		11 min	12	7.405	0.5844	6.54	7.288	8.45	7.9
		12 min	12	7.482	0.6645	6.52	7.291	8.57	8.9
		13 min	12	7.402	0.7038	6.50	7.112	8.51	9.5
		14 min	12	7.215	0.4896	6.48	7.098	7.95	6.8
		15 min	12	7.202	0.6088	6.18	7.306	8.04	8.5
		16 min	12	7.215	0.5496	6.47	7.165	8.04	7.6
		17 min	12	7.300	0.4903	6.62	7.254	8.15	6.7
		18 min	12	7.142	0.4119	6.67	7.011	7.93	5.8
		19 min	12	7.296	0.4079	6.68	7.326	7.86	5.6
		20 min	12	7.303	0.5628	6.65	7.193	8.14	7.7
		21 min	11	7.261	0.6315	6.50	7.080	8.26	8.7
		22 min	10	7.325	0.5806	6.66	7.052	8.26	7.9
		23 min	10	7.195	0.7238	6.21	6.962	8.26	10.1
		24 min	10	7.130	0.7630	5.79	7.075	8.21	10.7
		25 min	10	7.023	0.5313	6.40	6.873	7.94	7.6
		26 min	10	7.051	0.5967	6.31	6.917	8.12	8.5
		27 min	10	7.113	0.5846	6.37	7.077	7.95	8.2
		28 min	10	6.767	1.3987	3.04	6.933	8.02	20.7
		29 min	10	7.085	0.5213	6.37	7.157	7.84	7.4
		30 min	10	7.160	0.6229	6.17	6.978	8.05	8.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 90 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	31 min	10	7.076	0.7193	6.02	6.985	8.12	10.2
		32 min	10	7.058	0.7174	6.22	6.972	8.07	10.2
		33 min	10	7.064	0.7335	6.10	6.814	8.37	10.4
		34 min	10	7.184	0.6486	6.47	6.905	8.06	9.0
		35 min	10	6.958	0.7780	6.08	6.644	8.42	11.2
		36 min	11	7.200	0.6685	6.18	7.132	8.26	9.3
		37 min	11	7.133	0.6206	6.26	6.938	8.02	8.7
		38 min	12	6.743	1.4618	2.41	7.069	7.97	21.7
		39 min	12	7.192	0.5697	6.22	7.374	7.81	7.9
		40 min	12	7.149	0.7058	6.11	6.940	7.97	9.9
		41 min	12	7.213	0.6832	6.05	7.320	8.18	9.5
		42 min	12	6.673	1.5387	2.26	6.809	8.02	23.1
		43 min	12	7.013	0.7858	5.93	7.010	8.23	11.2
		44 min	12	7.231	0.6752	6.04	7.255	8.03	9.3
		45 min	11	7.160	0.7412	6.08	7.358	8.28	10.4
		46 min	12	7.037	0.6360	6.00	7.039	7.92	9.0
		47 min	12	7.230	0.7481	5.87	7.473	8.08	10.3
		48 min	12	7.102	0.7553	5.84	7.125	8.17	10.6
		49 min	12	6.992	0.8210	5.53	7.047	8.03	11.7
		50 min	11	7.180	0.6808	5.73	7.116	8.33	9.5
		51 min	11	7.112	0.6571	5.78	7.119	7.94	9.2
		52 min	11	7.143	0.7303	5.87	7.081	7.96	10.2
		53 min	12	7.010	0.7571	5.79	6.904	8.34	10.8
		54 min	12	6.729	1.7988	1.44	6.926	8.52	26.7
		55 min	12	7.027	0.9345	4.72	7.166	7.97	13.3
		56 min	12	7.088	0.7816	5.71	7.134	8.28	11.0
		57 min	12	7.072	0.7532	5.75	7.062	8.28	10.6
		58 min	12	6.985	0.7046	5.89	6.964	8.18	10.1
		59 min	12	7.091	0.8292	5.73	7.080	8.41	11.7
		60 min	12	7.217	0.7566	5.88	7.179	8.46	10.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 91 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	61 min	12	6.565	1.8478	1.14	6.961	8.42	28.1
		62 min	12	7.147	0.7258	5.90	6.949	8.37	10.2
		63 min	11	7.033	0.5508	6.45	6.964	8.22	7.8
		64 min	11	7.018	0.7446	5.68	6.887	8.34	10.6
		65 min	11	6.962	0.5712	6.44	6.714	8.28	8.2
		66 min	11	7.013	0.5719	6.25	6.788	8.07	8.2
		67 min	11	6.942	0.5334	6.20	6.775	7.77	7.7
		68 min	11	6.956	0.4703	6.33	6.945	7.73	6.8
		69 min	11	7.122	0.6219	6.19	6.959	8.12	8.7
		70 min	10	6.878	0.8657	5.80	6.929	8.28	12.6
		71 min	10	6.418	2.1273	0.59	6.770	8.37	33.1
		72 min	9	6.953	0.6347	6.00	7.003	8.22	9.1
		73 min	9	6.929	0.7622	5.98	6.891	8.47	11.0
		74 min	9	7.019	0.5302	6.39	6.807	7.87	7.6
		75 min	9	7.054	0.6255	6.31	6.799	7.88	8.9
		76 min	9	6.849	0.8505	5.67	6.567	8.27	12.4
		77 min	9	6.899	0.7504	5.69	6.812	7.92	10.9
		78 min	9	7.000	0.7717	6.08	6.969	8.38	11.0
		79 min	9	7.048	0.8287	6.04	6.868	8.49	11.8
		80 min	9	7.023	0.5904	6.32	7.149	8.07	8.4
		81 min	9	6.899	0.6139	6.23	6.645	7.88	8.9
		82 min	9	6.703	0.5633	5.83	6.569	7.62	8.4
		83 min	9	6.978	0.8837	5.69	6.839	8.32	12.7
		84 min	9	6.826	0.7886	5.82	6.780	8.33	11.6
		85 min	9	6.697	0.8719	4.91	6.689	8.11	13.0
		86 min	9	6.178	2.0269	1.06	6.625	8.36	32.8
		87 min	9	6.799	0.6453	5.96	6.958	7.50	9.5
		88 min	9	6.914	0.8174	5.89	6.822	8.41	11.8
		89 min	10	6.926	0.8020	5.67	6.929	8.42	11.6
		90 min	10	7.056	0.7039	6.00	6.985	8.29	10.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 92 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	91 min	10	7.104	0.7180	6.26	6.890	8.42	10.1
		92 min	10	7.013	0.7812	5.72	6.958	8.46	11.1
		93 min	10	6.986	0.7410	5.71	6.923	8.33	10.6
		94 min	10	7.021	0.6904	6.07	6.996	8.23	9.8
		95 min	9	7.003	0.8491	5.62	6.930	8.44	12.1
		96 min	9	7.012	0.5971	6.11	6.943	8.27	8.5
		97 min	9	6.835	0.9383	5.26	6.805	8.43	13.7
		98 min	9	6.961	0.6417	6.16	6.863	8.27	9.2
		99 min	10	7.084	0.7024	6.37	6.829	8.32	9.9
		100 min	9	6.445	1.4497	2.84	6.836	7.58	22.5
		101 min	9	6.879	0.6211	5.61	6.871	7.67	9.0
		102 min	9	6.958	0.4903	6.25	6.911	7.73	7.0
		103 min	9	7.129	0.6579	5.53	7.296	7.88	9.2
		104 min	10	6.937	0.5151	6.18	6.810	7.89	7.4
		105 min	10	7.142	0.7208	5.67	7.093	8.21	10.1
		106 min	10	6.975	0.5004	6.15	6.972	8.01	7.2
		107 min	10	6.867	0.7850	5.58	6.603	8.05	11.4
		108 min	10	6.907	0.6891	5.62	6.837	7.77	10.0
		109 min	10	6.884	0.7104	5.53	6.833	7.96	10.3
		110 min	10	6.972	0.8177	5.82	6.948	8.13	11.7
		111 min	10	6.948	0.7703	5.58	6.866	8.19	11.1
		112 min	10	7.049	0.8647	5.64	6.945	8.34	12.3
		113 min	11	6.960	0.6791	6.02	6.930	8.18	9.8
		114 min	11	6.913	0.7635	5.43	6.798	7.85	11.0
		115 min	11	7.062	0.8309	5.75	6.885	8.31	11.8
		116 min	11	6.905	0.9142	5.57	6.767	8.28	13.2
		117 min	11	7.032	0.8799	5.69	6.927	8.36	12.5
		118 min	12	7.071	0.6568	6.04	7.034	7.99	9.3
		119 min	12	7.024	0.7547	5.61	6.960	7.95	10.7
		120 min	12	7.012	0.6553	5.84	6.979	8.21	9.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 93 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	121 min	12	6.855	0.5762	6.05	6.748	7.71	8.4
		122 min	12	6.934	0.6109	5.67	7.107	7.73	8.8
		123 min	12	7.040	0.7004	6.02	6.834	8.27	9.9
		124 min	12	6.483	1.4479	2.20	6.684	7.55	22.3
		125 min	12	6.992	0.6928	5.58	6.970	7.93	9.9
		126 min	12	6.940	0.7075	5.59	6.868	7.94	10.2
		127 min	12	7.022	0.7061	5.54	6.959	8.16	10.1
		128 min	12	7.150	0.7567	5.58	7.240	8.22	10.6
		129 min	12	6.943	1.0338	4.57	7.269	8.35	14.9
		130 min	12	6.998	0.9143	4.96	7.119	8.21	13.1
		131 min	12	7.031	0.5275	6.05	7.058	7.96	7.5
		132 min	12	6.999	0.5883	6.00	7.152	7.88	8.4
		133 min	12	6.989	0.6954	6.04	6.980	8.31	9.9
		134 min	12	7.087	0.5774	6.07	7.112	8.07	8.1
		135 min	12	6.877	0.5190	5.76	6.974	7.52	7.5
		136 min	12	6.922	0.5960	5.66	7.112	7.59	8.6
		137 min	12	6.921	0.5819	6.00	7.060	7.84	8.4
		138 min	12	7.245	0.5355	6.41	7.383	8.00	7.4
		139 min	12	6.940	0.5284	5.96	6.874	7.75	7.6
		140 min	12	6.944	0.6587	5.59	6.781	7.96	9.5
		141 min	12	6.943	0.7147	5.64	6.917	8.05	10.3
		142 min	12	7.014	0.7984	5.47	7.194	8.27	11.4
		143 min	12	7.011	0.5918	5.85	6.921	7.88	8.4
		144 min	12	7.147	0.6159	6.24	7.220	8.06	8.6
		145 min	12	6.674	1.8282	1.12	7.180	8.04	27.4
		146 min	12	6.825	1.8535	1.27	7.304	8.05	27.2
		147 min	12	6.833	1.5681	2.31	7.283	8.26	22.9
		148 min	12	6.857	1.4709	2.45	7.325	7.83	21.5
		149 min	12	6.966	0.9407	4.38	7.265	7.88	13.5
		150 min	12	6.921	1.1647	3.67	7.237	7.93	16.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 94 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	151 min	12	6.811	1.1050	3.69	7.085	8.04	16.2
		152 min	12	6.754	1.0560	3.86	7.035	7.65	15.6
		153 min	12	6.738	0.9519	4.27	7.006	7.65	14.1
		154 min	12	6.998	0.8404	4.84	7.289	7.80	12.0
		155 min	12	6.755	0.7480	4.89	6.698	7.74	11.1
		156 min	12	6.839	0.7487	5.09	6.803	8.15	10.9
		157 min	12	6.952	0.8923	4.89	6.992	8.01	12.8
		158 min	12	7.043	0.7159	5.45	6.915	8.09	10.2
		159 min	12	7.027	0.6255	5.56	7.113	7.72	8.9
		160 min	12	6.915	0.8452	4.98	6.850	8.04	12.2
		161 min	12	6.890	0.6412	5.56	6.911	7.72	9.3
		162 min	12	6.591	1.1319	3.57	6.829	7.71	17.2
		163 min	12	7.065	0.5769	6.11	6.895	7.96	8.2
		164 min	11	7.060	0.5420	5.82	7.032	7.69	7.7
		165 min	11	7.168	0.7954	5.35	7.649	8.13	11.1
		166 min	11	7.017	0.6985	5.83	7.053	7.90	10.0
		167 min	11	6.937	0.6354	5.79	7.011	7.65	9.2
		168 min	11	6.950	0.7031	5.60	6.847	8.15	10.1
		169 min	11	7.023	0.5099	6.23	6.849	7.68	7.3
		170 min	11	7.178	0.7388	5.83	7.362	8.42	10.3
		171 min	11	6.919	0.8206	5.18	7.082	8.20	11.9
		172 min	10	7.167	0.7226	5.67	7.298	8.13	10.1
		173 min	10	7.184	0.6219	6.06	7.299	8.02	8.7
		174 min	10	6.646	1.5427	2.82	7.076	8.06	23.2
		175 min	10	7.121	0.7858	5.58	7.387	7.95	11.0
		176 min	10	7.170	0.8135	5.87	7.288	8.54	11.3
		177 min	10	6.963	0.7928	5.98	6.950	8.23	11.4
		178 min	10	6.897	0.7586	5.75	6.660	8.51	11.0
		179 min	10	7.070	0.8010	5.93	7.071	8.58	11.3
		180 min	10	6.832	1.6993	2.51	7.168	8.58	24.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 95 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	181 min	10	7.009	1.1161	4.39	7.160	8.50	15.9
		182 min	9	7.181	0.8259	5.86	7.199	8.49	11.5
		183 min	9	6.993	0.7614	5.88	7.096	8.42	10.9
		184 min	9	6.938	0.7222	6.18	6.667	8.44	10.4
		185 min	9	7.062	0.6817	6.36	6.833	8.44	9.7
		186 min	9	6.881	0.5106	5.97	6.799	7.68	7.4
		187 min	9	7.026	0.7521	6.18	7.114	8.40	10.7
		188 min	9	7.142	0.6964	5.87	7.299	8.25	9.8
		189 min	10	6.997	0.6341	5.69	7.131	7.88	9.1
		190 min	10	7.172	0.6578	6.09	7.392	8.36	9.2
		191 min	10	7.197	0.6955	6.29	7.103	8.56	9.7
		192 min	10	7.203	0.7180	6.24	7.050	8.52	10.0
		193 min	10	6.936	0.6959	5.66	7.067	7.69	10.0
		194 min	10	7.040	0.7622	5.56	7.392	7.87	10.8
		195 min	10	7.050	0.6460	5.63	7.217	7.77	9.2
		196 min	10	6.879	0.6591	5.57	6.862	7.65	9.6
		197 min	11	7.041	0.6644	5.54	7.246	7.70	9.4
		198 min	11	6.981	0.6717	5.69	6.938	8.08	9.6
		199 min	11	6.948	0.5705	5.67	6.860	7.92	8.2
		200 min	11	7.180	0.8093	5.65	7.458	8.28	11.3
		201 min	11	7.014	0.7134	5.66	6.962	7.95	10.2
		202 min	12	7.106	0.5972	6.01	7.293	7.91	8.4
		203 min	12	6.983	0.5656	6.17	6.995	8.00	8.1
		204 min	12	7.058	0.6486	5.65	7.294	7.89	9.2
		205 min	12	7.043	0.7045	5.67	7.221	8.10	10.0
		206 min	12	6.975	0.7204	5.57	7.016	8.11	10.3
		207 min	11	6.793	0.6770	5.78	6.613	7.96	10.0
		208 min	11	6.739	0.4584	5.90	6.648	7.46	6.8
		209 min	11	6.853	0.5046	5.68	7.002	7.37	7.4
		210 min	11	6.893	0.6228	5.58	6.987	7.79	9.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 96 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	211 min	12	6.964	0.6105	5.61	6.930	7.98	8.8
		212 min	12	7.044	0.6968	5.63	7.001	8.01	9.9
		213 min	12	6.904	0.7012	5.58	6.810	8.14	10.2
		214 min	12	6.981	0.7449	5.64	6.862	8.06	10.7
		215 min	12	7.139	0.7829	5.65	6.967	8.08	11.0
		216 min	12	6.972	0.5930	6.16	6.814	7.99	8.5
		217 min	12	6.674	1.9249	0.98	7.262	7.87	28.8
		218 min	12	6.880	0.8402	4.68	6.950	7.89	12.2
		219 min	12	7.142	0.6164	6.00	7.342	7.78	8.6
		220 min	12	7.157	0.6226	6.23	7.256	8.15	8.7
		221 min	11	7.018	0.7147	5.83	7.062	8.47	10.2
		222 min	11	7.100	0.6361	6.12	7.048	8.20	9.0
		223 min	11	6.909	0.6399	5.80	6.670	7.80	9.3
		224 min	11	7.049	0.6567	5.71	7.187	8.11	9.3
		225 min	10	7.142	0.4759	6.43	7.224	7.84	6.7
		226 min	10	7.250	0.5404	6.59	7.186	8.32	7.5
		227 min	10	7.388	0.4636	6.74	7.430	8.21	6.3
		228 min	10	7.273	0.5021	6.63	7.313	8.24	6.9
		229 min	10	6.929	1.3617	3.43	7.054	8.44	19.7
		230 min	11	7.122	0.4358	6.40	7.297	7.73	6.1
		231 min	11	6.983	0.7764	5.38	7.162	8.16	11.1
		232 min	11	7.125	0.4636	6.44	6.976	8.03	6.5
		233 min	11	7.193	0.4351	6.57	7.157	8.14	6.0
		234 min	11	7.235	0.7224	6.28	7.102	8.38	10.0
		235 min	12	7.332	0.6333	6.56	7.193	8.50	8.6
		236 min	12	7.375	0.5583	6.45	7.443	8.45	7.6
		237 min	12	7.118	0.6691	6.26	6.925	8.55	9.4
		238 min	12	7.116	0.6269	6.15	7.191	8.41	8.8
		239 min	12	7.221	0.6075	6.30	7.154	8.41	8.4
		240 min	1	7.509		7.51	7.509	7.51	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 97 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	1 min	12	8.123	0.4554	7.51	7.952	9.12	5.6
		2 min	12	8.022	0.4449	7.45	7.975	9.15	5.5
		3 min	12	8.004	0.4870	7.23	8.060	8.84	6.1
		4 min	12	8.044	0.5839	7.20	8.028	9.09	7.3
		5 min	12	7.853	0.7253	7.11	7.459	9.02	9.2
		6 min	12	7.848	0.7781	6.44	7.952	8.95	9.9
		7 min	12	7.717	0.9089	5.48	7.903	8.81	11.8
		8 min	12	7.842	0.5928	6.84	8.035	8.75	7.6
		9 min	12	7.687	0.7209	6.55	7.719	8.64	9.4
		10 min	12	7.304	1.4949	2.98	7.851	8.62	20.5
		11 min	12	7.297	0.5723	6.54	7.092	8.37	7.8
		12 min	12	7.352	0.7025	6.18	7.296	8.23	9.6
		13 min	12	7.346	0.7906	5.97	7.418	8.54	10.8
		14 min	12	7.366	0.7112	5.85	7.646	8.15	9.7
		15 min	12	7.103	1.3200	3.41	7.465	8.30	18.6
		16 min	12	6.950	1.5992	2.33	7.428	8.36	23.0
		17 min	12	7.161	0.7965	5.20	7.276	8.16	11.1
		18 min	12	7.069	1.2197	3.58	7.440	8.07	17.3
		19 min	12	7.164	0.8701	5.01	7.197	8.13	12.1
		20 min	12	6.956	1.6481	2.11	7.396	8.48	23.7
		21 min	11	6.781	1.8357	1.54	7.190	8.14	27.1
		22 min	10	6.667	1.9400	1.40	7.120	8.13	29.1
		23 min	10	6.633	1.6464	2.16	6.992	7.91	24.8
		24 min	10	6.032	2.0999	1.47	6.793	8.06	34.8
		25 min	10	6.449	1.8585	1.34	6.922	8.08	28.8
		26 min	10	6.799	0.7364	5.35	6.852	7.87	10.8
		27 min	10	6.931	0.6064	5.84	6.937	7.78	8.7
		28 min	10	6.492	1.8716	1.43	7.024	7.90	28.8
		29 min	10	6.645	1.6970	2.00	7.202	7.92	25.5
		30 min	10	6.670	1.1360	3.67	6.890	7.64	17.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 98 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	31 min	10	6.628	1.1642	3.64	6.860	7.67	17.6
		32 min	10	6.734	1.1323	3.79	6.923	7.72	16.8
		33 min	10	6.602	1.2353	3.93	7.030	7.99	18.7
		34 min	10	6.279	1.7863	1.38	6.820	7.59	28.5
		35 min	10	6.466	1.5079	2.42	6.712	7.77	23.3
		36 min	11	6.582	1.4899	2.45	7.041	7.77	22.6
		37 min	11	6.494	1.7447	1.41	6.746	7.68	26.9
		38 min	12	6.718	1.7933	1.20	7.122	7.95	26.7
		39 min	12	6.647	1.7484	1.32	7.300	7.84	26.3
		40 min	12	6.922	1.2169	3.50	7.185	8.11	17.6
		41 min	12	6.526	1.3189	2.79	6.743	7.86	20.2
		42 min	12	6.064	1.9844	1.82	6.827	7.66	32.7
		43 min	12	6.406	1.7257	1.29	6.815	7.86	26.9
		44 min	12	6.580	1.7874	1.18	6.935	7.75	27.2
		45 min	11	6.640	1.8542	1.29	7.267	7.97	27.9
		46 min	12	6.508	1.7601	1.20	6.954	8.14	27.0
		47 min	12	6.606	1.7092	1.40	7.024	7.81	25.9
		48 min	12	6.463	1.6872	1.44	6.942	7.91	26.1
		49 min	12	6.177	1.9747	1.56	6.963	7.96	32.0
		50 min	11	6.514	1.9318	1.08	6.915	8.07	29.7
		51 min	11	6.729	1.4216	2.80	7.178	7.92	21.1
		52 min	11	6.538	1.7998	1.76	7.162	7.85	27.5
		53 min	12	6.571	1.7402	1.33	6.914	7.84	26.5
		54 min	12	6.209	2.4585	0.94	7.150	8.16	39.6
		55 min	12	6.525	1.8066	1.63	7.311	7.89	27.7
		56 min	12	6.612	1.8587	1.08	7.188	7.96	28.1
		57 min	12	6.566	1.7062	1.45	7.096	7.66	26.0
		58 min	12	6.485	1.8371	1.36	7.007	8.09	28.3
		59 min	12	6.754	1.5054	2.35	7.025	7.97	22.3
		60 min	12	6.761	1.3547	3.02	6.884	8.32	20.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 99 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	61 min	12	6.500	1.8116	1.07	6.999	7.69	27.9
		62 min	12	6.580	1.8161	1.26	6.914	8.35	27.6
		63 min	11	6.354	1.5363	2.07	6.722	8.06	24.2
		64 min	11	6.361	1.9015	1.16	6.828	8.33	29.9
		65 min	11	6.506	1.9129	1.03	6.904	8.43	29.4
		66 min	11	6.266	1.6134	1.72	6.756	7.49	25.7
		67 min	11	6.331	1.7756	1.08	6.687	7.46	28.0
		68 min	11	6.326	1.7953	1.01	6.793	7.51	28.4
		69 min	11	6.460	1.8129	1.09	6.961	7.81	28.1
		70 min	10	6.052	2.2417	1.37	6.859	8.02	37.0
		71 min	10	6.176	1.9215	1.54	6.700	8.20	31.1
		72 min	9	6.152	1.9499	1.32	6.604	7.87	31.7
		73 min	9	6.203	1.8931	1.47	6.595	8.36	30.5
		74 min	9	6.206	1.9050	1.24	6.609	7.56	30.7
		75 min	9	6.179	1.9566	1.15	6.841	7.55	31.7
		76 min	9	6.155	1.9442	1.24	6.523	8.21	31.6
		77 min	9	6.187	1.9634	1.16	6.620	7.96	31.7
		78 min	9	6.303	1.9434	1.33	6.599	8.09	30.8
		79 min	9	6.445	2.0438	1.24	6.771	8.31	31.7
		80 min	9	6.291	1.8440	1.47	6.810	7.48	29.3
		81 min	9	6.284	1.9856	1.11	6.856	7.62	31.6
		82 min	9	6.085	2.0290	0.84	6.859	7.48	33.3
		83 min	9	6.321	1.9914	1.24	6.859	7.72	31.5
		84 min	9	6.203	1.9984	1.13	6.736	8.13	32.2
		85 min	9	6.225	2.0650	1.02	6.695	8.00	33.2
		86 min	9	6.815	1.0859	4.69	6.691	8.47	15.9
		87 min	9	6.003	2.0757	1.61	6.724	7.98	34.6
		88 min	9	6.091	2.1816	1.11	6.830	8.40	35.8
		89 min	10	6.146	1.9011	1.04	6.711	7.60	30.9
		90 min	10	6.147	1.9276	1.02	6.619	8.35	31.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 100 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	91 min	10	6.353	1.8642	1.37	6.640	8.40	29.3
		92 min	10	6.370	1.8345	1.38	6.850	7.71	28.8
		93 min	10	6.308	1.9468	1.29	6.593	8.42	30.9
		94 min	10	6.366	1.8329	1.47	6.710	8.28	28.8
		95 min	9	6.345	1.7930	1.96	6.816	8.21	28.3
		96 min	9	6.455	2.0432	1.27	6.772	8.21	31.7
		97 min	9	6.048	2.2839	1.14	6.822	8.36	37.8
		98 min	9	6.117	2.0023	1.29	6.670	7.78	32.7
		99 min	10	6.421	1.9653	1.18	6.697	8.25	30.6
		100 min	9	6.090	1.9156	1.09	6.588	7.36	31.5
		101 min	9	6.108	1.8463	1.32	6.767	7.16	30.2
		102 min	9	6.252	1.8891	1.26	6.700	7.34	30.2
		103 min	9	6.414	1.9691	1.38	6.979	7.85	30.7
		104 min	10	6.461	1.5943	2.13	6.858	7.71	24.7
		105 min	10	6.632	1.9805	1.18	7.184	7.93	29.9
		106 min	10	6.303	1.5455	1.98	6.728	7.25	24.5
		107 min	10	6.277	1.7705	1.41	6.643	7.60	28.2
		108 min	10	6.312	1.7584	1.39	6.877	7.30	27.9
		109 min	10	6.332	1.7797	1.40	6.779	7.43	28.1
		110 min	10	6.310	1.8810	1.16	6.641	7.71	29.8
		111 min	10	6.347	1.8239	1.36	6.762	7.74	28.7
		112 min	10	6.446	1.9311	1.12	7.033	8.00	30.0
		113 min	11	6.265	1.6861	1.35	6.671	7.71	26.9
		114 min	11	6.281	1.7547	1.11	6.738	7.27	27.9
		115 min	11	6.427	1.8586	1.18	6.709	8.17	28.9
		116 min	11	6.456	1.8313	1.14	7.119	7.69	28.4
		117 min	11	6.474	1.7742	1.38	6.761	8.06	27.4
		118 min	12	6.574	1.8423	1.08	7.129	8.17	28.0
		119 min	12	6.494	1.6160	1.70	6.885	7.79	24.9
		120 min	12	6.550	1.8623	1.16	6.738	8.19	28.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 101 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	121 min	12	6.463	1.1959	2.89	6.562	7.44	18.5
		122 min	12	6.414	1.7148	1.13	6.974	7.42	26.7
		123 min	12	6.566	1.4295	2.24	6.924	7.80	21.8
		124 min	12	6.357	1.4102	3.07	6.793	7.54	22.2
		125 min	12	6.411	1.7141	1.28	6.680	7.71	26.7
		126 min	12	6.450	1.7521	1.24	6.801	7.82	27.2
		127 min	12	6.468	1.7347	1.13	6.947	7.61	26.8
		128 min	12	6.601	1.7732	1.19	7.177	7.86	26.9
		129 min	12	5.901	2.4588	0.56	6.898	8.25	41.7
		130 min	12	6.082	2.3853	0.96	7.108	7.68	39.2
		131 min	12	6.379	1.8456	1.06	7.135	7.88	28.9
		132 min	12	6.363	1.7861	1.43	6.940	7.95	28.1
		133 min	12	6.427	1.8204	1.27	7.036	7.93	28.3
		134 min	12	6.495	1.7602	1.15	6.966	7.85	27.1
		135 min	12	6.170	1.8435	1.50	6.710	7.82	29.9
		136 min	12	6.452	1.6918	1.32	6.853	7.69	26.2
		137 min	12	6.415	1.7163	1.16	6.774	7.58	26.8
		138 min	12	6.556	1.4504	2.22	6.756	7.64	22.1
		139 min	12	6.571	1.4857	2.12	6.991	7.73	22.6
		140 min	12	6.681	1.3529	2.69	7.219	7.62	20.2
		141 min	12	6.557	1.2693	3.32	6.790	7.79	19.4
		142 min	12	7.025	0.7428	5.95	7.197	8.40	10.6
		143 min	12	6.981	0.6950	5.80	7.088	7.86	10.0
		144 min	12	6.997	0.5908	5.69	6.950	7.90	8.4
		145 min	12	6.410	1.8997	1.30	7.111	8.37	29.6
		146 min	12	6.737	1.2688	3.05	7.024	7.76	18.8
		147 min	12	6.329	1.8779	1.84	6.922	8.38	29.7
		148 min	12	6.537	1.1596	3.88	6.834	7.61	17.7
		149 min	12	6.816	0.8405	4.66	6.841	7.74	12.3
		150 min	12	6.947	0.7553	5.03	7.019	7.89	10.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 102 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	151 min	12	6.856	0.6151	5.59	6.816	7.86	9.0
		152 min	12	6.783	0.7431	5.52	7.014	7.60	11.0
		153 min	12	6.037	1.7633	1.46	6.712	7.77	29.2
		154 min	12	6.324	1.7787	1.27	6.877	7.87	28.1
		155 min	12	6.286	1.6726	1.21	6.577	7.56	26.6
		156 min	12	6.222	1.8241	1.12	6.718	8.06	29.3
		157 min	12	6.470	1.7911	1.13	6.926	7.69	27.7
		158 min	12	6.530	1.7548	1.15	6.998	7.96	26.9
		159 min	12	6.616	1.7645	1.16	7.135	7.55	26.7
		160 min	12	6.699	1.6212	1.79	7.088	8.12	24.2
		161 min	12	6.624	1.8180	1.03	7.189	7.63	27.4
		162 min	12	6.597	1.7475	1.19	7.047	7.55	26.5
		163 min	12	6.638	1.7340	1.30	7.066	7.70	26.1
		164 min	11	6.521	1.8122	1.18	6.969	7.60	27.8
		165 min	11	6.588	1.8503	1.24	7.262	7.72	28.1
		166 min	11	6.479	1.7915	1.16	6.998	7.46	27.7
		167 min	11	6.600	1.8218	1.26	7.141	7.82	27.6
		168 min	11	6.607	1.9018	1.17	7.101	8.13	28.8
		169 min	11	6.610	1.8745	1.08	7.009	7.70	28.4
		170 min	11	6.524	1.9452	1.06	6.995	8.43	29.8
		171 min	11	6.565	1.8622	1.16	6.858	8.11	28.4
		172 min	10	6.794	1.4993	2.74	7.144	8.02	22.1
		173 min	10	6.763	1.6926	2.10	7.264	7.83	25.0
		174 min	10	6.510	2.0535	0.80	7.053	7.78	31.5
		175 min	10	6.716	1.1800	4.15	7.078	7.72	17.6
		176 min	10	6.640	1.9714	1.25	6.905	8.31	29.7
		177 min	10	7.086	0.5685	6.38	6.967	8.21	8.0
		178 min	10	6.834	1.2336	3.71	7.104	8.30	18.1
		179 min	10	7.038	0.7013	5.99	6.944	8.48	10.0
		180 min	10	6.465	1.6916	2.72	6.733	8.48	26.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 103 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	181 min	10	6.787	1.1445	4.17	7.017	8.52	16.9
		182 min	9	6.948	0.8190	5.61	7.037	8.38	11.8
		183 min	9	6.537	1.6651	2.48	6.860	8.29	25.5
		184 min	9	6.437	2.0094	1.42	6.668	8.63	31.2
		185 min	9	6.609	2.0176	1.49	7.103	8.60	30.5
		186 min	9	6.269	1.8864	1.40	6.874	7.67	30.1
		187 min	9	6.306	2.0445	1.15	6.591	7.93	32.4
		188 min	9	6.369	2.0678	1.24	7.154	8.00	32.5
		189 min	10	6.706	0.8128	4.91	6.824	7.80	12.1
		190 min	10	6.369	1.8911	1.16	6.828	7.87	29.7
		191 min	10	6.602	1.9664	1.45	7.115	8.36	29.8
		192 min	10	6.582	1.7251	2.09	6.722	8.21	26.2
		193 min	10	6.531	1.3902	3.40	6.778	7.88	21.3
		194 min	10	6.500	1.6015	2.49	6.958	7.97	24.6
		195 min	10	6.399	1.4697	2.36	6.772	7.62	23.0
		196 min	10	6.539	1.5703	2.34	6.981	7.86	24.0
		197 min	11	6.817	0.5214	5.95	6.800	7.54	7.6
		198 min	11	6.778	0.8257	4.82	6.805	7.78	12.2
		199 min	11	6.423	1.5500	2.07	6.780	7.75	24.1
		200 min	11	6.719	1.8952	1.33	7.343	8.05	28.2
		201 min	11	6.606	1.8068	1.43	7.020	7.92	27.4
		202 min	12	6.516	1.7371	1.27	6.808	7.77	26.7
		203 min	12	6.477	1.6805	1.33	6.686	7.78	25.9
		204 min	12	6.563	1.7455	1.23	6.987	7.69	26.6
		205 min	12	6.449	1.6731	1.51	6.810	7.89	25.9
		206 min	12	6.542	1.7872	1.12	6.881	7.99	27.3
		207 min	11	6.699	0.8748	4.75	6.731	7.81	13.1
		208 min	11	6.417	1.6427	1.92	6.691	7.94	25.6
		209 min	11	6.414	1.7100	1.56	6.823	7.86	26.7
		210 min	11	6.466	1.8008	1.23	6.827	7.88	27.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 104 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	211 min	12	6.390	1.3516	2.49	6.606	7.89	21.2
		212 min	12	6.440	1.6711	1.31	6.915	7.77	25.9
		213 min	12	6.429	1.7238	1.23	6.695	7.79	26.8
		214 min	12	6.735	1.1525	3.41	6.841	7.89	17.1
		215 min	12	6.596	1.7720	1.38	6.858	8.21	26.9
		216 min	12	6.485	1.9215	1.21	6.799	8.53	29.6
		217 min	12	6.326	2.3372	1.10	7.032	8.85	36.9
		218 min	12	6.394	1.8864	1.26	6.715	8.63	29.5
		219 min	12	6.761	1.9020	1.10	7.014	8.61	28.1
		220 min	12	6.785	1.8264	1.34	7.142	8.50	26.9
		221 min	11	6.516	1.8505	1.19	6.937	8.09	28.4
		222 min	11	6.367	1.9118	1.27	6.991	8.10	30.0
		223 min	11	6.662	1.8253	1.38	7.106	7.80	27.4
		224 min	11	6.691	1.9275	1.28	6.904	8.88	28.8
		225 min	10	6.811	2.0811	1.20	7.358	8.88	30.6
		226 min	10	6.751	2.0216	1.28	7.358	8.01	29.9
		227 min	10	6.819	2.0793	1.19	7.268	8.59	30.5
		228 min	10	6.687	2.0306	1.20	6.918	8.57	30.4
		229 min	10	6.652	2.1128	0.94	7.142	8.24	31.8
		230 min	11	6.615	1.6865	1.87	6.996	7.83	25.5
		231 min	11	6.298	1.8666	1.53	6.869	8.07	29.6
		232 min	11	6.535	1.7616	1.43	6.963	7.90	27.0
		233 min	11	6.998	0.6132	6.12	6.874	7.98	8.8
		234 min	11	6.742	1.6935	1.91	7.220	8.01	25.1
		235 min	12	6.664	1.6216	1.75	7.041	8.03	24.3
		236 min	12	6.743	1.6420	1.84	7.178	7.89	24.4
		237 min	12	6.817	1.5959	2.32	7.253	8.43	23.4
		238 min	12	6.732	1.3189	3.07	6.728	8.07	19.6
		239 min	12	6.805	1.2144	3.50	6.968	8.32	17.8
		240 min	1	7.139		7.14	7.139	7.14	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 105 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	1 min	12	7.441	2.3300	0.93	8.235	9.77	31.3
		2 min	12	7.491	1.9836	1.79	8.104	9.41	26.5
		3 min	12	7.950	0.7415	6.98	7.975	9.67	9.3
		4 min	12	7.884	0.7159	6.74	7.911	9.37	9.1
		5 min	12	7.587	0.7820	6.20	7.701	9.03	10.3
		6 min	12	7.420	0.8669	5.54	7.433	8.68	11.7
		7 min	12	7.370	0.8726	5.61	7.463	8.65	11.8
		8 min	12	6.873	1.5745	2.50	7.241	8.37	22.9
		9 min	12	6.486	1.7997	2.95	7.363	8.32	27.7
		10 min	12	6.403	1.9712	1.76	7.052	8.25	30.8
		11 min	12	6.229	2.1437	1.90	7.314	8.29	34.4
		12 min	12	6.100	1.8366	2.76	6.708	8.15	30.1
		13 min	12	5.522	2.6352	1.34	6.810	8.03	47.7
		14 min	12	5.348	2.5114	1.31	5.950	7.86	47.0
		15 min	12	4.877	2.7139	1.08	5.371	8.08	55.6
		16 min	12	5.172	2.7797	1.04	6.569	8.14	53.8
		17 min	12	5.036	2.9021	1.07	6.500	8.06	57.6
		18 min	12	4.882	3.1103	1.08	6.893	7.98	63.7
		19 min	12	4.543	3.0055	1.04	4.418	8.17	66.2
		20 min	12	4.366	2.9813	0.86	5.399	7.96	68.3
		21 min	11	4.250	3.1229	0.11	5.477	7.89	73.5
		22 min	10	4.442	2.9108	0.93	5.126	7.80	65.5
		23 min	10	4.503	3.0360	1.03	4.872	7.77	67.4
		24 min	10	4.227	2.7532	1.14	4.228	7.67	65.1
		25 min	10	4.227	2.7477	1.19	4.162	7.66	65.0
		26 min	10	3.611	2.4781	1.04	3.252	7.57	68.6
		27 min	10	4.058	2.5382	1.20	4.444	6.89	62.5
		28 min	10	3.722	2.7563	1.09	2.079	7.07	74.1
		29 min	10	3.791	2.8328	1.23	2.307	7.37	74.7
		30 min	10	4.483	2.5581	1.10	5.519	7.24	57.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 106 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	31 min	10	3.805	2.5226	1.07	3.741	6.90	66.3
		32 min	10	4.192	2.2305	1.37	3.895	6.74	53.2
		33 min	10	4.317	2.5281	1.08	4.824	7.21	58.6
		34 min	10	4.054	2.3212	0.95	3.685	7.01	57.3
		35 min	10	4.609	2.3890	1.36	5.468	7.30	51.8
		36 min	11	4.756	2.5596	1.06	5.876	7.89	53.8
		37 min	11	4.494	2.5578	1.24	5.347	7.96	56.9
		38 min	12	4.440	2.3762	1.16	5.279	7.42	53.5
		39 min	12	3.629	2.5458	0.22	3.183	7.13	70.1
		40 min	12	4.247	2.6381	0.92	4.459	7.34	62.1
		41 min	12	4.119	2.5190	1.11	3.348	7.46	61.2
		42 min	12	3.645	2.5315	0.67	3.370	7.20	69.4
		43 min	12	3.730	2.2533	0.72	3.265	7.08	60.4
		44 min	12	4.065	2.4612	0.94	3.841	7.37	60.5
		45 min	11	3.893	2.6197	1.03	3.408	7.28	67.3
		46 min	12	4.180	2.7655	0.48	4.134	7.28	66.2
		47 min	12	4.508	2.4861	0.95	5.264	7.24	55.2
		48 min	12	4.173	2.3940	0.89	4.900	7.48	57.4
		49 min	12	4.049	2.6647	1.00	3.911	7.51	65.8
		50 min	11	4.123	2.6950	0.89	3.057	7.45	65.4
		51 min	11	4.213	2.7366	0.97	4.641	7.19	65.0
		52 min	11	3.871	2.7127	0.89	3.587	7.86	70.1
		53 min	12	3.878	2.6666	0.96	3.575	7.70	68.8
		54 min	12	3.422	2.5906	1.05	1.767	7.70	75.7
		55 min	12	4.020	2.7866	0.76	4.151	7.31	69.3
		56 min	12	3.842	2.7983	0.39	3.692	7.14	72.8
		57 min	12	3.351	2.4904	0.35	2.989	6.90	74.3
		58 min	12	3.538	2.8159	0.19	2.327	7.71	79.6
		59 min	12	3.584	2.7711	0.13	2.545	7.53	77.3
		60 min	12	3.375	2.4485	0.74	2.521	7.52	72.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 107 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	61 min	12	3.647	2.5230	0.85	2.918	7.42	69.2
		62 min	12	3.655	2.6660	0.75	2.312	7.09	72.9
		63 min	11	3.357	2.4458	0.67	2.034	6.96	72.9
		64 min	11	3.536	2.5284	0.98	1.717	7.09	71.5
		65 min	11	3.475	2.6046	0.66	2.533	7.16	74.9
		66 min	11	2.969	2.2686	0.11	2.061	6.55	76.4
		67 min	11	3.594	2.6075	0.01	2.849	6.96	72.6
		68 min	11	3.936	2.4781	1.00	2.886	6.87	63.0
		69 min	11	3.500	2.6776	0.51	2.071	7.12	76.5
		70 min	10	3.652	2.7045	0.63	2.687	7.75	74.0
		71 min	10	3.572	2.5559	1.28	2.043	7.83	71.6
		72 min	9	2.813	2.1841	0.95	1.664	6.86	77.7
		73 min	9	2.821	2.2707	1.14	1.488	6.80	80.5
		74 min	9	2.986	2.0202	1.08	1.924	6.51	67.7
		75 min	9	2.683	1.9511	1.00	1.819	6.59	72.7
		76 min	9	2.844	2.0281	0.82	1.629	6.53	71.3
		77 min	9	3.167	2.4064	0.77	2.235	7.31	76.0
		78 min	9	3.195	2.5273	0.94	1.718	6.77	79.1
		79 min	9	2.740	2.0293	0.86	1.713	6.92	74.0
		80 min	9	2.993	2.4854	0.86	1.917	6.89	83.0
		81 min	9	3.121	2.5401	0.96	1.872	6.94	81.4
		82 min	9	2.853	2.2787	0.95	1.829	6.73	79.9
		83 min	9	3.261	2.6192	0.75	1.818	6.81	80.3
		84 min	9	3.089	2.3121	1.22	1.655	6.62	74.9
		85 min	9	3.139	2.3342	1.02	1.585	6.47	74.4
		86 min	9	3.801	2.5468	1.17	3.981	6.91	67.0
		87 min	9	3.537	2.5449	0.99	2.626	7.57	71.9
		88 min	9	3.359	2.2589	1.19	2.377	7.26	67.2
		89 min	10	3.096	2.2472	1.15	2.060	6.88	72.6
		90 min	10	2.854	2.3443	0.34	1.900	7.17	82.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 108 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	91 min	10	2.826	2.2945	0.21	1.862	6.93	81.2
		92 min	10	2.761	2.0153	0.71	2.201	6.90	73.0
		93 min	10	3.223	2.1889	1.15	2.153	7.18	67.9
		94 min	10	3.029	2.0105	1.15	2.085	7.02	66.4
		95 min	9	3.706	2.2675	1.11	3.035	6.79	61.2
		96 min	9	4.053	2.4702	1.15	4.077	7.20	61.0
		97 min	9	3.120	2.5598	0.41	1.873	6.89	82.0
		98 min	9	3.138	2.0838	1.19	1.872	6.33	66.4
		99 min	10	4.206	2.5494	0.78	4.014	7.10	60.6
		100 min	9	3.160	2.1138	1.35	1.975	6.43	66.9
		101 min	9	3.433	2.3379	1.16	2.315	6.78	68.1
		102 min	9	4.182	2.5791	1.15	4.498	7.20	61.7
		103 min	9	3.576	2.5913	0.69	2.168	7.01	72.5
		104 min	10	3.238	2.1255	1.05	2.631	7.02	65.6
		105 min	10	2.870	2.1531	1.09	1.795	6.73	75.0
		106 min	10	2.817	1.8712	1.13	2.400	6.61	66.4
		107 min	10	2.865	2.0449	1.09	2.107	6.64	71.4
		108 min	10	2.666	2.2366	1.04	1.797	6.94	83.9
		109 min	10	3.139	2.3251	0.73	1.954	7.01	74.1
		110 min	10	3.111	2.4568	0.91	1.866	7.16	79.0
		111 min	10	3.706	2.4601	0.94	2.756	7.49	66.4
		112 min	10	2.906	2.0206	0.90	2.526	6.80	69.5
		113 min	11	2.604	1.5398	1.02	2.212	6.70	59.1
		114 min	11	3.379	2.0389	1.02	2.816	6.74	60.3
		115 min	11	3.045	1.9588	0.84	1.986	6.76	64.3
		116 min	11	3.045	2.1260	1.02	1.935	6.87	69.8
		117 min	11	2.921	2.0464	1.01	2.225	6.59	70.1
		118 min	12	3.178	2.2419	0.87	2.112	6.62	70.6
		119 min	12	3.362	2.2921	0.93	2.239	6.81	68.2
		120 min	12	3.018	2.0743	1.02	2.085	6.61	68.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 109 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	121 min	12	3.407	2.1807	0.94	2.722	6.93	64.0
		122 min	12	2.916	2.1061	1.00	1.881	6.85	72.2
		123 min	12	3.201	1.9448	1.08	2.522	6.60	60.8
		124 min	12	3.391	2.2048	1.08	2.247	6.70	65.0
		125 min	12	3.280	2.0459	1.17	2.749	6.78	62.4
		126 min	12	3.213	2.0977	0.36	2.744	6.57	65.3
		127 min	12	3.549	1.9427	1.14	2.815	6.71	54.7
		128 min	12	3.522	2.3837	0.83	2.470	7.21	67.7
		129 min	12	3.317	2.2013	0.46	2.955	6.76	66.4
		130 min	12	3.520	2.1560	1.15	2.595	7.01	61.3
		131 min	12	2.845	1.9098	0.84	2.311	6.78	67.1
		132 min	12	3.199	2.1933	0.56	2.624	6.63	68.6
		133 min	12	3.468	2.3329	0.34	2.957	6.64	67.3
		134 min	12	3.666	2.1272	0.73	3.688	6.68	58.0
		135 min	12	3.359	1.9958	0.50	3.255	6.71	59.4
		136 min	12	3.507	2.2868	0.33	3.376	7.13	65.2
		137 min	12	4.153	2.3226	0.94	4.460	7.15	55.9
		138 min	12	4.276	2.3016	1.02	5.197	6.77	53.8
		139 min	12	4.127	2.2657	1.05	3.584	7.41	54.9
		140 min	12	3.360	2.4051	0.91	2.213	7.04	71.6
		141 min	12	3.609	2.2735	1.12	2.386	7.02	63.0
		142 min	12	3.623	2.5040	1.02	2.353	6.94	69.1
		143 min	12	3.671	2.4492	1.18	2.458	7.27	66.7
		144 min	12	4.423	2.5188	1.07	5.286	7.36	56.9
		145 min	12	3.875	2.5243	0.99	3.763	7.42	65.1
		146 min	12	3.372	2.4573	0.72	2.551	7.04	72.9
		147 min	12	3.337	2.4171	0.62	2.232	7.07	72.4
		148 min	12	3.430	2.4904	0.53	2.584	7.21	72.6
		149 min	12	3.579	2.5820	0.32	3.080	7.45	72.1
		150 min	12	3.251	2.6915	0.20	1.928	7.53	82.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 110 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	151 min	12	3.396	2.7960	0.19	1.858	7.20	82.3
		152 min	12	3.689	2.7489	0.14	2.762	6.97	74.5
		153 min	12	3.723	2.8792	0.14	2.350	7.33	77.3
		154 min	12	3.635	2.6820	1.00	2.004	7.47	73.8
		155 min	12	3.725	2.4893	0.96	3.118	7.13	66.8
		156 min	12	4.077	2.5457	1.00	4.029	7.20	62.4
		157 min	12	4.380	2.4761	0.99	5.448	6.93	56.5
		158 min	12	4.259	2.6253	1.05	4.411	7.96	61.6
		159 min	12	3.714	2.5943	0.57	3.367	7.40	69.9
		160 min	12	3.657	2.5936	0.51	2.881	7.06	70.9
		161 min	12	3.500	2.3908	1.11	2.160	6.96	68.3
		162 min	12	3.131	2.3287	0.54	2.011	7.17	74.4
		163 min	12	3.655	2.3832	0.24	4.026	6.74	65.2
		164 min	11	3.254	2.4126	0.18	1.956	6.73	74.1
		165 min	11	3.508	2.8020	0.12	1.675	7.15	79.9
		166 min	11	3.405	2.3892	0.93	2.420	7.10	70.2
		167 min	11	3.565	2.9067	0.26	2.094	7.41	81.5
		168 min	11	3.445	2.5784	0.18	1.806	6.71	74.9
		169 min	11	3.629	2.6361	0.90	1.865	7.16	72.6
		170 min	11	4.248	2.6534	1.05	4.310	7.36	62.5
		171 min	11	3.305	2.3186	1.07	1.926	6.79	70.2
		172 min	10	3.356	2.6100	0.53	1.814	6.85	77.8
		173 min	10	3.780	2.7810	1.07	2.280	7.40	73.6
		174 min	10	3.086	2.3053	1.05	1.794	7.11	74.7
		175 min	10	3.346	2.6685	0.47	1.699	6.66	79.7
		176 min	10	3.474	2.8344	0.30	1.757	7.54	81.6
		177 min	10	3.507	2.5376	0.15	2.876	6.97	72.4
		178 min	10	3.256	2.3271	0.61	2.498	6.88	71.5
		179 min	10	4.471	2.6399	1.03	6.055	7.00	59.0
		180 min	10	3.509	2.6345	0.33	2.734	6.80	75.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 111 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	181 min	10	2.791	1.8884	0.47	2.350	6.73	67.7
		182 min	9	2.785	2.1597	0.89	1.886	6.66	77.5
		183 min	9	2.706	2.5087	0.52	1.521	7.39	92.7
		184 min	9	2.773	2.5601	0.28	1.593	7.13	92.3
		185 min	9	2.609	2.5035	0.20	1.578	7.11	96.0
		186 min	9	2.195	2.0221	0.31	1.434	6.93	92.1
		187 min	9	2.127	1.6679	0.14	1.637	5.40	78.4
		188 min	9	2.262	1.4387	0.14	1.593	4.26	63.6
		189 min	10	2.988	2.0616	0.16	2.691	6.61	69.0
		190 min	10	3.392	2.3758	0.15	3.214	6.58	70.0
		191 min	10	3.466	2.4355	0.44	2.929	6.55	70.3
		192 min	10	3.212	2.1595	0.40	3.127	6.63	67.2
		193 min	10	3.212	2.3763	0.35	2.296	6.50	74.0
		194 min	10	2.930	2.0500	0.99	1.802	6.41	70.0
		195 min	10	3.171	2.0433	1.05	2.479	6.69	64.4
		196 min	10	3.234	2.4691	0.43	1.978	6.75	76.4
		197 min	11	3.261	2.3867	0.03	2.134	6.81	73.2
		198 min	11	2.932	2.0885	0.99	1.638	6.61	71.2
		199 min	11	2.990	2.2739	1.08	1.720	7.04	76.0
		200 min	11	3.488	2.5748	0.32	1.801	6.95	73.8
		201 min	11	3.009	2.4142	0.30	1.561	6.61	80.2
		202 min	12	3.198	2.3640	0.25	1.905	6.61	73.9
		203 min	12	2.927	2.3121	0.19	2.244	6.68	79.0
		204 min	12	3.993	2.3409	0.77	4.991	6.62	58.6
		205 min	12	3.153	2.5245	0.27	2.031	7.28	80.1
		206 min	12	3.598	2.6335	0.89	2.025	7.00	73.2
		207 min	11	2.920	2.1951	0.06	1.935	6.35	75.2
		208 min	11	3.028	2.3851	0.02	1.719	6.64	78.8
		209 min	11	2.867	2.0071	0.05	2.356	6.79	70.0
		210 min	11	3.554	2.4249	0.46	2.702	6.76	68.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 112 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	211 min	12	3.013	2.1120	-0.00	2.380	7.20	70.1
		212 min	12	3.458	2.3077	0.05	2.879	6.86	66.7
		213 min	12	2.834	2.2945	0.02	1.921	7.08	81.0
		214 min	12	3.478	2.6098	0.05	2.388	7.55	75.0
		215 min	12	3.066	2.1494	-0.04	2.451	6.55	70.1
		216 min	12	3.537	2.5873	-0.01	2.794	6.87	73.2
		217 min	12	3.563	2.3460	0.21	2.969	6.89	65.8
		218 min	12	3.182	2.4035	0.10	2.061	6.70	75.5
		219 min	12	3.660	2.3160	0.09	4.408	6.55	63.3
		220 min	12	3.506	2.6924	0.03	2.431	7.46	76.8
		221 min	11	3.614	2.7789	0.02	2.022	6.96	76.9
		222 min	11	3.200	2.3906	0.10	1.614	6.72	74.7
		223 min	11	3.208	2.5127	0.06	1.681	6.49	78.3
		224 min	11	3.076	2.4595	0.03	1.773	6.70	79.9
		225 min	10	3.119	2.4334	0.18	1.851	6.64	78.0
		226 min	10	3.569	2.7155	0.84	1.965	7.05	76.1
		227 min	10	3.652	2.5479	0.63	2.856	6.59	69.8
		228 min	10	3.102	2.5834	0.65	1.566	7.57	83.3
		229 min	10	3.105	2.3057	1.37	1.769	6.57	74.2
		230 min	11	4.256	2.4449	1.40	4.279	7.38	57.4
		231 min	11	3.334	2.2291	1.46	2.318	7.25	66.9
		232 min	11	3.513	2.1963	1.31	2.263	6.75	62.5
		233 min	11	3.790	2.7084	1.39	1.634	7.40	71.5
		234 min	11	3.601	2.7798	0.61	1.646	7.44	77.2
		235 min	12	3.588	2.4528	0.78	3.035	7.71	68.4
		236 min	12	3.378	2.6248	0.53	1.757	7.86	77.7
		237 min	12	4.332	2.5817	0.89	4.639	7.45	59.6
		238 min	12	3.983	2.2999	0.66	3.995	7.55	57.7
		239 min	12	3.358	2.3269	0.79	2.768	7.90	69.3
		240 min	1	1.828		1.83	1.828	1.83	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 113 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	1 min	12	5.848	3.1673	0.67	7.060	9.01	54.2
		2 min	12	6.059	3.0887	1.09	7.473	8.64	51.0
		3 min	12	6.246	3.0947	0.67	7.879	8.59	49.6
		4 min	12	6.076	3.0520	0.86	7.879	8.61	50.2
		5 min	12	6.062	2.9126	0.53	7.818	8.46	48.0
		6 min	12	6.627	2.2743	1.47	7.657	8.32	34.3
		7 min	12	6.557	2.1549	0.67	7.419	8.20	32.9
		8 min	12	6.362	2.1139	1.23	7.115	8.24	33.2
		9 min	12	6.053	2.3048	0.31	6.729	7.95	38.1
		10 min	12	6.110	2.1291	0.61	7.034	8.03	34.8
		11 min	12	5.469	2.3515	0.40	5.954	7.86	43.0
		12 min	12	5.341	2.3671	1.56	6.432	7.88	44.3
		13 min	12	4.779	2.5242	1.81	4.835	7.84	52.8
		14 min	12	4.001	2.9844	0.13	2.377	7.71	74.6
		15 min	12	3.865	3.0731	0.66	2.116	7.85	79.5
		16 min	12	4.033	2.6657	1.04	3.179	7.87	66.1
		17 min	12	4.659	3.0183	1.07	4.749	8.89	64.8
		18 min	12	4.641	2.8940	1.09	4.591	8.48	62.4
		19 min	12	4.219	3.0550	1.06	2.906	8.55	72.4
		20 min	12	4.351	2.9452	1.01	3.345	8.49	67.7
		21 min	11	4.177	2.6701	1.03	4.241	7.79	63.9
		22 min	10	3.841	2.9853	0.93	1.833	7.77	77.7
		23 min	10	3.771	3.0672	1.03	1.718	7.91	81.3
		24 min	10	3.448	2.7990	1.07	1.591	7.85	81.2
		25 min	10	3.577	2.7468	1.30	1.863	7.83	76.8
		26 min	10	3.218	2.4846	1.04	2.304	7.84	77.2
		27 min	10	3.969	2.8532	1.21	2.486	7.84	71.9
		28 min	10	3.641	2.7422	0.94	2.242	7.33	75.3
		29 min	10	3.626	2.7548	1.16	2.090	7.53	76.0
		30 min	10	4.089	2.7347	0.95	3.874	7.64	66.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 114 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	31 min	10	3.357	2.6117	0.61	2.098	7.16	77.8
		32 min	10	2.954	2.3351	1.19	1.686	7.26	79.0
		33 min	10	3.792	2.6662	0.98	2.711	7.60	70.3
		34 min	10	3.442	2.4774	0.77	2.129	7.67	72.0
		35 min	10	3.397	2.2677	1.11	2.777	7.45	66.8
		36 min	11	3.615	2.5501	0.93	2.020	7.61	70.5
		37 min	11	2.946	2.1910	0.82	1.712	7.50	74.4
		38 min	12	3.113	2.2075	0.15	2.845	7.01	70.9
		39 min	12	2.571	1.9071	0.07	2.322	7.30	74.2
		40 min	12	2.883	2.3192	0.09	1.928	7.45	80.5
		41 min	12	2.611	2.1821	0.05	1.726	7.02	83.6
		42 min	12	2.427	2.0176	0.17	1.838	7.32	83.1
		43 min	12	2.160	1.7885	0.17	1.675	7.29	82.8
		44 min	12	2.680	2.3090	0.10	1.810	7.69	86.2
		45 min	11	2.902	2.4861	0.06	1.600	7.62	85.7
		46 min	12	2.608	2.2342	0.02	1.634	7.87	85.7
		47 min	12	2.850	2.4375	0.05	1.884	7.82	85.5
		48 min	12	2.516	2.2893	0.05	1.670	8.26	91.0
		49 min	12	3.443	2.6033	0.00	2.778	8.17	75.6
		50 min	11	3.393	2.9274	0.13	1.630	8.29	86.3
		51 min	11	3.112	2.7162	0.08	1.640	7.41	87.3
		52 min	11	3.079	2.4797	0.12	1.981	7.45	80.5
		53 min	12	2.893	2.5530	0.05	1.742	7.52	88.2
		54 min	12	2.435	2.4023	0.18	1.547	7.53	98.6
		55 min	12	2.913	2.5265	0.05	1.754	7.50	86.7
		56 min	12	3.030	2.6964	0.03	1.647	7.42	89.0
		57 min	12	3.160	2.4103	0.06	2.455	7.39	76.3
		58 min	12	2.647	2.3672	0.03	1.809	7.34	89.4
		59 min	12	2.704	2.3676	0.20	1.662	7.16	87.6
		60 min	12	2.828	2.5270	-0.07	1.787	7.39	89.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 115 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	61 min	12	2.600	2.1259	0.10	1.787	7.25	81.8
		62 min	12	2.891	2.1572	1.00	2.095	7.50	74.6
		63 min	11	2.285	1.7548	0.84	1.984	7.29	76.8
		64 min	11	2.162	1.9095	0.68	1.705	7.42	88.3
		65 min	11	2.526	1.8340	0.16	2.618	7.25	72.6
		66 min	11	2.554	2.1132	0.22	1.731	7.22	82.7
		67 min	11	2.612	2.0283	0.19	1.972	7.07	77.7
		68 min	11	2.129	1.7847	0.14	1.686	7.11	83.8
		69 min	11	2.666	2.2485	0.14	1.822	7.30	84.3
		70 min	10	3.118	2.2910	0.87	2.165	7.02	73.5
		71 min	10	2.669	2.1294	0.88	1.816	7.17	79.8
		72 min	9	2.524	2.0765	0.96	1.590	7.18	82.3
		73 min	9	2.361	1.9408	0.95	1.460	7.06	82.2
		74 min	9	2.304	1.9067	0.91	1.580	7.02	82.8
		75 min	9	2.451	1.9610	0.93	1.530	7.06	80.0
		76 min	9	2.360	1.9041	0.93	1.450	6.97	80.7
		77 min	9	2.687	2.0767	0.93	2.082	7.18	77.3
		78 min	9	2.956	2.3481	0.89	1.874	6.89	79.4
		79 min	9	2.418	2.0295	0.85	1.686	7.05	83.9
		80 min	9	2.309	1.9684	0.87	1.867	7.11	85.3
		81 min	9	2.657	2.1439	0.82	1.862	7.01	80.7
		82 min	9	2.456	1.9567	0.92	1.651	7.05	79.7
		83 min	9	2.463	1.8944	0.91	1.815	7.02	76.9
		84 min	9	2.597	2.0093	1.03	1.832	6.97	77.4
		85 min	9	2.361	1.8940	0.89	1.587	6.99	80.2
		86 min	9	2.541	1.9615	0.78	1.886	7.08	77.2
		87 min	9	2.450	1.9562	0.78	1.826	7.06	79.8
		88 min	9	2.425	1.8753	0.95	1.921	7.05	77.3
		89 min	10	2.201	1.9233	0.10	1.644	7.09	87.4
		90 min	10	2.176	1.8643	0.30	1.689	7.08	85.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 116 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	91 min	10	2.055	1.8300	0.20	1.666	6.94	89.1
		92 min	10	2.227	1.8984	0.09	1.803	7.05	85.2
		93 min	10	2.317	1.9185	0.23	1.788	6.99	82.8
		94 min	10	2.018	1.7156	0.15	1.666	6.61	85.0
		95 min	9	2.063	1.9022	0.02	1.630	6.83	92.2
		96 min	9	2.155	1.9185	-0.01	1.789	6.89	89.0
		97 min	9	2.155	1.9083	0.00	1.733	6.89	88.5
		98 min	9	2.050	1.4865	-0.04	1.872	5.07	72.5
		99 min	10	2.822	2.3674	0.09	1.969	7.30	83.9
		100 min	9	2.191	1.8179	-0.11	1.860	6.52	83.0
		101 min	9	2.878	2.4355	-0.06	1.933	6.73	84.6
		102 min	9	3.153	2.6271	0.15	1.878	7.32	83.3
		103 min	9	3.055	2.4941	0.25	1.840	6.76	81.6
		104 min	10	2.568	2.2087	0.03	1.733	6.68	86.0
		105 min	10	2.319	1.8505	0.17	1.883	6.55	79.8
		106 min	10	2.199	1.7510	0.33	1.723	6.66	79.6
		107 min	10	2.515	2.0842	0.48	1.770	6.55	82.9
		108 min	10	2.241	1.8133	0.59	1.757	7.08	80.9
		109 min	10	2.410	2.0932	0.53	1.625	6.96	86.9
		110 min	10	2.726	1.8633	0.59	2.210	6.60	68.4
		111 min	10	2.713	2.1975	0.68	1.770	7.41	81.0
		112 min	10	2.615	2.0936	0.59	1.930	7.15	80.0
		113 min	11	2.212	1.6764	0.59	1.688	6.85	75.8
		114 min	11	2.061	1.6859	0.69	1.696	6.88	81.8
		115 min	11	2.208	1.5983	0.56	1.806	6.63	72.4
		116 min	11	2.420	1.8134	0.40	1.733	6.75	74.9
		117 min	11	2.043	1.7044	0.30	1.591	6.87	83.4
		118 min	12	1.980	1.5570	0.59	1.631	6.71	78.6
		119 min	12	2.101	1.6827	0.59	1.619	6.72	80.1
		120 min	12	1.928	1.5667	0.54	1.573	6.69	81.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 117 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	121 min	12	2.815	2.2909	1.00	1.668	6.72	81.4
		122 min	12	2.461	1.8386	0.94	1.732	6.85	74.7
		123 min	12	2.093	1.6176	0.51	1.649	6.80	77.3
		124 min	12	2.075	1.6531	0.49	1.666	6.75	79.7
		125 min	12	2.245	1.7470	0.26	1.679	6.69	77.8
		126 min	12	2.644	2.0206	0.49	1.820	6.73	76.4
		127 min	12	2.077	1.7162	0.60	1.580	6.86	82.6
		128 min	12	2.131	1.7013	0.48	1.711	6.91	79.8
		129 min	12	2.228	1.7382	0.55	1.703	6.80	78.0
		130 min	12	2.270	1.7858	0.39	1.695	6.99	78.7
		131 min	12	2.101	1.7057	0.51	1.564	6.94	81.2
		132 min	12	2.114	1.5907	0.38	1.642	6.69	75.2
		133 min	12	2.349	1.8193	0.34	1.741	6.71	77.4
		134 min	12	2.408	1.8396	0.30	1.920	6.94	76.4
		135 min	12	2.273	1.9082	0.35	1.641	6.76	83.9
		136 min	12	2.083	1.7404	0.36	1.701	7.22	83.6
		137 min	12	2.249	2.0090	0.32	1.610	6.90	89.3
		138 min	12	2.677	2.3007	0.37	1.736	6.79	85.9
		139 min	12	2.506	1.9839	0.38	1.717	6.96	79.2
		140 min	12	2.654	2.2447	0.28	1.748	7.15	84.6
		141 min	12	2.128	1.5963	0.27	1.869	6.85	75.0
		142 min	12	2.590	2.2113	0.36	1.872	7.29	85.4
		143 min	12	2.410	2.1117	0.21	1.946	6.99	87.6
		144 min	12	2.119	1.7100	0.33	1.850	7.09	80.7
		145 min	12	2.441	2.1083	0.21	1.813	7.09	86.4
		146 min	12	2.241	1.7863	0.18	1.891	7.26	79.7
		147 min	12	2.609	2.2732	0.10	1.840	7.18	87.1
		148 min	12	2.678	2.3811	0.07	1.917	7.35	88.9
		149 min	12	2.549	2.3647	0.10	1.962	7.33	92.8
		150 min	12	2.513	2.3380	0.03	1.823	7.35	93.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 118 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	151 min	12	2.470	2.3585	0.07	1.782	7.41	95.5
		152 min	12	2.654	2.4212	0.08	1.970	7.49	91.2
		153 min	12	2.767	2.4507	0.11	1.890	7.43	88.6
		154 min	12	2.640	2.3201	0.16	1.909	7.49	87.9
		155 min	12	2.526	2.2266	0.06	1.894	7.11	88.1
		156 min	12	2.776	2.2997	0.05	2.078	7.50	82.8
		157 min	12	2.626	2.2107	0.41	1.899	7.23	84.2
		158 min	12	2.525	2.3216	0.39	1.772	7.51	91.9
		159 min	12	2.749	2.2653	0.42	2.010	7.71	82.4
		160 min	12	2.660	2.2834	0.20	1.818	7.60	85.8
		161 min	12	3.212	2.6896	0.28	1.828	7.33	83.7
		162 min	12	3.072	2.5132	0.20	1.773	7.13	81.8
		163 min	12	2.997	2.4408	0.13	1.897	7.42	81.4
		164 min	11	2.615	2.2695	0.06	1.800	7.12	86.8
		165 min	11	2.859	2.5438	0.06	1.750	7.16	89.0
		166 min	11	2.826	2.0983	0.41	1.761	6.78	74.3
		167 min	11	2.397	1.9428	0.12	1.719	6.84	81.1
		168 min	11	2.821	2.3397	0.17	1.800	7.26	82.9
		169 min	11	2.568	2.2898	0.25	1.780	7.13	89.2
		170 min	11	2.798	2.1759	1.02	1.793	6.78	77.8
		171 min	11	2.541	1.8103	1.16	1.811	6.68	71.2
		172 min	10	2.570	2.0309	0.77	1.777	6.79	79.0
		173 min	10	2.143	1.8420	0.23	1.817	7.00	85.9
		174 min	10	2.469	2.1313	0.15	1.782	6.92	86.3
		175 min	10	2.365	2.1115	0.20	1.686	6.96	89.3
		176 min	10	2.526	2.3213	0.11	1.703	6.83	91.9
		177 min	10	2.597	2.5486	0.15	1.712	7.61	98.2
		178 min	10	2.504	2.4319	0.26	1.646	7.18	97.1
		179 min	10	2.543	2.4373	0.42	1.618	7.32	95.8
		180 min	10	2.792	2.2844	1.03	1.736	6.96	81.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 119 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	181 min	10	2.566	2.1943	1.01	1.722	7.02	85.5
		182 min	9	1.983	1.8156	0.58	1.552	6.71	91.6
		183 min	9	1.945	1.9517	0.18	1.526	6.97	100.3
		184 min	9	1.868	1.8445	0.07	1.432	6.53	98.7
		185 min	9	1.901	1.9336	0.06	1.474	6.82	101.7
		186 min	9	1.811	1.7042	0.04	1.651	6.11	94.1
		187 min	9	1.751	1.2549	0.06	1.637	4.79	71.7
		188 min	9	1.708	1.4079	0.03	1.449	5.20	82.4
		189 min	10	2.416	2.4564	0.09	1.566	7.04	101.7
		190 min	10	2.453	2.0871	0.09	1.778	6.79	85.1
		191 min	10	2.672	2.4532	0.10	1.734	7.12	91.8
		192 min	10	2.467	2.4324	0.05	1.687	7.12	98.6
		193 min	10	2.482	2.3912	0.07	1.721	7.10	96.3
		194 min	10	2.187	1.9495	0.06	1.676	7.01	89.1
		195 min	10	2.148	1.8911	0.04	1.790	7.03	88.0
		196 min	10	2.636	2.3342	0.06	1.936	6.92	88.6
		197 min	11	2.508	2.1119	0.22	1.800	7.10	84.2
		198 min	11	2.637	2.3466	0.21	1.684	7.04	89.0
		199 min	11	2.696	2.1210	0.99	1.640	7.05	78.7
		200 min	11	2.689	2.0807	1.01	1.694	7.06	77.4
		201 min	11	2.856	2.4897	0.28	1.670	7.15	87.2
		202 min	12	2.529	2.2372	0.10	1.630	7.29	88.5
		203 min	12	2.192	1.8723	0.06	1.703	7.52	85.4
		204 min	12	2.847	2.3595	0.93	1.826	7.62	82.9
		205 min	12	2.856	2.4829	0.26	1.720	7.97	86.9
		206 min	12	2.636	2.4371	0.12	1.679	7.82	92.4
		207 min	11	2.015	1.7471	0.14	1.589	6.85	86.7
		208 min	11	2.492	2.3492	0.02	1.580	7.20	94.3
		209 min	11	2.258	1.9084	0.14	1.635	7.11	84.5
		210 min	11	2.081	1.8335	-0.32	1.860	7.11	88.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 120 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	211 min	12	2.261	1.7775	0.37	1.962	7.51	78.6
		212 min	12	2.328	1.8765	0.11	1.879	7.57	80.6
		213 min	12	2.206	1.7762	0.33	1.826	7.36	80.5
		214 min	12	2.120	1.9900	0.04	1.851	8.11	93.9
		215 min	12	2.483	2.3351	0.05	1.807	7.75	94.0
		216 min	12	2.317	1.7657	0.09	1.824	6.85	76.2
		217 min	12	2.472	1.8049	0.20	1.973	6.96	73.0
		218 min	12	2.410	1.8458	0.29	1.896	6.87	76.6
		219 min	12	2.786	2.0478	0.16	2.066	6.92	73.5
		220 min	12	2.636	2.2423	0.09	1.673	6.93	85.1
		221 min	11	2.947	2.5340	0.15	1.923	6.97	86.0
		222 min	11	2.803	2.5943	0.22	1.466	6.96	92.6
		223 min	11	2.642	2.2594	0.24	1.637	6.88	85.5
		224 min	11	2.064	1.7156	0.45	1.579	6.90	83.1
		225 min	10	2.269	1.9292	0.65	1.571	6.98	85.0
		226 min	10	3.028	2.6510	0.75	1.621	7.04	87.5
		227 min	10	2.244	1.8213	0.82	1.635	6.94	81.1
		228 min	10	2.496	2.1216	0.71	1.594	7.19	85.0
		229 min	10	2.480	2.2867	0.36	1.633	7.09	92.2
		230 min	11	2.384	1.9916	0.42	1.475	7.06	83.5
		231 min	11	2.100	1.6991	0.71	1.658	6.97	80.9
		232 min	11	2.434	1.7571	0.98	1.734	7.05	72.2
		233 min	11	2.636	2.2136	1.04	1.630	7.21	84.0
		234 min	11	2.505	2.0888	1.11	1.587	6.88	83.4
		235 min	12	2.890	2.3115	1.15	1.845	7.42	80.0
		236 min	12	2.842	2.3947	0.88	1.766	7.16	84.3
		237 min	12	2.417	1.7434	0.78	1.796	7.12	72.1
		238 min	12	2.481	2.0322	0.82	1.778	7.54	81.9
		239 min	12	2.297	1.8762	0.69	1.764	7.46	81.7
		240 min	1	0.881		0.88	0.881	0.88	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 121 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	1 min	12	4.708	3.2542	1.24	3.981	8.75	69.1
		2 min	12	5.896	3.2306	1.24	7.844	9.46	54.8
		3 min	12	5.719	3.3252	1.28	7.689	9.39	58.1
		4 min	12	6.200	3.0920	1.34	7.616	9.52	49.9
		5 min	12	6.491	2.6643	1.55	7.331	9.69	41.0
		6 min	12	6.639	2.6216	1.83	7.633	9.85	39.5
		7 min	12	6.858	2.4534	1.83	7.923	9.61	35.8
		8 min	12	6.372	2.4293	1.66	7.225	8.63	38.1
		9 min	12	6.538	2.3205	1.85	7.185	9.49	35.5
		10 min	12	6.462	2.2650	1.57	6.942	9.21	35.0
		11 min	12	6.112	2.2010	1.97	6.688	8.92	36.0
		12 min	12	6.153	2.4376	1.55	6.847	9.26	39.6
		13 min	12	5.455	2.7036	1.54	6.650	9.17	49.6
		14 min	12	5.017	2.9900	1.54	6.482	8.74	59.6
		15 min	12	5.000	3.0243	1.07	6.972	8.37	60.5
		16 min	12	5.254	2.8637	1.09	6.439	8.81	54.5
		17 min	12	4.783	2.9112	1.06	5.700	8.48	60.9
		18 min	12	4.353	2.9094	0.99	4.072	8.42	66.8
		19 min	12	4.314	2.8327	1.04	4.053	8.08	65.7
		20 min	12	4.141	2.8874	0.92	2.974	8.37	69.7
		21 min	11	4.055	2.9761	1.01	2.265	8.17	73.4
		22 min	10	3.658	2.7534	1.05	1.997	7.89	75.3
		23 min	10	3.564	2.8281	1.10	1.739	8.03	79.3
		24 min	10	3.340	2.8291	0.97	1.739	7.94	84.7
		25 min	10	3.197	2.7049	1.14	1.667	7.90	84.6
		26 min	10	3.096	2.5634	1.11	1.583	7.89	82.8
		27 min	10	3.598	2.6972	1.17	2.137	7.87	75.0
		28 min	10	3.319	2.6438	1.05	1.980	7.80	79.6
		29 min	10	3.319	2.7149	1.21	1.750	7.75	81.8
		30 min	10	3.273	2.6205	0.99	1.667	7.73	80.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 122 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	31 min	10	2.895	2.1455	1.01	1.999	7.48	74.1
		32 min	10	2.743	2.1667	1.20	1.656	7.19	79.0
		33 min	10	3.446	2.4958	1.00	2.215	7.77	72.4
		34 min	10	2.812	2.2891	0.83	1.676	7.79	81.4
		35 min	10	3.015	2.3297	0.93	1.670	7.78	77.3
		36 min	11	2.724	2.0329	0.72	1.650	7.69	74.6
		37 min	11	2.573	1.9667	1.00	1.569	7.56	76.4
		38 min	12	2.415	1.8975	0.77	1.631	7.50	78.6
		39 min	12	2.687	2.1159	0.89	1.703	7.61	78.7
		40 min	12	3.149	2.2671	0.51	1.997	7.60	72.0
		41 min	12	2.739	1.9056	1.06	1.915	7.28	69.6
		42 min	12	2.296	1.8513	0.57	1.706	7.48	80.6
		43 min	12	2.458	1.9480	0.89	1.646	7.51	79.2
		44 min	12	2.543	2.1084	0.92	1.707	7.54	82.9
		45 min	11	2.555	2.2000	0.99	1.605	7.53	86.1
		46 min	12	2.490	2.1564	0.77	1.600	7.58	86.6
		47 min	12	2.633	2.1963	0.45	1.758	7.58	83.4
		48 min	12	2.657	2.2248	0.22	1.835	7.65	83.7
		49 min	12	2.813	2.2741	0.57	1.793	7.63	80.8
		50 min	11	2.992	2.2304	1.08	1.772	7.60	74.5
		51 min	11	2.712	2.3505	0.57	1.644	7.44	86.7
		52 min	11	2.337	1.9210	0.93	1.913	7.84	82.2
		53 min	12	2.569	2.0815	0.52	1.775	7.61	81.0
		54 min	12	2.558	1.9811	0.90	1.930	7.64	77.5
		55 min	12	2.227	1.8092	0.58	1.954	7.55	81.2
		56 min	12	2.281	1.8426	0.23	1.807	7.56	80.8
		57 min	12	2.302	1.8248	0.05	1.828	7.21	79.3
		58 min	12	2.421	2.0011	-0.00	1.774	7.26	82.7
		59 min	12	2.480	1.9240	0.03	1.736	7.32	77.6
		60 min	12	2.489	2.0560	0.22	1.945	7.24	82.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 123 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	61 min	12	2.442	1.9216	0.91	1.767	7.28	78.7
		62 min	12	2.369	1.7809	0.80	1.693	7.20	75.2
		63 min	11	2.286	1.7885	1.04	1.665	7.26	78.2
		64 min	11	2.245	1.7809	0.93	1.663	7.18	79.3
		65 min	11	2.189	1.8184	0.63	1.645	7.16	83.1
		66 min	11	2.229	1.8557	0.42	1.676	7.14	83.3
		67 min	11	2.188	1.8382	0.32	1.682	7.17	84.0
		68 min	11	2.209	1.8558	0.25	1.687	7.13	84.0
		69 min	11	2.648	2.0418	0.14	1.861	7.12	77.1
		70 min	10	2.396	1.8164	0.95	1.910	7.09	75.8
		71 min	10	2.359	1.8853	1.01	1.773	7.05	79.9
		72 min	9	2.423	1.9800	0.94	1.646	7.09	81.7
		73 min	9	2.368	1.9131	1.05	1.623	7.01	80.8
		74 min	9	2.327	1.8911	0.94	1.655	6.97	81.3
		75 min	9	2.360	1.9181	0.97	1.632	7.09	81.3
		76 min	9	2.242	1.8846	0.96	1.600	7.03	84.1
		77 min	9	2.250	1.8750	0.98	1.659	7.01	83.3
		78 min	9	2.216	1.8562	1.00	1.839	6.95	83.8
		79 min	9	2.216	1.8463	0.96	1.737	6.93	83.3
		80 min	9	2.195	1.8883	0.89	1.682	6.99	86.0
		81 min	9	2.187	1.8840	0.85	1.693	6.99	86.1
		82 min	9	2.162	1.8764	0.97	1.669	7.02	86.8
		83 min	9	2.199	1.8671	0.98	1.656	7.02	84.9
		84 min	9	2.194	1.8627	1.03	1.652	7.02	84.9
		85 min	9	2.177	1.8378	0.98	1.593	6.93	84.4
		86 min	9	2.236	1.8495	0.83	1.796	7.00	82.7
		87 min	9	2.223	1.8289	0.82	1.787	6.87	82.3
		88 min	9	2.277	1.7910	0.90	1.770	6.83	78.6
		89 min	10	2.044	1.7878	0.14	1.674	6.77	87.5
		90 min	10	2.030	1.7774	0.15	1.660	6.79	87.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 124 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	91 min	10	2.019	1.8535	0.09	1.638	6.98	91.8
		92 min	10	2.013	1.7621	0.37	1.573	6.75	87.6
		93 min	10	2.058	1.7429	0.62	1.625	6.80	84.7
		94 min	10	2.086	1.6462	0.59	1.701	6.55	78.9
		95 min	9	2.145	1.8379	0.32	1.749	6.79	85.7
		96 min	9	2.125	1.8142	0.20	1.767	6.68	85.4
		97 min	9	2.145	1.7262	0.23	1.810	6.45	80.5
		98 min	9	2.084	1.6644	0.07	1.792	6.17	79.9
		99 min	10	2.402	1.8586	0.14	1.891	6.33	77.4
		100 min	9	2.532	1.9794	0.56	1.813	6.37	78.2
		101 min	9	2.235	1.5540	0.39	1.871	5.92	69.5
		102 min	9	2.143	1.4268	0.66	1.825	5.69	66.6
		103 min	9	2.181	1.5433	0.71	1.824	6.10	70.8
		104 min	10	2.303	1.7193	0.63	1.811	6.26	74.7
		105 min	10	2.245	1.6808	0.65	1.854	6.49	74.9
		106 min	10	2.120	1.6169	0.72	1.829	6.52	76.3
		107 min	10	2.090	1.5685	0.71	1.770	6.35	75.0
		108 min	10	2.150	1.7197	0.96	1.787	6.92	80.0
		109 min	10	2.092	1.6302	0.79	1.751	6.58	77.9
		110 min	10	2.106	1.6574	0.88	1.745	6.70	78.7
		111 min	10	2.031	1.6387	0.74	1.700	6.58	80.7
		112 min	10	2.033	1.6253	0.73	1.732	6.53	79.9
		113 min	11	2.033	1.4993	0.86	1.695	6.43	73.8
		114 min	11	2.003	1.5381	1.01	1.683	6.55	76.8
		115 min	11	1.937	1.5808	0.79	1.607	6.60	81.6
		116 min	11	1.990	1.6183	0.73	1.669	6.76	81.3
		117 min	11	2.091	1.5967	1.14	1.692	6.82	76.3
		118 min	12	1.975	1.4736	1.20	1.652	6.59	74.6
		119 min	12	2.012	1.5435	1.19	1.632	6.84	76.7
		120 min	12	1.963	1.5410	0.99	1.603	6.77	78.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 125 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	121 min	12	2.013	1.5026	1.15	1.639	6.63	74.7
		122 min	12	2.301	1.8172	1.04	1.663	6.74	79.0
		123 min	12	1.999	1.5263	0.98	1.596	6.74	76.3
		124 min	12	1.987	1.5342	0.92	1.634	6.75	77.2
		125 min	12	1.938	1.5569	0.68	1.552	6.75	80.3
		126 min	12	2.074	1.5406	0.74	1.698	6.64	74.3
		127 min	12	2.068	1.4890	1.15	1.634	6.71	72.0
		128 min	12	1.946	1.5829	0.89	1.623	6.86	81.4
		129 min	12	2.122	1.6411	0.76	1.651	6.86	77.3
		130 min	12	1.996	1.5898	0.63	1.642	6.84	79.7
		131 min	12	1.932	1.6602	0.61	1.539	7.07	85.9
		132 min	12	1.994	1.6360	0.53	1.691	7.03	82.0
		133 min	12	1.957	1.6156	0.60	1.585	6.93	82.6
		134 min	12	2.127	1.6868	0.47	1.732	6.97	79.3
		135 min	12	2.242	1.8229	0.49	1.681	6.87	81.3
		136 min	12	1.960	1.7126	0.50	1.573	7.26	87.4
		137 min	12	1.904	1.6439	0.49	1.545	6.95	86.3
		138 min	12	2.325	1.8469	1.15	1.692	6.87	79.4
		139 min	12	2.029	1.5645	0.96	1.675	6.87	77.1
		140 min	12	2.183	1.7268	0.89	1.680	7.22	79.1
		141 min	12	2.527	2.0352	1.12	1.778	7.01	80.5
		142 min	12	2.099	1.6501	0.63	1.720	7.03	78.6
		143 min	12	2.162	1.7684	0.40	1.715	7.21	81.8
		144 min	12	2.092	1.6954	0.55	1.770	7.26	81.0
		145 min	12	2.462	2.0782	0.45	1.775	7.27	84.4
		146 min	12	2.260	1.7458	0.44	1.923	7.33	77.2
		147 min	12	2.079	1.7647	0.22	1.737	7.34	84.9
		148 min	12	2.059	1.7752	0.28	1.790	7.37	86.2
		149 min	12	2.058	1.7960	0.12	1.742	7.34	87.3
		150 min	12	2.143	1.8499	0.17	1.786	7.42	86.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 126 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	151 min	12	2.112	1.8118	0.04	1.803	7.41	85.8
		152 min	12	2.402	2.2415	0.08	1.840	7.41	93.3
		153 min	12	2.536	2.2685	0.05	1.861	7.46	89.4
		154 min	12	2.554	2.1226	0.90	1.904	7.42	83.1
		155 min	12	2.335	1.9051	0.43	1.802	7.49	81.6
		156 min	12	2.639	2.1788	0.15	1.889	7.45	82.6
		157 min	12	2.514	2.1040	0.49	1.857	7.34	83.7
		158 min	12	2.107	1.7135	0.95	1.805	7.35	81.3
		159 min	12	2.141	1.6123	1.08	1.837	7.13	75.3
		160 min	12	2.373	1.9282	0.76	1.806	7.52	81.3
		161 min	12	2.125	1.7782	0.62	1.776	7.44	83.7
		162 min	12	2.294	1.9322	0.41	1.750	7.49	84.2
		163 min	12	2.247	1.7834	0.28	1.794	7.46	79.4
		164 min	11	2.218	1.9145	0.29	1.717	7.30	86.3
		165 min	11	2.149	1.8836	0.09	1.726	7.32	87.6
		166 min	11	2.447	1.8824	0.16	1.758	7.07	76.9
		167 min	11	2.330	2.0192	0.12	1.729	6.92	86.7
		168 min	11	2.339	2.1736	0.09	1.608	7.27	92.9
		169 min	11	2.179	1.8923	0.19	1.695	7.26	86.8
		170 min	11	2.343	2.1157	0.27	1.690	7.04	90.3
		171 min	11	2.396	2.0982	0.90	1.661	7.02	87.6
		172 min	10	2.338	1.9397	0.54	1.760	6.96	83.0
		173 min	10	2.146	1.8179	0.21	1.702	6.94	84.7
		174 min	10	2.586	2.3944	0.28	1.710	7.13	92.6
		175 min	10	2.586	2.3947	0.26	1.636	7.01	92.6
		176 min	10	2.482	2.3499	0.23	1.608	7.00	94.7
		177 min	10	2.508	2.4812	0.28	1.599	7.29	98.9
		178 min	10	2.252	2.0781	0.10	1.606	6.92	92.3
		179 min	10	2.442	2.3268	0.32	1.563	6.96	95.3
		180 min	10	2.112	1.8150	0.52	1.768	7.01	86.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 127 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	181 min	10	2.279	1.9859	0.57	1.613	7.07	87.1
		182 min	9	1.526	0.5583	0.44	1.498	2.38	36.6
		183 min	9	1.580	0.7567	0.36	1.502	3.19	47.9
		184 min	9	1.531	0.8937	0.23	1.490	3.53	58.4
		185 min	9	1.450	0.6221	0.26	1.618	2.20	42.9
		186 min	9	1.511	0.7430	0.22	1.480	3.00	49.2
		187 min	9	1.371	0.6134	0.11	1.470	2.29	44.7
		188 min	9	1.539	0.8081	0.18	1.559	3.20	52.5
		189 min	10	2.285	2.1599	0.24	1.596	7.26	94.5
		190 min	10	1.973	1.8733	0.19	1.549	7.04	95.0
		191 min	10	2.087	1.8744	0.12	1.629	7.03	89.8
		192 min	10	2.335	2.1505	0.17	1.662	7.14	92.1
		193 min	10	2.410	2.1467	0.13	1.755	7.04	89.1
		194 min	10	2.063	1.8617	0.09	1.739	7.01	90.2
		195 min	10	2.056	1.8957	0.07	1.583	7.09	92.2
		196 min	10	2.109	1.8905	0.09	1.653	7.06	89.7
		197 min	11	1.929	1.7737	0.43	1.451	7.05	91.9
		198 min	11	2.060	1.8512	0.09	1.524	6.99	89.9
		199 min	11	2.440	2.3019	0.03	1.625	7.03	94.3
		200 min	11	2.003	1.7803	0.22	1.775	7.08	88.9
		201 min	11	2.015	1.7591	0.60	1.454	7.15	87.3
		202 min	12	2.031	1.7283	0.28	1.530	7.15	85.1
		203 min	12	2.260	1.7958	0.10	1.661	7.04	79.5
		204 min	12	2.093	1.7758	0.11	1.619	7.22	84.8
		205 min	12	2.042	1.7251	0.30	1.503	7.18	84.5
		206 min	12	1.980	1.6984	0.40	1.455	7.14	85.8
		207 min	11	1.960	1.7473	0.45	1.421	7.01	89.1
		208 min	11	2.008	1.8491	0.21	1.538	7.33	92.1
		209 min	11	2.003	1.8409	0.27	1.499	7.32	91.9
		210 min	11	2.121	1.9083	0.27	1.414	7.38	90.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 128 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	211 min	12	2.167	1.8689	0.21	1.546	7.37	86.3
		212 min	12	2.016	1.7605	0.28	1.695	7.38	87.3
		213 min	12	1.970	1.7522	0.08	1.633	7.24	89.0
		214 min	12	2.410	2.1269	0.34	1.727	7.32	88.2
		215 min	12	2.172	1.8266	0.12	1.709	7.36	84.1
		216 min	12	2.048	1.9015	0.00	1.660	7.79	92.9
		217 min	12	2.082	1.8313	0.45	1.652	7.72	88.0
		218 min	12	2.018	1.7978	0.65	1.681	7.59	89.1
		219 min	12	2.203	1.8334	0.37	1.736	7.52	83.2
		220 min	12	2.025	1.8078	0.24	1.615	7.48	89.3
		221 min	11	2.152	1.9122	0.24	1.587	7.53	88.9
		222 min	11	2.580	2.1635	0.36	1.665	7.49	83.9
		223 min	11	2.501	2.3885	0.31	1.539	7.48	95.5
		224 min	11	2.216	1.8538	0.72	1.582	7.39	83.7
		225 min	10	2.286	1.8644	0.95	1.610	7.40	81.6
		226 min	10	2.803	2.4451	1.00	1.669	7.45	87.2
		227 min	10	2.728	2.4032	1.13	1.606	7.26	88.1
		228 min	10	2.703	2.3175	1.17	1.649	7.32	85.7
		229 min	10	2.665	2.0059	1.11	1.698	7.38	75.3
		230 min	11	2.230	1.9280	0.81	1.584	7.41	86.5
		231 min	11	2.097	1.8135	0.82	1.673	7.43	86.5
		232 min	11	2.083	1.8080	0.93	1.616	7.38	86.8
		233 min	11	2.109	1.8006	0.88	1.557	7.39	85.4
		234 min	11	2.264	1.9830	0.68	1.528	7.28	87.6
		235 min	12	2.153	1.8096	0.29	1.593	7.40	84.0
		236 min	12	2.432	2.0144	0.47	1.633	7.45	82.8
		237 min	12	2.326	1.8618	0.64	1.688	7.38	80.0
		238 min	12	2.049	1.8093	0.32	1.611	7.33	88.3
		239 min	12	2.032	1.7277	0.38	1.677	7.32	85.0
		240 min	1	0.230		0.23	0.230	0.23	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 129 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	1 min	12	3.732	3.1086	1.15	1.901	8.94	83.3
		2 min	12	4.864	3.2179	1.15	4.707	10.01	66.2
		3 min	12	5.612	2.9303	1.16	6.678	10.16	52.2
		4 min	12	5.775	3.1087	1.05	7.396	10.18	53.8
		5 min	12	5.646	3.1425	1.43	7.095	9.92	55.7
		6 min	12	6.055	2.8548	2.17	7.376	9.97	47.1
		7 min	12	6.615	2.1408	2.20	7.194	9.82	32.4
		8 min	12	6.213	2.3552	2.13	7.029	9.88	37.9
		9 min	12	5.711	2.6383	1.98	6.351	9.74	46.2
		10 min	12	5.913	2.5824	1.64	6.853	9.78	43.7
		11 min	12	5.464	2.7964	1.64	6.611	9.71	51.2
		12 min	12	5.299	2.8720	1.52	6.577	9.30	54.2
		13 min	12	5.405	2.8015	1.57	6.598	9.17	51.8
		14 min	12	5.005	2.9329	1.40	5.124	9.24	58.6
		15 min	12	4.808	3.0689	1.19	5.250	9.03	63.8
		16 min	12	5.132	2.9189	1.20	6.327	8.86	56.9
		17 min	12	4.716	2.9231	1.13	5.055	8.58	62.0
		18 min	12	4.555	2.9268	1.05	4.950	8.70	64.3
		19 min	12	4.535	2.8855	1.02	5.435	8.64	63.6
		20 min	12	4.128	2.8437	0.82	3.446	8.53	68.9
		21 min	11	3.831	2.6904	1.03	3.262	8.32	70.2
		22 min	10	3.473	2.5283	0.95	2.588	7.68	72.8
		23 min	10	3.420	2.4874	1.02	2.213	7.82	72.7
		24 min	10	3.635	2.6877	0.92	2.209	7.71	73.9
		25 min	10	3.531	2.5418	0.98	2.551	7.75	72.0
		26 min	10	3.444	2.6023	0.96	1.963	7.74	75.6
		27 min	10	3.560	2.6638	1.07	1.943	7.69	74.8
		28 min	10	3.379	2.4369	1.12	2.211	7.62	72.1
		29 min	10	3.315	2.5929	1.07	1.567	7.66	78.2
		30 min	10	3.000	2.3093	1.05	1.551	7.60	77.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 130 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	31 min	10	2.846	2.2427	0.96	1.748	7.58	78.8
		32 min	10	2.909	2.1535	1.05	2.057	7.19	74.0
		33 min	10	3.396	2.6053	0.90	1.868	7.68	76.7
		34 min	10	3.031	2.3814	0.93	1.528	7.66	78.6
		35 min	10	2.789	2.3412	0.85	1.536	7.51	83.9
		36 min	11	2.659	2.1559	0.90	1.545	7.61	81.1
		37 min	11	2.625	1.9922	0.98	1.527	7.39	75.9
		38 min	12	2.699	1.9366	0.55	1.784	7.52	71.8
		39 min	12	3.103	2.2644	1.01	1.597	7.47	73.0
		40 min	12	2.939	2.1194	0.88	2.167	7.47	72.1
		41 min	12	2.860	2.0840	0.96	1.651	7.37	72.9
		42 min	12	2.742	1.9595	1.00	1.831	7.38	71.5
		43 min	12	3.046	2.3284	0.95	1.640	7.23	76.4
		44 min	12	3.085	2.3834	1.06	1.786	7.22	77.3
		45 min	11	2.797	2.2067	0.91	1.713	7.37	78.9
		46 min	12	2.862	2.2835	0.88	1.620	7.38	79.8
		47 min	12	2.962	2.2761	0.98	1.943	7.38	76.9
		48 min	12	2.817	2.1186	0.72	2.010	7.36	75.2
		49 min	12	2.768	2.1239	0.94	1.839	7.31	76.7
		50 min	11	2.587	1.9731	1.04	1.706	7.22	76.3
		51 min	11	2.870	2.1445	0.94	1.712	7.27	74.7
		52 min	11	2.945	2.4487	0.54	1.650	7.48	83.1
		53 min	12	3.013	2.3713	0.79	1.683	7.52	78.7
		54 min	12	2.745	2.1522	0.58	1.696	7.46	78.4
		55 min	12	2.519	1.9223	0.91	1.699	7.47	76.3
		56 min	12	2.440	1.8327	0.70	1.740	7.52	75.1
		57 min	12	2.322	1.7968	0.62	1.639	7.37	77.4
		58 min	12	2.374	1.8153	0.70	1.757	7.31	76.5
		59 min	12	2.200	1.7719	0.30	1.825	7.25	80.5
		60 min	12	2.101	1.7676	0.13	1.718	7.18	84.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 131 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	61 min	12	2.272	1.8238	0.19	1.650	7.16	80.3
		62 min	12	2.330	1.7528	0.88	1.653	7.13	75.2
		63 min	11	2.161	1.7917	0.77	1.653	7.12	82.9
		64 min	11	2.242	1.7331	0.92	1.648	7.05	77.3
		65 min	11	2.201	1.7050	0.98	1.662	6.99	77.5
		66 min	11	2.119	1.7407	0.73	1.628	6.99	82.1
		67 min	11	2.064	1.7906	0.21	1.572	7.02	86.8
		68 min	11	2.077	1.7654	0.43	1.599	7.01	85.0
		69 min	11	2.157	1.7029	0.48	1.632	6.88	79.0
		70 min	10	2.204	1.7708	0.97	1.692	6.92	80.4
		71 min	10	2.184	1.7140	1.04	1.633	6.72	78.5
		72 min	9	2.298	1.8544	0.96	1.592	6.90	80.7
		73 min	9	2.262	1.8640	0.99	1.549	6.87	82.4
		74 min	9	2.295	1.8427	0.98	1.645	6.82	80.3
		75 min	9	2.246	1.8769	0.84	1.595	6.86	83.6
		76 min	9	2.243	1.8784	0.93	1.521	6.86	83.7
		77 min	9	2.255	1.8651	0.95	1.523	6.84	82.7
		78 min	9	2.233	1.8591	0.92	1.611	6.84	83.2
		79 min	9	2.219	1.8389	0.90	1.618	6.76	82.9
		80 min	9	2.199	1.8487	0.85	1.613	6.73	84.1
		81 min	9	2.167	1.8577	0.78	1.643	6.77	85.7
		82 min	9	2.163	1.8683	0.90	1.600	6.83	86.4
		83 min	9	2.214	1.8462	0.97	1.655	6.82	83.4
		84 min	9	2.203	1.8393	1.01	1.600	6.82	83.5
		85 min	9	2.160	1.8301	0.99	1.528	6.80	84.7
		86 min	9	2.238	1.8058	0.91	1.623	6.79	80.7
		87 min	9	2.205	1.8009	0.83	1.602	6.74	81.7
		88 min	9	2.289	1.7767	0.92	1.757	6.69	77.6
		89 min	10	2.116	1.8005	0.09	1.623	6.73	85.1
		90 min	10	2.109	1.7439	0.27	1.705	6.68	82.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 132 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	91 min	10	2.113	1.7207	0.39	1.674	6.65	81.4
		92 min	10	2.096	1.7122	0.29	1.669	6.54	81.7
		93 min	10	2.062	1.6600	0.51	1.694	6.46	80.5
		94 min	10	2.114	1.6861	0.37	1.701	6.54	79.8
		95 min	9	2.163	1.6378	0.49	1.790	6.18	75.7
		96 min	9	2.151	1.6269	0.39	1.801	6.14	75.6
		97 min	9	2.106	1.5185	0.49	1.816	5.83	72.1
		98 min	9	2.140	1.7915	0.35	1.827	6.62	83.7
		99 min	10	2.198	1.7582	0.40	1.862	6.95	80.0
		100 min	9	2.398	1.6907	1.15	1.782	6.66	70.5
		101 min	9	2.117	1.3223	1.20	1.780	5.59	62.4
		102 min	9	2.013	1.4968	0.72	1.769	5.81	74.3
		103 min	9	2.007	1.3511	0.59	1.796	5.40	67.3
		104 min	10	1.756	0.7228	0.59	1.766	3.32	41.2
		105 min	10	1.991	1.2313	0.59	1.746	5.04	61.8
		106 min	10	1.859	1.0454	0.57	1.775	4.52	56.2
		107 min	10	1.960	1.4216	0.53	1.822	5.79	72.5
		108 min	10	2.099	1.5497	1.06	1.733	6.39	73.8
		109 min	10	1.879	0.9727	0.83	1.791	4.43	51.8
		110 min	10	1.820	0.7655	0.87	1.688	3.63	42.1
		111 min	10	1.849	1.1259	0.78	1.663	4.82	60.9
		112 min	10	1.950	1.1775	0.73	1.758	5.04	60.4
		113 min	11	1.990	1.3530	0.82	1.729	5.93	68.0
		114 min	11	1.970	1.4659	0.80	1.707	6.27	74.4
		115 min	11	1.925	1.4685	0.75	1.635	6.24	76.3
		116 min	11	1.932	1.5856	0.55	1.609	6.58	82.1
		117 min	11	2.001	1.5689	1.07	1.679	6.66	78.4
		118 min	12	1.913	1.4755	1.06	1.610	6.51	77.1
		119 min	12	1.956	1.4453	1.21	1.615	6.48	73.9
		120 min	12	1.944	1.4603	1.12	1.582	6.52	75.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 133 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	121 min	12	1.927	1.4446	1.10	1.593	6.45	75.0
		122 min	12	1.909	1.4654	1.08	1.535	6.49	76.8
		123 min	12	1.929	1.4713	1.03	1.556	6.53	76.3
		124 min	12	1.932	1.4906	0.95	1.619	6.59	77.1
		125 min	12	1.923	1.4937	0.93	1.558	6.57	77.7
		126 min	12	1.913	1.5475	0.77	1.537	6.73	80.9
		127 min	12	1.913	1.5327	0.93	1.571	6.70	80.1
		128 min	12	1.921	1.5462	0.93	1.626	6.76	80.5
		129 min	12	1.895	1.5591	0.65	1.582	6.74	82.3
		130 min	12	1.880	1.6264	0.09	1.655	6.81	86.5
		131 min	12	1.863	1.6500	0.09	1.559	6.89	88.6
		132 min	12	1.890	1.6457	0.18	1.615	6.91	87.1
		133 min	12	1.826	1.5942	0.09	1.597	6.67	87.3
		134 min	12	1.993	1.6274	0.03	1.707	6.80	81.6
		135 min	12	1.860	1.6582	0.02	1.591	6.90	89.1
		136 min	12	1.883	1.6874	0.09	1.581	7.03	89.6
		137 min	12	1.890	1.5912	0.66	1.592	6.81	84.2
		138 min	12	2.194	1.8076	0.72	1.687	6.86	82.4
		139 min	12	1.928	1.5860	1.03	1.607	6.88	82.3
		140 min	12	2.069	1.6728	0.99	1.709	7.22	80.9
		141 min	12	1.958	1.5934	0.93	1.632	6.93	81.4
		142 min	12	1.998	1.5993	0.92	1.696	6.99	80.1
		143 min	12	1.971	1.6574	0.63	1.700	7.10	84.1
		144 min	12	2.067	1.6864	0.63	1.716	7.20	81.6
		145 min	12	2.051	1.7118	0.60	1.756	7.30	83.5
		146 min	12	1.983	1.7379	0.54	1.735	7.35	87.6
		147 min	12	1.984	1.7291	0.48	1.737	7.31	87.1
		148 min	12	1.968	1.7723	0.42	1.708	7.42	90.1
		149 min	12	1.989	1.7527	0.43	1.689	7.38	88.1
		150 min	12	2.010	1.7734	0.26	1.766	7.37	88.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 134 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	151 min	12	1.994	1.7493	0.19	1.788	7.31	87.7
		152 min	12	1.968	1.7647	0.17	1.740	7.32	89.7
		153 min	12	1.987	1.7548	0.21	1.770	7.30	88.3
		154 min	12	2.067	1.7230	0.77	1.799	7.38	83.3
		155 min	12	2.012	1.7038	0.59	1.761	7.21	84.7
		156 min	12	2.078	1.8036	0.44	1.797	7.53	86.8
		157 min	12	2.100	1.7925	0.48	1.770	7.48	85.4
		158 min	12	2.046	1.7379	0.38	1.782	7.31	84.9
		159 min	12	2.026	1.7142	0.57	1.754	7.24	84.6
		160 min	12	2.023	1.7755	0.32	1.747	7.42	87.8
		161 min	12	2.076	1.7836	0.62	1.749	7.56	85.9
		162 min	12	2.044	1.8511	0.28	1.736	7.68	90.6
		163 min	12	2.023	1.7813	0.25	1.707	7.42	88.1
		164 min	11	2.069	1.9069	0.27	1.725	7.62	92.2
		165 min	11	2.052	1.9179	0.11	1.697	7.53	93.5
		166 min	11	2.274	1.9877	0.14	1.764	7.70	87.4
		167 min	11	2.062	1.8640	0.05	1.719	7.36	90.4
		168 min	11	2.050	1.9047	0.15	1.630	7.51	92.9
		169 min	11	2.038	1.8254	0.04	1.683	7.23	89.6
		170 min	11	2.065	1.9720	0.14	1.669	7.74	95.5
		171 min	11	2.069	1.9343	0.20	1.685	7.67	93.5
		172 min	10	2.183	1.8551	0.42	1.718	7.04	85.0
		173 min	10	2.156	1.9434	0.33	1.709	7.40	90.1
		174 min	10	2.127	1.8729	0.26	1.714	7.21	88.1
		175 min	10	2.086	1.8642	0.22	1.648	7.12	89.4
		176 min	10	2.077	1.8394	0.22	1.648	7.03	88.6
		177 min	10	2.088	1.8749	0.23	1.634	7.02	89.8
		178 min	10	2.045	1.8319	0.16	1.645	6.89	89.6
		179 min	10	2.057	1.8249	0.20	1.652	6.94	88.7
		180 min	10	2.070	1.8426	0.41	1.678	7.09	89.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 135 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	181 min	10	2.065	1.7947	0.55	1.611	6.97	86.9
		182 min	9	1.499	0.5105	0.52	1.539	2.26	34.0
		183 min	9	1.433	0.5061	0.56	1.440	2.25	35.3
		184 min	9	1.457	0.5474	0.33	1.543	2.28	37.6
		185 min	9	1.400	0.5559	0.46	1.504	2.21	39.7
		186 min	9	1.412	0.5233	0.33	1.467	2.15	37.1
		187 min	9	1.384	0.5290	0.37	1.474	2.09	38.2
		188 min	9	1.432	0.5313	0.36	1.493	2.16	37.1
		189 min	10	1.989	1.8302	0.33	1.619	6.97	92.0
		190 min	10	1.950	1.8394	0.13	1.643	6.91	94.3
		191 min	10	1.980	1.8024	0.08	1.626	6.84	91.0
		192 min	10	1.987	1.8307	0.15	1.601	6.93	92.1
		193 min	10	2.040	1.8249	0.18	1.696	6.99	89.4
		194 min	10	1.989	1.8344	0.18	1.607	6.95	92.2
		195 min	10	1.979	1.8543	0.06	1.629	6.95	93.7
		196 min	10	1.987	1.8354	0.04	1.661	6.91	92.4
		197 min	11	1.936	1.7024	0.44	1.513	6.84	87.9
		198 min	11	1.941	1.7175	0.34	1.468	6.88	88.5
		199 min	11	1.941	1.7244	0.23	1.504	6.88	88.8
		200 min	11	2.157	1.8057	0.33	1.726	6.90	83.7
		201 min	11	2.020	1.7002	0.36	1.723	6.92	84.2
		202 min	12	1.947	1.6313	0.31	1.575	6.89	83.8
		203 min	12	1.955	1.6499	0.11	1.633	6.89	84.4
		204 min	12	1.907	1.6599	0.07	1.576	6.85	87.0
		205 min	12	1.970	1.6105	0.30	1.722	6.81	81.8
		206 min	12	1.912	1.5917	0.27	1.536	6.70	83.2
		207 min	11	1.949	1.7148	0.32	1.413	6.88	88.0
		208 min	11	1.948	1.6769	0.17	1.542	6.72	86.1
		209 min	11	1.934	1.6974	0.16	1.504	6.78	87.8
		210 min	11	1.951	1.7206	0.18	1.506	6.86	88.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 136 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	211 min	12	1.907	1.6377	0.06	1.523	6.80	85.9
		212 min	12	1.926	1.6162	0.07	1.592	6.75	83.9
		213 min	12	1.924	1.6577	0.03	1.597	6.87	86.1
		214 min	12	1.948	1.6350	0.15	1.632	6.85	83.9
		215 min	12	2.283	1.9569	0.16	1.679	6.90	85.7
		216 min	12	2.211	1.7649	0.09	1.703	6.61	79.8
		217 min	12	2.317	1.9099	0.43	1.708	6.96	82.4
		218 min	12	2.055	1.6212	0.35	1.720	6.82	78.9
		219 min	12	1.948	1.5877	0.23	1.655	6.70	81.5
		220 min	12	1.953	1.6072	0.07	1.639	6.69	82.3
		221 min	11	1.935	1.6570	0.16	1.636	6.65	85.6
		222 min	11	1.985	1.6442	0.32	1.654	6.68	82.8
		223 min	11	2.067	1.7145	0.31	1.515	6.76	83.0
		224 min	11	1.954	1.6670	0.60	1.554	6.77	85.3
		225 min	10	2.409	1.9503	0.93	1.552	6.77	81.0
		226 min	10	2.433	1.9831	0.97	1.554	6.83	81.5
		227 min	10	2.463	1.8044	1.11	1.603	6.82	73.3
		228 min	10	2.530	2.0057	1.15	1.603	6.68	79.3
		229 min	10	2.005	1.7291	0.70	1.581	6.75	86.2
		230 min	11	1.922	1.6123	0.57	1.526	6.60	83.9
		231 min	11	1.914	1.6588	0.44	1.509	6.72	86.7
		232 min	11	1.940	1.6676	0.59	1.506	6.80	86.0
		233 min	11	1.909	1.6974	0.59	1.453	6.85	88.9
		234 min	11	1.992	1.7706	0.50	1.473	6.90	88.9
		235 min	12	1.902	1.5915	0.60	1.529	6.77	83.7
		236 min	12	1.870	1.6792	0.41	1.470	7.00	89.8
		237 min	12	1.915	1.6570	0.62	1.515	6.96	86.5
		238 min	12	1.872	1.6723	0.44	1.559	6.94	89.3
		239 min	12	1.859	1.6537	0.53	1.542	6.89	88.9
		240 min	1	0.488		0.49	0.488	0.49	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 137 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	1 min	12	3.220	2.7322	0.96	1.803	8.54	84.8
		2 min	12	5.525	3.1613	0.91	6.718	9.71	57.2
		3 min	12	5.542	2.9474	1.03	6.927	9.99	53.2
		4 min	12	5.863	3.0191	0.97	7.415	9.72	51.5
		5 min	12	6.414	2.5360	0.88	7.517	8.92	39.5
		6 min	12	6.456	2.6322	0.98	7.590	9.02	40.8
		7 min	12	6.336	2.4644	2.23	7.446	8.77	38.9
		8 min	12	6.481	2.3682	2.14	7.428	9.44	36.5
		9 min	12	7.007	1.4300	3.57	7.489	8.91	20.4
		10 min	12	6.298	2.4478	1.99	7.528	9.09	38.9
		11 min	12	6.293	2.2449	1.90	7.313	8.95	35.7
		12 min	12	6.097	2.5116	1.87	7.320	8.51	41.2
		13 min	12	6.177	2.3964	1.74	7.310	8.46	38.8
		14 min	12	5.913	2.5727	1.59	7.166	8.76	43.5
		15 min	12	5.322	2.9536	1.30	6.842	8.67	55.5
		16 min	12	5.331	2.8472	1.40	6.811	8.67	53.4
		17 min	12	5.083	3.0964	1.14	6.302	8.70	60.9
		18 min	12	5.065	3.1588	1.13	6.826	8.51	62.4
		19 min	12	5.060	3.1086	1.08	6.874	8.52	61.4
		20 min	12	4.625	3.0263	0.84	5.123	8.35	65.4
		21 min	11	5.192	2.9250	1.06	6.598	8.31	56.3
		22 min	10	4.674	2.9201	0.97	6.170	7.74	62.5
		23 min	10	4.375	2.8296	1.01	4.867	7.79	64.7
		24 min	10	4.415	2.8428	0.95	5.126	7.74	64.4
		25 min	10	4.486	2.8355	1.07	5.199	7.74	63.2
		26 min	10	3.667	2.6339	0.94	3.023	7.67	71.8
		27 min	10	3.812	2.9151	1.09	1.900	7.60	76.5
		28 min	10	3.816	2.8622	1.14	1.872	7.70	75.0
		29 min	10	3.581	2.6986	1.20	1.862	7.72	75.4
		30 min	10	3.341	2.5574	1.16	1.632	7.74	76.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 138 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	31 min	10	2.887	2.3259	1.14	1.650	7.69	80.6
		32 min	10	3.020	2.2584	1.18	1.750	7.17	74.8
		33 min	10	3.232	2.6709	0.96	1.780	7.60	82.6
		34 min	10	3.075	2.5850	1.06	1.596	7.67	84.1
		35 min	10	2.998	2.5153	1.02	1.583	7.54	83.9
		36 min	11	2.953	2.5585	0.92	1.524	7.65	86.7
		37 min	11	2.787	2.3579	0.99	1.451	7.35	84.6
		38 min	12	3.147	2.4811	0.88	1.522	7.48	78.8
		39 min	12	2.979	2.4315	0.93	1.557	7.55	81.6
		40 min	12	3.110	2.4523	0.85	1.674	7.52	78.9
		41 min	12	3.142	2.2468	1.03	2.382	7.36	71.5
		42 min	12	2.980	2.2270	1.03	1.966	7.42	74.7
		43 min	12	3.138	2.2582	0.99	2.183	7.36	72.0
		44 min	12	3.306	2.5963	0.99	2.026	7.51	78.5
		45 min	11	2.887	2.3111	1.01	1.656	7.36	80.1
		46 min	12	3.140	2.5271	1.00	1.697	7.36	80.5
		47 min	12	3.049	2.5282	0.98	1.545	7.40	82.9
		48 min	12	2.995	2.3775	0.87	1.603	7.30	79.4
		49 min	12	3.052	2.5504	0.83	1.593	7.19	83.6
		50 min	11	2.728	2.2875	0.79	1.514	7.02	83.9
		51 min	11	2.967	2.5216	0.72	1.513	7.14	85.0
		52 min	11	3.070	2.6158	0.83	1.516	7.74	85.2
		53 min	12	3.073	2.4682	0.48	1.579	7.55	80.3
		54 min	12	2.794	2.2703	0.37	1.609	7.42	81.3
		55 min	12	2.632	2.2553	0.21	1.605	7.59	85.7
		56 min	12	2.533	2.2985	0.01	1.622	7.48	90.7
		57 min	12	2.408	1.9554	0.04	1.609	7.29	81.2
		58 min	12	2.551	2.1343	0.10	1.608	7.39	83.7
		59 min	12	2.494	2.0906	0.10	1.609	7.45	83.8
		60 min	12	2.206	1.8580	0.25	1.612	7.43	84.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 139 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	61 min	12	2.325	1.8746	0.29	1.606	7.37	80.6
		62 min	12	2.248	1.8355	0.39	1.664	7.34	81.7
		63 min	11	2.112	1.8135	0.39	1.649	7.03	85.9
		64 min	11	2.201	1.8892	0.37	1.653	7.22	85.8
		65 min	11	2.097	1.8555	0.44	1.529	7.16	88.5
		66 min	11	2.100	1.8656	0.34	1.597	7.20	88.9
		67 min	11	2.174	1.8077	0.33	1.638	6.94	83.2
		68 min	11	2.107	1.7990	0.39	1.627	7.02	85.4
		69 min	11	2.140	1.8265	0.30	1.611	7.12	85.4
		70 min	10	2.250	1.7739	0.98	1.637	6.88	78.8
		71 min	10	2.342	1.8416	1.10	1.613	7.09	78.6
		72 min	9	2.355	1.9358	1.00	1.594	7.09	82.2
		73 min	9	2.307	1.9687	0.94	1.584	7.14	85.3
		74 min	9	2.516	1.8523	1.08	1.813	6.97	73.6
		75 min	9	2.400	1.9197	0.98	1.747	7.05	80.0
		76 min	9	2.377	1.9245	0.95	1.637	7.01	81.0
		77 min	9	2.348	1.9067	1.05	1.685	7.05	81.2
		78 min	9	2.284	1.9247	0.81	1.610	7.03	84.3
		79 min	9	2.270	1.8183	1.00	1.580	6.67	80.1
		80 min	9	2.269	1.8881	0.85	1.625	6.85	83.2
		81 min	9	2.275	1.9166	0.84	1.624	6.95	84.2
		82 min	9	2.148	1.8929	0.90	1.620	6.87	88.1
		83 min	9	2.261	1.9104	0.92	1.609	6.99	84.5
		84 min	9	2.260	1.8330	0.99	1.619	6.82	81.1
		85 min	9	2.260	1.9337	1.03	1.585	7.12	85.6
		86 min	9	2.309	1.9302	0.90	1.684	7.20	83.6
		87 min	9	2.642	1.9436	0.85	1.672	7.01	73.6
		88 min	9	2.638	1.9727	0.93	1.659	6.85	74.8
		89 min	10	2.391	1.9804	0.04	1.621	6.79	82.8
		90 min	10	2.636	2.1251	0.19	1.943	6.73	80.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 140 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	91 min	10	2.998	2.4005	0.02	2.047	7.06	80.1
		92 min	10	2.738	2.1935	0.68	1.989	7.00	80.1
		93 min	10	2.461	1.8133	0.32	2.047	6.78	73.7
		94 min	10	2.479	2.0814	-0.08	1.653	6.60	84.0
		95 min	9	2.707	2.3539	0.07	1.677	6.95	86.9
		96 min	9	2.650	2.2221	0.03	1.720	6.96	83.9
		97 min	9	2.318	1.8715	0.05	1.657	6.63	80.8
		98 min	9	2.443	2.1133	0.09	1.770	7.41	86.5
		99 min	10	2.198	1.8965	0.01	1.798	7.20	86.3
		100 min	9	2.172	1.9576	0.09	1.725	7.09	90.1
		101 min	9	2.068	1.7427	0.11	1.720	6.41	84.3
		102 min	9	2.096	1.7858	0.16	1.755	6.59	85.2
		103 min	9	2.045	1.7646	0.22	1.757	6.50	86.3
		104 min	10	1.884	1.3271	0.28	1.678	5.35	70.5
		105 min	10	1.937	1.4628	0.28	1.729	5.84	75.5
		106 min	10	1.578	0.5874	0.24	1.762	2.40	37.2
		107 min	10	1.763	0.9942	0.28	1.745	4.20	56.4
		108 min	10	1.645	0.5274	0.59	1.769	2.61	32.1
		109 min	10	1.506	0.4230	0.56	1.588	1.97	28.1
		110 min	10	1.528	0.3864	0.58	1.630	1.85	25.3
		111 min	10	1.699	0.9223	0.26	1.735	3.91	54.3
		112 min	10	1.880	1.2485	0.41	1.771	5.20	66.4
		113 min	11	1.941	1.3684	0.44	1.792	5.86	70.5
		114 min	11	1.962	1.5565	0.41	1.731	6.44	79.3
		115 min	11	1.944	1.4953	0.38	1.713	6.25	76.9
		116 min	11	1.927	1.4844	0.36	1.738	6.20	77.0
		117 min	11	1.979	1.4715	0.71	1.675	6.27	74.4
		118 min	12	1.923	1.5007	0.75	1.619	6.56	78.1
		119 min	12	1.959	1.5034	0.94	1.610	6.63	76.7
		120 min	12	1.964	1.5062	0.93	1.620	6.64	76.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 141 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	121 min	12	1.970	1.4958	0.94	1.591	6.61	75.9
		122 min	12	1.963	1.5303	0.88	1.617	6.71	78.0
		123 min	12	1.973	1.5066	0.90	1.603	6.65	76.4
		124 min	12	1.953	1.5014	0.76	1.620	6.59	76.9
		125 min	12	1.960	1.5140	0.77	1.603	6.64	77.3
		126 min	12	1.927	1.5011	0.66	1.585	6.56	77.9
		127 min	12	1.932	1.5063	0.69	1.595	6.58	78.0
		128 min	12	1.949	1.5556	0.60	1.618	6.75	79.8
		129 min	12	1.904	1.5587	0.63	1.556	6.72	81.9
		130 min	12	1.907	1.5891	0.43	1.540	6.79	83.3
		131 min	12	1.907	1.6528	0.24	1.569	6.96	86.7
		132 min	12	1.940	1.6601	0.38	1.631	7.04	85.6
		133 min	12	1.890	1.6033	0.46	1.591	6.83	84.8
		134 min	12	1.910	1.6093	0.36	1.623	6.85	84.3
		135 min	12	1.875	1.6652	0.28	1.555	6.98	88.8
		136 min	12	1.930	1.6701	0.36	1.578	7.06	86.6
		137 min	12	1.907	1.6454	0.42	1.566	6.97	86.3
		138 min	12	1.894	1.6526	0.29	1.560	6.96	87.3
		139 min	12	1.901	1.6160	0.67	1.529	6.91	85.0
		140 min	12	1.941	1.7074	0.55	1.576	7.23	88.0
		141 min	12	1.939	1.6155	0.69	1.648	6.95	83.3
		142 min	12	1.956	1.6536	0.56	1.651	7.07	84.6
		143 min	12	2.047	1.6932	0.55	1.691	7.17	82.7
		144 min	12	1.976	1.7053	0.52	1.666	7.25	86.3
		145 min	12	1.999	1.7648	0.31	1.683	7.41	88.3
		146 min	12	1.960	1.7631	0.29	1.649	7.37	90.0
		147 min	12	1.967	1.7766	0.35	1.663	7.43	90.3
		148 min	12	1.940	1.7897	0.17	1.656	7.41	92.3
		149 min	12	1.938	1.7969	0.05	1.676	7.41	92.7
		150 min	12	1.947	1.8063	0.10	1.682	7.46	92.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 142 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	151 min	12	1.982	1.8926	0.07	1.657	7.77	95.5
		152 min	12	1.967	1.8284	0.10	1.690	7.53	93.0
		153 min	12	1.954	1.8406	0.09	1.686	7.55	94.2
		154 min	12	2.010	1.8299	0.25	1.718	7.61	91.0
		155 min	12	2.005	1.8219	0.27	1.704	7.56	90.9
		156 min	12	2.054	1.8436	0.23	1.753	7.61	89.8
		157 min	12	2.061	1.8421	0.32	1.710	7.64	89.4
		158 min	12	1.978	1.7059	0.25	1.722	7.16	86.3
		159 min	12	1.969	1.7669	0.22	1.691	7.34	89.7
		160 min	12	2.047	1.7829	0.08	1.713	7.32	87.1
		161 min	12	2.149	1.9404	0.23	1.685	7.64	90.3
		162 min	12	2.028	1.7946	0.21	1.698	7.38	88.5
		163 min	12	1.996	1.8216	0.24	1.688	7.51	91.3
		164 min	11	2.031	1.8471	0.20	1.687	7.35	90.9
		165 min	11	2.023	1.8789	0.03	1.693	7.37	92.9
		166 min	11	2.023	1.8588	0.15	1.709	7.30	91.9
		167 min	11	2.052	1.8717	0.15	1.629	7.39	91.2
		168 min	11	2.092	1.9882	0.21	1.611	7.78	95.1
		169 min	11	2.124	1.9826	0.18	1.697	7.83	93.3
		170 min	11	2.083	1.9521	0.13	1.608	7.68	93.7
		171 min	11	2.088	1.8660	0.20	1.657	7.39	89.4
		172 min	10	2.128	1.9272	0.19	1.696	7.34	90.5
		173 min	10	2.038	1.8549	0.14	1.677	7.08	91.0
		174 min	10	2.083	1.8679	0.15	1.645	7.01	89.7
		175 min	10	2.073	1.7824	0.14	1.622	6.74	86.0
		176 min	10	2.100	1.8151	0.14	1.627	6.85	86.4
		177 min	10	2.090	1.8946	0.15	1.618	7.10	90.6
		178 min	10	1.989	1.7191	0.14	1.588	6.50	86.4
		179 min	10	2.091	1.8770	0.05	1.613	7.02	89.8
		180 min	10	2.088	1.8999	0.13	1.615	7.10	91.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 143 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	181 min	10	2.038	1.7740	0.14	1.599	6.67	87.1
		182 min	9	1.510	0.6751	0.29	1.524	2.80	44.7
		183 min	9	1.421	0.5741	0.30	1.503	2.35	40.4
		184 min	9	1.390	0.6203	0.03	1.516	2.22	44.6
		185 min	9	1.397	0.6379	0.10	1.472	2.32	45.7
		186 min	9	1.347	0.5915	0.10	1.438	2.15	43.9
		187 min	9	1.373	0.5681	0.17	1.435	2.10	41.4
		188 min	9	1.385	0.6063	0.13	1.463	2.14	43.8
		189 min	10	2.393	2.4155	0.05	1.573	7.14	101.0
		190 min	10	1.972	1.8066	0.06	1.595	6.79	91.6
		191 min	10	1.983	1.7055	0.14	1.600	6.54	86.0
		192 min	10	1.939	1.7448	0.06	1.520	6.60	90.0
		193 min	10	1.972	1.8147	0.11	1.608	6.83	92.0
		194 min	10	1.949	1.7592	0.09	1.571	6.65	90.3
		195 min	10	1.939	1.8322	0.05	1.579	6.84	94.5
		196 min	10	1.998	1.8632	0.17	1.562	7.03	93.3
		197 min	11	1.911	1.7557	0.27	1.452	6.94	91.9
		198 min	11	1.881	1.6761	0.06	1.412	6.62	89.1
		199 min	11	1.870	1.6650	0.05	1.435	6.56	89.0
		200 min	11	1.993	1.6554	0.03	1.704	6.52	83.1
		201 min	11	2.435	2.1469	0.12	1.677	6.68	88.2
		202 min	12	1.954	1.6208	0.08	1.628	6.78	82.9
		203 min	12	1.951	1.6767	0.09	1.543	6.95	85.9
		204 min	12	1.940	1.7274	0.02	1.508	7.07	89.0
		205 min	12	1.988	1.6447	0.50	1.581	6.95	82.7
		206 min	12	1.961	1.7083	0.14	1.540	7.08	87.1
		207 min	11	1.985	1.8331	-0.04	1.479	7.15	92.3
		208 min	11	2.014	1.7846	0.05	1.559	7.02	88.6
		209 min	11	2.060	1.7647	0.33	1.682	7.03	85.7
		210 min	11	2.041	1.7543	0.48	1.574	7.04	85.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 144 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	211 min	12	1.983	1.6636	0.49	1.556	7.00	83.9
		212 min	12	2.014	1.6886	0.41	1.628	7.11	83.8
		213 min	12	1.945	1.6708	0.27	1.529	6.95	85.9
		214 min	12	1.998	1.7089	0.13	1.614	7.07	85.5
		215 min	12	2.003	1.7006	0.04	1.681	7.05	84.9
		216 min	12	1.967	1.6640	0.03	1.635	6.92	84.6
		217 min	12	2.094	1.6910	0.13	1.689	6.98	80.7
		218 min	12	2.223	1.8024	0.13	1.715	6.85	81.1
		219 min	12	1.956	1.6506	-0.02	1.689	6.85	84.4
		220 min	12	1.923	1.6308	0.06	1.584	6.78	84.8
		221 min	11	1.957	1.7188	-0.01	1.595	6.81	87.8
		222 min	11	1.986	1.6958	0.08	1.652	6.78	85.4
		223 min	11	1.977	1.7996	0.05	1.528	7.10	91.0
		224 min	11	2.010	1.7736	0.05	1.638	7.03	88.3
		225 min	10	1.986	1.8535	0.12	1.524	6.98	93.3
		226 min	10	1.972	1.8252	0.11	1.487	6.89	92.5
		227 min	10	1.963	1.8130	0.17	1.502	6.84	92.4
		228 min	10	2.324	1.7131	1.27	1.641	6.94	73.7
		229 min	10	1.967	1.7977	0.34	1.477	6.83	91.4
		230 min	11	1.934	1.7629	0.37	1.438	7.03	91.2
		231 min	11	1.905	1.7786	0.25	1.446	7.01	93.4
		232 min	11	1.935	1.7688	0.36	1.477	7.05	91.4
		233 min	11	1.943	1.7750	0.39	1.453	7.08	91.4
		234 min	11	1.891	1.8138	0.03	1.419	7.04	95.9
		235 min	12	1.944	1.7261	0.44	1.517	7.20	88.8
		236 min	12	1.854	1.6274	0.33	1.476	6.78	87.8
		237 min	12	1.939	1.7282	0.43	1.511	7.19	89.1
		238 min	12	1.903	1.6408	0.38	1.474	6.82	86.2
		239 min	12	1.903	1.6126	0.43	1.431	6.75	84.7
		240 min	1	0.403		0.40	0.403	0.40	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 145 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	1 min	12	2.491	1.7992	1.24	1.751	6.75	72.2
		2 min	12	4.348	2.7593	1.19	4.837	8.55	63.5
		3 min	12	5.246	2.8302	1.28	6.790	8.32	53.9
		4 min	12	6.132	2.3667	1.36	7.154	8.49	38.6
		5 min	12	6.779	2.4471	0.98	7.606	8.51	36.1
		6 min	12	6.419	2.4202	1.17	7.666	8.38	37.7
		7 min	12	6.909	1.9765	2.11	7.740	8.73	28.6
		8 min	12	6.706	2.3888	1.28	7.476	9.26	35.6
		9 min	12	7.385	0.7608	5.94	7.559	8.36	10.3
		10 min	12	6.822	1.9852	2.80	7.718	8.99	29.1
		11 min	12	6.481	2.3333	1.86	7.628	8.52	36.0
		12 min	12	6.278	2.6982	1.25	7.691	8.39	43.0
		13 min	12	6.305	2.4671	1.68	7.328	8.42	39.1
		14 min	12	5.980	2.5725	1.56	6.776	8.43	43.0
		15 min	12	5.544	2.8811	1.40	6.968	8.50	52.0
		16 min	12	5.286	3.1133	1.49	7.003	8.92	58.9
		17 min	12	5.197	3.1224	1.14	6.679	8.68	60.1
		18 min	12	5.135	3.1850	1.07	6.253	8.66	62.0
		19 min	12	5.025	3.1393	1.05	6.367	8.51	62.5
		20 min	12	4.884	3.2380	0.87	5.557	8.44	66.3
		21 min	11	5.109	3.1857	0.96	7.043	8.32	62.4
		22 min	10	4.709	3.1825	0.94	5.105	8.25	67.6
		23 min	10	4.721	3.2813	0.73	5.081	8.34	69.5
		24 min	10	4.706	3.3008	1.00	5.071	8.18	70.1
		25 min	10	4.526	3.2496	0.91	4.286	8.27	71.8
		26 min	10	4.483	3.2588	0.97	3.727	8.23	72.7
		27 min	10	4.121	3.3330	1.00	1.852	8.21	80.9
		28 min	10	4.154	3.2588	0.98	2.127	8.25	78.4
		29 min	10	4.046	3.3072	1.04	1.687	8.22	81.7
		30 min	10	3.987	3.2624	1.15	1.642	8.06	81.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 146 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	31 min	10	3.893	3.1622	1.08	1.691	8.00	81.2
		32 min	10	3.934	3.0161	1.12	2.198	7.94	76.7
		33 min	10	3.878	3.1766	1.09	1.696	8.05	81.9
		34 min	10	3.718	3.0248	1.06	1.743	8.01	81.3
		35 min	10	3.661	2.9207	1.01	1.747	7.75	79.8
		36 min	11	3.553	3.0193	0.92	1.624	7.89	85.0
		37 min	11	3.405	2.9167	0.95	1.502	7.97	85.7
		38 min	12	3.537	2.7663	0.89	1.652	7.92	78.2
		39 min	12	3.452	2.6351	0.99	1.564	7.40	76.3
		40 min	12	3.489	2.7071	0.90	1.584	7.59	77.6
		41 min	12	3.014	2.5342	0.99	1.608	7.93	84.1
		42 min	12	3.156	2.4456	0.94	1.865	7.88	77.5
		43 min	12	2.926	2.2816	0.95	1.891	7.56	78.0
		44 min	12	2.816	2.2626	1.02	1.686	7.51	80.3
		45 min	11	3.018	2.4778	0.95	1.508	7.61	82.1
		46 min	12	3.005	2.5208	0.85	1.492	7.77	83.9
		47 min	12	2.874	2.6182	0.26	1.525	7.59	91.1
		48 min	12	2.713	2.4211	0.47	1.532	7.70	89.2
		49 min	12	2.866	2.5606	0.28	1.555	7.47	89.3
		50 min	11	2.534	2.2624	0.20	1.493	7.46	89.3
		51 min	11	2.517	2.3050	0.12	1.502	7.44	91.6
		52 min	11	2.542	2.3848	0.14	1.468	7.62	93.8
		53 min	12	2.664	2.3149	0.17	1.521	7.72	86.9
		54 min	12	2.805	2.4003	0.22	1.522	7.60	85.6
		55 min	12	2.776	2.4127	0.17	1.566	7.64	86.9
		56 min	12	2.776	2.3896	0.28	1.555	7.74	86.1
		57 min	12	2.872	2.4591	0.19	1.555	7.65	85.6
		58 min	12	2.814	2.4360	0.13	1.567	7.66	86.6
		59 min	12	2.675	2.2893	0.08	1.574	7.35	85.6
		60 min	12	2.621	2.2512	0.19	1.578	7.30	85.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 147 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	61 min	12	2.693	2.2649	0.42	1.658	7.27	84.1
		62 min	12	2.662	2.2375	0.19	1.684	7.25	84.1
		63 min	11	2.848	2.3678	0.25	1.601	7.22	83.1
		64 min	11	3.108	2.5886	0.25	1.664	7.35	83.3
		65 min	11	3.137	2.6638	0.28	1.638	7.40	84.9
		66 min	11	3.034	2.6895	0.18	1.617	7.19	88.6
		67 min	11	2.639	2.3484	0.05	1.612	7.05	89.0
		68 min	11	2.672	2.3792	0.06	1.624	7.20	89.0
		69 min	11	2.684	2.3513	0.06	1.592	7.26	87.6
		70 min	10	2.807	2.2550	1.30	1.651	7.06	80.3
		71 min	10	2.919	2.1858	1.13	1.748	7.03	74.9
		72 min	9	2.824	2.3411	0.99	1.825	7.15	82.9
		73 min	9	2.816	2.5084	0.84	1.654	7.30	89.1
		74 min	9	3.056	2.1817	1.09	2.324	7.16	71.4
		75 min	9	2.697	2.2770	0.95	1.570	7.02	84.4
		76 min	9	2.637	2.3065	0.75	1.592	7.14	87.5
		77 min	9	2.723	2.2077	1.06	1.615	7.10	81.1
		78 min	9	2.556	2.1348	0.94	1.579	7.04	83.5
		79 min	9	2.505	2.1038	0.78	1.576	6.58	84.0
		80 min	9	2.481	2.0902	0.87	1.562	6.81	84.2
		81 min	9	2.514	2.1429	0.82	1.627	7.00	85.2
		82 min	9	2.410	2.1774	0.78	1.590	6.90	90.4
		83 min	9	2.743	2.1213	0.91	1.702	7.08	77.3
		84 min	9	2.810	2.1623	0.87	1.661	7.01	76.9
		85 min	9	2.829	2.1199	1.00	1.684	6.82	74.9
		86 min	9	3.264	2.5009	0.91	1.723	6.95	76.6
		87 min	9	3.040	2.2265	0.88	2.441	6.73	73.3
		88 min	9	2.710	2.0755	0.97	1.680	7.03	76.6
		89 min	10	2.499	2.2217	-0.53	1.623	6.86	88.9
		90 min	10	2.946	2.3829	-0.45	2.167	6.97	80.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 148 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	91 min	10	2.926	2.5391	-0.33	2.161	7.69	86.8
		92 min	10	2.775	2.5481	-0.20	1.781	7.65	91.8
		93 min	10	2.610	2.0753	-0.04	2.053	6.81	79.5
		94 min	10	2.261	1.7354	0.12	1.809	6.67	76.7
		95 min	9	2.299	1.8825	0.03	1.718	6.82	81.9
		96 min	9	2.572	2.1011	-0.06	1.702	6.86	81.7
		97 min	9	2.753	2.3208	0.00	1.687	6.89	84.3
		98 min	9	2.530	2.0625	0.06	1.634	6.53	81.5
		99 min	10	2.125	1.6677	0.07	1.739	6.43	78.5
		100 min	9	2.148	1.9139	0.09	1.707	6.93	89.1
		101 min	9	2.080	1.7794	0.12	1.706	6.55	85.5
		102 min	9	2.073	1.7764	0.07	1.686	6.52	85.7
		103 min	9	2.052	1.7943	0.02	1.707	6.53	87.4
		104 min	10	1.980	1.6712	0.05	1.660	6.43	84.4
		105 min	10	1.952	1.6003	0.06	1.629	6.22	82.0
		106 min	10	1.905	1.3858	0.23	1.687	5.55	72.8
		107 min	10	1.935	1.4276	0.57	1.712	5.80	73.8
		108 min	10	1.939	1.3110	0.55	1.668	5.49	67.6
		109 min	10	1.962	1.5207	0.39	1.615	6.09	77.5
		110 min	10	1.961	1.4875	0.32	1.647	5.98	75.8
		111 min	10	1.887	1.4843	0.46	1.607	5.94	78.6
		112 min	10	1.992	1.4838	0.56	1.631	6.05	74.5
		113 min	11	2.033	1.5736	0.50	1.627	6.61	77.4
		114 min	11	2.025	1.5311	0.56	1.667	6.48	75.6
		115 min	11	1.997	1.5422	0.48	1.640	6.48	77.2
		116 min	11	1.978	1.5903	0.37	1.655	6.58	80.4
		117 min	11	1.976	1.5924	0.45	1.621	6.60	80.6
		118 min	12	1.911	1.5516	0.40	1.627	6.65	81.2
		119 min	12	1.999	1.5151	0.81	1.688	6.69	75.8
		120 min	12	1.995	1.5189	0.72	1.627	6.68	76.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 149 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	121 min	12	2.005	1.4623	0.79	1.661	6.53	72.9
		122 min	12	2.045	1.5122	0.75	1.743	6.71	73.9
		123 min	12	2.008	1.4942	0.73	1.686	6.61	74.4
		124 min	12	1.974	1.5188	0.65	1.639	6.64	76.9
		125 min	12	1.962	1.5495	0.61	1.665	6.72	79.0
		126 min	12	1.955	1.5316	0.75	1.585	6.67	78.4
		127 min	12	1.948	1.5581	0.62	1.573	6.73	80.0
		128 min	12	1.992	1.6260	0.51	1.647	6.96	81.6
		129 min	12	1.972	1.5862	0.70	1.603	6.87	80.5
		130 min	12	1.931	1.5889	0.68	1.567	6.86	82.3
		131 min	12	1.926	1.6193	0.67	1.572	6.96	84.1
		132 min	12	1.967	1.6373	0.68	1.613	7.08	83.2
		133 min	12	1.951	1.6455	0.56	1.621	7.04	84.4
		134 min	12	1.969	1.6272	0.55	1.616	6.98	82.6
		135 min	12	1.949	1.6799	0.55	1.562	7.14	86.2
		136 min	12	1.979	1.7146	0.67	1.539	7.30	86.6
		137 min	12	1.957	1.7136	0.49	1.516	7.22	87.6
		138 min	12	1.964	1.6566	0.48	1.537	7.04	84.4
		139 min	12	1.949	1.6522	0.47	1.570	7.01	84.8
		140 min	12	2.015	1.7145	0.36	1.620	7.24	85.1
		141 min	12	1.997	1.7426	0.46	1.636	7.33	87.3
		142 min	12	2.164	1.7220	0.59	1.578	7.17	79.6
		143 min	12	2.050	1.6917	0.55	1.594	7.22	82.5
		144 min	12	2.346	1.9119	0.53	1.644	7.23	81.5
		145 min	12	2.002	1.6976	0.46	1.571	7.22	84.8
		146 min	12	1.970	1.7076	0.45	1.504	7.19	86.7
		147 min	12	2.009	1.7407	0.39	1.609	7.32	86.6
		148 min	12	1.994	1.7611	0.33	1.597	7.38	88.3
		149 min	12	1.983	1.7775	0.27	1.548	7.39	89.7
		150 min	12	1.971	1.7934	0.36	1.540	7.47	91.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 150 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	151 min	12	1.959	1.6741	0.28	1.605	7.04	85.5
		152 min	12	1.997	1.8138	0.22	1.555	7.49	90.8
		153 min	12	2.004	1.8371	0.19	1.573	7.48	91.7
		154 min	12	2.056	1.7859	0.34	1.666	7.47	86.9
		155 min	12	2.215	1.8286	0.40	1.704	7.33	82.6
		156 min	12	2.324	2.0213	0.35	1.741	7.48	87.0
		157 min	12	2.325	2.0255	0.41	1.675	7.36	87.1
		158 min	12	2.087	1.7274	0.26	1.662	7.07	82.8
		159 min	12	2.420	2.2487	0.35	1.708	7.21	92.9
		160 min	12	2.432	2.1567	0.26	1.742	7.62	88.7
		161 min	12	1.979	1.8697	0.29	1.658	7.64	94.5
		162 min	12	2.008	1.8545	0.31	1.684	7.63	92.3
		163 min	12	2.025	1.8417	0.26	1.659	7.60	90.9
		164 min	11	2.064	1.9026	0.26	1.632	7.60	92.2
		165 min	11	2.093	1.9074	0.17	1.644	7.58	91.1
		166 min	11	2.097	1.9227	0.27	1.627	7.62	91.7
		167 min	11	2.325	1.9818	0.45	1.740	7.73	85.2
		168 min	11	2.538	1.8983	1.22	1.879	7.68	74.8
		169 min	11	2.341	1.8880	0.64	1.702	7.66	80.6
		170 min	11	2.161	1.8932	0.61	1.586	7.64	87.6
		171 min	11	2.216	1.8634	0.62	1.693	7.63	84.1
		172 min	10	2.234	1.8819	0.32	1.696	7.31	84.2
		173 min	10	2.144	1.8360	0.17	1.669	7.04	85.6
		174 min	10	2.170	1.9034	0.24	1.663	7.11	87.7
		175 min	10	2.127	1.9610	0.19	1.642	7.44	92.2
		176 min	10	2.133	1.9807	0.15	1.558	7.46	92.8
		177 min	10	2.102	1.9639	0.25	1.576	7.46	93.4
		178 min	10	2.009	1.8581	0.15	1.541	7.07	92.5
		179 min	10	2.011	1.7306	0.14	1.534	6.64	86.1
		180 min	10	1.948	1.7364	0.06	1.545	6.59	89.1

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 151 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	181 min	10	2.016	1.8396	0.14	1.563	6.99	91.3
		182 min	9	1.447	0.5797	0.16	1.485	2.12	40.1
		183 min	9	1.361	0.5866	0.13	1.467	2.19	43.1
		184 min	9	1.438	0.6192	0.16	1.466	2.36	43.0
		185 min	9	1.395	0.5870	0.18	1.432	2.16	42.1
		186 min	9	1.420	0.5943	0.13	1.468	2.36	41.8
		187 min	9	1.402	0.6041	0.11	1.457	2.31	43.1
		188 min	9	1.448	0.6090	0.18	1.388	2.18	42.1
		189 min	10	2.041	1.8499	0.14	1.538	6.89	90.6
		190 min	10	2.027	1.7902	0.26	1.506	6.82	88.3
		191 min	10	2.001	1.7452	0.15	1.566	6.66	87.2
		192 min	10	2.042	1.8142	0.19	1.557	6.89	88.8
		193 min	10	2.018	1.7982	0.45	1.505	6.84	89.1
		194 min	10	2.036	1.7840	0.29	1.540	6.80	87.6
		195 min	10	2.015	1.7902	0.17	1.511	6.71	88.9
		196 min	10	2.082	1.7706	0.19	1.575	6.57	85.1
		197 min	11	1.954	1.6336	0.41	1.432	6.57	83.6
		198 min	11	1.938	1.7057	0.18	1.465	6.78	88.0
		199 min	11	1.963	1.6961	0.20	1.384	6.71	86.4
		200 min	11	2.194	1.7853	0.30	1.679	6.80	81.4
		201 min	11	2.286	1.9034	0.25	1.621	6.97	83.3
		202 min	12	2.176	1.7562	0.17	1.636	7.07	80.7
		203 min	12	2.136	1.6740	0.17	1.675	6.84	78.4
		204 min	12	2.199	1.7374	0.17	1.643	6.72	79.0
		205 min	12	2.180	1.7312	0.06	1.666	6.54	79.4
		206 min	12	2.398	2.1815	0.09	1.653	7.17	91.0
		207 min	11	2.476	2.2671	0.02	1.612	7.00	91.6
		208 min	11	2.502	2.2598	-0.02	1.626	6.99	90.3
		209 min	11	2.477	2.1690	0.01	1.608	6.65	87.6
		210 min	11	2.397	2.0563	0.01	1.607	6.76	85.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 152 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	211 min	12	2.260	1.9630	-0.04	1.596	6.80	86.9
		212 min	12	2.323	2.0719	-0.12	1.637	6.85	89.2
		213 min	12	2.075	1.7234	-0.21	1.628	6.76	83.1
		214 min	12	2.378	2.1596	-0.28	1.640	6.82	90.8
		215 min	12	2.342	2.0543	-0.31	1.705	6.62	87.7
		216 min	12	2.101	1.7271	-0.27	1.625	6.61	82.2
		217 min	12	2.037	1.7143	-0.14	1.619	7.01	84.2
		218 min	12	2.277	1.7221	0.14	1.668	6.99	75.6
		219 min	12	2.022	1.6407	0.14	1.640	6.89	81.1
		220 min	12	1.950	1.7034	0.05	1.509	7.03	87.4
		221 min	11	1.993	1.7980	0.03	1.542	7.07	90.2
		222 min	11	2.012	1.8175	0.02	1.534	7.14	90.3
		223 min	11	1.973	1.8179	0.03	1.497	7.09	92.2
		224 min	11	2.018	1.7861	0.09	1.582	7.04	88.5
		225 min	10	2.000	1.8572	0.13	1.503	6.95	92.9
		226 min	10	2.071	1.8075	0.47	1.612	6.99	87.3
		227 min	10	2.042	1.7915	0.71	1.496	6.94	87.7
		228 min	10	2.180	1.7179	1.33	1.580	6.95	78.8
		229 min	10	2.825	2.5993	1.01	1.583	8.31	92.0
		230 min	11	2.742	2.3991	1.29	1.591	8.09	87.5
		231 min	11	2.183	1.6344	1.18	1.534	6.80	74.9
		232 min	11	2.024	1.5939	0.95	1.605	6.67	78.7
		233 min	11	1.963	1.6624	0.66	1.384	6.76	84.7
		234 min	11	1.974	1.6762	0.51	1.421	6.76	84.9
		235 min	12	1.955	1.6003	0.50	1.526	6.83	81.9
		236 min	12	2.002	1.6493	0.45	1.467	6.83	82.4
		237 min	12	2.333	2.2236	0.42	1.449	7.17	95.3
		238 min	12	2.307	2.2045	0.36	1.462	7.10	95.6
		239 min	12	2.387	2.3154	0.45	1.453	7.74	97.0
		240 min	1	0.412		0.41	0.412	0.41	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 153 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	1 min	12	2.270	1.6968	1.23	1.638	6.66	74.8
		2 min	12	3.714	2.5739	1.26	2.584	7.92	69.3
		3 min	12	4.590	2.8563	1.37	3.856	8.50	62.2
		4 min	12	5.964	2.6710	1.27	7.303	8.33	44.8
		5 min	12	6.824	2.4434	1.48	7.613	8.68	35.8
		6 min	12	6.945	2.4851	1.36	7.884	9.01	35.8
		7 min	12	6.880	2.4693	1.30	7.768	8.55	35.9
		8 min	12	6.660	2.5019	0.92	7.555	8.70	37.6
		9 min	12	6.584	2.0942	2.17	7.349	8.53	31.8
		10 min	12	6.273	2.2626	2.33	7.404	8.39	36.1
		11 min	12	6.143	2.4846	1.17	7.262	8.48	40.4
		12 min	12	6.050	2.6381	1.06	7.369	8.56	43.6
		13 min	12	6.205	2.5290	1.51	7.001	8.98	40.8
		14 min	12	6.137	2.7249	1.29	7.127	8.94	44.4
		15 min	12	5.577	2.9651	1.46	7.408	8.54	53.2
		16 min	12	5.341	3.1302	1.48	7.133	8.68	58.6
		17 min	12	5.193	3.0068	1.17	6.621	8.47	57.9
		18 min	12	5.184	3.1483	1.06	6.524	8.44	60.7
		19 min	12	5.162	3.2299	0.98	6.567	8.50	62.6
		20 min	12	5.079	3.2579	0.89	6.193	8.51	64.1
		21 min	11	5.268	3.2016	0.98	7.509	8.29	60.8
		22 min	10	4.816	3.3583	0.89	5.220	8.31	69.7
		23 min	10	4.796	3.3883	0.76	5.024	8.34	70.6
		24 min	10	4.709	3.3929	0.98	4.756	8.39	72.1
		25 min	10	4.660	3.4372	0.90	4.590	8.35	73.8
		26 min	10	4.618	3.3513	0.93	4.153	8.35	72.6
		27 min	10	4.561	3.3256	0.99	3.819	8.36	72.9
		28 min	10	4.281	3.3262	0.93	2.464	8.30	77.7
		29 min	10	4.149	3.3156	1.07	2.085	8.18	79.9
		30 min	10	4.164	3.3190	1.09	2.045	8.24	79.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 154 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	31 min	10	3.982	3.2325	0.92	1.806	8.01	81.2
		32 min	10	3.987	3.1875	1.08	1.750	8.02	79.9
		33 min	10	3.923	3.2227	1.10	1.688	7.89	82.1
		34 min	10	3.705	2.9900	1.02	1.684	7.73	80.7
		35 min	10	3.693	2.9467	1.04	1.751	7.74	79.8
		36 min	11	3.577	3.0258	1.00	1.621	7.73	84.6
		37 min	11	3.413	2.8420	1.04	1.522	7.65	83.3
		38 min	12	3.709	2.9210	0.93	1.681	7.74	78.7
		39 min	12	3.423	2.4940	1.10	1.730	7.52	72.9
		40 min	12	3.419	2.6185	0.92	1.806	7.54	76.6
		41 min	12	3.325	2.6866	1.05	1.811	7.73	80.8
		42 min	12	3.219	2.5340	1.03	2.063	7.85	78.7
		43 min	12	3.067	2.3401	0.97	2.050	7.48	76.3
		44 min	12	2.998	2.3956	0.96	1.899	7.50	79.9
		45 min	11	2.844	2.3292	1.14	1.587	7.52	81.9
		46 min	12	2.917	2.3749	0.73	1.881	7.50	81.4
		47 min	12	2.491	2.3458	0.49	1.552	7.39	94.2
		48 min	12	2.833	2.4314	0.48	1.631	7.40	85.8
		49 min	12	2.917	2.4994	0.67	1.621	7.37	85.7
		50 min	11	2.505	2.2620	0.36	1.596	7.41	90.3
		51 min	11	2.549	2.2724	0.43	1.612	7.50	89.2
		52 min	11	2.462	2.2658	0.24	1.535	7.61	92.0
		53 min	12	2.571	2.2579	0.29	1.603	7.74	87.8
		54 min	12	2.729	2.2933	0.29	1.609	7.47	84.0
		55 min	12	2.627	2.1608	0.20	1.634	7.53	82.3
		56 min	12	2.515	2.1448	0.17	1.633	7.57	85.3
		57 min	12	2.641	2.1263	0.18	1.634	7.47	80.5
		58 min	12	2.548	2.0884	0.11	1.659	7.50	82.0
		59 min	12	2.507	2.0174	0.08	1.656	7.44	80.5
		60 min	12	2.580	2.0626	0.15	1.722	7.44	80.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 155 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	61 min	12	2.636	2.0473	0.29	1.716	7.41	77.7
		62 min	12	2.910	2.3131	0.11	1.721	7.42	79.5
		63 min	11	3.005	2.5378	0.15	1.677	7.63	84.5
		64 min	11	3.038	2.6357	0.05	1.777	8.26	86.8
		65 min	11	2.938	2.4521	0.19	1.724	7.31	83.5
		66 min	11	2.814	2.4343	0.09	1.716	7.22	86.5
		67 min	11	2.887	2.3188	0.07	1.710	7.17	80.3
		68 min	11	2.501	1.9915	0.03	1.713	7.02	79.6
		69 min	11	2.629	2.0372	0.03	1.711	7.11	77.5
		70 min	10	2.889	1.9992	1.18	1.778	6.94	69.2
		71 min	10	2.744	1.9226	0.86	2.003	6.98	70.1
		72 min	9	2.720	2.0406	0.93	1.840	7.06	75.0
		73 min	9	2.671	2.0995	0.91	1.787	7.09	78.6
		74 min	9	2.836	2.2086	1.04	1.690	7.08	77.9
		75 min	9	2.710	2.2229	0.86	1.662	7.07	82.0
		76 min	9	2.590	2.1425	0.79	1.684	7.04	82.7
		77 min	9	2.625	2.0523	0.99	1.695	7.10	78.2
		78 min	9	2.331	1.8734	0.94	1.686	7.00	80.4
		79 min	9	2.284	1.8669	0.83	1.667	6.77	81.7
		80 min	9	2.310	1.9321	0.79	1.680	6.93	83.6
		81 min	9	2.310	1.8836	0.74	1.666	6.88	81.6
		82 min	9	2.220	1.8689	0.86	1.673	6.80	84.2
		83 min	9	2.346	1.8619	0.99	1.673	6.87	79.4
		84 min	9	2.622	1.9291	0.91	1.730	6.99	73.6
		85 min	9	2.724	2.1019	0.97	1.666	7.05	77.2
		86 min	9	2.920	2.3541	0.90	1.664	7.01	80.6
		87 min	9	3.177	2.1665	0.85	2.458	6.86	68.2
		88 min	9	2.201	1.8578	1.00	1.490	6.87	84.4
		89 min	10	2.138	1.8246	0.07	1.511	6.86	85.3
		90 min	10	2.594	2.1421	0.02	1.697	6.95	82.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 156 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	91 min	10	2.607	2.3288	0.00	1.647	6.77	89.3
		92 min	10	2.225	1.8611	0.04	1.566	6.81	83.7
		93 min	10	2.487	2.0630	0.09	1.561	6.76	82.9
		94 min	10	2.120	1.7641	0.00	1.591	6.72	83.2
		95 min	9	2.102	1.8928	0.01	1.649	6.75	90.1
		96 min	9	2.071	1.9246	0.18	1.444	6.81	92.9
		97 min	9	2.121	1.9710	-0.02	1.580	7.00	92.9
		98 min	9	2.025	1.7115	0.35	1.469	6.21	84.5
		99 min	10	2.300	1.4485	1.34	1.769	6.12	63.0
		100 min	9	1.970	1.7024	0.12	1.654	6.18	86.4
		101 min	9	1.996	1.7660	0.11	1.647	6.41	88.5
		102 min	9	2.037	1.7899	0.10	1.587	6.51	87.9
		103 min	9	1.999	1.7502	0.03	1.634	6.34	87.6
		104 min	10	1.939	1.6747	0.07	1.497	6.40	86.4
		105 min	10	1.716	0.9817	0.07	1.599	4.01	57.2
		106 min	10	1.963	1.4923	0.41	1.568	5.98	76.0
		107 min	10	2.067	1.3920	0.56	1.716	5.73	67.4
		108 min	10	2.038	1.4563	1.02	1.551	6.08	71.5
		109 min	10	2.043	1.5700	0.62	1.614	6.35	76.9
		110 min	10	2.019	1.6360	0.47	1.661	6.52	81.0
		111 min	10	2.017	1.6696	0.44	1.632	6.57	82.8
		112 min	10	2.001	1.6865	0.55	1.578	6.64	84.3
		113 min	11	2.039	1.6020	0.59	1.599	6.71	78.6
		114 min	11	2.036	1.5570	0.62	1.650	6.55	76.5
		115 min	11	2.021	1.5373	0.54	1.603	6.49	76.0
		116 min	11	2.002	1.5616	0.48	1.669	6.53	78.0
		117 min	11	1.994	1.5817	0.47	1.637	6.60	79.3
		118 min	12	1.889	1.5205	0.55	1.584	6.56	80.5
		119 min	12	1.977	1.4786	0.74	1.627	6.55	74.8
		120 min	12	2.033	1.4978	0.68	1.779	6.65	73.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 157 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	121 min	12	2.098	1.4648	0.66	1.718	6.51	69.8
		122 min	12	2.095	1.4802	0.58	1.721	6.54	70.7
		123 min	12	2.119	1.5079	0.69	1.782	6.69	71.2
		124 min	12	1.977	1.5540	0.55	1.655	6.73	78.6
		125 min	12	1.934	1.5427	0.50	1.651	6.68	79.8
		126 min	12	1.959	1.5403	0.73	1.577	6.70	78.6
		127 min	12	1.986	1.5353	0.70	1.617	6.69	77.3
		128 min	12	1.992	1.6011	0.61	1.691	6.91	80.4
		129 min	12	1.969	1.5850	0.53	1.612	6.81	80.5
		130 min	12	1.953	1.6501	0.35	1.575	6.97	84.5
		131 min	12	2.213	1.8595	0.07	1.666	7.02	84.0
		132 min	12	2.282	1.9519	0.35	1.623	7.11	85.5
		133 min	12	1.986	1.6525	0.59	1.596	7.09	83.2
		134 min	12	1.988	1.6529	0.51	1.569	7.06	83.1
		135 min	12	1.966	1.6858	0.54	1.546	7.16	85.7
		136 min	12	1.998	1.7546	0.61	1.497	7.42	87.8
		137 min	12	1.995	1.6526	0.96	1.520	7.12	82.8
		138 min	12	2.061	1.6277	0.67	1.600	7.06	79.0
		139 min	12	1.922	1.6863	0.48	1.531	7.11	87.8
		140 min	12	2.377	2.0781	0.48	1.570	7.36	87.4
		141 min	12	2.096	1.6753	0.66	1.637	7.20	79.9
		142 min	12	2.023	1.6591	0.67	1.562	7.16	82.0
		143 min	12	2.026	1.6939	0.60	1.534	7.24	83.6
		144 min	12	2.283	1.8181	0.56	1.704	7.24	79.6
		145 min	12	2.030	1.7102	0.45	1.619	7.28	84.3
		146 min	12	2.349	2.0361	0.53	1.563	7.25	86.7
		147 min	12	2.081	1.7347	0.49	1.674	7.35	83.4
		148 min	12	2.334	2.0151	0.41	1.534	7.37	86.3
		149 min	12	2.016	1.7605	0.37	1.517	7.36	87.3
		150 min	12	2.056	1.8027	0.46	1.524	7.44	87.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 158 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	151 min	12	1.996	1.7893	0.38	1.529	7.46	89.6
		152 min	12	1.998	1.8449	0.34	1.474	7.57	92.4
		153 min	12	1.995	1.8514	0.34	1.521	7.57	92.8
		154 min	12	2.447	2.2142	0.30	1.632	7.46	90.5
		155 min	12	2.473	2.3086	0.34	1.621	7.47	93.4
		156 min	12	2.483	2.2265	0.40	1.567	7.45	89.7
		157 min	12	2.585	2.2143	0.40	1.607	7.31	85.7
		158 min	12	2.642	2.3437	0.45	1.564	7.22	88.7
		159 min	12	2.711	2.4099	0.48	1.607	7.43	88.9
		160 min	12	2.757	2.4698	0.27	1.725	7.74	89.6
		161 min	12	2.267	2.1760	0.35	1.646	7.67	96.0
		162 min	12	2.323	2.1419	0.66	1.686	7.61	92.2
		163 min	12	2.532	2.0586	0.74	1.693	7.57	81.3
		164 min	11	2.421	1.9117	0.48	1.692	7.37	79.0
		165 min	11	2.260	1.8712	0.28	1.816	7.47	82.8
		166 min	11	2.423	1.7151	1.26	1.824	7.23	70.8
		167 min	11	2.812	2.3014	0.98	1.848	7.82	81.8
		168 min	11	3.001	2.2844	1.18	1.871	7.46	76.1
		169 min	11	3.185	2.4012	1.25	1.841	7.72	75.4
		170 min	11	2.600	2.1337	0.53	1.785	7.79	82.1
		171 min	11	2.547	1.8377	1.30	1.770	7.18	72.1
		172 min	10	2.367	1.8325	0.53	1.922	7.25	77.4
		173 min	10	2.365	1.9016	0.31	1.881	7.31	80.4
		174 min	10	2.162	1.9012	0.28	1.683	7.16	87.9
		175 min	10	2.143	1.9462	0.30	1.738	7.45	90.8
		176 min	10	2.127	1.8662	0.22	1.637	7.15	87.7
		177 min	10	2.014	1.8572	0.30	1.552	7.10	92.2
		178 min	10	2.076	1.9294	0.21	1.595	7.35	93.0
		179 min	10	2.075	1.9058	0.24	1.585	7.28	91.9
		180 min	10	1.982	1.8702	0.08	1.641	7.03	94.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 159 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	181 min	10	1.997	1.8831	0.20	1.600	7.17	94.3
		182 min	9	1.454	0.5660	0.20	1.578	2.05	38.9
		183 min	9	1.338	0.5688	0.11	1.405	2.04	42.5
		184 min	9	1.410	0.5658	0.13	1.531	2.04	40.1
		185 min	9	1.377	0.5707	0.19	1.511	2.04	41.4
		186 min	9	1.520	0.5942	0.19	1.586	2.16	39.1
		187 min	9	1.402	0.5676	0.15	1.579	2.09	40.5
		188 min	9	1.867	1.3789	0.17	1.586	5.23	73.9
		189 min	10	1.956	1.8037	0.12	1.594	6.79	92.2
		190 min	10	2.011	1.7874	0.24	1.564	6.86	88.9
		191 min	10	2.038	1.7513	0.08	1.687	6.74	85.9
		192 min	10	2.163	1.7852	0.17	1.759	6.78	82.5
		193 min	10	2.072	1.7462	0.98	1.551	6.84	84.3
		194 min	10	2.367	1.9195	0.32	1.782	6.79	81.1
		195 min	10	2.555	2.3377	0.18	1.744	6.82	91.5
		196 min	10	2.406	2.0141	0.15	1.739	6.81	83.7
		197 min	11	2.067	1.6743	0.42	1.698	6.67	81.0
		198 min	11	1.949	1.7514	0.23	1.523	6.92	89.9
		199 min	11	2.219	1.7212	0.31	1.643	6.80	77.6
		200 min	11	2.120	1.6938	0.51	1.595	6.82	79.9
		201 min	11	2.478	2.1434	0.47	1.566	6.82	86.5
		202 min	12	2.924	2.4172	0.29	1.751	6.87	82.7
		203 min	12	2.892	2.3216	0.32	1.798	6.99	80.3
		204 min	12	2.514	2.2274	0.18	1.623	7.17	88.6
		205 min	12	2.547	2.2449	0.03	1.662	7.21	88.1
		206 min	12	2.460	2.1816	0.14	1.657	7.16	88.7
		207 min	11	2.468	2.2546	0.08	1.608	7.16	91.3
		208 min	11	2.461	2.1865	0.10	1.631	6.84	88.8
		209 min	11	2.378	2.0228	0.12	1.623	6.64	85.1
		210 min	11	2.336	2.1140	-0.26	1.639	6.74	90.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 160 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	211 min	12	2.318	2.0716	-0.09	1.583	6.69	89.4
		212 min	12	2.358	2.0695	0.05	1.624	6.88	87.8
		213 min	12	2.405	2.0405	0.42	1.619	6.74	84.8
		214 min	12	2.465	2.0737	0.97	1.614	6.82	84.1
		215 min	12	2.378	1.9762	0.55	1.648	6.58	83.1
		216 min	12	2.348	2.1624	-0.54	1.631	6.86	92.1
		217 min	12	2.641	2.2201	0.02	1.695	7.25	84.1
		218 min	12	2.652	2.2422	0.07	1.697	7.38	84.5
		219 min	12	2.420	1.9734	0.30	1.701	6.80	81.5
		220 min	12	2.174	1.7870	0.03	1.563	6.72	82.2
		221 min	11	2.387	1.9931	0.11	1.628	6.82	83.5
		222 min	11	2.472	2.1787	0.20	1.608	7.00	88.1
		223 min	11	2.209	1.7952	0.19	1.560	6.87	81.3
		224 min	11	2.097	1.6701	1.15	1.568	6.90	79.7
		225 min	10	2.794	2.5991	1.05	1.605	8.50	93.0
		226 min	10	3.278	2.6800	1.30	1.718	8.57	81.7
		227 min	10	2.899	2.6485	1.31	1.637	8.77	91.4
		228 min	10	3.139	2.6580	1.28	1.659	8.91	84.7
		229 min	10	2.724	2.5211	0.99	1.536	7.93	92.6
		230 min	11	2.661	1.8788	1.27	1.713	6.91	70.6
		231 min	11	2.206	1.7016	1.10	1.561	6.90	77.1
		232 min	11	2.487	2.1964	0.66	1.561	6.95	88.3
		233 min	11	2.696	2.2289	0.51	1.662	6.95	82.7
		234 min	11	2.118	1.7886	0.42	1.423	6.89	84.4
		235 min	12	2.508	2.1113	0.34	1.568	6.87	84.2
		236 min	12	2.353	2.2073	0.34	1.467	7.10	93.8
		237 min	12	2.343	2.3103	0.29	1.464	7.49	98.6
		238 min	12	2.346	2.3222	0.36	1.476	7.68	99.0
		239 min	12	2.403	2.3533	0.38	1.465	7.93	97.9
		240 min	1	0.365		0.36	0.365	0.36	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 161 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	1 min	12	2.008	1.4448	1.27	1.636	6.53	71.9
		2 min	12	3.596	2.5465	1.27	2.336	7.51	70.8
		3 min	12	4.910	3.0256	1.30	5.478	8.41	61.6
		4 min	12	6.057	2.7735	1.36	7.038	9.08	45.8
		5 min	12	6.847	2.5259	1.13	7.803	9.06	36.9
		6 min	12	6.929	2.5452	1.19	7.681	9.21	36.7
		7 min	12	6.963	2.6082	0.99	7.876	9.25	37.5
		8 min	12	6.763	2.6600	0.73	7.771	9.17	39.3
		9 min	12	6.819	2.2799	1.49	7.646	8.85	33.4
		10 min	12	6.285	2.5441	1.45	7.789	8.42	40.5
		11 min	12	6.499	2.4963	1.14	7.558	8.63	38.4
		12 min	12	6.406	2.5453	1.29	7.352	9.05	39.7
		13 min	12	6.432	2.5865	1.10	7.254	9.52	40.2
		14 min	12	6.236	2.8623	0.89	7.400	9.27	45.9
		15 min	12	5.905	2.8030	1.39	7.272	8.89	47.5
		16 min	12	5.371	3.0935	1.52	6.905	8.74	57.6
		17 min	12	5.354	3.2488	1.07	6.810	9.39	60.7
		18 min	12	5.435	3.2144	1.05	6.828	9.26	59.1
		19 min	12	5.263	3.3088	1.05	6.740	9.34	62.9
		20 min	12	5.216	3.3280	0.92	6.590	9.40	63.8
		21 min	11	5.415	3.2610	1.02	7.584	8.98	60.2
		22 min	10	4.941	3.2386	1.00	6.015	8.33	65.5
		23 min	10	4.891	3.2695	1.03	5.621	8.39	66.8
		24 min	10	4.724	3.3337	1.07	4.915	8.30	70.6
		25 min	10	4.536	3.3936	0.88	4.090	8.33	74.8
		26 min	10	4.582	3.3604	0.91	4.043	8.38	73.3
		27 min	10	4.309	3.3020	0.96	2.760	8.22	76.6
		28 min	10	4.216	3.2871	1.04	2.350	8.26	78.0
		29 min	10	4.385	3.2803	1.10	3.235	8.29	74.8
		30 min	10	4.384	3.2813	1.06	3.149	8.26	74.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 162 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	31 min	10	4.087	3.3219	0.99	1.857	8.17	81.3
		32 min	10	4.024	3.2725	1.09	1.878	8.17	81.3
		33 min	10	3.894	3.2152	1.21	1.593	8.04	82.6
		34 min	10	3.722	2.9662	1.14	1.759	7.70	79.7
		35 min	10	3.410	2.6743	1.06	1.749	7.68	78.4
		36 min	11	3.601	3.0422	1.06	1.697	7.73	84.5
		37 min	11	3.465	2.9561	1.00	1.525	7.60	85.3
		38 min	12	3.783	3.0352	0.89	1.638	7.66	80.2
		39 min	12	3.765	2.7861	1.29	1.781	7.60	74.0
		40 min	12	3.543	2.6903	1.00	1.750	7.65	75.9
		41 min	12	3.613	2.6962	1.16	1.988	7.67	74.6
		42 min	12	3.257	2.5466	1.03	2.080	7.66	78.2
		43 min	12	3.243	2.4760	0.99	2.022	7.58	76.3
		44 min	12	3.170	2.4769	1.01	1.895	7.58	78.1
		45 min	11	3.064	2.3093	1.02	2.274	7.54	75.4
		46 min	12	2.885	2.3228	0.90	1.717	7.55	80.5
		47 min	12	2.692	2.2882	0.86	1.678	7.55	85.0
		48 min	12	2.931	2.4864	0.72	1.865	7.57	84.8
		49 min	12	2.944	2.4836	0.76	1.644	7.55	84.3
		50 min	11	2.616	2.1872	1.29	1.544	7.60	83.6
		51 min	11	2.526	2.2599	0.72	1.463	7.61	89.5
		52 min	11	2.522	2.2389	0.64	1.577	7.70	88.8
		53 min	12	2.861	2.3143	0.77	1.613	7.70	80.9
		54 min	12	2.900	2.1427	1.24	1.631	7.59	73.9
		55 min	12	2.793	2.1875	1.11	1.585	7.73	78.3
		56 min	12	2.900	2.2243	1.06	1.651	7.62	76.7
		57 min	12	2.815	1.9992	1.15	1.651	7.60	71.0
		58 min	12	2.713	1.9315	0.99	1.683	7.54	71.2
		59 min	12	2.731	1.9144	1.41	1.708	7.58	70.1
		60 min	12	2.650	1.9490	0.98	1.653	7.51	73.6

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 163 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	61 min	12	2.681	1.9840	0.61	1.607	7.45	74.0
		62 min	12	2.825	2.2506	0.16	1.663	7.29	79.7
		63 min	11	2.799	2.3754	0.21	1.654	7.20	84.9
		64 min	11	3.361	2.7433	0.06	2.569	8.07	81.6
		65 min	11	2.894	2.6356	0.18	1.680	8.38	91.1
		66 min	11	2.734	2.5380	0.16	1.646	7.96	92.8
		67 min	11	2.809	2.4057	0.29	1.630	7.14	85.6
		68 min	11	2.704	2.1153	0.15	1.630	7.10	78.2
		69 min	11	2.925	2.3741	0.07	2.378	7.51	81.2
		70 min	10	2.995	2.4393	0.90	1.722	7.74	81.4
		71 min	10	3.029	2.5151	0.93	1.555	7.86	83.0
		72 min	9	3.226	2.2971	1.18	2.122	7.11	71.2
		73 min	9	3.188	2.5656	0.82	1.879	7.59	80.5
		74 min	9	2.942	2.2766	0.79	1.613	7.16	77.4
		75 min	9	2.405	1.9960	0.83	1.593	7.06	83.0
		76 min	9	2.309	1.9396	0.93	1.610	7.13	84.0
		77 min	9	2.374	1.8972	0.95	1.633	7.12	79.9
		78 min	9	2.437	1.8699	0.97	1.621	7.06	76.7
		79 min	9	2.252	1.8732	0.99	1.513	6.86	83.2
		80 min	9	2.355	1.9336	0.94	1.598	7.08	82.1
		81 min	9	2.323	1.9154	0.95	1.617	7.06	82.5
		82 min	9	2.212	1.9396	0.69	1.509	7.00	87.7
		83 min	9	2.478	1.7988	1.33	1.821	7.04	72.6
		84 min	9	2.658	1.8989	0.92	1.838	6.90	71.4
		85 min	9	2.308	1.8220	1.02	1.718	6.92	79.0
		86 min	9	2.484	1.7567	0.98	2.265	6.86	70.7
		87 min	9	3.387	2.4761	0.87	2.391	6.88	73.1
		88 min	9	2.563	1.8921	0.98	1.723	6.65	73.8
		89 min	10	2.554	1.8840	0.26	2.007	6.76	73.8
		90 min	10	3.227	2.6756	0.18	2.137	7.41	82.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 164 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	91 min	10	3.219	2.7672	-0.57	2.370	7.59	86.0
		92 min	10	3.252	2.2358	1.11	2.488	6.72	68.7
		93 min	10	2.837	2.3915	-0.01	2.009	6.72	84.3
		94 min	10	2.579	2.2670	-0.07	1.969	6.77	87.9
		95 min	9	2.723	2.3324	0.16	2.266	7.15	85.7
		96 min	9	2.571	2.2970	0.05	1.725	7.17	89.3
		97 min	9	2.519	2.2041	-0.01	1.673	7.06	87.5
		98 min	9	2.417	2.0618	-0.07	1.629	5.99	85.3
		99 min	10	2.510	2.1326	0.02	1.870	6.47	85.0
		100 min	9	2.582	2.2028	0.36	1.737	6.40	85.3
		101 min	9	2.495	2.0378	0.17	1.725	6.44	81.7
		102 min	9	2.281	1.8009	0.18	1.853	6.47	79.0
		103 min	9	2.300	1.8036	0.22	1.946	6.41	78.4
		104 min	10	2.083	1.6544	0.58	1.768	6.54	79.4
		105 min	10	2.025	1.4535	0.78	1.785	5.98	71.8
		106 min	10	2.076	1.5323	0.36	1.842	6.18	73.8
		107 min	10	1.984	1.5001	0.51	1.770	5.96	75.6
		108 min	10	2.239	1.3882	1.14	1.891	5.97	62.0
		109 min	10	2.139	1.5776	0.68	1.707	6.41	73.7
		110 min	10	2.482	2.0275	0.44	1.749	6.45	81.7
		111 min	10	1.993	1.6629	0.31	1.611	6.48	83.4
		112 min	10	2.018	1.6679	0.54	1.610	6.60	82.7
		113 min	11	2.069	1.5447	1.16	1.638	6.64	74.7
		114 min	11	2.019	1.4937	0.91	1.626	6.39	74.0
		115 min	11	2.012	1.5382	0.76	1.688	6.53	76.4
		116 min	11	1.990	1.5746	0.45	1.676	6.54	79.1
		117 min	11	2.438	2.0555	0.43	1.735	6.57	84.3
		118 min	12	1.891	1.4312	0.46	1.597	6.21	75.7
		119 min	12	2.194	1.6774	0.67	1.613	6.29	76.5
		120 min	12	2.424	2.1666	0.64	1.672	7.30	89.4

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 165 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	121 min	12	2.399	1.9893	0.67	1.629	6.85	82.9
		122 min	12	2.772	2.3284	0.66	1.651	6.87	84.0
		123 min	12	2.575	1.9743	0.68	1.672	6.75	76.7
		124 min	12	2.251	1.8283	0.66	1.669	6.74	81.2
		125 min	12	1.951	1.5227	0.60	1.579	6.63	78.0
		126 min	12	1.996	1.5155	0.59	1.680	6.59	75.9
		127 min	12	2.110	1.5784	0.67	1.671	6.76	74.8
		128 min	12	2.119	1.6790	0.58	1.679	6.92	79.2
		129 min	12	2.190	1.7557	0.52	1.623	6.87	80.2
		130 min	12	1.993	1.6579	0.31	1.622	6.97	83.2
		131 min	12	2.823	2.2359	0.47	1.601	7.04	79.2
		132 min	12	2.349	2.0787	0.08	1.684	7.11	88.5
		133 min	12	2.143	1.7941	0.38	1.619	7.04	83.7
		134 min	12	2.192	1.8681	0.35	1.634	7.06	85.2
		135 min	12	2.133	1.8586	0.39	1.522	7.10	87.1
		136 min	12	2.309	2.0419	0.64	1.595	7.38	88.4
		137 min	12	2.407	1.8899	1.09	1.602	7.07	78.5
		138 min	12	2.189	1.8040	0.81	1.583	7.12	82.4
		139 min	12	2.132	1.8160	0.56	1.545	7.15	85.2
		140 min	12	2.526	2.0976	0.59	1.659	7.34	83.0
		141 min	12	2.500	2.0407	0.74	1.630	7.23	81.6
		142 min	12	2.521	2.1195	0.70	1.627	7.14	84.1
		143 min	12	2.498	2.1617	0.58	1.742	7.13	86.5
		144 min	12	2.421	2.0081	0.69	1.714	7.24	82.9
		145 min	12	2.063	1.6931	0.47	1.661	7.21	82.1
		146 min	12	2.197	1.6805	0.48	1.748	7.14	76.5
		147 min	12	2.620	2.1299	0.56	1.693	7.29	81.3
		148 min	12	2.478	2.1829	0.48	1.615	7.21	88.1
		149 min	12	2.108	1.7602	0.38	1.587	7.25	83.5
		150 min	12	1.978	1.7312	0.55	1.527	7.18	87.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 166 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	151 min	12	1.929	1.7531	0.33	1.533	7.28	90.9
		152 min	12	2.231	1.9278	0.32	1.572	7.34	86.4
		153 min	12	1.909	1.7872	0.25	1.508	7.31	93.6
		154 min	12	2.419	2.1070	1.01	1.668	7.30	87.1
		155 min	12	2.456	2.2476	0.60	1.694	7.22	91.5
		156 min	12	2.537	2.1603	0.47	1.744	7.25	85.2
		157 min	12	2.461	2.1729	0.52	1.700	7.22	88.3
		158 min	12	2.376	2.2212	0.48	1.625	7.05	93.5
		159 min	12	2.430	2.1190	1.04	1.647	7.08	87.2
		160 min	12	2.446	2.2716	0.26	1.692	7.51	92.9
		161 min	12	1.913	1.8511	0.34	1.631	7.55	96.8
		162 min	12	2.066	1.7554	1.01	1.677	7.54	85.0
		163 min	12	2.106	1.7314	1.18	1.703	7.52	82.2
		164 min	11	2.014	1.8692	0.55	1.566	7.47	92.8
		165 min	11	2.126	1.8466	0.19	1.702	7.44	86.9
		166 min	11	2.543	1.9731	1.20	1.808	7.48	77.6
		167 min	11	3.015	2.3881	1.13	1.838	7.55	79.2
		168 min	11	3.244	2.6709	1.16	1.820	7.53	82.3
		169 min	11	3.303	2.5933	1.21	1.900	7.47	78.5
		170 min	11	2.113	1.8725	0.80	1.705	7.62	88.6
		171 min	11	2.612	2.0104	1.25	1.801	7.53	77.0
		172 min	10	2.617	2.0133	1.00	1.892	7.51	76.9
		173 min	10	2.547	2.0697	0.56	1.970	7.39	81.3
		174 min	10	2.072	1.9263	0.36	1.646	7.36	93.0
		175 min	10	2.122	1.8995	0.62	1.706	7.36	89.5
		176 min	10	2.129	1.9618	0.27	1.597	7.51	92.2
		177 min	10	2.039	1.9294	0.71	1.588	7.41	94.6
		178 min	10	2.144	1.8865	0.74	1.601	7.40	88.0
		179 min	10	2.146	1.9405	0.22	1.749	7.43	90.4
		180 min	10	1.995	1.9709	0.11	1.553	7.35	98.8

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 167 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	181 min	10	1.973	1.9820	0.29	1.476	7.47	100.5
		182 min	9	1.409	0.5024	0.22	1.539	1.99	35.6
		183 min	9	1.306	0.5340	0.13	1.430	2.05	40.9
		184 min	9	1.494	0.7235	0.11	1.457	2.75	48.4
		185 min	9	1.311	0.5554	0.19	1.443	2.16	42.4
		186 min	9	1.681	1.0237	0.12	1.547	4.03	60.9
		187 min	9	1.709	0.8308	0.09	1.701	3.17	48.6
		188 min	9	1.986	1.2591	0.15	1.784	4.84	63.4
		189 min	10	1.831	1.8646	0.11	1.561	6.87	101.8
		190 min	10	2.404	2.2278	0.22	1.555	6.99	92.7
		191 min	10	1.927	1.8090	0.02	1.605	6.80	93.9
		192 min	10	2.459	2.3295	0.09	1.603	6.78	94.7
		193 min	10	1.946	1.7168	0.65	1.522	6.65	88.2
		194 min	10	2.020	1.7503	0.28	1.616	6.78	86.6
		195 min	10	2.419	2.2187	0.18	1.692	6.75	91.7
		196 min	10	2.545	2.3376	0.13	1.754	6.91	91.9
		197 min	11	2.581	2.1891	0.59	1.836	7.09	84.8
		198 min	11	1.926	1.6694	0.26	1.466	6.69	86.7
		199 min	11	2.304	1.9565	0.33	1.660	6.75	84.9
		200 min	11	2.108	1.5698	1.24	1.563	6.71	74.5
		201 min	11	2.481	2.3251	0.63	1.520	7.38	93.7
		202 min	12	2.803	2.4086	0.23	1.653	6.97	85.9
		203 min	12	2.924	2.5689	0.34	1.654	7.42	87.8
		204 min	12	2.422	2.1486	0.31	1.652	7.01	88.7
		205 min	12	2.362	2.2053	0.02	1.594	6.91	93.3
		206 min	12	2.340	2.1197	0.08	1.635	6.77	90.6
		207 min	11	2.330	2.1479	0.22	1.589	6.74	92.2
		208 min	11	2.336	2.1714	0.05	1.419	6.64	92.9
		209 min	11	2.336	2.1001	0.03	1.607	6.63	89.9
		210 min	11	2.292	2.1538	-0.00	1.570	6.88	94.0

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 168 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	211 min	12	2.234	2.0198	0.02	1.467	6.72	90.4
		212 min	12	2.264	2.0610	0.05	1.586	6.91	91.0
		213 min	12	2.315	1.9649	0.62	1.596	6.87	84.9
		214 min	12	2.534	1.9431	1.27	1.658	6.72	76.7
		215 min	12	2.608	2.0441	0.69	1.704	6.87	78.4
		216 min	12	2.157	2.2395	-1.66	1.607	6.90	103.8
		217 min	12	2.611	2.5626	-1.58	1.600	6.98	98.1
		218 min	12	2.657	2.1744	0.58	1.697	7.23	81.8
		219 min	12	2.427	2.2341	0.21	1.633	7.31	92.1
		220 min	12	2.025	1.6813	0.09	1.609	6.84	83.0
		221 min	11	1.918	1.7219	0.15	1.462	6.74	89.8
		222 min	11	2.369	2.0562	0.41	1.556	6.81	86.8
		223 min	11	2.420	1.9858	0.95	1.510	6.83	82.1
		224 min	11	2.706	2.5576	0.91	1.616	8.69	94.5
		225 min	10	2.859	2.8450	0.96	1.627	9.31	99.5
		226 min	10	3.296	2.8358	1.10	1.688	9.28	86.0
		227 min	10	2.859	2.7593	0.97	1.629	9.10	96.5
		228 min	10	2.845	2.7737	1.18	1.577	9.12	97.5
		229 min	10	1.971	1.7613	0.71	1.424	6.85	89.4
		230 min	11	2.241	1.8387	0.20	1.681	6.64	82.0
		231 min	11	1.895	1.8142	0.29	1.380	7.17	95.7
		232 min	11	2.382	2.2641	0.21	1.639	6.89	95.0
		233 min	11	1.974	1.6923	0.36	1.507	6.79	85.7
		234 min	11	1.982	1.7489	0.26	1.357	6.84	88.2
		235 min	12	2.498	2.1640	0.30	1.599	7.06	86.6
		236 min	12	2.315	2.1891	0.14	1.541	6.92	94.6
		237 min	12	2.242	2.2423	0.21	1.411	7.05	100.0
		238 min	12	2.227	2.2696	0.14	1.438	7.06	101.9
		239 min	12	2.266	2.3462	0.15	1.378	7.62	103.5
		240 min	1	0.220		0.22	0.220	0.22	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 169 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	1 min	12	2.716	2.3284	0.95	1.662	7.18	85.7
		2 min	12	3.454	2.8179	0.99	1.797	8.14	81.6
		3 min	12	5.136	3.2139	1.14	6.948	9.10	62.6
		4 min	12	5.930	2.7376	1.45	6.547	9.12	46.2
		5 min	12	6.638	2.4965	1.58	6.963	9.80	37.6
		6 min	12	6.640	2.5041	1.45	7.114	9.75	37.7
		7 min	12	6.780	2.5519	1.28	7.352	9.78	37.6
		8 min	12	6.832	2.6292	1.14	7.437	9.84	38.5
		9 min	12	7.136	2.0644	1.29	7.476	9.74	28.9
		10 min	12	6.848	2.1707	1.08	7.339	9.74	31.7
		11 min	12	6.764	2.3985	1.06	7.619	9.56	35.5
		12 min	12	6.717	2.5996	0.97	7.400	9.96	38.7
		13 min	12	6.452	2.4635	1.25	7.086	9.67	38.2
		14 min	12	6.405	2.5876	1.06	7.344	9.66	40.4
		15 min	12	6.581	2.5297	1.32	7.432	9.39	38.4
		16 min	12	5.862	2.9115	0.86	7.209	9.49	49.7
		17 min	12	5.755	2.8429	1.27	6.564	9.71	49.4
		18 min	12	5.976	2.8301	1.03	6.987	9.80	47.4
		19 min	12	5.819	2.9006	1.23	6.996	10.05	49.8
		20 min	12	5.176	3.2526	1.05	5.964	9.76	62.8
		21 min	11	5.752	2.9835	1.16	6.828	9.49	51.9
		22 min	10	5.157	3.0308	1.06	6.887	7.93	58.8
		23 min	10	5.137	3.1322	0.98	6.900	7.93	61.0
		24 min	10	4.606	3.2741	1.06	4.237	8.27	71.1
		25 min	10	4.523	3.4013	0.79	4.279	8.25	75.2
		26 min	10	4.512	3.3636	0.74	4.098	8.23	74.5
		27 min	10	4.474	3.2925	1.12	3.928	8.11	73.6
		28 min	10	4.776	3.0075	1.21	5.370	8.05	63.0
		29 min	10	4.809	3.0337	1.28	5.614	8.17	63.1
		30 min	10	4.417	3.1893	1.21	3.599	8.16	72.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 170 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	31 min	10	4.261	3.1678	1.26	2.798	7.99	74.4
		32 min	10	4.392	3.1336	1.30	3.545	8.04	71.4
		33 min	10	4.454	3.0266	1.32	4.102	7.84	67.9
		34 min	10	3.737	3.1232	0.81	1.687	7.75	83.6
		35 min	10	4.360	2.7442	1.36	4.499	7.68	62.9
		36 min	11	3.440	2.8018	1.08	1.658	7.74	81.4
		37 min	11	3.803	2.7600	1.16	1.708	7.69	72.6
		38 min	12	4.226	2.7631	1.41	4.088	8.46	65.4
		39 min	12	4.266	2.7105	1.40	4.145	8.16	63.5
		40 min	12	4.443	2.6859	1.03	5.418	7.75	60.4
		41 min	12	4.065	2.7437	1.03	4.114	7.69	67.5
		42 min	12	3.871	2.2971	1.00	3.960	7.70	59.3
		43 min	12	3.767	2.2981	0.92	3.383	7.73	61.0
		44 min	12	4.095	2.5416	1.17	3.714	7.63	62.1
		45 min	11	3.488	2.3575	1.35	2.728	7.62	67.6
		46 min	12	3.459	2.5169	0.97	2.711	7.64	72.8
		47 min	12	3.533	2.5534	0.99	2.273	7.65	72.3
		48 min	12	3.518	2.4689	0.93	2.688	7.74	70.2
		49 min	12	4.417	2.4690	1.23	5.305	7.73	55.9
		50 min	11	3.334	2.4297	1.24	2.049	7.75	72.9
		51 min	11	3.179	2.3917	1.07	1.861	7.61	75.2
		52 min	11	3.258	2.2956	1.05	2.474	7.69	70.5
		53 min	12	3.614	2.4673	1.32	2.855	7.75	68.3
		54 min	12	3.675	2.2647	1.23	3.202	7.66	61.6
		55 min	12	2.867	2.1731	1.05	2.037	7.65	75.8
		56 min	12	2.839	2.3058	0.80	1.590	7.78	81.2
		57 min	12	3.832	2.6075	0.62	3.206	7.76	68.0
		58 min	12	4.324	2.6464	0.53	4.508	7.71	61.2
		59 min	12	3.818	2.4948	0.49	3.909	7.60	65.3
		60 min	12	3.877	2.4498	1.27	3.491	7.57	63.2

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 171 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	61 min	12	3.428	2.4296	0.90	2.004	7.51	70.9
		62 min	12	3.518	2.5454	0.93	2.467	7.68	72.3
		63 min	11	3.640	2.5868	0.65	2.993	7.84	71.1
		64 min	11	4.275	2.6638	0.82	3.483	7.71	62.3
		65 min	11	3.835	2.6980	0.41	2.533	7.86	70.3
		66 min	11	3.382	2.5010	0.42	2.101	7.62	74.0
		67 min	11	3.229	2.3804	0.42	2.763	7.84	73.7
		68 min	11	3.795	2.4146	0.65	3.264	7.81	63.6
		69 min	11	3.828	2.5226	0.67	2.863	7.74	65.9
		70 min	10	3.276	2.3848	1.47	2.143	7.88	72.8
		71 min	10	4.289	2.6140	1.38	4.142	7.83	61.0
		72 min	9	5.351	2.5840	1.61	6.726	7.99	48.3
		73 min	9	3.866	2.9866	0.79	2.066	7.96	77.3
		74 min	9	4.594	2.3891	1.51	4.687	7.33	52.0
		75 min	9	4.393	2.7509	1.26	3.309	8.04	62.6
		76 min	9	4.823	2.8845	1.22	6.395	7.77	59.8
		77 min	9	3.734	2.8127	1.40	2.084	7.75	75.3
		78 min	9	4.335	2.6439	1.05	4.138	7.49	61.0
		79 min	9	3.115	2.4681	0.94	2.160	7.41	79.2
		80 min	9	3.808	2.6811	0.98	3.068	7.72	70.4
		81 min	9	4.136	2.8435	1.18	2.902	7.53	68.8
		82 min	9	3.208	2.5154	1.24	2.145	7.74	78.4
		83 min	9	4.265	2.7842	1.32	3.113	7.79	65.3
		84 min	9	4.180	2.9982	0.68	3.053	7.83	71.7
		85 min	9	4.328	2.8778	1.29	2.949	7.99	66.5
		86 min	9	4.732	2.7064	1.36	4.812	8.04	57.2
		87 min	9	4.393	2.9251	1.24	3.016	8.28	66.6
		88 min	9	3.479	2.9141	0.63	2.079	8.38	83.8
		89 min	10	4.726	2.4615	1.23	6.034	7.46	52.1
		90 min	10	4.468	2.9698	1.19	4.592	7.72	66.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 172 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	91 min	10	4.294	3.0551	0.18	4.385	7.75	71.1
		92 min	10	3.830	3.1156	0.11	2.115	7.58	81.3
		93 min	10	4.290	3.1608	-0.18	4.578	7.82	73.7
		94 min	10	3.560	3.4341	-2.42	2.212	7.52	96.5
		95 min	9	3.337	3.1763	-2.17	2.491	7.32	95.2
		96 min	9	3.943	2.8557	-0.59	4.231	7.68	72.4
		97 min	9	4.346	2.6393	1.36	4.862	7.24	60.7
		98 min	9	3.247	2.9387	-0.54	1.965	7.23	90.5
		99 min	10	3.756	2.8465	0.01	2.116	7.24	75.8
		100 min	9	2.627	2.4340	0.27	1.681	6.82	92.6
		101 min	9	3.330	2.4676	0.36	2.183	6.71	74.1
		102 min	9	4.136	2.6607	0.33	3.617	7.51	64.3
		103 min	9	3.044	2.0219	1.42	2.041	6.58	66.4
		104 min	10	4.194	2.6726	1.17	4.241	7.35	63.7
		105 min	10	3.947	2.6653	1.35	2.453	7.62	67.5
		106 min	10	3.771	2.6349	1.37	2.029	7.70	69.9
		107 min	10	2.762	1.9934	1.34	2.056	6.80	72.2
		108 min	10	3.514	2.4219	1.37	2.074	7.26	68.9
		109 min	10	3.083	2.5528	1.00	1.731	7.25	82.8
		110 min	10	3.127	2.6448	0.10	1.900	7.41	84.6
		111 min	10	2.368	2.1315	0.10	1.671	6.50	90.0
		112 min	10	2.773	1.9643	1.17	1.869	6.42	70.8
		113 min	11	2.246	1.8741	0.18	1.689	6.51	83.4
		114 min	11	2.306	1.7729	0.23	1.831	6.48	76.9
		115 min	11	2.905	1.9275	1.29	1.883	6.42	66.3
		116 min	11	2.737	2.0567	-0.08	1.881	6.61	75.1
		117 min	11	3.121	2.2744	0.62	1.954	6.71	72.9
		118 min	12	2.359	1.4854	0.97	1.830	6.29	63.0
		119 min	12	2.398	2.0082	0.40	1.587	6.84	83.7
		120 min	12	2.498	2.1343	0.25	1.688	7.29	85.5

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 173 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	121 min	12	2.481	2.0493	0.49	1.787	6.88	82.6
		122 min	12	2.857	2.3318	0.47	1.808	7.21	81.6
		123 min	12	2.774	2.1742	0.49	1.836	7.23	78.4
		124 min	12	2.389	1.5725	0.51	1.881	6.68	65.8
		125 min	12	2.838	2.3200	0.41	1.751	6.85	81.7
		126 min	12	3.318	2.2079	1.25	2.043	7.19	66.5
		127 min	12	2.992	2.3411	0.67	1.741	7.02	78.2
		128 min	12	2.800	2.1659	0.66	1.765	7.24	77.3
		129 min	12	3.167	2.2124	1.36	1.926	6.98	69.8
		130 min	12	3.393	2.5304	1.23	1.690	7.11	74.6
		131 min	12	3.688	2.5325	1.41	2.023	7.25	68.7
		132 min	12	3.725	2.5152	1.39	2.570	7.46	67.5
		133 min	12	3.040	2.5641	1.16	1.660	7.66	84.3
		134 min	12	3.558	2.6678	1.04	2.140	7.67	75.0
		135 min	12	3.490	2.7994	1.13	1.865	8.00	80.2
		136 min	12	3.060	2.6933	1.11	1.694	7.77	88.0
		137 min	12	3.064	2.6489	1.25	1.681	7.58	86.4
		138 min	12	3.298	2.5699	1.24	1.754	7.32	77.9
		139 min	12	2.885	2.5355	0.56	1.662	7.56	87.9
		140 min	12	3.039	2.6664	0.51	1.727	7.81	87.7
		141 min	12	3.029	2.6974	0.60	1.715	7.69	89.0
		142 min	12	3.085	2.6629	0.81	1.772	7.63	86.3
		143 min	12	3.258	2.6348	0.48	1.856	7.86	80.9
		144 min	12	3.319	2.5478	0.72	1.921	7.70	76.8
		145 min	12	3.282	2.8204	0.14	1.739	7.68	85.9
		146 min	12	2.885	2.5843	0.17	1.847	7.54	89.6
		147 min	12	3.289	2.7541	0.37	1.840	7.82	83.7
		148 min	12	3.663	2.8031	0.23	1.945	7.76	76.5
		149 min	12	3.742	2.8592	0.37	1.986	7.64	76.4
		150 min	12	3.259	2.7348	0.36	1.813	7.29	83.9

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 174 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	151 min	12	3.271	2.5024	0.15	1.997	7.37	76.5
		152 min	12	2.964	2.6116	0.21	1.840	7.29	88.1
		153 min	12	2.958	2.5291	0.18	1.853	7.45	85.5
		154 min	12	2.838	2.1975	1.37	1.875	7.37	77.4
		155 min	12	2.803	2.3964	0.94	1.690	7.29	85.5
		156 min	12	2.816	2.2332	0.60	1.803	7.31	79.3
		157 min	12	2.788	2.4214	0.15	1.715	7.15	86.9
		158 min	12	2.429	2.2144	0.43	1.666	7.15	91.2
		159 min	12	3.131	2.4371	0.99	1.747	7.22	77.8
		160 min	12	2.780	2.2545	1.18	1.756	7.50	81.1
		161 min	12	1.959	1.8171	0.12	1.575	7.51	92.8
		162 min	12	2.300	1.8962	0.86	1.633	7.40	82.4
		163 min	12	2.172	1.7281	0.95	1.843	7.48	79.5
		164 min	11	2.037	1.8472	0.98	1.405	7.53	90.7
		165 min	11	2.280	2.1046	-0.10	1.682	7.36	92.3
		166 min	11	2.656	2.2779	0.94	1.747	7.54	85.8
		167 min	11	2.988	2.5195	1.06	1.798	7.52	84.3
		168 min	11	2.973	2.4539	1.11	1.698	7.28	82.6
		169 min	11	3.121	2.5370	0.88	1.917	7.47	81.3
		170 min	11	2.903	2.4700	0.96	1.841	7.51	85.1
		171 min	11	3.088	2.2310	1.22	2.022	7.22	72.3
		172 min	10	3.696	2.5982	1.42	1.935	7.50	70.3
		173 min	10	3.341	2.2853	1.35	2.129	7.32	68.4
		174 min	10	2.538	2.0743	0.73	1.790	7.14	81.7
		175 min	10	2.913	2.2079	0.94	1.846	7.41	75.8
		176 min	10	2.877	2.3399	0.04	1.924	7.60	81.3
		177 min	10	2.773	2.1107	1.21	1.835	7.50	76.1
		178 min	10	2.538	1.9777	1.05	1.800	7.44	77.9
		179 min	10	2.714	2.3069	0.33	1.752	7.38	85.0
		180 min	10	2.580	2.4580	0.23	1.594	7.39	95.3

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 175 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	181 min	10	3.055	2.4500	1.13	1.741	7.31	80.2
		182 min	9	2.415	2.0338	0.24	1.758	6.33	84.2
		183 min	9	1.597	0.8068	0.15	1.584	3.09	50.5
		184 min	9	3.174	2.5854	0.24	1.797	7.05	81.5
		185 min	9	3.147	2.2382	0.87	2.169	6.90	71.1
		186 min	9	1.950	1.0890	0.54	1.624	4.40	55.9
		187 min	9	2.466	2.1175	0.27	1.636	6.18	85.9
		188 min	9	2.445	1.6510	0.63	1.895	6.24	67.5
		189 min	10	3.233	2.4182	0.04	2.026	7.21	74.8
		190 min	10	4.285	2.2337	1.62	4.814	7.26	52.1
		191 min	10	3.959	2.5481	1.30	2.674	7.17	64.4
		192 min	10	3.846	2.6052	1.25	2.261	7.83	67.7
		193 min	10	2.499	1.9640	0.79	1.798	7.31	78.6
		194 min	10	3.584	2.5398	1.20	2.126	7.33	70.9
		195 min	10	3.265	2.6700	1.00	1.795	7.43	81.8
		196 min	10	3.080	2.2962	0.88	1.898	7.38	74.6
		197 min	11	3.212	2.2579	1.23	2.354	7.46	70.3
		198 min	11	2.333	2.1200	0.05	1.559	7.35	90.9
		199 min	11	2.913	2.6359	0.02	1.707	7.53	90.5
		200 min	11	3.234	2.7775	-0.17	1.963	7.39	85.9
		201 min	11	3.056	2.6441	0.90	1.712	7.39	86.5
		202 min	12	2.835	2.5995	0.11	1.661	7.48	91.7
		203 min	12	2.813	2.5631	0.13	1.626	7.17	91.1
		204 min	12	2.447	2.1606	0.36	1.710	7.20	88.3
		205 min	12	2.784	2.5877	0.08	1.602	7.35	93.0
		206 min	12	2.402	2.1745	0.31	1.627	6.97	90.5
		207 min	11	2.830	2.4225	0.97	1.574	7.03	85.6
		208 min	11	2.937	2.4134	-0.82	2.115	6.89	82.2
		209 min	11	2.687	2.4035	-0.00	1.558	6.82	89.5
		210 min	11	2.431	2.1572	0.04	1.614	6.89	88.7

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 176 of 176

Table 14.2.1.1 Summary of pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	211 min	12	2.596	2.3894	-0.03	1.530	7.05	92.1
		212 min	12	2.276	2.2257	0.11	1.573	7.17	97.8
		213 min	12	2.095	2.3733	-1.37	1.452	7.21	113.3
		214 min	12	2.414	2.9933	-3.62	1.638	7.25	124.0
		215 min	12	2.351	2.6116	-2.43	1.575	7.24	111.1
		216 min	12	3.395	2.3559	1.21	1.943	7.36	69.4
		217 min	12	2.777	2.5730	-0.20	1.592	7.01	92.7
		218 min	12	3.396	2.3763	1.29	1.957	6.98	70.0
		219 min	12	3.393	2.2222	1.52	1.968	7.16	65.5
		220 min	12	2.785	1.9063	1.17	1.932	6.94	68.4
		221 min	11	2.253	1.8246	0.10	1.670	7.03	81.0
		222 min	11	3.664	2.5298	1.04	2.031	7.28	69.0
		223 min	11	3.474	2.6265	1.03	2.077	8.85	75.6
		224 min	11	2.844	2.6829	0.95	1.730	9.16	94.3
		225 min	10	3.312	2.9027	1.10	1.827	9.18	87.6
		226 min	10	3.798	2.9129	1.32	1.895	8.88	76.7
		227 min	10	3.520	2.9031	1.06	1.808	8.88	82.5
		228 min	10	3.970	2.6195	1.54	3.266	9.06	66.0
		229 min	10	3.013	2.5454	1.01	1.885	8.14	84.5
		230 min	11	3.015	2.7515	0.90	1.719	7.87	91.3
		231 min	11	3.392	2.7942	0.95	1.905	8.16	82.4
		232 min	11	3.152	2.7629	1.11	1.750	8.11	87.7
		233 min	11	3.664	2.7674	1.19	1.968	7.77	75.5
		234 min	11	3.603	2.6922	1.02	1.937	8.75	74.7
		235 min	12	3.210	2.8073	0.78	1.675	8.60	87.4
		236 min	12	3.160	2.7138	0.96	1.679	8.74	85.9
		237 min	12	3.006	2.8162	1.09	1.611	8.28	93.7
		238 min	12	3.021	2.7289	0.98	1.752	8.27	90.3
		239 min	12	3.018	2.6943	0.91	1.757	8.05	89.3
		240 min	1	7.914		7.91	7.914	7.91	

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_01.sas

29JAN2013 4:47

14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	1 min	12	-0.206	0.5954	-1.89	-0.044	0.51
		2 min	12	0.040	0.2085	-0.52	0.079	0.27
		3 min	12	-0.176	0.2308	-0.49	-0.215	0.28
		4 min	12	-0.290	0.3781	-1.10	-0.310	0.45
		5 min	12	0.001	0.3146	-0.39	-0.112	0.69
		6 min	12	-0.180	0.3675	-0.88	-0.120	0.38
		7 min	12	-0.006	0.3913	-0.62	-0.007	0.71
		8 min	12	-0.039	0.6045	-1.55	0.069	0.58
		9 min	12	-0.295	0.3783	-0.96	-0.224	0.43
		10 min	12	-0.171	0.2810	-0.76	-0.214	0.32
		11 min	12	0.024	0.2196	-0.34	0.035	0.42
		12 min	12	-0.058	0.2627	-0.46	-0.088	0.35
		13 min	12	-0.058	0.2933	-0.67	-0.026	0.29
		14 min	12	-0.085	0.3659	-0.88	-0.094	0.55
		15 min	12	-0.201	0.4005	-0.87	-0.034	0.33
		16 min	12	-0.412	1.3871	-4.66	-0.110	0.59
		17 min	12	-0.252	0.8674	-2.91	-0.020	0.31
		18 min	12	0.013	0.3542	-0.67	0.005	0.52
		19 min	12	0.077	0.5846	-1.30	0.017	0.80
		20 min	12	-0.249	0.5221	-1.65	-0.133	0.49
		21 min	12	-0.525	0.7113	-2.04	-0.253	0.16
		22 min	12	-0.131	0.3872	-0.77	-0.136	0.58
		23 min	12	-0.257	0.4421	-1.13	-0.158	0.46
		24 min	12	-0.030	0.3926	-0.69	-0.024	0.63
		25 min	12	-0.266	1.0383	-3.30	-0.056	0.74
		26 min	12	-0.037	0.3623	-0.77	-0.024	0.57
		27 min	12	-0.332	0.7570	-2.59	-0.030	0.12
		28 min	12	0.257	1.1762	-0.65	0.008	3.86
		29 min	12	-0.184	0.4865	-0.99	-0.064	0.66
		30 min	12	-0.077	0.4408	-0.72	0.004	0.56

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	31 min	12	-0.021	0.3640	-0.71	0.043	0.49
		32 min	11	-0.128	0.4602	-1.20	0.036	0.28
		33 min	10	-0.031	0.5112	-1.16	0.084	0.60
		34 min	10	-0.217	1.6425	-4.43	0.027	2.03
		35 min	10	-0.359	1.0530	-3.06	0.022	0.54
		36 min	10	-0.283	0.6135	-1.44	-0.130	0.36
		37 min	10	-0.188	0.6158	-1.30	-0.019	0.48
		38 min	10	-0.532	1.3829	-4.32	-0.021	0.35
		39 min	10	-0.544	1.1135	-3.46	-0.401	0.48
		40 min	10	-0.181	1.0063	-2.92	0.047	0.58
		41 min	10	-0.121	0.8426	-2.24	0.045	0.75
		42 min	11	-0.025	0.6550	-1.55	0.196	0.76
		43 min	12	-0.060	0.8182	-2.27	-0.018	0.73
		44 min	12	-0.568	1.4672	-4.82	-0.261	0.76
		45 min	12	-0.098	0.6105	-1.59	-0.024	0.60
		46 min	12	-0.238	1.1853	-3.70	0.042	0.79
		47 min	12	-0.116	0.7846	-1.83	0.035	0.82
		48 min	12	-0.287	0.7196	-1.60	-0.182	0.75
		49 min	12	-0.186	0.6137	-1.10	-0.147	0.95
		50 min	12	-0.506	1.5766	-5.22	-0.008	0.54
		51 min	11	-0.488	1.1821	-3.55	-0.119	0.48
		52 min	11	-0.370	0.4822	-1.06	-0.130	0.30
		53 min	11	-0.375	0.5261	-1.07	-0.323	0.28
		54 min	11	-0.203	0.4544	-0.90	-0.128	0.51
		55 min	11	-0.160	0.5864	-1.52	-0.071	0.56
		56 min	11	-0.144	0.6377	-1.71	0.003	0.56
		57 min	11	-0.051	0.5851	-1.32	0.016	0.87
		58 min	11	-0.199	0.5574	-0.95	-0.284	0.68
		59 min	11	-0.061	0.4021	-0.58	-0.104	0.56
		60 min	11	-0.323	0.5565	-1.65	-0.388	0.34

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	61 min	11	-0.273	0.6748	-1.84	-0.044	0.41
		62 min	11	-0.078	0.3764	-0.70	0.011	0.55
		63 min	10	-0.620	1.1502	-3.37	-0.157	0.35
		64 min	10	-0.670	1.3604	-4.26	-0.393	0.43
		65 min	9	-0.302	0.8113	-1.78	-0.212	0.82
		66 min	9	-0.528	1.1365	-3.26	-0.150	0.44
		67 min	9	-0.527	1.4385	-4.02	-0.308	0.85
		68 min	9	-0.171	1.0071	-2.68	0.047	0.86
		69 min	9	-0.152	0.7604	-1.95	-0.163	0.84
		70 min	9	-0.228	0.9420	-2.52	-0.087	0.83
		71 min	9	-0.360	0.6829	-1.96	-0.040	0.30
		72 min	9	-0.187	0.5769	-1.36	0.032	0.42
		73 min	9	-0.292	0.8543	-1.87	-0.060	0.81
		74 min	9	-0.297	0.5794	-1.33	-0.204	0.52
		75 min	9	-0.359	0.4986	-1.18	-0.301	0.52
		76 min	9	-0.629	1.1187	-3.13	-0.226	0.71
		77 min	9	-0.205	0.5959	-1.51	0.083	0.50
		78 min	9	0.013	0.4100	-0.67	0.096	0.58
		79 min	9	-0.042	0.6796	-1.13	0.064	0.94
		80 min	9	-0.184	0.5249	-0.86	-0.187	0.56
		81 min	9	-0.964	1.9802	-4.42	-0.145	0.57
		82 min	9	0.064	0.3665	-0.69	0.048	0.55
		83 min	9	-0.236	0.4400	-0.80	-0.130	0.46
		84 min	9	-0.207	0.4869	-0.95	-0.174	0.53
		85 min	9	-0.685	1.1323	-3.50	-0.280	0.27
		86 min	9	-0.213	0.3507	-0.78	-0.106	0.22
		87 min	9	-0.112	0.4674	-0.81	0.006	0.46
		88 min	9	-0.009	0.3781	-0.49	0.096	0.44
		89 min	9	-0.146	0.6179	-1.09	-0.137	0.64
		90 min	9	-0.071	0.4560	-0.66	-0.126	0.64

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	91 min	9	-0.266	1.0948	-2.76	0.157	0.77
		92 min	9	-0.112	0.9814	-2.09	0.096	1.11
		93 min	10	-0.542	1.6079	-4.61	-0.080	1.15
		94 min	10	-0.083	0.7792	-1.44	-0.052	1.30
		95 min	11	0.296	1.0449	-0.79	0.023	3.02
		96 min	11	-0.071	0.5220	-0.98	-0.160	0.92
		97 min	11	-0.021	0.3862	-0.91	-0.030	0.52
		98 min	11	-0.217	1.0007	-2.96	0.147	0.60
		99 min	11	-0.082	0.4684	-0.76	-0.171	0.96
		100 min	11	-0.066	0.5527	-0.95	0.034	0.95
		101 min	11	0.059	0.4894	-0.71	0.026	0.96
		102 min	11	-0.017	0.3292	-0.55	-0.069	0.49
		103 min	11	0.072	0.3420	-0.67	0.048	0.77
		104 min	11	-0.004	0.4039	-0.73	0.138	0.48
		105 min	11	-0.135	1.1764	-3.57	0.075	0.78
		106 min	11	-0.171	0.5053	-1.12	-0.180	0.56
		107 min	11	-0.160	0.4990	-1.06	-0.111	0.53
		108 min	11	-0.097	0.4054	-0.80	-0.215	0.51
		109 min	11	-0.015	0.4748	-0.94	0.018	0.74
		110 min	11	-0.013	0.4427	-0.86	0.136	0.59
		111 min	11	-0.211	0.6879	-1.93	-0.110	0.67
		112 min	11	-0.168	0.6154	-1.73	-0.008	0.38
		113 min	11	-0.471	1.1928	-3.70	-0.067	0.66
		114 min	11	-0.239	0.8136	-2.30	-0.024	0.60
		115 min	11	-0.086	0.5828	-1.07	-0.151	0.68
		116 min	11	-0.093	0.6020	-1.29	-0.025	0.78
		117 min	10	-0.055	0.6423	-1.29	0.079	0.65
		118 min	10	-0.166	0.7435	-1.59	-0.118	0.93
		119 min	10	-0.242	0.6368	-1.21	-0.197	0.54
		120 min	10	-0.426	0.5022	-1.34	-0.376	0.23

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	121 min	10	-0.084	0.5323	-1.04	0.084	0.51
		122 min	10	-0.104	0.5911	-0.96	-0.120	0.62
		123 min	11	-0.391	0.7661	-2.26	-0.225	0.47
		124 min	11	-0.202	0.3846	-0.89	-0.187	0.28
		125 min	11	-0.036	0.3104	-0.70	-0.066	0.52
		126 min	11	-0.507	1.4023	-4.58	-0.084	0.47
		127 min	11	0.058	0.3384	-0.63	0.021	0.65
		128 min	11	-0.100	0.4287	-0.70	-0.086	0.87
		129 min	11	-0.062	0.4463	-0.68	-0.283	0.86
		130 min	11	-0.062	0.5733	-0.92	0.033	0.83
		131 min	11	-0.092	0.5856	-1.14	-0.028	0.87
		132 min	11	-0.094	0.5530	-1.08	-0.124	0.83
		133 min	10	-0.290	0.8014	-2.23	-0.121	0.75
		134 min	11	-0.255	0.5744	-1.52	-0.138	0.76
		135 min	11	-0.023	0.5818	-0.88	-0.195	0.95
		136 min	11	0.112	0.4100	-0.47	0.196	0.80
		137 min	11	-0.039	0.4902	-0.91	-0.129	0.78
		138 min	11	0.029	0.5255	-0.66	-0.051	0.83
		139 min	11	0.059	0.5937	-0.69	0.061	0.95
		140 min	11	0.046	0.5860	-0.60	-0.014	1.03
		141 min	11	0.056	0.5452	-0.81	0.083	0.91
		142 min	11	-0.408	1.2624	-3.97	0.080	0.73
		143 min	11	-0.115	0.4144	-1.17	-0.096	0.38
		144 min	11	-0.020	0.4650	-0.99	0.023	0.61
		145 min	10	-0.037	0.4070	-0.61	0.011	0.72
		146 min	10	-0.033	0.4745	-0.92	-0.058	0.70
		147 min	10	-0.424	1.0704	-3.29	-0.250	0.33
		148 min	10	-0.211	0.8541	-2.42	-0.060	0.72
		149 min	10	-0.061	0.5946	-1.69	0.158	0.34
		150 min	10	-0.046	0.4693	-0.94	0.034	0.72

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	151 min	10	0.008	0.3582	-0.95	0.109	0.31
		152 min	10	-0.062	0.3870	-0.75	-0.028	0.63
		153 min	10	-0.026	0.6050	-0.89	0.080	0.74
		154 min	10	-0.030	0.3577	-0.70	0.021	0.46
		155 min	10	-0.076	0.4378	-0.85	-0.023	0.66
		156 min	10	-0.106	0.4315	-0.86	0.038	0.34
		157 min	10	0.040	0.5671	-0.79	0.151	1.01
		158 min	10	0.101	0.4576	-0.66	0.019	0.96
		159 min	10	0.054	0.4273	-0.94	0.173	0.50
		160 min	10	0.044	0.4952	-0.69	0.022	0.95
		161 min	10	0.192	0.3017	-0.13	0.040	0.67
		162 min	10	-0.150	0.6349	-1.33	-0.205	1.02
		163 min	11	-0.056	0.5273	-1.06	-0.077	0.93
		164 min	11	0.035	0.5005	-0.77	-0.059	0.91
		165 min	11	0.063	0.4983	-1.13	0.070	0.87
		166 min	11	0.169	0.3964	-0.50	0.015	0.87
		167 min	11	0.193	0.4467	-0.31	0.155	0.99
		168 min	11	-0.004	0.6351	-1.36	0.029	0.91
		169 min	10	0.075	0.3641	-0.59	0.157	0.48
		170 min	10	-0.069	0.5271	-1.15	0.022	0.86
		171 min	10	0.064	0.4180	-1.03	0.098	0.49
		172 min	10	-0.081	0.2738	-0.50	-0.058	0.36
		173 min	10	0.174	0.3846	-0.55	0.146	0.80
		174 min	10	0.350	0.6464	-0.71	0.431	1.08
		175 min	10	0.240	0.4274	-0.66	0.315	0.75
		176 min	10	-0.094	0.8550	-1.95	0.054	0.99
		177 min	10	0.046	0.6051	-0.84	0.138	1.04
		178 min	10	0.067	0.4540	-0.74	-0.046	0.80
		179 min	10	0.097	0.5536	-0.67	-0.061	0.88
		180 min	10	0.051	0.5051	-0.86	-0.022	1.08

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	181 min	10	0.133	0.3121	-0.29	0.093	0.74
		182 min	10	0.057	0.4505	-0.67	0.088	0.65
		183 min	10	0.132	0.4890	-0.57	0.121	0.74
		184 min	10	0.053	0.6142	-1.00	0.155	0.88
		185 min	9	0.045	0.4015	-0.69	0.086	0.54
		186 min	8	0.366	0.3659	-0.18	0.416	0.91
		187 min	9	0.179	0.4033	-0.34	0.173	0.76
		188 min	9	-0.116	0.4880	-0.86	-0.185	0.94
		189 min	9	0.135	0.3120	-0.27	0.120	0.88
		190 min	9	-0.123	0.2673	-0.77	-0.034	0.13
		191 min	9	0.177	0.4038	-0.28	0.130	0.99
		192 min	9	-0.098	0.4656	-0.98	-0.041	0.56
		193 min	9	-0.435	1.0226	-2.98	-0.342	0.46
		194 min	9	-0.315	0.9880	-2.72	-0.108	0.49
		195 min	9	-0.056	0.3964	-0.55	0.038	0.54
		196 min	9	-0.060	0.7076	-1.48	-0.000	0.78
		197 min	9	-0.092	0.7758	-1.75	0.105	0.70
		198 min	10	-0.171	0.8296	-2.42	-0.020	0.48
		199 min	10	-0.232	0.8152	-1.62	-0.009	0.74
		200 min	10	-0.149	0.6109	-1.22	-0.215	0.87
		201 min	10	-0.405	0.5569	-1.51	-0.327	0.36
		202 min	10	-0.203	0.6226	-1.36	0.100	0.44
		203 min	11	0.254	0.4056	-0.40	0.356	0.85
		204 min	11	0.124	0.4709	-0.87	0.172	0.77
		205 min	11	-0.018	0.5344	-1.10	0.001	0.73
		206 min	11	-0.522	1.4550	-4.78	-0.152	0.45
		207 min	10	0.033	0.3385	-0.46	0.153	0.46
		208 min	10	-0.497	1.5441	-4.73	0.073	0.53
		209 min	10	-0.352	1.0439	-3.07	-0.044	0.49
		210 min	10	-0.213	0.5793	-0.99	-0.030	0.46

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	1	211 min	10	0.151	0.8828	-0.90	0.239	2.20
		212 min	10	-0.071	0.5903	-0.90	-0.050	0.66
		213 min	10	-0.063	0.4522	-0.84	-0.056	0.60
		214 min	10	-0.155	0.7426	-2.05	0.161	0.42
		215 min	10	-0.698	2.0132	-6.14	0.122	0.70
		216 min	10	-0.345	0.9246	-2.56	0.095	0.42
		217 min	10	-0.283	0.7172	-1.73	-0.102	0.40
		218 min	10	-0.197	0.4084	-0.80	-0.211	0.44
		219 min	10	-0.082	0.6359	-0.97	-0.115	0.71
		220 min	10	0.036	0.5475	-0.75	0.146	0.89
		221 min	10	-0.351	1.6865	-4.92	0.115	1.08
		222 min	10	-0.372	1.6575	-4.89	0.171	0.75
		223 min	10	-0.275	1.3368	-3.78	0.012	1.08
		224 min	10	-0.170	0.5608	-0.95	-0.098	0.73
		225 min	10	-0.068	0.2758	-0.43	-0.076	0.35
		226 min	10	-0.251	0.9171	-2.53	-0.154	0.62
		227 min	10	0.032	0.6268	-1.06	0.246	0.67
		228 min	10	0.055	0.4325	-0.85	0.075	0.66
		229 min	11	0.140	0.4279	-0.72	0.259	0.64
		230 min	11	-0.005	0.5099	-1.00	0.136	0.59
		231 min	11	0.083	0.4851	-0.86	0.184	0.67
		232 min	11	-0.064	0.5108	-0.92	-0.052	0.81
		233 min	11	0.010	0.3970	-0.74	0.101	0.69
		234 min	11	-0.314	1.5200	-4.80	0.177	0.52
		235 min	10	-0.454	1.8467	-4.29	0.047	2.27
		236 min	11	-0.067	0.6299	-1.78	0.062	0.57
		237 min	11	-0.128	0.6860	-1.86	-0.189	0.66
		238 min	11	-0.110	0.6665	-1.77	-0.071	0.71
		239 min	11	-0.254	0.5030	-1.41	-0.263	0.49
		240 min	6	-0.010	0.4091	-0.45	-0.074	0.77

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 9 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	1 min	12	-0.111	0.3659	-0.81	-0.078	0.49
		2 min	12	-0.039	0.4742	-0.76	-0.038	1.07
		3 min	12	-0.140	0.3713	-0.80	-0.195	0.50
		4 min	12	-0.094	0.7593	-2.33	0.074	0.53
		5 min	12	0.020	0.3280	-0.67	-0.027	0.66
		6 min	12	-0.099	0.3455	-1.02	-0.008	0.29
		7 min	12	-0.179	0.4711	-1.17	-0.195	0.88
		8 min	12	0.090	0.3563	-0.36	-0.045	0.65
		9 min	12	-0.185	0.4163	-1.21	-0.071	0.44
		10 min	12	-0.068	0.2222	-0.54	-0.095	0.29
		11 min	12	-0.067	0.2881	-0.69	-0.020	0.35
		12 min	12	-0.148	0.3739	-0.67	-0.113	0.76
		13 min	12	-0.032	0.4590	-0.82	0.029	0.66
		14 min	12	-0.151	0.4143	-0.72	-0.067	0.68
		15 min	12	-0.232	1.0488	-3.37	-0.028	0.77
		16 min	12	-0.382	1.2882	-4.17	-0.070	0.86
		17 min	12	-0.299	0.6999	-2.07	-0.021	0.40
		18 min	12	0.037	0.5021	-1.20	0.018	0.65
		19 min	12	0.037	0.6534	-1.60	0.124	0.79
		20 min	12	-0.211	0.5114	-1.55	-0.058	0.50
		21 min	12	-0.883	1.6039	-4.82	-0.089	0.57
		22 min	12	-0.106	0.4508	-1.03	-0.024	0.50
		23 min	12	-0.234	0.3505	-0.88	-0.224	0.35
		24 min	12	-0.193	0.3357	-0.66	-0.220	0.37
		25 min	12	-0.310	1.1413	-3.72	-0.088	0.79
		26 min	12	-0.126	0.5315	-1.51	-0.039	0.58
		27 min	12	-0.642	1.9381	-6.77	-0.074	0.18
		28 min	12	-0.330	0.8187	-2.80	-0.113	0.28
		29 min	12	-0.232	0.8516	-2.66	0.020	0.65
		30 min	12	-0.321	0.7374	-2.35	-0.196	0.72

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 10 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	31 min	12	-0.278	0.6570	-2.33	-0.121	0.08
		32 min	11	-0.338	1.3075	-4.15	-0.127	0.94
		33 min	10	-0.203	0.5957	-1.24	-0.125	0.56
		34 min	10	-0.648	1.2641	-3.68	-0.105	0.51
		35 min	10	-0.631	1.0027	-2.30	-0.386	0.36
		36 min	10	-0.548	0.9724	-2.50	-0.269	0.33
		37 min	10	-0.562	1.0606	-3.21	-0.317	0.40
		38 min	10	-0.527	1.5347	-4.67	-0.011	0.59
		39 min	10	-0.767	1.3590	-4.05	-0.253	0.35
		40 min	10	-0.308	0.9445	-2.85	-0.161	0.49
		41 min	10	-0.761	1.4273	-3.69	-0.050	0.57
		42 min	11	-0.394	0.9477	-2.33	-0.210	0.63
		43 min	12	-0.761	1.7244	-4.35	0.039	0.64
		44 min	12	-0.816	1.8349	-5.75	-0.099	0.50
		45 min	12	-0.258	0.8378	-2.12	0.051	0.60
		46 min	12	-0.336	1.0583	-3.25	0.059	0.73
		47 min	12	-0.363	0.8166	-1.97	-0.249	0.82
		48 min	12	-0.555	0.8276	-2.22	-0.396	0.36
		49 min	12	-0.371	0.5301	-1.38	-0.185	0.49
		50 min	12	-0.735	1.4705	-4.93	-0.305	0.59
		51 min	11	-1.026	1.2990	-4.00	-0.704	0.34
		52 min	11	-0.497	0.7101	-2.25	-0.235	0.28
		53 min	11	-0.748	1.3814	-4.75	-0.356	0.30
		54 min	11	-0.304	0.6966	-2.15	-0.220	0.30
		55 min	11	-0.574	1.7292	-5.54	-0.082	0.74
		56 min	11	-0.556	1.7622	-5.73	0.083	0.48
		57 min	11	-0.231	0.8005	-2.40	-0.053	0.40
		58 min	11	-0.280	0.6899	-2.03	-0.221	0.60
		59 min	11	-0.120	0.6813	-1.59	-0.093	0.50
		60 min	11	-0.574	1.5021	-5.02	-0.133	0.19

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 11 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	61 min	11	-0.420	0.8430	-2.39	-0.045	0.33
		62 min	11	-0.450	1.1016	-3.24	-0.192	0.48
		63 min	10	-0.578	1.3141	-4.09	-0.264	0.65
		64 min	10	-0.477	0.7911	-2.36	-0.477	0.37
		65 min	9	-0.378	0.7025	-1.68	-0.401	0.76
		66 min	9	-0.876	1.1819	-3.25	-0.488	0.22
		67 min	9	-1.116	2.4765	-6.61	-0.104	0.80
		68 min	9	-0.329	0.8564	-2.11	-0.048	0.73
		69 min	9	-0.099	0.6996	-1.63	-0.030	0.56
		70 min	9	-0.282	0.9161	-1.79	-0.034	0.76
		71 min	9	-0.155	0.5587	-1.32	-0.075	0.49
		72 min	9	-0.038	0.4145	-0.56	-0.036	0.70
		73 min	9	-0.467	1.1241	-2.86	-0.059	0.69
		74 min	9	-0.272	0.6229	-1.23	-0.367	0.56
		75 min	9	-0.500	0.7958	-2.36	-0.363	0.23
		76 min	9	-0.794	1.5173	-3.81	-0.128	0.34
		77 min	9	-0.712	1.7156	-5.06	-0.167	0.43
		78 min	9	-0.391	0.7533	-1.60	-0.129	0.54
		79 min	9	-0.505	0.6232	-1.41	-0.363	0.17
		80 min	9	-0.444	0.8669	-2.29	-0.093	0.59
		81 min	9	-1.489	2.4606	-6.73	-0.324	0.55
		82 min	9	-0.567	1.0616	-2.12	-0.153	0.50
		83 min	9	-0.677	0.8313	-2.11	-0.402	0.35
		84 min	9	-0.359	0.5062	-1.22	-0.272	0.23
		85 min	9	-1.395	2.0008	-4.98	-0.561	0.29
		86 min	9	-0.322	0.4809	-1.23	-0.360	0.36
		87 min	9	-0.204	0.5227	-1.25	0.073	0.33
		88 min	9	-0.399	1.0345	-3.14	-0.146	0.15
		89 min	9	-0.692	1.5273	-4.63	-0.267	0.21
		90 min	9	-0.284	0.4218	-1.13	-0.142	0.09

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 12 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	91 min	9	-0.801	1.4928	-3.79	-0.074	0.36
		92 min	9	-0.705	1.3983	-3.81	-0.269	0.60
		93 min	10	-0.630	1.2960	-3.91	-0.284	0.82
		94 min	10	-0.606	0.9076	-2.12	-0.383	0.82
		95 min	11	-0.400	0.6586	-1.69	-0.264	0.85
		96 min	11	-0.381	0.4507	-1.15	-0.399	0.43
		97 min	11	-0.183	0.4994	-1.26	-0.100	0.73
		98 min	11	-0.355	0.8802	-2.74	-0.097	0.55
		99 min	11	-0.324	0.6779	-1.62	-0.165	0.70
		100 min	11	-0.294	1.1449	-3.50	-0.102	0.92
		101 min	11	-0.014	0.3702	-0.50	0.076	0.74
		102 min	11	-0.249	0.8654	-2.56	-0.119	0.83
		103 min	11	-0.094	0.4595	-1.03	-0.010	0.44
		104 min	11	-0.026	0.3161	-0.50	0.046	0.48
		105 min	11	-0.314	1.2306	-3.91	-0.011	0.75
		106 min	11	-0.183	0.6775	-2.02	0.020	0.33
		107 min	11	-0.189	0.6506	-1.71	0.018	0.67
		108 min	11	-0.127	0.4747	-1.05	-0.172	0.46
		109 min	11	-0.177	0.4361	-1.10	-0.147	0.44
		110 min	11	-0.070	0.4581	-0.78	0.010	0.47
		111 min	11	-0.748	1.8047	-5.93	-0.054	0.41
		112 min	11	-0.499	0.8895	-2.73	-0.178	0.57
		113 min	11	-0.482	1.0341	-2.64	-0.242	0.46
		114 min	11	-0.536	0.9771	-3.13	-0.108	0.15
		115 min	11	-0.456	0.7573	-2.08	-0.137	0.33
		116 min	11	-0.299	0.7015	-1.74	-0.080	0.42
		117 min	10	-0.269	0.8010	-1.79	0.025	0.54
		118 min	10	-0.355	1.0641	-3.07	-0.164	0.87
		119 min	10	-0.264	1.0141	-2.80	-0.081	0.66
		120 min	10	-0.267	0.8551	-2.46	-0.141	0.52

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 13 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	121 min	10	-0.012	0.5308	-0.81	0.095	0.79
		122 min	10	-0.246	0.8427	-2.00	-0.195	0.65
		123 min	11	-0.417	0.8380	-2.74	-0.120	0.20
		124 min	11	-0.615	1.3880	-4.45	-0.111	0.44
		125 min	11	-0.343	0.9429	-2.90	-0.131	0.54
		126 min	11	-0.723	1.8170	-5.80	0.130	0.32
		127 min	11	-0.439	1.3700	-4.21	-0.035	0.84
		128 min	11	-0.469	1.1816	-3.41	-0.102	0.91
		129 min	11	-0.320	1.0418	-3.18	-0.235	0.82
		130 min	11	-0.215	1.1134	-3.36	0.048	0.74
		131 min	11	-0.050	0.6528	-1.55	-0.050	0.92
		132 min	11	-0.252	1.1197	-3.21	0.074	0.80
		133 min	10	-0.481	1.4830	-4.24	0.175	0.73
		134 min	11	-0.111	0.5362	-1.06	-0.013	0.81
		135 min	11	0.021	0.5582	-1.17	0.088	0.82
		136 min	11	-0.058	0.5859	-1.21	0.032	0.79
		137 min	11	0.008	0.6335	-1.08	-0.000	0.79
		138 min	11	-0.305	0.6700	-1.36	-0.220	0.67
		139 min	11	-0.130	0.7472	-1.98	0.050	0.72
		140 min	11	-0.060	0.6145	-0.91	0.040	0.71
		141 min	11	0.154	0.4290	-0.51	0.129	0.77
		142 min	11	-0.244	0.6546	-1.41	-0.009	0.52
		143 min	11	-0.226	0.9634	-2.98	-0.061	0.74
		144 min	11	-0.231	0.5902	-1.63	-0.059	0.51
		145 min	10	-0.183	0.6974	-1.88	-0.137	0.86
		146 min	10	-0.224	0.7143	-1.86	0.031	0.77
		147 min	10	-0.463	1.3272	-4.07	-0.063	0.60
		148 min	10	-0.120	0.5105	-0.90	0.039	0.68
		149 min	10	-0.313	1.1964	-3.63	0.013	0.68
		150 min	10	-0.068	0.6213	-1.02	-0.006	1.18

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 14 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	151 min	10	-0.276	0.8706	-2.63	-0.025	0.44
		152 min	10	-0.019	0.3014	-0.41	-0.057	0.47
		153 min	10	-0.087	0.4087	-0.67	-0.064	0.65
		154 min	10	-0.094	0.4497	-0.71	-0.144	0.70
		155 min	10	0.045	0.3436	-0.48	-0.014	0.76
		156 min	10	0.093	0.5262	-0.84	0.093	1.02
		157 min	10	-0.068	0.5427	-1.10	0.073	0.61
		158 min	10	0.030	0.3490	-0.58	0.101	0.59
		159 min	10	0.082	0.3907	-0.58	0.165	0.58
		160 min	10	-0.204	0.8184	-2.27	-0.030	0.70
		161 min	10	0.009	0.3452	-0.57	0.116	0.41
		162 min	10	-0.656	1.3938	-3.68	-0.216	0.70
		163 min	11	-0.007	0.4487	-1.03	0.112	0.51
		164 min	11	-0.196	0.5570	-1.21	-0.070	0.59
		165 min	11	-0.189	0.9892	-2.96	0.010	0.64
		166 min	11	0.138	0.5483	-0.85	-0.008	0.85
		167 min	11	0.147	0.5426	-0.62	-0.030	0.89
		168 min	11	0.033	0.8331	-1.97	0.091	1.16
		169 min	10	-0.136	1.0548	-2.65	0.223	0.78
		170 min	10	-0.123	0.6105	-1.16	0.004	1.09
		171 min	10	-0.490	2.0131	-6.15	0.063	0.68
		172 min	10	-0.138	0.5517	-1.11	-0.060	0.90
		173 min	10	0.052	0.7737	-1.57	0.088	1.28
		174 min	10	-0.107	0.9387	-2.37	-0.010	0.86
		175 min	10	-0.255	1.1229	-2.89	-0.140	1.09
		176 min	10	-0.409	1.1177	-2.25	-0.094	1.04
		177 min	10	-0.193	0.6426	-1.27	-0.301	1.17
		178 min	10	-0.172	0.6627	-1.70	-0.166	0.77
		179 min	10	-0.059	0.7081	-1.44	0.074	1.23
		180 min	10	-0.244	1.0477	-3.09	0.051	0.54

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 15 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	181 min	10	0.058	0.6891	-1.40	0.117	1.04
		182 min	10	0.041	0.5543	-0.79	-0.017	0.91
		183 min	10	-0.176	0.8467	-1.78	0.095	0.82
		184 min	10	-0.207	0.5881	-1.28	-0.140	0.56
		185 min	9	-0.365	0.5829	-1.52	-0.463	0.37
		186 min	8	-0.352	1.1323	-2.90	-0.220	0.84
		187 min	9	-0.346	1.1503	-3.22	-0.234	0.75
		188 min	9	-0.097	0.4006	-0.65	-0.075	0.58
		189 min	9	-0.006	0.3877	-0.69	0.031	0.54
		190 min	9	-0.008	0.4166	-0.59	0.046	0.48
		191 min	9	-0.082	0.5807	-1.11	-0.114	0.68
		192 min	9	-0.283	1.1653	-2.75	0.064	1.24
		193 min	9	-0.630	0.9877	-2.74	-0.249	0.24
		194 min	9	-0.319	0.7112	-1.85	-0.035	0.41
		195 min	9	-0.201	0.7989	-1.97	0.109	0.54
		196 min	9	-0.189	0.6830	-1.89	0.079	0.29
		197 min	9	-0.506	1.4753	-4.32	-0.062	0.51
		198 min	10	-0.445	1.7810	-5.45	0.084	0.56
		199 min	10	-0.716	1.6512	-4.59	0.063	0.58
		200 min	10	-0.551	1.5170	-4.22	0.090	0.71
		201 min	10	-0.459	1.1417	-3.25	0.074	0.39
		202 min	10	-0.542	0.9372	-2.16	-0.270	0.64
		203 min	11	-0.032	0.6708	-1.33	0.225	0.65
		204 min	11	-0.013	0.6411	-1.27	0.141	0.79
		205 min	11	-0.096	0.4616	-1.23	-0.028	0.50
		206 min	11	-0.629	1.1735	-3.85	-0.480	0.44
		207 min	10	-0.289	0.8067	-2.11	-0.021	0.68
		208 min	10	-0.660	1.4846	-4.71	-0.148	0.35
		209 min	10	-0.449	0.6118	-1.73	-0.433	0.23
		210 min	10	-0.545	0.7358	-1.84	-0.315	0.24

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 16 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	2	211 min	10	-0.339	0.6014	-1.76	-0.245	0.44
		212 min	10	-0.186	0.5041	-1.07	-0.157	0.64
		213 min	10	-0.153	0.5731	-1.33	-0.109	0.59
		214 min	10	-0.732	2.0590	-6.46	-0.062	0.53
		215 min	10	-0.811	1.4709	-4.47	-0.604	0.68
		216 min	10	-0.677	1.0663	-3.49	-0.441	0.26
		217 min	10	-0.536	0.7175	-1.97	-0.594	0.42
		218 min	10	-0.354	0.7832	-2.38	-0.125	0.24
		219 min	10	-0.220	0.5551	-1.18	-0.311	0.63
		220 min	10	-0.049	0.3646	-0.57	0.034	0.41
		221 min	10	-0.466	1.5395	-4.67	-0.084	0.66
		222 min	10	-0.263	0.5880	-1.65	-0.162	0.41
		223 min	10	-0.241	0.5238	-1.23	-0.131	0.28
		224 min	10	-0.370	0.7167	-2.11	-0.173	0.21
		225 min	10	-0.426	0.8599	-2.69	-0.232	0.27
		226 min	10	-0.208	0.4610	-1.14	-0.203	0.57
		227 min	10	-0.160	0.5680	-0.96	0.035	0.67
		228 min	10	-0.312	0.7870	-1.99	-0.106	0.57
		229 min	11	-0.086	0.4417	-0.88	0.118	0.39
		230 min	11	-0.341	1.0038	-3.11	0.083	0.46
		231 min	11	-0.109	0.3885	-0.75	0.002	0.36
		232 min	11	-0.145	0.4680	-1.06	-0.116	0.73
		233 min	11	-0.175	0.4691	-0.79	-0.113	0.64
		234 min	11	-0.499	1.4541	-4.57	-0.204	0.66
		235 min	10	-0.797	1.9390	-5.59	-0.304	0.63
		236 min	11	-0.202	0.8538	-2.29	-0.168	0.74
		237 min	11	-0.235	0.7294	-1.48	-0.075	0.66
		238 min	11	-0.195	0.8034	-1.76	0.045	0.77
		239 min	11	-0.096	0.4277	-1.14	0.080	0.33
		240 min	6	0.172	0.1557	-0.03	0.203	0.37

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 17 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	1 min	12	1.384	2.7171	-1.93	0.363	7.40
		2 min	12	1.667	2.6141	-1.06	0.532	6.47
		3 min	12	1.236	2.5749	-1.56	0.238	6.42
		4 min	12	0.803	1.7613	-1.37	0.164	5.01
		5 min	12	0.159	1.4517	-1.77	-0.042	3.43
		6 min	12	0.769	1.7809	-1.43	0.155	4.63
		7 min	12	0.545	1.7872	-1.37	0.066	4.77
		8 min	12	0.512	2.3820	-1.45	-0.252	5.74
		9 min	12	0.042	1.7830	-3.89	-0.038	4.17
		10 min	12	0.429	1.7582	-1.81	-0.024	4.34
		11 min	12	-0.144	2.2152	-3.76	-0.119	5.05
		12 min	12	0.445	2.2586	-3.71	-0.024	4.65
		13 min	12	0.107	2.0654	-4.41	0.174	4.31
		14 min	12	0.560	1.8282	-1.88	0.080	4.11
		15 min	12	0.577	1.8313	-2.55	0.101	4.19
		16 min	12	0.148	1.8400	-3.27	-0.052	4.19
		17 min	12	0.329	2.2215	-3.21	0.111	4.19
		18 min	12	0.129	1.8076	-3.09	0.013	4.11
		19 min	12	0.106	1.8790	-3.15	0.030	4.27
		20 min	12	0.024	1.5747	-3.50	0.092	2.96
		21 min	12	0.160	1.7235	-3.12	0.012	3.91
		22 min	12	-0.417	1.8027	-3.41	-0.095	3.66
		23 min	12	-0.289	1.9079	-3.37	-0.101	3.64
		24 min	12	-0.021	1.6742	-3.22	-0.124	3.80
		25 min	12	-0.194	1.8263	-3.78	-0.207	3.99
		26 min	12	-0.266	2.0934	-3.93	-0.189	3.88
		27 min	12	-0.120	2.1519	-3.97	-0.006	3.62
		28 min	12	-0.096	2.2881	-4.56	0.113	3.82
		29 min	12	0.199	1.9265	-4.05	-0.043	3.75
		30 min	12	-0.112	2.0045	-4.02	-0.252	3.86

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 18 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	31 min	12	-0.010	1.8122	-3.59	-0.198	3.88
		32 min	11	-0.311	1.4556	-3.99	-0.213	1.93
		33 min	10	-0.406	1.5038	-4.16	-0.163	1.78
		34 min	10	-0.256	1.6070	-3.93	-0.211	2.60
		35 min	10	-0.636	1.4101	-4.13	-0.317	0.85
		36 min	10	-0.446	1.3347	-3.96	-0.289	1.14
		37 min	10	-0.490	1.2769	-3.86	-0.263	0.93
		38 min	10	-0.096	1.5771	-4.01	0.080	2.22
		39 min	10	-0.453	1.5156	-4.15	-0.182	1.28
		40 min	10	-0.619	1.4168	-4.11	-0.313	1.24
		41 min	10	-0.420	1.4160	-4.07	-0.233	1.33
		42 min	11	-0.006	1.7262	-3.97	0.048	3.56
		43 min	12	-0.356	1.6514	-4.14	-0.234	2.60
		44 min	12	-0.257	1.5659	-4.19	-0.130	2.75
		45 min	12	-0.301	1.3258	-3.98	-0.171	1.43
		46 min	12	-0.806	1.8183	-4.80	-0.207	1.05
		47 min	12	-0.953	1.6522	-4.54	-0.405	0.55
		48 min	12	-0.971	1.4828	-3.98	-0.420	0.47
		49 min	12	-0.710	1.2362	-4.03	-0.246	0.49
		50 min	12	-0.740	1.3438	-4.18	-0.248	0.51
		51 min	11	-0.784	1.3155	-4.14	-0.440	0.57
		52 min	11	-0.624	1.1214	-3.65	-0.273	0.52
		53 min	11	-0.809	1.2699	-3.88	-0.334	0.46
		54 min	11	-0.601	1.2222	-3.94	-0.265	0.44
		55 min	11	-0.716	1.2908	-4.03	-0.299	0.67
		56 min	11	-0.548	1.3872	-4.06	-0.259	1.29
		57 min	11	-0.571	1.0601	-2.76	-0.419	1.02
		58 min	11	-0.073	2.2652	-3.82	-0.294	4.44
		59 min	11	-0.124	2.0495	-3.99	-0.347	4.06
		60 min	11	-0.045	1.7025	-2.39	-0.223	4.42

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 19 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	61 min	11	-0.066	1.8863	-3.36	-0.270	4.33
		62 min	11	-0.234	2.0206	-3.83	-0.358	4.83
		63 min	10	-0.327	2.1299	-4.05	-0.309	4.67
		64 min	10	-0.364	1.8634	-4.01	-0.252	3.63
		65 min	9	-0.088	2.0593	-3.45	-0.324	4.53
		66 min	9	-0.134	2.1476	-3.99	-0.277	4.38
		67 min	9	-0.246	2.1356	-4.07	-0.286	4.35
		68 min	9	-0.248	2.1483	-4.20	-0.318	4.32
		69 min	9	-0.229	2.0544	-4.14	-0.286	4.01
		70 min	9	-0.195	2.0997	-4.12	-0.174	4.21
		71 min	9	-0.090	2.0906	-3.93	-0.112	4.29
		72 min	9	-0.179	1.9040	-3.97	-0.225	3.50
		73 min	9	-0.196	2.0677	-4.05	-0.313	4.10
		74 min	9	-0.072	2.1801	-3.88	-0.238	4.63
		75 min	9	0.225	2.2800	-4.09	-0.080	4.50
		76 min	9	-0.026	2.2620	-4.19	-0.103	4.67
		77 min	9	0.270	2.3819	-4.07	-0.057	4.60
		78 min	9	0.161	2.3463	-4.21	-0.121	4.58
		79 min	9	-0.038	2.0908	-4.13	-0.082	3.94
		80 min	9	0.164	2.1739	-4.08	0.084	4.42
		81 min	9	-0.300	1.6282	-4.12	0.120	1.92
		82 min	9	-0.287	1.6333	-4.12	0.029	1.94
		83 min	9	-0.101	1.9622	-4.17	-0.181	3.08
		84 min	9	0.147	1.8655	-3.19	-0.052	3.20
		85 min	9	-0.036	1.8826	-4.05	-0.071	2.74
		86 min	9	-0.293	1.6019	-4.07	-0.003	1.74
		87 min	9	-0.384	1.5045	-4.05	-0.014	1.36
		88 min	9	-0.453	1.4353	-4.14	0.014	0.38
		89 min	9	-0.201	1.7712	-3.97	-0.035	2.88
		90 min	9	-0.364	1.3159	-3.56	-0.028	0.99

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 20 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	91 min	9	-0.552	1.4631	-4.24	-0.056	0.63
		92 min	9	-0.485	1.4798	-4.25	-0.075	0.55
		93 min	10	-0.538	1.3942	-4.30	-0.175	0.48
		94 min	10	-0.565	1.3593	-4.31	-0.143	0.44
		95 min	11	-1.057	1.9780	-5.37	-0.254	0.61
		96 min	11	-0.880	2.2070	-5.36	-0.247	2.44
		97 min	11	-0.842	2.0887	-5.39	-0.192	1.30
		98 min	11	-0.900	2.0365	-5.26	-0.126	0.72
		99 min	11	-0.962	1.8580	-5.03	-0.214	0.33
		100 min	11	-1.087	1.8355	-4.79	-0.437	0.21
		101 min	11	-1.145	1.8495	-5.03	-0.368	0.20
		102 min	11	-0.896	1.8801	-4.93	-0.147	0.55
		103 min	11	-0.504	2.5610	-5.18	-0.247	4.23
		104 min	11	-0.761	1.9485	-4.75	-0.110	0.95
		105 min	11	-0.879	2.0183	-5.00	-0.456	1.49
		106 min	11	-0.493	2.5883	-5.22	-0.074	4.76
		107 min	11	-0.674	2.4542	-5.25	-0.383	4.31
		108 min	11	-0.789	2.0577	-5.33	-0.058	0.79
		109 min	11	-0.975	1.9592	-5.32	-0.133	0.67
		110 min	11	-0.961	2.0166	-5.34	-0.405	0.84
		111 min	11	-1.122	1.8828	-5.42	-0.554	0.72
		112 min	11	-1.020	1.6597	-4.52	-0.452	0.40
		113 min	11	-0.881	1.9710	-4.93	-0.283	1.86
		114 min	11	-0.581	2.4313	-5.18	-0.329	4.69
		115 min	11	-0.661	2.4415	-5.28	-0.384	4.30
		116 min	11	-1.001	1.8111	-5.29	-0.182	0.41
		117 min	10	-0.574	0.8717	-2.66	-0.319	0.47
		118 min	10	-0.675	1.1729	-3.78	-0.435	0.55
		119 min	10	-0.763	1.2926	-4.07	-0.455	0.74
		120 min	10	-0.736	1.3087	-4.13	-0.488	0.51

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 21 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	121 min	10	-0.681	1.0115	-3.13	-0.453	0.49
		122 min	10	-0.514	0.5539	-1.35	-0.440	0.28
		123 min	11	-0.326	1.2683	-2.90	-0.273	2.35
		124 min	11	-0.192	0.8826	-1.27	-0.187	1.58
		125 min	11	-0.443	1.3804	-3.53	-0.223	2.14
		126 min	11	-0.458	0.7988	-1.92	-0.284	1.15
		127 min	11	-0.436	0.8920	-2.45	-0.303	0.76
		128 min	11	-0.303	1.6732	-4.00	-0.325	2.61
		129 min	11	-0.131	1.9515	-3.55	-0.451	4.08
		130 min	11	-0.191	1.6548	-3.87	-0.230	2.57
		131 min	11	-0.402	1.6661	-4.00	-0.288	3.01
		132 min	11	-0.274	1.0562	-1.49	-0.318	2.42
		133 min	10	-0.507	1.1583	-3.61	-0.190	0.40
		134 min	11	-0.566	1.2892	-3.70	-0.297	1.57
		135 min	11	-0.626	1.2297	-3.96	-0.367	0.47
		136 min	11	-0.570	1.3441	-4.09	-0.405	0.67
		137 min	11	-0.286	1.7970	-4.40	-0.240	3.29
		138 min	11	-0.337	1.2503	-3.00	-0.224	1.98
		139 min	11	-0.273	1.6261	-3.89	-0.115	2.83
		140 min	11	0.067	2.0534	-4.06	-0.232	3.30
		141 min	11	-0.402	1.5436	-4.08	-0.459	2.13
		142 min	11	-0.319	1.6077	-4.04	-0.219	1.83
		143 min	11	-0.111	1.6970	-3.92	-0.267	2.49
		144 min	11	-0.138	1.9302	-3.88	-0.340	3.10
		145 min	10	-0.473	1.7728	-4.10	-0.430	3.17
		146 min	10	0.084	2.2238	-4.17	-0.343	4.40
		147 min	10	-0.598	1.3228	-3.98	-0.371	0.51
		148 min	10	-0.611	1.2511	-3.81	-0.263	0.59
		149 min	10	-0.554	1.3739	-3.84	-0.315	1.49
		150 min	10	-0.587	1.3077	-3.89	-0.255	1.02

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 22 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	151 min	10	-0.565	1.3282	-3.96	-0.244	0.68
		152 min	10	-0.431	1.3976	-3.97	-0.118	0.94
		153 min	10	-0.556	1.2820	-3.80	-0.206	0.70
		154 min	10	-0.493	1.4416	-4.04	-0.134	1.30
		155 min	10	-0.303	1.3687	-3.60	-0.222	1.68
		156 min	10	-0.419	1.3057	-3.49	-0.150	1.23
		157 min	10	0.068	1.5859	-3.81	0.164	1.97
		158 min	10	-0.136	1.5721	-3.43	0.016	2.26
		159 min	10	-0.108	1.3613	-2.28	-0.153	2.86
		160 min	10	-0.229	1.6714	-3.75	-0.147	2.89
		161 min	10	-0.189	1.5798	-3.42	0.070	2.89
		162 min	10	-0.091	1.5942	-3.46	0.155	2.49
		163 min	11	0.125	1.7640	-3.91	0.030	3.22
		164 min	11	0.151	1.8501	-3.86	0.074	3.31
		165 min	11	-0.037	1.6795	-3.91	-0.069	2.95
		166 min	11	-0.044	1.3542	-2.75	-0.055	2.89
		167 min	11	-0.383	1.3873	-3.93	-0.087	1.72
		168 min	11	-0.203	1.3874	-3.93	-0.056	1.45
		169 min	10	0.312	2.0613	-3.99	0.132	4.04
		170 min	10	-0.321	1.3403	-3.96	0.037	0.95
		171 min	10	0.067	1.6272	-3.85	0.063	2.67
		172 min	10	-0.137	1.6262	-3.88	0.047	2.89
		173 min	10	-0.107	1.4692	-3.95	0.124	1.55
		174 min	10	-0.062	1.5699	-3.92	0.154	2.31
		175 min	10	-0.075	1.6000	-3.93	0.070	2.58
		176 min	10	0.041	1.8026	-3.91	0.069	3.63
		177 min	10	0.219	1.6753	-2.33	0.044	4.12
		178 min	10	0.305	1.8393	-3.74	0.108	3.61
		179 min	10	0.133	1.7957	-4.06	0.055	2.47
		180 min	10	-0.099	1.4908	-3.97	0.058	1.46

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 23 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	181 min	10	-0.386	1.6137	-4.10	0.106	1.33
		182 min	10	0.095	1.7134	-3.93	0.145	2.89
		183 min	10	0.210	1.7474	-3.89	0.134	2.81
		184 min	10	0.079	1.5369	-3.52	0.045	2.60
		185 min	9	0.267	1.9038	-3.42	0.255	4.09
		186 min	8	0.208	2.2534	-4.17	0.076	4.15
		187 min	9	0.153	1.9777	-4.35	0.292	3.11
		188 min	9	0.308	2.1140	-4.25	0.049	3.06
		189 min	9	0.281	2.0298	-4.20	0.104	3.03
		190 min	9	0.472	2.2399	-3.99	0.154	3.70
		191 min	9	0.917	2.1417	-2.71	0.216	4.21
		192 min	9	0.799	2.3523	-4.07	0.948	4.24
		193 min	9	1.173	2.7984	-4.12	0.374	4.38
		194 min	9	1.097	2.7674	-4.17	0.360	4.22
		195 min	9	1.304	3.0592	-4.27	0.173	4.79
		196 min	9	0.863	2.7242	-4.29	0.657	4.91
		197 min	9	0.837	2.7012	-4.33	0.477	4.82
		198 min	10	0.961	2.5775	-4.39	0.772	4.93
		199 min	10	0.124	1.7793	-3.62	0.070	3.49
		200 min	10	-0.198	1.9678	-4.33	0.027	2.90
		201 min	10	0.225	2.1475	-4.24	0.149	4.69
		202 min	10	0.227	2.1500	-4.28	0.057	4.18
		203 min	11	0.076	2.7895	-5.02	0.084	4.36
		204 min	11	-0.243	1.9731	-4.37	0.104	3.67
		205 min	11	0.054	2.7355	-5.02	0.034	3.75
		206 min	11	-0.445	2.5632	-5.05	-0.058	3.64
		207 min	10	-0.483	2.5543	-5.06	0.090	3.89
		208 min	10	-0.609	2.3801	-5.10	0.010	2.98
		209 min	10	-0.964	1.9829	-5.00	-0.139	0.55
		210 min	10	-0.062	2.7508	-4.38	-0.122	4.45

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 24 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	3	211 min	10	-0.253	2.8497	-5.00	-0.129	4.00
		212 min	10	-0.560	1.6070	-5.01	-0.093	0.57
		213 min	10	-0.489	2.5083	-4.97	-0.042	3.84
		214 min	10	-0.737	2.4105	-5.17	-0.187	3.28
		215 min	10	-0.991	1.9845	-5.10	-0.144	0.25
		216 min	10	-0.519	2.3228	-5.11	0.009	2.40
		217 min	10	-0.901	2.0174	-5.05	-0.214	0.90
		218 min	10	-1.043	1.8735	-4.82	-0.240	0.21
		219 min	10	-0.881	1.7309	-4.37	-0.194	0.17
		220 min	10	-0.802	1.6030	-4.39	-0.269	0.55
		221 min	10	-0.617	2.1585	-4.33	-0.085	2.74
		222 min	10	-0.875	1.8775	-4.41	0.002	0.30
		223 min	10	-0.904	1.9044	-4.59	-0.128	0.81
		224 min	10	-0.767	2.2214	-4.89	-0.232	2.02
		225 min	10	-0.412	2.4412	-4.78	0.039	3.57
		226 min	10	-0.325	1.6461	-4.22	0.069	1.80
		227 min	10	-0.828	1.6863	-4.12	-0.376	0.81
		228 min	10	-0.517	2.3653	-4.88	-0.081	2.38
		229 min	11	-0.573	1.3336	-4.17	-0.168	0.40
		230 min	11	-0.071	2.2436	-4.23	0.035	3.37
		231 min	11	-0.598	1.6071	-4.01	-0.281	1.56
		232 min	11	-0.061	2.5932	-5.11	0.299	4.38
		233 min	11	-0.393	2.3879	-5.24	-0.175	3.77
		234 min	11	-0.716	1.9840	-5.27	-0.245	1.80
		235 min	10	-1.136	1.8719	-5.39	-0.518	0.22
		236 min	11	-0.765	1.9922	-5.26	-0.250	1.54
		237 min	11	-0.846	2.0788	-5.43	-0.327	1.96
		238 min	11	-1.290	1.7123	-5.14	-0.684	0.53
		239 min	11	-0.805	2.2363	-5.48	-0.490	3.34
		240 min	6	-0.675	1.6895	-3.20	0.226	0.80

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 25 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	1 min	12	0.743	2.3214	-2.43	0.034	4.70
		2 min	12	0.742	2.0802	-2.70	0.716	3.75
		3 min	12	0.867	2.4640	-2.31	0.339	5.35
		4 min	12	1.066	1.4746	-1.26	0.805	4.04
		5 min	12	0.629	1.7741	-2.12	0.517	4.27
		6 min	12	0.149	1.2175	-3.05	0.252	2.14
		7 min	12	0.437	1.9266	-2.41	0.083	5.58
		8 min	12	0.295	1.7943	-1.82	0.043	5.34
		9 min	12	0.469	0.8582	-0.89	0.247	1.81
		10 min	12	1.167	1.8920	-1.34	0.499	5.10
		11 min	12	-0.136	1.4359	-2.38	0.016	2.55
		12 min	12	-0.588	1.4842	-3.71	-0.095	1.59
		13 min	12	-0.282	1.1349	-2.86	0.129	0.83
		14 min	12	-0.052	1.7442	-3.07	0.061	4.20
		15 min	12	-0.378	1.3147	-3.13	0.138	1.15
		16 min	12	0.167	1.3363	-3.27	0.225	2.37
		17 min	12	-0.330	1.2894	-3.21	0.046	1.73
		18 min	12	-0.162	1.4393	-3.09	0.158	2.27
		19 min	12	-0.698	1.4972	-3.20	0.078	0.68
		20 min	12	-0.770	1.5295	-3.50	0.038	0.43
		21 min	12	-0.108	1.4107	-3.12	0.022	2.91
		22 min	12	-0.584	1.2654	-3.41	0.047	0.34
		23 min	12	-0.687	1.2427	-3.37	-0.018	0.34
		24 min	12	-0.772	1.3095	-3.21	-0.079	0.38
		25 min	12	-0.884	1.5051	-3.78	0.010	0.46
		26 min	12	-0.767	1.5957	-3.69	-0.095	0.91
		27 min	12	-0.681	1.6731	-3.84	0.025	1.64
		28 min	12	-0.793	1.5657	-3.79	0.049	0.46
		29 min	12	-0.871	1.5739	-4.05	-0.053	0.50
		30 min	12	-0.945	1.5314	-4.02	-0.123	0.30

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 26 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	31 min	12	-0.552	1.3984	-3.59	-0.025	1.36
		32 min	11	-0.399	1.2157	-3.99	-0.020	0.36
		33 min	10	-0.808	1.3510	-4.16	-0.256	0.29
		34 min	10	-0.882	1.4434	-3.94	-0.079	0.34
		35 min	10	-0.428	1.6674	-4.13	-0.070	2.26
		36 min	10	-0.721	1.4509	-3.95	-0.098	0.40
		37 min	10	-0.521	1.5961	-3.86	-0.037	1.62
		38 min	10	-0.867	1.8831	-4.01	-0.121	1.93
		39 min	10	-0.920	1.8333	-4.15	-0.085	1.45
		40 min	10	-1.069	1.6296	-4.11	-0.182	0.38
		41 min	10	-1.071	1.6334	-4.07	-0.147	0.42
		42 min	11	-0.974	1.5345	-3.97	-0.142	0.45
		43 min	12	-0.989	1.5804	-4.14	-0.152	0.47
		44 min	12	-1.017	1.6028	-4.19	-0.132	0.44
		45 min	12	-0.879	1.6650	-3.98	-0.150	1.35
		46 min	12	-0.751	1.4295	-4.11	-0.119	0.49
		47 min	12	-1.009	1.5116	-4.07	-0.228	0.48
		48 min	12	-0.978	1.4586	-3.86	-0.259	0.48
		49 min	12	-1.070	1.5097	-4.03	-0.310	0.41
		50 min	12	-0.679	1.9072	-4.17	-0.147	2.70
		51 min	11	-0.811	1.4001	-4.14	-0.203	0.41
		52 min	11	-0.776	1.3049	-3.65	-0.196	0.47
		53 min	11	-0.834	1.3286	-3.88	-0.244	0.42
		54 min	11	-0.818	1.3625	-3.94	-0.207	0.42
		55 min	11	-0.830	1.3606	-4.03	-0.182	0.38
		56 min	11	-0.868	1.3581	-4.06	-0.264	0.38
		57 min	11	-0.762	1.0788	-2.76	-0.374	0.33
		58 min	11	-0.708	1.1400	-3.82	-0.234	0.22
		59 min	11	-0.732	1.2945	-3.99	-0.211	0.26
		60 min	11	-0.571	0.8222	-2.39	-0.228	0.23

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 27 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	61 min	11	-0.756	1.1727	-3.37	-0.177	0.30
		62 min	11	-0.788	1.3031	-3.83	-0.259	0.40
		63 min	10	-0.734	1.3013	-4.06	-0.179	0.32
		64 min	10	-0.754	1.3796	-4.01	-0.220	0.50
		65 min	9	-0.857	1.2516	-3.45	-0.419	0.48
		66 min	9	-0.848	1.4598	-3.99	-0.248	0.72
		67 min	9	-0.762	1.4632	-4.08	-0.253	0.60
		68 min	9	-0.796	1.4374	-4.19	-0.241	0.55
		69 min	9	-0.868	1.4369	-4.14	-0.225	0.47
		70 min	9	-0.812	1.4037	-4.12	-0.250	0.63
		71 min	9	-0.785	1.3161	-3.93	-0.278	0.47
		72 min	9	-0.856	1.4355	-3.97	-0.281	0.46
		73 min	9	-0.781	1.4878	-4.05	-0.151	0.69
		74 min	9	-0.710	1.3151	-3.88	-0.249	0.50
		75 min	9	-0.724	1.4978	-4.09	-0.174	0.52
		76 min	9	-0.691	1.3993	-4.19	-0.307	0.45
		77 min	9	-0.701	1.4168	-4.07	-0.245	0.46
		78 min	9	-0.664	1.4491	-4.21	-0.187	0.56
		79 min	9	-0.716	1.4617	-4.13	-0.252	0.58
		80 min	9	-0.105	1.7488	-4.09	-0.049	2.68
		81 min	9	-0.643	1.4281	-4.12	-0.249	0.55
		82 min	9	-0.705	1.4731	-4.13	-0.225	0.60
		83 min	9	-0.602	1.4706	-4.17	-0.142	0.70
		84 min	9	-0.513	1.1978	-3.19	-0.155	0.70
		85 min	9	-0.638	1.3908	-4.05	-0.195	0.49
		86 min	9	-0.689	1.5189	-4.07	-0.240	0.68
		87 min	9	-0.667	1.5330	-4.05	-0.003	0.58
		88 min	9	-0.714	1.6347	-4.14	-0.061	0.49
		89 min	9	-0.712	1.5892	-3.97	-0.117	0.50
		90 min	9	-0.761	1.4565	-3.56	-0.342	0.43

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 28 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	91 min	9	-0.747	1.7361	-4.24	-0.444	1.09
		92 min	9	-0.751	1.7052	-4.25	-0.172	0.66
		93 min	10	-0.641	1.6675	-4.29	-0.108	0.63
		94 min	10	-0.675	1.6531	-4.30	-0.102	0.73
		95 min	11	-0.946	1.7514	-4.40	-0.292	0.57
		96 min	11	-0.920	1.7631	-4.40	-0.228	0.80
		97 min	11	-0.748	1.9412	-4.41	-0.088	1.84
		98 min	11	-0.754	1.9253	-4.57	-0.111	1.74
		99 min	11	-0.909	1.7027	-4.26	-0.330	0.58
		100 min	11	-0.918	1.8059	-4.67	-0.002	0.50
		101 min	11	-0.768	2.0785	-4.55	-0.311	3.05
		102 min	11	-0.980	1.6487	-4.33	-0.308	0.45
		103 min	11	-0.946	1.7174	-4.53	-0.361	1.07
		104 min	11	-1.001	1.7648	-4.75	-0.266	0.52
		105 min	11	-0.999	1.6716	-4.51	-0.323	0.45
		106 min	11	-0.932	1.7278	-4.36	-0.231	0.63
		107 min	11	-0.891	1.6838	-4.22	-0.260	0.55
		108 min	11	-0.823	1.8451	-4.37	-0.144	1.39
		109 min	11	-1.015	1.6946	-4.41	-0.346	0.52
		110 min	11	-1.056	1.7091	-4.35	-0.431	0.55
		111 min	11	-1.069	1.6393	-4.17	-0.453	0.45
		112 min	11	-1.094	1.6166	-4.13	-0.468	0.47
		113 min	11	-1.072	1.6505	-4.17	-0.455	0.43
		114 min	11	-0.955	1.5015	-3.38	-0.394	0.59
		115 min	11	-1.069	1.5876	-4.02	-0.407	0.42
		116 min	11	-1.008	1.4752	-3.62	-0.318	0.46
		117 min	10	-0.734	1.1586	-3.07	-0.356	0.38
		118 min	10	-0.738	1.4788	-3.78	-0.243	0.69
		119 min	10	-0.821	1.4961	-4.07	-0.254	0.53
		120 min	10	-0.857	1.4886	-4.12	-0.311	0.45

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 29 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	121 min	10	-0.763	1.2680	-3.13	-0.279	0.57
		122 min	10	-0.599	0.9425	-3.03	-0.402	0.38
		123 min	11	-0.676	1.1651	-2.95	-0.353	0.56
		124 min	11	-0.587	0.9456	-2.95	-0.471	0.46
		125 min	11	-0.825	1.2911	-3.53	-0.307	0.53
		126 min	11	-0.598	1.0893	-2.97	-0.518	0.60
		127 min	11	-0.715	1.0570	-2.94	-0.424	0.60
		128 min	11	-0.837	1.3128	-4.00	-0.480	0.74
		129 min	11	-0.639	1.3450	-3.55	-0.301	0.89
		130 min	11	-0.867	1.3817	-3.88	-0.456	1.09
		131 min	11	-0.919	1.3658	-4.00	-0.494	0.28
		132 min	11	-0.641	0.8854	-2.93	-0.464	0.42
		133 min	10	-0.948	1.3257	-3.61	-0.547	0.49
		134 min	11	-0.913	1.3392	-3.70	-0.431	0.55
		135 min	11	-0.808	1.3648	-3.96	-0.311	0.60
		136 min	11	-1.075	1.5255	-4.09	-0.388	0.63
		137 min	11	-0.926	1.4743	-4.40	-0.193	0.49
		138 min	11	-0.552	1.4627	-2.99	-0.369	2.19
		139 min	11	-0.588	1.7112	-3.89	-0.166	2.39
		140 min	11	-0.880	1.3919	-4.06	-0.456	0.40
		141 min	11	-0.441	1.8068	-4.07	-0.119	2.84
		142 min	11	-0.878	1.3992	-4.04	-0.555	0.61
		143 min	11	-0.776	1.3981	-3.92	-0.254	0.57
		144 min	11	-0.765	1.2056	-3.88	-0.530	0.63
		145 min	10	-0.901	1.4834	-4.10	-0.438	0.43
		146 min	10	-0.686	1.3786	-4.17	-0.190	0.43
		147 min	10	-0.763	1.5252	-3.98	-0.280	0.54
		148 min	10	-0.759	1.4944	-3.81	-0.253	0.51
		149 min	10	-0.553	1.6719	-3.84	-0.151	1.53
		150 min	10	-0.626	1.5995	-3.89	0.108	0.81

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 30 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	151 min	10	-0.575	1.6665	-3.96	-0.141	1.06
		152 min	10	-0.672	1.4837	-3.97	-0.150	0.49
		153 min	10	-0.666	1.5548	-3.80	-0.003	0.66
		154 min	10	-0.697	1.6336	-4.04	-0.112	0.75
		155 min	10	-0.510	1.6802	-3.60	0.147	0.91
		156 min	10	-0.559	1.6216	-3.49	0.022	1.09
		157 min	10	-0.551	1.4346	-3.81	-0.028	1.10
		158 min	10	-0.507	1.6742	-3.44	-0.048	2.16
		159 min	10	-0.438	1.4251	-3.40	-0.092	1.48
		160 min	10	-0.570	1.6626	-3.76	-0.170	1.53
		161 min	10	-0.408	1.7595	-3.42	-0.080	2.35
		162 min	10	-0.290	1.8793	-3.46	-0.078	3.11
		163 min	11	-0.175	1.9749	-3.91	-0.022	3.02
		164 min	11	-0.117	2.1419	-3.86	-0.017	3.47
		165 min	11	-0.576	1.5361	-3.91	-0.014	1.01
		166 min	11	-0.533	1.2842	-3.17	-0.230	1.08
		167 min	11	-0.690	1.5337	-3.93	-0.154	1.25
		168 min	11	-0.214	2.1215	-3.93	0.002	4.15
		169 min	10	-0.291	2.0622	-4.00	-0.033	2.66
		170 min	10	-0.379	1.9239	-3.97	-0.034	2.57
		171 min	10	-0.127	2.1158	-3.85	0.013	3.03
		172 min	10	-0.093	2.1690	-3.88	0.064	3.01
		173 min	10	-0.038	2.3487	-3.95	0.115	3.85
		174 min	10	-0.061	2.2276	-3.93	0.207	3.67
		175 min	10	-0.210	2.0398	-3.94	0.215	2.83
		176 min	10	-0.195	1.9463	-3.92	0.156	2.21
		177 min	10	-0.292	1.4253	-3.07	0.109	1.81
		178 min	10	-0.422	1.7268	-3.74	-0.014	2.18
		179 min	10	-0.592	1.7259	-4.06	-0.157	1.73
		180 min	10	-0.496	1.6703	-3.98	0.121	1.08

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 31 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	181 min	10	-0.577	1.6961	-4.10	0.114	1.09
		182 min	10	-0.324	1.8823	-3.93	0.106	2.32
		183 min	10	-0.284	1.9365	-3.90	0.071	2.78
		184 min	10	-0.257	1.9207	-3.52	0.044	3.19
		185 min	9	-0.608	1.5196	-3.42	-0.019	0.86
		186 min	8	-0.755	1.8443	-4.17	0.073	0.85
		187 min	9	-0.670	1.7594	-4.35	0.066	0.92
		188 min	9	-0.500	1.9164	-4.25	0.117	1.56
		189 min	9	-0.694	1.7663	-4.20	0.048	1.08
		190 min	9	-0.308	2.1256	-4.00	0.048	3.09
		191 min	9	-0.485	1.4129	-2.85	-0.011	1.10
		192 min	9	-0.059	2.1329	-4.07	0.117	3.49
		193 min	9	-0.247	2.1331	-4.12	0.058	3.44
		194 min	9	-0.152	2.1181	-4.17	0.121	3.66
		195 min	9	-0.020	1.8864	-4.27	0.111	2.88
		196 min	9	-0.295	1.6745	-4.29	0.162	1.21
		197 min	9	-0.067	2.3995	-4.33	0.152	3.44
		198 min	10	-0.300	1.9622	-4.39	0.032	2.93
		199 min	10	-0.524	1.5539	-3.62	-0.287	1.67
		200 min	10	-0.728	1.6110	-4.33	-0.167	0.68
		201 min	10	-0.631	1.6283	-4.24	-0.054	0.62
		202 min	10	-0.253	2.1827	-4.28	-0.012	3.80
		203 min	11	-0.220	2.0760	-4.37	0.134	3.78
		204 min	11	-0.888	2.5025	-5.15	-0.135	3.31
		205 min	11	-0.342	1.9176	-4.41	0.117	2.88
		206 min	11	-0.930	1.5968	-4.23	-0.368	0.87
		207 min	10	-0.828	1.6014	-4.48	-0.422	0.67
		208 min	10	-0.946	1.5791	-4.41	-0.351	0.37
		209 min	10	-1.020	1.6009	-4.30	-0.337	0.33
		210 min	10	-0.789	1.5734	-4.38	-0.020	0.34

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 32 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	4	211 min	10	-0.807	1.6374	-4.39	0.008	0.56
		212 min	10	-0.866	1.3412	-2.99	-0.338	0.48
		213 min	10	-1.174	1.7566	-4.37	-0.243	0.83
		214 min	10	-0.589	1.6864	-4.37	-0.097	1.34
		215 min	10	-1.039	1.6815	-4.28	-0.390	0.83
		216 min	10	-1.133	1.6242	-4.09	-0.510	0.53
		217 min	10	-1.060	1.6668	-4.25	-0.291	0.46
		218 min	10	-1.142	1.6772	-4.32	-0.447	0.33
		219 min	10	-1.136	1.6750	-4.37	-0.510	0.27
		220 min	10	-0.977	1.9266	-4.39	-0.413	1.72
		221 min	10	-1.052	1.7173	-4.33	-0.371	0.35
		222 min	10	-1.101	1.7030	-4.41	-0.460	0.38
		223 min	10	-1.050	1.6501	-4.29	-0.332	0.33
		224 min	10	-0.965	1.7375	-4.36	-0.191	1.05
		225 min	10	-0.883	1.5331	-4.23	-0.351	0.91
		226 min	10	-0.691	2.2311	-4.22	-0.261	3.30
		227 min	10	-1.074	1.6965	-4.12	-0.412	0.56
		228 min	10	-0.904	1.5605	-4.16	-0.408	0.50
		229 min	11	-0.462	1.8489	-4.17	-0.046	2.43
		230 min	11	-1.022	1.5550	-4.23	-0.607	0.43
		231 min	11	-0.937	1.4772	-4.01	-0.540	0.49
		232 min	11	-0.900	1.5634	-3.88	-0.170	0.40
		233 min	11	-0.792	1.4325	-3.76	-0.638	0.86
		234 min	11	-1.200	1.4617	-3.44	-0.680	0.31
		235 min	10	-1.322	1.5622	-3.57	-0.654	0.27
		236 min	11	-1.160	1.5001	-3.45	-0.547	0.26
		237 min	11	-0.879	1.8260	-3.76	-0.558	1.71
		238 min	11	-0.816	1.3335	-3.40	-0.540	0.62
		239 min	11	-1.100	1.4135	-3.50	-0.535	0.73
		240 min	6	-1.167	1.8308	-3.41	-0.874	1.09

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 33 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	1 min	12	1.092	1.8112	-0.40	0.253	5.70
		2 min	12	0.675	1.1120	-0.61	0.358	3.21
		3 min	12	0.671	0.9944	-0.75	0.423	2.87
		4 min	12	0.787	0.9286	-0.16	0.441	3.08
		5 min	12	0.349	1.1237	-1.42	0.198	3.24
		6 min	12	0.297	1.2543	-2.30	0.135	3.21
		7 min	12	0.291	1.3725	-2.83	0.319	3.35
		8 min	12	0.166	1.3573	-2.90	0.172	3.28
		9 min	12	0.441	0.9648	-0.54	0.078	3.32
		10 min	12	0.248	1.1312	-1.78	0.135	3.27
		11 min	12	0.049	1.2640	-2.92	0.059	2.82
		12 min	12	0.194	1.6592	-3.51	0.041	2.93
		13 min	12	-0.222	1.0930	-3.45	0.080	0.57
		14 min	12	-0.257	1.1949	-3.82	0.093	0.58
		15 min	12	-0.204	1.0332	-3.17	0.082	0.57
		16 min	12	0.307	1.7200	-2.22	0.194	5.12
		17 min	12	-0.178	1.0337	-3.13	0.115	0.61
		18 min	12	-0.180	1.0569	-3.14	0.097	0.86
		19 min	12	-0.254	1.1311	-3.56	0.088	0.68
		20 min	12	-0.343	1.2372	-3.92	0.049	0.60
		21 min	12	-0.036	1.6525	-3.96	0.057	3.49
		22 min	12	-0.306	1.2261	-3.85	0.121	0.52
		23 min	12	-0.333	1.2234	-3.95	0.090	0.47
		24 min	12	-0.374	1.2255	-3.97	0.069	0.42
		25 min	12	-0.412	1.2105	-3.96	0.039	0.39
		26 min	12	-0.403	1.2173	-3.99	0.040	0.39
		27 min	12	-0.432	1.2300	-4.09	0.013	0.32
		28 min	12	-0.460	1.2141	-4.03	-0.027	0.32
		29 min	12	-0.381	1.1228	-3.65	0.056	0.39
		30 min	12	-0.437	1.3513	-4.48	0.085	0.50

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 34 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	31 min	12	-0.433	1.0887	-3.56	0.031	0.20
		32 min	11	-0.266	0.7508	-2.31	0.054	0.12
		33 min	10	-0.126	0.4482	-1.03	0.060	0.24
		34 min	10	-0.023	0.5956	-0.99	0.070	1.02
		35 min	10	-0.179	0.4986	-0.91	-0.026	0.45
		36 min	10	-0.082	0.5402	-1.04	0.021	0.71
		37 min	10	-0.012	0.7455	-1.16	0.042	1.40
		38 min	10	0.027	0.6422	-1.03	0.041	1.14
		39 min	10	-0.528	1.4047	-4.25	-0.032	0.48
		40 min	10	-0.473	1.3055	-3.92	-0.035	0.50
		41 min	10	-0.538	1.3887	-4.28	-0.061	0.34
		42 min	11	-0.448	1.3547	-4.31	-0.047	0.40
		43 min	12	-0.456	1.2952	-4.35	-0.051	0.36
		44 min	12	-0.430	1.3329	-4.43	0.018	0.42
		45 min	12	-0.464	1.3283	-4.38	-0.081	0.49
		46 min	12	-0.387	0.9652	-3.04	-0.095	0.51
		47 min	12	-0.442	1.1874	-3.91	-0.031	0.51
		48 min	12	-0.433	1.2761	-4.20	-0.026	0.59
		49 min	12	-0.438	1.3223	-4.38	-0.031	0.59
		50 min	12	-0.459	1.3321	-4.40	-0.083	0.64
		51 min	11	-0.188	0.5698	-1.46	-0.123	0.62
		52 min	11	-0.132	0.4946	-1.19	-0.033	0.60
		53 min	11	-0.121	0.5129	-1.22	-0.066	0.64
		54 min	11	0.371	1.8980	-1.19	-0.038	5.90
		55 min	11	-0.175	0.4817	-1.26	-0.020	0.52
		56 min	11	-0.156	0.4644	-1.17	-0.074	0.56
		57 min	11	-0.184	0.5287	-1.34	-0.014	0.62
		58 min	11	-0.162	0.4901	-1.22	-0.045	0.61
		59 min	11	-0.195	0.5086	-1.26	-0.153	0.72
		60 min	11	-0.204	0.4985	-1.27	-0.102	0.72

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	61 min	11	-0.135	0.5264	-1.34	-0.126	0.72
		62 min	11	-0.154	0.5249	-1.37	-0.085	0.69
		63 min	10	0.322	1.7302	-1.42	-0.084	5.00
		64 min	10	-0.201	0.5086	-1.30	-0.153	0.67
		65 min	9	-0.183	0.5778	-1.40	-0.123	0.65
		66 min	9	-0.182	0.5611	-1.26	-0.155	0.67
		67 min	9	-0.224	0.5749	-1.40	-0.153	0.68
		68 min	9	-0.202	0.5440	-1.38	-0.154	0.56
		69 min	9	-0.210	0.5646	-1.46	-0.126	0.62
		70 min	9	-0.195	0.5371	-1.39	-0.115	0.60
		71 min	9	-0.194	0.5310	-1.31	-0.217	0.62
		72 min	9	-0.166	0.5436	-1.37	-0.128	0.56
		73 min	9	-0.168	0.5447	-1.30	-0.165	0.57
		74 min	9	0.056	0.8865	-1.40	-0.043	1.87
		75 min	9	-0.094	0.5917	-1.41	-0.169	0.54
		76 min	9	-0.149	0.5826	-1.50	-0.149	0.55
		77 min	9	-0.156	0.5335	-1.38	-0.183	0.52
		78 min	9	-0.145	0.6026	-1.48	-0.196	0.56
		79 min	9	-0.109	0.5948	-1.43	-0.151	0.58
		80 min	9	-0.119	0.6053	-1.50	-0.158	0.54
		81 min	9	-0.070	0.6048	-1.50	0.024	0.58
		82 min	9	-0.143	0.5994	-1.46	-0.184	0.57
		83 min	9	-0.123	0.6391	-1.47	-0.189	0.67
		84 min	9	-0.097	0.6259	-1.42	-0.109	0.66
		85 min	9	-0.127	0.6308	-1.44	-0.187	0.61
		86 min	9	-0.104	0.6428	-1.50	-0.057	0.75
		87 min	9	-0.098	0.6363	-1.47	-0.081	0.52
		88 min	9	-0.115	0.6574	-1.49	-0.012	0.55
		89 min	9	0.194	1.2001	-1.54	0.212	2.81
		90 min	9	-0.072	0.7252	-1.54	0.238	0.51

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 36 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	91 min	9	-0.174	0.7097	-1.58	0.107	0.49
		92 min	9	-0.074	0.8114	-1.53	0.124	0.95
		93 min	10	-0.085	0.7648	-1.62	0.209	0.58
		94 min	10	-0.091	0.7977	-1.67	0.220	0.63
		95 min	11	-0.462	1.3632	-3.92	0.079	0.56
		96 min	11	-0.475	1.3693	-3.96	0.084	0.52
		97 min	11	-0.377	1.4946	-4.05	0.147	1.29
		98 min	11	-0.441	1.4537	-4.05	0.102	0.67
		99 min	11	-0.498	1.4005	-4.07	0.124	0.61
		100 min	11	-0.514	1.4045	-4.13	-0.037	0.60
		101 min	11	-0.372	1.5127	-4.13	0.255	1.01
		102 min	11	-0.447	1.4358	-4.08	0.185	0.73
		103 min	11	-0.375	1.5041	-4.07	0.034	1.26
		104 min	11	-0.540	1.4419	-4.14	0.057	0.68
		105 min	11	-0.503	1.3934	-4.07	0.034	0.73
		106 min	11	-0.546	1.3865	-4.11	-0.047	0.69
		107 min	11	-0.521	1.3909	-4.12	0.030	0.63
		108 min	11	-0.590	1.3801	-4.22	-0.107	0.57
		109 min	11	-0.609	1.3827	-4.23	-0.191	0.58
		110 min	11	-0.578	1.4319	-4.38	-0.050	0.46
		111 min	11	-0.590	1.4062	-4.31	-0.039	0.48
		112 min	11	-0.675	1.3847	-4.40	-0.243	0.35
		113 min	11	-0.670	1.4068	-4.50	-0.240	0.33
		114 min	11	-0.671	1.4004	-4.47	-0.206	0.31
		115 min	11	-0.619	1.3703	-4.31	-0.168	0.45
		116 min	11	-0.614	1.2790	-4.03	-0.098	0.34
		117 min	10	-0.150	0.9014	-1.69	-0.126	1.75
		118 min	10	-0.298	0.6320	-1.69	-0.096	0.47
		119 min	10	-0.262	0.6491	-1.68	-0.081	0.47
		120 min	10	-0.272	0.6280	-1.66	-0.054	0.37

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 37 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	121 min	10	-0.302	0.6109	-1.62	-0.143	0.44
		122 min	10	-0.294	0.6448	-1.66	-0.189	0.52
		123 min	11	-0.345	0.5582	-1.61	-0.155	0.22
		124 min	11	-0.294	0.5773	-1.62	-0.066	0.31
		125 min	11	-0.284	0.5814	-1.60	-0.068	0.34
		126 min	11	-0.302	0.5564	-1.64	-0.150	0.40
		127 min	11	-0.250	0.5728	-1.58	-0.128	0.42
		128 min	11	-0.361	0.5583	-1.55	-0.249	0.34
		129 min	11	0.021	1.4384	-1.59	-0.282	4.06
		130 min	11	-0.359	0.5774	-1.65	-0.237	0.28
		131 min	11	-0.725	1.5107	-4.99	-0.196	0.27
		132 min	11	-0.709	1.4979	-5.08	-0.324	0.30
		133 min	10	-0.758	1.4114	-4.51	-0.336	0.28
		134 min	11	-0.735	1.5997	-5.32	-0.168	0.30
		135 min	11	-0.352	1.7423	-4.17	-0.129	3.29
		136 min	11	-0.558	1.4804	-4.62	-0.016	0.55
		137 min	11	-0.263	0.5608	-1.60	-0.025	0.36
		138 min	11	-0.465	1.0293	-2.97	-0.109	0.68
		139 min	11	-0.376	0.8550	-2.16	-0.108	0.58
		140 min	11	-0.695	1.6206	-5.28	-0.055	0.35
		141 min	11	-0.442	0.8605	-2.39	-0.137	0.34
		142 min	11	-0.298	0.5690	-1.51	-0.072	0.38
		143 min	11	-0.375	0.9789	-2.69	-0.139	0.63
		144 min	11	-0.169	0.5925	-1.50	-0.038	0.43
		145 min	10	-0.499	1.3673	-3.83	0.016	0.74
		146 min	10	0.261	1.9630	-1.50	-0.103	5.57
		147 min	10	0.399	2.1467	-1.45	0.039	6.19
		148 min	10	0.241	2.2923	-1.57	-0.006	6.37
		149 min	10	0.347	2.2244	-1.60	-0.014	6.32
		150 min	10	0.309	1.9958	-1.47	0.003	5.62

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	151 min	10	0.323	1.9911	-1.63	0.024	5.55
		152 min	10	-0.076	0.6637	-1.49	0.027	0.58
		153 min	10	-0.127	0.7517	-1.52	0.140	0.49
		154 min	10	-0.167	0.8197	-1.78	-0.011	0.60
		155 min	10	-0.112	0.8526	-1.73	0.058	0.74
		156 min	10	-0.107	0.8761	-1.76	0.148	0.96
		157 min	10	0.074	1.1150	-1.68	0.088	2.24
		158 min	10	-0.055	0.9446	-1.70	0.055	1.55
		159 min	10	-0.083	0.8902	-1.71	0.031	1.31
		160 min	10	-0.060	0.7931	-1.47	-0.020	1.22
		161 min	10	-0.020	0.8978	-1.42	-0.029	1.56
		162 min	10	0.002	0.9093	-1.30	-0.035	1.80
		163 min	11	0.020	0.8033	-1.31	0.019	1.45
		164 min	11	-0.045	0.7363	-1.34	-0.009	1.14
		165 min	11	0.017	0.7804	-1.37	0.044	1.12
		166 min	11	-0.062	0.7358	-1.37	-0.033	0.97
		167 min	11	-0.062	0.7005	-1.35	0.055	1.03
		168 min	11	-0.102	0.7191	-1.38	-0.034	1.11
		169 min	10	-0.043	0.8296	-1.43	0.007	1.51
		170 min	10	-0.041	0.8057	-1.40	0.009	1.44
		171 min	10	0.088	0.9498	-1.30	0.104	2.17
		172 min	10	0.383	1.3350	-1.35	0.136	3.00
		173 min	10	0.467	1.7622	-1.42	0.213	4.97
		174 min	10	0.471	1.6959	-1.35	0.261	4.79
		175 min	10	0.431	1.7129	-1.40	0.226	4.77
		176 min	10	0.332	1.1937	-1.38	0.254	2.89
		177 min	10	0.125	0.8124	-1.32	0.219	1.25
		178 min	10	0.181	0.7326	-1.12	0.189	1.18
		179 min	10	0.069	0.7669	-1.17	0.154	1.10
		180 min	10	0.125	0.8270	-1.30	0.223	1.13

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 39 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	181 min	10	0.143	0.9480	-1.36	0.156	1.81
		182 min	10	0.142	1.0430	-1.42	0.093	2.22
		183 min	10	0.164	1.1372	-1.37	0.158	2.68
		184 min	10	0.095	0.9835	-1.41	0.111	2.09
		185 min	9	0.090	1.1850	-1.41	-0.032	2.67
		186 min	8	-0.042	0.8915	-1.38	0.005	1.26
		187 min	9	0.084	0.9284	-1.41	0.154	1.59
		188 min	9	0.005	0.8606	-1.46	0.093	1.30
		189 min	9	0.013	0.8117	-1.41	0.179	1.05
		190 min	9	0.100	0.9276	-1.39	0.264	1.65
		191 min	9	0.075	0.9023	-1.43	0.225	1.61
		192 min	9	0.155	0.8344	-1.48	0.302	1.48
		193 min	9	0.053	0.8124	-1.55	0.248	0.99
		194 min	9	0.088	0.7589	-1.53	0.280	0.99
		195 min	9	0.145	0.9578	-1.56	0.228	1.60
		196 min	9	0.073	0.8006	-1.56	0.393	0.90
		197 min	9	0.055	0.8243	-1.62	0.274	1.04
		198 min	10	-0.126	0.9445	-1.70	0.128	1.03
		199 min	10	0.053	0.8041	-1.67	0.295	0.97
		200 min	10	-0.461	1.7540	-4.91	0.289	0.85
		201 min	10	-0.060	0.7589	-1.73	0.188	0.63
		202 min	10	-0.481	1.7489	-4.96	0.397	0.58
		203 min	11	-0.918	2.0180	-5.34	0.116	0.54
		204 min	11	-0.908	2.1133	-5.74	0.176	0.58
		205 min	11	-0.653	1.4736	-3.99	-0.050	0.49
		206 min	11	-0.518	1.3986	-4.04	0.067	0.54
		207 min	10	-0.585	1.4491	-4.02	-0.044	0.57
		208 min	10	-0.606	1.4193	-4.03	0.017	0.46
		209 min	10	-0.660	1.3774	-4.00	-0.032	0.40
		210 min	10	-0.581	1.3790	-4.00	-0.060	0.42

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 40 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	5	211 min	10	-0.591	1.4063	-4.06	0.008	0.36
		212 min	10	-0.998	1.8083	-4.11	0.075	0.36
		213 min	10	-1.008	2.0300	-5.15	0.085	0.85
		214 min	10	-0.764	1.5146	-3.88	0.110	0.50
		215 min	10	-0.427	2.1335	-3.98	0.085	4.08
		216 min	10	-0.338	1.9271	-4.05	-0.002	3.59
		217 min	10	-0.993	1.6520	-4.06	-0.093	0.44
		218 min	10	-1.143	1.9628	-5.18	-0.017	0.26
		219 min	10	-1.214	2.0261	-5.52	-0.047	0.24
		220 min	10	-1.207	1.9576	-5.24	-0.120	0.25
		221 min	10	-1.180	1.9903	-5.29	-0.040	0.30
		222 min	10	-1.212	1.9769	-5.31	-0.108	0.30
		223 min	10	-1.025	1.6743	-4.01	-0.069	0.36
		224 min	10	-0.828	1.3411	-3.93	-0.124	0.23
		225 min	10	-1.017	1.7027	-4.13	-0.127	0.39
		226 min	10	-0.839	1.9487	-4.12	0.010	1.72
		227 min	10	-0.922	1.7564	-3.99	-0.012	0.94
		228 min	10	-0.930	1.5729	-3.72	-0.163	0.60
		229 min	11	-0.790	1.4143	-3.34	-0.167	0.55
		230 min	11	-0.835	1.3983	-3.75	-0.070	0.34
		231 min	11	-0.771	1.2519	-3.16	-0.140	0.42
		232 min	11	-0.796	1.2649	-3.58	-0.168	0.35
		233 min	11	-0.706	1.1894	-3.46	-0.404	0.47
		234 min	11	-0.756	1.3023	-4.09	-0.103	0.26
		235 min	10	-0.737	1.3746	-4.24	-0.223	0.26
		236 min	11	-0.719	1.3234	-4.26	-0.156	0.28
		237 min	11	-0.695	1.3515	-4.34	-0.149	0.32
		238 min	11	-0.664	1.3338	-4.25	-0.119	0.36
		239 min	11	-0.708	1.3385	-4.44	-0.393	0.35
		240 min	6	-0.475	0.6504	-1.41	-0.279	0.16

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 41 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	1 min	12	0.233	1.1546	-1.73	0.031	2.82
		2 min	12	0.479	1.7328	-1.72	0.081	5.23
		3 min	12	0.572	1.9088	-1.65	0.051	5.82
		4 min	12	0.052	0.6982	-1.74	0.160	0.77
		5 min	12	0.259	0.8493	-1.67	0.111	1.71
		6 min	12	-0.056	0.5675	-1.50	0.036	0.53
		7 min	12	0.023	0.7541	-1.75	0.097	1.29
		8 min	12	-0.029	0.8461	-1.64	0.104	1.46
		9 min	12	-0.020	0.6235	-1.45	0.110	0.81
		10 min	12	-0.103	0.7363	-1.69	0.091	0.50
		11 min	12	0.068	0.5468	-1.48	0.136	0.75
		12 min	12	0.044	0.9708	-1.76	0.137	2.04
		13 min	12	-0.138	0.7323	-1.70	0.087	0.54
		14 min	12	-0.164	0.7074	-1.64	0.043	0.50
		15 min	12	-0.152	0.6949	-1.62	0.063	0.52
		16 min	12	-0.093	0.6769	-1.50	0.132	0.49
		17 min	12	-0.114	0.7145	-1.61	0.101	0.53
		18 min	12	-0.160	0.6987	-1.64	0.093	0.47
		19 min	12	-0.139	0.6798	-1.59	0.097	0.46
		20 min	12	-0.178	0.7152	-1.75	0.054	0.49
		21 min	12	-0.133	0.7537	-1.84	0.169	0.44
		22 min	12	-0.177	0.7253	-1.84	0.128	0.33
		23 min	12	-0.048	0.9075	-1.81	0.086	1.84
		24 min	12	-0.216	0.7078	-1.77	0.067	0.32
		25 min	12	-0.258	0.7051	-1.86	-0.004	0.34
		26 min	12	-0.252	0.7027	-1.77	0.046	0.23
		27 min	12	-0.271	0.7513	-1.96	0.033	0.28
		28 min	12	-0.274	0.7144	-1.89	-0.016	0.26
		29 min	12	-0.282	0.7056	-1.84	-0.042	0.26
		30 min	12	-0.261	0.8252	-2.25	0.078	0.50

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 42 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	31 min	12	-0.267	0.7482	-1.96	0.032	0.46
		32 min	11	-0.293	0.7097	-1.71	0.035	0.20
		33 min	10	-0.348	0.6918	-1.64	-0.051	0.20
		34 min	10	-0.317	0.7076	-1.62	0.023	0.26
		35 min	10	-0.299	0.7574	-1.71	0.057	0.37
		36 min	10	-0.347	0.7780	-1.89	0.066	0.22
		37 min	10	-0.326	0.8098	-1.83	-0.015	0.35
		38 min	10	-0.250	0.7100	-1.62	0.057	0.47
		39 min	10	-0.367	0.8325	-2.04	0.063	0.26
		40 min	10	-0.332	0.8565	-2.08	0.128	0.29
		41 min	10	-0.419	0.8602	-2.11	-0.041	0.27
		42 min	11	-0.354	0.8701	-2.26	0.088	0.40
		43 min	12	-0.355	0.8157	-2.28	-0.050	0.24
		44 min	12	-0.329	0.8444	-2.29	0.065	0.31
		45 min	12	-0.314	0.8624	-2.34	0.021	0.39
		46 min	12	-0.321	0.8489	-2.27	-0.016	0.43
		47 min	12	-0.230	0.7624	-2.22	0.069	0.44
		48 min	12	-0.222	0.7678	-2.29	0.065	0.42
		49 min	12	-0.115	0.7284	-2.22	0.053	0.55
		50 min	12	-0.318	0.8916	-2.27	0.014	0.48
		51 min	11	-0.089	0.5295	-1.37	0.026	0.64
		52 min	11	-0.071	0.6816	-1.73	0.047	1.03
		53 min	11	0.386	1.1334	-0.52	0.087	3.65
		54 min	11	0.397	1.3830	-0.59	0.040	4.45
		55 min	11	-0.155	0.5593	-1.58	0.078	0.43
		56 min	11	0.259	0.8305	-0.66	0.118	2.43
		57 min	11	0.009	0.3771	-0.61	0.148	0.53
		58 min	11	0.302	0.9845	-0.61	0.112	3.05
		59 min	11	0.069	0.5243	-0.68	0.035	1.00
		60 min	11	0.409	1.3588	-0.66	0.053	4.32

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 43 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	61 min	11	0.427	1.4501	-0.66	-0.010	4.56
		62 min	11	0.111	0.5216	-0.67	0.040	0.97
		63 min	10	0.409	1.2588	-0.72	0.090	3.79
		64 min	10	0.220	0.8540	-0.69	0.005	2.37
		65 min	9	-0.183	0.6221	-1.24	-0.273	0.78
		66 min	9	0.427	1.5531	-0.65	-0.029	4.38
		67 min	9	0.469	1.5293	-0.66	-0.042	4.37
		68 min	9	0.342	1.1234	-0.70	-0.022	3.13
		69 min	9	-0.229	0.7344	-1.76	-0.130	0.75
		70 min	9	-0.131	0.7187	-1.55	-0.004	0.90
		71 min	9	-0.136	0.7474	-1.61	-0.103	1.00
		72 min	9	0.387	1.1113	-0.67	0.068	3.07
		73 min	9	0.553	1.3867	-0.73	0.202	3.97
		74 min	9	0.460	1.2858	-0.70	0.151	3.67
		75 min	9	0.426	1.3002	-0.78	0.204	3.61
		76 min	9	0.490	1.2802	-0.83	0.108	3.55
		77 min	9	0.513	1.3021	-0.83	0.166	3.60
		78 min	9	0.097	0.5812	-0.89	0.163	1.12
		79 min	9	-0.092	0.8002	-1.76	0.157	0.93
		80 min	9	-0.132	0.7861	-1.85	0.123	0.71
		81 min	9	0.302	0.8238	-0.84	0.310	2.12
		82 min	9	0.378	1.1013	-0.83	0.126	3.08
		83 min	9	-0.102	0.8032	-1.75	0.132	0.80
		84 min	9	-0.026	0.5889	-0.92	0.127	0.62
		85 min	9	-0.052	0.6049	-1.08	0.051	0.67
		86 min	9	-0.150	0.7440	-1.73	0.001	0.56
		87 min	9	0.429	1.1934	-0.82	0.224	3.39
		88 min	9	0.342	0.9643	-0.90	0.213	2.64
		89 min	9	0.418	1.2309	-0.94	0.137	3.50
		90 min	9	0.458	1.3777	-1.02	0.170	3.92

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 44 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	91 min	9	0.501	1.4499	-0.95	0.190	4.19
		92 min	9	-0.083	0.5283	-1.06	-0.016	0.51
		93 min	10	-0.171	0.7147	-1.77	-0.044	0.51
		94 min	10	0.157	0.6106	-1.06	0.138	1.31
		95 min	11	0.242	1.5131	-1.88	0.047	4.25
		96 min	11	0.259	1.5553	-1.92	0.038	4.38
		97 min	11	-0.044	0.8360	-1.90	0.096	1.12
		98 min	11	-0.291	0.8441	-1.91	0.102	0.44
		99 min	11	-0.307	0.8825	-1.90	0.054	0.51
		100 min	11	-0.314	0.9008	-1.96	0.111	0.51
		101 min	11	-0.338	0.8922	-2.00	0.049	0.47
		102 min	11	-0.325	0.9037	-1.95	0.042	0.56
		103 min	11	-0.322	0.8928	-1.97	0.022	0.73
		104 min	11	-0.306	0.8790	-1.99	0.065	0.69
		105 min	11	-0.328	0.9032	-1.97	0.019	0.62
		106 min	11	-0.377	0.9267	-1.97	0.025	0.55
		107 min	11	-0.329	0.8473	-1.96	0.057	0.44
		108 min	11	-0.448	0.8677	-2.01	-0.214	0.49
		109 min	11	-0.489	0.8782	-2.07	-0.206	0.36
		110 min	11	-0.265	0.7576	-2.09	-0.098	0.52
		111 min	11	-0.421	0.8848	-2.14	-0.095	0.63
		112 min	11	-0.417	0.8933	-2.24	0.066	0.42
		113 min	11	-0.494	0.8510	-2.22	-0.149	0.28
		114 min	11	-0.473	0.8314	-2.23	-0.143	0.31
		115 min	11	-0.493	0.8125	-2.21	-0.214	0.24
		116 min	11	-0.348	0.7374	-1.76	-0.032	0.38
		117 min	10	-0.356	0.6124	-1.64	-0.174	0.21
		118 min	10	-0.332	0.6165	-1.72	-0.126	0.30
		119 min	10	-0.292	0.6110	-1.66	-0.095	0.31
		120 min	10	-0.237	0.5730	-1.44	-0.018	0.31

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 45 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	121 min	10	-0.399	0.6863	-2.02	-0.201	0.24
		122 min	10	0.063	0.7653	-1.03	-0.022	1.99
		123 min	11	-0.135	0.3728	-1.11	-0.083	0.20
		124 min	11	0.105	1.3227	-1.04	-0.185	3.91
		125 min	11	0.236	1.4559	-1.07	-0.209	4.50
		126 min	11	0.038	1.2395	-1.58	-0.182	3.33
		127 min	11	-0.181	2.1013	-4.91	-0.172	4.32
		128 min	11	-0.270	2.0484	-5.34	-0.095	3.50
		129 min	11	-0.751	1.6305	-5.48	-0.232	0.41
		130 min	11	-0.432	1.9610	-5.73	-0.092	2.45
		131 min	11	-0.653	1.6199	-5.40	-0.262	0.41
		132 min	11	-0.491	1.8371	-5.63	-0.144	1.74
		133 min	10	-0.498	2.0234	-5.80	-0.133	2.06
		134 min	11	-0.325	1.9938	-5.39	-0.094	3.20
		135 min	11	-0.356	0.6172	-1.67	-0.204	0.33
		136 min	11	-0.593	1.3830	-4.53	-0.094	0.31
		137 min	11	-0.219	2.1973	-5.50	-0.100	4.13
		138 min	11	0.050	2.4929	-5.72	0.015	4.51
		139 min	11	-0.171	2.0317	-5.57	0.067	2.48
		140 min	11	-0.712	1.7765	-5.67	-0.031	0.38
		141 min	11	-0.798	1.8706	-6.00	-0.062	0.35
		142 min	11	-0.382	1.6486	-4.91	-0.098	1.89
		143 min	11	-0.434	1.0806	-3.11	0.006	0.48
		144 min	11	-0.076	2.3958	-4.31	-0.060	5.95
		145 min	10	-0.100	2.5920	-4.61	-0.158	6.01
		146 min	10	0.179	1.9350	-1.42	-0.121	5.39
		147 min	10	0.151	2.1736	-1.96	-0.087	5.96
		148 min	10	0.070	1.6605	-1.31	-0.162	4.51
		149 min	10	0.270	2.0412	-2.80	-0.012	5.17
		150 min	10	0.005	2.2913	-4.06	-0.103	5.43

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 46 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	151 min	10	-0.264	2.1225	-4.93	-0.175	3.81
		152 min	10	-0.059	2.4744	-5.03	-0.157	5.29
		153 min	10	-0.073	2.2242	-4.45	0.038	4.74
		154 min	10	-0.095	2.1426	-3.90	-0.132	4.77
		155 min	10	-0.045	2.0217	-2.66	-0.035	4.77
		156 min	10	-0.139	1.6621	-2.61	-0.002	3.47
		157 min	10	-0.065	1.5016	-2.44	0.082	3.21
		158 min	10	0.131	2.0027	-2.46	-0.040	5.15
		159 min	10	-0.009	1.4869	-2.37	-0.085	3.16
		160 min	10	0.223	2.0268	-2.33	-0.153	5.32
		161 min	10	-0.058	1.1317	-2.51	-0.099	1.64
		162 min	10	-0.123	1.0872	-2.66	-0.096	1.05
		163 min	11	-0.086	0.7422	-1.74	-0.031	0.78
		164 min	11	0.449	1.2690	-0.75	0.320	4.03
		165 min	11	0.189	0.6195	-0.80	0.296	1.13
		166 min	11	0.060	0.4015	-0.80	0.286	0.46
		167 min	11	0.274	1.0146	-0.82	0.204	3.10
		168 min	11	0.093	0.6027	-0.80	0.044	1.48
		169 min	10	-0.058	0.4760	-0.82	0.008	0.59
		170 min	10	-0.138	0.5058	-0.90	-0.053	0.61
		171 min	10	0.348	1.2357	-0.79	0.181	3.62
		172 min	10	0.417	1.3370	-0.77	0.204	3.99
		173 min	10	0.428	1.4104	-0.87	0.147	4.25
		174 min	10	0.399	1.2636	-0.76	0.171	3.76
		175 min	10	0.356	1.3515	-0.98	0.099	3.94
		176 min	10	0.420	1.3667	-1.11	0.208	3.92
		177 min	10	0.356	1.1120	-1.00	0.327	3.06
		178 min	10	0.350	1.3748	-1.76	0.357	3.53
		179 min	10	0.563	1.8227	-2.36	0.266	3.64
		180 min	10	0.639	1.6676	-1.61	0.356	4.01

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 47 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	181 min	10	0.555	1.9654	-2.66	0.318	4.27
		182 min	10	0.307	1.8177	-3.45	0.318	3.53
		183 min	10	0.222	1.9793	-4.07	0.320	3.82
		184 min	10	0.076	2.0261	-4.60	0.276	3.66
		185 min	9	0.112	2.1266	-4.56	0.249	3.05
		186 min	8	0.755	1.3387	-0.82	0.365	3.25
		187 min	9	0.693	1.2095	-0.87	0.382	2.90
		188 min	9	0.483	1.1089	-0.88	0.218	3.14
		189 min	9	0.526	1.0415	-0.89	0.266	2.56
		190 min	9	0.255	0.5579	-0.79	0.259	1.22
		191 min	9	0.226	0.5411	-0.79	0.183	0.98
		192 min	9	0.041	0.6784	-1.14	0.287	0.83
		193 min	9	-0.094	0.7738	-1.73	0.259	0.50
		194 min	9	0.019	0.7355	-1.37	0.258	0.91
		195 min	9	-0.047	0.6818	-1.29	0.190	0.75
		196 min	9	-0.036	0.7182	-1.39	0.218	0.76
		197 min	9	0.070	0.4656	-1.01	0.230	0.48
		198 min	10	-0.228	1.2641	-3.58	0.296	0.49
		199 min	10	-0.431	1.6148	-4.84	0.175	0.60
		200 min	10	-0.612	1.6688	-4.96	0.204	0.42
		201 min	10	-0.658	1.7497	-5.31	0.150	0.40
		202 min	10	-0.589	1.5154	-4.41	0.231	0.39
		203 min	11	-0.737	1.8334	-5.45	0.098	1.16
		204 min	11	-0.842	1.8032	-5.70	0.133	0.30
		205 min	11	-0.843	1.8342	-5.74	0.173	0.32
		206 min	11	-0.755	1.9416	-5.81	0.204	1.36
		207 min	10	-0.948	1.9004	-5.67	-0.063	0.39
		208 min	10	-0.985	1.9802	-6.06	-0.072	0.36
		209 min	10	-0.811	1.5774	-4.62	-0.070	0.37
		210 min	10	-0.481	0.8895	-1.88	-0.113	0.38

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 48 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	6	211 min	10	-0.181	1.4084	-1.94	0.111	2.83
		212 min	10	-0.317	2.2188	-4.87	0.127	3.98
		213 min	10	-0.334	2.3664	-5.52	0.094	4.05
		214 min	10	-0.318	2.1533	-4.60	0.104	3.96
		215 min	10	-0.071	1.6840	-2.08	0.037	3.94
		216 min	10	-0.081	1.6168	-1.92	0.068	3.76
		217 min	10	-0.492	1.9857	-4.89	0.028	2.86
		218 min	10	-0.393	2.3261	-5.42	0.058	3.93
		219 min	10	-0.593	1.9941	-5.39	0.074	2.15
		220 min	10	-0.504	2.2081	-5.37	-0.024	3.42
		221 min	10	-0.661	1.7212	-4.93	0.002	1.02
		222 min	10	-0.485	1.6864	-4.18	-0.029	2.24
		223 min	10	-0.556	1.2852	-3.54	-0.022	0.69
		224 min	10	-0.602	1.1718	-3.26	-0.153	0.41
		225 min	10	-0.344	1.2099	-2.49	-0.120	1.82
		226 min	10	-0.104	1.4150	-1.93	-0.043	3.23
		227 min	10	-0.182	1.1488	-1.91	-0.057	2.31
		228 min	10	-0.171	1.0624	-1.78	-0.140	2.23
		229 min	11	0.090	1.5849	-1.64	-0.189	4.53
		230 min	11	-0.480	0.6577	-1.73	-0.278	0.26
		231 min	11	-0.451	0.6313	-1.60	-0.217	0.26
		232 min	11	-0.409	0.5240	-1.52	-0.290	0.22
		233 min	11	-0.477	0.6395	-1.67	-0.217	0.31
		234 min	11	-0.361	0.5567	-1.56	-0.146	0.24
		235 min	10	-0.607	0.7332	-1.92	-0.246	0.29
		236 min	11	-0.481	0.6824	-1.98	-0.237	0.38
		237 min	11	-0.154	1.2520	-2.13	-0.185	3.08
		238 min	11	-0.407	0.5681	-1.90	-0.176	0.21
		239 min	11	-0.374	0.6709	-2.09	-0.157	0.38
		240 min	6	-0.436	0.4490	-1.16	-0.250	-0.06

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 49 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	1 min	12	0.045	0.9631	-2.26	0.068	1.95
		2 min	12	-0.047	1.5418	-2.85	0.137	3.54
		3 min	12	-0.178	0.8632	-2.27	0.115	0.69
		4 min	12	0.054	0.8347	-2.10	0.135	1.30
		5 min	12	0.168	0.8789	-2.22	0.140	1.40
		6 min	12	-0.090	0.8894	-2.53	0.145	0.97
		7 min	12	0.036	0.9742	-1.89	0.099	2.28
		8 min	12	0.089	1.0213	-1.89	0.094	2.59
		9 min	12	0.111	1.0325	-1.92	0.159	2.66
		10 min	12	-0.185	0.6691	-1.79	0.027	0.55
		11 min	12	-0.039	0.6868	-1.83	0.153	0.59
		12 min	12	-0.016	0.8564	-1.92	0.165	1.50
		13 min	12	-0.266	0.7862	-1.90	0.058	0.57
		14 min	12	-0.387	0.9961	-2.63	0.042	0.47
		15 min	12	-0.287	0.7876	-1.78	0.040	0.50
		16 min	12	0.068	1.0800	-1.78	0.101	2.71
		17 min	12	0.081	1.0944	-1.84	0.214	2.69
		18 min	12	-0.089	0.7668	-1.84	0.133	0.66
		19 min	12	0.102	1.1403	-1.89	0.209	2.84
		20 min	12	-0.184	0.8168	-1.85	0.111	0.58
		21 min	12	-0.002	0.8863	-1.85	0.171	1.42
		22 min	12	-0.321	1.0383	-2.49	0.120	0.56
		23 min	12	-0.243	0.8144	-1.97	0.013	0.61
		24 min	12	-0.396	1.0530	-2.64	0.040	0.53
		25 min	12	-0.351	0.9078	-1.98	0.070	0.41
		26 min	12	-0.465	1.1883	-3.07	0.018	0.68
		27 min	12	-0.445	1.0659	-2.81	-0.066	0.51
		28 min	12	-0.476	1.0597	-2.81	-0.050	0.36
		29 min	12	-0.471	1.0790	-2.76	0.003	0.33
		30 min	12	-0.493	1.1498	-2.79	0.003	0.40

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 50 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	31 min	12	-0.518	0.9561	-2.38	-0.024	0.25
		32 min	11	-0.524	1.1443	-2.72	0.119	0.28
		33 min	10	-0.632	1.1313	-2.71	-0.063	0.32
		34 min	10	-0.614	1.1365	-2.67	-0.055	0.26
		35 min	10	-0.524	1.0610	-2.60	-0.033	0.21
		36 min	10	-0.687	1.1294	-2.42	-0.156	0.27
		37 min	10	-0.671	1.2275	-2.89	-0.113	0.30
		38 min	10	-0.334	1.0145	-2.41	0.075	0.75
		39 min	10	-0.064	1.5524	-2.40	0.097	3.43
		40 min	10	-0.448	0.9950	-2.44	-0.084	0.32
		41 min	10	-0.242	1.1442	-2.48	0.114	1.05
		42 min	11	-0.105	1.3378	-2.49	0.132	2.48
		43 min	12	-0.634	1.2037	-3.03	-0.187	0.39
		44 min	12	-0.040	1.3959	-2.50	0.154	3.13
		45 min	12	-0.082	1.4822	-2.48	0.028	3.44
		46 min	12	-0.077	1.3341	-2.56	0.127	2.72
		47 min	12	-0.107	1.2627	-2.58	0.094	2.29
		48 min	12	-0.133	1.2396	-2.59	0.129	2.22
		49 min	12	-0.157	1.1465	-2.53	0.079	1.52
		50 min	12	-0.399	1.1217	-2.56	0.035	0.91
		51 min	11	0.116	1.4331	-2.70	0.097	3.58
		52 min	11	0.043	1.0596	-2.60	0.217	1.94
		53 min	11	0.025	1.0360	-2.60	0.187	1.83
		54 min	11	0.106	1.3545	-2.63	0.077	3.29
		55 min	11	-0.160	0.8706	-2.66	0.080	0.54
		56 min	11	-0.010	1.1104	-2.53	0.167	2.24
		57 min	11	-0.229	0.8251	-2.55	-0.105	0.38
		58 min	11	-0.016	1.0366	-2.61	0.197	1.61
		59 min	11	-0.482	1.2267	-3.09	-0.150	0.62
		60 min	11	-0.189	0.8654	-2.55	0.024	0.66

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 51 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	61 min	11	0.151	1.3565	-2.55	0.127	3.32
		62 min	11	-0.018	1.0072	-2.52	0.107	1.51
		63 min	10	0.125	1.3634	-2.52	0.161	3.09
		64 min	10	-0.346	0.9555	-2.58	-0.131	0.61
		65 min	9	-0.433	1.2099	-2.49	0.045	0.69
		66 min	9	0.141	1.3567	-2.42	0.097	2.83
		67 min	9	0.185	1.4752	-2.41	0.107	3.28
		68 min	9	0.065	1.2095	-2.38	0.117	2.30
		69 min	9	-0.523	1.2097	-2.74	-0.255	0.64
		70 min	9	0.161	1.4542	-2.50	0.137	3.13
		71 min	9	0.303	1.6830	-2.58	0.207	3.96
		72 min	9	0.284	1.6862	-2.58	0.340	3.97
		73 min	9	0.211	1.5220	-2.57	0.217	3.35
		74 min	9	0.253	1.2922	-2.50	0.396	2.41
		75 min	9	0.210	1.4134	-2.49	0.372	3.00
		76 min	9	0.040	1.0439	-2.41	0.217	1.22
		77 min	9	-0.016	1.0705	-2.53	0.276	1.29
		78 min	9	0.250	1.3659	-2.22	0.353	3.05
		79 min	9	0.172	1.2003	-2.16	0.352	2.47
		80 min	9	0.284	1.3724	-2.27	0.362	3.03
		81 min	9	0.211	1.4101	-2.50	0.320	2.96
		82 min	9	0.209	1.4268	-2.54	0.279	3.02
		83 min	9	0.254	1.5252	-2.44	0.314	3.47
		84 min	9	0.264	1.4365	-2.39	0.391	3.13
		85 min	9	0.147	1.1865	-2.31	0.330	2.20
		86 min	9	0.164	1.3311	-2.40	0.235	2.73
		87 min	9	-0.102	0.9247	-2.37	0.247	0.68
		88 min	9	0.095	1.1957	-2.43	0.251	2.07
		89 min	9	0.254	1.4724	-2.35	0.318	3.30
		90 min	9	0.263	1.4587	-2.34	0.253	3.22

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 52 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	91 min	9	0.279	1.4515	-2.27	0.240	3.15
		92 min	9	0.273	1.4458	-2.27	0.351	3.19
		93 min	10	0.236	1.3416	-2.28	0.219	2.98
		94 min	10	0.185	1.1569	-2.20	0.220	1.99
		95 min	11	0.039	1.2796	-2.01	0.224	2.46
		96 min	11	0.101	1.4665	-2.24	0.223	3.23
		97 min	11	-0.042	1.2344	-2.32	0.224	1.90
		98 min	11	0.042	1.3044	-2.00	0.211	2.68
		99 min	11	-0.055	1.1777	-2.16	0.134	1.83
		100 min	11	-0.487	1.2330	-2.70	0.020	0.92
		101 min	11	-0.173	1.0159	-2.12	0.201	0.97
		102 min	11	-0.383	1.0415	-2.06	-0.009	0.92
		103 min	11	-0.408	1.1270	-2.20	-0.020	0.96
		104 min	11	-0.503	1.2133	-2.43	-0.019	0.77
		105 min	11	-0.128	1.1814	-2.34	0.271	1.61
		106 min	11	-0.508	1.0937	-2.56	-0.203	0.71
		107 min	11	-0.522	1.1677	-2.61	-0.053	0.74
		108 min	11	-0.590	1.2812	-2.68	-0.113	0.79
		109 min	11	-0.402	1.0179	-2.32	-0.203	0.83
		110 min	11	-0.119	1.2087	-2.31	0.087	1.81
		111 min	11	-0.474	1.4207	-3.05	0.015	1.01
		112 min	11	-0.655	1.2365	-2.89	-0.183	0.81
		113 min	11	-0.611	1.3013	-2.82	-0.042	0.81
		114 min	11	-0.304	1.1815	-2.82	-0.014	0.84
		115 min	11	-0.126	1.4886	-2.80	0.005	2.87
		116 min	11	-0.481	1.1446	-2.66	-0.061	0.86
		117 min	10	0.102	1.4959	-2.95	0.294	3.08
		118 min	10	0.022	1.0757	-2.40	0.167	1.67
		119 min	10	-0.126	0.9767	-2.51	0.076	0.81
		120 min	10	-0.105	0.7433	-1.85	0.060	0.70

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 53 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	121 min	10	-0.360	0.9150	-2.08	-0.026	0.71
		122 min	10	-0.361	0.8844	-2.41	-0.112	0.68
		123 min	11	-0.169	0.8508	-2.40	0.031	0.82
		124 min	11	-0.178	0.8304	-2.05	-0.074	0.96
		125 min	11	0.038	1.2226	-2.17	-0.072	2.73
		126 min	11	-0.562	1.6930	-4.78	-0.114	1.29
		127 min	11	-0.466	2.0347	-5.17	-0.150	2.96
		128 min	11	-0.500	2.0439	-5.44	-0.128	2.68
		129 min	11	-0.576	2.0569	-5.73	-0.132	2.09
		130 min	11	-0.648	1.9369	-5.77	-0.121	0.90
		131 min	11	-0.872	1.8041	-5.52	-0.197	0.59
		132 min	11	-0.711	1.9218	-5.82	-0.123	0.64
		133 min	10	-0.961	1.9684	-5.94	-0.252	0.64
		134 min	11	-0.391	2.0768	-5.57	-0.146	2.92
		135 min	11	-0.385	2.1470	-5.20	-0.149	3.37
		136 min	11	-0.256	2.0612	-5.50	-0.158	3.38
		137 min	11	-0.384	2.1694	-5.62	-0.195	3.48
		138 min	11	0.043	2.3338	-5.69	-0.153	3.41
		139 min	11	0.050	2.3848	-5.76	-0.135	3.78
		140 min	11	-0.337	2.3059	-6.01	-0.103	3.88
		141 min	11	-0.021	2.2808	-5.78	-0.122	3.48
		142 min	11	0.006	2.3654	-5.78	-0.143	3.85
		143 min	11	0.101	2.4251	-5.78	0.057	4.04
		144 min	11	0.091	2.1277	-4.67	-0.160	4.18
		145 min	10	0.191	2.5599	-5.43	-0.030	4.19
		146 min	10	0.165	2.6386	-5.75	-0.066	4.24
		147 min	10	0.232	2.4336	-4.85	-0.047	4.34
		148 min	10	0.216	2.6534	-5.68	0.163	4.50
		149 min	10	0.507	2.5393	-4.78	0.133	4.43
		150 min	10	0.406	2.4504	-4.75	0.112	4.43

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 54 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	151 min	10	0.584	3.0361	-5.76	0.104	4.88
		152 min	10	0.215	2.5587	-5.50	0.102	4.39
		153 min	10	0.328	2.4046	-4.90	0.183	4.17
		154 min	10	0.312	2.3050	-4.53	0.163	4.26
		155 min	10	0.383	2.1403	-3.77	0.214	4.37
		156 min	10	0.461	1.8792	-2.79	0.349	4.17
		157 min	10	1.042	2.2146	-1.77	0.383	5.01
		158 min	10	0.755	1.7319	-0.94	0.313	4.44
		159 min	10	0.729	1.6963	-0.99	0.280	4.30
		160 min	10	1.067	1.9019	-0.73	0.352	4.34
		161 min	10	0.618	1.6212	-1.18	0.162	3.86
		162 min	10	0.693	1.5008	-0.63	0.217	3.90
		163 min	11	0.632	1.4115	-0.64	0.235	3.55
		164 min	11	0.632	1.2874	-0.54	0.229	3.38
		165 min	11	0.485	0.9903	-0.55	0.447	2.70
		166 min	11	0.652	1.1632	-0.55	0.481	3.29
		167 min	11	0.627	1.3085	-0.57	0.312	3.91
		168 min	11	0.453	0.8795	-0.54	0.291	2.26
		169 min	10	-0.251	0.8508	-2.04	0.053	0.54
		170 min	10	-0.197	0.8117	-2.13	0.050	0.56
		171 min	10	0.157	1.1593	-2.00	0.214	2.71
		172 min	10	0.196	1.2011	-1.93	0.200	2.94
		173 min	10	0.204	1.2679	-2.18	0.239	3.00
		174 min	10	0.114	1.2205	-2.14	0.175	2.79
		175 min	10	0.086	1.2355	-2.28	0.145	2.69
		176 min	10	0.253	1.3134	-2.39	0.309	2.76
		177 min	10	0.612	1.9565	-2.30	0.284	4.83
		178 min	10	0.051	1.4166	-2.26	0.291	2.61
		179 min	10	0.166	1.5763	-2.29	0.227	2.75
		180 min	10	0.337	1.6817	-2.30	0.279	3.10

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 55 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	181 min	10	0.311	1.9265	-2.34	0.284	4.01
		182 min	10	0.554	1.8864	-2.33	0.328	4.69
		183 min	10	0.579	1.9600	-2.40	0.277	4.97
		184 min	10	0.559	1.9561	-2.37	0.271	4.84
		185 min	9	0.624	2.1206	-2.36	0.197	5.04
		186 min	8	0.545	1.7938	-2.39	0.369	3.48
		187 min	9	0.505	1.6676	-2.33	0.253	3.42
		188 min	9	0.380	1.5275	-2.41	0.217	2.80
		189 min	9	0.465	1.6067	-2.38	0.276	2.94
		190 min	9	0.526	1.7700	-2.44	0.231	3.42
		191 min	9	0.504	1.6767	-2.37	0.225	3.44
		192 min	9	0.524	1.7344	-2.51	0.297	3.19
		193 min	9	0.309	1.4708	-2.45	0.241	3.10
		194 min	9	0.274	1.4242	-2.37	0.208	2.91
		195 min	9	0.309	1.4665	-2.37	0.258	3.13
		196 min	9	0.376	1.4766	-2.47	0.477	2.96
		197 min	9	0.276	1.4437	-2.57	0.427	2.74
		198 min	10	-0.281	2.0400	-4.78	0.300	2.55
		199 min	10	-0.307	2.0914	-4.98	0.305	2.56
		200 min	10	-0.362	2.1593	-5.35	0.318	2.54
		201 min	10	-0.429	2.2807	-5.60	0.164	2.92
		202 min	10	-0.397	2.2570	-5.42	0.243	3.06
		203 min	11	-0.557	2.1700	-5.60	0.226	2.83
		204 min	11	-0.561	2.2924	-5.91	0.198	3.23
		205 min	11	-0.553	2.3808	-6.29	0.257	2.98
		206 min	11	-0.451	2.3650	-5.94	0.237	2.92
		207 min	10	-0.661	2.4291	-6.11	0.222	2.96
		208 min	10	-0.679	2.4022	-6.11	0.161	2.88
		209 min	10	-0.830	2.1462	-5.92	0.214	1.19
		210 min	10	-0.994	1.9153	-5.53	-0.265	0.51

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 56 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	7	211 min	10	-0.665	2.1276	-5.19	0.204	2.46
		212 min	10	-0.525	2.0630	-4.49	0.166	3.12
		213 min	10	-0.582	2.3043	-5.46	0.203	3.20
		214 min	10	-0.549	2.2043	-4.83	0.175	3.34
		215 min	10	-0.689	2.3273	-5.78	0.056	2.96
		216 min	10	-0.634	2.3200	-5.53	0.149	3.18
		217 min	10	-0.783	2.1202	-5.64	0.160	1.82
		218 min	10	-0.669	2.3471	-5.83	0.188	2.93
		219 min	10	-0.641	2.2896	-5.51	0.172	3.08
		220 min	10	-0.659	2.2860	-5.43	0.121	3.14
		221 min	10	-0.686	2.2373	-5.46	0.112	2.91
		222 min	10	-0.648	2.1314	-5.01	0.010	2.99
		223 min	10	-0.531	1.9518	-3.99	-0.020	3.12
		224 min	10	-0.453	1.7815	-3.26	-0.034	3.06
		225 min	10	-0.336	1.6637	-2.54	0.012	2.98
		226 min	10	-0.440	1.2183	-2.44	0.117	1.12
		227 min	10	-0.604	1.0632	-2.54	-0.273	0.65
		228 min	10	-0.439	0.9995	-2.38	-0.087	0.69
		229 min	11	-0.154	1.4315	-2.47	-0.020	3.13
		230 min	11	-0.673	1.1252	-2.75	-0.246	0.61
		231 min	11	-0.553	0.9392	-2.51	-0.180	0.39
		232 min	11	-0.565	0.8932	-2.53	-0.295	0.45
		233 min	11	-0.668	0.9665	-2.42	-0.258	0.27
		234 min	11	-0.458	0.9058	-2.51	-0.197	0.38
		235 min	10	-0.691	0.9076	-2.32	-0.427	0.39
		236 min	11	-0.656	0.9914	-2.29	-0.221	0.57
		237 min	11	-0.525	0.8768	-2.38	-0.264	0.49
		238 min	11	-0.524	0.9101	-2.48	-0.206	0.37
		239 min	11	-0.669	0.9869	-2.22	-0.255	0.48
		240 min	6	-0.447	0.5310	-1.47	-0.187	-0.12

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 57 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	1 min	12	0.356	0.9516	-0.44	0.040	3.27
		2 min	12	-0.038	0.7633	-2.27	0.111	0.62
		3 min	12	-0.201	0.8575	-2.70	0.105	0.41
		4 min	12	-0.016	1.8973	-2.93	0.111	4.84
		5 min	12	-0.139	0.7934	-2.59	0.061	0.32
		6 min	12	-0.178	0.9336	-3.07	0.066	0.36
		7 min	12	-0.061	0.7152	-2.10	0.139	0.64
		8 min	12	-0.045	0.6556	-1.77	0.071	0.78
		9 min	12	-0.067	0.7645	-2.32	0.198	0.48
		10 min	12	-0.497	1.2247	-3.67	-0.035	0.39
		11 min	12	-0.586	1.2176	-2.80	0.010	0.46
		12 min	12	-0.354	1.1148	-2.89	0.108	0.45
		13 min	12	-0.262	0.8769	-2.39	0.015	0.58
		14 min	12	0.318	0.7791	-0.42	0.115	2.62
		15 min	12	0.370	0.8315	-0.46	0.202	2.86
		16 min	12	0.227	0.8745	-0.67	0.068	2.75
		17 min	12	-0.160	0.6629	-1.72	0.068	0.46
		18 min	12	-0.141	0.7633	-2.35	0.113	0.48
		19 min	12	-0.234	0.8661	-2.42	0.057	0.56
		20 min	12	-0.464	1.4282	-4.29	0.103	0.51
		21 min	12	0.222	0.5052	-1.07	0.293	0.81
		22 min	12	-0.110	0.7647	-2.15	0.164	0.48
		23 min	12	-0.660	1.7689	-5.58	0.045	0.49
		24 min	12	-0.678	1.7693	-5.67	0.004	0.50
		25 min	12	-0.527	1.4994	-4.82	0.102	0.44
		26 min	12	-0.660	1.5548	-4.82	0.039	0.49
		27 min	12	-0.722	1.7527	-5.59	0.093	0.49
		28 min	12	-0.634	1.5971	-5.01	0.049	0.37
		29 min	12	-0.454	1.0836	-2.63	0.088	0.36
		30 min	12	-0.661	1.7691	-5.44	0.147	0.36

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 58 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	31 min	12	-0.600	1.6124	-4.96	0.088	0.33
		32 min	11	-0.713	1.6804	-4.90	0.056	0.32
		33 min	10	-0.644	1.1340	-2.69	0.057	0.32
		34 min	10	-0.809	1.6192	-4.53	0.064	0.29
		35 min	10	-1.033	1.8418	-5.40	-0.009	0.24
		36 min	10	-0.840	1.5559	-4.28	-0.043	0.15
		37 min	10	-0.511	1.3264	-2.95	0.088	1.00
		38 min	10	-0.810	1.6725	-4.67	0.003	0.29
		39 min	10	-0.204	0.9430	-2.81	0.127	0.33
		40 min	10	-0.678	1.1180	-2.94	0.007	0.28
		41 min	10	-0.481	1.0240	-2.91	-0.018	0.31
		42 min	11	-0.862	1.4726	-3.42	-0.049	0.43
		43 min	12	-1.231	2.0924	-5.62	-0.173	0.45
		44 min	12	-0.792	1.5590	-4.36	0.016	0.47
		45 min	12	-0.524	1.2596	-3.05	0.023	0.52
		46 min	12	-0.791	1.6078	-4.65	0.097	0.38
		47 min	12	-0.399	0.9755	-3.00	0.013	0.45
		48 min	12	-0.505	1.2611	-3.11	0.053	0.44
		49 min	12	-0.379	1.0242	-3.01	0.017	0.43
		50 min	12	-0.659	1.5517	-4.44	0.016	0.42
		51 min	11	-0.206	1.0361	-3.27	0.063	0.38
		52 min	11	-0.262	1.0021	-3.00	0.098	0.40
		53 min	11	-0.167	0.9974	-3.14	0.161	0.33
		54 min	11	-0.027	1.0613	-3.08	0.312	0.96
		55 min	11	-0.332	1.0863	-3.12	0.113	0.43
		56 min	11	-0.271	1.0869	-3.21	0.143	0.66
		57 min	11	-0.275	1.1488	-3.26	0.165	0.63
		58 min	11	-0.172	1.0261	-3.14	0.155	0.71
		59 min	11	-0.643	1.8830	-5.36	0.125	0.87
		60 min	11	-0.171	1.0442	-3.08	0.176	0.88

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 59 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	61 min	11	-0.084	1.0508	-3.08	0.165	0.91
		62 min	11	-0.259	1.1466	-3.25	0.124	0.99
		63 min	10	-0.173	1.1863	-3.38	0.125	0.97
		64 min	10	-0.380	1.2606	-3.06	0.075	0.97
		65 min	9	-0.800	2.0513	-5.29	0.005	0.93
		66 min	9	-0.195	1.2645	-3.41	0.145	1.00
		67 min	9	-0.127	1.2828	-3.38	0.115	0.98
		68 min	9	-0.194	1.1477	-3.12	0.076	0.90
		69 min	9	-0.719	1.9753	-4.83	0.045	0.99
		70 min	9	0.032	1.2749	-3.16	0.405	1.08
		71 min	9	0.166	0.7755	-1.56	0.307	1.07
		72 min	9	-0.054	1.1920	-3.02	0.085	1.00
		73 min	9	0.260	1.4944	-2.92	0.357	2.78
		74 min	9	-0.045	1.3413	-3.33	0.409	1.17
		75 min	9	0.328	1.7927	-2.98	0.320	4.01
		76 min	9	0.401	0.4088	-0.30	0.363	1.07
		77 min	9	0.642	0.9330	-0.30	0.341	2.91
		78 min	9	0.312	0.3895	-0.34	0.306	1.11
		79 min	9	0.081	0.7725	-1.69	0.272	1.10
		80 min	9	0.615	1.0592	-0.42	0.319	3.23
		81 min	9	0.302	1.0359	-1.52	0.264	2.33
		82 min	9	0.432	0.7935	-0.44	0.304	2.31
		83 min	9	0.502	0.8384	-0.37	0.302	2.47
		84 min	9	0.477	0.9357	-0.42	0.257	2.77
		85 min	9	0.568	0.9207	-0.41	0.299	2.75
		86 min	9	0.438	0.6942	-0.40	0.308	1.92
		87 min	9	-0.353	1.3042	-2.63	0.168	1.10
		88 min	9	-0.447	1.6501	-3.51	0.139	1.18
		89 min	9	0.522	2.6075	-3.16	0.142	6.72
		90 min	9	0.585	2.6985	-2.80	0.185	7.20

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 60 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	91 min	9	0.595	2.6416	-2.29	-0.035	7.23
		92 min	9	0.841	2.4675	-0.83	0.158	7.27
		93 min	10	0.516	2.3512	-3.03	0.187	6.40
		94 min	10	0.392	2.5313	-3.04	0.172	6.88
		95 min	11	0.656	2.1068	-1.12	0.233	6.79
		96 min	11	0.389	2.4810	-3.27	0.126	7.05
		97 min	11	0.232	2.5326	-3.22	0.115	7.03
		98 min	11	0.410	2.4202	-3.03	0.138	6.90
		99 min	11	0.361	2.4559	-3.26	0.151	6.93
		100 min	11	0.404	2.4534	-3.04	0.207	7.03
		101 min	11	0.234	2.5688	-3.41	0.187	7.10
		102 min	11	0.323	2.5265	-3.49	0.181	7.02
		103 min	11	0.091	2.7228	-3.62	0.178	7.13
		104 min	11	0.315	2.5470	-2.85	0.230	7.17
		105 min	11	0.703	2.2317	-1.15	0.281	7.21
		106 min	11	0.146	2.6785	-3.25	0.187	7.08
		107 min	11	0.466	2.4343	-2.72	0.250	7.05
		108 min	11	0.381	3.0337	-4.50	0.333	7.10
		109 min	11	0.060	2.7227	-3.70	-0.135	7.04
		110 min	11	0.336	2.5528	-2.83	0.118	7.12
		111 min	11	-0.233	3.0159	-4.90	-0.225	6.92
		112 min	11	-0.163	3.0987	-5.29	-0.125	7.16
		113 min	11	-0.216	3.1547	-5.41	-0.365	7.10
		114 min	11	0.354	3.1098	-4.22	0.228	7.19
		115 min	11	0.195	3.0265	-5.56	-0.088	7.08
		116 min	11	-0.000	3.1257	-5.27	-0.185	7.18
		117 min	10	-0.216	3.5355	-5.56	-0.089	7.09
		118 min	10	0.099	3.1811	-5.37	-0.080	6.94
		119 min	10	0.038	3.0029	-4.34	0.183	6.53
		120 min	10	0.297	2.1600	-3.16	0.137	4.92

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 61 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	121 min	10	-0.511	2.2118	-5.54	0.071	2.15
		122 min	10	-0.469	1.8498	-3.16	-0.107	3.19
		123 min	11	0.663	1.6363	-0.69	0.108	4.86
		124 min	11	-0.271	1.6849	-4.54	-0.112	2.48
		125 min	11	-0.476	1.6815	-4.00	-0.082	2.32
		126 min	11	-0.395	1.8559	-4.98	-0.155	1.95
		127 min	11	-0.720	1.8788	-5.47	0.002	0.80
		128 min	11	-0.841	1.9608	-5.84	-0.208	0.82
		129 min	11	-0.928	1.8621	-5.35	-0.160	0.85
		130 min	11	-0.803	1.8417	-5.50	-0.116	0.82
		131 min	11	-0.848	1.8834	-5.44	-0.185	0.88
		132 min	11	-0.769	1.8886	-5.44	-0.131	0.88
		133 min	10	-0.532	1.7962	-5.42	-0.190	0.74
		134 min	11	-0.518	1.4754	-4.34	-0.125	0.73
		135 min	11	-0.677	1.8769	-5.31	-0.091	0.72
		136 min	11	0.106	1.4035	-2.92	0.010	2.96
		137 min	11	0.015	1.9949	-4.78	0.028	3.85
		138 min	11	-0.027	2.0740	-5.19	0.060	3.78
		139 min	11	-0.072	2.0163	-5.14	0.026	3.60
		140 min	11	-0.509	2.4550	-5.12	-0.134	3.75
		141 min	11	-0.131	1.9967	-5.06	-0.135	3.57
		142 min	11	-0.181	1.8927	-4.82	-0.075	3.36
		143 min	11	-0.106	1.9239	-5.00	-0.062	3.31
		144 min	11	-0.085	1.7966	-4.45	-0.058	3.36
		145 min	10	0.195	1.5316	-2.84	0.057	3.39
		146 min	10	-0.020	2.0315	-4.96	0.097	3.26
		147 min	10	0.003	1.9677	-4.63	0.084	3.37
		148 min	10	0.662	2.4434	-3.93	0.355	5.35
		149 min	10	0.455	2.6797	-5.12	0.322	5.24
		150 min	10	0.456	2.6168	-4.93	0.358	5.21

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 62 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	151 min	10	0.394	2.6337	-5.18	0.309	5.03
		152 min	10	0.404	2.5357	-4.86	0.248	4.94
		153 min	10	0.459	2.4262	-4.31	0.238	5.01
		154 min	10	0.455	2.4066	-4.37	0.292	4.88
		155 min	10	0.278	1.8908	-3.97	0.459	3.27
		156 min	10	0.772	2.1576	-2.59	0.537	5.25
		157 min	10	1.038	2.0339	-0.55	0.463	6.00
		158 min	10	0.733	2.2792	-2.59	0.213	5.77
		159 min	10	0.740	2.1686	-2.16	0.181	5.58
		160 min	10	0.814	1.9655	-1.21	0.250	5.48
		161 min	10	0.545	1.1766	-0.51	0.258	3.10
		162 min	10	0.386	0.9559	-0.52	0.169	2.78
		163 min	11	0.518	1.2585	-0.52	0.040	3.36
		164 min	11	0.543	1.2526	-0.48	0.046	3.28
		165 min	11	0.418	1.0520	-0.45	0.049	2.85
		166 min	11	0.399	1.0054	-0.45	0.042	3.07
		167 min	11	0.335	0.9092	-0.45	0.046	2.90
		168 min	11	0.087	0.3391	-0.47	0.083	0.69
		169 min	10	-0.143	0.8189	-2.27	0.002	0.62
		170 min	10	-0.165	0.9689	-2.79	0.148	0.63
		171 min	10	-0.147	0.8618	-2.47	0.034	0.47
		172 min	10	-0.082	0.9871	-2.77	0.264	0.56
		173 min	10	-0.133	1.0917	-3.15	0.248	0.48
		174 min	10	0.032	1.1887	-3.04	0.358	1.57
		175 min	10	-0.023	1.2785	-3.22	0.173	1.95
		176 min	10	0.135	1.2332	-2.74	0.280	2.33
		177 min	10	-0.012	1.0105	-2.68	0.283	1.03
		178 min	10	0.057	1.1787	-2.94	0.308	1.70
		179 min	10	0.069	1.2938	-3.10	0.269	2.10
		180 min	10	0.049	1.2365	-2.92	0.188	2.05

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 63 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	181 min	10	0.080	1.1963	-2.73	0.163	2.10
		182 min	10	0.093	1.2409	-2.77	0.189	2.30
		183 min	10	0.144	1.2616	-2.63	0.215	2.58
		184 min	10	0.068	1.3099	-2.70	0.102	2.73
		185 min	9	-0.240	1.9321	-3.52	0.105	3.13
		186 min	8	-0.017	1.2768	-2.86	0.163	1.56
		187 min	9	0.046	1.3195	-2.93	0.105	2.18
		188 min	9	0.016	1.2856	-2.87	0.138	2.09
		189 min	9	0.110	1.4724	-2.96	0.065	2.84
		190 min	9	0.172	1.6210	-2.83	0.090	3.56
		191 min	9	0.180	1.8546	-3.24	0.062	4.10
		192 min	9	0.233	1.9042	-3.25	0.115	4.25
		193 min	9	-0.134	1.2602	-3.29	0.067	0.99
		194 min	9	-0.053	1.2825	-3.05	0.105	1.71
		195 min	9	0.399	0.7944	-0.51	0.202	2.26
		196 min	9	0.008	1.6184	-3.50	0.170	2.78
		197 min	9	0.076	1.6010	-3.14	0.166	3.12
		198 min	10	-0.324	2.1769	-4.21	0.065	3.76
		199 min	10	-0.495	2.1651	-4.88	0.135	2.85
		200 min	10	-0.588	2.0220	-4.98	0.101	1.91
		201 min	10	-0.690	1.9808	-5.04	0.120	1.16
		202 min	10	-0.724	2.0264	-5.28	0.133	0.89
		203 min	11	-0.556	2.1060	-5.36	-0.015	2.61
		204 min	11	-0.268	2.6649	-5.30	0.115	5.59
		205 min	11	-0.783	1.9439	-5.64	0.152	0.83
		206 min	11	-0.726	1.9345	-5.55	0.153	0.80
		207 min	10	-0.872	1.9615	-5.39	-0.157	0.78
		208 min	10	-0.860	1.9931	-5.53	-0.056	0.79
		209 min	10	-0.979	1.9974	-5.58	-0.359	0.76
		210 min	10	-0.970	1.9348	-5.15	-0.291	0.89

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 64 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	8	211 min	10	-0.845	2.0118	-5.25	0.096	0.79
		212 min	10	-0.762	1.9823	-5.14	0.133	0.82
		213 min	10	-0.801	1.9520	-5.10	0.152	0.77
		214 min	10	-0.828	1.9636	-5.12	0.169	0.77
		215 min	10	-0.789	1.8392	-4.86	0.087	0.83
		216 min	10	-0.859	1.9932	-5.31	0.150	0.83
		217 min	10	-0.875	1.9532	-5.33	0.133	0.73
		218 min	10	-0.833	1.9660	-5.34	0.132	0.85
		219 min	10	-0.853	1.8456	-4.95	0.044	0.78
		220 min	10	-0.696	1.5115	-3.44	0.013	0.74
		221 min	10	-0.625	1.4371	-3.16	-0.003	0.73
		222 min	10	-0.388	1.1340	-3.14	0.029	0.66
		223 min	10	-0.547	1.2670	-3.16	-0.018	0.71
		224 min	10	-0.427	1.2018	-3.25	0.144	0.72
		225 min	10	-0.235	1.2040	-3.18	0.163	0.85
		226 min	10	0.141	1.8525	-3.37	0.226	4.14
		227 min	10	-0.363	2.2384	-4.60	0.167	3.51
		228 min	10	-0.250	2.2182	-4.19	0.112	4.05
		229 min	11	0.066	1.6186	-3.15	0.036	3.73
		230 min	11	-0.274	1.2627	-3.14	0.165	1.05
		231 min	11	-0.377	1.1168	-3.36	0.011	0.64
		232 min	11	-0.407	1.0689	-3.25	-0.140	0.73
		233 min	11	-0.542	1.2343	-3.23	-0.027	0.59
		234 min	11	-0.336	1.0669	-3.08	0.027	0.68
		235 min	10	-0.569	1.1280	-3.15	-0.155	0.71
		236 min	11	-0.355	0.8375	-1.76	-0.217	0.82
		237 min	11	-0.520	1.0625	-3.03	-0.245	0.58
		238 min	11	-0.606	1.2330	-3.28	-0.229	0.64
		239 min	11	-0.554	1.1428	-2.91	-0.254	0.72
		240 min	6	-0.314	0.5699	-1.35	-0.107	0.22

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 65 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	1 min	12	-0.014	0.8366	-1.90	0.051	1.85
		2 min	12	0.020	0.7599	-1.80	0.102	1.60
		3 min	12	-0.088	0.7205	-1.84	0.002	1.29
		4 min	12	-0.387	1.3976	-4.18	-0.006	1.39
		5 min	12	-0.065	0.6625	-1.81	-0.004	1.00
		6 min	12	-0.107	0.6398	-1.81	0.012	0.78
		7 min	12	-0.078	0.6295	-1.86	0.119	0.53
		8 min	12	-0.065	0.7140	-1.84	-0.035	1.25
		9 min	12	0.007	0.7076	-1.83	0.061	0.91
		10 min	12	-0.191	1.0094	-2.29	-0.009	1.58
		11 min	12	-0.331	0.9704	-2.66	-0.073	0.70
		12 min	12	-0.098	0.6307	-1.60	0.046	0.87
		13 min	12	-0.154	0.9729	-2.90	0.087	1.02
		14 min	12	-0.056	0.7116	-1.62	-0.049	1.31
		15 min	12	0.068	0.6712	-1.46	0.095	1.48
		16 min	12	-0.247	0.9835	-2.82	-0.082	1.12
		17 min	12	-0.215	0.4410	-1.22	-0.240	0.43
		18 min	12	-0.339	1.4311	-4.80	0.064	0.56
		19 min	12	-0.427	1.3881	-4.53	0.080	0.48
		20 min	12	-0.647	1.2427	-3.91	-0.174	0.47
		21 min	12	-0.362	0.9482	-2.81	-0.077	0.54
		22 min	12	-0.648	1.2616	-4.06	-0.157	0.57
		23 min	12	-0.913	1.9649	-5.13	-0.022	0.60
		24 min	12	-1.002	1.9628	-5.54	-0.215	0.50
		25 min	12	-0.134	0.6313	-1.65	0.033	0.71
		26 min	12	-0.519	1.3191	-4.29	0.001	0.48
		27 min	12	-0.926	1.7079	-4.97	-0.164	0.48
		28 min	12	-0.674	1.3865	-4.33	-0.036	0.38
		29 min	12	-0.875	1.7985	-4.62	0.023	0.45
		30 min	12	-0.875	1.6705	-4.83	-0.039	0.43

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 66 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	31 min	12	-0.846	1.6994	-4.18	0.050	0.37
		32 min	11	-1.044	1.9501	-4.83	-0.033	0.52
		33 min	10	-1.221	1.8821	-4.76	-0.494	0.29
		34 min	10	-1.360	2.1170	-5.58	-0.417	0.24
		35 min	10	-1.278	2.1146	-5.45	-0.165	0.15
		36 min	10	-1.112	1.8142	-4.70	-0.113	0.24
		37 min	10	-0.568	1.5806	-4.80	0.107	0.35
		38 min	10	-0.926	1.6940	-4.69	0.094	0.35
		39 min	10	-0.663	1.5314	-4.68	-0.072	0.34
		40 min	10	-0.845	1.5829	-4.83	-0.253	0.26
		41 min	10	-1.102	1.8067	-4.91	-0.267	0.33
		42 min	11	-1.258	1.8570	-4.76	-0.095	0.31
		43 min	12	-1.371	2.1261	-5.21	-0.081	0.41
		44 min	12	-0.978	1.8809	-4.87	-0.063	0.38
		45 min	12	-0.820	1.8267	-4.78	0.211	0.39
		46 min	12	-1.250	2.0158	-4.89	-0.017	0.34
		47 min	12	-0.919	1.7145	-4.72	-0.059	0.31
		48 min	12	-0.943	1.6813	-5.00	-0.122	0.40
		49 min	12	-0.806	1.5017	-4.87	-0.121	0.37
		50 min	12	-0.735	1.5238	-4.91	-0.141	0.39
		51 min	11	-0.587	1.6088	-4.86	-0.019	0.43
		52 min	11	-0.541	1.5348	-4.57	-0.014	0.41
		53 min	11	-0.379	1.0279	-2.56	-0.069	0.39
		54 min	11	-0.493	1.6480	-4.95	-0.099	0.65
		55 min	11	-0.784	1.6810	-4.96	-0.160	0.41
		56 min	11	-0.636	1.6391	-4.87	0.054	0.51
		57 min	11	-0.510	1.5972	-4.75	-0.011	0.59
		58 min	11	-0.566	1.6170	-4.84	0.036	0.63
		59 min	11	-1.027	2.2337	-5.71	0.004	0.78
		60 min	11	-0.625	1.6489	-4.88	0.095	0.87

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 67 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	61 min	11	-0.511	1.7085	-5.08	0.142	0.88
		62 min	11	-0.598	1.5915	-4.61	-0.085	0.94
		63 min	10	-0.556	1.7883	-5.00	0.036	0.88
		64 min	10	-0.834	1.8564	-5.12	-0.033	0.86
		65 min	9	-1.083	2.0843	-4.93	-0.219	1.03
		66 min	9	-0.645	1.8971	-5.06	0.023	1.02
		67 min	9	-0.605	1.8282	-4.79	0.022	1.03
		68 min	9	-0.623	1.7397	-4.60	-0.019	0.91
		69 min	9	-1.018	2.1153	-5.26	-0.097	0.97
		70 min	9	-0.472	1.9712	-5.07	0.241	1.10
		71 min	9	0.155	0.9487	-2.02	0.171	1.11
		72 min	9	0.171	1.0430	-2.27	0.381	1.30
		73 min	9	0.339	1.9485	-2.19	0.369	4.59
		74 min	9	0.069	2.8316	-5.00	0.291	5.74
		75 min	9	-0.024	2.5335	-4.66	0.256	4.76
		76 min	9	0.535	1.8522	-2.40	0.267	4.62
		77 min	9	0.648	1.8677	-2.22	0.263	4.82
		78 min	9	0.070	0.9997	-2.42	0.331	1.09
		79 min	9	0.312	1.1438	-1.99	0.370	2.29
		80 min	9	0.143	1.1693	-2.50	0.329	1.80
		81 min	9	-0.631	1.8609	-4.81	0.295	1.05
		82 min	9	0.015	1.0204	-2.46	0.359	0.98
		83 min	9	0.115	1.0931	-2.46	0.262	1.25
		84 min	9	-0.049	0.9826	-2.48	0.219	1.07
		85 min	9	0.166	1.1514	-2.50	0.281	1.61
		86 min	9	0.107	1.0978	-2.47	0.299	1.34
		87 min	9	-0.143	1.7742	-2.45	0.124	3.42
		88 min	9	0.345	2.6587	-2.51	0.091	6.82
		89 min	9	0.769	2.5918	-2.40	0.014	7.04
		90 min	9	0.698	2.6128	-2.55	0.194	7.13

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 68 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	91 min	9	0.674	2.4587	-2.68	0.257	6.60
		92 min	9	0.456	2.5646	-2.66	0.100	6.64
		93 min	10	0.210	2.6741	-4.28	0.177	6.53
		94 min	10	0.199	2.7871	-4.18	0.248	6.68
		95 min	11	0.551	2.0933	-2.41	0.347	6.22
		96 min	11	0.181	2.3395	-3.18	0.233	6.03
		97 min	11	0.047	2.2474	-2.92	0.112	5.90
		98 min	11	0.270	2.0635	-2.39	0.023	5.94
		99 min	11	-0.039	2.5142	-4.72	0.101	5.93
		100 min	11	0.228	2.0931	-2.58	0.186	5.93
		101 min	11	-0.118	2.5850	-4.97	0.166	5.92
		102 min	11	-0.241	2.5774	-4.71	-0.050	5.95
		103 min	11	-0.134	2.4361	-4.12	-0.121	5.80
		104 min	11	-0.062	2.2734	-2.95	-0.355	5.96
		105 min	11	0.166	2.2925	-2.89	0.202	5.89
		106 min	11	-0.084	2.4449	-3.54	0.086	5.96
		107 min	11	0.102	2.4255	-3.50	0.145	6.02
		108 min	11	-0.717	2.9085	-4.25	-0.466	6.05
		109 min	11	-0.239	2.7733	-4.49	0.100	6.01
		110 min	11	-0.023	2.5273	-4.23	0.087	6.00
		111 min	11	-0.968	3.2167	-5.35	-0.462	6.00
		112 min	11	-0.446	2.7961	-4.17	0.038	6.03
		113 min	11	-0.353	2.8136	-4.30	0.111	6.00
		114 min	11	-0.348	2.9006	-4.58	0.159	6.09
		115 min	11	-0.243	2.5917	-3.49	-0.525	6.40
		116 min	11	-0.648	2.8687	-4.45	-0.375	6.19
		117 min	10	-1.023	3.4176	-5.31	-0.222	6.36
		118 min	10	-0.438	3.2885	-5.28	0.114	6.89
		119 min	10	-0.288	3.0229	-4.85	-0.032	6.71
		120 min	10	0.028	2.9596	-3.34	0.051	7.29

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 69 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	121 min	10	-0.256	3.2548	-4.28	-0.001	7.18
		122 min	10	-0.323	3.0202	-3.43	-0.250	7.10
		123 min	11	0.331	2.2095	-2.72	0.039	6.42
		124 min	11	0.106	2.6612	-3.96	0.070	6.70
		125 min	11	-0.487	2.9444	-4.60	-0.135	6.58
		126 min	11	-0.008	2.9517	-4.72	-0.123	7.36
		127 min	11	-0.713	1.8944	-5.33	-0.019	1.48
		128 min	11	-0.974	2.0491	-5.48	-0.185	1.40
		129 min	11	-1.035	2.3298	-5.70	-0.205	2.05
		130 min	11	-0.661	1.8745	-5.15	-0.062	1.26
		131 min	11	-1.188	2.1427	-5.39	-0.297	0.67
		132 min	11	-0.515	1.8881	-5.14	-0.091	1.84
		133 min	10	-0.691	1.9409	-5.14	-0.209	1.43
		134 min	11	-0.971	1.5583	-3.64	-0.344	0.67
		135 min	11	-1.000	2.1005	-4.84	-0.134	0.78
		136 min	11	-0.202	1.4172	-2.80	0.040	1.83
		137 min	11	-0.358	1.7646	-4.41	0.047	2.06
		138 min	11	-0.433	1.8701	-5.03	0.111	1.86
		139 min	11	-0.420	1.8983	-5.10	0.030	1.84
		140 min	11	-0.848	2.1623	-5.25	-0.100	1.93
		141 min	11	-0.576	1.9077	-5.32	-0.103	1.88
		142 min	11	-0.612	1.8311	-4.96	-0.185	1.91
		143 min	11	-0.530	1.7902	-4.83	-0.100	1.89
		144 min	11	-0.439	1.7102	-4.45	-0.044	1.86
		145 min	10	-0.096	1.2151	-2.60	0.021	1.87
		146 min	10	-0.394	1.8042	-4.37	0.145	1.80
		147 min	10	-0.410	1.9812	-5.02	0.185	1.81
		148 min	10	-0.108	1.9711	-4.13	0.272	2.46
		149 min	10	-0.137	2.3724	-5.20	0.253	3.53
		150 min	10	-0.073	2.3221	-5.35	0.554	2.90

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 70 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	151 min	10	-0.394	2.0650	-5.24	0.275	1.85
		152 min	10	-0.168	2.2999	-4.95	0.016	3.59
		153 min	10	-0.062	2.5320	-5.00	-0.031	4.70
		154 min	10	0.192	2.2936	-3.27	0.090	5.16
		155 min	10	0.223	1.9539	-2.61	-0.066	4.62
		156 min	10	0.046	1.4460	-2.64	0.210	2.07
		157 min	10	-0.140	1.1983	-2.65	0.207	1.54
		158 min	10	-0.250	1.4284	-2.82	0.099	1.83
		159 min	10	-0.269	1.5217	-3.28	-0.005	1.69
		160 min	10	-0.269	1.3214	-2.62	-0.024	1.72
		161 min	10	-0.320	1.3036	-2.59	-0.130	1.70
		162 min	10	-0.276	1.0852	-2.59	-0.167	1.45
		163 min	11	-0.320	1.1367	-2.61	-0.149	1.46
		164 min	11	-0.232	1.1348	-2.59	-0.021	1.34
		165 min	11	-0.118	0.9790	-2.59	-0.030	1.53
		166 min	11	-0.103	1.0716	-2.52	-0.046	1.51
		167 min	11	-0.001	0.9958	-2.57	0.044	1.46
		168 min	11	-0.098	0.8768	-2.55	0.151	0.77
		169 min	10	-0.061	0.9471	-2.56	0.129	0.88
		170 min	10	-0.126	0.8911	-2.55	0.041	0.62
		171 min	10	-0.157	0.8404	-2.47	-0.027	0.49
		172 min	10	-0.090	0.8878	-2.51	0.187	0.70
		173 min	10	-0.534	1.6242	-4.43	0.064	0.52
		174 min	10	-0.488	1.6852	-4.53	0.049	0.85
		175 min	10	-0.554	1.6614	-4.54	0.062	0.90
		176 min	10	-0.461	1.7272	-4.60	0.162	1.14
		177 min	10	-0.458	1.7217	-4.51	0.076	1.33
		178 min	10	-0.399	1.7311	-4.41	0.178	1.42
		179 min	10	-0.297	1.5693	-3.64	0.191	1.64
		180 min	10	-0.325	1.7819	-4.40	0.198	1.78

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 71 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	181 min	10	-0.394	1.8724	-4.77	0.184	1.79
		182 min	10	-0.406	1.8372	-4.66	0.066	1.91
		183 min	10	-0.312	1.7896	-4.34	0.184	2.04
		184 min	10	-0.306	1.7973	-4.83	-0.016	2.17
		185 min	9	-0.435	1.9845	-4.84	-0.089	2.33
		186 min	8	-0.545	2.0189	-4.83	0.166	1.33
		187 min	9	-0.487	1.9035	-4.80	0.195	1.43
		188 min	9	-0.463	1.9368	-4.82	0.244	1.47
		189 min	9	-0.424	1.8848	-4.59	0.001	1.62
		190 min	9	-0.498	1.9132	-4.85	0.073	1.69
		191 min	9	-0.521	1.8539	-4.64	0.028	1.46
		192 min	9	-0.549	1.9440	-4.91	-0.036	1.51
		193 min	9	-0.571	1.8716	-4.76	-0.027	0.94
		194 min	9	0.205	1.1832	-2.56	0.336	1.63
		195 min	9	0.041	1.0891	-2.56	0.173	1.47
		196 min	9	-0.060	1.0783	-2.60	-0.015	1.32
		197 min	9	-0.212	1.2043	-2.58	0.044	1.34
		198 min	10	-0.412	1.8514	-4.64	0.121	1.59
		199 min	10	-0.979	2.2717	-4.86	-0.016	1.60
		200 min	10	-0.991	2.2524	-4.96	0.083	1.05
		201 min	10	-1.119	2.2770	-5.05	-0.058	0.89
		202 min	10	-0.919	2.5277	-5.13	-0.036	2.47
		203 min	11	-0.818	2.1476	-5.08	0.029	1.96
		204 min	11	-0.857	2.4072	-5.19	0.033	2.58
		205 min	11	-1.140	2.2344	-5.49	-0.086	0.59
		206 min	11	-1.150	2.2331	-5.51	-0.080	0.64
		207 min	10	-1.258	2.3096	-5.44	-0.080	0.60
		208 min	10	-1.288	2.2946	-5.45	-0.148	0.63
		209 min	10	-1.304	2.3456	-5.54	-0.221	0.74
		210 min	10	-1.291	2.2602	-5.23	-0.371	0.75

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 72 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	9	211 min	10	-1.155	2.2374	-5.07	0.062	0.69
		212 min	10	-1.146	2.2918	-5.12	-0.001	0.80
		213 min	10	-1.103	2.1947	-5.15	0.014	0.74
		214 min	10	-1.136	2.1352	-4.84	0.009	0.69
		215 min	10	-1.125	2.1792	-5.05	-0.026	0.74
		216 min	10	-1.231	2.3248	-5.34	0.010	0.75
		217 min	10	-1.270	2.2981	-5.41	0.005	0.70
		218 min	10	-1.276	2.3261	-5.44	-0.039	0.78
		219 min	10	-1.301	2.3209	-5.39	-0.023	0.77
		220 min	10	-1.241	2.2823	-5.25	-0.017	0.77
		221 min	10	-0.895	2.1927	-4.99	0.203	1.42
		222 min	10	-0.637	2.1690	-4.85	0.076	2.78
		223 min	10	-0.685	1.8387	-4.94	0.097	0.76
		224 min	10	-0.458	2.0048	-5.04	0.308	1.71
		225 min	10	-0.526	1.8188	-4.84	0.120	1.36
		226 min	10	-0.154	1.8242	-4.98	0.253	1.52
		227 min	10	-0.310	1.8866	-5.02	0.116	2.04
		228 min	10	-0.456	2.0254	-4.74	0.109	2.25
		229 min	11	-0.298	1.6528	-4.87	0.061	1.57
		230 min	11	-0.494	1.9258	-4.61	0.247	1.13
		231 min	11	-0.609	1.6149	-4.93	0.075	0.67
		232 min	11	-0.449	1.3531	-4.05	0.119	0.72
		233 min	11	-0.238	1.6625	-4.74	0.012	2.13
		234 min	11	-0.240	1.7360	-5.00	-0.018	2.08
		235 min	10	-0.645	1.5645	-4.64	-0.163	0.73
		236 min	11	-0.408	0.9419	-2.15	-0.217	0.82
		237 min	11	-0.691	1.6297	-5.01	-0.090	0.51
		238 min	11	-0.146	0.8352	-2.21	-0.055	0.99
		239 min	11	-0.878	1.5981	-4.63	-0.284	0.62
		240 min	6	-0.531	1.0447	-2.62	-0.108	0.15

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 73 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	1 min	12	0.017	0.4032	-1.00	0.070	0.49
		2 min	12	-0.022	0.4638	-1.04	0.024	0.58
		3 min	12	-0.227	0.7828	-2.39	-0.008	0.41
		4 min	12	-0.291	0.8138	-2.49	-0.019	0.43
		5 min	12	-0.229	0.7197	-2.15	-0.012	0.43
		6 min	12	-0.090	0.4592	-1.00	-0.065	0.44
		7 min	12	-0.193	0.7793	-2.33	0.052	0.32
		8 min	12	-0.270	0.8257	-2.58	-0.026	0.37
		9 min	12	-0.424	1.0557	-2.75	0.007	0.47
		10 min	12	-0.250	0.7678	-2.33	-0.033	0.42
		11 min	12	-0.301	0.6664	-1.95	-0.155	0.52
		12 min	12	-0.340	0.7829	-2.39	-0.175	0.54
		13 min	12	-0.462	1.2036	-3.27	-0.063	0.84
		14 min	12	-0.181	0.8366	-2.44	-0.054	0.70
		15 min	12	-0.329	0.7940	-1.86	-0.034	0.46
		16 min	12	-0.235	0.7063	-1.82	-0.085	0.48
		17 min	12	-0.472	1.2579	-3.95	-0.177	0.78
		18 min	12	-0.696	1.7449	-5.81	-0.019	0.65
		19 min	12	-0.493	1.1269	-3.01	-0.076	0.69
		20 min	12	-0.684	1.6347	-5.15	-0.097	0.97
		21 min	12	-0.275	0.8028	-1.92	-0.076	1.04
		22 min	12	-0.454	1.0839	-2.64	-0.077	0.69
		23 min	12	-0.681	1.4434	-3.35	-0.130	1.08
		24 min	12	-0.659	1.2750	-3.65	-0.177	0.57
		25 min	12	-0.157	1.4254	-2.67	0.004	3.22
		26 min	12	-0.652	1.6831	-5.28	-0.139	0.57
		27 min	12	-0.698	1.6772	-5.13	-0.180	0.63
		28 min	12	-0.375	1.5764	-3.11	-0.070	2.89
		29 min	12	-0.624	1.3355	-3.17	-0.030	0.77
		30 min	12	-0.738	1.9966	-6.14	-0.020	0.75

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 74 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	31 min	12	-0.722	1.8449	-5.59	-0.024	0.81
		32 min	11	-1.306	2.3434	-6.08	-0.099	0.78
		33 min	10	-1.227	2.0561	-4.83	-0.388	0.62
		34 min	10	-1.368	2.3901	-5.61	-0.394	0.81
		35 min	10	-0.596	1.2393	-3.16	-0.332	0.79
		36 min	10	-1.003	1.8569	-4.44	-0.307	0.91
		37 min	10	-0.528	1.5123	-3.51	0.158	0.74
		38 min	10	-0.652	1.3268	-3.05	-0.209	0.72
		39 min	10	-0.562	1.0604	-2.57	-0.228	0.57
		40 min	10	-0.673	1.2824	-2.87	-0.373	0.81
		41 min	10	-1.342	2.0718	-6.22	-0.696	0.59
		42 min	11	-1.520	2.2236	-6.23	-0.758	0.64
		43 min	12	-1.157	1.7556	-4.44	-0.457	0.63
		44 min	12	-1.165	2.1821	-6.24	-0.045	0.64
		45 min	12	-1.095	2.2703	-6.17	0.058	0.67
		46 min	12	-1.477	2.5690	-6.28	0.031	1.08
		47 min	12	-1.094	2.0573	-6.11	-0.080	0.70
		48 min	12	-1.037	1.9879	-6.25	-0.497	0.70
		49 min	12	-1.048	2.0024	-6.43	-0.369	0.70
		50 min	12	-0.841	2.0618	-6.36	-0.004	0.92
		51 min	11	-0.714	2.0025	-5.63	-0.014	0.91
		52 min	11	-0.375	1.1968	-3.34	-0.073	0.76
		53 min	11	-0.404	1.2019	-3.34	-0.103	0.75
		54 min	11	-0.708	2.1193	-6.33	-0.070	1.20
		55 min	11	-0.817	2.0666	-6.20	-0.072	0.72
		56 min	11	-0.771	2.1513	-6.28	-0.021	1.13
		57 min	11	-0.733	2.1393	-6.27	0.103	1.11
		58 min	11	-0.811	2.0750	-6.10	-0.065	1.00
		59 min	11	-1.205	2.4419	-6.26	-0.019	1.11
		60 min	11	-0.822	2.1401	-6.27	0.000	1.13

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 75 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	61 min	11	-0.796	2.2065	-6.48	0.002	1.14
		62 min	11	-0.763	2.0489	-5.85	-0.141	1.30
		63 min	10	-0.841	2.3250	-6.44	-0.005	1.14
		64 min	10	-1.387	2.6364	-6.53	-0.124	1.20
		65 min	9	-1.408	2.4587	-6.02	-0.289	1.25
		66 min	9	-0.896	2.4400	-6.45	0.081	1.20
		67 min	9	-0.851	2.4006	-6.22	-0.043	1.28
		68 min	9	-0.898	2.1092	-5.37	-0.074	1.13
		69 min	9	-1.175	2.4139	-6.45	-0.064	1.23
		70 min	9	-0.690	2.0596	-4.87	0.211	1.27
		71 min	9	0.399	2.1856	-3.01	0.235	5.13
		72 min	9	0.513	2.4181	-3.22	0.330	5.77
		73 min	9	0.452	2.4057	-2.99	0.222	5.93
		74 min	9	-0.112	3.3109	-6.50	0.359	5.93
		75 min	9	0.345	2.3624	-3.27	0.252	5.57
		76 min	9	0.295	2.1603	-3.40	0.138	4.80
		77 min	9	0.411	2.2603	-3.06	0.155	5.50
		78 min	9	-0.408	1.5035	-3.38	0.223	1.17
		79 min	9	-0.050	1.4160	-3.38	0.426	1.38
		80 min	9	-0.082	1.4489	-3.59	0.363	1.29
		81 min	9	-0.904	2.4246	-6.17	0.332	1.38
		82 min	9	-0.874	2.3469	-5.95	0.313	1.30
		83 min	9	-0.328	1.4490	-3.50	0.284	1.28
		84 min	9	-0.355	1.3652	-3.50	0.182	1.28
		85 min	9	-0.183	1.3945	-3.51	0.219	1.34
		86 min	9	-0.236	1.4012	-3.51	0.188	1.32
		87 min	9	-0.783	2.1646	-5.16	0.094	1.16
		88 min	9	-0.402	3.5163	-6.04	0.071	6.66
		89 min	9	0.045	2.6049	-3.54	0.029	5.82
		90 min	9	0.194	2.4779	-3.80	0.166	5.63

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 76 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	91 min	9	0.324	2.4028	-3.60	0.210	5.59
		92 min	9	0.358	2.5174	-3.47	0.079	6.06
		93 min	10	0.127	2.5618	-3.15	0.107	6.30
		94 min	10	-0.011	2.9368	-4.56	0.229	6.38
		95 min	11	0.348	2.3881	-3.27	0.154	6.64
		96 min	11	0.305	2.4664	-3.45	0.181	6.68
		97 min	11	0.059	2.6027	-3.42	0.070	6.60
		98 min	11	-0.014	2.5250	-3.69	-0.002	6.31
		99 min	11	0.189	2.3562	-3.19	0.127	6.54
		100 min	11	0.001	2.4474	-3.25	-0.401	6.62
		101 min	11	-0.368	3.0187	-6.03	-0.301	6.59
		102 min	11	0.179	2.3559	-3.00	0.122	6.60
		103 min	11	-0.130	2.5476	-3.61	-0.388	6.63
		104 min	11	0.118	2.4876	-3.89	0.155	6.61
		105 min	11	0.242	2.4334	-3.83	0.242	6.52
		106 min	11	-0.052	2.3380	-3.66	-0.588	6.09
		107 min	11	0.038	2.4197	-3.74	-0.048	6.39
		108 min	11	-0.159	2.5573	-3.88	-0.612	6.51
		109 min	11	-0.206	2.6357	-3.73	0.027	6.39
		110 min	11	-0.254	2.6955	-4.19	-0.176	6.39
		111 min	11	-0.787	3.1255	-4.84	-0.711	6.40
		112 min	11	-0.615	2.8975	-4.69	-0.878	6.42
		113 min	11	-0.369	2.8549	-4.37	-0.367	6.64
		114 min	11	-0.096	2.6018	-3.82	-0.214	6.71
		115 min	11	-0.288	2.5342	-3.82	-0.772	6.33
		116 min	11	-0.176	2.6387	-3.73	0.027	6.61
		117 min	10	-0.464	3.3837	-6.54	-0.084	6.77
		118 min	10	-0.213	2.7166	-3.82	-0.386	6.48
		119 min	10	-0.106	2.7729	-3.82	-0.013	6.48
		120 min	10	0.035	2.5544	-3.82	-0.182	6.35

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 77 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	121 min	10	-0.345	2.8431	-3.78	-0.097	6.49
		122 min	10	0.174	2.6370	-3.83	-0.004	6.75
		123 min	11	0.123	2.4103	-3.68	0.067	6.45
		124 min	11	0.149	2.4567	-3.82	0.035	6.60
		125 min	11	-0.371	3.0969	-6.02	-0.072	6.68
		126 min	11	0.035	2.4858	-3.74	-0.247	6.66
		127 min	11	-0.717	2.1695	-5.43	-0.011	2.36
		128 min	11	-1.046	1.7021	-3.74	-0.252	0.77
		129 min	11	-1.489	2.4325	-6.06	-0.194	1.43
		130 min	11	-1.112	1.8570	-4.09	-0.147	0.63
		131 min	11	-1.419	2.3084	-6.01	-0.185	0.67
		132 min	11	-0.724	1.6218	-4.20	-0.072	0.65
		133 min	10	-0.595	1.9575	-4.11	0.029	2.11
		134 min	11	-0.992	1.6176	-4.27	-0.233	0.69
		135 min	11	-1.043	1.8256	-4.04	-0.092	0.75
		136 min	11	-0.629	1.7376	-4.15	-0.001	0.77
		137 min	11	-0.706	1.7634	-4.56	-0.021	0.70
		138 min	11	-0.700	1.8916	-4.82	0.045	0.93
		139 min	11	-0.621	1.7964	-4.52	0.051	0.85
		140 min	11	-0.986	1.9274	-4.92	-0.122	0.82
		141 min	11	-0.967	1.9543	-5.01	-0.029	0.79
		142 min	11	-0.585	1.9922	-4.78	-0.042	1.92
		143 min	11	-0.254	2.2034	-4.23	-0.052	4.10
		144 min	11	-0.696	1.7652	-4.46	-0.044	0.74
		145 min	10	-0.512	1.4664	-3.59	-0.005	0.72
		146 min	10	-0.517	1.6957	-3.63	0.163	1.07
		147 min	10	-0.191	2.6660	-4.43	0.211	5.30
		148 min	10	0.154	2.2985	-3.62	0.075	5.51
		149 min	10	-0.226	2.6410	-4.65	0.213	5.04
		150 min	10	-0.118	2.7429	-4.84	0.123	5.50

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 78 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	151 min	10	-0.023	2.6974	-4.52	0.392	5.51
		152 min	10	-0.183	2.7652	-5.17	0.044	5.27
		153 min	10	-0.319	2.7929	-5.09	-0.088	5.44
		154 min	10	-0.172	2.5934	-4.08	-0.155	5.37
		155 min	10	-0.238	2.5416	-3.96	-0.207	5.28
		156 min	10	-0.318	2.6662	-4.53	-0.299	5.36
		157 min	10	-0.267	2.2096	-3.65	-0.210	4.48
		158 min	10	-0.618	1.4328	-3.58	-0.218	0.70
		159 min	10	-0.578	1.3588	-3.44	-0.140	0.78
		160 min	10	-0.484	1.3395	-3.64	0.076	0.75
		161 min	10	-0.586	1.3245	-3.54	-0.049	0.58
		162 min	10	-0.508	1.2264	-3.60	-0.097	0.66
		163 min	11	-0.474	1.1775	-3.63	-0.000	0.58
		164 min	11	-0.482	1.1835	-3.63	-0.105	0.64
		165 min	11	-0.431	1.1966	-3.54	-0.031	0.61
		166 min	11	-0.153	1.0969	-3.39	0.141	0.63
		167 min	11	-0.218	1.1418	-3.58	0.026	0.69
		168 min	11	-0.025	1.5293	-3.60	0.014	3.08
		169 min	10	-0.404	1.2226	-3.62	-0.036	0.63
		170 min	10	-0.451	1.2711	-3.60	-0.056	0.73
		171 min	10	-0.428	1.2486	-3.48	0.064	0.60
		172 min	10	-0.328	1.2291	-3.50	0.086	0.76
		173 min	10	-0.844	2.0844	-5.69	-0.129	0.93
		174 min	10	-0.722	2.1340	-5.57	0.087	1.19
		175 min	10	-0.713	2.1163	-5.55	0.209	1.24
		176 min	10	-0.700	2.0987	-5.57	0.202	1.32
		177 min	10	-0.600	1.8979	-4.66	0.046	1.46
		178 min	10	-0.599	2.1784	-5.43	0.161	1.93
		179 min	10	-0.434	1.7803	-3.55	0.068	1.89
		180 min	10	-0.664	2.2261	-5.73	0.100	1.55

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 79 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	181 min	10	-0.707	2.2873	-6.00	0.017	1.47
		182 min	10	-0.702	2.1890	-5.77	0.119	1.14
		183 min	10	-0.616	1.8972	-4.68	0.046	1.07
		184 min	10	-0.529	2.0255	-6.03	0.056	1.02
		185 min	9	-0.619	1.7044	-4.09	-0.095	0.94
		186 min	8	-1.030	2.4902	-6.18	-0.084	1.17
		187 min	9	-0.865	2.3384	-6.00	-0.029	1.19
		188 min	9	-0.871	2.3023	-5.96	-0.076	1.22
		189 min	9	-0.390	1.3242	-3.32	-0.107	1.20
		190 min	9	-0.956	2.2897	-6.18	-0.125	1.15
		191 min	9	-0.931	2.2173	-5.84	-0.094	1.08
		192 min	9	-0.935	2.3090	-6.09	-0.082	1.02
		193 min	9	-0.903	2.3332	-6.09	-0.053	1.00
		194 min	9	-0.288	1.3256	-3.50	-0.089	0.95
		195 min	9	-0.509	1.3795	-3.60	-0.094	0.96
		196 min	9	-0.414	1.3852	-3.54	-0.082	0.98
		197 min	9	-0.473	1.3662	-3.57	-0.058	0.97
		198 min	10	-0.746	1.7797	-4.33	-0.138	0.97
		199 min	10	-1.298	2.3564	-6.11	-0.224	1.08
		200 min	10	-1.187	2.3455	-6.36	-0.224	1.14
		201 min	10	-1.275	2.3460	-6.39	-0.232	0.88
		202 min	10	-1.366	2.4669	-6.37	-0.199	0.81
		203 min	11	-1.140	1.9622	-4.68	-0.552	0.75
		204 min	11	-1.236	2.1980	-5.54	-0.491	0.85
		205 min	11	-1.309	2.5019	-6.26	-0.560	1.23
		206 min	11	-1.333	2.5514	-6.31	-0.554	0.84
		207 min	10	-1.550	2.5624	-6.31	-0.672	0.94
		208 min	10	-1.570	2.6420	-6.36	-0.475	0.89
		209 min	10	-1.619	2.5895	-6.40	-0.693	0.86
		210 min	10	-1.534	2.5301	-6.25	-0.712	0.91

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 80 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	10	211 min	10	-1.485	2.5615	-6.41	-0.393	0.85
		212 min	10	-1.270	2.3514	-6.20	-0.321	0.82
		213 min	10	-1.451	2.4592	-5.96	-0.390	0.70
		214 min	10	-1.383	2.2962	-5.21	-0.357	0.71
		215 min	10	-1.512	2.5455	-6.24	-0.325	0.75
		216 min	10	-1.485	2.5934	-6.22	-0.275	0.79
		217 min	10	-1.502	2.5750	-6.26	-0.280	0.83
		218 min	10	-1.529	2.5933	-6.39	-0.302	0.84
		219 min	10	-1.471	2.5188	-6.38	-0.379	0.81
		220 min	10	-1.390	2.4941	-6.39	-0.342	0.82
		221 min	10	-0.721	2.5547	-6.24	0.067	2.36
		222 min	10	-0.802	2.3889	-6.06	-0.239	1.93
		223 min	10	-0.671	2.1020	-5.09	0.183	1.42
		224 min	10	-0.746	2.3714	-6.28	0.177	1.19
		225 min	10	-0.516	2.2949	-5.12	0.081	2.89
		226 min	10	-0.658	2.3842	-6.08	0.149	2.20
		227 min	10	-0.404	2.1608	-6.30	0.220	1.19
		228 min	10	-0.646	2.0764	-5.78	-0.218	1.42
		229 min	11	-0.419	1.9918	-5.87	0.054	1.55
		230 min	11	-0.449	1.3900	-3.90	-0.170	0.82
		231 min	11	-0.545	1.4960	-4.69	-0.283	0.75
		232 min	11	-0.416	1.6245	-4.85	-0.403	1.45
		233 min	11	-0.255	1.0459	-2.71	-0.426	1.44
		234 min	11	-0.584	2.0490	-6.41	-0.278	1.47
		235 min	10	-0.466	2.0424	-5.99	-0.130	1.53
		236 min	11	-0.061	0.9879	-2.13	-0.132	1.81
		237 min	11	-0.466	1.9464	-6.06	-0.098	1.43
		238 min	11	0.034	0.5593	-0.72	-0.141	1.29
		239 min	11	-0.422	0.7669	-1.79	-0.185	0.58
		240 min	6	-0.928	1.3388	-3.28	-0.272	0.07

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 81 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	1 min	12	-0.021	0.6555	-1.89	0.054	0.69
		2 min	12	0.089	0.7951	-1.98	0.106	1.32
		3 min	12	0.030	0.7855	-2.01	0.082	1.28
		4 min	12	-0.233	0.9310	-3.10	0.019	0.45
		5 min	12	-0.551	1.1017	-2.94	-0.110	0.56
		6 min	12	-0.430	0.8608	-2.52	-0.069	0.20
		7 min	12	-0.369	0.8803	-2.93	-0.085	0.33
		8 min	12	-0.093	1.1650	-3.07	-0.060	2.02
		9 min	12	-0.192	1.1737	-2.96	0.067	1.45
		10 min	12	0.071	1.3666	-3.13	0.082	2.80
		11 min	12	-0.187	1.3637	-3.00	0.023	1.62
		12 min	12	-0.276	1.1331	-2.57	-0.007	1.82
		13 min	12	-0.270	1.3238	-3.08	0.076	1.48
		14 min	12	-0.134	1.2422	-3.12	0.125	1.55
		15 min	12	0.105	1.2208	-2.82	0.196	2.24
		16 min	12	-0.309	1.1372	-2.83	0.016	1.46
		17 min	12	-0.330	1.0953	-2.79	-0.116	1.47
		18 min	12	-0.382	1.0640	-2.40	-0.112	1.36
		19 min	12	-0.234	0.9861	-2.16	0.004	1.53
		20 min	12	-0.097	1.5003	-2.67	-0.000	3.21
		21 min	12	0.225	1.0237	-1.35	0.209	2.81
		22 min	12	0.316	1.1966	-1.31	0.160	3.45
		23 min	12	0.304	1.1056	-1.24	0.091	3.07
		24 min	12	0.282	1.2726	-1.41	0.130	3.29
		25 min	12	0.142	1.7341	-4.00	0.104	3.49
		26 min	12	-0.495	2.2888	-4.88	0.078	2.80
		27 min	12	-0.426	1.9536	-4.89	-0.054	3.05
		28 min	12	-0.005	2.1650	-5.65	0.098	3.55
		29 min	12	-0.551	1.8406	-5.08	-0.267	1.76
		30 min	12	0.223	2.0720	-2.58	-0.054	4.91

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 82 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	31 min	12	0.144	2.1549	-2.34	-0.258	6.21
		32 min	11	-0.383	2.2060	-5.75	0.005	2.59
		33 min	10	-0.619	1.7006	-2.90	-0.495	1.90
		34 min	10	-0.741	2.1086	-5.67	-0.358	2.06
		35 min	10	-0.411	2.4265	-5.23	-0.435	3.27
		36 min	10	-0.687	1.6241	-3.15	-0.440	1.95
		37 min	10	-0.276	1.7377	-3.20	-0.435	2.58
		38 min	10	-0.054	1.6564	-3.29	-0.270	2.74
		39 min	10	-0.082	1.4874	-3.13	-0.238	2.01
		40 min	10	-0.077	1.7463	-3.28	-0.260	2.95
		41 min	10	-0.591	2.3021	-6.72	0.045	1.31
		42 min	11	-0.448	2.5653	-5.42	-0.359	4.08
		43 min	12	-0.390	2.3094	-4.85	-0.096	3.46
		44 min	12	-1.091	2.2980	-6.65	-0.362	1.15
		45 min	12	-0.528	2.1303	-6.25	-0.115	1.90
		46 min	12	-0.651	2.3909	-6.86	-0.177	2.74
		47 min	12	-0.715	2.3459	-6.73	-0.186	2.55
		48 min	12	-0.605	2.2598	-6.79	0.085	1.53
		49 min	12	-0.893	2.3328	-6.93	-0.300	2.17
		50 min	12	-0.407	2.7182	-6.95	-0.042	4.58
		51 min	11	-0.000	2.2950	-3.75	0.251	4.86
		52 min	11	-0.243	2.7020	-6.60	0.070	4.16
		53 min	11	-0.296	1.3959	-3.17	0.072	1.31
		54 min	11	-0.743	2.6102	-6.84	0.359	1.60
		55 min	11	-0.915	2.3821	-6.78	-0.259	1.58
		56 min	11	-1.177	2.5397	-6.30	-0.020	1.63
		57 min	11	-0.454	1.5831	-3.59	0.068	1.67
		58 min	11	-0.280	1.4081	-3.52	0.077	1.66
		59 min	11	-0.846	2.3844	-6.71	-0.220	1.75
		60 min	11	-0.360	2.5985	-6.68	0.081	2.34

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 83 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	61 min	11	-0.445	2.6168	-7.03	0.244	1.85
		62 min	11	-0.569	2.4748	-6.87	0.279	1.86
		63 min	10	-0.647	2.6489	-6.94	0.135	1.96
		64 min	10	-0.630	2.6898	-6.98	0.026	2.20
		65 min	9	-1.194	2.5475	-6.76	-0.570	1.82
		66 min	9	-0.624	2.9373	-7.05	0.271	2.66
		67 min	9	-0.605	2.8327	-6.59	-0.084	2.55
		68 min	9	-0.666	2.1087	-4.96	-0.332	1.88
		69 min	9	-1.237	2.5771	-6.68	-0.330	1.97
		70 min	9	-0.412	2.9396	-6.94	0.425	3.28
		71 min	9	0.285	2.4144	-5.20	0.600	3.25
		72 min	9	0.930	1.6606	-1.27	0.790	3.94
		73 min	9	-0.310	2.6300	-6.27	-0.059	2.61
		74 min	9	-0.401	2.6722	-6.79	-0.067	2.39
		75 min	9	-0.165	2.5327	-6.44	0.235	2.31
		76 min	9	0.150	1.4843	-2.32	0.113	2.25
		77 min	9	0.403	1.1246	-1.00	0.159	2.25
		78 min	9	-0.690	2.0016	-4.55	-0.122	1.86
		79 min	9	0.042	1.1098	-2.09	0.163	2.01
		80 min	9	0.185	1.1327	-2.21	0.099	2.04
		81 min	9	-0.462	1.2437	-1.81	-0.955	2.09
		82 min	9	0.039	1.8485	-2.43	0.006	3.35
		83 min	9	-0.045	2.8706	-4.94	-0.157	5.09
		84 min	9	-0.054	2.4293	-3.12	-0.244	4.85
		85 min	9	0.056	1.4370	-3.04	0.161	2.15
		86 min	9	-0.315	1.4252	-2.98	-0.128	2.16
		87 min	9	0.292	2.5995	-2.84	-0.235	6.09
		88 min	9	0.551	2.4123	-1.84	-0.419	6.26
		89 min	9	0.139	3.3526	-6.13	-0.086	6.30
		90 min	9	0.550	2.7424	-2.52	-0.183	6.52

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 84 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	91 min	9	0.648	2.6711	-2.26	-0.127	6.57
		92 min	9	0.329	3.3625	-5.95	0.036	6.53
		93 min	10	0.358	3.2715	-6.44	0.137	6.65
		94 min	10	0.749	2.4884	-2.18	0.293	6.55
		95 min	11	0.908	2.1217	-0.90	0.319	6.53
		96 min	11	0.588	2.3284	-1.92	0.152	6.71
		97 min	11	0.438	2.9971	-5.83	0.363	6.78
		98 min	11	0.437	2.8929	-5.06	0.116	6.79
		99 min	11	0.140	3.0448	-6.06	0.174	6.83
		100 min	11	0.264	2.5210	-2.51	-0.240	6.86
		101 min	11	-0.022	3.0982	-5.96	-0.077	6.88
		102 min	11	0.172	2.5963	-3.14	-0.219	6.78
		103 min	11	0.495	2.5305	-3.17	0.145	7.00
		104 min	11	0.335	2.5476	-3.22	-0.108	6.91
		105 min	11	0.410	2.3452	-3.18	0.072	6.45
		106 min	11	0.406	2.5641	-3.23	0.297	6.68
		107 min	11	0.108	2.8112	-3.50	0.159	6.97
		108 min	11	0.763	2.6005	-3.22	0.145	6.88
		109 min	11	0.084	2.8481	-3.42	-0.233	7.30
		110 min	11	0.566	2.4886	-2.79	-0.086	6.84
		111 min	11	0.101	2.6608	-3.90	-0.112	6.47
		112 min	11	0.487	2.9277	-3.20	0.017	7.22
		113 min	11	0.426	2.6599	-3.07	-0.107	6.72
		114 min	11	0.028	2.5381	-3.05	-0.341	6.52
		115 min	11	0.093	2.4448	-3.22	-0.395	6.18
		116 min	11	0.277	3.1153	-5.52	0.112	6.32
		117 min	10	0.148	2.6895	-3.18	-0.119	6.42
		118 min	10	-0.015	2.7866	-3.64	-0.224	6.39
		119 min	10	-0.021	2.7907	-4.09	-0.210	6.41
		120 min	10	0.718	2.7028	-2.83	0.160	6.31

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 85 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	121 min	10	0.506	2.9134	-3.49	0.171	6.37
		122 min	10	0.306	2.6054	-3.12	0.114	6.64
		123 min	11	1.006	2.2017	-1.01	0.143	6.31
		124 min	11	0.135	2.3797	-3.07	0.080	6.20
		125 min	11	0.067	2.9391	-6.30	0.165	6.18
		126 min	11	0.568	2.3195	-2.49	0.242	6.20
		127 min	11	0.130	2.3372	-3.27	0.073	5.54
		128 min	11	-0.482	3.0682	-6.01	0.060	5.54
		129 min	11	0.398	2.5343	-3.59	0.056	6.06
		130 min	11	-0.371	0.9981	-2.28	-0.165	0.98
		131 min	11	-1.379	2.1077	-5.99	-0.253	0.81
		132 min	11	0.265	2.0553	-3.24	-0.039	4.96
		133 min	10	0.115	2.4104	-3.07	0.079	6.13
		134 min	11	-0.065	1.7760	-3.45	0.034	2.81
		135 min	11	-0.059	1.3226	-1.99	0.105	2.89
		136 min	11	-0.474	1.3130	-3.14	0.064	0.87
		137 min	11	0.089	2.0592	-3.29	0.133	3.43
		138 min	11	-0.499	2.1966	-4.09	-0.050	3.79
		139 min	11	-0.214	1.1703	-2.76	0.071	1.31
		140 min	11	-0.383	1.5001	-3.39	0.081	1.53
		141 min	11	-0.480	1.9650	-2.98	-0.116	3.74
		142 min	11	-0.232	1.8123	-3.53	-0.051	3.44
		143 min	11	-0.214	1.7394	-2.93	-0.034	3.63
		144 min	11	-0.212	1.1390	-3.04	0.056	1.27
		145 min	10	0.307	1.9771	-2.06	-0.244	3.78
		146 min	10	-0.352	0.9775	-2.10	-0.295	1.03
		147 min	10	-0.126	1.0244	-1.82	-0.125	1.91
		148 min	10	0.149	0.8341	-0.75	-0.091	2.04
		149 min	10	-0.034	1.5567	-3.78	0.054	1.89
		150 min	10	0.168	2.0889	-4.14	0.036	4.10

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 86 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	151 min	10	0.110	1.8030	-3.86	0.047	3.06
		152 min	10	0.180	1.8946	-3.65	0.045	3.76
		153 min	10	-0.379	1.3297	-2.99	-0.124	1.97
		154 min	10	-0.567	1.8729	-4.87	-0.031	1.95
		155 min	10	-0.038	1.3982	-2.36	-0.087	2.29
		156 min	10	-0.578	1.9686	-5.29	-0.072	1.99
		157 min	10	-0.562	1.5199	-3.57	-0.238	2.12
		158 min	10	-0.539	1.7257	-4.92	-0.100	1.84
		159 min	10	-0.299	1.0461	-2.25	-0.102	1.86
		160 min	10	-0.456	1.4740	-3.81	-0.101	1.92
		161 min	10	-0.108	1.0836	-2.03	0.042	1.89
		162 min	10	-0.064	0.9906	-1.42	-0.139	1.76
		163 min	11	-0.064	1.0884	-2.06	0.030	1.84
		164 min	11	-0.375	1.8670	-5.20	-0.068	1.83
		165 min	11	-0.351	1.7787	-4.95	0.011	1.74
		166 min	11	-0.343	1.0318	-2.32	-0.031	1.36
		167 min	11	-0.796	1.9378	-5.31	-0.070	1.38
		168 min	11	-0.807	1.8450	-4.92	-0.101	1.29
		169 min	10	-0.407	2.3911	-5.24	-0.083	3.35
		170 min	10	-0.423	2.4064	-5.20	-0.388	3.65
		171 min	10	0.176	1.7436	-3.05	-0.062	3.74
		172 min	10	0.036	1.7488	-2.73	-0.497	3.66
		173 min	10	0.129	2.1198	-2.97	-0.162	3.75
		174 min	10	0.265	1.7662	-2.95	0.015	3.79
		175 min	10	0.526	1.5145	-1.11	0.284	4.08
		176 min	10	0.067	1.9325	-2.92	-0.107	3.80
		177 min	10	-0.290	2.8340	-6.44	0.047	3.93
		178 min	10	0.148	2.0223	-3.33	0.022	3.85
		179 min	10	-0.294	2.7045	-6.25	0.006	3.75
		180 min	10	-0.420	2.4587	-6.24	-0.082	2.31

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 87 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	181 min	10	-0.062	2.3335	-5.96	0.150	2.78
		182 min	10	-0.239	2.4831	-5.72	0.143	3.26
		183 min	10	0.311	1.6344	-2.03	-0.213	3.86
		184 min	10	0.145	1.7918	-3.10	0.030	3.48
		185 min	9	-0.318	1.4055	-3.07	-0.271	1.63
		186 min	8	-0.929	1.2317	-2.93	-0.961	1.13
		187 min	9	-1.243	2.0593	-4.39	-0.661	1.15
		188 min	9	-1.141	2.4313	-5.22	-0.372	1.68
		189 min	9	-0.810	2.4037	-5.75	-0.446	2.57
		190 min	9	-0.561	3.2038	-5.49	-0.483	4.48
		191 min	9	-0.758	2.4077	-5.12	-0.344	2.97
		192 min	9	-0.604	2.4262	-5.40	-0.250	3.10
		193 min	9	-0.595	2.3681	-5.31	-0.306	2.83
		194 min	9	-0.390	2.2505	-4.88	-0.238	3.35
		195 min	9	-0.781	2.4205	-5.33	-0.528	2.86
		196 min	9	-0.043	2.3581	-3.17	-0.464	3.38
		197 min	9	-0.515	2.2696	-3.84	-0.660	3.44
		198 min	10	-0.129	1.9965	-3.26	-0.223	3.79
		199 min	10	-0.608	2.1655	-5.53	-0.118	1.29
		200 min	10	-1.361	2.4799	-5.91	-0.504	1.11
		201 min	10	-0.744	2.5250	-6.95	-0.089	1.06
		202 min	10	-1.199	2.5165	-6.58	-0.555	1.57
		203 min	11	-0.828	2.6868	-5.50	-0.539	4.27
		204 min	11	-0.025	2.4700	-3.32	-0.596	5.62
		205 min	11	-0.656	2.4928	-6.27	-0.488	3.02
		206 min	11	-1.357	3.0658	-6.77	-0.574	3.27
		207 min	10	-1.602	3.1665	-6.91	-0.746	3.84
		208 min	10	-1.434	2.2626	-6.50	-0.586	0.69
		209 min	10	-1.751	2.8149	-6.98	-0.695	1.74
		210 min	10	-0.837	1.9361	-3.25	-0.763	2.99

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 88 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
A	11	211 min	10	-0.965	2.9460	-6.92	-0.282	3.63
		212 min	10	-0.629	1.8344	-3.81	-0.064	2.55
		213 min	10	-0.361	2.3378	-4.38	-0.499	3.64
		214 min	10	-0.952	2.4147	-5.06	-0.376	3.41
		215 min	10	-1.048	2.4360	-5.24	-0.447	3.45
		216 min	10	-0.949	2.8499	-6.89	-0.324	3.63
		217 min	10	-0.678	2.0752	-3.36	-0.416	3.73
		218 min	10	-0.960	2.7121	-6.87	-0.334	3.51
		219 min	10	-1.126	2.7991	-6.77	-0.371	3.63
		220 min	10	-0.813	2.1483	-4.36	-0.396	3.18
		221 min	10	-0.970	2.4177	-5.63	-0.420	3.15
		222 min	10	-0.619	1.7918	-3.06	-0.399	3.09
		223 min	10	-0.625	2.4193	-5.41	-0.106	3.70
		224 min	10	-1.009	2.5463	-7.00	-0.030	2.00
		225 min	10	-0.087	1.6458	-3.37	0.075	2.41
		226 min	10	-0.592	2.6461	-6.87	0.217	2.99
		227 min	10	-0.625	2.4005	-6.47	0.112	2.49
		228 min	10	-0.594	2.5825	-6.32	0.064	3.42
		229 min	11	-0.733	2.2569	-6.66	-0.245	1.59
		230 min	11	-0.272	2.2763	-6.75	0.190	2.49
		231 min	11	-0.566	1.9137	-5.17	-0.071	2.00
		232 min	11	0.049	1.2386	-2.82	0.000	1.84
		233 min	11	-0.331	1.6389	-3.78	-0.088	2.49
		234 min	11	-0.790	2.1980	-6.29	-0.033	1.32
		235 min	10	-0.829	2.0265	-5.34	-0.046	0.83
		236 min	11	-0.315	1.1434	-3.03	-0.082	1.38
		237 min	11	0.030	0.8832	-1.87	-0.044	1.35
		238 min	11	-0.306	1.0677	-3.00	-0.072	1.20
		239 min	11	-0.283	1.0814	-2.93	-0.031	1.35
		240 min	6	-0.071	0.8840	-1.24	-0.040	1.41

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 89 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	1 min	12	0.964	0.5555	-0.18	0.946	1.89
		2 min	12	0.865	0.5316	-0.07	0.820	1.74
		3 min	12	0.846	0.5991	-0.14	0.862	1.99
		4 min	12	0.863	0.3953	0.10	0.888	1.55
		5 min	12	0.678	0.4749	-0.24	0.792	1.29
		6 min	12	0.746	0.4000	-0.04	0.919	1.17
		7 min	12	0.650	0.6599	-0.58	0.477	1.83
		8 min	12	0.626	0.5247	-0.30	0.790	1.27
		9 min	12	0.585	0.5059	-0.46	0.584	1.18
		10 min	12	0.444	0.5482	-0.44	0.315	1.29
		11 min	12	0.276	0.5684	-0.67	0.124	1.48
		12 min	12	0.354	0.4488	-0.36	0.377	1.25
		13 min	12	0.274	0.4583	-0.32	0.201	1.08
		14 min	12	0.087	0.3269	-0.54	0.064	0.67
		15 min	12	0.074	0.5005	-0.70	0.076	1.04
		16 min	12	0.087	0.2574	-0.34	0.046	0.59
		17 min	12	0.172	0.2614	-0.23	0.177	0.71
		18 min	12	0.013	0.3287	-0.60	0.032	0.74
		19 min	12	0.167	0.2314	-0.14	0.139	0.65
		20 min	12	0.174	0.5212	-0.87	0.124	0.96
		21 min	11	0.138	0.3968	-0.62	0.149	0.69
		22 min	10	0.222	0.4550	-0.54	0.132	0.82
		23 min	10	0.091	0.4803	-0.72	0.129	0.82
		24 min	10	0.026	0.7113	-1.73	0.161	0.78
		25 min	10	-0.080	0.4451	-1.01	-0.003	0.60
		26 min	10	-0.052	0.3094	-0.57	0.037	0.33
		27 min	10	0.010	0.3453	-0.55	-0.070	0.54
		28 min	10	-0.337	1.6297	-4.89	0.119	0.61
		29 min	10	-0.018	0.3882	-0.64	-0.068	0.80
		30 min	10	0.057	0.4467	-0.66	0.007	1.05

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 90 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	31 min	10	-0.027	0.5451	-0.86	-0.042	1.12
		32 min	10	-0.045	0.4852	-0.67	-0.117	1.07
		33 min	10	-0.040	0.6876	-1.03	-0.011	0.97
		34 min	10	0.081	0.4303	-0.65	0.058	1.02
		35 min	10	-0.145	0.5393	-0.94	-0.081	0.98
		36 min	11	0.089	0.5944	-0.85	0.122	0.89
		37 min	11	0.022	0.5225	-0.67	0.048	1.02
		38 min	12	-0.386	1.7019	-5.52	-0.001	0.94
		39 min	12	0.063	0.5418	-0.74	0.099	0.96
		40 min	12	0.020	0.5341	-0.84	-0.019	0.90
		41 min	12	0.084	0.5407	-0.83	0.039	0.86
		42 min	12	-0.456	1.5730	-5.26	-0.007	0.69
		43 min	12	-0.116	0.6347	-1.60	-0.030	0.61
		44 min	12	0.103	0.4746	-0.84	0.159	0.65
		45 min	11	-0.007	0.4410	-0.81	-0.028	0.65
		46 min	12	-0.092	0.5039	-1.19	0.006	0.48
		47 min	12	0.101	0.5726	-1.01	0.113	0.76
		48 min	12	-0.026	0.5775	-1.04	-0.166	0.84
		49 min	12	-0.136	0.7283	-2.00	0.038	0.71
		50 min	11	0.012	0.6775	-1.16	0.091	0.71
		51 min	11	-0.056	0.5319	-1.10	0.009	0.66
		52 min	11	-0.026	0.5746	-1.01	-0.106	0.92
		53 min	12	-0.119	0.5061	-1.10	-0.179	0.71
		54 min	12	-0.400	1.7018	-5.45	-0.014	1.09
		55 min	12	-0.102	0.7743	-2.17	-0.005	0.71
		56 min	12	-0.041	0.5780	-1.18	-0.065	0.79
		57 min	12	-0.056	0.5025	-1.14	0.003	0.65
		58 min	12	-0.143	0.4383	-0.93	-0.162	0.55
		59 min	12	-0.038	0.6922	-1.16	-0.058	0.98
		60 min	12	0.089	0.5791	-1.00	0.133	1.03

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 91 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	61 min	12	-0.563	2.0412	-6.80	-0.029	0.79
		62 min	12	0.018	0.6375	-0.99	-0.018	0.77
		63 min	11	-0.068	0.4187	-0.56	-0.144	0.60
		64 min	11	-0.083	0.7034	-1.84	-0.053	0.71
		65 min	11	-0.139	0.6237	-1.43	-0.005	0.65
		66 min	11	-0.087	0.4528	-0.74	-0.052	0.67
		67 min	11	-0.159	0.4695	-0.75	-0.158	0.78
		68 min	11	-0.145	0.2432	-0.58	-0.043	0.14
		69 min	11	0.021	0.4659	-0.57	-0.014	0.80
		70 min	10	-0.200	0.6473	-0.92	-0.405	0.71
		71 min	10	-0.661	1.9701	-6.10	-0.073	0.74
		72 min	9	-0.114	0.5083	-0.80	-0.075	0.61
		73 min	9	-0.138	0.5487	-1.08	-0.040	0.84
		74 min	9	-0.048	0.3206	-0.72	-0.060	0.30
		75 min	9	-0.013	0.4406	-0.73	-0.058	0.68
		76 min	9	-0.218	0.6703	-1.22	-0.177	0.78
		77 min	9	-0.168	0.5427	-1.20	-0.187	0.80
		78 min	9	-0.067	0.5203	-0.65	-0.153	0.76
		79 min	9	-0.019	0.5173	-0.85	-0.098	0.86
		80 min	9	-0.044	0.4049	-0.56	-0.169	0.77
		81 min	9	-0.168	0.2229	-0.47	-0.211	0.25
		82 min	9	-0.364	0.3186	-1.05	-0.315	-0.07
		83 min	9	-0.089	0.5604	-1.19	0.016	0.69
		84 min	9	-0.241	0.5347	-0.91	-0.321	0.70
		85 min	9	-0.370	1.0316	-3.02	-0.030	0.48
		86 min	9	-0.889	1.8855	-5.63	-0.349	0.73
		87 min	9	-0.267	0.4629	-0.92	-0.445	0.50
		88 min	9	-0.153	0.5632	-0.99	-0.235	0.78
		89 min	10	-0.166	0.6434	-1.21	-0.162	0.79
		90 min	10	-0.036	0.5065	-0.89	-0.108	0.66

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 92 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	91 min	10	0.012	0.4084	-0.47	-0.083	0.79
		92 min	10	-0.079	0.6812	-1.17	-0.041	0.83
		93 min	10	-0.106	0.6579	-1.18	-0.105	0.70
		94 min	10	-0.072	0.4668	-0.82	-0.096	0.61
		95 min	9	-0.133	0.6047	-1.27	-0.069	0.81
		96 min	9	-0.124	0.4952	-0.77	-0.057	0.64
		97 min	9	-0.301	0.8592	-1.74	0.038	0.80
		98 min	9	-0.175	0.4243	-0.72	-0.225	0.64
		99 min	10	-0.082	0.6602	-1.03	-0.170	0.89
		100 min	9	-0.669	1.6950	-5.09	-0.040	0.29
		101 min	9	-0.235	0.5040	-1.27	-0.165	0.26
		102 min	9	-0.157	0.6517	-1.44	0.157	0.48
		103 min	9	0.015	0.6540	-1.35	0.082	0.87
		104 min	10	-0.136	0.4877	-1.09	0.052	0.37
		105 min	10	0.069	0.6564	-1.21	0.250	0.70
		106 min	10	-0.098	0.4601	-0.85	-0.002	0.49
		107 min	10	-0.206	0.6025	-1.31	-0.233	0.61
		108 min	10	-0.166	0.5260	-1.26	-0.124	0.57
		109 min	10	-0.189	0.5592	-1.36	-0.107	0.43
		110 min	10	-0.101	0.5918	-1.07	-0.017	0.70
		111 min	10	-0.125	0.7844	-1.31	0.020	0.76
		112 min	10	-0.023	0.6886	-1.25	0.092	0.81
		113 min	11	-0.163	0.5216	-0.96	-0.205	0.75
		114 min	11	-0.210	0.5508	-1.45	0.011	0.29
		115 min	11	-0.062	0.6011	-1.13	-0.001	0.84
		116 min	11	-0.218	0.6809	-1.31	-0.233	0.75
		117 min	11	-0.091	0.5667	-1.19	-0.116	0.83
		118 min	12	-0.058	0.3870	-0.73	-0.004	0.47
		119 min	12	-0.104	0.6591	-1.28	0.015	0.76
		120 min	12	-0.117	0.4897	-1.04	-0.107	0.77

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 93 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	121 min	12	-0.274	0.4644	-1.13	-0.223	0.53
		122 min	12	-0.194	0.5792	-1.21	-0.197	0.68
		123 min	12	-0.089	0.5604	-1.30	-0.093	0.84
		124 min	12	-0.646	1.5377	-5.32	-0.185	0.55
		125 min	12	-0.137	0.6078	-1.31	-0.069	0.65
		126 min	12	-0.189	0.5508	-1.29	-0.181	0.61
		127 min	12	-0.106	0.5394	-1.35	-0.013	0.64
		128 min	12	0.022	0.6320	-1.31	0.084	0.78
		129 min	12	-0.186	0.8490	-2.14	-0.178	0.92
		130 min	12	-0.131	0.7642	-1.75	-0.031	0.77
		131 min	12	-0.097	0.5390	-1.01	-0.146	0.77
		132 min	12	-0.130	0.3809	-0.89	-0.177	0.69
		133 min	12	-0.140	0.4674	-0.67	-0.162	0.88
		134 min	12	-0.042	0.5152	-0.81	-0.168	0.82
		135 min	12	-0.251	0.3651	-1.12	-0.226	0.37
		136 min	12	-0.207	0.4219	-1.23	-0.197	0.53
		137 min	12	-0.207	0.5138	-0.89	-0.208	0.65
		138 min	12	0.116	0.4667	-0.53	-0.013	0.79
		139 min	12	-0.188	0.5199	-1.23	-0.131	0.50
		140 min	12	-0.185	0.6291	-1.30	-0.062	0.55
		141 min	12	-0.186	0.6116	-1.30	-0.105	0.76
		142 min	12	-0.115	0.5998	-1.42	-0.140	0.84
		143 min	12	-0.118	0.4222	-0.67	-0.152	0.74
		144 min	12	0.018	0.3909	-0.64	-0.010	0.68
		145 min	12	-0.455	1.7182	-5.76	-0.093	0.91
		146 min	12	-0.304	1.7287	-5.61	0.132	0.99
		147 min	12	-0.295	1.4571	-4.57	-0.006	0.96
		148 min	12	-0.272	1.3825	-4.43	0.001	1.01
		149 min	12	-0.162	0.8036	-2.50	-0.081	0.96
		150 min	12	-0.208	1.0518	-3.21	-0.079	0.95

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 94 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	151 min	12	-0.318	0.9399	-3.19	-0.098	0.47
		152 min	12	-0.375	0.9548	-3.03	-0.116	0.65
		153 min	12	-0.391	0.8103	-2.61	-0.295	0.95
		154 min	12	-0.130	0.7660	-2.05	-0.135	0.90
		155 min	12	-0.374	0.6870	-2.00	-0.203	0.36
		156 min	12	-0.290	0.5818	-1.79	-0.289	0.71
		157 min	12	-0.176	0.7652	-1.99	-0.046	0.82
		158 min	12	-0.085	0.6213	-1.43	-0.098	0.90
		159 min	12	-0.102	0.5622	-1.32	-0.075	0.91
		160 min	12	-0.213	0.6995	-1.90	-0.110	0.61
		161 min	12	-0.239	0.6809	-1.33	-0.104	0.90
		162 min	12	-0.538	1.3529	-4.36	-0.217	1.01
		163 min	12	-0.064	0.6529	-1.30	-0.117	1.02
		164 min	11	-0.108	0.5382	-1.06	-0.216	0.85
		165 min	11	-0.001	0.6876	-1.53	0.123	0.95
		166 min	11	-0.151	0.6568	-1.33	-0.101	1.01
		167 min	11	-0.232	0.7426	-1.48	-0.029	0.83
		168 min	11	-0.218	0.7176	-1.41	-0.081	0.72
		169 min	11	-0.145	0.3379	-0.65	-0.240	0.60
		170 min	11	0.010	0.6340	-1.06	-0.073	0.99
		171 min	11	-0.249	0.9366	-2.75	-0.134	0.77
		172 min	10	-0.047	0.6825	-1.22	0.095	0.69
		173 min	10	-0.030	0.4911	-0.82	0.046	0.60
		174 min	10	-0.568	1.7600	-5.11	0.255	0.72
		175 min	10	-0.092	0.7387	-1.30	0.110	0.74
		176 min	10	-0.044	0.7603	-1.45	-0.057	1.11
		177 min	10	-0.250	0.5756	-1.10	-0.259	0.80
		178 min	10	-0.316	0.7048	-1.34	-0.298	1.08
		179 min	10	-0.144	0.6820	-1.18	-0.155	1.15
		180 min	10	-0.382	1.7375	-5.02	-0.005	1.15

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 95 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	181 min	10	-0.204	1.1305	-3.13	-0.052	1.06
		182 min	9	-0.090	0.7681	-1.67	-0.055	1.06
		183 min	9	-0.278	0.6843	-1.12	-0.358	0.99
		184 min	9	-0.332	0.6788	-0.98	-0.702	1.01
		185 min	9	-0.208	0.6955	-1.10	-0.346	1.01
		186 min	9	-0.389	0.4764	-1.13	-0.349	0.50
		187 min	9	-0.245	0.6996	-1.45	-0.195	0.96
		188 min	9	-0.129	0.5667	-1.01	-0.062	0.81
		189 min	10	-0.216	0.4200	-1.20	-0.090	0.38
		190 min	10	-0.042	0.5322	-0.80	-0.071	0.93
		191 min	10	-0.017	0.5704	-1.03	0.009	1.13
		192 min	10	-0.011	0.5594	-0.95	-0.069	1.09
		193 min	10	-0.277	0.4864	-1.22	-0.140	0.30
		194 min	10	-0.173	0.6749	-1.32	0.076	0.65
		195 min	10	-0.164	0.5894	-1.26	-0.116	0.53
		196 min	10	-0.334	0.4713	-1.31	-0.224	0.22
		197 min	11	-0.127	0.5037	-1.35	0.059	0.38
		198 min	11	-0.187	0.5745	-1.20	-0.061	0.72
		199 min	11	-0.220	0.5750	-1.22	-0.169	0.76
		200 min	11	0.011	0.6673	-1.24	0.084	0.85
		201 min	11	-0.154	0.5839	-1.22	-0.198	0.76
		202 min	12	-0.023	0.4165	-0.87	0.003	0.68
		203 min	12	-0.146	0.4391	-0.87	-0.226	0.60
		204 min	12	-0.071	0.4997	-1.24	0.007	0.71
		205 min	12	-0.085	0.5892	-1.21	-0.186	0.85
		206 min	12	-0.154	0.5771	-1.31	-0.159	0.92
		207 min	11	-0.308	0.5878	-1.12	-0.155	0.77
		208 min	11	-0.362	0.4035	-0.99	-0.345	0.50
		209 min	11	-0.248	0.5593	-1.21	-0.205	0.61
		210 min	11	-0.208	0.4786	-1.31	-0.151	0.60

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 96 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	1	211 min	12	-0.165	0.5493	-1.27	-0.173	0.79
		212 min	12	-0.084	0.5448	-1.25	-0.063	0.83
		213 min	12	-0.225	0.4830	-1.30	-0.161	0.51
		214 min	12	-0.148	0.5171	-1.25	-0.183	0.62
		215 min	12	0.011	0.5447	-1.23	0.036	0.77
		216 min	12	-0.157	0.3728	-0.72	-0.206	0.55
		217 min	12	-0.454	1.7271	-5.72	0.171	0.63
		218 min	12	-0.248	0.6442	-2.01	-0.035	0.30
		219 min	12	0.013	0.4398	-0.85	0.147	0.68
		220 min	12	0.029	0.4801	-0.59	-0.036	0.96
		221 min	11	-0.148	0.5760	-1.06	-0.110	1.04
		222 min	11	-0.067	0.3757	-0.77	-0.099	0.77
		223 min	11	-0.258	0.4121	-0.90	-0.304	0.61
		224 min	11	-0.117	0.4621	-0.99	-0.077	0.68
		225 min	10	-0.072	0.2713	-0.44	-0.084	0.40
		226 min	10	0.036	0.5233	-0.63	0.157	0.88
		227 min	10	0.174	0.5552	-0.55	0.180	1.12
		228 min	10	0.059	0.5570	-0.78	-0.048	0.80
		229 min	10	-0.285	1.5895	-4.50	-0.059	1.00
		230 min	11	-0.046	0.4647	-0.86	-0.028	0.61
		231 min	11	-0.185	0.8182	-2.05	-0.136	0.97
		232 min	11	-0.043	0.5137	-0.99	-0.204	0.85
		233 min	11	0.025	0.4912	-0.74	-0.030	0.73
		234 min	11	0.067	0.5160	-0.47	-0.133	0.95
		235 min	12	0.204	0.5429	-0.87	0.206	1.06
		236 min	12	0.246	0.3184	-0.16	0.195	1.01
		237 min	12	-0.011	0.6292	-0.95	0.055	1.11
		238 min	12	-0.012	0.5094	-0.93	-0.019	0.97
		239 min	12	0.093	0.4903	-0.56	0.063	0.98
		240 min	1	0.187		0.19	0.187	0.19

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 97 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	1 min	12	1.205	0.5668	0.15	1.323	2.17
		2 min	12	1.104	0.4502	0.40	1.241	1.79
		3 min	12	1.087	0.5122	0.24	1.170	1.79
		4 min	12	1.126	0.4220	0.27	1.230	1.62
		5 min	12	0.936	0.4837	0.12	0.811	1.59
		6 min	12	0.930	0.5934	-0.21	1.086	1.89
		7 min	12	0.800	0.5702	-0.24	0.702	1.64
		8 min	12	0.925	0.4293	0.30	0.824	1.67
		9 min	12	0.769	0.4743	0.20	0.745	1.68
		10 min	12	0.386	1.0954	-2.75	0.641	1.45
		11 min	12	0.379	0.6152	-0.64	0.271	1.54
		12 min	12	0.435	0.4192	0.00	0.422	1.50
		13 min	12	0.429	0.4866	-0.22	0.380	1.62
		14 min	12	0.449	0.3871	-0.11	0.377	1.35
		15 min	12	0.185	0.9230	-2.31	0.265	1.39
		16 min	12	0.033	1.1805	-3.40	0.249	0.95
		17 min	12	0.243	0.4586	-0.52	0.174	1.26
		18 min	12	0.152	0.7702	-2.14	0.268	0.82
		19 min	12	0.247	0.5287	-0.72	0.271	1.09
		20 min	12	0.038	1.2121	-3.62	0.188	1.01
		21 min	11	-0.078	1.4464	-4.19	0.382	1.12
		22 min	10	-0.094	1.5215	-4.33	0.294	1.01
		23 min	10	-0.128	1.2468	-3.56	0.092	0.84
		24 min	10	-0.728	1.7727	-4.26	-0.046	0.86
		25 min	10	-0.312	1.4587	-4.38	0.050	0.62
		26 min	10	0.038	0.3184	-0.38	0.047	0.41
		27 min	10	0.171	0.1716	-0.16	0.148	0.46
		28 min	10	-0.269	1.4429	-4.29	0.206	0.62
		29 min	10	-0.115	1.2894	-3.72	0.289	0.64
		30 min	10	-0.090	0.7065	-2.05	0.155	0.33

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 98 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	31 min	10	-0.133	0.7419	-2.08	-0.037	0.68
		32 min	10	-0.027	0.7124	-1.93	0.047	0.73
		33 min	10	-0.159	0.8990	-1.79	0.112	0.72
		34 min	10	-0.482	1.4002	-4.34	-0.172	0.52
		35 min	10	-0.295	1.0796	-3.30	-0.033	0.49
		36 min	11	-0.251	1.0587	-3.28	0.049	0.47
		37 min	11	-0.339	1.3697	-4.31	0.027	0.67
		38 min	12	-0.200	1.4116	-4.53	0.198	0.81
		39 min	12	-0.271	1.3456	-4.40	0.043	0.74
		40 min	12	0.004	0.8135	-2.22	0.301	0.68
		41 min	12	-0.391	0.9425	-2.93	0.039	0.35
		42 min	12	-0.854	1.7496	-5.18	-0.233	0.55
		43 min	12	-0.512	1.3556	-4.44	-0.125	0.51
		44 min	12	-0.337	1.4255	-4.54	-0.004	0.72
		45 min	11	-0.302	1.4452	-4.43	-0.020	0.70
		46 min	12	-0.409	1.4150	-4.52	-0.107	0.86
		47 min	12	-0.312	1.3337	-4.32	-0.031	0.56
		48 min	12	-0.454	1.3454	-4.28	-0.134	0.76
		49 min	12	-0.740	1.6732	-4.16	-0.201	0.68
		50 min	11	-0.421	1.5260	-4.64	0.257	0.56
		51 min	11	-0.205	0.9969	-2.92	0.043	0.65
		52 min	11	-0.397	1.3554	-3.96	-0.038	0.70
		53 min	12	-0.347	1.3214	-4.39	0.025	0.65
		54 min	12	-0.709	2.0581	-5.44	-0.030	0.88
		55 min	12	-0.393	1.3909	-4.10	0.152	0.55
		56 min	12	-0.306	1.3982	-4.64	0.167	0.45
		57 min	12	-0.352	1.2860	-4.27	-0.030	0.60
		58 min	12	-0.432	1.3826	-4.37	-0.128	0.58
		59 min	12	-0.164	1.0604	-3.38	0.108	0.52
		60 min	12	-0.157	0.9284	-2.70	0.021	0.81

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 99 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	61 min	12	-0.418	1.4215	-4.65	0.071	0.50
		62 min	12	-0.337	1.4089	-4.46	0.118	0.84
		63 min	11	-0.531	1.1490	-3.65	-0.183	0.55
		64 min	11	-0.524	1.5020	-4.56	0.018	0.82
		65 min	11	-0.379	1.5015	-4.69	-0.103	0.92
		66 min	11	-0.619	1.2251	-4.00	-0.173	0.29
		67 min	11	-0.554	1.3743	-4.65	-0.145	0.28
		68 min	11	-0.559	1.4315	-4.71	-0.002	0.39
		69 min	11	-0.425	1.4311	-4.63	-0.049	0.43
		70 min	10	-0.737	2.1492	-5.36	0.104	0.79
		71 min	10	-0.613	1.7074	-5.19	-0.047	0.69
		72 min	9	-0.551	1.5343	-4.41	0.144	0.41
		73 min	9	-0.500	1.4701	-4.25	-0.120	0.85
		74 min	9	-0.498	1.5038	-4.48	0.049	0.22
		75 min	9	-0.525	1.5479	-4.58	-0.081	0.40
		76 min	9	-0.549	1.5369	-4.48	-0.284	0.70
		77 min	9	-0.517	1.5491	-4.56	-0.172	0.53
		78 min	9	-0.401	1.5214	-4.39	-0.106	0.58
		79 min	9	-0.258	1.6137	-4.48	0.200	0.80
		80 min	9	-0.412	1.4687	-4.25	0.152	0.35
		81 min	9	-0.420	1.5886	-4.61	0.047	0.48
		82 min	9	-0.618	1.6412	-4.88	-0.332	0.49
		83 min	9	-0.382	1.5666	-4.48	0.194	0.51
		84 min	9	-0.500	1.5690	-4.59	0.016	0.63
		85 min	9	-0.478	1.6277	-4.70	-0.034	0.60
		86 min	9	0.111	0.5893	-1.04	0.033	0.96
		87 min	9	-0.700	1.7065	-4.11	-0.009	0.59
		88 min	9	-0.612	1.7817	-4.61	-0.054	0.89
		89 min	10	-0.672	1.5128	-4.68	-0.304	0.59
		90 min	10	-0.670	1.5089	-4.71	-0.194	0.84

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 100 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	91 min	10	-0.464	1.4634	-4.35	-0.128	0.89
		92 min	10	-0.447	1.4175	-4.34	-0.047	0.56
		93 min	10	-0.509	1.5714	-4.43	-0.100	0.91
		94 min	10	-0.451	1.4157	-4.25	-0.099	0.77
		95 min	9	-0.482	1.3917	-3.76	-0.178	0.70
		96 min	9	-0.373	1.6616	-4.45	0.172	0.70
		97 min	9	-0.779	1.9813	-4.58	0.047	0.86
		98 min	9	-0.710	1.6392	-4.43	-0.004	0.68
		99 min	10	-0.451	1.5865	-4.54	0.146	0.74
		100 min	9	-0.712	1.5463	-4.64	-0.142	0.37
		101 min	9	-0.694	1.4806	-4.40	-0.174	0.37
		102 min	9	-0.549	1.5470	-4.47	0.036	0.52
		103 min	9	-0.388	1.5379	-4.34	-0.100	0.85
		104 min	10	-0.333	1.2061	-3.60	-0.173	0.52
		105 min	10	-0.162	1.5890	-4.54	0.244	0.96
		106 min	10	-0.491	1.2104	-3.75	-0.037	0.30
		107 min	10	-0.517	1.4124	-4.31	-0.171	0.61
		108 min	10	-0.482	1.4319	-4.34	0.035	0.31
		109 min	10	-0.462	1.3898	-4.32	-0.054	0.44
		110 min	10	-0.485	1.5173	-4.56	-0.035	0.72
		111 min	10	-0.447	1.4694	-4.36	-0.162	0.65
		112 min	10	-0.348	1.5651	-4.60	0.030	1.01
		113 min	11	-0.594	1.3211	-4.37	-0.261	0.72
		114 min	11	-0.579	1.3835	-4.61	-0.150	0.40
		115 min	11	-0.433	1.4378	-4.54	-0.246	0.89
		116 min	11	-0.403	1.4481	-4.58	0.094	0.47
		117 min	11	-0.385	1.4019	-4.34	0.009	1.07
		118 min	12	-0.344	1.4310	-4.64	-0.071	1.18
		119 min	12	-0.423	1.1753	-4.02	-0.197	0.36
		120 min	12	-0.367	1.4617	-4.56	-0.124	1.05

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 101 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	121 min	12	-0.454	0.8532	-2.83	-0.235	0.45
		122 min	12	-0.504	1.3084	-4.59	-0.140	0.41
		123 min	12	-0.351	1.0519	-3.48	-0.158	0.53
		124 min	12	-0.561	1.2155	-3.92	-0.118	0.39
		125 min	12	-0.507	1.2802	-4.44	-0.122	0.30
		126 min	12	-0.468	1.3343	-4.48	-0.143	0.54
		127 min	12	-0.450	1.3314	-4.59	-0.192	0.41
		128 min	12	-0.316	1.3918	-4.54	0.064	0.75
		129 min	12	-1.016	2.1996	-6.09	-0.188	0.97
		130 min	12	-0.836	2.0440	-5.70	-0.055	0.51
		131 min	12	-0.538	1.4292	-4.66	-0.091	0.70
		132 min	12	-0.555	1.3279	-4.29	-0.083	0.39
		133 min	12	-0.491	1.4231	-4.45	-0.032	0.68
		134 min	12	-0.422	1.3441	-4.57	-0.015	0.50
		135 min	12	-0.747	1.5380	-4.22	-0.152	0.46
		136 min	12	-0.466	1.3195	-4.40	-0.181	0.81
		137 min	12	-0.502	1.3453	-4.56	-0.104	0.43
		138 min	12	-0.361	1.0829	-3.50	-0.052	0.64
		139 min	12	-0.347	1.1279	-3.61	-0.041	0.59
		140 min	12	-0.237	0.9514	-3.03	-0.068	0.78
		141 min	12	-0.361	0.9541	-2.40	-0.068	0.80
		142 min	12	0.108	0.5202	-0.58	-0.005	1.13
		143 min	12	0.064	0.4123	-0.77	0.138	0.78
		144 min	12	0.079	0.3576	-0.41	0.040	0.90
		145 min	12	-0.508	1.5696	-5.07	-0.054	1.09
		146 min	12	-0.181	1.1039	-3.33	0.155	0.95
		147 min	12	-0.588	1.4570	-3.88	-0.123	1.10
		148 min	12	-0.381	0.8399	-2.50	-0.009	0.43
		149 min	12	-0.101	0.7739	-1.71	-0.031	1.19
		150 min	12	0.029	0.7384	-1.34	0.084	1.65

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 102 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	151 min	12	-0.062	0.6063	-1.27	0.090	0.86
		152 min	12	-0.134	0.5657	-1.36	-0.055	0.49
		153 min	12	-0.881	1.3480	-4.26	-0.536	0.35
		154 min	12	-0.594	1.3734	-4.45	-0.175	0.59
		155 min	12	-0.632	1.2952	-4.51	-0.282	0.39
		156 min	12	-0.695	1.4380	-4.60	-0.204	0.79
		157 min	12	-0.448	1.4166	-4.60	0.097	0.44
		158 min	12	-0.388	1.3869	-4.57	0.022	0.43
		159 min	12	-0.301	1.3686	-4.56	0.072	0.45
		160 min	12	-0.219	1.2460	-3.93	0.115	0.84
		161 min	12	-0.294	1.4826	-4.69	0.225	0.74
		162 min	12	-0.320	1.3661	-4.53	0.081	0.43
		163 min	12	-0.280	1.3666	-4.42	0.107	0.95
		164 min	11	-0.413	1.4144	-4.54	-0.008	0.43
		165 min	11	-0.346	1.4711	-4.48	0.212	0.72
		166 min	11	-0.456	1.4201	-4.56	0.080	0.45
		167 min	11	-0.334	1.4431	-4.46	0.141	0.65
		168 min	11	-0.328	1.4816	-4.55	0.107	0.86
		169 min	11	-0.325	1.4819	-4.64	0.115	0.64
		170 min	11	-0.411	1.5824	-4.67	0.262	1.15
		171 min	11	-0.369	1.4610	-4.56	-0.012	0.84
		172 min	10	-0.169	1.0880	-2.99	0.109	0.75
		173 min	10	-0.200	1.2631	-3.62	0.163	0.83
		174 min	10	-0.452	1.6549	-4.92	0.114	0.79
		175 min	10	-0.246	0.8350	-1.59	0.103	0.65
		176 min	10	-0.322	1.5713	-4.47	0.192	1.04
		177 min	10	0.124	0.6695	-1.47	0.158	0.95
		178 min	10	-0.128	0.7858	-2.01	0.019	1.03
		179 min	10	0.076	0.7471	-1.36	0.058	1.20
		180 min	10	-0.497	1.3661	-3.01	0.097	1.20

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 103 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	181 min	10	-0.175	0.7682	-1.55	-0.120	1.25
		182 min	9	-0.050	0.5403	-0.81	-0.116	1.10
		183 min	9	-0.461	1.2386	-3.24	-0.163	1.01
		184 min	9	-0.561	1.5498	-4.30	-0.184	1.36
		185 min	9	-0.388	1.5703	-4.23	0.109	1.33
		186 min	9	-0.728	1.4167	-4.33	-0.277	0.31
		187 min	9	-0.692	1.6402	-4.57	0.037	0.65
		188 min	9	-0.628	1.6036	-4.48	-0.081	0.73
		189 min	10	-0.256	0.4224	-0.98	-0.196	0.29
		190 min	10	-0.594	1.4712	-4.56	-0.153	0.36
		191 min	10	-0.360	1.5678	-4.27	0.209	1.08
		192 min	10	-0.380	1.2896	-3.63	0.025	0.94
		193 min	10	-0.431	0.9977	-2.32	0.031	0.50
		194 min	10	-0.463	1.1779	-3.23	-0.052	0.82
		195 min	10	-0.564	1.0624	-3.36	-0.182	0.13
		196 min	10	-0.423	1.1051	-3.38	-0.113	0.36
		197 min	11	-0.117	0.3596	-0.87	-0.089	0.35
		198 min	11	-0.157	0.5506	-1.06	-0.091	0.54
		199 min	11	-0.512	1.1023	-3.65	-0.118	0.24
		200 min	11	-0.215	1.4286	-4.39	0.133	0.74
		201 min	11	-0.329	1.3798	-4.29	-0.032	0.77
		202 min	12	-0.401	1.3560	-4.45	-0.042	0.62
		203 min	12	-0.440	1.3089	-4.39	-0.047	0.35
		204 min	12	-0.355	1.3283	-4.49	-0.041	0.47
		205 min	12	-0.469	1.2537	-4.22	-0.147	0.42
		206 min	12	-0.375	1.3648	-4.60	-0.065	0.43
		207 min	11	-0.186	0.4918	-0.97	-0.022	0.51
		208 min	11	-0.468	1.2263	-3.80	-0.084	0.44
		209 min	11	-0.471	1.2938	-4.16	0.029	0.35
		210 min	11	-0.419	1.4067	-4.49	0.046	0.38

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 104 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	2	211 min	12	-0.527	1.0870	-3.23	-0.046	0.44
		212 min	12	-0.477	1.2986	-4.42	-0.094	0.38
		213 min	12	-0.488	1.3664	-4.49	-0.079	0.55
		214 min	12	-0.183	0.8260	-2.31	0.097	0.46
		215 min	12	-0.321	1.3665	-4.34	0.110	0.70
		216 min	12	-0.433	1.5357	-4.51	0.146	1.02
		217 min	12	-0.591	1.9742	-4.78	0.135	1.34
		218 min	12	-0.524	1.5089	-4.47	-0.018	1.12
		219 min	12	-0.157	1.5083	-4.62	0.263	1.10
		220 min	12	-0.132	1.4229	-4.38	0.218	0.99
		221 min	11	-0.425	1.4318	-4.53	-0.018	0.58
		222 min	11	-0.574	1.4495	-4.45	-0.002	0.59
		223 min	11	-0.279	1.3675	-4.35	0.025	0.62
		224 min	11	-0.251	1.4406	-4.44	0.115	1.04
		225 min	10	-0.152	1.5673	-4.52	0.180	1.03
		226 min	10	-0.211	1.5186	-4.44	0.234	0.68
		227 min	10	-0.144	1.5632	-4.54	0.264	0.75
		228 min	10	-0.275	1.5155	-4.52	0.120	0.72
		229 min	10	-0.310	1.7072	-4.78	0.224	0.97
		230 min	11	-0.320	1.2664	-3.85	0.243	0.53
		231 min	11	-0.637	1.5148	-4.19	-0.094	0.51
		232 min	11	-0.400	1.3323	-4.29	0.102	0.36
		233 min	11	0.064	0.4967	-0.67	0.140	0.83
		234 min	11	-0.193	1.2820	-3.82	0.256	0.73
		235 min	12	-0.253	1.2337	-3.97	0.137	0.52
		236 min	12	-0.174	1.2333	-3.89	0.200	0.65
		237 min	12	-0.101	1.1514	-3.40	0.099	1.15
		238 min	12	-0.186	1.0231	-2.65	-0.037	1.34
		239 min	12	-0.113	0.8500	-2.23	0.055	1.05
		240 min	1	-0.703		-0.70	-0.703	-0.70

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 105 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	1 min	12	2.955	1.7583	-0.18	3.119	5.59
		2 min	12	3.005	1.7679	0.69	2.785	5.81
		3 min	12	3.463	2.0391	0.75	3.325	7.11
		4 min	12	3.398	1.9990	0.52	3.220	7.23
		5 min	12	3.101	2.0842	0.43	3.057	7.07
		6 min	12	2.933	2.3826	-0.67	2.755	7.26
		7 min	12	2.883	1.9649	0.49	2.648	7.28
		8 min	12	2.387	2.2470	-0.31	2.078	7.26
		9 min	12	1.999	2.2582	-1.25	1.904	7.21
		10 min	12	1.917	1.9649	-0.05	1.658	7.14
		11 min	12	1.743	1.9398	-0.40	1.531	7.18
		12 min	12	1.614	1.8972	-0.43	1.152	7.05
		13 min	12	1.036	2.1680	-1.13	0.503	6.92
		14 min	12	0.862	2.2354	-1.34	0.650	6.75
		15 min	12	0.391	2.3595	-2.11	-0.363	6.97
		16 min	12	0.685	2.4367	-2.15	0.277	7.03
		17 min	12	0.550	2.6737	-4.09	0.685	6.95
		18 min	12	0.396	2.7462	-4.55	0.742	6.87
		19 min	12	0.056	2.8176	-4.88	-0.211	6.72
		20 min	12	-0.120	2.8283	-5.07	-0.096	6.83
		21 min	11	-0.012	3.0427	-5.81	0.134	6.79
		22 min	10	0.346	2.5779	-2.26	-0.226	6.69
		23 min	10	0.407	2.6732	-2.53	-0.094	6.63
		24 min	10	0.131	2.5013	-2.05	-0.498	6.56
		25 min	10	0.131	2.7046	-3.79	-0.057	6.55
		26 min	10	-0.485	2.6287	-3.03	-0.983	6.33
		27 min	10	-0.038	2.2439	-2.97	-0.130	5.11
		28 min	10	-0.374	2.8992	-4.04	-0.574	5.92
		29 min	10	-0.305	2.8197	-4.24	-0.770	5.50
		30 min	10	0.387	2.4353	-3.75	0.411	5.36

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 106 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	31 min	10	-0.291	2.4449	-4.05	-0.153	5.42
		32 min	10	0.096	2.3978	-3.80	-0.155	5.32
		33 min	10	0.221	2.5362	-3.20	0.143	4.85
		34 min	10	-0.042	2.4908	-3.40	-0.014	5.12
		35 min	10	0.513	1.5875	-1.45	0.119	4.04
		36 min	11	0.400	2.2189	-2.52	0.216	4.95
		37 min	11	0.138	2.1549	-4.37	0.289	4.24
		38 min	12	-0.046	2.3181	-4.33	0.016	4.91
		39 min	12	-0.857	2.2051	-5.70	0.008	1.85
		40 min	12	-0.240	2.2116	-5.00	0.200	2.65
		41 min	12	-0.367	2.1674	-4.23	-0.048	3.38
		42 min	12	-0.841	1.7387	-5.25	-0.267	1.17
		43 min	12	-0.756	1.1444	-2.56	-0.257	0.72
		44 min	12	-0.421	1.7767	-4.98	0.312	1.11
		45 min	11	-0.482	1.6792	-4.89	0.069	1.10
		46 min	12	-0.306	1.8710	-5.44	0.225	1.43
		47 min	12	0.021	1.6245	-2.86	0.062	3.34
		48 min	12	-0.313	0.8316	-1.78	-0.191	1.27
		49 min	12	-0.437	1.8377	-4.66	-0.100	2.20
		50 min	11	-0.285	1.3512	-2.86	-0.041	2.13
		51 min	11	-0.196	1.1476	-1.83	-0.099	1.88
		52 min	11	-0.538	1.7554	-4.18	-0.216	2.55
		53 min	12	-0.609	1.9810	-4.68	-0.008	1.59
		54 min	12	-1.064	1.7920	-4.62	-0.802	0.83
		55 min	12	-0.466	1.7723	-4.99	-0.048	1.91
		56 min	12	-0.644	1.7897	-5.53	0.001	1.45
		57 min	12	-1.135	1.6597	-5.57	-0.739	1.19
		58 min	12	-0.948	1.9812	-5.73	-0.756	2.00
		59 min	12	-0.902	1.9108	-5.79	-0.507	1.95
		60 min	12	-1.112	1.5932	-4.21	-0.735	1.30

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 107 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	61 min	12	-0.840	1.5656	-4.19	-0.437	2.10
		62 min	12	-0.831	1.7446	-4.52	-0.455	1.77
		63 min	11	-1.054	1.3782	-3.58	-0.776	1.25
		64 min	11	-0.875	1.5056	-4.49	-0.195	0.91
		65 min	11	-0.936	1.7880	-5.26	-0.339	1.46
		66 min	11	-1.442	2.5118	-5.81	-1.573	2.44
		67 min	11	-0.817	2.0258	-5.91	-0.096	0.74
		68 min	11	-0.475	1.1878	-3.09	-0.137	1.16
		69 min	11	-0.911	2.0897	-5.41	-0.186	1.96
		70 min	10	-0.608	1.8323	-3.16	-0.383	3.21
		71 min	10	-0.688	1.9901	-3.87	-0.368	2.71
		72 min	9	-1.148	1.7010	-4.06	-0.322	0.95
		73 min	9	-1.139	1.7433	-3.86	-0.159	0.97
		74 min	9	-0.974	1.6389	-3.42	-1.103	2.11
		75 min	9	-1.278	1.1333	-3.52	-1.030	-0.11
		76 min	9	-1.117	1.2765	-3.71	-1.128	0.71
		77 min	9	-0.794	1.4643	-3.11	-0.406	1.16
		78 min	9	-0.766	1.3269	-3.62	-0.283	0.55
		79 min	9	-1.220	1.1610	-3.63	-1.432	0.01
		80 min	9	-0.967	1.3559	-3.43	-0.870	1.18
		81 min	9	-0.839	1.2814	-3.47	-0.150	0.57
		82 min	9	-1.108	1.2833	-3.51	-0.891	0.50
		83 min	9	-0.700	1.3873	-3.53	-0.145	0.81
		84 min	9	-0.872	1.3618	-3.69	-0.542	0.91
		85 min	9	-0.822	1.3338	-3.80	-0.313	0.34
		86 min	9	-0.159	1.6514	-3.78	0.138	1.58
		87 min	9	-0.423	1.4122	-3.49	-0.082	1.35
		88 min	9	-0.601	1.5647	-3.64	-0.240	1.30
		89 min	10	-1.060	1.6691	-4.34	-0.250	0.45
		90 min	10	-1.303	1.9494	-5.58	-0.865	0.96

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 108 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	91 min	10	-1.331	1.8857	-5.71	-0.734	-0.03
		92 min	10	-1.395	1.6382	-5.21	-0.961	-0.06
		93 min	10	-0.933	1.2802	-3.41	-0.714	0.28
		94 min	10	-1.128	1.4686	-3.61	-0.589	0.15
		95 min	9	-0.319	1.3171	-2.67	-0.164	2.27
		96 min	9	0.028	1.4864	-1.84	-0.038	3.33
		97 min	9	-0.905	2.6909	-5.51	-0.472	4.09
		98 min	9	-0.887	1.9270	-4.24	-0.831	2.81
		99 min	10	0.052	1.8326	-2.34	-0.370	4.20
		100 min	9	-0.765	1.3561	-4.08	-0.416	0.37
		101 min	9	-0.492	2.1480	-4.31	-0.178	3.62
		102 min	9	0.257	2.2757	-4.45	0.042	3.91
		103 min	9	-0.349	2.3495	-4.43	-0.417	4.21
		104 min	10	-0.829	2.5150	-4.66	-0.940	4.22
		105 min	10	-1.197	2.3844	-4.59	-0.732	3.17
		106 min	10	-1.250	1.9803	-4.62	-0.652	1.13
		107 min	10	-1.201	2.0437	-4.62	-0.409	1.31
		108 min	10	-1.400	2.1736	-4.72	-0.874	1.63
		109 min	10	-0.928	2.3417	-5.19	-0.328	2.85
		110 min	10	-0.956	2.0006	-4.58	-0.505	1.84
		111 min	10	-0.360	2.2601	-4.77	0.184	3.52
		112 min	10	-1.161	2.0119	-5.02	-0.172	0.41
		113 min	11	-1.658	1.6251	-4.69	-0.803	0.35
		114 min	11	-0.883	2.4615	-4.69	-0.388	4.58
		115 min	11	-1.217	1.7560	-4.87	-0.819	0.35
		116 min	11	-1.217	1.7416	-4.68	-0.870	1.56
		117 min	11	-1.341	1.7072	-4.70	-0.872	0.25
		118 min	12	-1.309	1.5976	-4.78	-1.105	1.03
		119 min	12	-1.124	1.5415	-4.78	-0.703	0.35
		120 min	12	-1.468	2.3328	-4.69	-1.102	3.32

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 109 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	121 min	12	-1.079	1.6864	-4.77	-0.949	1.61
		122 min	12	-1.570	1.8137	-4.81	-0.872	0.22
		123 min	12	-1.285	1.6793	-4.52	-1.106	1.14
		124 min	12	-1.096	1.5784	-4.63	-0.485	0.35
		125 min	12	-1.206	1.6508	-4.54	-1.265	1.46
		126 min	12	-1.274	1.9542	-5.56	-0.891	0.82
		127 min	12	-0.937	1.7660	-4.56	-0.477	1.04
		128 min	12	-0.964	2.1739	-5.09	-0.519	1.89
		129 min	12	-1.170	2.2069	-5.46	-0.366	1.44
		130 min	12	-0.967	1.7617	-4.19	-0.501	1.69
		131 min	12	-1.641	2.0919	-5.08	-0.894	0.80
		132 min	12	-1.288	2.0169	-5.36	-0.750	1.81
		133 min	12	-1.018	2.2311	-5.58	-0.353	1.48
		134 min	12	-0.821	1.5061	-5.19	-0.493	0.52
		135 min	12	-1.127	1.7124	-5.42	-1.129	1.03
		136 min	12	-0.980	2.0592	-5.59	-0.765	2.05
		137 min	12	-0.333	1.2544	-3.14	-0.158	1.84
		138 min	12	-0.210	0.8352	-1.45	-0.141	1.28
		139 min	12	-0.359	1.3408	-2.89	-0.080	2.09
		140 min	12	-1.126	1.8653	-5.01	-1.129	1.43
		141 min	12	-0.878	1.6917	-3.70	-0.297	1.47
		142 min	12	-0.863	1.9668	-4.90	-0.564	1.55
		143 min	12	-0.815	1.7896	-3.56	-0.533	1.93
		144 min	12	-0.063	1.5902	-3.46	0.104	2.02
		145 min	12	-0.611	2.2898	-4.93	-0.365	2.91
		146 min	12	-1.114	2.0187	-5.20	-0.122	1.70
		147 min	12	-1.149	1.9502	-5.30	-0.690	1.73
		148 min	12	-1.057	1.7963	-5.39	-0.892	1.51
		149 min	12	-0.908	2.1158	-5.60	-0.482	2.11
		150 min	12	-1.235	2.2022	-5.72	-0.660	2.15

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 110 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	151 min	12	-1.090	2.2415	-5.73	-0.609	1.85
		152 min	12	-0.797	1.9664	-5.78	-0.247	1.66
		153 min	12	-0.763	2.2316	-5.79	0.019	1.99
		154 min	12	-0.852	1.9156	-4.59	-0.401	1.84
		155 min	12	-0.762	1.8525	-4.57	-0.184	1.81
		156 min	12	-0.409	1.2537	-3.00	-0.137	1.85
		157 min	12	-0.107	1.5160	-2.65	-0.113	2.80
		158 min	12	-0.227	1.6171	-3.53	-0.135	2.25
		159 min	12	-0.772	1.7481	-5.35	-0.495	2.08
		160 min	12	-0.830	1.8668	-5.41	-0.684	1.72
		161 min	12	-0.986	1.7090	-4.37	-0.807	1.62
		162 min	12	-1.355	1.8829	-5.38	-1.195	1.83
		163 min	12	-0.831	1.6696	-5.68	-0.259	0.70
		164 min	11	-1.154	1.7730	-5.74	-0.928	0.95
		165 min	11	-0.900	1.9362	-5.80	-0.304	1.83
		166 min	11	-1.003	1.3034	-3.37	-0.446	0.17
		167 min	11	-0.844	2.1311	-5.66	-0.177	2.10
		168 min	11	-0.964	1.7504	-5.74	-0.569	0.59
		169 min	11	-0.779	1.5665	-4.06	-0.376	1.84
		170 min	11	-0.160	1.0673	-1.73	-0.059	1.84
		171 min	11	-1.103	1.4772	-4.85	-0.841	0.18
		172 min	10	-0.922	1.8012	-5.39	-0.637	1.44
		173 min	10	-0.499	1.4306	-3.07	-0.279	1.76
		174 min	10	-1.193	1.4113	-4.49	-1.038	0.19
		175 min	10	-0.932	1.7416	-5.45	-0.309	0.40
		176 min	10	-0.804	1.8807	-5.62	-0.240	1.32
		177 min	10	-0.772	1.9867	-5.77	-0.406	1.65
		178 min	10	-1.022	1.6618	-5.32	-0.550	0.53
		179 min	10	0.192	1.4384	-1.75	-0.057	3.41
		180 min	10	-0.769	1.8972	-5.60	-0.111	0.91

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 111 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	181 min	10	-1.488	1.8096	-5.45	-1.031	0.24
		182 min	9	-1.195	1.6078	-4.86	-0.796	0.38
		183 min	9	-1.275	2.0749	-5.40	-1.289	1.27
		184 min	9	-1.208	2.0292	-5.64	-1.217	1.41
		185 min	9	-1.372	2.1901	-5.72	-0.975	1.35
		186 min	9	-1.785	2.1856	-5.61	-1.701	1.61
		187 min	9	-1.854	1.9988	-5.78	-1.287	0.08
		188 min	9	-1.718	1.8996	-5.78	-1.805	0.41
		189 min	10	-1.291	1.9769	-5.76	-1.369	1.73
		190 min	10	-0.886	2.1169	-5.77	-0.199	1.88
		191 min	10	-0.813	1.8335	-5.48	-0.239	1.04
		192 min	10	-1.066	1.8660	-5.52	-0.352	1.25
		193 min	10	-1.067	2.1890	-5.57	-0.776	2.56
		194 min	10	-1.348	1.3142	-4.54	-1.174	0.09
		195 min	10	-1.108	1.0419	-2.82	-1.206	0.30
		196 min	10	-1.045	1.6904	-5.49	-0.652	0.28
		197 min	11	-1.148	1.9909	-5.89	-0.914	0.73
		198 min	11	-1.477	1.6861	-4.61	-1.189	0.20
		199 min	11	-1.418	1.5580	-3.99	-1.294	0.83
		200 min	11	-0.920	1.7026	-5.60	-0.250	0.74
		201 min	11	-1.399	1.8440	-5.63	-1.287	0.40
		202 min	12	-1.288	1.7221	-5.67	-0.781	0.05
		203 min	12	-1.559	1.8640	-5.73	-0.830	0.29
		204 min	12	-0.493	1.7069	-3.90	-0.337	2.44
		205 min	12	-1.333	1.9651	-5.65	-0.925	1.49
		206 min	12	-0.888	1.7543	-4.10	-0.747	1.69
		207 min	11	-1.491	1.6786	-5.86	-1.026	0.26
		208 min	11	-1.383	1.9954	-5.90	-0.572	0.64
		209 min	11	-1.544	2.0646	-5.88	-0.454	0.74
		210 min	11	-0.857	1.7789	-5.46	-0.197	0.78

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 112 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	3	211 min	12	-1.473	2.0194	-5.92	-1.011	0.56
		212 min	12	-1.028	2.3944	-5.88	-0.751	4.05
		213 min	12	-1.652	2.1051	-5.90	-1.329	0.86
		214 min	12	-1.008	2.1262	-5.87	-0.737	2.23
		215 min	12	-1.420	1.7002	-5.96	-1.088	0.21
		216 min	12	-0.950	1.7882	-5.93	-0.684	0.80
		217 min	12	-0.923	1.8488	-5.71	-0.329	0.68
		218 min	12	-1.305	2.0002	-5.82	-0.831	1.39
		219 min	12	-0.827	1.8586	-5.83	-0.400	1.64
		220 min	12	-0.981	1.9408	-5.89	-0.465	2.15
		221 min	11	-0.762	1.9766	-5.90	-0.393	1.65
		222 min	11	-1.175	1.9106	-5.82	-1.294	1.41
		223 min	11	-1.167	1.9093	-5.86	-0.932	1.01
		224 min	11	-1.299	1.9268	-5.90	-1.037	1.34
		225 min	10	-1.159	1.8676	-5.74	-0.551	0.42
		226 min	10	-0.709	1.7628	-5.08	-0.211	1.28
		227 min	10	-0.627	1.8726	-5.29	-0.256	1.27
		228 min	10	-1.177	2.1631	-5.27	-0.873	2.26
		229 min	10	-1.173	1.4077	-4.00	-0.804	0.27
		230 min	11	-0.152	1.4098	-3.04	-0.023	2.07
		231 min	11	-1.074	1.3515	-3.39	-1.072	1.03
		232 min	11	-0.896	1.2736	-4.40	-0.646	0.38
		233 min	11	-0.619	1.6401	-4.53	-0.322	1.40
		234 min	11	-0.807	1.9151	-5.32	-0.537	1.69
		235 min	12	-0.899	1.6946	-5.14	-0.435	1.49
		236 min	12	-1.108	2.0458	-5.39	-0.866	1.65
		237 min	12	-0.155	1.5844	-4.32	0.143	1.66
		238 min	12	-0.503	1.7388	-3.90	0.038	2.01
		239 min	12	-1.129	1.9191	-5.13	-0.943	1.68
		240 min	1	-4.093		-4.09	-4.093	-4.09

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 113 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	1 min	12	2.780	2.2048	-0.14	2.801	5.59
		2 min	12	2.991	2.2425	0.08	2.725	5.58
		3 min	12	3.178	2.2684	-0.14	3.789	5.91
		4 min	12	3.008	2.2747	0.05	3.541	6.14
		5 min	12	2.994	2.1548	-0.29	2.843	6.18
		6 min	12	3.559	1.9301	0.66	4.118	6.02
		7 min	12	3.489	1.9759	-0.15	4.141	6.47
		8 min	12	3.294	1.8645	0.42	3.790	6.76
		9 min	12	2.985	2.2238	-0.61	3.528	6.97
		10 min	12	3.042	1.8968	-0.20	3.380	7.05
		11 min	12	2.401	2.1938	-0.95	2.626	6.72
		12 min	12	2.273	2.7258	-1.86	1.587	6.56
		13 min	12	1.711	2.4713	-1.61	1.044	6.13
		14 min	12	0.933	2.5453	-1.53	-0.124	6.37
		15 min	12	0.797	2.6801	-2.24	-0.053	6.31
		16 min	12	0.965	2.4072	-2.15	0.426	6.14
		17 min	12	1.591	3.1980	-2.12	0.496	8.08
		18 min	12	1.573	3.0303	-2.11	0.918	7.67
		19 min	12	1.151	3.2358	-2.13	0.208	7.74
		20 min	12	1.283	3.1337	-2.18	0.326	7.68
		21 min	11	1.120	2.6439	-2.17	0.707	6.56
		22 min	10	0.559	2.7072	-2.26	-0.068	6.59
		23 min	10	0.489	2.7658	-2.16	-0.251	6.49
		24 min	10	0.167	2.5974	-2.05	-0.331	6.37
		25 min	10	0.296	2.4487	-2.13	-0.197	6.52
		26 min	10	-0.063	2.6516	-3.50	-0.313	6.43
		27 min	10	0.688	2.5183	-1.98	-0.076	6.35
		28 min	10	0.360	2.4278	-2.07	-0.121	6.35
		29 min	10	0.345	2.4298	-1.90	-0.239	6.43
		30 min	10	0.808	2.4819	-2.06	0.013	6.41

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 114 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	31 min	10	0.076	2.7855	-3.38	-0.204	6.13
		32 min	10	-0.327	2.6266	-4.27	-0.648	5.88
		33 min	10	0.511	2.8159	-4.30	0.278	5.25
		34 min	10	0.161	2.6521	-4.27	-0.024	5.52
		35 min	10	0.115	2.0115	-1.90	-0.159	5.37
		36 min	11	0.342	2.3989	-2.18	-0.072	4.54
		37 min	11	-0.327	2.3098	-3.70	-0.396	5.18
		38 min	12	0.045	1.7793	-3.05	0.000	3.38
		39 min	12	-0.497	1.4517	-3.68	-0.537	1.69
		40 min	12	-0.185	2.0291	-3.76	-0.540	2.89
		41 min	12	-0.457	1.9496	-4.29	-0.580	3.37
		42 min	12	-0.641	2.0457	-4.16	-0.553	4.35
		43 min	12	-0.908	1.2750	-3.78	-0.747	0.75
		44 min	12	-0.388	1.7524	-3.94	-0.429	3.12
		45 min	11	-0.167	1.3429	-2.00	-0.423	2.92
		46 min	12	-0.460	0.9889	-2.35	-0.256	0.79
		47 min	12	-0.218	1.3739	-2.07	-0.327	3.34
		48 min	12	-0.552	0.9728	-2.34	-0.490	1.18
		49 min	12	0.375	1.7692	-2.40	0.155	3.99
		50 min	11	0.584	1.9314	-1.90	0.170	4.24
		51 min	11	0.303	1.8494	-2.11	-0.006	3.80
		52 min	11	0.270	1.5499	-2.00	0.159	3.57
		53 min	12	-0.175	2.1490	-4.22	0.012	3.96
		54 min	12	-0.633	1.9777	-4.59	-0.475	3.77
		55 min	12	-0.155	1.9053	-2.77	-0.323	3.50
		56 min	12	-0.038	1.7047	-2.09	-0.180	3.27
		57 min	12	0.092	1.3738	-2.01	0.016	3.29
		58 min	12	-0.421	1.8886	-4.01	-0.432	3.45
		59 min	12	-0.364	1.5383	-2.18	-0.497	3.73
		60 min	12	-0.240	1.5302	-2.13	-0.485	3.97

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 115 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	61 min	12	-0.468	1.5803	-3.92	-0.195	2.33
		62 min	12	-0.177	1.8176	-3.97	0.092	3.49
		63 min	11	-0.750	1.3925	-3.88	-0.162	1.23
		64 min	11	-0.874	1.5177	-4.62	-0.119	0.35
		65 min	11	-0.509	1.0174	-3.15	-0.143	0.32
		66 min	11	-0.481	0.6940	-1.57	-0.084	0.25
		67 min	11	-0.424	0.5424	-1.33	-0.146	0.19
		68 min	11	-0.907	1.1780	-3.65	-0.677	0.20
		69 min	11	-0.369	1.2656	-2.08	0.035	2.44
		70 min	10	-0.140	1.5229	-2.11	-0.080	3.16
		71 min	10	-0.588	1.9876	-4.42	-0.440	2.74
		72 min	9	-0.741	1.8086	-4.39	-0.017	1.81
		73 min	9	-0.904	1.7147	-4.54	-0.030	1.08
		74 min	9	-0.961	1.6343	-4.47	-0.293	0.77
		75 min	9	-0.815	1.7306	-4.45	-0.051	0.97
		76 min	9	-0.905	1.6285	-4.50	-0.111	0.56
		77 min	9	-0.578	0.9896	-2.02	-0.049	0.44
		78 min	9	-0.309	1.3172	-2.06	-0.091	2.35
		79 min	9	-0.847	1.6802	-4.23	-0.065	1.51
		80 min	9	-0.957	1.5236	-4.02	-0.057	0.52
		81 min	9	-0.609	0.9573	-2.18	-0.154	0.66
		82 min	9	-0.809	1.0374	-2.24	-0.056	0.20
		83 min	9	-0.802	1.0965	-2.76	-0.152	0.08
		84 min	9	-0.668	0.8104	-1.96	-0.322	0.06
		85 min	9	-0.904	1.5571	-4.43	-0.093	0.17
		86 min	9	-0.724	1.5917	-4.32	-0.002	0.79
		87 min	9	-0.815	1.6424	-4.61	-0.018	0.45
		88 min	9	-0.841	1.5567	-4.47	-0.029	0.33
		89 min	10	-0.819	1.4652	-4.56	-0.228	0.16
		90 min	10	-0.844	1.4896	-4.77	-0.305	0.19

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 116 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	91 min	10	-0.965	1.3986	-4.48	-0.450	0.14
		92 min	10	-0.793	0.9286	-2.78	-0.551	0.06
		93 min	10	-0.703	0.7650	-1.92	-0.481	0.10
		94 min	10	-1.002	1.3063	-4.27	-0.655	0.24
		95 min	9	-0.636	0.6515	-1.58	-0.579	0.12
		96 min	9	-0.543	0.5708	-1.37	-0.355	0.09
		97 min	9	-0.543	0.5945	-1.44	-0.546	0.17
		98 min	9	-0.648	0.8449	-2.01	-0.624	0.51
		99 min	10	0.051	1.6304	-1.45	-0.364	4.29
		100 min	9	-0.563	0.5580	-1.37	-0.570	0.12
		101 min	9	0.123	1.3984	-1.44	-0.006	3.01
		102 min	9	0.398	1.7891	-1.49	0.057	3.89
		103 min	9	0.300	1.5704	-1.44	-0.096	3.52
		104 min	10	-0.503	1.7735	-4.48	-0.364	2.51
		105 min	10	-0.752	1.5722	-4.65	-0.587	1.03
		106 min	10	-0.871	1.4056	-4.58	-0.452	0.38
		107 min	10	-0.556	1.8201	-4.61	-0.435	2.71
		108 min	10	-0.830	1.4835	-4.75	-0.363	0.41
		109 min	10	-0.661	1.7301	-4.55	-0.212	2.07
		110 min	10	-0.345	1.2540	-2.69	-0.185	1.88
		111 min	10	-0.357	1.5123	-3.33	-0.148	2.50
		112 min	10	-0.455	1.5449	-3.78	-0.169	2.22
		113 min	11	-0.845	0.9951	-2.92	-0.616	0.57
		114 min	11	-0.996	1.3455	-4.37	-0.390	0.34
		115 min	11	-0.849	1.2137	-4.01	-0.447	0.50
		116 min	11	-0.637	0.9521	-2.22	-0.416	0.78
		117 min	11	-1.014	1.3375	-4.54	-0.867	0.38
		118 min	12	-1.088	1.2883	-4.65	-1.086	0.20
		119 min	12	-0.967	1.3975	-4.64	-0.615	0.58
		120 min	12	-1.140	1.3433	-4.77	-0.927	0.31

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 117 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	121 min	12	-0.253	1.3499	-1.78	-0.270	2.89
		122 min	12	-0.607	1.6345	-4.70	-0.172	1.33
		123 min	12	-0.975	1.3444	-4.59	-0.545	0.55
		124 min	12	-0.993	1.4108	-4.78	-0.599	0.46
		125 min	12	-0.823	1.4595	-4.53	-0.594	1.18
		126 min	12	-0.424	1.3193	-2.03	-0.339	2.79
		127 min	12	-0.991	1.4578	-4.34	-0.644	0.77
		128 min	12	-0.937	1.3310	-4.03	-0.724	0.64
		129 min	12	-0.840	1.0335	-2.25	-0.706	0.66
		130 min	12	-0.798	1.3960	-3.94	-0.447	1.17
		131 min	12	-0.967	1.4766	-4.63	-0.701	0.88
		132 min	12	-0.954	1.2949	-4.24	-0.446	0.78
		133 min	12	-0.719	1.5382	-4.34	-0.420	1.64
		134 min	12	-0.660	1.3989	-3.70	-0.608	1.93
		135 min	12	-0.795	1.6317	-4.39	-0.783	2.45
		136 min	12	-0.985	1.3643	-4.39	-0.816	0.69
		137 min	12	-0.819	1.7236	-4.46	-0.809	2.74
		138 min	12	-0.391	1.9942	-4.37	-0.367	3.03
		139 min	12	-0.562	1.6723	-4.21	-0.282	1.94
		140 min	12	-0.414	1.8723	-4.32	-0.123	3.68
		141 min	12	-0.940	1.1728	-3.94	-0.748	0.59
		142 min	12	-0.478	0.9405	-1.99	-0.464	1.37
		143 min	12	-0.658	0.9260	-1.99	-0.877	0.64
		144 min	12	-0.949	0.9859	-2.84	-1.074	0.47
		145 min	12	-0.627	1.6473	-3.81	-0.668	3.03
		146 min	12	-0.827	1.2559	-3.83	-0.405	0.55
		147 min	12	-0.459	1.7998	-3.88	-0.364	3.30
		148 min	12	-0.390	1.9316	-3.83	-0.355	3.92
		149 min	12	-0.519	1.8934	-3.80	-0.347	3.88
		150 min	12	-0.555	1.8292	-3.81	-0.468	3.77

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 118 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	151 min	12	-0.598	1.8725	-3.68	-0.782	3.98
		152 min	12	-0.414	2.0107	-3.81	-0.408	4.07
		153 min	12	-0.301	2.0083	-3.52	-0.079	4.00
		154 min	12	-0.428	1.8921	-3.66	-0.170	4.07
		155 min	12	-0.542	1.7323	-3.62	-0.327	3.45
		156 min	12	-0.292	1.8083	-3.31	-0.007	4.08
		157 min	12	-0.442	1.6622	-2.74	-0.280	3.80
		158 min	12	-0.543	1.8682	-3.64	-0.433	4.08
		159 min	12	-0.319	1.8446	-3.47	-0.298	4.28
		160 min	12	-0.408	1.6773	-2.54	-0.632	4.17
		161 min	12	0.144	1.6881	-1.60	-0.307	3.91
		162 min	12	0.004	1.4844	-1.62	-0.244	3.70
		163 min	12	-0.071	1.9236	-2.56	-0.527	3.99
		164 min	11	-0.194	1.4519	-1.74	-0.307	3.69
		165 min	11	0.050	1.8236	-1.72	-0.438	3.73
		166 min	11	0.017	1.2982	-1.60	-0.061	3.35
		167 min	11	-0.412	1.0209	-1.64	-0.238	1.68
		168 min	11	0.012	1.4962	-1.66	-0.142	3.84
		169 min	11	-0.241	1.4511	-1.71	-0.492	3.70
		170 min	11	-0.011	1.4915	-1.78	-0.166	3.14
		171 min	11	-0.268	1.2124	-1.79	-0.396	2.32
		172 min	10	-0.214	1.1252	-1.66	-0.186	2.38
		173 min	10	-0.640	0.7592	-1.78	-0.567	0.37
		174 min	10	-0.314	1.1768	-1.93	-0.117	2.09
		175 min	10	-0.419	1.1323	-1.79	-0.389	1.98
		176 min	10	-0.258	1.4279	-1.53	-0.479	3.36
		177 min	10	-0.187	1.6804	-1.77	-0.438	4.19
		178 min	10	-0.279	1.6103	-1.84	-0.374	3.76
		179 min	10	-0.240	1.6736	-1.76	-0.309	3.90
		180 min	10	0.009	1.8615	-1.97	-0.037	3.38

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 119 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	181 min	10	-0.217	1.4996	-1.91	-0.034	2.91
		182 min	9	-0.323	1.5997	-1.81	-0.237	3.29
		183 min	9	-0.361	1.6762	-1.83	-0.631	3.55
		184 min	9	-0.438	1.6081	-2.06	-0.740	3.11
		185 min	9	-0.405	1.6382	-1.84	-0.755	3.39
		186 min	9	-0.495	1.4507	-1.95	-0.769	2.68
		187 min	9	-0.555	1.1383	-1.87	-0.751	1.36
		188 min	9	-0.598	1.1966	-1.80	-0.778	1.77
		189 min	10	-0.368	1.5706	-2.07	-0.443	3.44
		190 min	10	-0.331	1.0816	-1.79	-0.381	2.15
		191 min	10	-0.112	1.5490	-1.92	-0.139	3.69
		192 min	10	-0.316	1.6052	-1.89	-0.529	3.69
		193 min	10	-0.301	1.4896	-1.97	-0.397	3.22
		194 min	10	-0.596	0.8759	-1.91	-0.379	0.40
		195 min	10	-0.636	0.8209	-1.98	-0.576	0.65
		196 min	10	-0.148	1.4443	-1.61	-0.381	3.41
		197 min	11	-0.301	1.1899	-1.71	-0.062	2.31
		198 min	11	-0.172	1.4398	-1.81	-0.036	3.39
		199 min	11	-0.113	1.3062	-1.94	-0.029	2.86
		200 min	11	-0.120	1.4890	-1.72	-0.015	2.87
		201 min	11	0.047	1.6991	-1.94	0.068	3.10
		202 min	12	-0.539	1.5756	-2.96	-0.446	3.21
		203 min	12	-0.876	1.1883	-3.61	-0.500	0.44
		204 min	12	-0.221	1.2010	-1.97	0.053	2.13
		205 min	12	-0.212	1.3332	-2.01	-0.102	2.96
		206 min	12	-0.432	1.1248	-1.96	-0.373	1.22
		207 min	11	-1.020	1.0567	-2.95	-0.803	0.32
		208 min	11	-0.544	0.9416	-1.69	-0.793	1.10
		209 min	11	-0.778	1.2810	-3.30	-0.674	0.99
		210 min	11	-0.954	1.1674	-3.38	-1.131	0.46

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 120 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	4	211 min	12	-0.807	1.1808	-3.33	-0.771	0.59
		212 min	12	-0.740	1.0426	-2.28	-0.714	0.69
		213 min	12	-0.862	1.3796	-3.94	-0.747	1.23
		214 min	12	-0.948	1.4092	-4.05	-0.941	1.03
		215 min	12	-0.585	1.8565	-3.83	-0.713	3.63
		216 min	12	-0.751	1.3649	-4.09	-0.400	1.02
		217 min	12	-0.596	1.3219	-3.88	-0.358	1.19
		218 min	12	-0.658	1.1514	-2.51	-0.580	1.46
		219 min	12	-0.282	0.9907	-1.95	-0.343	1.64
		220 min	12	-0.432	1.2124	-2.10	-0.420	1.87
		221 min	11	-0.121	1.3605	-1.76	-0.113	3.09
		222 min	11	-0.266	1.5060	-1.83	-0.511	3.52
		223 min	11	-0.426	0.9926	-1.92	-0.201	1.38
		224 min	11	-1.004	1.0588	-3.21	-0.689	0.17
		225 min	10	-0.514	0.9181	-2.04	-0.298	0.85
		226 min	10	0.245	1.8067	-2.06	-0.052	3.59
		227 min	10	-0.539	0.8346	-1.88	-0.104	0.28
		228 min	10	-0.288	1.2432	-1.93	0.004	1.94
		229 min	10	-0.304	1.3927	-2.00	-0.284	2.89
		230 min	11	-0.425	1.0702	-2.10	-0.135	1.09
		231 min	11	-0.709	0.8355	-2.00	-0.601	0.33
		232 min	11	-0.375	1.3993	-2.03	-0.075	2.91
		233 min	11	-0.173	1.6597	-1.97	-0.192	3.35
		234 min	11	-0.304	1.3854	-1.90	-0.201	2.85
		235 min	12	-0.178	1.5423	-1.86	-0.134	3.81
		236 min	12	-0.226	1.4146	-1.98	0.045	3.19
		237 min	12	-0.651	1.3414	-3.60	0.033	0.63
		238 min	12	-0.587	1.7287	-4.13	-0.296	2.38
		239 min	12	-0.771	1.4984	-4.19	-0.377	0.97
		240 min	1	0.068		0.07	0.068	0.07

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 121 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	1 min	12	2.108	2.8833	-1.00	0.254	6.78
		2 min	12	3.296	2.7584	-0.03	3.672	6.98
		3 min	12	3.118	2.8254	0.04	2.775	6.95
		4 min	12	3.599	2.7305	0.09	4.894	6.98
		5 min	12	3.891	2.3510	0.13	4.767	6.99
		6 min	12	4.039	2.3539	0.41	5.002	7.01
		7 min	12	4.258	2.1951	0.41	5.168	6.73
		8 min	12	3.772	2.4306	-1.22	4.728	6.49
		9 min	12	3.938	2.3922	-1.03	4.592	6.33
		10 min	12	3.862	2.3816	-1.32	4.638	6.57
		11 min	12	3.512	2.2224	-0.91	3.719	6.38
		12 min	12	3.553	2.4899	-1.33	4.366	6.43
		13 min	12	2.855	2.6101	-1.34	2.838	5.92
		14 min	12	2.416	2.8508	-1.34	2.485	5.90
		15 min	12	2.400	2.9307	-1.56	2.501	5.98
		16 min	12	2.654	2.7149	-1.34	3.396	6.09
		17 min	12	2.183	2.7192	-1.28	2.095	6.13
		18 min	12	1.753	2.6367	-1.61	1.065	6.04
		19 min	12	1.714	2.5128	-1.43	1.472	6.01
		20 min	12	1.541	2.5134	-1.20	0.887	6.19
		21 min	11	1.463	2.5383	-1.11	0.642	6.23
		22 min	10	1.188	2.4385	-1.12	0.350	6.23
		23 min	10	1.094	2.4586	-1.24	0.091	6.15
		24 min	10	0.869	2.4769	-1.34	-0.105	6.02
		25 min	10	0.727	2.3670	-1.45	-0.078	5.93
		26 min	10	0.625	2.1839	-1.40	-0.111	5.85
		27 min	10	1.128	2.2630	-0.95	-0.067	5.84
		28 min	10	0.849	2.2303	-0.96	-0.050	5.60
		29 min	10	0.849	2.3879	-1.27	-0.068	5.85
		30 min	10	0.803	2.2281	-1.17	-0.080	5.72

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 122 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	31 min	10	0.424	1.5934	-0.81	-0.252	4.41
		32 min	10	0.273	1.8059	-1.21	-0.221	5.23
		33 min	10	0.976	1.9768	-0.67	-0.026	4.93
		34 min	10	0.341	1.5432	-1.19	-0.267	3.58
		35 min	10	0.545	1.7229	-1.17	-0.157	3.83
		36 min	11	0.233	1.1458	-1.24	-0.049	2.65
		37 min	11	0.082	1.3023	-1.32	-0.358	2.85
		38 min	12	-0.185	1.3175	-3.04	-0.279	2.26
		39 min	12	0.087	1.6422	-2.51	-0.289	4.02
		40 min	12	0.548	1.4605	-0.97	0.067	3.65
		41 min	12	0.139	1.0841	-1.02	-0.119	3.07
		42 min	12	-0.304	1.3120	-3.24	-0.188	1.54
		43 min	12	-0.142	1.2705	-2.40	-0.115	2.85
		44 min	12	-0.057	1.5067	-2.89	-0.116	3.75
		45 min	11	-0.008	1.5733	-2.64	-0.017	3.86
		46 min	12	-0.110	1.6113	-3.03	-0.085	3.84
		47 min	12	0.033	1.7455	-3.35	-0.149	3.72
		48 min	12	0.057	1.7101	-3.59	0.052	3.09
		49 min	12	0.213	1.6903	-3.24	0.111	4.09
		50 min	11	0.370	1.3787	-2.27	0.218	3.33
		51 min	11	0.090	1.6204	-2.63	-0.008	4.24
		52 min	11	-0.285	0.8885	-2.52	-0.180	1.02
		53 min	12	-0.032	1.4108	-3.29	0.059	2.79
		54 min	12	-0.043	1.0198	-1.38	-0.226	2.59
		55 min	12	-0.373	1.0680	-3.23	-0.268	0.99
		56 min	12	-0.320	1.1560	-3.58	-0.137	1.02
		57 min	12	-0.299	1.2688	-3.76	-0.194	1.32
		58 min	12	-0.179	1.3897	-3.81	0.009	1.99
		59 min	12	-0.120	1.2907	-3.77	0.075	1.24
		60 min	12	-0.111	1.4556	-3.59	-0.166	3.00

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 123 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	61 min	12	-0.159	1.2294	-2.77	-0.290	2.29
		62 min	12	-0.231	1.1204	-3.01	-0.141	1.66
		63 min	11	-0.289	0.9358	-2.14	-0.404	1.57
		64 min	11	-0.330	1.0037	-2.71	-0.414	1.35
		65 min	11	-0.386	1.1406	-3.18	-0.404	1.51
		66 min	11	-0.346	1.2701	-3.39	-0.353	1.96
		67 min	11	-0.387	1.2811	-3.48	-0.252	1.72
		68 min	11	-0.365	1.3492	-3.56	-0.043	2.00
		69 min	11	0.074	1.6085	-3.67	0.210	2.13
		70 min	10	-0.055	0.8091	-0.87	-0.246	1.57
		71 min	10	-0.092	0.9531	-0.96	-0.235	2.24
		72 min	9	-0.002	0.8474	-0.96	-0.049	1.90
		73 min	9	-0.057	0.7075	-1.03	0.018	1.31
		74 min	9	-0.097	0.7150	-0.99	-0.124	1.37
		75 min	9	-0.064	0.7646	-1.11	-0.092	1.10
		76 min	9	-0.183	0.5818	-0.94	-0.100	0.64
		77 min	9	-0.174	0.5807	-0.99	-0.052	0.70
		78 min	9	-0.208	0.6486	-1.11	-0.060	0.62
		79 min	9	-0.209	0.5336	-1.06	-0.101	0.44
		80 min	9	-0.230	0.5657	-1.06	-0.148	0.56
		81 min	9	-0.237	0.5740	-0.99	-0.111	0.54
		82 min	9	-0.263	0.5973	-1.15	-0.058	0.47
		83 min	9	-0.226	0.5498	-0.93	0.079	0.41
		84 min	9	-0.230	0.5331	-0.92	0.060	0.34
		85 min	9	-0.248	0.5541	-1.08	-0.031	0.51
		86 min	9	-0.188	0.4854	-0.90	-0.058	0.35
		87 min	9	-0.201	0.5256	-0.99	0.054	0.43
		88 min	9	-0.147	0.5067	-0.97	0.013	0.38
		89 min	10	-0.519	1.1760	-3.67	-0.111	0.36
		90 min	10	-0.532	1.1783	-3.66	-0.121	0.37

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 124 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	91 min	10	-0.544	1.1999	-3.72	-0.152	0.36
		92 min	10	-0.550	1.1011	-3.44	-0.181	0.42
		93 min	10	-0.505	1.0402	-3.19	-0.130	0.34
		94 min	10	-0.477	1.0631	-3.21	-0.123	0.42
		95 min	9	-0.440	1.1954	-3.49	0.026	0.36
		96 min	9	-0.461	1.2367	-3.61	-0.137	0.31
		97 min	9	-0.440	1.2532	-3.57	0.110	0.45
		98 min	9	-0.501	1.3027	-3.73	0.036	0.58
		99 min	10	-0.213	1.7715	-3.67	-0.151	3.61
		100 min	9	-0.159	1.8765	-3.24	-0.309	3.99
		101 min	9	-0.456	1.3818	-3.42	-0.333	1.63
		102 min	9	-0.548	1.2022	-3.15	-0.296	1.04
		103 min	9	-0.510	1.1863	-3.09	-0.315	0.98
		104 min	10	-0.355	1.5509	-3.18	-0.402	3.02
		105 min	10	-0.413	1.3790	-3.16	-0.289	2.21
		106 min	10	-0.538	1.1303	-3.09	-0.275	0.98
		107 min	10	-0.568	1.1244	-3.10	-0.350	0.95
		108 min	10	-0.508	1.0656	-2.85	-0.100	0.79
		109 min	10	-0.566	1.0734	-3.02	-0.235	0.76
		110 min	10	-0.552	1.0616	-2.92	-0.188	0.59
		111 min	10	-0.627	1.0421	-3.06	-0.262	0.46
		112 min	10	-0.625	1.0625	-3.08	-0.255	0.43
		113 min	11	-0.559	0.9930	-2.94	-0.235	0.61
		114 min	11	-0.589	0.9297	-2.80	-0.240	0.37
		115 min	11	-0.654	0.9492	-3.01	-0.239	0.18
		116 min	11	-0.601	0.9850	-3.07	-0.215	0.32
		117 min	11	-0.500	0.8950	-2.40	-0.213	0.82
		118 min	12	-0.625	0.8519	-2.61	-0.220	0.37
		119 min	12	-0.588	0.8114	-2.51	-0.219	0.23
		120 min	12	-0.637	0.9013	-2.82	-0.126	0.24

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 125 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	121 min	12	-0.587	0.8845	-2.66	-0.193	0.34
		122 min	12	-0.299	1.2582	-2.76	-0.106	2.59
		123 min	12	-0.601	0.9454	-2.83	-0.161	0.50
		124 min	12	-0.613	0.9371	-2.89	-0.097	0.41
		125 min	12	-0.662	1.0160	-3.12	-0.153	0.51
		126 min	12	-0.526	1.0289	-3.07	-0.164	0.62
		127 min	12	-0.532	0.7179	-1.62	-0.160	0.51
		128 min	12	-0.654	0.9806	-2.92	-0.193	0.57
		129 min	12	-0.478	1.1278	-3.05	-0.158	1.20
		130 min	12	-0.604	1.0389	-3.17	-0.176	0.58
		131 min	12	-0.668	1.0552	-3.20	-0.269	0.56
		132 min	12	-0.606	1.0493	-3.28	-0.244	0.70
		133 min	12	-0.643	1.0439	-3.20	-0.311	0.71
		134 min	12	-0.474	1.1618	-3.34	-0.242	1.17
		135 min	12	-0.358	1.2830	-3.31	-0.243	2.15
		136 min	12	-0.640	1.0846	-3.31	-0.284	0.60
		137 min	12	-0.696	1.0487	-3.31	-0.359	0.59
		138 min	12	-0.276	1.2412	-2.47	-0.222	2.63
		139 min	12	-0.571	0.9176	-2.85	-0.322	0.59
		140 min	12	-0.417	1.0167	-2.91	-0.228	0.72
		141 min	12	-0.073	1.5450	-1.71	-0.264	4.29
		142 min	12	-0.502	1.0141	-3.18	-0.223	0.62
		143 min	12	-0.438	1.1441	-3.40	-0.183	0.77
		144 min	12	-0.508	1.0374	-3.25	-0.324	0.59
		145 min	12	-0.138	1.5137	-3.35	-0.273	3.41
		146 min	12	-0.340	1.0340	-3.37	0.015	0.57
		147 min	12	-0.522	1.1446	-3.59	-0.314	0.59
		148 min	12	-0.541	1.1289	-3.53	-0.291	0.55
		149 min	12	-0.542	1.1652	-3.68	-0.275	0.55
		150 min	12	-0.457	1.2273	-3.63	-0.250	0.95

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 126 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	151 min	12	-0.488	1.2217	-3.76	-0.144	0.60
		152 min	12	-0.198	1.7189	-3.73	-0.195	3.75
		153 min	12	-0.064	1.8190	-3.76	-0.141	3.99
		154 min	12	-0.046	1.5748	-2.91	-0.102	3.73
		155 min	12	-0.266	1.2449	-3.37	0.079	1.15
		156 min	12	0.039	1.7268	-3.66	0.216	3.01
		157 min	12	-0.086	1.5492	-3.31	0.106	3.17
		158 min	12	-0.493	0.9843	-2.85	-0.414	0.54
		159 min	12	-0.459	0.8348	-2.36	-0.406	0.45
		160 min	12	-0.227	1.2983	-3.05	0.096	2.09
		161 min	12	-0.475	1.0929	-3.18	-0.111	0.62
		162 min	12	-0.306	1.3119	-3.40	-0.002	1.79
		163 min	12	-0.353	1.1379	-3.53	0.052	0.64
		164 min	11	-0.404	1.2982	-3.51	0.066	1.15
		165 min	11	-0.473	1.2120	-3.72	0.045	0.50
		166 min	11	-0.174	1.3112	-3.65	0.107	1.59
		167 min	11	-0.292	1.5376	-3.68	-0.035	2.61
		168 min	11	-0.283	1.6080	-3.71	-0.049	2.95
		169 min	11	-0.443	1.2667	-3.61	-0.047	0.87
		170 min	11	-0.279	1.5867	-3.54	0.015	3.06
		171 min	11	-0.226	1.5024	-2.91	0.014	3.25
		172 min	10	-0.245	1.2751	-3.27	0.089	1.71
		173 min	10	-0.437	1.1714	-3.59	0.060	0.24
		174 min	10	0.002	1.8786	-3.52	0.093	4.25
		175 min	10	0.003	1.8746	-3.54	0.082	4.13
		176 min	10	-0.101	1.7925	-3.57	0.025	3.80
		177 min	10	-0.075	1.9336	-3.53	-0.069	4.41
		178 min	10	-0.331	1.4694	-3.70	-0.100	2.21
		179 min	10	-0.141	1.7671	-3.48	0.027	3.73
		180 min	10	-0.472	1.0590	-3.29	-0.178	0.44

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 127 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	181 min	10	-0.304	1.2597	-3.24	-0.035	1.62
		182 min	9	-0.587	1.1641	-3.36	-0.270	0.59
		183 min	9	-0.533	1.2143	-3.45	-0.063	0.45
		184 min	9	-0.582	1.2707	-3.58	-0.294	0.64
		185 min	9	-0.663	1.1473	-3.55	-0.492	0.42
		186 min	9	-0.602	1.2205	-3.58	-0.248	0.44
		187 min	9	-0.741	1.2168	-3.69	-0.430	0.42
		188 min	9	-0.574	1.2455	-3.63	-0.162	0.37
		189 min	10	-0.298	1.4579	-3.57	-0.052	2.17
		190 min	10	-0.611	1.1740	-3.61	-0.279	0.40
		191 min	10	-0.497	1.2068	-3.69	-0.002	0.39
		192 min	10	-0.248	1.5021	-3.64	0.020	2.35
		193 min	10	-0.173	1.5463	-3.68	0.018	2.63
		194 min	10	-0.520	1.1982	-3.72	-0.170	0.27
		195 min	10	-0.527	1.2450	-3.74	-0.221	0.56
		196 min	10	-0.475	1.2431	-3.71	-0.021	0.43
		197 min	11	-0.692	1.1408	-3.37	-0.354	0.39
		198 min	11	-0.562	1.2675	-3.72	-0.027	0.67
		199 min	11	-0.182	1.8717	-3.78	0.050	4.09
		200 min	11	-0.619	1.1937	-3.58	-0.352	0.47
		201 min	11	-0.606	1.1120	-3.21	-0.416	0.38
		202 min	12	-0.569	1.1593	-3.53	-0.312	0.71
		203 min	12	-0.340	1.2816	-3.71	0.123	0.89
		204 min	12	-0.507	1.2459	-3.70	-0.149	0.91
		205 min	12	-0.558	1.1416	-3.51	-0.282	0.68
		206 min	12	-0.620	1.1052	-3.41	-0.400	0.62
		207 min	11	-0.615	1.1398	-3.36	-0.364	0.61
		208 min	11	-0.567	1.2285	-3.59	-0.272	0.61
		209 min	11	-0.571	1.1822	-3.54	-0.168	0.51
		210 min	11	-0.453	1.2421	-3.54	-0.092	0.70

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 128 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	5	211 min	12	-0.434	1.2722	-3.59	-0.198	1.30
		212 min	12	-0.584	1.1596	-3.52	-0.512	0.56
		213 min	12	-0.630	1.2108	-3.72	-0.514	0.50
		214 min	12	-0.190	1.6654	-3.46	-0.071	3.62
		215 min	12	-0.428	1.2978	-3.69	-0.124	0.93
		216 min	12	-0.552	1.2716	-3.80	-0.453	0.97
		217 min	12	-0.518	1.1431	-3.36	-0.422	0.90
		218 min	12	-0.582	1.0702	-3.15	-0.518	0.77
		219 min	12	-0.397	1.1849	-3.44	-0.240	1.09
		220 min	12	-0.575	1.1852	-3.56	-0.233	0.67
		221 min	11	-0.411	1.2168	-3.57	0.127	0.71
		222 min	11	0.017	1.6065	-3.44	0.242	3.26
		223 min	11	-0.062	1.9404	-3.50	-0.075	4.59
		224 min	11	-0.347	1.1356	-3.08	-0.069	0.99
		225 min	10	-0.297	0.7869	-1.81	-0.207	0.58
		226 min	10	0.220	1.3240	-1.14	-0.009	3.64
		227 min	10	0.145	1.3151	-1.28	0.072	3.45
		228 min	10	0.120	1.1622	-1.21	0.101	2.97
		229 min	10	0.082	1.1570	-2.70	0.239	1.50
		230 min	11	-0.392	1.2068	-3.00	0.004	1.16
		231 min	11	-0.525	1.0668	-2.98	-0.361	0.61
		232 min	11	-0.539	1.0405	-2.88	-0.447	0.56
		233 min	11	-0.513	0.9716	-2.59	-0.491	0.57
		234 min	11	-0.358	1.3144	-3.13	0.080	1.89
		235 min	12	-0.447	1.1965	-3.51	0.103	0.58
		236 min	12	-0.168	1.4475	-3.34	0.053	2.07
		237 min	12	-0.274	1.2215	-3.17	0.178	1.21
		238 min	12	-0.551	1.2196	-3.48	-0.275	0.91
		239 min	12	-0.568	1.1980	-3.43	-0.204	0.50
		240 min	1	-3.576		-3.58	-3.576	-3.58

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 129 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	1 min	12	1.405	2.5556	-0.24	0.025	6.71
		2 min	12	2.537	2.8350	-0.23	1.281	7.16
		3 min	12	3.285	2.7123	0.03	3.996	6.35
		4 min	12	3.448	2.8361	-0.07	3.769	7.07
		5 min	12	3.319	2.9228	-0.09	3.293	7.24
		6 min	12	3.728	2.5901	0.20	4.213	7.17
		7 min	12	4.288	2.1014	0.27	5.009	6.98
		8 min	12	3.886	2.2313	0.20	4.798	6.91
		9 min	12	3.384	2.4860	-0.03	3.749	7.11
		10 min	12	3.586	2.3296	-0.37	4.781	7.08
		11 min	12	3.137	2.4891	-0.36	3.052	6.99
		12 min	12	2.972	2.5424	-0.49	3.032	6.91
		13 min	12	3.078	2.5495	-0.44	2.979	6.90
		14 min	12	2.678	2.6078	-0.61	1.852	6.93
		15 min	12	2.481	2.7640	-0.85	1.800	6.72
		16 min	12	2.805	2.6687	-0.84	2.816	6.75
		17 min	12	2.389	2.6156	-0.91	1.869	6.67
		18 min	12	2.228	2.5565	-0.99	2.122	6.13
		19 min	12	2.208	2.5141	-1.02	2.444	6.08
		20 min	12	1.801	2.4075	-1.21	1.095	6.04
		21 min	11	1.483	2.0244	-1.01	1.417	5.90
		22 min	10	1.389	2.1953	-1.09	0.850	5.70
		23 min	10	1.337	2.0557	-1.02	0.628	5.24
		24 min	10	1.551	2.3572	-1.12	0.694	5.85
		25 min	10	1.447	2.1953	-1.06	1.000	5.78
		26 min	10	1.360	2.2270	-1.08	0.630	5.96
		27 min	10	1.476	2.2759	-0.97	0.308	5.65
		28 min	10	1.295	1.9914	-0.92	0.436	5.55
		29 min	10	1.232	2.1267	-0.92	0.039	4.78
		30 min	10	0.916	1.7545	-0.74	0.020	4.77

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 130 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	31 min	10	0.762	1.6527	-0.87	0.022	4.79
		32 min	10	0.825	1.6679	-0.78	0.351	5.10
		33 min	10	1.312	2.1568	-0.72	0.183	5.08
		34 min	10	0.947	1.8043	-0.71	-0.017	3.98
		35 min	10	0.705	1.6205	-0.65	0.001	4.65
		36 min	11	0.574	1.4302	-0.60	-0.114	3.96
		37 min	11	0.540	1.3036	-0.80	-0.077	2.92
		38 min	12	0.372	1.0257	-0.66	0.020	1.97
		39 min	12	0.776	1.8039	-0.62	-0.121	4.79
		40 min	12	0.612	1.6596	-1.40	0.043	4.81
		41 min	12	0.532	1.2659	-0.82	0.016	3.42
		42 min	12	0.415	0.9380	-0.66	0.133	2.72
		43 min	12	0.719	1.7934	-0.69	0.039	4.55
		44 min	12	0.758	1.9544	-1.21	0.020	4.90
		45 min	11	0.441	1.5862	-1.25	0.079	4.70
		46 min	12	0.535	1.9524	-2.58	0.012	4.25
		47 min	12	0.635	1.9315	-2.39	0.153	4.45
		48 min	12	0.490	1.7766	-2.92	0.101	4.10
		49 min	12	0.441	1.9522	-3.98	0.221	4.09
		50 min	11	0.216	1.6034	-3.29	0.179	3.48
		51 min	11	0.499	1.7696	-2.79	0.079	3.57
		52 min	11	0.574	2.1857	-3.48	0.130	4.30
		53 min	12	0.686	2.2402	-4.17	0.261	4.26
		54 min	12	0.418	2.0004	-4.41	0.181	4.09
		55 min	12	0.192	1.5743	-3.69	0.102	3.08
		56 min	12	0.113	1.5640	-4.30	0.221	1.76
		57 min	12	-0.005	1.5246	-4.38	0.142	1.46
		58 min	12	0.047	1.5578	-4.29	0.233	2.04
		59 min	12	-0.127	1.5359	-4.69	0.152	1.34
		60 min	12	-0.226	1.5570	-4.86	-0.030	1.27

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 131 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	61 min	12	-0.055	1.6504	-4.81	0.143	1.39
		62 min	12	0.003	1.4910	-4.12	0.151	1.98
		63 min	11	-0.195	1.4804	-4.23	-0.037	1.49
		64 min	11	-0.114	1.2844	-3.54	0.000	1.33
		65 min	11	-0.155	1.3143	-3.72	0.003	1.29
		66 min	11	-0.237	1.3832	-4.03	-0.102	1.24
		67 min	11	-0.292	1.5937	-4.78	0.012	1.22
		68 min	11	-0.279	1.5314	-4.56	-0.038	1.20
		69 min	11	-0.199	1.5551	-4.51	0.087	1.27
		70 min	10	0.112	0.6377	-1.00	0.033	1.17
		71 min	10	0.092	0.6165	-0.95	0.026	1.23
		72 min	9	0.206	0.6141	-0.62	0.215	1.27
		73 min	9	0.170	0.6503	-0.85	0.197	1.23
		74 min	9	0.203	0.6612	-0.98	0.265	1.28
		75 min	9	0.154	0.6760	-1.03	0.315	1.18
		76 min	9	0.151	0.6972	-1.09	0.261	1.24
		77 min	9	0.162	0.6889	-1.06	0.218	1.27
		78 min	9	0.141	0.6942	-1.12	-0.026	1.23
		79 min	9	0.127	0.6632	-1.10	0.188	1.18
		80 min	9	0.107	0.6913	-1.16	0.189	1.18
		81 min	9	0.075	0.6575	-0.98	0.036	1.11
		82 min	9	0.071	0.6634	-0.98	-0.214	1.11
		83 min	9	0.121	0.6561	-1.05	0.057	1.07
		84 min	9	0.111	0.6263	-0.97	0.026	1.03
		85 min	9	0.067	0.5860	-0.80	-0.074	0.95
		86 min	9	0.146	0.5237	-0.49	0.077	0.97
		87 min	9	0.113	0.5254	-0.46	-0.057	0.98
		88 min	9	0.197	0.4552	-0.44	0.200	0.95
		89 min	10	-0.266	1.6775	-4.90	0.217	0.92
		90 min	10	-0.273	1.6092	-4.72	0.093	0.86

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 132 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	91 min	10	-0.270	1.5704	-4.61	0.186	0.85
		92 min	10	-0.286	1.5968	-4.71	0.174	0.85
		93 min	10	-0.320	1.5057	-4.48	0.101	0.71
		94 min	10	-0.269	1.5686	-4.63	0.235	0.63
		95 min	9	-0.279	1.6030	-4.50	0.187	0.72
		96 min	9	-0.291	1.6300	-4.60	0.197	0.68
		97 min	9	-0.336	1.5807	-4.51	0.120	0.60
		98 min	9	-0.302	1.6519	-4.65	0.134	0.71
		99 min	10	-0.201	1.5913	-4.60	0.149	1.04
		100 min	9	-0.053	0.7412	-1.83	0.025	0.75
		101 min	9	-0.333	1.1854	-3.40	-0.018	0.57
		102 min	9	-0.437	1.4777	-4.27	-0.101	0.86
		103 min	9	-0.444	1.5347	-4.40	0.002	0.86
		104 min	10	-0.634	1.6239	-4.40	-0.128	1.00
		105 min	10	-0.399	1.5807	-4.40	-0.130	1.77
		106 min	10	-0.531	1.5157	-4.43	-0.213	1.09
		107 min	10	-0.430	1.4723	-4.47	-0.148	0.69
		108 min	10	-0.291	1.3679	-3.93	-0.060	1.11
		109 min	10	-0.511	1.4338	-4.16	-0.205	0.89
		110 min	10	-0.570	1.5420	-4.13	-0.209	1.32
		111 min	10	-0.541	1.4012	-4.22	-0.175	1.00
		112 min	10	-0.440	1.4698	-4.27	-0.194	1.07
		113 min	11	-0.358	1.3277	-4.17	-0.163	0.83
		114 min	11	-0.378	1.3231	-4.19	-0.175	0.65
		115 min	11	-0.423	1.3101	-4.25	-0.196	0.48
		116 min	11	-0.416	1.3855	-4.44	-0.200	0.67
		117 min	11	-0.348	1.2602	-3.93	-0.174	0.75
		118 min	12	-0.414	1.1905	-3.94	-0.186	0.65
		119 min	12	-0.371	1.1434	-3.79	-0.151	0.57
		120 min	12	-0.383	1.1778	-3.87	-0.166	0.61

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 133 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	121 min	12	-0.400	1.1697	-3.90	-0.174	0.54
		122 min	12	-0.418	1.1768	-3.92	-0.155	0.58
		123 min	12	-0.398	1.1944	-3.97	-0.182	0.62
		124 min	12	-0.395	1.2173	-4.05	-0.154	0.68
		125 min	12	-0.404	1.2277	-4.07	-0.143	0.66
		126 min	12	-0.414	1.2759	-4.22	-0.167	0.83
		127 min	12	-0.414	1.2283	-4.07	-0.179	0.79
		128 min	12	-0.406	1.2299	-4.07	-0.186	0.85
		129 min	12	-0.432	1.3002	-4.34	-0.227	0.83
		130 min	12	-0.447	1.4734	-4.90	-0.113	0.90
		131 min	12	-0.464	1.4776	-4.90	-0.202	0.98
		132 min	12	-0.437	1.4604	-4.81	-0.225	1.00
		133 min	12	-0.501	1.4503	-4.90	-0.222	0.76
		134 min	12	-0.334	1.5096	-4.96	-0.031	0.89
		135 min	12	-0.467	1.4921	-4.97	-0.232	0.99
		136 min	12	-0.444	1.4903	-4.90	-0.224	1.12
		137 min	12	-0.437	1.3159	-4.33	-0.218	0.90
		138 min	12	-0.133	1.6177	-4.28	-0.095	2.90
		139 min	12	-0.399	1.2222	-3.96	-0.258	0.97
		140 min	12	-0.258	1.2943	-4.00	-0.080	1.32
		141 min	12	-0.369	1.2560	-4.06	-0.255	1.02
		142 min	12	-0.329	1.2717	-4.08	-0.140	1.08
		143 min	12	-0.356	1.3554	-4.36	-0.135	1.19
		144 min	12	-0.260	1.3979	-4.37	-0.029	1.29
		145 min	12	-0.276	1.4017	-4.39	-0.070	1.39
		146 min	12	-0.344	1.4112	-4.45	-0.091	1.44
		147 min	12	-0.343	1.4281	-4.52	-0.107	1.40
		148 min	12	-0.359	1.4501	-4.57	-0.152	1.51
		149 min	12	-0.339	1.4438	-4.56	-0.118	1.47
		150 min	12	-0.317	1.5010	-4.74	-0.059	1.47

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 134 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	151 min	12	-0.333	1.5088	-4.81	-0.077	1.40
		152 min	12	-0.359	1.5106	-4.82	-0.057	1.41
		153 min	12	-0.340	1.5024	-4.78	-0.039	1.39
		154 min	12	-0.260	1.3630	-4.23	-0.006	1.47
		155 min	12	-0.315	1.3872	-4.40	-0.075	1.30
		156 min	12	-0.249	1.4833	-4.55	-0.059	1.62
		157 min	12	-0.227	1.4848	-4.51	-0.040	1.57
		158 min	12	-0.281	1.4662	-4.61	-0.007	1.40
		159 min	12	-0.301	1.4085	-4.43	-0.053	1.33
		160 min	12	-0.304	1.4907	-4.68	0.038	1.51
		161 min	12	-0.251	1.4458	-4.37	0.034	1.66
		162 min	12	-0.283	1.5263	-4.71	0.076	1.77
		163 min	12	-0.304	1.5110	-4.74	0.065	1.52
		164 min	11	-0.302	1.5980	-4.72	0.049	1.71
		165 min	11	-0.319	1.6404	-4.88	0.059	1.63
		166 min	11	-0.096	1.8478	-4.85	0.140	2.47
		167 min	11	-0.309	1.6448	-4.95	0.127	1.45
		168 min	11	-0.321	1.6211	-4.84	0.023	1.60
		169 min	11	-0.333	1.6313	-4.96	0.147	1.32
		170 min	11	-0.306	1.6552	-4.85	0.137	1.83
		171 min	11	-0.302	1.6238	-4.79	0.032	1.76
		172 min	10	-0.224	1.6331	-4.58	0.057	1.24
		173 min	10	-0.250	1.6529	-4.66	0.069	1.49
		174 min	10	-0.279	1.6443	-4.73	0.109	1.30
		175 min	10	-0.321	1.6409	-4.77	0.080	1.21
		176 min	10	-0.330	1.6339	-4.77	0.074	1.12
		177 min	10	-0.319	1.6653	-4.76	-0.030	1.11
		178 min	10	-0.361	1.6553	-4.84	-0.028	0.98
		179 min	10	-0.350	1.6411	-4.80	0.070	1.03
		180 min	10	-0.336	1.5763	-4.58	-0.012	1.18

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 135 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	181 min	10	-0.342	1.5274	-4.44	0.057	1.06
		182 min	9	-0.518	1.5365	-4.48	-0.105	0.68
		183 min	9	-0.584	1.5011	-4.44	-0.123	0.62
		184 min	9	-0.560	1.5884	-4.66	-0.040	0.59
		185 min	9	-0.617	1.5276	-4.54	-0.234	0.59
		186 min	9	-0.605	1.5741	-4.66	-0.111	0.60
		187 min	9	-0.633	1.5454	-4.62	-0.271	0.58
		188 min	9	-0.585	1.5590	-4.63	-0.161	0.54
		189 min	10	-0.418	1.5731	-4.66	-0.062	1.06
		190 min	10	-0.457	1.6356	-4.86	-0.003	1.00
		191 min	10	-0.426	1.6420	-4.91	0.059	0.93
		192 min	10	-0.419	1.6314	-4.84	-0.032	1.03
		193 min	10	-0.366	1.6401	-4.81	0.047	1.08
		194 min	10	-0.417	1.6243	-4.81	-0.015	1.04
		195 min	10	-0.427	1.6750	-4.94	-0.111	1.05
		196 min	10	-0.420	1.6679	-4.96	-0.045	1.00
		197 min	11	-0.435	1.4561	-4.55	-0.141	0.93
		198 min	11	-0.430	1.4994	-4.66	-0.095	0.97
		199 min	11	-0.430	1.5318	-4.76	-0.085	0.97
		200 min	11	-0.214	1.6301	-4.67	-0.055	1.72
		201 min	11	-0.351	1.5189	-4.63	-0.115	1.01
		202 min	12	-0.380	1.4490	-4.68	-0.081	0.98
		203 min	12	-0.372	1.5057	-4.88	-0.037	0.98
		204 min	12	-0.420	1.5237	-4.93	-0.065	0.94
		205 min	12	-0.357	1.4450	-4.69	-0.048	0.90
		206 min	12	-0.415	1.4451	-4.72	0.023	0.79
		207 min	11	-0.407	1.5099	-4.68	-0.047	0.97
		208 min	11	-0.408	1.5444	-4.82	-0.037	0.81
		209 min	11	-0.422	1.5387	-4.84	0.039	0.87
		210 min	11	-0.405	1.5411	-4.81	-0.055	0.95

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 136 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	6	211 min	12	-0.420	1.4983	-4.93	-0.070	0.89
		212 min	12	-0.401	1.5107	-4.92	-0.071	0.84
		213 min	12	-0.403	1.5259	-4.97	-0.079	0.96
		214 min	12	-0.379	1.4919	-4.85	-0.063	0.94
		215 min	12	-0.044	1.8675	-4.84	0.045	3.56
		216 min	12	-0.116	1.7391	-4.91	0.177	2.75
		217 min	12	-0.010	1.7804	-4.56	0.063	3.40
		218 min	12	-0.272	1.4619	-4.65	0.024	0.91
		219 min	12	-0.379	1.4362	-4.76	-0.108	0.80
		220 min	12	-0.374	1.4896	-4.92	-0.033	0.78
		221 min	11	-0.420	1.5344	-4.84	0.117	0.74
		222 min	11	-0.370	1.4934	-4.67	-0.005	0.77
		223 min	11	-0.289	1.5714	-4.68	0.065	1.28
		224 min	11	-0.401	1.4209	-4.39	-0.036	0.87
		225 min	10	0.002	0.5066	-0.75	0.069	0.86
		226 min	10	0.027	0.5371	-0.81	0.108	0.92
		227 min	10	0.056	0.4859	-0.59	0.099	0.91
		228 min	10	0.124	0.5199	-0.59	0.148	0.86
		229 min	10	-0.401	1.4341	-4.29	-0.102	0.84
		230 min	11	-0.449	1.3888	-4.43	-0.133	0.69
		231 min	11	-0.457	1.4405	-4.55	-0.064	0.81
		232 min	11	-0.431	1.4076	-4.41	-0.197	0.89
		233 min	11	-0.462	1.4069	-4.40	-0.264	0.94
		234 min	11	-0.379	1.5168	-4.49	0.061	1.09
		235 min	12	-0.425	1.3376	-4.40	-0.118	0.86
		236 min	12	-0.457	1.4064	-4.59	-0.242	1.09
		237 min	12	-0.412	1.3450	-4.38	-0.134	1.05
		238 min	12	-0.455	1.3526	-4.40	-0.303	1.03
		239 min	12	-0.468	1.3680	-4.46	-0.314	0.98
		240 min	1	-4.505		-4.51	-4.505	-4.51

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 137 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	1 min	12	1.309	2.2928	-0.09	0.028	6.77
		2 min	12	3.613	2.9495	-0.15	5.016	7.25
		3 min	12	3.631	2.7247	0.09	4.344	7.53
		4 min	12	3.951	2.8010	-0.14	5.373	7.27
		5 min	12	4.502	2.3904	-0.06	5.495	6.72
		6 min	12	4.544	2.5374	-0.23	5.725	6.89
		7 min	12	4.424	2.4366	0.29	5.211	6.82
		8 min	12	4.569	2.3573	0.15	5.370	6.99
		9 min	12	5.096	1.6207	1.58	5.602	6.66
		10 min	12	4.387	2.4789	0.29	5.313	6.77
		11 min	12	4.382	2.1254	0.20	5.271	6.73
		12 min	12	4.185	2.3247	0.17	5.052	6.75
		13 min	12	4.265	2.2258	0.04	4.782	6.75
		14 min	12	4.002	2.3935	-0.10	4.445	6.81
		15 min	12	3.410	2.7792	-0.65	4.067	6.81
		16 min	12	3.419	2.6598	-0.55	4.096	6.65
		17 min	12	3.171	2.8970	-0.80	3.663	6.73
		18 min	12	3.154	2.9647	-0.82	4.193	6.83
		19 min	12	3.148	2.9144	-0.87	4.092	6.57
		20 min	12	2.713	2.8085	-1.10	2.688	6.43
		21 min	11	3.267	2.7200	-0.89	3.544	6.36
		22 min	10	2.803	2.7402	-0.98	3.432	6.45
		23 min	10	2.503	2.6433	-0.94	2.367	6.38
		24 min	10	2.543	2.6575	-0.99	2.405	5.83
		25 min	10	2.614	2.6504	-0.87	2.935	6.29
		26 min	10	1.795	2.2993	-1.00	1.386	6.33
		27 min	10	1.940	2.6322	-0.85	0.509	6.39
		28 min	10	1.945	2.5667	-0.81	0.635	6.11
		29 min	10	1.709	2.3549	-0.75	0.447	5.81
		30 min	10	1.470	2.1232	-0.67	0.289	4.52

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 138 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	31 min	10	1.015	1.8715	-0.80	0.264	5.10
		32 min	10	1.148	1.8782	-0.68	0.300	4.95
		33 min	10	1.360	2.3252	-0.71	0.449	5.44
		34 min	10	1.203	2.1746	-0.68	0.198	5.60
		35 min	10	1.126	2.0779	-0.65	0.233	5.64
		36 min	11	1.090	2.1969	-0.57	-0.040	5.44
		37 min	11	0.925	1.9609	-0.60	-0.044	5.25
		38 min	12	1.236	2.0848	-0.64	0.218	5.21
		39 min	12	1.067	1.9923	-0.64	0.207	5.84
		40 min	12	1.198	2.0401	-0.49	0.235	5.82
		41 min	12	1.231	1.7518	-0.48	0.779	5.18
		42 min	12	1.069	1.6949	-0.43	0.503	5.18
		43 min	12	1.226	1.7676	-0.43	0.588	5.35
		44 min	12	1.394	2.1896	-0.79	0.699	5.80
		45 min	11	0.982	1.8012	-0.42	0.556	5.65
		46 min	12	1.228	2.0838	-0.43	0.566	5.30
		47 min	12	1.138	2.1236	-0.89	0.328	5.69
		48 min	12	1.084	1.9406	-1.19	0.432	4.70
		49 min	12	1.140	2.1494	-1.11	0.149	5.15
		50 min	11	0.798	1.8051	-1.67	0.234	5.03
		51 min	11	1.037	2.0953	-1.73	0.119	5.12
		52 min	11	1.140	2.1368	-1.63	0.028	5.01
		53 min	12	1.161	2.0712	-1.97	0.325	4.45
		54 min	12	0.882	1.8072	-2.09	0.351	4.74
		55 min	12	0.720	1.7548	-2.25	0.128	4.20
		56 min	12	0.621	1.8100	-2.44	0.040	4.73
		57 min	12	0.496	1.4066	-2.42	0.181	2.82
		58 min	12	0.640	1.6303	-2.35	0.089	3.25
		59 min	12	0.582	1.5632	-2.35	0.048	3.21
		60 min	12	0.295	1.2180	-2.20	0.070	2.96

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 139 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	61 min	12	0.414	1.2656	-2.16	0.173	2.90
		62 min	12	0.336	1.2074	-2.07	0.074	2.87
		63 min	11	0.181	1.1487	-2.06	-0.102	2.56
		64 min	11	0.270	1.2309	-2.08	-0.046	2.75
		65 min	11	0.166	1.1870	-2.01	-0.042	2.70
		66 min	11	0.168	1.2034	-2.11	0.006	2.73
		67 min	11	0.242	1.1783	-2.13	-0.036	2.47
		68 min	11	0.176	1.1487	-2.06	-0.016	2.55
		69 min	11	0.208	1.1968	-2.15	0.192	2.66
		70 min	10	0.371	0.9204	-0.97	0.119	2.41
		71 min	10	0.463	0.9849	-0.78	0.244	2.62
		72 min	9	0.464	1.0114	-0.84	0.353	2.63
		73 min	9	0.416	1.0423	-0.82	0.296	2.68
		74 min	9	0.625	0.9373	-0.86	0.404	2.50
		75 min	9	0.509	0.9945	-0.91	0.329	2.58
		76 min	9	0.486	1.0132	-0.99	0.344	2.54
		77 min	9	0.456	0.9840	-0.90	0.341	2.58
		78 min	9	0.393	1.0220	-1.13	0.217	2.56
		79 min	9	0.379	0.9158	-0.95	0.360	2.20
		80 min	9	0.378	0.9887	-1.09	0.286	2.38
		81 min	9	0.384	1.0044	-1.03	0.320	2.48
		82 min	9	0.257	0.9818	-0.96	0.063	2.40
		83 min	9	0.369	0.9960	-1.02	0.364	2.52
		84 min	9	0.369	0.8939	-0.69	0.274	2.35
		85 min	9	0.369	0.9945	-0.70	0.012	2.66
		86 min	9	0.418	0.9456	-0.26	0.156	2.73
		87 min	9	0.751	1.0029	-0.29	0.615	2.55
		88 min	9	0.747	1.1149	-0.29	0.510	2.75
		89 min	10	0.444	1.4090	-2.41	0.370	2.69
		90 min	10	0.689	1.6745	-2.26	0.479	4.13

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 140 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	91 min	10	1.050	2.1347	-2.43	0.501	4.94
		92 min	10	0.791	1.8907	-1.78	0.503	5.21
		93 min	10	0.514	1.2661	-2.13	0.555	2.31
		94 min	10	0.531	1.6158	-2.53	0.482	3.71
		95 min	9	0.733	1.8371	-2.39	0.380	4.32
		96 min	9	0.676	1.6730	-2.43	0.536	3.59
		97 min	9	0.344	1.2389	-2.40	0.395	2.16
		98 min	9	0.469	1.4151	-2.36	0.338	2.94
		99 min	10	0.252	1.2345	-2.44	0.246	2.73
		100 min	9	0.247	1.2619	-2.36	0.251	2.62
		101 min	9	0.144	1.1166	-2.34	0.231	1.95
		102 min	9	0.171	1.1418	-2.29	0.216	2.12
		103 min	9	0.121	1.1133	-2.23	0.211	2.03
		104 min	10	-0.020	0.8547	-2.17	0.112	0.88
		105 min	10	0.034	0.9281	-2.18	0.134	1.37
		106 min	10	-0.325	1.0193	-2.22	-0.017	0.89
		107 min	10	-0.140	0.8136	-2.17	-0.023	0.93
		108 min	10	-0.258	0.9180	-1.86	0.016	0.84
		109 min	10	-0.398	1.1986	-3.06	-0.037	1.03
		110 min	10	-0.376	1.1361	-2.86	-0.030	0.91
		111 min	10	-0.204	0.8204	-2.19	-0.120	0.82
		112 min	10	-0.023	0.8332	-2.04	0.087	0.87
		113 min	11	0.016	0.8685	-2.01	0.044	1.39
		114 min	11	0.038	0.9959	-2.04	-0.022	1.97
		115 min	11	0.020	0.9421	-2.07	-0.008	1.78
		116 min	11	0.003	0.9426	-2.10	-0.006	1.73
		117 min	11	0.055	0.8972	-1.74	-0.022	1.80
		118 min	12	0.011	0.9038	-1.71	-0.127	2.09
		119 min	12	0.048	0.8976	-1.52	-0.058	2.16
		120 min	12	0.052	0.8981	-1.52	-0.091	2.17

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 141 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	121 min	12	0.059	0.8933	-1.51	-0.058	2.14
		122 min	12	0.051	0.9319	-1.57	-0.093	2.24
		123 min	12	0.062	0.9148	-1.56	-0.060	2.18
		124 min	12	0.041	0.9220	-1.69	-0.079	2.12
		125 min	12	0.048	0.9320	-1.69	-0.109	2.17
		126 min	12	0.016	0.9252	-1.79	-0.128	2.09
		127 min	12	0.020	0.9225	-1.76	-0.120	2.12
		128 min	12	0.038	0.9613	-1.85	-0.119	2.28
		129 min	12	-0.008	0.9667	-1.83	-0.182	2.25
		130 min	12	-0.005	1.0085	-2.02	-0.159	2.32
		131 min	12	-0.004	1.0827	-2.21	-0.157	2.49
		132 min	12	0.028	1.0701	-2.08	-0.126	2.58
		133 min	12	-0.022	1.0197	-2.00	-0.155	2.36
		134 min	12	-0.002	1.0293	-2.09	-0.172	2.38
		135 min	12	-0.037	1.0824	-2.17	-0.164	2.52
		136 min	12	0.018	1.0861	-2.09	-0.144	2.59
		137 min	12	-0.005	1.0526	-2.03	-0.147	2.50
		138 min	12	-0.018	1.0778	-2.16	-0.161	2.49
		139 min	12	-0.010	0.9993	-1.78	-0.185	2.44
		140 min	12	0.029	1.0816	-1.90	-0.157	2.77
		141 min	12	0.028	0.9964	-1.77	-0.075	2.49
		142 min	12	0.044	1.0480	-1.89	-0.043	2.61
		143 min	12	0.135	1.1031	-1.90	-0.025	2.70
		144 min	12	0.064	1.0891	-1.93	-0.062	2.79
		145 min	12	0.087	1.1664	-2.15	0.020	2.94
		146 min	12	0.048	1.1541	-2.16	-0.067	2.90
		147 min	12	0.055	1.1691	-2.11	-0.040	2.96
		148 min	12	0.028	1.1948	-2.28	-0.068	2.95
		149 min	12	0.027	1.2160	-2.41	-0.036	2.94
		150 min	12	0.036	1.2177	-2.35	-0.036	2.99

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 142 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	151 min	12	0.071	1.2921	-2.38	0.006	3.30
		152 min	12	0.055	1.2346	-2.35	-0.033	3.07
		153 min	12	0.043	1.2438	-2.37	-0.064	3.08
		154 min	12	0.098	1.2182	-2.20	-0.031	3.14
		155 min	12	0.093	1.2118	-2.18	-0.021	3.10
		156 min	12	0.142	1.2504	-2.22	-0.008	3.14
		157 min	12	0.149	1.2362	-2.14	-0.018	3.17
		158 min	12	0.066	1.1205	-2.20	-0.023	2.69
		159 min	12	0.057	1.1698	-2.23	-0.049	2.87
		160 min	12	0.135	1.2313	-2.37	0.015	2.86
		161 min	12	0.237	1.3894	-2.22	-0.004	3.17
		162 min	12	0.116	1.2044	-2.25	-0.040	2.91
		163 min	12	0.084	1.2062	-2.21	-0.070	3.05
		164 min	11	0.101	1.2352	-2.26	-0.059	2.88
		165 min	11	0.093	1.2802	-2.42	-0.015	2.90
		166 min	11	0.092	1.2433	-2.30	-0.060	2.83
		167 min	11	0.122	1.2602	-2.30	-0.037	2.92
		168 min	11	0.161	1.3508	-2.24	-0.029	3.31
		169 min	11	0.194	1.3607	-2.27	-0.039	3.37
		170 min	11	0.153	1.3355	-2.32	-0.075	3.21
		171 min	11	0.158	1.2690	-2.26	-0.045	2.93
		172 min	10	0.204	1.2717	-2.27	0.066	2.87
		173 min	10	0.114	1.2140	-2.31	0.050	2.61
		174 min	10	0.159	1.2406	-2.31	-0.025	2.54
		175 min	10	0.149	1.1931	-2.31	-0.014	2.27
		176 min	10	0.176	1.2147	-2.32	0.042	2.38
		177 min	10	0.166	1.2748	-2.31	-0.043	2.63
		178 min	10	0.065	1.1531	-2.32	-0.041	2.03
		179 min	10	0.167	1.2799	-2.40	0.025	2.55
		180 min	10	0.164	1.2917	-2.32	-0.019	2.63

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 143 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	181 min	10	0.114	1.1996	-2.32	-0.001	2.20
		182 min	9	-0.131	0.9454	-2.16	-0.040	1.10
		183 min	9	-0.221	0.8784	-2.15	-0.216	0.90
		184 min	9	-0.252	0.9335	-2.42	-0.144	0.90
		185 min	9	-0.245	0.9262	-2.35	-0.344	0.88
		186 min	9	-0.295	0.9125	-2.36	-0.195	0.89
		187 min	9	-0.269	0.8934	-2.28	-0.154	0.92
		188 min	9	-0.257	0.8998	-2.33	-0.226	0.92
		189 min	10	0.468	2.0817	-2.40	-0.185	5.44
		190 min	10	0.047	1.1938	-2.39	-0.112	2.32
		191 min	10	0.059	1.1104	-2.32	0.017	2.08
		192 min	10	0.015	1.1489	-2.40	-0.057	2.13
		193 min	10	0.047	1.1781	-2.34	0.037	2.37
		194 min	10	0.025	1.1451	-2.37	0.001	2.18
		195 min	10	0.014	1.2048	-2.40	-0.016	2.37
		196 min	10	0.074	1.2110	-2.28	0.038	2.56
		197 min	11	-0.019	1.1358	-2.18	-0.066	2.47
		198 min	11	-0.049	1.1085	-2.39	-0.078	2.15
		199 min	11	-0.060	1.0990	-2.41	-0.046	2.09
		200 min	11	0.063	1.1147	-2.42	0.214	2.05
		201 min	11	0.504	1.9436	-2.33	0.188	5.34
		202 min	12	0.043	1.0812	-2.37	0.108	2.31
		203 min	12	0.039	1.1165	-2.36	0.113	2.48
		204 min	12	0.029	1.1641	-2.43	0.120	2.60
		205 min	12	0.076	1.0416	-1.95	0.086	2.48
		206 min	12	0.050	1.1325	-2.31	0.085	2.61
		207 min	11	0.054	1.2493	-2.49	0.070	2.68
		208 min	11	0.083	1.2086	-2.41	0.093	2.55
		209 min	11	0.129	1.1691	-2.13	0.093	2.56
		210 min	11	0.110	1.1267	-1.97	0.031	2.57

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 144 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	7	211 min	12	0.071	1.0541	-1.96	0.049	2.53
		212 min	12	0.102	1.1024	-2.05	0.057	2.64
		213 min	12	0.033	1.0840	-2.18	0.048	2.48
		214 min	12	0.086	1.1493	-2.32	0.070	2.60
		215 min	12	0.091	1.1456	-2.42	0.132	2.58
		216 min	12	0.056	1.1131	-2.42	0.078	2.45
		217 min	12	0.183	1.1573	-2.32	0.085	2.51
		218 min	12	0.312	1.3496	-2.32	0.136	2.88
		219 min	12	0.045	1.0874	-2.48	0.031	2.38
		220 min	12	0.011	1.0724	-2.39	0.013	2.31
		221 min	11	0.052	1.1228	-2.47	0.036	2.34
		222 min	11	0.081	1.1015	-2.37	0.124	2.31
		223 min	11	0.073	1.1744	-2.41	0.073	2.63
		224 min	11	0.105	1.1611	-2.41	0.059	2.56
		225 min	10	0.062	1.1939	-2.33	0.058	2.51
		226 min	10	0.048	1.1781	-2.35	0.057	2.42
		227 min	10	0.039	1.1547	-2.28	0.063	2.37
		228 min	10	0.399	0.9271	-0.80	0.197	2.47
		229 min	10	0.042	1.1089	-2.11	0.052	2.37
		230 min	11	0.004	1.1157	-2.08	0.025	2.57
		231 min	11	-0.025	1.1472	-2.21	0.056	2.54
		232 min	11	0.005	1.1223	-2.10	0.023	2.58
		233 min	11	0.012	1.1267	-2.06	0.057	2.61
		234 min	11	-0.039	1.1936	-2.43	-0.064	2.57
		235 min	12	0.032	1.0940	-2.01	-0.034	2.73
		236 min	12	-0.057	1.0222	-2.12	-0.095	2.31
		237 min	12	0.027	1.1001	-2.02	-0.130	2.72
		238 min	12	-0.009	1.0663	-2.07	-0.132	2.35
		239 min	12	-0.009	1.0580	-2.03	-0.129	2.28
		240 min	1	-2.050		-2.05	-2.050	-2.05

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 145 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	1 min	12	0.476	1.1573	-0.57	0.048	3.90
		2 min	12	2.332	2.6221	-0.81	1.690	6.71
		3 min	12	3.231	2.7466	-0.01	3.616	6.48
		4 min	12	4.116	2.5900	0.33	5.698	6.73
		5 min	12	4.763	2.6924	-0.14	6.042	6.80
		6 min	12	4.403	2.5831	0.14	6.154	6.67
		7 min	12	4.893	2.3405	-0.29	6.204	6.88
		8 min	12	4.691	2.5947	-0.00	5.474	7.42
		9 min	12	5.370	1.4915	1.60	5.736	6.97
		10 min	12	4.806	2.2515	1.05	5.372	7.15
		11 min	12	4.465	2.4051	0.11	5.146	6.94
		12 min	12	4.262	2.6962	-0.01	5.263	7.04
		13 min	12	4.290	2.4890	-0.07	5.152	6.92
		14 min	12	3.965	2.5571	-0.20	4.468	6.81
		15 min	12	3.529	2.8136	-0.35	3.922	6.65
		16 min	12	3.271	3.0123	-0.27	3.153	7.07
		17 min	12	3.182	3.0113	-0.61	2.997	6.84
		18 min	12	3.119	3.0829	-0.69	2.555	6.87
		19 min	12	3.009	3.0382	-0.70	2.374	6.66
		20 min	12	2.869	3.1619	-0.88	1.622	7.04
		21 min	11	3.066	3.1207	-0.79	1.676	6.70
		22 min	10	2.646	3.0924	-0.81	1.216	6.48
		23 min	10	2.658	3.1909	-1.02	1.199	6.93
		24 min	10	2.643	3.2302	-0.76	0.957	6.86
		25 min	10	2.463	3.1314	-0.84	0.946	6.77
		26 min	10	2.420	3.1243	-0.78	1.025	6.91
		27 min	10	2.058	3.0975	-0.76	0.583	6.89
		28 min	10	2.091	3.0396	-0.77	0.957	6.73
		29 min	10	1.983	3.0573	-0.71	0.475	6.67
		30 min	10	1.924	2.9920	-0.61	0.361	6.40

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 146 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	31 min	10	1.830	2.8546	-0.68	0.321	6.22
		32 min	10	1.871	2.7799	-0.63	0.569	6.16
		33 min	10	1.815	2.8867	-0.80	0.223	6.40
		34 min	10	1.655	2.6645	-0.68	0.173	6.23
		35 min	10	1.598	2.5380	-0.63	0.161	5.29
		36 min	11	1.522	2.7035	-0.64	-0.097	6.11
		37 min	11	1.374	2.6092	-0.79	-0.055	6.19
		38 min	12	1.522	2.4778	-0.81	0.172	6.14
		39 min	12	1.437	2.3055	-0.86	0.173	5.03
		40 min	12	1.474	2.3916	-0.80	0.167	5.81
		41 min	12	0.999	2.0955	-0.55	-0.142	6.15
		42 min	12	1.140	1.9710	-0.42	0.153	6.10
		43 min	12	0.911	1.6980	-0.44	0.185	4.95
		44 min	12	0.801	1.6476	-0.48	0.063	4.27
		45 min	11	0.980	1.8735	-0.36	0.459	5.83
		46 min	12	0.989	2.0071	-0.37	0.174	5.99
		47 min	12	0.858	2.1043	-1.58	0.172	5.80
		48 min	12	0.697	1.8406	-1.37	0.185	5.92
		49 min	12	0.851	2.0231	-1.56	0.157	5.68
		50 min	11	0.497	1.4803	-1.65	-0.081	4.06
		51 min	11	0.481	1.5196	-1.73	-0.141	4.03
		52 min	11	0.505	1.5637	-1.70	-0.103	3.96
		53 min	12	0.648	1.5373	-1.67	-0.021	3.90
		54 min	12	0.790	1.7015	-1.62	-0.037	4.25
		55 min	12	0.760	1.6891	-1.67	-0.029	3.88
		56 min	12	0.760	1.6262	-1.56	-0.090	3.78
		57 min	12	0.856	1.7632	-1.66	-0.051	3.90
		58 min	12	0.798	1.7162	-1.71	-0.067	3.85
		59 min	12	0.660	1.5572	-1.77	-0.037	4.07
		60 min	12	0.606	1.4953	-1.66	-0.023	4.27

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 147 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	61 min	12	0.678	1.5350	-1.43	0.243	4.45
		62 min	12	0.646	1.5028	-1.66	0.349	4.44
		63 min	11	0.809	1.6525	-1.59	0.573	4.64
		64 min	11	1.069	2.0165	-1.60	0.636	4.93
		65 min	11	1.098	2.0854	-1.56	0.605	5.17
		66 min	11	0.995	2.1521	-1.67	0.570	5.20
		67 min	11	0.600	1.6225	-1.79	0.489	4.64
		68 min	11	0.633	1.6251	-1.78	0.352	4.80
		69 min	11	0.645	1.6483	-1.79	0.564	4.85
		70 min	10	0.749	1.3994	-0.26	0.197	4.47
		71 min	10	0.861	1.3489	-0.56	0.436	3.95
		72 min	9	0.727	1.3840	-0.76	0.269	4.05
		73 min	9	0.719	1.5573	-0.65	0.223	4.48
		74 min	9	0.959	1.2478	-0.66	0.650	3.48
		75 min	9	0.600	1.3207	-0.80	0.235	3.40
		76 min	9	0.540	1.3094	-1.00	0.234	3.40
		77 min	9	0.626	1.1857	-0.59	0.297	3.36
		78 min	9	0.458	1.0582	-0.81	0.245	2.86
		79 min	9	0.408	1.1703	-0.97	0.145	2.95
		80 min	9	0.384	1.0527	-0.88	0.183	2.45
		81 min	9	0.417	1.0699	-0.91	0.150	2.56
		82 min	9	0.312	1.1176	-0.97	0.100	2.81
		83 min	9	0.646	1.0340	-0.45	0.578	2.92
		84 min	9	0.713	1.1435	-0.41	0.549	3.18
		85 min	9	0.732	1.1556	-0.19	0.508	3.49
		86 min	9	1.167	1.8914	-0.41	0.557	5.20
		87 min	9	0.942	1.6456	-0.56	0.504	4.98
		88 min	9	0.613	1.1258	-0.51	0.532	3.27
		89 min	10	0.427	1.5272	-2.38	0.331	3.75
		90 min	10	0.874	1.9617	-2.29	0.688	4.39

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 148 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	91 min	10	0.854	2.2360	-2.18	0.655	6.56
		92 min	10	0.703	2.2216	-2.04	0.337	6.51
		93 min	10	0.538	1.5842	-1.88	0.468	4.40
		94 min	10	0.190	0.7875	-1.72	0.522	0.80
		95 min	9	0.194	0.7977	-1.81	0.454	0.76
		96 min	9	0.467	1.2922	-1.91	0.418	3.12
		97 min	9	0.649	1.6690	-1.84	0.318	4.57
		98 min	9	0.426	1.3495	-1.78	0.243	3.47
		99 min	10	0.056	0.6796	-1.78	0.174	0.66
		100 min	9	0.115	0.7632	-1.75	0.205	0.81
		101 min	9	0.048	0.7109	-1.73	0.150	0.66
		102 min	9	0.041	0.7363	-1.78	0.130	0.77
		103 min	9	0.020	0.7603	-1.82	0.190	0.85
		104 min	10	-0.027	0.7132	-1.80	0.051	0.80
		105 min	10	-0.056	0.6841	-1.78	0.133	0.61
		106 min	10	-0.102	0.6757	-1.61	-0.006	0.79
		107 min	10	-0.072	0.5617	-1.27	-0.021	0.72
		108 min	10	-0.068	0.5931	-1.29	0.066	0.78
		109 min	10	-0.045	0.6129	-1.46	0.052	0.82
		110 min	10	-0.046	0.6267	-1.52	0.044	0.73
		111 min	10	-0.120	0.5393	-1.39	-0.042	0.45
		112 min	10	-0.015	0.5631	-1.28	0.044	0.75
		113 min	11	-0.010	0.5759	-1.34	0.061	0.74
		114 min	11	-0.018	0.5736	-1.28	0.066	0.78
		115 min	11	-0.047	0.5658	-1.37	0.084	0.68
		116 min	11	-0.065	0.6141	-1.48	-0.004	0.79
		117 min	11	-0.068	0.6078	-1.39	-0.020	0.87
		118 min	12	-0.105	0.5811	-1.45	-0.072	0.76
		119 min	12	-0.017	0.5497	-1.03	-0.013	0.93
		120 min	12	-0.020	0.5323	-1.12	0.013	0.89

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 149 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	121 min	12	-0.011	0.4780	-1.06	0.006	0.72
		122 min	12	0.029	0.5501	-1.09	0.056	0.91
		123 min	12	-0.007	0.5444	-1.11	-0.003	1.06
		124 min	12	-0.042	0.5643	-1.19	-0.035	1.08
		125 min	12	-0.053	0.5842	-1.23	-0.078	1.08
		126 min	12	-0.061	0.5356	-1.09	-0.121	1.07
		127 min	12	-0.068	0.5677	-1.23	-0.157	1.09
		128 min	12	-0.023	0.6167	-1.33	-0.083	1.10
		129 min	12	-0.044	0.5531	-1.15	-0.107	1.03
		130 min	12	-0.084	0.5777	-1.17	-0.145	1.03
		131 min	12	-0.090	0.5965	-1.17	-0.125	0.99
		132 min	12	-0.048	0.5984	-1.16	-0.043	0.95
		133 min	12	-0.065	0.5950	-1.28	-0.047	0.92
		134 min	12	-0.046	0.5816	-1.30	-0.014	0.88
		135 min	12	-0.066	0.5933	-1.30	-0.088	1.02
		136 min	12	-0.036	0.6134	-1.18	-0.081	1.18
		137 min	12	-0.058	0.6295	-1.35	-0.059	1.10
		138 min	12	-0.052	0.6153	-1.36	-0.072	1.01
		139 min	12	-0.067	0.6097	-1.38	-0.139	1.02
		140 min	12	-0.001	0.6563	-1.48	-0.048	1.12
		141 min	12	-0.019	0.6640	-1.39	-0.080	1.21
		142 min	12	0.149	0.9160	-1.25	-0.095	2.26
		143 min	12	0.035	0.7024	-1.30	-0.091	1.10
		144 min	12	0.331	1.2980	-1.31	-0.068	3.92
		145 min	12	-0.014	0.6512	-1.39	-0.018	1.10
		146 min	12	-0.046	0.6472	-1.40	-0.086	1.07
		147 min	12	-0.006	0.6684	-1.45	-0.031	1.20
		148 min	12	-0.022	0.6936	-1.52	-0.064	1.26
		149 min	12	-0.033	0.6933	-1.57	-0.011	1.27
		150 min	12	-0.045	0.6994	-1.48	-0.168	1.35

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 150 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	151 min	12	-0.057	0.6442	-1.57	-0.118	1.01
		152 min	12	-0.018	0.7317	-1.63	-0.021	1.37
		153 min	12	-0.012	0.7531	-1.65	-0.071	1.36
		154 min	12	0.041	0.6941	-1.51	0.024	1.35
		155 min	12	0.199	1.0036	-1.45	0.017	2.64
		156 min	12	0.309	1.3792	-1.49	0.051	4.07
		157 min	12	0.309	1.4239	-1.43	0.043	4.29
		158 min	12	0.072	0.8951	-1.59	-0.015	2.01
		159 min	12	0.405	1.7970	-1.49	-0.034	5.71
		160 min	12	0.417	1.5575	-1.59	0.035	4.78
		161 min	12	-0.036	0.7521	-1.56	0.028	1.52
		162 min	12	-0.007	0.7326	-1.53	0.031	1.51
		163 min	12	0.010	0.7306	-1.59	0.027	1.48
		164 min	11	0.028	0.7643	-1.58	0.010	1.48
		165 min	11	0.056	0.7871	-1.67	0.088	1.46
		166 min	11	0.060	0.7664	-1.57	0.071	1.50
		167 min	11	0.289	1.0260	-1.40	0.057	2.39
		168 min	11	0.501	0.9649	-0.53	0.170	2.86
		169 min	11	0.304	0.8745	-1.20	0.159	1.84
		170 min	11	0.124	0.7068	-1.24	0.092	1.52
		171 min	11	0.180	0.7170	-1.22	0.158	1.51
		172 min	10	0.171	0.7263	-1.52	0.290	1.18
		173 min	10	0.081	0.7178	-1.67	0.159	0.92
		174 min	10	0.107	0.7634	-1.61	0.094	0.98
		175 min	10	0.064	0.7805	-1.65	0.025	1.32
		176 min	10	0.070	0.7955	-1.69	0.043	1.34
		177 min	10	0.040	0.7732	-1.60	-0.033	1.34
		178 min	10	-0.053	0.7496	-1.70	-0.035	0.95
		179 min	10	-0.052	0.6917	-1.71	-0.018	0.83
		180 min	10	-0.115	0.7023	-1.79	-0.094	0.82

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 151 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	181 min	10	-0.047	0.7419	-1.70	-0.017	0.87
		182 min	9	-0.165	0.7100	-1.69	-0.073	0.87
		183 min	9	-0.251	0.7140	-1.71	-0.232	0.75
		184 min	9	-0.173	0.7100	-1.69	-0.150	0.76
		185 min	9	-0.217	0.6868	-1.67	-0.276	0.76
		186 min	9	-0.191	0.7507	-1.72	-0.139	0.76
		187 min	9	-0.209	0.7473	-1.74	-0.125	0.80
		188 min	9	-0.164	0.6775	-1.66	-0.123	0.79
		189 min	10	-0.022	0.7739	-1.70	-0.035	0.96
		190 min	10	-0.036	0.6756	-1.59	0.003	0.79
		191 min	10	-0.062	0.6726	-1.69	-0.005	0.78
		192 min	10	-0.020	0.7060	-1.65	0.087	0.88
		193 min	10	-0.045	0.6363	-1.39	0.023	0.83
		194 min	10	-0.027	0.6576	-1.56	0.048	0.83
		195 min	10	-0.048	0.7177	-1.67	0.062	0.89
		196 min	10	0.019	0.7453	-1.66	0.092	1.01
		197 min	11	-0.083	0.5858	-1.43	0.015	0.81
		198 min	11	-0.099	0.6532	-1.67	0.043	0.81
		199 min	11	-0.073	0.6595	-1.65	0.090	0.79
		200 min	11	0.158	1.0218	-1.54	0.123	2.53
		201 min	11	0.249	1.1783	-1.59	0.065	3.15
		202 min	12	0.161	0.9306	-1.67	0.102	2.15
		203 min	12	0.121	0.8577	-1.68	0.139	1.87
		204 min	12	0.184	1.0665	-1.68	0.068	2.85
		205 min	12	0.165	1.1241	-1.79	0.012	3.09
		206 min	12	0.382	1.8330	-1.76	0.003	5.85
		207 min	11	0.437	1.8854	-1.83	0.011	5.69
		208 min	11	0.463	1.9059	-1.86	0.039	5.67
		209 min	11	0.438	1.7178	-1.83	0.106	4.97
		210 min	11	0.358	1.4863	-1.83	-0.051	4.02

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 152 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	8	211 min	12	0.244	1.4475	-1.88	-0.028	4.30
		212 min	12	0.308	1.6055	-1.96	-0.052	4.85
		213 min	12	0.060	0.9757	-2.05	-0.048	2.12
		214 min	12	0.362	1.7899	-2.13	-0.012	5.50
		215 min	12	0.327	1.6290	-2.15	-0.005	4.87
		216 min	12	0.086	1.0738	-2.11	-0.002	2.58
		217 min	12	0.022	0.8077	-1.98	0.015	1.22
		218 min	12	0.261	1.0406	-1.70	0.011	2.47
		219 min	12	0.007	0.6502	-1.70	0.115	0.81
		220 min	12	-0.066	0.6776	-1.80	-0.025	0.91
		221 min	11	-0.045	0.7179	-1.81	0.073	0.95
		222 min	11	-0.025	0.7228	-1.83	0.059	1.02
		223 min	11	-0.065	0.7131	-1.81	-0.009	0.96
		224 min	11	-0.019	0.7115	-1.76	0.074	0.91
		225 min	10	-0.063	0.6940	-1.72	-0.019	0.83
		226 min	10	0.008	0.6230	-1.38	0.093	0.87
		227 min	10	-0.021	0.5455	-1.14	0.021	0.82
		228 min	10	0.117	0.3871	-0.40	0.045	0.82
		229 min	10	0.762	2.0366	-0.40	0.110	6.47
		230 min	11	0.706	1.8842	-0.46	0.232	6.25
		231 min	11	0.147	0.4390	-0.44	0.110	0.76
		232 min	11	-0.012	0.4918	-0.90	0.071	0.63
		233 min	11	-0.074	0.5528	-1.18	0.021	0.81
		234 min	11	-0.063	0.5853	-1.34	0.103	0.82
		235 min	12	-0.061	0.5867	-1.35	0.012	0.83
		236 min	12	-0.013	0.7398	-1.40	-0.034	1.68
		237 min	12	0.317	1.9024	-1.42	-0.122	6.15
		238 min	12	0.291	1.8845	-1.48	-0.208	6.07
		239 min	12	0.371	2.0538	-1.39	-0.087	6.72
		240 min	1	-1.433		-1.43	-1.433	-1.43

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 153 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	1 min	12	0.260	0.9096	-0.13	0.004	3.13
		2 min	12	1.704	2.3933	-0.18	0.222	6.12
		3 min	12	2.579	2.8456	-0.12	1.288	6.70
		4 min	12	3.954	2.9518	-0.28	5.958	6.55
		5 min	12	4.814	2.7677	-0.20	6.160	7.18
		6 min	12	4.935	2.8290	-0.09	6.344	7.51
		7 min	12	4.870	2.7798	-0.15	6.085	7.05
		8 min	12	4.650	2.7897	-0.52	5.774	7.20
		9 min	12	4.574	2.4355	0.05	5.566	7.14
		10 min	12	4.263	2.5210	0.58	5.317	6.78
		11 min	12	4.133	2.6266	-0.28	5.306	6.98
		12 min	12	4.040	2.7441	-0.39	5.064	7.03
		13 min	12	4.195	2.6818	0.06	4.987	7.48
		14 min	12	4.127	2.8592	-0.16	4.878	7.44
		15 min	12	3.567	3.0157	-0.24	3.817	7.00
		16 min	12	3.331	3.1589	-0.28	3.025	7.19
		17 min	12	3.183	3.0249	-0.53	2.612	6.83
		18 min	12	3.174	3.1648	-0.64	2.449	6.88
		19 min	12	3.152	3.2619	-0.72	2.349	6.91
		20 min	12	3.069	3.2926	-0.81	1.943	7.01
		21 min	11	3.238	3.2437	-0.72	2.135	6.88
		22 min	10	2.733	3.3500	-0.82	0.985	6.94
		23 min	10	2.713	3.3675	-0.94	0.914	6.97
		24 min	10	2.626	3.3945	-0.72	0.645	7.02
		25 min	10	2.577	3.4197	-0.80	0.694	6.99
		26 min	10	2.535	3.3249	-0.77	0.652	6.98
		27 min	10	2.479	3.2651	-0.72	0.690	6.99
		28 min	10	2.198	3.1767	-0.77	0.709	6.94
		29 min	10	2.066	3.1428	-0.63	0.643	6.69
		30 min	10	2.082	3.1419	-0.61	0.588	6.72

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 154 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	31 min	10	1.899	2.9873	-0.78	0.306	6.30
		32 min	10	1.904	3.0059	-0.62	0.268	6.39
		33 min	10	1.841	2.9707	-0.61	0.055	6.52
		34 min	10	1.622	2.6706	-0.68	0.059	5.90
		35 min	10	1.610	2.6158	-0.63	0.039	5.89
		36 min	11	1.521	2.7364	-0.61	-0.068	6.22
		37 min	11	1.357	2.4987	-0.55	-0.075	5.87
		38 min	12	1.699	2.6837	-0.66	0.078	6.03
		39 min	12	1.412	2.1845	-0.38	0.023	5.18
		40 min	12	1.409	2.2960	-0.47	0.002	5.61
		41 min	12	1.315	2.3282	-0.44	0.114	6.02
		42 min	12	1.209	2.1206	-0.43	0.201	6.13
		43 min	12	1.057	1.8583	-0.44	0.249	4.96
		44 min	12	0.987	1.9038	-0.48	0.240	5.10
		45 min	11	0.797	1.7123	-0.41	0.138	5.57
		46 min	12	0.907	1.8458	-0.43	0.303	5.79
		47 min	12	0.481	1.7126	-1.01	0.052	5.64
		48 min	12	0.823	1.9034	-1.02	0.092	5.61
		49 min	12	0.907	2.0097	-0.83	0.067	5.45
		50 min	11	0.468	1.5184	-1.14	-0.078	4.58
		51 min	11	0.512	1.5184	-1.07	-0.073	4.59
		52 min	11	0.425	1.4292	-1.26	-0.114	4.09
		53 min	12	0.561	1.4798	-1.21	-0.018	4.48
		54 min	12	0.719	1.6512	-1.21	0.038	4.90
		55 min	12	0.616	1.4150	-1.30	0.004	3.61
		56 min	12	0.505	1.3312	-1.32	-0.133	3.34
		57 min	12	0.631	1.3876	-1.31	-0.024	3.32
		58 min	12	0.538	1.2839	-1.39	-0.066	2.83
		59 min	12	0.497	1.1724	-1.42	-0.009	2.42
		60 min	12	0.570	1.2606	-1.35	0.133	2.63

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 155 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	61 min	12	0.626	1.2730	-1.20	0.087	3.10
		62 min	12	0.900	1.7602	-1.39	0.151	5.31
		63 min	11	0.971	2.0239	-1.35	0.202	6.08
		64 min	11	1.005	2.1746	-1.45	0.328	6.71
		65 min	11	0.905	1.8984	-1.30	0.274	5.65
		66 min	11	0.781	1.8646	-1.41	0.245	5.55
		67 min	11	0.854	1.7317	-1.43	0.251	3.87
		68 min	11	0.468	1.1536	-1.47	0.248	2.77
		69 min	11	0.596	1.2433	-1.47	0.246	2.88
		70 min	10	0.802	1.2462	-0.52	0.266	2.98
		71 min	10	0.658	1.0690	-0.84	0.397	2.63
		72 min	9	0.601	1.0520	-0.77	0.287	2.62
		73 min	9	0.552	1.0981	-0.76	0.234	2.74
		74 min	9	0.717	1.3709	-0.66	0.240	3.05
		75 min	9	0.591	1.3413	-0.84	0.186	3.02
		76 min	9	0.471	1.1707	-0.92	0.213	2.87
		77 min	9	0.506	1.0172	-0.71	0.245	2.34
		78 min	9	0.212	0.5642	-0.76	0.236	0.95
		79 min	9	0.165	0.7061	-0.87	0.114	1.51
		80 min	9	0.191	0.7458	-0.91	0.177	1.58
		81 min	9	0.191	0.6911	-0.96	0.113	1.55
		82 min	9	0.101	0.6223	-0.78	0.120	1.27
		83 min	9	0.227	0.6692	-0.69	0.147	1.56
		84 min	9	0.503	0.8711	-0.46	0.211	2.13
		85 min	9	0.605	1.2147	-0.39	0.113	3.48
		86 min	9	0.801	1.7532	-0.33	0.215	5.31
		87 min	9	1.058	1.6764	-0.49	0.340	3.97
		88 min	9	0.082	0.4988	-0.36	-0.167	1.13
		89 min	10	0.081	0.6689	-1.43	0.152	1.06
		90 min	10	0.537	1.5791	-1.48	0.086	4.60

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 156 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	91 min	10	0.550	1.9168	-1.50	0.186	5.61
		92 min	10	0.168	0.9781	-1.46	0.064	2.19
		93 min	10	0.430	1.5110	-1.41	0.068	4.34
		94 min	10	0.063	0.7107	-1.50	0.126	1.01
		95 min	9	0.006	0.6973	-1.49	0.233	0.92
		96 min	9	-0.025	0.6611	-1.32	0.034	0.96
		97 min	9	0.026	0.6898	-1.52	0.131	0.89
		98 min	9	-0.071	0.5722	-1.15	0.019	0.91
		99 min	10	0.238	0.5109	-0.36	0.114	1.34
		100 min	9	-0.085	0.6269	-1.38	-0.059	0.93
		101 min	9	-0.059	0.6111	-1.39	0.017	0.81
		102 min	9	-0.019	0.6232	-1.40	0.071	0.82
		103 min	9	-0.057	0.6312	-1.47	-0.060	0.73
		104 min	10	-0.082	0.5844	-1.43	-0.069	0.73
		105 min	10	-0.305	0.9185	-2.38	-0.057	0.65
		106 min	10	-0.058	0.5079	-1.09	0.048	0.58
		107 min	10	0.046	0.6316	-0.94	0.061	1.11
		108 min	10	0.017	0.3763	-0.48	0.054	0.61
		109 min	10	0.022	0.4317	-0.88	0.101	0.57
		110 min	10	-0.002	0.4591	-1.03	0.097	0.45
		111 min	10	-0.004	0.5029	-1.06	0.005	0.70
		112 min	10	-0.020	0.4506	-0.95	0.031	0.53
		113 min	11	0.010	0.4115	-0.91	0.017	0.49
		114 min	11	0.007	0.4315	-0.88	0.016	0.66
		115 min	11	-0.008	0.4249	-0.96	0.085	0.57
		116 min	11	-0.027	0.4495	-1.02	-0.043	0.60
		117 min	11	-0.035	0.4286	-1.03	-0.021	0.50
		118 min	12	-0.121	0.4067	-0.95	-0.087	0.45
		119 min	12	-0.033	0.4058	-0.76	0.007	0.63
		120 min	12	0.023	0.4059	-0.81	0.031	0.60

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 157 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	121 min	12	0.088	0.5268	-0.84	0.052	1.27
		122 min	12	0.085	0.5524	-0.92	0.078	1.19
		123 min	12	0.109	0.5211	-0.81	0.108	1.12
		124 min	12	-0.033	0.4484	-0.95	-0.041	0.83
		125 min	12	-0.076	0.3759	-1.00	-0.047	0.33
		126 min	12	-0.051	0.3838	-0.77	-0.087	0.78
		127 min	12	-0.024	0.3920	-0.80	-0.056	0.83
		128 min	12	-0.018	0.4244	-0.89	-0.019	0.77
		129 min	12	-0.041	0.4501	-0.97	-0.044	0.87
		130 min	12	-0.057	0.5116	-1.15	-0.085	0.91
		131 min	12	0.203	1.1216	-1.43	-0.001	3.37
		132 min	12	0.272	1.2618	-1.15	-0.004	4.03
		133 min	12	-0.024	0.4303	-0.90	-0.010	0.70
		134 min	12	-0.022	0.4534	-0.99	-0.049	0.67
		135 min	12	-0.044	0.4436	-0.95	-0.061	0.76
		136 min	12	-0.013	0.5150	-0.89	-0.083	1.02
		137 min	12	-0.015	0.3944	-0.54	-0.059	0.75
		138 min	12	0.051	0.4667	-0.83	-0.027	0.89
		139 min	12	-0.088	0.4539	-1.02	-0.115	0.72
		140 min	12	0.367	1.3303	-1.02	-0.004	4.31
		141 min	12	0.086	0.5209	-0.84	-0.034	1.01
		142 min	12	0.013	0.4277	-0.83	-0.075	0.77
		143 min	12	0.016	0.4763	-0.90	-0.031	0.84
		144 min	12	0.273	0.9958	-0.94	0.034	3.11
		145 min	12	0.020	0.4689	-1.05	-0.013	0.88
		146 min	12	0.338	1.2872	-0.97	0.009	4.15
		147 min	12	0.071	0.5116	-1.00	0.054	0.96
		148 min	12	0.324	1.3046	-1.09	-0.015	4.12
		149 min	12	0.006	0.5367	-1.13	-0.049	0.97
		150 min	12	0.046	0.5727	-1.04	-0.092	1.05

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 158 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	151 min	12	-0.014	0.5310	-1.12	-0.057	1.06
		152 min	12	-0.012	0.5914	-1.16	-0.171	1.17
		153 min	12	-0.015	0.6036	-1.15	-0.017	1.18
		154 min	12	0.437	1.6175	-1.20	0.034	5.28
		155 min	12	0.463	1.7443	-1.16	-0.011	5.72
		156 min	12	0.473	1.6376	-1.10	0.002	5.39
		157 min	12	0.575	1.6593	-1.10	0.026	5.37
		158 min	12	0.632	1.8419	-1.04	-0.046	5.82
		159 min	12	0.701	1.9399	-1.02	0.006	6.06
		160 min	12	0.747	1.8891	-1.22	0.027	5.65
		161 min	12	0.257	1.2362	-1.15	0.028	3.69
		162 min	12	0.313	1.2158	-0.84	0.049	3.79
		163 min	12	0.522	1.2367	-0.76	0.002	3.34
		164 min	11	0.384	0.9908	-1.02	0.136	2.75
		165 min	11	0.223	0.7150	-1.22	0.062	1.10
		166 min	11	0.385	0.5831	-0.35	0.265	1.42
		167 min	11	0.775	1.6154	-0.35	0.085	5.22
		168 min	11	0.963	1.8070	-0.43	0.121	5.32
		169 min	11	1.147	1.9387	-0.35	0.506	5.25
		170 min	11	0.563	1.2945	-0.97	0.123	3.81
		171 min	11	0.510	1.0157	-0.32	0.104	3.20
		172 min	10	0.287	0.6352	-0.97	0.351	1.29
		173 min	10	0.285	0.7533	-1.19	0.235	1.50
		174 min	10	0.082	0.6262	-1.22	0.104	0.94
		175 min	10	0.063	0.5834	-1.20	0.106	1.05
		176 min	10	0.047	0.5661	-1.28	0.095	0.75
		177 min	10	-0.066	0.5205	-1.20	-0.121	0.71
		178 min	10	-0.004	0.5815	-1.29	-0.033	0.95
		179 min	10	-0.005	0.5611	-1.26	-0.021	0.88
		180 min	10	-0.098	0.5899	-1.42	-0.101	0.63

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 159 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	181 min	10	-0.083	0.5400	-1.30	-0.045	0.77
		182 min	9	-0.146	0.5256	-1.30	-0.057	0.59
		183 min	9	-0.263	0.5497	-1.39	-0.213	0.45
		184 min	9	-0.191	0.5262	-1.37	-0.064	0.46
		185 min	9	-0.223	0.5154	-1.31	-0.283	0.44
		186 min	9	-0.080	0.6596	-1.31	-0.145	0.99
		187 min	9	-0.198	0.5387	-1.34	-0.209	0.49
		188 min	9	0.266	1.5147	-1.33	-0.063	4.06
		189 min	10	-0.124	0.5327	-1.37	-0.037	0.47
		190 min	10	-0.069	0.5181	-1.26	0.016	0.54
		191 min	10	-0.042	0.5701	-1.42	0.063	0.57
		192 min	10	0.083	0.7884	-1.33	0.095	1.72
		193 min	10	-0.008	0.3867	-0.43	-0.033	0.56
		194 min	10	0.287	1.2272	-1.18	0.127	3.49
		195 min	10	0.475	1.9075	-1.31	0.089	5.66
		196 min	10	0.326	1.3870	-1.35	0.085	3.96
		197 min	11	0.030	0.7171	-1.08	0.100	1.69
		198 min	11	-0.089	0.5172	-1.27	-0.076	0.52
		199 min	11	0.181	0.8584	-1.19	0.110	2.23
		200 min	11	0.083	0.6300	-0.99	0.042	1.28
		201 min	11	0.441	1.6097	-1.03	0.004	5.04
		202 min	12	0.914	2.2004	-1.21	0.096	5.50
		203 min	12	0.882	2.0777	-1.18	0.111	5.62
		204 min	12	0.504	1.8059	-1.32	0.017	5.80
		205 min	12	0.537	1.8448	-1.47	0.093	5.84
		206 min	12	0.450	1.7921	-1.36	0.005	5.79
		207 min	11	0.435	1.8667	-1.42	0.024	5.80
		208 min	11	0.428	1.7694	-1.40	0.094	5.47
		209 min	11	0.345	1.4775	-1.38	0.070	4.45
		210 min	11	0.303	1.5545	-1.76	-0.003	4.58

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 160 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	9	211 min	12	0.308	1.5870	-1.59	-0.007	5.03
		212 min	12	0.348	1.5353	-1.45	0.004	4.89
		213 min	12	0.395	1.5559	-1.08	-0.011	5.10
		214 min	12	0.455	1.5994	-0.53	-0.039	5.40
		215 min	12	0.368	1.5059	-0.95	-0.013	4.95
		216 min	12	0.338	1.6566	-2.04	0.021	5.07
		217 min	12	0.631	1.9168	-1.48	0.025	6.08
		218 min	12	0.642	1.9577	-1.43	-0.012	6.21
		219 min	12	0.410	1.4963	-1.20	-0.011	4.85
		220 min	12	0.164	1.1373	-1.47	-0.079	3.38
		221 min	11	0.340	1.4340	-1.39	-0.037	4.32
		222 min	11	0.426	1.6763	-1.30	-0.068	5.17
		223 min	11	0.163	0.9303	-1.31	-0.117	2.30
		224 min	11	0.050	0.3826	-0.42	-0.048	0.90
		225 min	10	0.714	2.2312	-0.43	-0.050	7.00
		226 min	10	1.198	2.5328	-0.40	0.141	7.07
		227 min	10	0.819	2.2948	-0.36	0.089	7.27
		228 min	10	1.059	2.3927	-0.42	0.123	7.41
		229 min	10	0.644	2.0505	-0.35	0.026	6.43
		230 min	11	0.623	1.3703	-0.39	0.175	3.94
		231 min	11	0.169	0.7729	-0.41	0.059	2.29
		232 min	11	0.449	1.7437	-0.84	0.022	5.57
		233 min	11	0.659	1.8549	-0.98	0.022	5.11
		234 min	11	0.081	0.8134	-1.08	0.029	2.18
		235 min	12	0.498	1.7240	-1.16	-0.064	5.19
		236 min	12	0.343	1.7242	-1.16	-0.019	5.65
		237 min	12	0.333	1.8487	-1.21	-0.076	6.04
		238 min	12	0.336	1.8970	-1.14	-0.161	6.23
		239 min	12	0.393	1.9568	-1.12	-0.121	6.49
		240 min	1	-1.134		-1.13	-1.134	-1.13

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 161 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	1 min	12	0.001	0.1764	-0.36	-0.007	0.38
		2 min	12	1.589	2.3844	-0.39	0.313	5.91
		3 min	12	2.903	3.1142	-0.08	1.693	6.66
		4 min	12	4.050	3.0680	-0.01	5.437	7.93
		5 min	12	4.840	2.9445	-0.24	6.192	7.91
		6 min	12	4.922	2.8584	-0.17	6.131	8.06
		7 min	12	4.955	2.9139	-0.37	6.238	8.10
		8 min	12	4.756	2.9325	-0.63	6.169	8.02
		9 min	12	4.811	2.5871	0.13	5.946	7.71
		10 min	12	4.278	2.8146	0.08	6.145	6.98
		11 min	12	4.492	2.7791	-0.23	5.809	7.48
		12 min	12	4.399	2.7590	-0.08	5.573	7.91
		13 min	12	4.424	2.7827	-0.26	5.436	8.37
		14 min	12	4.228	2.9908	-0.48	5.439	8.13
		15 min	12	3.898	2.9200	0.03	4.937	7.74
		16 min	12	3.364	3.1640	-0.20	2.751	7.59
		17 min	12	3.347	3.3172	-0.34	2.654	8.24
		18 min	12	3.428	3.2811	-0.81	3.185	8.11
		19 min	12	3.255	3.3721	-0.81	2.604	8.19
		20 min	12	3.208	3.3828	-0.94	2.435	8.25
		21 min	11	3.384	3.3281	-0.84	3.268	7.83
		22 min	10	2.821	3.1704	-0.86	2.003	6.68
		23 min	10	2.772	3.1925	-0.83	1.680	6.74
		24 min	10	2.604	3.2621	-0.79	0.904	6.66
		25 min	10	2.416	3.3005	-0.98	0.635	6.70
		26 min	10	2.462	3.2826	-0.95	0.631	6.74
		27 min	10	2.189	3.1656	-0.90	0.647	6.69
		28 min	10	2.096	3.1203	-0.82	0.645	6.62
		29 min	10	2.265	3.1518	-0.76	0.644	6.64
		30 min	10	2.265	3.1426	-0.80	0.640	6.62

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 162 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	31 min	10	1.967	3.1356	-0.87	0.183	6.62
		32 min	10	1.904	3.1235	-0.77	0.233	6.53
		33 min	10	1.774	2.9898	-0.65	-0.011	6.40
		34 min	10	1.602	2.6827	-0.72	0.155	5.52
		35 min	10	1.291	2.2884	-0.80	0.093	5.66
		36 min	11	1.515	2.7815	-0.80	-0.019	6.04
		37 min	11	1.380	2.6832	-0.75	-0.069	5.91
		38 min	12	1.776	2.9134	-0.77	0.070	6.26
		39 min	12	1.757	2.6328	-0.57	0.059	5.61
		40 min	12	1.536	2.4601	-0.66	0.023	5.68
		41 min	12	1.606	2.4705	-0.61	0.331	6.03
		42 min	12	1.250	2.2066	-0.63	0.333	6.02
		43 min	12	1.236	2.1457	-0.67	0.393	5.12
		44 min	12	1.163	2.1178	-0.65	0.395	5.29
		45 min	11	1.015	1.8337	-0.73	0.725	5.50
		46 min	12	0.878	1.8243	-0.77	0.292	5.66
		47 min	12	0.685	1.6857	-0.61	0.175	5.45
		48 min	12	0.924	1.9967	-0.89	0.275	5.68
		49 min	12	0.937	1.9980	-0.47	0.155	5.26
		50 min	11	0.576	1.4399	-0.46	0.129	4.47
		51 min	11	0.485	1.4964	-0.65	-0.023	4.43
		52 min	11	0.481	1.4297	-0.81	0.028	4.10
		53 min	12	0.854	1.7126	-0.59	0.063	4.99
		54 min	12	0.893	1.5322	-0.42	0.284	4.51
		55 min	12	0.786	1.5075	-0.53	0.041	4.05
		56 min	12	0.892	1.6262	-0.57	0.101	4.32
		57 min	12	0.808	1.2805	-0.51	0.171	3.08
		58 min	12	0.706	1.1501	-0.36	0.223	3.18
		59 min	12	0.724	1.1315	-0.45	0.191	2.63
		60 min	12	0.643	1.1686	-0.69	0.109	2.95

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 163 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	61 min	12	0.674	1.2376	-0.57	0.037	2.48
		62 min	12	0.818	1.7143	-0.99	0.109	4.89
		63 min	11	0.767	1.8268	-0.93	0.282	5.50
		64 min	11	1.329	2.3931	-1.08	0.682	6.48
		65 min	11	0.862	2.1771	-0.97	0.315	6.79
		66 min	11	0.702	2.0495	-0.99	0.216	6.37
		67 min	11	0.777	1.9057	-0.86	0.213	5.34
		68 min	11	0.672	1.4901	-1.00	0.264	4.16
		69 min	11	0.893	1.9276	-1.08	0.576	5.92
		70 min	10	0.875	2.0188	-0.76	0.252	6.14
		71 min	10	0.908	2.0947	-0.58	0.043	6.26
		72 min	9	1.064	1.8016	-0.68	0.636	5.33
		73 min	9	1.026	2.0992	-0.89	0.393	5.99
		74 min	9	0.779	1.6535	-0.94	0.248	4.01
		75 min	9	0.243	0.9983	-1.03	0.229	2.36
		76 min	9	0.146	0.7564	-0.93	0.245	1.52
		77 min	9	0.212	0.7178	-0.91	0.269	1.40
		78 min	9	0.275	0.7511	-0.89	0.257	1.50
		79 min	9	0.090	0.7601	-0.87	0.149	1.64
		80 min	9	0.192	0.8217	-0.84	0.234	1.67
		81 min	9	0.161	0.7756	-0.91	0.229	1.74
		82 min	9	0.050	0.7758	-0.97	0.144	1.54
		83 min	9	0.316	0.5650	-0.33	0.248	1.60
		84 min	9	0.496	1.0224	-0.57	0.244	2.42
		85 min	9	0.145	0.5540	-0.64	0.124	1.29
		86 min	9	0.321	0.6210	-0.69	0.406	1.25
		87 min	9	1.224	2.1130	-0.79	0.439	5.39
		88 min	9	0.401	1.0201	-0.50	0.128	2.65
		89 min	10	0.493	1.0226	-0.89	0.214	2.31
		90 min	10	1.166	2.2585	-0.97	0.304	5.74

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 164 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	91 min	10	1.158	2.3928	-1.72	0.368	5.93
		92 min	10	1.192	1.8307	-0.38	0.355	4.45
		93 min	10	0.776	1.8250	-1.16	0.207	4.55
		94 min	10	0.518	1.5757	-1.22	0.210	4.64
		95 min	9	0.615	1.4751	-0.99	0.457	4.17
		96 min	9	0.464	1.3495	-1.10	0.131	3.64
		97 min	9	0.412	1.2398	-1.16	0.134	3.31
		98 min	9	0.310	1.4321	-1.22	0.035	3.78
		99 min	10	0.440	1.4736	-1.13	0.085	4.33
		100 min	9	0.491	1.5954	-0.79	0.142	4.54
		101 min	9	0.404	1.2563	-0.97	0.131	3.47
		102 min	9	0.190	0.7323	-0.97	0.144	1.57
		103 min	9	0.210	0.7922	-0.92	0.197	1.77
		104 min	10	0.037	0.4424	-0.57	0.102	0.77
		105 min	10	-0.021	0.3827	-0.44	-0.141	0.69
		106 min	10	0.030	0.4352	-0.79	0.099	0.66
		107 min	10	-0.062	0.4564	-0.75	0.005	0.56
		108 min	10	0.194	0.4558	-0.45	0.090	0.90
		109 min	10	0.094	0.3753	-0.47	0.104	0.68
		110 min	10	0.437	1.4766	-0.71	0.075	4.52
		111 min	10	-0.052	0.4626	-0.83	-0.029	0.73
		112 min	10	-0.028	0.3734	-0.61	-0.051	0.56
		113 min	11	0.038	0.2936	-0.40	0.044	0.54
		114 min	11	-0.012	0.3357	-0.51	-0.057	0.64
		115 min	11	-0.019	0.2692	-0.39	-0.057	0.44
		116 min	11	-0.042	0.3283	-0.70	0.030	0.39
		117 min	11	0.407	1.5515	-0.72	-0.031	4.96
		118 min	12	-0.117	0.3990	-0.68	-0.253	0.76
		119 min	12	0.186	1.0922	-0.48	-0.080	3.57
		120 min	12	0.417	1.7193	-0.51	0.032	5.81

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 165 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	121 min	12	0.391	1.4263	-0.48	0.057	4.83
		122 min	12	0.765	1.9290	-0.49	0.039	5.16
		123 min	12	0.568	1.4953	-0.47	0.086	4.81
		124 min	12	0.243	1.2013	-0.51	-0.088	3.95
		125 min	12	-0.056	0.3824	-0.55	-0.095	0.86
		126 min	12	-0.011	0.4370	-0.56	0.016	1.07
		127 min	12	0.103	0.5578	-0.47	-0.088	1.29
		128 min	12	0.112	0.7018	-0.57	-0.066	1.52
		129 min	12	0.183	0.9162	-0.63	-0.094	2.46
		130 min	12	-0.015	0.5145	-0.84	-0.069	1.08
		131 min	12	0.816	1.8415	-0.68	-0.097	4.97
		132 min	12	0.342	1.4604	-1.07	-0.102	4.56
		133 min	12	0.136	0.9469	-0.77	-0.076	2.95
		134 min	12	0.184	1.1082	-0.79	-0.091	3.54
		135 min	12	0.126	1.0514	-0.75	-0.156	3.30
		136 min	12	0.302	1.3434	-0.51	-0.109	4.40
		137 min	12	0.400	1.3343	-0.58	-0.088	3.69
		138 min	12	0.182	0.9815	-0.44	-0.101	3.17
		139 min	12	0.124	0.9499	-0.59	-0.111	2.96
		140 min	12	0.519	1.4581	-0.56	-0.067	4.40
		141 min	12	0.493	1.4429	-0.58	-0.038	4.56
		142 min	12	0.514	1.5799	-0.44	-0.041	5.23
		143 min	12	0.491	1.6195	-0.57	0.023	5.40
		144 min	12	0.414	1.3399	-0.52	0.035	4.47
		145 min	12	0.056	0.5089	-0.68	0.017	1.17
		146 min	12	0.190	0.5969	-0.66	0.080	1.09
		147 min	12	0.613	1.5511	-0.58	0.026	5.04
		148 min	12	0.471	1.6262	-0.67	-0.097	5.28
		149 min	12	0.100	0.7391	-0.77	-0.062	1.62
		150 min	12	-0.029	0.5793	-0.64	-0.115	1.24

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 166 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	151 min	12	-0.078	0.5070	-0.82	-0.098	0.85
		152 min	12	0.224	1.0903	-0.82	-0.075	3.21
		153 min	12	-0.098	0.5550	-0.89	-0.109	0.88
		154 min	12	0.412	1.4830	-0.65	-0.001	4.90
		155 min	12	0.449	1.6972	-0.70	0.046	5.64
		156 min	12	0.530	1.5875	-0.67	0.071	5.31
		157 min	12	0.454	1.5989	-0.63	0.034	5.36
		158 min	12	0.368	1.6898	-0.67	-0.010	5.56
		159 min	12	0.423	1.5744	-0.62	0.074	5.27
		160 min	12	0.438	1.6408	-0.89	0.024	5.40
		161 min	12	-0.094	0.5695	-0.81	-0.034	1.13
		162 min	12	0.059	0.4559	-0.50	0.022	1.12
		163 min	12	0.099	0.4191	-0.44	0.047	1.10
		164 min	11	-0.026	0.5175	-0.64	-0.170	1.05
		165 min	11	0.085	0.5465	-0.95	0.101	1.01
		166 min	11	0.503	1.1789	-0.46	0.089	3.72
		167 min	11	0.975	1.9932	-0.53	0.102	5.02
		168 min	11	1.203	2.4074	-0.46	0.103	6.35
		169 min	11	1.263	2.3434	-0.48	0.509	6.32
		170 min	11	0.073	0.5102	-0.53	0.063	1.19
		171 min	11	0.572	1.3427	-0.48	0.065	4.38
		172 min	10	0.527	1.0894	-0.45	0.153	3.40
		173 min	10	0.456	1.2031	-0.58	0.210	3.61
		174 min	10	-0.018	0.5259	-0.79	-0.023	0.94
		175 min	10	0.031	0.4928	-0.53	0.038	0.93
		176 min	10	0.038	0.5477	-0.88	-0.060	1.09
		177 min	10	-0.051	0.5024	-0.57	-0.178	0.98
		178 min	10	0.054	0.4613	-0.45	0.021	0.98
		179 min	10	0.056	0.6018	-0.93	0.027	1.00
		180 min	10	-0.095	0.6194	-1.03	-0.204	0.92

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 167 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	181 min	10	-0.117	0.5163	-0.86	-0.229	1.05
		182 min	9	-0.199	0.3917	-0.93	-0.202	0.31
		183 min	9	-0.303	0.4182	-1.01	-0.458	0.32
		184 min	9	-0.115	0.6493	-1.04	-0.293	1.26
		185 min	9	-0.298	0.4376	-0.96	-0.378	0.42
		186 min	9	0.073	1.0141	-1.03	-0.254	2.54
		187 min	9	0.100	0.7935	-1.06	0.107	1.68
		188 min	9	0.377	1.2094	-1.00	0.098	3.18
		189 min	10	-0.259	0.4786	-1.04	-0.240	0.45
		190 min	10	0.314	1.4795	-0.92	-0.079	4.36
		191 min	10	-0.163	0.4621	-1.13	-0.044	0.38
		192 min	10	0.369	1.7060	-1.05	0.087	5.05
		193 min	10	-0.144	0.4053	-0.75	-0.147	0.35
		194 min	10	-0.070	0.4195	-0.86	-0.012	0.40
		195 min	10	0.329	1.5525	-0.97	0.130	4.51
		196 min	10	0.455	1.7561	-1.02	0.089	5.25
		197 min	11	0.540	1.6728	-0.56	0.170	5.43
		198 min	11	-0.114	0.4407	-0.89	-0.196	0.56
		199 min	11	0.263	1.2213	-0.82	0.111	3.70
		200 min	11	0.067	0.3763	-0.56	0.129	0.63
		201 min	11	0.441	1.8540	-0.61	-0.052	5.90
		202 min	12	0.796	2.0514	-0.92	0.078	5.48
		203 min	12	0.917	2.2805	-0.81	0.087	5.93
		204 min	12	0.415	1.6760	-0.84	0.009	5.53
		205 min	12	0.355	1.6852	-1.13	0.010	5.42
		206 min	12	0.333	1.6350	-1.07	0.008	5.28
		207 min	11	0.298	1.7054	-0.93	-0.113	5.26
		208 min	11	0.304	1.6272	-1.10	-0.031	5.01
		209 min	11	0.304	1.5356	-1.12	-0.036	4.71
		210 min	11	0.260	1.5182	-1.15	-0.074	4.58

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 168 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	10	211 min	12	0.227	1.4364	-1.13	-0.084	4.59
		212 min	12	0.257	1.4473	-1.10	-0.075	4.60
		213 min	12	0.308	1.3579	-0.60	-0.058	4.42
		214 min	12	0.526	1.4628	-0.58	0.080	4.94
		215 min	12	0.601	1.5464	-0.54	0.040	4.62
		216 min	12	0.150	1.6243	-2.80	-0.012	4.47
		217 min	12	0.604	2.1300	-2.73	-0.002	5.32
		218 min	12	0.650	1.7571	-0.58	0.032	5.57
		219 min	12	0.420	1.7134	-0.94	-0.028	5.64
		220 min	12	0.018	0.6195	-1.06	-0.069	1.13
		221 min	11	-0.132	0.5264	-0.99	-0.182	0.95
		222 min	11	0.320	1.3727	-0.74	-0.062	4.20
		223 min	11	0.370	1.4705	-0.54	-0.061	4.59
		224 min	11	0.656	2.3280	-0.58	-0.018	7.54
		225 min	10	0.769	2.6412	-0.71	-0.038	8.16
		226 min	10	1.206	2.7250	-0.52	0.162	8.13
		227 min	10	0.769	2.5703	-0.60	-0.036	7.96
		228 min	10	0.754	2.5624	-0.53	-0.048	7.98
		229 min	10	-0.119	0.3519	-0.65	-0.102	0.43
		230 min	11	0.201	1.0412	-0.94	0.150	2.96
		231 min	11	-0.146	0.4495	-0.86	-0.182	0.75
		232 min	11	0.342	1.6745	-0.93	0.044	5.23
		233 min	11	-0.066	0.5288	-0.78	-0.155	1.08
		234 min	11	-0.059	0.6694	-0.88	-0.238	1.56
		235 min	12	0.491	1.6397	-0.85	-0.063	4.45
		236 min	12	0.308	1.6946	-1.01	-0.112	5.55
		237 min	12	0.235	1.7705	-0.98	-0.183	5.69
		238 min	12	0.220	1.7829	-1.14	-0.155	5.69
		239 min	12	0.259	1.9232	-0.99	-0.214	6.25
		240 min	1	-0.927		-0.93	-0.927	-0.93

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 169 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	1 min	12	0.115	1.2752	-2.64	0.071	3.22
		2 min	12	0.853	2.4703	-2.78	0.123	7.27
		3 min	12	2.535	3.4160	-2.64	1.215	8.22
		4 min	12	3.329	3.0624	-0.01	2.861	8.24
		5 min	12	4.036	3.0819	0.08	4.280	8.93
		6 min	12	4.039	3.0220	-0.01	4.056	8.87
		7 min	12	4.179	3.0467	-0.18	4.641	8.91
		8 min	12	4.231	3.0734	-0.32	4.334	8.97
		9 min	12	4.534	2.7015	-0.16	4.724	8.87
		10 min	12	4.246	2.8733	-0.38	4.324	8.86
		11 min	12	4.162	2.9711	-0.40	4.766	8.69
		12 min	12	4.116	2.9705	-0.49	4.449	9.09
		13 min	12	3.851	2.7795	-0.21	4.003	8.80
		14 min	12	3.804	2.8013	-0.40	3.592	8.78
		15 min	12	3.979	2.7903	-0.14	3.843	8.52
		16 min	12	3.261	2.8890	-0.59	2.730	8.62
		17 min	12	3.154	3.0534	-0.56	3.540	8.83
		18 min	12	3.374	2.8880	-0.42	3.673	8.92
		19 min	12	3.217	2.9108	-0.23	2.642	9.17
		20 min	12	2.574	3.5581	-3.59	2.210	8.88
		21 min	11	3.070	2.9719	-0.30	2.533	8.62
		22 min	10	2.293	2.5003	-0.40	1.758	6.36
		23 min	10	2.273	2.5815	-0.48	1.801	6.52
		24 min	10	1.742	3.2300	-3.31	0.726	6.70
		25 min	10	1.660	3.4284	-4.37	0.736	6.68
		26 min	10	1.649	3.4210	-4.41	0.776	6.72
		27 min	10	1.610	3.3167	-4.04	0.681	6.70
		28 min	10	1.913	2.6242	-0.25	0.902	6.64
		29 min	10	1.945	2.6190	-0.28	1.146	6.76
		30 min	10	1.554	3.2260	-3.94	0.741	6.75

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 170 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	31 min	10	1.397	3.2128	-3.56	0.066	6.56
		32 min	10	1.528	3.1728	-3.52	0.543	6.63
		33 min	10	1.591	2.7441	-1.12	0.148	6.43
		34 min	10	0.874	3.3213	-4.35	0.067	6.22
		35 min	10	1.496	2.4777	-2.42	0.844	5.20
		36 min	11	0.682	2.7746	-3.81	-0.127	5.03
		37 min	11	1.045	2.4848	-3.45	-0.050	4.78
		38 min	12	1.624	2.6354	-1.24	0.468	7.58
		39 min	12	1.665	2.7668	-2.64	0.768	7.28
		40 min	12	1.842	2.8623	-2.75	0.813	6.29
		41 min	12	1.463	2.8424	-4.13	0.898	5.87
		42 min	12	1.270	2.6722	-4.16	0.663	5.23
		43 min	12	1.166	2.6098	-2.85	0.480	5.28
		44 min	12	1.494	2.2321	-1.87	1.123	5.77
		45 min	11	0.778	2.0420	-3.76	0.813	3.86
		46 min	12	0.858	2.7709	-4.19	1.021	5.38
		47 min	12	0.931	2.7823	-4.17	0.556	5.07
		48 min	12	0.917	2.6983	-4.23	0.998	5.44
		49 min	12	1.815	1.8904	-0.33	1.391	4.96
		50 min	11	0.639	2.0517	-3.11	0.037	4.94
		51 min	11	0.483	2.1058	-2.68	0.085	5.12
		52 min	11	0.563	2.0614	-2.73	0.084	4.69
		53 min	12	1.013	2.3508	-2.37	0.780	5.69
		54 min	12	1.074	1.9959	-2.27	0.713	4.91
		55 min	12	0.266	2.2137	-4.11	-0.070	4.70
		56 min	12	0.237	2.5487	-3.87	0.424	4.53
		57 min	12	1.231	2.0504	-2.62	1.152	4.25
		58 min	12	1.723	1.9025	-1.09	1.193	5.67
		59 min	12	1.216	1.9184	-1.13	0.684	5.47
		60 min	12	1.275	2.1407	-2.31	0.607	5.42

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 171 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	61 min	12	0.826	2.4943	-3.40	0.654	4.78
		62 min	12	0.917	2.0572	-2.60	0.610	6.11
		63 min	11	0.949	2.1436	-2.34	0.356	6.27
		64 min	11	1.585	1.9326	-0.07	1.023	6.14
		65 min	11	1.145	2.3349	-2.63	0.646	6.30
		66 min	11	0.692	2.2211	-2.92	0.284	6.06
		67 min	11	0.538	2.3294	-2.39	0.310	6.27
		68 min	11	1.105	1.9890	-1.25	0.656	6.24
		69 min	11	1.138	2.2198	-2.29	0.889	6.17
		70 min	10	0.404	2.5244	-2.09	0.056	6.32
		71 min	10	1.417	1.9091	-0.19	1.173	6.26
		72 min	9	2.350	2.1970	0.15	1.819	6.42
		73 min	9	0.864	3.3031	-4.37	0.253	6.39
		74 min	9	1.592	1.8899	-0.06	0.880	5.77
		75 min	9	1.392	2.6011	-2.71	0.761	6.47
		76 min	9	1.821	2.1506	-0.35	1.137	6.20
		77 min	9	0.733	2.8145	-3.24	0.271	6.18
		78 min	9	1.334	2.1552	-1.02	0.694	5.73
		79 min	9	0.113	2.5901	-3.02	-0.215	5.85
		80 min	9	0.807	2.5902	-2.80	0.402	6.15
		81 min	9	1.134	2.4116	-2.43	0.530	5.96
		82 min	9	0.207	2.7793	-3.83	-0.024	6.17
		83 min	9	1.263	2.3666	-1.93	0.856	6.22
		84 min	9	1.179	2.6354	-3.28	0.640	6.26
		85 min	9	1.326	2.3910	-1.98	0.767	6.42
		86 min	9	1.730	2.1227	-0.21	1.034	6.47
		87 min	9	1.392	2.4745	-1.52	0.636	6.71
		88 min	9	0.477	2.8889	-3.33	0.266	6.81
		89 min	10	1.938	1.9562	-0.23	1.646	4.94
		90 min	10	1.679	2.0648	-0.38	0.631	5.87

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 172 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	91 min	10	1.505	2.0877	-0.70	0.599	5.41
		92 min	10	1.041	2.3362	-1.89	0.429	5.90
		93 min	10	1.501	2.2243	-1.06	0.720	6.25
		94 min	10	0.772	1.9992	-3.29	0.474	3.54
		95 min	9	0.412	1.8848	-3.04	0.473	3.46
		96 min	9	1.019	1.4585	-1.46	0.404	2.66
		97 min	9	1.421	1.6632	-0.10	0.848	4.91
		98 min	9	0.322	1.4665	-1.42	0.152	3.27
		99 min	10	0.962	1.3748	-0.87	0.471	3.29
		100 min	9	-0.276	1.5069	-2.96	0.225	1.63
		101 min	9	0.426	1.3672	-2.40	0.399	2.36
		102 min	9	1.233	1.8550	-0.54	0.555	4.99
		103 min	9	0.141	1.4363	-2.36	0.416	1.96
		104 min	10	1.425	2.6108	-2.61	0.616	6.47
		105 min	10	1.177	2.3957	-2.32	0.545	6.75
		106 min	10	1.001	2.4168	-2.41	0.420	6.82
		107 min	10	-0.008	1.2055	-2.43	0.342	1.64
		108 min	10	0.744	1.7739	-2.32	0.424	3.74
		109 min	10	0.313	1.4547	-2.45	0.082	3.29
		110 min	10	0.357	1.4063	-1.90	0.304	3.46
		111 min	10	-0.402	1.2725	-2.80	0.016	0.88
		112 min	10	0.003	1.6892	-2.78	0.220	3.39
		113 min	11	-0.437	1.0761	-2.60	0.069	0.44
		114 min	11	-0.377	0.8745	-2.35	-0.236	0.48
		115 min	11	0.222	1.5889	-2.44	0.118	4.32
		116 min	11	0.054	1.0252	-2.16	0.299	1.91
		117 min	11	0.438	1.8144	-1.47	0.025	4.76
		118 min	12	-0.243	1.1797	-2.17	-0.126	2.30
		119 min	12	-0.203	1.3469	-2.46	-0.117	2.88
		120 min	12	-0.104	1.3803	-2.57	-0.038	3.33

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 173 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	121 min	12	-0.121	1.4614	-3.29	-0.002	2.93
		122 min	12	0.256	1.4563	-2.74	0.128	3.26
		123 min	12	0.173	1.2670	-2.42	0.172	3.27
		124 min	12	-0.213	1.1151	-2.41	-0.078	2.15
		125 min	12	0.237	1.4523	-2.84	0.144	2.89
		126 min	12	0.717	1.8533	-2.79	0.013	3.64
		127 min	12	0.390	1.4952	-2.63	0.036	3.07
		128 min	12	0.199	1.4938	-2.70	-0.016	3.28
		129 min	12	0.566	1.4987	-2.57	0.093	2.75
		130 min	12	0.791	2.5846	-2.73	0.017	5.60
		131 min	12	1.086	2.4036	-2.89	0.080	5.85
		132 min	12	1.123	2.6332	-2.93	0.096	6.59
		133 min	12	0.439	2.9130	-2.80	-0.034	6.79
		134 min	12	0.957	2.8113	-2.88	0.135	6.79
		135 min	12	0.889	2.9829	-3.19	0.050	7.13
		136 min	12	0.458	3.0714	-3.33	-0.052	6.90
		137 min	12	0.463	3.0347	-2.95	-0.010	6.71
		138 min	12	0.696	2.8074	-3.15	0.016	6.32
		139 min	12	0.284	2.2608	-2.70	0.008	6.10
		140 min	12	0.438	2.3543	-2.93	0.023	6.35
		141 min	12	0.428	2.3908	-2.76	-0.005	6.24
		142 min	12	0.484	2.3687	-2.65	0.031	6.17
		143 min	12	0.657	2.0748	-1.48	0.006	6.40
		144 min	12	0.717	1.9355	-1.56	0.101	6.24
		145 min	12	0.680	2.1469	-2.68	0.014	6.22
		146 min	12	0.284	2.1697	-3.44	0.053	6.08
		147 min	12	0.688	2.1497	-2.51	0.084	6.36
		148 min	12	1.061	1.9483	-0.65	0.255	6.30
		149 min	12	1.141	2.0340	-0.51	0.106	6.18
		150 min	12	0.657	2.0980	-2.70	0.114	5.82

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 174 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	151 min	12	0.670	1.7426	-0.77	0.106	5.84
		152 min	12	0.363	2.3132	-2.96	0.071	5.80
		153 min	12	0.357	2.3078	-3.67	0.062	5.99
		154 min	12	0.237	1.8813	-3.64	0.151	3.42
		155 min	12	0.202	2.1359	-3.70	0.064	4.30
		156 min	12	0.215	1.7703	-3.68	0.084	3.23
		157 min	12	0.187	1.6120	-3.70	0.112	2.91
		158 min	12	-0.173	1.6480	-3.68	0.071	3.09
		159 min	12	0.529	2.5000	-3.65	0.106	5.59
		160 min	12	0.179	1.9853	-3.72	0.151	3.43
		161 min	12	-0.642	1.4433	-3.70	0.021	1.21
		162 min	12	-0.301	1.5231	-3.74	0.111	1.10
		163 min	12	-0.429	1.5733	-3.69	0.064	1.57
		164 min	11	-0.658	1.5763	-3.79	-0.174	1.23
		165 min	11	-0.415	1.3918	-3.80	-0.024	1.14
		166 min	11	-0.040	1.5469	-3.72	0.090	2.73
		167 min	11	0.292	2.4099	-3.73	0.092	5.34
		168 min	11	0.277	2.3390	-3.78	-0.007	5.12
		169 min	11	0.426	2.4434	-3.77	0.085	6.08
		170 min	11	0.208	2.8458	-3.74	0.216	5.97
		171 min	11	0.392	2.3566	-3.75	0.249	6.34
		172 min	10	0.872	2.5823	-3.73	0.315	6.59
		173 min	10	0.517	1.7123	-3.80	0.598	2.49
		174 min	10	-0.286	2.4178	-3.70	0.167	4.67
		175 min	10	0.089	2.2043	-3.79	0.171	3.93
		176 min	10	0.053	1.5241	-3.72	0.274	1.92
		177 min	10	-0.051	1.8054	-3.74	0.210	1.97
		178 min	10	-0.286	1.6533	-3.71	0.187	1.13
		179 min	10	-0.110	1.6411	-3.93	0.046	2.48
		180 min	10	-0.244	1.8550	-4.04	-0.038	2.94

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 175 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	181 min	10	0.231	2.5303	-3.98	0.257	5.53
		182 min	9	-0.022	2.2845	-3.59	-0.045	3.92
		183 min	9	-0.840	1.7062	-3.34	-0.312	1.63
		184 min	9	0.737	2.5209	-3.47	0.020	5.60
		185 min	9	0.710	2.1271	-2.90	0.225	4.54
		186 min	9	-0.487	0.9525	-2.68	-0.188	0.49
		187 min	9	0.029	1.8359	-4.05	0.069	2.23
		188 min	9	0.008	1.1345	-1.62	0.047	2.46
		189 min	10	0.410	1.8925	-2.15	0.141	5.13
		190 min	10	1.461	1.9535	0.04	0.695	6.17
		191 min	10	1.135	2.9679	-3.86	0.346	6.29
		192 min	10	1.022	2.5674	-3.91	0.610	6.37
		193 min	10	-0.325	2.1243	-4.15	0.053	3.45
		194 min	10	0.760	2.2404	-3.95	0.409	4.29
		195 min	10	0.441	2.7955	-4.16	0.232	6.04
		196 min	10	0.256	2.3152	-4.27	0.359	4.15
		197 min	11	0.517	1.6814	-1.55	0.012	3.76
		198 min	11	-0.362	1.5142	-3.86	-0.080	1.44
		199 min	11	0.217	1.8501	-4.06	0.165	3.57
		200 min	11	0.539	2.3887	-4.05	0.340	5.33
		201 min	11	0.360	2.4647	-4.09	0.024	5.47
		202 min	12	0.233	1.8065	-4.04	0.149	3.48
		203 min	12	0.212	1.7818	-3.95	0.059	3.08
		204 min	12	-0.154	1.5395	-3.84	-0.013	2.73
		205 min	12	0.182	1.7753	-3.96	0.034	3.03
		206 min	12	-0.200	1.5737	-3.93	-0.037	2.95
		207 min	11	0.139	2.4727	-4.19	0.038	5.13
		208 min	11	0.247	1.6247	-2.68	0.014	2.97
		209 min	11	-0.004	1.6471	-4.01	-0.026	2.36
		210 min	11	-0.259	1.4746	-3.96	-0.069	2.24

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 176 of 176

Table 14.2.1.2 Summary of Change from Baseline in pH Smoothed Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum
B	11	211 min	12	-0.006	1.6492	-4.23	-0.011	2.53
		212 min	12	-0.325	1.6942	-4.09	-0.055	2.71
		213 min	12	-0.507	1.7779	-4.20	-0.118	2.46
		214 min	12	-0.188	2.1292	-4.50	0.071	2.83
		215 min	12	-0.250	1.7846	-4.06	0.044	2.59
		216 min	12	0.794	2.2566	-3.73	0.218	4.56
		217 min	12	0.176	1.8080	-3.95	0.073	3.12
		218 min	12	0.795	2.1397	-3.72	0.239	4.77
		219 min	12	0.792	1.9986	-3.64	0.357	3.79
		220 min	12	0.184	1.9324	-3.82	0.101	4.13
		221 min	11	-0.457	1.6458	-3.89	-0.025	2.43
		222 min	11	0.955	2.7926	-4.12	0.228	6.40
		223 min	11	0.764	2.6715	-2.93	0.142	7.98
		224 min	11	0.134	3.0962	-3.57	0.079	8.29
		225 min	10	0.488	3.5029	-4.00	0.024	8.31
		226 min	10	0.974	2.9726	-3.84	0.215	8.01
		227 min	10	0.696	3.4744	-4.10	0.071	8.01
		228 min	10	1.146	2.9376	-3.37	0.418	8.18
		229 min	10	0.190	2.8314	-2.96	0.062	7.27
		230 min	11	0.320	2.9013	-4.14	0.108	7.00
		231 min	11	0.697	3.1811	-4.21	0.131	7.28
		232 min	11	0.457	2.8651	-4.05	0.066	7.24
		233 min	11	0.969	3.0455	-3.96	0.156	6.89
		234 min	11	0.907	3.0554	-4.13	0.124	7.88
		235 min	12	0.609	3.1546	-4.14	0.053	7.72
		236 min	12	0.559	3.1527	-3.97	0.039	7.86
		237 min	12	0.404	3.3120	-4.07	-0.020	7.40
		238 min	12	0.420	3.2662	-3.76	0.021	7.40
		239 min	12	0.416	3.1808	-3.45	-0.028	7.18
		240 min	1	7.039		7.04	7.039	7.04

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_02.sas

29JAN2013 4:53

14.2.1.3 Summary of pH Original Values by Treatment and Electrode (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	1 min	12	6.448	1.6590	1.31	6.850	7.57	25.7
		2 min	12	6.739	1.7962	1.48	7.000	9.10	26.7
		3 min	12	6.500	1.7279	1.30	6.935	8.15	26.6
		4 min	12	6.458	1.7142	1.42	6.740	8.04	26.5
		5 min	12	6.670	1.6841	1.63	6.990	7.98	25.2
		6 min	12	6.478	1.6608	1.49	6.900	7.71	25.6
		7 min	12	6.688	1.8424	1.32	7.025	8.65	27.6
		8 min	12	6.643	1.7582	1.38	7.040	8.13	26.5
		9 min	12	6.453	1.7162	1.43	6.830	8.47	26.6
		10 min	12	6.484	1.6904	1.50	6.820	8.39	26.1
		11 min	12	6.710	1.8588	1.39	7.005	8.92	27.7
		12 min	12	6.625	1.7475	1.56	6.925	8.89	26.4
		13 min	12	6.633	1.8151	1.43	6.900	8.87	27.4
		14 min	12	6.568	1.7275	1.40	6.790	8.46	26.3
		15 min	12	6.515	1.6781	1.54	6.820	7.93	25.8
		16 min	12	6.270	2.2378	1.57	6.860	9.21	35.7
		17 min	12	6.463	1.9881	1.46	6.855	9.18	30.8
		18 min	12	6.731	1.8120	1.39	7.080	8.31	26.9
		19 min	12	6.768	1.9299	1.47	7.180	9.31	28.5
		20 min	12	6.458	1.8233	1.47	6.980	9.10	28.2
		21 min	12	6.232	1.6206	1.45	6.805	7.33	26.0
		22 min	12	6.548	1.8411	1.39	6.850	9.20	28.1
		23 min	12	6.432	1.7614	1.43	6.775	8.98	27.4
		24 min	12	6.643	1.8438	1.49	6.865	9.13	27.8
		25 min	12	6.462	2.0005	1.35	6.710	8.99	31.0
		26 min	12	6.647	1.8050	1.55	6.835	9.15	27.2
		27 min	11	6.355	1.6523	1.57	6.840	7.57	26.0
		28 min	12	6.923	0.8461	5.36	6.885	8.65	12.2
		29 min	12	6.447	1.7060	1.37	6.835	8.20	26.5
		30 min	12	6.568	1.7272	1.80	6.725	8.97	26.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	31 min	12	6.672	1.7549	1.67	6.935	8.80	26.3
		32 min	11	6.497	1.5770	1.96	6.910	7.79	24.3
		33 min	10	6.651	1.9256	1.85	6.785	8.97	29.0
		34 min	10	6.573	1.7506	2.81	7.020	8.41	26.6
		35 min	10	6.253	2.2350	1.58	6.690	8.32	35.7
		36 min	10	6.314	1.7562	1.79	6.735	8.14	27.8
		37 min	10	6.429	2.0291	1.37	6.660	8.76	31.6
		38 min	10	6.098	2.4261	1.37	6.805	8.60	39.8
		39 min	10	6.064	2.2450	1.35	6.740	8.46	37.0
		40 min	10	6.400	2.3391	1.28	6.695	9.19	36.5
		41 min	10	6.469	2.1919	1.42	6.900	8.73	33.9
		42 min	10	6.532	2.1319	1.12	6.965	8.47	32.6
		43 min	11	6.515	2.1257	1.23	6.820	8.80	32.6
		44 min	11	5.895	2.3247	1.21	6.760	7.96	39.4
		45 min	11	6.476	1.9301	1.20	6.760	7.89	29.8
		46 min	11	6.360	2.0891	1.20	6.770	8.28	32.8
		47 min	11	6.386	2.0652	1.15	6.780	8.89	32.3
		48 min	11	6.359	1.8938	1.21	6.760	8.10	29.8
		49 min	11	6.510	2.0774	1.04	6.540	8.97	31.9
		50 min	11	6.141	2.4586	1.13	6.950	8.06	40.0
		51 min	10	5.950	2.2216	1.26	6.795	8.00	37.3
		52 min	10	6.144	1.8009	1.28	6.655	7.55	29.3
		53 min	10	6.107	1.8395	1.17	6.700	7.61	30.1
		54 min	10	6.352	1.8764	1.29	6.795	8.03	29.5
		55 min	10	6.307	1.8433	1.29	6.710	8.09	29.2
		56 min	10	6.370	1.8942	1.25	6.760	7.98	29.7
		57 min	10	6.439	1.9923	1.19	6.950	8.08	30.9
		58 min	10	6.249	1.8478	1.23	6.670	7.74	29.6
		59 min	10	6.499	1.9605	1.19	7.025	8.00	30.2
		60 min	10	6.058	1.8144	1.02	6.705	7.21	30.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	61 min	10	6.383	1.9161	1.18	6.905	8.14	30.0
		62 min	10	6.455	1.9705	1.14	6.915	8.43	30.5
		63 min	10	5.873	2.0875	1.37	6.755	7.51	35.5
		64 min	10	5.877	2.1589	1.26	6.855	7.48	36.7
		65 min	9	6.198	2.1315	1.25	7.170	8.06	34.4
		66 min	9	5.949	2.4721	1.31	6.970	8.18	41.6
		67 min	8	5.810	2.5497	1.19	6.685	8.02	43.9
		68 min	9	6.336	2.3792	1.28	6.840	8.95	37.6
		69 min	9	6.362	2.2431	1.23	6.800	8.44	35.3
		70 min	9	6.308	2.2047	1.44	7.050	8.27	35.0
		71 min	9	6.108	1.9289	1.54	6.930	7.54	31.6
		72 min	9	6.342	1.9253	1.59	7.150	7.65	30.4
		73 min	9	6.260	2.1409	1.44	6.790	8.08	34.2
		74 min	9	6.239	2.1419	1.05	6.780	8.40	34.3
		75 min	9	6.232	2.1011	1.27	6.690	8.76	33.7
		76 min	9	5.690	2.4341	1.28	6.830	7.78	42.8
		77 min	9	6.344	1.9692	1.28	7.000	7.68	31.0
		78 min	9	6.586	2.1717	1.17	7.300	8.52	33.0
		79 min	9	6.521	2.0682	1.20	7.310	7.70	31.7
		80 min	9	6.304	1.9612	1.31	6.900	7.72	31.1
		81 min	8	5.846	2.1706	1.37	6.510	7.84	37.1
		82 min	8	6.366	2.0823	1.39	6.935	7.70	32.7
		83 min	8	6.061	1.9651	1.40	6.660	7.73	32.4
		84 min	8	6.076	1.7483	1.96	6.660	7.17	28.8
		85 min	8	5.634	2.1906	1.17	6.610	7.55	38.9
		86 min	8	6.031	1.9571	1.41	6.720	7.69	32.4
		87 min	8	6.128	1.9012	1.76	6.580	8.05	31.0
		88 min	8	6.301	2.0766	1.37	6.950	7.85	33.0
		89 min	8	6.146	2.0664	1.35	6.685	8.03	33.6
		90 min	8	6.206	2.0335	1.41	6.780	7.80	32.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	91 min	8	6.075	2.1417	1.52	6.795	8.06	35.3
		92 min	8	6.300	2.2532	1.20	6.880	8.27	35.8
		93 min	8	5.603	2.5516	1.28	6.295	8.31	45.5
		94 min	8	6.249	2.1984	1.38	6.865	8.50	35.2
		95 min	8	6.708	1.0705	5.09	6.660	8.28	16.0
		96 min	8	6.306	2.1285	1.42	6.795	8.07	33.8
		97 min	8	6.174	2.0893	1.29	6.665	7.69	33.8
		98 min	8	6.233	2.0641	1.38	6.830	7.85	33.1
		99 min	8	6.188	2.1202	1.28	6.615	8.17	34.3
		100 min	8	6.263	2.2010	1.23	6.555	8.11	35.1
		101 min	8	6.209	2.0481	1.47	6.595	8.11	33.0
		102 min	8	6.250	1.9873	1.67	6.570	7.88	31.8
		103 min	8	6.349	2.0572	1.55	6.755	7.84	32.4
		104 min	8	6.140	2.0039	1.31	6.870	7.53	32.6
		105 min	8	6.091	2.5166	1.38	6.930	8.14	41.3
		106 min	8	5.951	2.0629	1.15	6.550	7.79	34.7
		107 min	8	6.096	2.1104	1.33	6.610	8.22	34.6
		108 min	8	6.124	2.0504	1.26	6.675	7.70	33.5
		109 min	8	6.311	2.1262	1.35	6.940	7.91	33.7
		110 min	8	6.265	2.1682	1.21	6.940	7.88	34.6
		111 min	8	6.323	2.1354	1.25	7.130	7.86	33.8
		112 min	8	6.163	2.0994	1.22	6.690	7.92	34.1
		113 min	8	5.748	2.2319	1.20	6.505	7.92	38.8
		114 min	8	5.999	2.1442	1.25	6.750	7.89	35.7
		115 min	8	6.266	2.1490	1.21	6.825	7.86	34.3
		116 min	8	6.178	2.1242	1.25	6.705	7.95	34.4
		117 min	8	6.305	2.0315	1.56	6.815	7.80	32.2
		118 min	8	6.190	2.0821	1.23	6.730	8.02	33.6
		119 min	8	6.071	2.0384	1.27	6.580	7.86	33.6
		120 min	8	5.883	1.9984	1.15	6.335	7.80	34.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	121 min	8	6.099	2.0490	1.32	6.610	7.77	33.6
		122 min	8	6.195	2.1006	1.20	6.970	7.71	33.9
		123 min	8	5.794	1.9934	1.32	6.430	7.67	34.4
		124 min	8	6.088	1.9977	1.28	6.570	7.79	32.8
		125 min	8	6.225	2.1204	1.15	6.660	7.82	34.1
		126 min	8	5.625	2.1746	1.13	6.605	7.59	38.7
		127 min	8	6.298	2.0761	1.28	6.875	7.81	33.0
		128 min	8	6.136	2.1103	1.18	6.645	8.02	34.4
		129 min	8	6.188	2.1454	1.16	6.960	8.02	34.7
		130 min	8	6.058	2.0286	1.28	6.585	7.99	33.5
		131 min	8	5.988	2.0276	1.24	6.270	8.03	33.9
		132 min	8	6.126	2.0876	1.28	6.785	8.00	34.1
		133 min	8	6.156	1.9417	1.62	6.585	7.95	31.5
		134 min	8	6.158	2.0299	1.36	6.725	7.94	33.0
		135 min	8	6.156	2.0934	1.21	6.710	8.11	34.0
		136 min	8	6.293	2.0850	1.34	6.870	7.90	33.1
		137 min	8	6.204	2.0725	1.31	6.690	7.91	33.4
		138 min	8	6.363	2.1428	1.33	7.195	7.91	33.7
		139 min	8	6.344	2.2047	1.18	7.130	8.17	34.8
		140 min	8	6.396	2.1208	1.44	7.155	7.90	33.2
		141 min	8	6.331	2.1071	1.35	6.935	7.93	33.3
		142 min	8	5.694	2.6484	1.25	6.605	7.90	46.5
		143 min	8	6.291	2.0202	1.36	6.870	7.46	32.1
		144 min	8	6.220	1.9882	1.40	6.795	7.75	32.0
		145 min	8	6.331	2.1159	1.19	6.860	7.88	33.4
		146 min	8	6.245	2.0888	1.32	6.780	7.87	33.4
		147 min	8	5.745	2.0125	1.30	6.520	7.34	35.0
		148 min	8	6.056	2.0445	1.48	6.495	7.89	33.8
		149 min	8	6.243	2.0336	1.47	6.730	7.84	32.6
		150 min	8	6.196	1.9386	1.52	6.695	7.89	31.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	151 min	8	6.291	2.0613	1.45	6.855	7.90	32.8
		152 min	8	6.209	1.9543	1.49	6.795	7.80	31.5
		153 min	8	6.190	2.0321	1.45	6.715	7.97	32.8
		154 min	8	6.285	2.0302	1.48	6.830	7.94	32.3
		155 min	8	6.203	1.9755	1.55	6.635	7.75	31.8
		156 min	8	6.136	1.9416	1.57	6.760	7.90	31.6
		157 min	8	6.415	2.1129	1.49	7.135	7.89	32.9
		158 min	8	6.449	2.1142	1.50	7.075	7.84	32.8
		159 min	8	6.414	2.0246	1.55	7.030	7.82	31.6
		160 min	8	6.451	2.0226	1.60	7.055	7.82	31.4
		161 min	8	6.470	2.0491	1.52	7.105	7.75	31.7
		162 min	8	6.115	1.9567	1.57	6.380	7.83	32.0
		163 min	8	6.204	1.9573	1.52	6.720	7.74	31.6
		164 min	8	6.389	2.1148	1.42	6.990	7.76	33.1
		165 min	8	6.438	2.1284	1.33	6.830	8.06	33.1
		166 min	8	6.513	2.1265	1.45	7.060	8.05	32.7
		167 min	8	6.548	2.1400	1.50	7.090	8.02	32.7
		168 min	8	6.378	2.0740	1.53	6.860	8.05	32.5
		169 min	8	6.428	2.1163	1.42	6.945	7.83	32.9
		170 min	8	6.246	1.9929	1.55	6.765	7.76	31.9
		171 min	8	6.541	2.1438	1.47	6.830	8.33	32.8
		172 min	8	6.239	1.9549	1.53	6.760	7.64	31.3
		173 min	8	6.525	2.1730	1.41	7.055	8.24	33.3
		174 min	8	6.504	2.1555	1.64	6.735	8.62	33.1
		175 min	8	6.546	2.2218	1.40	7.455	8.26	33.9
		176 min	8	6.445	2.0744	1.48	7.070	7.80	32.2
		177 min	8	6.329	2.1040	1.45	6.810	8.08	33.2
		178 min	8	6.306	2.0263	1.57	6.640	8.16	32.1
		179 min	8	6.574	2.1985	1.40	7.105	8.38	33.4
		180 min	8	6.239	1.9694	1.52	6.615	7.76	31.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	181 min	8	6.396	2.0746	1.44	6.740	7.91	32.4
		182 min	8	6.280	2.0943	1.40	6.865	8.25	33.3
		183 min	8	6.355	2.0964	1.45	6.830	7.90	33.0
		184 min	8	6.308	2.0389	1.44	6.795	7.79	32.3
		185 min	8	6.343	2.1328	1.33	7.010	7.89	33.6
		186 min	7	6.499	2.3372	1.49	7.680	8.07	36.0
		187 min	8	6.559	2.1620	1.47	7.155	8.12	33.0
		188 min	8	6.304	2.0760	1.31	6.905	7.74	32.9
		189 min	8	6.553	2.0862	1.50	7.370	7.70	31.8
		190 min	8	6.216	1.9661	1.48	6.665	7.67	31.6
		191 min	8	6.499	2.1128	1.37	6.970	7.84	32.5
		192 min	8	6.348	1.9657	1.56	6.950	7.61	31.0
		193 min	8	5.887	2.1426	1.48	6.850	7.44	36.4
		194 min	8	6.066	2.1008	1.52	6.995	7.60	34.6
		195 min	8	6.330	1.9908	1.53	6.815	7.77	31.5
		196 min	8	6.408	2.0442	1.51	7.015	8.02	31.9
		197 min	8	6.485	2.0654	1.62	6.950	8.25	31.8
		198 min	8	6.388	1.9815	1.55	6.975	7.51	31.0
		199 min	8	6.151	1.9953	1.49	6.830	7.87	32.4
		200 min	8	6.174	1.9383	1.63	6.545	7.96	31.4
		201 min	8	5.939	1.8833	1.57	6.485	7.60	31.7
		202 min	8	6.021	1.9418	1.53	6.490	7.77	32.2
		203 min	9	6.704	1.9885	1.65	7.410	8.26	29.7
		204 min	9	6.600	2.0581	1.58	7.580	8.22	31.2
		205 min	9	6.351	1.9929	1.44	6.620	8.27	31.4
		206 min	9	5.788	2.3555	1.52	6.670	7.94	40.7
		207 min	8	6.504	2.0597	1.59	7.145	7.91	31.7
		208 min	8	5.636	2.4327	1.56	6.270	7.88	43.2
		209 min	8	5.880	2.3275	1.38	6.750	7.94	39.6
		210 min	8	6.166	2.0163	1.65	6.405	8.03	32.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	1	211 min	8	6.448	1.3284	3.79	6.525	8.13	20.6
		212 min	8	6.285	2.0300	1.64	6.475	8.12	32.3
		213 min	8	6.300	2.0761	1.56	6.580	8.28	33.0
		214 min	8	6.393	2.0518	1.60	6.900	8.11	32.1
		215 min	8	5.570	2.5752	1.49	6.545	7.86	46.2
		216 min	8	6.053	2.0503	1.60	6.985	7.79	33.9
		217 min	8	6.111	1.8864	1.74	6.720	7.85	30.9
		218 min	8	6.239	1.9487	1.70	6.650	7.92	31.2
		219 min	8	6.291	2.0396	1.60	6.870	7.98	32.4
		220 min	8	6.195	2.0126	1.61	6.355	7.95	32.5
		221 min	8	5.875	2.5349	1.82	6.895	7.95	43.1
		222 min	8	5.839	2.5822	1.74	6.630	8.07	44.2
		223 min	8	5.869	2.3330	1.59	6.540	8.06	39.8
		224 min	8	6.066	1.9270	1.52	6.425	7.83	31.8
		225 min	8	6.304	2.0203	1.49	6.835	7.79	32.0
		226 min	8	5.944	1.9010	1.65	6.465	7.76	32.0
		227 min	8	6.221	2.0082	1.65	6.560	8.15	32.3
		228 min	8	6.415	2.0050	1.66	6.900	8.07	31.3
		229 min	9	6.508	1.9339	1.67	6.870	8.15	29.7
		230 min	9	6.549	1.9739	1.58	6.950	8.17	30.1
		231 min	9	6.547	1.8906	1.67	7.090	8.08	28.9
		232 min	9	6.424	1.9466	1.68	7.020	8.26	30.3
		233 min	9	6.458	1.8672	1.77	6.800	8.13	28.9
		234 min	9	6.043	2.2896	1.84	6.780	7.93	37.9
		235 min	8	6.494	1.3707	4.20	6.820	7.85	21.1
		236 min	9	6.391	1.8928	1.77	6.760	7.84	29.6
		237 min	9	6.278	1.8310	1.89	6.670	7.81	29.2
		238 min	9	6.397	1.9710	1.57	6.640	8.16	30.8
		239 min	9	6.252	1.9063	1.50	6.590	8.01	30.5
		240 min	5	5.928	2.5561	1.51	6.710	7.91	43.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 9 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	1 min	12	6.495	1.4873	1.82	6.960	7.21	22.9
		2 min	12	6.601	1.5829	1.84	6.910	8.44	24.0
		3 min	12	6.491	1.5439	1.72	6.865	7.55	23.8
		4 min	12	6.639	1.6285	1.69	6.965	8.04	24.5
		5 min	12	6.613	1.6036	1.71	7.085	7.67	24.3
		6 min	12	6.544	1.5633	1.69	7.020	7.48	23.9
		7 min	12	6.418	1.6186	1.55	6.755	8.25	25.2
		8 min	12	6.735	1.7029	1.53	7.145	7.94	25.3
		9 min	12	6.413	1.5462	1.58	6.815	7.25	24.1
		10 min	12	6.567	1.5503	1.85	6.945	7.70	23.6
		11 min	12	6.581	1.6485	1.55	6.965	7.69	25.1
		12 min	12	6.477	1.6291	1.58	6.835	7.85	25.2
		13 min	12	6.578	1.7246	1.57	6.995	8.23	26.2
		14 min	12	6.456	1.6139	1.57	6.755	7.66	25.0
		15 min	12	6.458	1.6913	1.58	6.830	7.79	26.2
		16 min	12	6.278	2.1378	1.55	6.880	8.16	34.0
		17 min	12	6.344	1.7414	1.54	6.965	7.80	27.4
		18 min	12	6.650	1.8135	1.53	7.115	8.28	27.3
		19 min	12	6.667	1.8394	1.57	7.280	8.23	27.6
		20 min	12	6.423	1.7135	1.60	6.980	7.90	26.7
		21 min	12	5.318	2.4831	1.48	6.800	7.64	46.7
		22 min	12	6.592	1.7499	1.48	6.895	8.04	26.5
		23 min	12	6.443	1.6478	1.54	6.865	7.89	25.6
		24 min	12	6.411	1.6515	1.51	6.720	7.65	25.8
		25 min	12	6.403	1.8641	1.53	6.835	8.25	29.1
		26 min	12	6.519	1.7468	1.48	6.845	7.98	26.8
		27 min	12	6.003	2.1542	1.28	6.780	7.49	35.9
		28 min	12	6.273	1.5987	1.73	6.800	7.44	25.5
		29 min	12	6.358	1.6741	1.62	6.660	8.02	26.3
		30 min	12	6.315	1.6724	1.46	6.775	8.19	26.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 10 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	31 min	12	6.349	1.5878	1.59	6.750	7.66	25.0
		32 min	11	6.021	2.2874	1.43	6.880	7.96	38.0
		33 min	10	6.406	1.7919	1.60	6.745	8.06	28.0
		34 min	10	6.013	2.0908	1.44	6.790	7.88	34.8
		35 min	10	6.080	1.9477	1.48	6.550	7.99	32.0
		36 min	10	6.071	1.9666	1.37	6.800	7.94	32.4
		37 min	10	5.815	2.3449	1.12	6.770	7.77	40.3
		38 min	10	6.031	2.4061	1.50	6.905	8.02	39.9
		39 min	10	5.862	2.1406	1.34	6.725	7.93	36.5
		40 min	10	6.186	1.9611	1.49	6.765	8.00	31.7
		41 min	10	5.835	2.1328	1.54	6.780	8.04	36.6
		42 min	10	6.209	1.8330	1.43	6.885	7.89	29.5
		43 min	11	5.666	2.2654	1.43	6.750	7.92	40.0
		44 min	11	5.625	2.3095	1.39	6.630	7.75	41.1
		45 min	11	6.251	1.7927	1.55	6.730	7.73	28.7
		46 min	11	6.180	2.0809	1.37	6.860	8.05	33.7
		47 min	11	6.120	1.8403	1.21	6.630	7.63	30.1
		48 min	11	6.163	1.7384	1.27	6.900	7.22	28.2
		49 min	11	6.340	1.7672	1.37	6.680	7.93	27.9
		50 min	11	5.769	2.2541	1.33	6.460	8.04	39.1
		51 min	10	5.366	1.9654	1.19	5.935	7.74	36.6
		52 min	10	5.963	1.8122	1.11	6.505	7.33	30.4
		53 min	10	5.710	1.7737	1.39	6.325	6.89	31.1
		54 min	10	6.265	1.7741	1.33	6.755	7.64	28.3
		55 min	10	5.768	2.2941	1.24	6.675	8.13	39.8
		56 min	10	5.881	2.3618	1.35	6.765	7.90	40.2
		57 min	10	6.247	1.8968	1.20	6.930	7.78	30.4
		58 min	10	6.136	1.7512	1.23	6.715	7.00	28.5
		59 min	10	6.440	1.8979	1.30	6.835	7.90	29.5
		60 min	10	5.905	1.9765	1.25	6.775	7.19	33.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 11 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	61 min	10	6.375	1.8637	1.21	6.995	7.69	29.2
		62 min	10	6.141	2.0349	1.15	6.890	7.95	33.1
		63 min	10	5.861	2.3224	1.20	6.880	7.54	39.6
		64 min	10	5.991	1.8845	1.20	6.715	7.25	31.5
		65 min	9	6.036	2.1239	1.35	6.880	7.84	35.2
		66 min	9	5.518	2.1852	1.27	6.480	7.22	39.6
		67 min	9	5.374	2.6657	1.36	6.290	7.84	49.6
		68 min	9	6.132	1.9586	1.38	6.640	7.86	31.9
		69 min	9	6.397	2.0717	1.35	6.970	7.77	32.4
		70 min	9	6.094	1.9606	1.46	6.740	7.75	32.2
		71 min	9	6.218	1.8991	1.46	6.730	7.72	30.5
		72 min	9	6.452	1.9279	1.53	6.900	7.74	29.9
		73 min	9	5.851	2.0716	1.57	6.560	8.07	35.4
		74 min	9	6.143	2.0102	1.22	6.800	7.97	32.7
		75 min	9	6.246	1.9610	1.29	6.940	7.66	31.4
		76 min	9	5.547	2.3298	1.42	6.400	7.78	42.0
		77 min	9	5.702	2.1629	1.50	6.740	7.84	37.9
		78 min	9	6.138	1.9303	1.39	6.490	7.78	31.4
		79 min	9	5.981	1.7765	1.42	6.580	7.22	29.7
		80 min	9	6.187	1.8715	1.31	6.870	7.19	30.3
		81 min	9	4.967	2.6023	1.22	5.990	7.79	52.4
		82 min	8	5.915	2.1273	1.46	6.950	7.77	36.0
		83 min	8	5.768	2.0269	1.30	6.445	7.78	35.1
		84 min	8	6.026	1.8926	1.53	6.510	7.68	31.4
		85 min	8	4.889	2.3117	1.62	6.130	7.11	47.3
		86 min	8	6.063	1.8237	1.63	6.670	7.33	30.1
		87 min	8	6.268	1.8321	1.84	6.730	7.70	29.2
		88 min	8	6.203	1.8693	1.62	6.830	7.24	30.1
		89 min	8	6.078	1.9007	1.51	6.720	7.62	31.3
		90 min	8	6.099	1.8628	1.55	6.805	7.07	30.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 12 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	91 min	8	5.905	2.0083	1.60	6.810	7.36	34.0
		92 min	8	6.011	2.0546	1.41	6.695	7.83	34.2
		93 min	8	5.650	2.3118	1.52	6.745	7.89	40.9
		94 min	8	5.790	1.9999	1.52	6.475	7.85	34.5
		95 min	8	5.909	2.0395	1.39	6.475	7.98	34.5
		96 min	8	5.941	1.8738	1.58	6.600	7.35	31.5
		97 min	8	6.125	1.9832	1.58	6.760	7.74	32.4
		98 min	8	6.124	1.8989	1.62	6.835	7.35	31.0
		99 min	8	6.308	2.0070	1.51	6.730	8.03	31.8
		100 min	8	6.464	2.0684	1.44	7.035	7.98	32.0
		101 min	8	6.298	1.9476	1.59	6.795	7.83	30.9
		102 min	8	6.018	1.6757	2.83	6.635	7.60	27.8
		103 min	8	6.185	1.9149	1.77	6.755	7.66	31.0
		104 min	8	6.208	1.9097	1.56	6.860	7.52	30.8
		105 min	8	6.008	2.2375	1.61	7.005	7.79	37.2
		106 min	8	6.111	2.0214	1.40	6.760	7.71	33.1
		107 min	8	6.259	2.0108	1.54	6.855	7.93	32.1
		108 min	8	6.155	1.9992	1.38	6.885	7.39	32.5
		109 min	8	6.114	2.0078	1.37	6.800	7.60	32.8
		110 min	8	6.289	2.0713	1.36	6.590	7.89	32.9
		111 min	8	6.213	1.9971	1.48	6.575	7.83	32.1
		112 min	8	6.086	1.9038	1.51	6.540	7.61	31.3
		113 min	8	5.910	2.1115	1.30	6.565	7.85	35.7
		114 min	8	5.821	2.0698	1.50	6.535	7.73	35.6
		115 min	8	5.899	1.9319	1.54	6.700	7.57	32.8
		116 min	8	6.116	2.0060	1.35	6.705	7.69	32.8
		117 min	8	6.276	1.9711	1.64	6.625	7.93	31.4
		118 min	8	6.246	1.9512	1.51	6.770	7.75	31.2
		119 min	8	6.215	2.0006	1.51	6.615	7.94	32.2
		120 min	8	6.179	1.9855	1.40	6.685	7.89	32.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 13 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	121 min	8	6.239	1.9484	1.71	6.775	7.85	31.2
		122 min	8	6.146	2.0563	1.24	6.855	7.71	33.5
		123 min	8	5.554	2.2794	1.55	6.650	7.58	41.0
		124 min	8	5.528	2.4417	1.37	6.750	7.85	44.2
		125 min	8	6.150	2.1413	1.12	6.745	7.84	34.8
		126 min	8	5.454	2.5213	1.38	6.710	7.40	46.2
		127 min	8	5.863	2.3228	1.21	6.855	7.86	39.6
		128 min	8	5.880	2.2185	1.16	6.610	7.97	37.7
		129 min	8	5.908	2.1825	1.22	6.680	7.89	36.9
		130 min	8	5.899	2.2110	1.24	6.695	7.80	37.5
		131 min	8	6.233	2.0123	1.42	6.730	7.97	32.3
		132 min	8	5.985	1.9037	1.71	6.675	7.86	31.8
		133 min	8	6.258	1.6127	2.58	6.515	7.80	25.8
		134 min	8	6.109	1.9688	1.39	6.700	7.32	32.2
		135 min	8	6.291	2.0450	1.39	6.770	7.89	32.5
		136 min	8	5.979	2.0150	1.06	6.595	7.18	33.7
		137 min	8	6.288	1.9876	1.56	6.665	7.75	31.6
		138 min	8	6.021	1.9073	1.44	6.445	7.48	31.7
		139 min	8	6.315	1.9536	1.58	6.845	7.81	30.9
		140 min	8	6.268	1.9199	1.66	6.710	7.75	30.6
		141 min	8	6.475	1.9206	1.80	7.065	7.67	29.7
		142 min	8	6.054	1.9785	1.44	6.560	7.58	32.7
		143 min	8	6.469	2.0859	1.37	7.085	7.76	32.2
		144 min	8	6.163	1.9539	1.46	6.655	7.61	31.7
		145 min	8	6.301	1.9879	1.48	6.770	7.91	31.5
		146 min	8	6.144	1.9453	1.62	6.695	7.83	31.7
		147 min	8	6.241	1.9247	1.53	6.900	7.26	30.8
		148 min	8	6.246	1.9633	1.62	6.800	7.73	31.4
		149 min	8	5.719	2.4659	1.66	6.845	7.62	43.1
		150 min	8	6.373	1.9049	1.72	6.875	7.46	29.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 14 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	151 min	8	5.935	2.0628	1.69	6.875	7.50	34.8
		152 min	8	6.275	1.8803	1.68	6.865	7.45	30.0
		153 min	8	6.215	1.8660	1.66	6.805	7.44	30.0
		154 min	8	6.359	1.9334	1.65	6.875	7.76	30.4
		155 min	8	6.325	1.8797	1.71	6.880	7.34	29.7
		156 min	8	6.335	1.9582	1.72	6.785	7.78	30.9
		157 min	8	6.359	1.9493	1.71	6.835	7.85	30.7
		158 min	8	6.410	1.9299	1.74	6.835	7.64	30.1
		159 min	8	6.451	1.9576	1.71	6.830	7.63	30.3
		160 min	8	6.370	1.9315	1.75	6.765	8.00	30.3
		161 min	8	6.288	1.8854	1.70	6.790	7.50	30.0
		162 min	8	5.805	2.0143	1.74	6.580	7.89	34.7
		163 min	8	6.346	1.9263	1.68	6.930	7.54	30.4
		164 min	8	6.163	1.9130	1.58	6.775	7.59	31.0
		165 min	8	6.311	1.9377	1.62	6.835	7.65	30.7
		166 min	8	6.524	2.0379	1.63	7.285	7.91	31.2
		167 min	8	6.471	2.0223	1.64	7.105	7.88	31.3
		168 min	8	6.439	1.9698	1.67	7.140	7.58	30.6
		169 min	8	6.473	2.0004	1.67	7.005	7.79	30.9
		170 min	8	6.238	1.8793	1.70	6.690	7.58	30.1
		171 min	8	6.520	2.0168	1.61	7.065	7.87	30.9
		172 min	8	6.234	1.8487	1.75	6.760	7.44	29.7
		173 min	8	6.486	1.9818	1.69	6.900	7.74	30.6
		174 min	8	6.505	1.9966	1.69	7.100	7.87	30.7
		175 min	8	6.329	2.0114	1.57	6.705	7.81	31.8
		176 min	8	6.335	1.9655	1.62	6.885	7.68	31.0
		177 min	8	6.273	1.9405	1.60	6.890	7.59	30.9
		178 min	8	6.305	1.9099	1.68	6.875	7.63	30.3
		179 min	8	6.468	2.0024	1.63	6.970	7.66	31.0
		180 min	8	5.834	2.5746	1.66	6.815	7.76	44.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 15 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	181 min	8	6.540	2.0309	1.66	7.135	7.86	31.1
		182 min	8	6.390	1.9488	1.69	6.890	7.94	30.5
		183 min	8	5.865	2.4687	1.65	6.935	7.60	42.1
		184 min	8	6.240	1.9406	1.56	6.755	7.63	31.1
		185 min	8	6.133	1.9126	1.51	6.705	7.60	31.2
		186 min	7	6.181	2.0747	1.56	6.680	7.63	33.6
		187 min	8	6.354	1.9635	1.55	6.960	7.58	30.9
		188 min	8	6.258	1.9046	1.57	6.930	7.20	30.4
		189 min	8	6.314	1.9213	1.59	6.980	7.28	30.4
		190 min	8	6.384	1.9524	1.62	6.925	7.53	30.6
		191 min	8	6.363	1.9875	1.50	6.935	7.73	31.2
		192 min	8	6.553	2.0425	1.62	7.175	7.85	31.2
		193 min	8	5.550	2.3566	1.65	7.100	7.42	42.5
		194 min	8	6.103	2.0144	1.70	6.950	7.70	33.0
		195 min	8	6.203	2.0806	1.68	7.125	7.63	33.5
		196 min	8	6.250	1.8922	1.72	6.875	7.49	30.3
		197 min	8	6.304	1.9598	1.69	6.945	7.83	31.1
		198 min	8	6.405	1.9254	1.73	6.950	7.63	30.1
		199 min	8	5.946	2.0189	1.69	6.760	7.53	34.0
		200 min	8	5.926	2.0640	1.67	6.760	7.68	34.8
		201 min	8	6.129	1.9006	1.67	6.845	7.46	31.0
		202 min	8	6.104	1.8957	1.63	6.530	8.06	31.1
		203 min	9	6.518	1.8945	1.73	6.940	7.86	29.1
		204 min	9	6.502	1.9564	1.69	6.760	8.19	30.1
		205 min	9	6.387	1.8523	1.67	6.920	7.54	29.0
		206 min	9	5.707	2.0832	1.70	6.440	7.57	36.5
		207 min	8	6.289	1.9304	1.68	7.000	7.52	30.7
		208 min	8	5.534	2.3921	1.72	6.595	7.46	43.2
		209 min	8	5.906	1.9929	1.54	6.525	7.69	33.7
		210 min	8	5.986	1.9993	1.70	6.620	7.84	33.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 16 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	2	211 min	8	5.930	1.8981	1.74	6.750	7.44	32.0
		212 min	8	6.290	1.9174	1.69	6.705	7.75	30.5
		213 min	8	6.350	1.9368	1.74	6.800	7.75	30.5
		214 min	8	6.251	1.9504	1.73	6.805	7.84	31.2
		215 min	8	5.406	2.2374	1.73	5.910	7.72	41.4
		216 min	8	5.716	2.0980	1.71	6.495	7.56	36.7
		217 min	8	5.927	1.7865	1.79	6.365	7.74	30.1
		218 min	8	6.266	1.8867	1.78	6.595	7.81	30.1
		219 min	8	6.129	1.8372	1.79	6.585	7.88	30.0
		220 min	8	6.335	1.8984	1.85	6.765	7.93	30.0
		221 min	8	5.738	2.5087	1.76	6.785	7.95	43.7
		222 min	8	6.168	2.0047	1.79	6.790	7.87	32.5
		223 min	8	6.091	1.9540	1.74	6.820	7.74	32.1
		224 min	8	5.928	1.9735	1.81	6.600	7.64	33.3
		225 min	8	6.230	1.8590	1.80	6.720	7.55	29.8
		226 min	8	6.115	1.8596	1.77	6.660	7.80	30.4
		227 min	8	6.258	1.9328	1.74	6.570	8.02	30.9
		228 min	8	6.234	1.8738	1.80	6.730	7.99	30.1
		229 min	9	6.344	1.7273	1.85	6.820	7.53	27.2
		230 min	9	6.339	1.7966	1.77	6.780	7.92	28.3
		231 min	9	6.362	1.7765	1.75	6.870	7.47	27.9
		232 min	9	6.490	1.8258	1.80	6.800	8.20	28.1
		233 min	9	6.368	1.7492	1.85	6.710	7.68	27.5
		234 min	9	5.882	2.3242	1.81	6.930	8.12	39.5
		235 min	8	6.218	1.9666	2.09	6.960	7.96	31.6
		236 min	9	6.453	1.6659	2.58	7.090	7.90	25.8
		237 min	9	6.460	1.7921	1.99	7.090	7.76	27.7
		238 min	9	6.410	1.8518	1.91	6.740	8.03	28.9
		239 min	9	6.472	1.7715	1.92	7.080	7.84	27.4
		240 min	5	6.056	2.3989	1.77	7.070	7.25	39.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 17 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	1 min	12	4.962	2.6805	1.31	4.760	8.82	54.0
		2 min	12	5.277	2.8133	1.41	6.510	8.54	53.3
		3 min	12	4.737	2.9284	1.02	5.215	8.70	61.8
		4 min	12	4.458	2.4736	1.13	4.415	8.15	55.5
		5 min	12	3.690	2.3505	1.04	2.935	7.48	63.7
		6 min	12	4.480	2.4359	1.12	4.550	7.53	54.4
		7 min	12	4.172	2.6113	0.93	4.255	7.80	62.6
		8 min	12	4.095	2.6572	0.95	3.250	8.18	64.9
		9 min	12	3.618	2.2610	1.27	2.595	7.41	62.5
		10 min	12	4.070	2.2842	1.16	4.590	7.33	56.1
		11 min	12	3.409	2.2567	1.16	2.550	8.04	66.2
		12 min	12	4.217	2.5418	1.32	3.625	7.90	60.3
		13 min	12	3.727	2.2883	1.19	2.860	7.56	61.4
		14 min	12	4.197	2.2163	1.33	4.135	7.36	52.8
		15 min	12	4.266	2.2876	1.38	4.765	7.21	53.6
		16 min	12	3.786	2.2977	1.35	3.145	7.31	60.7
		17 min	12	3.998	2.2360	1.41	3.395	7.16	55.9
		18 min	12	3.756	2.3769	1.22	3.095	7.26	63.3
		19 min	12	3.737	2.5290	1.42	2.555	7.71	67.7
		20 min	12	3.988	2.3430	1.48	3.525	7.36	58.7
		21 min	12	3.747	2.3481	1.49	2.715	7.18	62.7
		22 min	12	3.177	2.1005	1.44	2.115	7.03	66.1
		23 min	12	3.422	2.3749	1.27	2.325	8.04	69.4
		24 min	12	3.566	2.4335	1.23	2.430	7.71	68.2
		25 min	12	3.402	2.5031	1.22	2.035	7.34	73.6
		26 min	12	3.283	2.2650	1.32	2.190	7.16	69.0
		27 min	12	3.435	2.4783	1.26	2.200	7.94	72.1
		28 min	12	3.576	2.5937	1.27	2.345	7.56	72.5
		29 min	12	3.777	2.6016	1.31	2.135	7.21	68.9
		30 min	12	3.554	2.5140	1.26	2.030	7.91	70.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 18 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	31 min	12	3.559	2.4844	1.19	2.190	7.12	69.8
		32 min	11	3.294	2.3556	1.24	2.160	7.89	71.5
		33 min	10	3.086	2.3563	1.17	1.835	7.39	76.4
		34 min	10	3.312	2.2523	1.22	2.080	7.29	68.0
		35 min	10	2.803	2.1063	1.14	1.925	7.68	75.1
		36 min	10	2.946	2.2305	1.17	1.770	6.95	75.7
		37 min	10	2.909	2.1865	1.20	1.825	7.43	75.2
		38 min	10	3.158	2.2574	1.05	2.040	7.38	71.5
		39 min	10	2.951	2.3572	1.13	1.740	7.23	79.9
		40 min	10	2.777	2.0845	1.10	1.755	7.20	75.1
		41 min	10	2.943	2.3615	1.10	1.825	7.67	80.2
		42 min	10	3.349	2.6590	1.24	1.995	7.90	79.4
		43 min	11	3.016	2.0951	1.15	2.030	7.32	69.5
		44 min	11	3.401	2.5613	1.16	1.980	7.34	75.3
		45 min	11	3.164	2.2953	1.22	1.900	7.38	72.6
		46 min	11	2.611	1.8819	1.27	1.840	7.35	72.1
		47 min	11	2.571	1.8561	1.19	2.090	7.37	72.2
		48 min	11	2.631	1.7839	1.19	1.910	7.25	67.8
		49 min	11	2.920	2.0508	1.08	1.960	7.22	70.2
		50 min	11	2.710	1.9454	1.16	1.880	7.42	71.8
		51 min	10	2.596	2.0216	1.01	1.810	7.61	77.9
		52 min	10	2.552	1.8763	1.15	1.820	7.26	73.5
		53 min	10	2.544	1.9023	1.02	1.780	7.24	74.8
		54 min	10	2.546	1.9149	1.10	1.735	7.42	75.2
		55 min	10	2.752	1.9399	0.92	2.020	7.15	70.5
		56 min	10	2.550	1.9720	1.09	1.780	7.40	77.3
		57 min	10	2.780	1.9927	0.84	1.855	7.43	71.7
		58 min	10	3.373	2.5812	1.09	2.190	7.56	76.5
		59 min	10	2.839	2.4293	1.00	1.645	7.21	85.6
		60 min	10	3.132	2.5860	0.95	1.810	7.84	82.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 19 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	61 min	10	3.001	2.6406	0.86	1.790	8.09	88.0
		62 min	10	3.013	2.6200	0.80	1.995	7.87	87.0
		63 min	10	2.871	2.5244	1.04	1.695	7.66	87.9
		64 min	10	2.809	2.2176	1.03	1.945	7.23	78.9
		65 min	9	2.927	2.7525	1.02	1.770	7.97	94.0
		66 min	9	2.916	2.9162	1.12	1.420	8.53	100.0
		67 min	9	2.779	2.6862	1.05	1.430	7.50	96.7
		68 min	9	2.730	2.5717	0.93	1.800	7.25	94.2
		69 min	9	2.741	2.4852	1.04	1.710	7.30	90.7
		70 min	9	2.867	2.5883	1.00	1.730	7.46	90.3
		71 min	9	2.920	2.5475	1.09	1.920	7.50	87.2
		72 min	9	2.710	2.3909	0.76	1.890	7.19	88.2
		73 min	9	2.791	2.6260	1.07	1.660	7.84	94.1
		74 min	9	2.980	2.8756	0.89	1.870	8.22	96.5
		75 min	9	3.267	2.5860	1.12	2.170	7.50	79.2
		76 min	9	2.994	2.6193	0.95	1.950	7.68	87.5
		77 min	9	3.384	2.8803	1.14	1.720	7.96	85.1
		78 min	9	3.253	2.7682	1.16	1.790	7.75	85.1
		79 min	9	2.982	2.5020	1.17	1.600	7.26	83.9
		80 min	9	3.039	2.5681	1.15	1.690	7.45	84.5
		81 min	9	2.788	2.2093	1.29	1.920	7.57	79.3
		82 min	8	2.845	2.2309	1.22	1.840	7.30	78.4
		83 min	8	3.159	2.4093	1.23	1.900	7.20	76.3
		84 min	8	3.476	2.4404	1.24	2.750	7.31	70.2
		85 min	8	3.090	2.3157	1.21	2.185	7.56	74.9
		86 min	8	2.929	2.1088	1.16	1.890	7.18	72.0
		87 min	8	2.733	2.1253	1.18	1.850	7.37	77.8
		88 min	8	2.615	2.0702	1.26	1.905	7.44	79.2
		89 min	8	2.981	2.0376	1.26	2.470	7.28	68.3
		90 min	8	2.715	2.0193	1.31	1.995	7.29	74.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 20 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	91 min	8	2.484	1.9668	1.20	1.715	7.08	79.2
		92 min	8	2.640	1.9644	1.26	1.965	7.26	74.4
		93 min	8	2.570	1.9982	1.31	1.780	7.32	77.8
		94 min	8	2.464	1.9372	1.24	1.765	7.08	78.6
		95 min	8	2.486	2.0035	1.19	1.680	7.23	80.6
		96 min	8	2.564	2.0531	1.20	1.905	7.44	80.1
		97 min	8	2.523	2.0486	1.22	1.730	7.43	81.2
		98 min	8	2.478	2.0087	1.36	1.665	7.32	81.1
		99 min	8	2.533	2.0520	1.33	1.740	7.45	81.0
		100 min	8	2.403	1.8893	1.33	1.580	6.92	78.6
		101 min	8	2.468	2.0131	1.39	1.560	7.30	81.6
		102 min	8	2.575	1.9709	1.28	1.760	7.23	76.5
		103 min	8	2.986	2.4026	1.28	1.605	7.07	80.5
		104 min	8	2.635	1.8613	1.46	1.970	7.08	70.6
		105 min	8	2.785	2.1241	1.52	1.730	7.68	76.3
		106 min	8	3.184	2.4942	1.50	1.845	7.35	78.3
		107 min	8	3.028	2.3398	1.40	1.815	7.12	77.3
		108 min	8	2.650	2.0664	1.33	1.905	7.63	78.0
		109 min	8	2.574	1.9621	1.37	1.890	7.29	76.2
		110 min	8	2.599	2.0813	1.31	1.865	7.62	80.1
		111 min	8	2.516	1.9336	1.34	1.845	7.16	76.8
		112 min	8	2.501	1.9140	1.32	1.780	7.11	76.5
		113 min	8	2.768	1.9801	1.40	1.840	7.13	71.5
		114 min	8	3.230	2.3789	1.37	2.200	7.03	73.7
		115 min	8	3.101	2.3373	1.45	1.915	7.06	75.4
		116 min	8	2.648	1.9754	1.27	2.060	7.36	74.6
		117 min	8	2.705	1.9300	1.38	1.780	6.93	71.4
		118 min	8	2.516	2.0105	1.33	1.640	7.29	79.9
		119 min	8	2.496	1.9797	1.34	1.765	7.24	79.3
		120 min	8	2.481	1.9813	1.36	1.545	7.12	79.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 21 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	121 min	8	2.463	1.9596	1.30	1.590	7.12	79.6
		122 min	8	2.880	2.3182	1.15	1.620	7.20	80.5
		123 min	8	2.740	2.0585	1.25	1.750	7.37	75.1
		124 min	8	2.928	2.2970	1.18	1.720	7.35	78.5
		125 min	8	2.540	2.0274	1.16	1.695	7.28	79.8
		126 min	8	2.833	2.0956	1.11	2.070	7.02	74.0
		127 min	8	2.741	2.1105	1.22	1.895	7.52	77.0
		128 min	8	2.810	2.3137	1.08	1.785	7.35	82.3
		129 min	8	2.994	2.5617	1.09	1.665	7.09	85.6
		130 min	8	2.600	2.1287	1.05	1.630	7.30	81.9
		131 min	8	2.464	2.1571	1.17	1.425	7.45	87.6
		132 min	8	2.717	2.2251	1.20	1.520	7.40	81.9
		133 min	8	2.524	2.1289	1.26	1.645	7.61	84.4
		134 min	8	2.589	2.1433	1.09	1.590	7.20	82.8
		135 min	8	2.546	2.1248	1.00	1.740	7.58	83.4
		136 min	8	2.528	1.9687	1.06	1.825	7.02	77.9
		137 min	8	2.530	2.0598	1.16	1.795	7.31	81.4
		138 min	8	2.760	2.2705	1.20	1.740	7.87	82.3
		139 min	8	2.620	2.2205	1.28	1.595	7.79	84.8
		140 min	8	2.774	2.2709	1.18	1.665	7.18	81.9
		141 min	8	2.468	1.9883	1.18	1.570	7.05	80.6
		142 min	8	2.555	2.0838	1.21	1.590	7.21	81.6
		143 min	8	2.956	2.3071	1.07	2.110	7.58	78.0
		144 min	8	2.791	2.3557	1.12	1.595	7.09	84.4
		145 min	8	2.729	2.0394	1.03	1.895	7.13	74.7
		146 min	8	3.718	2.3523	1.21	3.400	6.85	63.3
		147 min	8	2.631	1.8538	1.06	1.975	6.78	70.5
		148 min	8	2.558	1.9865	1.19	1.875	7.23	77.7
		149 min	8	2.630	1.9417	1.36	2.295	7.30	73.8
		150 min	8	2.595	1.7610	1.37	2.150	6.75	67.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 22 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	151 min	8	2.659	2.1866	1.32	2.025	7.98	82.2
		152 min	8	2.810	1.9668	1.35	1.990	7.19	70.0
		153 min	8	2.624	1.9330	1.33	1.955	7.20	73.7
		154 min	8	2.771	1.9340	1.41	2.310	7.33	69.8
		155 min	8	2.778	1.8640	1.24	2.435	7.13	67.1
		156 min	8	2.875	1.8025	1.37	2.265	6.96	62.7
		157 min	8	3.185	2.2233	1.34	2.690	8.30	69.8
		158 min	8	3.199	2.1922	1.40	2.635	8.09	68.5
		159 min	8	3.175	2.0920	1.37	2.305	7.21	65.9
		160 min	8	3.064	1.9856	1.31	2.305	7.03	64.8
		161 min	8	3.130	2.2515	1.41	2.305	7.88	71.9
		162 min	8	3.104	2.0601	1.34	2.545	7.37	66.4
		163 min	8	3.109	2.3534	1.24	2.195	7.86	75.7
		164 min	8	3.150	2.4649	1.21	2.300	8.17	78.2
		165 min	8	3.046	2.2541	1.29	2.200	7.68	74.0
		166 min	8	3.054	2.0553	1.25	2.440	7.01	67.3
		167 min	8	2.895	2.0962	1.32	2.225	7.64	72.4
		168 min	8	2.763	1.9966	1.29	2.180	7.31	72.3
		169 min	8	3.178	2.3506	1.32	2.130	7.03	74.0
		170 min	8	2.676	1.8895	1.16	2.215	7.04	70.6
		171 min	8	2.945	2.0947	1.28	2.580	7.77	71.1
		172 min	8	2.660	1.8717	1.45	2.220	7.12	70.4
		173 min	8	2.906	2.2227	1.31	2.450	8.16	76.5
		174 min	8	2.808	1.8839	1.40	2.325	7.11	67.1
		175 min	8	2.783	2.0314	1.31	2.225	7.55	73.0
		176 min	8	3.210	2.4057	1.41	2.230	7.98	74.9
		177 min	8	3.613	2.1477	1.52	3.070	7.12	59.5
		178 min	8	3.394	2.2652	1.52	2.320	7.71	66.7
		179 min	8	3.090	1.9848	1.44	2.315	7.30	64.2
		180 min	8	3.025	1.9457	1.37	2.430	7.43	64.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 23 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	181 min	8	3.009	2.1295	1.37	2.195	7.91	70.8
		182 min	8	2.886	1.9760	1.35	2.230	7.50	68.5
		183 min	8	3.211	2.0611	1.48	2.330	7.34	64.2
		184 min	8	3.100	1.8777	1.43	2.840	7.43	60.6
		185 min	8	3.588	2.4056	1.48	2.460	7.76	67.1
		186 min	7	2.841	1.5983	1.48	2.220	6.19	56.2
		187 min	8	2.986	1.9400	1.40	2.220	7.41	65.0
		188 min	8	3.110	2.0698	1.39	2.175	7.25	66.6
		189 min	8	3.178	1.9805	1.40	2.315	7.46	62.3
		190 min	8	3.435	2.1273	1.12	2.815	7.18	61.9
		191 min	8	4.096	2.2389	1.36	4.040	7.23	54.7
		192 min	8	3.770	2.2257	1.47	2.745	7.12	59.0
		193 min	8	4.195	2.5762	1.46	3.750	7.16	61.4
		194 min	8	4.074	2.5372	1.31	3.605	7.33	62.3
		195 min	8	4.329	2.8572	1.36	3.870	7.81	66.0
		196 min	8	3.681	2.4267	1.47	2.795	7.95	65.9
		197 min	8	3.819	2.2667	1.51	3.695	7.84	59.4
		198 min	8	4.098	2.2850	1.55	3.250	7.23	55.8
		199 min	8	2.884	1.6779	1.36	2.515	6.63	58.2
		200 min	8	2.594	1.4915	1.51	1.930	5.99	57.5
		201 min	8	3.008	2.1531	1.49	1.915	7.66	71.6
		202 min	8	3.005	2.2109	1.32	2.100	7.14	73.6
		203 min	9	3.261	2.3641	1.53	1.850	7.39	72.5
		204 min	9	3.082	2.0427	1.49	1.900	7.12	66.3
		205 min	9	3.409	2.2580	1.49	2.140	6.80	66.2
		206 min	9	2.724	1.7845	1.53	1.940	6.83	65.5
		207 min	8	2.473	1.7629	1.44	1.940	6.77	71.3
		208 min	8	2.395	1.5562	1.42	1.755	6.11	65.0
		209 min	8	2.006	0.6339	1.33	1.915	3.39	31.6
		210 min	8	2.958	2.2253	1.38	2.005	7.46	75.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 24 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	3	211 min	8	2.791	2.0970	1.33	1.815	6.87	75.1
		212 min	8	2.581	1.5419	1.43	1.975	5.72	59.7
		213 min	8	2.368	1.8882	1.35	1.835	7.00	79.8
		214 min	8	2.176	1.6747	1.34	1.590	6.29	77.0
		215 min	8	1.916	0.4949	1.44	1.855	2.90	25.8
		216 min	8	2.361	1.0540	1.30	1.970	4.47	44.6
		217 min	8	2.279	1.1246	1.32	1.850	4.77	49.3
		218 min	8	1.906	0.3905	1.33	1.905	2.62	20.5
		219 min	8	1.926	0.4672	1.22	1.840	2.64	24.3
		220 min	8	2.233	1.0586	1.37	1.875	4.69	47.4
		221 min	8	2.408	1.0524	1.64	2.155	4.81	43.7
		222 min	8	2.031	0.5301	1.32	2.075	2.66	26.1
		223 min	8	2.040	0.5788	1.33	2.005	3.04	28.4
		224 min	8	2.161	1.5048	1.28	1.700	5.81	69.6
		225 min	8	2.806	1.9117	1.28	2.200	7.30	68.1
		226 min	8	2.521	1.4848	1.28	2.070	5.89	58.9
		227 min	8	2.196	0.6198	1.47	2.145	3.33	28.2
		228 min	8	2.495	1.5250	1.34	2.005	5.79	61.1
		229 min	9	2.634	1.3412	1.53	2.110	5.02	50.9
		230 min	9	3.350	1.8373	1.16	2.630	6.21	54.8
		231 min	9	2.417	1.0549	1.39	2.230	4.15	43.7
		232 min	9	3.188	2.0068	1.28	2.280	6.29	63.0
		233 min	9	2.878	1.8465	1.25	2.030	6.88	64.2
		234 min	9	2.441	1.4295	1.32	1.880	5.83	58.6
		235 min	8	1.885	0.7019	0.97	1.680	2.89	37.2
		236 min	9	2.650	1.0105	1.59	2.790	4.29	38.1
		237 min	9	2.597	1.6791	1.37	2.010	6.61	64.7
		238 min	9	2.023	0.8970	0.98	1.780	3.67	44.3
		239 min	9	2.709	1.4426	1.27	2.280	5.91	53.3
		240 min	5	2.906	1.6388	1.53	2.410	5.64	56.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 25 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	1 min	12	4.137	2.0872	1.23	3.915	7.38	50.5
		2 min	12	4.295	1.9247	1.34	3.980	7.51	44.8
		3 min	12	4.310	2.2125	1.40	3.715	7.52	51.3
		4 min	12	4.457	2.4412	1.37	4.105	8.31	54.8
		5 min	12	4.096	2.3419	1.29	3.285	7.58	57.2
		6 min	12	3.586	2.4632	1.32	2.265	8.04	68.7
		7 min	12	3.858	2.5302	1.40	2.350	7.78	65.6
		8 min	12	3.849	2.1123	1.44	3.425	7.51	54.9
		9 min	12	3.913	2.2938	1.36	3.145	7.53	58.6
		10 min	12	4.727	2.2282	1.42	4.720	8.29	47.1
		11 min	12	3.194	1.6573	1.34	2.820	7.35	51.9
		12 min	12	2.861	1.7174	1.32	2.275	7.39	60.0
		13 min	12	3.261	1.9976	1.42	2.275	7.53	61.3
		14 min	12	3.359	2.0120	1.32	2.270	7.21	59.9
		15 min	12	3.063	1.8313	1.39	2.325	7.57	59.8
		16 min	12	3.615	2.1803	1.36	2.695	7.47	60.3
		17 min	12	3.132	2.2283	1.34	2.170	7.71	71.2
		18 min	12	3.275	2.0769	1.38	2.305	7.64	63.4
		19 min	12	2.701	1.7241	1.38	2.180	7.65	63.8
		20 min	12	2.784	1.7330	1.20	2.150	7.26	62.2
		21 min	12	3.376	2.0353	1.31	2.605	7.46	60.3
		22 min	12	2.789	1.7110	1.45	2.105	7.53	61.3
		23 min	12	2.699	1.7350	1.23	2.050	7.52	64.3
		24 min	12	2.648	1.7410	1.30	1.900	7.44	65.8
		25 min	12	2.552	1.7521	1.35	1.925	7.66	68.7
		26 min	12	2.670	1.7642	1.31	2.045	7.42	66.1
		27 min	12	2.770	1.7820	1.28	2.030	7.37	64.3
		28 min	12	2.654	1.6621	1.31	2.020	7.07	62.6
		29 min	12	2.550	1.7612	1.27	2.010	7.49	69.1
		30 min	12	2.498	1.7396	1.33	1.905	7.49	69.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 26 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	31 min	12	2.853	2.0039	1.31	2.010	7.35	70.2
		32 min	11	3.131	2.2048	1.23	2.120	7.28	70.4
		33 min	10	2.527	1.8461	1.17	1.925	7.22	73.1
		34 min	10	2.571	1.8970	1.30	1.940	7.49	73.8
		35 min	10	3.026	2.3951	1.31	1.945	7.55	79.1
		36 min	10	2.803	2.0514	1.29	1.935	7.50	73.2
		37 min	10	2.927	2.2426	1.18	1.995	7.63	76.6
		38 min	10	2.780	2.1079	1.14	1.980	7.48	75.8
		39 min	10	2.498	1.8905	1.26	1.950	7.57	75.7
		40 min	10	2.380	1.8320	1.23	1.790	7.37	77.0
		41 min	10	2.380	1.8945	1.25	1.740	7.52	79.6
		42 min	10	2.482	1.9462	1.21	1.880	7.62	78.4
		43 min	11	2.491	1.8744	1.14	1.940	7.57	75.2
		44 min	11	2.524	1.8713	1.21	1.970	7.58	74.2
		45 min	11	2.627	1.9738	1.18	1.960	7.60	75.1
		46 min	11	2.702	1.8376	1.20	1.980	7.58	68.0
		47 min	11	2.495	1.8592	1.18	1.980	7.52	74.5
		48 min	11	2.511	1.8681	1.17	1.970	7.58	74.4
		49 min	11	2.424	1.8653	1.15	1.900	7.48	77.0
		50 min	11	2.499	1.8489	1.09	1.980	7.51	74.0
		51 min	10	2.553	1.9456	1.15	1.920	7.51	76.2
		52 min	10	2.561	1.9155	1.12	1.935	7.41	74.8
		53 min	10	2.533	1.9369	1.09	1.940	7.46	76.5
		54 min	10	2.580	1.9560	1.20	1.950	7.61	75.8
		55 min	10	2.609	1.8929	1.23	1.940	7.49	72.6
		56 min	10	2.516	1.9965	1.03	1.940	7.57	79.4
		57 min	10	2.710	2.0495	0.86	1.875	7.59	75.6
		58 min	10	2.772	2.1764	1.01	1.865	7.51	78.5
		59 min	10	2.529	2.0100	1.07	1.825	7.56	79.5
		60 min	10	2.822	2.1307	1.16	1.780	7.69	75.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 27 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	61 min	10	2.624	2.0007	1.20	1.880	7.66	76.2
		62 min	10	2.620	2.0075	1.09	1.900	7.69	76.6
		63 min	10	2.596	1.9800	1.12	1.875	7.50	76.3
		64 min	10	2.541	1.9881	0.91	1.885	7.51	78.2
		65 min	9	2.413	2.0361	0.94	1.820	7.42	84.4
		66 min	9	2.459	2.0255	1.11	1.820	7.51	82.4
		67 min	9	2.527	2.0743	1.08	1.790	7.66	82.1
		68 min	9	2.496	2.0494	1.10	1.770	7.44	82.1
		69 min	9	2.398	2.0231	0.90	1.880	7.39	84.4
		70 min	9	2.499	2.1066	0.82	1.790	7.46	84.3
		71 min	9	2.500	2.1206	0.86	1.750	7.57	84.8
		72 min	9	2.419	2.0100	1.01	1.780	7.44	83.1
		73 min	9	2.516	1.9987	1.23	1.750	7.54	79.5
		74 min	9	2.607	2.0305	1.12	1.790	7.38	77.9
		75 min	9	2.563	1.9676	1.18	2.030	7.43	76.8
		76 min	9	2.620	2.0764	1.06	2.000	7.35	79.3
		77 min	9	2.584	1.9994	1.23	1.890	7.37	77.4
		78 min	9	2.617	2.0521	1.20	1.890	7.43	78.4
		79 min	9	2.550	2.0292	1.15	1.940	7.52	79.6
		80 min	9	3.221	2.3328	1.12	2.160	7.53	72.4
		81 min	9	2.628	2.0613	1.14	1.880	7.50	78.4
		82 min	8	2.751	2.0894	1.24	2.085	7.46	75.9
		83 min	8	2.900	2.1681	1.23	2.120	7.46	74.8
		84 min	8	3.103	2.1233	1.35	2.270	7.46	68.4
		85 min	8	2.833	2.1346	1.23	2.065	7.42	75.4
		86 min	8	2.770	2.0131	1.25	2.020	7.37	72.7
		87 min	8	2.753	2.0754	1.29	2.050	7.60	75.4
		88 min	8	2.680	2.0484	1.30	2.020	7.56	76.4
		89 min	8	2.678	2.0382	1.25	2.105	7.50	76.1
		90 min	8	2.630	1.9570	1.31	2.045	7.27	74.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 28 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	91 min	8	2.618	1.9303	1.22	2.090	7.16	73.7
		92 min	8	2.613	2.0338	1.25	2.065	7.45	77.8
		93 min	8	2.620	2.0144	1.25	2.010	7.45	76.9
		94 min	8	2.608	1.9523	1.39	2.045	7.29	74.9
		95 min	8	2.545	1.9880	1.23	1.910	7.31	78.1
		96 min	8	2.586	2.0015	1.17	1.940	7.39	77.4
		97 min	8	2.764	2.0648	1.28	2.050	7.53	74.7
		98 min	8	2.560	2.0621	1.23	1.860	7.50	80.6
		99 min	8	2.571	1.9534	1.26	2.005	7.24	76.0
		100 min	8	2.638	1.9681	1.30	2.110	7.31	74.6
		101 min	8	2.828	2.1354	1.23	1.905	7.30	75.5
		102 min	8	2.519	2.0030	1.11	1.835	7.30	79.5
		103 min	8	2.565	1.9539	1.20	1.915	7.18	76.2
		104 min	8	2.563	2.0404	1.32	1.855	7.45	79.6
		105 min	8	2.541	2.0406	1.13	1.860	7.41	80.3
		106 min	8	2.554	2.0173	1.14	1.995	7.37	79.0
		107 min	8	2.603	1.9739	1.39	1.960	7.36	75.8
		108 min	8	2.551	2.0605	1.25	1.865	7.50	80.8
		109 min	8	2.514	1.9878	1.25	1.895	7.27	79.1
		110 min	8	2.530	1.9386	1.35	1.920	7.19	76.6
		111 min	8	2.481	1.9469	1.25	1.855	7.15	78.5
		112 min	8	2.439	1.9641	1.21	1.775	7.13	80.5
		113 min	8	2.460	1.9602	1.27	1.730	7.15	79.7
		114 min	8	2.564	1.9682	1.29	1.785	7.22	76.8
		115 min	8	2.461	1.9866	1.29	1.730	7.21	80.7
		116 min	8	2.495	2.0173	1.21	1.775	7.30	80.9
		117 min	8	2.688	1.9983	1.34	1.700	7.09	74.4
		118 min	8	2.555	1.9888	1.25	1.785	7.28	77.8
		119 min	8	2.546	2.0116	1.22	1.865	7.37	79.0
		120 min	8	2.470	1.9945	1.25	1.770	7.24	80.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 29 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	121 min	8	2.528	2.0147	1.25	1.830	7.36	79.7
		122 min	8	2.886	2.2942	1.24	1.720	7.21	79.5
		123 min	8	2.590	2.0805	1.15	1.635	7.26	80.3
		124 min	8	2.851	2.2491	1.23	1.705	7.25	78.9
		125 min	8	2.561	2.0179	1.15	1.810	7.31	78.8
		126 min	8	2.909	2.0425	1.11	2.215	7.09	70.2
		127 min	8	2.676	2.0502	1.23	1.860	7.35	76.6
		128 min	8	2.508	2.0333	1.12	1.860	7.18	81.1
		129 min	8	2.561	1.9902	1.00	1.915	7.15	77.7
		130 min	8	2.526	1.8829	1.05	1.935	6.90	74.5
		131 min	8	2.363	1.9331	1.03	1.665	6.91	81.8
		132 min	8	2.683	2.0323	0.81	1.770	6.78	75.8
		133 min	8	2.440	1.7166	1.22	1.895	6.45	70.4
		134 min	8	2.358	1.6220	1.17	1.830	6.11	68.8
		135 min	8	2.444	1.8741	1.05	1.840	6.82	76.7
		136 min	8	2.248	1.1463	1.30	1.915	4.76	51.0
		137 min	8	2.390	1.6890	1.24	1.795	6.37	70.7
		138 min	8	2.588	1.7861	1.25	1.835	6.35	69.0
		139 min	8	2.351	1.5892	1.19	1.735	6.03	67.6
		140 min	8	2.423	1.7157	1.23	1.750	6.43	70.8
		141 min	8	3.045	2.1279	1.24	2.030	6.70	69.9
		142 min	8	2.400	1.7731	1.02	1.845	6.50	73.9
		143 min	8	2.408	1.6225	0.81	2.040	6.03	67.4
		144 min	8	2.664	2.1458	0.91	1.780	6.68	80.6
		145 min	8	2.360	1.7390	0.94	1.740	6.41	73.7
		146 min	8	2.501	1.8777	1.04	1.750	6.66	75.1
		147 min	8	2.555	1.9282	1.25	2.010	7.18	75.5
		148 min	8	2.541	1.8999	1.35	1.905	7.12	74.8
		149 min	8	2.804	1.9037	1.39	2.210	7.35	67.9
		150 min	8	2.661	1.8964	1.43	2.095	7.24	71.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 30 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	151 min	8	2.756	1.8860	1.42	2.295	7.30	68.4
		152 min	8	2.689	1.8881	1.45	2.075	7.16	70.2
		153 min	8	2.644	1.9047	1.30	2.135	7.24	72.0
		154 min	8	2.621	1.8705	1.36	2.120	7.12	71.4
		155 min	8	2.753	1.8290	1.27	2.430	7.11	66.4
		156 min	8	2.811	1.8408	1.38	2.420	7.17	65.5
		157 min	8	2.826	1.9191	1.34	2.285	7.15	67.9
		158 min	8	2.793	1.9073	1.24	2.335	7.06	68.3
		159 min	8	2.973	1.9182	1.28	2.635	7.08	64.5
		160 min	8	2.786	1.9327	1.15	2.460	7.20	69.4
		161 min	8	2.871	1.9530	1.22	2.475	7.26	68.0
		162 min	8	3.068	2.0557	1.11	2.800	7.27	67.0
		163 min	8	2.986	2.0988	1.25	2.475	7.32	70.3
		164 min	8	2.906	2.0624	1.08	2.410	7.22	71.0
		165 min	8	2.655	1.9564	1.04	2.245	7.27	73.7
		166 min	8	2.763	1.9161	1.09	2.460	7.12	69.4
		167 min	8	2.699	1.8996	1.24	2.225	7.15	70.4
		168 min	8	3.030	2.2738	1.17	2.175	7.21	75.0
		169 min	8	2.801	1.9465	1.20	2.165	7.03	69.5
		170 min	8	2.863	2.0066	1.24	2.370	7.24	70.1
		171 min	8	2.975	2.0897	1.24	2.405	7.32	70.2
		172 min	8	2.946	2.0006	1.39	2.465	7.37	67.9
		173 min	8	2.973	2.0397	1.42	2.325	7.32	68.6
		174 min	8	3.003	1.9497	1.58	2.320	7.32	64.9
		175 min	8	2.839	1.8644	1.27	2.335	7.05	65.7
		176 min	8	2.989	1.8868	1.34	2.300	7.28	63.1
		177 min	8	3.128	1.8624	1.48	2.565	7.15	59.5
		178 min	8	3.015	1.8422	1.54	2.385	7.17	61.1
		179 min	8	2.916	1.8635	1.48	2.235	7.24	63.9
		180 min	8	2.900	1.8306	1.44	2.550	7.22	63.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 31 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	181 min	8	2.760	1.8653	1.12	2.335	7.15	67.6
		182 min	8	2.823	1.8967	1.09	2.375	7.27	67.2
		183 min	8	2.850	1.9062	1.37	2.355	7.38	66.9
		184 min	8	2.811	1.9373	1.16	2.400	7.37	68.9
		185 min	8	2.888	1.8880	1.35	2.365	7.26	65.4
		186 min	7	2.081	0.6725	0.93	2.260	2.92	32.3
		187 min	8	2.201	0.6491	1.21	2.335	3.09	29.5
		188 min	8	2.385	1.0516	1.13	2.330	4.58	44.1
		189 min	8	2.096	0.5344	1.35	2.170	2.81	25.5
		190 min	8	2.590	1.5093	1.06	2.365	6.00	58.3
		191 min	8	2.401	1.0146	1.31	2.365	4.37	42.3
		192 min	8	2.744	1.5532	1.43	2.330	6.23	56.6
		193 min	8	2.655	1.5314	1.37	2.245	6.14	57.7
		194 min	8	2.770	1.7108	1.27	2.265	6.54	61.8
		195 min	8	3.000	1.9769	1.22	2.375	6.31	65.9
		196 min	8	2.521	1.6482	1.28	2.120	6.46	65.4
		197 min	8	2.874	1.6959	1.33	2.255	6.32	59.0
		198 min	8	2.655	1.2264	1.22	2.285	4.44	46.2
		199 min	8	2.350	0.7474	1.39	2.280	3.44	31.8
		200 min	8	2.093	0.5725	1.54	1.955	3.25	27.4
		201 min	8	2.118	0.6490	1.10	2.235	3.08	30.6
		202 min	8	2.779	1.7433	1.44	2.045	6.71	62.7
		203 min	9	2.950	1.9530	1.12	2.130	6.79	66.2
		204 min	9	2.666	1.5387	1.28	1.990	6.21	57.7
		205 min	9	2.934	1.9035	1.45	2.050	6.67	64.9
		206 min	9	2.069	0.5349	1.51	1.920	3.01	25.9
		207 min	8	2.290	1.1876	1.15	2.005	4.95	51.9
		208 min	8	2.086	0.8549	1.19	1.875	3.98	41.0
		209 min	8	2.035	0.6245	1.25	1.930	3.14	30.7
		210 min	8	2.390	1.6767	1.18	1.870	6.46	70.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 32 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	4	211 min	8	2.356	1.8169	1.23	1.815	6.79	77.1
		212 min	8	2.448	1.3941	1.37	2.010	5.72	57.0
		213 min	8	2.025	0.5192	1.42	1.985	2.96	25.6
		214 min	8	2.625	1.8469	1.50	2.035	7.04	70.4
		215 min	8	2.009	0.5783	1.42	1.920	3.21	28.8
		216 min	8	1.916	0.5342	1.18	1.955	2.97	27.9
		217 min	8	1.931	0.4703	1.39	1.920	2.90	24.4
		218 min	8	1.889	0.4192	1.35	1.820	2.67	22.2
		219 min	8	1.835	0.5042	1.27	1.735	2.65	27.5
		220 min	8	1.795	0.4570	1.15	1.720	2.58	25.5
		221 min	8	1.911	0.4434	1.35	1.865	2.66	23.2
		222 min	8	1.870	0.4924	1.16	1.860	2.61	26.3
		223 min	8	2.016	0.4674	1.32	1.980	2.61	23.2
		224 min	8	2.041	0.4879	1.49	2.000	2.63	23.9
		225 min	8	2.068	0.5117	1.35	2.070	2.76	24.7
		226 min	8	2.304	1.0757	1.31	1.995	4.80	46.7
		227 min	8	1.960	0.4404	1.31	2.055	2.57	22.5
		228 min	8	2.210	1.1609	0.99	1.920	4.73	52.5
		229 min	9	2.690	1.6294	1.19	2.020	5.43	60.6
		230 min	9	2.037	0.5207	1.24	1.950	2.96	25.6
		231 min	9	2.017	0.8093	1.11	1.980	3.77	40.1
		232 min	9	2.287	0.8948	1.07	2.280	4.32	39.1
		233 min	9	2.336	0.9352	1.00	2.340	4.17	40.0
		234 min	9	1.788	0.6280	1.13	1.660	2.76	35.1
		235 min	8	1.733	0.5790	1.08	1.595	2.70	33.4
		236 min	9	1.984	0.9330	1.06	1.610	3.85	47.0
		237 min	9	2.317	1.1736	0.94	2.160	4.51	50.7
		238 min	9	2.521	1.5303	0.96	2.070	5.82	60.7
		239 min	9	2.089	0.9019	0.93	2.050	3.79	43.2
		240 min	5	2.890	1.6495	1.62	2.460	5.63	57.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 33 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	1 min	12	3.968	2.7529	1.20	2.820	8.53	69.4
		2 min	12	3.647	2.5958	1.26	2.315	8.44	71.2
		3 min	12	3.577	2.4973	1.33	2.280	8.15	69.8
		4 min	12	3.672	2.3937	1.35	2.490	8.02	65.2
		5 min	12	3.205	2.1874	1.23	2.465	8.02	68.2
		6 min	12	3.158	2.1836	0.93	2.650	7.84	69.1
		7 min	12	3.226	2.0926	1.34	2.545	7.80	64.9
		8 min	12	3.094	2.0760	1.45	2.195	7.57	67.1
		9 min	12	3.350	2.2476	1.37	2.095	7.04	67.1
		10 min	12	3.158	1.9920	1.30	2.140	7.01	63.1
		11 min	12	2.958	1.8772	1.35	2.120	6.86	63.5
		12 min	12	3.193	2.0695	1.28	2.270	7.03	64.8
		13 min	12	2.721	1.5706	1.40	2.225	7.13	57.7
		14 min	12	2.648	1.6363	1.29	2.100	7.23	61.8
		15 min	12	2.748	1.5636	1.30	2.215	7.00	56.9
		16 min	12	3.194	1.8683	1.33	2.595	6.85	58.5
		17 min	12	2.738	1.5663	1.08	2.380	6.89	57.2
		18 min	12	2.758	1.5142	1.41	2.560	6.90	54.9
		19 min	12	2.679	1.5610	1.45	2.240	6.99	58.3
		20 min	12	2.570	1.6316	1.08	2.225	7.05	63.5
		21 min	12	2.934	1.7142	1.40	2.315	6.87	58.4
		22 min	12	2.603	1.5110	1.47	2.115	6.76	58.1
		23 min	12	2.609	1.5761	1.31	2.115	7.07	60.4
		24 min	12	2.554	1.5657	1.40	2.010	6.95	61.3
		25 min	12	2.518	1.5474	1.29	2.015	6.85	61.4
		26 min	12	2.528	1.6028	1.33	2.035	7.06	63.4
		27 min	12	2.499	1.5429	1.30	1.985	6.80	61.7
		28 min	12	2.478	1.5114	1.20	1.985	6.72	61.0
		29 min	12	2.550	1.6922	1.24	2.055	7.38	66.4
		30 min	12	2.482	1.7562	1.24	1.865	7.48	70.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 34 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	31 min	12	2.487	1.5838	1.29	2.015	6.89	63.7
		32 min	11	2.766	1.7534	1.22	2.100	7.10	63.4
		33 min	10	2.838	2.0648	1.16	2.020	7.20	72.8
		34 min	10	2.953	2.2838	1.24	1.930	7.45	77.3
		35 min	10	2.795	1.9694	1.29	2.065	7.42	70.5
		36 min	10	2.900	2.1706	1.22	2.045	7.13	74.8
		37 min	10	2.968	2.3868	1.20	2.085	7.51	80.4
		38 min	10	3.019	2.2962	1.25	2.080	7.48	76.1
		39 min	10	2.441	1.8548	1.25	1.945	7.47	76.0
		40 min	10	2.522	1.7790	1.28	2.015	7.29	70.5
		41 min	10	2.423	1.8168	1.17	1.925	7.29	75.0
		42 min	10	2.429	1.8545	1.21	1.895	7.40	76.3
		43 min	11	2.556	1.7743	1.24	1.950	7.30	69.4
		44 min	11	2.533	1.8179	1.18	2.000	7.38	71.8
		45 min	11	2.540	1.8663	1.16	2.030	7.48	73.5
		46 min	11	2.658	1.8264	1.18	2.060	7.48	68.7
		47 min	11	2.591	1.8082	1.16	2.040	7.46	69.8
		48 min	11	2.572	1.8383	1.25	1.990	7.56	71.5
		49 min	11	2.547	1.8404	1.09	1.980	7.56	72.3
		50 min	11	2.508	1.9318	0.90	1.990	7.62	77.0
		51 min	10	2.547	1.9752	1.12	2.035	7.59	77.5
		52 min	10	2.609	1.9543	1.19	2.010	7.56	74.9
		53 min	10	2.590	1.9912	1.11	1.995	7.62	76.9
		54 min	10	3.182	2.3832	1.16	2.220	7.57	74.9
		55 min	10	2.576	1.9416	1.06	1.930	7.49	75.4
		56 min	10	2.580	1.9676	0.97	1.955	7.54	76.3
		57 min	10	2.537	2.0007	0.77	1.960	7.60	78.9
		58 min	10	2.560	1.9844	0.98	1.975	7.56	77.5
		59 min	10	2.551	2.0482	1.06	1.925	7.70	80.3
		60 min	10	2.538	2.0230	1.03	1.760	7.70	79.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 35 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	61 min	10	2.625	1.9725	1.16	1.905	7.70	75.1
		62 min	10	2.603	1.9939	1.12	1.910	7.66	76.6
		63 min	10	3.117	2.2541	1.25	2.095	7.63	72.3
		64 min	10	2.556	2.0036	1.06	1.850	7.63	78.4
		65 min	9	2.436	2.0689	1.01	1.870	7.62	84.9
		66 min	9	2.458	2.0563	1.07	1.920	7.65	83.7
		67 min	9	2.463	2.0592	1.13	1.880	7.65	83.6
		68 min	9	2.442	2.0232	1.09	1.880	7.51	82.8
		69 min	9	2.470	2.0465	1.17	1.880	7.60	82.9
		70 min	9	2.486	2.0606	1.12	1.890	7.58	82.9
		71 min	9	2.463	2.0630	1.05	1.780	7.60	83.7
		72 min	9	2.499	2.0157	1.20	1.790	7.51	80.7
		73 min	9	2.513	2.0218	1.10	1.860	7.55	80.4
		74 min	9	2.664	1.9441	1.13	2.010	7.53	73.0
		75 min	9	2.593	1.9734	1.21	1.940	7.51	76.1
		76 min	9	2.526	2.0194	1.17	1.880	7.52	80.0
		77 min	9	2.490	2.0384	1.14	1.860	7.49	81.9
		78 min	9	2.520	2.0312	1.08	1.990	7.46	80.6
		79 min	9	2.552	2.0599	1.06	1.970	7.56	80.7
		80 min	9	2.572	2.0745	1.11	2.000	7.51	80.7
		81 min	9	2.589	2.0577	1.12	2.000	7.55	79.5
		82 min	8	2.674	2.1140	1.12	2.030	7.54	79.1
		83 min	8	2.696	2.0891	1.14	2.060	7.53	77.5
		84 min	8	2.748	2.0788	1.15	2.155	7.55	75.7
		85 min	8	2.670	2.0782	1.14	2.125	7.53	77.8
		86 min	8	2.709	2.0739	1.14	1.945	7.50	76.6
		87 min	8	2.719	2.0367	1.31	2.160	7.51	74.9
		88 min	8	2.685	2.0412	1.29	2.080	7.52	76.0
		89 min	8	3.128	2.1315	1.44	2.065	7.51	68.2
		90 min	8	2.709	1.9833	1.49	2.075	7.49	73.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 36 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	91 min	8	2.610	1.9125	1.33	2.025	7.20	73.3
		92 min	8	2.681	1.9542	1.18	2.165	7.32	72.9
		93 min	8	2.615	2.0412	1.15	2.080	7.53	78.1
		94 min	8	2.635	2.0132	1.33	2.065	7.51	76.4
		95 min	8	2.611	2.0336	1.29	2.015	7.53	77.9
		96 min	8	2.624	1.9795	1.39	2.015	7.42	75.4
		97 min	8	2.714	2.0179	1.26	2.065	7.54	74.4
		98 min	8	2.634	2.0163	1.40	2.015	7.51	76.6
		99 min	8	2.591	2.0035	1.27	1.905	7.42	77.3
		100 min	8	2.580	2.0055	1.28	1.955	7.38	77.7
		101 min	8	2.675	1.9693	1.42	1.990	7.39	73.6
		102 min	8	2.603	1.9569	1.28	1.860	7.29	75.2
		103 min	8	2.656	1.8244	1.45	2.035	7.02	68.7
		104 min	8	2.553	1.8125	1.40	1.945	6.87	71.0
		105 min	8	2.623	1.8107	1.44	2.000	6.94	69.0
		106 min	8	2.549	1.8966	1.24	1.865	7.08	74.4
		107 min	8	2.594	1.9149	1.40	1.870	7.18	73.8
		108 min	8	2.520	1.8406	1.22	1.970	6.87	73.0
		109 min	8	2.491	1.9495	1.02	1.965	7.09	78.3
		110 min	8	2.566	1.9436	1.26	1.910	7.23	75.7
		111 min	8	2.561	1.9391	1.30	1.910	7.21	75.7
		112 min	8	2.420	1.9963	1.10	1.740	7.17	82.5
		113 min	8	2.470	1.9662	1.02	1.880	7.13	79.6
		114 min	8	2.464	1.8888	1.19	1.850	6.97	76.7
		115 min	8	2.503	2.0658	1.13	1.805	7.43	82.6
		116 min	8	2.491	2.0139	1.14	1.810	7.28	80.8
		117 min	8	2.425	1.9081	1.16	1.815	6.98	78.7
		118 min	8	2.465	1.9243	1.17	1.785	7.05	78.1
		119 min	8	2.518	2.0087	1.25	1.780	7.32	79.8
		120 min	8	2.485	1.8705	1.46	1.765	6.97	75.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 37 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	121 min	8	2.490	1.9434	1.32	1.830	7.13	78.0
		122 min	8	2.478	2.1136	1.04	1.795	7.52	85.3
		123 min	8	2.388	2.0320	0.90	1.750	7.19	85.1
		124 min	8	2.419	1.9186	1.07	1.810	6.96	79.3
		125 min	8	2.421	2.0307	0.95	1.815	7.23	83.9
		126 min	8	2.429	1.9471	1.20	1.750	7.04	80.2
		127 min	8	2.521	1.9448	1.25	1.855	7.16	77.1
		128 min	8	2.363	1.6170	1.09	1.820	6.09	68.4
		129 min	8	2.350	1.8272	0.99	1.760	6.58	77.8
		130 min	8	2.333	1.6265	1.00	1.765	6.07	69.7
		131 min	8	1.805	0.5832	1.09	1.780	2.98	32.3
		132 min	8	2.010	0.8836	0.96	1.805	3.60	44.0
		133 min	8	1.863	0.6671	1.13	1.790	3.14	35.8
		134 min	8	1.839	0.6045	1.19	1.730	3.15	32.9
		135 min	8	1.824	0.5862	1.19	1.755	3.00	32.1
		136 min	8	2.035	0.5198	1.38	2.045	3.03	25.5
		137 min	8	2.448	1.6554	1.19	2.025	6.26	67.6
		138 min	8	2.095	1.0331	1.13	1.850	4.17	49.3
		139 min	8	2.190	1.2345	1.20	1.810	4.91	56.4
		140 min	8	1.833	0.5466	1.28	1.630	2.99	29.8
		141 min	8	2.204	1.3762	0.92	1.765	5.24	62.4
		142 min	8	2.389	1.7113	1.08	1.865	6.39	71.6
		143 min	8	2.155	0.9162	0.97	1.990	3.82	42.5
		144 min	8	2.488	1.9519	1.04	1.845	7.10	78.5
		145 min	8	2.080	0.4964	1.38	2.095	2.86	23.9
		146 min	8	3.081	2.3104	1.43	1.960	6.88	75.0
		147 min	8	3.249	2.5426	1.43	2.120	7.56	78.3
		148 min	8	3.066	2.3510	1.41	1.995	7.67	76.7
		149 min	8	3.185	2.4415	1.40	2.145	7.61	76.7
		150 min	8	3.155	2.2345	1.41	2.205	7.03	70.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 38 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	151 min	8	3.155	2.2013	1.40	2.180	6.93	69.8
		152 min	8	2.650	1.7242	1.43	2.060	6.77	65.1
		153 min	8	2.559	1.8561	1.30	2.015	7.07	72.5
		154 min	8	2.539	1.7580	1.44	2.115	6.83	69.2
		155 min	8	2.551	1.7680	1.33	2.135	6.83	69.3
		156 min	8	2.578	1.6889	1.33	2.185	6.63	65.5
		157 min	8	2.838	1.7175	1.44	2.200	6.62	60.5
		158 min	8	2.655	1.7938	1.43	2.125	6.88	67.6
		159 min	8	2.651	1.7292	1.40	2.260	6.75	65.2
		160 min	8	2.661	1.7611	1.37	2.400	6.81	66.2
		161 min	8	2.705	1.7498	1.39	2.390	6.78	64.7
		162 min	8	2.761	1.7174	1.37	2.505	6.61	62.2
		163 min	8	2.723	1.7029	1.36	2.440	6.65	62.5
		164 min	8	2.705	1.6808	1.40	2.445	6.63	62.1
		165 min	8	2.656	1.8431	1.18	2.360	7.02	69.4
		166 min	8	2.606	1.7852	1.12	2.255	6.80	68.5
		167 min	8	2.651	1.7475	1.35	2.240	6.80	65.9
		168 min	8	2.594	1.7858	1.05	2.210	6.78	68.9
		169 min	8	2.681	1.7701	1.36	2.140	6.78	66.0
		170 min	8	2.709	1.8426	1.29	2.250	6.99	68.0
		171 min	8	2.839	1.8957	1.32	2.305	7.08	66.8
		172 min	8	3.208	1.8471	1.31	2.545	7.02	57.6
		173 min	8	3.325	2.0803	1.32	2.525	6.93	62.6
		174 min	8	3.301	2.1553	1.13	2.405	7.09	65.3
		175 min	8	3.269	1.9940	1.08	2.490	6.79	61.0
		176 min	8	2.849	1.8001	1.40	2.315	7.15	63.2
		177 min	8	2.883	1.8511	1.34	2.470	7.24	64.2
		178 min	8	2.969	1.7796	1.48	2.785	7.14	59.9
		179 min	8	2.841	1.7132	1.25	2.675	6.83	60.3
		180 min	8	2.900	1.6970	1.48	2.625	6.90	58.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 39 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	181 min	8	2.923	1.8446	1.38	2.460	7.14	63.1
		182 min	8	2.925	1.8435	0.95	2.560	6.92	63.0
		183 min	8	2.939	1.8002	1.07	2.450	6.71	61.3
		184 min	8	2.889	1.7472	1.33	2.355	6.77	60.5
		185 min	8	2.896	1.8009	1.18	2.380	6.61	62.2
		186 min	7	2.171	0.7215	1.10	2.250	2.96	33.2
		187 min	8	2.200	0.7090	1.11	2.230	3.30	32.2
		188 min	8	2.165	0.6547	1.27	2.235	3.11	30.2
		189 min	8	2.151	0.5297	1.40	2.240	2.81	24.6
		190 min	8	2.266	0.6435	1.32	2.255	3.40	28.4
		191 min	8	2.230	0.6163	1.32	2.190	3.31	27.6
		192 min	8	2.290	0.6339	1.48	2.185	3.24	27.7
		193 min	8	2.201	0.4621	1.51	2.145	2.99	21.0
		194 min	8	2.243	0.5588	1.40	2.170	3.29	24.9
		195 min	8	2.265	0.5572	1.26	2.185	2.97	24.6
		196 min	8	2.144	0.5035	1.26	2.095	3.00	23.5
		197 min	8	2.200	0.5015	1.39	2.075	3.07	22.8
		198 min	8	2.198	0.5314	1.39	2.105	3.03	24.2
		199 min	8	2.181	0.4978	1.38	2.040	3.00	22.8
		200 min	8	2.196	0.4023	1.76	2.065	2.92	18.3
		201 min	8	2.051	0.4218	1.40	1.980	2.86	20.6
		202 min	8	2.179	0.3852	1.83	2.060	3.02	17.7
		203 min	9	2.008	0.5585	1.34	1.830	3.21	27.8
		204 min	9	2.097	0.4465	1.56	1.950	3.00	21.3
		205 min	9	2.028	0.4357	1.33	1.900	2.87	21.5
		206 min	9	2.031	0.4252	1.50	1.950	2.85	20.9
		207 min	8	2.033	0.4803	1.30	1.960	2.89	23.6
		208 min	8	2.035	0.4497	1.46	1.910	2.88	22.1
		209 min	8	1.960	0.5507	1.27	1.925	2.98	28.1
		210 min	8	1.965	0.5890	1.12	1.955	3.10	30.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 40 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	5	211 min	8	1.938	0.5387	1.34	1.865	3.03	27.8
		212 min	8	1.974	0.4380	1.48	1.905	2.89	22.2
		213 min	8	2.070	0.3760	1.55	1.975	2.82	18.2
		214 min	8	2.064	0.3924	1.71	1.975	2.95	19.0
		215 min	8	2.493	1.4531	1.55	1.925	5.94	58.3
		216 min	8	2.433	1.3176	1.49	1.920	5.51	54.2
		217 min	8	1.929	0.4217	1.36	1.920	2.78	21.9
		218 min	8	1.916	0.4231	1.55	1.810	2.81	22.1
		219 min	8	1.863	0.4410	1.40	1.780	2.74	23.7
		220 min	8	1.828	0.4454	1.31	1.765	2.67	24.4
		221 min	8	1.881	0.4488	1.34	1.760	2.73	23.9
		222 min	8	1.815	0.4523	1.07	1.785	2.57	24.9
		223 min	8	1.896	0.4262	1.31	1.945	2.63	22.5
		224 min	8	1.844	0.4005	1.38	1.875	2.54	21.7
		225 min	8	1.945	0.3802	1.45	1.980	2.63	19.5
		226 min	8	2.143	0.5195	1.50	2.090	2.87	24.2
		227 min	8	2.030	0.4579	1.49	1.915	2.69	22.6
		228 min	8	1.939	0.4992	1.26	2.145	2.63	25.7
		229 min	9	1.947	0.4565	1.32	1.930	2.59	23.4
		230 min	9	1.870	0.4122	1.40	2.050	2.55	22.0
		231 min	9	1.951	0.5143	1.27	1.940	2.70	26.4
		232 min	9	1.853	0.5052	1.09	1.960	2.61	27.3
		233 min	9	1.873	0.5708	0.95	2.120	2.71	30.5
		234 min	9	1.806	0.4182	1.32	1.730	2.55	23.2
		235 min	8	1.753	0.4477	1.30	1.595	2.56	25.5
		236 min	9	1.986	0.7755	1.37	1.600	3.79	39.1
		237 min	9	1.986	0.7775	1.19	1.740	3.73	39.2
		238 min	9	1.936	0.7695	1.24	1.560	3.61	39.8
		239 min	9	1.971	0.8544	1.20	1.430	3.78	43.3
		240 min	5	2.394	0.9358	1.51	2.540	3.80	39.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 41 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	1 min	12	2.899	1.7467	1.24	2.330	6.75	60.2
		2 min	12	3.217	2.0459	1.33	2.350	7.03	63.6
		3 min	12	3.406	2.1848	1.12	2.550	7.70	64.1
		4 min	12	2.797	1.5626	1.07	2.470	6.95	55.9
		5 min	12	2.959	1.7182	1.25	2.440	7.01	58.1
		6 min	12	2.633	1.6264	0.95	2.245	6.95	61.8
		7 min	12	2.765	1.6336	1.09	2.320	6.97	59.1
		8 min	12	2.701	1.6753	1.12	2.130	7.01	62.0
		9 min	12	2.775	1.4993	1.23	2.210	6.79	54.0
		10 min	12	2.628	1.5110	1.20	2.100	6.84	57.5
		11 min	12	2.861	1.5739	1.31	2.165	6.86	55.0
		12 min	12	2.762	1.5314	1.30	2.195	6.90	55.5
		13 min	12	2.604	1.4964	1.28	2.120	6.77	57.5
		14 min	12	2.571	1.5487	1.06	2.100	6.87	60.2
		15 min	12	2.575	1.5778	0.84	2.120	6.95	61.3
		16 min	12	2.655	1.5618	1.46	2.160	7.07	58.8
		17 min	12	2.601	1.5661	1.39	2.130	6.93	60.2
		18 min	12	2.575	1.5984	1.27	2.120	7.07	62.1
		19 min	12	2.588	1.5858	0.96	2.095	6.97	61.3
		20 min	12	2.553	1.5513	1.09	2.135	6.87	60.8
		21 min	12	2.603	1.5480	1.29	2.125	7.00	59.5
		22 min	12	2.553	1.5868	1.35	2.000	7.09	62.1
		23 min	12	2.803	1.7908	1.12	2.190	7.06	63.9
		24 min	12	2.533	1.6176	1.24	2.015	7.17	63.9
		25 min	12	2.473	1.5493	1.01	2.015	6.82	62.7
		26 min	12	2.477	1.6017	1.30	1.955	7.04	64.7
		27 min	12	2.467	1.6443	1.04	1.945	7.11	66.7
		28 min	12	2.462	1.5634	1.06	1.990	6.89	63.5
		29 min	12	2.451	1.5686	0.99	1.955	6.87	64.0
		30 min	12	2.469	1.7313	1.18	1.950	7.43	70.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 42 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	31 min	12	2.479	1.6851	0.96	1.935	7.34	68.0
		32 min	11	2.530	1.6554	1.06	1.990	6.97	65.4
		33 min	10	2.365	1.6946	0.97	1.950	6.95	71.7
		34 min	10	2.409	1.7169	0.99	1.980	7.06	71.3
		35 min	10	2.454	1.7323	1.21	2.060	7.16	70.6
		36 min	10	2.387	1.7079	1.39	1.875	7.09	71.5
		37 min	10	2.387	1.7474	1.21	1.895	7.19	73.2
		38 min	10	2.462	1.8075	1.10	2.070	7.36	73.4
		39 min	10	2.366	1.7160	1.33	1.835	7.04	72.5
		40 min	10	2.394	1.7417	1.34	1.890	7.15	72.8
		41 min	10	2.314	1.7134	0.98	1.905	6.91	74.0
		42 min	10	2.338	1.7264	1.22	1.895	6.98	73.8
		43 min	11	2.412	1.5786	1.17	1.990	6.59	65.5
		44 min	11	2.445	1.7777	1.15	2.040	7.24	72.7
		45 min	11	2.505	1.7418	1.29	2.080	7.24	69.5
		46 min	11	2.488	1.7069	1.28	2.020	7.09	68.6
		47 min	11	2.565	1.7184	1.35	2.040	7.19	67.0
		48 min	11	2.529	1.7207	1.31	2.000	7.22	68.0
		49 min	11	2.687	1.7755	1.14	2.050	7.35	66.1
		50 min	11	2.455	1.8299	0.88	2.050	7.33	74.5
		51 min	10	2.610	1.9162	1.00	2.060	7.54	73.4
		52 min	10	2.638	1.9923	1.29	2.050	7.80	75.5
		53 min	10	3.147	2.2258	1.03	2.250	7.48	70.7
		54 min	10	3.170	2.4062	0.84	2.235	7.51	75.9
		55 min	10	2.563	1.8617	1.27	2.015	7.34	72.6
		56 min	10	3.067	2.1683	1.09	2.290	7.81	70.7
		57 min	10	2.605	1.9662	1.07	2.005	7.41	75.5
		58 min	10	3.108	2.0687	1.28	2.255	7.22	66.6
		59 min	10	2.887	2.0715	0.66	2.150	7.61	71.8
		60 min	10	3.185	2.3748	1.23	2.135	7.48	74.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 43 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	61 min	10	3.216	2.4526	1.03	2.135	7.59	76.3
		62 min	10	2.897	1.9584	1.01	2.150	7.44	67.6
		63 min	10	3.184	2.2572	1.15	2.150	7.38	70.9
		64 min	10	2.973	2.0646	1.17	2.135	7.44	69.4
		65 min	9	2.424	2.0407	0.51	1.900	7.44	84.2
		66 min	9	3.048	2.5459	0.52	2.000	7.38	83.5
		67 min	9	3.071	2.4788	0.80	1.970	7.42	80.7
		68 min	9	2.979	2.2578	0.86	1.980	7.32	75.8
		69 min	9	2.390	2.0091	0.64	1.910	7.35	84.1
		70 min	9	2.533	2.0094	1.17	1.940	7.53	79.3
		71 min	9	2.494	2.0312	1.12	1.840	7.52	81.4
		72 min	9	3.031	2.2769	1.11	2.060	7.33	75.1
		73 min	9	3.153	2.4085	1.22	2.050	7.44	76.4
		74 min	9	3.120	2.3689	1.32	2.060	7.48	75.9
		75 min	9	3.044	2.4035	0.94	2.050	7.38	78.9
		76 min	9	3.126	2.3352	1.11	2.110	7.38	74.7
		77 min	9	3.158	2.3494	1.20	2.020	7.37	74.4
		78 min	9	2.568	1.9717	0.70	2.000	7.38	76.8
		79 min	9	2.533	1.9623	1.18	1.970	7.42	77.5
		80 min	9	2.502	1.9688	1.21	1.850	7.47	78.7
		81 min	9	2.942	2.0568	1.30	2.030	7.45	69.9
		82 min	8	3.224	2.3110	1.11	2.080	7.45	71.7
		83 min	8	2.673	2.0311	1.25	2.025	7.45	76.0
		84 min	8	2.720	1.9874	1.30	2.035	7.43	73.1
		85 min	8	2.639	2.0286	1.17	2.070	7.37	76.9
		86 min	8	2.628	2.0400	1.10	2.055	7.45	77.6
		87 min	8	3.273	2.3586	1.14	2.135	7.49	72.1
		88 min	8	3.175	2.2167	1.13	2.070	7.33	69.8
		89 min	8	3.245	2.3367	1.34	2.050	7.39	72.0
		90 min	8	3.278	2.4320	1.18	2.055	7.36	74.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 44 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	91 min	8	3.329	2.4805	1.19	2.085	7.37	74.5
		92 min	8	2.699	1.9248	0.97	2.155	7.26	71.3
		93 min	8	2.548	2.0190	1.15	2.040	7.41	79.3
		94 min	8	2.970	2.0032	1.29	2.215	7.28	67.4
		95 min	8	3.313	2.5114	1.27	2.175	7.35	75.8
		96 min	8	3.348	2.5107	1.49	2.140	7.45	75.0
		97 min	8	2.834	1.8838	1.48	2.235	7.31	66.5
		98 min	8	2.603	1.9261	1.40	1.950	7.26	74.0
		99 min	8	2.574	1.9990	1.27	1.930	7.39	77.7
		100 min	8	2.550	1.9540	1.15	1.935	7.22	76.6
		101 min	8	2.554	1.9621	1.33	1.860	7.27	76.8
		102 min	8	2.561	1.9675	1.36	1.850	7.28	76.8
		103 min	8	2.559	1.8833	1.27	1.905	7.06	73.6
		104 min	8	2.563	1.8867	1.33	1.885	7.07	73.6
		105 min	8	2.570	1.9074	1.26	1.945	7.12	74.2
		106 min	8	2.541	1.9137	1.12	1.945	7.11	75.3
		107 min	8	2.549	1.8910	1.33	1.945	7.08	74.2
		108 min	8	2.429	1.9068	0.83	1.895	6.89	78.5
		109 min	8	2.356	1.9051	0.89	1.845	6.82	80.9
		110 min	8	2.849	1.9844	0.98	2.135	7.20	69.7
		111 min	8	2.510	1.8007	1.23	1.950	6.76	71.7
		112 min	8	2.510	1.8978	1.27	1.835	7.08	75.6
		113 min	8	2.430	1.8988	0.98	1.890	6.94	78.1
		114 min	8	2.436	1.8953	0.97	1.910	6.94	77.8
		115 min	8	2.405	1.8119	0.90	1.895	6.68	75.3
		116 min	8	2.456	1.8590	1.22	1.845	6.88	75.7
		117 min	8	2.381	1.8580	0.90	1.845	6.77	78.0
		118 min	8	2.364	1.8557	0.98	1.770	6.78	78.5
		119 min	8	2.440	1.8585	1.02	1.805	6.84	76.2
		120 min	8	2.476	1.8540	1.05	1.825	6.88	74.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 45 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	121 min	8	2.308	1.7907	0.93	1.760	6.49	77.6
		122 min	8	2.943	2.1011	0.97	2.030	6.99	71.4
		123 min	8	2.480	1.9318	0.95	1.850	7.09	77.9
		124 min	8	2.965	2.2858	0.93	1.970	6.93	77.1
		125 min	8	3.115	2.4814	0.92	2.050	7.53	79.7
		126 min	8	2.850	1.8938	1.16	2.030	6.42	66.4
		127 min	8	2.544	1.9454	1.43	1.825	7.24	76.5
		128 min	8	2.406	1.7271	1.30	1.765	6.52	71.8
		129 min	8	1.853	0.5076	1.18	1.855	2.74	27.4
		130 min	8	2.276	1.5497	1.15	1.775	5.93	68.1
		131 min	8	1.838	0.4602	1.49	1.690	2.88	25.0
		132 min	8	2.309	1.5943	1.26	1.730	6.09	69.1
		133 min	8	2.374	1.8281	1.06	1.805	6.70	77.0
		134 min	8	2.345	1.5634	1.43	1.725	6.06	66.7
		135 min	8	2.310	1.6154	1.34	1.715	6.15	69.9
		136 min	8	1.966	0.4395	1.39	1.930	2.66	22.4
		137 min	8	2.475	1.9239	1.40	1.775	7.11	77.7
		138 min	8	2.490	2.0593	1.21	1.815	7.45	82.7
		139 min	8	2.235	1.3524	1.36	1.755	5.40	60.5
		140 min	8	1.773	0.5112	1.20	1.620	2.68	28.8
		141 min	8	1.630	0.6428	0.74	1.550	2.81	39.4
		142 min	8	2.430	1.6075	1.33	2.070	6.25	66.2
		143 min	8	2.179	0.8267	1.38	1.995	3.88	37.9
		144 min	8	1.921	0.5821	1.35	1.840	2.79	30.3
		145 min	8	1.830	0.4686	1.30	1.775	2.67	25.6
		146 min	8	2.371	1.4884	1.40	1.825	5.91	62.8
		147 min	8	2.238	1.2731	1.45	1.825	5.26	56.9
		148 min	8	2.345	1.6060	1.39	1.855	6.23	68.5
		149 min	8	2.558	1.4012	1.44	2.095	5.40	54.8
		150 min	8	2.086	0.4489	1.40	2.105	2.67	21.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 46 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	151 min	8	1.935	0.3249	1.30	1.990	2.32	16.8
		152 min	8	2.029	0.3566	1.45	2.105	2.48	17.6
		153 min	8	2.074	0.2978	1.47	2.135	2.48	14.4
		154 min	8	2.048	0.4700	1.44	2.085	3.00	23.0
		155 min	8	2.105	1.0379	0.64	2.110	4.26	49.3
		156 min	8	2.163	1.2132	0.45	2.085	4.76	56.1
		157 min	8	2.266	1.4135	0.50	2.095	5.42	62.4
		158 min	8	2.310	1.4578	0.56	2.115	5.60	63.1
		159 min	8	2.386	1.3998	0.82	2.215	5.50	58.7
		160 min	8	2.366	1.4798	0.73	2.250	5.65	62.5
		161 min	8	2.488	1.7827	0.43	2.355	6.47	71.7
		162 min	8	2.494	1.8136	0.45	2.320	6.54	72.7
		163 min	8	2.545	1.6640	1.28	2.265	6.44	65.4
		164 min	8	3.261	2.2277	1.43	2.370	7.00	68.3
		165 min	8	2.930	1.5649	1.43	2.420	6.22	53.4
		166 min	8	2.763	1.6352	1.38	2.230	6.54	59.2
		167 min	8	3.104	2.0257	1.44	2.250	6.51	65.3
		168 min	8	2.874	1.7677	1.33	2.250	6.57	61.5
		169 min	8	2.633	1.6042	1.43	2.215	6.49	60.9
		170 min	8	2.529	1.4601	1.12	2.265	5.96	57.7
		171 min	8	3.144	2.0040	1.37	2.250	6.56	63.7
		172 min	8	3.224	2.0603	1.42	2.285	6.85	63.9
		173 min	8	3.234	2.1910	1.28	2.245	7.08	67.8
		174 min	8	3.211	2.0376	1.24	2.275	6.74	63.5
		175 min	8	3.128	2.0483	0.99	2.255	6.77	65.5
		176 min	8	3.275	2.0113	1.82	2.335	6.93	61.4
		177 min	8	3.165	1.7582	1.61	2.375	6.09	55.6
		178 min	8	3.159	1.7246	1.56	2.395	6.53	54.6
		179 min	8	3.429	1.8391	1.62	2.520	6.66	53.6
		180 min	8	3.564	1.8925	1.65	2.515	6.24	53.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 47 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	181 min	8	3.414	1.9248	1.43	2.440	6.44	56.4
		182 min	8	3.144	1.5893	1.54	2.555	6.55	50.6
		183 min	8	2.991	1.6658	1.51	2.475	6.83	55.7
		184 min	8	2.851	1.5837	1.62	2.280	6.65	55.5
		185 min	8	2.859	1.4241	1.51	2.310	6.03	49.8
		186 min	7	3.086	1.6459	1.59	2.250	6.26	53.3
		187 min	8	2.888	1.4576	1.52	2.205	5.94	50.5
		188 min	8	2.644	1.4595	1.39	2.180	6.11	55.2
		189 min	8	2.693	1.2158	1.34	2.175	4.74	45.2
		190 min	8	2.448	0.7658	1.32	2.250	3.88	31.3
		191 min	8	2.395	0.8367	1.16	2.185	4.08	34.9
		192 min	8	2.191	0.3747	1.70	2.100	2.80	17.1
		193 min	8	2.029	0.4932	1.31	2.075	2.85	24.3
		194 min	8	2.170	0.5552	1.43	2.070	3.08	25.6
		195 min	8	2.040	0.5339	1.14	2.040	2.81	26.2
		196 min	8	2.104	0.5239	1.36	2.030	3.04	24.9
		197 min	8	2.209	0.5051	1.35	2.120	2.94	22.9
		198 min	8	2.296	0.6352	1.44	2.145	3.49	27.7
		199 min	8	2.200	0.5295	1.26	2.130	2.89	24.1
		200 min	8	1.984	0.4675	1.33	1.925	2.81	23.6
		201 min	8	1.995	0.4136	1.44	1.930	2.80	20.7
		202 min	8	1.959	0.4968	1.34	1.945	2.89	25.4
		203 min	9	2.024	0.4672	1.24	2.020	2.91	23.1
		204 min	9	1.917	0.4699	1.27	1.830	2.87	24.5
		205 min	9	1.922	0.4738	1.28	1.870	2.89	24.6
		206 min	9	1.976	0.5199	1.28	1.970	2.83	26.3
		207 min	8	1.911	0.5213	1.22	1.905	2.87	27.3
		208 min	8	1.899	0.4940	1.33	1.885	2.80	26.0
		209 min	8	1.864	0.5314	1.13	1.895	2.79	28.5
		210 min	8	1.924	0.4665	1.40	1.900	2.81	24.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 48 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	6	211 min	8	2.483	1.7378	1.34	1.920	6.64	70.0
		212 min	8	2.603	1.8270	1.54	1.920	7.02	70.2
		213 min	8	2.626	1.7850	1.47	2.040	6.94	68.0
		214 min	8	2.578	1.7849	1.57	1.925	6.90	69.2
		215 min	8	2.569	1.8188	1.56	1.810	6.97	70.8
		216 min	8	2.518	1.7481	1.49	1.815	6.72	69.4
		217 min	8	2.404	1.5540	1.36	1.750	6.11	64.7
		218 min	8	2.541	1.6848	1.61	1.835	6.62	66.3
		219 min	8	2.118	0.7185	1.39	1.835	3.57	33.9
		220 min	8	2.404	1.6351	1.32	1.795	6.31	68.0
		221 min	8	2.208	0.9456	1.51	1.805	4.38	42.8
		222 min	8	2.355	1.3997	1.35	1.840	5.70	59.4
		223 min	8	2.234	0.9847	1.40	1.870	4.52	44.1
		224 min	8	2.204	1.0500	1.43	1.825	4.64	47.6
		225 min	8	2.354	1.2630	1.49	1.940	5.37	53.7
		226 min	8	2.443	1.5490	1.62	1.860	6.20	63.4
		227 min	8	2.279	1.0966	1.48	1.885	4.88	48.1
		228 min	8	2.339	1.3400	1.13	2.040	5.45	57.3
		229 min	9	2.508	1.9296	1.42	2.020	7.55	76.9
		230 min	9	1.797	0.4161	1.29	1.890	2.51	23.2
		231 min	9	1.838	0.4067	1.36	1.850	2.53	22.1
		232 min	9	1.874	0.4868	1.21	1.870	2.56	26.0
		233 min	9	1.856	0.4068	1.31	1.930	2.52	21.9
		234 min	9	1.843	0.4010	1.34	1.800	2.51	21.8
		235 min	8	1.713	0.4147	1.31	1.610	2.49	24.2
		236 min	9	1.986	0.7453	1.41	1.700	3.80	37.5
		237 min	9	2.390	1.4459	1.26	1.840	5.67	60.5
		238 min	9	2.090	0.7757	1.30	1.890	3.68	37.1
		239 min	9	2.060	0.7445	1.21	1.870	3.71	36.1
		240 min	5	2.474	0.8066	1.57	2.340	3.77	32.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 49 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	1 min	12	2.981	1.7790	1.43	2.345	6.77	59.7
		2 min	12	2.908	1.7058	1.08	2.425	6.97	58.7
		3 min	12	2.656	1.5873	0.92	2.130	6.93	59.8
		4 min	12	2.997	1.6774	1.04	2.600	6.86	56.0
		5 min	12	3.163	1.9459	1.08	2.610	6.88	61.5
		6 min	12	2.775	1.6461	1.03	2.380	6.82	59.3
		7 min	12	2.957	1.8109	0.96	2.240	6.65	61.2
		8 min	12	3.028	1.8767	1.11	2.385	6.76	62.0
		9 min	12	3.052	1.8977	1.17	2.400	6.77	62.2
		10 min	12	2.650	1.4856	1.22	2.120	6.63	56.1
		11 min	12	2.872	1.5240	1.34	2.360	6.70	53.1
		12 min	12	2.952	1.7981	1.31	2.225	6.98	60.9
		13 min	12	2.594	1.3864	1.28	2.100	6.29	53.4
		14 min	12	2.532	1.4548	1.22	2.010	6.43	57.5
		15 min	12	2.699	1.4705	1.13	2.190	6.69	54.5
		16 min	12	3.004	1.9139	1.08	2.175	6.82	63.7
		17 min	12	3.000	1.9260	1.32	2.080	7.01	64.2
		18 min	12	2.817	1.7017	0.76	2.175	7.18	60.4
		19 min	12	3.064	2.0417	1.14	2.130	7.27	66.6
		20 min	12	2.798	1.6742	0.87	2.110	7.34	59.8
		21 min	12	2.915	1.7987	1.12	2.100	7.33	61.7
		22 min	12	2.634	1.6571	1.13	2.065	7.35	62.9
		23 min	12	2.612	1.6746	1.13	2.055	7.43	64.1
		24 min	12	2.529	1.7000	0.72	1.990	7.27	67.2
		25 min	12	2.573	1.5481	1.13	2.005	6.92	60.2
		26 min	12	2.474	1.7507	1.00	1.980	7.37	70.8
		27 min	12	2.499	1.7064	0.72	2.015	7.27	68.3
		28 min	12	2.453	1.6089	0.78	1.985	6.87	65.6
		29 min	12	2.455	1.6605	0.76	1.935	7.07	67.6
		30 min	12	2.427	1.7003	0.83	1.875	7.17	70.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 50 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	31 min	12	2.373	1.3736	0.93	1.850	6.02	57.9
		32 min	11	2.529	1.6785	1.02	1.880	6.98	66.4
		33 min	10	2.362	1.6194	0.97	2.000	6.74	68.6
		34 min	10	2.363	1.5616	1.16	1.865	6.59	66.1
		35 min	10	2.416	1.6579	0.92	1.865	6.79	68.6
		36 min	10	2.260	1.7049	0.56	1.835	6.78	75.4
		37 min	10	2.310	1.7782	0.71	1.835	7.08	77.0
		38 min	10	2.789	2.1298	0.55	2.000	6.86	76.4
		39 min	10	2.906	2.2019	1.12	1.975	7.48	75.8
		40 min	10	2.472	1.6627	0.75	1.990	6.69	67.3
		41 min	10	2.736	2.0619	0.76	1.965	7.47	75.4
		42 min	10	2.845	2.2515	0.78	1.985	7.35	79.1
		43 min	11	2.395	1.7471	0.63	1.980	6.91	73.0
		44 min	11	2.985	2.1212	1.02	2.030	7.12	71.1
		45 min	11	2.948	2.1973	0.64	2.090	7.55	74.5
		46 min	11	2.987	2.2933	0.69	2.030	7.34	76.8
		47 min	11	2.892	2.1274	0.69	2.050	7.46	73.6
		48 min	11	2.832	1.9351	0.84	2.100	7.00	68.3
		49 min	11	2.863	2.0463	0.90	2.000	7.52	71.5
		50 min	11	2.490	1.9223	1.01	2.010	7.66	77.2
		51 min	10	3.104	2.3768	0.55	2.200	7.48	76.6
		52 min	10	2.985	2.0423	0.85	2.255	7.22	68.4
		53 min	10	3.018	2.0482	0.98	2.220	7.02	67.9
		54 min	10	3.104	2.3603	0.55	2.230	7.39	76.0
		55 min	10	2.934	1.9888	1.18	2.205	7.28	67.8
		56 min	10	3.024	2.3060	0.60	2.195	7.15	76.3
		57 min	10	2.963	2.1429	0.86	2.160	7.19	72.3
		58 min	10	2.963	2.0859	0.77	2.205	6.97	70.4
		59 min	10	2.469	1.9637	0.69	1.965	7.33	79.5
		60 min	10	2.846	1.9689	0.94	2.115	7.44	69.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 51 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	61 min	10	3.161	2.3973	0.88	2.140	7.41	75.8
		62 min	10	2.958	2.1729	0.60	2.135	7.52	73.5
		63 min	10	3.157	2.4262	0.64	2.130	7.37	76.9
		64 min	10	2.536	1.9252	0.67	1.995	7.34	75.9
		65 min	9	2.408	2.0373	0.88	1.940	7.48	84.6
		66 min	9	3.072	2.3996	1.10	2.010	7.35	78.1
		67 min	9	3.102	2.5149	0.91	1.960	7.50	81.1
		68 min	9	2.994	2.3170	0.75	1.960	7.26	77.4
		69 min	9	2.394	1.9998	0.58	1.890	7.37	83.5
		70 min	9	3.062	2.4751	0.66	1.980	7.43	80.8
		71 min	9	3.212	2.6563	1.15	1.990	8.01	82.7
		72 min	9	3.190	2.6342	1.26	2.050	8.04	82.6
		73 min	9	3.089	2.4937	1.13	2.020	7.44	80.7
		74 min	9	3.192	2.2714	1.37	2.250	7.48	71.2
		75 min	9	3.100	2.3741	0.91	2.050	7.30	76.6
		76 min	9	3.021	2.1515	1.26	2.050	7.39	71.2
		77 min	9	2.893	2.1933	0.63	1.910	7.37	75.8
		78 min	9	3.150	2.3378	1.42	1.990	7.31	74.2
		79 min	9	3.060	2.1994	1.23	2.020	7.23	71.9
		80 min	9	3.181	2.2945	1.53	2.030	7.36	72.1
		81 min	9	3.124	2.3879	1.37	1.990	7.42	76.4
		82 min	8	3.359	2.5036	1.20	2.085	7.51	74.5
		83 min	8	3.369	2.5733	1.21	2.060	7.53	76.4
		84 min	8	3.370	2.4984	1.31	2.020	7.48	74.1
		85 min	8	3.246	2.2760	1.30	2.030	7.33	70.1
		86 min	8	3.265	2.4435	1.21	2.075	7.44	74.8
		87 min	8	3.005	2.0773	1.34	2.065	7.48	69.1
		88 min	8	3.184	2.2814	1.37	2.020	7.46	71.7
		89 min	8	3.380	2.5472	1.57	1.960	7.50	75.4
		90 min	8	3.376	2.5102	1.62	2.030	7.49	74.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 52 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	91 min	8	3.384	2.4602	1.70	2.000	7.46	72.7
		92 min	8	3.365	2.4233	1.74	2.000	7.28	72.0
		93 min	8	3.355	2.3181	1.81	2.090	7.30	69.1
		94 min	8	3.344	2.1358	1.67	2.380	7.31	63.9
		95 min	8	3.344	2.2115	1.67	2.185	7.21	66.1
		96 min	8	3.418	2.4049	1.76	2.100	7.38	70.4
		97 min	8	3.268	2.1894	1.71	2.085	7.35	67.0
		98 min	8	3.319	2.3234	1.80	2.055	7.33	70.0
		99 min	8	3.311	2.3595	1.74	2.065	7.48	71.3
		100 min	8	2.598	1.9527	1.15	1.945	7.29	75.2
		101 min	8	3.224	2.1943	1.65	2.045	7.26	68.1
		102 min	8	2.914	1.8894	1.70	2.000	7.20	64.8
		103 min	8	2.741	1.8761	1.69	2.080	7.28	68.4
		104 min	8	2.630	1.9072	1.56	1.905	7.22	72.5
		105 min	8	3.220	2.2124	1.64	2.090	7.10	68.7
		106 min	8	2.483	1.6693	1.18	1.915	6.39	67.2
		107 min	8	2.605	1.5747	1.67	2.015	6.35	60.4
		108 min	8	2.555	1.6783	1.36	1.940	6.52	65.7
		109 min	8	2.611	1.7391	1.64	1.950	6.79	66.6
		110 min	8	3.183	2.1076	1.69	2.190	7.03	66.2
		111 min	8	2.939	1.6998	1.64	2.355	6.70	57.8
		112 min	8	2.366	1.3564	1.13	1.905	5.48	57.3
		113 min	8	2.634	1.6945	1.55	2.005	6.71	64.3
		114 min	8	3.063	1.9144	1.64	2.095	6.60	62.5
		115 min	8	3.238	2.2722	1.49	2.105	7.00	70.2
		116 min	8	2.630	1.6764	1.59	2.055	6.66	63.7
		117 min	8	3.231	2.2779	1.51	2.080	7.12	70.5
		118 min	8	3.235	2.2413	1.60	2.025	6.86	69.3
		119 min	8	2.911	1.7984	1.59	2.115	6.69	61.8
		120 min	8	2.693	1.6486	1.64	2.050	6.61	61.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 53 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	121 min	8	2.850	1.8003	1.59	2.025	6.72	63.2
		122 min	8	2.641	1.5943	1.57	1.975	6.33	60.4
		123 min	8	3.026	2.0321	1.53	1.985	6.87	67.1
		124 min	8	2.863	1.7898	1.38	2.015	6.25	62.5
		125 min	8	3.105	2.0228	1.53	2.185	6.63	65.1
		126 min	8	2.434	1.4944	1.43	1.965	5.95	61.4
		127 min	8	2.481	1.7926	1.48	1.710	6.75	72.2
		128 min	8	2.429	1.8400	1.08	1.755	6.74	75.8
		129 min	8	2.350	1.6413	1.06	1.725	6.14	69.8
		130 min	8	2.266	1.3773	0.96	1.780	5.34	60.8
		131 min	8	2.146	1.1024	1.21	1.780	4.51	51.4
		132 min	8	2.274	1.4114	0.93	1.815	5.46	62.1
		133 min	8	2.116	1.2161	0.74	1.730	4.64	57.5
		134 min	8	2.511	1.9093	1.08	1.790	7.00	76.0
		135 min	8	2.551	2.0511	0.98	1.765	7.38	80.4
		136 min	8	2.505	2.0729	1.26	1.710	7.47	82.8
		137 min	8	2.546	2.1090	1.17	1.750	7.55	82.8
		138 min	8	2.541	2.1520	1.05	1.770	7.67	84.7
		139 min	8	2.418	1.9313	1.01	1.765	7.00	79.9
		140 min	8	1.726	0.6387	0.69	1.565	2.80	37.0
		141 min	8	2.464	1.9879	0.97	1.790	7.16	80.7
		142 min	8	2.434	2.0083	0.94	1.860	7.21	82.5
		143 min	8	2.495	1.9723	0.89	2.005	7.16	79.1
		144 min	8	2.359	1.3954	1.33	2.045	5.59	59.2
		145 min	8	2.503	2.0636	1.22	1.865	7.44	82.5
		146 min	8	2.471	1.9909	0.99	1.845	7.24	80.6
		147 min	8	2.558	1.9300	1.40	1.990	7.23	75.5
		148 min	8	2.499	1.9363	1.29	1.970	7.16	77.5
		149 min	8	2.926	1.9813	1.39	2.115	7.22	67.7
		150 min	8	2.660	1.8594	1.40	2.090	7.17	69.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 54 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	151 min	8	2.971	2.3772	0.93	2.030	7.03	80.0
		152 min	8	2.539	1.8433	1.28	2.035	6.94	72.6
		153 min	8	2.683	1.7968	1.44	2.020	7.01	67.0
		154 min	8	2.659	1.7729	1.45	2.110	6.97	66.7
		155 min	8	2.719	1.7371	1.37	2.140	6.87	63.9
		156 min	8	2.840	1.7274	1.43	2.130	6.75	60.8
		157 min	8	3.558	2.2597	1.39	2.250	6.85	63.5
		158 min	8	3.208	2.1585	1.38	2.340	7.33	67.3
		159 min	8	3.173	2.0888	1.41	2.335	7.15	65.8
		160 min	8	3.666	2.2967	1.44	2.390	6.95	62.6
		161 min	8	3.095	2.1310	1.23	2.265	7.22	68.9
		162 min	8	3.188	2.1760	1.38	2.330	6.94	68.3
		163 min	8	3.210	2.2080	1.34	2.385	7.19	68.8
		164 min	8	3.254	2.2228	1.46	2.390	6.96	68.3
		165 min	8	3.255	2.1625	1.37	2.300	6.71	66.4
		166 min	8	3.218	2.1010	1.38	2.470	6.68	65.3
		167 min	8	3.168	2.1396	1.45	2.225	6.67	67.5
		168 min	8	3.113	2.1196	1.37	2.200	6.87	68.1
		169 min	8	2.726	1.7315	1.36	2.170	6.77	63.5
		170 min	8	2.729	1.7099	1.39	2.175	6.72	62.7
		171 min	8	3.213	2.2627	1.33	2.180	6.86	70.4
		172 min	8	3.250	2.2819	1.38	2.125	7.07	70.2
		173 min	8	3.335	2.3090	1.21	2.305	7.22	69.2
		174 min	8	3.159	2.1534	0.97	2.140	7.02	68.2
		175 min	8	3.134	2.1015	0.90	2.225	6.70	67.1
		176 min	8	3.356	2.0756	1.42	2.530	6.79	61.8
		177 min	8	3.788	2.3130	1.50	2.505	6.96	61.1
		178 min	8	3.108	1.7641	1.37	2.460	6.62	56.8
		179 min	8	3.225	1.7722	1.38	2.540	6.70	55.0
		180 min	8	3.419	1.9006	1.50	2.545	6.91	55.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 55 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	181 min	8	3.451	2.0011	1.38	2.445	6.86	58.0
		182 min	8	3.733	2.2132	1.45	2.550	6.49	59.3
		183 min	8	3.756	2.3141	1.46	2.435	6.60	61.6
		184 min	8	3.754	2.3270	1.32	2.470	6.84	62.0
		185 min	8	3.764	2.3266	1.40	2.460	6.73	61.8
		186 min	7	3.193	1.8880	1.49	2.160	6.52	59.1
		187 min	8	2.985	1.8132	1.34	2.135	6.46	60.7
		188 min	8	2.856	1.7272	1.17	2.095	6.43	60.5
		189 min	8	2.935	1.7215	1.53	2.120	6.49	58.7
		190 min	8	3.063	1.9905	1.38	2.230	7.13	65.0
		191 min	8	2.995	1.8414	1.30	2.150	6.58	61.5
		192 min	8	3.033	1.9128	1.42	2.135	7.08	63.1
		193 min	8	2.800	1.8301	1.51	2.060	7.17	65.4
		194 min	8	2.759	1.8347	1.34	2.045	7.11	66.5
		195 min	8	2.816	1.9422	1.25	2.100	7.41	69.0
		196 min	8	2.859	1.7322	1.40	2.340	6.95	60.6
		197 min	8	2.770	1.7038	1.34	2.170	6.79	61.5
		198 min	8	2.700	1.6502	1.41	2.035	6.62	61.1
		199 min	8	2.690	1.6588	1.26	2.055	6.59	61.7
		200 min	8	2.678	1.6711	1.38	2.095	6.64	62.4
		201 min	8	2.628	1.7450	1.45	2.050	6.81	66.4
		202 min	8	2.664	1.8629	1.39	2.045	7.12	69.9
		203 min	9	2.530	1.7191	1.28	2.030	6.94	67.9
		204 min	9	2.553	1.8240	1.37	1.850	7.27	71.4
		205 min	9	2.602	1.7100	1.33	2.100	7.01	65.7
		206 min	9	2.691	1.7262	1.35	2.080	6.98	64.1
		207 min	8	2.623	1.7926	1.45	2.040	6.92	68.4
		208 min	8	2.599	1.8013	1.34	2.015	6.94	69.3
		209 min	8	2.479	1.3729	1.48	2.055	5.71	55.4
		210 min	8	1.974	0.4620	1.42	1.880	2.98	23.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 56 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	7	211 min	8	2.553	1.7357	1.49	1.970	6.70	68.0
		212 min	8	2.620	1.9334	1.26	1.985	7.26	73.8
		213 min	8	2.621	1.8553	1.49	1.960	7.09	70.8
		214 min	8	2.609	1.8986	1.49	1.940	7.19	72.8
		215 min	8	2.551	1.8615	1.53	1.845	7.05	73.0
		216 min	8	2.586	1.9047	1.54	1.845	7.17	73.6
		217 min	8	2.463	1.5581	1.41	1.870	6.16	63.3
		218 min	8	2.593	1.7831	1.61	1.885	6.89	68.8
		219 min	8	2.558	1.7674	1.51	1.840	6.81	69.1
		220 min	8	2.566	1.9467	1.44	1.800	7.27	75.9
		221 min	8	2.530	1.8650	1.37	1.850	7.02	73.7
		222 min	8	2.483	1.8489	1.25	1.835	6.95	74.5
		223 min	8	2.523	1.8641	1.46	1.845	7.06	73.9
		224 min	8	2.520	1.8146	1.53	1.795	6.93	72.0
		225 min	8	2.626	1.8952	1.65	1.870	7.23	72.2
		226 min	8	2.390	1.1800	1.57	1.985	5.15	49.4
		227 min	8	2.190	0.6970	1.59	2.005	3.57	31.8
		228 min	8	2.406	1.1225	1.57	2.060	4.95	46.7
		229 min	9	2.473	1.8762	1.21	1.830	7.33	75.9
		230 min	9	1.788	0.5094	1.06	1.860	2.76	28.5
		231 min	9	1.856	0.4353	1.30	1.860	2.76	23.5
		232 min	9	2.000	0.6279	1.30	2.000	3.17	31.4
		233 min	9	1.772	0.4835	1.10	1.710	2.75	27.3
		234 min	9	2.240	1.3998	1.28	1.820	5.78	62.5
		235 min	8	1.876	0.5780	1.27	1.785	2.70	30.8
		236 min	9	2.003	0.7926	1.37	1.760	3.78	39.6
		237 min	9	2.288	1.1528	1.32	1.890	4.57	50.4
		238 min	9	2.237	1.1001	1.27	1.890	4.29	49.2
		239 min	9	1.904	0.8224	1.25	1.440	3.68	43.2
		240 min	5	2.618	0.8779	1.44	2.660	3.71	33.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 57 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	1 min	12	3.380	2.2955	1.47	2.435	7.68	67.9
		2 min	12	3.015	1.9432	1.30	2.215	7.28	64.5
		3 min	12	2.808	1.9425	0.80	1.920	6.84	69.2
		4 min	12	3.003	1.8335	1.06	2.350	6.61	61.0
		5 min	12	2.882	1.9308	0.74	2.235	6.99	67.0
		6 min	12	2.809	1.8147	0.89	2.185	6.39	64.6
		7 min	12	2.958	1.8413	1.21	2.305	7.05	62.3
		8 min	12	2.929	2.0102	0.91	2.000	7.51	68.6
		9 min	12	2.948	1.9367	1.30	2.180	7.12	65.7
		10 min	12	2.418	1.2382	1.26	2.055	5.70	51.2
		11 min	12	2.438	0.9040	1.37	2.205	3.84	37.1
		12 min	12	2.685	1.4971	1.38	2.100	6.85	55.8
		13 min	12	2.704	1.1459	1.56	2.375	5.56	42.4
		14 min	12	3.328	2.1040	1.29	2.455	7.10	63.2
		15 min	12	3.390	2.1592	1.31	2.405	7.12	63.7
		16 min	12	3.238	1.9862	1.24	2.405	7.02	61.3
		17 min	12	2.798	1.6012	1.13	2.055	6.29	57.2
		18 min	12	2.860	1.6542	1.10	2.150	6.37	57.8
		19 min	12	2.914	1.7787	1.36	2.035	6.98	61.0
		20 min	12	2.515	1.4872	0.91	2.035	6.70	59.1
		21 min	12	3.238	2.0926	1.14	2.365	7.11	64.6
		22 min	12	2.917	1.8365	0.94	2.210	6.77	62.9
		23 min	12	2.363	1.4008	0.85	1.995	6.10	59.3
		24 min	12	2.339	1.3744	1.02	1.920	6.07	58.8
		25 min	12	2.504	1.3888	1.19	2.030	6.40	55.5
		26 min	12	2.391	1.3498	0.86	2.020	6.04	56.5
		27 min	12	2.305	1.3411	0.97	1.935	5.82	58.2
		28 min	12	2.447	1.4258	0.95	1.990	6.43	58.3
		29 min	12	2.463	1.1913	1.17	2.040	5.62	48.4
		30 min	12	2.348	1.5306	1.11	1.865	6.61	65.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 58 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	31 min	12	2.431	1.4806	0.98	1.920	6.66	60.9
		32 min	11	2.365	1.5723	0.98	1.870	6.53	66.5
		33 min	10	2.430	1.1622	1.19	2.160	5.27	47.8
		34 min	10	2.284	1.3423	1.14	1.875	5.92	58.8
		35 min	10	2.021	0.8009	0.84	1.920	3.82	39.6
		36 min	10	2.398	1.5432	0.91	1.880	6.27	64.4
		37 min	10	2.354	1.5425	1.01	1.815	6.37	65.5
		38 min	10	2.291	1.5684	1.09	1.810	6.59	68.5
		39 min	10	2.857	1.9449	1.13	2.050	6.87	68.1
		40 min	10	2.396	1.4159	0.95	1.930	5.66	59.1
		41 min	10	2.678	1.8579	0.91	1.955	6.50	69.4
		42 min	10	2.398	1.3945	1.06	2.050	5.85	58.2
		43 min	11	1.806	0.8704	0.67	1.720	3.73	48.2
		44 min	11	2.369	1.3487	1.01	2.090	5.79	56.9
		45 min	11	2.558	1.7421	0.67	2.150	7.07	68.1
		46 min	11	2.210	1.1300	1.14	2.000	4.75	51.1
		47 min	11	2.724	1.7289	0.96	2.070	6.03	63.5
		48 min	11	2.547	1.5613	1.01	2.090	6.52	61.3
		49 min	11	2.727	1.7611	1.26	2.060	6.33	64.6
		50 min	11	2.295	1.6224	0.83	1.940	6.49	70.7
		51 min	10	2.936	2.0979	0.67	2.115	6.92	71.5
		52 min	10	2.777	1.6428	1.23	2.115	6.34	59.2
		53 min	10	2.980	2.1270	0.95	2.155	6.95	71.4
		54 min	10	3.164	2.2778	1.31	2.165	7.68	72.0
		55 min	10	2.817	1.9132	0.83	2.155	6.67	67.9
		56 min	10	3.052	2.2505	1.21	2.130	7.17	73.7
		57 min	10	3.012	2.1603	1.07	2.145	6.89	71.7
		58 min	10	2.969	2.1090	1.22	2.130	6.96	71.0
		59 min	10	2.480	1.8270	1.14	1.940	7.15	73.7
		60 min	10	2.975	2.0751	1.23	2.070	7.16	69.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 59 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	61 min	10	3.082	2.2974	1.09	2.125	7.19	74.5
		62 min	10	2.870	2.0105	0.84	2.100	7.27	70.1
		63 min	10	2.999	2.2457	1.01	2.090	7.25	74.9
		64 min	10	2.800	1.9304	0.92	2.080	7.24	68.9
		65 min	9	2.376	1.9035	1.01	1.850	7.24	80.1
		66 min	9	2.936	2.3617	0.95	2.000	7.33	80.5
		67 min	9	2.980	2.4719	0.84	1.990	7.26	82.9
		68 min	9	2.948	2.3445	1.06	1.990	7.15	79.5
		69 min	9	2.341	1.9301	1.11	1.890	7.27	82.4
		70 min	9	3.182	2.5389	1.28	2.180	7.79	79.8
		71 min	9	3.181	2.5140	1.20	2.010	7.63	79.0
		72 min	9	3.084	2.5367	0.89	2.080	7.64	82.2
		73 min	9	3.244	2.4510	1.07	2.100	7.43	75.5
		74 min	9	3.139	2.2281	1.00	2.190	7.35	71.0
		75 min	9	3.514	2.4498	1.24	2.150	7.35	69.7
		76 min	9	3.653	2.4466	1.03	2.290	7.33	67.0
		77 min	9	3.804	2.6726	1.24	2.230	7.68	70.2
		78 min	9	3.473	2.3940	1.19	2.080	7.40	68.9
		79 min	9	3.134	2.3029	1.40	2.010	7.37	73.5
		80 min	9	3.732	2.6815	1.33	2.020	7.50	71.8
		81 min	9	3.444	2.3309	1.41	2.090	7.26	67.7
		82 min	8	3.188	2.3477	1.25	1.980	7.18	73.7
		83 min	8	3.241	2.3506	1.41	2.010	7.35	72.5
		84 min	8	3.129	2.3871	1.03	1.945	7.28	76.3
		85 min	8	3.299	2.3447	1.60	2.020	7.36	71.1
		86 min	8	3.249	2.4039	1.45	2.020	7.37	74.0
		87 min	8	2.905	2.0381	1.50	1.925	7.47	70.2
		88 min	8	2.826	1.9001	1.76	1.980	7.40	67.2
		89 min	8	3.946	2.7254	1.78	2.275	7.64	69.1
		90 min	8	3.993	2.7272	1.75	2.325	8.05	68.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 60 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	91 min	8	3.924	2.7728	1.60	2.250	8.12	70.7
		92 min	8	4.039	2.8127	1.75	2.315	8.14	69.6
		93 min	8	3.965	2.6595	1.80	2.330	7.51	67.1
		94 min	8	3.805	2.5271	1.66	2.340	7.71	66.4
		95 min	8	3.909	2.6436	1.72	2.270	7.68	67.6
		96 min	8	4.004	2.7488	1.74	2.305	7.89	68.7
		97 min	8	3.855	2.5066	1.76	2.395	7.93	65.0
		98 min	8	4.043	2.7611	1.68	2.405	7.79	68.3
		99 min	8	3.999	2.7699	1.72	2.290	7.81	69.3
		100 min	8	4.021	2.8611	1.68	2.365	7.94	71.1
		101 min	8	4.025	2.8436	1.61	2.315	7.99	70.6
		102 min	8	3.965	2.7611	1.54	2.355	7.92	69.6
		103 min	8	3.398	2.5977	1.61	2.055	8.04	76.5
		104 min	8	3.663	2.5976	1.56	2.500	8.06	70.9
		105 min	8	3.950	2.6254	1.62	2.560	8.06	66.5
		106 min	8	3.778	2.5096	1.59	2.635	7.99	66.4
		107 min	8	4.049	2.6754	1.62	2.770	7.92	66.1
		108 min	8	3.624	2.3729	1.68	2.815	7.99	65.5
		109 min	8	3.290	2.4334	1.03	2.345	7.86	74.0
		110 min	8	3.920	2.4877	1.71	2.890	8.03	63.5
		111 min	8	3.231	2.1896	1.15	2.620	7.76	67.8
		112 min	8	3.031	2.1845	1.32	2.240	8.05	72.1
		113 min	8	3.163	2.2046	1.35	2.405	7.97	69.7
		114 min	8	3.115	2.1839	1.61	2.400	8.10	70.1
		115 min	8	3.398	2.4147	1.10	2.365	7.94	71.1
		116 min	8	3.204	2.2135	1.66	2.315	8.06	69.1
		117 min	8	3.114	2.2736	1.08	2.275	7.97	73.0
		118 min	8	3.081	2.1603	1.34	2.230	7.85	70.1
		119 min	8	2.698	1.9254	1.46	2.105	7.39	71.4
		120 min	8	3.068	1.6306	1.49	2.385	5.81	53.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 61 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	121 min	8	2.193	0.7053	1.48	1.930	3.34	32.2
		122 min	8	2.538	0.9499	1.56	2.410	4.13	37.4
		123 min	8	3.565	2.2654	1.60	2.415	6.78	63.5
		124 min	8	2.586	1.3528	1.58	1.975	5.47	52.3
		125 min	8	2.658	1.7212	1.48	2.005	6.66	64.8
		126 min	8	2.166	1.0189	1.24	1.925	4.44	47.0
		127 min	8	2.370	1.8509	0.76	1.705	6.76	78.1
		128 min	8	2.234	1.6718	0.46	1.765	6.10	74.8
		129 min	8	2.041	1.0964	0.91	1.720	4.48	53.7
		130 min	8	2.246	1.5799	0.77	1.765	5.94	70.3
		131 min	8	2.269	1.6071	0.84	1.750	6.04	70.8
		132 min	8	2.335	1.6619	0.85	1.805	6.25	71.2
		133 min	8	2.218	1.5147	0.92	1.675	5.75	68.3
		134 min	8	2.544	1.8046	1.49	1.920	6.93	70.9
		135 min	8	2.473	2.0521	1.00	1.735	7.41	83.0
		136 min	8	2.711	2.0709	1.40	2.065	7.65	76.4
		137 min	8	2.530	2.0182	1.41	1.760	7.43	79.8
		138 min	8	2.466	2.0330	1.09	1.720	7.36	82.4
		139 min	8	2.443	1.7818	1.21	1.830	6.71	72.9
		140 min	8	1.835	0.5271	1.09	1.745	2.56	28.7
		141 min	8	2.393	1.6570	1.30	1.810	6.33	69.3
		142 min	8	2.375	1.7191	1.30	1.830	6.52	72.4
		143 min	8	2.381	1.5144	1.31	1.995	6.01	63.6
		144 min	8	2.443	1.7148	1.30	2.005	6.57	70.2
		145 min	8	2.859	2.0488	1.49	2.150	7.48	71.7
		146 min	8	2.534	2.0404	1.28	1.825	7.51	80.5
		147 min	8	2.589	2.0205	1.42	1.910	7.52	78.0
		148 min	8	3.229	2.5773	1.30	2.190	7.75	79.8
		149 min	8	3.124	2.4866	1.16	2.110	7.35	79.6
		150 min	8	3.119	2.4481	1.33	2.090	7.26	78.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 62 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	151 min	8	3.051	2.4012	1.13	2.070	7.17	78.7
		152 min	8	3.093	2.3475	1.47	2.070	7.15	75.9
		153 min	8	3.153	2.2859	1.50	2.130	7.14	72.5
		154 min	8	3.155	2.3038	1.48	2.045	7.10	73.0
		155 min	8	2.868	1.8391	1.49	2.170	7.14	64.1
		156 min	8	3.484	2.2993	1.47	2.610	7.13	66.0
		157 min	8	3.854	2.6724	1.49	2.165	7.84	69.3
		158 min	8	3.484	2.4612	1.47	2.170	7.61	70.6
		159 min	8	3.485	2.4019	1.56	2.110	7.42	68.9
		160 min	8	3.634	2.4984	1.47	2.135	7.32	68.8
		161 min	8	3.271	2.1901	1.36	2.190	7.20	66.9
		162 min	8	3.099	2.1458	1.32	2.160	6.97	69.2
		163 min	8	3.380	2.2283	1.37	2.165	6.90	65.9
		164 min	8	3.381	2.1819	1.44	2.170	6.62	64.5
		165 min	8	3.174	2.0695	1.45	2.165	6.74	65.2
		166 min	8	3.129	2.0423	1.53	2.190	6.35	65.3
		167 min	8	3.068	2.1532	1.42	2.190	6.74	70.2
		168 min	8	3.020	2.0772	1.48	2.120	6.36	68.8
		169 min	8	3.074	2.1614	1.42	2.180	6.65	70.3
		170 min	8	3.103	2.2753	1.48	2.035	7.09	73.3
		171 min	8	3.033	2.0410	1.33	2.175	6.39	67.3
		172 min	8	3.178	2.3477	1.28	2.075	7.19	73.9
		173 min	8	3.179	2.2947	1.33	2.045	7.07	72.2
		174 min	8	3.388	2.2493	1.34	2.330	7.17	66.4
		175 min	8	3.299	2.1856	1.04	2.295	6.93	66.3
		176 min	8	3.461	2.2203	1.39	2.310	7.06	64.1
		177 min	8	3.294	2.1824	1.54	2.275	6.98	66.3
		178 min	8	3.399	2.1916	1.51	2.315	7.00	64.5
		179 min	8	3.435	2.1212	1.61	2.395	6.84	61.8
		180 min	8	3.421	2.1537	1.66	2.280	7.13	63.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 63 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	181 min	8	3.395	2.0959	1.67	2.235	6.68	61.7
		182 min	8	3.381	2.0428	1.60	2.285	6.67	60.4
		183 min	8	3.490	2.2082	1.51	2.270	7.18	63.3
		184 min	8	3.435	2.0881	1.45	2.285	6.83	60.8
		185 min	8	3.058	1.8061	1.47	2.330	6.81	59.1
		186 min	7	2.893	1.7888	1.66	2.190	6.80	61.8
		187 min	8	2.806	1.6810	1.44	2.095	6.59	59.9
		188 min	8	2.788	1.6681	1.47	2.075	6.57	59.8
		189 min	8	2.911	1.8134	1.52	2.125	6.80	62.3
		190 min	8	2.949	1.9384	1.35	2.110	6.78	65.7
		191 min	8	3.010	1.9979	1.32	2.080	6.64	66.4
		192 min	8	3.074	1.9985	1.61	2.060	6.65	65.0
		193 min	8	2.681	1.6504	1.76	1.985	6.68	61.6
		194 min	8	2.741	1.6670	1.63	1.985	6.65	60.8
		195 min	8	2.735	1.7005	1.12	2.005	6.46	62.2
		196 min	8	2.855	1.7588	1.53	2.000	6.62	61.6
		197 min	8	2.895	1.7723	1.47	2.015	6.49	61.2
		198 min	8	2.948	1.8845	1.58	1.920	6.42	63.9
		199 min	8	2.833	1.7090	1.43	2.005	6.38	60.3
		200 min	8	2.706	1.6580	1.53	2.010	6.48	61.3
		201 min	8	2.614	1.5794	1.55	1.975	6.40	60.4
		202 min	8	2.579	1.6248	1.48	1.965	6.50	63.0
		203 min	9	2.677	1.6003	1.46	1.830	6.32	59.8
		204 min	9	3.044	2.1863	1.45	1.960	7.33	71.8
		205 min	9	2.464	1.5001	1.49	1.930	6.35	60.9
		206 min	9	2.543	1.6895	1.59	1.910	6.96	66.4
		207 min	8	2.511	1.5621	1.56	1.965	6.29	62.2
		208 min	8	2.523	1.6543	1.49	1.960	6.53	65.6
		209 min	8	2.398	1.2023	1.64	1.965	5.28	50.1
		210 min	8	2.509	1.4466	1.66	1.910	5.96	57.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 64 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	8	211 min	8	2.575	1.7933	1.54	1.935	6.92	69.6
		212 min	8	2.671	1.9733	1.67	1.950	7.49	73.9
		213 min	8	2.603	1.9131	1.58	1.895	7.26	73.5
		214 min	8	2.569	1.9076	1.35	1.930	7.19	74.3
		215 min	8	2.550	1.7561	1.50	1.945	6.83	68.9
		216 min	8	2.534	1.7389	1.53	1.910	6.75	68.6
		217 min	8	2.518	1.8218	1.47	1.905	6.94	72.4
		218 min	8	2.570	1.8368	1.66	1.875	7.05	71.5
		219 min	8	2.481	1.7027	1.41	1.890	6.61	68.6
		220 min	8	2.479	1.8826	1.42	1.820	7.05	75.9
		221 min	8	2.530	1.8818	1.46	1.940	7.12	74.4
		222 min	8	2.524	1.8174	1.47	1.900	6.95	72.0
		223 min	8	2.518	1.8519	1.54	1.880	7.05	73.6
		224 min	8	2.589	1.8199	1.61	2.005	7.02	70.3
		225 min	8	2.634	1.7703	1.65	2.140	6.96	67.2
		226 min	8	3.171	2.1229	1.62	2.130	6.65	66.9
		227 min	8	2.364	1.3503	1.34	1.905	5.55	57.1
		228 min	8	2.705	1.6336	1.62	2.085	6.54	60.4
		229 min	9	2.920	2.0873	1.45	2.050	6.59	71.5
		230 min	9	2.481	1.1255	1.33	2.040	4.93	45.4
		231 min	9	2.334	1.4371	1.35	2.010	6.05	61.6
		232 min	9	2.393	1.7574	1.40	1.850	6.98	73.4
		233 min	9	2.113	0.9057	1.40	1.990	4.33	42.9
		234 min	9	2.404	1.4495	1.43	1.900	5.96	60.3
		235 min	8	2.176	1.1017	1.47	1.755	4.78	50.6
		236 min	9	2.333	1.0612	1.35	1.940	4.46	45.5
		237 min	9	2.306	1.2450	1.38	1.840	5.04	54.0
		238 min	9	2.281	1.1326	1.35	1.900	4.58	49.7
		239 min	9	2.337	1.2464	1.35	1.890	5.06	53.3
		240 min	5	3.162	1.9191	1.61	2.390	6.29	60.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 65 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	1 min	12	3.286	2.2900	1.26	2.285	7.77	69.7
		2 min	12	3.381	2.3166	1.24	2.335	7.57	68.5
		3 min	12	3.235	2.3109	0.94	2.305	7.21	71.4
		4 min	12	2.886	1.9950	0.61	2.160	7.27	69.1
		5 min	12	3.259	2.2083	1.07	2.325	7.10	67.8
		6 min	12	3.163	2.0328	0.89	2.490	6.46	64.3
		7 min	12	3.278	2.1741	1.05	2.280	6.93	66.3
		8 min	12	3.275	2.2769	0.71	2.330	7.22	69.5
		9 min	12	3.344	2.2242	1.41	2.330	7.32	66.5
		10 min	12	3.116	2.0355	1.34	2.335	7.40	65.3
		11 min	12	2.966	1.6343	1.41	2.525	6.49	55.1
		12 min	12	3.265	2.0824	1.39	2.395	6.84	63.8
		13 min	12	3.220	1.8505	1.51	2.350	6.94	57.5
		14 min	12	3.290	2.0750	1.46	2.480	7.20	63.1
		15 min	12	3.435	2.2769	1.29	2.435	7.42	66.3
		16 min	12	3.091	1.7870	1.32	2.445	7.05	57.8
		17 min	12	3.218	2.0275	1.28	2.365	6.96	63.0
		18 min	12	3.022	1.9853	1.13	2.150	6.84	65.7
		19 min	12	2.897	1.9111	1.39	2.005	6.91	66.0
		20 min	12	2.735	1.5660	1.06	2.020	5.90	57.3
		21 min	12	2.979	1.8309	1.36	2.345	6.73	61.5
		22 min	12	2.697	1.4884	1.35	2.095	5.58	55.2
		23 min	12	2.459	1.4853	1.20	2.070	6.67	60.4
		24 min	12	2.324	1.6032	1.16	1.820	6.78	69.0
		25 min	12	3.152	2.0320	0.99	2.305	7.06	64.5
		26 min	12	2.829	1.8831	1.11	2.050	7.12	66.6
		27 min	12	2.330	1.2464	1.22	1.885	5.60	53.5
		28 min	12	2.713	1.6122	1.08	2.035	6.16	59.4
		29 min	12	2.432	1.5213	1.16	1.935	6.77	62.6
		30 min	12	2.429	1.6284	0.84	1.895	6.81	67.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 66 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	31 min	12	2.378	1.5298	1.05	1.900	6.73	64.3
		32 min	11	2.402	1.6392	1.05	1.860	6.87	68.2
		33 min	10	2.384	1.4196	0.99	1.940	6.12	59.5
		34 min	10	2.180	1.5414	1.03	1.775	6.31	70.7
		35 min	10	2.171	1.3893	1.03	1.800	5.88	64.0
		36 min	10	2.206	1.4855	0.76	1.790	6.19	67.3
		37 min	10	2.867	2.0229	1.13	2.145	6.64	70.6
		38 min	10	2.684	1.8467	1.22	1.995	6.40	68.8
		39 min	10	2.779	1.9488	0.98	1.955	6.64	70.1
		40 min	10	2.579	1.8417	0.93	1.895	6.13	71.4
		41 min	10	2.242	1.5140	1.05	1.870	6.23	67.5
		42 min	10	2.180	1.0732	1.23	1.945	4.82	49.2
		43 min	11	1.905	0.7609	1.06	1.710	3.67	40.0
		44 min	11	2.316	1.5104	1.07	1.910	6.27	65.2
		45 min	11	2.585	1.6475	1.23	2.460	6.99	63.7
		46 min	11	2.040	0.9051	0.90	1.870	3.73	44.4
		47 min	11	2.445	1.5983	0.89	1.980	6.65	65.4
		48 min	11	2.473	1.4470	0.89	1.980	5.97	58.5
		49 min	11	2.579	1.6673	0.88	1.970	5.55	64.6
		50 min	11	2.674	1.8937	0.72	1.940	6.20	70.8
		51 min	10	2.899	2.0567	0.63	2.100	6.56	70.9
		52 min	10	2.941	2.0522	0.83	2.060	6.68	69.8
		53 min	10	3.122	1.9675	0.83	2.555	6.56	63.0
		54 min	10	3.027	2.3344	0.62	2.215	7.47	77.1
		55 min	10	2.797	2.0236	0.62	2.095	6.70	72.3
		56 min	10	3.029	2.2331	1.09	2.080	7.14	73.7
		57 min	10	3.043	2.1449	1.20	2.190	6.96	70.5
		58 min	10	2.941	2.0576	1.07	2.215	6.90	70.0
		59 min	10	2.396	1.8782	0.96	1.925	7.11	78.4
		60 min	10	2.883	2.0938	0.99	2.055	7.24	72.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 67 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	61 min	10	2.981	2.3150	0.80	2.160	7.18	77.7
		62 min	10	2.924	2.0700	0.72	2.155	7.27	70.8
		63 min	10	3.019	2.3249	1.00	2.080	7.18	77.0
		64 min	10	2.825	1.9643	0.83	2.205	7.07	69.5
		65 min	9	2.261	2.0060	0.98	1.840	7.35	88.7
		66 min	9	2.910	2.4094	0.83	2.120	7.33	82.8
		67 min	9	2.953	2.4975	0.60	2.140	7.33	84.6
		68 min	9	2.934	2.2947	1.18	1.990	7.20	78.2
		69 min	9	2.461	1.9492	0.63	1.990	7.28	79.2
		70 min	9	3.106	2.6025	0.83	2.000	7.71	83.8
		71 min	9	3.678	2.7245	0.98	2.490	7.54	74.1
		72 min	9	3.696	2.7279	1.22	2.240	7.46	73.8
		73 min	9	3.860	2.5236	1.15	2.850	7.56	65.4
		74 min	9	3.654	2.6669	1.03	2.360	7.38	73.0
		75 min	9	3.493	2.5506	1.00	2.260	7.45	73.0
		76 min	9	4.124	2.7532	0.59	2.780	7.42	66.8
		77 min	9	4.200	2.6710	1.09	2.770	7.41	63.6
		78 min	9	3.573	2.4843	1.34	2.090	7.38	69.5
		79 min	9	3.848	2.8065	1.41	2.520	8.12	72.9
		80 min	9	3.693	2.7346	1.27	2.020	7.66	74.0
		81 min	9	2.941	2.2077	1.08	1.930	7.34	75.1
		82 min	8	3.250	2.3050	1.60	1.995	7.33	70.9
		83 min	8	3.250	2.3557	1.71	1.945	7.38	72.5
		84 min	8	3.133	2.4637	1.02	1.910	7.43	78.6
		85 min	8	3.311	2.3596	1.81	2.010	7.43	71.3
		86 min	8	3.239	2.3716	1.61	1.945	7.26	73.2
		87 min	8	3.320	2.0363	1.73	2.365	7.28	61.3
		88 min	8	3.816	2.6316	1.62	2.325	7.72	69.0
		89 min	8	3.959	2.8082	1.53	2.295	7.99	70.9
		90 min	8	3.969	2.8098	1.52	2.340	8.05	70.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 68 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	91 min	8	3.981	2.7868	1.75	2.270	7.56	70.0
		92 min	8	3.959	2.7136	1.80	2.260	7.65	68.5
		93 min	8	4.024	2.5773	1.80	2.705	7.43	64.1
		94 min	8	3.978	2.6890	1.65	2.350	7.73	67.6
		95 min	8	3.975	2.6691	1.75	2.330	7.26	67.1
		96 min	8	3.971	2.6854	1.76	2.295	7.34	67.6
		97 min	8	3.796	2.3839	1.67	2.395	6.81	62.8
		98 min	8	3.838	2.4510	1.76	2.365	6.86	63.9
		99 min	8	3.853	2.4952	1.76	2.435	6.92	64.8
		100 min	8	3.829	2.4994	1.81	2.335	6.88	65.3
		101 min	8	3.801	2.5126	1.61	2.370	6.98	66.1
		102 min	8	3.585	2.3251	1.71	2.235	6.86	64.9
		103 min	8	3.660	2.3579	1.69	2.290	6.73	64.4
		104 min	8	3.363	2.0497	1.53	2.305	6.88	61.0
		105 min	8	3.400	2.1656	1.62	2.390	6.81	63.7
		106 min	8	3.216	2.0580	1.65	2.335	6.91	64.0
		107 min	8	3.391	2.2766	1.64	2.395	7.05	67.1
		108 min	8	2.906	1.8064	1.63	2.200	6.97	62.2
		109 min	8	2.534	1.8454	0.91	2.045	6.94	72.8
		110 min	8	3.184	2.2247	1.69	2.120	6.93	69.9
		111 min	8	2.623	1.7810	1.13	2.195	6.88	67.9
		112 min	8	2.581	1.7888	1.69	1.915	6.96	69.3
		113 min	8	2.884	1.7456	1.53	2.390	6.92	60.5
		114 min	8	2.696	1.7929	1.63	2.150	7.04	66.5
		115 min	8	3.226	2.0210	1.62	2.490	7.33	62.6
		116 min	8	2.951	1.7846	1.67	2.465	7.13	60.5
		117 min	8	2.619	1.9300	1.54	1.805	7.29	73.7
		118 min	8	2.593	2.1426	1.24	1.825	7.82	82.6
		119 min	8	2.893	2.0553	1.53	2.010	7.65	71.1
		120 min	8	3.230	2.3328	1.69	2.225	8.22	72.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 69 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	121 min	8	2.796	2.1845	1.53	2.225	8.13	78.1
		122 min	8	2.983	2.1433	1.60	2.360	8.07	71.9
		123 min	8	3.648	2.5124	1.34	2.280	7.37	68.9
		124 min	8	3.263	2.4410	1.55	2.155	7.58	74.8
		125 min	8	3.114	2.4071	1.45	1.820	7.52	77.3
		126 min	8	3.111	2.5159	1.34	1.945	8.27	80.9
		127 min	8	2.430	1.9069	0.97	1.845	6.99	78.5
		128 min	8	2.350	1.7772	0.81	1.895	6.55	75.6
		129 min	8	2.378	1.7067	0.54	1.955	6.15	71.8
		130 min	8	2.278	1.4041	1.16	1.860	5.58	61.7
		131 min	8	2.305	1.7081	0.92	1.755	6.35	74.1
		132 min	8	2.310	1.5151	1.13	1.780	5.89	65.6
		133 min	8	2.263	1.5281	1.29	1.715	5.89	67.5
		134 min	8	2.379	1.2354	1.51	1.910	5.28	51.9
		135 min	8	2.493	1.9071	1.41	1.775	7.11	76.5
		136 min	8	2.743	2.0369	1.42	1.930	7.57	74.3
		137 min	8	2.540	1.9212	1.33	1.880	7.21	75.6
		138 min	8	2.485	1.9447	1.37	1.735	7.19	78.3
		139 min	8	2.503	2.0968	1.25	1.790	7.60	83.8
		140 min	8	1.803	0.5176	1.06	1.730	2.56	28.7
		141 min	8	2.298	1.7513	0.96	1.745	6.47	76.2
		142 min	8	2.389	1.6744	1.32	1.980	6.42	70.1
		143 min	8	2.275	1.1383	1.45	2.000	4.96	50.0
		144 min	8	2.433	1.9548	1.31	1.815	7.18	80.4
		145 min	8	2.928	2.1378	1.50	1.960	7.24	73.0
		146 min	8	2.556	1.9931	1.52	1.865	7.45	78.0
		147 min	8	2.544	2.1015	1.30	1.950	7.66	82.6
		148 min	8	2.786	1.9968	1.48	1.970	7.44	71.7
		149 min	8	2.848	2.0954	1.08	2.015	7.19	73.6
		150 min	8	2.738	2.0669	0.94	2.025	7.13	75.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 70 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	151 min	8	2.489	1.9781	1.05	2.005	7.26	79.5
		152 min	8	2.876	2.0174	1.31	2.005	6.71	70.1
		153 min	8	2.959	2.1884	1.19	1.955	6.66	74.0
		154 min	8	3.355	2.1634	1.48	2.280	6.78	64.5
		155 min	8	3.328	2.0511	1.48	2.115	6.49	61.6
		156 min	8	3.036	1.7642	1.50	2.120	6.52	58.1
		157 min	8	2.833	1.8346	1.50	2.000	6.69	64.8
		158 min	8	2.679	1.6477	1.54	2.085	6.54	61.5
		159 min	8	2.718	1.6532	1.47	2.070	6.52	60.8
		160 min	8	2.719	1.7400	1.48	2.080	6.57	64.0
		161 min	8	2.635	1.6768	1.37	1.975	6.41	63.6
		162 min	8	2.766	1.8097	1.36	1.945	6.29	65.4
		163 min	8	2.615	1.7029	1.38	1.890	6.29	65.1
		164 min	8	2.793	1.9373	1.52	1.905	7.05	69.4
		165 min	8	2.936	2.0009	1.49	2.030	6.38	68.1
		166 min	8	2.916	1.7521	1.48	2.180	5.85	60.1
		167 min	8	3.091	2.2278	1.53	2.150	7.41	72.1
		168 min	8	3.024	2.1285	1.43	2.120	6.88	70.4
		169 min	8	3.076	2.1749	1.46	2.120	7.12	70.7
		170 min	8	3.058	2.1868	1.48	2.000	7.00	71.5
		171 min	8	3.035	2.1665	1.44	2.055	6.78	71.4
		172 min	8	3.118	2.1875	1.64	2.015	6.98	70.2
		173 min	8	3.145	2.2239	1.41	2.105	7.11	70.7
		174 min	8	3.205	2.1410	1.48	2.225	7.03	66.8
		175 min	8	3.116	2.1771	1.14	2.190	7.02	69.9
		176 min	8	3.250	2.1706	1.35	2.285	6.95	66.8
		177 min	8	3.271	2.1631	1.49	2.250	6.88	66.1
		178 min	8	3.310	2.1905	1.55	2.235	6.89	66.2
		179 min	8	3.331	2.1518	1.59	2.285	6.92	64.6
		180 min	8	3.400	2.2471	1.66	2.245	7.43	66.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 71 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	181 min	8	3.351	2.1621	1.68	2.155	6.86	64.5
		182 min	8	3.336	2.0518	1.62	2.235	6.62	61.5
		183 min	8	3.378	2.1633	1.60	2.185	6.98	64.1
		184 min	8	3.496	2.0264	1.50	2.860	7.00	58.0
		185 min	8	3.363	1.9330	1.50	2.510	6.42	57.5
		186 min	7	2.914	1.9024	1.65	2.340	7.14	65.3
		187 min	8	2.766	1.7575	1.66	2.125	7.01	63.5
		188 min	8	2.781	1.8670	1.53	2.075	7.28	67.1
		189 min	8	2.804	1.9164	1.60	2.105	7.39	68.4
		190 min	8	2.724	1.7399	1.29	2.150	6.81	63.9
		191 min	8	2.685	1.7740	1.51	2.025	6.93	66.1
		192 min	8	2.694	1.6822	1.61	2.025	6.71	62.4
		193 min	8	2.659	1.6461	1.55	2.240	6.63	61.9
		194 min	8	2.725	1.9011	1.58	1.960	7.34	69.8
		195 min	8	2.670	1.6848	1.47	2.010	6.68	63.1
		196 min	8	2.691	1.6786	1.67	1.985	6.73	62.4
		197 min	8	2.683	1.6842	1.53	2.015	6.73	62.8
		198 min	8	2.650	1.7756	1.60	1.865	6.87	67.0
		199 min	8	2.671	1.7246	1.38	1.960	6.74	64.6
		200 min	8	2.699	1.9050	1.41	2.045	7.31	70.6
		201 min	8	2.551	1.6058	1.44	1.960	6.43	62.9
		202 min	8	2.845	1.7423	1.45	2.045	6.55	61.2
		203 min	9	2.669	1.7065	1.46	1.920	6.89	63.9
		204 min	9	2.784	1.8176	1.50	2.100	7.08	65.3
		205 min	9	2.462	1.5037	1.53	2.060	6.39	61.1
		206 min	9	2.436	1.4926	1.64	1.880	6.34	61.3
		207 min	8	2.521	1.6573	1.56	1.970	6.56	65.7
		208 min	8	2.499	1.6775	1.53	1.905	6.59	67.1
		209 min	8	2.463	1.4820	1.70	1.940	6.07	60.2
		210 min	8	2.471	1.3401	1.73	1.950	5.70	54.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 72 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	9	211 min	8	2.561	1.7172	1.62	1.980	6.73	67.0
		212 min	8	2.631	1.8974	1.65	1.925	7.27	72.1
		213 min	8	2.603	1.9073	1.62	1.925	7.26	73.3
		214 min	8	2.541	1.8750	1.45	1.855	7.10	73.8
		215 min	8	2.581	1.8766	1.48	1.980	7.16	72.7
		216 min	8	2.568	1.9134	1.52	1.845	7.23	74.5
		217 min	8	2.524	1.8119	1.60	1.815	6.93	71.8
		218 min	8	2.524	1.7161	1.64	1.850	6.71	68.0
		219 min	8	2.480	1.7228	1.43	1.815	6.66	69.5
		220 min	8	2.510	1.7981	1.47	1.840	6.86	71.6
		221 min	8	2.815	1.8591	1.56	1.890	6.80	66.0
		222 min	8	2.915	2.1293	1.50	1.905	7.21	73.0
		223 min	8	2.639	1.9194	1.59	1.870	7.26	72.7
		224 min	8	2.878	1.8889	1.68	1.855	6.93	65.6
		225 min	8	2.846	1.7968	1.75	2.075	6.86	63.1
		226 min	8	3.336	2.1182	1.69	2.085	7.01	63.5
		227 min	8	3.110	1.9722	1.74	1.980	6.62	63.4
		228 min	8	2.611	1.7337	1.69	1.955	6.78	66.4
		229 min	9	2.846	1.9354	1.28	1.900	6.25	68.0
		230 min	9	2.661	1.2506	1.26	2.130	5.50	47.0
		231 min	9	2.460	1.4310	1.48	1.860	6.12	58.2
		232 min	9	2.574	1.8082	1.36	1.850	7.19	70.2
		233 min	9	2.898	2.2135	1.30	1.800	6.83	76.4
		234 min	9	2.938	2.2475	1.37	2.030	7.06	76.5
		235 min	8	2.540	1.7988	1.45	1.870	6.85	70.8
		236 min	9	2.503	1.3351	1.31	1.960	5.47	53.3
		237 min	9	2.543	1.7561	1.36	1.940	6.83	69.0
		238 min	9	2.537	1.6760	1.37	1.970	6.60	66.1
		239 min	9	2.218	1.0713	1.23	1.880	4.32	48.3
		240 min	5	3.156	1.9101	1.54	2.490	6.26	60.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 73 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	1 min	12	3.575	2.3599	1.33	2.330	7.77	66.0
		2 min	12	3.623	2.4422	1.11	2.375	7.93	67.4
		3 min	12	3.347	2.3430	1.04	2.415	7.65	70.0
		4 min	12	3.274	2.3626	0.73	2.355	7.73	72.2
		5 min	12	3.342	2.3609	0.97	2.385	7.37	70.6
		6 min	12	3.413	2.1757	1.10	2.360	6.94	63.8
		7 min	12	3.361	2.2890	1.07	2.345	7.61	68.1
		8 min	12	3.279	2.2656	0.74	2.420	7.69	69.1
		9 min	12	3.150	2.1137	1.31	2.350	7.66	67.1
		10 min	12	3.336	2.1648	1.24	2.360	7.16	64.9
		11 min	12	3.268	1.9758	1.41	2.325	6.70	60.5
		12 min	12	3.183	1.9877	1.41	2.360	6.81	62.4
		13 min	12	3.083	1.8874	1.47	2.345	6.90	61.2
		14 min	12	3.375	2.3052	1.30	2.285	7.22	68.3
		15 min	12	3.269	2.0483	1.34	2.320	7.44	62.7
		16 min	12	3.333	2.0820	1.32	2.370	7.17	62.5
		17 min	12	2.983	2.0409	1.11	2.035	7.13	68.4
		18 min	12	2.888	1.7558	1.30	2.040	6.65	60.8
		19 min	12	3.011	1.7635	0.99	2.345	6.61	58.6
		20 min	12	2.898	1.8381	0.99	2.215	6.94	63.4
		21 min	12	3.318	2.0158	1.09	2.660	6.44	60.8
		22 min	12	3.138	1.8532	1.31	2.445	6.60	59.0
		23 min	12	2.840	1.5699	1.14	2.565	6.85	55.3
		24 min	12	2.869	1.7144	1.06	2.375	6.34	59.8
		25 min	12	3.394	1.9754	1.02	2.775	6.90	58.2
		26 min	12	2.964	1.8927	1.29	2.225	7.07	63.9
		27 min	12	2.852	1.8981	1.05	2.185	6.66	66.6
		28 min	12	3.271	1.7615	1.12	2.580	6.07	53.9
		29 min	12	3.024	1.7647	1.08	2.370	6.74	58.4
		30 min	12	2.844	1.9777	1.05	2.250	6.80	69.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 74 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	31 min	12	2.838	1.7349	1.23	2.305	6.80	61.1
		32 min	11	2.411	1.6073	0.96	1.960	6.76	66.7
		33 min	10	2.566	1.5483	1.08	2.200	6.65	60.3
		34 min	10	2.348	1.6521	1.21	1.810	6.86	70.4
		35 min	10	2.992	1.9799	1.18	2.235	6.81	66.2
		36 min	10	2.708	1.5961	1.25	2.190	6.77	58.9
		37 min	10	3.285	2.2312	0.99	2.625	7.60	67.9
		38 min	10	3.146	1.9094	1.22	2.495	6.78	60.7
		39 min	10	3.194	1.9113	1.17	2.495	6.30	59.8
		40 min	10	3.018	1.8696	1.22	2.350	6.87	61.9
		41 min	10	2.241	1.3040	0.80	1.930	5.51	58.2
		42 min	10	2.021	0.6620	1.05	2.050	3.02	32.8
		43 min	11	2.267	0.9552	1.16	1.970	4.34	42.1
		44 min	11	2.348	1.5917	1.08	1.880	6.52	67.8
		45 min	11	2.508	1.8361	1.08	1.940	7.43	73.2
		46 min	11	2.035	0.9581	0.97	1.750	3.73	47.1
		47 min	11	2.547	1.6826	0.83	2.340	6.97	66.1
		48 min	11	2.616	1.4847	1.12	2.010	5.79	56.7
		49 min	11	2.575	1.5856	0.89	2.080	5.41	61.6
		50 min	11	2.682	1.7576	0.99	1.990	6.09	65.5
		51 min	10	3.046	1.8533	1.12	2.235	6.37	60.8
		52 min	10	3.415	2.1486	0.78	2.545	6.55	62.9
		53 min	10	3.315	2.0498	0.67	2.545	6.58	61.8
		54 min	10	3.054	2.3888	0.60	2.405	7.30	78.2
		55 min	10	2.994	2.2145	0.80	2.255	6.99	74.0
		56 min	10	3.014	2.3260	0.65	2.135	7.17	77.2
		57 min	10	3.058	2.2001	1.02	2.315	7.13	71.9
		58 min	10	2.929	2.2350	0.70	2.255	7.00	76.3
		59 min	10	2.424	1.8716	0.79	1.975	7.16	77.2
		60 min	10	2.953	2.1879	1.10	2.080	7.23	74.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 75 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	61 min	10	2.930	2.2933	0.73	2.115	7.15	78.3
		62 min	10	3.019	2.1584	1.00	2.155	7.36	71.5
		63 min	10	3.035	2.3216	0.89	2.135	7.21	76.5
		64 min	10	2.538	1.8439	0.87	2.050	7.23	72.7
		65 min	9	2.278	1.9806	0.74	1.690	7.28	87.0
		66 min	9	2.967	2.5213	0.53	2.190	7.23	85.0
		67 min	9	3.064	2.5456	0.94	2.110	7.48	83.1
		68 min	9	3.066	2.2272	1.20	2.150	7.09	72.7
		69 min	9	2.834	2.2327	0.81	2.080	7.26	78.8
		70 min	9	3.121	2.4753	1.34	1.800	7.56	79.3
		71 min	9	4.272	2.7935	1.09	2.770	7.57	65.4
		72 min	9	4.424	3.0104	1.33	2.800	8.14	68.0
		73 min	9	4.358	2.8629	0.96	2.790	7.60	65.7
		74 min	9	3.823	2.7431	0.95	2.740	7.54	71.7
		75 min	9	4.292	2.7703	1.25	2.840	7.42	64.5
		76 min	9	4.178	2.7626	0.72	2.730	7.43	66.1
		77 min	9	4.334	2.7271	1.24	2.830	7.36	62.9
		78 min	9	3.306	2.1797	1.44	2.130	7.13	65.9
		79 min	9	3.840	2.7584	1.44	2.080	7.95	71.8
		80 min	9	3.819	2.6727	1.29	2.350	7.77	70.0
		81 min	9	3.010	2.2375	1.17	2.000	7.42	74.3
		82 min	8	3.256	2.3608	1.34	2.025	7.28	72.5
		83 min	8	3.294	2.3281	1.60	2.030	7.27	70.7
		84 min	8	3.128	2.4046	0.99	1.930	7.33	76.9
		85 min	8	3.283	2.5152	1.11	2.005	7.36	76.6
		86 min	8	3.239	2.4443	1.60	1.930	7.33	75.5
		87 min	8	3.204	2.3765	1.41	1.975	7.24	74.2
		88 min	8	3.793	2.5182	1.75	2.375	7.56	66.4
		89 min	8	3.791	2.5001	1.50	2.320	7.08	65.9
		90 min	8	3.739	2.4657	1.55	2.360	7.26	66.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 76 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	91 min	8	3.846	2.5243	1.70	2.350	7.11	65.6
		92 min	8	3.911	2.5873	1.65	2.380	7.15	66.1
		93 min	8	4.031	2.3869	1.85	3.015	7.21	59.2
		94 min	8	4.045	2.7237	1.69	2.420	7.38	67.3
		95 min	8	4.020	2.6941	1.66	2.460	7.49	67.0
		96 min	8	4.101	2.8073	1.79	2.340	7.58	68.4
		97 min	8	4.123	2.6468	1.72	2.690	7.49	64.2
		98 min	8	3.888	2.5030	1.85	2.335	7.26	64.4
		99 min	8	3.838	2.3605	1.69	2.625	7.35	61.5
		100 min	8	3.725	2.3240	1.79	2.545	7.49	62.4
		101 min	8	3.746	2.3271	1.60	2.575	7.49	62.1
		102 min	8	4.075	2.4934	1.82	3.090	7.50	61.2
		103 min	8	3.624	2.4068	1.67	2.330	7.53	66.4
		104 min	8	3.604	2.3450	1.49	2.375	7.43	65.1
		105 min	8	3.716	2.4548	1.67	2.375	7.36	66.1
		106 min	8	3.628	2.3199	1.68	2.305	7.00	64.0
		107 min	8	3.711	2.4586	1.72	2.310	7.14	66.2
		108 min	8	3.731	2.4873	1.61	2.370	7.44	66.7
		109 min	8	2.778	1.8534	1.22	2.130	7.01	66.7
		110 min	8	3.305	2.3503	1.69	2.025	7.47	71.1
		111 min	8	3.039	1.9624	1.77	2.035	7.31	64.6
		112 min	8	2.940	2.1022	1.45	1.895	7.34	71.5
		113 min	8	3.165	2.1236	1.41	2.405	7.36	67.1
		114 min	8	3.559	2.3157	1.67	2.405	7.67	65.1
		115 min	8	3.395	2.2086	1.60	2.335	7.28	65.1
		116 min	8	3.336	2.3051	1.70	2.380	7.63	69.1
		117 min	8	3.686	2.4994	1.49	2.335	7.60	67.8
		118 min	8	3.223	1.9803	1.70	2.265	7.18	61.5
		119 min	8	3.404	2.2794	1.56	2.275	7.41	67.0
		120 min	8	3.671	2.4243	1.60	2.330	7.36	66.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 77 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	121 min	8	2.738	2.0333	1.26	1.850	7.31	74.3
		122 min	8	3.745	2.5662	1.65	2.290	7.85	68.5
		123 min	8	3.753	2.5734	1.54	2.285	7.27	68.6
		124 min	8	3.669	2.5633	1.43	2.260	7.34	69.9
		125 min	8	3.768	2.6450	1.48	2.300	7.62	70.2
		126 min	8	3.704	2.5271	1.31	2.320	7.52	68.2
		127 min	8	2.912	2.1091	1.47	1.835	7.10	72.4
		128 min	8	2.491	1.5862	1.38	1.915	6.22	63.7
		129 min	8	2.091	0.7406	1.37	1.925	3.51	35.4
		130 min	8	1.924	0.4396	1.46	1.840	2.76	22.9
		131 min	8	2.304	1.7107	1.18	1.745	6.35	74.3
		132 min	8	2.335	1.7184	0.75	1.870	6.34	73.6
		133 min	8	2.676	1.8625	1.55	1.985	7.16	69.6
		134 min	8	2.281	1.3439	1.17	1.855	5.42	58.9
		135 min	8	2.366	1.9899	1.17	1.595	7.13	84.1
		136 min	8	2.559	2.0151	1.38	1.870	7.45	78.8
		137 min	8	2.448	1.9635	1.08	1.890	7.17	80.2
		138 min	8	2.453	1.9476	1.11	1.800	7.13	79.4
		139 min	8	2.574	1.8782	1.52	1.925	7.15	73.0
		140 min	8	2.180	1.1357	1.05	1.860	4.72	52.1
		141 min	8	2.033	1.0141	0.94	1.785	4.25	49.9
		142 min	8	2.824	1.8127	1.21	2.165	6.11	64.2
		143 min	8	3.139	2.1897	1.40	2.055	7.13	69.8
		144 min	8	2.478	2.0079	1.36	1.810	7.34	81.0
		145 min	8	2.861	1.9777	1.54	1.955	7.24	69.1
		146 min	8	2.969	1.8867	1.50	2.230	7.18	63.6
		147 min	8	3.163	2.4154	1.55	1.915	7.14	76.4
		148 min	8	3.644	2.5066	1.41	2.305	7.31	68.8
		149 min	8	3.135	2.4780	1.32	1.985	7.46	79.0
		150 min	8	3.118	2.4786	1.19	1.910	7.18	79.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 78 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	151 min	8	3.366	2.4226	1.50	2.175	7.22	72.0
		152 min	8	3.065	2.3674	0.84	2.045	6.89	77.2
		153 min	8	3.053	2.4297	0.92	1.970	7.11	79.6
		154 min	8	3.194	2.2305	1.67	2.095	7.01	69.8
		155 min	8	3.138	2.2129	1.64	2.075	6.94	70.5
		156 min	8	2.998	2.2527	1.37	1.970	6.83	75.2
		157 min	8	3.079	1.9620	1.50	2.090	6.33	63.7
		158 min	8	2.653	1.6452	1.56	2.030	6.48	62.0
		159 min	8	2.675	1.6682	1.52	2.040	6.54	62.4
		160 min	8	2.829	1.9507	1.55	1.930	7.07	69.0
		161 min	8	2.685	1.8323	1.44	1.965	6.90	68.2
		162 min	8	2.844	1.9631	1.36	1.925	6.78	69.0
		163 min	8	2.776	1.9168	1.41	1.925	6.57	69.0
		164 min	8	2.776	1.8152	1.56	1.870	6.48	65.4
		165 min	8	2.781	1.7914	1.52	2.065	6.68	64.4
		166 min	8	3.201	2.1341	1.37	2.270	6.96	66.7
		167 min	8	3.189	2.2066	1.51	2.210	7.13	69.2
		168 min	8	3.509	2.3944	1.22	2.185	6.78	68.2
		169 min	8	3.133	2.1209	1.44	2.175	6.73	67.7
		170 min	8	3.039	2.0470	1.37	2.170	6.60	67.4
		171 min	8	3.086	2.1022	1.37	2.270	6.47	68.1
		172 min	8	3.175	2.2194	1.64	2.140	7.08	69.9
		173 min	8	3.131	2.0360	1.52	2.160	6.71	65.0
		174 min	8	3.330	2.2069	1.53	2.315	7.26	66.3
		175 min	8	3.231	2.2387	1.18	2.330	7.20	69.3
		176 min	8	3.261	2.1479	1.33	2.375	7.06	65.9
		177 min	8	3.274	2.0794	1.53	2.375	6.68	63.5
		178 min	8	3.375	2.1621	1.52	2.380	6.98	64.1
		179 min	8	3.358	2.1174	1.66	2.335	6.73	63.1
		180 min	8	3.315	2.1237	1.67	2.320	6.84	64.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 79 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	181 min	8	3.296	2.1183	1.72	2.295	6.77	64.3
		182 min	8	3.279	2.1420	1.70	2.305	6.90	65.3
		183 min	8	3.244	2.1497	1.59	2.255	6.73	66.3
		184 min	8	3.559	2.1242	1.57	2.365	6.63	59.7
		185 min	8	3.271	2.0861	1.62	2.365	6.69	63.8
		186 min	7	2.824	1.8316	1.70	2.250	6.93	64.9
		187 min	8	2.729	1.7386	1.73	2.110	6.99	63.7
		188 min	8	2.701	1.6962	1.44	2.190	6.81	62.8
		189 min	8	2.673	1.7275	1.50	2.120	6.87	64.6
		190 min	8	2.591	1.6090	1.17	2.195	6.42	62.1
		191 min	8	2.619	1.6113	1.43	2.145	6.52	61.5
		192 min	8	2.679	1.6600	1.65	2.140	6.74	62.0
		193 min	8	2.681	1.5260	1.77	2.185	6.40	56.9
		194 min	8	2.550	1.5604	1.57	2.100	6.34	61.2
		195 min	8	2.528	1.5099	1.50	2.050	6.19	59.7
		196 min	8	2.610	1.5820	1.58	2.080	6.47	60.6
		197 min	8	2.588	1.5913	1.52	2.070	6.46	61.5
		198 min	8	2.575	1.6677	1.60	2.010	6.64	64.8
		199 min	8	2.530	1.6603	0.96	2.085	6.47	65.6
		200 min	8	2.571	1.5845	1.35	2.080	6.39	61.6
		201 min	8	2.556	1.6067	1.42	2.035	6.45	62.9
		202 min	8	2.563	1.6481	1.33	2.085	6.55	64.3
		203 min	9	2.417	1.4358	1.46	1.990	6.16	59.4
		204 min	9	2.456	1.5251	1.50	2.030	6.44	62.1
		205 min	9	2.512	1.4803	1.33	1.890	6.19	58.9
		206 min	9	2.509	1.4674	1.68	2.070	6.34	58.5
		207 min	8	2.503	1.5242	1.54	2.025	6.19	60.9
		208 min	8	2.550	1.6487	1.59	1.965	6.56	64.7
		209 min	8	2.416	1.3803	1.56	1.985	5.76	57.1
		210 min	8	2.519	1.4024	1.69	1.970	5.90	55.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 80 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	10	211 min	8	2.596	1.7714	1.62	1.980	6.90	68.2
		212 min	8	2.620	1.8904	1.68	1.860	7.24	72.2
		213 min	8	2.535	1.7254	1.56	1.890	6.72	68.1
		214 min	8	2.561	1.7253	1.32	2.020	6.73	67.4
		215 min	8	2.528	1.7410	1.52	1.855	6.75	68.9
		216 min	8	2.579	1.8922	1.57	1.835	7.19	73.4
		217 min	8	2.563	1.8246	1.68	1.785	7.00	71.2
		218 min	8	2.515	1.7617	1.62	1.795	6.81	70.0
		219 min	8	2.516	1.7852	1.43	1.830	6.84	70.9
		220 min	8	2.596	1.7555	1.59	1.890	6.80	67.6
		221 min	8	3.261	2.0064	1.65	2.265	6.76	61.5
		222 min	8	2.860	1.9470	1.55	2.000	7.06	68.1
		223 min	8	2.769	1.9077	1.67	1.925	7.08	68.9
		224 min	8	2.780	1.8322	1.79	1.855	7.08	65.9
		225 min	8	2.985	2.0231	1.60	1.945	6.80	67.8
		226 min	8	2.916	1.9472	1.60	2.040	6.85	66.8
		227 min	8	3.219	2.0565	1.71	2.005	6.99	63.9
		228 min	8	2.806	1.4166	1.67	1.980	5.10	50.5
		229 min	9	2.927	2.0277	1.24	1.920	7.07	69.3
		230 min	9	2.611	1.2667	1.48	2.180	5.13	48.5
		231 min	9	2.652	1.6364	1.25	1.810	5.67	61.7
		232 min	9	2.937	2.0987	1.29	2.050	6.92	71.5
		233 min	9	2.931	2.2358	1.30	1.830	7.02	76.3
		234 min	9	2.923	2.2356	1.33	1.930	6.89	76.5
		235 min	8	3.039	2.4377	1.25	1.830	7.10	80.2
		236 min	9	3.177	2.2297	1.34	1.970	7.38	70.2
		237 min	9	3.086	2.1579	1.18	1.990	6.91	69.9
		238 min	9	3.006	2.2413	1.19	1.870	6.86	74.6
		239 min	9	2.632	1.7142	1.27	1.860	6.42	65.1
		240 min	5	2.908	1.3613	1.30	2.500	4.76	46.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 81 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	1 min	12	3.929	2.4858	1.11	3.535	7.74	63.3
		2 min	12	4.042	2.6021	0.97	3.330	7.98	64.4
		3 min	12	3.973	2.5763	1.16	3.300	7.86	64.9
		4 min	12	3.813	2.4399	1.30	3.170	7.81	64.0
		5 min	12	3.434	2.1756	1.31	2.770	7.49	63.4
		6 min	12	3.565	2.2823	1.25	2.645	7.09	64.0
		7 min	12	3.643	2.4653	1.01	2.475	7.69	67.7
		8 min	12	3.938	2.5800	1.04	3.330	7.67	65.5
		9 min	12	3.772	2.3036	1.38	3.120	7.28	61.1
		10 min	12	4.043	2.5878	1.29	3.185	7.39	64.0
		11 min	12	3.885	2.3712	1.47	3.145	7.37	61.0
		12 min	12	3.678	2.3690	1.43	2.485	7.55	64.4
		13 min	12	3.786	2.2717	1.42	3.155	7.37	60.0
		14 min	12	3.865	2.3849	1.38	3.130	7.40	61.7
		15 min	12	4.086	2.4984	1.42	3.160	7.35	61.1
		16 min	12	3.668	2.3636	1.51	2.325	7.30	64.4
		17 min	12	3.641	2.3178	1.49	2.330	6.96	63.7
		18 min	12	3.569	2.1843	1.05	2.615	7.37	61.2
		19 min	12	3.753	2.3422	1.44	2.685	7.45	62.4
		20 min	12	3.891	2.3423	1.33	3.205	7.11	60.2
		21 min	12	4.223	2.4565	1.38	3.895	7.37	58.2
		22 min	12	4.349	2.4057	1.47	4.320	7.32	55.3
		23 min	12	4.271	2.4590	1.26	4.710	6.86	57.6
		24 min	12	4.287	2.3911	1.34	4.685	7.00	55.8
		25 min	12	4.120	2.3498	1.14	3.335	7.01	57.0
		26 min	12	3.506	1.9816	1.24	2.885	6.81	56.5
		27 min	12	3.528	1.9633	1.39	3.040	6.78	55.7
		28 min	12	3.985	2.4442	1.24	3.320	7.13	61.3
		29 min	12	3.410	2.1436	1.26	2.710	6.85	62.9
		30 min	12	4.249	2.3093	1.18	4.720	6.94	54.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 82 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	31 min	12	4.116	2.6501	1.13	3.235	7.54	64.4
		32 min	11	3.731	2.3458	1.02	3.670	7.10	62.9
		33 min	10	3.830	2.3538	0.91	3.455	7.02	61.5
		34 min	10	3.364	2.3876	0.95	2.355	7.16	71.0
		35 min	10	3.869	2.7619	1.37	2.250	7.18	71.4
		36 min	10	3.497	2.3387	1.12	2.320	7.17	66.9
		37 min	10	3.998	2.3931	1.20	4.245	6.98	59.9
		38 min	10	4.208	2.6477	1.12	4.640	6.98	62.9
		39 min	10	4.282	2.6319	1.32	4.725	7.05	61.5
		40 min	10	4.177	2.5908	0.96	4.635	7.03	62.0
		41 min	10	3.808	2.4508	1.06	3.575	7.20	64.4
		42 min	10	3.504	2.2767	1.31	2.745	6.74	65.0
		43 min	11	3.420	2.1624	1.27	2.990	6.87	63.2
		44 min	11	2.948	1.8681	1.07	2.460	6.22	63.4
		45 min	11	3.543	2.3842	0.95	2.990	7.32	67.3
		46 min	11	3.452	2.3478	0.89	2.760	6.86	68.0
		47 min	11	3.353	2.2103	0.95	3.050	6.80	65.9
		48 min	11	3.480	2.2657	1.00	3.220	7.32	65.1
		49 min	11	3.001	2.1642	0.82	1.940	6.68	72.1
		50 min	11	3.335	2.4956	0.84	2.040	7.63	74.8
		51 min	10	3.983	2.3224	1.35	3.685	7.59	58.3
		52 min	10	3.722	2.2838	1.18	3.550	6.96	61.4
		53 min	10	3.976	2.5000	0.79	3.515	7.81	62.9
		54 min	10	3.463	2.2880	0.93	3.320	7.61	66.1
		55 min	10	3.416	2.4441	0.98	2.445	6.94	71.5
		56 min	10	3.124	2.2818	1.33	2.130	7.64	73.0
		57 min	10	3.837	2.2538	1.18	3.440	7.31	58.7
		58 min	10	3.932	2.5263	1.19	3.235	7.63	64.2
		59 min	10	3.469	2.6170	0.80	2.490	7.54	75.4
		60 min	10	3.934	2.7329	1.05	3.160	7.36	69.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 83 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	61 min	10	3.782	2.5422	0.73	3.285	7.14	67.2
		62 min	10	3.751	2.5216	0.88	3.320	7.26	67.2
		63 min	10	3.677	2.6293	0.87	3.205	7.72	71.5
		64 min	10	3.839	2.5648	0.77	3.385	6.99	66.8
		65 min	9	3.573	2.5731	1.00	2.760	7.05	72.0
		66 min	9	3.834	2.8095	0.69	2.770	7.22	73.3
		67 min	9	3.937	2.8616	1.05	2.890	7.76	72.7
		68 min	9	3.857	2.5810	1.23	2.710	7.79	66.9
		69 min	9	3.252	2.4365	1.00	1.930	7.08	74.9
		70 min	9	4.136	2.8329	0.86	2.760	7.45	68.5
		71 min	9	4.693	2.7692	0.86	6.430	7.52	59.0
		72 min	9	5.394	2.5500	1.61	6.430	8.02	47.3
		73 min	9	4.214	2.9766	0.87	3.010	7.72	70.6
		74 min	9	4.152	2.7319	0.87	2.870	7.16	65.8
		75 min	9	4.278	2.7292	0.98	3.270	7.28	63.8
		76 min	9	4.703	2.6864	1.24	6.310	7.39	57.1
		77 min	9	4.886	2.6795	1.27	6.910	7.29	54.8
		78 min	9	3.948	2.5157	1.33	3.130	7.29	63.7
		79 min	9	4.534	2.6270	1.23	5.150	7.41	57.9
		80 min	9	4.726	2.8443	1.00	5.750	7.83	60.2
		81 min	9	4.070	2.2795	0.89	3.750	7.16	56.0
		82 min	8	4.031	2.2990	1.51	3.380	7.21	57.0
		83 min	8	4.231	2.4480	1.55	3.755	7.19	57.9
		84 min	8	4.089	2.5493	1.45	3.580	7.15	62.3
		85 min	8	3.986	2.4680	1.21	3.415	7.26	61.9
		86 min	8	3.748	2.6951	1.10	2.315	7.21	71.9
		87 min	8	4.444	2.7021	1.52	4.625	7.24	60.8
		88 min	8	4.778	2.4338	1.52	5.660	7.31	50.9
		89 min	8	5.049	2.6737	1.38	6.605	7.41	53.0
		90 min	8	4.824	2.5573	1.47	5.530	7.59	53.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 84 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	91 min	8	4.971	2.5788	1.50	5.945	7.67	51.9
		92 min	8	5.198	2.6588	1.51	6.745	7.63	51.2
		93 min	8	5.249	2.4891	1.90	6.595	7.71	47.4
		94 min	8	5.164	2.5886	1.52	6.470	7.57	50.1
		95 min	8	5.534	2.2477	1.85	6.680	7.55	40.6
		96 min	8	5.243	2.4607	1.89	6.325	7.80	46.9
		97 min	8	5.320	2.6324	1.70	6.840	7.88	49.5
		98 min	8	5.341	2.6737	1.76	7.035	7.89	50.1
		99 min	8	5.085	2.5446	1.70	5.890	7.93	50.0
		100 min	8	4.656	2.7240	1.60	4.805	7.96	58.5
		101 min	8	4.801	2.4671	1.35	5.255	7.98	51.4
		102 min	8	4.529	2.7706	1.60	4.660	7.84	61.2
		103 min	8	5.104	2.6474	1.51	6.310	8.07	51.9
		104 min	8	4.635	2.8017	1.54	4.865	8.01	60.4
		105 min	8	4.718	2.5568	1.57	5.040	7.55	54.2
		106 min	8	4.500	2.7600	1.55	4.560	7.70	61.3
		107 min	8	4.609	2.9560	1.50	4.875	8.02	64.1
		108 min	8	5.259	2.6918	1.54	6.900	7.79	51.2
		109 min	8	3.870	2.9501	1.19	2.250	8.34	76.2
		110 min	8	5.240	2.5171	1.61	6.580	7.92	48.0
		111 min	8	4.640	2.7513	1.73	4.855	7.54	59.3
		112 min	8	5.305	2.8418	1.51	6.600	8.31	53.6
		113 min	8	4.878	2.5749	1.50	5.620	7.82	52.8
		114 min	8	4.336	2.5684	1.70	3.975	7.66	59.2
		115 min	8	4.269	2.5196	1.73	3.380	7.43	59.0
		116 min	8	4.561	2.9266	1.31	4.785	7.48	64.2
		117 min	8	4.904	2.4649	1.58	5.720	7.57	50.3
		118 min	8	4.075	2.5954	1.77	2.790	7.48	63.7
		119 min	8	4.275	2.4525	1.38	3.325	7.50	57.4
		120 min	8	4.906	2.6249	1.65	5.350	7.59	53.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 85 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	121 min	8	4.517	2.9713	0.86	4.650	7.62	65.8
		122 min	8	4.545	2.8936	1.51	4.630	7.70	63.7
		123 min	8	5.639	2.4634	1.47	7.175	7.51	43.7
		124 min	8	4.338	2.5989	1.44	4.520	7.31	59.9
		125 min	8	5.011	2.3656	1.94	5.800	7.38	47.2
		126 min	8	5.096	2.5988	1.24	6.350	7.37	51.0
		127 min	8	4.503	2.7596	1.44	4.625	7.72	61.3
		128 min	8	4.309	2.3175	1.62	3.525	7.72	53.8
		129 min	8	5.060	2.4436	1.76	6.380	7.22	48.3
		130 min	8	3.626	2.1082	1.15	2.740	6.82	58.1
		131 min	8	2.961	1.9856	1.45	2.035	6.91	67.1
		132 min	8	4.251	2.1408	1.55	4.100	7.00	50.4
		133 min	8	4.373	1.9191	1.90	3.900	7.27	43.9
		134 min	8	4.103	2.4226	1.27	3.545	7.12	59.1
		135 min	8	4.004	2.4802	1.54	2.685	7.19	61.9
		136 min	8	3.205	2.4849	1.32	2.090	7.66	77.5
		137 min	8	4.241	2.5311	1.60	3.585	7.29	59.7
		138 min	8	3.316	2.4397	1.30	2.365	7.49	73.6
		139 min	8	3.954	2.4801	1.20	2.865	7.30	62.7
		140 min	8	3.624	2.2212	1.36	2.715	6.86	61.3
		141 min	8	3.294	2.2762	0.96	2.500	7.36	69.1
		142 min	8	3.754	2.7618	1.17	2.325	7.17	73.6
		143 min	8	3.856	2.3828	1.34	2.910	7.21	61.8
		144 min	8	3.975	2.2954	1.55	3.390	7.31	57.7
		145 min	8	4.595	2.3400	1.87	4.580	7.37	50.9
		146 min	8	3.786	2.4254	1.06	3.160	7.36	64.1
		147 min	8	4.155	2.3470	1.12	3.665	7.39	56.5
		148 min	8	4.309	2.4865	0.94	4.015	7.75	57.7
		149 min	8	4.171	2.6397	1.04	4.395	7.23	63.3
		150 min	8	4.288	2.9600	0.91	4.475	7.46	69.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 86 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	151 min	8	4.281	2.8819	0.91	4.670	7.25	67.3
		152 min	8	4.353	2.7617	1.12	4.650	7.41	63.4
		153 min	8	3.545	2.5792	0.89	2.115	6.82	72.8
		154 min	8	3.450	2.2117	1.06	2.595	6.94	64.1
		155 min	8	4.109	2.4719	1.00	4.360	6.75	60.2
		156 min	8	3.500	2.3732	1.06	2.555	6.75	67.8
		157 min	8	3.634	2.2719	1.10	2.900	6.95	62.5
		158 min	8	3.486	2.2396	1.15	2.595	6.97	64.2
		159 min	8	3.758	2.3204	1.05	3.555	6.96	61.8
		160 min	8	3.505	2.2392	1.09	2.550	6.93	63.9
		161 min	8	4.023	2.3742	1.11	3.920	6.76	59.0
		162 min	8	4.031	2.4686	0.79	4.105	6.68	61.2
		163 min	8	3.803	2.3507	1.05	3.010	6.75	61.8
		164 min	8	3.530	2.5112	0.97	2.170	6.64	71.1
		165 min	8	3.574	2.4258	1.08	2.300	6.67	67.9
		166 min	8	3.700	2.2564	1.13	3.500	6.73	61.0
		167 min	8	2.960	2.3250	1.05	1.765	6.89	78.5
		168 min	8	2.939	2.2494	0.97	2.030	6.64	76.5
		169 min	8	3.599	2.6545	1.32	2.120	7.25	73.8
		170 min	8	3.558	2.7147	0.66	2.205	7.38	76.3
		171 min	8	4.325	2.7062	1.21	4.520	7.43	62.6
		172 min	8	4.233	2.7049	0.56	4.460	7.37	63.9
		173 min	8	4.436	2.4433	1.13	4.445	7.46	55.1
		174 min	8	4.734	2.3557	1.13	5.445	7.53	49.8
		175 min	8	4.799	2.4428	1.06	5.720	7.85	50.9
		176 min	8	4.467	2.7389	0.86	4.550	7.75	61.3
		177 min	8	4.486	2.7824	1.18	4.660	7.68	62.0
		178 min	8	4.491	2.7053	1.23	4.750	7.49	60.2
		179 min	8	4.451	2.6171	1.30	4.565	7.28	58.8
		180 min	8	4.406	2.5618	1.09	4.535	6.93	58.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 87 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	181 min	8	4.749	2.3493	1.25	5.620	7.13	49.5
		182 min	8	4.493	2.6815	1.20	4.680	7.33	59.7
		183 min	8	4.468	2.5975	1.03	4.590	7.51	58.1
		184 min	8	4.389	2.6388	1.35	4.555	7.17	60.1
		185 min	8	3.926	2.4006	1.37	2.870	6.98	61.1
		186 min	7	3.176	2.1850	1.02	2.190	6.71	68.8
		187 min	8	2.781	1.6487	1.30	2.380	6.62	59.3
		188 min	8	2.905	1.9811	1.00	2.055	6.58	68.2
		189 min	8	3.539	2.3392	0.78	2.415	6.51	66.1
		190 min	8	3.828	2.1885	1.81	2.730	6.51	57.2
		191 min	8	3.071	2.1961	1.21	2.090	6.59	71.5
		192 min	8	3.035	2.2564	1.16	1.985	6.81	74.3
		193 min	8	3.134	2.1545	1.51	2.070	6.66	68.8
		194 min	8	3.326	2.2467	1.32	2.305	6.95	67.5
		195 min	8	3.015	2.1675	1.32	2.035	6.55	71.9
		196 min	8	3.836	2.1640	1.60	3.120	7.15	56.4
		197 min	8	3.311	2.2535	1.19	2.345	7.25	68.1
		198 min	8	3.421	2.3590	1.25	2.300	7.53	69.0
		199 min	8	3.675	2.4360	1.16	2.405	6.90	66.3
		200 min	8	2.499	1.7486	1.07	2.025	6.64	70.0
		201 min	8	3.505	2.2220	1.35	2.450	6.69	63.4
		202 min	8	3.375	2.0535	1.07	2.565	6.36	60.8
		203 min	9	3.180	2.2487	0.90	1.990	6.61	70.7
		204 min	9	3.819	2.4802	1.23	2.630	7.09	64.9
		205 min	9	3.634	2.1515	1.53	2.760	6.70	59.2
		206 min	9	3.013	2.1500	1.10	1.900	6.93	71.3
		207 min	8	3.011	2.4515	1.02	1.800	7.57	81.4
		208 min	8	3.118	2.1803	1.37	2.180	6.62	69.9
		209 min	8	2.934	1.7998	1.02	2.290	6.04	61.3
		210 min	8	3.481	2.3759	1.11	2.280	6.75	68.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 88 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
A	11	211 min	8	3.254	2.3761	1.17	2.260	7.35	73.0
		212 min	8	3.693	2.6511	1.22	2.290	7.20	71.8
		213 min	8	4.208	2.4255	1.37	4.015	7.31	57.6
		214 min	8	3.131	2.3933	1.19	1.890	7.07	76.4
		215 min	8	3.356	2.3988	1.13	2.260	7.14	71.5
		216 min	8	3.871	2.4392	1.75	2.665	7.34	63.0
		217 min	8	3.609	2.6928	1.27	2.165	7.44	74.6
		218 min	8	3.755	2.6890	1.15	2.575	7.19	71.6
		219 min	8	3.530	2.6114	1.34	2.190	7.32	74.0
		220 min	8	3.575	2.6009	1.25	2.185	6.83	72.8
		221 min	8	3.545	2.5990	1.33	2.110	6.76	73.3
		222 min	8	3.551	2.6610	0.95	2.180	7.24	74.9
		223 min	8	3.956	2.8220	1.32	2.570	7.44	71.3
		224 min	8	3.631	2.6634	1.15	2.470	7.15	73.3
		225 min	8	3.785	2.5361	1.39	3.285	7.45	67.0
		226 min	8	3.824	2.8181	1.29	2.485	7.35	73.7
		227 min	8	3.771	2.6310	1.42	2.410	7.32	69.8
		228 min	8	3.786	2.8685	1.13	2.300	7.22	75.8
		229 min	9	3.402	2.5648	1.12	1.870	7.11	75.4
		230 min	9	3.929	2.6420	1.18	2.770	7.29	67.2
		231 min	9	3.292	2.4852	1.04	1.870	7.25	75.5
		232 min	9	3.738	2.5461	1.12	2.630	7.14	68.1
		233 min	9	3.339	2.4552	1.11	2.420	7.09	73.5
		234 min	9	3.078	2.2947	1.25	1.810	7.23	74.6
		235 min	8	2.988	2.5323	1.03	1.750	7.32	84.8
		236 min	9	3.041	2.1630	1.22	1.910	6.98	71.1
		237 min	9	3.549	2.3728	1.15	2.580	6.98	66.9
		238 min	9	3.090	2.3475	1.00	1.770	7.18	76.0
		239 min	9	3.086	2.3038	1.10	1.700	7.24	74.7
		240 min	5	4.094	2.3078	1.37	3.640	7.08	56.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 89 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	1 min	12	8.132	0.5561	7.16	8.165	9.02	6.8
		2 min	12	8.003	0.4902	7.19	7.980	9.05	6.1
		3 min	12	7.949	0.4586	7.16	8.030	8.49	5.8
		4 min	12	8.011	0.5551	7.12	8.000	8.87	6.9
		5 min	12	7.684	0.8275	5.77	7.765	8.76	10.8
		6 min	12	7.868	0.6315	6.71	7.925	8.82	8.0
		7 min	12	7.716	0.8397	6.76	7.310	9.22	10.9
		8 min	12	7.684	0.6434	6.68	7.810	8.48	8.4
		9 min	12	7.745	0.6990	6.59	7.755	8.83	9.0
		10 min	12	7.642	0.7210	6.63	7.605	8.93	9.4
		11 min	12	7.453	0.6281	6.57	7.380	8.52	8.4
		12 min	12	7.529	0.6975	6.53	7.320	8.80	9.3
		13 min	12	7.469	0.7368	6.53	7.110	8.65	9.9
		14 min	12	7.225	0.4736	6.47	7.105	8.00	6.6
		15 min	12	7.144	0.6198	6.16	7.160	8.04	8.7
		16 min	12	7.181	0.6084	6.38	7.080	8.29	8.5
		17 min	12	7.296	0.4890	6.69	7.295	8.20	6.7
		18 min	12	7.168	0.4070	6.72	7.050	7.93	5.7
		19 min	12	7.271	0.4381	6.53	7.280	7.95	6.0
		20 min	12	7.317	0.5668	6.63	7.235	8.19	7.7
		21 min	11	7.306	0.6511	6.48	7.070	8.38	8.9
		22 min	10	7.371	0.5745	6.66	7.115	8.29	7.8
		23 min	10	7.199	0.7312	6.13	6.985	8.26	10.2
		24 min	10	7.133	0.7885	5.57	7.085	8.17	11.1
		25 min	10	7.059	0.5256	6.47	6.880	8.01	7.4
		26 min	10	7.078	0.5755	6.27	7.000	8.08	8.1
		27 min	10	7.048	0.6809	6.05	7.060	7.87	9.7
		28 min	10	6.645	1.9272	1.34	6.925	8.13	29.0
		29 min	10	7.056	0.5067	6.36	7.015	7.83	7.2
		30 min	10	7.189	0.5790	6.29	7.145	8.06	8.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 90 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	31 min	10	7.077	0.7387	5.94	7.015	8.10	10.4
		32 min	10	7.004	0.7755	5.81	6.980	8.07	11.1
		33 min	10	7.058	0.7386	6.10	6.755	8.38	10.5
		34 min	10	7.194	0.6654	6.46	6.950	8.05	9.2
		35 min	10	6.940	0.7838	6.10	6.620	8.42	11.3
		36 min	10	7.125	0.7295	5.96	6.955	8.30	10.2
		37 min	10	7.171	0.6373	6.33	6.950	8.05	8.9
		38 min	10	6.436	1.9047	1.22	6.875	7.95	29.6
		39 min	10	7.075	0.5323	6.27	6.995	7.77	7.5
		40 min	10	7.051	0.8178	6.12	6.720	8.11	11.6
		41 min	10	7.128	0.7325	5.99	6.995	8.16	10.3
		42 min	10	6.411	1.5348	2.38	6.705	7.88	23.9
		43 min	10	6.957	0.8359	5.94	6.740	8.34	12.0
		44 min	10	7.155	0.7211	6.11	7.190	8.33	10.1
		45 min	9	7.138	0.8375	6.12	7.300	8.32	11.7
		46 min	9	7.022	0.8050	5.95	6.680	8.27	11.5
		47 min	9	7.132	0.8078	5.82	7.310	8.21	11.3
		48 min	9	7.018	0.8066	5.60	7.130	8.01	11.5
		49 min	9	6.820	0.8437	5.52	6.940	7.87	12.4
		50 min	8	7.183	0.7703	5.76	7.220	8.36	10.7
		51 min	8	7.009	0.7178	5.74	6.990	7.93	10.2
		52 min	8	7.124	0.7315	5.92	7.220	7.94	10.3
		53 min	9	6.971	0.7876	5.72	6.940	8.36	11.3
		54 min	9	6.452	2.0559	1.33	6.630	8.55	31.9
		55 min	9	6.881	0.9918	4.81	7.000	7.88	14.4
		56 min	9	6.977	0.8787	5.68	6.780	8.31	12.6
		57 min	9	7.036	0.8844	5.64	6.930	8.28	12.6
		58 min	9	6.973	0.7940	5.87	7.120	8.26	11.4
		59 min	9	7.138	0.9435	5.83	7.300	8.45	13.2
		60 min	9	7.246	0.8779	5.95	7.080	8.53	12.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 91 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	61 min	9	6.392	2.1718	1.03	6.970	8.41	34.0
		62 min	9	7.173	0.8118	5.98	7.080	8.36	11.3
		63 min	8	7.149	0.6652	6.47	7.030	8.34	9.3
		64 min	8	6.941	0.7983	5.62	6.790	8.34	11.5
		65 min	8	6.778	0.7598	5.72	6.585	8.28	11.2
		66 min	8	7.016	0.5967	6.47	6.730	8.13	8.5
		67 min	8	6.854	0.5210	6.22	6.730	7.69	7.6
		68 min	8	6.914	0.4935	6.27	6.980	7.63	7.1
		69 min	8	6.916	0.5876	6.12	6.870	7.65	8.5
		70 min	8	6.924	0.8875	5.85	6.955	8.31	12.8
		71 min	8	6.281	2.3764	0.59	6.790	8.36	37.8
		72 min	8	7.071	0.7392	6.00	7.045	8.39	10.5
		73 min	8	6.898	0.7915	5.98	6.810	8.44	11.5
		74 min	8	7.126	0.6768	6.39	6.820	8.44	9.5
		75 min	8	7.075	0.7112	6.26	7.140	7.89	10.1
		76 min	8	6.883	0.9632	5.61	6.495	8.46	14.0
		77 min	8	6.910	0.8458	5.60	6.865	8.06	12.2
		78 min	8	7.083	0.7838	6.11	7.110	8.36	11.1
		79 min	8	7.055	0.9701	5.58	7.165	8.51	13.7
		80 min	8	7.149	0.6009	6.37	7.365	8.08	8.4
		81 min	8	6.975	0.7203	6.30	6.630	8.21	10.3
		82 min	8	6.691	0.6174	5.80	6.590	7.61	9.2
		83 min	8	7.011	0.9272	5.55	7.105	8.32	13.2
		84 min	8	6.790	0.8281	5.86	6.680	8.32	12.2
		85 min	8	6.756	0.8874	5.21	6.695	8.25	13.1
		86 min	8	6.178	2.1768	1.06	6.690	8.38	35.2
		87 min	8	6.836	0.7202	5.92	6.985	7.69	10.5
		88 min	8	6.921	0.8463	6.01	6.925	8.47	12.2
		89 min	9	6.910	0.9123	5.45	6.940	8.41	13.2
		90 min	9	7.049	0.8119	5.65	7.120	8.33	11.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 92 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	91 min	9	7.129	0.7740	6.12	7.100	8.42	10.9
		92 min	9	7.058	0.8174	5.73	7.100	8.44	11.6
		93 min	9	6.894	0.8759	5.69	6.730	8.30	12.7
		94 min	9	7.106	0.6953	6.13	7.350	8.28	9.8
		95 min	8	7.044	0.9182	5.60	7.040	8.49	13.0
		96 min	8	7.013	0.6960	5.85	7.080	8.27	9.9
		97 min	8	6.873	1.0270	5.31	7.065	8.47	14.9
		98 min	8	6.953	0.5634	6.35	6.790	7.91	8.1
		99 min	9	7.059	0.7635	6.38	6.680	8.31	10.8
		100 min	8	6.258	2.0595	1.37	6.895	7.72	32.9
		101 min	8	6.825	0.7242	5.33	6.820	7.60	10.6
		102 min	8	6.996	0.5182	6.29	6.960	7.67	7.4
		103 min	8	7.201	0.6813	5.62	7.330	7.88	9.5
		104 min	8	7.026	0.5914	6.23	6.920	7.89	8.4
		105 min	8	7.205	0.8006	5.71	7.255	8.25	11.1
		106 min	8	7.063	0.4892	6.40	6.950	7.96	6.9
		107 min	8	6.890	0.9219	5.41	6.580	8.06	13.4
		108 min	8	6.960	0.7475	5.70	7.045	7.83	10.7
		109 min	8	6.885	0.8012	5.58	6.750	8.01	11.6
		110 min	8	7.010	0.9365	5.60	7.045	8.10	13.4
		111 min	8	6.959	0.8843	5.56	6.905	8.17	12.7
		112 min	8	7.156	0.9436	5.53	7.160	8.34	13.2
		113 min	8	6.956	0.8376	5.82	6.860	8.19	12.0
		114 min	8	6.850	0.8685	5.50	6.700	7.83	12.7
		115 min	8	7.049	0.9265	5.97	6.700	8.31	13.1
		116 min	8	6.804	1.0888	5.57	6.405	8.28	16.0
		117 min	8	7.055	1.0225	5.74	7.005	8.37	14.5
		118 min	8	6.916	0.7758	6.03	6.870	8.00	11.2
		119 min	8	6.955	0.8018	5.76	7.085	7.95	11.5
		120 min	8	6.985	0.8115	5.87	6.810	8.19	11.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 93 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	121 min	8	6.684	0.6279	6.01	6.500	7.65	9.4
		122 min	8	7.000	0.8290	5.48	7.145	7.92	11.8
		123 min	8	7.128	0.8392	6.02	6.990	8.26	11.8
		124 min	8	6.214	1.7738	2.15	6.470	7.67	28.5
		125 min	8	6.945	0.6846	5.57	7.010	7.94	9.9
		126 min	8	6.771	0.8311	5.54	6.720	8.21	12.3
		127 min	8	6.901	0.8726	5.35	7.005	8.16	12.6
		128 min	8	7.146	0.8918	5.62	7.265	8.22	12.5
		129 min	8	7.046	0.9331	5.30	7.260	8.36	13.2
		130 min	8	7.204	0.7948	6.03	7.335	8.18	11.0
		131 min	8	7.021	0.3631	6.40	7.145	7.56	5.2
		132 min	8	6.906	0.6161	5.85	7.100	7.74	8.9
		133 min	8	7.150	0.7413	6.03	7.215	8.33	10.4
		134 min	8	7.030	0.5804	6.26	6.950	8.07	8.3
		135 min	8	6.901	0.6023	5.78	7.025	7.50	8.7
		136 min	8	6.876	0.7418	5.48	7.075	7.60	10.8
		137 min	8	6.849	0.5719	6.03	7.100	7.40	8.3
		138 min	8	7.339	0.5925	6.42	7.445	8.11	8.1
		139 min	8	6.749	0.6541	5.47	6.795	7.49	9.7
		140 min	8	7.043	0.8394	5.58	6.935	8.15	11.9
		141 min	8	6.741	0.8146	5.54	6.765	8.05	12.1
		142 min	8	7.126	0.9734	5.43	7.355	8.29	13.7
		143 min	8	7.051	0.6951	5.84	7.150	7.83	9.9
		144 min	8	7.254	0.7282	6.20	7.360	8.09	10.0
		145 min	8	6.585	2.3058	1.12	7.405	8.14	35.0
		146 min	8	6.684	2.2667	1.38	7.585	8.13	33.9
		147 min	8	6.683	1.9709	2.19	7.480	8.30	29.5
		148 min	8	6.743	1.8068	2.48	7.460	7.80	26.8
		149 min	8	7.023	0.9760	4.89	7.390	7.90	13.9
		150 min	8	6.799	1.3800	3.70	7.245	7.87	20.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 94 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	151 min	8	6.699	1.3432	3.66	7.120	8.03	20.1
		152 min	8	6.678	1.3632	3.68	7.180	7.63	20.4
		153 min	8	6.740	1.1839	4.25	7.135	7.69	17.6
		154 min	8	7.009	0.9824	4.96	7.440	7.71	14.0
		155 min	8	6.674	0.9227	4.73	6.705	7.73	13.8
		156 min	8	6.859	0.8891	5.20	6.965	8.17	13.0
		157 min	8	6.821	1.0152	4.80	6.970	7.90	14.9
		158 min	8	7.029	0.7027	5.75	7.040	7.99	10.0
		159 min	8	7.085	0.7016	5.56	7.370	7.70	9.9
		160 min	8	6.776	1.0158	5.00	6.755	7.99	15.0
		161 min	8	6.950	0.7894	5.56	7.090	7.92	11.4
		162 min	8	6.531	1.1485	4.24	6.855	7.72	17.6
		163 min	8	6.995	0.6993	6.03	7.050	7.98	10.0
		164 min	8	7.015	0.4907	6.10	6.915	7.55	7.0
		165 min	8	7.106	0.8634	5.38	7.335	8.15	12.1
		166 min	8	6.926	0.7724	5.86	6.890	7.93	11.2
		167 min	8	6.849	0.6189	5.86	7.030	7.57	9.0
		168 min	8	6.761	0.8895	5.50	6.770	8.43	13.2
		169 min	8	6.971	0.5574	6.20	6.975	7.66	8.0
		170 min	8	7.175	0.8003	6.05	7.150	8.42	11.2
		171 min	8	6.945	0.9029	5.42	7.230	8.23	13.0
		172 min	8	7.085	0.7551	5.60	7.170	8.04	10.7
		173 min	8	7.104	0.6387	6.15	7.250	8.02	9.0
		174 min	8	6.335	2.2627	1.17	7.115	8.03	35.7
		175 min	8	6.924	0.8310	5.53	7.170	7.96	12.0
		176 min	8	7.158	0.8487	5.96	7.060	8.53	11.9
		177 min	8	6.894	0.8353	5.97	6.585	8.26	12.1
		178 min	8	6.690	0.8635	5.82	6.485	8.50	12.9
		179 min	8	7.039	0.9610	5.76	7.140	8.57	13.7
		180 min	8	6.738	1.9078	2.47	7.280	8.57	28.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 95 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	181 min	8	6.906	1.2259	4.41	6.990	8.48	17.8
		182 min	7	7.134	0.9401	5.90	7.320	8.49	13.2
		183 min	7	6.887	0.8981	5.76	6.540	8.45	13.0
		184 min	7	6.821	0.7699	6.27	6.560	8.44	11.3
		185 min	7	6.973	0.7403	6.33	6.620	8.46	10.6
		186 min	7	6.689	0.3734	6.12	6.630	7.25	5.6
		187 min	7	7.229	0.7319	6.22	7.250	8.38	10.1
		188 min	7	7.113	0.7592	6.15	7.170	8.26	10.7
		189 min	8	6.974	0.7534	5.50	7.205	7.83	10.8
		190 min	8	7.226	0.7062	6.24	7.345	8.38	9.8
		191 min	8	7.096	0.9318	5.40	7.105	8.52	13.1
		192 min	8	7.245	0.7394	6.31	7.015	8.52	10.2
		193 min	8	6.909	0.6984	5.59	7.060	7.62	10.1
		194 min	8	7.064	0.7875	5.54	7.380	7.92	11.1
		195 min	8	6.805	0.6790	5.54	6.855	7.78	10.0
		196 min	8	6.783	0.7251	5.56	6.825	7.88	10.7
		197 min	9	7.009	0.7713	5.45	7.190	7.79	11.0
		198 min	9	7.056	0.7260	5.80	7.230	8.11	10.3
		199 min	9	6.979	0.6612	5.73	6.860	8.08	9.5
		200 min	9	7.198	0.8756	5.63	7.520	8.26	12.2
		201 min	9	6.907	0.6720	5.70	6.990	7.64	9.7
		202 min	10	7.038	0.6045	6.08	7.230	7.93	8.6
		203 min	10	6.980	0.6990	5.95	6.955	8.14	10.0
		204 min	9	7.028	0.7514	5.64	7.350	8.03	10.7
		205 min	9	7.002	0.6943	5.73	7.180	8.17	9.9
		206 min	9	6.806	0.7200	5.38	6.730	7.86	10.6
		207 min	8	6.583	0.5537	5.96	6.600	7.35	8.4
		208 min	8	6.704	0.3680	6.00	6.730	7.06	5.5
		209 min	8	6.799	0.5468	5.70	6.950	7.31	8.0
		210 min	8	6.669	0.5534	5.58	6.835	7.25	8.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 96 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	1	211 min	8	6.818	0.5779	5.65	6.890	7.48	8.5
		212 min	8	6.823	0.7286	5.48	6.855	7.87	10.7
		213 min	8	6.713	0.6412	5.53	6.760	7.72	9.6
		214 min	8	6.630	0.6024	5.67	6.675	7.62	9.1
		215 min	8	6.911	0.7016	5.67	6.880	7.84	10.2
		216 min	8	6.800	0.6016	6.11	6.745	7.97	8.8
		217 min	8	6.950	0.7390	5.61	6.840	7.81	10.6
		218 min	8	6.873	0.5428	6.31	6.720	7.88	7.9
		219 min	8	7.136	0.6182	6.03	7.290	7.78	8.7
		220 min	8	7.085	0.5122	6.38	7.260	7.84	7.2
		221 min	7	6.714	0.5632	5.77	6.850	7.27	8.4
		222 min	7	6.881	0.6602	5.95	7.020	7.71	9.6
		223 min	7	6.739	0.6513	5.67	6.650	7.72	9.7
		224 min	7	6.901	0.6410	5.74	6.800	7.59	9.3
		225 min	7	6.981	0.4838	6.38	6.920	7.65	6.9
		226 min	7	6.991	0.4903	6.37	6.910	7.82	7.0
		227 min	7	7.249	0.4492	6.76	7.260	7.80	6.2
		228 min	7	7.031	0.3876	6.57	7.080	7.42	5.5
		229 min	7	6.486	1.4447	3.32	6.850	7.61	22.3
		230 min	7	7.029	0.4129	6.31	7.080	7.44	5.9
		231 min	7	7.050	0.5591	6.10	7.200	7.65	7.9
		232 min	7	7.137	0.3876	6.63	7.040	7.66	5.4
		233 min	7	7.123	0.2721	6.80	7.130	7.44	3.8
		234 min	7	6.896	0.6518	6.16	6.720	7.77	9.5
		235 min	7	7.177	0.4527	6.70	6.950	7.90	6.3
		236 min	7	7.317	0.4922	6.46	7.370	7.81	6.7
		237 min	7	7.011	0.4829	6.30	6.960	7.85	6.9
		238 min	7	6.926	0.4837	6.12	7.130	7.35	7.0
		239 min	7	7.230	0.5059	6.28	7.420	7.63	7.0
		240 min	1	7.540		7.54	7.540	7.54	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 97 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	1 min	12	8.110	0.4276	7.63	7.960	9.00	5.3
		2 min	12	8.057	0.4468	7.50	8.025	9.15	5.5
		3 min	12	7.963	0.4714	7.32	8.030	8.76	5.9
		4 min	12	8.068	0.6225	7.19	8.015	9.11	7.7
		5 min	12	7.784	0.7910	6.78	7.410	8.98	10.2
		6 min	12	7.779	0.8096	6.27	7.845	8.95	10.4
		7 min	12	7.617	1.0982	4.83	7.800	8.85	14.4
		8 min	12	7.781	0.6312	6.67	7.970	8.74	8.1
		9 min	12	7.634	0.6873	6.56	7.535	8.61	9.0
		10 min	12	7.374	1.4393	3.27	7.895	8.66	19.5
		11 min	12	7.256	0.5820	6.48	7.000	8.39	8.0
		12 min	12	7.370	0.7350	6.20	7.315	8.23	10.0
		13 min	12	7.330	0.7581	5.93	7.420	8.32	10.3
		14 min	12	7.377	0.6769	5.93	7.535	8.19	9.2
		15 min	12	6.888	1.8934	1.26	7.340	8.31	27.5
		16 min	12	6.922	1.5876	2.43	7.445	8.36	22.9
		17 min	12	7.152	0.7828	5.29	7.115	8.26	10.9
		18 min	12	7.088	1.2305	3.54	7.500	8.04	17.4
		19 min	12	7.202	0.8501	5.02	7.365	8.09	11.8
		20 min	12	6.943	1.6599	2.08	7.405	8.47	23.9
		21 min	11	6.821	1.8642	1.55	7.150	8.53	27.3
		22 min	10	6.670	1.9301	1.42	7.115	8.11	28.9
		23 min	10	6.670	1.6272	2.23	6.985	7.92	24.4
		24 min	10	6.135	2.0204	1.50	6.850	8.08	32.9
		25 min	10	6.467	1.8792	1.32	6.925	8.10	29.1
		26 min	10	6.791	0.7942	5.11	6.890	7.86	11.7
		27 min	10	6.927	0.6589	5.70	7.020	7.77	9.5
		28 min	10	6.486	1.9346	1.29	7.005	8.01	29.8
		29 min	10	6.628	1.8693	1.46	7.245	7.90	28.2
		30 min	10	6.729	1.2069	3.49	7.010	7.68	17.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 98 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	31 min	10	6.679	1.1643	3.68	6.965	7.69	17.4
		32 min	10	6.705	1.1529	3.73	6.895	7.70	17.2
		33 min	10	6.533	1.4624	3.12	7.100	7.98	22.4
		34 min	10	6.329	1.7886	1.36	6.815	7.52	28.3
		35 min	10	6.486	1.4632	2.63	6.650	7.77	22.6
		36 min	10	6.466	1.6227	2.06	6.930	7.62	25.1
		37 min	10	6.394	1.8207	1.34	6.815	7.65	28.5
		38 min	10	6.543	1.9802	1.04	7.060	7.99	30.3
		39 min	10	6.494	1.8744	1.35	7.180	7.81	28.9
		40 min	10	6.768	1.5574	2.78	7.170	8.41	23.0
		41 min	10	6.465	1.5548	2.38	6.760	7.96	24.0
		42 min	10	5.713	2.2102	1.63	6.700	7.67	38.7
		43 min	10	6.242	1.8402	1.29	6.835	7.60	29.5
		44 min	10	6.516	1.9017	1.28	6.870	7.73	29.2
		45 min	9	6.534	2.0493	1.31	7.210	7.96	31.4
		46 min	9	6.312	2.0487	1.12	6.780	8.25	32.5
		47 min	9	6.439	1.9882	1.32	7.130	7.92	30.9
		48 min	9	6.280	1.9342	1.46	6.690	7.90	30.8
		49 min	9	5.753	2.1407	1.55	6.480	7.87	37.2
		50 min	8	6.323	2.1917	1.21	6.800	8.08	34.7
		51 min	8	6.513	1.5059	3.10	6.855	7.78	23.1
		52 min	8	6.541	1.9920	1.81	7.230	7.84	30.5
		53 min	9	6.464	1.9948	1.34	6.780	8.04	30.9
		54 min	9	5.893	2.7978	0.97	7.230	8.18	47.5
		55 min	9	6.166	2.0514	1.63	7.190	7.62	33.3
		56 min	9	6.280	2.0731	1.08	6.840	7.94	33.0
		57 min	9	6.299	1.9265	1.44	6.720	7.86	30.6
		58 min	9	6.400	2.0038	1.27	6.890	7.97	31.3
		59 min	9	6.433	2.0382	1.25	6.760	7.99	31.7
		60 min	9	6.610	1.5316	3.03	6.750	8.29	23.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 99 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	61 min	9	6.337	2.1422	0.99	6.970	7.89	33.8
		62 min	9	6.362	2.0473	1.26	6.900	8.35	32.2
		63 min	8	6.168	1.7801	2.18	6.580	8.33	28.9
		64 min	8	6.073	2.1449	1.19	6.665	8.31	35.3
		65 min	8	6.240	2.2184	1.06	6.515	8.43	35.6
		66 min	8	6.164	1.8446	1.66	6.785	7.40	29.9
		67 min	8	6.094	2.0774	1.01	6.680	7.27	34.1
		68 min	8	6.199	2.1409	1.01	6.880	7.57	34.5
		69 min	8	6.123	2.0489	1.08	6.865	7.13	33.5
		70 min	8	6.261	2.0044	1.50	6.855	7.92	32.0
		71 min	8	6.195	2.0707	1.45	6.750	8.20	33.4
		72 min	8	6.243	2.1254	1.26	6.825	8.07	34.0
		73 min	8	6.141	1.9924	1.53	6.560	8.34	32.4
		74 min	8	6.134	2.0385	1.23	6.620	7.78	33.2
		75 min	8	6.140	2.1342	1.13	6.875	7.53	34.8
		76 min	8	6.028	2.0501	1.25	6.485	8.19	34.0
		77 min	8	6.075	2.0550	1.19	6.440	7.91	33.8
		78 min	8	6.321	2.0968	1.33	6.770	8.06	33.2
		79 min	8	6.383	2.1634	1.27	6.900	8.30	33.9
		80 min	8	6.273	1.9863	1.48	6.840	7.74	31.7
		81 min	8	6.225	2.1271	1.12	6.765	7.85	34.2
		82 min	8	6.064	2.1399	0.91	6.930	7.48	35.3
		83 min	8	6.296	2.1315	1.24	6.935	7.75	33.9
		84 min	8	6.033	2.1133	1.10	6.535	8.09	35.0
		85 min	8	6.235	2.2197	1.03	6.760	8.17	35.6
		86 min	8	6.946	0.9326	5.63	6.905	8.45	13.4
		87 min	8	5.954	2.1835	1.57	6.580	8.05	36.7
		88 min	8	5.964	2.2997	1.13	6.600	8.39	38.6
		89 min	9	5.949	1.9604	1.08	6.230	7.63	33.0
		90 min	9	6.082	2.0050	1.06	6.640	8.33	33.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 100 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	91 min	9	6.284	2.0076	1.23	6.820	8.40	31.9
		92 min	9	6.284	1.8426	1.58	6.960	7.72	29.3
		93 min	9	6.348	2.0463	1.38	6.420	8.43	32.2
		94 min	9	6.314	1.9411	1.45	6.570	8.32	30.7
		95 min	8	6.294	1.8924	1.99	6.555	8.22	30.1
		96 min	8	6.408	2.1669	1.27	6.905	8.08	33.8
		97 min	8	5.870	2.5425	1.06	6.865	8.35	43.3
		98 min	8	6.008	2.0886	1.28	6.685	7.74	34.8
		99 min	9	6.331	2.0825	1.10	6.650	8.23	32.9
		100 min	8	5.899	2.0198	1.06	6.390	7.41	34.2
		101 min	8	6.070	1.9878	1.40	6.925	7.52	32.7
		102 min	8	6.199	1.9993	1.29	6.820	7.28	32.3
		103 min	8	6.384	2.1142	1.33	6.955	7.82	33.1
		104 min	8	6.400	2.0246	1.53	6.935	7.76	31.6
		105 min	8	6.624	2.2203	1.23	7.450	7.92	33.5
		106 min	8	6.260	1.5408	2.58	6.645	7.39	24.6
		107 min	8	6.118	1.9699	1.47	6.610	7.80	32.2
		108 min	8	6.264	1.9730	1.42	6.915	7.33	31.5
		109 min	8	6.314	1.9922	1.48	6.970	7.58	31.6
		110 min	8	6.243	2.1144	1.17	6.730	7.65	33.9
		111 min	8	6.281	2.2375	1.00	6.995	7.88	35.6
		112 min	8	6.470	2.1911	1.11	7.170	7.89	33.9
		113 min	8	6.078	2.0069	1.27	6.600	7.76	33.0
		114 min	8	6.138	2.0730	1.10	6.820	7.31	33.8
		115 min	8	6.216	2.1567	1.20	6.640	8.19	34.7
		116 min	8	6.264	2.1055	1.14	7.110	7.33	33.6
		117 min	8	6.451	2.1053	1.44	7.170	8.06	32.6
		118 min	8	6.356	2.2283	1.08	7.130	8.18	35.1
		119 min	8	6.155	1.8496	1.78	6.830	7.41	30.1
		120 min	8	6.441	2.2480	1.17	7.145	8.18	34.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 101 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	121 min	8	6.550	1.1213	3.95	6.895	7.43	17.1
		122 min	8	6.090	2.0649	1.16	6.920	7.29	33.9
		123 min	8	6.230	2.0559	1.29	6.750	7.81	33.0
		124 min	8	5.974	1.9222	2.21	6.665	7.56	32.2
		125 min	8	6.059	2.0201	1.25	6.580	7.47	33.3
		126 min	8	6.159	2.1021	1.24	6.750	7.84	34.1
		127 min	8	6.269	2.0753	1.21	7.035	7.42	33.1
		128 min	8	6.338	2.1736	1.17	7.205	7.90	34.3
		129 min	8	6.195	2.1283	1.21	6.905	8.27	34.4
		130 min	8	6.290	2.1212	1.12	7.110	7.40	33.7
		131 min	8	6.193	2.1085	1.10	7.130	7.30	34.0
		132 min	8	6.191	2.0261	1.38	6.985	7.48	32.7
		133 min	8	6.338	2.1263	1.25	7.075	8.02	33.6
		134 min	8	6.199	2.0787	1.15	6.985	7.25	33.5
		135 min	8	5.725	2.1532	1.51	6.660	7.27	37.6
		136 min	8	6.301	2.0675	1.32	6.910	7.85	32.8
		137 min	8	6.146	2.0526	1.19	6.705	7.52	33.4
		138 min	8	6.423	1.6157	2.60	6.755	7.65	25.2
		139 min	8	6.144	2.1060	1.11	6.925	7.59	34.3
		140 min	8	6.361	2.0980	1.35	7.145	7.71	33.0
		141 min	8	5.956	2.2806	1.50	6.965	7.77	38.3
		142 min	8	6.946	0.8750	5.78	6.950	8.44	12.6
		143 min	8	6.836	0.7450	5.69	6.900	7.77	10.9
		144 min	8	6.996	0.6431	5.87	6.930	7.90	9.2
		145 min	8	6.156	2.1923	1.37	7.060	8.37	35.6
		146 min	8	6.533	1.5036	3.05	7.025	7.72	23.0
		147 min	8	5.964	2.2213	1.97	6.895	8.45	37.2
		148 min	8	6.313	1.2062	3.85	6.690	7.49	19.1
		149 min	8	6.593	1.2101	3.87	6.835	7.72	18.4
		150 min	8	6.810	0.7304	5.25	6.900	7.65	10.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 102 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	151 min	8	6.666	0.6609	5.50	6.625	7.45	9.9
		152 min	8	6.714	0.7398	5.72	6.685	7.69	11.0
		153 min	8	5.855	1.9331	1.40	6.515	7.50	33.0
		154 min	8	6.144	2.1115	1.26	7.075	7.61	34.4
		155 min	8	6.083	2.0350	1.20	6.685	7.58	33.5
		156 min	8	5.970	2.1415	1.13	6.510	8.12	35.9
		157 min	8	6.181	2.1617	1.14	7.020	7.64	35.0
		158 min	8	6.318	2.0726	1.25	7.060	7.48	32.8
		159 min	8	6.420	2.1500	1.20	7.170	7.58	33.5
		160 min	8	6.488	1.9092	1.97	7.030	8.12	29.4
		161 min	8	6.310	2.2051	0.96	7.020	7.68	34.9
		162 min	8	6.371	2.1046	1.23	7.035	7.49	33.0
		163 min	8	6.264	2.0339	1.28	6.940	7.41	32.5
		164 min	8	6.273	2.0675	1.18	6.920	7.45	33.0
		165 min	8	6.341	2.1308	1.26	7.060	7.73	33.6
		166 min	8	6.281	2.0665	1.22	6.875	7.50	32.9
		167 min	8	6.346	2.1057	1.24	6.975	7.86	33.2
		168 min	8	6.405	2.1682	1.21	6.950	8.18	33.9
		169 min	8	6.408	2.1530	1.14	6.995	7.72	33.6
		170 min	8	6.336	2.2390	1.01	7.015	8.43	35.3
		171 min	8	6.424	2.1850	1.16	6.885	8.19	34.0
		172 min	8	6.490	2.0236	1.62	6.930	8.03	31.2
		173 min	8	6.458	2.0483	1.50	7.075	7.83	31.7
		174 min	8	6.346	2.2974	0.79	6.945	7.82	36.2
		175 min	8	6.611	1.0251	4.59	6.855	7.62	15.5
		176 min	8	6.410	2.1982	1.16	6.790	8.29	34.3
		177 min	8	7.023	0.5442	6.44	6.900	8.17	7.7
		178 min	8	6.594	1.6127	2.97	6.805	8.43	24.5
		179 min	8	7.038	0.7270	6.03	6.905	8.41	10.3
		180 min	8	6.138	2.0411	1.87	6.685	8.45	33.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 103 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	181 min	8	6.493	1.4182	3.55	6.735	8.49	21.8
		182 min	7	6.824	0.9342	5.52	6.520	8.32	13.7
		183 min	7	6.221	2.0484	1.92	6.790	8.33	32.9
		184 min	7	6.137	2.2040	1.46	6.560	8.62	35.9
		185 min	7	6.363	2.4086	1.15	6.740	8.68	37.9
		186 min	7	5.944	2.0112	1.49	6.650	7.30	33.8
		187 min	7	6.139	2.2891	1.14	6.590	7.87	37.3
		188 min	7	6.159	2.2639	1.25	6.530	7.89	36.8
		189 min	8	6.639	0.5048	5.81	6.810	7.29	7.6
		190 min	8	6.129	2.0370	1.20	6.830	7.39	33.2
		191 min	8	6.268	2.1346	1.40	6.800	8.34	34.1
		192 min	8	6.269	1.9546	1.76	6.725	8.25	31.2
		193 min	8	6.555	0.9250	4.76	6.735	7.64	14.1
		194 min	8	6.130	1.8536	2.05	6.635	7.96	30.2
		195 min	8	6.271	1.3172	3.07	6.640	7.29	21.0
		196 min	8	6.276	1.5376	2.70	6.685	7.51	24.5
		197 min	9	6.767	0.4701	6.22	6.490	7.58	6.9
		198 min	9	6.783	0.9506	4.88	6.810	7.87	14.0
		199 min	9	6.182	1.5644	2.12	6.770	7.10	25.3
		200 min	9	6.466	2.0110	1.36	6.790	8.01	31.1
		201 min	9	6.379	1.8819	1.55	7.000	7.94	29.5
		202 min	10	6.268	1.8287	1.26	6.585	7.76	29.2
		203 min	10	6.291	1.7947	1.33	6.600	7.63	28.5
		204 min	9	6.334	2.0008	1.15	6.710	7.65	31.6
		205 min	9	6.178	1.8478	1.55	6.530	7.86	29.9
		206 min	9	6.257	1.9675	1.12	6.850	7.43	31.4
		207 min	8	6.658	0.5205	5.90	6.680	7.66	7.8
		208 min	8	5.967	1.9469	1.31	6.660	7.11	32.6
		209 min	8	5.951	1.9855	1.23	6.755	7.30	33.4
		210 min	8	6.074	1.9983	1.18	6.725	7.21	32.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 104 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	2	211 min	8	5.984	1.9080	1.43	6.515	7.53	31.9
		212 min	8	5.969	1.9283	1.31	6.585	7.23	32.3
		213 min	8	5.951	1.9788	1.30	6.540	7.69	33.3
		214 min	8	6.608	0.7282	5.06	6.750	7.62	11.0
		215 min	8	6.119	1.9307	1.40	6.770	7.12	31.6
		216 min	8	6.133	2.0244	1.17	6.735	7.51	33.0
		217 min	8	6.238	2.1062	1.11	6.795	7.63	33.8
		218 min	8	6.036	1.9897	1.27	6.575	7.61	33.0
		219 min	8	6.326	2.1222	1.18	6.900	7.87	33.5
		220 min	8	6.419	2.0949	1.31	6.900	7.77	32.6
		221 min	7	6.050	2.1533	1.20	6.700	7.18	35.6
		222 min	7	5.904	2.1024	1.27	6.800	7.09	35.6
		223 min	7	6.281	2.2393	1.34	6.820	7.73	35.6
		224 min	7	6.356	2.3761	1.28	6.820	8.87	37.4
		225 min	7	6.449	2.4585	1.18	6.900	8.97	38.1
		226 min	7	6.209	2.2238	1.29	6.950	7.67	35.8
		227 min	7	6.444	2.4128	1.20	6.940	8.61	37.4
		228 min	7	6.224	2.3243	1.19	6.660	8.56	37.3
		229 min	7	6.057	2.3292	0.90	6.750	7.65	38.5
		230 min	7	6.229	1.9875	1.86	6.810	7.65	31.9
		231 min	7	6.187	2.1032	1.52	6.880	7.53	34.0
		232 min	7	6.219	2.1387	1.43	6.910	7.51	34.4
		233 min	7	6.867	0.5881	6.26	6.710	7.96	8.6
		234 min	7	6.423	2.0284	1.91	7.110	7.74	31.6
		235 min	7	6.141	2.1403	1.32	6.890	7.26	34.9
		236 min	7	6.374	2.0504	1.87	6.990	7.81	32.2
		237 min	7	6.079	2.2696	1.19	6.550	7.89	37.3
		238 min	7	6.239	1.1367	3.81	6.400	7.37	18.2
		239 min	7	6.359	1.5073	3.12	6.530	7.66	23.7
		240 min	1	7.130		7.13	7.130	7.13	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 105 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	1 min	12	7.448	2.2859	0.93	8.230	9.60	30.7
		2 min	12	7.523	2.0177	1.72	8.265	9.36	26.8
		3 min	12	7.946	0.7110	7.12	7.905	9.76	8.9
		4 min	12	7.897	0.7123	6.78	7.865	9.37	9.0
		5 min	12	7.629	0.6604	6.57	7.725	9.00	8.7
		6 min	12	7.344	1.2155	4.23	7.495	9.09	16.6
		7 min	12	7.448	0.7285	6.12	7.495	8.69	9.8
		8 min	12	6.928	1.5041	2.71	7.210	8.38	21.7
		9 min	12	6.510	1.7721	2.94	7.235	8.29	27.2
		10 min	12	6.394	1.9865	1.84	7.145	8.21	31.1
		11 min	12	6.183	2.2018	2.07	7.285	8.30	35.6
		12 min	12	5.857	2.1456	1.46	6.740	8.12	36.6
		13 min	12	5.466	2.6254	1.34	6.710	8.02	48.0
		14 min	12	5.329	2.4684	1.31	5.775	7.85	46.3
		15 min	12	4.886	2.7595	1.06	5.540	8.08	56.5
		16 min	12	5.270	2.7259	1.05	6.515	8.14	51.7
		17 min	12	5.199	2.8907	1.05	6.720	8.08	55.6
		18 min	12	4.963	3.1650	1.05	7.115	8.02	63.8
		19 min	12	4.416	2.9951	1.06	4.195	8.05	67.8
		20 min	12	4.258	3.1464	0.79	4.425	7.95	73.9
		21 min	11	4.322	3.2285	0.05	5.660	7.90	74.7
		22 min	10	4.349	2.8959	0.91	4.740	7.85	66.6
		23 min	10	4.374	3.1977	1.04	4.395	8.03	73.1
		24 min	10	4.167	2.8545	1.14	3.595	7.66	68.5
		25 min	10	4.198	2.8729	1.19	4.135	7.66	68.4
		26 min	10	3.776	2.6521	0.99	2.990	7.74	70.2
		27 min	10	4.248	2.7119	1.19	4.800	7.00	63.8
		28 min	10	3.724	2.7414	1.11	2.070	7.22	73.6
		29 min	10	3.740	2.7990	1.19	2.130	7.21	74.8
		30 min	10	4.532	2.5692	1.24	5.525	7.24	56.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 106 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	31 min	10	3.958	2.6761	1.04	3.945	6.95	67.6
		32 min	10	3.969	2.3002	1.35	3.435	6.54	58.0
		33 min	10	4.417	2.6022	0.99	5.555	7.22	58.9
		34 min	10	3.980	2.3315	1.01	3.535	7.04	58.6
		35 min	10	4.566	2.3716	1.36	5.315	7.26	51.9
		36 min	10	4.379	2.5091	1.08	5.285	7.18	57.3
		37 min	10	4.269	2.5890	1.20	4.905	7.78	60.6
		38 min	10	4.270	2.5526	1.22	5.025	7.58	59.8
		39 min	10	3.285	2.3756	0.93	2.410	7.21	72.3
		40 min	10	4.559	2.5658	1.26	5.115	7.41	56.3
		41 min	10	3.770	2.5257	1.14	2.665	7.23	67.0
		42 min	10	3.455	2.2857	0.98	2.800	7.02	66.2
		43 min	10	3.077	2.1311	0.67	2.575	7.07	69.3
		44 min	10	3.840	2.2011	1.45	3.365	7.36	57.3
		45 min	9	3.798	2.4781	1.37	3.960	7.31	65.3
		46 min	9	3.933	2.6082	0.98	3.350	7.30	66.3
		47 min	9	4.140	2.6620	0.94	3.860	7.05	64.3
		48 min	9	3.677	2.6693	0.89	2.800	7.91	72.6
		49 min	9	3.892	2.6587	1.06	3.670	7.37	68.3
		50 min	8	3.673	2.9052	0.81	2.335	7.24	79.1
		51 min	8	3.488	2.8477	0.96	1.755	7.12	81.7
		52 min	8	3.865	3.0209	0.87	2.600	7.84	78.2
		53 min	9	3.787	2.7643	0.88	2.430	7.30	73.0
		54 min	9	2.723	2.2019	1.02	1.680	6.59	80.9
		55 min	9	3.770	2.7777	0.72	2.170	7.29	73.7
		56 min	9	3.640	2.7431	0.97	1.640	6.92	75.4
		57 min	9	2.881	2.1134	0.74	1.580	6.47	73.4
		58 min	9	3.420	2.8203	0.73	1.880	7.78	82.5
		59 min	9	3.363	2.5767	1.05	1.830	7.12	76.6
		60 min	9	2.923	2.2228	0.84	2.250	6.63	76.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 107 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	61 min	9	3.503	2.6569	0.86	2.450	7.74	75.8
		62 min	9	3.353	2.7824	0.68	1.640	7.06	83.0
		63 min	8	2.715	2.3943	0.61	1.690	6.81	88.2
		64 min	8	3.105	2.4016	1.03	1.655	7.21	77.3
		65 min	8	2.913	2.2835	0.77	1.950	6.77	78.4
		66 min	8	3.499	2.4778	1.04	2.630	6.77	70.8
		67 min	8	3.234	2.3428	0.99	2.335	7.07	72.4
		68 min	8	3.484	2.5712	0.92	2.260	6.87	73.8
		69 min	8	2.946	2.2220	1.03	1.800	6.78	75.4
		70 min	8	3.149	2.5315	0.57	1.935	6.89	80.4
		71 min	8	3.290	2.2540	1.26	1.970	6.77	68.5
		72 min	8	3.134	2.5616	0.93	1.765	7.22	81.7
		73 min	8	2.821	2.3280	1.05	1.425	6.80	82.5
		74 min	8	2.963	2.1889	1.07	1.740	6.54	73.9
		75 min	8	2.681	2.2451	0.91	1.800	6.62	83.7
		76 min	8	2.854	2.3219	0.86	1.545	6.44	81.4
		77 min	8	3.035	2.5150	0.62	1.855	7.05	82.9
		78 min	8	2.856	2.4363	0.92	1.545	6.70	85.3
		79 min	8	2.638	2.1241	0.89	1.750	6.98	80.5
		80 min	8	2.499	2.1281	0.90	1.695	6.82	85.2
		81 min	8	2.821	2.5428	0.99	1.690	7.00	90.1
		82 min	8	2.419	2.0321	0.72	1.725	6.68	84.0
		83 min	8	2.793	2.5277	0.69	1.515	6.93	90.5
		84 min	8	2.633	1.9974	1.21	1.530	6.40	75.9
		85 min	8	2.838	2.2512	0.99	1.605	6.47	79.3
		86 min	8	3.388	2.3741	1.12	2.685	6.79	70.1
		87 min	8	3.229	2.5831	0.89	2.195	7.57	80.0
		88 min	8	3.350	2.4450	1.11	2.165	7.21	73.0
		89 min	9	2.759	2.3692	0.84	1.540	6.87	85.9
		90 min	9	2.677	2.3780	0.30	1.890	7.06	88.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 108 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	91 min	9	2.606	2.2616	0.31	1.840	6.92	86.8
		92 min	9	2.391	1.8415	0.82	2.070	6.88	77.0
		93 min	9	3.150	2.2620	1.19	2.040	7.25	71.8
		94 min	9	3.167	2.1107	1.21	1.980	7.02	66.7
		95 min	8	3.865	2.4508	1.15	3.625	6.73	63.4
		96 min	8	3.879	2.5453	1.17	3.155	7.00	65.6
		97 min	8	3.346	2.6949	0.44	1.900	6.72	80.5
		98 min	8	3.469	2.3518	1.23	2.640	7.16	67.8
		99 min	9	4.437	2.7248	0.66	6.460	7.09	61.4
		100 min	8	3.328	2.1477	1.33	2.350	6.45	64.5
		101 min	8	3.609	2.4661	1.04	2.300	6.81	68.3
		102 min	8	4.574	2.4748	1.21	5.310	7.20	54.1
		103 min	8	3.934	2.5952	0.66	3.470	7.07	66.0
		104 min	8	3.738	2.1884	1.07	3.515	7.04	58.6
		105 min	8	3.269	2.2393	1.11	2.030	6.80	68.5
		106 min	8	3.093	2.4140	0.90	2.275	7.15	78.1
		107 min	8	3.203	2.1839	1.28	2.330	6.77	68.2
		108 min	8	3.031	2.3428	1.22	2.020	6.82	77.3
		109 min	8	3.140	2.3670	0.83	2.030	6.96	75.4
		110 min	8	3.083	2.4969	1.06	1.860	7.20	81.0
		111 min	8	3.515	2.5632	1.04	2.305	7.50	72.9
		112 min	8	2.754	1.8847	0.94	2.405	6.77	68.4
		113 min	8	2.698	1.7409	0.98	2.215	6.77	64.5
		114 min	8	4.189	2.3270	1.13	3.740	7.45	55.6
		115 min	8	2.909	1.9126	1.15	2.050	6.91	65.8
		116 min	8	3.221	2.1952	1.10	2.130	6.58	68.1
		117 min	8	3.274	2.2132	1.16	2.080	6.57	67.6
		118 min	8	3.116	2.5237	0.73	1.915	7.26	81.0
		119 min	8	3.095	2.0848	0.98	2.220	6.84	67.4
		120 min	8	3.389	2.3118	1.11	2.140	6.59	68.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 109 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	121 min	8	3.420	2.4726	1.06	2.030	6.97	72.3
		122 min	8	2.660	2.1230	0.99	1.850	6.89	79.8
		123 min	8	3.408	2.3041	1.07	2.275	6.62	67.6
		124 min	8	3.290	2.1655	1.28	2.130	6.69	65.8
		125 min	8	3.191	2.2969	1.21	2.405	7.02	72.0
		126 min	8	2.811	1.9964	0.60	2.070	6.41	71.0
		127 min	8	3.705	2.0679	1.20	3.080	6.73	55.8
		128 min	8	3.213	2.5644	0.89	2.000	7.22	79.8
		129 min	8	3.116	2.4201	0.26	2.620	6.83	77.7
		130 min	8	3.605	2.3409	1.11	2.540	6.97	64.9
		131 min	8	2.763	1.8911	0.84	2.290	6.66	68.5
		132 min	8	2.623	1.8981	0.50	2.230	6.48	72.4
		133 min	8	3.271	2.4059	0.42	2.675	6.63	73.5
		134 min	8	2.994	2.3513	0.83	2.255	6.73	78.5
		135 min	8	2.919	2.1605	0.49	2.080	6.56	74.0
		136 min	8	3.094	2.4572	0.36	2.410	6.78	79.4
		137 min	8	3.926	2.5905	0.93	3.645	7.60	66.0
		138 min	8	3.500	2.4484	0.91	2.215	6.65	70.0
		139 min	8	3.474	2.4532	1.01	2.540	7.60	70.6
		140 min	8	3.018	2.6920	0.96	1.835	7.38	89.2
		141 min	8	2.973	2.3986	1.06	1.980	6.91	80.7
		142 min	8	2.879	2.4746	0.86	1.875	6.87	86.0
		143 min	8	3.511	2.6270	1.13	1.965	6.87	74.8
		144 min	8	3.846	2.6305	1.12	3.430	7.06	68.4
		145 min	8	3.278	2.7178	0.89	1.700	6.97	82.9
		146 min	8	2.751	2.4178	0.76	1.675	6.69	87.9
		147 min	8	2.501	2.0909	0.56	1.860	6.70	83.6
		148 min	8	2.319	1.9869	0.70	1.755	6.84	85.7
		149 min	8	2.690	2.5686	0.37	1.710	6.78	95.5
		150 min	8	2.303	2.1307	0.16	1.610	6.77	92.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 110 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	151 min	8	2.653	2.6473	0.18	1.710	6.94	99.8
		152 min	8	2.643	2.6502	0.15	1.565	6.90	100.3
		153 min	7	2.976	2.5980	1.14	1.830	6.76	87.3
		154 min	8	2.716	2.4366	0.96	1.570	6.78	89.7
		155 min	8	2.924	2.5717	0.97	1.610	7.25	88.0
		156 min	8	3.320	2.5081	1.06	1.900	6.83	75.5
		157 min	8	3.738	2.6853	1.01	3.545	6.98	71.8
		158 min	8	3.714	2.6253	1.07	3.170	7.24	70.7
		159 min	8	2.784	2.7631	0.38	1.650	7.70	99.3
		160 min	8	2.726	2.5686	0.58	1.690	6.90	94.2
		161 min	8	2.689	2.3904	1.03	1.555	6.76	88.9
		162 min	8	2.286	2.0120	0.43	1.640	6.71	88.0
		163 min	8	2.499	2.1167	0.16	1.680	6.70	84.7
		164 min	7	3.031	2.6913	0.90	1.670	7.15	88.8
		165 min	8	2.739	2.8628	0.12	1.605	7.81	104.5
		166 min	8	2.588	1.9769	1.05	1.630	6.83	76.4
		167 min	8	2.729	2.7906	0.31	1.595	7.59	102.3
		168 min	8	2.584	2.4217	0.27	1.655	6.62	93.7
		169 min	8	2.913	2.6061	0.94	1.640	7.61	89.5
		170 min	8	3.423	2.7020	1.16	1.665	7.18	78.9
		171 min	8	2.601	2.2091	0.98	1.605	6.46	84.9
		172 min	8	2.769	2.6268	0.50	1.770	7.30	94.9
		173 min	8	2.885	2.4556	1.12	1.615	7.06	85.1
		174 min	8	2.246	1.8101	0.93	1.620	6.53	80.6
		175 min	8	2.705	2.6514	0.42	1.615	7.20	98.0
		176 min	8	2.414	2.1709	0.25	1.635	6.64	89.9
		177 min	8	2.974	2.4806	0.18	1.990	6.93	83.4
		178 min	8	2.454	1.9511	0.56	1.650	6.56	79.5
		179 min	8	3.895	2.6752	1.03	3.905	6.55	68.7
		180 min	8	2.673	2.2510	0.20	1.550	6.57	84.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 111 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	181 min	8	2.374	2.0455	0.39	1.680	6.72	86.2
		182 min	7	2.011	1.6058	0.92	1.520	5.52	79.8
		183 min	7	1.984	1.9102	0.54	1.520	6.23	96.3
		184 min	7	1.980	2.1371	0.26	1.300	6.71	107.9
		185 min	7	1.971	2.0156	0.20	1.390	6.38	102.2
		186 min	7	1.886	2.1508	0.33	1.310	6.67	114.1
		187 min	7	2.023	2.1643	0.12	1.530	6.75	107.0
		188 min	7	1.887	1.4645	0.05	1.450	4.44	77.6
		189 min	8	2.450	2.1618	0.16	1.485	6.59	88.2
		190 min	8	2.960	2.4402	0.15	1.895	6.65	82.4
		191 min	8	2.918	2.4030	0.18	2.195	6.55	82.4
		192 min	8	2.818	2.2095	0.40	2.000	6.60	78.4
		193 min	8	2.948	2.6018	0.18	1.530	6.45	88.3
		194 min	8	2.223	1.8098	0.87	1.590	6.41	81.4
		195 min	8	2.211	1.8017	1.02	1.730	6.58	81.5
		196 min	8	2.486	2.0015	0.45	1.725	6.65	80.5
		197 min	8	3.176	2.1893	0.99	1.890	6.53	68.9
		198 min	9	2.481	1.9311	0.72	1.570	6.59	77.8
		199 min	9	2.036	1.8270	0.38	1.560	6.60	89.8
		200 min	9	2.913	2.4816	0.31	1.660	6.75	85.2
		201 min	9	2.454	2.2852	0.35	1.450	6.61	93.1
		202 min	10	2.553	2.1318	0.18	1.550	6.64	83.5
		203 min	10	2.210	1.8073	0.19	1.780	6.76	81.8
		204 min	9	3.546	2.5897	0.83	1.960	7.13	73.0
		205 min	9	2.673	2.6257	0.33	1.650	7.67	98.2
		206 min	9	2.668	2.1880	0.90	1.580	6.45	82.0
		207 min	8	1.909	1.9680	0.08	1.465	6.53	103.1
		208 min	7	2.424	1.9753	0.94	1.560	6.66	81.5
		209 min	7	2.607	1.9104	1.28	2.270	6.82	73.3
		210 min	7	3.140	2.1861	1.35	2.390	6.84	69.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 112 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	3	211 min	7	2.941	1.8864	1.37	2.070	6.64	64.1
		212 min	8	2.776	2.5322	0.05	1.845	6.78	91.2
		213 min	7	2.303	1.9139	1.23	1.770	6.59	83.1
		214 min	7	3.066	2.5488	1.04	1.860	6.88	83.1
		215 min	7	2.914	2.4727	1.24	1.660	6.54	84.8
		216 min	7	2.889	2.3728	1.28	1.640	6.45	82.1
		217 min	8	2.975	2.5098	0.21	1.765	6.80	84.4
		218 min	8	2.059	1.9641	0.05	1.550	6.69	95.4
		219 min	8	2.564	2.1790	0.07	1.575	6.62	85.0
		220 min	8	2.074	2.0546	0.02	1.600	6.68	99.1
		221 min	7	2.030	2.1395	0.00	1.630	6.64	105.4
		222 min	7	2.020	2.0807	0.17	1.450	6.60	103.0
		223 min	7	1.914	2.0584	0.01	1.360	6.41	107.5
		224 min	6	2.347	2.0673	1.27	1.570	6.55	88.1
		225 min	7	2.039	2.0355	0.14	1.550	6.44	99.9
		226 min	7	2.179	1.9388	0.76	1.500	6.46	89.0
		227 min	7	2.709	2.3412	0.63	1.590	6.40	86.4
		228 min	7	2.033	1.9895	0.54	1.520	6.47	97.9
		229 min	7	2.100	2.0163	0.37	1.520	6.55	96.0
		230 min	7	2.744	1.9776	1.40	1.680	6.60	72.1
		231 min	7	2.760	1.9806	1.44	1.730	6.58	71.8
		232 min	7	3.153	2.5524	1.51	1.740	7.23	81.0
		233 min	7	2.224	1.9848	1.16	1.530	6.71	89.2
		234 min	7	2.099	1.9433	0.59	1.510	6.43	92.6
		235 min	7	2.340	1.9237	0.91	1.590	6.54	82.2
		236 min	7	2.029	2.0537	0.56	1.490	6.58	101.2
		237 min	7	2.511	1.9476	0.84	1.650	6.54	77.5
		238 min	7	2.830	2.1067	0.71	1.850	6.42	74.4
		239 min	7	2.300	1.9036	0.95	1.840	6.46	82.8
		240 min	1	1.550		1.55	1.550	1.55	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 113 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	1 min	12	5.878	3.1577	0.59	7.235	8.97	53.7
		2 min	12	5.977	3.1024	0.96	7.215	8.67	51.9
		3 min	12	6.204	3.1001	0.61	7.555	8.61	50.0
		4 min	12	6.098	3.0121	1.04	7.845	8.61	49.4
		5 min	12	5.976	2.9573	0.53	7.815	8.48	49.5
		6 min	12	6.594	2.4404	0.70	7.675	8.37	37.0
		7 min	12	6.673	2.0328	0.91	7.415	8.13	30.5
		8 min	12	6.357	2.2804	0.46	7.145	8.25	35.9
		9 min	12	6.040	2.2968	0.39	6.700	7.94	38.0
		10 min	12	6.098	2.1204	0.69	6.990	8.01	34.8
		11 min	12	5.493	2.3392	0.27	5.850	7.88	42.6
		12 min	12	5.406	2.5076	1.58	6.670	7.87	46.4
		13 min	12	4.845	2.5240	1.80	5.145	7.88	52.1
		14 min	11	4.345	2.8655	1.29	2.610	7.68	66.0
		15 min	12	3.854	3.0901	0.53	2.040	7.86	80.2
		16 min	12	3.944	2.8119	1.06	2.480	7.86	71.3
		17 min	12	4.683	3.0917	1.06	5.210	8.84	66.0
		18 min	12	4.703	2.8953	1.06	5.125	8.36	61.6
		19 min	12	4.223	3.0468	1.07	2.890	8.50	72.1
		20 min	12	4.367	2.9571	1.02	3.455	8.55	67.7
		21 min	11	4.381	2.7964	1.04	4.570	7.79	63.8
		22 min	10	3.839	2.9820	0.91	1.915	7.76	77.7
		23 min	10	3.794	3.0745	1.04	1.740	7.99	81.0
		24 min	10	3.433	2.7914	1.01	1.595	7.85	81.3
		25 min	10	3.487	2.7994	1.25	1.695	7.82	80.3
		26 min	10	3.167	2.5671	0.99	1.820	7.83	81.1
		27 min	10	4.013	2.8277	1.19	2.770	7.86	70.5
		28 min	10	3.662	2.7597	0.93	2.205	7.31	75.4
		29 min	10	3.706	2.8119	1.18	2.120	7.56	75.9
		30 min	10	4.083	2.7099	1.01	3.905	7.64	66.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 114 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	31 min	10	3.326	2.6874	0.60	1.790	7.49	80.8
		32 min	10	2.929	2.2749	1.17	1.700	6.88	77.7
		33 min	10	3.790	2.6957	0.99	2.575	7.56	71.1
		34 min	10	3.394	2.4363	0.79	2.175	7.65	71.8
		35 min	10	3.463	2.3183	1.16	2.775	7.45	66.9
		36 min	10	3.813	2.6198	0.90	2.890	7.60	68.7
		37 min	10	3.082	2.2450	0.75	2.065	7.47	72.8
		38 min	10	3.032	1.8706	0.79	2.870	6.96	61.7
		39 min	10	2.618	1.9199	0.94	1.975	7.30	73.3
		40 min	10	3.349	2.4293	0.87	2.045	7.44	72.5
		41 min	10	2.983	2.2167	0.75	1.855	7.12	74.3
		42 min	10	2.782	2.0341	0.67	1.930	7.35	73.1
		43 min	10	2.327	1.8556	0.89	1.660	7.35	79.7
		44 min	10	3.031	2.3920	0.77	1.940	7.73	78.9
		45 min	9	3.417	2.4516	1.07	2.490	7.59	71.8
		46 min	9	2.956	2.4100	0.65	1.670	7.94	81.5
		47 min	9	3.393	2.5748	1.03	2.390	7.83	75.9
		48 min	9	3.026	2.4621	0.81	2.800	8.37	81.4
		49 min	9	3.757	2.5954	1.20	2.880	8.17	69.1
		50 min	8	3.666	2.9234	1.15	2.365	8.30	79.7
		51 min	8	3.331	2.8413	0.85	1.785	7.54	85.3
		52 min	8	3.534	2.6825	1.00	2.505	7.45	75.9
		53 min	9	3.350	2.7615	0.92	1.670	7.55	82.4
		54 min	9	2.917	2.5904	1.00	1.590	7.49	88.8
		55 min	9	3.477	2.7658	0.76	1.770	7.49	79.6
		56 min	9	3.699	2.8221	0.79	1.780	7.43	76.3
		57 min	9	3.397	2.5839	0.88	1.690	7.41	76.1
		58 min	9	3.023	2.5435	0.85	1.650	7.37	84.1
		59 min	9	3.099	2.5361	0.67	1.680	7.15	81.8
		60 min	9	3.367	2.6521	0.79	2.250	7.38	78.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 115 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	61 min	9	2.764	2.1886	0.84	1.730	7.16	79.2
		62 min	9	3.083	2.4572	0.98	2.230	7.46	79.7
		63 min	8	2.383	2.0879	0.92	1.635	7.29	87.6
		64 min	8	2.315	2.1708	1.00	1.530	7.47	93.8
		65 min	8	2.630	1.9888	0.94	2.035	7.24	75.6
		66 min	8	2.875	2.3357	1.00	1.730	7.22	81.2
		67 min	8	2.969	2.2019	1.09	1.875	7.09	74.2
		68 min	8	2.494	1.9779	1.06	1.765	7.19	79.3
		69 min	8	2.773	2.2821	1.02	1.740	7.27	82.3
		70 min	8	3.136	2.5156	0.84	1.955	6.98	80.2
		71 min	8	2.790	2.4009	0.91	1.520	7.26	86.1
		72 min	8	2.634	2.2187	1.03	1.570	7.28	84.2
		73 min	8	2.405	2.0526	1.01	1.465	7.08	85.3
		74 min	8	2.275	2.0116	0.86	1.540	6.95	88.4
		75 min	8	2.425	2.0795	0.92	1.500	6.99	85.8
		76 min	8	2.361	2.0175	0.93	1.420	6.92	85.4
		77 min	8	2.824	2.3377	0.95	1.855	7.21	82.8
		78 min	8	3.064	2.4426	0.95	1.750	6.93	79.7
		79 min	8	2.514	2.1588	0.76	1.745	7.09	85.9
		80 min	8	2.303	2.0927	0.86	1.715	7.07	90.9
		81 min	8	2.721	2.2674	0.75	1.645	7.05	83.3
		82 min	8	2.564	2.1037	0.88	1.660	7.05	82.1
		83 min	8	2.421	2.0042	0.95	1.640	6.96	82.8
		84 min	8	2.769	2.3509	1.01	1.630	7.04	84.9
		85 min	8	2.266	1.9903	0.86	1.570	6.97	87.8
		86 min	8	2.566	2.0522	0.75	1.730	7.04	80.0
		87 min	8	2.511	2.0662	0.77	1.690	7.02	82.3
		88 min	8	2.465	1.9973	0.97	1.710	7.03	81.0
		89 min	9	2.151	2.0257	0.19	1.420	7.07	94.2
		90 min	9	2.159	1.9674	0.27	1.680	7.06	91.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 116 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	91 min	8	2.326	1.9342	1.14	1.665	6.97	83.1
		92 min	9	2.440	2.1493	0.02	1.750	6.99	88.1
		93 min	9	2.550	2.2476	0.10	1.790	6.94	88.1
		94 min	9	2.087	1.8219	0.15	1.780	6.64	87.3
		95 min	8	2.110	2.0416	0.00	1.625	6.86	96.8
		96 min	7	2.486	2.0151	0.93	1.990	6.95	81.1
		97 min	7	2.513	1.9700	1.10	1.900	6.89	78.4
		98 min	7	2.289	1.2020	1.03	1.890	4.57	52.5
		99 min	8	3.343	2.4018	1.13	2.145	7.46	71.9
		100 min	7	2.517	1.8126	1.11	1.970	6.49	72.0
		101 min	7	3.496	2.4339	0.96	2.030	6.79	69.6
		102 min	7	3.883	2.6280	1.12	2.500	7.33	67.7
		103 min	7	3.681	2.4719	1.08	2.290	6.79	67.1
		104 min	7	3.174	2.3233	1.01	2.210	6.72	73.2
		105 min	8	2.535	2.0359	0.16	2.075	6.53	80.3
		106 min	8	2.398	1.9499	0.29	2.005	6.71	81.3
		107 min	8	2.756	2.3005	0.34	1.995	6.41	83.5
		108 min	8	2.486	1.9614	0.68	2.095	7.03	78.9
		109 min	8	2.736	2.4441	0.49	1.845	6.96	89.3
		110 min	8	2.929	2.1569	0.54	2.260	6.90	73.6
		111 min	8	2.919	2.5471	0.78	1.770	7.45	87.3
		112 min	8	2.745	2.3054	0.62	1.810	7.07	84.0
		113 min	8	2.256	1.9644	0.59	1.830	6.85	87.1
		114 min	8	2.225	1.9866	0.74	1.595	6.88	89.3
		115 min	8	2.361	1.8923	0.41	1.830	6.58	80.1
		116 min	8	2.379	2.0509	0.17	1.810	6.72	86.2
		117 min	8	2.216	1.9646	0.46	1.655	6.85	88.6
		118 min	8	2.193	1.8996	0.88	1.670	6.76	86.6
		119 min	8	2.466	1.9682	0.61	1.795	6.74	79.8
		120 min	8	2.115	1.9211	0.44	1.570	6.67	90.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 117 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	121 min	8	2.735	2.3676	0.84	1.700	6.72	86.6
		122 min	8	2.593	2.1496	0.97	1.710	6.86	82.9
		123 min	8	2.331	2.0034	0.30	1.810	6.78	85.9
		124 min	8	2.323	1.9346	0.49	1.765	6.68	83.3
		125 min	8	2.555	2.0403	0.40	1.890	6.58	79.9
		126 min	8	2.854	2.4024	0.52	1.840	6.67	84.2
		127 min	8	2.316	2.0984	0.71	1.410	6.95	90.6
		128 min	8	2.299	2.1036	0.49	1.480	6.90	91.5
		129 min	8	2.281	2.1116	0.55	1.490	6.86	92.6
		130 min	8	2.221	2.0660	0.35	1.620	7.00	93.0
		131 min	8	2.391	2.0724	0.59	1.550	6.90	86.7
		132 min	8	2.184	1.9301	0.39	1.585	6.63	88.4
		133 min	8	2.265	1.9872	0.25	1.715	6.71	87.7
		134 min	8	2.174	2.0655	0.17	1.850	6.96	95.0
		135 min	8	2.096	1.9859	0.36	1.615	6.82	94.7
		136 min	8	2.063	2.0169	0.22	1.635	6.84	97.8
		137 min	8	2.019	2.0394	0.25	1.545	6.87	101.0
		138 min	8	2.618	2.4982	0.31	1.770	6.74	95.4
		139 min	8	2.118	2.0323	0.38	1.710	6.97	96.0
		140 min	8	2.818	2.7510	0.42	1.715	7.42	97.6
		141 min	8	2.119	1.9601	0.37	1.685	6.79	92.5
		142 min	8	2.185	2.0245	0.33	1.875	6.93	92.7
		143 min	8	2.145	2.0774	0.04	1.920	7.00	96.8
		144 min	8	2.120	2.0818	0.37	1.740	7.07	98.2
		145 min	8	2.655	2.6068	0.19	1.715	7.07	98.2
		146 min	8	2.126	2.1839	0.23	1.650	7.29	102.7
		147 min	7	3.071	2.7115	0.92	1.850	7.21	88.3
		148 min	8	2.863	2.8744	0.02	1.820	7.36	100.4
		149 min	8	2.749	2.8835	0.14	1.695	7.33	104.9
		150 min	8	2.760	2.8496	0.02	1.670	7.33	103.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 118 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	151 min	7	3.170	2.8728	1.03	1.810	7.42	90.6
		152 min	8	2.738	2.8390	0.09	1.650	7.45	103.7
		153 min	7	2.984	2.9090	0.54	1.810	7.44	97.5
		154 min	8	2.744	2.8430	0.17	1.660	7.49	103.6
		155 min	8	2.666	2.7281	0.07	1.740	7.10	102.3
		156 min	8	2.784	2.8442	0.05	1.715	7.50	102.2
		157 min	8	2.716	2.7889	0.15	1.600	7.23	102.7
		158 min	8	2.849	2.8929	0.42	1.705	7.57	101.5
		159 min	8	2.794	2.8982	0.12	1.735	7.71	103.7
		160 min	8	2.851	2.7913	0.10	1.840	7.58	97.9
		161 min	8	2.708	2.7144	0.34	1.670	7.28	100.3
		162 min	8	2.701	2.6404	0.20	1.665	7.15	97.7
		163 min	8	2.781	2.7096	0.09	1.720	7.43	97.4
		164 min	8	2.666	2.6903	0.07	1.670	7.09	100.9
		165 min	8	2.629	2.7069	0.06	1.635	7.19	103.0
		166 min	8	2.749	2.4529	0.41	1.745	6.73	89.2
		167 min	8	2.409	2.1852	0.04	1.695	6.78	90.7
		168 min	8	3.308	2.9765	0.12	1.675	7.23	90.0
		169 min	8	2.709	2.7096	0.33	1.585	7.13	100.0
		170 min	8	3.189	2.5596	0.96	1.710	6.81	80.3
		171 min	8	2.298	1.7963	1.17	1.705	6.61	78.2
		172 min	8	2.619	2.3555	0.68	1.630	6.74	89.9
		173 min	8	2.234	2.0895	0.25	1.630	7.06	93.5
		174 min	8	2.435	2.3427	0.15	1.600	6.92	96.2
		175 min	8	2.485	2.3849	0.26	1.535	6.94	96.0
		176 min	8	2.666	2.6011	0.19	1.670	6.84	97.6
		177 min	8	2.826	2.8590	0.27	1.660	7.67	101.2
		178 min	8	2.728	2.7026	0.42	1.640	7.23	99.1
		179 min	8	2.746	2.7098	0.34	1.550	7.31	98.7
		180 min	8	3.104	2.5046	1.03	1.810	6.93	80.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 119 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	181 min	8	2.669	2.4985	0.99	1.535	7.00	93.6
		182 min	7	2.109	2.1075	0.56	1.530	6.79	100.0
		183 min	7	2.049	2.2385	0.19	1.520	6.97	109.3
		184 min	6	2.265	2.1426	0.95	1.530	6.55	94.6
		185 min	7	1.956	2.1938	0.02	1.390	6.74	112.2
		186 min	6	2.142	1.9787	0.93	1.465	6.13	92.4
		187 min	6	2.170	1.2566	1.11	1.760	4.66	57.9
		188 min	7	1.754	1.6203	0.04	1.390	5.20	92.4
		189 min	7	2.909	2.8265	0.69	1.680	7.12	97.2
		190 min	8	2.584	2.2937	0.10	1.730	6.65	88.8
		191 min	7	3.323	2.6829	0.99	1.780	7.12	80.7
		192 min	7	2.979	2.7285	0.92	1.680	7.10	91.6
		193 min	8	2.654	2.7354	0.07	1.600	7.30	103.1
		194 min	8	2.236	2.1853	0.08	1.680	7.04	97.7
		195 min	8	2.279	2.1465	0.06	1.815	6.99	94.2
		196 min	8	2.843	2.6013	0.05	1.915	6.92	91.5
		197 min	9	2.497	2.3209	0.18	1.800	7.12	93.0
		198 min	9	2.753	2.6085	0.28	1.480	7.06	94.7
		199 min	8	2.834	2.4372	0.99	1.625	7.14	86.0
		200 min	9	2.574	2.3594	1.00	1.510	7.13	91.6
		201 min	9	2.979	2.7185	0.25	1.670	7.16	91.3
		202 min	10	2.562	2.4255	0.10	1.620	7.23	94.7
		203 min	10	2.195	2.0538	0.02	1.695	7.53	93.6
		204 min	9	2.524	2.5023	0.26	1.730	7.46	99.1
		205 min	8	3.019	2.6960	0.97	1.755	7.96	89.3
		206 min	9	2.314	2.3682	0.14	1.540	7.87	102.3
		207 min	8	1.945	2.0533	0.22	1.340	6.89	105.6
		208 min	7	2.294	2.1591	1.19	1.560	7.17	94.1
		209 min	7	2.240	2.1984	1.14	1.510	7.19	98.1
		210 min	7	2.379	2.1530	1.15	1.720	7.18	90.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 120 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	4	211 min	8	2.218	2.2423	0.31	1.570	7.56	101.1
		212 min	8	2.198	2.3407	0.08	1.510	7.77	106.5
		213 min	7	2.544	2.1981	1.22	1.360	7.11	86.4
		214 min	7	2.409	2.4942	1.04	1.390	8.01	103.6
		215 min	8	2.031	2.3726	0.06	1.325	7.74	116.8
		216 min	7	2.221	2.0485	0.92	1.490	6.82	92.2
		217 min	8	2.198	2.0866	0.10	1.735	6.99	95.0
		218 min	8	2.011	2.0241	0.25	1.485	6.83	100.6
		219 min	8	2.433	2.2286	0.11	1.730	6.91	91.6
		220 min	8	2.131	2.1195	0.03	1.555	6.88	99.4
		221 min	7	2.204	2.2095	0.14	1.730	7.00	100.2
		222 min	7	1.986	2.2443	0.32	1.330	7.00	113.0
		223 min	7	2.027	2.1968	0.18	1.580	6.87	108.4
		224 min	7	1.989	2.1743	0.38	1.410	6.83	109.3
		225 min	7	2.037	2.1620	0.62	1.400	6.88	106.1
		226 min	7	2.101	2.2251	0.86	1.330	7.10	105.9
		227 min	7	2.124	2.0776	0.86	1.590	6.78	97.8
		228 min	7	2.314	2.3364	0.57	1.590	7.35	101.0
		229 min	7	2.057	2.2477	0.30	1.530	7.03	109.3
		230 min	7	2.461	2.4148	0.38	1.460	7.16	98.1
		231 min	7	2.173	2.1624	0.69	1.680	6.99	99.5
		232 min	7	2.597	2.1327	0.99	1.770	6.99	82.1
		233 min	7	2.399	2.1586	1.04	1.640	7.20	90.0
		234 min	7	2.204	2.1636	1.12	1.550	7.09	98.2
		235 min	7	2.517	2.3184	1.03	1.650	7.64	92.1
		236 min	7	2.246	2.1966	0.91	1.700	7.16	97.8
		237 min	7	2.456	2.2334	0.76	1.740	7.25	90.9
		238 min	7	2.331	2.3102	0.84	1.700	7.51	99.1
		239 min	7	2.370	2.3685	0.73	1.840	7.60	99.9
		240 min	1	1.040		1.04	1.040	1.04	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 121 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	1 min	12	4.901	3.4177	1.22	4.615	9.31	69.7
		2 min	12	6.063	3.1794	1.26	7.910	9.55	52.4
		3 min	12	5.719	3.2983	1.30	7.560	9.45	57.7
		4 min	12	6.197	3.1297	1.34	7.620	9.67	50.5
		5 min	12	6.652	2.5333	1.59	7.355	9.75	38.1
		6 min	12	6.709	2.5717	1.77	7.550	9.95	38.3
		7 min	12	6.905	2.4750	1.75	7.920	9.67	35.8
		8 min	12	6.363	2.5183	1.65	7.225	8.80	39.6
		9 min	12	6.496	2.3604	1.59	7.165	9.40	36.3
		10 min	12	6.453	2.2592	1.58	6.930	9.24	35.0
		11 min	12	6.171	2.3475	1.65	6.825	8.97	38.0
		12 min	12	6.106	2.4678	1.57	6.910	9.24	40.4
		13 min	12	5.353	2.8016	1.55	6.615	9.18	52.3
		14 min	12	5.032	2.9986	1.54	6.620	8.76	59.6
		15 min	12	4.978	3.0464	1.09	6.950	8.37	61.2
		16 min	12	5.304	2.8607	1.12	6.400	8.79	53.9
		17 min	12	4.808	2.9317	1.04	5.800	8.51	61.0
		18 min	12	4.349	2.9154	0.96	3.900	8.44	67.0
		19 min	12	4.303	2.8306	1.02	3.980	7.97	65.8
		20 min	12	4.163	2.8773	0.89	3.145	8.39	69.1
		21 min	11	4.099	2.9563	1.01	2.230	8.07	72.1
		22 min	10	3.703	2.7747	1.06	1.970	7.88	74.9
		23 min	10	3.602	2.8451	1.12	1.735	8.11	79.0
		24 min	10	3.303	2.8429	0.93	1.740	7.96	86.1
		25 min	10	3.203	2.6961	1.18	1.665	7.93	84.2
		26 min	10	3.110	2.5559	1.10	1.585	7.87	82.2
		27 min	10	3.625	2.7280	1.15	2.130	7.91	75.3
		28 min	10	3.304	2.6202	1.04	1.910	7.77	79.3
		29 min	10	3.309	2.7115	1.23	1.775	7.78	81.9
		30 min	10	3.242	2.6006	1.13	1.650	7.73	80.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 122 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	31 min	10	2.972	2.2510	0.98	2.050	7.53	75.7
		32 min	10	2.703	2.1012	1.20	1.650	6.89	77.7
		33 min	10	3.465	2.5146	0.99	2.215	7.75	72.6
		34 min	10	2.847	2.2922	0.90	1.730	7.79	80.5
		35 min	10	2.916	2.2815	0.91	1.660	7.78	78.2
		36 min	10	2.750	2.1101	0.70	1.800	7.70	76.7
		37 min	10	2.704	2.0341	1.02	1.630	7.56	75.2
		38 min	10	2.702	2.0060	0.91	1.780	7.48	74.2
		39 min	10	2.827	2.2814	0.86	1.685	7.64	80.7
		40 min	10	3.147	2.3998	0.52	1.850	7.61	76.3
		41 min	10	2.607	2.0765	1.02	1.785	7.37	79.6
		42 min	10	2.575	1.9916	0.88	1.735	7.49	77.3
		43 min	10	2.649	2.0926	0.91	1.715	7.55	79.0
		44 min	10	2.792	2.2442	1.06	1.815	7.62	80.4
		45 min	9	2.842	2.3530	1.00	1.930	7.53	82.8
		46 min	9	2.770	2.4117	0.90	1.660	7.60	87.1
		47 min	9	3.058	2.3997	1.02	1.820	7.63	78.5
		48 min	9	3.079	2.3912	0.52	2.000	7.64	77.7
		49 min	9	3.062	2.4742	0.55	1.960	7.60	80.8
		50 min	8	2.905	2.5183	1.13	1.720	7.64	86.7
		51 min	8	2.900	2.7697	0.57	1.610	7.59	95.5
		52 min	8	2.508	2.2426	1.05	1.755	7.84	89.4
		53 min	9	2.810	2.3096	0.60	1.780	7.66	82.2
		54 min	9	2.701	2.3123	0.89	1.790	7.62	85.6
		55 min	9	2.446	2.0223	0.83	1.840	7.53	82.7
		56 min	9	2.458	2.0218	1.07	1.730	7.64	82.3
		57 min	9	2.412	1.8907	1.20	1.760	7.24	78.4
		58 min	9	2.623	2.1926	0.56	1.690	7.30	83.6
		59 min	9	2.514	2.0046	0.91	1.720	7.28	79.7
		60 min	9	2.760	2.2505	0.92	1.660	7.20	81.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 123 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	61 min	9	2.681	2.1489	0.97	1.690	7.24	80.2
		62 min	9	2.528	1.9668	0.99	1.710	7.15	77.8
		63 min	8	2.360	2.1024	0.99	1.620	7.23	89.1
		64 min	8	2.373	2.0669	0.98	1.595	7.15	87.1
		65 min	8	2.354	2.0934	0.87	1.580	7.15	88.9
		66 min	8	2.430	2.1277	1.01	1.580	7.14	87.6
		67 min	8	2.414	2.0928	1.00	1.590	7.19	86.7
		68 min	8	2.530	2.0623	1.01	1.685	7.13	81.5
		69 min	8	2.845	2.1307	1.08	1.785	7.24	74.9
		70 min	8	2.463	2.0786	0.91	1.655	7.15	84.4
		71 min	8	2.439	2.1299	0.95	1.595	7.03	87.3
		72 min	8	2.406	2.1470	0.96	1.540	7.16	89.2
		73 min	8	2.316	2.0205	1.02	1.475	6.96	87.2
		74 min	8	2.335	2.0035	0.97	1.630	6.93	85.8
		75 min	8	2.334	2.0619	0.92	1.630	7.11	88.4
		76 min	8	2.224	2.0226	0.94	1.485	7.04	91.0
		77 min	8	2.250	2.0211	0.99	1.570	7.09	89.8
		78 min	8	2.229	1.9874	0.98	1.635	6.96	89.2
		79 min	8	2.203	1.9832	0.94	1.695	6.94	90.0
		80 min	8	2.185	2.0033	0.90	1.615	6.97	91.7
		81 min	8	2.189	2.0361	0.84	1.515	7.06	93.0
		82 min	8	2.184	2.0349	0.87	1.590	7.07	93.2
		83 min	8	2.194	2.0004	0.95	1.560	7.02	91.2
		84 min	8	2.199	1.9829	0.96	1.560	7.00	90.2
		85 min	8	2.206	1.9612	0.97	1.585	6.93	88.9
		86 min	8	2.248	1.9787	0.74	1.715	6.99	88.0
		87 min	8	2.233	1.9624	0.75	1.650	6.87	87.9
		88 min	8	2.304	1.9009	0.91	1.685	6.82	82.5
		89 min	9	1.982	1.9082	0.14	1.540	6.79	96.3
		90 min	9	2.019	1.8648	0.13	1.640	6.74	92.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 124 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	91 min	9	2.010	1.9918	0.09	1.490	7.06	99.1
		92 min	9	1.990	1.8779	0.34	1.360	6.76	94.4
		93 min	9	2.028	1.8354	0.64	1.430	6.76	90.5
		94 min	9	2.069	1.7371	0.57	1.580	6.51	84.0
		95 min	8	2.153	1.9632	0.32	1.715	6.79	91.2
		96 min	8	2.123	1.9369	0.18	1.730	6.68	91.3
		97 min	8	2.155	1.8724	0.22	1.765	6.52	86.9
		98 min	8	2.066	1.7705	0.02	1.785	6.12	85.7
		99 min	9	2.474	2.0181	0.16	1.760	6.27	81.6
		100 min	8	2.604	2.2823	0.20	1.765	6.35	87.7
		101 min	8	2.170	1.6036	0.32	1.790	5.72	73.9
		102 min	8	2.196	1.5376	0.75	1.790	5.79	70.0
		103 min	8	2.203	1.6691	0.74	1.810	6.17	75.8
		104 min	8	2.473	1.9450	0.58	1.830	6.49	78.7
		105 min	8	2.441	1.8510	0.65	1.875	6.46	75.8
		106 min	8	2.294	1.8645	0.77	1.840	6.73	81.3
		107 min	8	2.234	1.7672	0.65	1.860	6.40	79.1
		108 min	8	2.318	1.9475	0.96	1.830	7.02	84.0
		109 min	8	2.240	1.8322	0.81	1.830	6.64	81.8
		110 min	8	2.235	1.8461	0.81	1.805	6.69	82.6
		111 min	8	2.155	1.8145	0.84	1.720	6.55	84.2
		112 min	8	2.195	1.8087	0.78	1.825	6.56	82.4
		113 min	8	2.199	1.7679	0.91	1.785	6.47	80.4
		114 min	8	2.213	1.7765	1.07	1.760	6.54	80.3
		115 min	8	2.075	1.8744	0.71	1.635	6.61	90.3
		116 min	8	2.139	1.9083	0.68	1.710	6.75	89.2
		117 min	8	2.283	1.8543	1.14	1.695	6.80	81.2
		118 min	8	2.169	1.8135	1.19	1.665	6.61	83.6
		119 min	8	2.210	1.8985	1.16	1.570	6.85	85.9
		120 min	8	2.156	1.9118	1.05	1.575	6.83	88.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 125 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	121 min	8	2.228	1.8602	1.11	1.655	6.71	83.5
		122 min	8	2.639	2.2101	0.98	1.655	6.76	83.8
		123 min	8	2.178	1.8747	0.90	1.680	6.72	86.1
		124 min	8	2.156	1.8786	0.98	1.640	6.73	87.1
		125 min	8	2.135	1.8973	0.74	1.585	6.72	88.9
		126 min	8	2.080	1.8604	0.75	1.500	6.56	89.4
		127 min	8	2.231	1.8576	1.11	1.655	6.77	83.3
		128 min	8	2.124	1.9701	0.82	1.480	6.90	92.8
		129 min	8	2.121	1.9523	0.79	1.485	6.85	92.0
		130 min	8	2.066	2.0065	0.52	1.430	6.89	97.1
		131 min	8	2.115	2.0498	0.56	1.490	7.06	96.9
		132 min	8	2.198	2.0382	0.56	1.735	7.09	92.7
		133 min	8	2.104	1.9906	0.59	1.580	6.89	94.6
		134 min	8	2.083	2.0281	0.42	1.590	6.94	97.4
		135 min	8	2.624	2.3220	0.61	1.740	6.86	88.5
		136 min	8	2.108	2.0025	0.41	1.560	6.92	95.0
		137 min	8	2.054	2.0291	0.53	1.580	6.93	98.8
		138 min	8	2.728	2.2407	1.12	1.715	6.92	82.2
		139 min	8	2.254	1.9105	0.99	1.655	6.86	84.8
		140 min	8	2.601	2.2621	1.03	1.675	7.49	87.0
		141 min	8	2.530	1.9684	1.07	1.795	7.00	77.8
		142 min	8	2.323	2.0605	0.58	1.640	7.06	88.7
		143 min	8	2.431	2.2520	0.38	1.635	7.24	92.6
		144 min	8	2.183	2.1037	0.56	1.765	7.25	96.4
		145 min	8	2.720	2.5379	0.43	1.725	7.27	93.3
		146 min	8	2.184	2.1580	0.45	1.715	7.34	98.8
		147 min	8	2.126	2.1824	0.22	1.705	7.34	102.6
		148 min	8	2.126	2.1911	0.28	1.715	7.37	103.0
		149 min	8	2.080	2.2123	0.09	1.630	7.34	106.4
		150 min	8	2.109	2.2292	0.12	1.620	7.42	105.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 126 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	151 min	8	2.153	2.2148	0.01	1.620	7.40	102.9
		152 min	8	2.710	2.7610	0.09	1.605	7.44	101.9
		153 min	8	2.130	2.2667	0.03	1.560	7.46	106.4
		154 min	8	2.349	2.0912	1.05	1.710	7.41	89.0
		155 min	8	2.409	2.3432	0.39	1.620	7.50	97.3
		156 min	8	2.619	2.5549	0.20	1.630	7.43	97.6
		157 min	8	2.650	2.6136	0.53	1.630	7.47	98.6
		158 min	8	2.339	2.1342	1.02	1.670	7.52	91.3
		159 min	8	2.349	1.9704	1.08	1.820	7.12	83.9
		160 min	8	2.651	2.3831	0.63	1.720	7.53	89.9
		161 min	8	2.365	2.1930	0.66	1.630	7.41	92.7
		162 min	8	2.513	2.3245	0.41	1.655	7.47	92.5
		163 min	8	2.366	2.2208	0.27	1.690	7.44	93.9
		164 min	8	2.466	2.2431	0.29	1.675	7.21	91.0
		165 min	8	2.239	2.2728	0.03	1.640	7.37	101.5
		166 min	8	2.458	2.1673	0.20	1.740	7.05	88.2
		167 min	8	2.520	2.3760	0.07	1.685	6.93	94.3
		168 min	8	2.545	2.5505	0.11	1.570	7.27	100.2
		169 min	8	2.316	2.2055	0.15	1.640	7.18	95.2
		170 min	8	2.596	2.4240	0.35	1.605	6.95	93.4
		171 min	8	2.660	2.4661	0.87	1.620	7.00	92.7
		172 min	8	2.495	2.2136	0.45	1.630	6.96	88.7
		173 min	8	2.219	2.0456	0.18	1.640	6.91	92.2
		174 min	8	2.718	2.7064	0.21	1.570	7.14	99.6
		175 min	8	2.724	2.6924	0.21	1.605	7.04	98.8
		176 min	8	2.626	2.6540	0.19	1.560	7.01	101.1
		177 min	8	2.716	2.7669	0.30	1.565	7.27	101.9
		178 min	8	2.403	2.3144	0.01	1.580	6.90	96.3
		179 min	8	2.676	2.5745	0.32	1.555	6.97	96.2
		180 min	8	2.181	2.0576	0.54	1.650	7.01	94.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 127 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	181 min	8	2.408	2.2308	0.55	1.585	7.08	92.7
		182 min	7	1.483	0.6449	0.45	1.480	2.44	43.5
		183 min	7	1.560	0.9414	0.33	1.460	3.34	60.3
		184 min	7	1.497	0.9810	0.17	1.470	3.33	65.5
		185 min	7	1.337	0.6620	0.24	1.480	2.13	49.5
		186 min	7	1.469	0.7953	0.21	1.490	2.79	54.2
		187 min	7	1.349	0.7003	0.11	1.480	2.27	51.9
		188 min	7	1.537	1.0024	0.19	1.530	3.47	65.2
		189 min	8	2.438	2.4365	0.21	1.600	7.30	100.0
		190 min	8	2.050	2.0568	0.21	1.530	6.88	100.3
		191 min	8	2.104	2.0637	0.16	1.600	6.93	98.1
		192 min	8	2.421	2.4510	0.04	1.530	7.20	101.2
		193 min	8	2.473	2.3974	0.13	1.625	7.02	97.0
		194 min	8	2.069	2.1169	0.13	1.485	7.04	102.3
		195 min	8	2.088	2.1314	0.10	1.580	7.10	102.1
		196 min	8	2.204	2.1537	0.06	1.610	7.02	97.7
		197 min	9	1.962	1.9422	0.42	1.480	6.98	99.0
		198 min	9	2.146	2.1539	0.08	1.390	7.05	100.4
		199 min	9	1.964	1.9836	0.06	1.430	7.01	101.0
		200 min	9	1.953	1.9845	0.16	1.430	7.05	101.6
		201 min	9	2.076	1.9634	0.50	1.560	7.17	94.6
		202 min	10	2.025	1.9196	0.28	1.545	7.28	94.8
		203 min	10	2.107	1.9257	0.07	1.560	7.00	91.4
		204 min	9	2.172	2.0887	0.13	1.360	7.22	96.2
		205 min	9	2.049	1.9918	0.25	1.450	7.14	97.2
		206 min	9	1.973	1.9411	0.34	1.390	7.02	98.4
		207 min	8	1.975	2.0836	0.44	1.380	7.05	105.5
		208 min	8	2.048	2.1851	0.18	1.495	7.32	106.7
		209 min	8	1.981	2.1829	0.30	1.340	7.29	110.2
		210 min	8	1.985	2.1973	0.32	1.350	7.33	110.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 128 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	5	211 min	8	1.979	2.2272	0.13	1.400	7.37	112.6
		212 min	8	2.074	2.2255	0.29	1.385	7.45	107.3
		213 min	7	2.259	2.1975	1.13	1.350	7.21	97.3
		214 min	8	2.119	2.1316	0.51	1.475	7.30	100.6
		215 min	8	2.081	2.2051	0.11	1.490	7.35	105.9
		216 min	7	2.329	2.3936	1.10	1.470	7.74	102.8
		217 min	8	2.141	2.3054	0.28	1.510	7.72	107.7
		218 min	8	2.071	2.2572	0.53	1.390	7.58	109.0
		219 min	8	2.004	2.2741	0.28	1.410	7.51	113.5
		220 min	8	2.053	2.2548	0.24	1.410	7.49	109.9
		221 min	7	2.144	2.4185	0.30	1.470	7.52	112.8
		222 min	7	2.174	2.3895	0.35	1.500	7.49	109.9
		223 min	7	2.137	2.4020	0.25	1.530	7.48	112.4
		224 min	7	2.190	2.3171	0.79	1.540	7.40	105.8
		225 min	7	2.263	2.2744	0.99	1.510	7.40	100.5
		226 min	7	3.140	2.9639	0.97	1.600	7.61	94.4
		227 min	7	3.097	2.8417	1.17	1.590	7.28	91.8
		228 min	7	3.096	2.8139	1.21	1.600	7.34	90.9
		229 min	7	2.284	2.2677	1.06	1.500	7.39	99.3
		230 min	7	2.233	2.3018	0.96	1.550	7.42	103.1
		231 min	7	2.301	2.2978	0.83	1.720	7.44	99.8
		232 min	7	2.231	2.2901	0.97	1.490	7.38	102.6
		233 min	7	2.246	2.2831	0.88	1.590	7.38	101.7
		234 min	7	2.169	2.3391	0.71	1.520	7.41	107.9
		235 min	7	2.173	2.3652	0.29	1.560	7.41	108.9
		236 min	7	2.183	2.3579	0.44	1.660	7.42	108.0
		237 min	7	2.151	2.3558	0.56	1.600	7.39	109.5
		238 min	7	2.084	2.3749	0.28	1.570	7.35	113.9
		239 min	7	2.163	2.3468	0.29	1.610	7.34	108.5
		240 min	1	0.180		0.18	0.180	0.18	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 129 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	1 min	12	3.729	3.1550	1.13	1.865	9.27	84.6
		2 min	12	4.830	3.2154	1.13	4.445	10.03	66.6
		3 min	12	5.512	2.9834	1.15	6.635	10.19	54.1
		4 min	12	5.736	3.1413	1.03	7.370	10.21	54.8
		5 min	12	5.599	3.2156	1.44	7.090	9.94	57.4
		6 min	12	5.968	2.8676	2.18	7.280	9.97	48.0
		7 min	12	6.761	2.0599	2.27	7.470	9.82	30.5
		8 min	12	6.312	2.2553	2.18	7.030	9.88	35.7
		9 min	12	5.655	2.7295	1.93	6.375	9.76	48.3
		10 min	12	5.970	2.5458	1.67	6.865	9.77	42.6
		11 min	12	5.493	2.8415	1.66	6.855	9.72	51.7
		12 min	12	5.318	2.8602	1.49	6.610	9.30	53.8
		13 min	12	5.411	2.8221	1.56	6.580	9.18	52.2
		14 min	12	4.978	2.9488	1.39	5.155	9.19	59.2
		15 min	12	4.830	3.1247	1.18	5.290	9.04	64.7
		16 min	12	5.153	2.9270	1.21	6.550	8.90	56.8
		17 min	12	4.722	2.9237	1.13	5.060	8.57	61.9
		18 min	12	4.481	2.9118	1.05	4.580	8.67	65.0
		19 min	12	4.496	2.8710	1.04	5.215	8.64	63.9
		20 min	12	4.122	2.8635	0.80	3.255	8.51	69.5
		21 min	11	3.843	2.6811	1.03	3.290	8.33	69.8
		22 min	10	3.506	2.5076	0.93	2.870	7.69	71.5
		23 min	10	3.478	2.5001	1.01	2.240	7.87	71.9
		24 min	10	3.677	2.7732	0.90	2.070	7.71	75.4
		25 min	10	3.560	2.5373	0.97	2.730	7.77	71.3
		26 min	10	3.419	2.5500	0.95	2.145	7.73	74.6
		27 min	10	3.479	2.6636	1.07	1.770	7.68	76.6
		28 min	10	3.377	2.4035	1.16	2.405	7.60	71.2
		29 min	10	3.301	2.5672	1.06	1.595	7.67	77.8
		30 min	10	2.998	2.2724	1.16	1.605	7.61	75.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 130 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	31 min	10	2.827	2.2734	0.95	1.775	7.62	80.4
		32 min	10	2.899	2.1000	1.05	2.170	7.00	72.4
		33 min	10	3.450	2.6342	0.90	1.920	7.68	76.4
		34 min	10	3.081	2.4378	0.90	1.510	7.66	79.1
		35 min	10	2.766	2.3313	0.84	1.525	7.47	84.3
		36 min	10	2.683	2.2347	0.88	1.555	7.60	83.3
		37 min	10	2.790	2.0486	0.98	1.545	7.36	73.4
		38 min	10	2.586	2.0654	0.54	1.610	7.55	79.9
		39 min	10	3.118	2.3789	1.00	1.605	7.48	76.3
		40 min	10	2.944	2.3132	0.84	1.750	7.46	78.6
		41 min	10	2.798	2.1060	0.93	1.670	7.39	75.3
		42 min	10	2.630	1.9708	0.99	1.835	7.37	74.9
		43 min	10	3.064	2.4777	0.91	1.620	7.24	80.9
		44 min	10	3.161	2.6018	1.08	1.765	7.19	82.3
		45 min	9	2.843	2.3821	0.88	1.700	7.29	83.8
		46 min	9	2.702	2.3211	0.91	1.560	7.38	85.9
		47 min	9	2.809	2.3838	0.96	1.450	7.39	84.9
		48 min	9	2.701	2.1234	0.75	2.100	7.39	78.6
		49 min	9	2.749	2.0592	0.98	2.190	7.33	74.9
		50 min	8	2.443	2.0288	1.06	1.585	7.23	83.1
		51 min	8	2.744	2.2808	0.99	1.560	7.28	83.1
		52 min	8	2.866	2.5307	0.54	1.570	7.48	88.3
		53 min	9	3.037	2.3657	0.80	1.590	7.52	77.9
		54 min	9	2.738	2.0529	0.88	1.710	7.42	75.0
		55 min	9	2.427	2.0105	0.91	1.710	7.49	82.8
		56 min	9	2.594	1.9921	1.08	1.870	7.57	76.8
		57 min	9	2.466	1.9730	1.09	1.560	7.37	80.0
		58 min	9	2.442	1.9434	0.92	1.860	7.32	79.6
		59 min	9	2.351	1.9517	0.85	1.560	7.26	83.0
		60 min	9	2.343	1.9297	0.90	1.600	7.19	82.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 131 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	61 min	9	2.450	1.9413	0.87	1.590	7.17	79.2
		62 min	9	2.489	1.9667	0.93	1.650	7.11	79.0
		63 min	8	2.380	2.0540	0.97	1.595	7.13	86.3
		64 min	8	2.368	2.0123	0.95	1.615	7.03	85.0
		65 min	8	2.354	1.9838	1.01	1.640	6.97	84.3
		66 min	8	2.336	2.0208	0.74	1.695	7.01	86.5
		67 min	8	2.348	1.9873	1.10	1.575	7.01	84.7
		68 min	8	2.349	1.9848	1.12	1.620	7.00	84.5
		69 min	8	2.345	1.9303	1.18	1.515	6.85	82.3
		70 min	8	2.268	2.0036	0.97	1.610	6.93	88.4
		71 min	8	2.259	1.9603	1.00	1.565	6.80	86.8
		72 min	8	2.330	1.9709	0.98	1.565	6.91	84.6
		73 min	8	2.256	1.9922	0.99	1.505	6.88	88.3
		74 min	8	2.288	1.9661	1.01	1.610	6.80	86.0
		75 min	8	2.233	2.0050	0.83	1.585	6.85	89.8
		76 min	8	2.241	2.0036	0.93	1.530	6.85	89.4
		77 min	8	2.259	1.9992	0.94	1.510	6.86	88.5
		78 min	8	2.268	1.9787	0.92	1.600	6.83	87.3
		79 min	8	2.223	1.9703	0.87	1.615	6.77	88.7
		80 min	8	2.191	1.9730	0.86	1.545	6.73	90.0
		81 min	8	2.179	1.9837	0.77	1.565	6.75	91.0
		82 min	8	2.201	2.0062	0.81	1.535	6.84	91.1
		83 min	8	2.228	1.9748	0.96	1.560	6.82	88.7
		84 min	8	2.230	1.9630	0.99	1.530	6.83	88.0
		85 min	8	2.209	1.9518	1.01	1.455	6.81	88.4
		86 min	8	2.251	1.9338	0.86	1.590	6.79	85.9
		87 min	8	2.275	1.9144	0.82	1.655	6.74	84.1
		88 min	8	2.275	1.8993	0.84	1.585	6.67	83.5
		89 min	9	2.100	1.9085	0.12	1.430	6.72	90.9
		90 min	9	2.127	1.8357	0.29	1.630	6.67	86.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 132 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	91 min	9	2.149	1.8275	0.44	1.520	6.68	85.0
		92 min	9	2.103	1.8172	0.32	1.510	6.56	86.4
		93 min	9	2.027	1.7440	0.53	1.580	6.39	86.1
		94 min	9	2.071	1.7984	0.28	1.580	6.53	86.8
		95 min	8	2.159	1.7469	0.46	1.745	6.15	80.9
		96 min	8	2.160	1.7261	0.51	1.720	6.16	79.9
		97 min	8	2.106	1.6466	0.46	1.690	5.89	78.2
		98 min	8	2.158	1.8983	0.47	1.620	6.61	88.0
		99 min	9	2.199	1.8182	0.33	1.860	6.78	82.7
		100 min	8	2.423	1.7740	1.17	1.775	6.60	73.2
		101 min	8	2.141	1.4033	1.23	1.740	5.58	65.5
		102 min	8	1.998	1.5775	0.72	1.760	5.74	79.0
		103 min	8	1.999	1.4427	0.54	1.800	5.37	72.2
		104 min	8	1.753	0.7482	0.55	1.755	3.15	42.7
		105 min	8	2.080	1.3976	0.52	1.725	5.14	67.2
		106 min	8	1.965	1.2047	0.58	1.785	4.66	61.3
		107 min	8	2.101	1.7068	0.50	1.840	6.13	81.2
		108 min	8	2.254	1.8052	0.94	1.735	6.61	80.1
		109 min	8	1.969	1.1127	0.87	1.780	4.55	56.5
		110 min	8	1.914	0.8816	0.86	1.760	3.75	46.1
		111 min	8	1.935	1.2346	0.81	1.760	4.76	63.8
		112 min	8	2.081	1.3051	0.75	1.840	5.06	62.7
		113 min	8	2.130	1.5853	0.84	1.790	5.93	74.4
		114 min	8	2.148	1.7145	0.82	1.755	6.29	79.8
		115 min	8	2.074	1.6954	0.75	1.680	6.17	81.8
		116 min	8	2.088	1.8701	0.57	1.655	6.60	89.6
		117 min	8	2.179	1.8181	1.02	1.735	6.61	83.4
		118 min	8	2.158	1.7882	1.10	1.745	6.51	82.9
		119 min	8	2.178	1.7655	1.19	1.710	6.49	81.1
		120 min	8	2.181	1.7803	1.12	1.710	6.54	81.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 133 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	121 min	8	2.150	1.7518	1.10	1.690	6.43	81.5
		122 min	8	2.124	1.7916	1.05	1.620	6.50	84.4
		123 min	8	2.126	1.8044	1.00	1.680	6.52	84.9
		124 min	8	2.128	1.8179	0.94	1.680	6.56	85.4
		125 min	8	2.115	1.8145	0.95	1.635	6.53	85.8
		126 min	8	2.096	1.8956	0.79	1.555	6.71	90.4
		127 min	8	2.124	1.8873	0.89	1.665	6.72	88.9
		128 min	8	2.101	1.9193	0.96	1.490	6.80	91.3
		129 min	8	2.071	1.9293	0.71	1.555	6.76	93.1
		130 min	8	1.980	2.0314	0.05	1.505	6.81	102.6
		131 min	8	2.016	2.0393	0.10	1.510	6.87	101.1
		132 min	8	2.050	2.0434	0.16	1.580	6.92	99.7
		133 min	8	1.958	1.9627	0.06	1.515	6.62	100.3
		134 min	7	2.280	1.9953	1.13	1.690	6.77	87.5
		135 min	7	2.290	2.0553	1.14	1.680	6.91	89.8
		136 min	8	2.009	2.0197	0.09	1.565	6.81	100.5
		137 min	8	2.019	1.9966	0.37	1.545	6.80	98.9
		138 min	8	2.605	2.2732	0.80	1.745	6.89	87.3
		139 min	8	2.128	1.9472	1.07	1.605	6.88	91.5
		140 min	8	2.454	2.1347	1.03	1.755	7.41	87.0
		141 min	8	2.119	1.9730	0.92	1.605	6.92	93.1
		142 min	8	2.186	1.9758	0.95	1.710	7.00	90.4
		143 min	8	2.083	2.0680	0.59	1.555	7.09	99.3
		144 min	8	2.351	2.1199	0.60	1.735	7.25	90.2
		145 min	8	2.285	2.1211	0.58	1.760	7.30	92.8
		146 min	8	2.118	2.1616	0.52	1.625	7.34	102.1
		147 min	8	2.126	2.1443	0.49	1.590	7.31	100.8
		148 min	8	2.100	2.2006	0.41	1.585	7.41	104.8
		149 min	8	2.134	2.1678	0.44	1.660	7.37	101.6
		150 min	8	2.100	2.1986	0.25	1.640	7.37	104.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 134 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	151 min	8	2.128	2.1615	0.16	1.670	7.27	101.6
		152 min	8	2.101	2.1788	0.20	1.645	7.29	103.7
		153 min	8	2.099	2.1667	0.23	1.625	7.26	103.2
		154 min	8	2.226	2.1321	0.87	1.675	7.40	95.8
		155 min	8	2.131	2.1113	0.63	1.665	7.20	99.1
		156 min	8	2.154	2.2272	0.41	1.660	7.50	103.4
		157 min	8	2.188	2.2549	0.42	1.650	7.61	103.1
		158 min	8	2.173	2.2467	0.34	1.700	7.57	103.4
		159 min	8	2.185	2.1550	0.55	1.690	7.35	98.6
		160 min	8	2.165	2.2073	0.27	1.685	7.43	102.0
		161 min	8	2.259	2.1846	0.64	1.705	7.54	96.7
		162 min	8	2.189	2.2947	0.30	1.675	7.69	104.8
		163 min	8	2.154	2.1842	0.19	1.660	7.36	101.4
		164 min	8	2.189	2.2508	0.28	1.675	7.60	102.8
		165 min	8	2.195	2.2380	0.17	1.680	7.49	102.0
		166 min	8	2.656	2.4444	0.12	1.795	7.74	92.0
		167 min	8	2.161	2.2046	0.03	1.685	7.34	102.0
		168 min	8	2.183	2.2488	0.16	1.610	7.51	103.0
		169 min	8	2.166	2.1671	0.03	1.680	7.27	100.0
		170 min	8	2.210	2.3339	0.13	1.665	7.75	105.6
		171 min	8	2.231	2.3086	0.21	1.645	7.74	103.5
		172 min	8	2.290	2.1107	0.39	1.635	7.05	92.2
		173 min	8	2.243	2.2272	0.30	1.665	7.49	99.3
		174 min	8	2.211	2.1261	0.26	1.670	7.25	96.1
		175 min	8	2.145	2.1239	0.17	1.645	7.16	99.0
		176 min	8	2.136	2.0696	0.25	1.665	7.02	96.9
		177 min	8	2.189	2.1070	0.19	1.640	7.01	96.3
		178 min	8	2.159	2.0606	0.18	1.660	6.90	95.5
		179 min	8	2.176	2.0347	0.26	1.650	6.92	93.5
		180 min	8	2.191	2.0648	0.47	1.690	7.10	94.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 135 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	181 min	8	2.170	2.0027	0.55	1.625	6.94	92.3
		182 min	7	1.473	0.5650	0.59	1.540	2.27	38.4
		183 min	7	1.430	0.5869	0.54	1.550	2.25	41.0
		184 min	7	1.434	0.6543	0.24	1.550	2.28	45.6
		185 min	7	1.367	0.6419	0.47	1.520	2.22	47.0
		186 min	7	1.401	0.5986	0.32	1.480	2.14	42.7
		187 min	7	1.343	0.5953	0.41	1.480	2.07	44.3
		188 min	7	1.379	0.5860	0.37	1.510	2.13	42.5
		189 min	8	2.076	2.0678	0.32	1.610	6.98	99.6
		190 min	8	2.041	2.0612	0.12	1.655	6.89	101.0
		191 min	8	2.024	2.0248	0.06	1.625	6.80	100.1
		192 min	8	2.015	2.0690	0.09	1.580	6.92	102.7
		193 min	8	2.100	2.0471	0.22	1.675	6.98	97.5
		194 min	8	2.039	2.0598	0.20	1.595	6.95	101.0
		195 min	8	2.023	2.0830	0.07	1.635	6.94	103.0
		196 min	8	2.014	2.0680	0.04	1.610	6.92	102.7
		197 min	9	1.939	1.8825	0.44	1.520	6.80	97.1
		198 min	9	1.947	1.9163	0.27	1.450	6.88	98.4
		199 min	9	1.948	1.9009	0.27	1.430	6.84	97.6
		200 min	9	1.952	1.9015	0.39	1.460	6.87	97.4
		201 min	9	2.042	1.8881	0.37	1.710	6.91	92.5
		202 min	10	1.968	1.7939	0.36	1.550	6.92	91.2
		203 min	10	1.950	1.8103	0.07	1.620	6.88	92.8
		204 min	9	1.937	1.9177	0.06	1.400	6.84	99.0
		205 min	9	1.962	1.8895	0.29	1.470	6.84	96.3
		206 min	9	1.939	1.8231	0.30	1.390	6.65	94.0
		207 min	8	1.969	1.9629	0.37	1.395	6.71	99.7
		208 min	8	1.993	1.9721	0.21	1.495	6.71	99.0
		209 min	8	1.936	1.9845	0.23	1.390	6.72	102.5
		210 min	8	1.948	2.0367	0.18	1.400	6.85	104.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 136 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	6	211 min	8	1.930	2.0317	0.02	1.445	6.78	105.3
		212 min	8	1.983	2.0350	0.07	1.430	6.82	102.7
		213 min	7	2.239	2.0788	1.04	1.450	6.91	92.9
		214 min	8	1.964	2.0448	0.05	1.445	6.83	104.1
		215 min	7	2.247	2.0843	1.07	1.540	6.95	92.8
		216 min	8	1.975	1.9526	0.03	1.490	6.62	98.9
		217 min	8	2.055	2.0313	0.41	1.475	6.96	98.8
		218 min	8	1.998	2.0220	0.35	1.415	6.86	101.2
		219 min	8	1.908	1.9911	0.18	1.410	6.69	104.4
		220 min	8	1.896	1.9869	0.09	1.460	6.65	104.8
		221 min	7	2.024	2.1225	0.16	1.450	6.69	104.9
		222 min	7	2.044	2.0824	0.41	1.470	6.66	101.9
		223 min	7	2.010	2.1251	0.30	1.470	6.72	105.7
		224 min	7	2.067	2.1000	0.67	1.470	6.77	101.6
		225 min	7	2.601	2.2504	0.89	1.540	6.73	86.5
		226 min	7	2.741	2.3689	0.93	1.540	6.83	86.4
		227 min	7	2.616	2.1811	1.10	1.520	6.78	83.4
		228 min	7	2.863	2.3977	1.18	1.600	6.83	83.8
		229 min	7	2.020	2.1089	0.66	1.480	6.73	104.4
		230 min	7	2.043	2.0733	0.61	1.480	6.67	101.5
		231 min	7	2.057	2.0972	0.49	1.510	6.72	101.9
		232 min	7	2.084	2.1339	0.57	1.500	6.84	102.4
		233 min	7	2.050	2.1559	0.64	1.430	6.87	105.2
		234 min	7	2.007	2.1918	0.51	1.460	6.89	109.2
		235 min	7	2.049	2.1404	0.54	1.530	6.82	104.5
		236 min	7	2.039	2.2039	0.43	1.440	6.94	108.1
		237 min	7	2.033	2.2174	0.61	1.480	6.97	109.1
		238 min	7	2.014	2.2348	0.45	1.530	6.96	110.9
		239 min	7	2.024	2.2156	0.46	1.490	6.91	109.5
		240 min	1	0.470		0.47	0.470	0.47	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 137 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	1 min	12	3.381	2.9229	1.10	1.800	8.63	86.5
		2 min	12	5.513	3.1759	0.73	6.640	9.69	57.6
		3 min	12	5.495	2.9677	1.01	6.755	10.03	54.0
		4 min	12	5.801	3.1115	0.89	7.485	9.65	53.6
		5 min	12	6.502	2.5229	0.80	7.545	8.94	38.8
		6 min	12	6.519	2.5604	0.91	7.615	8.95	39.3
		7 min	12	6.351	2.6210	1.84	7.550	8.72	41.3
		8 min	12	6.411	2.4951	2.32	7.430	9.38	38.9
		9 min	12	7.047	1.4384	3.28	7.400	8.94	20.4
		10 min	12	6.298	2.4685	1.92	7.550	9.07	39.2
		11 min	12	6.239	2.3083	1.90	7.305	8.94	37.0
		12 min	12	6.058	2.5557	1.79	7.355	8.50	42.2
		13 min	12	6.163	2.4342	1.73	7.355	8.46	39.5
		14 min	12	5.975	2.5000	1.58	7.135	8.68	41.8
		15 min	12	5.316	2.9801	1.28	6.820	8.72	56.1
		16 min	12	5.408	2.7710	1.45	6.860	8.66	51.2
		17 min	12	5.078	3.0940	1.16	6.315	8.73	60.9
		18 min	12	5.088	3.1466	1.10	6.890	8.50	61.8
		19 min	12	5.043	3.1400	1.11	6.880	8.51	62.3
		20 min	12	4.582	3.0384	0.82	4.890	8.34	66.3
		21 min	11	5.213	2.9213	1.06	6.570	8.22	56.0
		22 min	10	4.668	2.9177	0.96	6.145	7.74	62.5
		23 min	10	4.356	2.8374	0.98	4.775	7.84	65.1
		24 min	10	4.393	2.8205	0.90	5.130	7.74	64.2
		25 min	10	4.493	2.8492	1.08	5.230	7.77	63.4
		26 min	10	3.664	2.6364	0.92	3.075	7.67	72.0
		27 min	10	3.803	2.9140	1.07	1.915	7.62	76.6
		28 min	10	3.832	2.8540	1.18	1.885	7.73	74.5
		29 min	10	3.573	2.6824	1.19	1.895	7.73	75.1
		30 min	10	3.280	2.4905	1.24	1.635	7.78	75.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 138 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	31 min	10	2.860	2.3238	1.11	1.660	7.65	81.3
		32 min	10	3.002	2.2424	1.19	1.650	6.98	74.7
		33 min	10	3.255	2.6663	0.96	1.815	7.58	81.9
		34 min	10	3.080	2.5945	1.06	1.600	7.70	84.2
		35 min	10	3.025	2.5190	1.06	1.580	7.50	83.3
		36 min	10	3.118	2.6340	0.92	1.575	7.65	84.5
		37 min	10	2.943	2.4473	0.97	1.510	7.35	83.2
		38 min	10	3.056	2.5018	0.89	1.525	7.48	81.9
		39 min	10	2.906	2.5075	0.90	1.560	7.61	86.3
		40 min	10	3.061	2.5158	0.79	1.740	7.53	82.2
		41 min	10	3.087	2.2775	1.04	2.285	7.37	73.8
		42 min	10	2.998	2.3107	1.04	2.085	7.43	77.1
		43 min	10	3.039	2.3494	0.98	2.155	7.37	77.3
		44 min	10	3.463	2.7533	1.05	2.070	7.51	79.5
		45 min	9	2.944	2.4912	1.00	1.690	7.41	84.6
		46 min	9	2.863	2.4887	1.03	1.620	7.36	86.9
		47 min	9	2.982	2.5658	0.96	1.520	7.44	86.0
		48 min	9	2.953	2.2953	0.89	1.670	7.33	77.7
		49 min	9	2.979	2.4865	0.79	1.610	7.18	83.5
		50 min	8	2.659	2.0353	1.03	1.545	7.05	76.6
		51 min	8	2.865	2.3021	1.00	1.545	7.09	80.4
		52 min	8	3.073	2.5717	0.98	1.590	7.76	83.7
		53 min	9	3.248	2.5616	0.74	1.600	7.56	78.9
		54 min	9	2.790	2.0581	0.99	1.640	7.42	73.8
		55 min	9	2.661	2.1793	0.89	1.600	7.63	81.9
		56 min	9	2.462	2.0400	1.06	1.660	7.47	82.9
		57 min	9	2.573	1.9805	1.16	1.630	7.28	77.0
		58 min	9	2.604	2.0825	0.87	1.610	7.36	80.0
		59 min	9	2.524	2.0512	1.00	1.570	7.43	81.3
		60 min	9	2.413	2.0325	1.05	1.610	7.45	84.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 139 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	61 min	9	2.509	2.0189	1.00	1.580	7.38	80.5
		62 min	9	2.379	1.9846	0.97	1.670	7.32	83.4
		63 min	8	2.331	2.0034	0.99	1.570	6.90	85.9
		64 min	8	2.383	2.0907	1.10	1.525	7.23	87.8
		65 min	8	2.318	2.1096	0.99	1.420	7.18	91.0
		66 min	8	2.369	2.1009	0.91	1.510	7.20	88.7
		67 min	8	2.353	1.9800	1.08	1.625	6.91	84.2
		68 min	8	2.380	1.9997	1.10	1.585	6.97	84.0
		69 min	8	2.439	2.0398	1.13	1.640	7.15	83.6
		70 min	8	2.306	1.9885	0.93	1.640	6.85	86.2
		71 min	8	2.333	2.0593	1.13	1.415	7.09	88.3
		72 min	8	2.350	2.0396	1.02	1.560	7.03	86.8
		73 min	8	2.323	2.1109	0.95	1.465	7.19	90.9
		74 min	8	2.483	1.9700	1.06	1.730	6.95	79.4
		75 min	8	2.318	2.0328	0.95	1.670	6.99	87.7
		76 min	8	2.310	2.0355	0.95	1.605	6.98	88.1
		77 min	8	2.344	2.0327	1.09	1.610	7.04	86.7
		78 min	8	2.285	2.0430	0.79	1.580	6.97	89.4
		79 min	8	2.220	1.9269	1.02	1.475	6.62	86.8
		80 min	8	2.244	2.0028	0.80	1.590	6.82	89.3
		81 min	8	2.230	2.0459	0.82	1.560	6.95	91.7
		82 min	8	2.141	2.0199	0.82	1.455	6.83	94.3
		83 min	8	2.251	2.0549	0.93	1.540	7.01	91.3
		84 min	8	2.235	1.9644	0.98	1.560	6.82	87.9
		85 min	8	2.290	2.0614	1.02	1.505	7.11	90.0
		86 min	8	2.333	2.0496	0.95	1.565	7.18	87.9
		87 min	8	2.664	2.1114	0.95	1.605	6.98	79.3
		88 min	8	2.595	2.0587	0.88	1.635	6.86	79.3
		89 min	8	2.670	2.0900	0.98	1.630	6.83	78.3
		90 min	8	2.889	2.2157	1.22	1.635	6.73	76.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 140 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	91 min	9	3.092	2.5668	0.02	1.760	7.06	83.0
		92 min	8	3.033	2.3592	1.10	1.995	7.00	77.8
		93 min	8	2.748	1.8991	1.10	2.130	6.82	69.1
		94 min	8	2.804	2.0945	1.11	1.685	6.50	74.7
		95 min	7	3.134	2.4264	1.08	1.680	6.93	77.4
		96 min	7	2.971	2.1964	1.11	1.760	6.97	73.9
		97 min	8	2.275	1.9795	0.05	1.580	6.59	87.0
		98 min	7	2.777	2.2734	1.14	1.770	7.54	81.9
		99 min	8	2.469	1.9199	1.18	1.800	7.10	77.8
		100 min	8	2.170	2.1181	0.11	1.685	7.18	97.6
		101 min	8	2.000	1.8810	0.07	1.625	6.43	94.0
		102 min	8	2.079	1.8938	0.19	1.735	6.56	91.1
		103 min	8	2.023	1.8802	0.17	1.750	6.46	93.0
		104 min	8	1.854	1.3642	0.23	1.670	4.96	73.6
		105 min	8	1.988	1.6199	0.25	1.730	5.78	81.5
		106 min	8	1.480	0.5641	0.20	1.675	1.92	38.1
		107 min	8	1.863	1.3404	0.20	1.725	4.90	72.0
		108 min	8	1.706	0.6523	0.62	1.785	2.94	38.2
		109 min	8	1.467	0.4554	0.57	1.550	2.03	31.0
		110 min	8	1.500	0.4120	0.57	1.620	1.80	27.5
		111 min	8	1.753	1.0396	0.21	1.765	3.89	59.3
		112 min	8	1.993	1.3894	0.42	1.825	5.20	69.7
		113 min	8	2.056	1.6400	0.47	1.750	5.95	79.8
		114 min	8	2.113	1.8480	0.36	1.735	6.51	87.5
		115 min	8	2.060	1.7876	0.31	1.725	6.30	86.8
		116 min	8	2.048	1.7381	0.34	1.710	6.17	84.9
		117 min	8	2.146	1.7256	0.70	1.745	6.29	80.4
		118 min	8	2.138	1.8444	0.79	1.705	6.61	86.3
		119 min	8	2.189	1.8256	0.89	1.725	6.62	83.4
		120 min	8	2.186	1.8452	0.97	1.685	6.68	84.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 141 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	121 min	8	2.218	1.8197	1.05	1.750	6.64	82.1
		122 min	8	2.190	1.8681	0.90	1.650	6.73	85.3
		123 min	8	2.208	1.8434	0.91	1.670	6.67	83.5
		124 min	8	2.140	1.8255	0.73	1.670	6.55	85.3
		125 min	8	2.154	1.8468	0.75	1.655	6.61	85.7
		126 min	8	2.119	1.8409	0.67	1.595	6.56	86.9
		127 min	8	2.108	1.8445	0.68	1.640	6.56	87.5
		128 min	8	2.095	1.9309	0.60	1.600	6.77	92.2
		129 min	8	2.076	1.8978	0.68	1.555	6.67	91.4
		130 min	8	2.050	1.9805	0.38	1.485	6.80	96.6
		131 min	8	2.081	2.0489	0.20	1.535	6.97	98.4
		132 min	8	2.099	2.0566	0.37	1.580	7.04	98.0
		133 min	8	2.056	1.9631	0.40	1.530	6.77	95.5
		134 min	8	2.058	1.9813	0.34	1.560	6.82	96.3
		135 min	8	2.059	2.0436	0.31	1.545	6.97	99.3
		136 min	8	2.068	1.9758	0.32	1.590	6.79	95.6
		137 min	8	2.079	2.0398	0.41	1.505	6.97	98.1
		138 min	8	2.066	2.0514	0.27	1.565	6.98	99.3
		139 min	8	2.070	1.9925	0.75	1.435	6.91	96.3
		140 min	8	2.150	2.1784	0.61	1.530	7.44	101.3
		141 min	8	2.070	2.0025	0.61	1.475	6.92	96.7
		142 min	8	2.104	2.0568	0.54	1.515	7.08	97.8
		143 min	8	2.436	2.1720	0.67	1.655	7.17	89.2
		144 min	8	2.135	2.1074	0.58	1.605	7.24	98.7
		145 min	8	2.149	2.1804	0.27	1.675	7.38	101.5
		146 min	8	2.101	2.1803	0.36	1.600	7.35	103.8
		147 min	8	2.123	2.1966	0.43	1.560	7.42	103.5
		148 min	8	2.080	2.2223	0.13	1.605	7.40	106.8
		149 min	8	2.100	2.2270	0.04	1.625	7.40	106.0
		150 min	8	2.105	2.2314	0.11	1.610	7.44	106.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 142 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	151 min	7	2.437	2.3715	1.17	1.560	7.77	97.3
		152 min	8	2.123	2.2660	0.17	1.570	7.55	106.8
		153 min	7	2.376	2.2955	1.03	1.620	7.52	96.6
		154 min	8	2.140	2.2839	0.09	1.625	7.59	106.7
		155 min	8	2.180	2.2649	0.29	1.595	7.59	103.9
		156 min	8	2.235	2.2926	0.24	1.620	7.64	102.6
		157 min	8	2.249	2.3150	0.27	1.595	7.74	102.9
		158 min	8	2.146	2.1650	0.29	1.655	7.32	100.9
		159 min	8	2.140	2.2193	0.21	1.650	7.44	103.7
		160 min	8	2.240	2.1771	0.12	1.650	7.28	97.2
		161 min	8	2.361	2.3564	0.20	1.590	7.55	99.8
		162 min	8	2.151	2.2044	0.13	1.625	7.29	102.5
		163 min	8	2.124	2.2863	0.21	1.590	7.59	107.7
		164 min	8	2.190	2.2158	0.19	1.660	7.46	101.2
		165 min	7	2.469	2.2409	0.97	1.690	7.46	90.8
		166 min	8	2.145	2.1917	0.16	1.665	7.30	102.2
		167 min	8	2.174	2.1607	0.19	1.620	7.26	99.4
		168 min	8	2.248	2.3128	0.31	1.590	7.72	102.9
		169 min	8	2.291	2.3235	0.19	1.625	7.81	101.4
		170 min	8	2.246	2.3108	0.13	1.585	7.71	102.9
		171 min	8	2.255	2.1991	0.21	1.625	7.39	97.5
		172 min	8	2.210	2.1905	0.20	1.605	7.38	99.1
		173 min	8	2.108	2.1163	0.14	1.620	7.14	100.4
		174 min	8	2.129	2.1150	0.14	1.610	7.01	99.4
		175 min	8	2.125	2.0060	0.12	1.580	6.71	94.4
		176 min	8	2.174	2.0775	0.16	1.635	6.95	95.6
		177 min	8	2.189	2.1381	0.15	1.625	7.12	97.7
		178 min	8	2.086	1.9173	0.14	1.610	6.46	91.9
		179 min	8	2.186	2.1398	0.01	1.620	7.08	97.9
		180 min	8	2.215	2.1359	0.14	1.620	7.11	96.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 143 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	181 min	8	2.143	1.9752	0.15	1.590	6.62	92.2
		182 min	7	1.500	0.7727	0.37	1.540	2.85	51.5
		183 min	7	1.410	0.6697	0.30	1.520	2.37	47.5
		184 min	7	1.346	0.7152	0.02	1.510	2.22	53.1
		185 min	7	1.366	0.7226	0.10	1.500	2.32	52.9
		186 min	7	1.326	0.6603	0.15	1.450	2.15	49.8
		187 min	7	1.316	0.6592	0.12	1.430	2.05	50.1
		188 min	7	1.323	0.6766	0.12	1.490	2.13	51.1
		189 min	8	2.555	2.6866	0.05	1.555	7.02	105.1
		190 min	7	2.341	2.0581	1.03	1.710	6.89	87.9
		191 min	7	2.290	1.8918	1.10	1.690	6.50	82.6
		192 min	8	1.980	1.9820	0.05	1.465	6.63	100.1
		193 min	7	2.271	2.0323	0.90	1.640	6.79	89.5
		194 min	8	1.955	1.9818	0.08	1.540	6.62	101.4
		195 min	8	2.026	2.0381	0.05	1.580	6.81	100.6
		196 min	7	2.320	2.1616	1.11	1.720	7.16	93.2
		197 min	9	1.943	1.9561	0.26	1.450	6.97	100.7
		198 min	9	1.881	1.8418	0.06	1.420	6.56	97.9
		199 min	8	2.091	1.8326	1.00	1.515	6.55	87.6
		200 min	8	2.103	1.8262	0.90	1.590	6.54	86.9
		201 min	9	2.520	2.3679	0.11	1.660	6.66	94.0
		202 min	10	1.948	1.7873	0.07	1.655	6.81	91.8
		203 min	10	1.956	1.8373	0.09	1.565	6.97	93.9
		204 min	9	1.942	1.9775	0.00	1.370	7.00	101.8
		205 min	8	2.215	1.9495	1.16	1.585	7.00	88.0
		206 min	9	1.976	1.9594	0.18	1.330	7.03	99.2
		207 min	7	2.283	2.1109	1.24	1.550	7.05	92.5
		208 min	8	2.035	2.0857	0.02	1.550	7.00	102.5
		209 min	7	2.319	2.0952	1.23	1.740	7.04	90.4
		210 min	7	2.294	2.1117	1.13	1.680	7.05	92.0

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 144 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	7	211 min	7	2.256	2.0977	1.10	1.440	6.98	93.0
		212 min	7	2.321	2.1426	1.10	1.560	7.14	92.3
		213 min	7	2.207	2.1095	1.08	1.410	6.96	95.6
		214 min	7	2.314	2.1169	1.10	1.510	7.07	91.5
		215 min	7	2.289	2.1149	1.12	1.490	7.05	92.4
		216 min	7	2.290	2.0810	1.17	1.510	6.98	90.9
		217 min	7	2.307	2.0922	1.25	1.460	7.00	90.7
		218 min	7	2.273	2.0467	1.15	1.520	6.88	90.0
		219 min	7	2.193	2.0767	1.10	1.520	6.87	94.7
		220 min	7	2.206	2.0346	1.06	1.490	6.79	92.2
		221 min	6	2.358	2.1822	1.15	1.540	6.79	92.5
		222 min	6	2.362	2.1603	1.13	1.550	6.74	91.5
		223 min	7	2.061	2.2901	0.04	1.470	7.10	111.1
		224 min	7	2.080	2.2588	0.08	1.440	7.05	108.6
		225 min	6	2.330	2.2676	1.04	1.525	6.94	97.3
		226 min	6	2.338	2.2103	1.19	1.500	6.84	94.5
		227 min	7	2.017	2.1808	0.18	1.410	6.83	108.1
		228 min	7	2.121	2.1363	0.53	1.470	6.89	100.7
		229 min	7	2.003	2.1666	0.39	1.370	6.83	108.2
		230 min	7	2.076	2.2337	0.38	1.400	7.05	107.6
		231 min	7	2.077	2.2325	0.25	1.450	7.02	107.5
		232 min	7	2.104	2.2381	0.42	1.480	7.08	106.4
		233 min	7	2.109	2.2654	0.48	1.450	7.15	107.4
		234 min	7	2.003	2.3775	0.00	1.380	7.24	118.7
		235 min	7	2.107	2.3102	0.41	1.500	7.25	109.6
		236 min	7	2.007	2.1213	0.37	1.460	6.70	105.7
		237 min	7	2.069	2.3166	0.45	1.440	7.21	112.0
		238 min	7	2.097	2.1533	0.42	1.470	6.80	102.7
		239 min	7	2.133	2.1168	0.41	1.430	6.76	99.2
		240 min	1	0.410		0.41	0.410	0.41	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 145 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	1 min	12	2.552	2.0979	1.23	1.750	7.21	82.2
		2 min	12	4.261	2.8116	1.19	4.235	8.62	66.0
		3 min	12	5.237	2.7966	1.48	6.640	8.42	53.4
		4 min	12	6.149	2.4741	1.31	7.230	8.46	40.2
		5 min	12	6.790	2.4358	0.95	7.770	8.53	35.9
		6 min	12	6.350	2.5301	1.14	7.680	8.35	39.8
		7 min	12	7.085	1.8277	2.12	7.725	8.98	25.8
		8 min	12	6.689	2.3660	1.33	7.475	9.22	35.4
		9 min	12	7.435	0.7175	6.16	7.555	8.35	9.7
		10 min	12	6.839	1.9413	2.78	7.740	8.98	28.4
		11 min	12	6.528	2.3792	1.72	7.620	8.51	36.4
		12 min	12	6.237	2.7213	1.18	7.665	8.41	43.6
		13 min	12	6.392	2.4661	1.55	7.445	8.40	38.6
		14 min	12	5.968	2.5557	1.56	6.795	8.44	42.8
		15 min	12	5.578	2.8955	1.36	6.935	8.70	51.9
		16 min	12	5.274	3.1128	1.52	7.105	8.89	59.0
		17 min	12	5.215	3.1188	1.16	6.710	8.71	59.8
		18 min	12	5.163	3.1911	1.08	6.235	8.69	61.8
		19 min	12	5.023	3.1284	1.10	6.395	8.49	62.3
		20 min	12	4.859	3.2435	0.85	5.440	8.43	66.7
		21 min	11	5.144	3.1481	1.02	7.040	8.30	61.2
		22 min	10	4.706	3.1945	0.90	5.055	8.24	67.9
		23 min	10	4.740	3.2882	0.73	5.115	8.34	69.4
		24 min	10	4.679	3.2624	0.98	5.080	8.14	69.7
		25 min	10	4.456	3.1897	0.84	3.930	8.27	71.6
		26 min	10	4.523	3.2812	0.98	3.865	8.27	72.5
		27 min	10	4.123	3.3348	0.98	1.890	8.23	80.9
		28 min	10	4.164	3.2558	1.00	2.115	8.24	78.2
		29 min	10	4.047	3.3082	1.05	1.695	8.22	81.7
		30 min	10	4.004	3.2408	1.16	1.680	8.06	80.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 146 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	31 min	10	3.907	3.1503	1.08	1.710	8.02	80.6
		32 min	10	3.971	2.9392	1.17	2.530	7.93	74.0
		33 min	10	3.895	3.1698	1.12	1.720	8.06	81.4
		34 min	10	3.689	2.9989	1.05	1.745	8.01	81.3
		35 min	10	3.650	2.9032	1.00	1.765	7.74	79.5
		36 min	10	3.757	3.0878	0.91	1.705	7.86	82.2
		37 min	10	3.623	2.9634	0.95	1.580	7.99	81.8
		38 min	10	3.573	2.9072	0.86	1.610	7.90	81.4
		39 min	10	3.447	2.7110	1.03	1.540	7.40	78.6
		40 min	10	3.529	2.8575	0.88	1.545	7.62	81.0
		41 min	10	3.314	2.6921	1.00	1.655	7.93	81.2
		42 min	10	3.253	2.6061	0.96	1.885	7.89	80.1
		43 min	10	3.119	2.4675	0.86	1.900	7.55	79.1
		44 min	10	3.089	2.4211	1.00	1.770	7.52	78.4
		45 min	9	3.039	2.6537	0.94	1.510	7.68	87.3
		46 min	9	3.022	2.6934	0.76	1.510	7.78	89.1
		47 min	9	3.011	2.6360	1.09	1.530	7.60	87.5
		48 min	9	3.049	2.6612	0.74	1.580	7.74	87.3
		49 min	9	3.019	2.6593	0.97	1.630	7.58	88.1
		50 min	8	2.564	2.1851	1.08	1.515	7.47	85.2
		51 min	8	2.544	2.2516	0.99	1.515	7.45	88.5
		52 min	8	2.576	2.3864	1.01	1.480	7.64	92.6
		53 min	9	2.998	2.5131	0.91	1.520	7.76	83.8
		54 min	9	3.084	2.5400	1.04	1.520	7.46	82.3
		55 min	9	3.047	2.5997	0.79	1.580	7.62	85.3
		56 min	9	2.998	2.5328	1.02	1.560	7.67	84.5
		57 min	9	3.061	2.5349	1.10	1.550	7.66	82.8
		58 min	9	3.027	2.5636	0.92	1.540	7.67	84.7
		59 min	9	2.917	2.4247	1.08	1.560	7.33	83.1
		60 min	9	2.857	2.4106	1.06	1.570	7.22	84.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 147 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	61 min	9	2.989	2.4700	1.02	1.730	7.25	82.6
		62 min	9	3.013	2.4339	0.92	1.740	7.28	80.8
		63 min	8	3.366	2.6225	0.96	2.170	7.24	77.9
		64 min	8	3.676	2.7875	1.24	2.105	7.31	75.8
		65 min	8	3.679	2.8969	0.78	2.330	7.41	78.7
		66 min	8	3.671	2.8918	0.90	2.510	7.18	78.8
		67 min	8	2.981	2.5427	0.99	1.955	7.04	85.3
		68 min	8	3.138	2.6045	1.04	1.755	7.23	83.0
		69 min	8	3.111	2.5168	1.13	2.020	7.28	80.9
		70 min	8	2.900	2.5141	1.26	1.665	7.03	86.7
		71 min	8	2.921	2.3550	1.19	1.745	6.97	80.6
		72 min	8	2.800	2.5088	0.97	1.730	7.17	89.6
		73 min	8	2.780	2.6836	0.85	1.580	7.33	96.5
		74 min	8	2.973	2.3201	1.05	2.130	7.23	78.1
		75 min	8	2.565	2.4023	0.87	1.470	6.97	93.7
		76 min	8	2.573	2.4658	0.68	1.500	7.16	95.9
		77 min	8	2.674	2.3756	1.04	1.550	7.11	88.9
		78 min	8	2.558	2.2722	0.98	1.510	7.01	88.8
		79 min	8	2.424	2.2167	0.73	1.410	6.52	91.5
		80 min	8	2.396	2.1973	0.90	1.405	6.79	91.7
		81 min	8	2.445	2.2653	0.79	1.490	6.98	92.7
		82 min	8	2.370	2.3299	0.72	1.430	6.88	98.3
		83 min	8	2.723	2.2475	0.93	1.665	7.08	82.6
		84 min	8	2.838	2.3546	0.89	1.620	7.06	83.0
		85 min	8	2.894	2.2871	0.94	1.720	6.86	79.0
		86 min	8	3.368	2.6586	0.85	1.830	7.04	78.9
		87 min	8	2.993	2.3929	0.86	2.005	6.78	80.0
		88 min	8	2.749	2.2315	0.96	1.660	7.03	81.2
		89 min	8	2.929	2.3291	1.00	1.650	6.74	79.5
		90 min	8	3.539	2.4671	1.31	2.405	6.96	69.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 148 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	91 min	8	3.335	2.5079	1.35	2.355	7.51	75.2
		92 min	8	3.136	2.6465	1.17	1.780	7.71	84.4
		93 min	8	2.683	1.9546	1.27	1.705	6.83	72.9
		94 min	9	2.186	1.8383	0.11	1.670	6.67	84.1
		95 min	7	2.613	1.9098	1.29	1.730	6.77	73.1
		96 min	7	2.891	2.1215	1.23	1.680	6.86	73.4
		97 min	7	3.174	2.3906	1.39	1.670	6.87	75.3
		98 min	7	2.956	2.2020	1.26	1.620	6.48	74.5
		99 min	8	2.370	1.6560	1.34	1.775	6.34	69.9
		100 min	8	2.126	2.0841	0.10	1.655	7.06	98.0
		101 min	7	2.287	1.9043	1.37	1.670	6.59	83.3
		102 min	8	2.049	1.8902	0.09	1.680	6.52	92.3
		103 min	7	2.290	1.8609	1.19	1.700	6.47	81.3
		104 min	7	2.319	1.8771	1.41	1.730	6.56	81.0
		105 min	7	2.269	1.7013	1.45	1.690	6.12	75.0
		106 min	8	1.865	1.3628	0.14	1.700	4.95	73.1
		107 min	8	1.970	1.6836	0.20	1.715	5.92	85.5
		108 min	8	2.043	1.5843	0.53	1.670	5.83	77.6
		109 min	8	2.041	1.7083	0.37	1.630	6.11	83.7
		110 min	8	2.043	1.6592	0.35	1.655	5.98	81.2
		111 min	8	1.950	1.6663	0.46	1.590	5.94	85.5
		112 min	8	2.069	1.6506	0.58	1.620	6.04	79.8
		113 min	8	2.114	1.8446	0.55	1.615	6.58	87.3
		114 min	8	2.164	1.7901	0.61	1.675	6.49	82.7
		115 min	8	2.086	1.8107	0.43	1.640	6.44	86.8
		116 min	8	2.070	1.8789	0.25	1.620	6.55	90.8
		117 min	8	2.099	1.8763	0.46	1.605	6.61	89.4
		118 min	8	2.058	1.8994	0.37	1.635	6.61	92.3
		119 min	8	2.203	1.8648	0.79	1.675	6.74	84.7
		120 min	8	2.155	1.8571	0.64	1.620	6.65	86.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 149 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	121 min	8	2.211	1.7702	0.83	1.735	6.52	80.1
		122 min	8	2.231	1.8423	0.75	1.710	6.70	82.6
		123 min	8	2.188	1.8401	0.72	1.620	6.63	84.1
		124 min	8	2.130	1.8475	0.65	1.615	6.58	86.7
		125 min	8	2.136	1.8958	0.63	1.675	6.70	88.7
		126 min	8	2.121	1.8550	0.81	1.560	6.61	87.4
		127 min	8	2.108	1.9474	0.60	1.595	6.81	92.4
		128 min	8	2.143	2.0181	0.55	1.595	7.01	94.2
		129 min	8	2.136	1.9613	0.82	1.545	6.91	91.8
		130 min	8	2.091	1.9765	0.51	1.525	6.85	94.5
		131 min	8	2.100	1.9855	0.63	1.490	6.91	94.5
		132 min	8	2.159	2.0364	0.71	1.560	7.13	94.3
		133 min	8	2.103	2.0370	0.52	1.510	7.05	96.9
		134 min	8	2.090	2.0188	0.43	1.545	6.97	96.6
		135 min	8	2.108	2.0903	0.57	1.475	7.19	99.2
		136 min	8	2.081	1.9976	0.65	1.460	6.94	96.0
		137 min	8	2.079	2.1417	0.38	1.415	7.25	103.0
		138 min	8	2.090	2.0363	0.47	1.495	7.01	97.4
		139 min	8	2.084	2.0376	0.52	1.500	7.01	97.8
		140 min	8	2.154	2.2159	0.40	1.560	7.51	102.9
		141 min	8	2.095	2.1694	0.50	1.430	7.34	103.6
		142 min	8	2.521	2.2218	0.57	1.560	7.18	88.1
		143 min	8	2.204	2.0844	0.54	1.585	7.21	94.6
		144 min	8	2.723	2.3998	0.62	1.665	7.25	88.1
		145 min	8	2.141	2.1003	0.43	1.555	7.20	98.1
		146 min	8	2.084	2.1104	0.49	1.440	7.17	101.3
		147 min	8	2.131	2.1560	0.43	1.545	7.33	101.2
		148 min	8	2.109	2.1827	0.34	1.520	7.37	103.5
		149 min	8	2.085	2.1983	0.24	1.510	7.39	105.4
		150 min	8	2.116	2.2255	0.36	1.560	7.49	105.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 150 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	151 min	8	2.073	2.0745	0.25	1.575	7.04	100.1
		152 min	8	2.108	2.2403	0.20	1.550	7.49	106.3
		153 min	8	2.051	2.2718	0.12	1.480	7.50	110.8
		154 min	8	2.130	2.2119	0.24	1.580	7.46	103.8
		155 min	8	2.492	2.2932	0.36	1.715	7.38	92.0
		156 min	8	2.725	2.5206	0.33	1.790	7.50	92.5
		157 min	8	2.769	2.6104	0.34	1.695	7.47	94.3
		158 min	8	2.299	2.1515	0.30	1.685	7.28	93.6
		159 min	8	2.805	2.6978	0.17	1.790	7.18	96.2
		160 min	8	2.638	2.5321	0.21	1.680	7.61	96.0
		161 min	8	2.069	2.2938	0.25	1.505	7.58	110.9
		162 min	8	2.110	2.2937	0.26	1.570	7.62	108.7
		163 min	8	2.135	2.2769	0.21	1.595	7.61	106.6
		164 min	8	2.151	2.2608	0.25	1.580	7.60	105.1
		165 min	8	2.214	2.2517	0.21	1.645	7.62	101.7
		166 min	8	2.159	2.2740	0.24	1.565	7.63	105.3
		167 min	8	2.471	2.3028	0.53	1.655	7.72	93.2
		168 min	8	2.845	2.2064	1.21	1.920	7.80	77.6
		169 min	8	2.459	2.1930	0.57	1.770	7.65	89.2
		170 min	8	2.259	2.2517	0.50	1.570	7.73	99.7
		171 min	8	2.314	2.1925	0.52	1.770	7.62	94.8
		172 min	8	2.228	2.0970	0.34	1.650	7.25	94.1
		173 min	8	2.116	2.0191	0.23	1.570	6.94	95.4
		174 min	8	2.086	2.0778	0.24	1.615	7.04	99.6
		175 min	8	2.166	2.2453	0.16	1.580	7.51	103.6
		176 min	8	2.126	2.2359	0.15	1.510	7.47	105.2
		177 min	8	2.189	2.2517	0.27	1.570	7.58	102.9
		178 min	8	2.063	2.0908	0.09	1.490	7.02	101.4
		179 min	8	2.045	1.9310	0.08	1.510	6.56	94.4
		180 min	8	1.988	1.9613	0.03	1.575	6.57	98.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 151 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	181 min	8	2.105	2.0757	0.14	1.555	7.00	98.6
		182 min	7	1.383	0.6369	0.17	1.520	2.14	46.1
		183 min	7	1.301	0.6556	0.14	1.330	2.14	50.4
		184 min	7	1.367	0.6730	0.17	1.490	2.28	49.2
		185 min	7	1.324	0.6539	0.14	1.470	2.06	49.4
		186 min	7	1.394	0.6754	0.12	1.400	2.34	48.4
		187 min	7	1.360	0.6870	0.09	1.390	2.28	50.5
		188 min	7	1.357	0.6251	0.21	1.400	2.16	46.1
		189 min	8	2.090	2.0978	0.10	1.415	6.92	100.4
		190 min	8	2.014	2.0089	0.22	1.440	6.78	99.8
		191 min	8	2.025	1.8947	0.24	1.510	6.51	93.6
		192 min	8	2.033	2.0607	0.12	1.455	6.91	101.4
		193 min	8	2.016	1.9801	0.55	1.450	6.78	98.2
		194 min	8	2.030	1.9838	0.33	1.500	6.80	97.7
		195 min	8	2.020	1.9762	0.21	1.540	6.69	97.8
		196 min	8	2.010	1.9228	0.14	1.605	6.57	95.7
		197 min	9	1.930	1.7660	0.48	1.370	6.49	91.5
		198 min	9	1.926	1.8997	0.23	1.380	6.81	98.7
		199 min	9	1.941	1.8412	0.21	1.350	6.67	94.9
		200 min	9	2.042	1.8789	0.19	1.690	6.82	92.0
		201 min	9	2.288	2.1087	0.28	1.600	7.02	92.2
		202 min	10	2.190	1.9770	0.22	1.620	7.35	90.3
		203 min	10	2.151	1.8259	0.21	1.680	6.92	84.9
		204 min	9	2.230	1.9728	0.12	1.660	6.73	88.5
		205 min	8	2.476	1.8947	1.07	1.715	6.49	76.5
		206 min	8	2.825	2.4806	1.12	1.710	7.17	87.8
		207 min	7	2.970	2.6221	1.11	1.680	7.04	88.3
		208 min	7	2.999	2.5496	1.20	1.720	6.97	85.0
		209 min	7	2.907	2.4582	1.23	1.690	6.68	84.6
		210 min	7	2.753	2.3291	1.03	1.600	6.74	84.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 152 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	8	211 min	7	2.846	2.4200	1.17	1.550	6.92	85.0
		212 min	7	2.917	2.4767	1.13	1.610	6.85	84.9
		213 min	7	2.297	1.9992	1.18	1.590	6.77	87.0
		214 min	7	3.006	2.5195	1.21	1.730	6.79	83.8
		215 min	7	2.876	2.3725	1.19	1.690	6.56	82.5
		216 min	7	2.634	2.0945	1.13	1.560	6.53	79.5
		217 min	7	2.333	2.0777	1.34	1.640	7.02	89.1
		218 min	7	2.809	2.1239	1.34	1.840	6.99	75.6
		219 min	8	2.030	2.0099	0.05	1.575	6.80	99.0
		220 min	7	2.276	2.0950	1.28	1.460	7.01	92.1
		221 min	6	2.403	2.2731	1.24	1.530	7.03	94.6
		222 min	6	2.415	2.3233	1.28	1.535	7.15	96.2
		223 min	6	2.388	2.3502	1.13	1.520	7.17	98.4
		224 min	7	2.106	2.2617	0.10	1.410	7.08	107.4
		225 min	7	2.033	2.2372	0.07	1.420	6.96	110.1
		226 min	7	2.204	2.1462	0.78	1.590	7.02	97.4
		227 min	7	2.124	2.1693	0.83	1.380	7.00	102.1
		228 min	6	2.407	2.2232	1.37	1.575	6.94	92.4
		229 min	7	3.177	3.1143	1.01	1.560	8.37	98.0
		230 min	7	3.219	2.9316	1.34	1.600	8.07	91.1
		231 min	7	2.357	2.0060	1.19	1.630	6.78	85.1
		232 min	7	2.224	1.9496	1.21	1.540	6.63	87.6
		233 min	7	2.100	2.0808	0.69	1.380	6.75	99.1
		234 min	7	2.066	2.1188	0.36	1.420	6.75	102.6
		235 min	7	2.153	2.1198	0.41	1.500	6.84	98.5
		236 min	7	2.200	2.1483	0.45	1.430	6.84	97.7
		237 min	7	2.799	2.8920	0.43	1.440	7.19	103.3
		238 min	7	2.734	2.8518	0.42	1.310	6.98	104.3
		239 min	7	2.924	2.9724	0.45	1.330	7.74	101.6
		240 min	1	0.370		0.37	0.370	0.37	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 153 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	1 min	12	2.284	1.7795	1.23	1.595	6.67	77.9
		2 min	12	3.808	2.6624	1.21	2.360	7.89	69.9
		3 min	12	4.596	2.8208	1.48	3.935	8.50	61.4
		4 min	12	6.108	2.5565	1.30	7.290	8.35	41.9
		5 min	12	6.835	2.4351	1.49	7.575	8.67	35.6
		6 min	12	6.953	2.5029	1.29	7.930	9.02	36.0
		7 min	12	6.875	2.4782	1.27	7.800	8.63	36.0
		8 min	12	6.687	2.5241	0.91	7.570	8.77	37.7
		9 min	12	6.610	2.0934	2.17	7.355	8.53	31.7
		10 min	12	6.316	2.1673	2.76	7.390	8.36	34.3
		11 min	12	5.972	2.6251	1.27	7.275	8.50	44.0
		12 min	12	6.024	2.7078	1.03	7.370	8.56	44.9
		13 min	12	6.238	2.5408	1.55	7.090	8.99	40.7
		14 min	12	6.138	2.7382	1.21	7.135	8.96	44.6
		15 min	12	5.613	2.9459	1.53	7.420	8.61	52.5
		16 min	12	5.310	3.0994	1.62	6.940	8.64	58.4
		17 min	12	5.173	3.0332	1.14	6.620	8.48	58.6
		18 min	12	5.182	3.1476	1.02	6.525	8.41	60.7
		19 min	12	5.162	3.2200	0.99	6.580	8.49	62.4
		20 min	12	5.064	3.2697	0.88	6.155	8.53	64.6
		21 min	11	5.301	3.1421	1.02	7.530	8.31	59.3
		22 min	10	4.837	3.3567	0.87	5.240	8.41	69.4
		23 min	10	4.830	3.4051	0.80	5.050	8.40	70.5
		24 min	10	4.671	3.3763	0.98	4.730	8.37	72.3
		25 min	10	4.657	3.4597	0.90	4.605	8.38	74.3
		26 min	10	4.604	3.3306	0.95	4.105	8.36	72.3
		27 min	10	4.593	3.3447	0.98	4.055	8.37	72.8
		28 min	10	4.296	3.3446	0.90	2.440	8.30	77.9
		29 min	10	4.156	3.3284	1.06	2.095	8.18	80.1
		30 min	10	4.149	3.3024	1.05	2.055	8.24	79.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 154 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	31 min	10	3.998	3.2202	0.97	1.830	7.93	80.5
		32 min	10	3.914	3.1862	1.02	1.725	8.03	81.4
		33 min	10	3.906	3.2122	1.12	1.725	7.91	82.2
		34 min	10	3.672	2.9610	1.00	1.690	7.73	80.6
		35 min	10	3.719	2.9507	1.09	1.755	7.74	79.3
		36 min	10	3.797	3.1182	0.99	1.655	7.73	82.1
		37 min	10	3.629	2.9168	1.00	1.620	7.64	80.4
		38 min	10	3.683	3.0130	0.95	1.695	7.75	81.8
		39 min	10	3.492	2.6565	1.15	1.660	7.52	76.1
		40 min	10	3.628	2.8356	0.93	1.840	7.53	78.2
		41 min	10	3.652	2.8536	1.05	1.945	7.72	78.1
		42 min	10	3.388	2.7266	1.05	2.080	7.84	80.5
		43 min	10	3.205	2.5194	0.94	2.025	7.46	78.6
		44 min	10	3.222	2.5838	1.02	1.905	7.47	80.2
		45 min	9	2.961	2.5376	1.12	1.600	7.49	85.7
		46 min	9	2.922	2.6232	0.73	1.610	7.48	89.8
		47 min	9	2.897	2.5968	0.91	1.630	7.43	89.6
		48 min	9	2.987	2.5638	0.94	1.670	7.44	85.8
		49 min	9	2.986	2.5239	1.24	1.600	7.38	84.5
		50 min	8	2.446	2.1256	1.01	1.605	7.39	86.9
		51 min	8	2.500	2.1689	1.01	1.680	7.52	86.8
		52 min	8	2.451	2.2449	0.99	1.520	7.63	91.6
		53 min	9	2.913	2.4734	0.89	1.640	7.75	84.9
		54 min	9	2.956	2.4227	1.01	1.630	7.33	82.0
		55 min	9	2.820	2.2704	1.10	1.630	7.54	80.5
		56 min	9	2.752	2.2963	1.05	1.640	7.55	83.4
		57 min	9	2.817	2.1963	1.15	1.640	7.41	78.0
		58 min	9	2.808	2.2566	1.04	1.660	7.52	80.4
		59 min	9	2.710	2.0858	1.11	1.650	7.35	77.0
		60 min	9	2.811	2.2100	0.96	1.690	7.41	78.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 155 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	61 min	9	3.046	2.2056	1.07	1.780	7.38	72.4
		62 min	9	3.344	2.4903	1.17	1.730	7.44	74.5
		63 min	8	3.434	2.7362	0.96	2.250	7.69	79.7
		64 min	8	3.464	2.8490	1.10	2.200	8.26	82.3
		65 min	8	3.333	2.6608	0.70	2.330	7.33	79.8
		66 min	8	3.283	2.6359	0.86	2.190	7.22	80.3
		67 min	8	3.095	2.4000	0.97	2.005	7.18	77.5
		68 min	8	2.794	2.1774	1.05	1.960	7.16	77.9
		69 min	8	2.941	2.1387	1.12	2.155	7.11	72.7
		70 min	8	3.003	2.2032	1.15	1.785	6.88	73.4
		71 min	8	2.718	2.1000	0.90	1.940	6.93	77.3
		72 min	8	2.598	2.1632	0.91	1.775	7.08	83.3
		73 min	8	2.590	2.2307	0.93	1.730	7.16	86.1
		74 min	8	2.601	2.2672	1.03	1.590	7.07	87.2
		75 min	8	2.484	2.3087	0.76	1.545	7.06	93.0
		76 min	8	2.498	2.2661	0.85	1.505	7.04	90.7
		77 min	8	2.569	2.2640	0.88	1.650	7.10	88.1
		78 min	8	2.304	2.0029	1.02	1.605	7.02	86.9
		79 min	8	2.171	1.9989	0.77	1.425	6.86	92.1
		80 min	8	2.235	2.0115	0.83	1.550	6.92	90.0
		81 min	8	2.195	1.9881	0.77	1.545	6.90	90.6
		82 min	8	2.135	2.0278	0.82	1.515	6.90	95.0
		83 min	8	2.205	1.8924	0.97	1.530	6.65	85.8
		84 min	8	2.666	2.1420	0.96	1.680	6.89	80.3
		85 min	8	2.690	2.2304	0.95	1.545	6.96	82.9
		86 min	8	2.969	2.5058	0.98	1.650	7.01	84.4
		87 min	8	3.304	2.5123	0.85	2.050	6.86	76.0
		88 min	8	2.140	1.9751	0.97	1.440	6.87	92.3
		89 min	8	2.228	1.9146	1.20	1.410	6.83	86.0
		90 min	8	2.965	2.2584	1.36	1.785	6.99	76.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 156 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	91 min	8	2.888	2.5023	1.02	1.580	6.90	86.7
		92 min	8	2.458	1.9508	1.14	1.545	6.82	79.4
		93 min	8	2.683	2.1291	1.07	1.565	6.74	79.4
		94 min	8	2.333	1.8111	1.38	1.530	6.72	77.6
		95 min	7	2.354	1.9959	1.15	1.690	6.78	84.8
		96 min	7	2.249	2.0662	1.01	1.540	6.80	91.9
		97 min	7	2.350	2.0736	1.21	1.540	6.97	88.2
		98 min	7	2.159	1.8596	1.17	1.220	6.23	86.2
		99 min	8	2.200	1.5996	1.34	1.565	6.04	72.7
		100 min	8	1.833	1.6375	0.05	1.535	5.66	89.4
		101 min	8	1.918	1.8979	0.06	1.445	6.43	99.0
		102 min	8	1.995	1.9150	0.14	1.505	6.55	96.0
		103 min	8	1.953	1.8479	0.02	1.570	6.28	94.6
		104 min	8	1.941	1.8860	0.09	1.495	6.42	97.2
		105 min	8	1.626	0.8934	0.03	1.605	3.35	54.9
		106 min	8	1.958	1.5530	0.38	1.580	5.61	79.3
		107 min	8	2.338	1.7019	0.38	1.720	5.28	72.8
		108 min	8	2.118	1.5762	1.11	1.585	5.95	74.4
		109 min	8	2.119	1.7546	0.59	1.615	6.34	82.8
		110 min	8	2.109	1.8568	0.47	1.625	6.58	88.1
		111 min	8	2.098	1.8821	0.39	1.630	6.58	89.7
		112 min	8	2.080	1.8771	0.63	1.590	6.63	90.2
		113 min	8	2.089	1.8924	0.62	1.605	6.69	90.6
		114 min	8	2.171	1.8312	0.64	1.640	6.58	84.3
		115 min	8	2.140	1.7981	0.56	1.595	6.46	84.0
		116 min	8	2.099	1.8143	0.41	1.630	6.43	86.4
		117 min	8	2.135	1.8600	0.49	1.650	6.61	87.1
		118 min	8	2.046	1.8827	0.59	1.575	6.59	92.0
		119 min	8	2.193	1.8262	0.75	1.630	6.62	83.3
		120 min	8	2.184	1.8318	0.62	1.705	6.60	83.9

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 157 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	121 min	8	2.438	1.8241	0.68	1.730	6.50	74.8
		122 min	8	2.281	1.8025	0.52	1.700	6.51	79.0
		123 min	8	2.378	1.8347	0.65	1.780	6.68	77.2
		124 min	8	2.135	1.8993	0.56	1.550	6.68	89.0
		125 min	8	2.060	1.8824	0.60	1.560	6.63	91.4
		126 min	8	2.090	1.8725	0.73	1.470	6.62	89.6
		127 min	8	2.158	1.9130	0.70	1.620	6.75	88.7
		128 min	8	2.135	1.9889	0.60	1.565	6.91	93.2
		129 min	8	2.130	1.9265	0.61	1.605	6.75	90.4
		130 min	8	2.081	2.0380	0.25	1.505	6.91	97.9
		131 min	8	2.455	2.2576	0.12	1.595	6.96	92.0
		132 min	8	2.609	2.4876	0.36	1.550	7.16	95.4
		133 min	8	2.153	2.0472	0.57	1.585	7.11	95.1
		134 min	8	2.126	2.0461	0.48	1.515	7.06	96.2
		135 min	8	2.116	2.1034	0.48	1.460	7.19	99.4
		136 min	8	2.125	2.0545	0.55	1.430	7.06	96.7
		137 min	8	2.215	1.9995	1.13	1.470	7.09	90.3
		138 min	8	2.110	2.0328	0.61	1.590	7.02	96.3
		139 min	8	2.084	2.0886	0.51	1.500	7.13	100.2
		140 min	8	2.215	2.2504	0.57	1.535	7.68	101.6
		141 min	8	2.124	2.0852	0.67	1.440	7.20	98.2
		142 min	8	2.223	2.0517	0.67	1.635	7.19	92.3
		143 min	8	2.104	2.1156	0.44	1.520	7.21	100.6
		144 min	8	2.735	2.4718	0.56	1.695	7.21	90.4
		145 min	8	2.164	2.1195	0.45	1.540	7.26	98.0
		146 min	8	2.648	2.4891	0.54	1.425	7.24	94.0
		147 min	8	2.229	2.1384	0.52	1.630	7.36	95.9
		148 min	8	2.669	2.5542	0.36	1.525	7.37	95.7
		149 min	8	2.125	2.1760	0.38	1.445	7.37	102.4
		150 min	8	2.119	2.1975	0.47	1.505	7.43	103.7

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 158 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	151 min	8	2.109	2.2508	0.36	1.485	7.54	106.7
		152 min	8	2.121	2.2565	0.34	1.475	7.56	106.4
		153 min	8	2.068	2.2893	0.23	1.465	7.57	110.7
		154 min	8	2.748	2.6918	0.18	1.525	7.40	98.0
		155 min	8	2.814	2.8032	0.38	1.555	7.47	99.6
		156 min	8	2.769	2.7313	0.35	1.490	7.44	98.6
		157 min	8	2.779	2.6818	0.34	1.600	7.45	96.5
		158 min	8	2.839	2.8075	0.51	1.515	7.45	98.9
		159 min	8	2.874	2.7619	0.43	1.655	7.32	96.1
		160 min	8	2.870	2.8619	0.20	1.660	7.75	99.7
		161 min	8	2.100	2.3031	0.35	1.500	7.65	109.7
		162 min	8	2.161	2.2595	0.63	1.525	7.64	104.5
		163 min	8	2.494	2.2390	0.72	1.625	7.70	89.8
		164 min	8	2.531	2.2139	0.52	1.635	7.37	87.5
		165 min	8	2.399	2.2066	0.35	1.705	7.56	92.0
		166 min	8	2.466	1.9301	1.47	1.755	7.16	78.3
		167 min	8	2.990	2.6367	0.93	1.830	7.80	88.2
		168 min	8	3.479	2.6104	1.28	1.955	7.55	75.0
		169 min	8	3.549	2.6536	1.47	1.830	7.74	74.8
		170 min	8	2.886	2.6168	0.52	1.780	7.79	90.7
		171 min	8	2.649	2.1749	0.93	1.740	7.20	82.1
		172 min	8	2.394	2.0815	0.52	1.780	7.22	87.0
		173 min	8	2.298	2.0846	0.31	1.740	7.17	90.7
		174 min	8	2.124	2.1881	0.27	1.560	7.34	103.0
		175 min	8	2.164	2.2252	0.27	1.515	7.49	102.8
		176 min	8	2.125	2.0886	0.28	1.550	7.11	98.3
		177 min	8	2.073	2.1110	0.30	1.470	7.13	101.9
		178 min	8	2.146	2.1589	0.14	1.545	7.28	100.6
		179 min	8	2.123	2.1392	0.18	1.485	7.22	100.8
		180 min	8	2.046	2.1244	0.12	1.550	7.06	103.8

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 159 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	181 min	8	2.058	2.1528	0.13	1.465	7.21	104.6
		182 min	7	1.387	0.6103	0.21	1.440	2.04	44.0
		183 min	7	1.293	0.6611	0.09	1.230	2.06	51.1
		184 min	7	1.336	0.6447	0.11	1.280	2.07	48.3
		185 min	7	1.327	0.6702	0.14	1.430	2.07	50.5
		186 min	7	1.587	0.7801	0.22	1.560	2.68	49.1
		187 min	7	1.347	0.6387	0.15	1.320	2.06	47.4
		188 min	7	1.936	1.5900	0.17	1.550	5.27	82.1
		189 min	8	1.980	2.0387	0.12	1.460	6.80	103.0
		190 min	8	2.010	2.0049	0.24	1.370	6.77	99.7
		191 min	8	2.060	1.9661	0.09	1.630	6.70	95.4
		192 min	8	2.098	2.0006	0.13	1.745	6.77	95.4
		193 min	8	2.088	1.9783	0.88	1.435	6.88	94.8
		194 min	8	2.333	2.0523	0.35	1.810	6.84	88.0
		195 min	8	2.705	2.6032	0.20	1.700	6.84	96.2
		196 min	8	2.584	2.3889	0.16	1.665	6.77	92.5
		197 min	9	2.242	1.9724	0.44	1.770	6.66	88.0
		198 min	9	1.933	1.9581	0.24	1.310	6.98	101.3
		199 min	9	2.441	2.1976	0.32	1.650	6.91	90.0
		200 min	9	2.094	1.8798	0.48	1.550	6.86	89.8
		201 min	9	2.516	2.3561	0.47	1.530	6.83	93.7
		202 min	10	3.046	2.6619	0.27	1.740	7.01	87.4
		203 min	10	3.069	2.6271	0.37	1.795	7.14	85.6
		204 min	9	2.574	2.5039	0.17	1.540	7.08	97.3
		205 min	9	2.572	2.5050	0.02	1.640	7.22	97.4
		206 min	9	2.509	2.4488	0.14	1.660	7.09	97.6
		207 min	8	2.644	2.6965	0.09	1.490	7.11	102.0
		208 min	7	2.999	2.5406	1.25	1.710	6.93	84.7
		209 min	7	2.856	2.3529	1.22	1.700	6.53	82.4
		210 min	7	2.846	2.3963	1.16	1.650	6.69	84.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 160 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	9	211 min	7	2.950	2.5366	1.16	1.620	6.79	86.0
		212 min	7	2.933	2.5029	1.20	1.610	6.93	85.3
		213 min	7	2.969	2.5304	1.24	1.600	6.70	85.2
		214 min	7	3.003	2.5813	1.16	1.620	6.93	86.0
		215 min	7	2.909	2.5178	1.13	1.580	6.57	86.6
		216 min	7	2.960	2.4949	1.17	1.550	6.77	84.3
		217 min	7	3.453	2.6020	1.29	1.760	7.13	75.4
		218 min	8	2.900	2.7231	0.04	1.640	7.34	93.9
		219 min	7	2.976	2.6824	1.11	1.480	6.91	90.1
		220 min	7	2.701	2.1850	1.23	1.590	6.71	80.9
		221 min	7	2.640	2.5272	0.09	1.600	6.79	95.7
		222 min	7	2.804	2.6797	0.32	1.580	7.30	95.6
		223 min	7	2.471	2.3522	0.19	1.550	7.13	95.2
		224 min	7	2.087	2.2050	0.53	1.320	7.00	105.6
		225 min	7	3.181	3.1271	1.10	1.590	8.68	98.3
		226 min	7	3.770	3.0247	1.31	1.610	8.61	80.2
		227 min	7	3.323	3.1309	1.25	1.620	8.73	94.2
		228 min	7	3.620	3.0456	1.31	1.630	8.85	84.1
		229 min	7	3.093	2.9919	1.01	1.500	7.94	96.7
		230 min	7	3.356	2.3895	1.33	1.740	6.90	71.2
		231 min	7	2.484	2.0925	1.20	1.540	6.91	84.2
		232 min	7	2.901	2.7111	0.58	1.590	6.95	93.4
		233 min	7	3.334	2.6856	0.51	1.670	6.93	80.5
		234 min	7	2.107	2.1512	0.40	1.420	6.83	102.1
		235 min	7	2.841	2.4979	0.31	1.610	6.83	87.9
		236 min	7	2.850	2.8428	0.37	1.350	7.08	99.7
		237 min	7	2.853	3.0431	0.29	1.380	7.62	106.7
		238 min	7	2.814	2.9784	0.39	1.390	7.60	105.8
		239 min	7	2.939	3.0126	0.40	1.370	7.87	102.5
		240 min	1	0.330		0.33	0.330	0.33	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 161 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	1 min	12	2.011	1.4520	1.23	1.615	6.52	72.2
		2 min	12	3.475	2.6145	1.29	1.895	7.35	75.2
		3 min	12	4.951	3.0406	1.23	5.525	8.39	61.4
		4 min	12	6.035	2.7347	1.37	7.030	9.06	45.3
		5 min	12	6.813	2.5056	1.11	7.740	9.04	36.8
		6 min	12	6.951	2.5289	1.26	7.750	9.20	36.4
		7 min	12	6.968	2.6068	1.00	7.855	9.25	37.4
		8 min	12	6.793	2.6839	0.72	7.820	9.24	39.5
		9 min	12	6.764	2.3905	1.50	7.675	8.88	35.3
		10 min	12	6.048	2.7304	1.47	7.710	8.42	45.1
		11 min	12	6.301	2.6706	1.10	7.510	8.59	42.4
		12 min	12	6.370	2.5778	1.19	7.330	9.10	40.5
		13 min	12	6.450	2.5434	1.16	7.250	9.53	39.4
		14 min	12	6.247	2.8596	0.93	7.420	9.30	45.8
		15 min	12	5.852	2.8929	1.35	7.260	8.90	49.4
		16 min	12	5.327	3.1506	1.50	6.880	8.70	59.1
		17 min	12	5.363	3.2341	0.98	6.795	9.38	60.3
		18 min	12	5.423	3.2418	1.01	6.775	9.33	59.8
		19 min	12	5.256	3.3176	1.04	6.755	9.34	63.1
		20 min	12	5.232	3.3083	0.95	6.570	9.38	63.2
		21 min	11	5.415	3.2594	1.01	7.580	8.97	60.2
		22 min	10	4.942	3.2407	0.96	6.065	8.30	65.6
		23 min	10	4.916	3.2567	1.12	5.625	8.39	66.2
		24 min	10	4.706	3.3116	1.08	4.930	8.24	70.4
		25 min	10	4.538	3.4113	0.82	4.045	8.30	75.2
		26 min	10	4.600	3.3626	0.89	4.125	8.38	73.1
		27 min	10	4.286	3.3066	0.96	2.670	8.21	77.1
		28 min	10	4.233	3.2764	1.10	2.360	8.30	77.4
		29 min	10	4.393	3.2945	1.08	3.250	8.29	75.0
		30 min	10	4.350	3.2680	1.10	3.010	8.24	75.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 162 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	31 min	10	4.093	3.3203	0.98	1.880	8.25	81.1
		32 min	10	3.971	3.2420	1.09	1.845	8.22	81.6
		33 min	10	3.904	3.2214	1.21	1.640	8.10	82.5
		34 min	10	3.772	2.9834	1.15	1.820	7.71	79.1
		35 min	10	3.380	2.6721	1.03	1.745	7.68	79.1
		36 min	10	3.827	3.1378	1.04	1.710	7.74	82.0
		37 min	10	3.755	3.0787	0.99	1.620	7.62	82.0
		38 min	10	3.671	3.0201	0.86	1.635	7.67	82.3
		39 min	10	3.655	2.7154	1.30	1.790	7.57	74.3
		40 min	10	3.595	2.8023	1.00	1.835	7.61	78.0
		41 min	10	3.669	2.8187	1.16	1.995	7.69	76.8
		42 min	10	3.396	2.7095	1.06	2.095	7.68	79.8
		43 min	10	3.266	2.5976	1.01	2.030	7.57	79.5
		44 min	10	3.213	2.6424	0.96	1.765	7.62	82.2
		45 min	9	3.064	2.3888	1.36	2.160	7.49	78.0
		46 min	9	2.908	2.5996	0.86	1.560	7.55	89.4
		47 min	9	2.960	2.4646	1.01	1.940	7.56	83.3
		48 min	9	3.034	2.6057	0.92	1.810	7.59	85.9
		49 min	9	3.004	2.5282	1.12	1.580	7.52	84.1
		50 min	8	2.506	2.1737	1.25	1.585	7.61	86.7
		51 min	8	2.468	2.2419	1.02	1.500	7.65	90.9
		52 min	8	2.534	2.2401	0.93	1.680	7.70	88.4
		53 min	9	3.090	2.4910	0.89	1.650	7.69	80.6
		54 min	9	2.993	2.3223	1.26	1.680	7.53	77.6
		55 min	9	2.947	2.3903	1.12	1.580	7.74	81.1
		56 min	9	2.921	2.2838	1.06	1.710	7.71	78.2
		57 min	9	3.039	2.1820	1.19	1.700	7.59	71.8
		58 min	9	2.679	2.0317	1.26	1.680	7.52	75.8
		59 min	9	2.909	2.1445	1.43	1.710	7.58	73.7
		60 min	9	2.731	2.0837	1.00	1.690	7.49	76.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 163 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	61 min	9	2.983	2.1566	1.12	1.660	7.43	72.3
		62 min	9	3.079	2.3642	1.10	1.730	7.26	76.8
		63 min	8	3.148	2.5957	1.02	1.775	7.17	82.5
		64 min	8	4.015	2.9116	1.21	2.730	8.10	72.5
		65 min	8	3.298	2.9000	0.70	2.195	8.38	87.9
		66 min	8	3.108	2.8290	0.80	1.780	8.03	91.0
		67 min	8	2.946	2.5713	1.09	1.685	7.14	87.3
		68 min	8	3.094	2.2488	1.27	2.130	7.09	72.7
		69 min	8	3.205	2.5406	1.21	2.160	7.43	79.3
		70 min	8	3.079	2.6933	0.77	1.730	7.62	87.5
		71 min	8	3.090	2.7583	0.88	1.560	7.78	89.3
		72 min	8	3.171	2.4744	1.08	2.050	7.08	78.0
		73 min	8	2.998	2.8030	0.77	1.755	7.62	93.5
		74 min	8	2.811	2.4341	0.68	1.550	7.17	86.6
		75 min	8	2.209	2.0441	0.85	1.515	7.04	92.5
		76 min	8	2.211	2.0618	0.87	1.400	7.14	93.2
		77 min	8	2.305	2.0098	1.00	1.525	7.11	87.2
		78 min	8	2.334	1.9961	1.01	1.470	7.05	85.5
		79 min	8	2.150	1.9570	1.05	1.370	6.86	91.0
		80 min	8	2.220	2.0207	1.01	1.460	7.07	91.0
		81 min	8	2.175	2.0207	0.98	1.475	7.05	92.9
		82 min	8	2.051	2.0634	0.69	1.410	6.99	100.6
		83 min	8	2.333	1.9198	1.32	1.660	7.03	82.3
		84 min	8	2.495	2.0001	0.94	1.655	6.94	80.2
		85 min	8	2.244	1.9263	0.97	1.585	6.89	85.9
		86 min	8	2.301	1.8850	1.06	1.630	6.83	81.9
		87 min	8	3.433	2.7295	0.85	2.035	7.39	79.5
		88 min	8	2.505	1.9726	1.05	1.545	6.64	78.7
		89 min	9	2.492	1.9618	0.29	1.730	6.77	78.7
		90 min	8	3.700	2.8357	1.34	2.145	7.86	76.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 164 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	91 min	8	3.751	2.7554	0.92	2.390	7.73	73.5
		92 min	8	3.371	2.5502	1.14	2.010	6.70	75.6
		93 min	8	3.209	2.4807	0.96	2.000	6.77	77.3
		94 min	8	2.898	2.3230	1.15	1.945	6.74	80.2
		95 min	7	3.113	2.4302	1.06	1.870	7.17	78.1
		96 min	7	2.899	2.3708	0.99	1.750	7.17	81.8
		97 min	7	2.913	2.3377	1.26	1.570	7.12	80.3
		98 min	7	2.786	2.1795	1.15	1.600	6.24	78.2
		99 min	9	2.494	2.2672	0.02	1.700	6.51	90.9
		100 min	7	2.870	2.2761	1.16	1.730	6.42	79.3
		101 min	7	2.847	2.1369	1.27	1.730	6.39	75.1
		102 min	8	2.299	1.9033	0.22	1.855	6.48	82.8
		103 min	8	2.298	1.9263	0.21	1.890	6.37	83.8
		104 min	8	2.100	1.8386	0.43	1.725	6.43	87.6
		105 min	8	2.084	1.6558	0.69	1.770	6.05	79.5
		106 min	8	2.180	1.7826	0.29	1.880	6.37	81.8
		107 min	8	2.018	1.6134	0.48	1.770	5.74	80.0
		108 min	8	2.358	1.4690	1.16	1.895	5.80	62.3
		109 min	8	2.223	1.7608	0.67	1.690	6.42	79.2
		110 min	8	2.651	2.2061	0.46	1.745	6.36	83.2
		111 min	8	2.093	1.8391	0.36	1.620	6.45	87.9
		112 min	8	2.100	1.8574	0.57	1.600	6.59	88.4
		113 min	8	2.204	1.8134	1.09	1.625	6.65	82.3
		114 min	8	2.146	1.7451	0.79	1.630	6.37	81.3
		115 min	8	2.148	1.8029	0.68	1.700	6.51	84.0
		116 min	8	2.113	1.8675	0.37	1.660	6.55	88.4
		117 min	8	2.754	2.3745	0.42	1.770	6.58	86.2
		118 min	8	2.021	1.7478	0.50	1.600	6.21	86.5
		119 min	8	2.508	2.0248	0.64	1.605	6.32	80.7
		120 min	8	2.803	2.5805	0.60	1.670	7.20	92.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 165 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	121 min	8	2.818	2.4871	0.67	1.630	6.88	88.3
		122 min	8	2.825	2.4939	0.65	1.645	6.88	88.3
		123 min	8	2.778	2.3739	0.67	1.745	6.77	85.5
		124 min	8	2.658	2.3630	0.66	1.620	6.65	88.9
		125 min	8	2.155	1.8729	0.61	1.595	6.67	86.9
		126 min	8	2.170	1.8001	0.62	1.685	6.45	83.0
		127 min	8	2.231	1.9267	0.67	1.660	6.79	86.3
		128 min	8	2.198	2.0276	0.59	1.660	6.96	92.3
		129 min	8	2.199	1.9921	0.61	1.590	6.85	90.6
		130 min	8	2.139	2.0301	0.28	1.605	6.92	94.9
		131 min	8	3.125	2.5916	0.47	1.665	6.96	82.9
		132 min	8	2.500	2.5473	0.06	1.575	7.14	101.9
		133 min	8	2.408	2.1752	0.35	1.615	7.04	90.4
		134 min	8	2.513	2.2661	0.34	1.605	7.05	90.2
		135 min	8	2.401	2.2611	0.36	1.465	7.09	94.2
		136 min	8	2.670	2.3952	0.71	1.620	7.02	89.7
		137 min	8	3.078	2.4974	1.08	1.645	7.06	81.1
		138 min	8	2.524	2.1805	0.83	1.630	7.13	86.4
		139 min	8	2.388	2.2274	0.58	1.445	7.18	93.3
		140 min	8	2.464	2.3056	0.59	1.615	7.69	93.6
		141 min	8	2.845	2.4974	0.74	1.570	7.26	87.8
		142 min	8	2.898	2.5789	0.65	1.545	7.19	89.0
		143 min	8	2.881	2.5833	0.52	1.870	7.13	89.7
		144 min	8	2.838	2.4819	0.76	1.825	7.21	87.5
		145 min	8	2.235	2.0965	0.39	1.595	7.19	93.8
		146 min	8	2.734	2.2212	0.48	2.020	7.14	81.3
		147 min	8	3.085	2.5376	0.58	2.285	7.29	82.3
		148 min	8	2.865	2.6446	0.50	1.605	7.25	92.3
		149 min	8	2.351	2.1735	0.43	1.530	7.27	92.4
		150 min	8	2.080	2.1484	0.57	1.410	7.20	103.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 166 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	151 min	8	2.019	2.1627	0.33	1.345	7.23	107.1
		152 min	8	2.278	2.1652	0.34	1.585	7.31	95.1
		153 min	8	1.971	2.2168	0.21	1.320	7.29	112.5
		154 min	8	2.745	2.5606	0.90	1.465	7.29	93.3
		155 min	8	2.816	2.7336	0.62	1.545	7.26	97.1
		156 min	8	2.880	2.6062	0.44	1.740	7.22	90.5
		157 min	8	2.835	2.6411	0.50	1.705	7.40	93.2
		158 min	8	2.763	2.7435	0.54	1.525	7.26	99.3
		159 min	8	2.859	2.5955	1.07	1.545	7.13	90.8
		160 min	8	2.808	2.7251	0.24	1.655	7.55	97.1
		161 min	8	2.009	2.2802	0.36	1.450	7.51	113.5
		162 min	8	2.234	2.1577	1.05	1.605	7.53	96.6
		163 min	8	2.256	2.1515	0.97	1.685	7.51	95.4
		164 min	8	2.134	2.2008	0.57	1.520	7.46	103.1
		165 min	8	2.324	2.1567	0.17	1.705	7.39	92.8
		166 min	8	2.900	2.2274	1.24	1.895	7.49	76.8
		167 min	8	3.540	2.7338	1.16	1.855	7.58	77.2
		168 min	8	3.861	2.9977	1.36	1.920	7.79	77.6
		169 min	8	3.905	2.8614	1.41	2.180	7.58	73.3
		170 min	8	2.300	2.1533	1.25	1.575	7.60	93.6
		171 min	8	2.915	2.2731	1.36	1.835	7.53	78.0
		172 min	8	2.673	2.3145	0.39	1.865	7.51	86.6
		173 min	8	2.678	2.3768	0.49	1.720	7.47	88.8
		174 min	8	2.140	2.1876	0.37	1.525	7.39	102.2
		175 min	8	2.164	2.1464	0.66	1.450	7.36	99.2
		176 min	8	2.213	2.2128	0.29	1.555	7.52	100.0
		177 min	8	2.113	2.2216	0.58	1.510	7.48	105.2
		178 min	8	2.191	2.1458	0.56	1.510	7.37	97.9
		179 min	8	2.251	2.1882	0.20	1.755	7.43	97.2
		180 min	8	2.129	2.2169	0.11	1.565	7.35	104.1

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 167 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	181 min	8	2.049	2.2465	0.29	1.345	7.49	109.7
		182 min	7	1.301	0.5445	0.21	1.390	1.96	41.8
		183 min	7	1.291	0.6131	0.17	1.260	2.07	47.5
		184 min	7	1.354	0.6340	0.15	1.400	2.17	46.8
		185 min	7	1.239	0.6708	0.16	1.460	2.17	54.2
		186 min	7	1.923	1.6620	0.10	1.600	5.44	86.4
		187 min	7	1.863	1.0912	0.04	1.720	3.22	58.6
		188 min	7	2.060	1.4262	0.19	1.830	4.93	69.2
		189 min	8	1.913	2.0865	0.08	1.360	6.85	109.1
		190 min	8	2.564	2.4489	0.29	1.460	6.85	95.5
		191 min	8	1.958	2.0301	0.00	1.515	6.76	103.7
		192 min	8	2.590	2.6176	0.06	1.575	6.75	101.1
		193 min	8	1.906	1.9454	0.56	1.395	6.59	102.1
		194 min	8	2.081	1.9835	0.26	1.700	6.81	95.3
		195 min	8	2.543	2.4818	0.16	1.765	6.70	97.6
		196 min	8	2.681	2.6024	0.12	1.765	6.91	97.1
		197 min	9	2.719	2.3991	0.45	1.800	7.01	88.2
		198 min	9	1.921	1.8275	0.26	1.420	6.63	95.1
		199 min	9	2.354	2.1458	0.30	1.650	6.85	91.1
		200 min	9	2.110	1.7306	1.28	1.620	6.70	82.0
		201 min	9	2.532	2.5690	0.50	1.290	7.23	101.5
		202 min	10	2.941	2.6242	0.23	1.665	6.91	89.2
		203 min	10	3.115	2.8191	0.37	1.655	7.45	90.5
		204 min	9	2.610	2.4603	0.45	1.720	7.06	94.3
		205 min	9	2.482	2.5350	0.03	1.570	6.89	102.1
		206 min	9	2.484	2.4386	0.13	1.700	6.77	98.2
		207 min	8	2.554	2.5825	0.29	1.490	6.74	101.1
		208 min	7	2.851	2.5091	1.13	1.400	6.54	88.0
		209 min	7	2.831	2.4182	1.12	1.670	6.52	85.4
		210 min	7	2.807	2.5166	1.03	1.620	6.88	89.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 168 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	10	211 min	7	2.851	2.4786	1.27	1.450	6.71	86.9
		212 min	7	2.864	2.5253	1.13	1.640	6.99	88.2
		213 min	7	2.881	2.5001	1.02	1.730	6.87	86.8
		214 min	7	3.091	2.4554	1.23	1.710	6.76	79.4
		215 min	7	3.366	2.4265	1.24	1.750	6.86	72.1
		216 min	7	2.920	2.4229	1.25	1.570	6.90	83.0
		217 min	7	3.659	2.7078	1.41	1.660	6.97	74.0
		218 min	7	3.341	2.5792	1.16	1.790	7.18	77.2
		219 min	7	2.994	2.7429	0.99	1.690	7.26	91.6
		220 min	7	2.360	2.0385	0.96	1.680	6.81	86.4
		221 min	7	1.950	2.1665	0.20	1.440	6.74	111.1
		222 min	7	2.763	2.7062	0.43	1.570	6.86	97.9
		223 min	7	2.781	2.5176	0.96	1.430	6.86	90.5
		224 min	7	3.214	3.1263	0.89	1.620	8.73	97.3
		225 min	7	3.244	3.3519	1.02	1.570	9.29	103.3
		226 min	7	3.879	3.2548	1.05	1.690	9.26	83.9
		227 min	7	3.303	3.2347	0.98	1.570	9.14	97.9
		228 min	7	3.289	3.2792	1.09	1.560	9.12	99.7
		229 min	7	2.020	2.1448	0.69	1.290	6.82	106.2
		230 min	7	2.483	2.2415	0.32	1.720	6.54	90.3
		231 min	7	2.084	2.4033	0.34	1.410	7.44	115.3
		232 min	7	2.770	2.8138	0.19	1.650	6.83	101.6
		233 min	7	2.110	2.1423	0.34	1.470	6.81	101.5
		234 min	7	2.151	2.2033	0.27	1.340	6.88	102.4
		235 min	7	3.143	2.6694	0.30	1.670	7.07	84.9
		236 min	7	2.837	2.7909	0.19	1.550	6.88	98.4
		237 min	7	2.641	2.9597	0.07	1.260	7.06	112.0
		238 min	7	2.723	2.9688	0.11	1.390	7.05	109.0
		239 min	7	2.763	3.0667	0.02	1.290	7.60	111.0
		240 min	1	0.260		0.26	0.260	0.26	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 169 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	1 min	12	2.730	2.3655	0.90	1.665	7.13	86.6
		2 min	12	3.459	2.8173	1.01	1.785	8.08	81.4
		3 min	12	5.091	3.2064	1.12	6.740	9.11	63.0
		4 min	12	5.882	2.7416	1.53	6.570	9.14	46.6
		5 min	12	6.671	2.4989	1.55	7.175	9.79	37.5
		6 min	12	6.660	2.4873	1.48	7.105	9.66	37.3
		7 min	12	6.796	2.5499	1.32	7.370	9.78	37.5
		8 min	12	6.830	2.6684	1.00	7.425	9.91	39.1
		9 min	12	7.100	2.0407	1.35	7.520	9.66	28.7
		10 min	12	6.918	2.1130	1.21	7.340	9.73	30.5
		11 min	12	6.664	2.4760	0.97	7.625	9.58	37.2
		12 min	12	6.718	2.5874	0.99	7.425	9.96	38.5
		13 min	12	6.484	2.4575	1.24	6.980	9.70	37.9
		14 min	12	6.423	2.5656	1.10	7.345	9.67	39.9
		15 min	12	6.586	2.5398	1.31	7.420	9.41	38.6
		16 min	12	5.858	2.9705	0.84	7.245	9.48	50.7
		17 min	12	5.734	2.8654	1.25	6.555	9.69	50.0
		18 min	12	6.012	2.8008	1.15	7.205	9.83	46.6
		19 min	12	5.784	2.9571	1.23	7.025	10.05	51.1
		20 min	12	5.155	3.2971	1.04	5.980	9.79	64.0
		21 min	11	5.777	2.9283	1.20	6.720	9.55	50.7
		22 min	10	5.136	3.0023	1.00	6.845	7.80	58.5
		23 min	10	5.091	3.1357	0.83	6.660	7.98	61.6
		24 min	10	4.494	3.3394	1.01	4.115	8.34	74.3
		25 min	10	4.521	3.4100	0.70	4.285	8.26	75.4
		26 min	10	4.530	3.3474	0.79	4.110	8.22	73.9
		27 min	10	4.448	3.3003	0.94	3.935	8.10	74.2
		28 min	10	4.838	3.0259	1.21	5.610	8.05	62.5
		29 min	10	4.804	3.0272	1.26	5.550	8.18	63.0
		30 min	10	4.385	3.2113	0.94	3.605	8.17	73.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 170 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	31 min	10	4.192	3.2338	0.90	2.760	8.00	77.1
		32 min	10	4.341	3.1291	1.32	3.515	8.07	72.1
		33 min	10	4.333	3.1828	1.08	3.675	7.86	73.5
		34 min	10	3.740	3.1506	0.79	1.710	7.75	84.2
		35 min	10	4.210	2.9238	1.05	4.110	7.67	69.4
		36 min	10	3.625	2.8793	1.19	1.755	7.75	79.4
		37 min	10	3.979	2.8325	1.00	3.865	7.65	71.2
		38 min	10	4.087	2.7151	1.40	3.780	7.71	66.4
		39 min	10	4.054	2.6904	1.16	4.010	7.69	66.4
		40 min	10	4.531	2.7068	1.05	5.565	7.75	59.7
		41 min	10	4.060	2.7718	0.98	4.110	7.68	68.3
		42 min	10	4.051	2.4095	0.98	3.930	7.68	59.5
		43 min	10	4.028	2.3947	0.93	3.640	7.74	59.5
		44 min	10	4.329	2.6345	1.23	4.265	7.68	60.9
		45 min	9	3.780	2.4855	1.35	2.730	7.57	65.8
		46 min	9	3.306	2.6494	0.93	2.240	7.66	80.2
		47 min	9	3.396	2.7681	0.96	1.690	7.66	81.5
		48 min	9	3.567	2.6561	0.94	2.630	7.72	74.5
		49 min	9	4.570	2.6514	1.23	5.570	7.71	58.0
		50 min	8	3.345	2.5407	1.23	2.450	7.75	76.0
		51 min	8	3.225	2.4317	0.99	2.470	7.65	75.4
		52 min	8	3.088	2.4185	0.93	2.180	7.69	78.3
		53 min	9	3.879	2.7424	1.08	3.750	7.75	70.7
		54 min	9	3.913	2.5874	1.22	3.520	7.65	66.1
		55 min	9	3.089	2.3794	1.06	2.310	7.65	77.0
		56 min	9	2.637	2.4621	0.81	1.490	7.85	93.4
		57 min	9	4.141	2.7345	0.62	4.210	7.74	66.0
		58 min	9	4.954	2.7644	0.52	6.500	7.73	55.8
		59 min	9	4.352	2.4588	0.47	5.310	7.49	56.5
		60 min	9	4.258	2.4838	1.51	4.770	7.56	58.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 171 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	61 min	9	3.713	2.6368	0.90	2.240	7.50	71.0
		62 min	9	3.999	2.7127	1.39	2.600	7.69	67.8
		63 min	8	4.123	2.7596	1.40	2.860	7.94	66.9
		64 min	8	5.120	2.5556	1.50	6.105	7.61	49.9
		65 min	8	4.680	2.8479	1.59	4.395	7.87	60.9
		66 min	8	3.991	2.6919	0.90	3.355	7.64	67.4
		67 min	8	3.578	2.7214	1.09	2.425	7.84	76.1
		68 min	8	4.501	2.4644	1.57	4.115	7.82	54.7
		69 min	8	4.421	2.5822	1.50	4.230	7.76	58.4
		70 min	8	3.386	2.6233	1.54	2.080	7.96	77.5
		71 min	8	4.776	2.7059	1.31	5.805	7.92	56.7
		72 min	8	5.215	2.7197	1.61	6.780	8.04	52.2
		73 min	8	3.659	3.1187	0.80	1.940	7.91	85.2
		74 min	8	4.693	2.5473	1.51	5.300	7.48	54.3
		75 min	8	4.599	2.8099	1.25	4.990	8.02	61.1
		76 min	8	5.149	2.9831	1.21	7.065	7.66	57.9
		77 min	8	3.719	3.0881	0.82	1.870	7.72	83.0
		78 min	8	4.590	2.7335	0.95	5.205	7.48	59.6
		79 min	8	2.758	2.6935	0.93	1.305	7.42	97.7
		80 min	8	3.739	2.9415	0.99	2.230	7.79	78.7
		81 min	8	4.308	3.0026	1.22	4.435	7.50	69.7
		82 min	8	3.484	2.8080	1.23	1.800	7.78	80.6
		83 min	8	4.411	2.9560	1.26	4.100	7.77	67.0
		84 min	8	4.298	3.1498	0.76	4.480	7.88	73.3
		85 min	8	4.485	3.0435	1.29	4.540	7.98	67.9
		86 min	8	4.978	2.8985	1.29	6.105	8.23	58.2
		87 min	8	4.391	3.2172	1.04	4.450	8.27	73.3
		88 min	8	3.546	3.0969	0.82	1.725	8.39	87.3
		89 min	9	4.989	2.5971	1.24	6.400	7.45	52.1
		90 min	9	4.684	3.1156	0.89	6.640	7.95	66.5

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 172 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	91 min	9	4.490	3.1311	0.18	6.450	7.57	69.7
		92 min	9	3.940	3.3121	0.12	2.160	7.59	84.1
		93 min	8	5.079	2.9478	1.16	6.810	7.80	58.0
		94 min	8	4.468	3.0119	1.18	4.445	7.54	67.4
		95 min	7	4.137	2.8462	1.37	2.460	7.32	68.8
		96 min	7	4.894	2.3503	1.49	6.120	7.64	48.0
		97 min	8	4.708	2.5863	1.44	5.690	7.22	54.9
		98 min	7	3.989	2.8774	0.85	2.580	7.29	72.1
		99 min	8	4.423	2.7198	1.46	4.265	7.34	61.5
		100 min	8	2.698	2.6159	0.19	1.635	6.87	97.0
		101 min	8	3.371	2.5837	0.32	2.265	6.70	76.6
		102 min	8	4.505	2.7144	0.34	5.485	7.51	60.3
		103 min	8	2.960	2.2438	1.19	1.925	6.57	75.8
		104 min	8	4.795	2.6274	1.15	6.370	7.33	54.8
		105 min	8	4.350	2.8814	1.37	4.245	7.59	66.2
		106 min	8	4.295	2.7049	1.40	4.130	7.69	63.0
		107 min	8	2.830	2.3610	0.62	1.910	6.82	83.4
		108 min	8	3.978	2.5411	1.39	3.445	7.21	63.9
		109 min	8	3.389	2.7950	0.91	1.725	7.26	82.5
		110 min	8	3.439	2.8837	0.05	1.905	7.44	83.9
		111 min	7	2.861	2.3470	0.92	1.930	6.49	82.0
		112 min	8	3.146	2.1630	1.18	1.870	6.41	68.7
		113 min	8	2.489	2.1541	0.12	1.780	6.44	86.6
		114 min	7	2.954	1.9202	1.46	1.950	6.49	65.0
		115 min	7	3.169	2.0858	1.30	1.930	6.46	65.8
		116 min	7	3.457	2.1488	1.48	2.000	6.64	62.2
		117 min	8	3.774	2.4591	0.77	3.085	6.72	65.2
		118 min	8	2.539	1.6827	1.21	1.815	6.28	66.3
		119 min	8	2.910	2.4161	0.40	1.755	6.93	83.0
		120 min	8	2.951	2.5486	0.13	2.040	7.33	86.4

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 173 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	121 min	8	2.866	2.4198	0.53	1.855	6.81	84.4
		122 min	8	3.468	2.7114	0.49	2.185	7.18	78.2
		123 min	8	3.379	2.5297	0.45	2.340	7.19	74.9
		124 min	8	2.970	1.9288	0.49	2.640	6.66	64.9
		125 min	8	3.499	2.6060	0.41	2.115	6.86	74.5
		126 min	8	4.330	2.2820	1.56	4.790	7.18	52.7
		127 min	8	3.780	2.5991	0.64	2.885	7.07	68.8
		128 min	8	3.330	2.4946	0.60	2.575	7.19	74.9
		129 min	8	3.963	2.3175	1.63	3.365	6.91	58.5
		130 min	8	4.296	2.6594	1.23	4.695	7.08	61.9
		131 min	8	4.750	2.5325	1.48	5.745	7.22	53.3
		132 min	8	4.659	2.6186	1.62	5.100	7.40	56.2
		133 min	8	3.773	2.9167	1.27	2.195	7.68	77.3
		134 min	8	4.500	2.8063	1.55	4.110	7.60	62.4
		135 min	8	4.400	3.0797	1.09	4.320	7.99	70.0
		136 min	8	3.728	3.0231	1.11	1.745	7.73	81.1
		137 min	8	3.778	3.0791	1.27	1.890	7.63	81.5
		138 min	8	4.209	2.8859	1.09	3.915	7.33	68.6
		139 min	8	3.431	2.9443	0.52	1.890	7.46	85.8
		140 min	8	3.754	3.1307	0.49	1.955	7.84	83.4
		141 min	8	3.675	3.1771	0.60	2.110	7.78	86.5
		142 min	8	3.729	3.1467	0.80	2.020	7.64	84.4
		143 min	8	4.001	2.9936	0.40	3.400	7.88	74.8
		144 min	8	4.061	2.8825	0.79	3.660	7.68	71.0
		145 min	8	4.081	3.2151	0.12	3.950	7.67	78.8
		146 min	8	3.449	3.0721	0.15	2.165	7.58	89.1
		147 min	8	4.089	3.1382	0.31	3.765	7.94	76.8
		148 min	8	4.576	3.0037	0.21	5.710	7.54	65.6
		149 min	8	4.735	3.0638	0.39	6.135	7.62	64.7
		150 min	8	3.985	3.1571	0.35	3.685	7.28	79.2

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 174 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	151 min	7	4.664	2.5071	1.59	5.330	7.40	53.8
		152 min	8	3.599	3.0348	0.23	2.170	7.29	84.3
		153 min	8	3.486	2.9734	0.13	1.930	7.32	85.3
		154 min	8	3.356	2.5607	1.46	1.910	7.44	76.3
		155 min	8	3.330	2.7786	0.99	1.625	7.24	83.4
		156 min	8	3.411	2.6434	0.52	2.260	7.31	77.5
		157 min	8	3.358	2.8632	0.16	1.760	7.30	85.3
		158 min	8	2.869	2.7252	0.46	1.695	7.39	95.0
		159 min	8	3.990	2.7854	1.06	3.640	7.31	69.8
		160 min	8	3.450	2.7257	1.20	1.740	7.52	79.0
		161 min	7	2.319	2.2755	1.13	1.480	7.46	98.1
		162 min	8	2.740	2.4860	0.86	1.530	7.36	90.7
		163 min	8	2.325	2.1177	0.93	1.610	7.47	91.1
		164 min	8	2.263	2.1589	0.98	1.460	7.53	95.4
		165 min	7	2.931	2.4043	0.93	1.890	7.12	82.0
		166 min	8	3.143	2.5996	0.93	1.760	7.55	82.7
		167 min	8	3.498	2.8601	1.04	1.745	7.53	81.8
		168 min	8	3.463	2.7430	1.09	1.735	7.33	79.2
		169 min	8	3.681	2.8225	0.91	2.190	7.50	76.7
		170 min	8	2.856	2.6622	1.00	1.645	7.49	93.2
		171 min	8	3.494	2.4568	1.41	2.285	7.22	70.3
		172 min	8	4.116	2.7401	1.40	3.375	7.46	66.6
		173 min	8	3.635	2.5462	1.36	2.295	7.45	70.0
		174 min	8	2.720	2.3357	0.64	1.800	7.12	85.9
		175 min	8	3.335	2.5372	0.96	1.940	7.41	76.1
		176 min	7	3.620	2.4433	1.45	1.930	7.60	67.5
		177 min	8	3.185	2.4728	1.29	1.975	7.50	77.6
		178 min	8	2.839	2.2151	0.99	1.965	7.53	78.0
		179 min	7	3.110	2.6036	1.24	1.820	7.37	83.7
		180 min	8	2.828	2.6675	0.26	1.800	7.31	94.3

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 175 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	181 min	8	3.385	2.6957	1.13	1.845	7.30	79.6
		182 min	7	2.746	2.5971	0.22	1.510	6.64	94.6
		183 min	7	1.391	0.6743	0.16	1.380	2.18	48.5
		184 min	6	4.182	2.6045	1.62	4.135	6.94	62.3
		185 min	7	3.741	2.4469	0.87	2.420	6.83	65.4
		186 min	7	2.187	1.4459	0.62	1.560	4.96	66.1
		187 min	7	2.746	2.4190	0.32	1.660	6.29	88.1
		188 min	6	3.092	1.7854	1.60	2.500	6.24	57.7
		189 min	8	3.763	2.6755	0.04	3.410	7.20	71.1
		190 min	8	5.048	2.1039	1.60	5.875	7.06	41.7
		191 min	8	4.401	2.6552	1.14	4.690	7.11	60.3
		192 min	8	4.270	2.7733	1.54	3.800	7.89	64.9
		193 min	8	2.503	2.2582	0.91	1.555	7.50	90.2
		194 min	8	4.098	2.7423	1.33	3.900	7.45	66.9
		195 min	8	3.508	3.0047	0.59	1.785	7.48	85.7
		196 min	8	3.238	2.4396	0.85	1.975	7.21	75.4
		197 min	9	3.607	2.3695	1.20	3.600	7.43	65.7
		198 min	9	2.459	2.3833	0.06	1.490	7.26	96.9
		199 min	8	3.525	2.8308	1.12	1.855	7.52	80.3
		200 min	8	4.030	2.8098	1.20	3.515	7.36	69.7
		201 min	9	3.218	2.9905	0.56	1.580	7.48	92.9
		202 min	10	3.040	2.8139	0.16	1.720	7.47	92.6
		203 min	9	3.349	2.7267	1.26	1.690	7.06	81.4
		204 min	9	2.643	2.5164	0.41	1.610	7.30	95.2
		205 min	8	3.536	2.8894	1.23	1.730	7.38	81.7
		206 min	9	2.648	2.4708	0.35	1.680	6.92	93.3
		207 min	8	3.309	2.8458	0.90	1.615	7.13	86.0
		208 min	7	3.943	2.5571	1.26	4.070	6.98	64.9
		209 min	7	3.483	2.7009	1.14	1.650	6.80	77.5
		210 min	7	2.853	2.4986	1.19	1.490	6.86	87.6

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 176 of 176

Table 14.2.1.3 Summary of pH Original Values by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Timepoints	n	Mean	SD	Minimum	Median	Maximum	CV (%)
B	11	211 min	7	3.516	2.7527	0.97	1.560	7.05	78.3
		212 min	8	2.614	2.7317	0.05	1.445	7.27	104.5
		213 min	7	2.809	2.7114	0.98	1.360	7.18	96.5
		214 min	7	3.677	2.8259	1.24	1.710	7.18	76.9
		215 min	7	3.424	2.6329	1.07	1.770	7.16	76.9
		216 min	8	4.440	2.6830	1.17	5.285	7.41	60.4
		217 min	7	3.753	2.9855	1.15	1.620	7.00	79.6
		218 min	7	4.360	2.7804	1.16	6.090	6.99	63.8
		219 min	8	4.371	2.4996	1.07	5.515	7.02	57.2
		220 min	7	3.359	2.3856	1.22	2.060	6.97	71.0
		221 min	6	3.000	2.2947	1.25	1.910	6.97	76.5
		222 min	7	4.957	2.6406	0.98	6.250	7.18	53.3
		223 min	7	4.193	2.9815	1.05	2.600	8.89	71.1
		224 min	7	3.564	3.2228	0.95	2.340	9.14	90.4
		225 min	7	3.813	3.3731	1.11	1.590	9.16	88.5
		226 min	7	4.716	3.1261	1.37	5.870	8.85	66.3
		227 min	7	4.466	3.2041	1.03	4.280	8.98	71.7
		228 min	7	4.429	3.1175	1.47	3.660	9.04	70.4
		229 min	7	3.326	3.1300	0.93	1.620	8.23	94.1
		230 min	7	3.816	3.2490	0.91	1.720	7.93	85.1
		231 min	7	4.441	3.0852	0.94	5.830	8.09	69.5
		232 min	7	4.056	3.1737	1.13	1.820	8.19	78.3
		233 min	7	4.930	2.7902	1.07	5.620	7.71	56.6
		234 min	7	4.766	2.9020	1.02	5.350	8.76	60.9
		235 min	7	4.433	3.2153	0.71	5.970	8.65	72.5
		236 min	7	4.240	3.1101	1.00	3.800	8.75	73.4
		237 min	7	3.969	3.4403	1.00	1.770	8.19	86.7
		238 min	7	3.896	3.4118	0.66	1.800	8.31	87.6
		239 min	7	3.947	3.2449	0.92	1.870	7.93	82.2
		240 min	1	7.870		7.87	7.870	7.87	

Data Source: Appendix 16.2.6.3

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_03.sas

29JAN2013 8:15

14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 5

Table 14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Summary Statistic	Time to reach pH 3 (min)	Time to reach pH 4 (min)	Duration at which ≥ 3 pH (min)	Duration at which ≥ 4 pH (min)
A	3	n	12	12	11	11
		Mean	24.9	27.4	75.8	55.4
		SD	76.39	77.18	73.19	67.55
		Median	0.1	0.3	47.7	36.5
		Min	0	0	10	5
		Max	266	267	229	229
	4	n	12	12	12	12
		Mean	5.3	5.8	52.1	32.6
		SD	15.46	15.35	70.26	62.63
		Median	0.5	0.8	20.7	12.5
		Min	0	0	0	0
		Max	54	54	228	227
	5	n	12	12	12	10
		Mean	18.8	65.0	42.0	25.4
		SD	46.78	102.57	66.05	60.93
		Median	1.2	3.8	13.0	5.3
		Min	0	0	0	0
		Max	159	269	206	198
	6	n	12	12	11	9
		Mean	61.1	81.3	45.1	31.3
		SD	86.90	105.84	61.94	57.98
		Median	6.1	32.3	15.7	4.7
		Min	0	0	0	0
		Max	259	299	180	172

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_04.sas

29JAN2013 5:06

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 5

Table 14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Summary Statistic	Time to reach pH 3 (min)	Time to reach pH 4 (min)	Duration at which ≥ 3 pH (min)	Duration at which ≥ 4 pH (min)
A	7	n	12	12	11	10
		Mean	62.3	90.9	56.3	39.8
		SD	94.49	107.96	73.41	70.30
		Median	1.1	30.0	16.1	3.3
		Min	0	0	1	0
		Max	259	282	189	173
	8	n	12	12	12	11
		Mean	47.7	96.1	55.8	43.5
		SD	61.94	91.68	71.42	65.67
		Median	1.8	96.9	23.0	9.8
		Min	0	0	0	1
		Max	150	282	198	185
	9	n	12	11	12	10
		Mean	39.3	73.5	58.3	51.4
		SD	54.69	91.38	73.40	71.21
		Median	9.0	45.2	14.4	9.9
		Min	0	0	0	1
		Max	178	261	211	201
	10	n	12	12	12	11
		Mean	53.9	83.8	64.5	53.4
		SD	78.64	99.77	78.97	76.33
		Median	12.6	36.4	26.7	17.3
		Min	0	0	0	0
		Max	234	261	228	220

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_04.sas

29JAN2013 5:06

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 5

Table 14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Summary Statistic	Time to reach pH 3 (min)	Time to reach pH 4 (min)	Duration at which ≥ 3 pH (min)	Duration at which ≥ 4 pH (min)
A	11	n	12	11	12	11
		Mean	30.9	35.0	102.8	90.6
		SD	57.42	57.68	84.35	85.72
		Median	0.1	0.1	101.4	60.2
		Min	0	0	1	0
		Max	172	173	228	220
B	3	n	12	12	12	12
		Mean	0.3	0.4	101.8	90.6
		SD	0.66	0.74	76.80	74.92
		Median	0.0	0.0	82.8	68.8
		Min	0	0	10	8
		Max	2	3	233	233
	4	n	12	12	12	12
		Mean	1.2	1.3	58.8	50.7
		SD	1.86	2.16	65.36	65.80
		Median	0.4	0.4	39.3	27.3
		Min	0	0	7	6
		Max	5	6	233	233
	5	n	12	12	12	12
		Mean	2.2	2.8	44.0	38.2
		SD	2.92	3.08	61.81	62.83
		Median	0.7	1.3	28.2	20.5
		Min	0	0	5	4
		Max	8	9	233	233

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_04.sas

29JAN2013 5:06

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 5

Table 14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Summary Statistic	Time to reach pH 3 (min)	Time to reach pH 4 (min)	Duration at which ≥ 3 pH (min)	Duration at which ≥ 4 pH (min)
B	6	n	12	12	12	12
		Mean	2.4	2.9	41.4	35.7
		SD	2.56	2.92	61.98	62.54
		Median	1.7	2.0	25.9	17.5
		Min	0	0	6	4
		Max	8	9	232	230
	7	n	12	12	12	12
		Mean	2.4	2.5	45.7	39.6
		SD	2.34	2.45	60.63	60.66
		Median	1.5	1.6	28.2	24.5
		Min	0	0	3	2
		Max	8	8	229	227
	8	n	12	12	12	12
		Mean	2.4	2.5	51.8	46.4
		SD	1.83	1.82	62.60	61.92
		Median	1.8	1.8	27.5	26.5
		Min	0	0	6	5
		Max	7	7	233	233
	9	n	12	12	12	12
		Mean	3.3	3.7	54.2	48.4
		SD	2.98	3.14	62.00	61.61
		Median	2.4	2.9	37.9	34.1
		Min	0	0	6	5
		Max	10	10	233	233

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_04.sas

29JAN2013 5:06

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 5

Table 14.2.1.4 Summary of pH Smoothed Parameters by Treatment and Electrode
PP Population (N=12)

Treatment	Electrode	Summary Statistic	Time to reach pH 3 (min)	Time to reach pH 4 (min)	Duration at which ≥ 3 pH (min)	Duration at which ≥ 4 pH (min)
B	10	n	12	12	12	12
		Mean	12.7	13.1	57.2	51.5
		SD	34.28	35.01	60.93	61.57
		Median	2.2	2.4	36.1	30.8
		Min	0	0	5	5
		Max	121	124	233	233
	11	n	12	12	12	12
		Mean	11.9	12.0	84.9	78.3
		SD	33.00	32.99	66.74	66.40
		Median	2.1	2.2	67.7	57.7
		Min	0	0	6	5
		Max	116	116	233	233

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo


B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_04.sas


29JAN2013 5:06

14.2.1.5 Mean Smoothed pH Values over Time by Electrode and Treatment (PP Population)


Electrode 1




Electrode 2




Electrode 3




Electrode 4




Electrode 5




Electrode 6




Electrode 7




Electrode 8




Electrode 9



Electrode 10




Electrode 11




14.2.1.6 Median Smoothed pH Values over Time by Electrode and Treatment (PP Population)


Electrode 1




Electrode 2




Electrode 3




Electrode 4




Electrode 5




Electrode 6




Electrode 7




Electrode 8




Electrode 9



Electrode 10




Electrode 11




14.2.1.7 Mean Change from Baseline in Smoothed pH Values over Time by Electrode and Treatment (PP Population)

Electrode 1




Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532


Electrode 2




Electrode 3




Electrode 4




Electrode 5




Electrode 6




Electrode 7




Electrode 8




Electrode 9



Electrode 10




Electrode 11




14.2.1.8 Median Change from Baseline in Smoothed pH Values over Time by Electrode and Treatment (PP Population)

Electrode 1




Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532


Electrode 2




Electrode 3




Electrode 4




Electrode 5




Electrode 6




Electrode 7




Electrode 8




Electrode 9



Electrode 10



Electrode 11



14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time-point (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	1	12	6.478	8.093	1.6151	[0.5762, 2.6540]	0.018
	2	12	6.723	7.994	1.2706	[0.2202, 2.3210]	0.053
	3	12	6.507	7.974	1.4669	[0.5423, 2.3915]	0.017
	4	12	6.393	7.991	1.5984	[0.7210, 2.4759]	0.008
	5	12	6.684	7.807	1.1231	[0.1743, 2.0718]	0.057
	6	12	6.503	7.874	1.3711	[0.4794, 2.2629]	0.019
	7	12	6.677	7.779	1.1021	[-0.0787, 2.2829]	0.122
	8	12	6.644	7.755	1.1108	[0.0783, 2.1434]	0.080
	9	12	6.389	7.713	1.3246	[0.3614, 2.2879]	0.032
	10	12	6.512	7.572	1.0606	[0.0239, 2.0973]	0.093
	11	12	6.707	7.405	0.6973	[-0.4220, 1.8166]	0.285
	12	12	6.625	7.482	0.8572	[-0.1938, 1.9082]	0.170
	13	12	6.625	7.402	0.7774	[-0.2535, 1.8083]	0.202
	14	12	6.599	7.215	0.6167	[-0.3300, 1.5634]	0.265
	15	12	6.482	7.202	0.7200	[-0.1738, 1.6139]	0.175
	16	12	6.271	7.215	0.9446	[-0.0506, 1.9398]	0.116
	17	12	6.431	7.300	0.8690	[-0.0203, 1.7583]	0.107
	18	12	6.696	7.142	0.4460	[-0.5261, 1.4180]	0.425
	19	12	6.760	7.296	0.5356	[-0.4056, 1.4768]	0.327
	20	12	6.434	7.303	0.8683	[0.0341, 1.7024]	0.089
	21	12	6.158	7.299	1.1412	[0.1880, 2.0944]	0.056
	22	12	6.553	6.869	0.3161	[-0.1815, 0.8136]	0.271
	23	12	6.426	6.732	0.3055	[-0.1184, 0.7295]	0.217
	24	12	6.654	6.715	0.0611	[-0.5683, 0.6904]	0.861
	25	12	6.417	6.633	0.2160	[-0.7528, 1.1849]	0.689
	26	12	6.647	6.614	-0.0325	[-0.3917, 0.3267]	0.871
	27	12	6.351	6.760	0.4087	[0.0334, 0.7841]	0.077
	28	12	6.940	6.656	-0.2846	[-1.4042, 0.8350]	0.649

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	29	12	6.499	6.676	0.1774	[-0.3141, 0.6689]	0.521
	30	12	6.606	6.719	0.1124	[-0.4296, 0.6544]	0.710
	31	12	6.662	6.722	0.0600	[-0.3590, 0.4789]	0.797
	32	11	6.628	6.654	0.0254	[-0.3133, 0.3640]	0.891
	33	10	6.893	6.643	-0.2499	[-0.7901, 0.2902]	0.403
	34	10	6.580	7.044	0.4638	[-0.6989, 1.6266]	0.468
	35	10	6.506	6.574	0.0681	[-0.7372, 0.8735]	0.875
	36	10	6.593	6.787	0.1940	[-0.2731, 0.6612]	0.457
	37	10	6.663	6.687	0.0248	[-0.2719, 0.3215]	0.879
	38	10	6.294	6.743	0.4489	[-1.1395, 2.0374]	0.613
	39	10	6.173	7.192	1.0186	[-0.1612, 2.1983]	0.147
	40	10	6.595	7.149	0.5538	[-0.6698, 1.7774]	0.424
	41	10	6.573	7.213	0.6393	[-0.6339, 1.9126]	0.378
	42	11	6.742	6.673	-0.0698	[-1.5733, 1.4338]	0.934
	43	12	6.623	7.013	0.3900	[-0.6356, 1.4156]	0.506
	44	12	6.115	7.231	1.1168	[-0.0889, 2.3224]	0.124
	45	12	6.585	7.209	0.6236	[-0.3884, 1.6356]	0.288
	46	12	6.445	7.037	0.5916	[-0.3922, 1.5754]	0.301
	47	12	6.567	7.230	0.6629	[-0.3965, 1.7223]	0.283
	48	12	6.396	7.102	0.7057	[-0.3830, 1.7944]	0.267
	49	12	6.497	6.992	0.4950	[-0.6165, 1.6065]	0.438
	50	12	6.177	7.432	1.2548	[0.0777, 2.4319]	0.082
	51	11	6.249	7.342	1.0931	[-0.1523, 2.3384]	0.141
	52	11	6.286	7.236	0.9504	[-0.2739, 2.1747]	0.187
	53	11	6.273	7.010	0.7370	[-0.4074, 1.8814]	0.268
	54	11	6.472	6.729	0.2571	[-1.2264, 1.7406]	0.758
	55	11	6.541	7.027	0.4852	[-0.7549, 1.7252]	0.491
	56	11	6.552	7.088	0.5354	[-0.6737, 1.7445]	0.438

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	57	11	6.618	7.072	0.4540	[-0.7105, 1.6185]	0.493
	58	11	6.431	6.985	0.5538	[-0.5559, 1.6636]	0.384
	59	11	6.592	7.091	0.4986	[-0.6937, 1.6910]	0.463
	60	11	6.348	7.217	0.8693	[-0.1941, 1.9328]	0.168
	61	11	6.482	6.565	0.0829	[-1.5450, 1.7108]	0.928
	62	11	6.628	7.147	0.5191	[-0.5117, 1.5499]	0.380
	72	9	6.415	6.405	-0.0101	[-0.6997, 0.6796]	0.978
	73	9	6.336	6.426	0.0892	[-0.7475, 0.9259]	0.843
	74	9	6.358	6.464	0.1056	[-0.4996, 0.7108]	0.746
	75	9	6.293	6.486	0.1934	[-0.4756, 0.8625]	0.595
	76	9	5.852	6.264	0.4128	[-0.7594, 1.5849]	0.519
	77	9	6.333	6.287	-0.0460	[-0.3947, 0.3026]	0.806
	78	9	6.594	6.380	-0.2140	[-0.6837, 0.2558]	0.410
	79	9	6.476	6.403	-0.0730	[-0.4510, 0.3050]	0.720
	80	9	6.421	6.443	0.0211	[-0.3382, 0.3805]	0.913
	81	9	5.596	6.443	0.8476	[-0.4250, 2.1203]	0.243
	82	9	6.662	6.130	-0.5321	[-0.8003, -0.2639]	0.008
	83	9	6.389	6.400	0.0109	[-0.5024, 0.5242]	0.968
	84	9	6.395	6.347	-0.0483	[-0.5917, 0.4951]	0.869
	85	9	5.931	6.144	0.2132	[-1.2752, 1.7015]	0.790
	86	9	6.418	5.558	-0.8601	[-2.4980, 0.7778]	0.347
	87	9	6.552	6.264	-0.2887	[-0.7031, 0.1256]	0.225
	88	9	6.536	6.306	-0.2294	[-0.6301, 0.1714]	0.309
	89	9	6.444	6.926	0.4824	[-1.0048, 1.9695]	0.558
	90	9	6.486	7.056	0.5699	[-0.9496, 2.0894]	0.500
	91	9	6.295	7.104	0.8087	[-0.5263, 2.1436]	0.289
	92	9	6.548	7.013	0.4648	[-1.0537, 1.9834]	0.580
	93	10	6.020	6.986	0.9658	[-0.2560, 2.1877]	0.180

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	94	10	6.479	7.021	0.5417	[-0.6968, 1.7802]	0.440
	99	11	6.577	7.186	0.6086	[-0.5309, 1.7482]	0.345
	100	11	6.479	6.726	0.2466	[-1.5478, 2.0409]	0.798
	101	11	6.582	7.127	0.5447	[-0.9881, 2.0775]	0.516
	102	11	6.567	7.109	0.5416	[-0.9189, 2.0022]	0.498
	103	11	6.677	7.360	0.6829	[-0.7771, 2.1428]	0.398
	104	11	6.644	6.900	0.2564	[-1.1156, 1.6284]	0.734
	105	11	6.485	7.198	0.7131	[-0.8309, 2.2571]	0.411
	106	11	6.402	6.897	0.4953	[-0.9044, 1.8949]	0.524
	107	11	6.539	6.810	0.2701	[-0.9634, 1.5036]	0.691
	108	11	6.568	6.965	0.3970	[-0.8463, 1.6403]	0.564
	109	11	6.603	6.959	0.3559	[-0.8074, 1.5193]	0.580
	110	11	6.695	7.004	0.3096	[-0.8981, 1.5173]	0.642
	111	11	6.513	6.993	0.4802	[-0.7073, 1.6676]	0.469
	112	11	6.514	7.124	0.6100	[-0.4861, 1.7062]	0.327
	113	11	6.192	6.979	0.7868	[-0.1487, 1.7224]	0.156
	114	11	6.408	6.942	0.5337	[-0.4428, 1.5103]	0.339
	115	11	6.629	7.044	0.4157	[-0.6431, 1.4745]	0.486
	116	11	6.612	6.942	0.3302	[-0.6212, 1.2817]	0.537
	118	10	6.480	7.071	0.5904	[-0.4756, 1.6564]	0.333
	119	10	6.496	7.024	0.5282	[-0.6373, 1.6937]	0.424
	120	10	6.263	7.012	0.7485	[-0.2791, 1.7760]	0.213
	121	10	6.625	6.855	0.2292	[-0.6983, 1.1568]	0.658
	122	10	6.507	6.934	0.4270	[-0.5304, 1.3845]	0.431
	123	11	6.269	7.040	0.7706	[0.0067, 1.5345]	0.097
	124	11	6.573	6.483	-0.0896	[-1.4072, 1.2279]	0.903
	125	11	6.711	6.992	0.2809	[-0.6634, 1.2252]	0.599
	126	11	6.201	6.940	0.7393	[-0.4317, 1.9104]	0.277

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	127	11	6.789	7.022	0.2330	[-0.8586, 1.3245]	0.705
	128	11	6.627	7.150	0.5231	[-0.6128, 1.6590]	0.420
	129	11	6.665	6.943	0.2773	[-0.9396, 1.4942]	0.686
	130	11	6.656	6.998	0.3425	[-0.8982, 1.5832]	0.625
	131	11	6.664	7.031	0.3673	[-0.7786, 1.5132]	0.571
	132	11	6.659	6.999	0.3398	[-0.7554, 1.4350]	0.583
	133	10	6.340	6.989	0.6492	[-0.5140, 1.8124]	0.330
	134	11	6.462	7.087	0.6247	[-0.3561, 1.6055]	0.273
	135	11	6.647	6.877	0.2301	[-0.8735, 1.3337]	0.711
	136	11	6.777	6.922	0.1449	[-0.9154, 1.2053]	0.808
	137	11	6.698	6.921	0.2235	[-0.7736, 1.2206]	0.691
	138	11	6.680	7.245	0.5650	[-0.5008, 1.6309]	0.357
	139	11	6.769	6.940	0.1717	[-0.8421, 1.1855]	0.763
	140	11	6.725	6.944	0.2187	[-0.7871, 1.2245]	0.699
	141	11	6.794	6.943	0.1489	[-0.9743, 1.2721]	0.813
	142	11	6.247	7.014	0.7666	[-0.3996, 1.9328]	0.259
	143	11	6.572	7.011	0.4382	[-0.6020, 1.4784]	0.460
	144	11	6.643	7.147	0.5039	[-0.6651, 1.6729]	0.450
	145	10	6.707	6.674	-0.0333	[-1.8299, 1.7633]	0.973
	146	10	6.755	6.825	0.0701	[-1.5704, 1.7106]	0.939
	147	10	6.371	6.833	0.4619	[-1.1835, 2.1072]	0.616
	148	10	6.495	6.857	0.3615	[-1.1310, 1.8540]	0.664
	149	10	6.606	6.966	0.3603	[-0.9093, 1.6300]	0.612
	150	10	6.662	6.921	0.2592	[-1.0799, 1.5984]	0.728
	151	10	6.687	6.811	0.1239	[-1.2270, 1.4747]	0.869
	152	10	6.602	6.754	0.1519	[-1.1598, 1.4637]	0.835
	153	10	6.638	6.738	0.0992	[-1.1772, 1.3756]	0.889
	154	10	6.655	6.998	0.3437	[-0.8998, 1.5872]	0.621

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	155	10	6.664	6.755	0.0903	[-1.0390, 1.2195]	0.886
	156	10	6.574	6.839	0.2647	[-0.8759, 1.4053]	0.677
	157	10	6.727	6.952	0.2252	[-0.7660, 1.2163]	0.684
	158	10	6.738	7.043	0.3054	[-0.8595, 1.4703]	0.639
	159	10	6.634	7.027	0.3926	[-0.6689, 1.4540]	0.511
	160	10	6.776	6.915	0.1391	[-0.8788, 1.1569]	0.806
	161	10	6.804	6.890	0.0857	[-0.9892, 1.1606]	0.886
	162	10	6.472	6.591	0.1187	[-1.4256, 1.6631]	0.890
	163	11	6.653	7.065	0.4118	[-0.6411, 1.4647]	0.492
	164	11	6.731	7.198	0.4673	[-0.6194, 1.5540]	0.447
	165	11	6.750	7.262	0.5115	[-0.5282, 1.5511]	0.387
	166	11	6.862	7.108	0.2457	[-0.7350, 1.2263]	0.654
	167	11	6.902	7.077	0.1747	[-0.9155, 1.2649]	0.773
	168	11	6.696	7.109	0.4121	[-0.5813, 1.4056]	0.463
	169	10	6.717	7.179	0.4619	[-0.6882, 1.6120]	0.472
	170	10	6.520	7.297	0.7768	[-0.4508, 2.0044]	0.270
	171	10	6.855	7.111	0.2559	[-1.1211, 1.6329]	0.735
	172	10	6.609	7.388	0.7791	[-0.7828, 2.3410]	0.370
	173	10	6.922	7.534	0.6125	[-0.9578, 2.1828]	0.477
	174	10	7.297	7.102	-0.1956	[-2.2950, 1.9038]	0.862
	175	10	6.993	7.458	0.4647	[-0.6779, 1.6072]	0.459
	176	10	6.625	7.585	0.9603	[-0.2521, 2.1727]	0.175
	177	10	6.781	7.401	0.6198	[-0.6030, 1.8425]	0.363
	178	10	6.867	7.263	0.3966	[-1.0082, 1.8015]	0.603
	179	10	6.741	7.494	0.7526	[-0.4405, 1.9456]	0.266
	180	10	7.049	7.065	0.0156	[-1.8535, 1.8847]	0.988
	181	10	7.012	7.292	0.2798	[-1.3237, 1.8833]	0.746
	182	10	6.926	7.465	0.5395	[-1.2288, 2.3077]	0.566

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	183	10	7.031	7.192	0.1605	[-1.5979, 1.9189]	0.861
	184	10	6.890	7.149	0.2593	[-1.3026, 1.8213]	0.752
	185	9	6.919	7.273	0.3536	[-1.6112, 2.3185]	0.721
	189	9	6.763	7.314	0.5512	[-1.3190, 2.4214]	0.578
	190	9	6.582	7.459	0.8766	[-0.8637, 2.6169]	0.357
	191	9	6.892	7.517	0.6249	[-0.8258, 2.0756]	0.425
	192	9	6.497	7.511	1.0142	[-0.5838, 2.6123]	0.257
	193	9	6.223	6.935	0.7120	[-0.9789, 2.4029]	0.435
	194	9	6.347	6.975	0.6285	[-1.4412, 2.6982]	0.567
	195	9	6.679	7.166	0.4863	[-1.2366, 2.2093]	0.594
	196	9	6.574	7.172	0.5979	[-1.2749, 2.4707]	0.548
	197	9	6.588	7.219	0.6306	[-1.0609, 2.3222]	0.496
	198	10	6.442	7.100	0.6578	[-0.6799, 1.9956]	0.383
	199	10	6.384	7.027	0.6436	[-0.6553, 1.9426]	0.379
	200	10	6.552	7.274	0.7224	[-0.6274, 2.0721]	0.344
	201	10	6.275	7.157	0.8820	[-0.4689, 2.2328]	0.256
	202	10	6.512	7.106	0.5936	[-0.5774, 1.7646]	0.373
	203	11	6.970	6.983	0.0133	[-1.1204, 1.1470]	0.983
	204	11	6.811	7.058	0.2467	[-0.7739, 1.2674]	0.668
	205	11	6.652	7.043	0.3919	[-0.7932, 1.5770]	0.559
	206	11	6.167	6.975	0.8074	[-0.4301, 2.0450]	0.262
	211	10	6.727	6.964	0.2371	[-0.6226, 1.0967]	0.622
	212	10	6.572	7.044	0.4724	[-0.6221, 1.5670]	0.445
	213	10	6.584	6.904	0.3199	[-0.9403, 1.5802]	0.649
	214	10	6.522	6.981	0.4589	[-0.6996, 1.6174]	0.482
	215	10	5.958	7.139	1.1811	[-0.0497, 2.4119]	0.112
	216	10	6.298	6.972	0.6743	[-0.3400, 1.6885]	0.251
	217	10	6.439	6.674	0.2357	[-1.5165, 1.9880]	0.809

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 01	218	10	6.502	6.880	0.3781	[-0.7269, 1.4831]	0.542
	219	10	6.550	7.142	0.5915	[-0.6505, 1.8336]	0.402
	220	10	6.700	7.157	0.4571	[-0.6905, 1.6047]	0.480
	221	10	6.473	6.661	0.1880	[-1.0426, 1.4185]	0.781
	222	10	6.413	6.745	0.3317	[-1.0183, 1.6817]	0.656
	223	10	6.397	6.676	0.2792	[-0.9537, 1.5121]	0.681
	224	10	6.513	7.074	0.5619	[-0.8067, 1.9304]	0.462
	225	10	6.503	7.432	0.9288	[-0.3651, 2.2226]	0.212
	226	10	6.397	7.306	0.9096	[-0.3463, 2.1655]	0.209
	227	10	6.557	7.658	1.1006	[-0.2368, 2.4379]	0.161
	228	10	6.634	7.628	0.9933	[-0.3753, 2.3620]	0.208
	229	11	6.902	7.185	0.2834	[-1.3739, 1.9406]	0.755
	230	11	6.678	7.288	0.6099	[-0.5442, 1.7640]	0.355
	231	11	6.740	7.050	0.3101	[-1.0668, 1.6870]	0.686
	232	11	6.609	7.248	0.6389	[-0.5385, 1.8164]	0.342
	233	11	6.711	7.316	0.6043	[-0.4695, 1.6781]	0.326
	234	11	6.296	7.363	1.0676	[-0.3564, 2.4916]	0.201
	235	10	6.053	7.332	1.2791	[0.2866, 2.2716]	0.043
	236	11	6.511	7.375	0.8638	[-0.2268, 1.9543]	0.180
	237	11	6.445	7.118	0.6724	[-0.5315, 1.8762]	0.333
	238	11	6.481	7.116	0.6352	[-0.3245, 1.5949]	0.256
	239	11	6.333	7.221	0.8886	[-0.1035, 1.8806]	0.135
Channel 02	1	12	6.518	8.123	1.6052	[0.6569, 2.5536]	0.012
	2	12	6.589	8.022	1.4323	[0.4411, 2.4234]	0.026
	3	12	6.488	8.004	1.5163	[0.6121, 2.4205]	0.012
	4	12	6.535	8.044	1.5089	[0.6102, 2.4077]	0.012
	5	12	6.648	7.853	1.2050	[0.1965, 2.2135]	0.056

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 9 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	6	12	6.529	7.848	1.3189	[0.3392, 2.2985]	0.035
	7	12	6.450	7.717	1.2675	[0.2452, 2.2897]	0.048
	8	12	6.719	7.842	1.1233	[0.1022, 2.1445]	0.074
	9	12	6.443	7.687	1.2436	[0.2663, 2.2209]	0.044
	10	12	6.561	7.304	0.7429	[-0.5589, 2.0447]	0.325
	11	12	6.561	7.297	0.7355	[-0.2356, 1.7067]	0.200
	12	12	6.481	7.352	0.8715	[-0.1323, 1.8753]	0.147
	13	12	6.597	7.346	0.7495	[-0.3432, 1.8422]	0.242
	14	12	6.477	7.366	0.8890	[-0.1191, 1.8970]	0.141
	15	12	6.396	7.103	0.7064	[-0.2532, 1.6661]	0.212
	16	12	6.246	6.950	0.7039	[-0.7010, 2.1088]	0.385
	17	12	6.330	7.161	0.8310	[-0.2526, 1.9146]	0.195
	18	12	6.666	7.069	0.4035	[-0.8294, 1.6364]	0.566
	19	12	6.666	7.164	0.4986	[-0.6421, 1.6394]	0.447
	20	12	6.417	6.956	0.5382	[-0.8002, 1.8766]	0.483
	21	12	5.745	6.914	1.1689	[-0.2534, 2.5912]	0.166
	22	12	6.523	6.251	-0.2723	[-1.6642, 1.1195]	0.725
	23	12	6.394	6.188	-0.2062	[-1.3761, 0.9638]	0.752
	24	12	6.435	5.627	-0.8088	[-2.1660, 0.5485]	0.300
	25	12	6.318	6.099	-0.2193	[-1.8763, 1.4378]	0.812
	26	12	6.502	6.406	-0.0960	[-0.9277, 0.7357]	0.835
	27	12	5.987	6.633	0.6460	[-0.2060, 1.4981]	0.196
	28	12	6.298	6.148	-0.1507	[-0.9448, 0.6434]	0.733
	29	12	6.397	6.319	-0.0772	[-0.8652, 0.7107]	0.860
	30	12	6.307	6.250	-0.0568	[-0.5323, 0.4187]	0.830
	31	12	6.351	6.269	-0.0812	[-0.5764, 0.4140]	0.768
	32	11	6.400	6.324	-0.0754	[-0.3132, 0.1624]	0.567
	33	10	6.650	6.226	-0.4238	[-1.2232, 0.3756]	0.343

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 10 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	34	10	6.166	5.990	-0.1757	[-1.7429, 1.3916]	0.835
	35	10	6.175	6.157	-0.0184	[-0.9410, 0.9043]	0.970
	36	10	6.205	6.222	0.0177	[-1.1300, 1.1654]	0.978
	37	10	6.281	6.134	-0.1475	[-1.4878, 1.1928]	0.841
	38	10	6.202	6.718	0.5158	[-1.1177, 2.1493]	0.573
	39	10	5.973	6.647	0.6736	[-0.7699, 2.1171]	0.411
	40	10	6.388	6.922	0.5334	[-0.7425, 1.8094]	0.459
	41	10	5.860	6.526	0.6659	[-0.5994, 1.9312]	0.356
	42	11	6.443	6.064	-0.3788	[-1.7569, 0.9993]	0.626
	43	12	5.868	6.406	0.5380	[-0.3991, 1.4750]	0.323
	44	12	5.812	6.580	0.7676	[-0.7998, 2.3351]	0.396
	45	12	6.371	6.758	0.3878	[-0.9081, 1.6836]	0.597
	46	12	6.293	6.508	0.2154	[-0.9674, 1.3982]	0.748
	47	12	6.265	6.606	0.3405	[-0.9325, 1.6135]	0.638
	48	12	6.074	6.463	0.3897	[-0.7077, 1.4870]	0.534
	49	12	6.257	6.177	-0.0801	[-1.4083, 1.2480]	0.915
	50	12	5.893	6.686	0.7929	[-0.5775, 2.1633]	0.317
	51	11	5.744	6.580	0.8359	[-0.5479, 2.2196]	0.294
	52	11	6.172	6.646	0.4745	[-0.9375, 1.8865]	0.549
	53	11	5.977	6.571	0.5935	[-0.4756, 1.6627]	0.335
	54	11	6.423	6.209	-0.2144	[-1.9107, 1.4818]	0.822
	55	11	6.141	6.525	0.3836	[-0.8644, 1.6316]	0.587
	56	11	6.159	6.612	0.4529	[-0.6963, 1.6021]	0.488
	57	11	6.509	6.566	0.0570	[-1.2283, 1.3423]	0.937
	58	11	6.449	6.485	0.0360	[-1.3997, 1.4717]	0.964
	59	11	6.622	6.754	0.1313	[-1.1162, 1.3787]	0.851
	60	11	6.101	6.761	0.6601	[-0.3524, 1.6725]	0.263
	61	11	6.294	6.500	0.2059	[-1.0483, 1.4601]	0.770

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 11 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	62	11	6.283	6.580	0.2971	[-1.1736, 1.7679]	0.720
	72	9	6.655	5.619	-1.0355	[-2.6304, 0.5594]	0.254
	73	9	6.235	5.790	-0.4456	[-1.9325, 1.0413]	0.582
	74	9	6.454	5.703	-0.7515	[-2.0581, 0.5550]	0.306
	75	9	6.225	5.680	-0.5454	[-1.7470, 0.6563]	0.412
	76	9	5.792	5.661	-0.1311	[-1.9559, 1.6938]	0.894
	77	9	5.895	5.672	-0.2225	[-1.1356, 0.6906]	0.653
	78	9	6.277	5.789	-0.4884	[-2.0550, 1.0783]	0.567
	79	9	6.162	5.931	-0.2311	[-1.9207, 1.4584]	0.799
	80	9	6.239	5.786	-0.4520	[-1.6120, 0.7080]	0.478
	81	9	5.257	5.981	0.7235	[-0.2506, 1.6976]	0.199
	82	9	6.169	5.668	-0.5011	[-1.8449, 0.8427]	0.496
	83	9	6.076	5.880	-0.1951	[-1.5012, 1.1109]	0.781
	84	9	6.353	5.746	-0.6075	[-2.0915, 0.8764]	0.457
	85	9	5.217	5.744	0.5269	[-1.9354, 2.9892]	0.692
	86	9	6.310	6.292	-0.0176	[-0.7622, 0.7269]	0.965
	87	9	6.524	5.499	-1.0254	[-2.6030, 0.5522]	0.253
	88	9	6.199	5.551	-0.6482	[-1.9402, 0.6438]	0.367
	89	9	6.030	6.146	0.1157	[-1.2301, 1.4616]	0.875
	90	9	6.370	6.147	-0.2232	[-2.0388, 1.5924]	0.823
	91	9	5.827	6.353	0.5257	[-0.8799, 1.9312]	0.502
	92	9	6.018	6.370	0.3524	[-1.0554, 1.7601]	0.650
	93	10	5.882	6.308	0.4265	[-1.2254, 2.0784]	0.644
	94	10	5.905	6.366	0.4610	[-0.9216, 1.8435]	0.552
	99	11	6.291	6.518	0.2275	[-1.3225, 1.7774]	0.789
	100	11	6.280	6.378	0.0984	[-1.4630, 1.6598]	0.906
	101	11	6.531	6.255	-0.2755	[-2.2991, 1.7482]	0.800
	102	11	6.277	6.419	0.1425	[-1.7378, 2.0227]	0.888

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 12 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	103	11	6.452	6.555	0.1033	[-1.9732, 2.1798]	0.926
	104	11	6.596	6.321	-0.2747	[-2.0708, 1.5214]	0.780
	105	11	6.263	6.480	0.2171	[-1.7350, 2.1693]	0.839
	106	11	6.380	6.096	-0.2840	[-1.9546, 1.3865]	0.757
	107	11	6.402	6.118	-0.2846	[-1.9153, 1.3460]	0.751
	108	11	6.452	6.166	-0.2860	[-2.0615, 1.4895]	0.769
	109	11	6.403	6.217	-0.1863	[-2.0838, 1.7112]	0.858
	110	11	6.539	6.169	-0.3695	[-2.1762, 1.4372]	0.710
	111	11	5.914	6.390	0.4756	[-0.7421, 1.6933]	0.483
	112	11	6.071	6.537	0.4663	[-1.0336, 1.9662]	0.574
	113	11	6.084	6.248	0.1646	[-1.1542, 1.4834]	0.822
	114	11	6.018	6.249	0.2314	[-1.2501, 1.7129]	0.779
	115	11	6.194	6.359	0.1653	[-1.4586, 1.7893]	0.855
	116	11	6.302	6.463	0.1608	[-1.2941, 1.6158]	0.842
	118	10	6.315	6.574	0.2588	[-1.1321, 1.6497]	0.738
	119	10	6.457	6.494	0.0377	[-1.2498, 1.3252]	0.958
	120	10	6.562	6.550	-0.0119	[-1.4242, 1.4004]	0.988
	121	10	6.651	6.463	-0.1875	[-1.5348, 1.1597]	0.802
	122	10	6.438	6.414	-0.0246	[-1.4557, 1.4065]	0.975
	123	11	6.316	6.566	0.2500	[-1.0208, 1.5208]	0.727
	124	11	6.112	6.357	0.2450	[-1.3731, 1.8631]	0.788
	125	11	6.386	6.411	0.0250	[-1.1872, 1.2372]	0.971
	126	11	5.930	6.450	0.5194	[-1.0938, 2.1326]	0.570
	127	11	6.231	6.468	0.2364	[-1.4420, 1.9148]	0.802
	128	11	6.212	6.601	0.3890	[-1.1164, 1.8944]	0.647
	129	11	6.380	5.901	-0.4787	[-2.3058, 1.3484]	0.642
	130	11	6.510	6.082	-0.4284	[-2.4560, 1.5991]	0.708
	131	11	6.695	6.379	-0.3162	[-1.8838, 1.2515]	0.720

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 13 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	132	11	6.527	6.363	-0.1637	[-1.7772, 1.4498]	0.857
	133	10	6.301	6.427	0.1253	[-1.1313, 1.3820]	0.857
	134	11	6.648	6.495	-0.1527	[-1.7272, 1.4217]	0.863
	135	11	6.836	6.170	-0.6652	[-2.2271, 0.8966]	0.455
	136	11	6.634	6.452	-0.1825	[-1.8011, 1.4360]	0.841
	137	11	6.732	6.415	-0.3167	[-1.7537, 1.1203]	0.696
	138	11	6.392	6.556	0.1645	[-1.0777, 1.4067]	0.814
	139	11	6.572	6.571	-0.0011	[-1.1026, 1.1003]	0.999
	140	11	6.627	6.681	0.0543	[-1.1961, 1.3047]	0.938
	141	11	6.850	6.557	-0.2932	[-1.5590, 0.9726]	0.681
	142	11	6.418	7.025	0.6074	[-0.3837, 1.5986]	0.290
	143	11	6.421	6.981	0.5604	[-0.5099, 1.6307]	0.362
	144	11	6.391	6.997	0.6062	[-0.4484, 1.6607]	0.319
	145	10	6.637	6.410	-0.2266	[-1.9479, 1.4947]	0.813
	146	10	6.468	6.737	0.2690	[-1.0540, 1.5921]	0.715
	147	10	6.402	6.329	-0.0728	[-1.4658, 1.3202]	0.925
	148	10	6.580	6.537	-0.0430	[-1.3037, 1.2177]	0.951
	149	10	6.348	6.816	0.4676	[-0.9921, 1.9273]	0.568
	150	10	6.605	6.947	0.3413	[-0.8120, 1.4945]	0.597
	151	10	6.396	6.856	0.4594	[-0.6541, 1.5729]	0.465
	152	10	6.616	6.783	0.1672	[-0.9526, 1.2870]	0.788
	153	10	6.752	6.037	-0.7150	[-2.3460, 0.9160]	0.439
	154	10	6.679	6.324	-0.3554	[-2.0731, 1.3622]	0.710
	155	10	6.800	6.286	-0.5145	[-2.1250, 1.0960]	0.569
	156	10	6.906	6.222	-0.6836	[-2.2945, 0.9273]	0.453
	157	10	6.653	6.470	-0.1837	[-1.6050, 1.2377]	0.816
	158	10	6.762	6.530	-0.2318	[-1.7154, 1.2519]	0.779
	159	10	6.744	6.616	-0.1280	[-1.8141, 1.5581]	0.891

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 14 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	160	10	6.525	6.699	0.1742	[-1.1244, 1.4727]	0.809
	161	10	6.715	6.624	-0.0918	[-1.7535, 1.5700]	0.921
	162	10	6.038	6.597	0.5589	[-1.0137, 2.1315]	0.527
	163	11	6.714	6.638	-0.0763	[-1.4940, 1.3415]	0.924
	164	11	6.529	6.715	0.1860	[-1.3004, 1.6724]	0.822
	165	11	6.493	6.762	0.2692	[-0.9200, 1.4584]	0.685
	166	11	6.836	6.647	-0.1886	[-1.6886, 1.3113]	0.821
	167	11	6.843	6.788	-0.0550	[-1.5797, 1.4698]	0.948
	168	11	6.741	6.750	0.0088	[-1.4061, 1.4236]	0.991
	169	10	6.677	6.784	0.1067	[-1.3733, 1.5867]	0.895
	170	10	6.604	6.693	0.0890	[-1.6052, 1.7832]	0.924
	171	10	6.161	6.771	0.6108	[-0.7207, 1.9422]	0.414
	172	10	6.637	7.139	0.5019	[-1.3089, 2.3126]	0.610
	173	10	6.881	7.138	0.2574	[-1.4778, 1.9926]	0.783
	174	10	6.769	6.883	0.1132	[-1.6391, 1.8656]	0.904
	175	10	6.407	7.042	0.6345	[-0.6958, 1.9648]	0.390
	176	10	6.354	7.107	0.7533	[-1.2297, 2.7362]	0.488
	177	10	6.460	7.427	0.9663	[-0.1423, 2.0750]	0.141
	178	10	6.604	7.197	0.5927	[-0.9347, 2.1201]	0.479
	179	10	6.620	7.357	0.7365	[-0.4703, 1.9433]	0.280
	180	10	6.829	6.529	-0.3002	[-1.9548, 1.3544]	0.736
	181	10	6.871	7.179	0.3076	[-1.0999, 1.7152]	0.686
	182	10	6.857	7.253	0.3957	[-1.3399, 2.1313]	0.665
	183	10	6.843	6.883	0.0408	[-1.5957, 1.6772]	0.962
	184	10	6.751	6.657	-0.0948	[-2.1722, 1.9827]	0.930
	185	9	6.678	6.811	0.1332	[-2.5267, 2.7931]	0.920
	189	9	6.830	6.990	0.1600	[-1.7113, 2.0312]	0.870
	190	9	7.073	6.712	-0.3610	[-2.9903, 2.2682]	0.793

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 15 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	191	9	7.043	6.935	-0.1082	[-2.1708, 1.9544]	0.920
	192	9	6.793	6.996	0.2025	[-1.3668, 1.7718]	0.805
	193	9	6.458	6.533	0.0746	[-1.6385, 1.7877]	0.933
	194	9	6.809	6.500	-0.3089	[-2.6784, 2.0605]	0.803
	195	9	6.925	6.475	-0.4500	[-2.4647, 1.5646]	0.671
	196	9	6.890	6.735	-0.1552	[-2.1748, 1.8644]	0.883
	197	9	6.003	6.978	0.9747	[-0.6246, 2.5741]	0.281
	198	10	6.168	6.938	0.7694	[-0.5623, 2.1010]	0.310
	199	10	5.972	6.546	0.5736	[-0.9330, 2.0801]	0.494
	200	10	6.465	6.952	0.4878	[-1.5637, 2.5392]	0.666
	201	10	6.379	6.728	0.3492	[-1.1984, 1.8967]	0.682
	202	10	6.415	6.516	0.1009	[-1.2653, 1.4670]	0.894
	203	11	6.730	6.477	-0.2524	[-1.5508, 1.0460]	0.730
	204	11	6.756	6.563	-0.1931	[-1.6605, 1.2743]	0.815
	205	11	6.674	6.449	-0.2252	[-1.7189, 1.2685]	0.788
	206	11	6.101	6.542	0.4413	[-1.1715, 2.0541]	0.628
	211	10	6.286	6.390	0.1042	[-1.2218, 1.4303]	0.887
	212	10	6.507	6.440	-0.0672	[-1.4870, 1.3527]	0.932
	213	10	6.581	6.429	-0.1518	[-1.5682, 1.2647]	0.847
	214	10	5.999	6.735	0.7359	[-0.3415, 1.8133]	0.240
	215	10	5.919	6.596	0.6771	[-0.7958, 2.1501]	0.417
	216	10	6.095	6.485	0.3895	[-1.0774, 1.8565]	0.635
	217	10	6.268	6.326	0.0580	[-1.7023, 1.8183]	0.953
	218	10	6.409	6.394	-0.0153	[-1.4336, 1.4030]	0.984
	219	10	6.450	6.761	0.3103	[-1.2223, 1.8429]	0.716
	220	10	6.690	6.785	0.0948	[-1.4968, 1.6864]	0.915
	221	10	6.356	6.227	-0.1287	[-1.9056, 1.6481]	0.895
	222	10	6.477	6.292	-0.1846	[-2.1455, 1.7763]	0.863

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 16 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 02	223	10	6.453	6.653	0.1996	[-1.7747, 2.1738]	0.854
	224	10	6.345	6.619	0.2740	[-1.9165, 2.4645]	0.819
	225	10	6.190	7.127	0.9363	[-1.1430, 3.0156]	0.415
	226	10	6.468	6.939	0.4714	[-1.9048, 2.8477]	0.713
	227	10	6.439	7.111	0.6716	[-1.6490, 2.9922]	0.594
	228	10	6.269	7.083	0.8142	[-1.2839, 2.9124]	0.479
	229	11	6.680	6.868	0.1876	[-1.5587, 1.9340]	0.844
	230	11	6.400	6.746	0.3460	[-0.8370, 1.5291]	0.601
	231	11	6.641	6.416	-0.2243	[-1.9749, 1.5263]	0.818
	232	11	6.566	6.678	0.1120	[-1.3830, 1.6071]	0.893
	233	11	6.551	7.073	0.5221	[-0.5684, 1.6126]	0.399
	234	11	6.223	6.897	0.6742	[-1.0532, 2.4016]	0.489
	235	10	5.861	6.664	0.8027	[-0.3472, 1.9527]	0.230
	236	11	6.367	6.743	0.3766	[-1.0335, 1.7868]	0.636
	237	11	6.303	6.817	0.5136	[-0.8135, 1.8408]	0.496
	238	11	6.386	6.732	0.3454	[-0.6764, 1.3672]	0.551
	239	11	6.461	6.805	0.3440	[-0.8851, 1.5732]	0.620
Channel 03	1	12	4.999	7.441	2.4419	[0.2788, 4.6050]	0.068
	2	12	5.282	7.491	2.2093	[0.0625, 4.3562]	0.092
	3	12	4.851	7.950	3.0983	[1.4544, 4.7422]	0.007
	4	12	4.418	7.884	3.4660	[2.0170, 4.9150]	0.001
	5	12	3.775	7.587	3.8125	[2.4758, 5.1491]	<0.001
	6	12	4.384	7.420	3.0357	[1.7401, 4.3313]	0.002
	7	12	4.160	7.370	3.2092	[1.7715, 4.6469]	0.002
	8	12	4.127	6.873	2.7462	[1.3377, 4.1546]	0.005
	9	12	3.658	6.486	2.8278	[1.4743, 4.1812]	0.004
	10	12	4.044	6.403	2.3590	[0.7604, 3.9576]	0.023

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 17 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	11	12	3.471	6.229	2.7576	[0.9740, 4.5411]	0.019
	12	12	4.061	6.100	2.0394	[0.4713, 3.6076]	0.040
	13	12	3.722	5.522	1.7999	[0.0117, 3.5882]	0.098
	14	12	4.176	5.348	1.1724	[-0.5525, 2.8973]	0.246
	15	12	4.193	4.877	0.6843	[-1.2400, 2.6086]	0.534
	16	12	3.764	5.172	1.4079	[-0.2386, 3.0544]	0.152
	17	12	3.945	5.036	1.0914	[-0.7350, 2.9178]	0.304
	18	12	3.745	4.882	1.1370	[-0.4442, 2.7183]	0.222
	19	12	3.721	4.543	0.8213	[-0.8029, 2.4455]	0.381
	20	12	3.639	4.366	0.7269	[-0.7829, 2.2367]	0.403
	21	12	3.776	4.539	0.7630	[-1.0650, 2.5910]	0.464
	22	12	3.199	4.418	1.2194	[-0.7575, 3.1962]	0.285
	23	12	3.327	4.336	1.0092	[-1.1051, 3.1235]	0.401
	24	12	3.595	4.294	0.6993	[-1.0707, 2.4694]	0.483
	25	12	3.422	4.282	0.8600	[-1.1747, 2.8948]	0.455
	26	12	3.350	3.380	0.0298	[-1.4646, 1.5241]	0.971
	27	12	3.495	3.792	0.2964	[-1.3550, 1.9478]	0.747
	28	12	3.519	3.392	-0.1275	[-1.6797, 1.4246]	0.882
	29	12	3.815	3.783	-0.0316	[-1.6227, 1.5596]	0.971
	30	12	3.504	4.381	0.8777	[-0.8005, 2.5559]	0.359
	31	12	3.606	3.870	0.2649	[-1.3935, 1.9232]	0.774
	32	11	3.454	4.300	0.8461	[-0.9438, 2.6360]	0.400
	33	10	2.895	4.473	1.5780	[-0.6473, 3.8034]	0.217
	34	10	3.161	4.189	1.0282	[-0.5151, 2.5714]	0.243
	35	10	2.711	4.712	2.0007	[0.4734, 3.5281]	0.044
	36	10	2.446	4.694	2.2483	[0.7322, 3.7643]	0.026
	37	10	2.788	4.405	1.6169	[0.3136, 2.9203]	0.051
	38	10	3.289	4.440	1.1514	[-0.4221, 2.7249]	0.211

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 18 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	39	10	2.810	3.629	0.8199	[-0.3703, 2.0100]	0.236
	40	10	2.761	4.247	1.4860	[0.3963, 2.5758]	0.035
	41	10	3.023	4.119	1.0959	[0.2778, 1.9139]	0.037
	42	11	3.265	3.645	0.3809	[-0.7278, 1.4896]	0.545
	43	12	3.260	3.730	0.4703	[-0.8729, 1.8136]	0.540
	44	12	3.359	4.065	0.7066	[-0.7562, 2.1693]	0.402
	45	12	3.314	3.775	0.4607	[-0.7862, 1.7076]	0.515
	46	12	2.810	4.180	1.3702	[-0.0491, 2.7894]	0.111
	47	12	2.663	4.508	1.8447	[0.5509, 3.1385]	0.027
	48	12	2.644	4.173	1.5294	[0.3042, 2.7545]	0.047
	49	12	2.905	4.049	1.1443	[-0.1766, 2.4653]	0.147
	50	12	2.875	4.187	1.3116	[-0.0654, 2.6886]	0.115
	51	11	2.865	4.333	1.4688	[-0.1906, 3.1281]	0.138
	52	11	2.956	3.930	0.9743	[-0.3828, 2.3315]	0.219
	53	11	2.848	3.878	1.0295	[-0.2098, 2.2689]	0.162
	54	11	3.126	3.422	0.2965	[-0.8553, 1.4484]	0.648
	55	11	2.949	4.020	1.0718	[-0.4243, 2.5680]	0.222
	56	11	3.112	3.842	0.7307	[-0.4686, 1.9301]	0.293
	57	11	3.067	3.351	0.2841	[-0.9584, 1.5266]	0.685
	58	11	3.637	3.538	-0.0993	[-1.5224, 1.3238]	0.901
	59	11	3.528	3.584	0.0565	[-1.2738, 1.3869]	0.940
	60	11	3.661	3.375	-0.2858	[-1.5644, 0.9928]	0.692
	61	11	3.559	3.647	0.0875	[-1.1672, 1.3423]	0.901
	62	11	3.370	3.655	0.2853	[-1.4569, 2.0275]	0.771
	72	9	2.840	2.503	-0.3372	[-2.0200, 1.3456]	0.710
	73	9	2.797	2.492	-0.3049	[-2.1500, 1.5403]	0.759
	74	9	3.065	2.619	-0.4457	[-2.2162, 1.3249]	0.642
	75	9	3.105	2.384	-0.7214	[-2.7220, 1.2791]	0.510

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 19 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	76	9	2.974	2.545	-0.4286	[-2.3156, 1.4583]	0.674
	77	9	3.235	2.786	-0.4486	[-2.6473, 1.7501]	0.705
	78	9	2.989	2.873	-0.1160	[-2.6190, 2.3871]	0.931
	79	9	2.820	2.456	-0.3642	[-2.1022, 1.3739]	0.698
	80	9	3.015	2.745	-0.2700	[-2.6767, 2.1367]	0.835
	81	9	2.536	2.926	0.3908	[-1.6877, 2.4692]	0.727
	82	9	2.591	2.665	0.0738	[-1.7730, 1.9206]	0.941
	83	9	2.782	2.992	0.2105	[-2.1491, 2.5701]	0.868
	84	9	3.037	2.795	-0.2413	[-2.5457, 2.0631]	0.845
	85	9	2.916	2.884	-0.0318	[-2.0957, 2.0320]	0.977
	86	9	2.768	3.621	0.8530	[-1.4019, 3.1079]	0.490
	87	9	2.487	3.365	0.8780	[-1.2541, 3.0100]	0.454
	88	9	2.591	3.164	0.5732	[-1.0570, 2.2035]	0.520
	89	9	2.738	3.096	0.3585	[-0.7580, 1.4750]	0.562
	90	9	2.465	2.854	0.3884	[-1.1822, 1.9590]	0.654
	91	9	2.327	2.826	0.4990	[-0.9383, 1.9362]	0.532
	92	9	2.452	2.761	0.3095	[-0.7631, 1.3821]	0.602
	93	10	2.688	3.223	0.5356	[-0.8366, 1.9077]	0.489
	94	10	2.661	3.029	0.3680	[-0.8034, 1.5393]	0.575
	99	11	2.752	4.116	1.3648	[-0.3401, 3.0696]	0.173
	100	11	2.551	2.884	0.3324	[-0.9278, 1.5926]	0.627
	101	11	2.256	3.196	0.9404	[-0.3686, 2.2494]	0.212
	102	11	2.859	3.799	0.9395	[-0.2454, 2.1243]	0.174
	103	11	3.296	3.011	-0.2845	[-1.5822, 1.0132]	0.685
	104	11	2.839	2.853	0.0137	[-1.3582, 1.3856]	0.985
	105	11	2.853	2.557	-0.2960	[-1.1809, 0.5888]	0.546
	106	11	3.351	2.438	-0.9130	[-2.2025, 0.3765]	0.222
	107	11	3.277	2.568	-0.7090	[-1.7114, 0.2934]	0.222

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 20 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	108	11	3.145	2.277	-0.8681	[-1.5624, -0.1739]	0.050
	109	11	2.734	2.742	0.0080	[-1.0989, 1.1150]	0.989
	110	11	2.942	2.763	-0.1791	[-1.0286, 0.6704]	0.701
	111	11	2.549	3.302	0.7527	[-0.4219, 1.9272]	0.264
	112	11	2.591	2.675	0.0835	[-0.7102, 0.8773]	0.848
	113	11	2.640	2.533	-0.1068	[-0.9001, 0.6864]	0.809
	114	11	3.288	3.334	0.0462	[-1.3814, 1.4738]	0.953
	115	11	3.048	2.936	-0.1124	[-1.4749, 1.2502]	0.882
	116	11	2.913	2.922	0.0084	[-0.9880, 1.0048]	0.988
	118	10	3.202	3.178	-0.0240	[-0.9738, 0.9258]	0.964
	119	10	2.811	3.362	0.5514	[-0.7166, 1.8195]	0.442
	120	10	2.319	3.018	0.6999	[-0.7013, 2.1010]	0.380
	121	10	3.017	3.407	0.3895	[-0.5756, 1.3547]	0.474
	122	10	3.140	2.916	-0.2231	[-1.3649, 0.9187]	0.726
	123	11	3.066	3.201	0.1350	[-0.9470, 1.2171]	0.824
	124	11	3.343	3.391	0.0473	[-1.3122, 1.4069]	0.951
	125	11	3.113	3.280	0.1672	[-0.4786, 0.8130]	0.646
	126	11	3.018	3.213	0.1946	[-0.6394, 1.0286]	0.679
	127	11	3.078	3.549	0.4709	[-0.4269, 1.3687]	0.361
	128	11	3.212	3.522	0.3101	[-0.2027, 0.8229]	0.296
	129	11	3.337	3.317	-0.0206	[-0.6099, 0.5687]	0.950
	130	11	3.415	3.520	0.1051	[-0.6597, 0.8698]	0.807
	131	11	3.229	2.845	-0.3832	[-1.4471, 0.6808]	0.526
	132	11	3.286	3.199	-0.0874	[-1.1661, 0.9913]	0.885
	133	10	2.945	3.468	0.5231	[-0.3822, 1.4283]	0.314
	134	11	3.041	3.666	0.6246	[-0.2209, 1.4701]	0.209
	135	11	3.010	3.359	0.3495	[-0.5077, 1.2066]	0.474
	136	11	3.053	3.507	0.4539	[-0.4221, 1.3298]	0.367

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 21 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	137	11	3.320	4.153	0.8330	[-0.4608, 2.1267]	0.268
	138	11	3.281	4.276	0.9952	[-0.2582, 2.2485]	0.180
	139	11	3.369	4.127	0.7579	[-0.0902, 1.6060]	0.136
	140	11	3.715	3.360	-0.3543	[-1.3638, 0.6552]	0.536
	141	11	3.259	3.609	0.3497	[-0.3055, 1.0048]	0.353
	142	11	3.366	3.623	0.2569	[-0.5402, 1.0539]	0.569
	143	11	3.532	3.671	0.1395	[-0.5303, 0.8092]	0.712
	144	11	3.432	4.423	0.9917	[-0.0985, 2.0820]	0.130
	145	10	3.136	3.875	0.7388	[-0.3849, 1.8625]	0.256
	146	10	3.875	3.372	-0.5027	[-1.3607, 0.3553]	0.308
	147	10	3.111	3.337	0.2263	[-0.6970, 1.1497]	0.661
	148	10	2.988	3.430	0.4414	[-0.7564, 1.6392]	0.513
	149	10	3.246	3.579	0.3328	[-0.8485, 1.5141]	0.615
	150	10	3.248	3.251	0.0032	[-1.0957, 1.1021]	0.996
	151	10	3.402	3.396	-0.0058	[-1.1777, 1.1661]	0.993
	152	10	3.420	3.689	0.2692	[-1.0922, 1.6307]	0.723
	153	10	3.306	3.723	0.4171	[-1.0246, 1.8589]	0.605
	154	10	3.408	3.635	0.2267	[-0.9282, 1.3816]	0.725
	155	10	3.311	3.725	0.4141	[-0.9084, 1.7365]	0.576
	156	10	3.282	4.077	0.7946	[-0.8341, 2.4233]	0.391
	157	10	3.771	4.380	0.6090	[-0.8551, 2.0732]	0.461
	158	10	3.790	4.259	0.4690	[-0.9541, 1.8921]	0.557
	159	10	3.760	3.714	-0.0460	[-1.6183, 1.5263]	0.958
	160	10	3.615	3.657	0.0418	[-1.3739, 1.4575]	0.958
	161	10	3.586	3.500	-0.0863	[-1.3948, 1.2222]	0.905
	162	10	3.523	3.131	-0.3921	[-1.4587, 0.6746]	0.514
	163	11	3.625	3.655	0.0296	[-1.4269, 1.4861]	0.971
	164	11	3.687	3.131	-0.5558	[-1.8810, 0.7694]	0.458

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 22 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	165	11	3.553	3.412	-0.1419	[-1.7009, 1.4170]	0.870
	166	11	3.571	3.285	-0.2860	[-1.7083, 1.1363]	0.718
	167	11	3.247	3.506	0.2597	[-1.3288, 1.8481]	0.769
	168	11	3.373	3.379	0.0059	[-1.4836, 1.4953]	0.994
	169	10	3.405	3.910	0.5053	[-0.8138, 1.8244]	0.492
	170	10	2.903	4.239	1.3355	[-0.5085, 3.1795]	0.212
	171	10	3.236	3.199	-0.0372	[-1.3772, 1.3027]	0.959
	172	10	3.106	3.099	-0.0065	[-0.9327, 0.9197]	0.990
	173	10	3.014	3.621	0.6067	[-1.1744, 2.3878]	0.533
	174	10	3.168	2.782	-0.3860	[-1.5921, 0.8201]	0.557
	175	10	3.071	3.055	-0.0160	[-1.3505, 1.3185]	0.982
	176	10	3.169	3.105	-0.0642	[-1.9266, 1.7982]	0.949
	177	10	3.619	3.169	-0.4500	[-2.2077, 1.3077]	0.637
	178	10	3.662	2.890	-0.7722	[-1.9142, 0.3697]	0.237
	179	10	3.645	4.192	0.5468	[-1.4033, 2.4970]	0.605
	180	10	3.227	3.319	0.0922	[-1.3156, 1.5000]	0.903
	181	10	2.722	2.717	-0.0052	[-1.0282, 1.0179]	0.993
	182	10	3.282	3.027	-0.2548	[-1.1239, 0.6143]	0.580
	183	10	3.512	3.074	-0.4379	[-0.8016, -0.0742]	0.060
	184	10	3.339	2.991	-0.3479	[-0.9865, 0.2907]	0.322
	185	9	3.907	3.118	-0.7891	[-1.1253, -0.4529]	0.007
	189	9	3.422	2.866	-0.5559	[-1.7203, 0.6084]	0.380
	190	9	3.515	3.269	-0.2457	[-0.8252, 0.3338]	0.432
	191	9	3.772	3.720	-0.0521	[-0.6927, 0.5885]	0.876
	192	9	3.902	3.294	-0.6078	[-1.1792, -0.0365]	0.085
	193	9	4.518	3.108	-1.4096	[-2.7990, -0.0203]	0.096
	194	9	4.000	2.866	-1.1345	[-2.5437, 0.2748]	0.166
	195	9	4.337	3.189	-1.1473	[-3.0752, 0.7807]	0.284

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 23 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	196	9	3.621	3.319	-0.3017	[-1.8933, 1.2899]	0.718
	197	9	3.439	3.624	0.1846	[-1.1291, 1.4982]	0.794
	198	10	3.825	3.231	-0.5947	[-1.3567, 0.1673]	0.183
	199	10	3.154	3.212	0.0578	[-1.1585, 1.2741]	0.931
	200	10	2.899	3.741	0.8416	[-0.6779, 2.3612]	0.329
	201	10	3.208	3.338	0.1304	[-0.9921, 1.2530]	0.832
	202	10	3.324	3.198	-0.1252	[-1.6234, 1.3731]	0.880
	203	11	3.334	2.927	-0.4068	[-1.6631, 0.8495]	0.567
	204	11	3.352	3.993	0.6413	[-0.3433, 1.6259]	0.263
	205	11	3.305	3.153	-0.1524	[-1.3487, 1.0438]	0.821
	206	11	2.779	3.598	0.8190	[-0.6651, 2.3030]	0.338
	211	10	2.948	3.013	0.0650	[-1.4569, 1.5869]	0.939
	212	10	3.338	3.458	0.1203	[-1.0738, 1.3144]	0.856
	213	10	3.008	2.834	-0.1741	[-1.5350, 1.1867]	0.818
	214	10	2.969	3.478	0.5095	[-1.0845, 2.1035]	0.569
	215	10	2.377	3.066	0.6899	[-0.5354, 1.9151]	0.326
	216	10	2.719	3.537	0.8172	[-1.1022, 2.7366]	0.451
	217	10	2.619	3.563	0.9434	[-0.5717, 2.4586]	0.280
	218	10	2.571	3.182	0.6103	[-0.4477, 1.6683]	0.315
	219	10	2.496	3.660	1.1640	[-0.1381, 2.4661]	0.135
	220	10	2.789	3.506	0.7172	[-0.5405, 1.9749]	0.320
	221	10	2.929	3.559	0.6307	[-1.2046, 2.4661]	0.536
	222	10	2.711	3.136	0.4245	[-0.7517, 1.6006]	0.516
	223	10	2.617	3.150	0.5334	[-0.8235, 1.8903]	0.481
	224	10	2.884	2.910	0.0265	[-1.2743, 1.3274]	0.970
	225	10	3.129	3.110	-0.0190	[-1.5961, 1.5582]	0.982
	226	10	3.304	3.203	-0.1015	[-1.8145, 1.6116]	0.912
	227	10	2.953	3.362	0.4090	[-1.1192, 1.9372]	0.622

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 24 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 03	228	10	3.158	3.125	-0.0330	[-1.6302, 1.5642]	0.969
	229	11	2.691	2.846	0.1550	[-1.0127, 1.3227]	0.809
	230	11	3.155	4.206	1.0508	[-0.7121, 2.8136]	0.300
	231	11	2.650	3.233	0.5837	[-0.7554, 1.9228]	0.441
	232	11	3.239	3.641	0.4022	[-1.4348, 2.2392]	0.695
	233	11	2.758	4.062	1.3041	[-0.1322, 2.7403]	0.130
	234	11	2.462	3.498	1.0360	[-0.3585, 2.4306]	0.204
	235	10	2.277	3.588	1.3110	[-0.1822, 2.8042]	0.141
	236	11	2.859	3.378	0.5189	[-0.9652, 2.0031]	0.538
	237	11	3.120	4.332	1.2118	[-0.3469, 2.7704]	0.188
	238	11	2.681	3.983	1.3014	[-0.0072, 2.6099]	0.102
	239	11	2.965	3.358	0.3927	[-1.2376, 2.0229]	0.669
Channel 04	1	12	4.179	5.848	1.6682	[0.1759, 3.1605]	0.070
	2	12	4.179	6.059	1.8804	[0.2430, 3.5179]	0.064
	3	12	4.304	6.246	1.9419	[0.1929, 3.6910]	0.072
	4	12	4.503	6.076	1.5736	[0.0647, 3.0825]	0.088
	5	12	4.066	6.062	1.9957	[0.1868, 3.8046]	0.073
	6	12	3.586	6.627	3.0409	[1.6133, 4.4685]	0.003
	7	12	3.874	6.557	2.6830	[1.3791, 3.9868]	0.004
	8	12	3.731	6.362	2.6306	[1.5308, 3.7303]	0.001
	9	12	3.905	6.053	2.1476	[0.9975, 3.2977]	0.007
	10	12	4.603	6.110	1.5066	[0.4137, 2.5995]	0.032
	11	12	3.300	5.469	2.1690	[1.1204, 3.2177]	0.004
	12	12	2.848	5.341	2.4930	[1.2798, 3.7062]	0.004
	13	12	3.155	4.779	1.6242	[0.2849, 2.9634]	0.053
	14	12	3.385	4.001	0.6162	[-1.0565, 2.2890]	0.519
	15	12	3.059	3.865	0.8065	[-0.8930, 2.5059]	0.410

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK

Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 25 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	16	12	3.603	4.033	0.4294	[-1.1209, 1.9797]	0.627
	17	12	3.106	4.659	1.5527	[-0.1313, 3.2367]	0.126
	18	12	3.275	4.641	1.3661	[-0.3122, 3.0443]	0.171
	19	12	2.739	4.219	1.4801	[-0.1670, 3.1272]	0.134
	20	12	2.666	4.351	1.6849	[-0.0029, 3.3727]	0.101
	21	12	3.329	4.322	0.9936	[-0.5971, 2.5844]	0.282
	22	12	2.853	3.832	0.9796	[-0.7378, 2.6970]	0.320
	23	12	2.750	3.623	0.8734	[-0.8686, 2.6154]	0.378
	24	12	2.664	3.247	0.5829	[-0.9592, 2.1250]	0.502
	25	12	2.552	3.401	0.8483	[-0.6733, 2.3700]	0.330
	26	12	2.669	2.975	0.3060	[-1.1958, 1.8079]	0.715
	27	12	2.755	3.719	0.9642	[-0.5227, 2.4510]	0.262
	28	12	2.644	3.424	0.7808	[-0.8102, 2.3718]	0.388
	29	12	2.566	3.433	0.8672	[-0.7660, 2.5004]	0.352
	30	12	2.491	3.909	1.4180	[-0.1736, 3.0096]	0.136
	31	12	2.885	3.536	0.6514	[-0.9404, 2.2433]	0.468
	32	11	3.026	2.940	-0.0860	[-1.9022, 1.7301]	0.931
	33	10	2.709	3.715	1.0062	[-0.8849, 2.8972]	0.341
	34	10	2.666	3.263	0.5969	[-0.9561, 2.1499]	0.483
	35	10	2.814	3.682	0.8681	[-0.4838, 2.2200]	0.259
	36	10	2.898	3.512	0.6136	[-0.9833, 2.2105]	0.490
	37	10	2.677	2.836	0.1596	[-1.6139, 1.9331]	0.869
	38	10	2.571	3.113	0.5416	[-0.7492, 1.8323]	0.458
	39	10	2.431	2.571	0.1400	[-0.7481, 1.0281]	0.777
	40	10	2.537	2.883	0.3454	[-0.6446, 1.3355]	0.535
	41	10	2.395	2.611	0.2155	[-0.8601, 1.2910]	0.719
	42	11	2.336	2.427	0.0912	[-0.7298, 0.9122]	0.843
	43	12	2.448	2.160	-0.2876	[-0.8216, 0.2465]	0.352

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 26 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	44	12	2.420	2.680	0.2600	[-0.7484, 1.2685]	0.650
	45	12	2.557	2.929	0.3718	[-0.7646, 1.5081]	0.563
	46	12	2.686	2.608	-0.0780	[-0.8506, 0.6945]	0.858
	47	12	2.427	2.850	0.4227	[-0.4433, 1.2887]	0.397
	48	12	2.458	2.516	0.0579	[-0.5724, 0.6881]	0.871
	49	12	2.367	3.443	1.0756	[-0.1535, 2.3046]	0.144
	50	12	2.758	3.379	0.6218	[-0.5626, 1.8063]	0.361
	51	11	2.759	3.161	0.4025	[-0.9777, 1.7827]	0.602
	52	11	2.451	3.176	0.7257	[-0.5751, 2.0265]	0.330
	53	11	2.371	2.893	0.5227	[-0.8154, 1.8607]	0.492
	54	11	2.434	2.435	0.0011	[-1.2373, 1.2396]	0.999
	55	11	2.381	2.913	0.5322	[-0.7842, 1.8485]	0.478
	56	11	2.352	3.030	0.6777	[-0.6732, 2.0285]	0.382
	57	11	2.568	3.160	0.5914	[-0.6662, 1.8491]	0.411
	58	11	2.518	2.647	0.1289	[-1.2368, 1.4945]	0.866
	59	11	2.562	2.704	0.1421	[-0.8473, 1.1315]	0.798
	60	11	2.679	2.828	0.1492	[-0.9996, 1.2979]	0.817
	61	11	2.489	2.600	0.1109	[-0.8943, 1.1162]	0.844
	62	11	2.624	2.891	0.2662	[-0.8223, 1.3547]	0.665
	72	9	2.357	2.311	-0.0460	[-0.8438, 0.7519]	0.915
	73	9	2.539	2.158	-0.3810	[-0.9622, 0.2001]	0.250
	74	9	2.577	2.077	-0.5004	[-1.2627, 0.2619]	0.249
	75	9	2.560	2.225	-0.3352	[-1.0220, 0.3516]	0.380
	76	9	2.535	2.138	-0.3965	[-1.2897, 0.4967]	0.421
	77	9	2.525	2.523	-0.0025	[-0.5684, 0.5635]	0.993
	78	9	2.501	2.766	0.2650	[-0.7873, 1.3173]	0.642
	79	9	2.455	2.199	-0.2557	[-1.1093, 0.5978]	0.582
	80	9	3.106	2.046	-1.0603	[-2.3724, 0.2519]	0.167

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 27 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	81	9	2.546	2.495	-0.0509	[-0.7197, 0.6178]	0.887
	82	9	2.497	2.274	-0.2231	[-0.6339, 0.1876]	0.332
	83	9	2.600	2.281	-0.3192	[-0.9385, 0.3000]	0.355
	84	9	2.689	2.420	-0.2694	[-0.8820, 0.3432]	0.426
	85	9	2.562	2.163	-0.3993	[-1.3749, 0.5764]	0.457
	86	9	2.522	2.384	-0.1386	[-1.0737, 0.7965]	0.783
	87	9	2.544	2.289	-0.2550	[-1.1651, 0.6550]	0.606
	88	9	2.504	2.259	-0.2451	[-0.9064, 0.4161]	0.498
	89	9	2.514	2.201	-0.3132	[-0.9338, 0.3074]	0.371
	90	9	2.445	2.176	-0.2695	[-0.7866, 0.2476]	0.356
	91	9	2.489	2.055	-0.4344	[-0.8459, -0.0228]	0.086
	92	9	2.484	2.227	-0.2574	[-0.7120, 0.1973]	0.319
	93	10	2.704	2.317	-0.3870	[-1.0086, 0.2345]	0.280
	94	10	2.670	2.018	-0.6517	[-1.1707, -0.1327]	0.048
	99	11	2.633	2.766	0.1331	[-1.1435, 1.4097]	0.849
	100	11	2.606	2.025	-0.5813	[-1.2496, 0.0871]	0.142
	101	11	2.995	2.847	-0.1483	[-1.0656, 0.7690]	0.764
	102	11	2.846	2.868	0.0216	[-1.1359, 1.1791]	0.972
	103	11	2.708	2.906	0.1983	[-1.1305, 1.5272]	0.782
	104	11	2.781	2.312	-0.4696	[-1.2478, 0.3087]	0.291
	105	11	2.692	2.169	-0.5231	[-1.2164, 0.1702]	0.196
	106	11	2.641	2.010	-0.6311	[-1.3187, 0.0564]	0.126
	107	11	2.930	2.287	-0.6433	[-1.3148, 0.0282]	0.112
	108	11	2.674	1.994	-0.6797	[-1.5209, 0.1615]	0.170
	109	11	2.765	2.220	-0.5448	[-1.1753, 0.0857]	0.146
	110	11	2.468	2.479	0.0108	[-0.8360, 0.8575]	0.981
	111	11	2.714	2.486	-0.2280	[-0.8391, 0.3830]	0.502
	112	11	2.670	2.387	-0.2833	[-0.9055, 0.3389]	0.417

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 28 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	113	11	2.381	2.099	-0.2822	[-0.8114, 0.2470]	0.350
	114	11	2.500	1.975	-0.5247	[-1.0735, 0.0242]	0.113
	115	11	2.442	2.107	-0.3357	[-0.8769, 0.2055]	0.282
	116	11	2.630	2.333	-0.2972	[-0.8029, 0.2085]	0.306
	118	10	2.597	1.980	-0.6169	[-1.1930, -0.0409]	0.082
	119	10	2.622	2.101	-0.5203	[-1.0134, -0.0272]	0.085
	120	10	2.428	1.928	-0.4996	[-1.0164, 0.0172]	0.110
	121	10	2.801	2.815	0.0140	[-0.8635, 0.8915]	0.977
	122	10	2.926	2.461	-0.4650	[-1.2968, 0.3669]	0.329
	123	11	2.575	2.093	-0.4811	[-0.9729, 0.0107]	0.107
	124	11	2.674	2.075	-0.5994	[-1.3800, 0.1811]	0.193
	125	11	2.452	2.245	-0.2076	[-0.9607, 0.5456]	0.626
	126	11	2.670	2.644	-0.0265	[-1.0118, 0.9589]	0.962
	127	11	2.554	2.077	-0.4767	[-0.9236, -0.0297]	0.082
	128	11	2.446	2.131	-0.3150	[-0.9233, 0.2933]	0.367
	129	11	2.627	2.228	-0.3991	[-1.0400, 0.2418]	0.283
	130	11	2.635	2.270	-0.3651	[-0.8169, 0.0868]	0.173
	131	11	2.394	2.101	-0.2928	[-0.8964, 0.3108]	0.397
	132	11	2.699	2.114	-0.5845	[-1.0872, -0.0817]	0.062
	133	10	2.433	2.349	-0.0837	[-0.4973, 0.3300]	0.717
	134	11	2.642	2.408	-0.2343	[-0.7714, 0.3027]	0.444
	135	11	2.794	2.273	-0.5206	[-0.9651, -0.0762]	0.060
	136	11	2.290	2.083	-0.2072	[-0.8582, 0.4439]	0.574
	137	11	2.700	2.249	-0.4515	[-0.9096, 0.0066]	0.104
	138	11	3.049	2.677	-0.3716	[-0.9498, 0.2067]	0.269
	139	11	2.922	2.506	-0.4155	[-1.4582, 0.6272]	0.484
	140	11	2.492	2.654	0.1622	[-0.9614, 1.2858]	0.797
	141	11	2.879	2.128	-0.7515	[-1.3435, -0.1594]	0.045

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 29 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	142	11	2.445	2.590	0.1448	[-0.7048, 0.9945]	0.762
	143	11	2.507	2.410	-0.0975	[-0.8721, 0.6771]	0.823
	144	11	2.539	2.119	-0.4201	[-0.8878, 0.0477]	0.134
	145	10	2.847	2.441	-0.4061	[-0.8655, 0.0534]	0.139
	146	10	2.757	2.241	-0.5163	[-1.2807, 0.2481]	0.245
	147	10	3.179	2.609	-0.5699	[-1.0048, -0.1350]	0.041
	148	10	3.191	2.678	-0.5136	[-0.8703, -0.1569]	0.028
	149	10	3.341	2.549	-0.7925	[-1.3115, -0.2735]	0.022
	150	10	3.239	2.513	-0.7264	[-1.1933, -0.2594]	0.020
	151	10	3.253	2.470	-0.7830	[-1.2527, -0.3133]	0.015
	152	10	3.366	2.654	-0.7118	[-1.1073, -0.3163]	0.010
	153	10	3.372	2.767	-0.6047	[-1.1571, -0.0524]	0.076
	154	10	3.218	2.640	-0.5781	[-1.0243, -0.1318]	0.043
	155	10	3.291	2.526	-0.7651	[-1.3795, -0.1507]	0.049
	156	10	3.172	2.776	-0.3954	[-1.0098, 0.2191]	0.266
	157	10	3.198	2.626	-0.5718	[-1.0785, -0.0651]	0.069
	158	10	3.255	2.525	-0.7298	[-1.3138, -0.1458]	0.049
	159	10	3.311	2.749	-0.5618	[-1.2172, 0.0935]	0.150
	160	10	3.184	2.660	-0.5241	[-1.0773, 0.0292]	0.116
	161	10	3.212	3.212	0.0002	[-1.3110, 1.3113]	1.000
	162	10	3.333	3.072	-0.2615	[-1.5426, 1.0196]	0.714
	163	11	3.060	2.997	-0.0627	[-1.1341, 1.0087]	0.917
	164	11	3.105	2.561	-0.5437	[-1.3659, 0.2785]	0.254
	165	11	2.689	2.924	0.2349	[-1.0198, 1.4896]	0.737
	166	11	2.716	2.872	0.1555	[-0.9099, 1.2208]	0.793
	167	11	2.558	2.414	-0.1444	[-1.0936, 0.8049]	0.784
	168	11	3.028	2.783	-0.2449	[-1.2466, 0.7569]	0.662
	169	10	2.781	2.532	-0.2486	[-1.0128, 0.5156]	0.557

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 30 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	170	10	2.673	2.807	0.1344	[-0.5867, 0.8555]	0.734
	171	10	2.914	2.499	-0.4151	[-1.6615, 0.8312]	0.548
	172	10	2.936	2.441	-0.4950	[-1.0031, 0.0130]	0.107
	173	10	2.998	1.822	-1.1757	[-1.9667, -0.3848]	0.028
	174	10	2.950	2.217	-0.7323	[-1.3489, -0.1158]	0.060
	175	10	2.811	2.188	-0.6229	[-1.0967, -0.1491]	0.043
	176	10	2.887	2.425	-0.4611	[-1.2965, 0.3742]	0.325
	177	10	2.772	2.550	-0.2213	[-1.7263, 1.2837]	0.785
	178	10	2.674	2.507	-0.1666	[-1.7151, 1.3820]	0.841
	179	10	2.529	2.606	0.0768	[-1.5645, 1.7180]	0.931
	180	10	2.624	2.927	0.3028	[-0.9663, 1.5720]	0.659
	181	10	2.533	2.617	0.0841	[-0.9728, 1.1411]	0.882
	182	10	2.717	2.444	-0.2727	[-1.1569, 0.6114]	0.561
	183	10	2.780	2.395	-0.3846	[-1.2030, 0.4339]	0.387
	184	10	2.804	2.267	-0.5363	[-1.1698, 0.0972]	0.149
	185	9	2.993	2.226	-0.7668	[-1.1062, -0.4275]	0.009
	189	9	2.450	2.481	0.0311	[-1.6211, 1.6832]	0.971
	190	9	2.691	2.355	-0.3360	[-0.7142, 0.0422]	0.133
	191	9	2.576	2.738	0.1617	[-1.5618, 1.8851]	0.857
	192	9	2.921	2.434	-0.4870	[-1.2152, 0.2411]	0.236
	193	9	2.768	2.409	-0.3594	[-0.8799, 0.1611]	0.223
	194	9	2.829	2.098	-0.7304	[-1.3202, -0.1406]	0.055
	195	9	2.894	2.235	-0.6593	[-1.4018, 0.0833]	0.134
	196	9	2.784	3.096	0.3123	[-1.4590, 2.0836]	0.737
	197	9	2.971	2.510	-0.4614	[-0.8901, -0.0328]	0.081
	198	10	2.846	2.732	-0.1140	[-0.9616, 0.7337]	0.806
	199	10	2.580	2.777	0.1967	[-0.9198, 1.3133]	0.748
	200	10	2.345	2.791	0.4454	[-0.7158, 1.6066]	0.491

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 31 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	201	10	2.373	2.935	0.5619	[-0.6249, 1.7486]	0.400
	202	10	2.676	2.529	-0.1469	[-0.5873, 0.2935]	0.552
	203	11	3.042	2.192	-0.8506	[-1.5181, -0.1830]	0.044
	204	11	2.368	2.847	0.4795	[-0.6649, 1.6238]	0.462
	205	11	2.928	2.856	-0.0716	[-0.4721, 0.3289]	0.751
	206	11	2.398	2.636	0.2381	[-0.6816, 1.1578]	0.646
	211	10	2.689	2.261	-0.4278	[-1.0653, 0.2097]	0.247
	212	10	2.635	2.328	-0.3071	[-1.1102, 0.4961]	0.497
	213	10	2.423	2.206	-0.2165	[-0.7038, 0.2709]	0.433
	214	10	2.878	2.120	-0.7584	[-1.5983, 0.0815]	0.132
	215	10	2.302	2.483	0.1806	[-0.6886, 1.0498]	0.709
	216	10	2.341	2.317	-0.0241	[-0.4638, 0.4157]	0.921
	217	10	2.535	2.472	-0.0627	[-0.5133, 0.3880]	0.802
	218	10	2.524	2.410	-0.1131	[-0.4985, 0.2723]	0.600
	219	10	2.365	2.786	0.4215	[-0.4126, 1.2555]	0.375
	220	10	2.761	2.636	-0.1251	[-1.0663, 0.8161]	0.811
	221	10	2.652	2.954	0.3015	[-0.7480, 1.3511]	0.603
	222	10	2.616	2.799	0.1832	[-0.7872, 1.1535]	0.731
	223	10	2.517	2.645	0.1284	[-0.8417, 1.0984]	0.809
	224	10	2.450	2.036	-0.4134	[-0.6822, -0.1446]	0.023
	225	10	2.678	2.288	-0.3900	[-0.6196, -0.1605]	0.016
	226	10	3.043	2.787	-0.2561	[-1.7472, 1.2350]	0.750
	227	10	2.470	2.203	-0.2670	[-0.4695, -0.0645]	0.043
	228	10	2.874	2.418	-0.4566	[-1.3470, 0.4339]	0.358
	229	11	2.886	2.480	-0.4057	[-1.3370, 0.5257]	0.436
	230	11	2.332	2.424	0.0918	[-0.6604, 0.8439]	0.826
	231	11	2.411	2.092	-0.3193	[-0.7639, 0.1253]	0.218
	232	11	2.434	2.447	0.0129	[-0.5868, 0.6127]	0.969

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 32 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 04	233	11	2.560	2.816	0.2560	[-0.8800, 1.3919]	0.686
	234	11	2.119	2.550	0.4317	[-0.6967, 1.5602]	0.497
	235	10	1.973	2.890	0.9170	[-0.2286, 2.0627]	0.175
	236	11	2.187	2.842	0.6552	[-0.5522, 1.8626]	0.346
	237	11	2.577	2.417	-0.1607	[-0.5696, 0.2482]	0.490
	238	11	2.593	2.481	-0.1122	[-1.1596, 0.9352]	0.849
	239	11	2.369	2.297	-0.0720	[-0.7608, 0.6167]	0.852
Channel 05	1	12	4.014	4.708	0.6937	[-1.3851, 2.7725]	0.559
	2	12	3.597	5.896	2.2991	[0.5889, 4.0092]	0.035
	3	12	3.594	5.719	2.1250	[0.4682, 3.7818]	0.042
	4	12	3.710	6.200	2.4899	[0.7095, 4.2702]	0.030
	5	12	3.272	6.491	3.2191	[1.5682, 4.8699]	0.005
	6	12	3.220	6.639	3.4198	[1.7365, 5.1031]	0.004
	7	12	3.213	6.858	3.6449	[2.4156, 4.8741]	<0.001
	8	12	3.089	6.372	3.2835	[1.8819, 4.6851]	0.002
	9	12	3.364	6.538	3.1739	[1.6715, 4.6763]	0.003
	10	12	3.171	6.462	3.2916	[1.8603, 4.7228]	0.002
	11	12	2.972	6.112	3.1402	[1.6653, 4.6151]	0.003
	12	12	3.117	6.153	3.0361	[1.3099, 4.7624]	0.010
	13	12	2.700	5.455	2.7548	[1.2995, 4.2100]	0.006
	14	12	2.665	5.017	2.3514	[0.6956, 4.0072]	0.028
	15	12	2.718	5.000	2.2819	[0.5279, 4.0360]	0.040
	16	12	3.229	5.254	2.0245	[-0.0598, 4.1089]	0.109
	17	12	2.745	4.783	2.0381	[0.4197, 3.6565]	0.046
	18	12	2.742	4.353	1.6104	[0.0538, 3.1671]	0.090
	19	12	2.669	4.314	1.6448	[0.0684, 3.2213]	0.088
	20	12	2.580	4.141	1.5614	[0.0257, 3.0971]	0.095

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 33 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	21	12	2.887	3.948	1.0611	[-0.8587, 2.9809]	0.337
	22	12	2.617	3.483	0.8658	[-0.7085, 2.4401]	0.336
	23	12	2.590	3.380	0.7902	[-0.7793, 2.3597]	0.377
	24	12	2.549	3.159	0.6107	[-0.9425, 2.1639]	0.486
	25	12	2.511	3.022	0.5115	[-0.9463, 1.9693]	0.532
	26	12	2.520	2.911	0.3913	[-0.9642, 1.7469]	0.606
	27	12	2.490	3.406	0.9154	[-0.6447, 2.4755]	0.307
	28	12	2.463	3.147	0.6846	[-0.7375, 2.1067]	0.397
	29	12	2.541	3.160	0.6188	[-0.8761, 2.1136]	0.464
	30	12	2.486	3.047	0.5610	[-0.8811, 2.0030]	0.490
	31	12	2.490	2.760	0.2700	[-0.8118, 1.3519]	0.655
	32	11	2.746	2.679	-0.0668	[-1.3881, 1.2544]	0.926
	33	10	2.714	3.626	0.9122	[-0.5957, 2.4201]	0.284
	34	10	2.641	3.101	0.4598	[-0.5713, 1.4909]	0.420
	35	10	2.487	3.157	0.6706	[-0.5646, 1.9058]	0.332
	36	10	2.822	2.623	-0.1984	[-1.6140, 1.2172]	0.798
	37	10	2.782	2.463	-0.3194	[-1.8709, 1.2321]	0.708
	38	10	2.949	2.415	-0.5339	[-1.7020, 0.6342]	0.420
	39	10	2.231	2.687	0.4564	[-0.3589, 1.2716]	0.328
	40	10	2.613	3.149	0.5359	[-0.3789, 1.4506]	0.308
	41	10	2.303	2.739	0.4363	[-0.3263, 1.1990]	0.318
	42	11	2.297	2.296	-0.0008	[-0.3163, 0.3148]	0.997
	43	12	2.467	2.458	-0.0085	[-0.5649, 0.5479]	0.978
	44	12	2.493	2.543	0.0500	[-0.5583, 0.6583]	0.885
	45	12	2.459	2.564	0.1051	[-0.6078, 0.8181]	0.793
	46	12	2.535	2.490	-0.0449	[-0.6726, 0.5827]	0.899
	47	12	2.481	2.633	0.1522	[-0.4931, 0.7976]	0.678
	48	12	2.490	2.657	0.1675	[-0.5188, 0.8539]	0.668

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 34 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	49	12	2.484	2.813	0.3292	[-0.4107, 1.0692]	0.439
	50	12	2.463	3.132	0.6682	[-0.2963, 1.6327]	0.236
	51	11	2.501	2.845	0.3442	[-0.7723, 1.4606]	0.582
	52	11	2.528	2.428	-0.1009	[-0.6570, 0.4553]	0.745
	53	11	2.501	2.569	0.0674	[-0.6123, 0.7471]	0.860
	54	11	2.940	2.558	-0.3825	[-1.6163, 0.8513]	0.584
	55	11	2.480	2.227	-0.2535	[-0.7641, 0.2572]	0.387
	56	11	2.457	2.281	-0.1768	[-0.7576, 0.4040]	0.590
	57	11	2.626	2.302	-0.3241	[-0.8630, 0.2148]	0.299
	58	11	2.475	2.421	-0.0545	[-0.9142, 0.8053]	0.910
	59	11	2.581	2.480	-0.1005	[-0.8942, 0.6932]	0.822
	60	11	2.461	2.489	0.0284	[-0.9383, 0.9951]	0.958
	61	11	2.483	2.442	-0.0413	[-0.9510, 0.8683]	0.935
	62	11	2.449	2.369	-0.0801	[-0.8577, 0.6975]	0.854
	72	9	2.385	2.231	-0.1539	[-0.9581, 0.6503]	0.723
	73	9	2.402	2.183	-0.2197	[-0.9848, 0.5454]	0.597
	74	9	2.616	2.335	-0.2809	[-0.8962, 0.3343]	0.409
	75	9	2.543	2.220	-0.3232	[-0.9064, 0.2599]	0.323
	76	9	2.455	2.057	-0.3975	[-0.9926, 0.1975]	0.242
	77	9	2.431	2.051	-0.3799	[-0.9803, 0.2205]	0.265
	78	9	2.443	1.999	-0.4438	[-1.0147, 0.1270]	0.182
	79	9	2.483	2.008	-0.4741	[-1.0961, 0.1479]	0.189
	80	9	2.460	1.989	-0.4709	[-1.1552, 0.2134]	0.230
	81	9	2.515	1.981	-0.5336	[-1.2014, 0.1341]	0.171
	82	9	2.440	1.954	-0.4858	[-1.0044, 0.0328]	0.119
	83	9	2.460	2.000	-0.4602	[-1.0246, 0.1043]	0.164
	84	9	2.488	1.989	-0.4988	[-1.0408, 0.0432]	0.124
	85	9	2.459	1.983	-0.4767	[-1.0097, 0.0562]	0.133

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 35 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	86	9	2.477	2.056	-0.4201	[-1.0180, 0.1778]	0.221
	87	9	2.499	2.055	-0.4435	[-1.0233, 0.1363]	0.188
	88	9	2.481	2.125	-0.3568	[-0.9462, 0.2327]	0.284
	89	9	2.763	2.044	-0.7192	[-1.5967, 0.1583]	0.164
	90	9	2.517	2.030	-0.4870	[-0.9594, -0.0146]	0.092
	91	9	2.425	2.019	-0.4059	[-0.8006, -0.0111]	0.092
	92	9	2.545	2.013	-0.5327	[-0.9179, -0.1475]	0.034
	93	10	2.680	2.058	-0.6223	[-1.1214, -0.1232]	0.049
	94	10	2.674	2.086	-0.5878	[-1.0823, -0.0933]	0.058
	99	11	2.466	2.364	-0.1014	[-0.9456, 0.7428]	0.827
	100	11	2.427	2.368	-0.0589	[-1.0306, 0.9128]	0.910
	101	11	2.605	2.090	-0.5145	[-1.1442, 0.1153]	0.163
	102	11	2.550	1.958	-0.5920	[-1.0986, -0.0855]	0.064
	103	11	2.606	2.106	-0.5005	[-0.9991, -0.0018]	0.099
	104	11	2.451	2.110	-0.3415	[-1.1371, 0.4542]	0.443
	105	11	2.498	2.093	-0.4046	[-1.0919, 0.2828]	0.302
	106	11	2.470	1.976	-0.4942	[-1.0786, 0.0901]	0.153
	107	11	2.506	1.934	-0.5717	[-1.1625, 0.0191]	0.109
	108	11	2.432	2.029	-0.4029	[-1.0358, 0.2299]	0.267
	109	11	2.416	1.962	-0.4540	[-1.0711, 0.1632]	0.206
	110	11	2.437	1.954	-0.4826	[-1.0844, 0.1192]	0.173
	111	11	2.434	1.892	-0.5426	[-1.0898, 0.0046]	0.102
	112	11	2.355	1.891	-0.4635	[-1.0928, 0.1658]	0.206
	113	11	2.371	1.940	-0.4312	[-1.0041, 0.1418]	0.199
	114	11	2.361	1.910	-0.4513	[-0.9725, 0.0698]	0.146
	115	11	2.414	1.854	-0.5601	[-1.0743, -0.0459]	0.077
	116	11	2.422	1.934	-0.4875	[-0.9873, 0.0123]	0.107
	118	10	2.405	1.975	-0.4300	[-0.9375, 0.0775]	0.154

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 36 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	119	10	2.454	2.012	-0.4421	[-0.9467, 0.0626]	0.142
	120	10	2.407	1.963	-0.4435	[-0.9439, 0.0568]	0.138
	121	10	2.364	2.013	-0.3516	[-0.8715, 0.1683]	0.244
	122	10	2.708	2.301	-0.4072	[-0.9001, 0.0857]	0.163
	123	11	2.266	1.999	-0.2662	[-0.7573, 0.2250]	0.346
	124	11	2.323	1.987	-0.3357	[-0.7949, 0.1236]	0.213
	125	11	2.341	1.938	-0.4029	[-0.8803, 0.0746]	0.156
	126	11	2.329	2.074	-0.2544	[-0.6662, 0.1575]	0.287
	127	11	2.379	2.068	-0.3106	[-0.7707, 0.1494]	0.247
	128	11	2.259	1.946	-0.3135	[-0.7929, 0.1660]	0.261
	129	11	2.619	2.122	-0.4971	[-1.3315, 0.3373]	0.303
	130	11	2.263	1.996	-0.2675	[-0.6963, 0.1613]	0.282
	131	11	1.858	1.932	0.0740	[-0.9479, 1.0959]	0.897
	132	11	1.871	1.994	0.1230	[-0.9157, 1.1617]	0.833
	133	10	1.575	1.957	0.3817	[-0.4694, 1.2329]	0.428
	134	11	1.846	2.127	0.2802	[-0.7529, 1.3133]	0.631
	135	11	2.237	2.242	0.0046	[-0.8629, 0.8721]	0.992
	136	11	2.022	1.960	-0.0619	[-1.0568, 0.9331]	0.912
	137	11	2.381	1.904	-0.4764	[-0.9419, -0.0110]	0.093
	138	11	2.148	2.325	0.1764	[-0.7641, 1.1170]	0.739
	139	11	2.259	2.029	-0.2292	[-0.8374, 0.3789]	0.507
	140	11	1.901	2.183	0.2816	[-0.8784, 1.4415]	0.667
	141	11	2.190	2.527	0.3372	[-0.5507, 1.2251]	0.504
	142	11	2.340	2.099	-0.2413	[-0.7669, 0.2843]	0.422
	143	11	2.234	2.162	-0.0717	[-0.8335, 0.6901]	0.867
	144	11	2.462	2.092	-0.3700	[-0.7872, 0.0471]	0.138
	145	10	2.584	2.462	-0.1221	[-1.1379, 0.8937]	0.829
	146	10	3.057	2.260	-0.7972	[-2.1277, 0.5334]	0.298

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 37 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	147	10	3.199	2.079	-1.1201	[-2.4689, 0.2287]	0.161
	148	10	3.039	2.059	-0.9805	[-2.4026, 0.4416]	0.236
	149	10	3.184	2.058	-1.1257	[-2.5298, 0.2783]	0.174
	150	10	3.206	2.143	-1.0627	[-2.3083, 0.1828]	0.151
	151	10	3.176	2.112	-1.0637	[-2.3301, 0.2026]	0.157
	152	10	3.095	2.402	-0.6928	[-1.1774, -0.2081]	0.029
	153	10	3.053	2.536	-0.5170	[-1.1018, 0.0678]	0.139
	154	10	2.986	2.554	-0.4317	[-0.8907, 0.0273]	0.118
	155	10	2.917	2.335	-0.5822	[-1.0789, -0.0854]	0.061
	156	10	3.021	2.639	-0.3814	[-1.0622, 0.2993]	0.328
	157	10	3.249	2.514	-0.7350	[-1.3421, -0.1280]	0.054
	158	10	2.704	2.107	-0.5965	[-1.1365, -0.0565]	0.074
	159	10	2.659	2.141	-0.5180	[-1.0393, 0.0032]	0.102
	160	10	2.902	2.373	-0.5288	[-0.9847, -0.0729]	0.063
	161	10	2.791	2.125	-0.6664	[-1.2117, -0.1211]	0.053
	162	10	2.952	2.294	-0.6583	[-1.2167, -0.0999]	0.060
	163	11	2.618	2.247	-0.3703	[-0.9511, 0.2104]	0.272
	164	11	2.553	2.216	-0.3370	[-1.1242, 0.4502]	0.449
	165	11	2.618	2.131	-0.4871	[-1.0266, 0.0525]	0.132
	166	11	2.540	2.473	-0.0663	[-0.7750, 0.6425]	0.866
	167	11	2.549	2.350	-0.1986	[-1.1361, 0.7388]	0.704
	168	11	2.507	2.366	-0.1417	[-1.1431, 0.8597]	0.799
	169	10	2.343	2.180	-0.1634	[-0.8320, 0.5051]	0.657
	170	10	2.361	2.367	0.0063	[-1.1337, 1.1463]	0.992
	171	10	2.479	2.417	-0.0622	[-1.2719, 1.1476]	0.925
	172	10	2.720	2.173	-0.5471	[-1.8666, 0.7725]	0.451
	173	10	2.800	1.912	-0.8878	[-2.3695, 0.5939]	0.288
	174	10	2.810	2.455	-0.3546	[-2.5216, 1.8124]	0.761

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 38 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	175	10	2.719	2.444	-0.2751	[-2.4243, 1.8741]	0.812
	176	10	2.703	2.432	-0.2707	[-1.1166, 0.5753]	0.557
	177	10	2.556	2.584	0.0275	[-1.5189, 1.5740]	0.974
	178	10	2.609	2.251	-0.3585	[-1.4714, 0.7544]	0.554
	179	10	2.486	2.513	0.0270	[-1.3727, 1.4267]	0.971
	180	10	2.563	2.075	-0.4877	[-1.0425, 0.0670]	0.138
	181	10	2.579	2.284	-0.2951	[-1.2773, 0.6871]	0.581
	182	10	2.623	1.995	-0.6283	[-1.4603, 0.2037]	0.189
	183	10	2.685	2.027	-0.6577	[-1.6440, 0.3287]	0.237
	184	10	2.580	1.992	-0.5884	[-1.6105, 0.4338]	0.298
	185	9	2.795	1.804	-0.9905	[-2.0801, 0.0991]	0.125
	189	9	2.489	2.314	-0.1756	[-1.4983, 1.1471]	0.800
	190	9	2.553	1.925	-0.6283	[-1.3700, 0.1134]	0.149
	191	9	2.542	2.057	-0.4854	[-1.2531, 0.2823]	0.259
	192	9	2.620	2.392	-0.2281	[-1.5819, 1.1256]	0.748
	193	9	2.499	2.451	-0.0481	[-1.4278, 1.3316]	0.947
	194	9	2.531	2.052	-0.4788	[-1.0395, 0.0818]	0.146
	195	9	2.500	1.968	-0.5322	[-0.9939, -0.0705]	0.068
	196	9	2.510	2.084	-0.4255	[-1.1052, 0.2542]	0.263
	197	9	2.463	1.954	-0.5090	[-0.8675, -0.1505]	0.033
	198	10	2.250	2.093	-0.1564	[-0.9015, 0.5886]	0.703
	199	10	2.902	2.409	-0.4929	[-0.9358, -0.0500]	0.073
	200	10	1.840	2.003	0.1636	[-0.9519, 1.2791]	0.789
	201	10	2.320	2.026	-0.2940	[-0.5864, -0.0017]	0.098
	202	10	1.771	2.031	0.2606	[-0.7507, 1.2718]	0.645
	203	11	1.784	2.260	0.4766	[-0.5241, 1.4773]	0.405
	204	11	1.812	2.093	0.2813	[-0.7631, 1.3258]	0.633
	205	11	2.110	2.042	-0.0680	[-0.6019, 0.4658]	0.821

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 39 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	206	11	2.264	1.980	-0.2836	[-0.5968, 0.0296]	0.131
	211	10	2.312	2.167	-0.1455	[-0.5598, 0.2687]	0.532
	212	10	1.931	2.016	0.0851	[-0.7553, 0.9256]	0.855
	213	10	1.933	1.970	0.0373	[-0.9931, 1.0676]	0.948
	214	10	2.076	2.410	0.3346	[-0.4892, 1.1584]	0.472
	215	10	2.461	2.172	-0.2890	[-1.2619, 0.6839]	0.596
	216	10	2.570	2.048	-0.5222	[-1.3440, 0.2997]	0.271
	217	10	1.914	2.082	0.1682	[-0.6187, 0.9551]	0.701
	218	10	1.779	2.018	0.2390	[-0.8326, 1.3106]	0.689
	219	10	1.665	2.203	0.5386	[-0.5821, 1.6593]	0.398
	220	10	1.728	2.025	0.2966	[-0.7697, 1.3629]	0.619
	221	10	1.748	2.124	0.3762	[-0.8998, 1.6522]	0.594
	222	10	1.782	2.571	0.7894	[-0.6680, 2.2467]	0.339
	223	10	1.774	2.525	0.7506	[-0.6935, 2.1947]	0.358
	224	10	2.050	2.202	0.1523	[-0.3654, 0.6699]	0.595
	225	10	1.914	2.285	0.3712	[-0.8556, 1.5979]	0.578
	226	10	1.874	2.921	1.0468	[-0.5721, 2.6657]	0.256
	227	10	1.788	2.939	1.1511	[-0.6714, 2.9735]	0.266
	228	10	1.818	2.911	1.0930	[-0.6048, 2.7908]	0.258
	229	11	1.937	2.682	0.7448	[-0.2767, 1.7662]	0.210
	230	11	1.932	2.264	0.3313	[-0.5698, 1.2323]	0.513
	231	11	2.000	2.105	0.1049	[-0.5782, 0.7881]	0.782
	232	11	1.981	2.102	0.1213	[-0.4976, 0.7402]	0.725
	233	11	2.073	2.134	0.0618	[-0.4527, 0.5764]	0.829
	234	11	2.029	2.305	0.2754	[-0.5412, 1.0921]	0.548
	235	10	2.094	2.153	0.0593	[-0.4161, 0.5347]	0.822
	236	11	2.157	2.432	0.2754	[-0.5502, 1.1009]	0.556
	237	11	2.207	2.326	0.1192	[-0.5301, 0.7686]	0.744

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 40 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 05	238	11	2.283	2.049	-0.2336	[-0.7074, 0.2402]	0.390
	239	11	2.260	2.032	-0.2278	[-0.7391, 0.2836]	0.435
Channel 06	1	12	2.970	3.732	0.7614	[-1.1532, 2.6760]	0.488
	2	12	3.217	4.864	1.6469	[-0.3808, 3.6746]	0.172
	3	12	3.310	5.612	2.3027	[0.0318, 4.5737]	0.096
	4	12	2.790	5.775	2.9858	[1.1563, 4.8153]	0.014
	5	12	2.996	5.646	2.6495	[0.8574, 4.4416]	0.023
	6	12	2.682	6.055	3.3734	[1.9447, 4.8021]	0.002
	7	12	2.760	6.615	3.8555	[2.4212, 5.2898]	<0.001
	8	12	2.708	6.213	3.5054	[1.8966, 5.1141]	0.003
	9	12	2.718	5.711	2.9930	[1.4101, 4.5760]	0.006
	10	12	2.634	5.913	3.2792	[1.9389, 4.6194]	0.001
	11	12	2.805	5.464	2.6594	[1.5469, 3.7720]	0.001
	12	12	2.782	5.299	2.5172	[0.8079, 4.2266]	0.024
	13	12	2.600	5.405	2.8054	[1.5202, 4.0906]	0.003
	14	12	2.573	5.005	2.4316	[0.9896, 3.8736]	0.012
	15	12	2.586	4.808	2.2219	[0.6088, 3.8350]	0.032
	16	12	2.645	5.132	2.4871	[0.8686, 4.1056]	0.019
	17	12	2.623	4.716	2.0925	[0.4966, 3.6883]	0.039
	18	12	2.577	4.555	1.9776	[0.4073, 3.5480]	0.046
	19	12	2.598	4.535	1.9370	[0.3366, 3.5374]	0.053
	20	12	2.559	4.128	1.5688	[0.0004, 3.1373]	0.100
	21	12	2.604	3.752	1.1479	[-0.4684, 2.7642]	0.225
	22	12	2.560	3.292	0.7320	[-0.6456, 2.1097]	0.352
	23	12	2.689	3.229	0.5396	[-0.8445, 1.9236]	0.489
	24	12	2.521	3.464	0.9426	[-0.5615, 2.4468]	0.277
	25	12	2.479	3.360	0.8806	[-0.5430, 2.3042]	0.283

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 41 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	26	12	2.485	3.274	0.7892	[-0.6729, 2.2513]	0.345
	27	12	2.467	3.369	0.9023	[-0.5854, 2.3900]	0.292
	28	12	2.464	3.203	0.7397	[-0.5993, 2.0786]	0.334
	29	12	2.455	3.144	0.6885	[-0.7154, 2.0925]	0.388
	30	12	2.477	2.787	0.3102	[-0.8731, 1.4935]	0.639
	31	12	2.471	2.666	0.1958	[-0.9110, 1.3026]	0.751
	32	11	2.548	2.736	0.1879	[-1.1227, 1.4985]	0.794
	33	10	2.090	3.329	1.2389	[-0.3946, 2.8725]	0.191
	34	10	2.122	2.957	0.8349	[-0.4453, 2.1151]	0.252
	35	10	2.196	2.688	0.4918	[-0.5819, 1.5655]	0.408
	36	10	2.178	2.608	0.4307	[-0.4518, 1.3131]	0.386
	37	10	2.200	2.547	0.3472	[-0.4897, 1.1842]	0.458
	38	10	2.400	2.699	0.2990	[-0.4743, 1.0724]	0.493
	39	10	2.057	3.103	1.0464	[-0.0602, 2.1529]	0.117
	40	10	2.231	2.939	0.7087	[-0.2189, 1.6362]	0.193
	41	10	2.047	2.860	0.8128	[-0.0964, 1.7220]	0.135
	42	11	2.201	2.742	0.5416	[-0.1634, 1.2466]	0.193
	43	12	2.382	3.046	0.6643	[-0.2724, 1.6010]	0.228
	44	12	2.408	3.085	0.6762	[-0.2575, 1.6099]	0.219
	45	12	2.424	2.821	0.3971	[-0.4283, 1.2225]	0.401
	46	12	2.416	2.862	0.4455	[-0.4052, 1.2961]	0.365
	47	12	2.507	2.962	0.4545	[-0.3793, 1.2882]	0.346
	48	12	2.515	2.817	0.3020	[-0.5003, 1.1044]	0.511
	49	12	2.623	2.768	0.1455	[-0.7859, 1.0768]	0.783
	50	12	2.420	2.670	0.2507	[-0.5180, 1.0194]	0.565
	51	11	2.518	2.976	0.4582	[-0.5667, 1.4830]	0.430
	52	11	2.536	3.068	0.5323	[-0.6713, 1.7359]	0.435
	53	11	2.951	3.013	0.0613	[-1.5727, 1.6954]	0.947

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 42 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	54	11	2.952	2.745	-0.2064	[-1.8065, 1.3937]	0.818
	55	11	2.448	2.519	0.0717	[-0.6420, 0.7853]	0.858
	56	11	2.836	2.440	-0.3965	[-1.3986, 0.6056]	0.487
	57	11	2.613	2.322	-0.2908	[-1.0068, 0.4252]	0.476
	58	11	2.867	2.374	-0.4929	[-1.6077, 0.6218]	0.439
	59	11	2.688	2.200	-0.4873	[-1.3279, 0.3533]	0.316
	60	11	2.982	2.101	-0.8811	[-2.1574, 0.3952]	0.237
	61	11	2.981	2.272	-0.7083	[-2.1139, 0.6972]	0.380
	62	11	2.676	2.330	-0.3461	[-1.2026, 0.5104]	0.478
	72	9	2.876	2.599	-0.2773	[-0.8902, 0.3356]	0.413
	73	9	3.030	2.640	-0.3901	[-1.0591, 0.2790]	0.301
	74	9	2.953	2.659	-0.2939	[-0.9183, 0.3304]	0.396
	75	9	2.927	2.599	-0.3282	[-0.9419, 0.2855]	0.339
	76	9	2.989	2.576	-0.4123	[-1.0625, 0.2379]	0.264
	77	9	3.007	2.586	-0.4210	[-1.0907, 0.2487]	0.268
	78	9	2.622	2.248	-0.3738	[-0.9959, 0.2482]	0.287
	79	9	2.458	2.030	-0.4284	[-1.0565, 0.1997]	0.233
	80	9	2.423	2.007	-0.4165	[-1.0641, 0.2311]	0.258
	81	9	2.818	2.371	-0.4464	[-1.0157, 0.1230]	0.178
	82	9	2.886	2.460	-0.4260	[-0.9240, 0.0720]	0.148
	83	9	2.457	2.020	-0.4362	[-1.0105, 0.1381]	0.190
	84	9	2.524	2.098	-0.4252	[-0.9767, 0.1263]	0.185
	85	9	2.492	2.039	-0.4533	[-0.9587, 0.0521]	0.132
	86	9	2.403	2.065	-0.3376	[-0.8847, 0.2096]	0.276
	87	9	2.928	2.545	-0.3830	[-0.9082, 0.1422]	0.206
	88	9	2.856	2.573	-0.2827	[-0.9018, 0.3365]	0.409
	89	9	2.928	2.116	-0.8118	[-2.1994, 0.5758]	0.304
	90	9	2.958	2.109	-0.8485	[-2.2545, 0.5574]	0.290

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 43 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	91	9	3.004	2.113	-0.8914	[-2.3231, 0.5402]	0.277
	92	9	2.481	2.096	-0.3847	[-0.9761, 0.2066]	0.257
	93	10	2.580	2.062	-0.5178	[-1.0222, -0.0134]	0.093
	94	10	2.908	2.114	-0.7946	[-1.6505, 0.0612]	0.123
	99	11	2.493	2.152	-0.3415	[-0.8407, 0.1578]	0.236
	100	11	2.430	2.243	-0.1864	[-0.8342, 0.4615]	0.596
	101	11	2.435	1.965	-0.4698	[-0.9882, 0.0486]	0.129
	102	11	2.453	1.867	-0.5855	[-1.0242, -0.1469]	0.041
	103	11	2.467	1.861	-0.6055	[-1.1440, -0.0670]	0.072
	104	11	2.502	1.509	-0.9932	[-1.8251, -0.1612]	0.058
	105	11	2.467	1.795	-0.6727	[-1.3580, 0.0127]	0.105
	106	11	2.432	1.669	-0.7631	[-1.4330, -0.0932]	0.068
	107	11	2.490	1.804	-0.6856	[-1.2710, -0.1002]	0.062
	108	11	2.357	1.976	-0.3818	[-1.0118, 0.2482]	0.289
	109	11	2.322	1.729	-0.5937	[-1.3718, 0.1845]	0.192
	110	11	2.559	1.613	-0.9459	[-1.8905, -0.0014]	0.100
	111	11	2.400	1.667	-0.7335	[-1.3275, -0.1395]	0.052
	112	11	2.398	1.767	-0.6318	[-1.3087, 0.0450]	0.120
	113	11	2.327	1.903	-0.4245	[-0.9731, 0.1241]	0.188
	114	11	2.354	1.886	-0.4678	[-0.9957, 0.0600]	0.138
	115	11	2.336	1.845	-0.4911	[-1.0136, 0.0314]	0.119
	116	11	2.472	1.909	-0.5629	[-1.0874, -0.0385]	0.081
	118	10	2.346	1.913	-0.4326	[-0.9566, 0.0914]	0.163
	119	10	2.411	1.956	-0.4554	[-0.9821, 0.0712]	0.147
	120	10	2.449	1.944	-0.5047	[-1.0283, 0.0190]	0.111
	121	10	2.280	1.927	-0.3530	[-0.8782, 0.1722]	0.247
	122	10	2.726	1.909	-0.8169	[-1.6296, -0.0042]	0.099
	123	11	2.468	1.929	-0.5384	[-1.0746, -0.0022]	0.099

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 44 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	124	11	2.670	1.932	-0.7383	[-1.8056, 0.3290]	0.237
	125	11	2.811	1.923	-0.8873	[-2.0389, 0.2643]	0.191
	126	11	2.618	1.913	-0.7045	[-1.7319, 0.3228]	0.240
	127	11	2.362	1.913	-0.4494	[-1.8520, 0.9533]	0.571
	128	11	2.269	1.921	-0.3478	[-1.6948, 0.9991]	0.647
	129	11	1.825	1.895	0.0704	[-0.9879, 1.1286]	0.906
	130	11	2.110	1.880	-0.2307	[-1.6049, 1.1434]	0.765
	131	11	1.908	1.863	-0.0452	[-1.1654, 1.0751]	0.943
	132	11	2.059	1.890	-0.1695	[-1.4820, 1.1430]	0.818
	133	10	1.755	1.826	0.0716	[-1.3173, 1.4605]	0.926
	134	11	2.227	1.993	-0.2331	[-1.7291, 1.2629]	0.782
	135	11	2.264	1.860	-0.4032	[-0.8841, 0.0778]	0.159
	136	11	1.981	1.883	-0.0988	[-1.0688, 0.8711]	0.856
	137	11	2.325	1.890	-0.4345	[-1.9228, 1.0539]	0.606
	138	11	2.608	2.194	-0.4139	[-2.2761, 1.4484]	0.693
	139	11	2.386	1.928	-0.4583	[-1.7925, 0.8758]	0.545
	140	11	1.866	2.069	0.2027	[-0.9851, 1.3905]	0.762
	141	11	1.786	1.958	0.1724	[-0.9991, 1.3440]	0.793
	142	11	2.176	1.998	-0.1786	[-1.3498, 0.9927]	0.786
	143	11	2.163	1.971	-0.1920	[-0.9319, 0.5479]	0.646
	144	11	2.565	2.067	-0.4973	[-2.0132, 1.0185]	0.562
	145	10	2.650	2.051	-0.5990	[-2.3248, 1.1268]	0.537
	146	10	2.858	1.983	-0.8749	[-2.1328, 0.3831]	0.232
	147	10	2.839	1.984	-0.8550	[-2.2411, 0.5312]	0.285
	148	10	2.762	1.968	-0.7934	[-1.9165, 0.3296]	0.225
	149	10	2.973	1.989	-0.9847	[-2.5199, 0.5505]	0.267
	150	10	2.766	2.010	-0.7561	[-2.3832, 0.8710]	0.413
	151	10	2.465	1.994	-0.4709	[-1.9820, 1.0402]	0.578

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 45 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	152	10	2.669	1.968	-0.7014	[-2.4323, 1.0296]	0.473
	153	10	2.658	1.987	-0.6702	[-2.2430, 0.9026]	0.451
	154	10	2.640	2.067	-0.5728	[-2.0456, 0.9000]	0.490
	155	10	2.699	2.012	-0.6868	[-1.9903, 0.6167]	0.356
	156	10	2.597	2.078	-0.5188	[-1.6342, 0.5966]	0.412
	157	10	2.663	2.100	-0.5633	[-1.5565, 0.4299]	0.322
	158	10	2.868	2.046	-0.8219	[-2.0502, 0.4065]	0.249
	159	10	2.727	2.026	-0.7005	[-1.6589, 0.2578]	0.211
	160	10	2.954	2.023	-0.9312	[-2.2133, 0.3509]	0.214
	161	10	2.658	2.076	-0.5819	[-1.2778, 0.1140]	0.159
	162	10	2.610	2.044	-0.5657	[-1.1929, 0.0615]	0.132
	163	11	2.514	2.023	-0.4918	[-1.0017, 0.0182]	0.111
	164	11	3.008	1.953	-1.0552	[-2.3178, 0.2074]	0.159
	165	11	2.759	1.982	-0.7767	[-1.6354, 0.0819]	0.131
	166	11	2.642	2.248	-0.3938	[-1.2795, 0.4920]	0.432
	167	11	2.844	1.966	-0.8779	[-2.0508, 0.2950]	0.201
	168	11	2.671	1.967	-0.7034	[-1.6039, 0.1972]	0.184
	169	10	2.305	2.014	-0.2910	[-0.7928, 0.2109]	0.308
	170	10	2.194	2.033	-0.1608	[-0.7887, 0.4671]	0.642
	171	10	2.615	1.982	-0.6328	[-1.9738, 0.7082]	0.401
	172	10	2.705	1.942	-0.7626	[-2.4164, 0.8912]	0.405
Channel 07	173	10	2.707	1.873	-0.8342	[-2.5157, 0.8473]	0.372
	174	10	2.688	1.874	-0.8133	[-2.3684, 0.7418]	0.349
	175	10	2.618	1.801	-0.8170	[-2.4055, 0.7715]	0.356
	176	10	2.699	1.810	-0.8888	[-2.4784, 0.7009]	0.319
	177	10	2.682	1.884	-0.7975	[-2.2966, 0.7016]	0.341
	178	10	2.655	1.788	-0.8667	[-2.5055, 0.7721]	0.344
	179	10	2.914	1.813	-1.1008	[-3.0581, 0.8566]	0.316

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 46 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	180	10	3.025	1.855	-1.1699	[-2.9261, 0.5862]	0.243
	181	10	2.912	1.837	-1.0750	[-3.0544, 0.9044]	0.332
	182	10	2.762	1.457	-1.3046	[-3.1265, 0.5173]	0.209
	183	10	2.699	1.335	-1.3633	[-3.2294, 0.5028]	0.201
	184	10	2.510	1.332	-1.1781	[-2.9971, 0.6409]	0.249
	185	9	2.858	1.164	-1.6937	[-3.5584, 0.1710]	0.125
	189	9	2.996	1.808	-1.1883	[-2.6153, 0.2386]	0.154
	190	9	2.638	1.810	-0.8279	[-1.8222, 0.1664]	0.154
	191	9	2.575	1.813	-0.7612	[-1.8447, 0.3223]	0.216
	192	9	2.465	1.932	-0.5332	[-1.0055, -0.0609]	0.072
	193	9	2.322	2.025	-0.2974	[-0.6164, 0.0217]	0.119
	194	9	2.438	1.967	-0.4716	[-0.9078, -0.0354]	0.081
	195	9	2.339	1.929	-0.4107	[-0.9471, 0.1257]	0.184
	196	9	2.377	1.951	-0.4265	[-0.8553, 0.0023]	0.101
	197	9	2.434	1.927	-0.5069	[-1.0611, 0.0473]	0.126
	198	10	2.040	1.927	-0.1130	[-1.0375, 0.8115]	0.823
	199	10	1.815	1.927	0.1112	[-0.9940, 1.2163]	0.854
	200	10	1.852	2.152	0.2995	[-0.7556, 1.3546]	0.607
	201	10	1.584	2.028	0.4435	[-0.6337, 1.5207]	0.461
	202	10	1.675	1.947	0.2715	[-0.5221, 1.0650]	0.542
	203	11	1.808	1.955	0.1472	[-0.8067, 1.1011]	0.784
	204	11	1.693	1.907	0.2144	[-0.7449, 1.1737]	0.692
	205	11	1.686	1.970	0.2833	[-0.6457, 1.2124]	0.590
	206	11	1.775	1.912	0.1372	[-0.8022, 1.0765]	0.795
	211	10	2.520	1.907	-0.6128	[-1.6395, 0.4138]	0.299
	212	10	2.379	1.926	-0.4535	[-1.8941, 0.9871]	0.574
	213	10	2.362	1.924	-0.4379	[-1.9659, 1.0901]	0.609
	214	10	2.369	1.948	-0.4209	[-1.8362, 0.9945]	0.595

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 47 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 06	215	10	2.547	2.283	-0.2642	[-1.5969, 1.0685]	0.722
	216	10	2.559	2.211	-0.3479	[-1.6122, 0.9164]	0.623
	217	10	2.121	2.317	0.1961	[-1.1072, 1.4994]	0.787
	218	10	2.274	2.055	-0.2195	[-1.6501, 1.2112]	0.783
	219	10	2.096	1.948	-0.1484	[-1.4098, 1.1129]	0.832
	220	10	2.179	1.953	-0.2262	[-1.6339, 1.1816]	0.773
	221	10	2.049	1.843	-0.2055	[-1.4359, 1.0248]	0.761
	222	10	2.225	1.865	-0.3596	[-1.6091, 0.8900]	0.603
	223	10	2.113	1.997	-0.1158	[-1.1465, 0.9149]	0.838
	224	10	2.088	1.883	-0.2057	[-1.0736, 0.6622]	0.667
	225	10	2.236	2.364	0.1276	[-0.5544, 0.8096]	0.729
	226	10	2.487	2.303	-0.1835	[-0.6409, 0.2740]	0.465
	227	10	2.405	2.336	-0.0697	[-0.3862, 0.2468]	0.684
	228	10	2.394	2.503	0.1084	[-0.2735, 0.4904]	0.601
	229	11	2.626	1.750	-0.8756	[-2.2686, 0.5174]	0.272
	230	11	2.110	1.931	-0.1786	[-0.4028, 0.0456]	0.177
	231	11	2.145	1.923	-0.2216	[-0.5089, 0.0658]	0.190
	232	11	2.168	1.938	-0.2306	[-0.7667, 0.3055]	0.447
	233	11	2.096	1.910	-0.1854	[-0.5659, 0.1952]	0.392
	234	11	2.218	1.990	-0.2281	[-0.8981, 0.4419]	0.544
	235	10	2.018	1.902	-0.1160	[-0.4535, 0.2215]	0.541
	236	11	2.295	1.870	-0.4247	[-0.9072, 0.0578]	0.141
	237	11	2.667	1.915	-0.7518	[-1.7040, 0.2005]	0.182
	238	11	2.399	1.872	-0.5273	[-1.0393, -0.0154]	0.092
	239	11	2.433	1.859	-0.5744	[-1.1333, -0.0155]	0.092
Channel 07	1	12	2.979	3.220	0.2412	[-0.8742, 1.3567]	0.703
	2	12	2.888	5.525	2.6369	[0.7248, 4.5490]	0.031

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 48 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	3	12	2.757	5.542	2.7857	[1.3487, 4.2226]	0.006
	4	12	2.988	5.863	2.8746	[1.5502, 4.1991]	0.003
	5	12	3.102	6.414	3.3120	[2.1988, 4.4252]	<0.001
	6	12	2.844	6.456	3.6112	[2.3658, 4.8566]	<0.001
	7	12	2.970	6.336	3.3657	[2.0450, 4.6865]	<0.001
	8	12	3.023	6.481	3.4574	[2.2607, 4.6540]	<0.001
	9	12	3.045	7.007	3.9623	[3.0159, 4.9086]	<0.001
	10	12	2.750	6.298	3.5487	[2.2438, 4.8536]	<0.001
	11	12	2.895	6.293	3.3984	[2.2931, 4.5037]	<0.001
	12	12	2.919	6.097	3.1782	[1.8498, 4.5066]	0.001
	13	12	2.669	6.177	3.5079	[2.2620, 4.7539]	<0.001
	14	12	2.548	5.913	3.3655	[1.9522, 4.7787]	0.002
	15	12	2.648	5.322	2.6741	[1.0319, 4.3162]	0.014
	16	12	3.003	5.331	2.3283	[0.8454, 3.8111]	0.017
	17	12	3.015	5.083	2.0676	[0.4613, 3.6738]	0.042
	18	12	2.846	5.065	2.2196	[0.6123, 3.8270]	0.031
	19	12	3.037	5.060	2.0232	[0.4406, 3.6059]	0.043
	20	12	2.750	4.625	1.8750	[0.2272, 3.5228]	0.066
	21	12	2.932	5.056	2.1235	[0.5261, 3.7208]	0.038
	22	12	2.614	4.504	1.8899	[0.0815, 3.6984]	0.088
	23	12	2.691	4.339	1.6477	[-0.0615, 3.3568]	0.111
	24	12	2.538	4.251	1.7123	[0.0115, 3.4131]	0.098
	25	12	2.583	4.365	1.7823	[0.0545, 3.5101]	0.091
	26	12	2.470	3.451	0.9815	[-0.5784, 2.5414]	0.276
	27	12	2.490	3.635	1.1455	[-0.5245, 2.8154]	0.238
	28	12	2.458	3.645	1.1864	[-0.4394, 2.8121]	0.212
	29	12	2.464	3.402	0.9383	[-0.5606, 2.4371]	0.278
	30	12	2.441	3.125	0.6837	[-0.6900, 2.0573]	0.382

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 49 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	31	12	2.416	2.789	0.3730	[-0.8048, 1.5509]	0.572
	32	11	2.447	2.839	0.3920	[-0.9858, 1.7699]	0.607
	33	10	2.060	3.147	1.0872	[-0.5735, 2.7478]	0.250
	34	10	2.072	2.977	0.9053	[-0.5746, 2.3852]	0.279
	35	10	2.145	3.004	0.8590	[-0.5009, 2.2189]	0.266
	36	10	2.000	2.900	0.8999	[-0.4671, 2.2669]	0.252
	37	10	2.044	2.705	0.6618	[-0.5608, 1.8844]	0.339
	38	10	2.302	3.147	0.8454	[-0.2712, 1.9621]	0.197
	39	10	2.616	2.979	0.3630	[-0.7523, 1.4783]	0.562
	40	10	2.203	3.110	0.9067	[-0.1691, 1.9826]	0.156
	41	10	2.404	3.142	0.7384	[-0.1511, 1.6279]	0.161
	42	11	2.590	2.980	0.3903	[-0.4455, 1.2261]	0.414
	43	12	2.300	3.138	0.8378	[-0.1652, 1.8407]	0.161
	44	12	2.894	3.306	0.4118	[-0.8945, 1.7182]	0.580
	45	12	2.852	2.803	-0.0488	[-1.2062, 1.1086]	0.940
	46	12	2.857	3.140	0.2831	[-1.0241, 1.5902]	0.703
	47	12	2.827	3.049	0.2225	[-1.1552, 1.6002]	0.776
	48	12	2.801	2.995	0.1944	[-1.1526, 1.5413]	0.799
	49	12	2.777	3.052	0.2747	[-1.1081, 1.6575]	0.726
	50	12	2.535	2.810	0.2746	[-0.8459, 1.3950]	0.664
	51	11	2.854	2.976	0.1212	[-1.9663, 2.2086]	0.917
	52	11	2.790	3.118	0.3278	[-1.5009, 2.1564]	0.747
	53	11	2.792	3.073	0.2806	[-1.3130, 1.8742]	0.754
	54	11	2.862	2.794	-0.0680	[-1.7824, 1.6463]	0.944
	55	11	2.629	2.632	0.0029	[-1.1862, 1.1920]	0.997
	56	11	2.767	2.533	-0.2341	[-1.7851, 1.3170]	0.788
	57	11	2.566	2.408	-0.1579	[-1.1493, 0.8336]	0.777
	58	11	2.762	2.551	-0.2102	[-1.5110, 1.0905]	0.774

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 50 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	59	11	2.336	2.494	0.1582	[-0.6680, 0.9844]	0.734
	60	11	2.607	2.206	-0.4008	[-1.2285, 0.4270]	0.398
	61	11	2.918	2.325	-0.5923	[-1.9475, 0.7630]	0.444
	62	11	2.760	2.248	-0.5123	[-1.6063, 0.5817]	0.413
	72	9	3.021	2.853	-0.1678	[-0.7961, 0.4606]	0.622
	73	9	2.950	2.739	-0.2110	[-0.8380, 0.4160]	0.537
	74	9	2.987	2.844	-0.1431	[-0.8455, 0.5592]	0.706
	75	9	2.949	2.797	-0.1516	[-0.8301, 0.5269]	0.679
	76	9	2.809	2.598	-0.2104	[-0.9265, 0.5057]	0.589
	77	9	2.748	2.570	-0.1780	[-0.7835, 0.4275]	0.589
	78	9	3.007	2.683	-0.3235	[-0.9331, 0.2861]	0.342
	79	9	2.949	2.623	-0.3264	[-1.0373, 0.3846]	0.407
	80	9	3.039	2.666	-0.3730	[-1.0453, 0.2993]	0.322
	81	9	2.971	2.672	-0.2982	[-0.9402, 0.3437]	0.401
	82	9	2.971	2.545	-0.4265	[-0.9706, 0.1176]	0.179
	83	9	3.012	2.707	-0.3047	[-0.9123, 0.3029]	0.367
	84	9	3.023	2.676	-0.3474	[-0.9856, 0.2908]	0.331
	85	9	2.902	2.571	-0.3307	[-0.8706, 0.2091]	0.279
	86	9	2.910	2.689	-0.2204	[-0.7630, 0.3222]	0.460
	87	9	2.673	2.830	0.1567	[-0.7315, 1.0448]	0.743
	88	9	2.861	3.009	0.1480	[-0.8376, 1.1336]	0.780
	89	9	3.008	2.391	-0.6171	[-2.4411, 1.2070]	0.542
	90	9	3.016	2.636	-0.3800	[-2.3626, 1.6026]	0.727
	91	9	3.045	2.998	-0.0470	[-2.2715, 2.1774]	0.969
	92	9	3.029	2.738	-0.2911	[-2.2295, 1.6473]	0.784
	93	10	3.244	2.461	-0.7830	[-2.2602, 0.6942]	0.353
	94	10	3.193	2.479	-0.7147	[-2.2674, 0.8380]	0.417
	99	11	3.028	2.052	-0.9751	[-2.3325, 0.3823]	0.216

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 51 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	100	11	2.531	2.020	-0.5106	[-1.1364, 0.1151]	0.164
	101	11	2.894	1.853	-1.0409	[-2.2632, 0.1814]	0.149
	102	11	2.651	1.931	-0.7207	[-1.4942, 0.0528]	0.120
	103	11	2.621	1.889	-0.7325	[-1.4094, -0.0556]	0.080
	104	11	2.542	1.693	-0.8489	[-1.4963, -0.2015]	0.042
	105	11	2.954	1.763	-1.1911	[-2.4053, 0.0232]	0.105
	106	11	2.557	1.373	-1.1838	[-2.1606, -0.2070]	0.055
	107	11	2.536	1.604	-0.9326	[-1.6667, -0.1986]	0.047
	108	11	2.455	1.435	-1.0198	[-1.9053, -0.1343]	0.065
	109	11	2.660	1.255	-1.4047	[-2.5595, -0.2498]	0.055
	110	11	2.963	1.266	-1.6972	[-3.2158, -0.1786]	0.072
	111	11	2.638	1.620	-1.0181	[-2.0632, 0.0271]	0.107
	112	11	2.397	1.727	-0.6703	[-1.2293, -0.1112]	0.057
	113	11	2.445	1.843	-0.6012	[-1.1229, -0.0795]	0.064
	114	11	2.786	1.877	-0.9092	[-1.8089, -0.0096]	0.097
	115	11	2.974	1.857	-1.1169	[-2.3578, 0.1239]	0.133
	116	11	2.581	1.838	-0.7430	[-1.3534, -0.1326]	0.053
	118	10	2.960	1.923	-1.0369	[-2.0043, -0.0696]	0.081
	119	10	2.808	1.959	-0.8491	[-1.6757, -0.0224]	0.093
	120	10	2.837	1.964	-0.8733	[-1.6087, -0.1378]	0.058
	121	10	2.584	1.970	-0.6134	[-1.1382, -0.0886]	0.061
	122	10	2.567	1.963	-0.6046	[-1.2316, 0.0225]	0.111
	123	11	2.650	1.973	-0.6773	[-1.3859, 0.0313]	0.114
	124	11	2.641	1.953	-0.6875	[-1.5349, 0.1598]	0.171
	125	11	2.843	1.960	-0.8827	[-1.9547, 0.1893]	0.165
	126	11	2.216	1.927	-0.2887	[-1.5046, 0.9272]	0.674
	127	11	2.296	1.932	-0.3635	[-1.8046, 1.0776]	0.655
	128	11	2.263	1.949	-0.3133	[-1.7902, 1.1636]	0.706

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 52 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	129	11	2.186	1.904	-0.2827	[-1.7065, 1.1410]	0.724
	130	11	2.123	1.907	-0.2158	[-1.5507, 1.1192]	0.774
	131	11	1.908	1.907	-0.0007	[-1.2014, 1.2000]	0.999
	132	11	2.058	1.940	-0.1185	[-1.4837, 1.2468]	0.877
	133	10	1.544	1.890	0.3461	[-0.9119, 1.6041]	0.623
	134	11	2.375	1.910	-0.4649	[-2.0360, 1.1062]	0.601
	135	11	2.375	1.875	-0.4998	[-2.0828, 1.0832]	0.577
	136	11	2.518	1.930	-0.5880	[-2.2848, 1.1088]	0.541
	137	11	2.377	1.907	-0.4700	[-2.1042, 1.1642]	0.611
	138	11	2.847	1.894	-0.9538	[-2.9127, 1.0051]	0.395
	139	11	2.869	1.901	-0.9676	[-2.9201, 0.9849]	0.387
	140	11	2.504	1.941	-0.5635	[-2.3483, 1.2213]	0.577
	141	11	2.801	1.939	-0.8616	[-2.7386, 1.0153]	0.422
	142	11	2.824	1.956	-0.8682	[-2.8284, 1.0920]	0.438
	143	11	2.916	2.047	-0.8689	[-2.9179, 1.1801]	0.457
	144	11	2.922	1.976	-0.9465	[-2.8255, 0.9326]	0.380
	145	10	3.179	1.999	-1.1804	[-3.4800, 1.1192]	0.368
	146	10	3.112	1.960	-1.1529	[-3.5082, 1.2024]	0.389
	147	10	3.171	1.967	-1.2047	[-3.4454, 1.0360]	0.347
	148	10	3.169	1.940	-1.2290	[-3.5955, 1.1375]	0.362
	149	10	3.475	1.938	-1.5362	[-3.7867, 0.7144]	0.240
	150	10	3.374	1.947	-1.4267	[-3.6599, 0.8064]	0.269
	151	10	3.550	1.982	-1.5675	[-4.0412, 0.9062]	0.273
	152	10	3.196	1.967	-1.2293	[-3.5418, 1.0831]	0.352
	153	10	3.306	1.954	-1.3516	[-3.5908, 0.8875]	0.294
	154	10	3.291	2.010	-1.2815	[-3.4576, 0.8945]	0.305
	155	10	3.387	2.005	-1.3821	[-3.4690, 0.7048]	0.253
	156	10	3.500	2.054	-1.4465	[-3.3930, 0.5001]	0.204

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 53 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	157	10	4.069	2.061	-2.0079	[-3.9451, -0.0708]	0.090
	158	10	3.756	1.978	-1.7782	[-3.6074, 0.0511]	0.108
	159	10	3.719	1.969	-1.7503	[-3.5821, 0.0815]	0.113
	160	10	4.117	2.047	-2.0700	[-3.8793, -0.2607]	0.066
	161	10	3.762	2.149	-1.6130	[-3.4695, 0.2436]	0.145
	162	10	3.735	2.028	-1.7076	[-3.4420, 0.0269]	0.105
	163	11	3.459	1.996	-1.4633	[-3.0576, 0.1310]	0.127
	164	11	3.468	1.930	-1.5377	[-3.2476, 0.1721]	0.133
	165	11	3.294	1.892	-1.4017	[-2.8624, 0.0590]	0.112
	166	11	3.486	1.938	-1.5480	[-3.1564, 0.0604]	0.111
	167	11	3.474	1.983	-1.4908	[-3.1957, 0.2141]	0.143
	168	11	3.280	2.031	-1.2484	[-2.7406, 0.2437]	0.158
	169	10	2.318	2.123	-0.1954	[-0.8132, 0.4223]	0.568
	170	10	2.368	2.074	-0.2935	[-1.0232, 0.4362]	0.471
	171	10	2.671	2.027	-0.6445	[-2.0540, 0.7649]	0.415
	172	10	2.724	1.879	-0.8457	[-2.4972, 0.8057]	0.358
	173	10	2.756	1.763	-0.9935	[-2.6189, 0.6318]	0.280
	174	10	2.643	1.847	-0.7958	[-2.4655, 0.8739]	0.390
	175	10	2.625	1.839	-0.7856	[-2.4414, 0.8702]	0.392
	176	10	2.807	1.867	-0.9397	[-2.5930, 0.7136]	0.312
	177	10	3.255	1.852	-1.4037	[-3.4590, 0.6517]	0.233
	178	10	2.600	1.765	-0.8358	[-2.5344, 0.8628]	0.376
	179	10	2.706	1.865	-0.8405	[-2.7212, 1.0401]	0.419
	180	10	2.903	1.861	-1.0424	[-2.9884, 0.9036]	0.338
	181	10	2.902	1.818	-1.0842	[-3.1192, 0.9509]	0.340
	182	10	3.284	1.658	-1.6263	[-3.9222, 0.6697]	0.213
	183	10	3.347	1.566	-1.7819	[-4.0901, 0.5263]	0.181
	184	10	3.302	1.501	-1.8007	[-4.1610, 0.5596]	0.185

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 54 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	185	9	3.618	1.369	-2.2487	[-4.9677, 0.4703]	0.153
	189	9	3.137	2.249	-0.8880	[-3.9050, 2.1290]	0.579
	190	9	3.212	1.683	-1.5282	[-3.7196, 0.6631]	0.219
	191	9	3.173	1.741	-1.4326	[-3.4780, 0.6128]	0.217
	192	9	3.152	1.671	-1.4802	[-3.6181, 0.6578]	0.222
	193	9	2.869	1.717	-1.1520	[-3.1733, 0.8692]	0.303
	194	9	2.836	1.683	-1.1522	[-3.1192, 0.8149]	0.291
	195	9	2.838	1.682	-1.1565	[-3.1929, 0.8799]	0.304
	196	9	2.920	1.699	-1.2217	[-3.0590, 0.6156]	0.238
	197	9	2.819	1.839	-0.9798	[-2.5277, 0.5682]	0.265
	198	10	2.151	1.812	-0.3391	[-1.9722, 1.2940]	0.706
	199	10	2.113	1.811	-0.3020	[-1.9506, 1.3466]	0.739
	200	10	2.139	1.928	-0.2113	[-1.8838, 1.4612]	0.818
	201	10	1.741	2.328	0.5874	[-1.2678, 2.4426]	0.567
	202	10	1.976	1.954	-0.0219	[-1.5916, 1.5479]	0.980
	203	11	2.127	1.951	-0.1755	[-1.5932, 1.2423]	0.826
	204	11	2.118	1.940	-0.1775	[-1.7093, 1.3542]	0.837
	205	11	2.121	1.988	-0.1331	[-1.5855, 1.3193]	0.870
	206	11	2.218	1.961	-0.2569	[-1.6950, 1.1812]	0.751
	211	10	2.255	1.983	-0.2722	[-1.6762, 1.1319]	0.728
	212	10	2.386	2.014	-0.3716	[-1.7870, 1.0437]	0.638
	213	10	2.338	1.945	-0.3931	[-1.9500, 1.1638]	0.651
	214	10	2.368	1.998	-0.3707	[-1.9074, 1.1660]	0.666
	215	10	2.226	2.003	-0.2228	[-1.8275, 1.3820]	0.803
	216	10	2.287	1.967	-0.3192	[-1.9202, 1.2817]	0.720
	217	10	2.111	2.094	-0.0162	[-1.3995, 1.3671]	0.983
	218	10	2.199	2.223	0.0240	[-1.5197, 1.5676]	0.978
	219	10	2.281	1.956	-0.3249	[-1.9243, 1.2745]	0.715

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 55 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 07	220	10	2.272	1.923	-0.3491	[-1.9078, 1.2096]	0.688
	221	10	2.268	1.782	-0.4856	[-2.2417, 1.2705]	0.617
	222	10	2.307	1.811	-0.4969	[-2.1869, 1.1931]	0.595
	223	10	2.418	1.798	-0.6204	[-2.2654, 1.0247]	0.498
	224	10	2.488	1.829	-0.6589	[-2.1945, 0.8767]	0.443
	225	10	2.640	1.618	-1.0226	[-2.7026, 0.6574]	0.282
	226	10	2.522	1.693	-0.8295	[-2.0083, 0.3493]	0.221
	227	10	2.331	1.828	-0.5038	[-1.1084, 0.1009]	0.157
	228	10	2.433	2.176	-0.2566	[-0.8585, 0.3453]	0.439
	229	11	2.585	1.744	-0.8413	[-2.2680, 0.5853]	0.301
	230	11	2.116	1.963	-0.1528	[-0.4663, 0.1607]	0.391
	231	11	2.229	1.913	-0.3163	[-0.7955, 0.1630]	0.255
	232	11	2.203	1.933	-0.2699	[-0.8726, 0.3329]	0.429
	233	11	2.112	1.959	-0.1526	[-0.5534, 0.2482]	0.499
	234	11	2.309	1.870	-0.4397	[-1.2475, 0.3681]	0.341
	235	10	2.173	1.944	-0.2296	[-0.7453, 0.2862]	0.432
	236	11	2.347	1.854	-0.4924	[-0.9670, -0.0177]	0.090
	237	11	2.496	1.939	-0.5577	[-1.2176, 0.1021]	0.156
	238	11	2.508	1.903	-0.6053	[-1.2590, 0.0485]	0.124
	239	11	2.342	1.903	-0.4390	[-0.9360, 0.0580]	0.140
Channel 08	1	12	3.385	2.491	-0.8937	[-2.2161, 0.4287]	0.249
	2	12	2.991	4.348	1.3570	[0.2785, 2.4354]	0.046
	3	12	2.828	5.246	2.4182	[1.1622, 3.6742]	0.006
	4	12	3.013	6.132	3.1190	[1.8218, 4.4162]	0.001
	5	12	2.890	6.779	3.8886	[2.6640, 5.1131]	<0.001
	6	12	2.851	6.419	3.5678	[2.3851, 4.7504]	<0.001
	7	12	2.968	6.909	3.9407	[2.8984, 4.9831]	<0.001

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 56 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	8	12	2.984	6.706	3.7220	[2.6813, 4.7626]	<0.001
	9	12	2.962	7.385	4.4238	[3.4615, 5.3861]	<0.001
	10	12	2.532	6.822	4.2903	[3.1144, 5.4662]	<0.001
	11	12	2.443	6.481	4.0380	[2.8907, 5.1853]	<0.001
	12	12	2.675	6.278	3.6033	[2.1548, 5.0517]	0.001
	13	12	2.767	6.305	3.5380	[2.3496, 4.7264]	<0.001
	14	12	3.347	5.980	2.6333	[1.4231, 3.8435]	0.003
	15	12	3.399	5.544	2.1450	[0.7330, 3.5569]	0.020
	16	12	3.256	5.286	2.0305	[0.6285, 3.4325]	0.025
	17	12	2.869	5.197	2.3283	[0.8014, 3.8552]	0.020
	18	12	2.888	5.135	2.2471	[0.6727, 3.8214]	0.027
	19	12	2.795	5.025	2.2291	[0.6745, 3.7838]	0.027
	20	12	2.565	4.884	2.3187	[0.6643, 3.9732]	0.029
	21	12	3.251	4.886	1.6350	[0.1254, 3.1446]	0.078
	22	12	2.919	4.943	2.0245	[0.1733, 3.8758]	0.076
	23	12	2.369	4.522	2.1528	[0.1762, 4.1295]	0.077
	24	12	2.351	4.514	2.1623	[0.1965, 4.1281]	0.075
	25	12	2.502	4.385	1.8828	[0.0355, 3.7301]	0.095
	26	12	2.369	4.354	1.9850	[0.0620, 3.9080]	0.091
	27	12	2.307	3.936	1.6294	[-0.3442, 3.6030]	0.163
	28	12	2.395	4.017	1.6223	[-0.2776, 3.5222]	0.151
	29	12	2.575	4.110	1.5348	[-0.4141, 3.4838]	0.181
	30	12	2.368	3.764	1.3958	[-0.5307, 3.3223]	0.215
	31	12	2.429	3.741	1.3119	[-0.5095, 3.1332]	0.217
	32	11	2.262	3.808	1.5454	[-0.4989, 3.5896]	0.195
	33	10	1.981	4.029	2.0475	[-0.0976, 4.1925]	0.113
	34	10	1.865	3.717	1.8518	[-0.1742, 3.8779]	0.126
	35	10	1.653	3.649	1.9960	[0.0478, 3.9442]	0.094

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 57 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	36	10	1.843	3.626	1.7831	[-0.0770, 3.6431]	0.112
	37	10	2.168	3.605	1.4371	[-0.4612, 3.3354]	0.195
	38	10	1.898	3.537	1.6395	[0.1532, 3.1258]	0.074
	39	10	2.512	3.452	0.9404	[-0.6254, 2.5062]	0.297
	40	10	2.028	3.489	1.4607	[-0.0556, 2.9770]	0.111
	41	10	2.309	3.014	0.7051	[-1.0213, 2.4314]	0.469
	42	11	1.936	3.156	1.2195	[-0.0200, 2.4591]	0.105
	43	12	1.798	2.926	1.1277	[-0.1533, 2.4087]	0.142
	44	12	2.237	2.816	0.5791	[-0.7809, 1.9391]	0.458
	45	12	2.505	2.943	0.4381	[-0.8857, 1.7618]	0.559
	46	12	2.238	3.005	0.7665	[-0.3922, 1.9252]	0.258
	47	12	2.630	2.874	0.2435	[-1.2160, 1.7030]	0.769
	48	12	2.524	2.713	0.1893	[-0.9335, 1.3120]	0.766
	49	12	2.650	2.866	0.2157	[-1.1957, 1.6270]	0.787
	50	12	2.370	2.557	0.1869	[-0.8351, 1.2089]	0.745
	51	11	2.682	2.459	-0.2228	[-1.9760, 1.5304]	0.819
	52	11	2.645	2.504	-0.1407	[-1.6860, 1.4046]	0.870
	53	11	2.718	2.664	-0.0543	[-1.5838, 1.4752]	0.950
	54	11	2.856	2.805	-0.0511	[-1.7690, 1.6668]	0.958
	55	11	2.569	2.776	0.2073	[-1.2047, 1.6193]	0.794
	56	11	2.626	2.776	0.1496	[-1.2836, 1.5828]	0.852
	57	11	2.622	2.872	0.2501	[-1.2145, 1.7148]	0.761
	58	11	2.718	2.814	0.0956	[-1.5113, 1.7026]	0.916
	59	11	2.287	2.675	0.3879	[-0.6689, 1.4447]	0.518
	60	11	2.726	2.621	-0.1054	[-1.5494, 1.3387]	0.897
	61	11	2.784	2.693	-0.0906	[-1.5841, 1.4030]	0.914
	62	11	2.621	2.662	0.0403	[-1.2633, 1.3440]	0.956
	72	9	2.829	3.262	0.4326	[-0.7106, 1.5757]	0.490

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 58 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	73	9	3.109	3.168	0.0590	[-1.4621, 1.5801]	0.942
	74	9	2.830	3.354	0.5245	[-0.6899, 1.7390]	0.433
	75	9	3.203	2.958	-0.2448	[-1.8398, 1.3502]	0.776
	76	9	3.349	2.988	-0.3612	[-1.9648, 1.2423]	0.677
	77	9	3.631	3.091	-0.5402	[-2.6017, 1.5212]	0.629
	78	9	3.281	2.940	-0.3416	[-1.7088, 1.0256]	0.645
	79	9	3.035	2.882	-0.1523	[-1.4063, 1.1017]	0.821
	80	9	3.646	2.875	-0.7709	[-2.8182, 1.2765]	0.492
	81	9	3.326	2.719	-0.6075	[-2.4555, 1.2405]	0.547
	82	9	3.437	2.761	-0.6760	[-2.5879, 1.2359]	0.518
	83	9	3.502	3.110	-0.3923	[-2.2879, 1.5033]	0.702
	84	9	3.472	3.201	-0.2710	[-2.3126, 1.7705]	0.805
	85	9	3.568	3.201	-0.3660	[-2.4054, 1.6734]	0.739
	86	9	3.410	3.707	0.2974	[-1.9037, 2.4985]	0.802
	87	9	2.648	3.236	0.5879	[-0.8417, 2.0176]	0.455
	88	9	2.584	2.795	0.2109	[-0.8616, 1.2834]	0.716
	89	9	3.577	2.499	-1.0776	[-3.4239, 1.2687]	0.413
	90	9	3.652	2.946	-0.7056	[-3.2511, 1.8398]	0.616
	91	9	3.668	2.926	-0.7414	[-3.3616, 1.8789]	0.609
	92	9	3.951	2.775	-1.1759	[-3.7570, 1.4052]	0.417
	93	10	3.699	2.610	-1.0890	[-3.0122, 0.8343]	0.323
	94	10	3.575	2.261	-1.3132	[-2.8815, 0.2551]	0.158
	99	11	3.504	1.859	-1.6453	[-3.5961, 0.3054]	0.154
	100	11	3.530	1.642	-1.8880	[-4.1534, 0.3774]	0.156
	101	11	3.357	1.612	-1.7447	[-3.6775, 0.1881]	0.130
	102	11	3.463	1.594	-1.8691	[-3.9794, 0.2413]	0.136
	103	11	3.174	1.617	-1.5567	[-3.0539, -0.0595]	0.090
	104	11	3.400	1.517	-1.8834	[-3.1732, -0.5936]	0.028

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 59 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	105	11	3.813	1.456	-2.3566	[-4.1586, -0.5547]	0.042
	106	11	3.249	1.534	-1.7144	[-3.0948, -0.3339]	0.051
	107	11	3.582	1.552	-2.0292	[-3.6357, -0.4227]	0.048
	108	11	3.432	1.962	-1.4705	[-2.6973, -0.2438]	0.057
	109	11	3.155	1.667	-1.4882	[-2.7959, -0.1805]	0.068
	110	11	3.445	1.635	-1.8100	[-3.3244, -0.2955]	0.058
	111	11	2.872	1.664	-1.2088	[-2.6810, 0.2635]	0.164
	112	11	2.918	1.833	-1.0850	[-2.6271, 0.4572]	0.224
	113	11	2.871	1.854	-1.0172	[-2.3625, 0.3281]	0.197
	114	11	3.417	1.760	-1.6575	[-3.3163, 0.0012]	0.100
	115	11	3.248	1.733	-1.5149	[-2.5940, -0.4359]	0.031
	116	11	3.075	1.754	-1.3212	[-2.6733, 0.0310]	0.107
	118	10	3.213	1.911	-1.3022	[-2.6437, 0.0393]	0.109
	119	10	3.126	1.999	-1.1274	[-2.7818, 0.5271]	0.241
	120	10	3.416	1.995	-1.4213	[-2.7221, -0.1206]	0.077
	121	10	2.616	2.005	-0.6108	[-1.7641, 0.5425]	0.354
	122	10	2.664	2.045	-0.6195	[-1.7621, 0.5230]	0.343
	123	11	3.735	2.008	-1.7270	[-3.0443, -0.4098]	0.040
	124	11	2.727	1.974	-0.7530	[-2.2277, 0.7218]	0.374
	125	11	2.476	1.962	-0.5137	[-1.8894, 0.8619]	0.511
	126	11	2.608	1.955	-0.6529	[-2.2066, 0.9009]	0.461
	127	11	2.206	1.948	-0.2586	[-1.7781, 1.2608]	0.762
	128	11	2.081	1.992	-0.0887	[-1.6084, 1.4310]	0.917
	129	11	2.015	1.972	-0.0439	[-1.3316, 1.2438]	0.952
	130	11	2.136	1.931	-0.2054	[-1.6432, 1.2324]	0.799
	131	11	2.088	1.926	-0.1625	[-1.5724, 1.2473]	0.837
	132	11	2.161	1.967	-0.1940	[-1.6831, 1.2951]	0.817
	133	10	2.226	1.951	-0.2756	[-2.0959, 1.5446]	0.785

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 60 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	134	11	2.424	1.969	-0.4552	[-1.9177, 1.0072]	0.582
	135	11	2.241	1.949	-0.2918	[-1.8996, 1.3160]	0.747
	136	11	3.101	1.979	-1.1219	[-2.8917, 0.6480]	0.275
	137	11	2.999	1.957	-1.0423	[-3.0839, 0.9993]	0.374
	138	11	2.954	1.964	-0.9907	[-3.0136, 1.0322]	0.393
	139	11	2.917	1.949	-0.9680	[-2.9342, 0.9983]	0.390
	140	11	2.512	2.015	-0.4968	[-2.2530, 1.2594]	0.617
	141	11	2.856	1.997	-0.8591	[-2.7989, 1.0807]	0.438
	142	11	2.777	2.164	-0.6129	[-2.2373, 1.0114]	0.507
	143	11	2.862	2.050	-0.8111	[-2.6127, 0.9906]	0.431
	144	11	2.836	2.346	-0.4897	[-2.0418, 1.0624]	0.577
	145	10	3.301	2.002	-1.2996	[-3.2885, 0.6894]	0.259
	146	10	3.082	1.970	-1.1119	[-3.3386, 1.1148]	0.380
	147	10	3.092	2.009	-1.0822	[-3.2873, 1.1229]	0.388
	148	10	3.754	1.994	-1.7604	[-3.9946, 0.4738]	0.181
	149	10	3.549	1.983	-1.5661	[-3.9133, 0.7812]	0.250
	150	10	3.569	1.971	-1.5978	[-3.9288, 0.7331]	0.238
	151	10	3.516	1.959	-1.5579	[-3.8470, 0.7312]	0.241
	152	10	3.520	1.997	-1.5231	[-3.8069, 0.7606]	0.250
	153	10	3.576	2.004	-1.5724	[-3.8433, 0.6985]	0.234
	154	10	3.567	2.056	-1.5105	[-3.6962, 0.6753]	0.235
	155	10	3.368	2.215	-1.1529	[-2.9142, 0.6085]	0.258
	156	10	3.848	2.324	-1.5243	[-3.1338, 0.0852]	0.116
	157	10	4.111	2.325	-1.7863	[-3.2714, -0.3012]	0.056
	158	10	3.849	2.087	-1.7617	[-3.5480, 0.0247]	0.104
	159	10	3.790	2.420	-1.3699	[-2.8601, 0.1203]	0.126
	160	10	3.865	2.432	-1.4334	[-2.9730, 0.1062]	0.122
	161	10	3.687	1.979	-1.7076	[-3.5373, 0.1220]	0.121

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 61 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	162	10	3.528	2.008	-1.5203	[-3.2663, 0.2257]	0.144
	163	11	3.489	2.025	-1.4636	[-3.0620, 0.1347]	0.128
	164	11	3.523	1.907	-1.6161	[-3.3220, 0.0898]	0.116
	165	11	3.402	1.951	-1.4508	[-3.1836, 0.2819]	0.158
	166	11	3.398	1.974	-1.4239	[-3.1219, 0.2742]	0.158
	167	11	3.293	2.188	-1.1053	[-2.5260, 0.3154]	0.186
	168	11	3.018	2.422	-0.5956	[-1.4736, 0.2824]	0.243
	169	10	2.481	2.215	-0.2655	[-1.4750, 0.9441]	0.690
	170	10	2.525	2.038	-0.4866	[-1.8015, 0.8283]	0.506
	171	10	2.524	2.100	-0.4234	[-1.6477, 0.8010]	0.533
	172	10	2.611	1.928	-0.6832	[-2.3158, 0.9494]	0.447
	173	10	2.575	1.819	-0.7556	[-2.3581, 0.8470]	0.395
	174	10	2.763	1.857	-0.9060	[-2.4854, 0.6733]	0.308
	175	10	2.726	1.832	-0.8935	[-2.5829, 0.7960]	0.344
	176	10	2.887	1.816	-1.0713	[-2.7326, 0.5899]	0.257
	177	10	2.739	1.814	-0.9247	[-2.5510, 0.7015]	0.312
	178	10	2.833	1.725	-1.1081	[-2.7514, 0.5352]	0.238
	179	10	2.855	1.756	-1.0986	[-2.7456, 0.5484]	0.243
	180	10	2.856	1.666	-1.1895	[-2.9021, 0.5230]	0.226
	181	10	2.891	1.734	-1.1570	[-2.7918, 0.4777]	0.218
	182	10	2.957	1.612	-1.3451	[-3.3122, 0.6219]	0.227
	183	10	3.045	1.512	-1.5332	[-3.5990, 0.5326]	0.195
	184	10	2.963	1.543	-1.4194	[-3.4444, 0.6056]	0.217
	185	9	3.024	1.080	-1.9439	[-4.2762, 0.3885]	0.150
	189	9	3.071	1.770	-1.3008	[-3.3364, 0.7349]	0.254
	190	9	3.142	1.721	-1.4210	[-3.4122, 0.5702]	0.210
	191	9	3.163	1.715	-1.4480	[-3.5506, 0.6545]	0.224
	192	9	3.229	1.767	-1.4617	[-3.5381, 0.6147]	0.215

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 62 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	193	9	2.683	1.733	-0.9494	[-2.6971, 0.7984]	0.324
	194	9	2.794	1.747	-1.0469	[-2.8177, 0.7239]	0.287
	195	9	3.471	1.745	-1.7259	[-3.8432, 0.3914]	0.161
	196	9	2.829	1.798	-1.0303	[-2.8282, 0.7676]	0.300
	197	9	2.995	1.875	-1.1210	[-2.6686, 0.4266]	0.209
	198	10	2.400	1.861	-0.5393	[-2.3529, 1.2742]	0.591
	199	10	2.161	1.880	-0.2816	[-2.0250, 1.4619]	0.769
	200	10	1.915	2.096	0.1806	[-1.5036, 1.8649]	0.845
	201	10	1.765	2.172	0.4070	[-1.2499, 2.0639]	0.656
	202	10	1.745	2.176	0.4315	[-1.0784, 1.9414]	0.610
	203	11	2.220	2.136	-0.0836	[-1.3978, 1.2306]	0.910
	204	11	2.463	2.199	-0.2635	[-1.7072, 1.1802]	0.746
	205	11	1.990	2.180	0.1904	[-1.1817, 1.5625]	0.805
	206	11	1.998	2.398	0.3996	[-1.1672, 1.9663]	0.651
	211	10	2.129	2.260	0.1306	[-1.5626, 1.8237]	0.890
	212	10	2.204	2.323	0.1192	[-1.6292, 1.8676]	0.902
	213	10	2.213	2.075	-0.1383	[-1.7328, 1.4562]	0.876
	214	10	2.134	2.378	0.2436	[-1.5307, 2.0179]	0.805
	215	10	2.183	2.342	0.1588	[-1.5051, 1.8227]	0.864
	216	10	2.153	2.101	-0.0523	[-1.6513, 1.5467]	0.953
	217	10	2.152	2.037	-0.1150	[-1.7333, 1.5032]	0.898
	218	10	2.145	2.277	0.1322	[-1.5092, 1.7736]	0.885
	219	10	2.181	2.022	-0.1587	[-1.6944, 1.3770]	0.852
	220	10	2.340	1.950	-0.3908	[-1.7916, 1.0099]	0.618
	221	10	2.443	1.825	-0.6177	[-2.2069, 0.9715]	0.485
	222	10	2.677	1.844	-0.8326	[-2.2093, 0.5441]	0.290
	223	10	2.519	1.800	-0.7193	[-2.1928, 0.7542]	0.386
	224	10	2.633	1.846	-0.7869	[-2.1554, 0.5815]	0.312

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 63 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 08	225	10	2.884	1.539	-1.3456	[-2.7702, 0.0790]	0.116
	226	10	3.273	1.470	-1.8029	[-3.0600, -0.5459]	0.032
	227	10	2.717	1.728	-0.9887	[-1.8736, -0.1037]	0.073
	228	10	2.800	1.864	-0.9359	[-2.0760, 0.2041]	0.162
	229	11	2.908	2.597	-0.3113	[-1.5096, 0.8871]	0.638
	230	11	2.612	2.740	0.1283	[-0.7541, 1.0107]	0.794
	231	11	2.504	2.129	-0.3745	[-1.0106, 0.2616]	0.306
	232	11	2.475	1.967	-0.5073	[-1.5151, 0.5005]	0.377
	233	11	2.350	1.916	-0.4340	[-1.0660, 0.1980]	0.237
	234	11	2.541	1.893	-0.6481	[-1.5899, 0.2938]	0.237
	235	10	2.435	1.955	-0.4800	[-1.3038, 0.3438]	0.310
	236	11	2.761	2.002	-0.7585	[-1.6132, 0.0962]	0.138
	237	11	2.620	2.333	-0.2868	[-1.5861, 1.0126]	0.695
	238	11	2.535	2.307	-0.2288	[-1.4352, 0.9775]	0.736
	239	11	2.576	2.387	-0.1892	[-1.5027, 1.1243]	0.798
Channel 09	1	12	3.318	2.270	-1.0476	[-2.4279, 0.3326]	0.199
	2	12	3.351	3.714	0.3630	[-1.4216, 2.1477]	0.720
	3	12	3.244	4.590	1.3457	[-0.5781, 3.2696]	0.234
	4	12	2.944	5.964	3.0197	[1.5581, 4.4814]	0.004
	5	12	3.267	6.824	3.5573	[2.4399, 4.6747]	<0.001
	6	12	3.225	6.945	3.7198	[2.7345, 4.7051]	<0.001
	7	12	3.254	6.880	3.6268	[2.4863, 4.7673]	<0.001
	8	12	3.266	6.660	3.3935	[2.4166, 4.3705]	<0.001
	9	12	3.339	6.584	3.2452	[2.2379, 4.2524]	<0.001
	10	12	3.141	6.273	3.1316	[1.9662, 4.2970]	<0.001
	11	12	3.001	6.143	3.1423	[1.8372, 4.4473]	0.001
	12	12	3.234	6.050	2.8163	[1.3897, 4.2429]	0.005

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 64 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	13	12	3.178	6.205	3.0267	[1.7815, 4.2718]	0.001
	14	12	3.276	6.137	2.8616	[1.6287, 4.0945]	0.002
	15	12	3.399	5.577	2.1780	[0.6653, 3.6906]	0.026
	16	12	3.084	5.341	2.2572	[0.7517, 3.7627]	0.022
	17	12	3.117	5.193	2.0759	[0.6382, 3.5136]	0.026
	18	12	2.993	5.184	2.1912	[0.3312, 4.0512]	0.059
	19	12	2.905	5.162	2.2571	[0.5386, 3.9757]	0.039
	20	12	2.684	5.079	2.3946	[0.7576, 4.0315]	0.024
	21	12	2.969	5.088	2.1187	[0.4361, 3.8012]	0.046
	22	12	2.684	5.002	2.3179	[0.2764, 4.3594]	0.068
	23	12	2.419	4.633	2.2146	[0.0977, 4.3315]	0.088
	24	12	2.330	4.532	2.2019	[0.1537, 4.2500]	0.081
	25	12	3.198	4.886	1.6876	[0.0006, 3.3747]	0.100
	26	12	2.812	4.894	2.0819	[0.0726, 4.0912]	0.090
	27	12	2.405	4.422	2.0170	[0.1305, 3.9034]	0.082
	28	12	2.658	4.406	1.7486	[-0.2372, 3.7345]	0.140
	29	12	2.457	4.064	1.6076	[-0.3892, 3.6043]	0.173
	30	12	2.456	4.148	1.6920	[-0.3393, 3.7234]	0.160
	31	12	2.486	3.900	1.4136	[-0.4688, 3.2961]	0.200
	32	11	2.176	3.916	1.7401	[-0.4607, 3.9408]	0.178
	33	10	1.769	3.926	2.1567	[-0.0638, 4.3773]	0.108
	34	10	1.702	3.616	1.9139	[-0.1398, 3.9675]	0.120
	35	10	1.778	3.649	1.8710	[-0.1334, 3.8755]	0.120
	36	10	1.925	3.680	1.7556	[-0.1476, 3.6588]	0.124
	37	10	2.424	3.831	1.4068	[-0.3736, 3.1871]	0.178
	38	10	2.119	3.709	1.5903	[0.0644, 3.1162]	0.089
	39	10	2.426	3.423	0.9969	[-0.4704, 2.4642]	0.242
	40	10	2.242	3.419	1.1768	[-0.4525, 2.8062]	0.216

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 65 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	41	10	1.986	3.325	1.3386	[-0.5846, 3.2618]	0.232
	42	11	1.871	3.219	1.3479	[0.0223, 2.6734]	0.095
	43	12	1.960	3.067	1.1062	[-0.1590, 2.3714]	0.144
	44	12	2.353	2.998	0.6443	[-0.8694, 2.1580]	0.458
	45	12	2.511	2.789	0.2773	[-1.2477, 1.8023]	0.747
	46	12	2.081	2.917	0.8357	[-0.3274, 1.9988]	0.222
	47	12	2.412	2.491	0.0787	[-1.4258, 1.5831]	0.926
	48	12	2.389	2.833	0.4443	[-1.0164, 1.9051]	0.594
	49	12	2.526	2.917	0.3919	[-0.9995, 1.7833]	0.621
	50	12	2.597	2.489	-0.1079	[-1.4903, 1.2746]	0.889
	51	11	2.676	2.520	-0.1563	[-1.8415, 1.5289]	0.867
	52	11	2.735	2.419	-0.3160	[-1.9623, 1.3304]	0.730
	53	11	2.914	2.571	-0.3430	[-1.7976, 1.1115]	0.676
	54	11	2.771	2.729	-0.0426	[-1.6659, 1.5807]	0.963
	55	11	2.510	2.627	0.1161	[-1.0767, 1.3088]	0.862
	56	11	2.662	2.515	-0.1474	[-1.4004, 1.1056]	0.834
	57	11	2.775	2.641	-0.1342	[-1.5568, 1.2885]	0.867
	58	11	2.724	2.548	-0.1762	[-1.5256, 1.1732]	0.816
	59	11	2.298	2.507	0.2089	[-0.5370, 0.9548]	0.620
	60	11	2.667	2.580	-0.0873	[-1.3524, 1.1778]	0.902
	61	11	2.736	2.636	-0.0998	[-1.3998, 1.2002]	0.891
	62	11	2.608	2.910	0.3019	[-0.8283, 1.4321]	0.636
	72	9	3.615	3.181	-0.4342	[-2.2965, 1.4280]	0.666
	73	9	3.686	3.006	-0.6792	[-2.4804, 1.1219]	0.491
	74	9	3.362	3.072	-0.2905	[-2.2225, 1.6416]	0.780
	75	9	3.285	2.974	-0.3108	[-2.0318, 1.4103]	0.738
	76	9	3.916	2.864	-1.0521	[-3.3153, 1.2111]	0.401
	77	9	4.050	2.892	-1.1579	[-3.3990, 1.0833]	0.354

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 66 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	78	9	3.563	2.721	-0.8413	[-2.2387, 0.5561]	0.286
	79	9	3.823	2.694	-1.1285	[-3.0382, 0.7812]	0.295
	80	9	3.651	2.729	-0.9220	[-2.7175, 0.8736]	0.357
	81	9	2.788	2.628	-0.1598	[-0.8243, 0.5047]	0.657
	82	9	3.519	2.575	-0.9442	[-2.4578, 0.5694]	0.271
	83	9	3.612	2.726	-0.8860	[-2.4814, 0.7094]	0.322
	84	9	3.444	3.071	-0.3727	[-2.0115, 1.2661]	0.674
	85	9	3.676	3.157	-0.5188	[-2.4092, 1.3715]	0.613
	86	9	3.601	3.385	-0.2168	[-2.2965, 1.8630]	0.846
	87	9	3.278	3.406	0.1277	[-1.2410, 1.4964]	0.862
	88	9	3.937	2.453	-1.4837	[-3.1990, 0.2316]	0.144
	89	9	4.372	2.138	-2.2345	[-4.3921, -0.0770]	0.091
	90	9	4.270	2.594	-1.6760	[-4.1079, 0.7559]	0.233
	91	9	4.254	2.607	-1.6470	[-4.1486, 0.8546]	0.252
	92	9	4.018	2.225	-1.7929	[-3.8019, 0.2161]	0.135
	93	10	3.788	2.487	-1.3004	[-3.1780, 0.5772]	0.234
	94	10	3.777	2.120	-1.6570	[-3.3431, 0.0290]	0.105
	99	11	3.404	2.060	-1.3440	[-2.7674, 0.0793]	0.117
	100	11	3.687	1.375	-2.3111	[-4.1902, -0.4320]	0.054
	101	11	3.372	1.555	-1.8162	[-3.7900, 0.1577]	0.124
	102	11	3.240	1.657	-1.5829	[-3.6548, 0.4889]	0.188
	103	11	3.338	1.578	-1.7599	[-3.6243, 0.1045]	0.116
	104	11	3.358	1.497	-1.8608	[-3.2913, -0.4303]	0.043
	105	11	3.605	1.213	-2.3926	[-4.1972, -0.5880]	0.040
	106	11	3.373	1.571	-1.8015	[-3.7029, 0.1000]	0.116
	107	11	3.560	1.673	-1.8868	[-3.8624, 0.0887]	0.113
	108	11	2.751	1.862	-0.8887	[-2.5363, 0.7589]	0.341
	109	11	3.197	1.670	-1.5275	[-3.5676, 0.5126]	0.199

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 67 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	110	11	3.437	1.658	-1.7787	[-4.0381, 0.4806]	0.179
	111	11	2.485	1.892	-0.5935	[-2.2607, 1.0738]	0.522
	112	11	2.983	1.613	-1.3701	[-3.3251, 0.5848]	0.226
	113	11	3.067	1.842	-1.2242	[-2.9362, 0.4878]	0.220
	114	11	3.068	1.839	-1.2287	[-2.9318, 0.4745]	0.217
	115	11	3.218	1.849	-1.3689	[-2.9856, 0.2478]	0.154
	116	11	2.793	1.858	-0.9352	[-2.3040, 0.4335]	0.240
	118	10	3.083	1.889	-1.1945	[-2.9324, 0.5433]	0.237
	119	10	3.210	1.977	-1.2339	[-2.6158, 0.1481]	0.135
	120	10	3.560	2.033	-1.5265	[-3.3205, 0.2674]	0.152
	121	10	3.260	2.098	-1.1625	[-2.8588, 0.5337]	0.238
	122	10	3.229	2.095	-1.1341	[-2.6869, 0.4187]	0.211
	123	11	3.756	2.119	-1.6373	[-3.0419, -0.2327]	0.061
	124	11	3.529	1.977	-1.5518	[-3.4502, 0.3467]	0.168
	125	11	2.881	1.934	-0.9471	[-2.6324, 0.7383]	0.330
	126	11	3.412	1.959	-1.4524	[-3.3263, 0.4215]	0.189
	127	11	2.618	1.986	-0.6325	[-2.2908, 1.0257]	0.502
	128	11	2.343	1.992	-0.3507	[-1.9251, 1.2238]	0.693
	129	11	2.279	1.969	-0.3092	[-1.8544, 1.2361]	0.722
	130	11	2.707	1.953	-0.7534	[-2.5328, 1.0260]	0.458
	131	11	2.055	2.213	0.1577	[-1.3753, 1.6907]	0.855
	132	11	2.789	2.282	-0.5066	[-2.5500, 1.5368]	0.660
	133	10	2.519	1.986	-0.5330	[-2.6061, 1.5400]	0.645
	134	11	2.359	1.988	-0.3707	[-1.5751, 0.8336]	0.586
	135	11	2.286	1.966	-0.3199	[-1.8523, 1.2125]	0.711
	136	11	3.159	1.998	-1.1614	[-2.9887, 0.6659]	0.274
	137	11	2.995	1.995	-0.9997	[-2.9171, 0.9176]	0.364
	138	11	2.904	2.061	-0.8426	[-2.7022, 1.0170]	0.428

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 68 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	139	11	2.929	1.922	-1.0075	[-3.0317, 1.0167]	0.385
	140	11	2.524	2.377	-0.1468	[-2.0286, 1.7350]	0.889
	141	11	2.755	2.096	-0.6588	[-2.4511, 1.1336]	0.517
	142	11	2.745	2.023	-0.7225	[-2.4825, 1.0375]	0.471
	143	11	2.816	2.026	-0.7896	[-2.5514, 0.9722]	0.433
	144	11	2.859	2.283	-0.5759	[-2.2296, 1.0779]	0.539
	145	10	3.408	2.030	-1.3787	[-3.2216, 0.4643]	0.202
	146	10	3.036	2.349	-0.6872	[-3.1046, 1.7303]	0.611
	147	10	3.067	2.081	-0.9858	[-3.2080, 1.2364]	0.433
	148	10	3.320	2.334	-0.9862	[-2.7282, 0.7558]	0.323
	149	10	3.354	2.016	-1.3384	[-3.5759, 0.8990]	0.298
	150	10	3.421	2.056	-1.3652	[-3.6111, 0.8808]	0.291
	151	10	3.116	1.996	-1.1197	[-3.3965, 1.1571]	0.387
	152	10	3.344	1.998	-1.3462	[-3.5720, 0.8797]	0.293
	153	10	3.442	1.995	-1.4468	[-3.7648, 0.8711]	0.279
	154	10	3.608	2.447	-1.1613	[-2.7535, 0.4308]	0.212
	155	10	3.636	2.473	-1.1635	[-2.5558, 0.2288]	0.159
	156	10	3.461	2.483	-0.9783	[-2.2674, 0.3107]	0.196
	157	10	3.268	2.585	-0.6836	[-2.0207, 0.6536]	0.370
	158	10	3.136	2.642	-0.4939	[-1.8972, 0.9094]	0.531
	159	10	3.114	2.711	-0.4029	[-1.8552, 1.0493]	0.620
	160	10	3.106	2.757	-0.3497	[-1.8710, 1.1716]	0.680
	161	10	3.160	2.267	-0.8935	[-3.0777, 1.2906]	0.469
	162	10	3.200	2.323	-0.8773	[-2.9054, 1.1508]	0.444
	163	11	2.943	2.532	-0.4115	[-1.9088, 1.0857]	0.626
	164	11	3.061	2.280	-0.7805	[-2.3680, 0.8070]	0.387
	165	11	3.223	2.147	-1.0759	[-2.7026, 0.5508]	0.254
	166	11	3.223	2.309	-0.9134	[-2.2819, 0.4551]	0.250

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 69 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	167	11	3.249	2.652	-0.5969	[-1.8007, 0.6070]	0.384
	168	11	3.167	2.885	-0.2819	[-0.9219, 0.3581]	0.436
	169	10	2.904	3.079	0.1745	[-0.2728, 0.6218]	0.484
	170	10	2.873	2.450	-0.4228	[-1.8654, 1.0199]	0.596
	171	10	2.893	2.415	-0.4776	[-1.7063, 0.7511]	0.485
	172	10	3.069	2.043	-1.0258	[-2.8591, 0.8074]	0.319
	173	10	2.484	2.007	-0.4777	[-2.0576, 1.1022]	0.578
	174	10	2.619	1.838	-0.7806	[-2.3815, 0.8203]	0.380
	175	10	2.577	1.835	-0.7415	[-2.3451, 0.8620]	0.403
	176	10	2.663	1.827	-0.8364	[-2.4131, 0.7403]	0.342
	177	10	2.709	1.742	-0.9674	[-2.5520, 0.6172]	0.280
	178	10	2.751	1.772	-0.9797	[-2.5854, 0.6260]	0.281
	179	10	2.876	1.789	-1.0874	[-2.7052, 0.5305]	0.239
	180	10	2.867	1.685	-1.1824	[-2.8836, 0.5188]	0.226
	181	10	2.797	1.699	-1.0988	[-2.7134, 0.5158]	0.234
	182	10	2.815	1.634	-1.1810	[-3.0607, 0.6987]	0.261
	183	10	2.955	1.495	-1.4604	[-3.4955, 0.5748]	0.208
	184	10	2.897	1.512	-1.3855	[-3.2910, 0.5201]	0.203
	185	9	3.128	1.401	-1.7272	[-3.8266, 0.3722]	0.154
	189	9	2.893	1.648	-1.2448	[-3.2917, 0.8021]	0.275
	190	9	2.784	1.698	-1.0854	[-2.9441, 0.7733]	0.292
	191	9	2.775	1.759	-1.0160	[-3.0069, 0.9749]	0.351
	192	9	2.731	1.915	-0.8169	[-2.8442, 1.2104]	0.454
	193	9	2.676	1.852	-0.8238	[-2.3848, 0.7372]	0.336
	194	9	3.821	2.155	-1.6659	[-4.7034, 1.3715]	0.319
	195	9	3.620	2.411	-1.2091	[-4.4532, 2.0349]	0.486
	196	9	3.473	2.226	-1.2472	[-3.9760, 1.4817]	0.399
	197	9	3.252	1.987	-1.2649	[-3.1153, 0.5856]	0.232

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 70 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	198	10	2.763	1.851	-0.9130	[-3.2085, 1.3826]	0.476
	199	10	2.019	2.135	0.1152	[-1.6965, 1.9268]	0.908
	200	10	1.915	2.013	0.0972	[-1.5459, 1.7403]	0.914
	201	10	1.640	2.347	0.7076	[-0.9819, 2.3971]	0.454
	202	10	1.763	2.924	1.1614	[-0.8317, 3.1544]	0.310
	203	11	2.210	2.892	0.6824	[-1.0169, 2.3817]	0.480
	204	11	2.143	2.514	0.3706	[-1.1118, 1.8529]	0.658
	205	11	1.883	2.547	0.6638	[-0.8310, 2.1586]	0.437
	206	11	1.887	2.460	0.5736	[-0.9278, 2.0749]	0.501
	211	10	2.171	2.318	0.1471	[-1.5138, 1.8079]	0.873
	212	10	2.174	2.358	0.1838	[-1.5263, 1.8939]	0.847
	213	10	2.204	2.405	0.2008	[-1.4108, 1.8124]	0.823
	214	10	2.163	2.465	0.3018	[-1.2403, 1.8438]	0.725
	215	10	2.193	2.378	0.1850	[-1.3857, 1.7556]	0.832
	216	10	2.095	2.348	0.2534	[-1.5415, 2.0483]	0.800
	217	10	1.998	2.641	0.6435	[-1.4460, 2.7330]	0.583
	218	10	1.982	2.652	0.6704	[-1.4143, 2.7550]	0.566
	219	10	2.004	2.420	0.4168	[-1.4846, 2.3182]	0.694
	220	10	2.113	2.174	0.0617	[-1.7314, 1.8547]	0.951
	221	10	2.422	2.387	-0.0342	[-2.0772, 2.0088]	0.976
	222	10	2.690	2.306	-0.3841	[-2.5252, 1.7571]	0.744
	223	10	2.681	2.054	-0.6271	[-2.2089, 0.9546]	0.477
	224	10	2.933	1.960	-0.9739	[-2.0637, 0.1159]	0.134
	225	10	2.684	2.855	0.1711	[-0.4444, 0.7865]	0.609
	226	10	2.972	3.309	0.3370	[-1.4591, 2.1332]	0.728
	227	10	2.920	2.736	-0.1840	[-1.9723, 1.6043]	0.848
	228	10	2.691	3.140	0.4488	[-1.8356, 2.7332]	0.716
	229	11	2.870	2.559	-0.3110	[-1.4927, 0.8708]	0.633

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 71 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 09	230	11	2.710	2.665	-0.0456	[-1.1141, 1.0229]	0.939
	231	11	2.591	2.152	-0.4390	[-1.4717, 0.5938]	0.452
	232	11	2.743	2.448	-0.2950	[-1.9997, 1.4096]	0.756
	233	11	2.883	2.565	-0.3185	[-2.2433, 1.6063]	0.766
	234	11	2.889	1.942	-0.9467	[-2.2983, 0.4049]	0.229
	235	10	2.557	2.508	-0.0489	[-1.8061, 1.7082]	0.960
	236	11	3.009	2.353	-0.6559	[-2.1274, 0.8157]	0.435
	237	11	2.769	2.343	-0.4261	[-1.9361, 1.0839]	0.617
	238	11	3.276	2.346	-0.9295	[-2.7812, 0.9223]	0.382
	239	11	2.554	2.403	-0.1514	[-1.5251, 1.2223]	0.844
Channel 10	1	12	3.585	2.008	-1.5764	[-2.8630, -0.2899]	0.051
	2	12	3.546	3.596	0.0506	[-1.7226, 1.8238]	0.960
	3	12	3.341	4.910	1.5692	[-0.1046, 3.2430]	0.120
	4	12	3.277	6.057	2.7804	[1.3387, 4.2221]	0.006
	5	12	3.338	6.847	3.5086	[2.3515, 4.6658]	<0.001
	6	12	3.478	6.929	3.4517	[2.3474, 4.5560]	<0.001
	7	12	3.375	6.963	3.5879	[2.4909, 4.6850]	<0.001
	8	12	3.298	6.763	3.4652	[2.3846, 4.5458]	<0.001
	9	12	3.144	6.819	3.6749	[2.7346, 4.6151]	<0.001
	10	12	3.318	6.285	2.9675	[1.6629, 4.2721]	0.002
	11	12	3.266	6.499	3.2327	[1.8835, 4.5819]	0.001
	12	12	3.228	6.406	3.1779	[1.8693, 4.4865]	0.001
	13	12	3.105	6.432	3.3261	[2.0165, 4.6357]	<0.001
	14	12	3.387	6.236	2.8487	[1.4938, 4.2036]	0.003
	15	12	3.238	5.905	2.6669	[1.1818, 4.1519]	0.009
	16	12	3.333	5.371	2.0381	[0.6118, 3.4644]	0.027
	17	12	3.096	5.354	2.2584	[0.6753, 3.8415]	0.027

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 72 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	18	12	2.872	5.435	2.5631	[0.7807, 4.3454]	0.026
	19	12	3.074	5.263	2.1881	[0.6555, 3.7208]	0.027
	20	12	2.884	5.216	2.3321	[0.6602, 4.0040]	0.030
	21	12	3.293	5.175	1.8824	[0.2934, 3.4713]	0.058
	22	12	3.114	5.109	1.9957	[0.2113, 3.7801]	0.071
	23	12	2.887	4.902	2.0151	[0.2290, 3.8012]	0.069
	24	12	2.909	4.903	1.9939	[0.1915, 3.7964]	0.074
	25	12	3.411	4.710	1.2991	[-0.3368, 2.9349]	0.178
	26	12	2.916	4.817	1.9012	[-0.0602, 3.8626]	0.109
	27	12	2.870	4.547	1.6776	[-0.1870, 3.5422]	0.133
	28	12	3.193	4.348	1.1551	[-0.7648, 3.0749]	0.296
	29	12	2.944	4.328	1.3842	[-0.1805, 2.9488]	0.139
	30	12	2.830	4.636	1.8068	[-0.2176, 3.8313]	0.136
	31	12	2.846	4.251	1.4050	[-0.6020, 3.4120]	0.229
	32	11	2.130	3.929	1.7994	[-0.4239, 4.0226]	0.169
	33	10	2.042	3.901	1.8593	[-0.2446, 3.9632]	0.137
	34	10	1.995	3.638	1.6430	[-0.3625, 3.6486]	0.163
	35	10	2.782	3.488	0.7061	[-0.5297, 1.9420]	0.309
	36	10	2.294	3.782	1.4882	[-0.2143, 3.1908]	0.142
	37	10	2.712	3.954	1.2417	[-0.2681, 2.7515]	0.163
	38	10	2.658	3.783	1.1258	[-0.1343, 2.3858]	0.135
	39	10	2.742	3.765	1.0228	[-0.2577, 2.3032]	0.176
	40	10	2.674	3.543	0.8686	[-0.3968, 2.1341]	0.238
	41	10	1.975	3.613	1.6378	[0.0389, 3.2366]	0.093
	42	11	1.868	3.257	1.3891	[0.0998, 2.6785]	0.080
	43	12	2.411	3.243	0.8322	[-0.4372, 2.1016]	0.262
	44	12	2.402	3.170	0.7676	[-0.6801, 2.2154]	0.359
	45	12	2.473	3.082	0.6093	[-0.9433, 2.1619]	0.490

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 73 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	46	12	2.091	2.885	0.7949	[-0.4558, 2.0456]	0.276
	47	12	2.474	2.692	0.2182	[-1.2777, 1.7141]	0.797
	48	12	2.531	2.931	0.4006	[-0.9812, 1.7825]	0.611
	49	12	2.520	2.944	0.4241	[-0.9324, 1.7806]	0.583
	50	12	2.727	2.588	-0.1394	[-1.4393, 1.1605]	0.849
	51	11	2.825	2.492	-0.3329	[-1.8837, 1.2179]	0.700
	52	11	3.200	2.481	-0.7190	[-2.4179, 0.9799]	0.454
	53	11	3.170	2.861	-0.3089	[-1.8764, 1.2586]	0.726
	54	11	2.814	2.900	0.0867	[-1.3488, 1.5222]	0.914
	55	11	2.717	2.793	0.0759	[-1.2812, 1.4330]	0.921
	56	11	2.753	2.900	0.1462	[-1.3595, 1.6519]	0.863
	57	11	2.783	2.815	0.0322	[-1.2885, 1.3528]	0.965
	58	11	2.730	2.713	-0.0172	[-1.3126, 1.2781]	0.981
	59	11	2.368	2.731	0.3632	[-0.3845, 1.1109]	0.396
	60	11	2.719	2.650	-0.0692	[-1.2425, 1.1041]	0.916
	61	11	2.713	2.681	-0.0319	[-1.2499, 1.1860]	0.963
	62	11	2.717	2.825	0.1082	[-1.1939, 1.4103]	0.882
	72	9	4.753	3.562	-1.1909	[-3.4183, 1.0365]	0.339
	73	9	4.756	3.434	-1.3218	[-3.5157, 0.8720]	0.286
	74	9	3.914	3.169	-0.7451	[-2.4984, 1.0083]	0.441
	75	9	4.134	2.690	-1.4435	[-3.6231, 0.7362]	0.246
	76	9	4.088	2.645	-1.4425	[-3.3990, 0.5140]	0.202
	77	9	4.246	2.637	-1.6087	[-3.6562, 0.4387]	0.178
	78	9	3.524	2.812	-0.7124	[-1.7483, 0.3234]	0.230
	79	9	3.838	2.649	-1.1895	[-3.0131, 0.6341]	0.252
	80	9	3.835	2.751	-1.0845	[-2.8368, 0.6678]	0.274
	81	9	2.861	2.664	-0.1968	[-0.8394, 0.4458]	0.573
	82	9	2.908	2.579	-0.3281	[-0.9733, 0.3170]	0.361

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 74 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	83	9	3.499	2.887	-0.6121	[-1.8706, 0.6465]	0.381
	84	9	3.501	3.105	-0.3962	[-2.0478, 1.2554]	0.658
	85	9	3.663	2.756	-0.9075	[-2.4168, 0.6019]	0.287
	86	9	3.572	2.917	-0.6547	[-1.8611, 0.5518]	0.332
	87	9	2.856	3.793	0.9365	[-0.7547, 2.6278]	0.323
	88	9	3.484	2.855	-0.6290	[-2.3695, 1.1116]	0.509
	89	9	3.936	2.554	-1.3817	[-3.4372, 0.6737]	0.243
	90	9	4.127	3.227	-0.8997	[-3.5809, 1.7814]	0.545
	91	9	4.233	3.219	-1.0139	[-3.8620, 1.8343]	0.522
	92	9	4.287	3.252	-1.0347	[-3.2532, 1.1837]	0.406
	93	10	4.006	2.837	-1.1685	[-3.1167, 0.7798]	0.297
	94	10	3.867	2.579	-1.2880	[-3.3396, 0.7636]	0.277
	99	11	3.816	2.205	-1.6112	[-3.9136, 0.6912]	0.227
	100	11	3.630	1.932	-1.6979	[-4.1624, 0.7667]	0.229
	101	11	3.319	2.026	-1.2932	[-3.6977, 1.1114]	0.336
	102	11	3.871	1.595	-2.2753	[-4.5672, 0.0165]	0.102
	103	11	3.564	1.707	-1.8568	[-4.1262, 0.4127]	0.163
	104	11	3.790	1.465	-2.3249	[-4.0953, -0.5545]	0.042
	105	11	3.929	1.361	-2.5678	[-4.2957, -0.8399]	0.026
	106	11	3.658	1.553	-2.1046	[-3.8105, -0.3987]	0.052
	107	11	3.745	1.397	-2.3477	[-4.1989, -0.4965]	0.047
	108	11	3.510	1.731	-1.7789	[-3.2845, -0.2732]	0.060
	109	11	3.468	1.585	-1.8825	[-3.7450, -0.0201]	0.097
	110	11	3.480	2.194	-1.2861	[-3.4923, 0.9200]	0.306
	111	11	2.926	1.667	-1.2585	[-2.5424, 0.0255]	0.106
	112	11	3.068	1.558	-1.5101	[-2.8625, -0.1578]	0.072
	113	11	3.288	1.814	-1.4745	[-2.7757, -0.1732]	0.068
	114	11	3.582	1.758	-1.8237	[-3.2265, -0.4209]	0.042

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 75 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	115	11	3.430	1.808	-1.6223	[-3.2503, 0.0057]	0.101
	116	11	3.502	1.727	-1.7749	[-3.1486, -0.4012]	0.043
	118	10	3.620	1.891	-1.7290	[-3.0709, -0.3870]	0.043
	119	10	3.670	2.194	-1.4765	[-2.6015, -0.3514]	0.041
	120	10	3.811	2.424	-1.3868	[-2.8900, 0.1165]	0.125
	121	10	3.461	2.399	-1.0623	[-2.4681, 0.3435]	0.198
	122	10	4.304	2.772	-1.5320	[-3.1370, 0.0729]	0.114
	123	11	3.885	2.575	-1.3099	[-2.6824, 0.0625]	0.114
	124	11	3.845	2.251	-1.5946	[-3.0426, -0.1467]	0.074
	125	11	3.304	1.951	-1.3523	[-2.6972, -0.0074]	0.098
	126	11	3.760	1.996	-1.7637	[-3.0794, -0.4480]	0.036
	127	11	2.998	2.110	-0.8877	[-2.0665, 0.2911]	0.201
	128	11	2.677	2.119	-0.5577	[-1.9542, 0.8387]	0.483
	129	11	2.302	2.190	-0.1113	[-1.3483, 1.1257]	0.873
	130	11	2.577	1.993	-0.5841	[-2.1170, 0.9487]	0.502
	131	11	2.243	2.823	0.5801	[-0.9938, 2.1539]	0.516
	132	11	2.941	2.349	-0.5924	[-2.7094, 1.5246]	0.620
	133	10	2.854	2.143	-0.7106	[-2.8860, 1.4648]	0.560
	134	11	2.577	2.192	-0.3849	[-2.1485, 1.3786]	0.698
	135	11	2.502	2.133	-0.3688	[-2.0486, 1.3111]	0.697
	136	11	2.918	2.309	-0.6091	[-2.7090, 1.4908]	0.608
	137	11	2.863	2.407	-0.4561	[-2.3368, 1.4246]	0.667
	138	11	2.878	2.189	-0.6885	[-2.7201, 1.3431]	0.550
	139	11	2.960	2.132	-0.8280	[-2.8361, 1.1800]	0.469
	140	11	2.618	2.526	-0.0920	[-2.0526, 1.8686]	0.933
	141	11	2.572	2.500	-0.0718	[-1.4504, 1.3067]	0.926
	142	11	2.920	2.521	-0.3987	[-1.7695, 0.9722]	0.607
	143	11	3.236	2.498	-0.7377	[-2.2688, 0.7934]	0.400

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 76 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	144	11	2.844	2.421	-0.4226	[-2.0179, 1.1728]	0.639
	145	10	3.264	2.063	-1.2000	[-3.1451, 0.7450]	0.284
	146	10	3.234	2.197	-1.0368	[-2.9880, 0.9144]	0.352
	147	10	3.465	2.620	-0.8455	[-2.8001, 1.1092]	0.444
	148	10	3.833	2.478	-1.3545	[-2.8579, 0.1488]	0.132
	149	10	3.530	2.108	-1.4223	[-3.6066, 0.7619]	0.260
	150	10	3.669	1.978	-1.6904	[-4.0084, 0.6276]	0.212
	151	10	3.770	1.929	-1.8409	[-4.1014, 0.4195]	0.168
	152	10	3.554	2.231	-1.3228	[-3.2901, 0.6445]	0.246
	153	10	3.478	1.909	-1.5684	[-3.9636, 0.8267]	0.258
	154	10	3.528	2.419	-1.1092	[-2.7876, 0.5693]	0.254
	155	10	3.469	2.456	-1.0129	[-2.6708, 0.6449]	0.289
	156	10	3.368	2.537	-0.8312	[-2.5114, 0.8490]	0.385
	157	10	3.430	2.461	-0.9690	[-2.3962, 0.4582]	0.242
	158	10	3.088	2.376	-0.7125	[-2.0308, 0.6058]	0.344
	159	10	3.133	2.430	-0.7029	[-1.9117, 0.5059]	0.311
	160	10	3.227	2.446	-0.7814	[-2.1958, 0.6330]	0.334
	161	10	3.257	1.913	-1.3439	[-3.3260, 0.6381]	0.243
	162	10	3.298	2.066	-1.2315	[-2.8617, 0.3986]	0.198
	163	11	3.160	2.106	-1.0532	[-2.5419, 0.4355]	0.227
	164	11	3.157	1.919	-1.2381	[-3.0590, 0.5829]	0.242
	165	11	3.181	2.012	-1.1690	[-2.9986, 0.6605]	0.269
	166	11	3.407	2.392	-1.0153	[-2.1067, 0.0761]	0.122
	167	11	3.329	2.904	-0.4250	[-1.0602, 0.2101]	0.249
	168	11	3.477	3.094	-0.3828	[-1.4522, 0.6866]	0.524
	169	10	2.864	3.223	0.3596	[-0.1670, 0.8863]	0.237
	170	10	3.040	1.999	-1.0408	[-2.6068, 0.5253]	0.248
	171	10	3.029	2.545	-0.4839	[-1.4208, 0.4530]	0.360

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 77 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	172	10	3.068	2.298	-0.7692	[-2.2710, 0.7327]	0.358
	173	10	2.461	2.213	-0.2473	[-1.9330, 1.4384]	0.785
	174	10	2.729	1.799	-0.9302	[-2.5801, 0.7198]	0.315
	175	10	2.735	1.833	-0.9025	[-2.4186, 0.6136]	0.291
	176	10	2.719	1.820	-0.8989	[-2.5069, 0.7091]	0.319
	177	10	2.894	1.775	-1.1183	[-2.5883, 0.3517]	0.190
	178	10	2.851	1.870	-0.9806	[-2.4742, 0.5130]	0.249
	179	10	3.043	1.855	-1.1876	[-2.7611, 0.3858]	0.193
	180	10	2.796	1.720	-1.0763	[-2.6669, 0.5142]	0.237
	181	10	2.768	1.709	-1.0592	[-2.5688, 0.4505]	0.222
	182	10	2.799	1.626	-1.1723	[-3.0141, 0.6694]	0.256
	183	10	2.968	1.502	-1.4655	[-3.3220, 0.3910]	0.173
	184	10	2.877	1.613	-1.2641	[-3.1666, 0.6383]	0.238
	185	9	3.309	1.337	-1.9722	[-3.9691, 0.0247]	0.103
	189	9	3.639	1.560	-2.0797	[-4.3339, 0.1744]	0.122
	190	9	2.725	2.222	-0.5032	[-3.0347, 2.0282]	0.705
	191	9	2.753	1.639	-1.1136	[-2.9356, 0.7084]	0.273
	192	9	2.718	2.315	-0.4033	[-3.1455, 2.3388]	0.779
	193	9	2.703	1.717	-0.9861	[-2.5496, 0.5775]	0.260
	194	9	3.702	1.788	-1.9145	[-4.4216, 0.5927]	0.184
	195	9	3.405	2.308	-1.0966	[-4.0293, 1.8360]	0.485
	196	9	3.454	2.403	-1.0505	[-4.1662, 2.0652]	0.527
	197	9	3.325	2.542	-0.7832	[-3.2627, 1.6963]	0.562
	198	10	2.714	1.838	-0.8754	[-3.1268, 1.3760]	0.485
	199	10	2.028	2.252	0.2237	[-1.6776, 2.1251]	0.830
	200	10	2.128	2.033	-0.0945	[-1.2535, 1.0645]	0.882
	201	10	1.816	2.355	0.5388	[-1.1395, 2.2170]	0.562
	202	10	1.693	2.803	1.1102	[-0.8276, 3.0480]	0.318

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 78 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	203	11	2.189	2.924	0.7353	[-0.9848, 2.4554]	0.453
	204	11	2.086	2.422	0.3365	[-1.0334, 1.7064]	0.663
	205	11	1.989	2.362	0.3730	[-1.0848, 1.8309]	0.650
	206	11	1.976	2.340	0.3641	[-1.1104, 1.8386]	0.662
	211	10	2.141	2.234	0.0932	[-1.5572, 1.7437]	0.919
	212	10	2.345	2.264	-0.0806	[-1.6454, 1.4843]	0.926
	213	10	2.165	2.315	0.1498	[-1.3482, 1.6478]	0.857
	214	10	2.190	2.534	0.3435	[-1.1327, 1.8196]	0.677
	215	10	2.047	2.608	0.5616	[-1.2366, 2.3597]	0.577
	216	10	2.158	2.157	-0.0010	[-1.9410, 1.9389]	0.999
	217	10	2.048	2.611	0.5635	[-1.8048, 2.9319]	0.670
	218	10	2.018	2.657	0.6391	[-1.3706, 2.6489]	0.571
	219	10	2.110	2.427	0.3168	[-1.7025, 2.3362]	0.778
	220	10	2.287	2.025	-0.2618	[-1.8009, 1.2774]	0.760
	221	10	2.952	1.980	-0.9722	[-2.3335, 0.3891]	0.218
	222	10	2.826	2.237	-0.5883	[-2.4909, 1.3144]	0.576
	223	10	2.930	2.294	-0.6364	[-1.2261, -0.0467]	0.080
	224	10	2.790	2.681	-0.1094	[-0.8400, 0.6211]	0.785
	225	10	2.925	3.114	0.1890	[-0.6756, 1.0535]	0.686
	226	10	2.687	3.614	0.9273	[-0.0195, 1.8741]	0.106
	227	10	3.116	2.722	-0.3944	[-1.7768, 0.9880]	0.599
	228	10	2.835	2.908	0.0729	[-1.6289, 1.7747]	0.936
	229	11	3.012	1.666	-1.3465	[-2.6176, -0.0754]	0.085
	230	11	3.039	2.203	-0.8364	[-2.1633, 0.4905]	0.275
	231	11	2.919	1.795	-1.1244	[-2.2316, -0.0172]	0.096
	232	11	3.012	2.297	-0.7156	[-2.6626, 1.2314]	0.514
	233	11	3.187	1.837	-1.3501	[-2.8719, 0.1717]	0.138
	234	11	2.814	1.815	-0.9986	[-2.3715, 0.3743]	0.213

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 79 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 10	235	10	2.947	2.498	-0.4483	[-2.3834, 1.4868]	0.678
	236	11	3.590	2.315	-1.2751	[-3.0451, 0.4949]	0.219
	237	11	3.226	2.242	-0.9836	[-2.5660, 0.5987]	0.284
	238	11	3.696	2.227	-1.4691	[-3.4105, 0.4724]	0.199
	239	11	3.213	2.266	-0.9473	[-2.7211, 0.8266]	0.353
Channel 11	1	12	3.954	2.716	-1.2380	[-2.1964, -0.2796]	0.041
	2	12	4.065	3.454	-0.6103	[-1.4536, 0.2331]	0.219
	3	12	4.005	5.136	1.1311	[-0.3989, 2.6611]	0.210
	4	12	3.742	5.930	2.1878	[0.8350, 3.5406]	0.015
	5	12	3.425	6.638	3.2125	[1.8315, 4.5936]	0.002
	6	12	3.546	6.640	3.0943	[1.8337, 4.3549]	0.001
	7	12	3.607	6.780	3.1736	[1.9140, 4.4332]	0.001
	8	12	3.883	6.832	2.9498	[1.6214, 4.2782]	0.002
	9	12	3.784	7.136	3.3519	[2.0824, 4.6215]	<0.001
	10	12	4.047	6.848	2.8010	[1.2801, 4.3219]	0.008
	11	12	3.789	6.764	2.9748	[1.4392, 4.5105]	0.006
	12	12	3.700	6.717	3.0169	[1.5481, 4.4857]	0.004
	13	12	3.706	6.452	2.7464	[1.4516, 4.0412]	0.003
	14	12	3.842	6.405	2.5633	[1.2810, 3.8455]	0.005
	15	12	4.081	6.581	2.4993	[1.1201, 3.8785]	0.008
	16	12	3.667	5.862	2.1947	[0.8671, 3.5224]	0.013
	17	12	3.646	5.755	2.1099	[0.5794, 3.6404]	0.032
	18	12	3.594	5.976	2.3818	[1.0531, 3.7105]	0.009
	19	12	3.742	5.819	2.0767	[0.8740, 3.2794]	0.011
	20	12	3.879	5.176	1.2966	[-0.3791, 2.9723]	0.191
	21	12	4.201	5.477	1.2765	[0.1811, 2.3718]	0.061
	22	12	4.291	5.099	0.8080	[-0.2460, 1.8619]	0.192

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 80 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	23	12	4.279	5.139	0.8596	[-0.2166, 1.9358]	0.176
	24	12	4.257	4.517	0.2594	[-1.3703, 1.8891]	0.775
	25	12	4.118	4.166	0.0479	[-1.6903, 1.7862]	0.960
	26	12	3.481	4.196	0.7157	[-1.1451, 2.5765]	0.495
	27	12	3.549	4.142	0.5926	[-1.0782, 2.2634]	0.528
	28	12	3.971	4.282	0.3104	[-0.8173, 1.4381]	0.623
	29	12	3.425	4.479	1.0546	[-0.2000, 2.3093]	0.157
	30	12	4.199	4.218	0.0193	[-2.0801, 2.1188]	0.987
	31	12	4.120	4.262	0.1415	[-2.2861, 2.5691]	0.916
	32	11	3.564	4.290	0.7259	[-1.5889, 3.0408]	0.571
	33	10	3.047	4.399	1.3525	[0.0411, 2.6639]	0.092
	34	10	3.070	3.859	0.7886	[-1.7898, 3.3670]	0.574
	35	10	3.384	4.006	0.6218	[-1.2693, 2.5128]	0.546
	36	10	3.184	3.568	0.3845	[-1.1234, 1.8924]	0.644
	37	10	3.423	4.107	0.6843	[-0.9747, 2.3434]	0.460
	38	10	3.680	4.226	0.5459	[-0.1092, 1.2011]	0.160
	39	10	3.660	4.266	0.6062	[-0.8597, 2.0722]	0.464
	40	10	4.050	4.443	0.3929	[-0.4411, 1.2269]	0.407
	41	10	3.151	4.065	0.9134	[-0.9363, 2.7631]	0.385
	42	11	3.631	3.871	0.2406	[-1.2224, 1.7037]	0.770
	43	12	3.586	3.767	0.1815	[-0.9619, 1.3249]	0.779
	44	12	2.885	4.095	1.2098	[0.2317, 2.1879]	0.049
	45	12	3.448	3.618	0.1706	[-1.6256, 1.9668]	0.866
	46	12	3.324	3.459	0.1348	[-1.3668, 1.6364]	0.874
	47	12	3.260	3.533	0.2724	[-1.3017, 1.8465]	0.760
	48	12	3.371	3.518	0.1473	[-1.3624, 1.6571]	0.863
	49	12	3.083	4.417	1.3335	[-0.1948, 2.8619]	0.145
	50	12	3.569	3.198	-0.3712	[-2.3091, 1.5668]	0.734

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 81 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	51	11	3.897	3.048	-0.8491	[-2.6373, 0.9391]	0.403
	52	11	3.669	3.138	-0.5313	[-1.6981, 0.6354]	0.422
	53	11	3.633	3.614	-0.0190	[-1.5959, 1.5579]	0.983
	54	11	3.143	3.675	0.5322	[-1.0626, 2.1270]	0.556
	55	11	3.065	2.867	-0.1977	[-1.7864, 1.3909]	0.825
	56	11	2.836	2.839	0.0026	[-1.4484, 1.4536]	0.997
	57	11	3.418	3.832	0.4147	[-0.8132, 1.6427]	0.551
	58	11	3.566	4.324	0.7586	[-0.8856, 2.4027]	0.420
	59	11	3.005	3.818	0.8132	[-0.8300, 2.4564]	0.388
	60	11	3.443	3.877	0.4338	[-0.8840, 1.7516]	0.561
	61	11	3.453	3.428	-0.0251	[-1.8302, 1.7800]	0.980
	62	11	3.317	3.518	0.2008	[-1.2234, 1.6250]	0.802
	72	9	5.685	5.575	-0.1098	[-0.5179, 0.2983]	0.620
	73	9	4.425	4.005	-0.4199	[-3.1019, 2.2620]	0.771
	74	9	4.277	4.750	0.4735	[-1.1747, 2.1218]	0.597
	75	9	4.575	4.512	-0.0625	[-1.6828, 1.5578]	0.943
	76	9	4.942	5.066	0.1233	[-0.5163, 0.7630]	0.721
	77	9	5.185	3.789	-1.3955	[-2.7128, -0.0782]	0.085
	78	9	4.075	4.637	0.5620	[-1.2432, 2.3672]	0.567
	79	9	5.013	3.363	-1.6499	[-3.5538, 0.2539]	0.143
	80	9	5.017	3.949	-1.0677	[-2.4286, 0.2932]	0.178
	81	9	4.363	4.256	-0.1080	[-0.9919, 0.7759]	0.820
	82	9	5.105	3.414	-1.6918	[-3.8067, 0.4231]	0.171
	83	9	4.926	4.539	-0.3870	[-2.0937, 1.3198]	0.675
	84	9	5.097	4.615	-0.4816	[-2.7577, 1.7945]	0.695
	85	9	4.959	4.513	-0.4466	[-1.0344, 0.1412]	0.190
	86	9	4.592	5.029	0.4372	[-0.5269, 1.4012]	0.412
	87	9	5.305	4.601	-0.7041	[-2.2794, 0.8711]	0.418

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 82 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	88	9	5.725	3.629	-2.0954	[-4.1881, -0.0027]	0.100
	89	9	4.831	4.726	-0.1048	[-2.2279, 2.0184]	0.928
	90	9	5.450	4.468	-0.9822	[-2.9893, 1.0249]	0.385
	91	9	5.489	4.294	-1.1949	[-3.3751, 0.9853]	0.334
	92	9	5.269	3.830	-1.4391	[-3.5033, 0.6251]	0.228
	93	10	4.790	4.290	-0.5001	[-2.8885, 1.8883]	0.707
	94	10	5.181	3.560	-1.6201	[-3.8747, 0.6345]	0.218
	99	11	4.244	3.384	-0.8600	[-3.5475, 1.8275]	0.563
	100	11	4.415	1.751	-2.6634	[-4.7754, -0.5513]	0.050
	101	11	4.180	2.672	-1.5082	[-4.3697, 1.3533]	0.345
	102	11	4.262	3.449	-0.8127	[-3.4462, 1.8208]	0.571
	103	11	4.620	2.099	-2.5203	[-4.1753, -0.8653]	0.025
	104	11	4.342	3.552	-0.7898	[-2.3008, 0.7213]	0.355
	105	11	4.421	3.242	-1.1788	[-2.2973, -0.0603]	0.086
	106	11	4.403	3.207	-1.1961	[-2.4150, 0.0229]	0.105
	107	11	4.245	2.167	-2.0778	[-3.6603, -0.4952]	0.042
	108	11	4.872	2.897	-1.9748	[-3.5051, -0.4446]	0.044
	109	11	4.176	2.431	-1.7449	[-3.1451, -0.3447]	0.050
	110	11	4.737	2.584	-2.1534	[-4.0135, -0.2933]	0.064
	111	11	4.289	1.798	-2.4906	[-4.0186, -0.9627]	0.018
	112	11	4.609	2.007	-2.6020	[-4.0788, -1.1253]	0.012
	113	11	4.612	1.947	-2.6650	[-4.0846, -1.2454]	0.008
	114	11	4.191	2.023	-2.1676	[-3.4427, -0.8924]	0.013
	115	11	4.164	2.594	-1.5696	[-2.6293, -0.5099]	0.025
	116	11	4.410	2.450	-1.9602	[-3.0597, -0.8606]	0.011
	118	10	4.276	2.359	-1.9175	[-2.9390, -0.8960]	0.008
	119	10	4.272	2.398	-1.8733	[-3.1264, -0.6202]	0.024
	120	10	5.009	2.498	-2.5118	[-4.0157, -1.0079]	0.015

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 83 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	121	10	4.871	2.481	-2.3900	[-3.9109, -0.8691]	0.019
	122	10	4.587	2.857	-1.7295	[-3.9067, 0.4478]	0.178
	123	11	5.018	2.774	-2.2443	[-3.8194, -0.6691]	0.028
	124	11	4.258	2.389	-1.8694	[-3.2482, -0.4906]	0.035
	125	11	4.059	2.838	-1.2209	[-3.1461, 0.7043]	0.275
	126	11	4.532	3.318	-1.2136	[-2.6794, 0.2521]	0.163
	127	11	4.151	2.992	-1.1595	[-3.0719, 0.7528]	0.295
	128	11	3.498	2.800	-0.6977	[-2.4003, 1.0049]	0.472
	129	11	4.359	3.167	-1.1911	[-2.8954, 0.5133]	0.232
	130	11	3.631	3.393	-0.2387	[-2.0264, 1.5489]	0.812
	131	11	2.478	3.688	1.2097	[-0.2991, 2.7185]	0.176
	132	11	4.256	3.725	-0.5316	[-2.3361, 1.2728]	0.602
	133	10	4.071	3.040	-1.0303	[-2.6324, 0.5718]	0.266
	134	11	3.842	3.558	-0.2837	[-1.7897, 1.2222]	0.738
	135	11	3.806	3.490	-0.3161	[-1.9137, 1.2815]	0.725
	136	11	3.495	3.060	-0.4352	[-2.4773, 1.6068]	0.705
	137	11	4.048	3.064	-0.9835	[-3.0235, 1.0564]	0.400
	138	11	3.400	3.298	-0.1019	[-1.8831, 1.6793]	0.919
	139	11	3.649	2.885	-0.7634	[-2.4934, 0.9665]	0.439
	140	11	3.484	3.039	-0.4454	[-2.0377, 1.1469]	0.620
	141	11	3.358	3.029	-0.3288	[-2.0474, 1.3899]	0.734
	142	11	3.595	3.085	-0.5096	[-2.3187, 1.2994]	0.618
	143	11	3.620	3.258	-0.3619	[-2.1813, 1.4575]	0.724
	144	11	3.700	3.319	-0.3813	[-1.8890, 1.1264]	0.654
	145	10	4.398	3.282	-1.1164	[-2.7921, 0.5592]	0.250
	146	10	3.822	2.885	-0.9366	[-3.3572, 1.4839]	0.492
	147	10	3.968	3.289	-0.6785	[-2.6141, 1.2570]	0.533
	148	10	4.169	3.663	-0.5062	[-2.3543, 1.3419]	0.624

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 84 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	149	10	3.969	3.742	-0.2266	[-2.2998, 1.8467]	0.844
	150	10	4.264	3.259	-1.0057	[-3.1233, 1.1119]	0.403
	151	10	4.217	3.271	-0.9453	[-3.1036, 1.2130]	0.439
	152	10	4.366	2.964	-1.4023	[-3.2814, 0.4768]	0.203
	153	10	3.806	2.958	-0.8478	[-3.2670, 1.5714]	0.533
	154	10	3.642	2.838	-0.8036	[-2.2774, 0.6702]	0.340
	155	10	4.171	2.803	-1.3678	[-2.9455, 0.2098]	0.146
	156	10	3.634	2.816	-0.8182	[-2.3540, 0.7176]	0.351
	157	10	3.662	2.788	-0.8739	[-2.2770, 0.5291]	0.280
	158	10	3.757	2.429	-1.3280	[-2.6890, 0.0330]	0.107
	159	10	3.856	3.131	-0.7258	[-2.0536, 0.6021]	0.339
	160	10	3.754	2.780	-0.9744	[-2.1498, 0.2010]	0.162
	161	10	4.283	1.959	-2.3238	[-4.0454, -0.6022]	0.036
	162	10	4.262	2.300	-1.9618	[-3.6213, -0.3023]	0.059
	163	11	4.022	2.172	-1.8499	[-3.3493, -0.3505]	0.050
	164	11	3.736	1.874	-1.8620	[-3.5216, -0.2023]	0.070
	165	11	3.689	2.083	-1.6057	[-3.0273, -0.1842]	0.069
	166	11	3.669	2.458	-1.2105	[-2.2848, -0.1362]	0.069
	167	11	3.261	2.911	-0.3495	[-0.8723, 0.1733]	0.249
	168	11	3.239	2.888	-0.3508	[-0.8886, 0.1870]	0.260
	169	10	3.447	2.980	-0.4667	[-1.8352, 0.9017]	0.539
	170	10	3.950	2.762	-1.1879	[-3.1083, 0.7325]	0.280
	171	10	4.104	2.910	-1.1940	[-3.3321, 0.9442]	0.325
	172	10	3.805	3.912	0.1071	[-1.9069, 2.1211]	0.921
	173	10	3.951	3.391	-0.5607	[-2.6960, 1.5747]	0.628
	174	10	4.156	2.561	-1.5950	[-3.0900, -0.1000]	0.084
	175	10	4.431	3.027	-1.4042	[-3.3129, 0.5046]	0.203
	176	10	3.816	2.896	-0.9199	[-3.3499, 1.5100]	0.490

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 85 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	177	10	3.331	2.762	-0.5690	[-2.2963, 1.1584]	0.546
	178	10	4.099	2.662	-1.4369	[-3.7871, 0.9133]	0.280
	179	10	3.329	2.649	-0.6800	[-2.8574, 1.4975]	0.566
	180	10	3.176	2.334	-0.8423	[-2.9227, 1.2381]	0.461
	181	10	3.529	2.878	-0.6507	[-2.8806, 1.5791]	0.591
	182	10	3.150	2.849	-0.3010	[-2.6740, 2.0721]	0.808
	183	10	4.335	1.939	-2.3956	[-5.1230, 0.3317]	0.137
	184	10	3.601	3.600	-0.0018	[-3.4398, 3.4362]	0.999
	185	9	3.592	3.212	-0.3805	[-4.5736, 3.8127]	0.856
	189	9	2.653	3.117	0.4638	[-1.8787, 2.8064]	0.706
	190	9	3.327	4.567	1.2408	[-0.1838, 2.6653]	0.140
	191	9	2.871	4.127	1.2561	[-0.4432, 2.9553]	0.197
	192	9	3.098	4.011	0.9125	[-2.2212, 4.0463]	0.583
	193	9	3.995	2.746	-1.2489	[-3.1048, 0.6069]	0.233
	194	9	3.669	3.834	0.1656	[-1.2782, 1.6094]	0.826
	195	9	3.715	3.688	-0.0277	[-2.2123, 2.1569]	0.981
	196	9	4.506	3.357	-1.1497	[-3.5418, 1.2425]	0.377
	197	9	3.859	3.131	-0.7287	[-3.2500, 1.7925]	0.595
	198	10	3.690	2.089	-1.6012	[-3.1832, -0.0192]	0.097
	199	10	2.983	2.682	-0.3006	[-2.5460, 1.9447]	0.807
	200	10	2.098	3.090	0.9918	[-1.1024, 3.0860]	0.399
	201	10	2.585	2.767	0.1825	[-1.6386, 2.0035]	0.855
	202	10	2.319	2.835	0.5151	[-1.5398, 2.5701]	0.654
	203	11	2.932	2.813	-0.1186	[-1.9680, 1.7308]	0.909
	204	11	3.693	2.447	-1.2456	[-2.5562, 0.0650]	0.115
	205	11	3.066	2.784	-0.2824	[-2.3311, 1.7663]	0.806
	206	11	2.373	2.402	0.0289	[-1.6531, 1.7108]	0.976
	211	10	3.119	2.596	-0.5229	[-2.5637, 1.5179]	0.647

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 86 of 86

Table 14.2.1.9 Statistical Assessment of pH Smoothed Values between Treatments by Electrode and Time Point
PP Population (N=12)

Electrode	Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Channel 11	212	10	3.527	2.276	-1.2510	[-2.6552, 0.1532]	0.136
	213	10	3.818	2.095	-1.7238	[-3.3659, -0.0818]	0.087
	214	10	3.181	2.414	-0.7669	[-3.3105, 1.7766]	0.590
	215	10	3.094	2.351	-0.7428	[-2.9298, 1.4443]	0.545
	216	10	2.977	3.395	0.4182	[-1.3639, 2.2003]	0.674
	217	10	3.362	2.777	-0.5851	[-2.8479, 1.6777]	0.644
	218	10	2.966	3.396	0.4303	[-1.6351, 2.4957]	0.709
	219	10	2.808	3.393	0.5858	[-1.4851, 2.6566]	0.613
	220	10	3.221	2.785	-0.4362	[-2.2744, 1.4019]	0.671
	221	10	3.157	2.385	-0.7719	[-2.6081, 1.0643]	0.452
	222	10	3.211	3.901	0.6902	[-1.4177, 2.7981]	0.555
	223	10	3.221	3.804	0.5829	[-0.6896, 1.8554]	0.414
	224	10	2.998	2.985	-0.0129	[-1.6244, 1.5986]	0.988
	225	10	3.796	3.539	-0.2564	[-2.8380, 2.3251]	0.853
	226	10	3.206	4.016	0.8094	[-1.7165, 3.3353]	0.556
	227	10	3.270	3.525	0.2559	[-2.0293, 2.5411]	0.835
	228	10	3.172	4.091	0.9183	[-1.0993, 2.9358]	0.411
	229	11	3.098	3.120	0.0212	[-1.2924, 1.3347]	0.976
	230	11	3.548	2.857	-0.6909	[-2.2451, 0.8633]	0.432
	231	11	3.213	3.265	0.0518	[-2.0199, 2.1236]	0.964
	232	11	3.884	2.985	-0.8997	[-2.4885, 0.6891]	0.323
	233	11	3.402	3.480	0.0774	[-1.9824, 2.1372]	0.946
	234	11	2.945	3.469	0.5247	[-1.2813, 2.3307]	0.604
	235	10	2.864	3.210	0.3462	[-1.6736, 2.3659]	0.758
	236	11	3.508	3.160	-0.3476	[-2.2854, 1.5901]	0.750
	237	11	3.955	3.006	-0.9490	[-2.9015, 1.0035]	0.396
	238	11	3.583	3.021	-0.5618	[-2.5022, 1.3787]	0.608
	239	11	3.601	3.018	-0.5835	[-2.4856, 1.3186]	0.588

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_09.sas

29JAN2013 6:20

14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time-point (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
1	12	-0.206	0.964	1.1696	[0.8501, 1.4891]	<0.001
2	12	0.040	0.865	0.8251	[0.5083, 1.1419]	<0.001
3	12	-0.176	0.846	1.0214	[0.6975, 1.3454]	<0.001
4	12	-0.290	0.863	1.1530	[0.9915, 1.3144]	<0.001
5	12	0.001	0.678	0.6776	[0.4148, 0.9404]	<0.001
6	12	-0.180	0.746	0.9256	[0.6983, 1.1530]	<0.001
7	12	-0.006	0.650	0.6566	[0.2249, 1.0884]	0.020
8	12	-0.039	0.626	0.6654	[0.3074, 1.0234]	0.007
9	12	-0.295	0.585	0.8792	[0.6236, 1.1347]	<0.001
10	12	-0.171	0.444	0.6151	[0.2917, 0.9386]	0.006
11	12	0.024	0.276	0.2518	[-0.1122, 0.6159]	0.238
12	12	-0.058	0.354	0.4117	[0.1245, 0.6989]	0.027
13	12	-0.058	0.274	0.3319	[0.0715, 0.5923]	0.043
14	12	-0.085	0.087	0.1712	[-0.1107, 0.4531]	0.297
15	12	-0.201	0.074	0.2746	[0.0145, 0.5346]	0.085
16	12	-0.412	0.087	0.4992	[-0.2282, 1.2265]	0.242
17	12	-0.252	0.172	0.4235	[-0.0469, 0.8940]	0.134
18	12	0.013	0.013	0.0005	[-0.2747, 0.2757]	0.997
19	12	0.077	0.167	0.0901	[-0.2710, 0.4512]	0.661
20	12	-0.249	0.174	0.4228	[0.0551, 0.7905]	0.064
21	12	-0.525	0.151	0.6764	[0.3062, 1.0466]	0.009
22	12	-0.131	0.208	0.3381	[0.0033, 0.6728]	0.097
23	12	-0.257	0.070	0.3275	[-0.0226, 0.6776]	0.120
24	12	-0.030	0.054	0.0830	[-0.4127, 0.5788]	0.763
25	12	-0.266	-0.028	0.2380	[-0.6313, 1.1074]	0.624
26	12	-0.037	-0.047	-0.0105	[-0.3216, 0.3006]	0.952
27	12	-0.332	0.099	0.4307	[0.0161, 0.8453]	0.089
28	12	0.257	-0.006	-0.2626	[-1.2202, 0.6949]	0.624

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
29	12	-0.184	0.015	0.1994	[-0.2150, 0.6138]	0.397
30	12	-0.077	0.058	0.1344	[-0.3159, 0.5847]	0.594
31	12	-0.021	0.061	0.0820	[-0.2533, 0.4172]	0.661
32	11	-0.088	-0.001	0.0873	[-0.3479, 0.5225]	0.715
33	10	0.162	-0.008	-0.1699	[-0.5511, 0.2112]	0.420
34	10	-0.151	0.393	0.5439	[-0.5875, 1.6752]	0.386
35	10	-0.226	-0.078	0.1481	[-0.6993, 0.9955]	0.746
36	10	-0.142	0.152	0.2936	[-0.2185, 0.8058]	0.313
37	10	-0.072	0.052	0.1244	[-0.2716, 0.5204]	0.571
38	10	-0.342	-0.386	-0.0436	[-1.2378, 1.1505]	0.948
39	10	-0.463	0.063	0.5260	[0.0101, 1.0420]	0.095
40	10	-0.041	0.020	0.0613	[-0.4800, 0.6026]	0.838
41	10	-0.063	0.084	0.1468	[-0.1753, 0.4688]	0.421
42	11	0.041	-0.456	-0.4969	[-1.4678, 0.4739]	0.373
43	12	-0.060	-0.116	-0.0555	[-0.5306, 0.4197]	0.837
44	12	-0.568	0.103	0.6713	[-0.0034, 1.3460]	0.102
45	12	-0.098	-0.025	0.0729	[-0.1694, 0.3152]	0.595
46	12	-0.238	-0.092	0.1462	[-0.4563, 0.7486]	0.669
47	12	-0.116	0.101	0.2174	[-0.1460, 0.5808]	0.304
48	12	-0.287	-0.026	0.2602	[-0.2163, 0.7368]	0.346
49	12	-0.186	-0.136	0.0495	[-0.3848, 0.4838]	0.840
50	12	-0.506	0.120	0.6263	[-0.2445, 1.4971]	0.220
51	11	-0.415	0.031	0.4452	[-0.2986, 1.1890]	0.298
52	11	-0.378	-0.075	0.3025	[-0.0176, 0.6227]	0.117
53	11	-0.391	-0.119	0.2722	[-0.0236, 0.5681]	0.126
54	11	-0.192	-0.400	-0.2077	[-1.0788, 0.6633]	0.672
55	11	-0.122	-0.102	0.0204	[-0.5196, 0.5604]	0.946
56	11	-0.111	-0.041	0.0706	[-0.3537, 0.4949]	0.767

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
57	11	-0.045	-0.056	-0.0108	[-0.3564, 0.3348]	0.956
58	11	-0.232	-0.143	0.0890	[-0.2060, 0.3841]	0.594
59	11	-0.072	-0.038	0.0338	[-0.3870, 0.4547]	0.886
60	11	-0.316	0.089	0.4045	[0.0637, 0.7453]	0.058
61	11	-0.181	-0.563	-0.3819	[-1.5342, 0.7704]	0.558
62	11	-0.036	0.018	0.0543	[-0.1972, 0.3058]	0.702
72	9	-0.165	-0.095	0.0699	[-0.3739, 0.5138]	0.770
73	9	-0.244	-0.075	0.1692	[-0.5491, 0.8875]	0.663
74	9	-0.222	-0.036	0.1856	[-0.2545, 0.6257]	0.444
75	9	-0.287	-0.014	0.2734	[-0.2127, 0.7596]	0.316
76	9	-0.729	-0.236	0.4928	[-0.5292, 1.5148]	0.385
77	9	-0.247	-0.213	0.0340	[-0.4029, 0.4709]	0.885
78	9	0.014	-0.120	-0.1339	[-0.4803, 0.2124]	0.481
79	9	-0.105	-0.098	0.0070	[-0.3319, 0.3459]	0.969
80	9	-0.159	-0.058	0.1012	[-0.3719, 0.5742]	0.692
81	9	-0.984	-0.057	0.9277	[-0.6462, 2.5015]	0.296
82	9	0.082	-0.370	-0.4521	[-0.7227, -0.1814]	0.018
83	9	-0.191	-0.100	0.0910	[-0.4182, 0.6001]	0.740
84	9	-0.185	-0.153	0.0317	[-0.4701, 0.5336]	0.906
85	9	-0.649	-0.356	0.2932	[-0.9655, 1.5518]	0.667
86	9	-0.162	-0.942	-0.7801	[-2.1011, 0.5409]	0.295
87	9	-0.028	-0.237	-0.2087	[-0.5615, 0.1441]	0.294
88	9	-0.045	-0.194	-0.1494	[-0.3992, 0.1004]	0.289
89	9	-0.136	-0.166	-0.0298	[-0.5609, 0.5014]	0.918
90	9	-0.094	-0.036	0.0578	[-0.2809, 0.3965]	0.756
91	9	-0.285	0.012	0.2965	[-0.3647, 0.9577]	0.424
92	9	-0.032	-0.079	-0.0473	[-0.7030, 0.6084]	0.895
93	10	-0.542	-0.106	0.4356	[-0.5426, 1.4139]	0.432

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
94	10	-0.083	-0.072	0.0115	[-0.4288, 0.4518]	0.962
99	11	0.000	-0.167	-0.1667	[-0.5286, 0.1951]	0.412
100	11	-0.098	-0.565	-0.4679	[-1.4281, 0.4924]	0.380
101	11	0.005	-0.164	-0.1697	[-0.6365, 0.2970]	0.506
102	11	-0.010	-0.183	-0.1728	[-0.6586, 0.3130]	0.515
103	11	0.100	0.068	-0.0316	[-0.4178, 0.3546]	0.879
104	11	0.026	-0.187	-0.2128	[-0.6559, 0.2303]	0.393
105	11	-0.133	0.111	0.2438	[-0.3637, 0.8514]	0.472
106	11	-0.216	-0.190	0.0260	[-0.3613, 0.4133]	0.902
107	11	-0.078	-0.277	-0.1992	[-0.5804, 0.1820]	0.355
108	11	-0.049	-0.122	-0.0723	[-0.4214, 0.2769]	0.707
109	11	-0.015	-0.128	-0.1133	[-0.2907, 0.0640]	0.265
110	11	0.077	-0.083	-0.1597	[-0.3673, 0.0479]	0.188
111	11	-0.105	-0.094	0.0109	[-0.2433, 0.2652]	0.937
112	11	-0.104	0.037	0.1408	[-0.3244, 0.6060]	0.584
113	11	-0.425	-0.169	0.2567	[-0.5223, 1.0356]	0.557
114	11	-0.209	-0.206	0.0035	[-0.5653, 0.5723]	0.991
115	11	0.011	-0.104	-0.1145	[-0.4942, 0.2652]	0.590
116	11	-0.006	-0.206	-0.2000	[-0.6506, 0.2507]	0.433
118	10	-0.118	-0.058	0.0602	[-0.4521, 0.5726]	0.832
119	10	-0.102	-0.104	-0.0020	[-0.3934, 0.3894]	0.993
120	10	-0.335	-0.117	0.2183	[-0.0883, 0.5248]	0.222
121	10	0.027	-0.274	-0.3010	[-0.6215, 0.0196]	0.119
122	10	-0.091	-0.194	-0.1031	[-0.4591, 0.2528]	0.605
123	11	-0.395	-0.089	0.3058	[-0.1918, 0.8034]	0.289
124	11	-0.091	-0.646	-0.5544	[-1.5522, 0.4433]	0.335
125	11	0.047	-0.137	-0.1839	[-0.5118, 0.1440]	0.331
126	11	-0.463	-0.189	0.2745	[-0.4883, 1.0373]	0.526

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
127	11	0.126	-0.106	-0.2318	[-0.6027, 0.1391]	0.281
128	11	-0.037	0.022	0.0583	[-0.3521, 0.4687]	0.801
129	11	0.002	-0.186	-0.1875	[-0.7606, 0.3856]	0.564
130	11	-0.008	-0.131	-0.1223	[-0.6531, 0.4086]	0.683
131	11	0.000	-0.097	-0.0975	[-0.4954, 0.3004]	0.664
132	11	-0.005	-0.130	-0.1250	[-0.4676, 0.2176]	0.520
133	10	-0.342	-0.140	0.2025	[-0.2629, 0.6679]	0.442
134	11	-0.202	-0.042	0.1599	[-0.1572, 0.4770]	0.379
135	11	-0.017	-0.251	-0.2347	[-0.6210, 0.1516]	0.294
136	11	0.113	-0.207	-0.3199	[-0.6246, -0.0152]	0.086
137	11	0.034	-0.207	-0.2413	[-0.5977, 0.1151]	0.246
138	11	0.016	0.116	0.1002	[-0.3169, 0.5173]	0.670
139	11	0.105	-0.188	-0.2931	[-0.6299, 0.0436]	0.145
140	11	0.062	-0.185	-0.2461	[-0.6962, 0.2040]	0.342
141	11	0.130	-0.186	-0.3159	[-0.7027, 0.0708]	0.168
142	11	-0.417	-0.115	0.3018	[-0.4619, 1.0654]	0.487
143	11	-0.091	-0.118	-0.0266	[-0.3461, 0.2929]	0.882
144	11	-0.021	0.018	0.0391	[-0.3832, 0.4614]	0.869
145	10	0.109	-0.455	-0.5635	[-1.7535, 0.6265]	0.404
146	10	0.156	-0.304	-0.4601	[-1.5102, 0.5900]	0.439
147	10	-0.227	-0.295	-0.0683	[-1.3247, 1.1880]	0.922
148	10	-0.103	-0.272	-0.1687	[-1.2320, 0.8946]	0.776
149	10	0.007	-0.162	-0.1698	[-0.8532, 0.5135]	0.656
150	10	0.063	-0.208	-0.2710	[-0.9786, 0.4367]	0.497
151	10	0.088	-0.318	-0.4063	[-1.0817, 0.2691]	0.296
152	10	0.003	-0.375	-0.3782	[-1.0040, 0.2475]	0.294
153	10	0.040	-0.391	-0.4310	[-0.9547, 0.0927]	0.164
154	10	0.056	-0.130	-0.1864	[-0.6948, 0.3219]	0.514

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
155	10	0.066	-0.374	-0.4399	[-0.8625, -0.0173]	0.089
156	10	-0.024	-0.290	-0.2655	[-0.5750, 0.0440]	0.149
157	10	0.129	-0.176	-0.3050	[-0.6380, 0.0280]	0.127
158	10	0.140	-0.085	-0.2248	[-0.5615, 0.1120]	0.250
159	10	0.036	-0.102	-0.1376	[-0.4222, 0.1470]	0.395
160	10	0.178	-0.213	-0.3911	[-0.7531, -0.0291]	0.079
161	10	0.206	-0.239	-0.4445	[-0.8754, -0.0136]	0.091
162	10	-0.126	-0.538	-0.4115	[-1.3515, 0.5285]	0.439
163	11	-0.011	-0.064	-0.0530	[-0.4702, 0.3643]	0.821
164	11	0.067	-0.113	-0.1806	[-0.3622, 0.0010]	0.102
165	11	0.087	-0.050	-0.1364	[-0.6179, 0.3451]	0.613
166	11	0.198	-0.204	-0.4022	[-0.8149, 0.0105]	0.108
167	11	0.238	-0.235	-0.4731	[-0.9294, -0.0169]	0.090
168	11	0.033	-0.203	-0.2357	[-0.5070, 0.0356]	0.145
169	10	0.035	-0.133	-0.1679	[-0.3717, 0.0358]	0.162
170	10	-0.161	-0.014	0.1470	[-0.2508, 0.5448]	0.506
171	10	0.173	-0.201	-0.3739	[-0.8140, 0.0662]	0.151
172	10	-0.073	-0.101	-0.0280	[-0.5968, 0.5408]	0.927
173	10	0.240	0.045	-0.1946	[-0.5173, 0.1281]	0.286
174	10	0.616	-0.387	-1.0027	[-2.6291, 0.6236]	0.276
175	10	0.311	-0.031	-0.3425	[-0.7746, 0.0897]	0.175
176	10	-0.057	0.096	0.1532	[-0.8957, 1.2020]	0.786
177	10	0.099	-0.088	-0.1874	[-0.8360, 0.4612]	0.595
178	10	0.185	-0.226	-0.4105	[-1.1813, 0.3603]	0.341
179	10	0.059	0.005	-0.0546	[-0.7997, 0.6906]	0.892
180	10	0.367	-0.424	-0.7915	[-2.1157, 0.5326]	0.290
181	10	0.330	-0.197	-0.5274	[-1.3700, 0.3153]	0.270
182	10	0.239	-0.014	-0.2528	[-0.7423, 0.2368]	0.346

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
183	10	0.344	-0.287	-0.6318	[-1.1734, -0.0902]	0.066
184	10	0.203	-0.330	-0.5329	[-1.1447, 0.0788]	0.140
185	9	0.385	-0.283	-0.6677	[-1.1220, -0.2135]	0.035
189	9	0.066	-0.175	-0.2411	[-0.6253, 0.1431]	0.262
190	9	-0.115	-0.030	0.0844	[-0.4136, 0.5823]	0.747
191	9	0.195	0.028	-0.1674	[-0.7875, 0.4528]	0.610
192	9	-0.200	0.022	0.2220	[-0.3631, 0.8071]	0.479
193	9	-0.473	-0.554	-0.0803	[-0.4004, 0.2399]	0.635
194	9	-0.350	-0.514	-0.1638	[-0.7130, 0.3855]	0.574
195	9	-0.017	-0.323	-0.3059	[-0.6915, 0.0797]	0.171
196	9	-0.123	-0.317	-0.1944	[-0.9153, 0.5266]	0.610
197	9	-0.109	-0.093	0.0157	[-0.6494, 0.6808]	0.965
198	10	-0.239	-0.211	0.0280	[-0.5912, 0.6473]	0.934
199	10	-0.298	-0.285	0.0138	[-0.3453, 0.3730]	0.944
200	10	-0.130	-0.037	0.0926	[-0.2279, 0.4131]	0.601
201	10	-0.407	-0.154	0.2522	[-0.0258, 0.5301]	0.129
202	10	-0.170	-0.023	0.1469	[-0.1488, 0.4426]	0.383
203	11	0.268	-0.146	-0.4139	[-0.6242, -0.2035]	0.006
204	11	0.110	-0.071	-0.1804	[-0.3592, -0.0017]	0.097
205	11	-0.050	-0.085	-0.0353	[-0.4530, 0.3824]	0.880
206	11	-0.534	-0.154	0.3803	[-0.5546, 1.3152]	0.475
211	10	0.090	-0.165	-0.2555	[-0.8178, 0.3068]	0.423
212	10	-0.064	-0.084	-0.0201	[-0.3909, 0.3507]	0.922
213	10	-0.052	-0.225	-0.1726	[-0.6168, 0.2716]	0.491
214	10	-0.114	-0.148	-0.0337	[-0.4147, 0.3473]	0.874
215	10	-0.678	0.011	0.6886	[-0.5057, 1.8829]	0.315
216	10	-0.338	-0.157	0.1817	[-0.3658, 0.7292]	0.554
217	10	-0.197	-0.454	-0.2568	[-1.1868, 0.6731]	0.621

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 8

Table 14.2.1.10 Statistical Assessment of Change in pH Smoothed Values at Electrode 1 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
218	10	-0.134	-0.248	-0.1145	[-0.4786, 0.2497]	0.575
219	10	-0.086	0.013	0.0990	[-0.1193, 0.3172]	0.424
220	10	0.064	0.029	-0.0354	[-0.3800, 0.3091]	0.853
221	10	-0.138	-0.591	-0.4525	[-0.6880, -0.2169]	0.008
222	10	-0.198	-0.507	-0.3087	[-0.6298, 0.0124]	0.111
223	10	-0.214	-0.575	-0.3612	[-0.7677, 0.0452]	0.136
224	10	-0.099	-0.177	-0.0786	[-0.5489, 0.3918]	0.761
225	10	-0.045	-0.133	-0.0879	[-0.2090, 0.0332]	0.208
226	10	-0.152	-0.259	-0.1070	[-0.5882, 0.3741]	0.681
227	10	0.008	0.092	0.0839	[-0.2817, 0.4495]	0.671
228	10	0.086	0.062	-0.0233	[-0.2649, 0.2182]	0.857
229	11	0.200	-0.304	-0.5042	[-1.6041, 0.5958]	0.414
230	11	-0.023	-0.024	-0.0003	[-0.2975, 0.2969]	0.999
231	11	0.038	-0.262	-0.3001	[-0.8263, 0.2261]	0.320
232	11	-0.092	-0.063	0.0287	[-0.3376, 0.3950]	0.888
233	11	0.010	0.004	-0.0059	[-0.4504, 0.4385]	0.981
234	11	-0.406	0.052	0.4574	[-0.4946, 1.4093]	0.398
235	10	-0.543	0.204	0.7467	[-0.0343, 1.5277]	0.113
236	11	-0.067	0.246	0.3130	[-0.0077, 0.6338]	0.107
237	11	-0.133	-0.011	0.1216	[-0.4250, 0.6682]	0.693
238	11	-0.097	-0.012	0.0845	[-0.3362, 0.5052]	0.721
239	11	-0.245	0.093	0.3378	[-0.0959, 0.7716]	0.187

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_10.sas

29JAN2013 6:30

14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time-point (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
1	12	-0.111	1.205	1.3162	[0.9502, 1.6823]	<0.001
2	12	-0.039	1.104	1.1432	[0.7768, 1.5096]	<0.001
3	12	-0.140	1.087	1.2273	[0.8468, 1.6078]	<0.001
4	12	-0.094	1.126	1.2199	[0.7706, 1.6692]	<0.001
5	12	0.020	0.936	0.9160	[0.6365, 1.1955]	<0.001
6	12	-0.099	0.930	1.0299	[0.7041, 1.3557]	<0.001
7	12	-0.179	0.800	0.9785	[0.6453, 1.3116]	<0.001
8	12	0.090	0.925	0.8343	[0.5383, 1.1304]	<0.001
9	12	-0.185	0.769	0.9546	[0.7015, 1.2077]	<0.001
10	12	-0.068	0.386	0.4539	[-0.1254, 1.0332]	0.186
11	12	-0.067	0.379	0.4465	[0.0307, 0.8624]	0.080
12	12	-0.148	0.435	0.5825	[0.2652, 0.8998]	0.008
13	12	-0.032	0.429	0.4605	[0.1189, 0.8021]	0.035
14	12	-0.151	0.449	0.6000	[0.3466, 0.8533]	0.002
15	12	-0.232	0.185	0.4174	[0.1712, 0.6637]	0.012
16	12	-0.382	0.033	0.4149	[-0.5097, 1.3395]	0.435
17	12	-0.299	0.243	0.5420	[0.0618, 1.0222]	0.068
18	12	0.037	0.152	0.1145	[-0.3602, 0.5892]	0.671
19	12	0.037	0.247	0.2096	[-0.2424, 0.6617]	0.420
20	12	-0.211	0.038	0.2492	[-0.4444, 0.9428]	0.530
21	12	-0.883	0.036	0.9196	[-0.0945, 1.9337]	0.131
22	12	-0.106	-0.087	0.0190	[-0.9444, 0.9825]	0.972
23	12	-0.234	-0.149	0.0852	[-0.6521, 0.8226]	0.835
24	12	-0.193	-0.710	-0.5174	[-1.5570, 0.5222]	0.382
25	12	-0.310	-0.238	0.0721	[-1.1973, 1.3415]	0.918
26	12	-0.126	0.069	0.1954	[-0.2820, 0.6728]	0.468
27	12	-0.642	0.296	0.9374	[-0.2963, 2.1711]	0.195
28	12	-0.330	-0.189	0.1407	[-0.2170, 0.4983]	0.485

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
29	12	-0.232	-0.018	0.2141	[-0.1517, 0.5800]	0.308
30	12	-0.321	-0.087	0.2346	[0.0701, 0.3991]	0.029
31	12	-0.278	-0.068	0.2102	[0.0536, 0.3668]	0.037
32	11	-0.283	-0.002	0.2807	[-0.2799, 0.8412]	0.374
33	10	-0.098	-0.087	0.0112	[-0.3880, 0.4105]	0.958
34	10	-0.582	-0.323	0.2594	[-0.8181, 1.3368]	0.656
35	10	-0.573	-0.156	0.4167	[-0.0063, 0.8397]	0.104
36	10	-0.533	-0.144	0.3893	[-0.3214, 1.1000]	0.334
37	10	-0.456	-0.232	0.2241	[-0.7252, 1.1734]	0.668
38	10	-0.425	-0.200	0.2256	[-0.9287, 1.3799]	0.726
39	10	-0.654	-0.271	0.3835	[-0.5062, 1.2731]	0.446
40	10	-0.239	0.004	0.2433	[-0.5323, 1.0189]	0.576
41	10	-0.767	-0.391	0.3757	[-0.5442, 1.2956]	0.469
42	11	-0.241	-0.854	-0.6126	[-1.5441, 0.3189]	0.259
43	12	-0.761	-0.512	0.2489	[-0.4578, 0.9557]	0.538
44	12	-0.816	-0.337	0.4786	[-0.7629, 1.7202]	0.501
45	12	-0.258	-0.222	0.0354	[-0.7145, 0.7853]	0.933
46	12	-0.336	-0.409	-0.0736	[-0.8297, 0.6825]	0.863
47	12	-0.363	-0.312	0.0515	[-0.7166, 0.8196]	0.906
48	12	-0.555	-0.454	0.1007	[-0.4287, 0.6300]	0.737
49	12	-0.371	-0.740	-0.3691	[-1.1418, 0.4035]	0.407
50	12	-0.735	-0.351	0.3844	[-0.6367, 1.4055]	0.508
51	11	-0.924	-0.457	0.4671	[-0.1738, 1.1081]	0.212
52	11	-0.497	-0.391	0.1057	[-0.3443, 0.5558]	0.674
53	11	-0.691	-0.347	0.3442	[0.0983, 0.5902]	0.030
54	11	-0.245	-0.709	-0.4638	[-1.4780, 0.5505]	0.424
55	11	-0.527	-0.393	0.1343	[-0.4055, 0.6741]	0.659
56	11	-0.510	-0.306	0.2036	[-0.0516, 0.4588]	0.178

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
57	11	-0.160	-0.352	-0.1923	[-0.5454, 0.1608]	0.344
58	11	-0.219	-0.432	-0.2133	[-0.7950, 0.3684]	0.518
59	11	-0.046	-0.164	-0.1181	[-0.4606, 0.2245]	0.543
60	11	-0.567	-0.157	0.4107	[0.0005, 0.8209]	0.100
61	11	-0.374	-0.418	-0.0434	[-0.5925, 0.5056]	0.888
62	11	-0.385	-0.337	0.0478	[-0.8149, 0.9105]	0.921
72	9	0.064	-0.536	-0.6004	[-1.7392, 0.5384]	0.345
73	9	-0.355	-0.366	-0.0106	[-0.9861, 0.9650]	0.984
74	9	-0.136	-0.453	-0.3165	[-1.1171, 0.4842]	0.472
75	9	-0.366	-0.476	-0.1103	[-0.7871, 0.5665]	0.762
76	9	-0.799	-0.495	0.3040	[-1.0824, 1.6903]	0.685
77	9	-0.696	-0.483	0.2126	[-0.3380, 0.7632]	0.482
78	9	-0.314	-0.367	-0.0533	[-1.0930, 0.9863]	0.924
79	9	-0.429	-0.225	0.2039	[-0.9730, 1.3808]	0.748
80	9	-0.352	-0.369	-0.0170	[-0.7310, 0.6971]	0.965
81	9	-1.334	-0.175	1.1586	[0.1473, 2.1698]	0.068
82	9	-0.421	-0.487	-0.0661	[-0.9387, 0.8065]	0.888
83	9	-0.515	-0.275	0.2399	[-0.5357, 1.0156]	0.570
84	9	-0.237	-0.410	-0.1725	[-1.0977, 0.7527]	0.730
85	9	-1.373	-0.411	0.9619	[-1.0400, 2.9638]	0.386
86	9	-0.281	0.136	0.4174	[0.1147, 0.7201]	0.037
87	9	-0.066	-0.657	-0.5904	[-1.7547, 0.5739]	0.363
88	9	-0.392	-0.605	-0.2132	[-1.0806, 0.6542]	0.650
89	9	-0.561	-0.672	-0.1110	[-0.3832, 0.1612]	0.465
90	9	-0.220	-0.670	-0.4499	[-1.3494, 0.4496]	0.375
91	9	-0.763	-0.464	0.2989	[-0.4812, 1.0790]	0.491
92	9	-0.573	-0.447	0.1257	[-0.4117, 0.6630]	0.671
93	10	-0.630	-0.509	0.1208	[-1.0812, 1.3227]	0.856

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
94	10	-0.606	-0.451	0.1553	[-0.5450, 0.8556]	0.691
99	11	-0.254	-0.496	-0.2416	[-1.0781, 0.5948]	0.601
100	11	-0.265	-0.533	-0.2682	[-0.7374, 0.2011]	0.309
101	11	-0.014	-0.656	-0.6421	[-1.7941, 0.5099]	0.320
102	11	-0.268	-0.492	-0.2241	[-1.6571, 1.2088]	0.771
103	11	-0.093	-0.356	-0.2633	[-1.4042, 0.8776]	0.670
104	11	0.024	-0.454	-0.4779	[-1.3414, 0.3857]	0.329
105	11	-0.309	-0.295	0.0139	[-1.3210, 1.3489]	0.985
106	11	-0.192	-0.679	-0.4872	[-1.4230, 0.4485]	0.357
107	11	-0.170	-0.658	-0.4878	[-1.3416, 0.3659]	0.315
108	11	-0.120	-0.610	-0.4892	[-1.5304, 0.5520]	0.403
109	11	-0.169	-0.559	-0.3895	[-1.4232, 0.6443]	0.498
110	11	-0.033	-0.606	-0.5727	[-1.5389, 0.3935]	0.298
111	11	-0.658	-0.386	0.2724	[-0.3943, 0.9391]	0.464
112	11	-0.501	-0.238	0.2631	[-0.4584, 0.9845]	0.512
113	11	-0.488	-0.629	-0.1411	[-0.8135, 0.5313]	0.707
114	11	-0.554	-0.629	-0.0743	[-0.9322, 0.7835]	0.876
115	11	-0.378	-0.518	-0.1403	[-1.0851, 0.8044]	0.789
116	11	-0.270	-0.415	-0.1448	[-0.8609, 0.5712]	0.717
118	10	-0.297	-0.344	-0.0469	[-0.6006, 0.5068]	0.879
119	10	-0.155	-0.423	-0.2680	[-0.6187, 0.0826]	0.193
120	10	-0.050	-0.367	-0.3176	[-0.8201, 0.1850]	0.274
121	10	0.039	-0.454	-0.4932	[-1.0573, 0.0708]	0.143
122	10	-0.174	-0.504	-0.3303	[-0.8835, 0.2229]	0.299
123	11	-0.352	-0.351	0.0007	[-0.6559, 0.6573]	0.999
124	11	-0.556	-0.561	-0.0043	[-1.0982, 1.0895]	0.994
125	11	-0.283	-0.507	-0.2243	[-0.4949, 0.0462]	0.163
126	11	-0.738	-0.468	0.2701	[-0.8260, 1.3662]	0.662

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
127	11	-0.437	-0.450	-0.0129	[-1.0806, 1.0547]	0.983
128	11	-0.456	-0.316	0.1397	[-0.7953, 1.0747]	0.790
129	11	-0.288	-1.016	-0.7280	[-2.2021, 0.7461]	0.389
130	11	-0.158	-0.836	-0.6777	[-2.1164, 0.7609]	0.410
131	11	0.027	-0.538	-0.5655	[-1.4175, 0.2865]	0.255
132	11	-0.142	-0.555	-0.4130	[-1.4873, 0.6612]	0.499
133	10	-0.446	-0.491	-0.0450	[-0.7359, 0.6458]	0.907
134	11	-0.020	-0.422	-0.4021	[-1.2716, 0.4675]	0.419
135	11	0.167	-0.747	-0.9145	[-1.8504, 0.0213]	0.107
136	11	-0.034	-0.466	-0.4318	[-1.3542, 0.4905]	0.413
137	11	0.064	-0.502	-0.5660	[-1.3784, 0.2464]	0.234
138	11	-0.276	-0.361	-0.0848	[-0.7117, 0.5421]	0.810
139	11	-0.096	-0.347	-0.2505	[-0.7055, 0.2046]	0.339
140	11	-0.042	-0.237	-0.1950	[-0.7042, 0.3142]	0.500
141	11	0.182	-0.361	-0.5425	[-1.1249, 0.0398]	0.122
142	11	-0.250	0.108	0.3581	[-0.0366, 0.7528]	0.131
143	11	-0.247	0.064	0.3111	[-0.2537, 0.8758]	0.339
144	11	-0.277	0.079	0.3568	[-0.0549, 0.7686]	0.147
145	10	0.025	-0.508	-0.5323	[-1.4865, 0.4219]	0.330
146	10	-0.144	-0.181	-0.0367	[-0.7897, 0.7163]	0.930
147	10	-0.210	-0.588	-0.3785	[-0.9816, 0.2246]	0.277
148	10	-0.032	-0.381	-0.3487	[-0.8527, 0.1554]	0.234
149	10	-0.263	-0.101	0.1619	[-0.6071, 0.9309]	0.706
150	10	-0.006	0.029	0.0356	[-0.6122, 0.6833]	0.921
151	10	-0.215	-0.062	0.1537	[-0.5388, 0.8462]	0.691
152	10	0.004	-0.134	-0.1385	[-0.4826, 0.2056]	0.476
153	10	0.140	-0.881	-1.0207	[-1.8989, -0.1425]	0.063
154	10	0.067	-0.594	-0.6611	[-1.6275, 0.3052]	0.239

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
155	10	0.189	-0.632	-0.8202	[-1.6633, 0.0229]	0.108
156	10	0.294	-0.695	-0.9893	[-1.8920, -0.0867]	0.076
157	10	0.042	-0.448	-0.4894	[-1.2429, 0.2642]	0.262
158	10	0.150	-0.388	-0.5375	[-1.3353, 0.2604]	0.246
159	10	0.132	-0.301	-0.4337	[-1.2798, 0.4124]	0.368
160	10	-0.087	-0.219	-0.1315	[-0.6322, 0.3691]	0.638
161	10	0.103	-0.294	-0.3974	[-1.4759, 0.6810]	0.513
162	10	-0.574	-0.320	0.2532	[-0.6489, 1.1553]	0.616
163	11	0.046	-0.280	-0.3256	[-1.0808, 0.4297]	0.450
164	11	-0.139	-0.322	-0.1827	[-0.9904, 0.6250]	0.685
165	11	-0.175	-0.275	-0.0995	[-0.6189, 0.4198]	0.731
166	11	0.168	-0.390	-0.5574	[-1.3471, 0.2323]	0.226
167	11	0.174	-0.249	-0.4237	[-1.2864, 0.4390]	0.388
168	11	0.073	-0.287	-0.3600	[-1.0133, 0.2933]	0.335
169	10	-0.070	-0.253	-0.1831	[-0.8625, 0.4963]	0.625
170	10	-0.143	-0.344	-0.2008	[-1.1957, 0.7941]	0.714
171	10	-0.587	-0.266	0.3210	[-0.1468, 0.7888]	0.235
172	10	-0.110	-0.007	0.1030	[-0.8412, 1.0472]	0.839
173	10	0.134	-0.008	-0.1415	[-0.8999, 0.6169]	0.729
174	10	0.022	-0.263	-0.2857	[-1.2008, 0.6294]	0.566
175	10	-0.340	-0.104	0.2356	[-0.4616, 0.9328]	0.536
176	10	-0.393	-0.039	0.3544	[-1.0408, 1.7496]	0.639
177	10	-0.287	0.281	0.5675	[-0.2118, 1.3467]	0.207
178	10	-0.143	0.051	0.1938	[-0.2923, 0.6800]	0.468
179	10	-0.127	0.211	0.3376	[-0.5570, 1.2323]	0.491
180	10	0.082	-0.617	-0.6991	[-1.6417, 0.2435]	0.200
181	10	0.124	0.033	-0.0912	[-0.6206, 0.4381]	0.749
182	10	0.081	0.163	0.0823	[-0.5141, 0.6788]	0.792

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
183	10	0.067	-0.206	-0.2726	[-1.1442, 0.5991]	0.556
184	10	-0.024	-0.432	-0.4081	[-1.4987, 0.6825]	0.485
185	9	0.016	-0.334	-0.3503	[-1.9290, 1.2285]	0.661
189	9	-0.002	-0.156	-0.1534	[-0.7321, 0.4254]	0.616
190	9	0.240	-0.434	-0.6744	[-2.2234, 0.8746]	0.420
191	9	0.211	-0.211	-0.4216	[-1.6989, 0.8558]	0.535
192	9	-0.040	-0.150	-0.1108	[-0.8263, 0.6046]	0.768
193	9	-0.375	-0.613	-0.2387	[-1.0062, 0.5287]	0.558
194	9	-0.023	-0.646	-0.6223	[-1.6047, 0.3602]	0.258
195	9	0.092	-0.671	-0.7633	[-1.5336, 0.0069]	0.102
196	9	0.058	-0.411	-0.4685	[-0.9531, 0.0161]	0.109
197	9	-0.829	-0.059	0.7705	[-0.3442, 1.8851]	0.228
198	10	-0.579	-0.099	0.4796	[-0.5415, 1.5006]	0.403
199	10	-0.775	-0.491	0.2838	[-0.3782, 0.9458]	0.443
200	10	-0.283	-0.085	0.1980	[-1.3193, 1.7153]	0.812
201	10	-0.368	-0.308	0.0594	[-0.5183, 0.6371]	0.851
202	10	-0.332	-0.401	-0.0695	[-0.8229, 0.6840]	0.868
203	11	0.046	-0.440	-0.4861	[-1.1102, 0.1380]	0.187
204	11	0.072	-0.355	-0.4269	[-1.1136, 0.2599]	0.284
205	11	-0.010	-0.469	-0.4590	[-1.2117, 0.2937]	0.293
206	11	-0.583	-0.375	0.2075	[-0.8729, 1.2879]	0.733
211	10	-0.341	-0.527	-0.1859	[-0.9520, 0.5801]	0.664
212	10	-0.120	-0.477	-0.3573	[-1.0419, 0.3272]	0.360
213	10	-0.046	-0.488	-0.4419	[-1.1635, 0.2796]	0.288
214	10	-0.629	-0.183	0.4457	[-0.4547, 1.3462]	0.384
215	10	-0.708	-0.321	0.3870	[-0.7489, 1.5229]	0.544
216	10	-0.532	-0.433	0.0993	[-0.8011, 0.9998]	0.843
217	10	-0.359	-0.591	-0.2322	[-1.3081, 0.8438]	0.699

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 8 of 8

Table 14.2.1.11 Statistical Assessment of Change in pH Smoothed Values at Electrode 2 by Time Point
PP Population (N=12)

Time Point (min)	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
218	10	-0.218	-0.524	-0.3055	[-1.0025, 0.3915]	0.439
219	10	-0.177	-0.157	0.0201	[-0.8460, 0.8862]	0.967
220	10	0.063	-0.132	-0.1953	[-1.0804, 0.6897]	0.692
221	10	-0.256	-0.768	-0.5122	[-1.4947, 0.4703]	0.356
222	10	-0.135	-0.703	-0.5681	[-1.6397, 0.5035]	0.349
223	10	-0.159	-0.342	-0.1839	[-1.2175, 0.8497]	0.746
224	10	-0.266	-0.376	-0.1095	[-1.2075, 0.9886]	0.856
225	10	-0.380	-0.076	0.3039	[-0.3590, 0.9668]	0.407
226	10	-0.102	-0.263	-0.1610	[-1.4265, 1.1045]	0.813
227	10	-0.131	-0.092	0.0392	[-1.0184, 1.0967]	0.945
228	10	-0.301	-0.119	0.1818	[-0.6418, 1.0054]	0.683
229	11	-0.003	-0.278	-0.2747	[-1.3684, 0.8191]	0.649
230	11	-0.284	-0.291	-0.0072	[-0.4656, 0.4512]	0.977
231	11	-0.043	-0.621	-0.5775	[-1.5677, 0.4126]	0.310
232	11	-0.117	-0.359	-0.2412	[-0.9705, 0.4882]	0.556
233	11	-0.133	0.036	0.1689	[-0.2303, 0.5681]	0.454
234	11	-0.461	-0.140	0.3210	[-0.8188, 1.4607]	0.615
235	10	-0.759	-0.253	0.5056	[-0.1814, 1.1926]	0.208
236	11	-0.199	-0.174	0.0242	[-0.7816, 0.8301]	0.957
237	11	-0.262	-0.101	0.1613	[-0.4705, 0.7931]	0.651
238	11	-0.179	-0.186	-0.0070	[-0.5683, 0.5543]	0.982
239	11	-0.104	-0.113	-0.0083	[-0.5735, 0.5568]	0.979

Data Source: Appendix 16.2.6.4

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_11.sas

29JAN2013 6:38

14.2.1.12 Statistical Assessment of pH Smoothed Parameters Between Treatments (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.2.1.12 Statistical Assessment of pH Smoothed Parameters between Treatments
PP Population (N=12)

Parameter	Electrode	Number of Subjects	LS Mean Treatment A	LS Mean Treatment B	LS Mean Difference	(90% CI)	P-value
Duration at which ≥ 3 pH (min)	Channel 03	11	72.46	101.776	29.3161	[-18.1291, 76.7613]	0.287
	Channel 04	12	52.069	58.789	6.7194	[-20.6001, 34.0390]	0.665
	Channel 05	12	42.036	44.035	1.9986	[-23.0796, 27.0768]	0.888
	Channel 06	11	42.385	41.422	-0.9628	[-30.6549, 28.7293]	0.954
	Channel 07	11	51.814	45.714	-6.1000	[-46.5645, 34.3645]	0.789
	Channel 08	12	55.81	51.758	-4.0514	[-43.9128, 35.8101]	0.858
	Channel 09	12	58.315	54.244	-4.0708	[-46.4339, 38.2922]	0.865
	Channel 10	12	64.513	57.175	-7.3375	[-48.7448, 34.0698]	0.755
	Channel 11	12	102.776	84.881	-17.8958	[-51.1021, 15.3104]	0.352
Duration at which ≥ 4 pH (min)	Channel 03	11	52.098	90.579	38.4817	[2.7586, 74.2047]	0.080
	Channel 04	12	32.639	50.746	18.1069	[4.6729, 31.5410]	0.035
	Channel 05	10	22.635	38.193	15.5583	[4.8919, 26.2248]	0.027
	Channel 06	9	26.93	35.708	8.7783	[-10.3740, 27.9307]	0.414
	Channel 07	10	36.906	39.561	2.6550	[-29.7385, 35.0485]	0.883
	Channel 08	11	45.666	46.368	0.7022	[-32.8599, 34.2644]	0.970
	Channel 09	10	45.912	48.406	2.4938	[-43.2627, 48.2502]	0.922
	Channel 10	11	49.808	51.542	1.7339	[-38.3821, 41.8498]	0.939
	Channel 11	11	82.154	78.331	-3.8233	[-39.1607, 31.5140]	0.847

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_12.sas

29JAN2013 6:43

14.2.1.13 Statistical Assessment of Time to Reach pH 3 and pH 4 on the Smoothed Curve in the Stomach (PP Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.2.1.13 Statistical Assessment of Time to Reach pH 3 and pH 4 on the Smoothed Curve in the Stomach
PP Population (N=12)

Parameter	Electrode	Test		Reference			Log-rank P-value
		Median Time (90% CI)		Median Time (90% CI)			
Time to reach pH 3	03	0.1[0.0, 0.5]	0.0 [0.0, 0.3]	0.3505	
	04	0.5[0.0, 2.2]	0.4 [0.0, 2.4]	0.6252	
	05	1.2[0.0, 3.7]	0.7 [0.0, 4.6]	0.5610	
	06	6.1[0.0,135.9]	1.7 [0.1, 2.9]	0.0858	
	07	1.1[0.0,155.8]	1.5 [0.7, 3.6]	0.3512	
	08	1.8[0.0,108.4]	1.8 [1.0, 3.5]	0.1914	
	09	9.0[0.0, 72.9]	2.4 [1.0, 4.1]	0.0439	
	10	12.6[0.0, 87.3]	2.2 [1.4, 4.3]	0.2789	
	11	0.1[0.0, 82.0]	2.1 [0.0, 4.4]	0.7491	
Time to reach pH 4	03	0.3[0.0, 1.6]	0.0 [0.0, 0.4]	0.1061	
	04	0.8[0.3, 3.7]	0.4 [0.0, 2.4]	0.3570	
	05	3.8[0.1,157.2]	1.3 [0.3, 5.6]	0.0617	
	06	32.3[0.1,137.4]	2.0 [0.1, 5.8]	0.0109	
	07	30.0[0.1,176.9]	1.6 [0.7, 3.6]	0.0094	
	08	96.9[0.1,155.3]	1.8 [1.0, 3.5]	0.0058	
	09	45.2[0.1,102.6]	2.9 [1.0, 4.5]	0.0143	
	10	36.4[0.1,220.9]	2.4 [1.4, 4.4]	0.0446	
	11	0.1[0.0, 82.1]	2.2 [0.2, 4.5]	0.6789	

Data Source: Appendix 16.2.6.7

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)


Note: Test is Treatment A. Reference is Treatment B.

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_02_01_13.sas


29JAN2013 6:48

14.2.1.14 Kaplan-Meier Plot of Time to Reach pH 3 by Electrode (3 to 11) and Treatment (PP Population)


Channel 03




Channel 04




Channel 05




Channel 06




Channel 07




Channel 08




Channel 09



Channel 10




Channel 11




14.2.1.15 Kaplan-Meier Plot of Time to Reach pH 4 by Electrode (3 to 11) and Treatment (PP Population)


Channel 03




Channel 04




Channel 05




Channel 06




Channel 07




Channel 08




Channel 09




Channel 10





Channel 11




14.2.1.16 Mean pH values over each 4 second interval










$\text{pH} \geq 4$




$3 \leq \text{pH} < 4$



$\text{ph} < 3$






$\text{pH} \geq 4$




$3 \leq \text{pH} < 4$




$\text{pH} < 3$








 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$














 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$


 $\text{ph} < 3$
















 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$







 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$





 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$







 $\text{pH} \geq 4$


 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$








 $\text{pH} \geq 4$

 $3 \leq \text{pH} < 4$

 $\text{ph} < 3$





14.2.1.17 Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 10-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
10 mins prior to dosing	Percentage of time \geq pH3	Mean	9.9	34.2
		SD	27.15	39.87
		Median	0.5	19.2
		Min	0.0	0.0
		Max	94.5	100.0
		N	12	12
0 - 10 mins post dose	Percentage of time \geq pH3	Mean	66.5	32.9
		SD	24.89	39.21
		Median	70.0	8.1
		Min	21.9	0.0
		Max	100.0	100.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p < 0.0001$				
10 - 20 mins post dose	Percentage of time \geq pH3	Mean	68.9	30.0
		SD	39.73	40.30
		Median	96.8	0.7
		Min	0.7	0.0
		Max	100.0	100.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p = 0.0015$				
20 - 30 mins post dose	Percentage of time \geq pH3	Mean	49.6	22.7
		SD	46.70	37.80
		Median	51.6	1.8
		Min	0.0	0.0
		Max	100.0	100.0
		N	10	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p = 0.0151$				
Generated: 20/09/2012 15:48:23 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 2				

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
(continued)				
30 - 40 mins post dose	Percentage of time >=pH3	Mean	37.5	15.5
		SD	47.83	30.86
		Median	2.1	3.9
		Min	0.0	0.0
		Max	100.0	98.3
		N	10	10
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0528				
40 - 50 mins post dose	Percentage of time >=pH3	Mean	32.2	22.5
		SD	42.16	36.32
		Median	9.4	1.4
		Min	0.0	0.0
		Max	100.0	100.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0165				
50 - 60 mins post dose	Percentage of time >=pH3	Mean	31.5	28.3
		SD	43.54	42.07
		Median	0.7	0.8
		Min	0.0	0.0
		Max	100.0	100.0
		N	12	11
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0861				
Generated: 20/09/2012 15:48:23 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 2 of 2				

14.2.1.18 Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 30-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
30 mins prior to dosing	Percentage of time \geq pH3	Mean	8.8	35.1
		SD	24.31	40.04
		Median	0.4	18.5
		Min	0.0	0.0
		Max	84.8	100.0
		N	12	12
0 - 30 mins post dose	Percentage of time \geq pH3	Mean	63.2	28.6
		SD	32.20	38.46
		Median	74.1	2.9
		Min	9.4	0.0
		Max	100.0	100.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0013				
30 - 60 mins post dose	Percentage of time \geq pH3	Mean	33.1	23.3
		SD	39.67	37.64
		Median	19.8	2.2
		Min	0.0	0.0
		Max	100.0	100.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0214				
Generated: 20/09/2012 15:48:25 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 1				

14.2.1.19 Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 10-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
10 mins prior to dosing	Percentage of time \geq pH4	Mean	9.0	22.9
		SD	26.39	34.54
		Median	0.3	3.1
		Min	0.0	0.0
		Max	92.1	100.0
		N	12	12
0 - 10 mins post dose	Percentage of time \geq pH4	Mean	64.3	20.2
		SD	25.86	33.29
		Median	67.9	2.7
		Min	19.3	0.0
		Max	99.6	97.7
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p < 0.0001$				
10 - 20 mins post dose	Percentage of time \geq pH4	Mean	65.8	16.5
		SD	41.32	30.59
		Median	92.0	0.1
		Min	0.1	0.0
		Max	100.0	92.7
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p = 0.0005$				
20 - 30 mins post dose	Percentage of time \geq pH4	Mean	46.3	12.5
		SD	46.95	28.78
		Median	37.7	0.3
		Min	0.0	0.0
		Max	100.0	97.7
		N	10	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: $p = 0.0125$				
Generated: 20/09/2012 15:48:26 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 2				

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
(continued)				
30 - 40 mins post dose	Percentage of time >=pH4	Mean	34.8	13.7
		SD	45.31	30.16
		Median	1.1	0.3
		Min	0.0	0.0
		Max	100.0	95.6
		N	10	10
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0544				
40 - 50 mins post dose	Percentage of time >=pH4	Mean	27.1	11.3
		SD	41.17	25.27
		Median	1.8	0.2
		Min	0.0	0.0
		Max	100.0	70.3
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0245				
50 - 60 mins post dose	Percentage of time >=pH4	Mean	24.4	15.5
		SD	35.95	34.65
		Median	0.3	0.0
		Min	0.0	0.0
		Max	100.0	100.0
		N	12	11
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0361				
Generated: 20/09/2012 15:48:26 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 2 of 2				

14.2.1.20 Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 30-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
30 mins prior to dosing	Percentage of time \geq pH4	Mean	7.5	27.0
		SD	22.09	32.51
		Median	0.1	14.0
		Min	0.0	0.0
		Max	77.1	80.2
		N	12	12
0 - 30 mins post dose	Percentage of time \geq pH4	Mean	60.5	16.4
		SD	33.03	30.42
		Median	70.7	1.2
		Min	7.7	0.0
		Max	99.9	96.0
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0005				
30 - 60 mins post dose	Percentage of time \geq pH4	Mean	28.2	12.4
		SD	37.20	28.25
		Median	10.1	0.4
		Min	0.0	0.0
		Max	100.0	88.6
		N	12	12
Random subject effect ANOVA with treatment, period, sequence and baseline covariate: p=0.0092				
Generated: 20/09/2012 15:48:28 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 1				

14.2.1.21 Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 10-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
0 - 10 mins post dose	Change in percentage of time \geq pH3	Mean	56.5	-1.3
		SD	26.73	8.68
		Median	61.7	0.0
		Min	5.5	-24.0
		Max	89.5	7.7
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
10 - 20 mins post dose	Change in percentage of time \geq pH3	Mean	59.0	-4.2
		SD	41.04	11.56
		Median	66.6	0.0
		Min	-1.3	-32.0
		Max	99.7	15.6
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
20 - 30 mins post dose	Change in percentage of time \geq pH3	Mean	39.5	-11.5
		SD	44.76	16.57
		Median	21.5	-0.3
		Min	-1.6	-37.9
		Max	99.9	2.5
		N	10	12
Wilcoxon Rank Sum Exact Test: p=0.0317				
30 - 40 mins post dose	Change in percentage of time \geq pH3	Mean	27.5	-15.5
		SD	43.21	19.55
		Median	0.5	-4.0
		Min	-0.3	-43.2
		Max	98.4	2.8
		N	10	10
Wilcoxon Rank Sum Exact Test: p=0.0286				
Generated: 20/09/2012 15:48:29 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 2				

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
(continued)				
40 - 50 mins post dose	Change in percentage of time >=pH3	Mean	22.3	-11.7
		SD	36.33	21.16
		Median	2.8	-1.5
		Min	-0.7	-51.9
		Max	100.0	22.8
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0260				
50 - 60 mins post dose	Change in percentage of time >=pH3	Mean	21.5	-6.1
		SD	39.75	22.21
		Median	0.1	0.0
		Min	-18.7	-50.0
		Max	93.6	32.9
		N	12	11
Wilcoxon Rank Sum Exact Test: p=0.0714				
Generated: 20/09/2012 15:48:29 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 2 of 2				

14.2.1.22 Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 3 over 30-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
0 - 30 mins post dose	Change in percentage of time \geq pH3	Mean	54.5	-6.5
		SD	31.31	22.71
		Median	60.1	0.3
		Min	9.4	-73.8
		Max	94.6	14.7
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
30 - 60 mins post dose	Change in percentage of time \geq pH3	Mean	24.4	-11.7
		SD	33.95	25.54
		Median	10.3	-0.0
		Min	-0.4	-74.3
		Max	93.1	18.8
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0087				
Generated: 20/09/2012 15:48:31 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 1				

14.2.1.23 Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 10-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
0 - 10 mins post dose	Change in percentage of time >=pH4	Mean	55.3	-2.7
		SD	27.04	5.56
		Median	58.9	-2.0
		Min	7.5	-16.2
		Max	89.6	5.6
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
10 - 20 mins post dose	Change in percentage of time >=pH4	Mean	56.8	-6.4
		SD	41.92	8.79
		Median	65.0	-2.2
		Min	-0.9	-27.0
		Max	99.2	1.1
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
20 - 30 mins post dose	Change in percentage of time >=pH4	Mean	36.7	-10.5
		SD	44.10	16.13
		Median	12.9	-1.9
		Min	-1.1	-39.2
		Max	98.3	1.6
		N	10	12
Wilcoxon Rank Sum Exact Test: p=0.0317				
30 - 40 mins post dose	Change in percentage of time >=pH4	Mean	25.2	-13.7
		SD	39.61	18.90
		Median	0.1	-4.4
		Min	-0.4	-45.4
		Max	94.3	0.0
		N	10	10
Wilcoxon Rank Sum Exact Test: p=0.0286				
Generated: 20/09/2012 15:48:32 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 2				

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
(continued)				
40 - 50 mins post dose	Change in percentage of time >=pH4	Mean	18.1	-11.7
		SD	34.34	17.06
		Median	1.3	-1.5
		Min	-0.8	-50.9
		Max	99.9	0.0
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0260				
50 - 60 mins post dose	Change in percentage of time >=pH4	Mean	15.4	-8.6
		SD	28.04	16.80
		Median	0.1	0.0
		Min	-11.8	-50.0
		Max	76.9	0.0
		N	12	11
Wilcoxon Rank Sum Exact Test: p=0.0519				
Generated: 20/09/2012 15:48:32 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 2 of 2				


14.2.1.24 Change from Baseline in Percentage of Time that the Mean pH from Electrodes 6 to 10 was \geq pH 4 over 30-minute Intervals

Time interval relative to dose			Gaviscon Double Action Aniseed	Placebo
0 - 30 mins post dose	Change in percentage of time \geq pH4	Mean	53.0	-10.6
		SD	31.07	22.18
		Median	53.0	-0.3
		Min	7.7	-66.9
		Max	93.4	16.4
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0022				
30 - 60 mins post dose	Change in percentage of time \geq pH4	Mean	20.7	-14.6
		SD	29.64	22.14
		Median	9.8	-0.9
		Min	-0.3	-66.4
		Max	85.8	9.0
		N	12	12
Wilcoxon Rank Sum Exact Test: p=0.0043				
Generated: 20/09/2012 15:48:33 by D:\Data\garysmit\Desktop\GA1109\report\tables.sas				
Page 1 of 1				

14.2.1.25

Mean % Time the pH \geq 3 over 10-minute Intervals (electrodes 6 to 10 Averaged)


Mean % time with pH \geq 3 - E Electrodes 6-10 combined



14.2.1.26


Mean Change from Baseline in % time pH ≥ 3 over 10-minute Intervals (Electrodes 6 to 10 Averaged)

Mean change from baseline in % time with pH ≥ 3 - Electrodes 6-10 combined



14.2.1.27


Mean % Time the pH ≥ 3 over 30-minute Intervals (Electrodes 6 to 10 Averaged)




14.2.1.28

Mean Change from Baseline in % Time pH ≥ 3 over 30-minute Intervals (Electrodes 6 to 10 Averaged)

Mean increase from baseline in % time with pH ≥ 3 - Electrodes 6-10 combined




14.2.1.29 Mean % Time the pH \geq 4 over 10-minute Intervals (Electrodes 6 to 10 Averaged)



14.2.1.30


Mean Change from Baseline in % Time pH ≥ 4 over 10-minute Intervals (Electrodes 6 to 10 Averaged)

Mean change from baseline in % time with pH ≥ 4 - Electrodes 6-10 combined



14.2.1.31


Mean % Time the pH \geq 4 over 30-minute Intervals (Electrodes 6 to 10 Averaged)



14.2.1.32

Mean Change from Baseline in % Time pH ≥ 4 over 30-minute Intervals (Electrodes 6 to 10 Averaged)

Mean increase from baseline in % time with pH ≥ 4 - Electrodes 6-10 combined



14.3 Safety Data

14.3.1 Displays of Adverse Events

14.3.1.1 Overall Summary of Treatment-emergent Adverse Events (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.3.1.1 Overall Summary of Treatment-Emergent Adverse Events
Safety Population (N=12)

AE Category	Number (%) of Subjects(1) and [Number of Events]		
	Treatment A	Treatment B	Overall
Any TEAE	0	3 (25.0%) [4]	3 (25.0%) [4]
Any mild TEAE	0	3 (25.0%) [4]	3 (25.0%) [4]
Any moderate TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE related to study medication	0	0	0
Any TEAE leading to discontinuation of treatment	0	0	0
Any SAE	0	0	0
Any SAE related to study medication	0	0	0
Any life-threatening SAE	0	0	0
Any SAE leading to death	0	0	0

Data Source: Appendix 16.2.7.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

(1) Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than one category are counted once in each of those categories.

Note: All adverse events starting or worsening after commencement of treatment with investigational product.

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_01_01.sas

29JAN2013 5:24

14.3.1.2 Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Treatment (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028) Page 1 of 1
Table 14.3.1.2 Overall Summary of Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Treatment
Safety Population (N=12)

System Organ Class (SOC) MedDRA Preferred Term (PT)	Number (%) of Subjects(1) and [Number of Events]		
	A	B	Overall
Subjects with any AE	0	3 (25.0%) [4]	3 (25.0%) [4]
Gastrointestinal disorders	0	1 (8.3%) [1]	1 (8.3%) [1]
Abdominal discomfort	0	1 (8.3%) [1]	1 (8.3%) [1]
Investigations	0	1 (8.3%) [1]	1 (8.3%) [1]
Aspartate aminotransferase increased	0	1 (8.3%) [1]	1 (8.3%) [1]
Nervous system disorders	0	1 (8.3%) [2]	1 (8.3%) [2]
Headache	0	1 (8.3%) [2]	1 (8.3%) [2]

Data Source: Appendix 16.2.7.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

(1) Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than one category are counted once in each of those categories.

Note: All adverse events starting or worsening after commencement of treatment with investigational product.

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_01_02.sas

29JAN2013 5:24

14.3.1.3 Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term, Severity Grade and Treatment (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028) Page 1 of 1
Table 14.3.1.3 Summary of Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, Severity Grade
and Treatment
Safety Population (N=12)

System Organ Class (SOC) MedDRA Preferred Term (PT)	Severity Grade	Number (%) of Subjects(1) and [Number of Events]		
		A	Treatment B	Overall
Subjects with any AE	MILD	0	3 (25.0%) [4]	3 (25.0%) [4]
Gastrointestinal disorders	MILD	0	1 (8.3%) [1]	1 (8.3%) [1]
Abdominal discomfort	MILD	0	1 (8.3%) [1]	1 (8.3%) [1]
Investigations	MILD	0	1 (8.3%) [1]	1 (8.3%) [1]
Aspartate aminotransferase increased	MILD	0	1 (8.3%) [1]	1 (8.3%) [1]
Nervous system disorders	MILD	0	1 (8.3%) [2]	1 (8.3%) [2]
Headache	MILD	0	1 (8.3%) [2]	1 (8.3%) [2]

Data Source: Appendix 16.2.7.1

Treatment Codes - A: Placebo

B: Gaviskon Double Action Aniseed Liquid (10 mL)

(1) Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than one category are counted once in each of those categories.

Note: All adverse events starting or worsening after commencement of treatment with investigational product.

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_01_03.sas

29JAN2013 5:25

14.3.1.4 Summary of Treatment-emergent Adverse Events by System Organ Class, Preferred Term, Relationship to Study Drug and Treatment (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.3.1.4 Summary of Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, Relationship to Study Drug and Treatment
Safety Population (N=12)

System Organ Class (SOC) MedDRA Preferred Term (PT)	Relationship	Number (%) of Subjects(1) and [Number of Events]		
		A	B	Overall
Subjects with any AE	None	0	3 (25.0%) [4]	3 (25.0%) [4]
Gastrointestinal disorders	None	0	1 (8.3%) [1]	1 (8.3%) [1]
Abdominal discomfort	None	0	1 (8.3%) [1]	1 (8.3%) [1]
Investigations	None	0	1 (8.3%) [1]	1 (8.3%) [1]
Aspartate aminotransferase increased	None	0	1 (8.3%) [1]	1 (8.3%) [1]
Nervous system disorders	None	0	1 (8.3%) [2]	1 (8.3%) [2]
Headache	None	0	1 (8.3%) [2]	1 (8.3%) [2]

Data Source: Appendix 16.2.7.1

Treatment Codes - A: Placebo

B: Gaviscon Double Action Aniseed Liquid (10 mL)

(1) Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than one category are counted once in each of those categories.

Note: All adverse events starting or worsening after commencement of treatment with investigational product.

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_01_04.sas

29JAN2013 5:25

14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events

14.3.2.1 Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 1

Table 14.3.2.1 Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events
Safety Population (N=12)

Screening Number/ Randomisation Number		MedDRA System Organ Class (SOC)	MedDRA Preferred Term (PT)	CRF Description (C)	Treatment	Start Date/Time (ON)	Stop Date/Time (DR)	Duration of Event (D)	Duration of IMP (DT)	Onset Relative to Last Dose (OR)	Serious (SER)	Serious Criteria (SC)	Severity (SEV)	Action Taken (A)	Relationship to Study Med (R)	Outcome (OUT)	Comment (COM)
-------------------------------------------------	--	---------------------------------	----------------------------	---------------------	-----------	----------------------	---------------------	-----------------------	----------------------	----------------------------------	---------------	-----------------------	----------------	------------------	-------------------------------	---------------	---------------

There are no deaths, other serious adverse events, or other adverse significant adverse events to report

Data Source: Appendix 16.2.7.1

MedDRA Version 15.0 used

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_02_01.sas

29JAN2013 5:26

14.3.3 Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events

Not applicable.

14.3.4 Abnormal Laboratory Value Listing

Not applicable.

14.3.5 Additional Safety Data Summaries

14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time-point (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Biochemistry	ALT	U/L	Screening	n	12	
				Arithmetic Mean	22.3	
				SD	8.27	
				CV (%)	37.2	
				Minimum	11	
				Median	20.0	
				Maximum	40	
			Follow-Up	n	12	12
				Arithmetic Mean	24.4	2.2
				SD	12.59	12.83
				CV (%)	51.6	
				Minimum	12	-13
				Median	21.5	0.0
				Maximum	55	39
	AST	U/L	Screening	n	12	
				Arithmetic Mean	23.3	
				SD	5.33	
				CV (%)	22.9	
				Minimum	16	
				Median	22.5	
				Maximum	31	
			Follow-Up	n	12	12
				Arithmetic Mean	36.3	13.0
				SD	44.94	45.78
				CV (%)	124.0	
				Minimum	17	-6
				Median	22.5	1.0
				Maximum	178	158

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Study Sponsor: Reckitt Benckiser Healthcare (UK) Ltd, Dansom Lane, Hull, HU8 7DS, UK
Telephone No: +44 (0) 1482 582050; Fax No: +44 (0) 1482 582532

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Biochemistry	Blood Urea Nitrogen (c)	mmol/L	Screening	n	12	
				Arithmetic Mean	2.02	
				SD	0.341	
				CV (%)	16.9	
				Minimum	1.6	
				Median	2.10	
				Maximum	2.4	
			Follow-Up	n	12	12
				Arithmetic Mean	2.08	0.07
				SD	0.484	0.423
				CV (%)	23.2	
				Minimum	1.2	-0.6
				Median	2.20	0.10
				Maximum	2.9	0.7
	Creatinine	umol/L	Screening	n	12	
				Arithmetic Mean	76.3	
				SD	7.25	
				CV (%)	9.5	
				Minimum	66	
				Median	74.0	
				Maximum	88	
			Follow-Up	n	12	12
				Arithmetic Mean	74.5	-1.8
				SD	6.05	4.61
				CV (%)	8.1	
				Minimum	67	-9
				Median	73.0	-1.5
				Maximum	84	8

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Haematology	Basophil Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	0.027	
				SD	0.0161	
				CV (%)	60.5	
				Minimum	0.01	
				Median	0.020	
				Maximum	0.06	
			Follow-Up	n	12	12
				Arithmetic Mean	0.028	0.001
				SD	0.0075	0.0144
				CV (%)	27.4	
				Minimum	0.02	-0.02
				Median	0.030	0.010
				Maximum	0.04	0.02
	Eosinophil Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	0.102	
				SD	0.0567	
				CV (%)	55.8	
				Minimum	0.02	
				Median	0.105	
				Maximum	0.18	
			Follow-Up	n	12	12
				Arithmetic Mean	0.111	0.009
				SD	0.0770	0.0440
				CV (%)	69.5	
				Minimum	0.00	-0.05
				Median	0.095	0.000
				Maximum	0.23	0.12

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Haematology	Haemoglobin	g/dL	Screening	n	12	
				Arithmetic Mean	14.10	
				SD	0.910	
				CV (%)	6.5	
				Minimum	12.6	
				Median	14.05	
				Maximum	15.4	
			Follow-Up	n	12	12
				Arithmetic Mean	13.78	-0.33
				SD	1.203	0.886
				CV (%)	8.7	
				Minimum	12.1	-2.0
				Median	13.90	-0.25
				Maximum	15.5	1.0
	Lymphocyte Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	1.688	
				SD	0.5157	
				CV (%)	30.6	
			Follow-Up	n	12	12
				Arithmetic Mean	1.714	0.027
				SD	0.3813	0.2729
				CV (%)	22.2	
			Follow-Up	Minimum	1.01	-0.50
				Median	1.805	0.070
				Maximum	2.39	0.48

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 5 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Haematology	Monocyte Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	0.533	
				SD	0.1779	
				CV (%)	33.4	
				Minimum	0.21	
				Median	0.510	
				Maximum	0.81	
			Follow-Up	n	12	12
				Arithmetic Mean	0.507	-0.026
				SD	0.1730	0.0962
				CV (%)	34.1	
				Minimum	0.20	-0.19
				Median	0.500	-0.030
				Maximum	0.78	0.11
	Neutrophil Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	3.464	
				SD	0.8318	
				CV (%)	24.0	
				Minimum	2.48	
				Median	3.400	
				Maximum	5.59	
			Follow-Up	n	12	12
				Arithmetic Mean	2.996	-0.468
				SD	0.6426	1.0071
				CV (%)	21.5	
				Minimum	2.19	-2.44
				Median	2.910	-0.705
				Maximum	4.51	1.04

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 6 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Haematology	Platelet Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	236.3	
				SD	39.57	
				CV (%)	16.8	
				Minimum	183	
				Median	229.5	
				Maximum	335	
			Follow-Up	n	12	12
				Arithmetic Mean	224.5	-11.8
				SD	37.82	35.92
				CV (%)	16.8	
				Minimum	170	-101
				Median	233.5	-5.5
				Maximum	294	31
	Red Cell Count	10 ¹² /L	Screening	n	12	
				Arithmetic Mean	4.551	
				SD	0.2787	
				CV (%)	6.1	
			Follow-Up	Minimum	4.02	
				Median	4.580	
				Maximum	4.88	
				n	12	12
				Arithmetic Mean	4.458	-0.093
				SD	0.4093	0.2640
				CV (%)	9.2	
				Minimum	3.54	-0.56
				Median	4.585	-0.085
				Maximum	4.99	0.25

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 7 of 7

Table 14.3.5.1 Summary of Haematology and Biochemistry Clinical Laboratory Parameters by Time Point
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Summary Statistic	Absolute	Change
Haematology	White Cell Count	10 ⁹ /L	Screening	n	12	
				Arithmetic Mean	5.81	
				SD	1.203	
				CV (%)	20.7	
				Minimum	4.4	
				Median	5.45	
				Maximum	8.7	
			Follow-Up	n	12	12
				Arithmetic Mean	5.36	-0.45
				SD	0.734	1.113
				CV (%)	13.7	
				Minimum	4.1	-2.8
				Median	5.35	-0.75
				Maximum	6.5	1.3

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_01.sas

29JAN2013 5:27

14.3.5.2 Shift Table of Haematology and Biochemistry Clinical Laboratory Parameters (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 2

Table 14.3.5.2 Shift Table of Haematology and Biochemistry Clinical Laboratory Parameters
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point		Pre-Study Screening		
					Low	Normal	High
Biochemistry	ALT	U/L	Follow-Up	Low	0	0	0
				Normal	0	11 (91.7%)	0
				High	0	1 (8.3%)	0
	AST	U/L	Follow-Up	Low	0	0	0
				Normal	0	11 (91.7%)	0
				High	0	1 (8.3%)	0
	Blood Urea Nitrogen (c)	mmol/L	Follow-Up	Low	0	0	0
				Normal	0	12 (100.0%)	0
				High	0	0	0
	Creatinine	umol/L	Follow-Up	Low	0	0	0
				Normal	0	11 (91.7%)	0
				High	0	0	1 (8.3%)
Haematology	Basophil Count	10 ⁹ /L	Follow-Up	Low	0	0	0
				Normal	3 (25.0%)	9 (75.0%)	0
				High	0	0	0
	Eosinophil Count	10 ⁹ /L	Follow-Up	Low	1 (8.3%)	0	0
				Normal	1 (8.3%)	10 (83.3%)	0
				High	0	0	0
	Haemoglobin	g/dL	Follow-Up	Low	0	3 (25.0%)	0
				Normal	0	9 (75.0%)	0
				High	0	0	0
	Lymphocyte Count	10 ⁹ /L	Follow-Up	Low	1 (8.3%)	0	0
				Normal	2 (16.7%)	9 (75.0%)	0
				High	0	0	0

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_02.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 2

Table 14.3.5.2 Shift Table of Haematology and Biochemistry Clinical Laboratory Parameters
Safety Population (N=12)

Category	Clinical Parameter	Units	Time Point	Pre-Study Screening		
				Low	Normal	High
Haematology	Monocyte Count	10 ⁹ /L	Follow-Up	Low	0	0
				Normal	0	12 (100.0%)
				High	0	0
	Neutrophil Count	10 ⁹ /L	Follow-Up	Low	0	0
				Normal	0	12 (100.0%)
				High	0	0
	Platelet Count	10 ⁹ /L	Follow-Up	Low	0	0
				Normal	0	11 (91.7%)
				High	0	1 (8.3%)
	Red Cell Count	10 ¹² /L	Follow-Up	Low	0	2 (16.7%)
				Normal	0	10 (83.3%)
				High	0	0
	White Cell Count	10 ⁹ /L	Follow-Up	Low	0	0
				Normal	0	12 (100.0%)
				High	0	0

Data Source: Appendix 16.2.8.2

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_02.sas

29JAN2013 5:27

14.3.5.3 Summary of Vital Signs by Time-point (Safety Population)

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 1 of 4

Table 14.3.5.3 Summary of Vital Signs by Time Point
Safety Population (N=12)

Vital Sign	Time Point	Summary Statistic	Absolute	Change
Systolic Blood Pressure (MMHG)	Screening	n	12	
		Arithmetic Mean	122.3	
		SD	13.41	
		CV (%)	11.0	
		Minimum	101	
		Median	125.5	
		Maximum	145	
	Period 1, Day 1	n	12	
		Arithmetic Mean	129.8	
		SD	14.77	
		CV (%)	11.4	
		Minimum	109	
		Median	127.0	
		Maximum	157	
	Period 2, Day 1	n	12	12
		Arithmetic Mean	118.8	-8.8
		SD	13.18	7.12
		CV (%)	11.1	
		Minimum	102	-18
		Median	116.5	-10.5
		Maximum	143	6
	Follow-Up	n	12	12
		Arithmetic Mean	126.3	-1.3
		SD	14.76	15.48
		CV (%)	11.7	
		Minimum	104	-24
		Median	127.0	-4.0
		Maximum	151	27

Data Source: Appendix 16.2.9.1

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_03.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 2 of 4

Table 14.3.5.3 Summary of Vital Signs by Time Point
Safety Population (N=12)

Vital Sign	Time Point	Summary Statistic	Absolute	Change
Diastolic Blood Pressure (MMHG)	Screening	n	12	
		Arithmetic Mean	70.6	
		SD	10.41	
		CV (%)	14.8	
		Minimum	49	
		Median	72.0	
		Maximum	84	
	Period 1, Day 1	n	12	
		Arithmetic Mean	70.3	
		SD	11.32	
		CV (%)	16.1	
		Minimum	44	
		Median	71.0	
		Maximum	88	
	Period 2, Day 1	n	12	12
		Arithmetic Mean	69.5	1.2
		SD	10.55	14.53
		CV (%)	15.2	
		Minimum	54	-19
		Median	71.0	0.0
		Maximum	84	38
	Follow-Up	n	12	12
		Arithmetic Mean	72.2	3.8
		SD	10.05	15.30
		CV (%)	13.9	
		Minimum	57	-14
		Median	71.5	0.5
		Maximum	89	44

Data Source: Appendix 16.2.9.1

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_03.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 3 of 4

Table 14.3.5.3 Summary of Vital Signs by Time Point
Safety Population (N=12)

Vital Sign	Time Point	Summary Statistic	Absolute	Change
Pulse Rate (BEATS/MIN)	Screening	n	12	
		Arithmetic Mean	67.3	
		SD	8.59	
		CV (%)	12.8	
		Minimum	51	
		Median	68.0	
		Maximum	77	
	Period 1, Day 1	n	12	
		Arithmetic Mean	72.3	
		SD	12.69	
		CV (%)	17.6	
		Minimum	54	
		Median	73.0	
		Maximum	94	
	Period 2, Day 1	n	12	12
		Arithmetic Mean	67.5	-4.8
		SD	10.81	9.77
		CV (%)	16.0	
		Minimum	45	-17
		Median	70.0	-5.5
		Maximum	82	20
	Follow-Up	n	12	12
		Arithmetic Mean	69.9	-2.3
		SD	14.68	10.49
		CV (%)	21.0	
		Minimum	50	-15
		Median	69.5	-5.0
		Maximum	92	15

Data Source: Appendix 16.2.9.1

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_03.sas

29JAN2013 5:27

Reckitt Benckiser Healthcare (UK) Ltd Study GA1109 (0543/028)

Page 4 of 4

Table 14.3.5.3 Summary of Vital Signs by Time Point
Safety Population (N=12)

Vital Sign	Time Point	Summary Statistic	Absolute	Change
Temperature (C)	Screening	n	12	
		Arithmetic Mean	36.56	
		SD	0.417	
		CV (%)	1.1	
		Minimum	36.0	
		Median	36.40	
		Maximum	37.3	
	Period 1, Day 1	n	12	
		Arithmetic Mean	36.50	
		SD	0.369	
		CV (%)	1.0	
		Minimum	36.0	
		Median	36.50	
		Maximum	37.2	
	Period 2, Day 1	n	12	12
		Arithmetic Mean	36.32	-0.18
		SD	0.361	0.402
		CV (%)	1.0	
		Minimum	35.9	-0.9
		Median	36.15	-0.15
		Maximum	37.2	0.5
	Follow-Up	n	12	12
		Arithmetic Mean	36.47	-0.03
		SD	0.274	0.507
		CV (%)	0.8	
		Minimum	36.1	-1.1
		Median	36.50	0.05
		Maximum	36.8	0.8

Data Source: Appendix 16.2.9.1

renyards: /sas/saseg_am/project/r/0543/0028/ids/statprog/reporting/original/prog/tfl/T14_03_05_03.sas

29JAN2013 5:27

15 REFERENCE LIST

1. Winkle Segmentation Research – Data on file, 2010.
2. Gaviscon Double Action Summary of Product Characteristics.
3. Department of Health & Human Services, Food & Drug Administration, 21 CFR Part 331.
4. Sulz MC et al. Digestion. 2007;75(2-3):69-73.
5. Tytgat GN et al. Aliment Pharmacol Ther. 2006 Mar 15;23(6):759-65.
6. Netzer P et al. Aliment Pharmacol Ther. 1998 Apr;12(4):337- 42.
7. Juvin P et al. Anesth Analg. 2001 Dec;93(6):1621-2.
8. Technostics Dada ANC Study.
9. Fletcher J et al. Gut. 2004;53:168–173.
10. The SAS® System for Windows, Version 9.1.3. SAS Institute Inc, Cary, North Carolina 27513, USA, 1999.
11. MedDRA® is a registered trademark of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).

16 APPENDICES